PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Lui, VCH; Ng, LJ; Sat, EWY; Nicholls, J; Cheah, KSE				Lui, VCH; Ng, LJ; Sat, EWY; Nicholls, J; Cheah, KSE			Extensive alternative splicing within the amino-propeptide coding domain of alpha 2(XI) procollagen mRNAs - Expression of transcripts encoding truncated pro-alpha chains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARGININE-RICH PROTEIN; NH2-TERMINAL DOMAIN; TERMINAL PROPEPTIDE; SEQUENCE-ANALYSIS; HUMAN CARTILAGE; MESSENGER-RNA; III COLLAGEN; XI COLLAGEN; V COLLAGEN; FIBRILLOGENESIS	Heterogeneity in type XI procollagen structure is extensive because all three alpha(XI) collagen genes undergo complex alternative splicing within the amino-propeptide coding domain, Exon 7 of the human and exons 6-8 of the mouse alpha 2(XI) collagen genes, encoding part of the amino-propeptide variable region, have recently been shown to be alternatively spliced. We show that exon 6-containing mRNAs for human alpha 2(XI) procollagen are expressed at 28 weeks in fetal tendon and cartilage but not at 38-44 days or 11 weeks, In the mouse, exon 6 is expressed in chondrocytes from 13.5 days onward, We recently identified conserved sequences within intron 6 of the human and mouse alpha 2(XI) collagen genes, containing additional consensus splice acceptor and donor sites that potentially increase the size of exon 7, dividing it into three parts, designated 7A, 7B, and 7C. We show by reverse transcription polymerase chain reaction and in situ hybridization that these potential splice sites are used to yield additional alpha 2(XI) procollagen mRNA splice variants that are expressed in fetal tissues, In human, expression of exon 7B-containing transcripts may be developmental stage-specific, Interestingly, inclusion of exon 7A or exon 7B in human and mouse alpha 2(XI) procollagen mRNAs, respectively, would result in the insertion of an in-frame termination codon, suggesting that some of the additional splice variants encode a truncated pro-alpha 2(XI) chain.	UNIV HONG KONG,DEPT BIOCHEM,HONG KONG,HONG KONG; UNIV HONG KONG,DEPT PATHOL,HONG KONG,HONG KONG	University of Hong Kong; University of Hong Kong			Cheah, Kathryn/C-4222-2009; Nicholls, John Malcolm/C-4375-2009; /C-4359-2009	Nicholls, John Malcolm/0000-0001-7217-7444; /0000-0002-1758-8854				AMENDT BA, 1995, MOL CELL BIOL, V15, P4606; BENNETT VD, 1990, J BIOL CHEM, V265, P2223; BIRK DE, 1990, J CELL SCI, V95, P649; Birk DE., 1991, MATRIX ASSEMBLY, P221; BURGESON RE, 1979, BIOCHEM BIOPH RES CO, V87, P1124, DOI 10.1016/S0006-291X(79)80024-8; Chu Mon-Li, 1993, P149; CUI Y, 1995, GENE DEV, V9, P423, DOI 10.1101/gad.9.4.423; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DIETZ HC, 1993, SCIENCE, V259, P680, DOI 10.1126/science.8430317; Eyre D, 1987, STRUCTURE FUNCTION C, P261; FLEISCHMAJER R, 1990, ANN NY ACAD SCI, V580, P161, DOI 10.1111/j.1749-6632.1990.tb17927.x; GREEN MR, 1991, ANNU REV CELL BIOL, V7, P559, DOI 10.1146/annurev.cellbio.7.1.559; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HUMPHREY MB, 1995, MOL CELL BIOL, V15, P3979; JUVONEN M, 1993, LAB INVEST, V69, P541; Kielty Cay M., 1993, P103; KIVIRIKKO KI, 1993, ANN MED, V25, P113, DOI 10.3109/07853899309164153; KUHN K, 1982, CONNECT TISSUE RES, V10, P43, DOI 10.3109/03008208209034405; LIM SK, 1992, MOL CELL BIOL, V12, P1149, DOI 10.1128/MCB.12.3.1149; LINSENMAYER TF, 1993, J CELL BIOL, V121, P1181, DOI 10.1083/jcb.121.5.1181; LOVELLBADGE RH, 1987, TERATOCARCINOMAS EMB, P153; LUI VCH, 1995, BIOCHEM J, V311, P511, DOI 10.1042/bj3110511; Lui VCH, 1996, GENOMICS, V32, P401, DOI 10.1006/geno.1996.0135; Mayne R, 1993, CURR OPIN CELL BIOL, V5, P883, DOI 10.1016/0955-0674(93)90039-S; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; NAH HD, 1994, J BIOL CHEM, V269, P16443; NEAME PJ, 1990, J BIOL CHEM, V265, P20401; NG LJ, 1993, DEV BIOL, V159, P403, DOI 10.1006/dbio.1993.1251; O'Rahilly R., 1987, DEV STAGES HUMAN EMB; OXFORD JT, 1995, J BIOL CHEM, V270, P9478, DOI 10.1074/jbc.270.16.9478; PAGLIA L, 1979, BIOCHEMISTRY-US, V18, P5030, DOI 10.1021/bi00589a034; Patten B. V, 1976, HUMAN EMBRYOLOGY; REHN M, 1995, J BIOL CHEM, V270, P4705, DOI 10.1074/jbc.270.9.4705; RYAN MC, 1990, J BIOL CHEM, V265, P10334; Sanger F, 1992, Biotechnology, V24, P104; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; STAFFA A, 1995, MOL CELL BIOL, V15, P4597; THOM JR, 1991, J BIOL CHEM, V266, P7262; TILLET E, 1995, EUR J BIOCHEM, V228, P160, DOI 10.1111/j.1432-1033.1995.tb20245.x; TSUMAKI N, 1995, J BIOL CHEM, V270, P2372, DOI 10.1074/jbc.270.5.2372; WAHLE E, 1992, ANNU REV BIOCHEM, V61, P419; WATAKABE A, 1993, GENE DEV, V7, P407, DOI 10.1101/gad.7.3.407; Wilkinson D. G., 1990, POSTIMPLANTATION MAM, P155; WU CH, 1991, J BIOL CHEM, V266, P2983; YOSHIOKA H, 1990, J BIOL CHEM, V265, P6423; ZHIDKOVA NI, 1993, FEBS LETT, V326, P25, DOI 10.1016/0014-5793(93)81753-M; ZHIDKOVA NI, 1995, J BIOL CHEM, V270, P9486, DOI 10.1074/jbc.270.16.9486	47	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16945	16951		10.1074/jbc.271.28.16945	http://dx.doi.org/10.1074/jbc.271.28.16945			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663204	hybrid, Green Published			2022-12-27	WOS:A1996UX12600079
J	DellaRagione, F; Russo, GL; Oliva, A; Mercurio, C; Mastropietro, S; DellaPietra, V; Zappia, V				DellaRagione, F; Russo, GL; Oliva, A; Mercurio, C; Mastropietro, S; DellaPietra, V; Zappia, V			Biochemical characterization of p16(INK4)- and p18-containing complexes in human cell lines	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE-DELTA; CYCLIN-DEPENDENT KINASES; TUMOR-SUPPRESSOR GENES; NUCLEAR ANTIGEN; HOMOZYGOUS DELETIONS; POTENTIAL MEDIATOR; AUXILIARY PROTEIN; G1 PHASE; P16 GENE; EXPRESSION	The regulation of the D-type cyclin-dependent kinase (CDK4 and CDK6) activity appears to be the key step in the progression of eukaryotic cells through the G(1) cell cycle phase, One of the mechanisms involved in this process is the binding of some small proteic inhibitors, with a molecular mass ranging between 14 and 20 kDa, to these CDKs, We have evaluated the amount of two such inhibitors, namely p16(INK4) and p18, in normal and transformed cells, as well as the biochemical features of the macromolecular complexes containing these proteins, The results obtained indicated that Ii) p18 gene expression, unlike p16(INK4) gene, is not regulated by pRb status, (ii) no evident relationship exists between the expression of p16(INK4) and p18 genes, (iii) significant amounts of the two proteins are not bound to CDKs but occur as free molecules, (iv) each inhibitor forms a complex with the CDK protein with a 1:1 stoichiometry, and Iv) a competition exists between cyclin D and the inhibitor protein toward the CDK protein resulting in the absence of detectable cellular free kinase. Moreover, employing the human native partially purified p16(INK4) or the pure recombinant protein, we have been able to demonstrate in vitro the dissociation of CDR4-cyclin D1 complex and the formation of CDK4-p16INK4 bimolecular complex, Our findings suggest that during the cell division cycle the members of the p16(INK4) protein family and cyclin Ds compete for binding to CDK4/CDK6 and that their quantitative ratio is essential for G(1) --> S transition.	CNR,INST FOOD SCI & TECHNOL,I-83100 AVELLINO,ITALY	Consiglio Nazionale delle Ricerche (CNR); Istituto di Scienze dell' Alimentazione (ISA-CNR)	DellaRagione, F (corresponding author), UNIV NAPLES 2,FAC MED & CHIRURG,IST BIOCHIM MACROMOLEC,SCH MED,VIA COSTANTINOPOLI 16,I-80138 NAPLES,ITALY.		RUSSO, GIAN LUIGI/GQB-0962-2022	Della Ragione, Fulvio/0000-0002-0592-4283; RUSSO, GIAN LUIGI/0000-0001-9321-1613; Mercurio, Ciro/0000-0001-6240-4607				AJCHENBAUM F, 1993, J BIOL CHEM, V268, P4113; BATES S, 1994, ONCOGENE, V9, P71; CALDAS C, 1994, NAT GENET, V8, P27, DOI 10.1038/ng0994-27; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; DELLARAGIONE F, 1995, ONCOGENE, V10, P827; DELLARAGIONE F, 1993, ADV EXP MED BIOL, V348, P31; DESAI D, 1992, MOL BIOL CELL, V3, P571, DOI 10.1091/mbc.3.5.571; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FIRPO EJ, 1994, MOL CELL BIOL, V14, P4889, DOI 10.1128/MCB.14.7.4889; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HEBERT J, 1994, BLOOD, V84, P4038, DOI 10.1182/blood.V84.12.4038.bloodjournal84124038; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HIRAI H, 1995, MOL CELL BIOL, V15, P2672; HUNTER T, 1994, CELL, V79, P573, DOI 10.1016/0092-8674(94)90543-6; JIANG HP, 1994, ONCOGENE, V9, P3397; KAMB A, 1994, NAT GENET, V8, P22, DOI 10.1038/ng0994-22; KAMB A, 1995, TRENDS GENET, V11, P136, DOI 10.1016/S0168-9525(00)89027-7; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; LEE SH, 1991, J BIOL CHEM, V266, P594; MATSUSHIME H, 1992, CELL, V71, P323, DOI 10.1016/0092-8674(92)90360-O; MATSUSHIME H, 1991, CELL, V65, P701, DOI 10.1016/0092-8674(91)90101-4; MEYERSON M, 1994, MOL CELL BIOL, V14, P2077, DOI 10.1128/MCB.14.3.2077; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; MULLER F, 1994, J BIOL CHEM, V269, P17086; NOBORI T, 1994, NATURE, V368, P753, DOI 10.1038/368753a0; NOURSE J, 1994, NATURE, V372, P570, DOI 10.1038/372570a0; NURSE P, 1994, CELL, V79, P547, DOI 10.1016/0092-8674(94)90539-8; OGAWA S, 1994, BLOOD, V84, P2431, DOI 10.1182/blood.V84.8.2431.bloodjournal8482431; OKAMOTO A, 1994, P NATL ACAD SCI USA, V91, P11045, DOI 10.1073/pnas.91.23.11045; OLIVA A, 1993, BIOCHEM BIOPH RES CO, V191, P908, DOI 10.1006/bbrc.1993.1303; PARRY D, 1995, EMBO J, V14, P503, DOI 10.1002/j.1460-2075.1995.tb07026.x; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRELICH G, 1987, NATURE, V326, P517, DOI 10.1038/326517a0; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHERR CJ, 1993, CELL, V73, P1059, DOI 10.1016/0092-8674(93)90636-5; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STEINMAN RA, 1994, ONCOGENE, V9, P3389; TAM SW, 1994, ONCOGENE, V9, P2663; TAN CK, 1986, J BIOL CHEM, V261, P2310; WINSTON JT, 1993, MOL BIOL CELL, V4, P1133, DOI 10.1091/mbc.4.11.1133; WON KA, 1992, P NATL ACAD SCI USA, V89, P9910, DOI 10.1073/pnas.89.20.9910; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZENG XR, 1994, J BIOL CHEM, V269, P13748	53	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15942	15949		10.1074/jbc.271.27.15942	http://dx.doi.org/10.1074/jbc.271.27.15942			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663131	hybrid			2022-12-27	WOS:A1996UW35200019
J	Varner, JA				Varner, JA			Isolation of a sponge-derived extracellular matrix adhesion protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-BINDING-SITE; AGGREGATION FACTOR; DISCOIDIN-I; DICTYOSTELIUM-DISCOIDEUM; MICROCIONA-PROLIFERA; AVIAN EMBRYOS; FIBRONECTIN; GASTRULATION; ATTACHMENT; RECEPTORS	The development of stable intercellular adhesions in the animal kingdom permitted the evolution of the metazoans, of which the sponges are primitive examples. Intercellular adhesion in these simple animals is mediated by a high affinity interaction between the sponge cell. surface and aggregation factor, a 2 x 10(7)-Da proteoglycan that is one of the major components of the sponge extracellular matrix. This report describes a sponge cell surface and extracellular matrix ligand for the sponge proteoglycan, aggregation factor. The 210-kDa protein binds aggregation factor proteoglycan with high affinity (K-d = 7 x 10(-9) M). Importantly, in soluble form, it also inhibits aggregation factor-mediated cell adhesion. This glycoprotein is expressed on the sponge cell surface and within the extracellular matrix. This novel sponge extracellular matrix protein may represent a primitive antecedent of the extracellular matrix adhesion proteins of higher organisms.			Varner, JA (corresponding author), UNIV CALIF SAN DIEGO, DEPT MED 0063, SAN DIEGO, CA 92093 USA.			Varner, Judith/0000-0002-9251-0600				ADELSON DL, 1992, J CELL BIOL, V116, P1283, DOI 10.1083/jcb.116.5.1283; ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; BARONDES SH, 1985, J CELL BIOL, V100, P1825, DOI 10.1083/jcb.100.6.1825; BOUCAUT JC, 1984, J CELL BIOL, V99, P1822, DOI 10.1083/jcb.99.5.1822; BRONNERFRASER M, 1992, DEVELOPMENT, V115, P197; BROOKS PC, 1994, SCIENCE, V264, P569, DOI 10.1126/science.7512751; Cheresh D.A., 1993, ADV MOL CELL BIOL, V6, P225; DESIMONE DW, 1994, INTEGRINS BIOL PROBL, P217; EDELMAN GM, 1988, CURR OPIN CELL BIOL, V5, P869; Erickson HP, 1993, CURR OPIN CELL BIOL, V5, P869, DOI 10.1016/0955-0674(93)90037-Q; EXPOSITO JY, 1991, J BIOL CHEM, V266, P21923; GABIUS HJ, 1985, CELL, V42, P449, DOI 10.1016/0092-8674(85)90102-3; GIANCOTTI FG, 1990, CELL, V60, P849, DOI 10.1016/0092-8674(90)90098-Y; HARDIN J, 1990, DEV BIOL, V142, P86, DOI 10.1016/0012-1606(90)90153-A; HELMER ME, 1990, ANNU REV IMMUNOL, V8, P365; HENKART P, 1973, BIOCHEMISTRY-US, V12, P3045, DOI 10.1021/bi00740a016; HUMBERTDAVID N, 1993, EUR J BIOCHEM, V216, P255, DOI 10.1111/j.1432-1033.1993.tb18140.x; HUMPHREYS T, 1963, DEV BIOL, V8, P27, DOI 10.1016/0012-1606(63)90024-1; HYNES R, 1985, ANNU REV CELL BIOL, V1, P67, DOI 10.1146/annurev.cb.01.110185.000435; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; JUMBLATT J, 1980, BIOCHEMISTRY-US, V12, P3045; KASSNER PD, 1992, MECHANISMS LYMPHOCYT, V4, P163; KINTNER C, 1992, CELL, V69, P225, DOI 10.1016/0092-8674(92)90404-Z; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALLIER T, 1993, SCIENCE, V259, P692, DOI 10.1126/science.8430321; Lallier T, 1994, INTEGRINS MOL BIOL R, P111; LASKY LA, 1994, N HORIZ TH, P37; LEE G, 1984, CELL, V36, P729, DOI 10.1016/0092-8674(84)90353-2; MARTIN GR, 1987, ANNU REV CELL BIOL, V3, P57, DOI 10.1146/annurev.cellbio.3.1.57; McClay DR, 1991, CURR OPIN GENET DEV, V1, P191, DOI 10.1016/S0959-437X(05)80069-3; MISEVIC GN, 1990, J BIOL CHEM, V265, P20577; MISEVIC GN, 1982, J BIOL CHEM, V257, P6931; MISEVIC GN, 1993, J BIOL CHEM, V268, P4922; MISEVIC GN, 1986, J BIOL CHEM, V261, P2853; PAN Y, 1992, P NATL ACAD SCI USA, V89, P2066, DOI 10.1073/pnas.89.6.2066; Righetti PG, 1989, PROTEIN STRUCTURE PR, P23; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; SPRINGER WR, 1984, CELL, V39, P557, DOI 10.1016/0092-8674(84)90462-8; TAKEICHI M, 1991, SCIENCE, V251, P1451, DOI 10.1126/science.2006419; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Varner JA, 1995, CELL ADHES COMMUN, V3, P367, DOI 10.3109/15419069509081020; VARNER JA, 1995, MOL BIOL CELL, V6, P725, DOI 10.1091/mbc.6.6.725; VARNER JA, 1995, J CELL SCI, V108, P3119; VARNER JA, 1988, J BIOL CHEM, V263, P8498; Wilson H.V., 1910, B BUR FISH, V30, P1; Wilson HV, 1907, J EXP ZOOL, V5, P245, DOI 10.1002/jez.1400050204; XUN X, 1990, P NATL ACAD SCI USA, V87, P2097, DOI 10.1073/pnas.87.6.2097; ZETTER BR, 1990, NEW ENGL J MED, V322, P605	50	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16119	16125						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663195				2022-12-27	WOS:A1996UW35200041
J	Isakov, N; Wange, RL; Watts, JD; Aebersold, R; Samelson, LE				Isakov, N; Wange, RL; Watts, JD; Aebersold, R; Samelson, LE			Purification and characterization of human ZAP-70 protein-tyrosine kinase from a baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL ANTIGEN RECEPTOR; T-CELL; ZETA-CHAIN; CYTOPLASMIC DOMAIN; INITIAL CHARACTERIZATION; HUMAN PLATELETS; SH2 DOMAINS; ACTIVATION; P56LCK; ASSOCIATION	The ZAP-70 protein tyrosine kinase is essential for T cell antigen receptor (TCR)-mediated signaling. The absence of ZAP-70 results in impaired differentiation of T cells and a lack of responsiveness to antigenic stimulation. In order to study the characteristics of ZAP-70 in vitro, we overexpressed an epitopically tagged human ZAP-70 in a recombinant baculovirus expression system and purified it by column chromatography. The kinase activity of purified, recombinant ZAP-70 required cation and exhibited a strong preference for Mn2+ over Mg2+. The apparent K-m of ZAP-70 for ATP was similar to 3.0 mu M. The activity of the recombinant ZAP-70, unlike that of the homologous protein tyrosine kinase, Syk, was not affected by binding of TCR-derived tyrosine phosphorylated immunoreceptor tyrosine-based activation motif peptides. Several proteins were tested as potential in vitro substrates of ZAP-70. Only alpha-tubulin and the cytoplasmic fragment of human erythrocyte band 3 (cfb3), which have a region of sequence identity at the phosphorylation site, proved to be good substrates, exhibiting K-m values of similar to 3.3 and similar to 2.5 mu M respectively ([ATP] = 50 mu M). alpha- and beta-Casein were poor substrates for ZAP-70, and no activity toward enolase, myelin basic protein, calmodulin, histone proteins, or angiotensin could be detected. In contrast to the T cell protein tyrosine kinase, Lck, ZAP-70 did not phosphorylate the cytoplasmic portion of the TCR zeta chain or short peptides corresponding to the CD3 epsilon or the TCR zeta immunoreceptor tyrosine-based activation motifs. Our studies suggest that ZAP-70 exhibits a high degree of substrate specificity.	NICHHD, CELL BIOL & METAB BRANCH, NIH, BETHESDA, MD 20892 USA; BEN GURION UNIV NEGEV, DEPT MICROBIOL & IMMUNOL, IL-84105 BEER SHEVA, ISRAEL; BEN GURION UNIV NEGEV, CANC RES CTR, IL-84105 BEER SHEVA, ISRAEL; UNIV WASHINGTON, DEPT MOLEC BIOTECHNOL, SEATTLE, WA 98195 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Ben Gurion University; Ben Gurion University; University of Washington; University of Washington Seattle			ISAKOV, NOAH/F-1659-2012	Isakov, Noah/0000-0002-1412-0957; Wange, Ronald/0000-0001-9593-3572				ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BANIYASH M, 1988, J BIOL CHEM, V263, P18225; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CAPLAN S, 1995, P NATL ACAD SCI USA, V92, P4768, DOI 10.1073/pnas.92.11.4768; CARPENTER CL, 1993, J BIOL CHEM, V268, P9478; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHAN AC, 1995, EMBO J, V14, P2499, DOI 10.1002/j.1460-2075.1995.tb07247.x; CHAN AC, 1991, P NATL ACAD SCI USA, V88, P9166, DOI 10.1073/pnas.88.20.9166; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; COLE PA, 1994, J BIOL CHEM, V269, P30880; COWAN NJ, 1983, MOL CELL BIOL, V3, P1738, DOI 10.1128/MCB.3.10.1738; DUPLAY P, 1994, J EXP MED, V179, P1163, DOI 10.1084/jem.179.4.1163; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FEDER D, 1990, J BIOL CHEM, V265, P8205; GAUEN LKT, 1994, MOL CELL BIOL, V14, P3729, DOI 10.1128/MCB.14.6.3729; GAUEN LKT, 1992, MOL CELL BIOL, V12, P5438, DOI 10.1128/MCB.12.12.5438; Huby RDJ, 1995, J BIOL CHEM, V270, P30241, DOI 10.1074/jbc.270.51.30241; IRVING BA, 1991, CELL, V64, P891, DOI 10.1016/0092-8674(91)90314-O; IRVING BA, 1993, J EXP MED, V177, P1093, DOI 10.1084/jem.177.4.1093; ISAKOV N, 1995, J EXP MED, V181, P375, DOI 10.1084/jem.181.1.375; ISAKOV N, 1994, J LEUKOCYTE BIOL, V55, P265, DOI 10.1002/jlb.55.2.265; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAUL RK, 1983, J BIOL CHEM, V258, P7891; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; LEY SC, 1994, EUR J IMMUNOL, V24, P99, DOI 10.1002/eji.1830240116; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; NEGISHI I, 1995, NATURE, V376, P435, DOI 10.1038/376435a0; NEUMEISTER EN, 1995, MOL CELL BIOL, V15, P3171; OFFRINGA R, 1993, J BIOL CHEM, V268, P4979; OKADA M, 1989, J BIOL CHEM, V264, P20886; PLUSKEY S, 1995, J BIOL CHEM, V270, P2897, DOI 10.1074/jbc.270.7.2897; QIAN DP, 1993, J BIOL CHEM, V268, P4488; RAMER SE, 1991, P NATL ACAD SCI USA, V88, P6254, DOI 10.1073/pnas.88.14.6254; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; REUTER C, 1990, EUR J BIOCHEM, V190, P343, DOI 10.1111/j.1432-1033.1990.tb15581.x; ROMEO C, 1992, CELL, V68, P889, DOI 10.1016/0092-8674(92)90032-8; ROMEO C, 1991, CELL, V64, P1037, DOI 10.1016/0092-8674(91)90327-U; ROWLEY RB, 1995, J BIOL CHEM, V270, P11590, DOI 10.1074/jbc.270.19.11590; ROZDZIAL MM, 1995, IMMUNITY, V3, P623, DOI 10.1016/1074-7613(95)90133-7; RUDD CE, 1988, P NATL ACAD SCI USA, V85, P5190, DOI 10.1073/pnas.85.14.5190; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SAMELSON LE, 1990, P NATL ACAD SCI USA, V87, P4358, DOI 10.1073/pnas.87.11.4358; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHENOYSCARIA AM, 1993, MOL CELL BIOL, V13, P6385, DOI 10.1128/MCB.13.10.6385; SHIUE L, 1995, J BIOL CHEM, V270, P10498, DOI 10.1074/jbc.270.18.10498; SHOELSON SE, 1993, EMBO J, V12, P795, DOI 10.1002/j.1460-2075.1993.tb05714.x; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SONGYANG Z, 1995, NATURE, V373, P536, DOI 10.1038/373536a0; VEILLETTE A, 1988, CELL, V55, P301, DOI 10.1016/0092-8674(88)90053-0; WANG CC, 1992, PROTEIN SCI, V1, P1206, DOI 10.1002/pro.5560010913; WANGE RL, 1992, J BIOL CHEM, V267, P11685; WANGE RL, 1993, J BIOL CHEM, V268, P19797; WANGE RL, 1995, J BIOL CHEM, V270, P18730, DOI 10.1074/jbc.270.32.18730; WANGE RL, 1995, J BIOL CHEM, V270, P944, DOI 10.1074/jbc.270.2.944; WATTS JD, 1994, J BIOL CHEM, V269, P29520; WATTS JD, 1992, J BIOL CHEM, V267, P901; WEGENER AMK, 1992, CELL, V68, P83, DOI 10.1016/0092-8674(92)90208-T; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; YANG C, 1994, EUR J BIOCHEM, V221, P973, DOI 10.1111/j.1432-1033.1994.tb18813.x; YANNOUKAKOS D, 1989, BIOCHIM BIOPHYS ACTA, V998, P43, DOI 10.1016/0167-4838(89)90116-7; YU G, 1987, J BIOL CHEM, V262, P17543; ZIONCHECK TF, 1986, J BIOL CHEM, V261, P5637	66	55	59	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15753	15761		10.1074/jbc.271.26.15753	http://dx.doi.org/10.1074/jbc.271.26.15753			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663155	hybrid			2022-12-27	WOS:A1996UV29900068
J	Jan, CR; Ribar, TJ; Means, AR; Augustine, GJ				Jan, CR; Ribar, TJ; Means, AR; Augustine, GJ			Alterations in calcium channel currents underlie defective insulin secretion in a transgenic mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PANCREATIC BETA-CELLS; PROTEIN KINASE-II; CA2+ CHANNELS; K+-CHANNELS; B-CELLS; CALMODULIN; GLUCOSE; ISLETS; ATP; MICE	A transgenic mouse overexpressing a mutant form of calmodulin (CaM-8) that is selectively targeted to pancreatic beta-cells has an impaired ability to secrete insulin in response to elevated blood glucose, Fluorescence measurements of cytosolic Ca2+ concentration ([Ca2+](i)) showed that intracellular Ca2+ rises produced by glucose were smaller than normal in beta-cells of CaM-8 mice, Glucose utilization rates were not different between the CaM-8 and control beta-cells, suggesting that glucose metabolism was unperturbed by CaM-8, Ion channel defects were implicated in the phenotype of CaM-8 beta-cells because treatment of these cells with tolbutamide, a blocker of ATP-sensitive K+ channels, produced smaller than normal amounts of insulin secretion and Ca2+ rises, Depolarization with elevated extracellular K+ also produced smaller Ca2+ rises in beta-cells from CaM-8 mice, Whole-cell patch-clamp recordings revealed that Ca2+ channel currents of beta-cells from CaM-8 mice were half as large as Ca2+ currents in control cells, while the currents carried by delayed rectifier and ATP-sensitive K+ channels were similar in magnitude in both cell types, We conclude that expression of the CaM-8 form of calmodulin causes a down-regulation of Ca2+ channel currents, which reduces Ca2+ entry and accumulation when glucose stimulates closure of the ATP-sensitive K+ channels, The reduction in intracellular Ca2+ accumulation then prevents an adequate amount of insulin from being secreted from beta-cells of CaM-8 mice.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT NEUROBIOL, DURHAM, NC 27710 USA	Duke University; Duke University			Augustine, George James/J-9228-2013		NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021624] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-43017] Funding Source: Medline; NINDS NIH HHS [NS-21624] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARKHAMMAR P, 1994, J BIOL CHEM, V269, P2743; ASHCROFT FM, 1988, ANNU REV NEUROSCI, V11, P97, DOI 10.1146/annurev.neuro.11.1.97; ASHCROFT SJ, 1972, BIOCHEM J, V126, P525, DOI 10.1042/bj1260525; ASHCROFT SJH, 1990, CELL SIGNAL, V2, P197, DOI 10.1016/0898-6568(90)90048-F; AUGUSTINE GJ, 1992, J PHYSIOL-LONDON, V450, P247, DOI 10.1113/jphysiol.1992.sp019126; BOKVIST K, 1990, J PHYSIOL-LONDON, V423, P327, DOI 10.1113/jphysiol.1990.sp018025; BOLAFFI JL, 1991, ENDOCRINOLOGY, V129, P2131, DOI 10.1210/endo-129-4-2131; CHAFOULEAS JG, 1982, CELL, V28, P41, DOI 10.1016/0092-8674(82)90373-7; EPSTEIN PN, 1989, CELL, V58, P1067, DOI 10.1016/0092-8674(89)90505-9; EPSTEIN PN, 1992, ENDOCRINOLOGY, V130, P1387, DOI 10.1210/en.130.3.1387; GERMAN MS, 1993, P NATL ACAD SCI USA, V90, P1781, DOI 10.1073/pnas.90.5.1781; GILLIS KD, 1992, PFLUG ARCH EUR J PHY, V420, P121, DOI 10.1007/BF00378654; GRODSKY GM, 1966, DIABETES, V15, P910, DOI 10.2337/diab.15.12.910; GRUVER CL, 1993, ENDOCRINOLOGY, V133, P376, DOI 10.1210/en.133.1.376; GRYNKIEWICZ G, 1985, J BIOL CHEM, V260, P3440; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HEDESKOV CJ, 1991, MOL CELL ENDOCRINOL, V78, P187, DOI 10.1016/0303-7207(91)90122-9; HENQUIN JC, 1981, BIOCHEM J, V196, P771, DOI 10.1042/bj1960771; HERCHUELZ A, 1991, CELL CALCIUM, V12, P577, DOI 10.1016/0143-4160(91)90076-Q; HESS P, 1984, NATURE, V309, P453, DOI 10.1038/309453a0; HOLZ GG, 1992, TRENDS BIOCHEM SCI, V17, P388, DOI 10.1016/0968-0004(92)90006-U; KUNG C, 1992, CELL CALCIUM, V13, P413, DOI 10.1016/0143-4160(92)90054-V; LEECH CA, 1994, ENDOCRINOLOGY, V135, P365, DOI 10.1210/en.135.1.365; LI GD, 1992, MOL PHARMACOL, V42, P489; LLEDO PM, 1992, NEURON, V9, P943, DOI 10.1016/0896-6273(92)90246-A; MEANS AR, 1988, RECENT PROG HORM RES, V44, P223; NEHER E, 1989, NEUROMUSCULAR JUNCTI, P65; PENNER R, 1988, J EXP BIOL, V139, P329; POLLO A, 1993, PFLUG ARCH EUR J PHY, V423, P462, DOI 10.1007/BF00374942; RAJAN AS, 1990, DIABETES CARE, V13, P340, DOI 10.2337/diacare.13.3.340; RIBAR TJ, 1995, J BIOL CHEM, V270, P28688, DOI 10.1074/jbc.270.48.28688; RIBAR TJ, 1995, ENDOCRINOLOGY, V136, P106, DOI 10.1210/en.136.1.106; RORSMAN P, 1985, PFLUG ARCH EUR J PHY, V405, P305, DOI 10.1007/BF00595682; RORSMAN P, 1986, J PHYSIOL-LONDON, V374, P531, DOI 10.1113/jphysiol.1986.sp016096; SAIMI Y, 1994, FEBS LETT, V350, P155, DOI 10.1016/0014-5793(94)00782-9; SMITH PA, 1989, NATURE, V342, P550, DOI 10.1038/342550a0; SMITH PA, 1993, J GEN PHYSIOL, V101, P767, DOI 10.1085/jgp.101.5.767; SMOLEN P, 1993, BIOPHYS J, V64, P1668, DOI 10.1016/S0006-3495(93)81539-X; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUGDEN MC, 1979, FEBS LETT, V105, P95, DOI 10.1016/0014-5793(79)80894-7; TRUBE G, 1986, PFLUG ARCH EUR J PHY, V407, P493, DOI 10.1007/BF00657506; VALVERDE I, 1984, EXPERIENTIA, V40, P1061, DOI 10.1007/BF01971452; VANBERKUM MFA, 1990, J BIOL CHEM, V265, P3750; WANG J, 1992, ENDOCRINOLOGY, V131, P146, DOI 10.1210/en.131.1.146; WENHAM RM, 1992, BIOCHEM BIOPH RES CO, V189, P128, DOI 10.1016/0006-291X(92)91534-W; YAN HM, 1994, ENDOCRINOLOGY, V134, P42	46	6	6	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15478	15485		10.1074/jbc.271.26.15478	http://dx.doi.org/10.1074/jbc.271.26.15478			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663103	hybrid			2022-12-27	WOS:A1996UV29900028
J	Liu, J; Nurse, P; Marians, KJ				Liu, J; Nurse, P; Marians, KJ			The ordered assembly of the phi X174-type primosome .3. PriB facilitates complex formation between PriA and DnaT	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-Y; DEPENDENT ATPASE ACTIVITY; ESCHERICHIA-COLI PRIA; GENE PRODUCT; PROTEIN PRIA; HELICASE; SEQUENCE; MUTANTS	The properties of two mutant PriA proteins, PriA C439Y and PriA. C445Y have been used to reveal the role of PriB during assembly of the phi X174-type primosome, The replication defects of both mutant PriA proteins could be rescued by high concentrations of DnaT. Analysis of the formation of intermediate complexes in primosome assembly and the effect of PriB on PriA binding to DNA demonstrated that the mutant PriA proteins could not form a PriA-PriB complex on DNA carrying a primosome assembly site, Consequently, the mutant proteins also could not form PriA-PriB-DnaT complexes at concentrations of DnaT sufficient to form such a complex with wild-type PriA. In addition, PriB was found to stabilize wild-type but not mutant PriA proteins on DNA. At high concentrations of DnaT, both mutant and wild-type PriA proteins could form a PricA-DnaT complex and support PriB-independent phi X174 complementary strand DNA replication, Thus, during primosome assembly, PriB facilitates complex formation between PriA and DnaT.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Liu, J (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOUCHE JP, 1975, J BIOL CHEM, V250, P5995; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; LEE MS, 1990, J BIOL CHEM, V265, P17078; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MOK M, 1987, J BIOL CHEM, V262, P2304; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; NURSE P, 1990, P NATL ACAD SCI USA, V87, P4615, DOI 10.1073/pnas.87.12.4615; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; SANDLER SJ, 1996, GENETICS, V143, P5313; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WRIGHT M, 1973, P NATL ACAD SCI USA, V70, P3120, DOI 10.1073/pnas.70.11.3120; ZAVITZ KH, 1993, J BIOL CHEM, V268, P4337; ZAVITZ KH, 1991, J BIOL CHEM, V266, P13988; ZAVITZ KH, 1992, J BIOL CHEM, V267, P6933	22	71	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15656	15661		10.1074/jbc.271.26.15656	http://dx.doi.org/10.1074/jbc.271.26.15656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663106	hybrid			2022-12-27	WOS:A1996UV29900054
J	Stephen, AG; TrauschAzar, JS; Ciechanover, A; Schwartz, AL				Stephen, AG; TrauschAzar, JS; Ciechanover, A; Schwartz, AL			The ubiquitin-activating enzyme E1 is phosphorylated and localized to the nucleus in a cell cycle-dependent manner	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY PURIFICATION; PROTEOLYSIS; SEQUENCE; EXTRACTS; SYSTEM; KINASE	The ubiquitin-activating enzyme E1 exists as two isoforms, E1a (117 kDa) and E1b (110 kDa). E1a is phosphorylated, whereas E1b is not. In the present study we have demonstrated the cell cycle dependence of Ela phosphorylation: a 2-fold increase in the specific phosphorylation of E1a in G(2) compared with the basal level of phosphorylation in the other stages of the cell cycle, Two-dimensional gel electrophoresis resolved E1 into the two isoforms E1a and E1b; E1a resolved further as three phosphorylated forms and one nonphosphorylated form, while E1b resolved as one nonphosphorylated form, E1a is found predominantly in the phosphorylated forms. However, the distribution of E1a among these different phosphorylated forms was not cell cycle-dependent. We next evaluated the enzymatic activity of E1 as well as its subcellular localization throughout the cell cycle, P-32-Pyrophosphate exchange activity of E1 did not vary along the cell cycle; however, the amount of ubiquitin-protein conjugates decreased by 50% in G(2), Nuclear and cytosolic fractionation of cells revealed the nuclear to cytosolic ratio of phosphorylated Ela was 3-fold greater in G(2) compared with the other stages of the cell cycle. Finally, purified nuclear extracts supported E1-dependent ubiquitin conjugation of exogenous substrates as did purified cytosol, However, in nuclear extracts but not in cytosol the amount of E1 activity was rate-limiting. Thus we establish nuclear E1-dependent protein ubiquitination and propose that an increase in phosphorylation of E1a in G(2) functions to increase the import and/or retention of E1a in the nucleus and may modulate nuclear protein ubiquitination.	WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA; CHILDRENS HOSP, DIV PEDIAT HEMATOL ONCOL, ST LOUIS, MO 63110 USA; TECHNION ISRAEL INST TECHNOL, FAC MED, BIOCHEM UNIT, IL-31096 HAIFA, ISRAEL; TECHNION ISRAEL INST TECHNOL, FAC MED, RAPPAPORT FAMILY INST RES MED SCI, IL-31096 HAIFA, ISRAEL	Washington University (WUSTL); St. Louis Children's Hospital; Technion Israel Institute of Technology; Rappaport Faculty of Medicine; Technion Israel Institute of Technology; Rappaport Faculty of Medicine	Stephen, AG (corresponding author), WASHINGTON UNIV, SCH MED, EDWARD MALLINCKRODT DEPT PEDIAT, ST LOUIS, MO 63110 USA.		Ciechanover, Aaron J/C-9166-2017; Stephen, Andrew/W-2636-2019	Stephen, Andrew/0000-0002-8259-621X				CIECHANOVER A, 1982, J BIOL CHEM, V257, P2537; CIECHANOVER A, 1981, P NATL ACAD SCI-BIOL, V78, P761, DOI 10.1073/pnas.78.2.761; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; COOK JC, 1995, P NATL ACAD SCI USA, V92, P3454, DOI 10.1073/pnas.92.8.3454; COOK JC, 1992, J BIOL CHEM, V267, P24315; DESHAIES RJ, 1995, TRENDS CELL BIOL, V5, P428, DOI 10.1016/S0962-8924(00)89102-3; DESHAIES RJ, 1995, EMBO J, V14, P303, DOI 10.1002/j.1460-2075.1995.tb07004.x; DEVERAUX Q, 1994, J BIOL CHEM, V269, P7059; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FINLEY D, 1984, CELL, V37, P43, DOI 10.1016/0092-8674(84)90299-X; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; GOEBL MG, 1988, SCIENCE, V241, P1331, DOI 10.1126/science.2842867; HANDLEY PM, 1991, P NATL ACAD SCI USA, V88, P258, DOI 10.1073/pnas.88.1.258; HANDLEYGEARHART PM, 1994, BIOCHEM J, V304, P1015, DOI 10.1042/bj3041015; HANDLEYGEARHART PM, 1994, J BIOL CHEM, V269, P33171; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HERSHKO A, 1994, J BIOL CHEM, V269, P4940; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HOCHSTRASSER M, 1995, CURR OPIN CELL BIOL, V7, P215, DOI 10.1016/0955-0674(95)80031-X; HOLLOWAY SL, 1993, CELL, V73, P1393, DOI 10.1016/0092-8674(93)90364-V; IRNIGER S, 1995, CELL, V81, P269, DOI 10.1016/0092-8674(95)90337-2; JANS DA, 1995, J BIOL CHEM, V270, P17064, DOI 10.1074/jbc.270.29.17064; JANS DA, 1994, ONCOGENE, V9, P2961; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KING RW, 1995, CELL, V81, P279, DOI 10.1016/0092-8674(95)90338-0; KONG SK, 1992, J BIOL CHEM, V267, P14189; KULKA RG, 1988, J BIOL CHEM, V263, P15726; MAHAFFEY D, 1993, J BIOL CHEM, V268, P21205; MOLL T, 1991, CELL, V66, P743, DOI 10.1016/0092-8674(91)90118-I; NAGAI Y, 1995, J CELL SCI, V108, P2145; PAGANO M, 1995, SCIENCE, V269, P682, DOI 10.1126/science.7624798; RIHS HP, 1991, EMBO J, V10, P633, DOI 10.1002/j.1460-2075.1991.tb07991.x; RIVETT AJ, 1993, BIOCHEM J, V291, P1; SCHWARTZ AL, 1992, P NATL ACAD SCI USA, V89, P5542, DOI 10.1073/pnas.89.12.5542; SCHWOB E, 1994, CELL, V79, P233, DOI 10.1016/0092-8674(94)90193-7; SEUFERT W, 1995, NATURE, V373, P78, DOI 10.1038/373078a0; SUDAKIN V, 1995, MOL BIOL CELL, V6, P185, DOI 10.1091/mbc.6.2.185; TAGAWA T, 1995, J CELL BIOL, V130, P255, DOI 10.1083/jcb.130.2.255; TRAUSCH JS, 1993, AM J PHYSIOL, V264, pC93, DOI 10.1152/ajpcell.1993.264.1.C93; YAGLOM J, 1995, MOL CELL BIOL, V15, P731	41	45	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15608	15614		10.1074/jbc.271.26.15608	http://dx.doi.org/10.1074/jbc.271.26.15608			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663123	hybrid			2022-12-27	WOS:A1996UV29900047
J	Tang, Y; Jiang, N; Parakh, C; Hilvert, D				Tang, Y; Jiang, N; Parakh, C; Hilvert, D			Selection of linkers for a catalytic single-chain antibody using phage display technology	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; BINDING; EXPRESSION; LIBRARIES; AFFINITY	Phage display has been evaluated as a means of rapidly selecting tailored linkers for single chain antibodies (scFvs) from protein linker libraries. Preliminary experiments with a conventional linker failed to yield a functional single-chain version of a catalytic antibody with chorismate mutase activity. A random linker library was therefore constructed in which the genes for the heavy and light chain variable domains were linked by a segment encoding an 18-amino acid polypeptide of variable composition, The scFv repertoire (approximate to 5 x 10(6) different members) was displayed on filamentous phage and subjected to affinity selection with hapten. The population of selected variants exhibited significant increases in binding activity but retained considerable sequence diversity, Screening 1054 individual variants subsequently yielded a catalytically active scFv that was produced efficiently in soluble form, Sequence analysis revealed a conserved proline in the linker two residues after the V-H C terminus and an abundance of arginines and prolines at other positions as the only common features of the selected tethers, There are apparently many viable solutions to the problem of linking individual V-H and V-L domains, but subtle differences in sequence dramatically influence the production, stability, and recognition properties of the scFv. The success of these experiments suggests that phage display will be generally useful for identifying peptide sequences for covalently linking any two protein domains.	Scripps Res Inst, DEPT CHEM, LA JOLLA, CA 92037 USA; SCRIPPS RES INST, DEPT BIOL MOLEC, LA JOLLA, CA 92037 USA	Scripps Research Institute; Scripps Research Institute								BARBAS CF, 1991, P NATL ACAD SCI USA, V88, P7978, DOI 10.1073/pnas.88.18.7978; BOWDISH K, 1991, J BIOL CHEM, V266, P11901; BURTON DR, 1994, ADV IMMUNOL, V57, P191, DOI 10.1016/S0065-2776(08)60674-4; CAMPBELL AP, 1993, P NATL ACAD SCI USA, V90, P8663, DOI 10.1073/pnas.90.18.8663; COLCHER D, 1990, JNCI-J NATL CANCER I, V82, P1191, DOI 10.1093/jnci/82.14.1191; DOPHEIDE TA, 1972, J BIOL CHEM, V247, P4447; FREUND C, 1993, FEBS LETT, V320, P97, DOI 10.1016/0014-5793(93)80070-B; HAYNES MR, 1994, SCIENCE, V263, P646, DOI 10.1126/science.8303271; HILVERT D, 1988, P NATL ACAD SCI USA, V85, P4953, DOI 10.1073/pnas.85.14.4953; HUSTON JS, 1991, METHOD ENZYMOL, V203, P46; JOHNSON S, 1991, METHOD ENZYMOL, V203, P88; KORTT AA, 1994, EUR J BIOCHEM, V221, P151, DOI 10.1111/j.1432-1033.1994.tb18724.x; MARKS JD, 1991, J MOL BIOL, V222, P581, DOI 10.1016/0022-2836(91)90498-U; MCCAFFERTY J, 1990, NATURE, V348, P552, DOI 10.1038/348552a0; ONEIL KT, 1995, CURR OPIN STRUC BIOL, V5, P443, DOI 10.1016/0959-440X(95)80027-1; PANTOLIANO MW, 1991, BIOCHEMISTRY-US, V30, P10117, DOI 10.1021/bi00106a007; RATH S, 1988, J IMMUNOL METHODS, V106, P245, DOI 10.1016/0022-1759(88)90204-9; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; STEMMER WPC, 1993, BIOTECHNIQUES, V14, P256; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TURNBULL J, 1990, BIOCHEMISTRY-US, V29, P10245, DOI 10.1021/bi00496a014; WINTER G, 1994, ANNU REV IMMUNOL, V12, P433, DOI 10.1146/annurev.iy.12.040194.002245; YANG WP, 1995, J MOL BIOL, V254, P392, DOI 10.1006/jmbi.1995.0626; ZDANOV A, 1994, P NATL ACAD SCI USA, V91, P6423, DOI 10.1073/pnas.91.14.6423	24	52	96	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15682	15686		10.1074/jbc.271.26.15682	http://dx.doi.org/10.1074/jbc.271.26.15682			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663068	hybrid			2022-12-27	WOS:A1996UV29900058
J	Wymore, RS; Negulescu, D; Kinoshita, K; Kalman, K; Aiyar, J; Gutman, GA; Chandy, KG				Wymore, RS; Negulescu, D; Kinoshita, K; Kalman, K; Aiyar, J; Gutman, GA; Chandy, KG			Characterization of the transcription unit of mouse Kv1.4, a voltage-gated potassium channel gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							3' UNTRANSLATED REGION; BETA MESSENGER-RNA; UA-RICH SEQUENCES; MOLECULAR-BASIS; TATA-LESS; EXPRESSION; PROMOTER; TRANSLATION; METHYLATION; PROTEIN	The mouse voltage-gated K+ channel gene, Kv1.4, is expressed in brain and heart as similar to 4.5- and similar to 3.5-kilobase kb) transcripts. Both mRNAs begin at a common site 1338 bp upstream of the initiation codon, contain 3477 and 4411 nucleotides, respectively, and are encoded by two exons; exon 1 contains 0.5 kb of the 5'-noncoding region (NCR), while exon 2 encodes the remaining 0.8 kb of the 5'-NCR, the entire coding region (2 kb), and all of the 3'-NCR. The 3.5-kb transcript terminates at a polyadenylation signal 177 bp 3' of the stop codon, while the 4.5-kb mRNA utilizes a signal 94 bp farther downstream. Although the proteins generated hom either transcript are identical, the two mRNAs are functionally different, the 3.5-kb transcript producing similar to 4-5-fold larger currents when expressed in Xenopus oocytes compared to the 4.5-kb mRNA. The decreased expression of the longer transcript is due to the presence of five ATTTA repeats in the 3'-NCR which inhibit translation; such motifs have also been reported to destabilize the messages of many other genes and might therefore shorten the life of the 4,5-kb transcript during its natural expression. The Kv1.4 basal promoter is GC-rich, contains three SP1 repeats (CCGCCC, -65 to -35), lacks canonical TATAAA and GGCAATCT motifs, and has no apparent tissue specificity. One region enhances activity of this promoter. Thus, transcriptional and post-transcriptional regulation of mKv1.4, coupled with selective usage of the two alternate Kv1.4 mRNAs, may modulate the levels of functional Kv1.4 channels.	UNIV CALIF IRVINE,DEPT PHYSIOL & BIOPHYS,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT MICROBIOL & MOLEC GENET,IRVINE,CA 92717; SUNY STONY BROOK,DEPT PHYSIOL & BIOPHYS,STONY BROOK,NY 11794	University of California System; University of California Irvine; University of California System; University of California Irvine; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024783] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24783] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AKASHI M, 1994, BLOOD, V83, P3182; ALBINI A, 1990, NUCLEIC ACIDS RES, V18, P5181, DOI 10.1093/nar/18.17.5181; ASSONBATRES MA, 1994, P NATL ACAD SCI USA, V91, P1318, DOI 10.1073/pnas.91.4.1318; AYTE J, 1993, BIOCHEM J, V295, P807, DOI 10.1042/bj2950807; Azizkhan Jane C., 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P229; BLAKE MC, 1990, MOL CELL BIOL, V10, P6632, DOI 10.1128/MCB.10.12.6632; CHANDY KG, 1990, SCIENCE, V247, P973, DOI 10.1126/science.2305265; CHANDY KG, 1995, HDB RECEPTORS CHANNE; DURET L, 1993, NUCLEIC ACIDS RES, V21, P2315, DOI 10.1093/nar/21.10.2315; KRUYS V, 1987, P NATL ACAD SCI USA, V84, P6030, DOI 10.1073/pnas.84.17.6030; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; KRUYS V, 1990, ENZYME, V44, P193, DOI 10.1159/000468757; KRUYS VI, 1988, GENE, V72, P191, DOI 10.1016/0378-1119(88)90144-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGNADO CA, 1994, MOL CELL BIOL, V14, P7984, DOI 10.1128/MCB.14.12.7984; LESAGE F, 1992, FEBS LETT, V310, P162, DOI 10.1016/0014-5793(92)81320-L; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MARINX O, 1994, FEBS LETT, V345, P107, DOI 10.1016/0014-5793(94)00413-7; MATSUBARA H, 1993, J CLIN INVEST, V92, P1659, DOI 10.1172/JCI116751; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; MURRAY KT, 1994, CIRC RES, V75, P999, DOI 10.1161/01.RES.75.6.999; NUSSINOV R, 1990, CRIT REV BIOCHEM MOL, V25, P185, DOI 10.3109/10409239009090609; PO S, 1993, CIRC RES, V72, P1326, DOI 10.1161/01.RES.72.6.1326; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; RUPPERSBERG JP, 1991, NATURE, V353, P657, DOI 10.1038/353657a0; SAUERWALD A, 1990, J BIOL CHEM, V265, P14932; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHENG ZH, 1994, DNA CELL BIOL, V13, P9, DOI 10.1089/dna.1994.13.9; SINGER J, 1979, SCIENCE, V203, P1019, DOI 10.1126/science.424726; SOREQ H, 1992, METHOD ENZYMOL, V207, P225; STUHMER W, 1989, EMBO J, V8, P3235, DOI 10.1002/j.1460-2075.1989.tb08483.x; TAMKUN MM, 1991, FASEB J, V5, P331, DOI 10.1096/fasebj.5.3.2001794; TSENGCRANK JCL, 1990, FEBS LETT, V268, P63, DOI 10.1016/0014-5793(90)80973-M; WYMORE RS, 1994, GENOMICS, V20, P191, DOI 10.1006/geno.1994.1153; YATANI A, 1993, CIRC RES, V73, P351, DOI 10.1161/01.RES.73.2.351	36	32	32	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15629	15634		10.1074/jbc.271.26.15629	http://dx.doi.org/10.1074/jbc.271.26.15629			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663090	hybrid			2022-12-27	WOS:A1996UV29900050
J	Armstrong, PB; Swarnakar, S; Srimal, S; Misquith, S; Hahn, EA; Aimes, RT; Quigley, JP				Armstrong, PB; Swarnakar, S; Srimal, S; Misquith, S; Hahn, EA; Aimes, RT; Quigley, JP			A cytolytic function for a sialic acid-binding lectin that is a member of the pentraxin family of proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; COMPLEMENT-LIKE ACTIVITY; LIMULUS-POLYPHEMUS; HEMOLYTIC SYSTEM; ALPHA-2-MACROGLOBULIN; INVERTEBRATES; RECOGNITION; ACTIVATION; PATHWAY	A variety of invertebrates possess plasma lectins with sialic acid recognition capabilities, One of the best studied of these lectins is limulin, which is a member of the pentraxin family of proteins and is found in the plasma of the American horseshoe crab, Limulus polyphemus, We find that limulin is one of several sialic acid-binding lectins of limulus plasma and is present at a much lower abundance than Limulus C-reactive protein, the other plasma pentraxin, Limulin was purified by sequential affinity chromatography on phosphorylethanolamine agarose, which isolates the pentraxins and separates limulin from the other sialic acid-binding lectins of the plasma, followed by fetuin-Sepharose, which binds limulin and separates it from Limulus C-reactive protein, the most abundant pentraxin of the plasma, We show here that limulin is the mediator of the Ca+2-dependent hemolytic activity found in the plasma of Limulus, Plasma that was depleted in the pentraxins by passage over phosphorylethanolamine-agarose or was depleted in the sialic acid-binding lectins by passage over fetuin Sepharose lacked hemolytic activity, Purified limulin was hemolytic at concentrations of 3-5 nM. The other sialic acid-binding lectins of Limulus plasma and Limulus C-reactive protein were nonhemolytic. Foreign cell cytolysis by limulin represents a novel function for a plasma lectin and is the first documented function for limulin.	MARINE BIOL LAB,WOODS HOLE,MA 02543; SUNY STONY BROOK,SCH MED,DEPT PATHOL,STONY BROOK,NY 11794; SUNY STONY BROOK,SCH MED,DEPT BIOCHEM,STONY BROOK,NY 11794	Marine Biological Laboratory - Woods Hole; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Armstrong, PB (corresponding author), UNIV CALIF DAVIS,DEPT MOLEC & CELLULAR BIOL,DAVIS,CA 95616, USA.			Armstrong, Peter/0000-0001-5197-1999				ARMSTRONG PB, 1993, MOL IMMUNOL, V30, P929, DOI 10.1016/0161-5890(93)90017-6; ARMSTRONG PB, 1985, BLOOD CELLS MARINE I, P253; BERTHEUSSEN K, 1983, DEV COMP IMMUNOL, V7, P21, DOI 10.1016/0145-305X(83)90051-4; BERTHEUSSEN K, 1982, DEV COMP IMMUNOL, V6, P635; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; CANICATTI C, 1990, EXPERIENTIA, V46, P239, DOI 10.1007/BF01951753; DAY N, 1972, J IMMUNOL, V109, P164; DAY NKB, 1970, J EXP MED, V132, P941, DOI 10.1084/jem.132.5.941; DEUTCHER MP, 1990, GUIDE PROTEIN PURIFI, P609; DRICKAMER K, 1993, ANNU REV CELL BIOL, V9, P237, DOI 10.1146/annurev.cb.09.110193.001321; ENGHILD JJ, 1990, BIOCHEMISTRY-US, V29, P10070, DOI 10.1021/bi00495a009; FEARON DT, 1978, P NATL ACAD SCI USA, V75, P1971, DOI 10.1073/pnas.75.4.1971; GEE AP, 1983, METHOD ENZYMOL, V93, P339; JIANG HX, 1991, J IMMUNOL, V146, P2324; Kabat EA, 1961, EXPT IMMUNOHISTOCHEM, P133; Kehoe J.M., 1986, P345; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW SKA, 1988, COMPLEMENT; MANDAL C, 1990, EXPERIENTIA, V46, P433, DOI 10.1007/BF01954221; MARCHALONIS JJ, 1968, J MOL BIOL, V32, P453, DOI 10.1016/0022-2836(68)90022-3; MARCHALONIS JJ, 1990, BIOSCIENCE, V40, P758, DOI 10.2307/1311509; MIYAZAWA K, 1990, J IMMUNOL, V145, P650; NGUYEN NY, 1986, J BIOL CHEM, V261, P456; NGUYEN NY, 1986, J BIOL CHEM, V261, P450; NOGUCHI H, 1903, ZBL BACTERIOL PARASI, V33, P353; PEPYS MB, 1983, ADV IMMUNOL, V34, P141, DOI 10.1016/S0065-2776(08)60379-X; QUIGLEY JP, 1983, J BIOL CHEM, V258, P7903; ROBEY FA, 1981, J BIOL CHEM, V256, P969; SARKAR M, 1981, ARCH BIOCHEM BIOPHYS, V209, P204, DOI 10.1016/0003-9861(81)90273-3; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SIM RB, 1981, METHOD ENZYMOL, V80, P6; SMITH LC, 1994, ANN NY ACAD SCI, V712, P213, DOI 10.1111/j.1749-6632.1994.tb33575.x; STOCKERT RJ, 1974, SCIENCE, V186, P365, DOI 10.1126/science.186.4161.365; TENNENT GA, 1994, BIOCHEM SOC T, V22, P74, DOI 10.1042/bst0220074; TENNENT GA, 1993, EUR J BIOCHEM, V214, P91, DOI 10.1111/j.1432-1033.1993.tb17900.x; VASTA GR, 1992, GLYCOCONJUGATES COMP, P593; WARREN L, 1959, J BIOL CHEM, V234, P1971; WRIGHT SD, 1993, CURR OPIN IMMUNOL, V5, P57, DOI 10.1016/0952-7915(93)90081-3; ZENG FY, 1992, Z NATURFORSCH C, V47, P641	40	77	79	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14717	14721		10.1074/jbc.271.25.14717	http://dx.doi.org/10.1074/jbc.271.25.14717			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662968	hybrid			2022-12-27	WOS:A1996UT10600015
J	Kurosawa, N; Inoue, M; Yoshida, Y; Tsuji, S				Kurosawa, N; Inoue, M; Yoshida, Y; Tsuji, S			Molecular cloning and genomic analysis of mouse Gal beta 1,3GalNAc-specific GalNAc alpha 2,6-sialyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; SIALYLTRANSFERASE GENE FAMILY; GAL-BETA-1,3(4)GLCNAC ALPHA-2,3-SIALYLTRANSFERASE; TRANSCRIPTION FACTORS; BINDING PROTEIN; EXPRESSION; SEQUENCE; ALPHA-2,6-SIALYTRANSFERASE; ORGANIZATION; PROMOTER	cDNA and genomic clones encoding mouse Gal beta 1, 3GalNAc-specific GalNAc alpha 2,6-sialyltransferase (ST6GalNAc II) were isolated, and the structure organization of the gene was determined, The predicted amino acid sequence is 57.4% identical to the chick ST6GalNAc II sequence but 33.8% identical to the chick STG6alNA I (GalNAc alpha 2,6-sialyltransferase) sequence. The ST6GalNAc II gene is constitutively expressed in various mouse tissues but highly expressed in lactating mammary gland and adult testis. The gene contains nine exons spanning about 25 kilobases of genomic DNA and encodes a messenger RNA of 1995 nucleotides. Primer extension and S1 nuclease protection analysis of submaxillary gland mRNA showed that the transcription of the ST6GalNAc II gene starts from 68 nucleotides upstream from the translation start site, Characterization of 5'-flanking genomic regions indicated that the Gal beta 1,3GalNAc-specific GalNAc alpha 2,6-sialyltransferase promoter is embedded in a G + C rich domain and contains no TATA or CAAT box but has putative binding sites for transcription factors Sp1 and AP-2. Transient transfection experiments involving luciferase reporter genes demonstrated promoter activity in NIH3T3 cells.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,DEPT MOL GLYCOBIOL,WAKO,SAITAMA 35101,JAPAN	RIKEN				Kurosawa, Nobuyuki/0000-0002-1548-4541				AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; Ausubel FM, 1988, MOL REPROD DEV; BIRD AP, 1986, NATURE, V321, P209, DOI 10.1038/321209a0; BIRNSTIEL ML, 1985, CELL, V41, P349, DOI 10.1016/S0092-8674(85)80007-6; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DAVISON BL, 1983, NATURE, V301, P680, DOI 10.1038/301680a0; DYNAN WS, 1986, NATURE, V319, P246, DOI 10.1038/319246a0; ECKHARDT M, 1995, NATURE, V373, P715, DOI 10.1038/373715a0; FROTHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; GRUNDMANN U, 1990, NUCLEIC ACIDS RES, V18, P667, DOI 10.1093/nar/18.3.667; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HARDUINLEPERS A, 1992, GLYCOBIOLOGY, V2, P361, DOI 10.1093/glycob/2.4.361; HARDUINLEPERS A, 1993, J BIOL CHEM, V268, P14384; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1993, BIOCHEM BIOPH RES CO, V194, P375, DOI 10.1006/bbrc.1993.1830; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KOJIMA N, 1995, FEBS LETT, V360, P1, DOI 10.1016/0014-5793(95)00059-I; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1995, BBA-GEN SUBJECTS, V1244, P216, DOI 10.1016/0304-4165(95)00012-Z; KUROSAWA N, 1994, EUR J BIOCHEM, V219, P375, DOI 10.1111/j.1432-1033.1994.tb19949.x; LEE YC, 1993, EUR J BIOCHEM, V216, P377, DOI 10.1111/j.1432-1033.1993.tb18155.x; LEE YC, 1994, J BIOL CHEM, V269, P10028; LIN YS, 1988, P NATL ACAD SCI USA, V85, P3396, DOI 10.1073/pnas.85.10.3396; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; MCLAUCHLAN J, 1985, NUCLEIC ACIDS RES, V13, P1347, DOI 10.1093/nar/13.4.1347; MITCHELL PJ, 1987, CELL, V50, P847, DOI 10.1016/0092-8674(87)90512-5; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; SAITOH O, 1991, CANCER RES, V41, P2854; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SASAKI K, 1993, J BIOL CHEM, V268, P22782; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; SHARP PA, 1992, CELL, V68, P819, DOI 10.1016/0092-8674(92)90023-6; SPIRO RG, 1974, J BIOL CHEM, V249, P5704; SVENSSON EC, 1992, J BIOL CHEM, V267, P3466; SVENSSON EC, 1990, J BIOL CHEM, V265, P20863; TAZI J, 1990, CELL, V60, P909, DOI 10.1016/0092-8674(90)90339-G; TSUJI T, 1986, CARBOHYD RES, V151, P391, DOI 10.1016/S0008-6215(00)90358-6; WANG X, 1990, Glycobiology, V1, P25, DOI 10.1093/glycob/1.1.25; WANG XC, 1993, J BIOL CHEM, V268, P4355; WEINSTEIN J, 1987, J BIOL CHEM, V262, P17735; WEN DX, 1992, J BIOL CHEM, V267, P21011; WEN DX, 1992, J BIOL CHEM, V267, P2512; WESTON BW, 1992, J BIOL CHEM, V267, P24575; YOSHIDA Y, 1995, J BIOCHEM-TOKYO, V118, P658, DOI 10.1093/oxfordjournals.jbchem.a124960; YOSHIDA Y, 1995, J BIOL CHEM, V270, P14628, DOI 10.1074/jbc.270.24.14628	52	56	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15109	15116		10.1074/jbc.271.25.15109	http://dx.doi.org/10.1074/jbc.271.25.15109			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662927	hybrid			2022-12-27	WOS:A1996UT10600069
J	Song, KS; Scherer, PE; Tang, ZL; Okamoto, T; Li, SW; Chafel, M; Chu, C; Kohtz, DS; Lisanti, MP				Song, KS; Scherer, PE; Tang, ZL; Okamoto, T; Li, SW; Chafel, M; Chu, C; Kohtz, DS; Lisanti, MP			Expression of caveolin-3 in skeletal, cardiac, and smooth muscle cells - Caveolin-3 is a component of the sarcolemma and co-fractionates with dystrophin and dystrophin-associated glycoproteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ROUS-SARCOMA VIRUS; PLASMA-MEMBRANE; MUSCULAR-DYSTROPHY; PROTEIN-COMPONENT; COMPLEX; PHOSPHORYLATION; DIFFERENTIATION; VESICLES; TYROSINE; SEQUENCE	Caveolae are microdomains of the plasma membrane that have been implicated in signal transduction, Caveolin, a 21-24-kDa integral membrane protein, is a principal component of the caveolae membrane, Recently, we and others have identified a family of caveolin-related proteins; caveolin has been retermed caveolin-1. Caveolin-3 is most closely related to caveolin-1, but caveolin-3 mRNA is expressed only in muscle tissue types, Here, we examine (i) the expression of caveolin-3 protein in muscle tissue types and (ii) its localization within skeletal muscle fibers by immunofluorescence microscopy and subcellular fractionation, For this purpose, we generated a novel monoclonal antibody (mAb) probe that recognizes the unique N-terminal region of caveolin-3, but not other members of the caveolin gene family, A survey of tissues and muscle cell types by Western blot analysis reveals that the caveolin 3 protein is selectively expressed only in heart and skeletal muscle tissues, cardiac myocytes, and smooth muscle cells, Immunolocalization of caveolin-3 in skeletal muscle fibers demonstrates that caveolin-3 is localized to the sarcolemma (muscle cell plasma membrane) and coincides with the distribution of another muscle-specific plasma membrane marker protein, dystrophin, In addition, caveolin-3 protein expression is dramatically induced during the differentiation of C2C12 skeletal myoblasts in culture, Using differentiated C2C12 skeletal myoblasts as a model system, we observe that caveolin-3 co-fractionates with cytoplasmic signaling molecules (G-proteins and Src-like kinases) and members of the dystrophin complex (dystrophin, alpha-sarcoglycan, and beta-dystroglycan), but is clearly separated from the bulk of cellular proteins. Caveolin-3 co-immunoprecipitates with antibodies directed against dystrophin, suggesting that they are physically associated as a discrete complex. These results are consistent with previous immunoelectron microscopic studies demonstrating that dystrophin is localized to plasma membrane caveolae in smooth muscle cells.	WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; HARVARD UNIV, MASSACHUSETTS GEN HOSP, SHRINERS HOSP CRIPPLED CHILDREN,SCH MED, DEPT ANESTHESIA, BOSTON, MA 02114 USA; MT SINAI SCH MED, DEPT PATHOL, NEW YORK, NY 10029 USA	Massachusetts Institute of Technology (MIT); Whitehead Institute; Harvard University; Harvard Medical School; Massachusetts General Hospital; Icahn School of Medicine at Mount Sinai			Lisanti, Michael/B-6131-2018; Lisanti, Michael P/C-6866-2013; Scherer, Philipp E/K-7819-2012; Li, Shengwen Calvin/H-1725-2012	Lisanti, Michael/0000-0003-2034-1382; Scherer, Philipp E/0000-0003-0680-3392; Li, Shengwen Calvin/0000-0002-9699-9204	NCI NIH HHS [CA071326, F32 CA071326] Funding Source: Medline; NIGMS NIH HHS [GM-50443] Funding Source: Medline; NATIONAL CANCER INSTITUTE [F32CA071326] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM050443] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Anderson RGW, 1993, CURR OPIN CELL BIOL, V5, P647, DOI 10.1016/0955-0674(93)90135-D; BLAU HM, 1983, CELL, V32, P1171, DOI 10.1016/0092-8674(83)90300-8; BONILLA E, 1981, AM J PATHOL, V104, P167; CHANG WJ, 1994, J CELL BIOL, V126, P127, DOI 10.1083/jcb.126.1.127; COLE F, 1993, J BIOL CHEM, V268, P1580; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERVASTI JM, 1991, CELL, V66, P1121, DOI 10.1016/0092-8674(91)90035-W; FAN JY, 1983, J CELL SCI, V61, P219; FRA AM, 1995, P NATL ACAD SCI USA, V92, P8655, DOI 10.1073/pnas.92.19.8655; GLENNEY JR, 1992, P NATL ACAD SCI USA, V89, P10517, DOI 10.1073/pnas.89.21.10517; GLENNEY JR, 1989, J BIOL CHEM, V264, P20163; GLENNEY JR, 1992, FEBS LETT, V314, P45, DOI 10.1016/0014-5793(92)81458-X; GRAVES LM, 1995, P NATL ACAD SCI USA, V92, P7222, DOI 10.1073/pnas.92.16.7222; HARLOW E, 1988, ANTIBIOTICS LAB MANU; HOFFMAN EP, 1989, NEURON, V2, P1019, DOI 10.1016/0896-6273(89)90226-2; KOLESKE AJ, 1995, P NATL ACAD SCI USA, V92, P1381, DOI 10.1073/pnas.92.5.1381; Li SW, 1996, J BIOL CHEM, V271, P568, DOI 10.1074/jbc.271.1.568; LI SW, 1995, J BIOL CHEM, V270, P15693, DOI 10.1074/jbc.270.26.15693; Lisanti Michael P., 1995, Seminars in Developmental Biology, V6, P47, DOI 10.1016/S1044-5781(06)80084-8; Lisanti Michael P., 1994, Trends in Cell Biology, V4, P231, DOI 10.1016/0962-8924(94)90114-7; LISANTI MP, 1995, METHOD ENZYMOL, V250, P655; LISANTI MP, 1993, J CELL BIOL, V123, P595, DOI 10.1083/jcb.123.3.595; LISANTI MP, 1994, J CELL BIOL, V126, P111, DOI 10.1083/jcb.126.1.111; MONIER S, 1995, MOL BIOL CELL, V6, P911, DOI 10.1091/mbc.6.7.911; MURATA M, 1995, P NATL ACAD SCI USA, V92, P10339, DOI 10.1073/pnas.92.22.10339; NORTH AJ, 1993, J CELL BIOL, V120, P1159, DOI 10.1083/jcb.120.5.1159; ROBBINS SM, 1995, MOL CELL BIOL, V15, P3507; ROTHBERG KG, 1992, CELL, V68, P673, DOI 10.1016/0092-8674(92)90143-Z; SARGIACOMO M, 1995, P NATL ACAD SCI USA, V92, P9407, DOI 10.1073/pnas.92.20.9407; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; Scherer PE, 1996, P NATL ACAD SCI USA, V93, P131, DOI 10.1073/pnas.93.1.131; SCHERER PE, 1994, J CELL BIOL, V127, P1233, DOI 10.1083/jcb.127.5.1233; SCHERER PE, 1995, J BIOL CHEM, V270, P16395, DOI 10.1074/jbc.270.27.16395; SCHNITZER JE, 1995, J BIOL CHEM, V270, P14399, DOI 10.1074/jbc.270.24.14399; SEED B, 1987, P NATL ACAD SCI USA, V84, P3365, DOI 10.1073/pnas.84.10.3365; SEVERS NJ, 1988, J CELL SCI, V90, P341; SIMIONESCU N, 1975, J CELL BIOL, V64, P586, DOI 10.1083/jcb.64.3.586; SMART EJ, 1995, P NATL ACAD SCI USA, V92, P10104, DOI 10.1073/pnas.92.22.10104; SMART EJ, 1995, J CELL BIOL, V131, P929, DOI 10.1083/jcb.131.4.929; Song KS, 1996, J BIOL CHEM, V271, P9690, DOI 10.1074/jbc.271.16.9690; SPRINGHORN JP, 1992, J BIOL CHEM, V267, P14360; Tang ZL, 1996, J BIOL CHEM, V271, P2255, DOI 10.1074/jbc.271.4.2255; TANG ZL, 1994, GENE, V147, P299, DOI 10.1016/0378-1119(94)90087-6; WAY M, 1995, FEBS LETT, V376, P108, DOI 10.1016/0014-5793(95)01256-7; WORTON R, 1995, SCIENCE, V270, P755, DOI 10.1126/science.270.5237.755	45	585	594	1	20	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15160	15165		10.1074/jbc.271.25.15160	http://dx.doi.org/10.1074/jbc.271.25.15160			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663016	hybrid			2022-12-27	WOS:A1996UT10600076
J	Fukuda, R; Umebayashi, K; Horiuchi, H; Ohta, A; Takagi, M				Fukuda, R; Umebayashi, K; Horiuchi, H; Ohta, A; Takagi, M			Degradation of Rhizopus niveus aspartic proteinase-I with mutated prosequences occurs in the endoplasmic reticulum of Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST; PATHWAY; LOCALIZATION; TRANSPORT; MEMBRANE	Rhizopus niveus aspartic proteinase-I (RNAP-I) is secreted by Saccharomyces cerevisiae extracellularly (Horiuchi, H., Ashikari, T., Amachi, T., Yoshizumi, H., Takagi, M., and Yano, K. (1990) Agric. Biol. Chem. 54, 1771-1779). The prosequence of RNAP-I has the function to promote correct folding of its mature part. Deletion (Delta pro) and amino acid substitutions (M1) in the prosequence block secretion of RNAP-I (Fukuda, R., Horiuchi, H., Ohta, A., and Takagi, M. (1994) J. Biol. Chem. 269, 9556-9561). In this study, little accumulation of Delta pro was observed in Western blot analysis of the cell extracts of the transformants producing Delta pro using anti-RNAP-I antisera. In contrast, M1 was accumulated in the yeast cells. Pulse-chase analysis revealed that they were synthesized at almost the same rates and that Delta pro was degraded in the cells more rapidly than M1. In subcellular fractionation analysis, Delta pro was found in the fraction that contained most of the activity of an endoplasmic reticulum (ER) marker enzyme, NADPH-cytochrome c reductase. In indirect immunofluorescence microscopy, Delta pro was observed in the ER. Similar result was also observed in a mutant which is deficient of the two vacuolar proteases, proteinase A and proteinase B. So, the vacuolar proteases are not involved in degradation of Delta pro. From these results, we concluded that RNAP-Is with the mutated prosequences, which probably could not be folded correctly, were retained and degraded in the ER.	UNIV TOKYO, DEPT BIOTECHNOL, BUNKYO KU, TOKYO 113, JAPAN	University of Tokyo								BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BORDALLO C, 1984, FEBS LETT, V173, P199, DOI 10.1016/0014-5793(84)81046-7; FINGER A, 1993, EUR J BIOCHEM, V218, P565, DOI 10.1111/j.1432-1033.1993.tb18410.x; FRANZUSOFF A, 1991, METHOD ENZYMOL, V194, P662; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; Gaut JR, 1993, CURR OPIN CELL BIOL, V5, P589, DOI 10.1016/0955-0674(93)90127-C; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Halvorson H., 1966, METHODS ENZYMOL, V8, P559, DOI [10.1016/0076-6879(66)08101-1, DOI 10.1016/0076-6879(66)08101-1]; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HILL KJ, 1994, MOL BIOL CELL, V5, P1039, DOI 10.1091/mbc.5.9.1039; HORIUCHI H, 1988, J BACTERIOL, V170, P272, DOI 10.1128/jb.170.1.272-278.1988; HORIUCHI H, 1990, AGR BIOL CHEM TOKYO, V54, P1771, DOI 10.1080/00021369.1990.10870223; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JONES EW, 1991, J BIOL CHEM, V266, P7963; KLIONSKY DJ, 1990, MICROBIOL REV, V54, P266, DOI 10.1128/MMBR.54.3.266-292.1990; KUBOTA S, 1977, J BIOCHEM-TOKYO, V81, P197, DOI 10.1093/oxfordjournals.jbchem.a131436; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MCCRACKEN AA, 1993, MOL BIOL CELL, V4, P729, DOI 10.1091/mbc.4.7.729; NAKANO A, 1988, J CELL BIOL, V107, P851, DOI 10.1083/jcb.107.3.851; PREUSS D, 1991, YEAST, V7, P891, DOI 10.1002/yea.320070902; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; Sakaguchi K, 1992, APPL MOL GENETICS FI, P54; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; WADA Y, 1992, J BIOL CHEM, V267, P18665; YAFFE MP, 1984, P NATL ACAD SCI-BIOL, V81, P4819, DOI 10.1073/pnas.81.15.4819	26	8	9	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14252	14255		10.1074/jbc.271.24.14252	http://dx.doi.org/10.1074/jbc.271.24.14252			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662920	hybrid			2022-12-27	WOS:A1996UQ66000049
J	Monia, BP; Johnston, JF; Sasmor, H; Cummins, LL				Monia, BP; Johnston, JF; Sasmor, H; Cummins, LL			Nuclease resistance and antisense activity of modified oligonucleotides targeted to Ha-ras	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLADDER-CARCINOMA ONCOGENE; XENOPUS OOCYTES; OLIGODEOXYNUCLEOTIDES; DEGRADATION; STABILITY; RNA; PHOSPHOROTHIOATES; EXPRESSION; PROBES; SERUM	We have previously described structure-activity studies on a 17-mer uniform phosphorothioate antisense sequence targeted to human Ha-ras. In an effort to further improve the pharmacological properties of antisense oligonucleotides, structure-activity studies on this 17-mer sequence were expanded to examine both the effects of replacing phosphorothioate backbone linkages with phosphodiester linkages and the effects of incorporating various 2'-sugar modifications into phosphorothioate and phosphodiester oligonucleotides on oligonucleotide stability against nucleases in vitro and on antisense activity in cells. Replacement of three or more phosphorothioate Linkages with phosphodiester linkages greatly compromised both nuclease resistance and antisense activity, and these effects correlated directly with the number of phosphodiester linkages incorporated into the oligonucleotide. However, substantial nuclease resistance, sufficient for obtaining potent antisense effects in cells, was conferred to phosphodiester oligonucleotides by incorporation of appropriate 2'-alkoxy sugar modifications. Nuclease stability and antisense activity imparted by these sugar modifications in phosphodiester backbones correlated with the size of the 2'-alkoxy substituent (pentoxy > propoxy > methoxy > deoxy). Furthermore, antisense activity mediated by oligonucleotides that exhibit partial resistance to nucleolytic degradation was dependent on both oligonucleotide concentration and the duration of oligonucleotide treatment.	ISIS PHARMACEUT,DIV MED CHEM,CARLSBAD,CA 92008	Isis Pharmaceuticals Inc	Monia, BP (corresponding author), ISIS PHARMACEUT,DEPT MOLEC PHARMACOL,2292 FARADAY AVE,CARLSBAD,CA 92008, USA.							AGRAWAL S, 1991, P NATL ACAD SCI USA, V88, P7595, DOI 10.1073/pnas.88.17.7595; AGRAWAL S, 1995, BIOCHEM PHARMACOL, V50, P571, DOI 10.1016/0006-2952(95)00160-2; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; BACON TA, 1988, J BIOCHEM BIOPH METH, V16, P311, DOI 10.1016/0165-022X(88)90065-6; CAZENAVE C, 1987, NUCLEIC ACIDS RES, V15, P10507, DOI 10.1093/nar/15.24.10507; Cook P.D., 1993, ANTISENSE RES APPL, P149; COOK PD, 1991, ANTI-CANCER DRUG DES, V6, P585; CORNISH KG, 1993, PHARM COMMUN, V3, P239; CROOKE RM, 1995, J PHARMACOL EXP THER, V275, P462; Crooke S. T., 1995, THERAPEUTIC APPL OLI, P63; CROOKE ST, 1995, BIOCHEM J, V312, P599, DOI 10.1042/bj3120599; CROOKE ST, 1996, IN PRESS J PHARM EXP; CUMMINS LL, 1995, NUCLEIC ACIDS RES, V23, P2019, DOI 10.1093/nar/23.11.2019; DEAN NM, 1994, J BIOL CHEM, V269, P16416; ECKSTEIN F, 1985, ANNU REV BIOCHEM, V54, P367, DOI 10.1146/annurev.bi.54.070185.002055; FISHER TL, 1993, NUCLEIC ACIDS RES, V21, P3857, DOI 10.1093/nar/21.16.3857; GALBRAITH WM, 1994, ANTISENSE RES DEV, V4, P201, DOI 10.1089/ard.1994.4.201; GAO WY, 1991, MOL PHARMACOL, V41, P223; GUINOSSO CJ, 1991, NUCLEOS NUCLEOT, V10, P259, DOI 10.1080/07328319108046455; GUVAKOVA MA, 1995, J BIOL CHEM, V270, P2620, DOI 10.1074/jbc.270.6.2620; HOKE GD, 1991, NUCLEIC ACIDS RES, V19, P5743, DOI 10.1093/nar/19.20.5743; IRIBARREN AM, 1990, P NATL ACAD SCI USA, V87, P7747, DOI 10.1073/pnas.87.19.7747; KAWASAKI AM, 1993, J MED CHEM, V36, P831, DOI 10.1021/jm00059a007; LINN SM, 1993, NUCLEASES, P1; MONIA BP, 1992, J BIOL CHEM, V267, P19954; MONIA BP, 1993, J BIOL CHEM, V268, P14514; MORVAN F, 1987, NUCLEIC ACIDS RES, V15, P3421, DOI 10.1093/nar/15.8.3421; PERBOST M, 1989, BIOCHEM BIOPH RES CO, V165, P742, DOI 10.1016/S0006-291X(89)80029-4; PISETSKY DS, 1994, LIFE SCI, V54, P101, DOI 10.1016/0024-3205(94)00780-2; REDDY EP, 1983, SCIENCE, V220, P1061, DOI 10.1126/science.6844927; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; SHAW JP, 1991, NUCLEIC ACIDS RES, V19, P747, DOI 10.1093/nar/19.4.747; SPROAT BS, 1989, NUCLEIC ACIDS RES, V17, P3373, DOI 10.1093/nar/17.9.3373; STEIN CA, 1988, NUCLEIC ACIDS RES, V16, P3209, DOI 10.1093/nar/16.8.3209; TIDD DM, 1989, BRIT J CANCER, V60, P343, DOI 10.1038/bjc.1989.283; WOOLF TM, 1990, NUCLEIC ACIDS RES, V18, P1763, DOI 10.1093/nar/18.7.1763	36	130	153	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14533	14540		10.1074/jbc.271.24.14533	http://dx.doi.org/10.1074/jbc.271.24.14533			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662854	hybrid			2022-12-27	WOS:A1996UQ66000088
J	Reddy, A; Maley, F				Reddy, A; Maley, F			Studies on identifying the catalytic role of Glu-204 in the active site of yeast invertase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-SEQUENCE SIMILARITIES; MESSENGER-RNAS; EXTERNAL INVERTASE; BETA-FRUCTOSIDASE; SIGNAL SEQUENCE; GENE; CLASSIFICATION; SCRB	In a previous study on yeast invertase (Reddy, A., and Maley, F. (1990) J. Biol, Chem. 265, 10817-10820), we identified Asp-23 through the procedures of affinity labeling and site-directed mutagenesis as a catalytic nucleophile, In the present study we undertook to determine other residues involved in the catalytic process. Earlier studies suggested histidine as a potential proton donor in the hydrolysis of sucrose, but by mutagenizing each of the enzyme's four histidines this amino acid was eliminated from consideration. Another candidate appeared to be cysteine, since iodine at about a S-fold molar excess inactivated invertase by modifying both of the enzyme's cysteine residues. Dithiothreitol treatment restored the sulfhydryl groups and enzyme activity, Replacement of each of the cysteines with alanines revealed that C108A invertase retained full activity whereas C205A was reduced about 4-fold in its k(cat). A comparison of the amino acid sequences of fructosylhydrolases revealed a conserved region coincident with Glu-204/Cys-205, Mutagenizing Glu-204 to Ala resulted in a 3,000-fold reduction in the k(cat) of invertase indicating that Glu-204 plays a major role in catalysis. Based on these findings, a mechanism is proposed for the hydrolysis of sucrose which involves Asp-23 as a nucleophile and Glu-204 as an acid/base catalyst.			Reddy, A (corresponding author), NEW YORK STATE DEPT HLTH,WADSWORTH CTR,BOX 509,ALBANY,NY 12201, USA.				NATIONAL CANCER INSTITUTE [R35CA044355] Funding Source: NIH RePORTER; NCI NIH HHS [CA44355] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		[Anonymous], ENZYMES 2E; BETTS L, 1994, J MOL BIOL, V235, P635, DOI 10.1006/jmbi.1994.1018; BRAUN H, 1977, BIOCHIM BIOPHYS ACTA, V485, P141, DOI 10.1016/0005-2744(77)90201-7; BRAUN H, 1976, BIOCHIM BIOPHYS ACTA, V452, P452, DOI 10.1016/0005-2744(76)90195-9; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; CARLSON M, 1983, MOL CELL BIOL, V3, P439, DOI 10.1128/MCB.3.3.439; CHU FK, 1983, ARCH BIOCHEM BIOPHYS, V223, P543, DOI 10.1016/0003-9861(83)90619-7; CLAIBORNE A, 1993, FASEB J, V7, P1483, DOI 10.1096/fasebj.7.15.8262333; DAVIES G, 1995, STRUCTURE, V3, P853, DOI 10.1016/S0969-2126(01)00220-9; DAVOODI J, 1995, EUR J BIOCHEM, V232, P839, DOI 10.1111/j.1432-1033.1995.tb20881.x; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; GASCON S, 1968, J BIOL CHEM, V243, P1573; Goldstein A, 1975, Methods Enzymol, V42, P504; HENRISSAT B, 1991, BIOCHEM J, V280, P309, DOI 10.1042/bj2800309; HENRISSAT B, 1993, BIOCHEM J, V293, P781, DOI 10.1042/bj2930781; IZZO JL, 1964, J BIOL CHEM, V239, P3743; JENKINS J, 1995, FEBS LETT, V362, P281, DOI 10.1016/0014-5793(95)00252-5; KERESZTESSY Z, 1994, ARCH BIOCHEM BIOPHYS, V315, P323, DOI 10.1006/abbi.1994.1507; KOSHLAND DE, 1954, J BIOL CHEM, V208, P139; KURAMITSU S, 1974, J BIOCHEM, V76, P671; KUROKI R, 1995, NAT STRUCT BIOL, V2, P1007, DOI 10.1038/nsb1195-1007; LESKOVAC V, 1975, BIOCHIM BIOPHYS ACTA, V405, P482, DOI 10.1016/0005-2795(75)90113-0; MCCARTER JD, 1994, CURR OPIN STRUC BIOL, V4, P885, DOI 10.1016/0959-440X(94)90271-2; PERLMAN D, 1981, CELL, V25, P525, DOI 10.1016/0092-8674(81)90071-4; PERLMAN D, 1982, P NATL ACAD SCI-BIOL, V79, P781, DOI 10.1073/pnas.79.3.781; RAO VH, 1995, STRUCTURE, V3, P449, DOI 10.1016/S0969-2126(01)00178-2; REDDY A, 1993, ANAL BIOCHEM, V208, P211, DOI 10.1006/abio.1993.1031; REDDY AV, 1990, BIOCHEMISTRY-US, V29, P2482, DOI 10.1021/bi00462a007; REDDY VA, 1988, J BIOL CHEM, V263, P6978; REDDY VA, 1990, J BIOL CHEM, V265, P10817; SATO Y, 1988, INFECT IMMUN, V56, P1956, DOI 10.1128/IAI.56.8.1956-1960.1988; SCHOLLE RR, 1989, GENE, V80, P49, DOI 10.1016/0378-1119(89)90249-7; SHOMI N, 1988, AGR BIOL CHEM TOKYO, V52, P2347; SINNOTT ML, 1990, CHEM REV, V90, P1171, DOI 10.1021/cr00105a006; TANG LB, 1990, GENE, V96, P89, DOI 10.1016/0378-1119(90)90345-R; VANROEY P, 1994, BIOCHEMISTRY-US, V33, P13989, DOI 10.1021/bi00251a005; VONEULER H, 1923, Z PHYSL CHEM, V127, P99; WAHEED A, 1971, BIOCHIM BIOPHYS ACTA, V242, P172, DOI 10.1016/0005-2744(71)90097-0; WANG Q, 1995, J AM CHEM SOC, V117, P10138; White A, 1996, NAT STRUCT BIOL, V3, P149, DOI 10.1038/nsb0296-149; WILLIAMS RS, 1985, J BIOL CHEM, V260, P3334; WILSON DK, 1991, SCIENCE, V252, P1278, DOI 10.1126/science.1925539	42	121	127	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13953	13958		10.1074/jbc.271.24.13953	http://dx.doi.org/10.1074/jbc.271.24.13953			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662946	hybrid			2022-12-27	WOS:A1996UQ66000007
J	Zhuang, P; Blackburn, MN; Peterson, CB				Zhuang, P; Blackburn, MN; Peterson, CB			Characterization of the denaturation and renaturation of human plasma vitronectin .1. Biophysical characterization of protein unfolding and multimerization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLASMINOGEN-ACTIVATOR INHIBITOR-1; RECEPTOR-MEDIATED ENDOCYTOSIS; S-PROTEIN; ANTITHROMBIN-III; ALPHA-THROMBIN; HEPARIN; COMPLEMENT; BINDING; CLEAVAGE; UREA	Upon treatment with denaturing agents, vitronectin has been observed to exhibit conformational alterations which are similar to the structural changes detected when vitronectin binds the thrombin-antithrombin complex or associates with the terminal attack complex of complement. Denaturation and renaturation of vitronectin isolated from human plasma were characterized by changes in intrinsic fluorescence. Unfolding by chemical denaturants was irreversible and accompanied by self-association of the protein to form vitronectin multimers. Self-association was evaluated by equilibrium analytical ultracentrifugation which demonstrated that multimers form only during the refolding process after removal of denaturant, that multimeric vitronectin dissociates to constituent subunits readily upon treatment with chemical denaturant, and that intermolecular disulfide crosslinking occurs primarily at the dimer level among a subset of constituent vitronectin subunits within the multimer. The monomeric form of vitronectin isolated from human plasma partially unfolds at intermediate concentrations of denaturant to an altered conformation with a high propensity to associate into multimers. Folding of vitronectin in vivo appears to be regulated by partitioning of folding intermediates toward either of two conformations, one that exists as a stable monomer and another that associates into a multimeric form.	UNIV TENNESSEE, DEPT BIOCHEM & CELLULAR & MOLEC BIOL, KNOXVILLE, TN 37996 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT MACROMOLEC SCI, KING OF PRUSSIA, PA 19406 USA	University of Tennessee System; University of Tennessee Knoxville; GlaxoSmithKline					NHLBI NIH HHS [HL50676] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050676, R29HL050676] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BROOKS I, 1994, METHOD ENZYMOL, V240, P459; BROOKS I, 1994, MODERN ANAL ULTRACEN, P15; CHAIN D, 1991, BIOCHEM J, V274, P387, DOI 10.1042/bj2740387; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; GEBB C, 1986, J BIOL CHEM, V261, P6698; GECHTMAN Z, 1993, FEBS LETT, V315, P293, DOI 10.1016/0014-5793(93)81181-X; HILDEBRAND A, 1989, J BIOL CHEM, V264, P15429; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; KAWAHARA K, 1966, J BIOL CHEM, V241, P3228; KOLB WP, 1975, J EXP MED, V141, P724; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lakowicz J.R., 2010, PRINCIPLE FLUORESCEN, DOI 10.1007/978-0-387-46312-4/COVER; MUNSON M, 1994, PROTEIN SCI, V3, P2015, DOI 10.1002/pro.5560031114; NASKI MC, 1993, J BIOL CHEM, V268, P12367; NEET KE, 1994, J PROETIN SCI, V3, P2167; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PANETTI TS, 1993, J BIOL CHEM, V268, P11492; PANETTI TS, 1993, J BIOL CHEM, V268, P11988; PETERSON CB, 1993, INT CONGR SER, V1042, P67; PITT WG, 1989, J COLLOID INTERF SCI, V129, P231, DOI 10.1016/0021-9797(89)90435-9; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1990, J BIOL CHEM, V265, P18490; PREISSNER KT, 1991, ANNU REV CELL BIOL, V7, P275, DOI 10.1146/annurev.cellbio.7.1.275; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1986, EUR J BIOCHEM, V156, P645, DOI 10.1111/j.1432-1033.1986.tb09626.x; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P189; ROYER CA, 1993, PROTEIN SCI, V2, P1844, DOI 10.1002/pro.5560021106; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1994, J BIOL CHEM, V269, P19836; STEIF C, 1993, BIOCHEMISTRY-US, V32, P3867, DOI 10.1021/bi00066a005; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; WEI Y, 1994, J BIOL CHEM, V269, P32380; YATOHGO T, 1988, CELL STRUCT FUNCT, V13, P281, DOI 10.1247/csf1975.13.281; ZANETTI A, 1994, BLOOD, V84, P1116, DOI 10.1182/blood.V84.4.1116.bloodjournal8441116; Zhuang P, 1996, J BIOL CHEM, V271, P14333, DOI 10.1074/jbc.271.24.14333	40	38	41	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14323	14332		10.1074/jbc.271.24.14323	http://dx.doi.org/10.1074/jbc.271.24.14323			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663084	hybrid			2022-12-27	WOS:A1996UQ66000060
J	Hutchcroft, JE; Tsai, B; Bierer, BE				Hutchcroft, JE; Tsai, B; Bierer, BE			Differential phosphorylation of the T lymphocyte costimulatory receptor CD28 - Activation-dependent changes and regulation by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; TYROSINE KINASE; RESPONSES; ANTIGEN; CELLS	Treatment of T lymphocytes with phorbol ester and anti-CD28 monoclonal antibody (mAb) can induce proliferation and interleukin 2 production by triggering still undefined intracellular signaling pathways. We have developed a deglycosylation procedure that allows the precise identification of a distinct CD28 protein band, facilitating the analysis of activation-dependent changes in the phosphorylation state of CD28. Phorbol 12-myristate 13-acetate (PMA) treatment induced the in vitro phosphorylation of CD28 on threonine as detected in immune complex kinase assays. This effect of PMA was (i) rapid, preceding a PMA-induced increase in CD28 surface expression; (ii) occurred using kinase buffer containing either manganese or magnesium; and cells, and in a Jurkat subclone, J. Cam1, that is deficient in Lek tyrosine kinase activity. In contrast, anti-CD28 monoclonal antibody stimulation led to in vitro phosphorylation of CD28 on tyrosine that was manganese-dependent and required Lek tyrosine kinase activity, as it was undetectable in J. Cam1 cells. Importantly, CD28 was phosphotyrosine antibodies after stimulation with anti-CD28 monoclonal antibody. The in vivo tyrosine phosphorylation of Cd28 was inhibited by PMA treatment and was absent in J. Cam1 cells. Thus, the CD28 coreceptor can trigger different intracellular signaling pathways, depending upon the nature of the initial co-stimulatory signal.	DANA FARBER CANC INST, DIV PEDIAT ONCOL, BOSTON, MA 02115 USA; BRIGHAM & WOMENS HOSP, DIV HEMATOL ONCOL, BOSTON, MA 02115 USA; HARVARD UNIV, SCH MED, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School				Bierer, Barbara/0000-0001-6448-8170	NIAID NIH HHS [AI35297] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035297] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARUFFO A, 1987, P NATL ACAD SCI USA, V84, P8573, DOI 10.1073/pnas.84.23.8573; AUGUST A, 1994, INT IMMUNOL, V6, P769, DOI 10.1093/intimm/6.5.769; AUGUST A, 1994, BIOCHEM BIOPH RES CO, V199, P1466, DOI 10.1006/bbrc.1994.1396; AUGUST A, 1994, P NATL ACAD SCI USA, V91, P9347, DOI 10.1073/pnas.91.20.9347; BIERER BE, 1993, CURR OPIN HEMATOL, P149; BLUM H, 1987, ELECTROPHORESIS, V8, P93, DOI 10.1002/elps.1150080203; GMUNDER H, 1984, EUR J BIOCHEM, V142, P153, DOI 10.1111/j.1432-1033.1984.tb08263.x; HARDING FA, 1992, NATURE, V356, P607, DOI 10.1038/356607a0; HUTCHCROFT JE, 1994, P NATL ACAD SCI USA, V91, P3260, DOI 10.1073/pnas.91.8.3260; HUTCHCROFT JE, 1995, P NATL ACAD SCI USA, V92, P8808, DOI 10.1073/pnas.92.19.8808; JELINEK T, 1993, BIOTECHNIQUES, V15, P629; JUNE CH, 1994, IMMUNOL TODAY, V15, P321, DOI 10.1016/0167-5699(94)90080-9; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; LINSLEY PS, 1993, ANNU REV IMMUNOL, V11, P191, DOI 10.1146/annurev.iy.11.040193.001203; LU YL, 1992, J IMMUNOL, V149, P24; LU YL, 1995, EUR J IMMUNOL, V25, P533, DOI 10.1002/eji.1830250234; LU YL, 1994, EUR J IMMUNOL, V24, P2732, DOI 10.1002/eji.1830241124; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PRASAD KVS, 1994, P NATL ACAD SCI USA, V91, P2834, DOI 10.1073/pnas.91.7.2834; RAAB M, 1995, P NATL ACAD SCI USA, V92, P8891, DOI 10.1073/pnas.92.19.8891; STEIN PH, 1994, MOL CELL BIOL, V14, P3392, DOI 10.1128/MCB.14.5.3392; STRAUS DB, 1992, CELL, V70, P585, DOI 10.1016/0092-8674(92)90428-F; TRUITT KE, 1994, J EXP MED, V179, P1071, DOI 10.1084/jem.179.3.1071; VANDENBERGHE P, 1992, J EXP MED, V175, P951, DOI 10.1084/jem.175.4.951	25	19	19	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13362	13370		10.1074/jbc.271.23.13362	http://dx.doi.org/10.1074/jbc.271.23.13362			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662792	hybrid			2022-12-27	WOS:A1996UP38500012
J	Reid, T; Furayashiki, T; Ishizaki, T; Watanabe, G; Watanabe, N; Fujisawa, K; Morii, N; Madaule, P; Narumiya, S				Reid, T; Furayashiki, T; Ishizaki, T; Watanabe, G; Watanabe, N; Fujisawa, K; Morii, N; Madaule, P; Narumiya, S			Rhotekin, a new putative target for Rho bearing homology to a serine/threonine kinase, PKN, and rhophilin in the Rho-binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; SWISS 3T3 CELLS; ADP-RIBOSYLATION; GENE-PRODUCT; RAS; GDI; PURIFICATION; AGGREGATION; P21	Using a mouse embryo cDNA library, we conducted a two-hybrid screening to identify new partners for the small GTPase Rho. One clone obtained by this procedure contained a novel cDNA of 291 base pairs and interacted strongly with RhoA and RhoC, weakly with RhoB, are not at all with Rac1 and Cdc42Hs. Full-length cDNAs were then isolated from a mouse brain library. While multiple splicing variants were common, we identified three cDNAs with an identical open reading frame encoding a 61-kDa protein that we named rhotekin (from the Japanese ''teki'', meaning target). The N-terminal part of rhotekin, encoded by the initial cDNA and produced in bacteria as a glutathione S-transferase fusion protein, exhibited in vitro binding to S-35-labeled guanosine 5'-3'O-(thio)triphosphate-bound Rho, but not to Rac1 of Cdc42Hs in ligand overlay assays. In addition, this peptide inhibited both endogenous and GTPase-activating proteins-stimulated Rho GTPase activity. The amino acid sequence of this region shares similar to 30% identity with the Rho-binding domains of rhophilin and a serine/threonine kinase, PKN, two other Rho target proteins that we recently identified (Watanabe, G., Saito, Y., Madaula, P., Ishizuki, T., Fujisawa, K., Morii, N., Mukai, H., Ono, Y., Kakizuka, A., and Narumiya, S. (1996) Science 271, 645-648). Thus, not only is rhotekin a novel partner for Rho, but it also belongs to a wide family of proteins that bear a consensus Rho-binding sequence at the N terminus. To our knowledge, this is the first conserved sequence for Rho effectors, and we have termed this region Rho effector motif class 1.	KYOTO UNIV,FAC MED,DEPT PHARMACOL,SAKYO KU,KYOTO 606,JAPAN	Kyoto University			Furuyashiki, Tomoyuki/B-8760-2014; Furuyashiki, Tomoyuki/AAG-5283-2019	Furuyashiki, Tomoyuki/0000-0001-8089-8399; Furuyashiki, Tomoyuki/0000-0001-8089-8399				ADAMSON P, 1992, J CELL BIOL, V119, P617, DOI 10.1083/jcb.119.3.617; ALEXANDROPOULOS K, 1995, P NATL ACAD SCI USA, V92, P3110, DOI 10.1073/pnas.92.8.3110; BOKOCH GM, 1993, FASEB J, V7, P750, DOI 10.1096/fasebj.7.9.8330683; CHARDIN P, 1988, NUCLEIC ACIDS RES, V16, P2717, DOI 10.1093/nar/16.6.2717; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; DIEKMANN D, 1995, EMBO J, V14, P5297, DOI 10.1002/j.1460-2075.1995.tb00214.x; DIEKMANN D, 1991, NATURE, V351, P400, DOI 10.1038/351400a0; ESTOJAK J, 1995, MOL CELL BIOL, V15, P5820; FRITZ G, 1995, J BIOL CHEM, V270, P25172, DOI 10.1074/jbc.270.42.25172; FUKUMOTO Y, 1990, ONCOGENE, V5, P1321; HABETS GGM, 1994, CELL, V77, P537, DOI 10.1016/0092-8674(94)90216-X; HART MJ, 1994, J BIOL CHEM, V269, P63; Ishizaki T, 1996, EMBO J, V15, P1885, DOI 10.1002/j.1460-2075.1996.tb00539.x; JAHNER D, 1991, MOL CELL BIOL, V11, P3682; KISHI K, 1993, J CELL BIOL, V120, P1187, DOI 10.1083/jcb.120.5.1187; LAMARCHE N, 1994, TRENDS GENET, V10, P436, DOI 10.1016/0168-9525(94)90114-7; LANCASTER CA, 1994, J BIOL CHEM, V269, P1137; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; Mabuchi I, 1993, ZYGOTE, V1, P325, DOI 10.1017/S0967199400001659; Madaule P, 1995, FEBS LETT, V377, P243, DOI 10.1016/0014-5793(95)01351-2; MANSER E, 1993, NATURE, V363, P364, DOI 10.1038/363364a0; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MIKI T, 1993, NATURE, V362, P462, DOI 10.1038/362462a0; MIURA Y, 1993, J BIOL CHEM, V268, P510; MORII N, 1991, J BIOL CHEM, V266, P7646; MORII N, 1993, J BIOL CHEM, V268, P27160; MORII N, 1992, J BIOL CHEM, V267, P20921; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V199, P897, DOI 10.1006/bbrc.1994.1313; MUKAI H, 1994, BIOCHEM BIOPH RES CO, V204, P348, DOI 10.1006/bbrc.1994.2466; NISHIYAMA T, 1994, MOL CELL BIOL, V14, P2447, DOI 10.1128/MCB.14.4.2447; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; Sambrook J., 2002, MOL CLONING LAB MANU; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TAKAISHI K, 1993, MOL CELL BIOL, V13, P72, DOI 10.1128/MCB.13.1.72; TOMINAGA T, 1993, J CELL BIOL, V120, P1529, DOI 10.1083/jcb.120.6.1529; UEDA T, 1990, J BIOL CHEM, V265, P9373; VANAELST L, 1993, P NATL ACAD SCI USA, V90, P6213, DOI 10.1073/pnas.90.13.6213; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; WHITE MA, 1995, CELL, V80, P533, DOI 10.1016/0092-8674(95)90507-3; YAMAMOTO M, 1993, ONCOGENE, V8, P1449	41	310	325	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13556	13560		10.1074/jbc.271.23.13556	http://dx.doi.org/10.1074/jbc.271.23.13556			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662891	hybrid			2022-12-27	WOS:A1996UP38500039
J	Ovadia, H; Rosenmann, H; Shezen, E; Halimi, M; Ofran, I; Gabizon, R				Ovadia, H; Rosenmann, H; Shezen, E; Halimi, M; Ofran, I; Gabizon, R			Effect of scrapie infection on the activity of neuronal nitric-oxide synthase in brain and neuroblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; MOLECULAR-CLONING; NADPH-DIAPHORASE; ALZHEIMERS-DISEASE; RELAXING FACTOR; BLASTOMA CELLS; PRION PROTEINS; EXPRESSION; MESSENGER; RESISTANT	Nitric-oxide synthase (NOS) is responsible for the synthesis of nitric oxide which serves as a neural messenger in the central nervous system. NOS activity was markedly inhibited in brains of mice and hamsters and neuroblastoma cells infected with scrapie (ScN2a). The decrease in activity was in accordance with decreased NADPH-diaphorase-positive cells and decreased staining of NOS-positive cells demonstrated by specific anti-NOS antibodies. However, the specific nNOS mRNA in ScN2a was elevated when compared with normal neuroblastoma cells (N2a). Immunoblotting of fractions from these cell lines with an anti-nNOS monoclonal antibody revealed a band of nNOS from N2a and two bands with a lower molecular weight in ScN2a cells. Furthermore, NOS in ScN2a cells was insoluble in nondenaturing detergents. This insolubility is one of the landmark properties of PrPSc. It is, therefore, possible that nNOS in scrapie-infected cells and brains is aberrantly folded, resulting in an insoluble and inactive enzyme.	HADASSAH UNIV HOSP, DEPT NEUROL, IL-91120 JERUSALEM, ISRAEL	Hebrew University of Jerusalem				Ofran, Yishai/0000-0002-5521-1337				AKAIKE T, 1995, J NEUROVIROL, V1, P118, DOI 10.3109/13550289509111016; BASLER K, 1986, CELL, V46, P417, DOI 10.1016/0092-8674(86)90662-8; BECKMANN RP, 1990, SCIENCE, V248, P850, DOI 10.1126/science.2188360; BOHME GA, 1991, EUR J PHARMACOL, V199, P379, DOI 10.1016/0014-2999(91)90505-K; BORCHELT DR, 1990, J CELL BIOL, V110, P743, DOI 10.1083/jcb.110.3.743; BREDT DS, 1992, NEURON, V8, P3, DOI 10.1016/0896-6273(92)90104-L; BREDT DS, 1991, NEURON, V7, P615, DOI 10.1016/0896-6273(91)90374-9; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BUTLER DA, 1988, J VIROL, V62, P1558, DOI 10.1128/JVI.62.5.1558-1564.1988; CAUGHEY B, 1991, J BIOL CHEM, V266, P18217; CAUGHEY B, 1989, J VIROL, V63, P175, DOI 10.1128/JVI.63.1.175-181.1989; CORRALIZA IM, 1994, J IMMUNOL METHODS, V174, P231, DOI 10.1016/0022-1759(94)90027-2; CROSS AJ, 1985, J NEUROL SCI, V70, P231, DOI 10.1016/0022-510X(85)90090-5; DAWSON TM, 1992, ANN NEUROL, V32, P297, DOI 10.1002/ana.410320302; DAWSON TM, 1991, P NATL ACAD SCI USA, V88, P7797, DOI 10.1073/pnas.88.17.7797; DESAIAH D, 1994, NEUROLOGY, V44, pA369; FERRANTE RJ, 1985, SCIENCE, V230, P561, DOI 10.1126/science.2931802; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GEORGOPOULOS C, 1993, ANNU REV CELL BIOL, V9, P601, DOI 10.1146/annurev.cb.09.110193.003125; HAMOS JE, 1991, NEUROLOGY, V41, P345, DOI 10.1212/WNL.41.3.345; HYMAN BT, 1992, ANN NEUROL, V32, P818, DOI 10.1002/ana.410320618; IGNARRO LJ, 1987, P NATL ACAD SCI USA, V84, P9265, DOI 10.1073/pnas.84.24.9265; KENWARD N, 1994, J NEUROCHEM, V62, P1870; KOH JY, 1986, SCIENCE, V234, P73, DOI 10.1126/science.2875522; KOH JY, 1988, J NEUROSCI, V8, P2153, DOI 10.1523/jneurosci.08-06-02153.1988; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; Liautard J P, 1993, Arch Virol Suppl, V7, P227; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MCCALL TB, 1991, EUR J IMMUNOL, V21, P2523, DOI 10.1002/eji.1830211032; MCKINLEY MP, 1983, CELL, V35, P57, DOI 10.1016/0092-8674(83)90207-6; MELDRUM B, 1990, TRENDS PHARMACOL SCI, V11, P379, DOI 10.1016/0165-6147(90)90184-A; MODOLELL M, 1995, EUR J IMMUNOL, V25, P1101, DOI 10.1002/eji.1830250436; MURPHY S, 1993, TRENDS NEUROSCI, V16, P323, DOI 10.1016/0166-2236(93)90109-Y; NAKANE M, 1993, FEBS LETT, V316, P175, DOI 10.1016/0014-5793(93)81210-Q; NAKANE M, 1991, BIOCHEM BIOPH RES CO, V180, P1396, DOI 10.1016/S0006-291X(05)81351-8; NOWICKI JP, 1991, EUR J PHARMACOL, V204, P339, DOI 10.1016/0014-2999(91)90862-K; ODELL TJ, 1994, SCIENCE, V265, P542, DOI 10.1126/science.7518615; OESCH B, 1985, CELL, V40, P735, DOI 10.1016/0092-8674(85)90333-2; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PAN KM, 1993, P NATL ACAD SCI USA, V90, P10962, DOI 10.1073/pnas.90.23.10962; PEREZ N, 1991, MOL BRAIN RES, V11, P249, DOI 10.1016/0169-328X(91)90033-T; PRICE DL, 1993, P NATL ACAD SCI USA, V90, P6381, DOI 10.1073/pnas.90.14.6381; PRUSINER SB, 1991, SCIENCE, V252, P1515, DOI 10.1126/science.1675487; PRUSINER SB, 1992, BIOCHEMISTRY-US, V31, P12277, DOI 10.1021/bi00164a001; RADI R, 1991, J BIOL CHEM, V266, P4244; RUBENSTEIN R, 1991, J GEN VIROL, V72, P1279, DOI 10.1099/0022-1317-72-6-1279; SCHUMAN EM, 1994, ANNU REV NEUROSCI, V17, P153, DOI 10.1146/annurev.neuro.17.1.153; SESSA WC, 1992, J BIOL CHEM, V267, P15274; SHIBUKI K, 1991, NATURE, V349, P326, DOI 10.1038/349326a0; STAHL N, 1993, BIOCHEMISTRY-US, V32, P1991, DOI 10.1021/bi00059a016; STUEHR DJ, 1989, J EXP MED, V169, P1543, DOI 10.1084/jem.169.5.1543; TAMAOKI T, 1991, METHOD ENZYMOL, V201, P340; TATZELT J, 1995, P NATL ACAD SCI USA, V92, P2944, DOI 10.1073/pnas.92.7.2944; UEMURA Y, 1990, ANN NEUROL, V27, P620, DOI 10.1002/ana.410270606; WEISSMANN C, 1991, NATURE, V352, P679, DOI 10.1038/352679a0	55	34	35	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16856	16861		10.1074/jbc.271.28.16856	http://dx.doi.org/10.1074/jbc.271.28.16856			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663207	hybrid			2022-12-27	WOS:A1996UX12600067
J	Becq, F; Verrier, B; Chang, XB; Riordan, JR; Hanrahan, JW				Becq, F; Verrier, B; Chang, XB; Riordan, JR; Hanrahan, JW			cAMP- and Ca2+-independent activation of cystic fibrosis transmembrane conductance regulator channels by phenylimidazothiazole drugs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR-CHLORIDE CHANNELS; ALKALINE-PHOSPHATASE; CL CHANNEL; PHOSPHOTYROSINE PHOSPHATASE; DUCT CELLS; R-DOMAIN; PHOSPHORYLATION; IDENTIFICATION; MEMBRANE; GENE	Patch-clamp, iodide efflux, and biochemical techniques were used to evaluate the ability of phenylimidazothiazoles to open normal and mutated cystic fibrosis transmembrane conductance regulator (CFTR) chloride channels and to investigate the mechanism of activation. As reported previously for bromotetramisole, levamisole activated wild-type CFTR channels stably expressed in Chinese hamster ovary cells in the absence of other secretagogues and without elevating intracellular cAMP or calcium. The protein kinase A (PKA) inhibitor N-(2-(p-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide abolished activation by forskolin but only partially inhibited stimulation by levamisole, suggesting the involvement of other kinases. CFTR channels bearing mutations at multiple phosphorylation sites, in the membrane domains, and in the first nucleotide binding domain (including the disease-causing mutations G551D and Delta F508) all responded to phenylimidazothiazoles. Moreover, levamisole and bromotetramisole increased the activity of wild-type and mutant channels already exposed to PKA + MgATP, consistent with the inhibition of a constitutive, membrane-associated phosphatase activity. We conclude that phenylimidazothiazole drugs can open normal and mutated CFTR channels by stabilization of phosphoforms of CFTR that are produced by basal activity of PKA and alternative protein kinases. If similar stimulation is observed in humans in vivo, phenylimidazothiazoles may be useful in the development of pharmacological therapies for cystic fibrosis.	MCGILL UNIV, DEPT PHYSIOL, MONTREAL, PQ H3G 1Y6, CANADA; FAC MED NORD, INSERM U270, F-13326 MARSEILLE, FRANCE; MAYO CLIN SCOTTSDALE, S C JOHNSON MED RES CTR, SCOTTSDALE, AZ 85259 USA	McGill University; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Mayo Clinic; Mayo Clinic Phoenix			Becq, Frederic/P-9233-2016; Hanrahan, John/AGG-1926-2022	Becq, Frederic/0000-0003-3915-0973; Hanrahan, John/0000-0001-9080-2039				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; BAUKROWITZ T, 1994, NEURON, V12, P473, DOI 10.1016/0896-6273(94)90206-2; BEAR CE, 1992, CELL, V68, P809, DOI 10.1016/0092-8674(92)90155-6; BECQ F, 1993, FEBS LETT, V327, P337, DOI 10.1016/0014-5793(93)81016-S; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BERGER HA, 1993, J BIOL CHEM, V268, P2037; BERGER HA, 1991, J CLIN INVEST, V88, P1422, DOI 10.1172/JCI115450; BHARGAVA KK, 1977, J MED CHEM, V20, P563, DOI 10.1021/jm00214a021; BORGERS M, 1973, J HISTOCHEM CYTOCHEM, V21, P812, DOI 10.1177/21.9.812; BORGERS M, 1975, HISTOCHEMISTRY, V44, P277, DOI 10.1007/BF00491496; CHAMPIGNY G, 1990, FEBS LETT, V259, P263, DOI 10.1016/0014-5793(90)80024-D; CHAN JRA, 1986, J BIOL CHEM, V261, P7635; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; CONSTANTOPOULOS A, 1977, EXPERIENTIA, V33, P395, DOI 10.1007/BF02002848; DALEMANS W, 1991, NATURE, V354, P526, DOI 10.1038/354526a0; DILS F, 1979, J INT MED RES, V7, P302, DOI 10.1177/030006057900700408; DOUSMANIS AG, 1995, PEDIATR PULM, V20, P418; DRUMM ML, 1991, SCIENCE, V254, P1797, DOI 10.1126/science.1722350; EIDELMAN O, 1992, P NATL ACAD SCI USA, V89, P5562, DOI 10.1073/pnas.89.12.5562; ELKOUNI MH, 1982, P NATL ACAD SCI-BIOL, V79, P1037; FERNLEY HN, 1967, BIOCHEM J, V104, P1011, DOI 10.1042/bj1041011; FIRTH JA, 1974, J HISTOCHEM CYTOCHEM, V22, P1163, DOI 10.1177/22.12.1163; GETTINS P, 1985, J BIOL CHEM, V260, P2875; GRAY MA, 1989, AM J PHYSIOL, V257, pC240, DOI 10.1152/ajpcell.1989.257.2.C240; GREM JL, 1990, CANCER CELL-MON REV, V2, P131; GRUBB BR, 1994, AM J PHYSIOL, V267, pC293, DOI 10.1152/ajpcell.1994.267.1.C293; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; HARRIS RA, 1993, AM J PHYSIOL, V265, pC781, DOI 10.1152/ajpcell.1993.265.3.C781; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; HOFFMANN WE, 1983, ENZYME, V30, P269, DOI 10.1159/000469588; HWANG TC, 1993, J GEN PHYSIOL, V101, P629, DOI 10.1085/jgp.101.5.629; ILLEK B, 1995, AM J PHYSIOL-CELL PH, V268, pC886, DOI 10.1152/ajpcell.1995.268.4.C886; KEREM BS, 1989, SCIENCE, V245, P1073, DOI 10.1126/science.2570460; KERSTING U, 1993, P NATL ACAD SCI USA, V90, P4047, DOI 10.1073/pnas.90.9.4047; KHODAPARASTSHARIFI SH, 1989, INT J BIOCHEM, V21, P401, DOI 10.1016/0020-711X(89)90364-9; LEAKE DS, 1983, BIOCHIM BIOPHYS ACTA, V762, P52, DOI 10.1016/0167-4889(83)90116-7; LEBEL D, 1980, J BIOL CHEM, V255, P1227; MAGNUSSON BC, 1974, HISTOCHEMISTRY, V42, P221, DOI 10.1007/BF00492654; METAYE T, 1992, BIOCHEM PHARMACOL, V43, P1507, DOI 10.1016/0006-2952(92)90208-Z; MOTOYAMA N, 1987, J BIOCHEM-TOKYO, V101, P939, DOI 10.1093/oxfordjournals.jbchem.a121963; PICCIOTTO MR, 1992, J BIOL CHEM, V267, P12742; REDDY M, 1994, PEDIATR PULM S, V10, P183; RICH DP, 1993, J BIOL CHEM, V268, P20259; RIORDAN JR, 1989, SCIENCE, V245, P1066; ROMMENS JM, 1989, SCIENCE, V245, P1059, DOI 10.1126/science.2772657; ROTENBERG SA, 1987, BIOCHEM J, V243, P747, DOI 10.1042/bj2430747; SARROUILHE D, 1992, BIOCHIM BIOPHYS ACTA, V1118, P116, DOI 10.1016/0167-4838(92)90137-3; SEIBERT FS, 1995, J BIOL CHEM, V270, P2158, DOI 10.1074/jbc.270.5.2158; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; SWARUP G, 1981, J BIOL CHEM, V256, P8197; Symoens J., 1979, PHARMACOLOGICAL BIOC, V2, P407; TABCHARANI JA, 1990, FEBS LETT, V270, P157, DOI 10.1016/0014-5793(90)81257-O; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VANBELLE H, 1977, CLIN CHEM, V23, P454; VANEYGEN M, 1979, EUR J PEDIATR, V131, P147, DOI 10.1007/BF00538939; VANEYGEN M, 1976, LANCET, V1, P382	58	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16171	16179		10.1074/jbc.271.27.16171	http://dx.doi.org/10.1074/jbc.271.27.16171			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663098	hybrid			2022-12-27	WOS:A1996UW35200048
J	Loo, TW; Clarke, DM				Loo, TW; Clarke, DM			Mutational analysis of the predicted first transmembrane segment of each homologous half of human P-glycoprotein suggests that they are symmetrically arranged in the membrane	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG-RESISTANCE; FUNCTIONAL CONSEQUENCES; BACTERIAL TRANSPORT; PROTEINS; RETICULUM; TOPOLOGY; DOMAIN; CELLS; MODEL	A recent study of P-glycoprotein membrane topology using phoA gene fusions provided evidence that the orientation of the first transmembrane segment of each homologous half of P-glycoprotein was different (Beja, O., and Bibi, E. (1995) J, Biol, Chem, 270, 12351-12354). To test this hypothesis, we compared the functional conse quences of mutations to residues in transmembrane segments (TMs) TM1 and TM7, Mutations to 3 residues occupying homologous positions in TM1 and TM7 resulted in mutant P-glycoproteins that were inactive, These mu tants were found to be misprocessed, By contrast, mutations to other residues in TM1 resulted in functional P-glycoproteins. When putative TM1 was replaced with TM7 or TM7 with TM1 to yield TM7/TM7 or TM1/TM1 chimeras, both constructs yielded P-glycoproteins that were capable of conferring drug resistance in transfected cells, The purified P-glycoproteins from mutants TM7/TM7 and TM1/TM1 retained 59 and 28% of verapamil-stimulated ATPase activity, respectively, By contrast, interchanging TM6 and TM12 to yield TM6/TM6, TM12/TM12, or TM12/TM6 constructs resulted in P-glycoproteins that did not have any detectable ATPase activity and did not confer drug resistance in transfected cells, These results suggest that TM1 and TM7 likely have similar structural and functional roles in P-glycoprotein and that they have identical topologies.	UNIV TORONTO,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA	University of Toronto	Loo, TW (corresponding author), UNIV TORONTO,DEPT MED,MRC,GRP MEMBRANE BIOL,RM 7342,MED SCI BLDG,1 KINGS COLL CIRCLE,TORONTO,ON M5S 1A8,CANADA.		Clarke, David M./A-1112-2008	Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188				BEJA O, 1995, J BIOL CHEM, V270, P12351; BIBI E, 1994, J BIOL CHEM, V269, P19910; CARROLL TP, 1995, J BIOL CHEM, V270, P11941, DOI 10.1074/jbc.270.20.11941; CHANG XB, 1994, J BIOL CHEM, V269, P18572; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; CIANFRIGLIA M, 1994, INT J CANCER, V56, P153; ENDICOTT JA, 1989, ANNU REV BIOCHEM, V58, P137, DOI 10.1146/annurev.bi.58.070189.001033; GEORGES E, 1993, J BIOL CHEM, V268, P1792; GOTTESMAN MM, 1988, J BIOL CHEM, V263, P12163; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREENBERGER LM, 1993, J BIOL CHEM, V268, P11417; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JURANKA PF, 1989, FASEB J, V3, P2583, DOI 10.1096/fasebj.3.14.2574119; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; LOO TW, 1994, J BIOL CHEM, V269, P7243; LOO TW, 1994, BIOCHEMISTRY-US, V33, P14049, DOI 10.1021/bi00251a013; LOO TW, 1995, J BIOL CHEM, V270, P21449, DOI 10.1074/jbc.270.37.21449; LOO TW, 1993, J BIOL CHEM, V268, P19965; LOO TW, 1994, J BIOL CHEM, V269, P28683; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; RAVIV Y, 1990, J BIOL CHEM, V265, P3975; RONINSON IBE, 1991, MOL CELLULAR BIOL MU; SHAPIRO AB, 1994, J BIOL CHEM, V269, P3745; Skach W. R., 1995, Biophysical Journal, V68, pA344; SKACH WR, 1993, J BIOL CHEM, V268, P23552; SKACH WR, 1993, J BIOL CHEM, V268, P6903; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZHANG JT, 1995, J BIOL CHEM, V270, P1742, DOI 10.1074/jbc.270.4.1742; ZHANG JT, 1993, J BIOL CHEM, V268, P15101; ZHANG X, 1995, BIOL CHEM, V270, P5441; ZUBRZYCKAGAARN E, 1984, J BIOENERG BIOMEMBR, V16, P441, DOI 10.1007/BF00743238	35	37	37	2	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15414	15419		10.1074/jbc.271.26.15414	http://dx.doi.org/10.1074/jbc.271.26.15414			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663176	hybrid			2022-12-27	WOS:A1996UV29900020
J	Zhu, YX; Kang, LY; Luo, W; Li, CCH; Yang, L; Yang, YC				Zhu, YX; Kang, LY; Luo, W; Li, CCH; Yang, L; Yang, YC			Multiple transcription factors are required for activation of human interleukin 9 gene in T cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS FACTOR-ALPHA; NF-KAPPA-B; GROWTH-FACTOR; EXPRESSION; MURINE; ELEMENT; IDENTIFICATION; PROLIFERATION; LYMPHOCYTES; LYMPHOMAS	The genetic elements and regulatory mechanisms responsible for human interleukin 9 (IL-9) gene expression in a human T cell leukemia virus type I-transformed human T cell line, C5MJ2, were investigated. We demonstrated that IL-9 gene expression is controlled, at least in part, by transcriptional activation. Transient expression of the luciferase reporter gene Linked to serially deleted sequences of the 5'-flanking region of the IL-9 gene has revealed several positive and negative regulatory elements involved in the basal and inducible expression of the IL-9 gene in C5MJ2 cells. An AP-1 site at -146 to -140 was shown to be involved in the expression of the IL-9 gene. A proximal region between -46 and -80 was identified as the minimum sequence for the basal and inducible expression of the IL-9 gene in C5MJ2 cells. Within this region, an NF-kappa B site at -59 to -50 and its adjacent 20-base pair upstream sequence were demonstrated to play a critical role for the IL-9 promoter activity. DNA-protein binding studies indicated that NF-kappa B, c-Jun, and potentially novel proteins (around 35 kDa) can bind to this important sequence. Mutations at different sites within this proximal promoter region abolished the promoter activity as well as the DNA binding. Taken together, these results suggest that the cooperation of different transcription factors is essential for IL-9 gene expression in T cells.	INDIANA UNIV,SCH MED,WALTHER ONCOL CTR,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT MED HEMATOL ONCOL,INDIANAPOLIS,IN 46202; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202; NCI,FREDERICK CANC RES & DEV CTR,BIOL CARCINOGENESIS & DEV PROGRAM,SAIC,FREDERICK,MD	Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick					NHLBI NIH HHS [R01HL48819] Funding Source: Medline; NIDDK NIH HHS [R01DK43105] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048819] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043105] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BOKAR JA, 1989, MOL CELL BIOL, V9, P5113, DOI 10.1128/MCB.9.11.5113; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHUVPILO S, 1993, NUCLEIC ACIDS RES, V21, P5694, DOI 10.1093/nar/21.24.5694; COLLART MA, 1990, MOL CELL BIOL, V10, P1498, DOI 10.1128/MCB.10.4.1498; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DONAHUE RE, 1990, BLOOD, V75, P2271; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; FURTH M, 1989, CANC CELLS MOL DIAGN, P53; GRUSS HJ, 1992, CANCER RES, V52, P1026; HO IC, 1991, EMBO J, V10, P1187, DOI 10.1002/j.1460-2075.1991.tb08059.x; HOYOS B, 1989, SCIENCE, V244, P457, DOI 10.1126/science.2497518; HULTNER L, 1989, J IMMUNOL, V142, P3440; HULTNER L, 1990, EUR J IMMUNOL, V20, P1413, DOI 10.1002/eji.1830200632; JENKINS F, 1995, J IMMUNOL, V155, P1240; KAUSHANSKY K, 1994, J IMMUNOL, V152, P1812; KELLEHER K, 1991, BLOOD, V77, P1436; KO LJ, 1991, MOL CELL BIOL, V11, P2778, DOI 10.1128/MCB.11.5.2778; LEE HJ, 1995, J BIOL CHEM, V270, P17541, DOI 10.1074/jbc.270.29.17196; LENARDO MJ, 1988, P NATL ACAD SCI USA, V85, P8825, DOI 10.1073/pnas.85.23.8825; LI CCH, 1994, BIOCHEM J, V303, P499, DOI 10.1042/bj3030499; LIBERMANN TA, 1990, MOL CELL BIOL, V10, P2327, DOI 10.1128/MCB.10.5.2327; LORD KA, 1991, MOL CELL BIOL, V11, P4371, DOI 10.1128/MCB.11.9.4371; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; MERZ H, 1991, BLOOD, V78, P1311; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; MIYATAKE S, 1988, MOL CELL BIOL, V8, P5581, DOI 10.1128/MCB.8.12.5581; MIYATAKE S, 1991, MOL CELL BIOL, V11, P5894, DOI 10.1128/MCB.11.12.5894; MOCK BA, 1990, IMMUNOGENETICS, V31, P265, DOI 10.1007/BF00204898; MUEGGE K, 1989, SCIENCE, V246, P249, DOI 10.1126/science.2799385; NAORA H, 1994, J IMMUNOL, V153, P3466; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; ORKIN SH, 1992, BLOOD, V80, P575; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; RENAULD JC, 1990, J IMMUNOL, V144, P4235; RENAULD JC, 1993, ADV IMMUNOL, V54, P79, DOI 10.1016/S0065-2776(08)60533-7; RENAULD JC, 1994, ONCOGENE, V9, P1327; RENAULD JC, 1995, BLOOD, V85, P1300, DOI 10.1182/blood.V85.5.1300.bloodjournal8551300; Sambrook J., 2002, MOL CLONING LAB MANU; SHRECK R, 1990, MOL CELL BIOL, V10, P1281; SIEGEL MD, 1995, J BIOL CHEM, V270, P24548, DOI 10.1074/jbc.270.41.24548; SUDA T, 1990, J IMMUNOL, V144, P1783; SZABO SJ, 1993, MOL CELL BIOL, V13, P4793, DOI 10.1128/MCB.13.8.4793; UYTTENHOVE C, 1988, P NATL ACAD SCI USA, V85, P6943; VINK A, 1993, EUR J IMMUNOL, V23, P1134, DOI 10.1002/eji.1830230523; WILLIAMS DE, 1990, BLOOD, V76, P906; YAMAMOTO M, 1990, GENE DEV, V4, P1650, DOI 10.1101/gad.4.10.1650; YANG YC, 1989, BLOOD, V74, P1880; ZINN K, 1983, CELL, V34, P865, DOI 10.1016/0092-8674(83)90544-5	49	22	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15815	15822		10.1074/jbc.271.26.15815	http://dx.doi.org/10.1074/jbc.271.26.15815			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663174	hybrid			2022-12-27	WOS:A1996UV29900077
J	Chevalier, S; Fourcin, M; Robledo, O; Wijdenes, J; PouplardBarthelaix, A; Gascan, H				Chevalier, S; Fourcin, M; Robledo, O; Wijdenes, J; PouplardBarthelaix, A; Gascan, H			Interleukin-6 family of cytokines induced activation of different functional sites expressed by gp130 transducing protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKEMIA-INHIBITORY FACTOR; CILIARY NEUROTROPHIC FACTOR; IL-6 SIGNAL TRANSDUCER; HEPATOCYTE-STIMULATING FACTOR; RECEPTOR GAMMA-CHAIN; ONCOSTATIN-M; GM-CSF; MOLECULAR-CLONING; CNTF RECEPTOR; GROWTH-FACTOR	Gp130 transducing protein was shown to be involved in the formation of the high affinity receptors for interleukin 6 (IL-6), interleukin-11 (IL-11), leukemia inhibitory factor, oncostatin M (OSM), ciliary neurotrophic factor (CNTF), and cardiotrophin-1. In the present study we have characterized the functional properties of antibodies directed against this protein and identified a group of monoclonal antibodies able to antagonize the biological activities of all the cytokines belonging to the IL-6 cytokine family, The B-R3 pan-blocking antibody weakly interfered with the binding of the radiolabeled ligands (with the exception of OSM, whose binding was abrogated in the presence of B-R3 monoclonal antibody) but inhibited the gp130 homodimerization or its association with gp190/leukemia inhibitory factor receptor, as well as the subsequent tyrosine phosphorylation events, In addition we identified antibodies that were able to neutralize only one single cytokine of the IL-6 family, This was the case for the B-K5 antibody, which antagonized the binding of OSM to gp130 but did not interfere with the signals provided by the related cytokines triggering the proliferation of the TF1 erythroleukemia cell line or the induction of haptoglobin synthesis in the HepG2 hepatoma cell line, Similarly, we also characterized two additional antibodies B-P8 and B-P4, which inhibited the TF1 cell proliferation observed in the presence of CNTF and IL-11, respectively, B-P8 antibody only faintly interfered with the binding of the gp130-ligands and might modulate the signal transduction pathways, This study indicates that in addition to functional site(s) required by the whole family of IL-6 type cytokines to transduce the signal insight the cell, specific cognate functional sites were recruited by OSM, CNTF, or IL-11.	CHU ANGERS,BIOL CELLULAIRE LAB,F-49033 ANGERS,FRANCE; DIACLONE,F-25020 BESANCON,FRANCE	Universite d'Angers; Centre Hospitalier Universitaire d'Angers								BAUMANN H, 1989, J IMMUNOL, V143, P1163; BAUMANN H, 1993, J BIOL CHEM, V268, P8414; CONOVER JC, 1993, DEVELOPMENT, V119, P559; DAMEN JE, 1995, EMBO J, V14, P5557, DOI 10.1002/j.1460-2075.1995.tb00243.x; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FOURCIN M, 1994, EUR J IMMUNOL, V24, P277, DOI 10.1002/eji.1830240143; GASCAN H, 1989, J BIOL CHEM, V264, P21509; GAULDIE J, 1987, P NATL ACAD SCI USA, V84, P7251, DOI 10.1073/pnas.84.20.7251; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; IHLE JN, 1995, TRENDS GENET, V11, P69, DOI 10.1016/S0168-9525(00)89000-9; KAWANO M, 1988, NATURE, V332, P83, DOI 10.1038/332083a0; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KOBAYASHI S, 1993, BLOOD, V81, P889; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LEARY AG, 1990, BLOOD, V75, P1960; LECRON JC, 1993, CLIN EXP IMMUNOL, V92, P23; LUTTICKEN C, 1994, SCIENCE, V263, P89, DOI 10.1126/science.8272872; MADRENAS J, 1995, SCIENCE, V267, P515, DOI 10.1126/science.7824949; MURAKAMI M, 1991, P NATL ACAD SCI USA, V88, P11349, DOI 10.1073/pnas.88.24.11349; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; MUSASHI M, 1991, BLOOD, V78, P1448; NAIR BC, 1992, SCIENCE, V255, P1430, DOI 10.1126/science.1542792; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; PENNICA D, 1995, J BIOL CHEM, V270, P10915, DOI 10.1074/jbc.270.18.10915; PENNICA D, 1995, P NATL ACAD SCI USA, V92, P1142, DOI 10.1073/pnas.92.4.1142; SLOANLANCASTER J, 1994, CELL, V79, P913, DOI 10.1016/0092-8674(94)90080-9; SMITH AG, 1988, NATURE, V336, P688, DOI 10.1038/336688a0; SPORENO E, 1994, J BIOL CHEM, V269, P10991; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TEJEDOR F, 1982, ANAL BIOCHEM, V127, P143, DOI 10.1016/0003-2697(82)90156-7; THOMA B, 1994, J BIOL CHEM, V269, P6215; VANDERHEYDEN J, 1991, J IMMUNOL, V147, P3413; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAMAMORI T, 1989, SCIENCE, V246, P1412, DOI 10.1126/science.2512641; YIN TG, 1992, J EXP MED, V175, P211, DOI 10.1084/jem.175.1.211; ZARLING JM, 1986, P NATL ACAD SCI USA, V83, P9739, DOI 10.1073/pnas.83.24.9739; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	56	63	66	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14764	14772		10.1074/jbc.271.25.14764	http://dx.doi.org/10.1074/jbc.271.25.14764			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662918	hybrid			2022-12-27	WOS:A1996UT10600022
J	Ellis, V				Ellis, V			Functional analysis of the cellular receptor for urokinase in plasminogen activation - Receptor binding has no influence on the zymogenic nature of pro-urokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE-CHAIN UROKINASE; MONOCLONAL-ANTIBODY; BOUND UROKINASE; PROENZYME FORM; SARCOMA-CELLS; PLASMA; INACTIVATION; POTENTIATION; INHIBITORS; MECHANISM	Plasminogen activation catalyzed by the urokinase-type plasminogen activator (uPA) constitutes a reciprocal zymogen activation system, as plasmin can efficiently activate pro-uPA, the single-chain zymogenic form of the protease, We have previously shown that the overall efficiency of this plasminogen activation system is greatly enhanced by its assembly on the cell surface, involving binding of pro-uPA to its cellular binding site uPAR, and the concurrent cellular binding of plasminogen. We have now studied the effect of a recombinant soluble form of uPAR (residues 1-277) on the proteolytic reactions of this system. In contrast to the increased efficiencies of plasminogen activation and pro-uPA activation observed with cell-surface uPAR, soluble uPAR had an inhibitory effect on both of these individual reactions, Soluble uPAR also caused no increase in the low, but discernible, intrinsic activity of pro-uPA, Consistent with the observations on the isolated reactions, the overall activity of the pro-uPA-mediated plasminogen activation system was significantly inhibited. These observations confirm the previous interpretation of the observations made with cell-surface uPAR that the mechanism of the enhanced plasmin generation is due to the catalytically favorable interaction of uPAR-bound uPA/pro-uPA with cell-bound plasminogen/plasmin, rather than direct effects on the properties of uPA or pro-uPA on binding to uPAR.			Ellis, V (corresponding author), THROMBOSIS RES INST,EMMANUEL KAYE BLDG,MANRESA RD,LONDON SW3 6LR,ENGLAND.		Ellis, Vincent/D-1860-2009	Ellis, Vincent/0000-0003-1956-073X				ANDREASEN PA, 1986, J BIOL CHEM, V261, P7644; BRUNNER G, 1990, FEBS LETT, V260, P141, DOI 10.1016/0014-5793(90)80087-Y; COLLEN D, 1986, J BIOL CHEM, V261, P1259; ELLIS V, 1991, J BIOL CHEM, V266, P12752; ELLIS V, 1993, J BIOL CHEM, V268, P4806; ELLIS V, 1987, J BIOL CHEM, V262, P14998; ELLIS V, 1990, J BIOL CHEM, V265, P9904; ELLIS V, 1989, J BIOL CHEM, V264, P2185; ELLIS V, 1992, ANN NY ACAD SCI, V667, P13, DOI 10.1111/j.1749-6632.1992.tb51591.x; Ellis Vincent, 1994, Fibrinolysis, V8, P1, DOI 10.1016/0268-9499(94)90288-7; FRIGUET B, 1989, PROTEIN STRUCTURE PR, P287; GOODSON RJ, 1994, P NATL ACAD SCI USA, V91, P7129, DOI 10.1073/pnas.91.15.7129; GORETZKI L, 1992, FEBS LETT, V297, P112, DOI 10.1016/0014-5793(92)80339-I; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P15418, DOI 10.1021/bi00255a023; HANSEN AP, 1994, BIOCHEMISTRY-US, V33, P4847, DOI 10.1021/bi00182a013; HIGAZI AA, 1995, J BIOL CHEM, V270, P17375, DOI 10.1074/jbc.270.29.17375; HUSAIN SS, 1991, BIOCHEMISTRY-US, V30, P5797, DOI 10.1021/bi00237a024; ICHINOSE A, 1986, J BIOL CHEM, V261, P3486; KIELBERG V, 1985, FEBS LETT, V182, P441, DOI 10.1016/0014-5793(85)80350-1; KOBAYASHI H, 1991, J BIOL CHEM, V266, P5147; LEE SW, 1994, J BIOL CHEM, V269, P2411; LIJNEN HR, 1990, J BIOL CHEM, V265, P5232; LIJNEN HR, 1986, BIOCHIM BIOPHYS ACTA, V884, P402, DOI 10.1016/0304-4165(86)90190-X; LONGSTAFF C, 1991, BIOCHEMISTRY-US, V30, P979, DOI 10.1021/bi00218a014; MANCHANDA N, 1991, J BIOL CHEM, V266, P14580; MANCHANDA N, 1985, J BIOL CHEM, V270, P20032; MANN KG, 1990, BLOOD, V76, P1; MARCOTTE PA, 1993, BIOCHIM BIOPHYS ACTA, V1161, P105, DOI 10.1016/0167-4838(93)90203-4; MORGAN PH, 1972, P NATL ACAD SCI USA, V69, P3312, DOI 10.1073/pnas.69.11.3312; NEURATH H, 1976, P NATL ACAD SCI USA, V73, P3825, DOI 10.1073/pnas.73.11.3825; NIELSEN LS, 1982, BIOCHEMISTRY-US, V21, P6410, DOI 10.1021/bi00268a014; PANNELL R, 1986, BLOOD, V67, P1215; PETERSEN LC, 1988, J BIOL CHEM, V263, P11189; PLOUG M, 1994, BIOCHEMISTRY-US, V33, P8991, DOI 10.1021/bi00196a017; REDDY KNN, 1972, J BIOL CHEM, V247, P1683; STACK MS, 1994, J BIOL CHEM, V269, P9416; TRAVIS J, 1983, ANNU REV BIOCHEM, V52, P655, DOI 10.1146/annurev.bi.52.070183.003255; WILLIAMS EB, 1989, J BIOL CHEM, V264, P7536; WUN TC, 1982, J BIOL CHEM, V257, P7262	39	50	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14779	14784		10.1074/jbc.271.25.14779	http://dx.doi.org/10.1074/jbc.271.25.14779			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662951	hybrid			2022-12-27	WOS:A1996UT10600024
J	Nystedt, S; Ramakrishnan, V; Sundelin, J				Nystedt, S; Ramakrishnan, V; Sundelin, J			The proteinase-activated receptor 2 is induced by inflammatory mediators in human endothelial cells - Comparison with the thrombin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR NECROSIS FACTOR; LEUKOCYTE ADHESION MOLECULE-1; EXPRESSION; CLONING; INTERLEUKIN-1; MECHANISM; SURFACE; CULTURE; ALPHA	The proteinase-activated receptor 2 (PAR-2) belongs to the family of seven transmembrane region receptors, and, like the related thrombin receptor, it is activated by specific proteolytic cleavage of its extracellular amino terminus. It is not known which proteinase is the physiological activator of the PAR-2, but candidates can be found among the enzymes involved in the inflammatory cascade systems. Here, we have studied the effects of various mediators on the expression of the PAR-S and the thrombin receptor in cultured human umbilical vein endothelial cells. Stimulation with the cytokines tumor necrosis factor alpha or interleukin-1 alpha as well as bacterial lipopolysaccharide elevated the expression of PAR-S in a dose-dependent manner. The time course of induction after cytokine stimulation was similar to those published for the adhesion molecules intercellular adhesion molecule-1 and vascular cell adhesion molecule-1. After 20 h of stimulation, PAR-2 mRNA and protein levels were increased to 5-10-fold basal values, and, in the continued presence of tumor necrosis factor cu, PAR-2 mRNA expression was found to remain elevated for up to 4 days, In contrast, the thrombin receptor gene was not induced by any of these inflammatory mediators, The responses to phorbol ester treatment also differed between the two genes. Thrombin receptor mRNA levels decreased steadily up to 20 h, whereas PAR-2 mRNA levels first rose to about 3-fold basal values at 4 h before decreasing again. Cell surface protein levels of both receptors were decreased after 20 h of phorbol ester stimulation, Elevating intracellular cAMP levels by treatment with forskolin resulted in decreased expression of both receptors, and inhibition of cAMP degradation appeared to blunt the cytokine-induced increase in PAR-2 expression. The induction of the PAR-2 by cytokine treatment supports the concept of PAR-2 involvement in the acute inflammatory response.	COR THERAPEUT INC,SAN FRANCISCO,CA 94080		Nystedt, S (corresponding author), LUND UNIV,WALLENBERG NEUROCTR,DIV MOLEC NEUROBIOL,WALLENBERG LAB,SOLVEGATAN 17,S-22362 LUND,SWEDEN.							BERMAN RS, 1993, BRIT J PHARMACOL, V110, P1282, DOI 10.1111/j.1476-5381.1993.tb13956.x; BEVILACQUA MP, 1984, J EXP MED, V160, P618, DOI 10.1084/jem.160.2.618; BEVILACQUA MP, 1989, SCIENCE, V243, P1160, DOI 10.1126/science.2466335; CHEN J, 1994, J BIOL CHEM, V269, P16041; DELUCA LG, 1994, J BIOL CHEM, V269, P19193; HEIN L, 1994, J BIOL CHEM, V269, P27719; HORVAT R, 1995, J CELL SCI, V108, P1155; JAFFE EA, 1973, J CLIN INVEST, V52, P2745, DOI 10.1172/JCI107470; KOGA S, 1995, AM J PHYSIOL-CELL PH, V268, pC1104, DOI 10.1152/ajpcell.1995.268.5.C1104; MOORE KL, 1989, BLOOD, V73, P159; MOORE KL, 1987, J CLIN INVEST, V79, P124, DOI 10.1172/JCI112772; NAWROTH PP, 1986, J EXP MED, V163, P740, DOI 10.1084/jem.163.3.740; NORTON KJ, 1993, BLOOD, V82, P2125; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1995, EUR J BIOCHEM, V232, P84, DOI 10.1111/j.1432-1033.1995.tb20784.x; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; OSBORN L, 1989, CELL, V59, P1203, DOI 10.1016/0092-8674(89)90775-7; POBER JS, 1993, J IMMUNOL, V150, P5114; POBER JS, 1986, J IMMUNOL, V137, P1893; POBER JS, 1990, TRANSPLANTATION, V50, P427; RASMUSSEN UB, 1991, FEBS LETT, V288, P123, DOI 10.1016/0014-5793(91)81017-3; ROLLINS BJ, 1990, AM J PATHOL, V136, P1229; ROYALL JA, 1989, AM J PHYSIOL, V257, pL399, DOI 10.1152/ajplung.1989.257.6.L399; SOIFER SJ, 1994, AM J PATHOL, V144, P60; SPRINGER TA, 1995, ANNU REV PHYSIOL, V57, P827, DOI 10.1146/annurev.ph.57.030195.004143; STRIETER RM, 1989, SCIENCE, V243, P1467, DOI 10.1126/science.2648570; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WOOLKALIS MJ, 1995, J BIOL CHEM, V270, P9868, DOI 10.1074/jbc.270.17.9868; XIE W, 1991, BIOTECHNIQUES, V11, P325; ZACHARIAS U, 1995, J BIOL CHEM, V270, P545, DOI 10.1074/jbc.270.2.545	31	311	317	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14910	14915		10.1074/jbc.271.25.14910	http://dx.doi.org/10.1074/jbc.271.25.14910			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663011	hybrid			2022-12-27	WOS:A1996UT10600043
J	Kumari, M; Stroud, JC; Anji, A; McCarrey, JR				Kumari, M; Stroud, JC; Anji, A; McCarrey, JR			Differential appearance of DNase I-hypersensitive sites correlates with differential transcription of Pgk genes during spermatogenesis in the mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LINKED PHOSPHOGLYCERATE KINASE; X-CHROMOSOME INACTIVATION; SEX-DETERMINING REGION; PDGF-B GENE; CHROMATIN STRUCTURE; MORPHOLOGICAL CHARACTERIZATION; NUCLEOTIDE-SEQUENCE; EXPRESSION; TESTIS; PROMOTER	Two functional genes encoding phosphoglycerate kinase are differentially expressed during spermatogenesis in the mouse. Expression of the X-linked Pgh-l gene is repressed coincident with X chromosome inactivation during prophase of meiosis I. At this same stage, expression of the autosomal Pgk-2 gene is initiated by tissue specific mechanisms, To investigate the role of chromatin structure in these processes, we have examined the appearance and disappearance of DNase I-hypersensitive (DH) sites in each gene, and correlated this with transcriptional activity as measured by nuclear run off analysis at specific stages of spermatogenesis, Our results demonstrate that the occurrence of DH sites is related to periods of active transcription, Results with the Pgk-1 gene indicate that transcriptional inactivation of the X chromosome in spermatogenic cells may not be as complete as that in somatic cells, and that maximum repression may be limited to a very transient period during the pachytene stage of first meiotic prophase. Results with the Pgk-2 gene indicate that DH sites appear coincident with, or just prior to, transcriptional activation of this gene, The implications of these results are discussed with respect to the role of X chromosome inactivation in spermatogenic cells and the developmental order of molecular events that regulate differential gene expression during spermatogenesis.	SW FDN BIOMED RES, DEPT GENET, SAN ANTONIO, TX 78245 USA	Texas Biomedical Research Institute			Stroud, James C/B-3230-2012	Stroud, James C/0000-0003-0850-4812	NICHD NIH HHS [HD 23126] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD023126] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; ARIEL M, 1994, NAT GENET, V7, P59, DOI 10.1038/ng0594-59; BECK KM, 1991, NUCLEIC ACIDS RES, V19, P4975, DOI 10.1093/nar/19.18.4975; BELLVE AR, 1977, J CELL BIOL, V74, P68, DOI 10.1083/jcb.74.1.68; BERG WM, 1993, LIFE SCI ADV MOL BIO, V12, P85; BOER PH, 1987, MOL CELL BIOL, V7, P3107, DOI 10.1128/MCB.7.9.3107; BURCH JBE, 1983, CELL, V33, P65, DOI 10.1016/0092-8674(83)90335-5; CHOUDHARY SK, 1995, J BIOL CHEM, V270, P8755, DOI 10.1074/jbc.270.15.8755; DIRKS RPH, 1993, EUR J BIOCHEM, V211, P509, DOI 10.1111/j.1432-1033.1993.tb17577.x; DIRKS RPH, 1993, EUR J BIOCHEM, V216, P487, DOI 10.1111/j.1432-1033.1993.tb18167.x; ELGIN SCR, 1984, NATURE, V309, P213, DOI 10.1038/309213a0; Forejt J., 1982, Genetic control of gamete production and function, P135; FRANKLIN GC, 1991, EMBO J, V10, P1365, DOI 10.1002/j.1460-2075.1991.tb07656.x; GEBARA MM, 1992, MOL CELL BIOL, V12, P1422, DOI 10.1128/MCB.12.4.1422; GOTO M, 1990, EXP CELL RES, V186, P273, DOI 10.1016/0014-4827(90)90306-U; GRANT M, 1992, NAT GENET, V2, P161, DOI 10.1038/ng1092-161; GREEN GR, 1994, MOL REPROD DEV, V37, P255, DOI 10.1002/mrd.1080370303; GROSS DS, 1988, ANNU REV BIOCHEM, V57, P159, DOI 10.1146/annurev.bi.57.070188.001111; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; Handel M A, 1987, Results Probl Cell Differ, V15, P1; HANDELMAN SL, 1987, COMMUNITY DENT ORAL, V15, P1, DOI 10.1111/j.1600-0528.1987.tb00470.x; HENDRIKSEN PJM, 1995, DEV BIOL, V170, P730, DOI 10.1006/dbio.1995.1252; HENKEL G, 1992, J IMMUNOL, V149, P3239; KUHNERT P, 1992, NUCLEIC ACIDS RES, V20, P1943, DOI 10.1093/nar/20.8.1943; LIFSCHYTZ E, 1972, P NATL ACAD SCI USA, V69, P182, DOI 10.1073/pnas.69.1.182; MCBURNEY MW, 1991, NUCLEIC ACIDS RES, V19, P5755, DOI 10.1093/nar/19.20.5755; MCBURNEY MW, 1994, SOMAT CELL MOLEC GEN, V20, P515, DOI 10.1007/BF02255842; McCarrey J, 1993, CELL MOL BIOL TESTIS, P58; MCCARREY JR, 1992, NAT GENET, V2, P200, DOI 10.1038/ng1192-200; MCCARREY JR, 1992, GENET ANAL-BIOMOL E, V9, P117, DOI 10.1016/1050-3862(92)90051-6; MCCARREY JR, 1992, DEV BIOL, V154, P160, DOI 10.1016/0012-1606(92)90056-M; MCKEE BD, 1993, CHROMOSOMA, V102, P71, DOI 10.1007/BF00356023; MIZUNO K, 1992, GENE, V119, P293, DOI 10.1016/0378-1119(92)90286-X; MONESI V, 1967, ARCH ANAT MICROSC MO, V56, P61; MORI N, 1986, GENE, V45, P275; NEBEL BR, 1961, SCIENCE, V134, P832, DOI 10.1126/science.134.3482.832; Penny GD, 1996, NATURE, V379, P131, DOI 10.1038/379131a0; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; RICHLER C, 1992, NAT GENET, V2, P192, DOI 10.1038/ng1192-192; RILEY DE, 1984, NUCLEIC ACIDS RES, V12, P1829, DOI 10.1093/nar/12.4.1829; RILEY DE, 1986, SOMAT CELL MOLEC GEN, V12, P73, DOI 10.1007/BF01560729; ROBINSON MO, 1989, P NATL ACAD SCI USA, V86, P8437, DOI 10.1073/pnas.86.21.8437; ROMRELL LJ, 1976, DEV BIOL, V49, P119, DOI 10.1016/0012-1606(76)90262-1; SALIDO EC, 1992, NAT GENET, V2, P196, DOI 10.1038/ng1192-196; SINCLAIR AH, 1990, NATURE, V346, P240, DOI 10.1038/346240a0; SINGERSAM J, 1992, P NATL ACAD SCI USA, V89, P1413, DOI 10.1073/pnas.89.4.1413; SINGERSAM J, 1990, NUCLEIC ACID METHYLA, V128, P285; SINGH S, 1991, BIOCHEM BIOPH RES CO, V181, P131, DOI 10.1016/S0006-291X(05)81391-9; Stott D, 1991, Methods Mol Biol, V7, P327, DOI 10.1385/0-89603-178-0:327; Sutherland Leslie C., 1995, Gene Expression, V4, P265; TOMMASI S, 1993, SOMAT CELL MOLEC GEN, V19, P529, DOI 10.1007/BF01233380; TUNNACLIFFE A, 1990, NUCLEIC ACIDS RES, V18, P459, DOI 10.1093/nar/18.3.459; VANDEBERG JL, 1985, ISOZYMES-CURR T BIOL, V12, P133; VUORIO E, 1990, ANNU REV BIOCHEM, V59, P837, DOI 10.1146/annurev.bi.59.070190.004201; WU C, 1980, NATURE, V286, P854, DOI 10.1038/286854a0; YANG TP, 1988, SOMAT CELL MOLEC GEN, V14, P461, DOI 10.1007/BF01534712; YANG TP, 1987, MOL CELL BIOL, V7, P2994, DOI 10.1128/MCB.7.8.2994	58	31	31	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14390	14397		10.1074/jbc.271.24.14390	http://dx.doi.org/10.1074/jbc.271.24.14390			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662942	hybrid			2022-12-27	WOS:A1996UQ66000068
J	Watabe, M; Masuda, Y; Nakajo, S; Yoshida, T; Kuroiwa, Y; Nakaya, K				Watabe, M; Masuda, Y; Nakajo, S; Yoshida, T; Kuroiwa, Y; Nakaya, K			The cooperative interaction of two different signaling pathways in response to bufalin induces apoptosis in human leukemia U937 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; ACTIVATED MAP KINASE; HL-60 CELLS; TOPOISOMERASE INHIBITORS; ANTICANCER DRUGS; PROTEIN; INDUCTION; CAMPTOTHECIN; PHOSPHATASE; THYMOCYTES	Bufalin, an active principle of Chinese medicine, chan'su, induced typical apoptosis in human leukemia U937 cells. When U937 cells were treated with 10(-8) bufalin in the absence of serum, mitogen-activated protein (MAP) kinase activity was markedly increased 6 h after the start of treatment and elevated so for 12 h. Prior to the activation of MAP kinase, increased activities of Pas, Raf-1, and MAP kinase kinase were found, but these enzymes were transiently activated by the treatment with bufalin. These results suggest that the signal was transmitted sequentially from Pas, Raf-1, and MAP kinase kinase to MAP kinase. In association with this signal transduction, the concentration of cAMP in the cells decreased markedly, suggesting that Raf-1 was also activated by a decrease in the extent of phosphorylation by protein kinase A. In fact, pretreatment of U937 cells with forskolin and 3-isobutyl-1-methylxanthine, which are known to increase the concentration of cAMP in the cells, and subsequent treatment with bufalin resulted in a decrease in both Raf-1 activity and DNA fragmentation. To confirm the participation of MAP kinase in the apoptotic process, antisense cDNA for MAP kinase kinase 1 was expressed in U937 cells. The transformants were significantly resistant to both DNA fragmentation and cell death in response to bufalin. Our findings suggest that a pathway with the persistent activation of MAP kinase in U937 cells in response to bufalin is at least one of the signal transduction pathways involved in the induction of apoptosis.	SHOWA UNIV,SCH PHARMACEUT SCI,BIOL CHEM LAB,SHINAGAWA KU,TOKYO 142,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,LAB BIOCHEM TOXICOL,SHINAGAWA KU,TOKYO 142,JAPAN; SHOWA UNIV,SCH PHARMACEUT SCI,CLIN PHARM LAB,SHINAGAWA KU,TOKYO 142,JAPAN	Showa University; Showa University; Showa University								BALL RL, 1990, J BIOL CHEM, V265, P12836; BARRY MA, 1990, BIOCHEM PHARMACOL, V40, P2353, DOI 10.1016/0006-2952(90)90733-2; BERTRAND R, 1993, EXP CELL RES, V207, P388, DOI 10.1006/excr.1993.1206; Bertrand R., 1993, Proceedings of the American Association for Cancer Research Annual Meeting, V34, P292; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU S, 1990, BIOCHEM BIOPH RES CO, V166, P160, DOI 10.1016/0006-291X(90)91925-I; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DREWES G, 1992, EMBO J, V11, P2121; EVANS DL, 1993, CANCER RES, V53, P2133; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; HOSHI M, 1988, J BIOL CHEM, V263, P5396; JING YK, 1994, JPN J CANCER RES, V85, P645, DOI 10.1111/j.1349-7006.1994.tb02408.x; JING YK, 1993, ANTICANCER RES, V13, P1049; KAUFMANN SH, 1989, CANCER RES, V49, P5870; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAVANDERO S, 1990, RES COMMUN CHEM PATH, V69, P317; LEE F, 1981, NATURE, V294, P228, DOI 10.1038/294228a0; MANIATIS T, 1982, MOL CLONING LABORATO, P187; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARTIN SJ, 1990, CLIN EXP IMMUNOL, V79, P448; NAIR BG, 1989, BIOCHEM J, V264, P563, DOI 10.1042/bj2640563; NAKAYA K, 1991, JPN J CANCER RES, V82, P184, DOI 10.1111/j.1349-7006.1991.tb01827.x; NOGUCHI K, 1995, JPN J CANCER RES, V86, P217, DOI 10.1111/j.1349-7006.1995.tb03042.x; ONISHI Y, 1993, BIOCHIM BIOPHYS ACTA, V1175, P147, DOI 10.1016/0167-4889(93)90017-J; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; SAKAI I, 1993, BIOCHEM BIOPH RES CO, V191, P873, DOI 10.1006/bbrc.1993.1298; SCHIEMANN WP, 1994, J BIOL CHEM, V269, P6376; SELVAKUMARAN M, 1994, MOL CELL BIOL, V14, P2352, DOI 10.1128/MCB.14.4.2352; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; YOSHIDA A, 1993, JPN J CANCER RES, V84, P566, DOI 10.1111/j.1349-7006.1993.tb00177.x; ZHANG LS, 1992, CANCER RES, V52, P4634	36	123	142	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14067	14073		10.1074/jbc.271.24.14067	http://dx.doi.org/10.1074/jbc.271.24.14067			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662906	hybrid			2022-12-27	WOS:A1996UQ66000023
J	Popp, B; Court, DA; Benz, R; Neupert, W; Lill, R				Popp, B; Court, DA; Benz, R; Neupert, W; Lill, R			The role of the N and C termini of recombinant Neurospora mitochondrial porin in channel formation and voltage-dependent gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANION-SELECTIVE CHANNEL; OUTER-MEMBRANE; ESCHERICHIA-COLI; PROTEIN; PURIFICATION; CRASSA; CDNA; CLONING; EXPRESSION; IMPORT	To investigate the role of the N and C termini in channel function and voltage-dependent gating of mitochondrial porin, we expressed wild-type and mutant porins from Neurospora crassa as His-tag fusion products in Escherichia coli, Large quantities of the proteins were purified by chromatography across a nickle-nitrilotriacetic acid-agarose column under denaturing conditions. The purified His-tagged wild-type protein could be functionally reconstituted in the presence of detergent and sterol and behaved in black lipid bilayer membranes indistinguishably from native porin isolated from Neurospora crassa mitochondria. Mutants of porin lacking part of the N terminus (Delta N2-12porin, Delta N3-20porin), part of the C terminus (Delta C269-283porin), or both (Delta N2-12/Delta C269-283porin) also showed channel forming activity. The mutant porin lacking the C terminus had a smaller single channel conductance than the wild-type protein, but its other biophysical properties were identical. Delta N2-12porin and Delta N3-20porin formed noisy channels with decreased channel stability. These channels were still voltage-dependent. Delta N2-12/Delta C269-283porin lost channel stability and had altered gating characteristics. These results are discussed with respect to different models that have been proposed in the literature for the structure of mitochondrial porin channels.	UNIV WURZBURG,THEODOR BOVERI INST BIOZENTRUM,LEHRSTUHL BIOTECHNOL,D-97074 WURZBURG,GERMANY; UNIV MUNICH,INST PHYSIOL CHEM PHYS BIOCHEM & ZELLBIOL,D-80336 MUNICH,GERMANY	University of Wurzburg; University of Munich				Lill, Roland/0000-0002-8345-6518; Benz, Roland/0000-0002-9510-9265; Court, Deborah A./0000-0003-1919-8339				BAUER K, 1989, J BIOL CHEM, V264, P16393; BENZ R, 1978, BIOCHIM BIOPHYS ACTA, V511, P305, DOI 10.1016/0005-2736(78)90269-9; BENZ R, 1994, BBA-REV BIOMEMBRANES, V1197, P167, DOI 10.1016/0304-4157(94)90004-3; BLACHLYDYSON E, 1990, SCIENCE, V247, P1233, DOI 10.1126/science.1690454; BLACHLYDYSON E, 1994, GENOMICS, V20, P62, DOI 10.1006/geno.1994.1127; BLACHLYDYSON E, 1993, J BIOL CHEM, V268, P1835; CARBONARA F, 1996, IN PRESS J BIOENERG; COLOMBINI M, 1980, J MEMBRANE BIOL, V53, P79, DOI 10.1007/BF01870576; COLOMBINI M, 1979, NATURE, V279, P643, DOI 10.1038/279643a0; COWAN SW, 1992, NATURE, V358, P727, DOI 10.1038/358727a0; Davis R.H., 1970, METHODS ENZYMOL, V17, P79, DOI [10.1016/0076-6879(71)17168-6, DOI 10.1016/0076-6879(71)17168-6]; DEPINTO V, 1989, EUR J BIOCHEM, V183, P179; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V894, P109, DOI 10.1016/0005-2728(87)90180-0; DEPINTO V, 1987, BIOCHIM BIOPHYS ACTA, V905, P499, DOI 10.1016/0005-2736(87)90480-9; DEPINTO V, 1991, BIOCHEMISTRY-US, V30, P10191, DOI 10.1021/bi00106a017; FISCHER K, 1994, J BIOL CHEM, V269, P25754; FREITAG H, 1982, EUR J BIOCHEM, V123, P629; GUO XW, 1995, J STRUCT BIOL, V114, P41, DOI 10.1006/jsbi.1995.1004; HA HJ, 1993, J BIOL CHEM, V268, P12143; HAMAJIMA S, 1988, J BIOCHEM-TOKYO, V104, P362, DOI 10.1093/oxfordjournals.jbchem.a122474; HEINS L, 1994, J BIOL CHEM, V269, P26402; KAYSER H, 1989, BIOL CHEM H-S, V370, P1265; KLEENE R, 1987, EMBO J, V6, P2627, DOI 10.1002/j.1460-2075.1987.tb02553.x; LINDEN M, 1982, BIOCHEM J, V208, P77, DOI 10.1042/bj2080077; MANNELLA CA, 1986, BIOPHYS J, V49, P307, DOI 10.1016/S0006-3495(86)83643-8; MANNELLA CA, 1989, FEBS LETT, V253, P231, DOI 10.1016/0014-5793(89)80965-2; MIHARA K, 1985, EMBO J, V4, P769, DOI 10.1002/j.1460-2075.1985.tb03695.x; OBRIEN RL, 1965, J BIOL CHEM, V240, P4527; PENG S, 1992, BIOPHYS J, V62, P123, DOI 10.1016/S0006-3495(92)81799-X; PFAFF E, 1968, EUR J BIOCHEM, V5, P222, DOI 10.1111/j.1432-1033.1968.tb00361.x; PFALLER R, 1985, J BIOL CHEM, V260, P8188; PFANNER N, 1985, EMBO J, V4, P2819, DOI 10.1002/j.1460-2075.1985.tb04009.x; POPP B, 1995, BIOCHEMISTRY-US, V34, P3352, DOI 10.1021/bi00010a026; ROOS N, 1982, BIOCHIM BIOPHYS ACTA, V686, P204, DOI 10.1016/0005-2736(82)90114-6; SCHEIN SJ, 1976, J MEMBRANE BIOL, V30, P99, DOI 10.1007/BF01869662; STANLEY S, 1995, J BIOL CHEM, V270, P16694, DOI 10.1074/jbc.270.28.16694; THOMAS L, 1993, P NATL ACAD SCI USA, V90, P5446, DOI 10.1073/pnas.90.12.5446; TROLL H, 1992, J BIOL CHEM, V267, P21072; VILLAREJO MR, 1974, J BACTERIOL, V120, P466, DOI 10.1128/JB.120.1.466-474.1974; WEISS MS, 1991, SCIENCE, V254, P1617; ZALMAN LS, 1980, J BIOL CHEM, V255, P1771; ZIZI M, 1995, J MEMBRANE BIOL, V144, P121	42	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13593	13599		10.1074/jbc.271.23.13593	http://dx.doi.org/10.1074/jbc.271.23.13593			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662769	hybrid			2022-12-27	WOS:A1996UP38500045
J	Stuart, RO; Sun, A; Bush, KT; Nigam, SK				Stuart, RO; Sun, A; Bush, KT; Nigam, SK			Dependence of epithelial intercellular junction biogenesis on thapsigargin-sensitive intracellular calcium stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL CELL CONTACT; TIGHT JUNCTION; ENDOPLASMIC-RETICULUM; PROTEIN; LOCALIZATION; RECEPTORS; POLARITY; MOUSE; ZO-1	Perturbation of potentially regulatable endoplasmic reticulum (ER) calcium stores with the Ca-ATPase inhibitor, thapsigargin (TG), perturbs the formation of desmosomes and tight junctions during polarized epithelial cell biogenesis, despite the development of cell contact. In Madin-Darby canine kidney cell model for intercellular junction assembly, TG treatment inhibited the development of transepithelial electrical resistance (TER), a measure of tight junction assembly, in a dose-dependent manner. The TG-induced inhibition of tight junction assembly was paralleled by a defect in the sorting of the tight junction protein, ZO-1. An even more dramatic delay in sorting of the desmosomal protein, desmoplakin, was observed in the presence of TG. In addition, while both ZO-1 and desmoplakin-I in control cells were shown to become associated with the Triton X-100 insoluble cytoskeleton during intercellular junction assembly, prior treatment with 100 nM TG diminished this biochemical stabilization into the detergent-insoluble fraction, particularly in the case of ZO-1. Although spectrofluorimetric measurements in fura-2 loaded Madin-Darby canine kidney cells confirmed the occurrence of TG-mediated release of calcium form internal stores, total cytosolic calcium during junction assembly remained similar to untreated cells. Therefore, the normal intercellular junction biogenesis if intracellular stores are perturbed by TG. The results indicate the presence of calcium-sensitive intracellular mechanisms involved in the sorting and cytoskeletal stabilization of both tight junction and desmosomes and suggest a role for calcium-dependent signaling pathways at an early (possible common) step in polarized epithelial biogenesis.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DIV RENAL,DEPT MED,BOSTON,MA 02115; BROWN UNIV,RHODE ISL HOSP,SCH MED,DIV RENAL,PROVIDENCE,RI 02903	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Brown University; Lifespan Health Rhode Island; Rhode Island Hospital					NIDDK NIH HHS [5-T32-DK07527-09, R01DK44503, 1 F32 DK08822-01A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK008822, R01DK044503, T32DK007527] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON JM, 1988, J CELL BIOL, V106, P1141, DOI 10.1083/jcb.106.4.1141; BALDA MS, 1993, J CELL BIOL, V123, P293, DOI 10.1083/jcb.123.2.293; BUSH KT, 1994, J BIOL CHEM, V269, P23694; BUSH KT, 1990, ANAT EMBRYOL, V181, P49; CEREIJIDO M, 1981, AM J PHYSIOL, V240, pC96, DOI 10.1152/ajpcell.1981.240.3.C96; CONTRERAS R G, 1992, News in Physiological Sciences, V7, P105; GHOSH TK, 1991, J BIOL CHEM, V266, P24690; GONZALEZMARISCAL L, 1990, AM J PHYSIOL, V259, pC978, DOI 10.1152/ajpcell.1990.259.6.C978; GUMBINER B, 1988, J CELL BIOL, V107, P1575, DOI 10.1083/jcb.107.4.1575; HANDLER JS, 1989, ANNU REV PHYSIOL, V51, P729, DOI 10.1146/annurev.ph.51.030189.003501; LYTTON J, 1992, Current Opinion in Cell Biology, V4, P220, DOI 10.1016/0955-0674(92)90036-C; NIGAM SK, 1991, BIOCHEM BIOPH RES CO, V181, P548, DOI 10.1016/0006-291X(91)91224-Z; NIGAM SK, 1989, J BIOL CHEM, V264, P16927; NIGAM SK, 1992, P NATL ACAD SCI USA, V89, P6162, DOI 10.1073/pnas.89.13.6162; PASDAR M, 1988, J CELL BIOL, V106, P677, DOI 10.1083/jcb.106.3.677; PUTNEY JW, 1987, TRENDS PHARMACOL SCI, V8, P481, DOI 10.1016/0165-6147(87)90043-5; RODRIGUEZBOULAN E, 1989, SCIENCE, V245, P718, DOI 10.1126/science.2672330; SHARP AH, 1992, J BIOL CHEM, V267, P7444; SILICIANO JD, 1988, J CELL BIOL, V107, P2389, DOI 10.1083/jcb.107.6.2389; SIMONS K, 1991, MORPHOREGULATORY MOL, P341; STUART RO, 1994, J CELL PHYSIOL, V159, P423, DOI 10.1002/jcp.1041590306; STUART RO, 1995, P NATL ACAD SCI USA, V92, P6072, DOI 10.1073/pnas.92.13.6072; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THASTRUP O, 1989, AGENTS ACTIONS, V27, P17, DOI 10.1007/BF02222186	24	92	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13636	13641		10.1074/jbc.271.23.13636	http://dx.doi.org/10.1074/jbc.271.23.13636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662885	hybrid			2022-12-27	WOS:A1996UP38500051
J	Jensen, PE; Gibson, LCD; Henningsen, KW; Hunter, CN				Jensen, PE; Gibson, LCD; Henningsen, KW; Hunter, CN			Expression of the chlI, chlD, and chlH genes from the cyanobacterium Synechocystis PCC6803 in Escherichia coli and demonstration that the three cognate proteins are required for magnesium-protoporphyrin chelatase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MG-CHELATASE; CHLOROPHYLL BIOSYNTHESIS; ARABIDOPSIS-THALIANA; CLUSTER; ASSAY; ATP; IX	Magnesium-protoporphyrin chelatase catalyzes the first step unique to chlorophyll synthesis: the insertion of Mg2+ into protoporphyrin IX, Genes from Synechocystis sp, PCC6803 with homology to the bchI and bchD genes of Rhodobacter sp, were cloned using degenerate oligonucleotides. The function of these genes, putatively encoding subunits of magnesium chelatase, was established by overexpression in Escherichia coli, including the overexpression of Synechocystis chlH, previously cloned as a homolog of the Rhodobacter bchH gene, The combined cell-free extracts were able to catalyze the insertion of Mg2+ into protoporphyrin IX in an ATP-dependent manner and only when the products of all three genes were present, The ChlH, ChlI, and ChlD gene products are therefore assigned to the magnesium chelatase step in chlorophyll a biosynthesis in Synechocystis PCC6803, The primary structure of the Synechocystis ChlD protein reveals some interesting features; the N-terminal half of the protein shows 40-41% identity to Rhodobacter BchI and Synechocystis ChlI, whereas the C-terminal half displays 33% identity to Rhodobacter BchD, This suggests a functional as well as an evolutionary relationship between the ''I'' and ''D'' genes.	UNIV SHEFFIELD,ROBERT HILLS INST PHOTOSYNTHESIS,DEPT MOLEC BIOL & BIOTECHNOL,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND; ROYAL VET & AGR UNIV,DEPT ECOL & MOLEC BIOL,DK-1870 FREDERIKSBERG C,DENMARK; CARLSBERG LAB,DEPT PHYSIOL,DK-2500 COPENHAGEN,DENMARK	University of Sheffield; University of Copenhagen	Jensen, PE (corresponding author), UNIV SHEFFIELD,KREBS INST BIOMOLEC RES,SHEFFIELD S10 2TN,S YORKSHIRE,ENGLAND.		Jensen, Poul Erik/A-4862-2014	Jensen, Poul Erik/0000-0001-6524-7723				ARMSTRONG GA, 1989, MOL GEN GENET, V216, P254, DOI 10.1007/BF00334364; Ausubel FM., 1987, CURRENT PROTOCOLS MO, DOI 10.1002/mrd.1080010210; CASTELFRANCO PA, 1979, ARCH BIOCHEM BIOPHYS, V192, P592, DOI 10.1016/0003-9861(79)90130-9; COOMBER SA, 1990, MOL MICROBIOL, V4, P977, DOI 10.1111/j.1365-2958.1990.tb00670.x; COWAN PM, 1955, NATURE, V176, P501, DOI 10.1038/176501a0; FUESLER TP, 1981, PLANT PHYSIOL, V67, P246, DOI 10.1104/pp.67.2.246; GIBSON LCD, 1995, P NATL ACAD SCI USA, V92, P1941, DOI 10.1073/pnas.92.6.1941; Gibson LCD, 1996, PLANT PHYSIOL, V111, P61, DOI 10.1104/pp.111.1.61; HENNINGSEN KW, 1993, BIOL SKRIFTER, V42, P1; HUDSON A, 1993, EMBO J, V12, P3711, DOI 10.1002/j.1460-2075.1993.tb06048.x; Jensen P., 1996, PLANT MOL BIOL, V30, P1075; Jensen PE, 1996, MOL GEN GENET, V250, P383; KONCZ C, 1990, EMBO J, V9, P1337, DOI 10.1002/j.1460-2075.1990.tb08248.x; Kotani H, 1995, DNA Res, V2, P133, DOI 10.1093/dnares/2.3.133; Kotani H, 1994, DNA Res, V1, P303, DOI 10.1093/dnares/1.6.303; LEE HJ, 1992, PLANT PHYSIOL, V99, P1134, DOI 10.1104/pp.99.3.1134; ORSAT B, 1992, FEBS LETT, V303, P181, DOI 10.1016/0014-5793(92)80514-H; PARDO AD, 1980, PLANT PHYSIOL, V65, P956, DOI 10.1104/pp.65.5.956; RICHTER ML, 1982, BIOCHIM BIOPHYS ACTA, V717, P255, DOI 10.1016/0304-4165(82)90177-5; ROSENBERG AH, 1987, GENE, V56, P125, DOI 10.1016/0378-1119(87)90165-X; Sambrook J., 2002, MOL CLONING LAB MANU; von Wettstein D., 1971, AUTONOMY BIOGENESIS, P205; WALKER CJ, 1991, P NATL ACAD SCI USA, V88, P5789, DOI 10.1073/pnas.88.13.5789; WALKER CJ, 1994, BIOCHEM J, V299, P277, DOI 10.1042/bj2990277; WALKER CJ, 1992, PLANT PHYSIOL BIOCH, V30, P263; WALKER CJ, 1995, PHYSIOL PLANTARUM, V94, P419, DOI 10.1111/j.1399-3054.1995.tb00948.x; WILLIAMSON MP, 1994, BIOCHEM J, V297, P249, DOI 10.1042/bj2970249; ZSEBO KM, 1984, CELL, V37, P937, DOI 10.1016/0092-8674(84)90428-8	28	118	130	1	15	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16662	16667		10.1074/jbc.271.28.16662	http://dx.doi.org/10.1074/jbc.271.28.16662			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663186	hybrid			2022-12-27	WOS:A1996UX12600039
J	Yanai, K; Nibu, Y; Murakami, K; Fukamizu, A				Yanai, K; Nibu, Y; Murakami, K; Fukamizu, A			A cis-acting DNA element located between TATA box and transcription initiation site is critical in response to regulatory sequences in human angiotensinogen gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMALIAN-CELLS; TRANSGENIC MICE; BINDING PROTEIN; TFIID COMPLEX; HUMAN RENIN; PROMOTER; EXPRESSION; MECHANISM; ENHANCER; SYSTEM	The promoter of the human angiotensinogen (hAG) gene functioned in its own core promoter context but not when replaced with simian virus 40 (SV40) core promoter, suggesting the presence of a transcriptionally important cis-acting sequence, Electrophoretic mobility shift assays demonstrated that a ubiquitously expressed nuclear factor, AGCF1, bound to AGCE1 (hAG core promoter element I; positions -25 to -1) located between the TATA box and transcription initiation site. Substitution mutation in AGCE 1 which disrupted AGCF1 binding affected the promoter activity more severely than a nonsense mutation of the hAG TATA sequences did, When AGCE1 was placed at the downstream of SV40 core promoter, the responsiveness to hAG upstream re gion was significantly restored. Furthermore, mutation and in vivo competition experiments suggested that AGCF1 acts as a critical regulator of hAG transcription by mediating the activity of the hAG upstream and downstream enhancer elements, DNase I footprinting and UV cross-linking analyses showed that AGCF1 with apparent molecular masses of 31, 33, and 43 kDa as the components protected the region from -26 to -9 which partially overlapped with the TATA box consensus sequences, These findings indicate that AGCE 1 in addition to the TATA box plays a key role in mediating the hAG regulatory elements.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,TSUKUBA ADV RES ALLIANCE,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba			fukamizu, akiyoshi/J-5350-2012; Nibu, Yutaka/J-4136-2019	fukamizu, akiyoshi/0000-0002-8786-6020; Nibu, Yutaka/0000-0002-4696-7503				AIRD WC, 1994, J BIOL CHEM, V269, P883; BKER KM, 1992, ANN REV PHYSL, V54, P227; CAULFIELD M, 1994, NEW ENGL J MED, V330, P1629, DOI 10.1056/NEJM199406093302301; CHATTERJEE VKK, 1989, P NATL ACAD SCI USA, V86, P9114, DOI 10.1073/pnas.86.23.9114; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; DESMARAIS D, 1992, EMBO J, V11, P2971, DOI 10.1002/j.1460-2075.1992.tb05367.x; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; FUKAMIZU A, 1990, J BIOL CHEM, V265, P7576; FUKAMIZU A, 1994, J BIOL CHEM, V269, P31252; FUKAMIZU A, 1993, J BIOL CHEM, V268, P11617; FUKAMIZU A, 1991, BIOMED BIOCHIM ACTA, V50, P659; GILMOUR DS, 1990, MOL CELL BIOL, V10, P4233, DOI 10.1128/MCB.10.8.4233; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HATA A, 1994, J CLIN INVEST, V93, P1285, DOI 10.1172/JCI117083; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HERNANDEZ N, 1993, GENE DEV, V7, P1219; JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4458; LANG D, 1993, J VIROL, V67, P323, DOI 10.1128/JVI.67.1.323-331.1993; MCCORMICK A, 1991, GENE DEV, V5, P1490, DOI 10.1101/gad.5.8.1490; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; NIBU Y, 1994, J BIOL CHEM, V269, P28598; NIBU Y, 1994, BIOCHEM BIOPH RES CO, V205, P1102, DOI 10.1006/bbrc.1994.2779; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; PUGH BF, 1991, GENE DEV, V5, P1935, DOI 10.1101/gad.5.11.1935; PUGH BF, 1992, J BIOL CHEM, V267, P679; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; REID IA, 1978, ANNU REV PHYSIOL, V40, P377, DOI 10.1146/annurev.ph.40.030178.002113; RIGBY PWJ, 1993, CELL, V72, P7, DOI 10.1016/0092-8674(93)90042-O; SADOSHIMA J, 1993, CELL, V75, P977, DOI 10.1016/0092-8674(93)90541-W; SHIMADA S, 1995, ENDOCRINE, V3, P543, DOI 10.1007/BF02738831; SMALE ST, 1989, CELL, V57, P103, DOI 10.1016/0092-8674(89)90176-1; STRUHL K, 1994, SCIENCE, V263, P1103, DOI 10.1126/science.8108728; TAKAHASHI S, 1991, BIOCHEM BIOPH RES CO, V180, P1103, DOI 10.1016/S0006-291X(05)81180-5; TAMURA T, 1990, EMBO J, V9, P3101, DOI 10.1002/j.1460-2075.1990.tb07507.x; TAYLOR ICA, 1990, MOL CELL BIOL, V10, P165, DOI 10.1128/MCB.10.1.165; TERRIEN M, 1991, MOL CELL BIOL, V11, P3492; THEILL LE, 1987, MOL CELL BIOL, V7, P4329, DOI 10.1128/MCB.7.12.4329; WEFALD FC, 1990, NATURE, V344, P260, DOI 10.1038/344260a0; WHITE RJ, 1992, CELL, V71, P1041, DOI 10.1016/0092-8674(92)90398-V	40	78	91	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15981	15986		10.1074/jbc.271.27.15981	http://dx.doi.org/10.1074/jbc.271.27.15981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663141	hybrid			2022-12-27	WOS:A1996UW35200023
J	Leterrier, JF; Kas, J; Hartwig, J; Vegners, R; Janmey, PA				Leterrier, JF; Kas, J; Hartwig, J; Vegners, R; Janmey, PA			Mechanical effects of neurofilament cross-bridges - Modulation by phosphorylation, lipids, and interactions with F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FILAMENT PROTEIN VIMENTIN; SLOW AXONAL-TRANSPORT; QUICK-FREEZE; INVITRO; VISCOELASTICITY; MICROTUBULES; CYTOSKELETON; PURIFICATION; IMPAIRMENT; SUBUNITS	The structure of gels formed by bovine spinal cord neurofilaments was determined by fluorescence and electron microscopy and compared to mechanical properties measured by their elastic and viscous response to shear forces. Neurofilaments formed gels of high elastic modulus (>100 Pa) after addition of millimolar Mg2+. Gelation caused a slow increase in shear moduli to levels similar to those of vimentin intermediate filament networks, followed by a rapid rise due to formation of links between neurofilaments, mediated by cross-bridging structures that vimentin filaments lack. Neurofilament gels are more resistant to large deformations than are vimentin networks, suggesting the importance of cross-bridges for neurofilament mechanical properties. Fluorescence imaging of single neurofilaments showed flexible filaments that became straighter when they adhered to glass or were incorporated into filament bundles. Electron microscopy of neurofilament gels showed a system of bundles intertwined within a more isotropic network of individual filaments. Neurofilament gel formation was stimulated in vitro by acid phosphatase treatment or by inositol phospholipids. In contrast, addition of actin filaments reduced the resistance of neurofilament gels to large stresses. These results suggest that dynamic and regulated interactions occur between neurofilaments to form viscoelastic networks with properties distinct from other cytoskeletal structures.	BRIGHAM & WOMENS HOSP,DIV EXPTL MED,BOSTON,MA 02115; CHRU,U298 INSERM,F-49033 ANGERS,FRANCE; LATVIAN INST ORGAN SYNTH,RIGA 1006,LATVIA; HARVARD UNIV,SCH MED,PROGRAM BIOL & BIOMED SCI,BOSTON,MA 02115	Harvard University; Brigham & Women's Hospital; Institut National de la Sante et de la Recherche Medicale (Inserm); Universite d'Angers; Centre Hospitalier Universitaire d'Angers; Latvian Institute of Organic Synthesis; Harvard University; Harvard Medical School				Kas, Josef A./0000-0003-3158-2480	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR038910, R01AR038910] Funding Source: NIH RePORTER; FIC NIH HHS [TW00100] Funding Source: Medline; NIAMS NIH HHS [AR38910] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); FIC NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALMAHBOHI G, 1990, J CELL SCI, P679; BIZZI A, 1984, J NEUROSCI, V4, P722; BROWN A, 1995, CELL MOTIL CYTOSKEL, V31, P9, DOI 10.1002/cm.970310103; CARY RB, 1994, J CELL SCI, V107, P1609; EAGLES PAM, 1990, CELLULAR MOL BIOL IN, P37; EYER J, 1988, BIOCHEM J, V252, P655, DOI 10.1042/bj2520655; EYER J, 1989, J NEUROCHEM, V52, P1759, DOI 10.1111/j.1471-4159.1989.tb07254.x; EYER J, 1994, NEURON, V12, P389, DOI 10.1016/0896-6273(94)90280-1; FARGE E, 1993, MACROMOLECULES, V26, P5041, DOI 10.1021/ma00071a009; FATH KR, 1988, J CELL BIOL, V107, P613, DOI 10.1083/jcb.107.2.613; FRAPPIER T, 1992, EUR J BIOCHEM, V205, P85, DOI 10.1111/j.1432-1033.1992.tb16754.x; GOTOW T, 1992, EUR J CELL BIOL, V58, P331; GOTOW T, 1994, J CELL SCI, V107, P1949; GOTOW T, 1994, J NEUROSCI RES, V37, P691, DOI 10.1002/jnr.490370604; GOU JP, 1995, BIOCHEM BIOPH RES CO, V215, P368, DOI 10.1006/bbrc.1995.2475; GRIFFIN JW, 1978, SCIENCE, V202, P633, DOI 10.1126/science.81524; HERIOT K, 1985, J CELL BIOL, V100, P1167, DOI 10.1083/jcb.100.4.1167; HIROKAWA N, 1982, J CELL BIOL, V94, P129, DOI 10.1083/jcb.94.1.129; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HIROKAWA N, 1991, NEURONAL CYTOSKELETO, P5; HISANAGA SI, 1988, J MOL BIOL, V20, P297; HORKOVICSKOVATS S, 1990, BIOCHEMISTRY-US, V29, P8652, DOI 10.1021/bi00489a022; ITOH T, 1992, ACTA NEUROPATHOL, V83, P240, DOI 10.1007/BF00296785; JANMEY PA, 1990, NATURE, V347, P95, DOI 10.1038/347095a0; JANMEY PA, 1991, J BIOCHEM BIOPH METH, V22, P41, DOI 10.1016/0165-022X(91)90080-G; JANMEY PA, 1994, J BIOL CHEM, V269, P32503; JANMEY PA, 1991, J CELL BIOL, V113, P155, DOI 10.1083/jcb.113.1.155; JANMEY PA, 1988, BIOCHEMISTRY-US, V27, P8218, DOI 10.1021/bi00421a035; JANMEY PA, 1994, ANN T NORDIC RHEOLOG, P8; KLYMKOWSKY MW, 1995, CURR OPIN CELL BIOL, V7, P46, DOI 10.1016/0955-0674(95)80044-1; KUROKAWA H, 1990, BIOCHEM BIOPH RES CO, V168, P451, DOI 10.1016/0006-291X(90)92342-W; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LETERRIER JF, 1984, J NEUROCHEM, V43, P1385, DOI 10.1111/j.1471-4159.1984.tb05398.x; LETERRIER JF, 1992, J NEUROCHEM, V58, P2060, DOI 10.1111/j.1471-4159.1992.tb10947.x; LETERRIER JF, 1991, AIP CONF PROC, V226, P91; LETERRIER JF, 1994, MICROSC RES TECHNIQ, V27, P233, DOI 10.1002/jemt.1070270305; LETERRIER JF, 1987, BIOCHEM J, V245, P93, DOI 10.1042/bj2450093; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; MACKINTOSH FC, 1995, PHYS REV LETT, V75, P4425, DOI 10.1103/PhysRevLett.75.4425; MATA M, 1992, J NEUROCYTOL, V21, P199, DOI 10.1007/BF01194978; MIYASAKA H, 1993, J BIOL CHEM, V268, P22695; NAGELE RG, 1988, BRAIN RES, V474, P279, DOI 10.1016/0006-8993(88)90441-6; NAKAGAWA T, 1995, J CELL BIOL, V129, P411, DOI 10.1083/jcb.129.2.411; NELSON WJ, 1982, J BIOL CHEM, V257, P5536; NIXON RA, 1994, J CELL BIOL, V126, P1031, DOI 10.1083/jcb.126.4.1031; PAPASOZOMENOS SC, 1985, J CELL BIOL, V100, P74, DOI 10.1083/jcb.100.1.74; ROGERS KR, 1995, EUR J CELL BIOL, V66, P136; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; STARR R, 1995, J NEUROCHEM, V64, P1860; TRAUB P, 1987, EUR J CELL BIOL, V43, P55; YAMAUCHI PS, 1993, BIOCHEM BIOPH RES CO, V190, P710, DOI 10.1006/bbrc.1993.1107	51	149	150	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15687	15694		10.1074/jbc.271.26.15687	http://dx.doi.org/10.1074/jbc.271.26.15687			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663092	hybrid			2022-12-27	WOS:A1996UV29900059
J	Donald, RGK; Carter, D; Ullman, B; Roos, DS				Donald, RGK; Carter, D; Ullman, B; Roos, DS			Insertional tagging, cloning, and expression of the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyltransferase gene - Use as a selectable marker for stable transformation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MUTAGENESIS; SEQUENCE; CELLS; DNA; APICOMPLEXA; ARABIDOPSIS; ALLOPURINOL; METABOLISM; MUTATIONS	A nonhomologous integration vector was used to identify the Toxoplasma gondii hypoxanthine-xanthine-guanine phosphoribosyl transferase (HXGPRT) gene by insertional mutagenesis. Parasite mutants resistant to 6-thioxanthine arose at a frequency of similar to 3 x 10(-7). Genomic DNA flanking the insertion sites was retrieved by marker rescue and used to identify molecular clones exhibiting unambiguous homology to H(X)GPRT genes from other species. Sequence analysis of vector/genome junction sites reveals that integration of the linearized vector occurred with minimal rearrangement of either vector or target sequences, although the addition of filler DNA and small duplications or deletions of genomic sequences at the transgene termini was observed. Two differentially spliced classes of cDNA clones were identified, both of which complement hpt and gpt mutations in Escherichia coli. Kinetic analysis of purified recombinant enzyme revealed no significant differences between the two isoforms. Internally deleted clones spanning the genomic locus were used to create ''knock-out'' parasites, which lack all detectable HXGPRT activity. Complete activity could be restored to these knock out mutants by transient transformation with either genomic DNA or cDNA-derived minigenes encoding both enzyme isoforms. Stable HXGPRT(+) transformants were isolated under selection with mycophenolic acid, demonstrating the feasibility of HXGPRT as both a positive and negative selectable marker for stable transformation of T. gondii.	UNIV PENN, DEPT BIOL, PHILADELPHIA, PA 19104 USA; OREGON HLTH SCI UNIV, DEPT BIOCHEM & MOLEC BIOL, PORTLAND, OR 97201 USA	University of Pennsylvania; Oregon Health & Science University			Donald, Robert George Konrad/GNP-4958-2022; Carter, Darrick/N-3304-2016	Roos, David Siker/0000-0001-6725-4089; Carter, Darrick/0000-0001-5901-3402	NIAID NIH HHS [AI-31808, AI-28724, AI-23682] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028724, U19AI031808, R01AI023682, R37AI028724, U01AI031808, R37AI023682] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALLEN TE, 1994, MOL BIOCHEM PARASIT, V65, P233, DOI 10.1016/0166-6851(94)90075-2; ALLEN TE, 1993, NUCLEIC ACIDS RES, V21, P5431, DOI 10.1093/nar/21.23.5431; BERG DE, 1984, COLD SPRING HARB SYM, V49, P215; Black M, 1995, MOL BIOCHEM PARASIT, V74, P55, DOI 10.1016/0166-6851(95)02483-2; BOOTHROYD JC, 1994, METHODS MOL GENET, V6, P1; BRENNER DA, 1984, COLD SPRING HARB SYM, V49, P151, DOI 10.1101/SQB.1984.049.01.018; CAVALIERSMITH T, 1993, MICROBIOL REV, V57, P953, DOI 10.1128/MMBR.57.4.953-994.1993; CRAIG SP, 1991, P NATL ACAD SCI USA, V88, P2500, DOI 10.1073/pnas.88.6.2500; DONALD RGK, 1994, MOL BIOCHEM PARASIT, V63, P243, DOI 10.1016/0166-6851(94)90060-4; DONALD RGK, 1995, P NATL ACAD SCI USA, V92, P5749, DOI 10.1073/pnas.92.12.5749; DONALD RGK, 1993, P NATL ACAD SCI USA, V90, P11703, DOI 10.1073/pnas.90.24.11703; EADS JC, 1994, CELL, V78, P325, DOI 10.1016/0092-8674(94)90301-8; EHRLICH SD, 1993, GENE, V135, P161, DOI 10.1016/0378-1119(93)90061-7; ELLIS J, 1993, GENE, V126, P163, DOI 10.1016/0378-1119(93)90363-8; FELDMANN KA, 1991, PLANT J, V1, P71, DOI 10.1111/j.1365-313X.1991.00071.x; FERNANDES AP, 1993, P NATL ACAD SCI USA, V90, P11608, DOI 10.1073/pnas.90.24.11608; GAGNON S, 1993, MOL BIOCHEM PARASIT, V60, P145, DOI 10.1016/0166-6851(93)90037-X; GALLERANO RH, 1990, AM J TROP MED HYG, V43, P159, DOI 10.4269/ajtmh.1990.43.159; GARFINKEL DJ, 1988, GENETICS, V120, P95; HENIKOFF S, 1993, TRENDS BIOCHEM SCI, V18, P267, DOI 10.1016/0968-0004(93)90179-Q; HERSHEY HV, 1986, GENE, V43, P287, DOI 10.1016/0378-1119(86)90218-0; HILLIS DM, 1993, SYST BIOL, V42, P182, DOI 10.2307/2992540; HOGLUND M, 1992, GENE, V116, P215, DOI 10.1016/0378-1119(92)90518-T; JOCHIMSEN B, 1975, MOL GEN GENET, V143, P85, DOI 10.1007/BF00269424; KIM K, 1993, SCIENCE, V262, P911, DOI 10.1126/science.8235614; KLECKNER N, 1983, MOBILE GENETIC ELEME, P261; KONCZ C, 1992, PLANT MOL BIOL, V20, P963, DOI 10.1007/BF00027166; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LUFT BJ, 1992, CLIN INFECT DIS, V15, P211, DOI 10.1093/clinids/15.2.211; MACKAY LC, 1993, GENET RES, V61, P177; Maniatis T., 1982, MOL CLONING; MARTINEZ S, 1992, NEW ENGL J MED, V326, P741, DOI 10.1056/NEJM199203123261105; MCCLARY JA, 1989, BIOTECHNIQUES, V7, P282; MCKEOWN M, 1992, ANNU REV CELL BIOL, V8, P133, DOI 10.1146/annurev.cb.08.110192.001025; Merrihew RV, 1996, MOL CELL BIOL, V16, P10; MESSINA M, 1995, GENE, V165, P213, DOI 10.1016/0378-1119(95)00548-K; MORTENSEN R, 1993, CURRENT PROTOCOLS S, V23; OPPERDOES FR, 1987, ANNU REV MICROBIOL, V41, P127, DOI 10.1146/annurev.mi.41.100187.001015; PARKERTHORNBURG J, 1987, CELL, V51, P763, DOI 10.1016/0092-8674(87)90099-7; PARMLEY SF, 1994, MOL BIOCHEM PARASIT, V66, P283, DOI 10.1016/0166-6851(94)90155-4; PELHAM HR, 1984, CELL, V37, P979; Pfefferkorn E.R., 1990, P26; PFEFFERKORN ER, 1978, EXP PARASITOL, V44, P26, DOI 10.1016/0014-4894(78)90077-2; PFEFFERKORN ER, 1984, INFECT IMMUN, V44, P211, DOI 10.1128/IAI.44.2.211-216.1984; PFEFFERKORN ER, 1978, J PARASITOL, V64, P486, DOI 10.2307/3279789; PFEFFERKORN ER, 1994, EXP PARASITOL, V79, P374, DOI 10.1006/expr.1994.1099; ROOS DS, 1994, METHOD CELL BIOL, V45, P27; ROOS DS, 1993, J BIOL CHEM, V268, P6269; ROTH DB, 1991, NUCLEIC ACIDS RES, V19, P7201, DOI 10.1093/nar/19.25.7201; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHULER GD, 1996, IN PRESS METHODS ENZ; SCHWARTZMAN JD, 1982, EXP PARASITOL, V53, P77, DOI 10.1016/0014-4894(82)90094-7; SCHWARTZMAN JD, 1981, J PARASITOL, V67, P150, DOI 10.2307/3280627; SIBLEY LD, 1994, P NATL ACAD SCI USA, V91, P5508, DOI 10.1073/pnas.91.12.5508; SOLDATI D, 1995, MOL CELL BIOL, V15, P87, DOI 10.1128/MCB.15.1.87; SOLDATI D, 1993, SCIENCE, V260, P349, DOI 10.1126/science.8469986; Swofford D. L., 1991, PAUP PHYLOGENETIC AN; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; ULLMAN B, 1995, INFECT AGENT DIS, V4, P29; Ullman Buddy, 1995, MBL (Marine Biology Laboratory) Lectures in Biology, V12, P123; VICKERMAN K, 1994, INT J PARASITOL, V24, P1317, DOI 10.1016/0020-7519(94)90198-8; WOLTERS J, 1991, BIOSYSTEMS, V25, P75, DOI 10.1016/0303-2647(91)90014-C	64	335	345	0	6	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14010	14019		10.1074/jbc.271.24.14010	http://dx.doi.org/10.1074/jbc.271.24.14010			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662859	hybrid			2022-12-27	WOS:A1996UQ66000015
J	Sun, DM; Leung, CL; Liem, RKH				Sun, DM; Leung, CL; Liem, RKH			Phosphorylation of the high molecular weight neurofilament protein (NF-H) by Cdk5 and p35	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODIES DISTINGUISH; NEURONAL INTERMEDIATE FILAMENTS; TAU-PROTEIN; KINASE-II; MAMMALIAN NEUROFILAMENTS; CDC2 KINASE; EXPRESSION; SEQUENCE; SUBUNIT; POLYPEPTIDES	The high molecular weight neurofilament protein (NF-H) is highly phosphorylated in the axon. The phosphorylation sites have been identified as KSP (Lys-Ser-Pro) repeats in the tail domain of NF-H. These KSP sequences are present more than 50 times in the NF-H tail, and most of these sites are normally phosphorylated in vivo. These RSP sites can be further divided into two separate consensus sequences, KSPXK and KSPXY (where Y is not K). The extensive phosphorylation of NF-H has been proposed to play a critical role in the determination of axonal diameter. Recent studies have shown that Cdk5, a kinase related to the cell cycle-dependent kinase Cdc2, is expressed in the brain and associates with the cytoskeleton. In vitro phosphorylation studies have shown that Cdk5 in conjunction with its activator, p35, is able to phosphorylate histone H1, dephosphorylated NF-H, as well as a synthetic peptide with the repetitive KSP motif. We have cloned the cDNAs for rat Cdk5 and p35 by reverse transcription-polymerase chain reaction and cDNA library screening and studied the phosphorylation of NF-H both in vivo and in vitro. By transient transfection assays, we have shown that NF-H can only be extensively phosphorylated in the presence of both Cdk5 and p35. This phosphorylation can be inhibited by a Cdk5-dominant negative mutant, an observation which further supports that Cdk5 is a kinase that is able to phosphorylate NF-H. By immunoprecipitating Cdk5 and p35 from the transfected cells, we have been able to show that the KSPXK repeats are the preferred phosphorylation sites for Cdk5, while the KSPXY repeats are not directly phosphorylated by Cdk5 and p35.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015182] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG013185] Funding Source: NIH RePORTER; NIA NIH HHS [AG00189, AG13185] Funding Source: Medline; NINDS NIH HHS [NS15182] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARIOKA M, 1993, J NEUROCHEM, V60, P461, DOI 10.1111/j.1471-4159.1993.tb03173.x; Barik S, 1993, Methods Mol Biol, V15, P277, DOI 10.1385/0-89603-244-2:277; BAUMANN K, 1993, FEBS LETT, V336, P417, DOI 10.1016/0014-5793(93)80849-P; CARDEN MJ, 1985, J BIOL CHEM, V260, P9805; CARDEN MJ, 1987, J NEUROSCI, V7, P3489; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; DOSEMECI A, 1990, CELL MOL NEUROBIOL, V10, P369, DOI 10.1007/BF00711181; DOSEMECI A, 1992, BIOCHEM J, V282, P477, DOI 10.1042/bj2820477; ELHANANY E, 1994, J NEUROCHEM, V63, P2324; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; FLOYD CC, 1991, J BIOL CHEM, V266, P4987; FORMAN BM, 1988, MOL ENDOCRINOL, V2, P902, DOI 10.1210/mend-2-10-902; GEISLER N, 1987, FEBS LETT, V221, P403, DOI 10.1016/0014-5793(87)80964-X; GUAN RJ, 1992, J NEUROCHEM, V58, P1365, DOI 10.1111/j.1471-4159.1992.tb11351.x; HELLMICH MR, 1992, P NATL ACAD SCI USA, V89, P10867, DOI 10.1073/pnas.89.22.10867; HIROKAWA N, 1984, J CELL BIOL, V98, P1523, DOI 10.1083/jcb.98.4.1523; HISANAGA S, 1989, J NEUROSCI, V9, P959; HISANAGA S, 1993, J BIOL CHEM, V268, P15056; HISANAGA S, 1991, J BIOL CHEM, V266, P21798; ISHIGURO K, 1994, FEBS LETT, V342, P203, DOI 10.1016/0014-5793(94)80501-6; JULIEN JP, 1982, J BIOL CHEM, V257, P467; JULIEN JP, 1983, J BIOL CHEM, V258, P4019; KAPLAN MP, 1991, J NEUROSCI RES, V30, P45; KOBAYASHI S, 1993, FEBS LETT, V335, P171, DOI 10.1016/0014-5793(93)80723-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LEE VMY, 1987, J NEUROSCI, V7, P3474; LEE VMY, 1988, P NATL ACAD SCI USA, V85, P1998, DOI 10.1073/pnas.85.6.1998; LEW J, 1992, J BIOL CHEM, V267, P25922; LEW J, 1994, NATURE, V371, P423, DOI 10.1038/371423a0; LIEM RKH, 1985, ANN NY ACAD SCI, V455, P492, DOI 10.1111/j.1749-6632.1985.tb50431.x; Liem RKH, 1993, CURR OPIN CELL BIOL, V5, P12, DOI 10.1016/S0955-0674(05)80003-1; LOVESTONE S, 1994, CURR BIOL, V4, P1077, DOI 10.1016/S0960-9822(00)00246-3; MANDELKOW EM, 1992, FEBS LETT, V314, P315, DOI 10.1016/0014-5793(92)81496-9; MEYERSON M, 1992, EMBO J, V11, P2909, DOI 10.1002/j.1460-2075.1992.tb05360.x; MYERS MW, 1987, EMBO J, V6, P1617, DOI 10.1002/j.1460-2075.1987.tb02409.x; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; NIXON RA, 1991, TRENDS NEUROSCI, V14, P501, DOI 10.1016/0166-2236(91)90062-Y; PEVSNER J, 1994, CURR OPIN CELL BIOL, V6, P555, DOI 10.1016/0955-0674(94)90076-0; QI Z, 1995, J BIOL CHEM, V270, P10847, DOI 10.1074/jbc.270.18.10847; Sambrook J., 2002, MOL CLONING LAB MANU; SATTIA AJ, 1990, J CELL BIOL, V111, P553; SHAW G, 1991, NEURONAL CYTOSKELETO, P185; SHETTY KT, 1995, J NEUROCHEM, V64, P1988; SHETTY KTV, 1995, J NEUROCHEM, V64, P2681; SIHAG RK, 1990, J BIOL CHEM, V265, P4166; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; TANG DM, 1995, J BIOL CHEM, V270, P26897, DOI 10.1074/jbc.270.45.26897; TSAI LH, 1993, DEVELOPMENT, V119, P1029; TSAI LH, 1994, NATURE, V371, P419, DOI 10.1038/371419a0; VALLANO ML, 1985, BIOCHEM BIOPH RES CO, V130, P957, DOI 10.1016/0006-291X(85)91708-5; VANDENHEUVEL S, 1993, SCIENCE, V262, P2050, DOI 10.1126/science.8266103; WONG J, 1984, J BIOL CHEM, V259, P867; WOODGETT JR, 1990, EMBO J, V9, P2431, DOI 10.1002/j.1460-2075.1990.tb07419.x; XIAO J, 1994, J NEUROSCI, V14, P820; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H	57	123	126	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14245	14251		10.1074/jbc.271.24.14245	http://dx.doi.org/10.1074/jbc.271.24.14245			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662984	hybrid			2022-12-27	WOS:A1996UQ66000048
J	Tolchinsky, S; Yuk, MH; Ayalon, M; Lodish, HF; Lederkremer, GZ				Tolchinsky, S; Yuk, MH; Ayalon, M; Lodish, HF; Lederkremer, GZ			Membrane-bound versus secreted forms of human asialoglycoprotein receptor subunits - Role of a juxtamembrane pentapeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL SIGNAL SEQUENCE; ENDOPLASMIC-RETICULUM; PRE-GOLGI; TRANSMEMBRANE PROTEIN; DEGRADATION; CLEAVAGE; RETENTION; PEPTIDE; DOMAIN; H2	The H2a alternatively spliced variant of the human asialoglycoprotein receptor H2 subunit differs from the H2b variant by an extra pentapeptide, EGHRG, present in the ectodomain next to the membrane-span. This difference causes retention and degradation in the endoplasmic reticulum (ER) of H2a when expressed without the H1 subunit in 3T3 cells (1). In contrast, a significant portion of singly expressed H2b is Golgi-processed and reaches the cell surface. Using a new specific anti-H2a antibody, we found that in HepG2 cells, H2a is rapidly cleaved to a 35-kDa fragment, comprising the entire ectodomain, most of which is secreted into the medium. The cleavage site for the secreted fragment was located at the lumenal end of the membrane span. No membrane-bound H2a exits the ER, indicating that the pentapeptide is a signal for ER retention and degradation of the membrane form but does not hinder secretion of the cleaved soluble form, H2a does not form a membrane receptor complex with H1 as H2b does, H2a is therefore not a subunit of the receptor but a precursor for a secreted form of the protein; signal peptidase is probably responsible for the cleavage to the soluble fragment (2). Therefore, the juxtamembrane sequence regulates the function of the transmembrane domain of a type ZI membrane protein as either a signal-anchor sequence (H2b) or as a cleaved signal sequence, which generates a secreted product (H2a).	TEL AVIV UNIV, GEORGE S WISE FAC LIFE SCI, DEPT CELL RES & IMMUNOL, IL-69978 TEL AVIV, ISRAEL; WHITEHEAD INST BIOMED RES, CAMBRIDGE, MA 02142 USA; MIT, DEPT BIOL, CAMBRIDGE, MA 02139 USA	Tel Aviv University; Massachusetts Institute of Technology (MIT); Whitehead Institute; Massachusetts Institute of Technology (MIT)				Lederkremer, Gerardo/0000-0002-9857-7152	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM035012] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-35012] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABRAMOVICH C, 1994, FEBS LETT, V338, P295, DOI 10.1016/0014-5793(94)80287-4; AMARA JF, 1989, J CELL BIOL, V109, P3315, DOI 10.1083/jcb.109.6.3315; BISCHOFF J, 1987, J BIOL CHEM, V262, P11825; BONIFACINO JS, 1991, EMBO J, V10, P2783, DOI 10.1002/j.1460-2075.1991.tb07827.x; CROWE PD, 1993, J IMMUNOL, V151, P6882; EHLERS MRW, 1991, BIOCHEMISTRY-US, V30, P10065, DOI 10.1021/bi00106a001; FISCHER DG, 1993, SCIENCE, V262, P250, DOI 10.1126/science.8211145; FRA AM, 1993, EMBO J, V12, P4755, DOI 10.1002/j.1460-2075.1993.tb06164.x; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GARROUSTE F, 1991, INT J CANCER, V47, P760, DOI 10.1002/ijc.2910470523; HENIS YI, 1990, J CELL BIOL, V111, P1409, DOI 10.1083/jcb.111.4.1409; HOGUE BG, 1994, J GEN VIROL, V75, P1015, DOI 10.1099/0022-1317-75-5-1015; KHIRE J, 1990, FEBS LETT, V272, P69, DOI 10.1016/0014-5793(90)80451-N; KOHNO T, 1990, P NATL ACAD SCI USA, V87, P8331, DOI 10.1073/pnas.87.21.8331; KRIEGLER M, 1988, CELL, V53, P45, DOI 10.1016/0092-8674(88)90486-2; LEDERKREMER GZ, 1991, J BIOL CHEM, V266, P1237; LOUGHNAN MS, 1990, J MOL CELL IMMUNOL, V4, P307; MASAKI R, 1994, J CELL BIOL, V126, P1407, DOI 10.1083/jcb.126.6.1407; MATSUDAIRA P, 1990, METHOD ENZYMOL, V182, P602; NILSSON I, 1994, J CELL BIOL, V126, P1127, DOI 10.1083/jcb.126.5.1127; PAIETTA E, 1992, J BIOL CHEM, V267, P11078; QUESENBERRY M S, 1991, Glycobiology, V1, P615, DOI 10.1093/glycob/1.6.615; ROY P, 1993, J BIOL CHEM, V268, P2699; SAUTES C, 1991, EUR J IMMUNOL, V21, P231, DOI 10.1002/eji.1830210135; SCHMID SR, 1988, J BIOL CHEM, V263, P16886; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; SHACHAR I, 1992, J BIOL CHEM, V267, P24241; SHAW AS, 1988, P NATL ACAD SCI USA, V85, P7592, DOI 10.1073/pnas.85.20.7592; SHIA MA, 1989, P NATL ACAD SCI USA, V86, P1158, DOI 10.1073/pnas.86.4.1158; SHIH YJ, 1990, J BIOL CHEM, V265, P19077; SPIESS M, 1990, BIOCHEMISTRY-US, V29, P1009, DOI 10.1021/bi00495a001; SPIESS M, 1986, CELL, V44, P177, DOI 10.1016/0092-8674(86)90496-4; STEWART WW, 1990, IMMUNOLOGY, V71, P328; SUTTON BJ, 1993, NATURE, V366, P421, DOI 10.1038/366421a0; TALJANIDISZ J, 1989, BIOCHEMISTRY-US, V28, P10054, DOI 10.1021/bi00452a026; WIKSTROM L, 1992, J BIOL CHEM, V267, P5; WIKSTROM L, 1991, J CELL BIOL, V113, P997, DOI 10.1083/jcb.113.5.997; YAGO H, 1995, HEPATOLOGY, V21, P383, DOI 10.1016/0270-9139(95)90096-9; YUK MH, 1993, J CELL BIOL, V123, P1735, DOI 10.1083/jcb.123.6.1735	39	46	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14496	14503		10.1074/jbc.271.24.14496	http://dx.doi.org/10.1074/jbc.271.24.14496			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662943	hybrid			2022-12-27	WOS:A1996UQ66000082
J	AlvarezDominguez, C; Barbieri, AM; Beron, W; WandingerNess, A; Stahl, PD				AlvarezDominguez, C; Barbieri, AM; Beron, W; WandingerNess, A; Stahl, PD			Phagocytosed live Listeria monocytogenes influences rab5-regulated in vitro phagosome-endosome fusion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; RAB GERANYLGERANYL TRANSFERASE; MACROPHAGES; HEMOLYSIN; VESICLES; COMPLEMENT; TRANSPORT; INVITRO; GROWTH; SYSTEM	Survival or destruction of a pathogen following phagocytosis depends, in part, on fusion events between the phagosome and the endosomal or lysosomal compartments. Here we use an in vitro assay to show that phagosome-endosome fusion is regulated by the small GTPase rab5 and that fusion events are influenced by an internalized live organism, Listeria monocytogenes (LM), We compare the in vitro fusion of phagosomes containing heat-killed organisms (dead LM) with that of phagosomes containing a Live nonhemolytic mutant (live LM(hly-)). Unlike the wild-type organism, LM(hly-) remains trapped inside the phagosome. Phagosome-endosome fusion was reconstituted using biotinylated organisms and endosomes containing horseradish peroxidase conjugated with avidin, With both Five LM(hly-) and dead LM preparations, in vitro phagosome-endosome fusion was time-, temperature-, and cytosol-dependent. Live LM(hly-) phagosomes exhibited a faster rate of fusion, Fusion in both preparations was regulated by rab5 and possibly by other GTPases. Anti-rab5 antibodies and immunodepletion of cytostolic rab5 inhibited fusion. Addition of glutatione S-transferase-rab5 in the GTP form stimulated phagosome-endosome fusion, whereas addition of a dominant negative mutant of rab5 blocked fusion. Purified live LM(hly-) phagosomal membranes were enriched in rab5 as revealed by Western blotting, compared with dead LM phagosomes. Fusion of endosomes with dead LM containing phagosomes required ATP and was inhibited by ATP depletion and by N-ethylmaleimide (NEM) and anti-NEM-sensitive factor (NSF) antibodies, Unexpectedly, phagosome-endosome fusion with live LM(hly-)-containing phagosomes was not inhibited by ATP depletion nor by NEM or anti-NSF antibodies. Western blot analysis revealed that live LM(hly-)-containing phagosomes were enriched for membrane-bound NSF, while dead LM containing phagosomes contained low or undetectable quantities, Washing live LM(hly-)-containing phagosomes with 0.5 M KCl removed NSF associated with the membranes and rendered them NEM, ATP, anti-NSF antibody sensitive for fusion. We conclude that rab5 regulates phagosome-endosome fusion and that live microorganisms can up-regulate this process by recruiting rab5 to the membrane.	ST LOUIS UNIV,SCH MED,DEPT PHYSIOL & CELL BIOL,ST LOUIS,MO 63110; UNIV NACL CUYO,FAC CIENCIAS MED,CONICET,INST HISTOL & EMBRIOL,MENDOZA,ARGENTINA; NORTHWESTERN UNIV,DEPT BIOCHEM MOLEC BIOL & CELL BIOL,EVANSTON,IL 60208	Saint Louis University; Consejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET); University Nacional Cuyo Mendoza; Northwestern University			Wandinger-Ness, Angela/J-9104-2012; Alvarez-Dominguez, Carmen/J-4675-2014; Stahl, Philip/D-6315-2012	Wandinger-Ness, Angela/0000-0003-0613-3157; Alvarez-Dominguez, Carmen/0000-0002-4585-6959; 				ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ALVAREZDOMINGUEZ C, 1993, INFECT IMMUN, V61, P3664, DOI 10.1128/IAI.61.9.3664-3672.1993; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; BARBIERI MA, 1994, J BIOL CHEM, V269, P18720; BERON W, 1995, ARCH BIOCHEM BIOPHYS, V317, P337, DOI 10.1006/abbi.1995.1172; BOMSEL M, 1992, MOL BIOL CELL, V3, P1317, DOI 10.1091/mbc.3.12.1317; BOUVIER G, 1994, J LEUKOCYTE BIOL, V55, P729, DOI 10.1002/jlb.55.6.729; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLUFF CW, 1990, INFECT IMMUN, V58, P3601, DOI 10.1128/IAI.58.11.3601-3612.1990; COSSART P, 1989, INFECT IMMUN, V57, P3629, DOI 10.1128/IAI.57.11.3629-3636.1989; DECHASTELLIER C, 1994, INFECT IMMUN, V62, P543, DOI 10.1128/IAI.62.2.543-553.1994; DESJARDINS M, 1994, J BIOL CHEM, V269, P32194; DESJARDINS M, 1994, J CELL BIOL, V124, P677, DOI 10.1083/jcb.124.5.677; DIAZ R, 1988, J BIOL CHEM, V263, P6093; DIRACSVEJSTRUP AB, 1994, J BIOL CHEM, V269, P15427; DREVETS DA, 1991, INFECT IMMUN, V59, P2645, DOI 10.1128/IAI.59.8.2645-2652.1991; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; GALLIARD JL, 1987, INFECT IMMUN, V55, P2822; GARRETT MD, 1994, EMBO J, V13, P1718, DOI 10.1002/j.1460-2075.1994.tb06436.x; GOUD B, 1991, Current Opinion in Cell Biology, V3, P626, DOI 10.1016/0955-0674(91)90033-U; GRAY ML, 1966, BACTERIOL REV, V30, P309, DOI 10.1128/MMBR.30.2.309-382.1966; GRIFFITHS G, 1984, J ULTRA MOL STRUCT R, V89, P65, DOI 10.1016/S0022-5320(84)80024-6; GRUENBERG J, 1989, J CELL BIOL, V108, P1301, DOI 10.1083/jcb.108.4.1301; GRUENBERG J, 1992, Current Opinion in Cell Biology, V4, P593, DOI 10.1016/0955-0674(92)90077-P; HARDING CV, 1992, J CELL BIOL, V119, P531, DOI 10.1083/jcb.119.3.531; IKONEN E, 1995, CELL, V81, P571, DOI 10.1016/0092-8674(95)90078-0; JONES S, 1994, INFECT IMMUN, V62, P5608, DOI 10.1128/IAI.62.12.5608-5613.1994; KOCKS C, 1992, CELL, V68, P521, DOI 10.1016/0092-8674(92)90188-I; KUHN M, 1988, INFECT IMMUN, V56, P79, DOI 10.1128/IAI.56.1.79-82.1988; LANG T, 1985, BIOL CELL, V53, P149, DOI 10.1111/j.1768-322X.1985.tb00362.x; LI GP, 1994, J BIOL CHEM, V269, P14631; LI GP, 1993, J BIOL CHEM, V268, P24475; MAYORGA LS, 1991, J BIOL CHEM, V266, P6511; MAYORGA LS, 1989, SCIENCE, V244, P1475, DOI 10.1126/science.2499930; MAYORGA LS, 1989, CELL REGUL, V1, P113, DOI 10.1091/mbc.1.1.113; Mengaud J, 1996, CELL, V84, P923, DOI 10.1016/S0092-8674(00)81070-3; OTSUKA FL, 1984, J NUCL MED, V25, P1343; PITT A, 1992, J CLIN INVEST, V90, P1978, DOI 10.1172/JCI116077; PITT A, 1992, J BIOL CHEM, V267, P126; PORTNOY DA, 1988, J EXP MED, V167, P1459, DOI 10.1084/jem.167.4.1459; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; RODRIGUEZ L, 1994, MOL BIOL CELL, V5, P773, DOI 10.1091/mbc.5.7.773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHIRATAKI H, 1992, J BIOL CHEM, V267, P10946; SLOT JW, 1991, J CELL BIOL, V113, P123, DOI 10.1083/jcb.113.1.123; SOLDATI T, 1993, MOL BIOL CELL, V4, P425, DOI 10.1091/mbc.4.4.425; STURGILLKOSZYCKI S, 1994, SCIENCE, V263, P678, DOI 10.1126/science.8303277; TILNEY LG, 1989, J CELL BIOL, V109, P1597, DOI 10.1083/jcb.109.4.1597; TOKUYASU KT, 1980, HISTOCHEM J, V12, P381, DOI 10.1007/BF01011956; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WATTENBERG BW, 1992, J CELL BIOL, V118, P1321, DOI 10.1083/jcb.118.6.1321; WEINBERG DS, 1981, J IMMUNOL, V126, P794; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I; ZIEGLER K, 1981, J IMMUNOL, V127, P1869	57	112	116	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13834	13843		10.1074/jbc.271.23.13834	http://dx.doi.org/10.1074/jbc.271.23.13834			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662791	hybrid			2022-12-27	WOS:A1996UP38500080
J	Dixon, BS; Sharma, RV; Dennis, MJ				Dixon, BS; Sharma, RV; Dennis, MJ			The bradykinin B-2 receptor is a delayed early response gene for platelet-derived growth factor in arterial smooth muscle cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS PROMOTER; MESSENGER-RNA; SIGNALING PATHWAYS; LYMPHOCYTE MITOGENS; SECRETORY PROTEIN; 3T3 CELLS; JE GENE; EXPRESSION; RAS; PDGF	Bradykinin and platelet-derived growth factor (PDGF) are inflammatory mediators important in the response to vascular injury. Based upon the known effect of oncogenic Ras to increase bradykinin receptor expression and the ability of PDGF to stimulate Ras, we examined whether PDGF regulates bradykinin B-2 receptor expression in cultured arterial smooth muscle cells. Treatment with PDGF (AB and BB, but not AA) produced a dose-and time-dependent increase in both mRNA (6-7-fold increase at 2-4 h) and cell surface receptors (2-4-fold at 6-12 h) for the B-2 receptor. There was a 60-min delay between exposure to PDGF and the initial increase in B-2 receptor mRNA. Transcriptional inhibitors, actinomycin D or 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole, completely blocked the increase in B-2 receptor mRNA when added up to 60 min after stimulation with PDGF. However, protein synthesis was not required, as treatment with cycloheximide did not block but rather superinduced the PDGF-induced increase in B-2 receptor mRNA. Comparison wit the immediate early response gene c-fos demonstrated that the increase in B-2 receptor mRNA was similarly inhibited by the tyrosine kinase inhibitor, tyrphostin, as well as staurosporine. However, stimulation of c-fos was slightly more sensitive to genistein, while the B-2 receptor mRNA was more sensitive to inhibition by the protein kinase C inhibitor, calphostin C. the increase in cell surface B-2 receptors were functionally coupled to an increase in phosphoinositide-specific phospholipase C, and the effects of PDGF were selective as there was no increase in either angiotensin II- or arginine vasopressin-induced inositol phosphate formation of intracellular calcium release. Taken together, these results demonstrate that the B-2 receptor is a delayed early response gene for PDGF in vascular smooth muscle cells.	UNIV IOWA,COLL MED,DEPT ANAT,IOWA CITY,IA 52242; DEPT VET AFFAIRS MED CTR,IOWA CITY,IA 52242	University of Iowa; US Department of Veterans Affairs; Veterans Health Administration (VHA); Iowa City VA Health Care System	Dixon, BS (corresponding author), UNIV IOWA,COLL MED,DEPT MED,E300D GH,IOWA CITY,IA 52242, USA.			Dixon, Bradley/0000-0002-2534-3259	NHLBI NIH HHS [HL-42377] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL042377] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALMENDRAL JM, 1988, MOL CELL BIOL, V8, P2140, DOI 10.1128/MCB.8.5.2140; ALONSO T, 1990, MOL CELL BIOL, V10, P3117, DOI 10.1128/MCB.10.6.3117; BAZENET CE, 1993, ONCOGENE, V9, P517; BERRIDGE MJ, 1983, BIOCHEM J, V212, P849, DOI 10.1042/bj2120849; BHOOLA KD, 1992, PHARMACOL REV, V44, P1; CHEN CYA, 1995, TRENDS BIOCHEM SCI, V20, P465, DOI 10.1016/S0968-0004(00)89102-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; CURRAN T, 1987, ONCOGENE, V2, P79; DECKER CJ, 1994, TRENDS BIOCHEM SCI, V19, P336, DOI 10.1016/0968-0004(94)90073-6; DEVRIESSMITH AMM, 1992, NATURE, V357, P603; DIXON BS, 1994, AM J PHYSIOL, V266, pC1406, DOI 10.1152/ajpcell.1994.266.5.C1406; DIXON BS, 1994, J CLIN INVEST, V93, P2535, DOI 10.1172/JCI117264; DIXON BS, 1990, AM J PHYSIOL, V258, pC299, DOI 10.1152/ajpcell.1990.258.2.C299; DIXON BS, 1996, IN PRESS IMMUNOPHARM; DOWNWARD J, 1988, P NATL ACAD SCI USA, V85, P5774, DOI 10.1073/pnas.85.16.5774; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FARHY RD, 1993, CIRC RES, V72, P1202, DOI 10.1161/01.RES.72.6.1202; FERNS GAA, 1991, SCIENCE, V253, P1129, DOI 10.1126/science.1653454; FORSTERMANN U, 1986, BRIT J PHARMACOL, V87, P521; FRETER RR, 1992, MOL CELL BIOL, V12, P5288, DOI 10.1128/MCB.12.12.5288; FRETER RR, 1995, MOL CELL BIOL, V15, P315, DOI 10.1128/MCB.15.1.315; GREENBERG ME, 1984, NATURE, V311, P433, DOI 10.1038/311433a0; HALL JM, 1992, PHARMACOL THERAPEUT, V56, P131, DOI 10.1016/0163-7258(92)90016-S; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HILL CS, 1995, EMBO J, V14, P5037, DOI 10.1002/j.1460-2075.1995.tb00186.x; HOHL RJ, 1995, J BIOL CHEM, V270, P17508, DOI 10.1074/jbc.270.29.17508; INUI H, 1993, J BIOL CHEM, V268, P17045; INUI H, 1994, J BIOL CHEM, V269, P30546; JOHNSON GL, 1994, CURR OPIN CELL BIOL, V6, P230, DOI 10.1016/0955-0674(94)90141-4; KARIN M, 1994, CURR OPIN CELL BIOL, V6, P415, DOI 10.1016/0955-0674(94)90035-3; KELLY K, 1983, CELL, V35, P603, DOI 10.1016/0092-8674(83)90092-2; KOZMA R, 1995, MOL CELL BIOL, V15, P1942; KRUIJER W, 1984, NATURE, V312, P711, DOI 10.1038/312711a0; LAU LF, 1985, EMBO J, V4, P3145, DOI 10.1002/j.1460-2075.1985.tb04057.x; LEVITZKI A, 1995, SCIENCE, V267, P1782, DOI 10.1126/science.7892601; LI BQ, 1993, P NATL ACAD SCI USA, V90, P8504, DOI 10.1073/pnas.90.18.8504; LIEBERMAN AP, 1992, J BIOL CHEM, V267, P2123; MAGISTRETTI J, 1991, EXP CELL RES, V192, P67, DOI 10.1016/0014-4827(91)90158-Q; MARCEAU F, 1995, IMMUNOPHARMACOLOGY, V30, P1, DOI 10.1016/0162-3109(95)00011-H; MCEACHERN AE, 1991, P NATL ACAD SCI USA, V88, P7724, DOI 10.1073/pnas.88.17.7724; MOMBOULI JV, 1995, ANNU REV PHARMACOL, V35, P679, DOI 10.1146/annurev.pa.35.040195.003335; MULCAHY LS, 1985, NATURE, V313, P241, DOI 10.1038/313241a0; MULLER R, 1984, NATURE, V312, P716, DOI 10.1038/312716a0; MUNDSCHAU LJ, 1994, J BIOL CHEM, V269, P16137; MUNSON PJ, 1984, SERONO S, V4, P117; NANBERG E, 1993, J BIOL CHEM, V268, P18187; NICKENIG G, 1994, MOL PHARMACOL, V46, P653; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; PARRIES G, 1987, P NATL ACAD SCI USA, V84, P2648, DOI 10.1073/pnas.84.9.2648; PERRONEBIZZOZERO NI, 1993, J CELL BIOL, V120, P1263, DOI 10.1083/jcb.120.5.1263; PESQUERO JB, 1994, J BIOL CHEM, V269, P26920; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, J BIOL CHEM, V263, P16523; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUGGIERO M, 1989, ONCOGENE, V4, P767; SACHINIDIS A, 1990, J BIOL CHEM, V265, P10238; SACHINIDIS A, 1993, FEBS LETT, V319, P221, DOI 10.1016/0014-5793(93)80550-E; SALHANY KE, 1992, J CELL PHYSIOL, V150, P386, DOI 10.1002/jcp.1041500223; SATOH T, 1993, MOL CELL BIOL, V13, P3706, DOI 10.1128/MCB.13.6.3706; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SUKHATME VP, 1987, ONCOGENE RES, V1, P343; TREISMAN R, 1985, CELL, V42, P889, DOI 10.1016/0092-8674(85)90285-5; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WILSON T, 1988, NATURE, V336, P396, DOI 10.1038/336396a0; ZHANG K, 1992, SCIENCE, V257, P671, DOI 10.1126/science.1496380; ZWILLER J, 1991, ONCOGENE, V6, P219	69	22	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13324	13332		10.1074/jbc.271.23.13324	http://dx.doi.org/10.1074/jbc.271.23.13324			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662783	hybrid			2022-12-27	WOS:A1996UP38500007
J	Herrmann, C; Volknandt, W; Wittich, B; Kellner, R; Zimmermann, H				Herrmann, C; Volknandt, W; Wittich, B; Kellner, R; Zimmermann, H			The major vault protein (MVP100) is contained in cholinergic nerve terminals of electric ray electric organ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTIC VESICLES; RIBONUCLEOPROTEIN-PARTICLES; SMALL RNA; SV2; GLYCOPROTEIN; PROTEOGLYCAN; COMPLEX; BRAIN	A protein of M(r) 100,000 (MVP100) is highly enriched in the electromotor system of electric rays, Biochemical analysis indicates that MVP100 is contained in the cholinergic nerve terminals of Torpedo electric organ as part of a large cytosolic complex. On sucrose density gradient centrifugation MVP100 comigrates with synaptic vesicles or synaptosomes. It can be partially separated from synaptic vesicles by gel filtration or glycerol velocity gradient centrifugation. Within the complex MVP100 behaves like a hydrophobic protein and is protected against proteolytic attack. MVP100 can be immunodetected by are antibody against phosphotyrosine, and it becomes phosphorylated on incubation with [gamma-P-32]ATP. By screening an electric ray electric lobe cDNA library the primary structure of MVP100 was analyzed MVP100 is highly homologous to the major vault proteins of slime mold and rat and to the human lung resistance-related protein. Compared with non-neural tissues the expression of MVP100 is highest in brain and enriched in the electric lobe that contains the somata of the electromotor neurons. Immunoelectron microscopic analysis reveals a close association of MVP100 and synaptic vesicles in the nerve terminals of the electric organ.	UNIV FRANKFURT, INST ZOOL, AK NEUROCHEM, BIOZENTRUM, D-60439 FRANKFURT, GERMANY; EUROPEAN MOLEC BIOL LAB, D-69012 HEIDELBERG, GERMANY	Goethe University Frankfurt; European Molecular Biology Laboratory (EMBL)								BAJJALIEH SM, 1992, SCIENCE, V257, P1271, DOI 10.1126/science.1519064; BENFENATI F, 1993, NEUROCHEM INT, V23, P27, DOI 10.1016/0197-0186(93)90140-Z; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BUCKLEY K, 1985, J CELL BIOL, V100, P1284, DOI 10.1083/jcb.100.4.1284; CHUGANI DC, 1991, J NEUROSCI, V11, P256; CHUGANI DC, 1993, J CELL SCI, V106, P23; CLIFTOGRADY L, 1990, J CELL BIOL, V110, P1693, DOI 10.1083/jcb.110.5.1693; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FEANY MB, 1992, CELL, V70, P861, DOI 10.1016/0092-8674(92)90319-8; JANETZKO A, 1989, NEUROSCIENCE, V32, P65, DOI 10.1016/0306-4522(89)90108-5; KEDERSHA NL, 1990, J CELL BIOL, V110, P895, DOI 10.1083/jcb.110.4.895; KEDERSHA NL, 1990, MOL BIOL REP, V14, P121, DOI 10.1007/BF00360441; KEDERSHA NL, 1986, J CELL BIOL, V103, P699, DOI 10.1083/jcb.103.3.699; KICKHOEFER VA, 1994, GENE, V151, P257, DOI 10.1016/0378-1119(94)90667-X; KICKHOEFER VA, 1993, J BIOL CHEM, V268, P7868; LI ZY, 1983, J NEUROCHEM, V40, P338, DOI 10.1111/j.1471-4159.1983.tb11288.x; OFARRELL PH, 1975, J BIOL CHEM, V250, P4007; Rome L, 1991, Trends Cell Biol, V1, P47, DOI 10.1016/0962-8924(91)90088-Q; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SCHEFFER GL, 1995, NAT MED, V1, P578, DOI 10.1038/nm0695-578; SCRANTON TW, 1993, J NEUROCHEM, V61, P29, DOI 10.1111/j.1471-4159.1993.tb03535.x; SHERIDAN MN, 1965, J CELL BIOL, V24, P129, DOI 10.1083/jcb.24.1.129; SPECTOR T, 1978, ANAL BIOCHEM, V86, P142, DOI 10.1016/0003-2697(78)90327-5; STANLEY PE, 1969, ANAL BIOCHEM, V29, P381, DOI 10.1016/0003-2697(69)90323-6; VASU SK, 1995, J BIOL CHEM, V270, P16588, DOI 10.1074/jbc.270.28.16588; VASU SK, 1993, J BIOL CHEM, V268, P15356; VILALTA A, 1994, J BIOL CHEM, V269, P29752; VOLKNANDT W, 1988, NEUROCHEM INT, V12, P337, DOI 10.1016/0197-0186(88)90172-6; VOLKNANDT W, 1990, NEUROCHEM INT, V16, P539, DOI 10.1016/0197-0186(90)90014-K; VOLKNANDT W, 1986, J NEUROCHEM, V47, P1449, DOI 10.1111/j.1471-4159.1986.tb00778.x; VOLKNANDT W, 1990, EMBO J, V9, P2465, DOI 10.1002/j.1460-2075.1990.tb07424.x; VOLKNANDT W, 1991, MOL BRAIN RES, V11, P283, DOI 10.1016/0169-328X(91)90037-X	32	40	41	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13908	13915		10.1074/jbc.271.23.13908	http://dx.doi.org/10.1074/jbc.271.23.13908			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662815	hybrid			2022-12-27	WOS:A1996UP38500090
J	Parker, A; Clarke, JB; Busby, WH; Clemmons, DR				Parker, A; Clarke, JB; Busby, WH; Clemmons, DR			Identification of the extracellular matrix binding sites for insulin-like growth factor-binding protein 5	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; FORMS; BETAGLYCAN; MEMBRANE; RECEPTOR; SERUM; BETA; RAT	Fibroblast extracellular matrix (ECM) contains two forms of insulin-like growth factor-binding proteins (IGFBPs), IGFBP-3 and IGFBP-5, These studies were undertaken to identify the regions within IGFBP-5 that mediate its binding to fibroblast ECM, Synthetic peptides were prepared that were homologous with two regions of basic amino acids within IGFBP-5 (Arg(201)-Arg(218) and Ala(131)-Thr(141)), Increasing concentrations of both peptides competed with IGFBP-5 for binding to ECM but the Arg(201)-Arg(218) peptide was more potent, Mutagenesis was used to define the effect of substituting for these basic residues on ECM binding, Substitution for two peptide B residues K134A and R136A reduced binding by 40%, Substitution of a single basic residue within the peptide A region (K211N) reduced binding to ECM by 49%, Substitution for R211N, K134A, and R136A reduced binding by 52%. More extensive substitutions in the peptide A region, e.g. K211N,R214A,K217A,R218N, resulted in a greater (e.g. 88%) decrease. The positional location of basic residues appeared to be more important than the total number of substitutions since the mutant K202N,R206A,R207A had a 79% reduction in ECM binding, Two basic regions of IGFBP-5 contribute to its binding to ECM, but the region containing amino acids 201-218 has a greater contribution. ECM binding is mediated by charged residues and acts to stabilize IGFBP-5 by protecting it from proteolysis.	UNIV N CAROLINA, DEPT MED, DIV ENDOCRINOL, SCH MED, CHAPEL HILL, NC 27599 USA	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina School of Medicine					NIA NIH HHS [AG-02331] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG002331, R37AG002331] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ANDRES JL, 1989, J CELL BIOL, V109, P3137, DOI 10.1083/jcb.109.6.3137; ARAI T, 1994, ENDOCRINOLOGY, V135, P2358, DOI 10.1210/en.135.6.2358; ARAI T, 1994, J BIOL CHEM, V269, P20388; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BASHKIN P, 1989, BIOCHEMISTRY-US, V28, P1737, DOI 10.1021/bi00430a047; BAXTER RC, 1991, MODERN CONCEPTS INSU, P371; BUSBY WH, 1988, J BIOL CHEM, V263, P14203; CAMACHOHUBNER C, 1992, J BIOL CHEM, V267, P11949; FOLKMAN J, 1988, AM J PATHOL, V130, P393; HOSSENLOPP P, 1986, ANAL BIOCHEM, V154, P138, DOI 10.1016/0003-2697(86)90507-5; JONES JI, 1993, J CELL BIOL, V121, P679, DOI 10.1083/jcb.121.3.679; KEIFER MC, 1991, J BIOL CHEM, V266, P9043; KNUTSON BS, 1988, J CLIN INVEST, V80, P1082; LAIHO M, 1989, CANCER RES, V49, P2533; LOPEZCASILLAS F, 1993, CELL, V73, P1435, DOI 10.1016/0092-8674(93)90368-Z; MADRI JA, 1991, J CELL BIOCHEM, V45, P123, DOI 10.1002/jcb.240450202; MERRIFIELD RB, 1964, J AM CHEM SOC, V86, P304, DOI 10.1021/ja01056a056; NAM TJ, 1994, ENDOCRINOLOGY, V135, P1385, DOI 10.1210/en.135.4.1385; OLSEN BR, 1989, CONNECT TISSUE RES, V23, P1115; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SAMBROOK J, 1989, MOL CLONING LAB MANU, P13454; SCHASTEEN CS, 1991, MOL IMMUNOL, V28, P17, DOI 10.1016/0161-5890(91)90082-U; SEIFFERT D, 1991, J BIOL CHEM, V266, P2824; SHIMASAKI S, 1991, J BIOL CHEM, V266, P10646; SHIMASAKI S, 1991, MOL ENDOCRINOL, V5, P938, DOI 10.1210/mend-5-7-938; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; YOON JB, 1987, J BIOL CHEM, V262, P4284	28	67	69	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13523	13529		10.1074/jbc.271.23.13523	http://dx.doi.org/10.1074/jbc.271.23.13523			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662813	hybrid, Green Published			2022-12-27	WOS:A1996UP38500034
J	Shintani, F; Kinoshita, T; Kanba, S; Ishikawa, T; Suzuki, E; Sasakawa, N; Kato, R; Asai, M; Nakaki, T				Shintani, F; Kinoshita, T; Kanba, S; Ishikawa, T; Suzuki, E; Sasakawa, N; Kato, R; Asai, M; Nakaki, T			Bioactive 6-nitronorepinephrine identified in mammalian brain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATECHOL-O-METHYLTRANSFERASE; NITRIC-OXIDE; RELEASE; NOREPINEPHRINE; DOPAMINE; SLICES	Norepinephrine (NE) (von Euler, U.S. (1972) in Catecholamines (Blaschko, H., and Muscholl, E., eds.) pp. 186-230, Springer-Verlag, Berlin) and nitric oxide (NO.) function as neurotransmitters in the nervous system. We have shown that NE levels in the rat hypothalamic paraventricular nucleus (Shintani, F., Kato, R., Kinoshita, N., Kanba, S., Asai, M., and Nakaki, T. (1995) Proceedings of the Satellite Symposium, 4th IBRO World Congress on Neuroscience, Otsu, 1995) diminish in the presence of NO.. This observation prompted us to explore the possibility of an in vivo interaction between NE and NO. or NO.-related molecules. In fact, nitration of NE has been shown to occur in vitro (d'Ischia, M., and Constantini, C. (1995) Bioorg. Med. Chem. 3, 923-927). We now report the identification of 6-nitronorepinephrine in the mammalian brain. Amounts of 6-nitronorepinephrine in the rat brain were attenuated by intraperitoneal administration of an inhibitor of nitric oxide synthase, N-G-nitro-L-arginine methyl ester (L-NAME). This was reversed by coadministration of L-arginine, suggesting that nitric oxide synthase participated in the formation of 6-nitronorepinephrine. Moreover, we found that 6-nitronorepinephrine inhibits the activity of catechol O-methyltransferase, as well as NE transport into rat synaptosomes. A rat brain microdialysis experiment showed that perfusion of 6-nitronorepinephrine into the rat paraventricular nucleus significantly elevated NE while decreasing 3-methoxy-4-hydroxyphenylglycol and that L-NAME administered intraperitoneally decreased NE and increased 3-methoxy-4-hydroxyphenylglycol. These observations suggest that 6-nitronorepinephrine generated in nuclei containing both adrenergic and nitrergic neurons inhibits NE inactivation. We propose that 6-nitronorepinephrine is a potential signal molecule linking the actions of NE and NO..	KEIO UNIV, SCH MED, DEPT PHARMACOL, SHINJUKU KU, TOKYO 160, JAPAN; KEIO UNIV, SCH MED, DEPT NEUROPSYCHIAT, SHINJUKU KU, TOKYO 160, JAPAN; SANKYO CO LTD, ANALYT & METAB RES LABS, TOKYO 140, JAPAN	Keio University; Keio University; Daiichi Sankyo Company Limited			Nakaki, Toshio/C-4832-2009					AXELROD J, 1958, J BIOL CHEM, V233, P702; BREDT DS, 1990, NATURE, V347, P768, DOI 10.1038/347768a0; DELABRETECHE ML, 1994, TETRAHEDRON LETT, V35, P7231, DOI 10.1016/0040-4039(94)85368-1; DISCHIA M, 1995, BIOORGAN MED CHEM, V3, P923, DOI 10.1016/0968-0896(95)00083-S; GARTHWAITE J, 1991, TRENDS NEUROSCI, V14, P60, DOI 10.1016/0166-2236(91)90022-M; GLOWINSKI J, 1966, J NEUROCHEM, V13, P655, DOI 10.1111/j.1471-4159.1966.tb09873.x; GRONBERG M, 1990, BIOCHEM PHARMACOL, V40, P351, DOI 10.1016/0006-2952(90)90698-K; HANBAUER I, 1992, NEUROREPORT, V3, P409, DOI 10.1097/00001756-199205000-00008; ISCHIROPOULOS H, 1992, ARCH BIOCHEM BIOPHYS, V298, P431, DOI 10.1016/0003-9861(92)90431-U; KAAKKOLA S, 1994, GEN PHARMACOL-VASC S, V25, P813, DOI 10.1016/0306-3623(94)90082-5; LONART G, 1992, EUR J PHARMACOL, V220, P271, DOI 10.1016/0014-2999(92)90759-W; MA SX, 1991, EUR J PHARMACOL, V199, P27, DOI 10.1016/0014-2999(91)90633-2; MANNISTO PT, 1988, LIFE SCI, V43, P1465, DOI 10.1016/0024-3205(88)90258-5; NAKADATE T, 1980, EUR J PHARMACOL, V64, P107, DOI 10.1016/0014-2999(80)90033-3; NISSINEN E, 1992, N-S ARCH PHARMACOL, V346, P262; PORZIG H, 1982, N-S ARCH PHARMACOL, V321, P89, DOI 10.1007/BF00518474; RICHELSON E, 1984, EUR J PHARMACOL, V103, P197, DOI 10.1016/0014-2999(84)90478-3; RICHELSON E, 1984, EUR J PHARMACOL, V104, P277, DOI 10.1016/0014-2999(84)90403-5; SHINTANI F, 1995, J NEUROSCI, V15, P1961, DOI 10.1523/JNEUROSCI.15-03-01961.1995; SHINTANI F, 1993, J NEUROSCI, V13, P3574; SHINTANI F, 1995, P SAT S 4 IBRO WORLD; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; VONEULER US, 1972, CATECHOLAMINES, P186; WURTMAN RJ, 1963, BIOCHEM PHARMACOL, V12, P1439, DOI 10.1016/0006-2952(63)90215-6; XU ZQ, 1994, EXP BRAIN RES, V98, P75	25	50	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13561	13565		10.1074/jbc.271.23.13561	http://dx.doi.org/10.1074/jbc.271.23.13561			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662880	hybrid			2022-12-27	WOS:A1996UP38500040
J	Cioce, V; Csaky, KG; Chan, AML; Bottaro, DP; Taylor, WG; Jensen, R; Aaronson, SA; Rubin, JS				Cioce, V; Csaky, KG; Chan, AML; Bottaro, DP; Taylor, WG; Jensen, R; Aaronson, SA; Rubin, JS			Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF scatter factor variant with partial agonist antagonist activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY RECEPTOR; EPITHELIAL-CELLS; MOLECULAR-CLONING; FIBROBLAST GROWTH; MET RECEPTOR; MESSENGER-RNA; HORMONE GENE; PROTEIN; IDENTIFICATION; PURIFICATION	Hepatocyte growth factor/scatter factor (HGF/SF) stimulates cell proliferation, motility, and morphogenesis by activation of its receptor, the c-Met tyrosine kinase. HGF/SF is structurally related to plasminogen, including an amino-terminal hairpin loop, four kringle domains, and a serine protease-like region. A truncated HGF/SF isoform, designated HGF/NK2, which extends through the second kringle domain and behaves as a competitive HGF/SF antagonist, was previously shown to be encoded by an alternative HGF/SF transcript. In this study, we describe a second naturally occurring HGF/SF variant, HGF/NK1, consisting of the HGF/SF amino-terminal sequence and first kringle domain. This product is encoded by a 2-kilobase alternative transcript containing intronic sequence that was contiguous with exon K1b. Analysis of baculovirus-expressed HGF/NR1 revealed that this isoform possesses the heparin binding properties of HGF/SF and modest mitogenic and scattering activity relative to HGF/SF. However, at a 40-fold molar excess, HGF/NK1 inhibited HGF/SF-dependent DNA synthesis. HGF/NK1 stimulated tyrosine phosphorylation of Met, and covalent affinity crosslinking demonstrated a direct HGF/NK1-receptor interaction. These findings establish that the HGF/SF gene encodes multiple alternative products, which include not only a mitogenic agonist (HGF/SF) and a pure antagonist (HGF/NK2) but also a molecule with partial agonist/antagonist properties.	NCI, DBS, LCMB, NIH, BETHESDA, MD 20892 USA; MT SINAI MED CTR, DERALD H RUTTENBERT CANC CTR, NEW YORK, NY 10029 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Icahn School of Medicine at Mount Sinai			Chan, Andrew Man-Lok/J-9497-2013; Chan, Andrew/AAC-1145-2020; Bottaro, Donald P/AAF-3853-2020; Bottaro, Donald P/F-8550-2010	Chan, Andrew Man-Lok/0000-0001-9923-5464; Chan, Andrew/0000-0001-9923-5464; Bottaro, Donald P/0000-0002-5057-5334; Bottaro, Donald P/0000-0002-5057-5334				AVIV H, 1972, P NATL ACAD SCI USA, V69, P1408, DOI 10.1073/pnas.69.6.1408; BOTTARO DP, 1990, J BIOL CHEM, V265, P12767; BOTTARO DP, 1991, SCIENCE, V251, P802, DOI 10.1126/science.1846706; CHAN AML, 1991, SCIENCE, V254, P1382, DOI 10.1126/science.1720571; COOPER CS, 1984, NATURE, V311, P29, DOI 10.1038/311029a0; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FUJII T, 1994, J IMMUNOL, V153, P5516; GAK E, 1992, FEBS LETT, V311, P17, DOI 10.1016/0014-5793(92)81356-Q; GALIMI F, 1994, J CELL BIOL, V127, P1743, DOI 10.1083/jcb.127.6.1743; GANDINO L, 1991, J BIOL CHEM, V266, P16098; GANDINO L, 1994, J BIOL CHEM, V269, P1815; GANDINO L, 1990, ONCOGENE, V5, P721; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GHERARDI E, 1990, NATURE, V346, P228, DOI 10.1038/346228b0; JACKSON RL, 1991, PHYSIOL REV, V71, P481, DOI 10.1152/physrev.1991.71.2.481; KAN M, 1991, BIOCHEM BIOPH RES CO, V174, P331, DOI 10.1016/0006-291X(91)90524-B; KMIECIK TE, 1992, BLOOD, V80, P2454; KOMADA M, 1993, ONCOGENE, V8, P2381; KOMADA M, 1994, J BIOL CHEM, V269, P16131; LAROCHELLE WJ, 1990, SCIENCE, V248, P1541, DOI 10.1126/science.2163109; LOKKER NA, 1992, EMBO J, V11, P2503, DOI 10.1002/j.1460-2075.1992.tb05315.x; LOKKER NA, 1993, J BIOL CHEM, V268, P17145; LONGATI P, 1994, ONCOGENE, V9, P49; LUCKOW VA, 1989, VIROLOGY, V170, P31, DOI 10.1016/0042-6822(89)90348-6; MACLEOD JN, 1992, J BIOL CHEM, V267, P14219; MIYAZAWA K, 1991, BIOCHEMISTRY-US, V30, P9170, DOI 10.1021/bi00102a007; MIYAZAWA K, 1989, BIOCHEM BIOPH RES CO, V163, P967, DOI 10.1016/0006-291X(89)92316-4; MIYAZAWA K, 1991, EUR J BIOCHEM, V197, P15, DOI 10.1111/j.1432-1033.1991.tb15876.x; MONTESANO R, 1991, CELL, V67, P901, DOI 10.1016/0092-8674(91)90363-4; NAKA D, 1993, EXP CELL RES, V209, P317, DOI 10.1006/excr.1993.1316; NAKA D, 1992, J BIOL CHEM, V267, P20114; NAKAMURA T, 1989, NATURE, V342, P440, DOI 10.1038/342440a0; NALDINI L, 1992, EMBO J, V11, P4825, DOI 10.1002/j.1460-2075.1992.tb05588.x; NALDINI L, 1991, EMBO J, V10, P2867, DOI 10.1002/j.1460-2075.1991.tb07836.x; PARK M, 1987, P NATL ACAD SCI USA, V84, P6379, DOI 10.1073/pnas.84.18.6379; PATTHY L, 1984, FEBS LETT, V171, P131, DOI 10.1016/0014-5793(84)80473-1; PONTING CP, 1992, BLOOD COAGUL FIBRIN, V3, P605, DOI 10.1097/00001721-199210000-00012; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; RADOVICK S, 1990, MOL ENDOCRINOL, V4, P476, DOI 10.1210/mend-4-3-476; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROSEN EM, 1994, J CELL BIOL, V127, P1783, DOI 10.1083/jcb.127.6.1783; ROSEN EM, 1991, EXP SUPPL, V59, P76; RUBIN JS, 1989, P NATL ACAD SCI USA, V86, P802, DOI 10.1073/pnas.86.3.802; RUBIN JS, 1991, P NATL ACAD SCI USA, V88, P415, DOI 10.1073/pnas.88.2.415; RUBIN JS, 1993, BIOCHIM BIOPHYS ACTA, V1155, P357, DOI 10.1016/0304-419X(93)90015-5; SAIKI RK, 1985, SCIENCE, V230, P1350, DOI 10.1126/science.2999980; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SEKI T, 1991, GENE, V102, P213; SHIMA N, 1991, CELL BIOL INT REP, V15, P397, DOI 10.1016/0309-1651(91)90128-6; SHIMA N, 1991, BIOCHEM BIOPH RES CO, V180, P1151, DOI 10.1016/S0006-291X(05)81187-8; SMITH CWJ, 1989, ANNU REV GENET, V23, P527, DOI 10.1146/annurev.genet.23.1.527; SPIVAKKROIZMAN T, 1994, CELL, V79, P1015, DOI 10.1016/0092-8674(94)90032-9; SPRINGHORN JP, 1994, J BIOL CHEM, V269, P5132; STOKER M, 1985, J CELL SCI, V77, P209; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; VILLAMORUZZI E, 1993, J BIOL CHEM, V268, P18176; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; WEIDNER KM, 1990, J CELL BIOL, V111, P2097, DOI 10.1083/jcb.111.5.2097; WEIDNER KM, 1993, J CELL BIOL, V121, P145, DOI 10.1083/jcb.121.1.145; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZIONCHECK TF, 1995, J BIOL CHEM, V270, P16871, DOI 10.1074/jbc.270.28.16871	62	124	131	1	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13110	13115		10.1074/jbc.271.22.13110	http://dx.doi.org/10.1074/jbc.271.22.13110			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662798	hybrid, Green Published			2022-12-27	WOS:A1996UN47400065
J	Dittmar, KD; Hutchison, KA; OwensGrillo, JK; Pratt, WB				Dittmar, KD; Hutchison, KA; OwensGrillo, JK; Pratt, WB			Reconstitution of the steroid receptor center dot hsp90 heterocomplex assembly system of rabbit reticulocyte lysate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; BACTERIAL DNAJ; HSP90; COMPLEXES; BINDING; EXISTS; HSP70	Rabbit reticulocyte lysate contains a multiprotein system that assembles steroid receptors into a heterocomplex with hsp90. In the case of the glucocorticoid receptor (GR), the receptor must be bound to hsp90 to bind steroid, and assembly of the GR . hsp90 complex restores the hormone binding domain of the receptor to the steroid binding conformation. Using both direct assay of heterocomplex assembly by Western blotting and indirect assay of assembly by steroid binding, it has previously been determined that the assembly system is both ATP/Mg2+-dependent and K+-dependent and that hsp70 and an acidic 23-kDa protein (p23) are required to form a functional GR . hsp90 complex. It is also thought that a 60-kDa protein (p60) may be required for progesterone receptor hsp90 heterocomplex assembly, but a complete heterocomplex assembly system has never been reconstituted from individual components. In this work, we separate the proteins of rabbit reticulocyte lysate into three fractions by DEAE chromatography and then reconstitute the GR . hsp90 heterocomplex assembly system in a manner that requires the presence of each fraction. Fraction A contains most of the hsp70 and all of the p60 in lysate, and elimination of p60 by immunoadsorption inactivates this fraction, with bioactivity being restored by the addition of bacterially expressed human p60. The activity of fraction A is replaced by a combination of highly purified rabbit hsp70 and lysate from p60-expressing bacteria. Fraction B contains hsp90, and its activity is replaced by purified rabbit hsp90. Fraction C contains p23, and its activity is replaced in the recombined system by highly purified bacterially expressed human p23. A minimal GR . hsp90 heterocomplex assembly system was reconstituted with purified rabbit hsp70 and hsp90 and bacterially expressed human p23 and p60. This reports the first reconstitution of this apparently ubiquitous protein folding/heterocomplex assembly system.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NCI NIH HHS [T32CA09676] Funding Source: Medline; NIDDK NIH HHS [DK31573] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009676] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK031573, R37DK031573] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRESNICK EH, 1989, J BIOL CHEM, V264, P4992; CAPLAN AJ, 1991, J CELL BIOL, V114, P609, DOI 10.1083/jcb.114.4.609; ERHART JC, 1988, ONCOGENE, V3, P595; HOHFELD J, 1995, CELL, V83, P589; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P14047; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1993, BIOCHEMISTRY-US, V32, P3953, DOI 10.1021/bi00066a015; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KIMURA Y, 1995, NATURE, V268, P1362; NICOLET CM, 1989, MOL CELL BIOL, V9, P3638, DOI 10.1128/MCB.9.9.3638; OHTSUKA K, 1993, BIOCHEM BIOPH RES CO, V197, P235, DOI 10.1006/bbrc.1993.2466; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PRATT WB, 1993, J BIOL CHEM, V268, P21455; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHERRER LC, 1990, J BIOL CHEM, V265, P21397; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1990, MOL ENDOCRINOL, V4, P1704, DOI 10.1210/mend-4-11-1704; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, J BIOL CHEM, V268, P18365; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; Stancato LF, 1996, BIOCHEMISTRY-US, V35, P554, DOI 10.1021/bi9511649; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; WALSH CT, 1992, J BIOL CHEM, V267, P13115; WHITELAW ML, 1991, J BIOL CHEM, V266, P6708; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324	35	141	143	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12833	12839		10.1074/jbc.271.22.12833	http://dx.doi.org/10.1074/jbc.271.22.12833			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662785	hybrid			2022-12-27	WOS:A1996UN47400024
J	Bouckaert, J; Poortmans, F; Wyns, L; Loris, R				Bouckaert, J; Poortmans, F; Wyns, L; Loris, R			Sequential structural changes upon zinc and calcium binding to metal-free concanavalin A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHARIDE-BINDING; ION BINDING; MANGANESE; SITE; CONFORMATION; TRANSITIONS; RESOLUTION; CRYSTAL	The lectin concanavalin A (ConA) sequentially binds a transition metal ion in the metal-binding site S1 and a calcium ion in the metal-binding site S2 to form its saccharide-binding site. Metal-free ConA crystals soaked with either Zn2+ (apoZn-ConA) or Co2+ (apoCo-ConA) display partial binding of these ions in the proto-transition metal-binding site, but no further conformational changes are observed, These structures can represent the very first step in going from metal-free ConA toward the holoprotein. In the co-crystals of metal-free ConA with Zn2+ (Zn-ConA), the zinc ion can fully occupy the S1 site, The positions of the carboxylate ligands Asp(10) and Asp(19) that bridge the S1 and S2 sites are affected, The ligation to Zn2+ orients Asp(10) optimally for calcium ligation and stabilizes Asp(19) by a hydrogen bond to one of its water ligands, The neutralizing and stabilizing effect of the binding of Zn2+ in S1 is necessary to allow for subsequent Ca2+ binding in the S2 site. However, the S2 site of monometallized ConA is still disrupted, The co crystals of met al-free ConA with both Zn2+ and Ca2+ contain the active holoprotein (ConA ZnCa). Ca2+ has induced large conformational changes to stabilize its hepta-coordination in the S2 site, which comprise the trans to cts isomerization of the Ala(207)-Asp(208) peptide bond accompanied by the formation of the saccharide-binding site, The Zn2+ Ligation in ConA ZnCa is similar to Mn2+, Cd2+, Co2+, or Ni2+ ligation in the S1 site, in disagreement with earlier extended x-ray absorption fine structure results that suggested a lower coordination number for Zn2+.	FREE UNIV BRUSSELS VIB, LAB ULTRASTRUCT, B-2400 BRUSSELS, BELGIUM; VLAAMSE INSTELLING TECHNOL ONDERZOEK, MOL, BELGIUM	Flanders Institute for Biotechnology (VIB); Vrije Universiteit Brussel; VITO			Loris, Remy/GPG-0894-2022	Loris, Remy/0000-0002-8862-3338; Bouckaert, Julie/0000-0001-8112-1442				BARBER BH, 1975, BIOCHEMISTRY-US, V14, P4075, DOI 10.1021/bi00689a024; BECKER JW, 1975, J BIOL CHEM, V250, P1513; Bertini I., 1994, BIOINORG CHEM, P37; Bouckaert J, 1995, PROTEINS, V23, P510, DOI 10.1002/prot.340230406; BOUCKAERT J, 1995, IN PREESS LECTINS BI, V11; BREWER CF, 1983, BIOCHEMISTRY-US, V22, P3691, DOI 10.1021/bi00284a024; BREWER CF, 1983, J BIOMOL STRUCT DYN, V1, P961, DOI 10.1080/07391102.1983.10507497; BROWN RD, 1982, BIOCHEMISTRY-US, V21, P465, DOI 10.1021/bi00532a008; BROWN RD, 1977, BIOCHEMISTRY-US, V16, P3883, DOI 10.1021/bi00636a026; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; DEREWENDA Z, 1989, EMBO J, V8, P2189, DOI 10.1002/j.1460-2075.1989.tb08341.x; EMMERICH C, 1994, ACTA CRYSTALLOGR D, V50, P749, DOI 10.1107/S0907444994002143; GLUSKER JP, 1991, ADV PROTEIN CHEM, V42, P3; GRIMALDI JJ, 1975, J BIOL CHEM, V250, P1618; HARDMAN KD, 1982, J MOL BIOL, V157, P69, DOI 10.1016/0022-2836(82)90513-7; HARRINGTON PC, 1978, BIOCHEMISTRY-US, V17, P4245, DOI 10.1021/bi00613a021; JONES TA, 1978, J APPL CRYSTALLOGR, V11, P268, DOI 10.1107/S0021889878013308; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KALB AJ, 1979, J MOL BIOL, V135, P501, DOI 10.1016/0022-2836(79)90449-2; KALB AJ, 1968, BIOCHEM J, V109, P669, DOI 10.1042/bj1090669; KLEYWEGT GJ, 1994, ESF CCP 4 NEWSL 1131, P9; KOENIG SH, 1978, BIOCHEMISTRY-US, V17, P4251, DOI 10.1021/bi00613a022; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LIN SL, 1991, BIOCHEMISTRY-US, V30, P2323, DOI 10.1021/bi00223a006; LIN SL, 1991, BIOCHEMISTRY-US, V30, P9705, DOI 10.1021/bi00104a019; LIN SL, 1990, BIOCHEMISTRY-US, V29, P3599, DOI 10.1021/bi00467a002; LUZATTI V, 1952, ACTA CRYSTALLOGR, V5, P802; MCPHALEN CA, 1991, ADV PROTEIN CHEM, V42, P77; MORRIS AL, 1992, PROTEINS, V12, P345, DOI 10.1002/prot.340120407; NAISMITH JH, 1993, ACTA CRYSTALLOGR D, V49, P561, DOI 10.1107/S0907444993006390; NAISMITH JH, 1994, ACTA CRYSTALLOGR D, V50, P847, DOI 10.1107/S0907444994005287; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; PALMER AR, 1980, BIOCHEMISTRY-US, V19, P5063, DOI 10.1021/bi00563a020; PFLUGRATH JW, 1989, MADNESS MANUAL FAST; SHARON N, 1989, SCIENCE, V246, P227, DOI 10.1126/science.2552581; SHERRY AD, 1973, ARCH BIOCHEM BIOPHYS, V156, P665, DOI 10.1016/0003-9861(73)90319-6; SHOHAM M, 1973, BIOCHEMISTRY-US, V12, P1914, DOI 10.1021/bi00734a012; WEISGERBER S, 1993, J CHEM SOC FARADAY T, V89, P2667, DOI 10.1039/ft9938902667	38	58	59	2	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16144	16150		10.1074/jbc.271.27.16144	http://dx.doi.org/10.1074/jbc.271.27.16144			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663112	hybrid			2022-12-27	WOS:A1996UW35200045
J	Mayer, T; Touchot, N; Elazar, Z				Mayer, T; Touchot, N; Elazar, Z			Transport between cis and medial Golgi cisternae requires the function of the Ras-related protein Rab6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; ADP-RIBOSYLATION FACTOR; YPT1 GENE-PRODUCT; ENDOPLASMIC-RETICULUM; VESICULAR TRANSPORT; EPITHELIAL-CELLS; MEMBRANE-FUSION; YEAST; SECRETION; COMPARTMENTS	The small GTP-binding protein Rab6, a member of the Ras superfamily, is localized on the membranes of the Golgi apparatus and the trans Golgi network. Recent studies revealed that the Rab6 protein might be involved in the transit of proteins through the Golgi complex. In this report we demonstrate the essential function of the Rab6 protein in a distinct step of reconstituted Golgi transport, Polyclonal antibodies and Fab fragments directed against the C-terminal part of the Rab6 protein inhibit transport between the cis and the medial Golgi cisternae, Inhibition also occurred when a trans-dominant mutant form of the Rab6 protein (N126I) was added to the reconstituted transport. Furthermore, Rab6 antibodies inhibit uncoupled fusion of Golgi membranes. From these data we conclude that Rab6 is involved in a process related to membrane fusion at the cisternal membranes of the Golgi apparatus and therefore is needed for the consumption of Golgi-derived vesicles by their target membranes.	WEIZMANN INST SCI,DEPT MEMBRANE RES & BIOPHYS,IL-76100 REHOVOT,ISRAEL	Weizmann Institute of Science	Mayer, T (corresponding author), UNIV MUNSTER,DEPT EXPT TUMOR BIOL,BADESTR 9,D-48149 MUNSTER,GERMANY.			Mayer, Thomas/0000-0001-6954-2287				BARBACID M, 1987, ANNU REV BIOCHEM, V56, P779, DOI 10.1146/annurev.bi.56.070187.004023; BECKERS CJM, 1992, METHOD ENZYMOL, V219, P5; BEDNAREK SY, 1994, PLANT PHYSIOL, V104, P591, DOI 10.1104/pp.104.2.591; BOURNE HR, 1988, CELL, V53, P669, DOI 10.1016/0092-8674(88)90081-5; CHAVRIER P, 1990, CELL, V62, P317, DOI 10.1016/0092-8674(90)90369-P; CHAVRIER P, 1992, GENE, V112, P261, DOI 10.1016/0378-1119(92)90387-5; CHAVRIER P, 1991, NATURE, V353, P769, DOI 10.1038/353769a0; CLARY DO, 1990, CELL, V61, P709, DOI 10.1016/0092-8674(90)90482-T; ELAZAR Z, 1994, J BIOL CHEM, V269, P794; ELAZAR Z, 1994, J CELL BIOL, V124, P415, DOI 10.1083/jcb.124.4.415; ELFERINK LA, 1992, J BIOL CHEM, V267, P5768; FEIG L, 1990, MOL CELL BIOL, V8, P3225; GOUD B, 1990, NATURE, V345, P553, DOI 10.1038/345553a0; GROVEL JP, 1991, CELL, V64, P915; HAUBRUCK H, 1989, EMBO J, V8, P1427, DOI 10.1002/j.1460-2075.1989.tb03524.x; HENGST L, 1990, EMBO J, V9, P1949, DOI 10.1002/j.1460-2075.1990.tb08322.x; KAHN RA, 1992, J BIOL CHEM, V267, P13039; LI GP, 1994, J BIOL CHEM, V269, P14631; LOMBARDI D, 1993, EMBO J, V12, P677, DOI 10.1002/j.1460-2075.1993.tb05701.x; LUTCKE A, 1993, J CELL BIOL, V121, P553, DOI 10.1083/jcb.121.3.553; MARTINEZ O, 1994, J CELL BIOL, V127, P1575, DOI 10.1083/jcb.127.6.1575; Melancon P, 1989, Soc Gen Physiol Ser, V44, P175; MUNRO S, 1987, CELL, V48, P899, DOI 10.1016/0092-8674(87)90086-9; NUOFFER C, 1994, J CELL BIOL, V125, P225, DOI 10.1083/jcb.125.2.225; ORCI L, 1993, NATURE, V362, P648, DOI 10.1038/362648a0; ORCI L, 1991, CELL, V64, P1183; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; PIND SN, 1994, J CELL BIOL, V125, P239, DOI 10.1083/jcb.125.2.239; PLUTNER H, 1991, J CELL BIOL, V115, P31, DOI 10.1083/jcb.115.1.31; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SALMINEN A, 1987, CELL, V49, P527, DOI 10.1016/0092-8674(87)90455-7; SCHMITT HD, 1988, CELL, V53, P635, DOI 10.1016/0092-8674(88)90579-X; SEGEV N, 1988, CELL, V52, P915, DOI 10.1016/0092-8674(88)90433-3; STOW JL, 1991, J CELL BIOL, V114, P1113, DOI 10.1083/jcb.114.6.1113; TISDALE EJ, 1992, J CELL BIOL, V119, P749, DOI 10.1083/jcb.119.4.749; TOOZE SA, 1990, NATURE, V347, P207, DOI 10.1038/347207a0; TOUCHOT N, 1987, P NATL ACAD SCI USA, V84, P8210, DOI 10.1073/pnas.84.23.8210; VANDERSLUIJS P, 1991, P NATL ACAD SCI USA, V88, P6313, DOI 10.1073/pnas.88.14.6313; VONMOLLARD GF, 1990, P NATL ACAD SCI USA, V87, P1988, DOI 10.1073/pnas.87.5.1988; WALWORTH NC, 1989, EMBO J, V8, P1685, DOI 10.1002/j.1460-2075.1989.tb03560.x; WHITEHEART SW, 1992, J BIOL CHEM, V267, P12239; WHITEHEART SW, 1993, NATURE, V362, P353, DOI 10.1038/362353a0; WILSON DW, 1992, J CELL BIOL, V117, P531, DOI 10.1083/jcb.117.3.531; ZAHRAOUI A, 1989, J BIOL CHEM, V264, P12394	44	21	21	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16097	16103		10.1074/jbc.271.27.16097	http://dx.doi.org/10.1074/jbc.271.27.16097			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663167	hybrid			2022-12-27	WOS:A1996UW35200038
J	Morris, JC; PingSheng, L; Zhai, HX; Shen, TY; MensaWilmot, K				Morris, JC; PingSheng, L; Zhai, HX; Shen, TY; MensaWilmot, K			Phosphatidylinositol phospholipase C is activated allosterically by the aminoglycoside G418 - 2-deoxy-2-fluoro-scyllo-inositol-1-O-dodecylphosphonate and its analogs inhibit glycosylphosphatidylinositol phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-CEREUS; TRYPANOSOMA-BRUCEI; SUBSTRATE; THURINGIENSIS	Phosphatidylinositol-specific phospholipase C (PI-PLC) from Bacillus cereus is inhibited by myo-inositol-1-O-dodecylphosphonate (Ins-1-O-dodecylphosphonate) (Morris, J, C,, Ping-Sheng, L,, Shen, T, Y,, and Mensa-Wilmot, K, (1995) J, Biol, Chem, 270, 2517-2524), A set of novel fluorinated 2-deoxy-Ins-1-Q-dodecylphosphonates were tested against PI-PLC, with potent competitive inhibition by 2-deoxy-2-fluoro-scyllo-Ins-1-O-dodecylphosphonate (VP-616L) (X(i(50)) = 0.09), 2-Deoxy-2-fluoro-myo-Ins-1-O-dodecylphosphonate and 2-deoxy-2,2-difluoro-myo-Ins-1-O-dodecylphosphonate were 8.3 fold and 4.8-fold less effective, respectively, than VP-616L, Methyl 2-deoxy-2,2-difluoro-myo-Ins-1-O-dodecylphosphonate was inactive, Also, a hundredfold less PI-PLC is required to cleave a glycosylphosphatidylinositol (GPI) than is needed to cleave PI, Implied in these observations are the following: (i) in powerful inhibitors an active site residue probably interacts with the equatorially oriented fluoro substituent; (ii) substrate recognition requires a negative charge on the phosphoryl at the Ins-1 position, and (iii) a GPI is better substrate than PI, for PI-PLC. Aminoglycoside antibiotics kanamycin A, gentamycin, and G418 stimulated PI-PLC cleavage of the GPI anchor of variant surface glycoprotein (VSG) from Trypanosoma brucei 2- to 4-fold, G418, which appears to act on the enzyme substrate complex, increased k(cat) and K-m 6.4-fold and 9.9-fold, respectively, PI-PLC was activated by G418 even in the presence of the inhibitor VP-616L, In control experiments, the lectin concanavalin A (ConA), which probably acts by substrate sequestration, inhibited both PI-PLC (X(i(50)) = 0.00025) and GPI-specific phospholipase D (X(i(50)) = 0.00018), G418 failed to activate PI-PLC when ConA was present, These observations indicate that G418 is an allosteric activator of Bacillus cereus PI-PLC, Since G418 stimulates a purified enzyme that is not involved in aminoglycoside metabolism, we propose that binding of aminoglycosides to cellular proteins could contribute to the development of the nephrotoxicity associated with the use of these aminoglycoside antibiotics.	UNIV GEORGIA, DEPT CELLULAR BIOL, ATHENS, GA 30602 USA; UNIV VIRGINIA, DEPT CHEM, CHARLOTTESVILLE, VA 22901 USA	University System of Georgia; University of Georgia; University of Virginia				Morris, James/0000-0003-2515-5714	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033383, R29AI033383] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047109] Funding Source: NIH RePORTER; NIAID NIH HHS [AI33383, 1-T32-AIO-4322] Funding Source: Medline; NIGMS NIH HHS [GM47109] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANGS JD, 1988, J BIOL CHEM, V263, P17697; BRUZIK KS, 1994, BIOCHEMISTRY-US, V33, P8367, DOI 10.1021/bi00193a026; DEEG MA, 1995, METHOD ENZYMOL, V250, P630; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; GUPTA D, 1988, SCIENCE, V242, P1446, DOI 10.1126/science.2904699; HELLER M, 1994, EUR J BIOCHEM, V224, P823, DOI 10.1111/j.1432-1033.1994.00823.x; HENNER DJ, 1988, NUCLEIC ACIDS RES, V16, P10383, DOI 10.1093/nar/16.21.10383; JAGER K, 1991, BIOCHIM BIOPHYS ACTA, V1074, P45, DOI 10.1016/0304-4165(91)90037-H; JONES GA, 1993, J BIOL CHEM, V268, P20845; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LEE SB, 1995, CURR OPIN CELL BIOL, V7, P183, DOI 10.1016/0955-0674(95)80026-3; LEE SJ, 1995, J BIOL CHEM, V270, P16378, DOI 10.1074/jbc.270.27.16378; LEWIS KA, 1993, BIOCHEMISTRY-US, V32, P8836, DOI 10.1021/bi00085a014; Low M.G., 1992, LIPID MODIFICATION P, P117; MANDAL DK, 1994, BIOCHEMISTRY-US, V33, P1157, DOI 10.1021/bi00171a015; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1995, METHOD ENZYMOL, V250, P641; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MINGEOTLECLERCQ MP, 1995, J TOXICOL ENV HEALTH, V44, P263, DOI 10.1080/15287399509531960; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; SAGAWA N, 1983, BIOCHIM BIOPHYS ACTA, V752, P153, DOI 10.1016/0005-2760(83)90243-6; SCALLON BJ, 1991, SCIENCE, V252, P446, DOI 10.1126/science.2017684; SCHNEIDER P, 1995, METHOD ENZYMOL, V250, P614; SCHRODER G, 1992, BIOCHEMISTRY-US, V31, P631, DOI 10.1021/bi00118a001; SCHWERTZ DW, 1984, J PHARMACOL EXP THER, V231, P48; SHASHIDHAR MS, 1990, BIOCHIM BIOPHYS ACTA, V1042, P410, DOI 10.1016/0005-2760(90)90172-T; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; VANBAMBEKE F, 1995, EUR J PHARM-MOLEC PH, V289, P321, DOI 10.1016/0922-4106(95)90110-8; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; VOLWERK JJ, 1994, BIOCHEMISTRY-US, V33, P3464, DOI 10.1021/bi00178a002; VONAHSEN U, 1992, J MOL BIOL, V226, P935, DOI 10.1016/0022-2836(92)91043-O; WAHL MI, 1992, J BIOL CHEM, V267, P10447; WALLIS MG, 1995, CHEM BIOL, V2, P543, DOI 10.1016/1074-5521(95)90188-4; WANG Y, 1995, CHEM BIOL, V2, P281, DOI 10.1016/1074-5521(95)90047-0; ZHAI HX, 1995, TETRAHEDRON LETT, V36, P7403, DOI 10.1016/0040-4039(95)01579-5	35	26	28	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15468	15477		10.1074/jbc.271.26.15468	http://dx.doi.org/10.1074/jbc.271.26.15468			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663028	hybrid			2022-12-27	WOS:A1996UV29900027
J	Poland, BW; Hou, ZL; Bruns, C; Fromm, HJ; Honzatko, RB				Poland, BW; Hou, ZL; Bruns, C; Fromm, HJ; Honzatko, RB			Refined crystal structures of guanine nucleotide complexes of adenylosuccinate synthetase from Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSENSUS SEQUENCE; MOLECULAR-CLONING; ISOTOPE EXCHANGE; MECHANISM; PURIFICATION; PROTEINS; PURA	Structures of adenylosuccinate synthetase from Escherichia coli complexed with guanosine-5'-(beta,gamma-imido) triphosphate and guanosine-5'-(beta,gamma-methylene)triphosphate in the presence and the absence of Mg2+ have been refined to R-factors below 0.2 against data to a nominal resolution of 2.7 Angstrom. Asp(333) of the synthetase hydrogen bonds to the exocyclic 2-amino and endocyclic N1 groups of the guanine nucleotide base, whereas the hydroxyl of Ser(414) and the backbone amide of Lys(331) hydrogen bond to the 6-oxo position. The side chains of Lys(331) and pro(417) pack against opposite faces of the guanine nucleotide base. The synthetase recognizes neither the N7 position of guanine nucleotides nor the ribose group. Electron density for the guanine-5'-(beta,gamma-imido) triphosphate complex is consistent with a mixture of the triphosphate nucleoside and its hydrolyzed diphosphate nucleoside bound to the active site. The base, ribose, and alpha-phosphate positions overlap, but the beta-phosphates occupy different binding sites. The binding of guanosine-5'-(beta,gamma-methylene)triphosphate to the active site is comparable with that of guanosine-5'-(beta,gamma-imido)triphosphate. No electron density, however, for the corresponding diphosphate nucleoside is observed. In addition, electron density for bound Mg2+ is absent in these nucleotide complexes. The guanine nucleotide complexes of the synthetase are compared with complexes of other GTP-binding proteins and to a preliminary structure of the complex of GDP, IMP, Mg2+, and succinate with the synthetase. The enzyme, under conditions reported here, does not undergo a conformational change in response to the binding of guanine nucleotides, and minimally IMP and/or Mg2+ must be present in order to facilitate the complete recognition of the guanine nucleotide by the synthetase.			Poland, BW (corresponding author), IOWA STATE UNIV SCI & TECHNOL,DEPT BIOCHEM & BIOPHYS,1210 MOL BIOL BLDG,AMES,IA 50011, USA.							ALEXEEV D, 1994, STRUCTURE, V2, P1061, DOI 10.1016/S0969-2126(94)00109-X; BASS MB, 1987, ARCH BIOCHEM BIOPHYS, V256, P335, DOI 10.1016/0003-9861(87)90454-1; BASS MB, 1984, J BIOL CHEM, V259, P2330; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; Brunger A. T., 1992, XPLOR VERSION 3 1 SY; CAMBILLAU C, 1987, J MOL GRAPHICS, V5, P174, DOI 10.1016/0263-7855(87)80024-3; CLARK SW, 1976, BIOCHIM BIOPHYS ACTA, V437, P87, DOI 10.1016/0304-4165(76)90349-4; COLEMAN DE, 1994, SCIENCE, V265, P1405, DOI 10.1126/science.8073283; COOPER BF, 1986, BIOCHEMISTRY-US, V25, P7323, DOI 10.1021/bi00371a013; DEVER TE, 1987, P NATL ACAD SCI USA, V84, P1814, DOI 10.1073/pnas.84.7.1814; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FROMM HJ, 1958, BIOCHIM BIOPHYS ACTA, V29, P255, DOI 10.1016/0006-3002(58)90182-3; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P87; GUICHERIT OM, 1994, J BIOL CHEM, V269, P4488; GUICHERIT OM, 1991, J BIOL CHEM, V266, P22582; HOWARD AJ, 1985, METHOD ENZYMOL, V114, P452; HUANG WJ, 1994, STRUCTURE, V2, P407, DOI 10.1016/S0969-2126(00)00042-3; JANCARIK J, 1991, J APPL CRYSTALLOGR, V24, P409, DOI 10.1107/S0021889891004430; KANG C, 1994, J BIOL CHEM, V269, P24046; KANG CH, 1994, ARCH BIOCHEM BIOPHYS, V310, P475, DOI 10.1006/abbi.1994.1195; KANG CH, 1995, J BIOL CHEM, V270, P15539, DOI 10.1074/jbc.270.26.15539; KJELDGAARD M, 1993, STRUCTURE, V1, P35, DOI 10.1016/0969-2126(93)90007-4; KUSANO T, 1992, J BIOL CHEM, V267, P11242; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LIEBERMAN I, 1956, J BIOL CHEM, V223, P327; LIU F, 1992, J BIOL CHEM, V267, P2388; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; MANTSALA P, 1992, J BACTERIOL, V174, P1883; MARKHAM DG, 1977, ARCH BIOCHEM BIOPHYS, V184, P24; MILLER RW, 1962, J BIOL CHEM, V237, P485; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAND BW, 1993, J BIOL CHEM, V268, P25334; POWELL SM, 1992, FEBS LETT, V303, P4, DOI 10.1016/0014-5793(92)80465-S; RANDERATH K, 1966, THIN LAYER CHROMATOG, P229; RUDOLPH FB, 1969, J BIOL CHEM, V244, P3832; Saenger W, 1984, PRINCIPLES NUCL ACID, P16; SILVA MM, 1995, J MOL BIOL, V254, P431, DOI 10.1006/jmbi.1995.0629; Soans C, 1991, ARCH BIOCHEM BIOPHYS, V310, P475; SPEISER DM, 1992, MOL CELL BIOL, V12, P5301, DOI 10.1128/MCB.12.12.5301; STAYTON MM, 1983, CURR TOP CELL REGUL, V22, P103; VANDERWE.MB, 1974, J BIOL CHEM, V249, P7282; WEBB MR, 1984, J BIOL CHEM, V259, P3044; WIESMULLER L, 1991, J BIOL CHEM, V266, P2480; WOLFE SA, 1988, J BIOL CHEM, V263, P19147; WYNGAARDEN JB, 1963, J BIOL CHEM, V238, P1054; ZEIDLER R, 1993, J BIOL CHEM, V268, P20191	46	25	26	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15407	15413		10.1074/jbc.271.26.15407	http://dx.doi.org/10.1074/jbc.271.26.15407			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663109	hybrid			2022-12-27	WOS:A1996UV29900019
J	Stein, T; Vater, J; Kruft, V; Otto, A; WittmannLiebold, B; Franke, P; Panico, M; McDowell, R; Morris, HR				Stein, T; Vater, J; Kruft, V; Otto, A; WittmannLiebold, B; Franke, P; Panico, M; McDowell, R; Morris, HR			The multiple carrier model of nonribosomal peptide biosynthesis at modular multienzymatic templates	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GRAMICIDIN-S SYNTHETASE; BACILLUS-SUBTILIS; SEQUENCE; ACTIVATION; BINDING; GRSB; GENE	Gramicidin S synthetase 1 and 2 were affinity-labeled at their thiolation centers either by thioesterification with the amino acid substrate or by specific alkylation with the thiol reagent N-ethylmaleimide in combination with a substrate protection technique. The labeled proteins were digested either chemically by cyanogen bromide or by proteases. An efficient multistep high pressure liquid chromatography methodology was developed and used to isolate the active site peptide fragments of all five thiolation centers of gramicidin S synthetase in pure form. The structures of these fragments are investigated by N-terminal sequencing, mass spectrometry, and amino acid analysis. Each of the active site peptide fragments contains the consensus motif LGG(HID)S(LII), which is specific for thioester formation in nonribosomal peptide biosynthesis. It was demonstrated that a 4'-phosphopantetheine cofactor is attached to the central serine of the thiolation motif in each amino acid-activating module of the gramicidin S synthetase multienzyme system forming the thioester binding sites for the amino acid substrates and catalyzing the elongation process. Our data are strong support for a ''multiple carrier model'' of nonribosomal peptide biosynthesis at multifunctional templates, which is discussed in detail.	TECH UNIV BERLIN,INST MOLEK BIOL & BIOCHEM,D-10587 BERLIN,GERMANY; MAX DELBRUCK CENTRUM MOLEK MED,D-13122 BERLIN,GERMANY; FREE UNIV BERLIN,INST BIOCHEM,D-14195 BERLIN,GERMANY; UNIV LONDON IMPERIAL COLL SCI TECHNOL & MED,DEPT BIOCHEM,LONDON SW7 2AY,ENGLAND	Technical University of Berlin; Helmholtz Association; Max Delbruck Center for Molecular Medicine; Free University of Berlin; Imperial College London				Vater, Joachim/0000-0002-4478-4244	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALVAREZ E, 1993, EUR J BIOCHEM, V215, P323, DOI 10.1111/j.1432-1033.1993.tb18038.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHIU CW, 1984, THESIS TU BERLIN; COSMINA P, 1993, MOL MICROBIOL, V8, P821, DOI 10.1111/j.1365-2958.1993.tb01629.x; DECRECYLAGARD V, 1995, CR ACAD SCI III-VIE, V318, P927; DIECKMANN R, 1995, FEBS LETT, V357, P212, DOI 10.1016/0014-5793(94)01342-X; FUMA S, 1993, NUCLEIC ACIDS RES, V21, P93, DOI 10.1093/nar/21.1.93; GEVERS W, 1969, P NATL ACAD SCI USA, V63, P1335, DOI 10.1073/pnas.63.4.1335; GOCHT M, 1994, J BACTERIOL, V176, P2654, DOI 10.1128/JB.176.9.2654-2662.1994; KLEINKAUF H, 1990, EUR J BIOCHEM, V192, P1, DOI 10.1111/j.1432-1033.1990.tb19188.x; KRATZSCHMAR J, 1989, J BACTERIOL, V171, P5422; KURAHASHI K, 1974, ANNU REV BIOCHEM, V43, P445, DOI 10.1146/annurev.bi.43.070174.002305; Laland S G, 1973, Essays Biochem, V9, P31; LALAND SG, 1972, NATURE-NEW BIOL, V239, P43, DOI 10.1038/newbio239043a0; LIPMANN F, 1973, ACCOUNTS CHEM RES, V6, P361, DOI 10.1021/ar50071a001; LIPMANN F, 1954, MECHANISM ENZYME ACT, P599; MANN M, 1989, ANAL CHEM, V61, P1702, DOI 10.1021/ac00190a023; MORRIS HR, 1982, NATURE, V300, P643, DOI 10.1038/300643a0; MORRIS HR, 1981, BIOCHEM BIOPH RES CO, V101, P623, DOI 10.1016/0006-291X(81)91304-8; PAVELAVRANCIC M, 1994, BIOCHEMISTRY-US, V33, P6276, DOI 10.1021/bi00186a030; PAVELAVRANCIC M, 1994, J BIOL CHEM, V269, P14962; PFEIFER E, 1995, BIOCHEMISTRY-US, V34, P7450, DOI 10.1021/bi00022a019; SAITO M, 1995, J BIOCHEM-TOKYO, V117, P276, DOI 10.1093/jb/117.2.276; SCHLUMBOHM W, 1991, J BIOL CHEM, V266, P23135; STACHELHAUS T, 1995, J BIOL CHEM, V270, P6163, DOI 10.1074/jbc.270.11.6163; STACHELHAUS T, 1995, FEMS MICROBIOL LETT, V125, P3, DOI 10.1111/j.1574-6968.1995.tb07328.x; STEIN T, 1995, BIOCHEMISTRY-US, V34, P4633, DOI 10.1021/bi00014a017; Stein T, 1996, AMINO ACIDS, V10, P201, DOI 10.1007/BF00807324; STEIN T, 1994, FEBS LETT, V340, P39, DOI 10.1016/0014-5793(94)80169-X; TOKITA K, 1993, J BIOCHEM-TOKYO, V114, P522, DOI 10.1093/oxfordjournals.jbchem.a124210; TURGAY K, 1992, MOL MICROBIOL, V6, P529, DOI 10.1111/j.1365-2958.1992.tb01498.x; VATER J, 1987, EUR J BIOCHEM, V163, P297, DOI 10.1111/j.1432-1033.1987.tb10800.x; VATER J, 1985, BIOCHEMISTRY-US, V24, P2022, DOI 10.1021/bi00329a033; VATER J, 1990, BIOCH PEPTIDE ANTIBI, V2, P33; Warburg O., 1942, BIOCHEM Z, V310, P384	35	165	175	1	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15428	15435		10.1074/jbc.271.26.15428	http://dx.doi.org/10.1074/jbc.271.26.15428			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663196	hybrid			2022-12-27	WOS:A1996UV29900022
J	Wylie, JL; Wang, LL; Tipples, G; McClarty, G				Wylie, JL; Wang, LL; Tipples, G; McClarty, G			A single point mutation in CTP synthetase of Chlamydia trachomatis confers resistance to cyclopentenyl cytosine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OUTER-MEMBRANE PROTEIN; CHINESE-HAMSTER CELLS; ESCHERICHIA-COLI; RELA GENE; PURIFICATION; INFECTIONS; MUTANTS	A Chlamydia trachomatis strain (L2/CPEC) resistant to the cytotoxic effects of cyclopentenyl cytosine (CPEC) was isolated by a stepwise selection procedure. This strain showed an approximate 350-fold increase in resistance to CPEC. Sequencing of the gene encoding CTP synthetase from this resistant strain revealed a single point mutation, resulting in a change of amino acid 149 from Asp to Glu, This appeared to be the only mutation in L2/CPEC, because no changes in CTP transport, CTP synthetase expression, or incorporation of CPEC into DNA or RNA could be detected, The mutation in the chlamydial CTP synthetase resulted in a loss of CTP feedback inhibition. This was demonstrated both in vivo using Escherichia coli cells carrying the cloned gene, and an in vitro assay using partially purified preparations of CTP synthetase, As a result of the loss of feedback inhibition, E. coli cells carrying the CPEC(R) CTP synthetase showed a 22-fold increase in their CTP pools, However, examination of the CTP pools of L2/CPEC revealed no change in CTP levels when compared with wild type C. trachomatis.	UNIV MANITOBA, DEPT MED MICROBIOL, WINNIPEG, MB R3E 0W3, CANADA	University of Manitoba								ANDERSON PM, 1983, BIOCHEMISTRY-US, V22, P3285, DOI 10.1021/bi00282a038; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BIRKELUND S, 1992, J BACTERIOL, V174, P2742, DOI 10.1128/JB.174.9.2742-2747.1992; BLANEY SM, 1993, BIOCHEM PHARMACOL, V45, P1493, DOI 10.1016/0006-2952(93)90050-7; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CALDWELL HD, 1981, INFECT IMMUN, V31, P1161, DOI 10.1128/IAI.31.3.1161-1176.1981; CHU EHY, 1984, BIOCHEM GENET, V22, P701, DOI 10.1007/BF00485854; FRAIZ J, 1988, ANNU REV MED, V39, P357, DOI 10.1146/annurev.me.39.020188.002041; FRIESEN JD, 1976, J BACTERIOL, V127, P917, DOI 10.1128/JB.127.2.917-922.1976; FRIESEN JD, 1978, CELL, V15, P1187, DOI 10.1016/0092-8674(78)90045-4; FUKUSHI H, 1993, MICROBIOL IMMUNOL, V27, P515; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; KANG GJ, 1989, J BIOL CHEM, V264, P713; KELLSALL A, 1988, SOMAT CELL MOLEC GEN, V14, P149; Long C, 1978, Methods Enzymol, V51, P79; LONG CW, 1967, J BIOL CHEM, V242, P4715; LUGTENBERG B, 1975, FEBS LETT, V58, P254, DOI 10.1016/0014-5793(75)80272-9; MCCLARTY G, 1991, J BACTERIOL, V173, P4922, DOI 10.1128/jb.173.16.4922-4931.1991; McClarty Grant, 1994, Trends in Microbiology, V2, P157, DOI 10.1016/0966-842X(94)90665-3; MCPARTLAND RP, 1979, J BIOL CHEM, V254, P1394; MOULDER JW, 1991, MICROBIOL REV, V55, P143, DOI 10.1128/MMBR.55.1.143-190.1991; Neuhard J, 1987, ESCHERICHIA COLI SAL, P445; PHEAR G, 1989, J MOL BIOL, V209, P577, DOI 10.1016/0022-2836(89)90595-0; PLAGEMANN PGW, 1978, J CELL PHYSIOL, V97, P49, DOI 10.1002/jcp.1040970107; QIN B, 1992, J BACTERIOL, V174, P2865, DOI 10.1128/JB.174.9.2865-2873.1992; Sambrook J., 2002, MOL CLONING LAB MANU; STEPHENS RS, 1992, INFECT AGENT DIS, V1, P279; TIPPLES G, 1993, MOL MICROBIOL, V8, P1105, DOI 10.1111/j.1365-2958.1993.tb01655.x; TIPPLES G, 1991, J BACTERIOL, V173, P4932, DOI 10.1128/jb.173.16.4932-4940.1991; TIPPLES G, 1995, J BIOL CHEM, V270, P7908, DOI 10.1074/jbc.270.14.7908; VANHAVERBEKE DA, 1978, J LIQ CHROMATOGR, V1, P507; WANG LL, 1994, MOL MICROBIOL, V14, P271, DOI 10.1111/j.1365-2958.1994.tb01288.x; WHELAN J, 1993, NAT GENET, V3, P317, DOI 10.1038/ng0493-317; ZHANG H, 1993, CANCER RES, V53, P5714; ZHANG LH, 1992, J MOL BIOL, V223, P627, DOI 10.1016/0022-2836(92)90979-T	35	27	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15393	15400		10.1074/jbc.271.26.15393	http://dx.doi.org/10.1074/jbc.271.26.15393			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663065	hybrid			2022-12-27	WOS:A1996UV29900017
J	Bhogal, N; Donnelly, D; Findlay, JBC				Bhogal, N; Donnelly, D; Findlay, JBC			The ligand binding site of the neurokinin 2 receptor. Site-directed mutagenesis and identification of neurokinin A binding residues in the human neurokinin 2 receptor (vol 269, pg 27269, 1994)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition													Donnelly, Dan/O-5374-2015	Donnelly, Dan/0000-0001-6048-6995				BHOGAL N, 1994, J BIOL CHEM, V269, P27269	1	1	1	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15298	15298		10.1074/jbc.271.25.15298	http://dx.doi.org/10.1074/jbc.271.25.15298			1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663137	hybrid			2022-12-27	WOS:A1996UT10600095
J	Cui, ZF; Hirata, D; Tsuchiya, E; Osada, H; Miyakawa, T				Cui, ZF; Hirata, D; Tsuchiya, E; Osada, H; Miyakawa, T			The multidrug resistance-associated protein (MRP) subfamily (Yrs1/Yor1) of Saccharomyces cerevisiae is important for the tolerance to a broad range of organic anions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; GENE; INHIBITORS; ENCODES; CLONING; DNA	We have cloned and characterized a Saccharomyces cerevisiae gene YRS1 that complements the phenotype of the mutant sensitive to the anionic drug reveromycin A, The YRS1 gene, which is identical to the recently identified YOR1 gene, encodes a protein with extensive homology to the human multidrug resistance-associated protein (MRP) and the yeast cadmium factor (Ycf1), A chromosomal deletion of YRS1 lead to viable Delta yrs1 cells, which exhibited hypersensitivity to reveromycin A. Elevation of the YRS1 gene dosage in wild type cells conferred increased resistance to reveromycin A, By analyzing the effect of YRS1 disruption and overexpression it was demonstrated that Yrs1 is involved in the detoxification of a wide range of the organic anions that con tain carboxyl group(s) but none of the other type of toxic compounds examined, Fluorescence-activated cell sorter analysis indicated the increased accumulation of the anionic fluorescent compound rhodamine B in Delta yrs1 cells, The expression of YRS1 was induced strikingly by reveromycin A. These results suggest that Yrs1 is a multispecific organic anion transporter important for tolerance against toxic environmental organic anions, Yrs1 had an overlapping specificity with Ycf1 in the resistance to cadmium.	HIROSHIMA UNIV,FAC ENGN,DEPT FERMENTAT TECHNOL,HIGASHIHIROSHIMA 739,JAPAN; RIKEN,INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	Hiroshima University; RIKEN			Osada, Hiroyuki/N-4305-2014; Osada, Hiroyuki/AAY-6254-2020					BALZI E, 1994, J BIOL CHEM, V269, P2206; BISSINGER PH, 1994, J BIOL CHEM, V269, P4180; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CHEN XC, 1990, J ANTIBIOT TOKYO, V40, P907; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HAMAMOTO T, 1983, J ANTIBIOT, V36, P646, DOI 10.7164/antibiotics.36.646; Hick J. B, 1986, METHODS YEAST GENETI, P9; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIRATA D, 1994, CURR GENET, V26, P285, DOI 10.1007/BF00310491; KATZMANN DJ, 1995, MOL CELL BIOL, V15, P6875; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEIER I, 1994, J BIOL CHEM, V269, P27807; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; Maniatis T., 1982, MOL CLONING; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; MEISTER A, 1988, J BIOL CHEM, V263, P17205; NISHIDA T, 1991, P NATL ACAD SCI USA, V88, P6590, DOI 10.1073/pnas.88.15.6590; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMITT ME, 1990, NUCLEIC ACIDS RES, V18, P3091, DOI 10.1093/nar/18.10.3091; SERVOS J, 1993, MOL GEN GENET, V236, P214, DOI 10.1007/BF00277115; STPIERRE MV, 1994, P NATL ACAD SCI USA, V91, P9476, DOI 10.1073/pnas.91.20.9476; STRATHDEE CA, 1989, J BACTERIOL, V171, P916, DOI 10.1128/jb.171.2.916-928.1989; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TAKAHASHI H, 1992, J ANTIBIOT, V45, P1414, DOI 10.7164/antibiotics.45.1414	27	107	110	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14712	14716		10.1074/jbc.271.25.14712	http://dx.doi.org/10.1074/jbc.271.25.14712			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663018	hybrid			2022-12-27	WOS:A1996UT10600014
J	Rensen, PCN; vanBerkel, TJC				Rensen, PCN; vanBerkel, TJC			Apolipoprotein E effectively inhibits lipoprotein lipase-mediated lipolysis of chylomicron-like triglyceride-rich lipid emulsions in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; RECEPTOR-RELATED PROTEIN; C-II; PLASMA-LIPOPROTEINS; HEPATIC LIPASE; RAT-LIVER; ENDOTHELIAL-CELLS; ARGININE RESIDUES; LYSINE RESIDUES; KUPFFER CELLS	Apolipoprotein E (apoE) is an important determinant for the liver uptake of triglyceride rich lipoproteins and emulsions by the remnant receptor, In the current study, we assessed an additional role of apoE as modulator of the metabolism of triglyceride-rich lipoproteins in vitro and in vivo. Glycerol tri[H-3]oleate [C-14]cholesteryl oleate double-labeled triglyceride-rich emulsions were injected into fasted rats, The serum half-life of glycerol tri[SH]oleate was 3-fold faster (5.4 min) than that of [C-14]cholesteryl oleate (16.7 min), confirming lipoprotein lipase (LPL) mediated processing. To establish a specific effect of apoE on emulsion lipolysis rather than liver uptake, rats were functionally hepatectomized, and hypo(apo)lipoproteinemia was induced by 17 alpha-ethinyl estradiol treatment. An apoE concentration-dependent inhibition of emulsion-triglyceride hydrolysis was observed, reaching a 14.8-fold increased half-life of glycerol tri[H-3]oleate as compared with that in the absence of exogenous apoE. The mechanism and specificity of the effect of apoE on emulsion lipolysis by purified LPL was assessed in vitro. Addition of apoE to glycerol tri[H-3]oleate-labeled emulsions led to a concentration-dependent inhibition of [H-3]oleate release (9.5% residual LPL activity at 60 mu g/ml apoE), while apoA-I was ineffective. The inhibitory effect of apoE was not abolished by reductive methylation of lysine residues, whereas selective modification of arginine residues by 1,2-cyclohexadione completely cancelled the inhibitory effect of apoE. It is concluded that apoE can specifically inhibit the LPL-mediated hydrolysis of emulsion triglycerides both in vitro and in vivo, and that arginine residues in apoE are essential for this effect. We suggest that in addition to its role in receptor recognition, apoE also modulates the LPL-mediated processing of triglyceride rich lipoproteins.			Rensen, PCN (corresponding author), LEIDEN UNIV,SYLVIUS LAB,DIV BIOPHARMACEUT,LEIDEN AMSTERDAM CTR DRUG RES,POB 9503,2300 RA LEIDEN,NETHERLANDS.		Van Berkel, Theo/ABD-7677-2021; Rensen, Patrick C.N./D-7176-2018	Rensen, Patrick C.N./0000-0002-8455-4988				AALTOSETALA K, 1992, J CLIN INVEST, V90, P1889, DOI 10.1172/JCI116066; ARBEENY CM, 1980, J BIOL CHEM, V255, P547; BEISIEGEL U, 1991, P NATL ACAD SCI USA, V88, P8342, DOI 10.1073/pnas.88.19.8342; BELFRAGE P, 1969, J LIPID RES, V10, P341; BIJSTERBOSCH MK, 1989, MOL PHARMACOL, V36, P484; BOGUSKI MS, 1986, J LIPID RES, V27, P1011; BORENSZTAJN J, 1986, BIOCHEM J, V233, P909, DOI 10.1042/bj2330909; BURRIER RE, 1983, J BIOL CHEM, V258, P2043; CHAO Y, 1979, J BIOL CHEM, V254, P1360; CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168; CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001; CLARK AB, 1985, J BIOL CHEM, V260, P4778; CONNELLY PW, 1994, J BIOL CHEM, V269, P20554; CRYER A, 1981, INT J BIOCHEM, V13, P525, DOI 10.1016/0020-711X(81)90177-4; DECKELBAUM RJ, 1992, BIOCHEMISTRY-US, V31, P8544, DOI 10.1021/bi00151a023; FIELDING PE, 1989, J BIOL CHEM, V264, P12462; GOLDBERG IJ, 1990, J BIOL CHEM, V265, P4266; GOMEZCORONADO D, 1993, BIOCHIM BIOPHYS ACTA, V1167, P70, DOI 10.1016/0005-2760(93)90219-Y; GROOT PHE, 1978, BIOCHIM BIOPHYS ACTA, V530, P91, DOI 10.1016/0005-2760(78)90129-7; HABEEB AFS, 1966, ANAL BIOCHEM, V14, P328, DOI 10.1016/0003-2697(66)90275-2; HAVEL RJ, 1984, J LIPID RES, V25, P1570; HAVEL RJ, 1973, J CLIN INVEST, V52, P32, DOI 10.1172/JCI107171; HOSPATTANKAR AV, 1984, J BIOL CHEM, V259, P318; ISHIKAWA Y, 1988, J BIOL CHEM, V263, P2744; JACKSON RL, 1986, BIOCHIM BIOPHYS ACTA, V875, P211, DOI 10.1016/0005-2760(86)90170-0; JONAS A, 1993, J BIOL CHEM, V268, P1596; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; LI WH, 1988, J LIPID RES, V29, P245; LIU GQ, 1992, BIOCHEM J, V285, P731, DOI 10.1042/bj2850731; LIU GQ, 1991, BIOCHEM J, V273, P747, DOI 10.1042/bj2730747; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARCEL YL, 1983, BIOCHIM BIOPHYS ACTA, V750, P411, DOI 10.1016/0005-2760(83)90047-4; MCCONATHY WJ, 1989, FEBS LETT, V251, P250, DOI 10.1016/0014-5793(89)81464-4; MCCONATHY WJ, 1992, J LIPID RES, V33, P995; MCFARLANE AS, 1958, NATURE, V182, P53, DOI 10.1038/182053a0; MJOS OD, 1975, J CLIN INVEST, V56, P603, DOI 10.1172/JCI108130; MULDER M, 1992, BIOCHEM BIOPH RES CO, V185, P582, DOI 10.1016/0006-291X(92)91664-C; NAKAYA Y, 1980, BIOCHEM BIOPH RES CO, V95, P1168, DOI 10.1016/0006-291X(80)91595-8; NYKJAER A, 1993, J BIOL CHEM, V268, P15048; OLIVECRONA T, 1993, HAEMOSTASIS, V23, P150; Olivecrona T, 1990, CURR OPIN LIPIDOL, V1, P222; OSBORNE JC, 1985, BIOCHEMISTRY-US, V24, P5606, DOI 10.1021/bi00341a048; PATTHY L, 1975, J BIOL CHEM, V250, P557; PERSSON E, 1985, EUR J CLIN INVEST, V15, P215, DOI 10.1111/j.1365-2362.1985.tb00171.x; PETERSON J, 1990, P NATL ACAD SCI USA, V87, P909, DOI 10.1073/pnas.87.3.909; PETERSON J, 1985, BIOCHIM BIOPHYS ACTA, V837, P262, DOI 10.1016/0005-2760(85)90049-9; REDGRAVE T G, 1970, Journal of Clinical Investigation, V49, P465, DOI 10.1172/JCI106255; REDGRAVE TG, 1975, ANAL BIOCHEM, V65, P42, DOI 10.1016/0003-2697(75)90488-1; REDGRAVE TG, 1985, BIOCHIM BIOPHYS ACTA, V835, P104, DOI 10.1016/0005-2760(85)90036-0; RENSEN PCN, 1995, NAT MED, V1, P221, DOI 10.1038/nm0395-221; SASAKI A, 1993, AM J PHYSIOL, V265, pE880, DOI 10.1152/ajpendo.1993.265.6.E880; SAXENA U, 1995, ARTERIOSCL THROM VAS, V15, P1240, DOI 10.1161/01.ATV.15.8.1240; SAXENA U, 1991, J BIOL CHEM, V266, P17516; SAXENA U, 1993, J BIOL CHEM, V268, P14812; SAXENA U, 1990, BIOCHIM BIOPHYS ACTA, V1043, P161, DOI 10.1016/0005-2760(90)90291-5; SAXENA U, 1992, J CLIN INVEST, V89, P373, DOI 10.1172/JCI115595; SHIRAI K, 1983, J LIPID RES, V24, P721; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SPARKS DL, 1992, J BIOL CHEM, V267, P25830; STINS MF, 1993, J LIPID RES, V34, P1853; VANDIJK MCM, 1992, EUR J BIOCHEM, V205, P775, DOI 10.1111/j.1432-1033.1992.tb16842.x; VANDIJK MCM, 1991, BIOCHEM J, V279, P863, DOI 10.1042/bj2790863; VANREE JH, 1994, ATHEROSCLEROSIS, V111, P25, DOI 10.1016/0021-9150(94)90188-0; VANTILBEURGH H, 1994, J BIOL CHEM, V269, P4626; VANTOL A, 1978, ATHEROSCLEROSIS, V29, P449, DOI 10.1016/0021-9150(78)90173-9; VOGEL T, 1985, P NATL ACAD SCI USA, V82, P8696, DOI 10.1073/pnas.82.24.8696; WANG CS, 1985, BIOCHIM BIOPHYS ACTA, V837, P111; WEISGRABER KH, 1980, J LIPID RES, V21, P316; WEISGRABER KH, 1978, J BIOL CHEM, V253, P9053; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653; WILLNOW TE, 1992, J BIOL CHEM, V267, P26172; WINDLER E, 1980, J BIOL CHEM, V255, P8303; WINDLER EET, 1986, J CLIN INVEST, V78, P658, DOI 10.1172/JCI112624; WONG H, 1994, J BIOL CHEM, V269, P10319; YAMADA N, 1980, BIOCHEM BIOPH RES CO, V94, P710, DOI 10.1016/0006-291X(80)91290-5; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375; ZIERE GJ, 1992, J BIOL CHEM, V267, P11229	78	122	129	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14791	14799		10.1074/jbc.271.25.14791	http://dx.doi.org/10.1074/jbc.271.25.14791			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662966				2022-12-27	WOS:A1996UT10600026
J	Sheppard, DN; Travis, SM; Ishihara, H; Welsh, MJ				Sheppard, DN; Travis, SM; Ishihara, H; Welsh, MJ			Contribution of proline residues in the membrane-spanning domains of cystic fibrosis transmembrane conductance regulator to chloride channel function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR; EXPRESSION; MUTATIONS; CELLS; IDENTIFICATION; LOCALIZATION; TRANSPORT; EPITHELIA; GENE	Proline residues located in membrane spanning domains of transport proteins are thought to play an important structural role, In the cystic fibrosis transmembrane conductance regulator (CFTR), the predicted transmembrane segments contain four prolines: Pro(99), Pro(205), Pro(324), and Pro(1021). These residues are conserved across species, and mutations of two (P99L and P205S) are associated with cystic fibrosis, To evaluate the contribution of these prolines to CFTR Cl- channel function, we mutated each residue individually to either alanine or glycine or mutated all four simultaneously to alanine (P-Quad-A), We also constructed the two cystic fibrosis-associated mutations, cAMP agonists stimulated whole cell Cl- currents in HeLa cells expressing the individual constructs that resembled those produced by wild-type CFTR, However, the amount of current was decreased in the rank order: wild-type CFTR = Pro(324) > Pro(1021) > Pro(99) greater than or equal to Pro(205) mutants, The anion selectivity sequence of the mutants (Br- greater than or equal to Cl- > I-) resembled wild-type except for P99L (Br- greater than or equal to Cl- = I-). Although the Pro(99), Pro(324) , and Pro(1021) mutants produced mature protein, the amount of mature protein was much reduced with the pro205 mutants, and the P-Quad-A made none. Because the Pro(99) constructs produced mature protein but had altered whole cell currents, we investigated their single-channel properties, Mutant channels were regulated like wild-type CFTR; however, single-channel conductance was decreased in the rank order: wild-type CFTR greater than or equal to P99G > P99L greater than or equal to P99A. These results suggest that proline residues in the transmembrane segments are important for CFTR function, Pro(205) is critical for correct protein processing, and Pro(99) may contribute either directly or indirectly to the Cl- channel pore.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242	Howard Hughes Medical Institute; University of Iowa	Sheppard, DN (corresponding author), UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT INTERNAL MED,500 EMRB,IOWA CITY,IA 52242, USA.		Sheppard, David N/AAV-4187-2021	Sheppard, David N/0000-0001-5533-9130; Welsh, Michael/0000-0002-1646-6206				AKABAS MH, 1994, J BIOL CHEM, V269, P14865; ANDERSON MP, 1991, SCIENCE, V253, P202, DOI 10.1126/science.1712984; BECQ F, 1994, P NATL ACAD SCI USA, V91, P9160, DOI 10.1073/pnas.91.19.9160; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BRANDL CJ, 1986, P NATL ACAD SCI USA, V83, P917, DOI 10.1073/pnas.83.4.917; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHILLON M, 1993, HUM MOL GENET, V2, P1741, DOI 10.1093/hmg/2.10.1741; DENNING GM, 1992, J CLIN INVEST, V89, P339, DOI 10.1172/JCI115582; DENNING GM, 1992, J CELL BIOL, V118, P551, DOI 10.1083/jcb.118.3.551; DESILVA AM, 1990, J CELL BIOL, V111, P857, DOI 10.1083/jcb.111.3.857; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; GREGORY RJ, 1990, NATURE, V347, P382, DOI 10.1038/347382a0; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GRIBKOFF VK, 1994, J BIOL CHEM, V269, P10983; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LOO TW, 1993, J BIOL CHEM, V268, P3143; LOO TW, 1994, J BIOL CHEM, V269, P28683; MCDONOUGH S, 1994, NEURON, V13, P623, DOI 10.1016/0896-6273(94)90030-2; OSTEDGAARD LS, 1992, J BIOL CHEM, V267, P26142; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; Richardson J. S., 1989, PREDICTION PROTEIN S, P1; RIORDAN JR, 1989, SCIENCE, V245, P1066; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCHWARTZ M, 1995, PEDIATR PULM, V12, P207; SHEPPARD DN, 1995, EMBO J, V14, P876, DOI 10.1002/j.1460-2075.1995.tb07069.x; SHEPPARD DN, 1994, CELL, V76, P1091, DOI 10.1016/0092-8674(94)90385-9; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; VOGEL H, 1986, BIOPHYS J, V50, P573, DOI 10.1016/S0006-3495(86)83497-X; VONHEIJNE G, 1991, J MOL BIOL, V218, P499, DOI 10.1016/0022-2836(91)90695-3; Welsh MJ, 1995, METABOLIC MOL BASES, V3, P3799	32	48	48	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14995	15001		10.1074/jbc.271.25.14995	http://dx.doi.org/10.1074/jbc.271.25.14995			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663008	hybrid			2022-12-27	WOS:A1996UT10600055
J	Eggen, RIL; vanKranenburg, R; Vriesema, AJM; Geerling, ACM; Verhagen, MFJM; Hagen, WR; deVos, WM				Eggen, RIL; vanKranenburg, R; Vriesema, AJM; Geerling, ACM; Verhagen, MFJM; Hagen, WR; deVos, WM			Carbon monoxide dehydrogenase from Methanosarcina frisia Go1 - Characterization of the enzyme and the regulated expression of two operon-like cdh gene clusters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ELECTRON-PARAMAGNETIC-RES; DESULFOVIBRIO-VULGARIS HILDENBOROUGH; 6FE-6S PRISMANE-CLUSTER; ANAEROBIC RIBONUCLEOTIDE REDUCTASE; ARCHAEON METHANOBACTERIUM-WOLFEI; DISSIMILATORY SULFITE REDUCTASE; COENZYME M-REDUCTASES; ACETYL-COA PATHWAY; METHANOTHRIX-SOEHNGENII; CLOSTRIDIUM-THERMOACETICUM	Carbon monoxide dehydrogenase (Cdh) has been anaerobically purified from Methanosarcina frisia Gol. The enzyme is a Ni2+-, Fe2+-, and S2--containing alpha(2) beta(2) heterotetramer of 214 kDa with a pI of 5.2 and subunits of 94 and 19 kDa. It has a V-max of 0.3 mmol of CO min(-1) mg(-1) and K-m values for CO and methyl viologen of approximate to 0.9 mM and 0.12 mM, respectively. EPR spectroscopy on the reduced enzyme showed two overlapping signals: one indicative for 2 (4Fe-4S)(+) clusters and a second signal that is atypical for standard Fe/S clusters. The latter was, together with high spin EPR signals of the oxidized enzyme tentatively assigned to an Fe/S cluster of high nuclearity.	AGR UNIV WAGENINGEN,DEPT MICROBIOL,6703 CT WAGENINGEN,NETHERLANDS; AGR UNIV WAGENINGEN,DEPT BIOCHEM,6703 CT WAGENINGEN,NETHERLANDS	Wageningen University & Research; Wageningen University & Research			Hagen, Wilfred R./H-8918-2017	Hagen, Wilfred R./0000-0002-1609-6671				ABBANAT DR, 1990, J BACTERIOL, V172, P7145, DOI 10.1128/jb.172.12.7145-7150.1990; ACETI DJ, 1988, J BIOL CHEM, V263, P15444; ALLEN G, 1989, LAB TECHNIQUES BIOCH, V9, P95; ARENDSEN AF, 1993, BIOCHEMISTRY-US, V32, P10323, DOI 10.1021/bi00090a007; BOLIN JT, 1990, NITROGEN FIXATION : ACHIEVEMENTS AND OBJECTIVES, P117; BONACKER LG, 1992, EUR J BIOCHEM, V206, P87, DOI 10.1111/j.1432-1033.1992.tb16904.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; COUCOUVANIS D, 1988, INORG CHEM, V27, P4066, DOI 10.1021/ic00295a034; EGGEN HIL, 1991, J BIOL CHEM, V266, P6883; EGGEN RIL, 1992, SYST APPL MICROBIOL, V15, P582, DOI 10.1016/S0723-2020(11)80118-9; FERRY JG, 1992, J BACTERIOL, V174, P5489, DOI 10.1128/JB.174.17.5489-5495.1992; FUCHS G, 1986, FEMS MICROBIOL LETT, V39, P181, DOI 10.1111/j.1574-6968.1986.tb01859.x; GEORGIADIS MM, 1992, SCIENCE, V257, P1653, DOI 10.1126/science.1529353; Gibson T. J., 1984, THESIS CAMBRIDGE U C; GRAHAME DA, 1991, J BIOL CHEM, V266, P22227; GRAHAME DA, 1989, J BIOL CHEM, V264, P12890; HAGEN WR, 1985, J MAGN RESON, V61, P233, DOI 10.1016/0022-2364(85)90078-2; HAGEN WR, 1985, J MAGN RESON, V61, P220, DOI 10.1016/0022-2364(85)90077-0; HAGEN WR, 1992, ADV INORG CHEM, V38, P165, DOI 10.1016/S0898-8838(08)60064-1; HAGEN WR, 1989, J CHEM SOC FARAD T 1, V85, P4083, DOI 10.1039/f19898504083; HAGEN WR, 1987, EUR J BIOCHEM, V169, P457, DOI 10.1111/j.1432-1033.1987.tb13633.x; HALBOTH S, 1992, MOL GEN GENET, V233, P217, DOI 10.1007/BF00587582; HENNESSY DJ, 1984, CAN J CHEM, V62, P721, DOI 10.1139/v84-121; HENNIGAN AN, 1994, MOL MICROBIOL, V11, P655, DOI 10.1111/j.1365-2958.1994.tb00344.x; JABLONSKI PE, 1990, J BACTERIOL, V172, P1271, DOI 10.1128/jb.172.3.1271-1275.1990; JETTEN MSM, 1989, J BACTERIOL, V171, P5430, DOI 10.1128/jb.171.10.5430-5435.1989; JETTEN MSM, 1989, EUR J BIOCHEM, V181, P437, DOI 10.1111/j.1432-1033.1989.tb14744.x; JETTEN MSM, 1991, EUR J BIOCHEM, V202, P1291, DOI 10.1111/j.1432-1033.1991.tb16502.x; JETTEN MSM, 1991, EUR J BIOCHEM, V195, P385, DOI 10.1111/j.1432-1033.1991.tb15717.x; KANATZIDIS MG, 1985, J AM CHEM SOC, V107, P953, DOI 10.1021/ja00290a034; KERBY RL, 1992, J BACTERIOL, V174, P5284, DOI 10.1128/JB.174.16.5284-5294.1992; KRZYCKI JA, 1989, J BIOL CHEM, V264, P7217; KRZYCKI JA, 1984, J BACTERIOL, V158, P231, DOI 10.1128/JB.158.1.231-237.1984; LINDAHL PA, 1990, J BIOL CHEM, V265, P3873; LJUNGDAHL LG, 1986, ANNU REV MICROBIOL, V40, P415, DOI 10.1146/annurev.mi.40.100186.002215; LOVENBERG W, 1963, J BIOL CHEM, V238, P3899; LUNDIE LL, 1989, J BIOL CHEM, V264, P18392; MORTON TA, 1991, J BIOL CHEM, V266, P23824; MULLIEZ E, 1993, J BIOL CHEM, V268, P2296; PALMER JR, 1993, GENETICS MOL BIOL AN, P13; PIERIK AJ, 1991, EUR J BIOCHEM, V195, P505, DOI 10.1111/j.1432-1033.1991.tb15731.x; PIERIK AJ, 1993, EUR J BIOCHEM, V212, P51, DOI 10.1111/j.1432-1033.1993.tb17632.x; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P705, DOI 10.1111/j.1432-1033.1992.tb16977.x; PIERIK AJ, 1992, EUR J BIOCHEM, V206, P697, DOI 10.1111/j.1432-1033.1992.tb16976.x; PIHL TD, 1994, J BACTERIOL, V176, P6384, DOI 10.1128/jb.176.20.6384-6391.1994; RAGSDALE SW, 1991, CRIT REV BIOCHEM MOL, V26, P261, DOI 10.3109/10409239109114070; REEVE JN, 1992, ANNU REV MICROBIOL, V46, P165; ROBERTS DL, 1989, P NATL ACAD SCI USA, V86, P32, DOI 10.1073/pnas.86.1.32; ROSPERT S, 1990, EUR J BIOCHEM, V194, P871, DOI 10.1111/j.1432-1033.1990.tb19481.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMITZ RA, 1992, EUR J BIOCHEM, V209, P1013, DOI 10.1111/j.1432-1033.1992.tb17376.x; SCHMITZ RA, 1992, EUR J BIOCHEM, V207, P559, DOI 10.1111/j.1432-1033.1992.tb17082.x; SOWERS KR, 1993, J BIOL CHEM, V268, P23172; STOKKERMANS JPWG, 1992, BIOCHIM BIOPHYS ACTA, V1132, P83, DOI 10.1016/0167-4781(92)90057-7; SUN XY, 1993, P NATL ACAD SCI USA, V90, P577, DOI 10.1073/pnas.90.2.577; TERLESKY KC, 1987, J BIOL CHEM, V262, P15392; TERLESKY KC, 1986, J BACTERIOL, V168, P1053, DOI 10.1128/jb.168.3.1053-1058.1986; THAUER RK, 1989, ANNU REV MICROBIOL, V43, P43, DOI 10.1146/annurev.mi.43.100189.000355; VANDENBERG WAM, 1994, BBA-PROTEIN STRUCT M, V1206, P240, DOI 10.1016/0167-4838(94)90214-3; WOOD HG, 1986, FEMS MICROBIOL LETT, V39, P345, DOI 10.1016/0378-1097(86)90022-4; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YELISEEV A, 1993, ARCH MICROBIOL, V159, P530, DOI 10.1007/BF00249031	63	26	31	1	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14256	14263		10.1074/jbc.271.24.14256	http://dx.doi.org/10.1074/jbc.271.24.14256			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662887	hybrid, Green Published			2022-12-27	WOS:A1996UQ66000050
J	Yoo, SJ; Seol, JH; Shin, DH; Rohrwild, M; Kang, MS; Tanaka, K; Goldberg, AL; Chung, CH				Yoo, SJ; Seol, JH; Shin, DH; Rohrwild, M; Kang, MS; Tanaka, K; Goldberg, AL; Chung, CH			Purification and characterization of the heat shock proteins HslV and HslU that form a new ATP-dependent protease in Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTIGEN PRESENTATION; SENSITIVE METHOD; CLP PROTEASE; PROTEOLYSIS; UBIQUITIN; TI; COMPONENT; CONTAINS; DISTINCT; SEQUENCE	The hslVU operon in Escherichia coli encodes two heat shock proteins, HslV, a 19-kDa protein homologous to beta-type subunits of the 20 S proteasomes, and HslU, a 50-kDa protein related to the ATPase ClpX We have recently shown that HslV and HslU can function together as a novel ATP-dependent protease, the HslVU protease. We have now purified both proteins to apparent homogeneity from extracts of E. coli carrying the hslVU operon on a multicopy plasmid. HslU by itself cleaved ATP, and pure HslV is a weak peptidase degrading certain hydrophobic peptides. HslU dramatically stimulated peptide hydrolysis by HslV when ATP is present. With a 1:4 molar ratio of HslV to HslU, approximately a 200-fold increase in peptide hydrolysis was observed. HslV stimulated the ATPase activity of HslU 2-4-fold, but had little influence on the affinity of HslU to ATP. The nonhydrolyzable ATP analog, beta,gamma-methylene-ATP, did not support peptide hydrolysis. Other nucleotides (CTP, dATP) that were slowly hydrolyzed by HslU allowed some peptide hydrolysis. Therefore, ATP cleavage appears essential for the HslV activity. Upon gel filtration on a Sephacryl S-300 column, HslV behaved as a 250-kDa oligomer (i.e. 12-14 subunits), and HslU behaved as a 100-kDa protein (i.e. a dimer) in the absence of ATP, but as a 450-kDa multimer (8-10 subunits) in its presence. Therefore ATP appears necessary for oligomerization of HslU. Thus the HslVU protease appears to be a two-component protease in which HslV harbors the peptidase activity, while HslU provides an essential ATPase activity.	SEOUL NATL UNIV, COLL NAT SCI, DEPT BIOL MOLEC, SEOUL 151742, SOUTH KOREA; SEOUL NATL UNIV, COLL NAT SCI, RES CTR CELL DIFFERENTIAT, SEOUL 151742, SOUTH KOREA; HARVARD UNIV, SCH MED, DEPT CELL BIOL, BOSTON, MA 02115 USA; UNIV TOKUSHIMA, INST ENZYME RES, TOKUSHIMA 770, JAPAN	Seoul National University (SNU); Seoul National University (SNU); Harvard University; Harvard Medical School; Tokushima University			Shin, Donghun/A-2092-2012		NIGMS NIH HHS [GM46147] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM046147] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; ARMON T, 1990, J BIOL CHEM, V265, P20723; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHUANG SE, 1993, J BACTERIOL, V175, P5242, DOI 10.1128/JB.175.16.5242-5252.1993; CHUANG SE, 1993, GENE, V134, P1, DOI 10.1016/0378-1119(93)90167-2; CHUNG CH, 1993, SCIENCE, V262, P372, DOI 10.1126/science.8211156; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; FEHLING HJ, 1994, SCIENCE, V265, P1234, DOI 10.1126/science.8066463; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; GOLDBERG AL, 1992, NATURE, V357, P375, DOI 10.1038/357375a0; GOLDBERG AL, 1992, EUR J BIOCHEM, V203, P9, DOI 10.1111/j.1432-1033.1992.tb19822.x; GOTTESMAN S, 1990, P NATL ACAD SCI USA, V87, P3513, DOI 10.1073/pnas.87.9.3513; GOTTESMAN S, 1993, J BIOL CHEM, V268, P22618; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; HWANG BJ, 1988, J BIOL CHEM, V263, P8727; HWANG BJ, 1987, P NATL ACAD SCI USA, V84, P5550, DOI 10.1073/pnas.84.16.5550; KATAYAMAFUJIMURA Y, 1987, J BIOL CHEM, V262, P4477; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHNHERR H, 1995, P NATL ACAD SCI USA, V92, P3274, DOI 10.1073/pnas.92.8.3274; MAURIZI MR, 1992, EXPERIENTIA, V48, P178, DOI 10.1007/BF01923511; MHAMMEDIALAOUI A, 1994, MOL MICROBIOL, V11, P1109, DOI 10.1111/j.1365-2958.1994.tb00387.x; MICHALEK MT, 1993, NATURE, V363, P552, DOI 10.1038/363552a0; PALMER A, 1994, EUR J CELL BIOL, V64, P163; PALOMBELLA VJ, 1994, CELL, V78, P773, DOI 10.1016/S0092-8674(94)90482-0; PETERS JM, 1994, J BIOL CHEM, V269, P7709; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; ROHRWILD M, 1996, IN PRESS P NATL ACAD; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEOL JH, 1995, J BIOL CHEM, V270, P8087, DOI 10.1074/jbc.270.14.8087; SEOL JH, 1994, J BIOL CHEM, V269, P29468; SEUFERT W, 1992, EMBO J, V11, P3077, DOI 10.1002/j.1460-2075.1992.tb05379.x; SQUIRES C, 1992, J BACTERIOL, V174, P1081, DOI 10.1128/jb.174.4.1081-1085.1992; TANAHASHI N, 1993, ENZYME PROTEIN, V47, P241, DOI 10.1159/000468683; TOMOYASU T, 1995, EMBO J, V14, P2551, DOI 10.1002/j.1460-2075.1995.tb07253.x; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WOO KM, 1989, J BIOL CHEM, V264, P2088	40	107	111	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14035	14040		10.1074/jbc.271.24.14035	http://dx.doi.org/10.1074/jbc.271.24.14035			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662828	hybrid			2022-12-27	WOS:A1996UQ66000018
J	Harnish, DC; Malik, S; Kilbourne, E; Costa, R; Karathanasis, SK				Harnish, DC; Malik, S; Kilbourne, E; Costa, R; Karathanasis, SK			Control of apolipoprotein AI gene expression through synergistic interactions between hepatocyte nuclear factors 3 and 4	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I GENE; TRANSCRIPTIONAL ACTIVATION; RECEPTOR SUPERFAMILY; ESTROGEN-RECEPTOR; RETINOIC ACID; PROTEIN; HNF-4; PROMOTERS; ESTRADIOL; MEMBER	Apolipoprotein AI (apoAI) gene expression in liver depends on synergistic interactions between transcription factors bound to three distinct sites (A, B, and C) within a hepatocyte-specific enhancer in the 5'-flanking region of the gene, In this study, we showed that a segment spanning sites A and B retains substantial levels of enhancer activity in hepatoblastoma HepG2 cells and that sites A and B are occupied by the liver-enriched hepatocyte nuclear factors (HNFs) 4 and 3, respectively, in these cells, In non-hepatic CV-1 cells, HNF-4 and HNF-3 beta activated this minimal enhancer synergistically, This synergy was dependent upon simultaneous binding of these factors to their cognate sites, but it was not due to cooperativity in DNA binding, Separation of these sites by varying helical turns of DNA did not affect simultaneous binding of HNF-3 beta and HNF-4 nor did it influence their functional synergy, The synergy was, however, dependent upon the cell type used for functional analysis, In addition, this synergy was further potentiated by estrogen treatment of cells cotransfected with the estrogen receptor, These data indicate that a cell type-restricted intermediary factor jointly recruited by HNF-4 and HNF-3 participates in activation of the apoAI enhancer in liver cells and suggest that the activity of this factor is regulated by estrogen.	LEDERLE LABS,DEPT CARDIOVASC MOL BIOL,PEARL RIVER,NY 10965; UNIV ILLINOIS,DEPT BIOCHEM,CHICAGO,IL 60612	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital								CHAN J, 1993, NUCLEIC ACIDS RES, V21, P1205, DOI 10.1093/nar/21.5.1205; CHEN JL, 1994, CELL, V79, P93, DOI 10.1016/0092-8674(94)90403-0; CHI TH, 1995, NATURE, V377, P254, DOI 10.1038/377254a0; COLLINS T, 1995, FASEB J, V9, P899, DOI 10.1096/fasebj.9.10.7542214; COSTA RH, 1988, MOL CELL BIOL, V8, P81, DOI 10.1128/MCB.8.1.81; FUERNKRANZ HA, 1994, NUCLEIC ACIDS RES, V22, P5665, DOI 10.1093/nar/22.25.5665; GAUB MP, 1990, CELL, V63, P1267, DOI 10.1016/0092-8674(90)90422-B; GE RW, 1994, J BIOL CHEM, V269, P13185; HALL RB, 1994, P NATL ACAD SCI USA, V92, P412; HARNISH DC, 1994, J BIOL CHEM, V269, P28220; HOEY T, 1993, CELL, V72, P247, DOI 10.1016/0092-8674(93)90664-C; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; KARATHANASIS SK, 1992, MONOGR HUM GENET, V14, P140; LADIAS JAA, 1991, SCIENCE, V251, P561, DOI 10.1126/science.1899293; LAI E, 1991, TRENDS BIOCHEM SCI, V16, P427, DOI 10.1016/0968-0004(91)90169-V; LEWIN B, 1990, CELL, V61, P1161, DOI 10.1016/0092-8674(90)90675-5; LIN YS, 1991, CELL, V64, P971, DOI 10.1016/0092-8674(91)90321-O; LIN YS, 1993, NATURE, V363, P741; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; MALIK S, 1993, MOL CELL BIOL, V13, P6253, DOI 10.1128/MCB.13.10.6253; MALIK S, 1995, NUCLEIC ACIDS RES, V23, P1536, DOI 10.1093/nar/23.9.1536; MARTINEZ E, 1991, MOL CELL BIOL, V11, P2937, DOI 10.1128/MCB.11.6.2937; METZGER S, 1993, J BIOL CHEM, V268, P16831; MITCHELL PJ, 1989, SCIENCE, V245, P371, DOI 10.1126/science.2667136; PANI L, 1992, MOL CELL BIOL, V12, P3723, DOI 10.1128/MCB.12.9.3723; PTASHNE M, 1988, NATURE, V335, P683, DOI 10.1038/335683a0; QIAN XB, 1995, NUCLEIC ACIDS RES, V23, P1184, DOI 10.1093/nar/23.7.1184; ROTTMAN JN, 1991, MOL CELL BIOL, V11, P3814, DOI 10.1128/MCB.11.7.3814; Sambrook J., 2002, MOL CLONING LAB MANU; SEISHIMA M, 1991, J LIPID RES, V32, P941; SHELDON M, 1995, CURR BIOL, V5, P43, DOI 10.1016/S0960-9822(95)00014-5; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; SRIVASTAVA RAK, 1993, EUR J BIOCHEM, V216, P527; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; SUKOVICH DA, 1994, MOL CELL BIOL, V14, P7134, DOI 10.1128/MCB.14.11.7134; TANG JJ, 1991, J LIPID RES, V32, P1571; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; WIDOM RL, 1991, MOL CELL BIOL, V11, P677, DOI 10.1128/MCB.11.2.677; WIDOM RL, 1992, MOL CELL BIOL, V12, P3380, DOI 10.1128/MCB.12.8.3380; WU KJ, 1994, J BIOL CHEM, V269, P1177; XANTHOPOULOS KG, 1993, EUR J BIOCHEM, V216, P353, DOI 10.1111/j.1432-1033.1993.tb18152.x	41	76	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13621	13628		10.1074/jbc.271.23.13621	http://dx.doi.org/10.1074/jbc.271.23.13621			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662915	hybrid			2022-12-27	WOS:A1996UP38500049
J	Xu, CJ; Klunk, WE; Kanfer, JN; Xiong, Q; Miller, G; Pettegrew, JW				Xu, CJ; Klunk, WE; Kanfer, JN; Xiong, Q; Miller, G; Pettegrew, JW			Phosphocreatine-dependent glutamate uptake by synaptic vesicles - A comparison with ATP-dependent glutamate uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; CREATINE-KINASE; ALZHEIMERS-DISEASE; BRAIN; INHIBITION; PROTEIN; QUANTIFICATION; SPECTROSCOPY; METABOLISM; TRANSPORT	ATP-dependent uptake of glutamate into synaptic vesicles has been well documented. Stimulation of glutamate uptake into synaptic vesicles by other high-energy phosphates has not been described, In this paper, we examine the stimulation of phosphocreatine (PCr)-induced glutamate uptake and determine whether this stimulation is secondary to conversion of PCr to ATP. We found the following, 1) PCr stimulates glutamate uptake into synaptic vesicles in the absence of added ATP. 2) At a glutamate concentration of 50 mu M, no concentration of added ATP could produce the degree of stimulation seen in the presence of PCr. 3) 0.5 mM iodoacetamide completely inhibits synaptic vesicle creatine kinase activity but does not inhibit PCr-stimulated glutamate uptake, 4) PCr-dependent glutamate uptake, unlike ATP-dependent uptake, is not magnesium- or chloride-dependent. 5) 0.5 mM N-ethylmaleimide, a selective H+-ATPase inhibitor, completely inhibits ATP-dependent glutamate uptake but only slightly inhibits PCr dependent glutamate uptake, 6) PCr-dependent glutamate uptake is sensitive to valinomycin, a K+/H+ translocator, whereas the ATP-dependent uptake is not, Therefore, it appears that in addition to the well-known ATP-dependent glutamate uptake system, there is a previously unreported PCr-dependent glutamate uptake system in synaptic vesicles, The total glutamate uptake by synaptic vesicles is likely the sum of both ATP- and PCr-dependent glutamate uptake.	UNIV PITTSBURGH, MED CTR, LAB NEUROPHYS, PITTSBURGH, PA 15213 USA; UNIV MANITOBA, DEPT BIOCHEM & MOLEC BIOL, WINNIPEG, MB R3E 0W3, CANADA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Manitoba				Klunk, William/0000-0001-5512-0251	NIA NIH HHS [AG08974] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R35AG008974] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		Bennet J.P., 1978, NEUROTRANSMITTER REC, P57; BOTTOMLEY PA, 1992, RADIOLOGY, V183, P695, DOI 10.1148/radiology.183.3.1584923; CARLSON MD, 1989, J NEUROCHEM, V53, P1889, DOI 10.1111/j.1471-4159.1989.tb09258.x; CARPENTER CL, 1983, BIOCHEM BIOPH RES CO, V111, P884, DOI 10.1016/0006-291X(83)91382-7; FAN XT, 1994, BIOCHEM J, V299, P701, DOI 10.1042/bj2990701; FOSSEL ET, 1987, AM J PHYSIOL, V252, pE124, DOI 10.1152/ajpendo.1987.252.1.E124; FREDHOLM BB, 1974, ACTA PHYSIOL SCAND, V91, P165, DOI 10.1111/j.1748-1716.1974.tb05672.x; FYKSE EM, 1992, NEUROSCI LETT, V135, P125, DOI 10.1016/0304-3940(92)90151-V; FYKSE EM, 1989, J NEUROCHEM, V52, P946, DOI 10.1111/j.1471-4159.1989.tb02546.x; HARTINGER J, 1993, J BIOL CHEM, V268, P23122; HERDER M, 1990, CLIN CHIM ACTA, V190, pS4; HOU LX, 1994, BBA-PROTEIN STRUCT M, V1205, P83, DOI 10.1016/0167-4838(94)90095-7; KISH PE, 1989, METHOD ENZYMOL, V174, P9; KLUNK WE, 1994, BIOL PSYCHIAT, V35, P627; LEE HJ, 1988, P NATL ACAD SCI USA, V85, P7265, DOI 10.1073/pnas.85.19.7265; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAYCOX PR, 1988, J BIOL CHEM, V263, P15423; MICHAELIS T, 1993, RADIOLOGY, V187, P219, DOI 10.1148/radiology.187.1.8451417; NAITO S, 1983, J BIOL CHEM, V258, P696; NAITO S, 1985, J NEUROCHEM, V44, P99, DOI 10.1111/j.1471-4159.1985.tb07118.x; OUELLET M, 1992, BIOCHEM J, V284, P115, DOI 10.1042/bj2840115; PETTEGREW JW, 1987, J NEUROPATH EXP NEUR, V46, P419, DOI 10.1097/00005072-198707000-00002; PETTEGREW JW, 1988, J NEUROPATH EXP NEUR, V47, P235, DOI 10.1097/00005072-198805000-00004; PETTEGREW JW, 1994, NEUROBIOL AGING, V15, P117, DOI 10.1016/0197-4580(94)90152-X; PETTEGREW JW, 1988, ARCH NEUROL-CHICAGO, V45, P1093, DOI 10.1001/archneur.1988.00520340047010; ROSENBERG PA, 1989, NEUROSCI LETT, V103, P162, DOI 10.1016/0304-3940(89)90569-7; TABB JS, 1992, J BIOL CHEM, V267, P15412; WOTHE DD, 1990, P NATL ACAD SCI USA, V87, P5203, DOI 10.1073/pnas.87.13.5203; WU H, 1989, BIOCHIM BIOPHYS ACTA, V997, P78, DOI 10.1016/0167-4838(89)90137-4; XU CJ, 1995, J NEUROCHEM, V64, pCS49; ZEMTSOV A, 1993, AM J MED SCI, V305, P8, DOI 10.1097/00000441-199301000-00002	31	74	77	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13435	13440		10.1074/jbc.271.23.13435	http://dx.doi.org/10.1074/jbc.271.23.13435			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662761				2022-12-27	WOS:A1996UP38500022
J	Bajzar, L; Morser, J; Nesheim, M				Bajzar, L; Morser, J; Nesheim, M			TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACTIVATED PROTEIN-C; CARBOXYPEPTIDASE; PROTHROMBIN; MODULATION; MECHANISM; INHIBITOR; SYSTEM; SITE	TAFI (thrombin-activatable fibrinolysis inhibitor) is a recently discovered plasma protein that can be activated by thrombin-catalyzed proteolysis to a carboxypeptidase B-like enzyme that inhibits fibrinolysis, This work shows that the thrombin-thrombomodulin complex, rather than free thrombin, is the most likely physiologic activator, Thrombomodulin increases the catalytic efficiency of the reaction by a factor of 1250, an effect expressed almost exclusively through an increase in k(cat). The kinetics of the reaction conform to a model whereby thrombin can interact with either TAFI (K-m = 1.0 mu M) or thrombomodulin (K-d = 8.6 nM), and either binary complex so formed can then interact with the third component to form the ternary thrombin-thrombomodulin-TAFI complex from which activated TAFI is produced with kcat = 1.2 s(-1). This work also shows that activated TAFI down-regulates tPA-induced fibrinolysis half maximally at a concentration of 1.0 nM in a system of purified components. This concentration of TAFI is about 2% of the level of the zymogen in plasma, which indicates that ample activated TAFI could be generated to very significantly modulate fibrinolysis in vivo. Therefore, TAFI in vitro and possibly in vivo defines an explicit molecular connection between the coagulation and fibrinolytic cascades, such that expression of activity in the former down-regulates the activity of the latter.	QUEENS UNIV, DEPT BIOCHEM, KINGSTON, ON K7L 3N6, CANADA; QUEENS UNIV, DEPT MED, KINGSTON, ON K7L 3N6, CANADA; BERLEX BIOSCI, RICHMOND, CA 94804 USA	Queens University - Canada; Queens University - Canada								ASTRUP T, 1991, SEMIN THROMB HEMOST, V17, P161, DOI 10.1055/s-2007-1002606; BAJZAR L, 1993, J BIOL CHEM, V268, P8608; BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BAJZAR L, 1990, J BIOL CHEM, V265, P16948; BOSKOVIC DS, 1990, J BIOL CHEM, V265, P10497; BURDICK MD, 1987, THROMB RES, V45, P413, DOI 10.1016/0049-3848(87)90230-1; COLLEN D, 1991, BLOOD, V78, P3114; DEFOUW NJ, 1990, ADV EXP MED BIOL, V281, P235; EATON DL, 1991, J BIOL CHEM, V266, P21833; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1991, ANN NY ACAD SCI, V614, P30; GLASER CB, 1992, J CLIN INVEST, V90, P2565, DOI 10.1172/JCI116151; HENDRIKS D, 1990, BIOCHIM BIOPHYS ACTA, V1034, P86, DOI 10.1016/0304-4165(90)90157-R; HIBBARD LS, 1982, BIOCHEMISTRY-US, V21, P2285, DOI 10.1021/bi00539a003; LEBONNIEC BF, 1991, J BIOL CHEM, V266, P13796; LEBONNIEC BF, 1991, P NATL ACAD SCI USA, V88, P7371, DOI 10.1073/pnas.88.16.7371; MANN KG, 1991, ANN NY ACAD SCI, V614, P63; NESHEIM ME, 1979, BIOCHEMISTRY-US, V18, P996, DOI 10.1021/bi00573a010; NEVILLE DM, 1971, J BIOL CHEM, V246, P6328; RAN AK, 1995, BIOCHEMISTRY-US, V34, P5811; REDLITZ A, 1995, J CLIN INVEST, V96, P2534, DOI 10.1172/JCI118315; SUENSON E, 1984, EUR J BIOCHEM, V140, P513, DOI 10.1111/j.1432-1033.1984.tb08132.x; TAYLOR FB, 1985, THROMB RES, V37, P639, DOI 10.1016/0049-3848(85)90193-8; WANG W, 1994, J BIOL CHEM, V269, P15937	24	542	562	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16603	16608		10.1074/jbc.271.28.16603	http://dx.doi.org/10.1074/jbc.271.28.16603			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663147	hybrid			2022-12-27	WOS:A1996UX12600030
J	Frolov, A; Woodford, JK; Murphy, EJ; Billheimer, JT; Schroeder, F				Frolov, A; Woodford, JK; Murphy, EJ; Billheimer, JT; Schroeder, F			Spontaneous and protein-mediated sterol transfer between intracellular membranes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACID-BINDING-PROTEIN; LIPID-TRANSFER PROTEIN; L-CELL FIBROBLASTS; CARRIER PROTEIN-2; PLASMA-MEMBRANE; SUBCELLULAR MEMBRANES; ESCHERICHIA-COLI; CHOLESTEROL; EXCHANGE; DEHYDROERGOSTEROL	Relatively little is known regarding intracellular cholesterol trafficking pathways. To resolve some of these potential pathways, spontaneous and protein-mediated sterol transfer was examined between different donor acceptor membrane pairs in vitro using L-cell fibroblast plasma membrane (PM) and microsomal (MICRO) and mitochondrial (MITO) membranes, Several new exciting insights were provided, First, the initial rate of spontaneous molecular sterol transfer was more dependent on the type of acceptor than donor membrane, i.e. spontaneous intracellular sterol trafficking was vectorial. Therefore, the rate of sterol desorption from the donor membrane was not necessarily the rate-limiting step in molecular sterol transfer. Second, the rate of molecular sterol transfer was not obligatorily correlated with the direction of the cholesterol gradient. For example, although PM had a 3.2-fold higher cholesterol/phospholipid ratio than MITO, spontaneous sterol transfer was 4-5 fold faster up (MITO to PM) rather than down (PM to MITO) the concentration gradient. Third, sterol carrier protein-2 differentially stimulated the initial rate of sterol transfer for all donor-acceptor combinations, being most effective with PM donors: PM-MICRO, 27-fold; and PM-MITO, Ig-fold, Sterol carrier protein-2 was less effective in enhancing sterol transfer in the reverse direction, i.e. MICRO-PM and MITO-PM (5- and 4-fold, respectively), Fourth, liver fatty acid-binding protein was limited in stimulating the initial rate of sterol transfer from PM to PM (1.5-fold), from PM to MITO (3-fold), and from MICRO to MITO (3-fold). In summary, these observations present important insights into potential sterol trafficking pathways between the major membrane components of the cell.	TEXAS A&M UNIV,TVMC,DEPT PHYSIOL & PHARMACOL,COLLEGE STN,TX 77843; ANDREW JERGENS CO,CINCINNATI,OH 45214; DUPONT MERCK PHARMACEUT CO,CARDIOVASC DEPT,WILMINGTON,DE 19898	Texas A&M University System; Texas A&M University College Station; DuPont					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041402] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM031651] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41402] Funding Source: Medline; NIGMS NIH HHS [GM31651] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Ames B.N., 1966, METHOD ENZYMOL, V8, P115, DOI [10.1016/0076-6879(66)08014-5, DOI 10.1016/0076-6879(66)08014-5]; Billheimer J T, 1990, Subcell Biochem, V16, P301; BILLHEIMER JT, 1990, BIOCHIM BIOPHYS ACTA, V1046, P136, DOI 10.1016/0005-2760(90)90180-6; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BLOCH K, 1991, BIOCH LIPIDS LIPOPRO, P363; BORCHERS T, 1989, BIOCHIM BIOPHYS ACTA, V1002, P54, DOI 10.1016/0005-2760(89)90063-5; BORDEWICK U, 1989, BIOL CHEM H-S, V370, P229, DOI 10.1515/bchm3.1989.370.1.229; BRETSCHER MS, 1993, SCIENCE, V261, P1280, DOI 10.1126/science.8362242; BROWN MS, 1974, J BIOL CHEM, V249, P7306; BROWN RE, 1992, BIOCHIM BIOPHYS ACTA, V1113, P3375; BUTKO P, 1992, J BIOCHEM BIOPH METH, V24, P15, DOI 10.1016/0165-022X(92)90043-A; BUTKO P, 1990, BIOCHEMISTRY-US, V29, P4070, DOI 10.1021/bi00469a007; CHANDERBHAN R, 1982, J BIOL CHEM, V257, P8928; CLARK BJ, 1994, J BIOL CHEM, V269, P28314; COLBEAU A, 1971, BIOCHIM BIOPHYS ACTA, V249, P462, DOI 10.1016/0005-2736(71)90123-4; CORNELL RB, 1983, BIOCHIM BIOPHYS ACTA, V750, P504, DOI 10.1016/0005-2760(83)90191-1; CORNELL RB, 1980, J CELL BIOL, V86, P810, DOI 10.1083/jcb.86.3.810; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; EDWARDS PA, 1991, BIOCH LIPIDS LIPOPRO, P383; FISHER RT, 1984, CHEM PHYS LIPIDS, V36, P1; FISHER RT, 1985, J BIOL PHYS, V13, P13; GADELLA TWJ, 1994, EUR J BIOCHEM, V220, P1019, DOI 10.1111/j.1432-1033.1994.tb18707.x; GAVEY KL, 1981, J BIOL CHEM, V256, P2993; HALE JE, 1982, EUR J BIOCHEM, V122, P649; HAPALA I, 1994, BIOCHEMISTRY-US, V33, P7682, DOI 10.1021/bi00190a023; INCERPI S, 1992, ARCH BIOCHEM BIOPHYS, V298, P35, DOI 10.1016/0003-9861(92)90090-J; JOHNSON WJ, 1994, J LIPID RES, V35, P563; KANDUTSCH AA, 1977, J BIOL CHEM, V252, P409; KAVECANSKY J, 1994, BIOCHEMISTRY-US, V33, P2880, DOI 10.1021/bi00176a018; KELLER GA, 1989, J CELL BIOL, V108, P1353, DOI 10.1083/jcb.108.4.1353; LANGE Y, 1985, J BIOL CHEM, V260, P5592; LANGE Y, 1991, J BIOL CHEM, V266, P21439; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MALTESE WA, 1990, FASEB J, V4, P3319, DOI 10.1096/fasebj.4.15.2123808; MATSUURA JE, 1993, BIOCHEMISTRY-US, V32, P567, DOI 10.1021/bi00053a023; Moncecchi DM, 1991, PHYSL BIOCH STEROLS, P1; MUCZYNSKI KA, 1983, BIOCHEMISTRY-US, V22, P6037, DOI 10.1021/bi00294a052; NEMECZ G, 1988, BIOCHEMISTRY-US, V27, P7740, DOI 10.1021/bi00420a024; NEMECZ G, 1988, BIOCHIM BIOPHYS ACTA, V943, P511, DOI 10.1016/0005-2736(88)90384-7; Nestler J. E., 1990, ADV CHOLESTEROL RES, P133; NICHOLS JW, 1988, BIOCHEMISTRY-US, V27, P1889, DOI 10.1021/bi00406a014; NOLAND BJ, 1980, J BIOL CHEM, V255, P4282; Paulussen R J, 1990, Subcell Biochem, V16, P175; PAULUSSEN RJA, 1989, BIOCHIM BIOPHYS ACTA, V1001, P201, DOI 10.1016/0005-2760(89)90149-5; PFEIFER SM, 1993, J STEROID BIOCHEM, V47, P167, DOI 10.1016/0960-0760(93)90071-4; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PUGLIELLI L, 1995, J BIOL CHEM, V270, P18723, DOI 10.1074/jbc.270.32.18723; REINHART MP, 1990, EXPERIENTIA, V46, P599, DOI 10.1007/BF01939699; SCHROEDER F, 1989, BIOCHEMISTRY-US, V28, P5992, DOI 10.1021/bi00440a041; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1976, J BIOL CHEM, V251, P5015; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P47; SCHROEDER F, 1990, LIPIDS, V25, P664; TRZASKOS JM, 1983, BIOCHIM BIOPHYS ACTA, V751, P52, DOI 10.1016/0005-2760(83)90256-4; VANHEUSDEN GPH, 1985, BIOCHIM BIOPHYS ACTA, V846, P21, DOI 10.1016/0167-4889(85)90105-3; VOLPE JJ, 1981, J BIOL CHEM, V256, P2016; WIRTZ KWA, 1990, EXPERIENTIA, V46, P592, DOI 10.1007/BF01939698; WOODFORD JK, 1995, MOL CELL BIOCHEM, V152, P51; WOODFORD JK, 1994, BBA-BIOMEMBRANES, V1189, P52, DOI 10.1016/0005-2736(94)90279-8; WOODFORD JK, 1993, BIOCHIM BIOPHYS ACTA, V1145, P257, DOI 10.1016/0005-2736(93)90297-D; WOODFORD JK, 1995, CHEM PHYS LIPIDS, V76, P73, DOI 10.1016/0009-3084(95)02436-M; YEAGLE PL, 1990, ADV CHOLESTEROL RES, P111	64	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16075	16083		10.1074/jbc.271.27.16075	http://dx.doi.org/10.1074/jbc.271.27.16075			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663152	hybrid			2022-12-27	WOS:A1996UW35200035
J	Kobayashi, M; Matsuo, Y; Takimoto, A; Suzuki, S; Maruo, F; Shoun, H				Kobayashi, M; Matsuo, Y; Takimoto, A; Suzuki, S; Maruo, F; Shoun, H			Denitrification, a novel type of respiratory metabolism in fungal mitochondrion	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NITRITE-INDUCIBLE CYTOCHROME-P-450; FUSARIUM-OXYSPORUM; NITRATE NITRITE; PARACOCCUS-DENITRIFICANS; ORIGINS; CDNA	Subcellular localization and coupling to ATP synthesis were investigated with respect to the denitrifying systems of two fungi, Fusarium oxysporum and Cylindrocarpon tonkinense. Dissimilatory nitrate reductase of F. oxysporum or nitrite reductase of C. tonkinense could be detected in the mitochondrial fraction prepared from denitrifying cells of each fungus. Fluorescence immunolocalization, cofractionation with mitochondrial marker enzymes, and cytochromes provided evidence that the denitrifying enzymes are co-purified with mitochondria. Respiratory substrates such as malate plus pyruvate, succinate, and formate were effective donors of electrons to these activities in the mitochondrial fractions, Moreover, nitrite and nitrate reduction were shown to be coupled to the synthesis of ATP with energy yields (P:NO3- or P:2e ratios) of 0.88 to 1.4, depending upon whether malate/pyruvate or succinate were provided as substrates, Nitrate or nitrite reductase activity was inhibited by inhibitors such as rotenone, antimycin A, and thenoyltrifluoroaeetone. Thus, fungal denitrification activities are localized to mitochondria and are coupled to the synthesis of ATP. The existence of these novel respiration systems are discussed with regard to the origin and evolution of mitochondria.	UNIV TSUKUBA,INST APPL BIOCHEM,TSUKUBA,IBARAKI 305,JAPAN; UNIV TSUKUBA,INST BIOL SCI,TSUKUBA,IBARAKI 305,JAPAN	University of Tsukuba; University of Tsukuba								FERGUSON SJ, 1994, ANTON LEEUW INT J G, V66, P89, DOI 10.1007/BF00871634; FERRY JG, 1990, FEMS MICROBIOL LETT, V87, P377, DOI 10.1111/j.1574-6968.1990.tb04940.x; JOHN P, 1975, NATURE, V254, P495, DOI 10.1038/254495a0; KIZAWA H, 1991, J BIOL CHEM, V266, P10632; KOBAYASHI M, 1995, J BIOL CHEM, V270, P4146, DOI 10.1074/jbc.270.8.4146; MARGULIS L, 1993, SYMBIOSIS CELL EVOLU, P305; NAKAHARA K, 1993, J BIOL CHEM, V268, P8350; NICHOLAS DJD, 1957, METHOD ENZYMOL, V3, P981; OBIKA K, 1993, BIOCHEM BIOPH RES CO, V196, P1255, DOI 10.1006/bbrc.1993.2387; SAWERS G, 1994, ANTON LEEUW INT J G, V66, P57, DOI 10.1007/BF00871633; SHIRO Y, 1995, J BIOL CHEM, V270, P1617, DOI 10.1074/jbc.270.4.1617; SHOUN H, 1992, FEMS MICROBIOL LETT, V94, P277, DOI 10.1111/j.1574-6968.1992.tb05331.x; SHOUN H, 1989, FEBS LETT, V244, P11, DOI 10.1016/0014-5793(89)81151-2; SHOUN H, 1991, J BIOL CHEM, V266, P11078; STOUTHAMER AH, 1992, ANTON LEEUW INT J G, V61, P1, DOI 10.1007/BF00572119; TANIMOTO T, 1992, BIOSCI BIOTECH BIOCH, V56, P2058, DOI 10.1271/bbb.56.2058; TOMURA D, 1994, J BIOCHEM-TOKYO, V116, P88, DOI 10.1093/oxfordjournals.jbchem.a124508; USUDA K, 1995, APPL ENVIRON MICROB, V61, P883, DOI 10.1128/AEM.61.3.883-889.1995; VANDEPEER Y, 1990, J MOL EVOL, V30, P463, DOI 10.1007/BF02101118; YAMANAKA T, 1962, J BIOCHEM-TOKYO, V51, P253, DOI 10.1093/oxfordjournals.jbchem.a127529; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; Zumft WG, 1992, PROKARYOTES, P554	22	142	150	3	41	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16263	16267		10.1074/jbc.271.27.16263	http://dx.doi.org/10.1074/jbc.271.27.16263			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663075	hybrid			2022-12-27	WOS:A1996UW35200060
J	Ricci, G; Caccuri, AM; LoBello, M; Rosato, N; Mei, G; Nicotra, M; Chiessi, E; Mazzetti, AO; Federici, G				Ricci, G; Caccuri, AM; LoBello, M; Rosato, N; Mei, G; Nicotra, M; Chiessi, E; Mazzetti, AO; Federici, G			Structural flexibility modulates the activity of human glutathione transferase P1-1 - Role of helix 2 flexibility in the catalytic mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; HUMAN PLACENTA; SITE; PI	Presteady-state and steady-state kinetic studies performed on human glutathione transferase P1-1 (EC 2.5.1.18) with 1-chloro-2,4-dinitrobenzene as co-substrate indicate that the rate-determining step is a physical event that occurs after binding of the two substrates and before the sigma-complex formation, It may be a structural transition involving the ternary complex, This event can be related to diffusion-controlled motions of protein portions as k(cat)degrees/k(cat) linearly increases by raising the relative viscosity of the solution, Similar viscosity dependence has been observed for K-m(GSH), while K-m(CDNB) is independent, No change of the enzyme structure by viscosogen has been found by circular dichroism analysis. Thus, k(cat) and K-m(GSH) Seem to be related to the frequency and extent of enzyme structural motions modulated by viscosity. Interestingly, the reactivity of Cys-47 which can act as a probe for the flexibility of helix 2 is also modulated by viscosity, Its viscosity dependence parallels that observed for k(cat) and K-m(GSH), thereby suggesting a possible correlation between k(cat), K-m(GSH), and diffusion-controlled motion of helix 2, The viscosity effect on the kinetic parameters of C47S and C47S/C101S mutants confirms the involvement of helix 2 motions in the modulation of K,GSH, whereas a similar role on k(cat) cannot be ascertained unequivocally, The flexibility of helix 2 modulates also the homotropic behavior of GSH in these mutants, Furthermore, fluorescence experiments support a structural motion of about 4 Angstrom occurring between helix 2 and helix 4 when GSH binds to the G-site.	UNIV ROMA TOR VERGATA,DEPT EXPTL MED & BIOCHEM SCI,I-00133 ROME,ITALY; UNIV ROMA TOR VERGATA,DEPT CHEM SCI & TECHNOL,I-00133 ROME,ITALY; OSP PEDIAT IRCCS BAMBIN GESU,I-00165 ROME,ITALY	University of Rome Tor Vergata; University of Rome Tor Vergata; IRCCS Bambino Gesu	Ricci, G (corresponding author), UNIV ROMA TOR VERGATA,DEPT BIOL,I-00133 ROME,ITALY.		CACCURI, ANNA MARIA/AFU-2643-2022	Chiessi, Ester/0000-0001-7529-2755; Ricci, Giorgio/0000-0002-7108-2846; CACCURI, ANNA MARIA/0000-0002-3756-4163				BROOKS CL, 1988, PROTEINS THEORETICAL, P1; CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; CACCURI AM, 1991, ITAL J BIOCHEM, V40, P304; Caccuri AM, 1996, J BIOL CHEM, V271, P16193, DOI 10.1074/jbc.271.27.16193; CAMERON AD, 1995, STRUCTURE, V3, P717, DOI 10.1016/S0969-2126(01)00206-4; CHEN WJ, 1988, BIOCHEMISTRY-US, V27, P647, DOI 10.1021/bi00402a023; DESIDERI A, 1991, J BIOL CHEM, V266, P2063; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; Habig W H, 1981, Methods Enzymol, V77, P398; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; JOHNSON WW, 1993, J BIOL CHEM, V268, P11508; Kramers HA, 1940, PHYSICA, V7, P284, DOI 10.1016/S0031-8914(40)90098-2; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKOWICZ JR, 1983, PRINCIPLES FLUORESCE, P303; LOBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804, DOI 10.1006/bbrc.1993.1893; LOBELLO M, 1993, J BIOL CHEM, V268, P19033; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1991, J BIOL CHEM, V266, P21409; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; Wolf AV, 1985, HDB CHEM PHYSICS, pD	22	74	75	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16187	16192		10.1074/jbc.271.27.16187	http://dx.doi.org/10.1074/jbc.271.27.16187			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663072	hybrid			2022-12-27	WOS:A1996UW35200050
J	Chang, PY; Jensen, J; Printz, RL; Granner, DK; Ivy, JL; Moller, DE				Chang, PY; Jensen, J; Printz, RL; Granner, DK; Ivy, JL; Moller, DE			Overexpression of hexokinase II in transgenic mice - Evidence that increased phosphorylation augments muscle glucose uptake	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; DIABETIC RATS; MESSENGER-RNA; INSULIN; TRANSPORT; EXPRESSION; KINETICS; HYPERINSULINEMIA; METABOLISM; GLYCOLYSIS	Hexokinase II (HKII) is the predominant isozyme expressed in peripheral insulin-responsive tissues, To explore the role of HKII in muscle glucose metabolism, two lines of transgenic mice were generated where overexpression was restricted to striated muscle; HKII protein levels and activity were increased by 3-8-fold, Oral glucose tolerance, intravenous insulin tolerance, and insulin and lactate levels were unaffected in transgenic mice, There was a trend toward increased levels of muscle glycogen; however, glucose-6-phosphate levels were increased by 43% in transgenic skeletal muscle following in vivo glucose and insulin administration, Using 2-[H-3]deoxyglucose as a tracer, in. vitro basal and insulin-stimulated glucose uptake were determined in extensor digitorum longus, soleus, and epitrochlearis muscles. Maximal insulin-stimulated glucose uptake was increased by 17% (extensor digitorum longus), 34% (soleus), and 90% (epitrochlearis) in transgenic muscles; basal and submaximal glucose uptake was also modestly increased in soleus and epitrochlearis. These data suggest that increased muscle HKII (corresponding to the upper end of the physiologic range) may not be sufficient to augment net in vivo glucose homeostasis, However, glucose phosphorylation can represent a rate-limiting step for skeletal muscle glucose utilization since muscle glucose-6-phosphate levels are increased during in vivo hyperinsulinemia and hyperglycemia; furthermore, basal and insulin-mediated muscle glucose uptake can be increased by a selective increase in HKII expression.	BETH ISRAEL HOSP,DEPT MED,BOSTON,MA 02215; HARVARD UNIV,SCH MED,BOSTON,MA 02215; UNIV TEXAS,DEPT KINESIOL,EXERCISE PHYSIOL & METAB LAB,AUSTIN,TX 78712; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; University of Texas System; University of Texas Austin; Vanderbilt University			Jensen, Jørgen/O-2245-2013		NIDDK NIH HHS [NIH-P30DK20593] Funding Source: Medline; PHS HHS [R01 45878, R01 46867] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020593] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Alzaid Aus, 1993, P143; BENECKE H, 1993, DIABETES, V42, P206, DOI 10.2337/diabetes.42.1.206; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; Brozinick JT, 1996, BIOCHEM J, V313, P133, DOI 10.1042/bj3130133; BURCELIN R, 1993, AM J PHYSIOL, V265, pE392, DOI 10.1152/ajpendo.1993.265.3.E392; CARTEE GD, 1989, AM J PHYSIOL, V256, pE494, DOI 10.1152/ajpendo.1989.256.4.E494; CHANG PY, 1994, J BIOL CHEM, V269, P16034; CHEUNG JY, 1978, AM J PHYSIOL, V234, pE70, DOI 10.1152/ajpendo.1978.234.1.E70; GALANTE P, 1995, DIABETES, V44, P646, DOI 10.2337/diabetes.44.6.646; GOODMAN MN, 1974, DIABETES, V23, P881, DOI 10.2337/diab.23.11.881; GULVE EA, 1994, J BIOL CHEM, V269, P18366; HANSEN PA, 1995, J BIOL CHEM, V270, P1679; HINTZ CS, 1982, AM J PHYSIOL, V242, pC218, DOI 10.1152/ajpcell.1982.242.3.C218; JOHNSON JE, 1989, MOL CELL BIOL, V9, P3393, DOI 10.1128/MCB.9.8.3393; KATZ A, 1991, AM J PHYSIOL, V260, pE411, DOI 10.1152/ajpendo.1991.260.3.E411; KATZ A, 1988, AM J PHYSIOL, V255, pE942, DOI 10.1152/ajpendo.1988.255.6.E942; Katzen H M, 1967, Adv Enzyme Regul, V5, P335, DOI 10.1016/0065-2571(67)90025-8; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; KONG XM, 1994, J BIOL CHEM, V269, P12963; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; LANG G, 1972, FLEXIBLE SYSTEM ENZY, P1238; LUECK JD, 1974, J BIOL CHEM, V249, P1341; MANCHESTER J, 1994, AM J PHYSIOL, V266, pE236; MANDARINO L, 1995, DIABETES, V44, pA75; MANDARINO LJ, 1986, AM J PHYSIOL, V251, pE489, DOI 10.1152/ajpendo.1986.251.4.E489; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; PENDERGRASS M, 1995, DIABETES, V44, pA197; PENDERGRASS M, 1994, DIABETES, V43, pA72; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRINTZ RL, 1995, DIABETES, V44, P290, DOI 10.2337/diabetes.44.3.290; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REN JM, 1993, J BIOL CHEM, V268, P16113; REN JM, 1994, J BIOL CHEM, V269, P14396; ROSSETTI L, 1990, J CLIN INVEST, V85, P1785, DOI 10.1172/JCI114636; ROTHMAN DL, 1992, J CLIN INVEST, V89, P1069, DOI 10.1172/JCI115686; ROTHMAN DL, 1995, P NATL ACAD SCI USA, V92, P983, DOI 10.1073/pnas.92.4.983; SACCOMANI MP, 1996, IN PRESS AM J PHYSL; THOMAS JA, 1968, ANAL BIOCHEM, V25, P486, DOI 10.1016/0003-2697(68)90127-9; VIITANEN PV, 1984, J BIOL CHEM, V259, P9679; WALTERS E, 1967, BIOCHEM J, V104, P778, DOI 10.1042/bj1040778; WEBER FE, 1990, EUR J BIOCHEM, V191, P85, DOI 10.1111/j.1432-1033.1990.tb19096.x; YKIJARVINEN H, 1987, J CLIN INVEST, V79, P1713, DOI 10.1172/JCI113011; ZIEL FH, 1988, DIABETES, V37, P885, DOI 10.2337/diabetes.37.7.885	44	70	71	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14834	14839		10.1074/jbc.271.25.14834	http://dx.doi.org/10.1074/jbc.271.25.14834			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662926	hybrid			2022-12-27	WOS:A1996UT10600032
J	Mukhopadhyay, CK; Ehrenwald, E; Fox, PL				Mukhopadhyay, CK; Ehrenwald, E; Fox, PL			Ceruloplasmin enhances smooth muscle cell and endothelial cell-mediated low density lipoprotein oxidation by a superoxide-dependent mechanism	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; ATHEROSCLEROTIC LESIONS; MACROPHAGE DEGRADATION; SERUM CERULOPLASMIN; FERRITIN; PROTEINS; CULTURE; INVITRO; INFLAMMATION; NEUTROPHILS	Cultured vascular smooth muscle cells (SMC) and endothelial cells (EC) stimulate low density lipoprotein (LDL) oxidation by free radical-mediated, transition metal-dependent mechanisms. The physiological source(s) of metal ions is not known; however, purified ceruloplasmin, a plasma protein containing 7 coppers, oxidizes LDL in vitro, We now show that ceruloplasmin also increases LDL oxidation by vascular cells, In metal ion-free medium, human ceruloplasmin increased bovine aortic SMC- and EC-mediated LDL oxidation by up to 30- and 15-fold, respectively, The maximal response was at 100-300 mu g ceruloplasmin/ml, a level at or below the unevoked physiological plasma concentration, Oxidant activity was dependent on protein structure as a specific proteolytic cleavage or removal of one of the seven ceruloplasmin copper atoms inhibited activity, Three lines of evidence indicated a critical role for cellular superoxide (O-2(radical anion)) in ceruloplasmin-stimulated oxidation, First, the rate of production of O-2(radical anion) by cells correlated with their rates of LDL oxidation, Second, superoxide dismutase effectively blocked ceruloplasmin-stimulated oxidation by both cell types, Finally, O-2(radical anion) production by SMC quantitatively accounted for the observed rate of LDL oxidation, To show this, the course of O-2(radical anion) production by SMC was simulated by repeated addition of xanthine and xanthine oxidase to culture medium under cell free conditions, Neither ceruloplasmin nor O-2(radical anion) alone increased LDL oxidation, but together they completely reconstituted the oxidation rate of ceruloplasmin-stimulated SMC, These results are the first to show that ceruloplasmin stimulates EC- and SMC-mediated oxidation of LDL and that cell-derived O-2(radical anion) accounts quantitatively for metal-dependent, free radical-initiated oxidation of LDL by these cells.	CLEVELAND CLIN FDN, RES INST, DEPT CELL BIOL, CLEVELAND, OH 44195 USA	Cleveland Clinic Foundation					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052692, P01HL029582] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL52692, HL29582] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDALLA DSP, 1992, ATHEROSCLEROSIS, V97, P149, DOI 10.1016/0021-9150(92)90128-4; AUTIO I, 1990, FEBS LETT, V277, P247, DOI 10.1016/0014-5793(90)80857-F; BALLA G, 1991, ARTERIOSCLER THROMB, V11, P1700, DOI 10.1161/01.ATV.11.6.1700; BELCH JJF, 1989, FREE RADICAL BIO MED, V6, P375, DOI 10.1016/0891-5849(89)90082-8; BERLINER JA, 1990, J CLIN INVEST, V85, P1260, DOI 10.1172/JCI114562; BIEMOND P, 1984, J CLIN INVEST, V73, P1576, DOI 10.1172/JCI111364; CATHCART MK, 1989, J IMMUNOL, V142, P1963; CATHCART MK, 1985, J LEUKOCYTE BIOL, V38, P341, DOI 10.1002/jlb.38.2.341; CHISOLM GM, 1995, ATHEROSCLEROSIS CORO; CRAIG WY, 1995, ARTERIOSCL THROM VAS, V15, P733, DOI 10.1161/01.ATV.15.6.733; Czapski G, 1988, Free Radic Res Commun, V4, P231, DOI 10.3109/10715768809055147; DABBAGH AJ, 1995, J CLIN INVEST, V96, P1958, DOI 10.1172/JCI118242; EHRENWALD E, 1994, ARCH BIOCHEM BIOPHYS, V309, P392, DOI 10.1006/abbi.1994.1129; EHRENWALD E, 1994, J CLIN INVEST, V93, P1493, DOI 10.1172/JCI117127; ELSAADANI M, 1989, J LIPID RES, V30, P627; ESTERBAUER H, 1989, FREE RADICAL RES COM, V6, P67, DOI 10.3109/10715768909073429; FLEMING RE, 1991, AM J PHYSIOL, V260, pL68, DOI 10.1152/ajplung.1991.260.2.L68; FOX PL, 1984, J CELL PHYSIOL, V121, P298, DOI 10.1002/jcp.1041210206; FOX PL, 1995, LIFE SCI, V56, P1749, DOI 10.1016/0024-3205(95)00146-W; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HARRIS ZL, 1995, P NATL ACAD SCI USA, V92, P2539, DOI 10.1073/pnas.92.7.2539; HEERY JM, 1995, J CLIN INVEST, V96, P2322, DOI 10.1172/JCI118288; HEINECKE JW, 1993, J LIPID RES, V34, P2051; HEINECKE JW, 1987, J BIOL CHEM, V262, P10098; HEINECKE JW, 1984, J CLIN INVEST, V74, P1890, DOI 10.1172/JCI111609; HEINECKE JW, 1986, J CLIN INVEST, V77, P757, DOI 10.1172/JCI112371; HEINECKE JW, 1993, J CLIN INVEST, V91, P2866, DOI 10.1172/JCI116531; HENRIKSEN T, 1983, ARTERIOSCLEROSIS, V3, P149, DOI 10.1161/01.ATV.3.2.149; HESSLER JR, 1983, ARTERIOSCLEROSIS, V3, P215, DOI 10.1161/01.ATV.3.3.215; HIRAMATSU K, 1987, ARTERIOSCLEROSIS, V7, P55, DOI 10.1161/01.ATV.7.1.55; HOFF HF, 1991, ARTERIOSCLER THROMB, V11, P1209, DOI 10.1161/01.ATV.11.5.1209; HOLLANDER W, 1979, ATHEROSCLEROSIS, V34, P391, DOI 10.1016/0021-9150(79)90064-9; JESSUP W, 1993, ATHEROSCLEROSIS, V99, P107, DOI 10.1016/0021-9150(93)90056-Z; KALANT N, 1992, BIOCHIM BIOPHYS ACTA, V1128, P211, DOI 10.1016/0005-2760(92)90310-R; KELNER MJ, 1990, J BIOL CHEM, V265, P1306; LAMB DJ, 1994, FEBS LETT, V352, P15, DOI 10.1016/0014-5793(94)00903-1; LAMB DJ, 1994, FEBS LETT, V338, P122, DOI 10.1016/0014-5793(94)80348-X; LOGAN JI, 1994, Q J MED, V87, P663; MANTTARI M, 1994, EUR HEART J, V15, P1599; MESSERSCHMIDT A, 1990, EUR J BIOCHEM, V187, P341, DOI 10.1111/j.1432-1033.1990.tb15311.x; MOREL DW, 1984, ARTERIOSCLEROSIS, V4, P357, DOI 10.1161/01.ATV.4.4.357; MURUGESAN G, 1993, J CELL BIOL, V120, P1011, DOI 10.1083/jcb.120.4.1011; NAKAMURA K, 1984, ANAL BIOCHEM, V142, P406, DOI 10.1016/0003-2697(84)90484-6; NAVAB M, 1991, J CLIN INVEST, V88, P2039, DOI 10.1172/JCI115532; OHARA Y, 1993, J CLIN INVEST, V91, P2546, DOI 10.1172/JCI116491; PAGANO PJ, 1995, AM J PHYSIOL-HEART C, V268, pH2274, DOI 10.1152/ajpheart.1995.268.6.H2274; PARTHASARATHY S, 1986, ARTERIOSCLEROSIS, V6, P505, DOI 10.1161/01.ATV.6.5.505; PARTHASARATHY S, 1989, P NATL ACAD SCI USA, V86, P1046, DOI 10.1073/pnas.86.3.1046; Parthasarathys S., 1994, MODIFIED LIPOPROTEIN, P91; POWELL JT, 1987, J CARDIOVASC SURG, V28, P528; QUINN MT, 1987, P NATL ACAD SCI USA, V84, P2995, DOI 10.1073/pnas.84.9.2995; REUNANEN A, 1992, AM J EPIDEMIOL, V136, P1082, DOI 10.1093/oxfordjournals.aje.a116573; ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P336, DOI 10.1161/01.ATV.10.3.336; ROSS R, 1971, J CELL BIOL, V50, P172, DOI 10.1083/jcb.50.1.172; Ryden L., 1984, COPP PROTEINS COPP E, V3, P37; SAVENKOVA MI, 1994, J BIOL CHEM, V269, P20394; STEINBRECHER UP, 1988, BIOCHIM BIOPHYS ACTA, V959, P20, DOI 10.1016/0005-2760(88)90145-2; STEINBRECHER UP, 1984, P NATL ACAD SCI-BIOL, V81, P3883, DOI 10.1073/pnas.81.12.3883; SUNDERMAN FW, 1970, CLIN CHEM, V16, P903; SVINGEN BA, 1979, J BIOL CHEM, V254, P5892; SWAIN J, 1995, FEBS LETT, V368, P513, DOI 10.1016/0014-5793(95)00726-P; SWAIN JA, 1994, FEBS LETT, V342, P49, DOI 10.1016/0014-5793(94)80582-2; THOMAS CE, 1985, J BIOL CHEM, V260, P3275; THOMAS CE, 1992, BIOCHIM BIOPHYS ACTA, V1128, P50, DOI 10.1016/0005-2760(92)90256-U; VANHINSBERGH VWM, 1986, BIOCHIM BIOPHYS ACTA, V878, P49, DOI 10.1016/0005-2760(86)90343-7; WIELAND E, 1993, P NATL ACAD SCI USA, V90, P5929, DOI 10.1073/pnas.90.13.5929; YLAHERTTUALA S, 1991, ANN MED, V23, P561, DOI 10.3109/07853899109150518; YLAHERTTUALA S, 1989, J CLIN INVEST, V84, P1086, DOI 10.1172/JCI114271; YOSHIDA K, 1995, GENET, V9, P267	69	62	64	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14773	14778		10.1074/jbc.271.25.14773	http://dx.doi.org/10.1074/jbc.271.25.14773			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663020	hybrid			2022-12-27	WOS:A1996UT10600023
J	Rintamaki, E; Kettunen, R; Aro, EM				Rintamaki, E; Kettunen, R; Aro, EM			Differential D1 dephosphorylation in functional and photodamaged photosystem II centers - Dephosphorylation is a prerequisite for degradation of damaged D1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-PHOSPHORYLATION; CHLOROPLAST THYLAKOIDS; PHOTOINHIBITION; LIGHT; PHOTOSYNTHESIS; HETEROGENEITY; TEMPERATURE; MEMBRANES; LEAVES; CORE	Light dependence and kinetics of reversible phosphorylation of the D1 reaction center protein of Photosystem LI was studied in pumpkin leaves, At growth light, maximal phosphorylation of D1 was observed after illumination of 1 h, with higher phosphorylation rates at stronger irradiances, 70-85% of D1 became phosphorylated, corresponding to the proportion of the protein in appressed thylakoid membranes, Comparison of the kinetics of D1 phosphorylation and photoinactivation of Photosystem II revealed that D1 phosphorylation became saturated before any significant photoinhibition of Photosystem II could be detected. Dephosphorylation of D1 in both dim light and darkness was determined in leaves preilluminated with high light for various periods. Similar rates of D1 dephosphorylation were observed after short preillumination conditions that induce no significant loss of functional Photosystem II centers, In contrast, photodamage to Photosystem ZI centers significantly decreased the dephosphorylation rate of D1 in darkness, and no dephosphorylation occurred in leaves containing mainly damaged Photosystem II centers, Darkness also blocked the degradation of damaged D1 after photoinhibitory preillumination. Degradation of damaged D1 could be prevented even in dim light by sodium fluoride, an inhibitor of protein phosphatases, indicating that dephosphorylation is a prerequisite for D1 proteolysis. We conclude that in higher plants (i) high light induced photodamage to Photosystem II occurs in the centers containing phosphorylated D1. (ii) Dephosphorylation of phosphorylated and photodamaged D1 is associated with the repair cycle of inactivated Photosystem II and is a light-dependent reaction in. vivo, (iii) Dephosphorylation of D1 in functional Photosystem II, centers, however, occurs rapidly and independent of light, We suggest that two reversible phosphorylation cycles with spatially segregated protein phosphatases are involved in dephosphorylation of functional and damaged phosphorylated D1, respectively.			Rintamaki, E (corresponding author), UNIV TURKU,DEPT BIOL,FIN-20014 TURKU,FINLAND.		Aro, Eva-Mari/Q-8664-2017; Rintamaki, Eevi/T-6903-2017	Aro, Eva-Mari/0000-0002-2922-1435; Rintamaki, Eevi/0000-0002-1353-3995				ADIR N, 1990, J BIOL CHEM, V265, P12562; ALLEN JF, 1995, PHYSIOL PLANTARUM, V93, P196, DOI 10.1034/j.1399-3054.1995.930128.x; ALLEN JF, 1992, BIOCHIM BIOPHYS ACTA, V1098, P275, DOI 10.1016/S0005-2728(09)91014-3; ANDERSON JM, 1994, PHOTOSYNTH RES, V41, P315, DOI 10.1007/BF00019409; ARO EM, 1993, PLANT PHYSIOL, V103, P835, DOI 10.1104/pp.103.3.835; ARO EM, 1993, BIOCHIM BIOPHYS ACTA, V1143, P113, DOI 10.1016/0005-2728(93)90134-2; ARO EM, 1992, FEBS LETT, V297, P29, DOI 10.1016/0014-5793(92)80320-G; ARO EM, 1994, PLANT PHYSIOL, V104, P1033, DOI 10.1104/pp.104.3.1033; BENNETT J, 1977, NATURE, V269, P344, DOI 10.1038/269344a0; BENNETT J, 1988, EUR J BIOCHEM, V171, P95, DOI 10.1111/j.1432-1033.1988.tb13763.x; BENNETT J, 1980, EUR J BIOCHEM, V104, P85, DOI 10.1111/j.1432-1033.1980.tb04403.x; BENNETT J, 1991, ANNU REV PLANT PHYS, V42, P281, DOI 10.1146/annurev.pp.42.060191.001433; BRACHT E, 1994, Z NATURFORSCH C, V49, P439; CALLAHAN FE, 1990, J BIOL CHEM, V265, P15357; CLELAND RE, 1990, AUST J PLANT PHYSIOL, V17, P641, DOI 10.1071/PP9900641; DEMMIGADAMS B, 1992, ANNU REV PLANT PHYS, V43, P599, DOI 10.1146/annurev.pp.43.060192.003123; DEVITRY C, 1991, J BIOL CHEM, V266, P16614; EBBERT V, 1994, BBA-BIOENERGETICS, V1187, P335, DOI 10.1016/0005-2728(94)90007-8; ELICH TD, 1993, EMBO J, V12, P4857, DOI 10.1002/j.1460-2075.1993.tb06175.x; GIARDI MT, 1993, PLANTA, V190, P107, DOI 10.1007/BF00195681; GONG HS, 1995, BBA-BIOENERGETICS, V1228, P181, DOI 10.1016/0005-2728(94)00170-A; GREER DH, 1986, PLANTA, V168, P253, DOI 10.1007/BF00402971; GUENTHER JE, 1990, PHOTOSYNTH RES, V23, P105, DOI 10.1007/BF00030070; HAMMER MF, 1995, PHOTOSYNTH RES, V44, P107, DOI 10.1007/BF00018301; IKEUCHI M, 1987, PLANT PHYSIOL, V85, P638, DOI 10.1104/pp.85.3.638; KETTUNEN R, 1991, FEBS LETT, V290, P153, DOI 10.1016/0014-5793(91)81247-6; KETTUNEN R, 1992, RES PHOTOSYNTHESIS, V4, P309; Koivuniemi A, 1995, BIOCHEMISTRY-US, V34, P16022, DOI 10.1021/bi00049a016; KOMENDA J, 1995, BIOCHEMISTRY-US, V34, P9625, DOI 10.1021/bi00029a040; KRAUSE GH, 1991, ANNU REV PLANT PHYS, V42, P313, DOI 10.1146/annurev.pp.42.060191.001525; KYLE DJ, 1984, P NATL ACAD SCI-BIOL, V81, P4070, DOI 10.1073/pnas.81.13.4070; MICHEL H, 1988, J BIOL CHEM, V263, P1123; MIYAO M, 1994, BIOCHEMISTRY-US, V33, P9722, DOI 10.1021/bi00198a043; PORRA RJ, 1989, BIOCHIM BIOPHYS ACTA, V975, P384, DOI 10.1016/S0005-2728(89)80347-0; PRASIL O, 1992, TOPICS PHOTOSYNTHESI, V11, P293; Rintamaki E, 1996, PLANT SCI, V115, P175, DOI 10.1016/0168-9452(96)04343-9; RINTAMAKI E, 1995, PLANTA, V195, P379, DOI 10.1007/BF00202595; RINTAMAKI E, 1994, PLANTA, V193, P520, DOI 10.1007/BF02411557; RNTAMAKI E, 1995, PHYSIOL PLANTARUM, V93, P191; SCHNETTGER B, 1994, PLANT CELL ENVIRON, V17, P55, DOI 10.1111/j.1365-3040.1994.tb00265.x; SILVERSTEIN T, 1993, FEBS LETT, V334, P101, DOI 10.1016/0014-5793(93)81690-2; SILVERSTEIN T, 1993, BIOCHIM BIOPHYS ACTA, V1183, P215, DOI 10.1016/0005-2728(93)90022-8; TYYSTJARVI E, 1990, PHOTOSYNTH RES, V26, P109, DOI 10.1007/BF00047082; VASS I, 1992, P NATL ACAD SCI USA, V89, P1408, DOI 10.1073/pnas.89.4.1408; VENER AV, 1995, J BIOL CHEM, V270, P25225, DOI 10.1074/jbc.270.42.25225	45	150	167	2	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14870	14875		10.1074/jbc.271.25.14870	http://dx.doi.org/10.1074/jbc.271.25.14870			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663006	hybrid			2022-12-27	WOS:A1996UT10600037
J	RodriguezCampos, A				RodriguezCampos, A			DNA knotting abolishes in vitro chromatin assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEOXYRIBONUCLEIC-ACID GYRASE; TOPOISOMERASE-II; DROSOPHILA-MELANOGASTER; SUPERCOILED DNA; DOUBLE HELIX; PROTEIN; RELAXATION; MICROSCOPY; COMPLEXES; INVITRO	Topological knots can be formed in vitro by incubating covalently closed double stranded DNA and purified topoisomerase II from the yeast Saccharomyces cerevisiae in an ATP-dependent reaction. Knotting production requires a starting enzyme/DNA mass ratio of 1. Analysis of knotted DNA was carried out by using both one- and two-dimensional agarose gel electrophoresis. The knots generated are efficiently untied, and give relaxed DNA rings, by catalytic amounts of topoisomerase II, but not by topoisomerase I. Time course analysis shows the knotting formation over relaxed and supercoiled DNA. When supercoiled DNA was used as a susbtrate, knots appear immediately whereas no transient relaxed rings were observed. The cell-free extract from Xenopus oocytes S-150 cannot assemble nucleosomes on knotted DNA templates as revealed by topological and micrococcal nuclease analysis. Nevertheless, the presence of knotted DNA templates does not inhibit the assembly over the relaxed plasmid. Finally, a pretreatment of knotted DNA with trace amounts of topoisomerase II before the addition of the S-150 yields a canonical minichromosome assembled in vitro. Taking into account these results, I suggest a mechanism of chromatin assembly regulation directed by topoisomerase II.	CSIC, CTR INVEST & DESARROLLO, DEPT BIOL MOLEC & CELULAR, E-08034 BARCELONA, SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC)								CHAMPOUX JJ, 1978, ANNU REV BIOCHEM, V47, P449, DOI 10.1146/annurev.bi.47.070178.002313; GELLERT M, 1976, P NATL ACAD SCI USA, V73, P3872, DOI 10.1073/pnas.73.11.3872; GELLERT M, 1981, ANNU REV BIOCHEM, V50, P879, DOI 10.1146/annurev.bi.50.070181.004311; GERMOND JE, 1975, P NATL ACAD SCI USA, V72, P1843, DOI 10.1073/pnas.72.5.1843; GLIKIN GC, 1984, CELL, V37, P33, DOI 10.1016/0092-8674(84)90298-8; GOTO T, 1982, J BIOL CHEM, V257, P5866; HIRANO T, 1995, TRENDS BIOCHEM SCI, V20, P357, DOI 10.1016/S0968-0004(00)89076-3; HSIEH T, 1983, J BIOL CHEM, V258, P8413; KIRCHHAUSEN T, 1985, CELL, V41, P933, DOI 10.1016/S0092-8674(85)80074-X; KIRKEGAARD K, 1981, CELL, V23, P721, DOI 10.1016/0092-8674(81)90435-9; KLEVAN L, 1980, BIOCHEMISTRY-US, V19, P5229, DOI 10.1021/bi00564a012; LASKEY RA, 1977, CELL, V10, P237, DOI 10.1016/0092-8674(77)90217-3; LEWIS CD, 1982, CELL, V29, P171, DOI 10.1016/0092-8674(82)90101-5; LIU LF, 1980, CELL, V19, P697, DOI 10.1016/S0092-8674(80)80046-8; LIU LF, 1981, NUCLEIC ACIDS RES, V9, P3979, DOI 10.1093/nar/9.16.3979; LIU LF, 1978, P NATL ACAD SCI USA, V75, P2098, DOI 10.1073/pnas.75.5.2098; LIU LF, 1976, J MOL BIOL, V106, P439, DOI 10.1016/0022-2836(76)90095-4; LIU LF, 1979, NATURE, V281, P456, DOI 10.1038/281456a0; OSHEROFF N, 1983, J BIOL CHEM, V258, P9536; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; ROCA J, 1993, J BIOL CHEM, V268, P14250; ROCA J, 1994, CELL, V77, P609, DOI 10.1016/0092-8674(94)90222-4; ROCA J, 1992, CELL, V71, P833, DOI 10.1016/0092-8674(92)90558-T; ROCA J, 1995, TRENDS BIOCHEM SCI, V20, P156, DOI 10.1016/S0968-0004(00)88993-8; RODRIGUEZCAMPOS A, 1989, J MOL BIOL, V209, P135, DOI 10.1016/0022-2836(89)90177-0; SHIMAMURA A, 1989, METHOD ENZYMOL, V170, P603; SHIMAMURA A, 1988, MOL CELL BIOL, V8, P4257, DOI 10.1128/MCB.8.10.4257; SUGINO A, 1980, J BACTERIOL, V141, P1331, DOI 10.1128/JB.141.3.1331-1339.1980; SWEDLOW JR, 1993, CELL, V73, P97, DOI 10.1016/0092-8674(93)90163-K; van Holde KE., 1989, SPRINGER SERIES MOL; WANG JC, 1991, J BIOL CHEM, V266, P6659; WANG JC, 1985, ANNU REV BIOCHEM, V54, P665, DOI 10.1146/annurev.biochem.54.1.665; WASSERMAN SA, 1991, J BIOL CHEM, V266, P20567; WOLFFE A, 1992, CHROMATIN STRUCTURE; ZECHIEDRICH EL, 1990, EMBO J, V9, P4555, DOI 10.1002/j.1460-2075.1990.tb07908.x; ZUCKER K, 1990, J BIOL CHEM, V265, P14487	36	20	20	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14150	14155		10.1074/jbc.271.24.14150	http://dx.doi.org/10.1074/jbc.271.24.14150			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662864	hybrid			2022-12-27	WOS:A1996UQ66000034
J	Taylor, DS; Laubach, JP; Nathan, DG; MatheyPrevot, B				Taylor, DS; Laubach, JP; Nathan, DG; MatheyPrevot, B			Cooperation between core binding factor and adjacent promoter elements contributes to the tissue-specific expression of interleukin-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE MYELOID-LEUKEMIA; GENE-EXPRESSION; MAMMALIAN-CELLS; LYMPHOCYTES-T; ENHANCER; PROTEIN; FUSION; CHAIN; SITES; AML1	Tissue specific expression of interleukin-3 (IL-3) is mediated via cis-acting elements located within 315 base pairs of the transcription start. This is achieved in part through the positive activities of the AP-1 and Elf-1 sites in the IL-3 promoter. The contribution to T cell-specific expression by other promoter sites was assessed in a transient expression assay with IL-3 promoter constructs linked to a luciferase gene, focusing initially on the core binding factor (CBF) site, which is footprinted in vivo upon T cell activation, Activity of the CBF site is shown to be critically dependent on the adjacent activator site Act-1. Together the Act-1 and CBF sites form a functional unit (AC unit) with dual activity. The AC unit is demonstrated to enhance basal activity of promoters both in fibroblasts and T cells. This activity is further inducible in activated T cells, but not in fibroblasts, In addition to the already identified NIP repressor site, evidence is presented for a second repressor region that restricts promoter activity in fibroblasts, Finally, a novel positive regulatory element has been mapped in the IL-3 promoter between nucleotide -180 and -210 that leads to increased expression in T cells. Together these results demonstrate that T cell expression of IL-3 is not specified by the activity of a single tissue-specific element, but instead involves multiple interacting elements that provide both specific positive regulation in T cells and specific negative regulation in fibroblasts.	DANA FARBER CANC INST,DEPT ONCOL,BOSTON,MA 02115; CHILDRENS HOSP,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School	Taylor, DS (corresponding author), DANA FARBER CANC INST,DIV PEDIAT HEAMTOL,44 BINNEY ST,BOSTON,MA 02115, USA.				NCI NIH HHS [T32CA09172-20] Funding Source: Medline; NIDDK NIH HHS [R01 DK41758] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009172] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041758] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BURGER H, 1994, J MOL EVOL, V39, P255, DOI 10.1007/BF00160149; CAMERON S, 1994, BLOOD, V83, P2851, DOI 10.1182/blood.V83.10.2851.2851; COCKERILL PN, 1993, P NATL ACAD SCI USA, V90, P2466, DOI 10.1073/pnas.90.6.2466; COWELL IG, 1992, MOL CELL BIOL, V12, P3070, DOI 10.1128/MCB.12.7.3070; DAVIES K, 1993, BLOOD, V81, P928; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ENGELAND K, 1995, J BIOL CHEM, V270, P24572, DOI 10.1074/jbc.270.41.24572; FARR A, 1992, NUCLEIC ACIDS RES, V20, P920, DOI 10.1093/nar/20.4.920; GIESE K, 1995, GENE DEV, V9, P995, DOI 10.1101/gad.9.8.995; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; KOZU T, 1993, BLOOD, V82, P1270; LAI JH, 1995, MOL CELL BIOL, V15, P4260; LEVANON D, 1994, GENOMICS, V23, P425, DOI 10.1006/geno.1994.1519; LIU P, 1993, SCIENCE, V261, P1041, DOI 10.1126/science.8351518; LIU P, 1993, BLOOD, V82, P716; MASUDA ES, 1993, MOL CELL BIOL, V13, P7399, DOI 10.1128/MCB.13.12.7399; MATHEYPREVOT B, 1990, P NATL ACAD SCI USA, V87, P5046, DOI 10.1073/pnas.87.13.5046; METCALF D, 1992, TRENDS BIOCHEM SCI, V17, P286, DOI 10.1016/0968-0004(92)90436-D; MEYERS S, 1995, MOL CELL BIOL, V15, P1974; MIYOSHI H, 1991, P NATL ACAD SCI USA, V88, P10431, DOI 10.1073/pnas.88.23.10431; MURPHEY JM, 1995, BIOTECHNIQUES, V18, P967; NIEMEYER CM, 1989, BLOOD, V73, P945; NORTHROP JP, 1994, NATURE, V369, P497, DOI 10.1038/369497a0; NUCIFORA G, 1993, P NATL ACAD SCI USA, V90, P7784, DOI 10.1073/pnas.90.16.7784; NUCIFORA G, 1995, BLOOD, V86, P1; PARVIN JD, 1995, NATURE, V373, P724, DOI 10.1038/373724a0; PROSSER HM, 1992, P NATL ACAD SCI USA, V89, P9934, DOI 10.1073/pnas.89.20.9934; REDONDO JM, 1992, MOL CELL BIOL, V12, P4817, DOI 10.1128/MCB.12.11.4817; SHOEMAKER SG, 1990, P NATL ACAD SCI USA, V87, P9650, DOI 10.1073/pnas.87.24.9650; SPECK NA, 1990, J VIROL, V64, P543, DOI 10.1128/JVI.64.2.543-550.1990; SPECK NA, 1990, GENE DEV, V4, P233, DOI 10.1101/gad.4.2.233; TAKAHASHI A, 1995, BLOOD, V86, P607, DOI 10.1182/blood.V86.2.607.bloodjournal862607; ULLMAN KS, 1991, SCIENCE, V254, P558, DOI 10.1126/science.1683003; WANG CY, 1994, MOL CELL BIOL, V14, P1153, DOI 10.1128/MCB.14.2.1153; ZHANG W, 1995, MOL CELL BIOL, V15, P6055	36	22	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14020	14027		10.1074/jbc.271.24.14020	http://dx.doi.org/10.1074/jbc.271.24.14020			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662845	hybrid			2022-12-27	WOS:A1996UQ66000016
J	Chan, D; Weng, YM; Hocking, AM; Golub, S; McQuillan, DJ; Bateman, JF				Chan, D; Weng, YM; Hocking, AM; Golub, S; McQuillan, DJ; Bateman, JF			Site-directed mutagenesis of human type X collagen - Expression of alpha 1(X) NC1, NC2, and helical mutations in vitro and in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OSTEOGENESIS IMPERFECTA; CARTILAGE; GENE; CHONDROCYTES; LOCALIZATION; ORGANIZATION; TRANSITION; SEQUENCE; REGIONS; SYSTEM	Type X collagen is a short chain collagen expressed in the hypertrophic zone of calcifying cartilage during skeletal development and bone growth. The alpha 1(X) homotrimer consists of three protein domains, a short triple helix (COL1) flanked by nonhelical amino-terminal (NC2) and carboxyl-terminal (NC1) domains. While mutations of the NC1 domain result in Schmid metaphyseal chondrodysplasia, which suggests a critical role for this protein domain, little biochemical detail is known about type X collagen synthesis, secretion, and the mechanisms of molecular assembly, To study these processes, a range of mutations were produced in human alpha 1(X) cDNA and the biochemical consequences determined by in vitro expression, using T7-driven coupled transcription and translation, and by transient transfection of cells, Three NC1 mutants, which were designed to be analogous to Schmid mutations (1952de1C, 1963del10, and Y598D), were unable to assemble into type X collagen homotrimers in vitro, but the mutant chains did not associate with, or interfere with, the efficiency of normal chain assembly in co-translations with a normal construct, Expression in transiently transfected cells confirmed that mutant type X collagen assembly was also compromised in vivo. The mutant chains were not secreted from the cells but did not accumulate intracellularly, suggesting that the unassociated mutant chains were rapidly degraded, In-frame deletions within the helix (amino acid residues 72-354) and the NC2 domain (amino acid residues 21-54) were also produced. In contrast to the NC1 mutations, these mutations did not prevent. assembly, Mutant homotrimers and mutant-normal heterotrimers were formed in vitro, and the mutant homotrimers formed in transiently transfected cells bars. assembled into pepsin-stable triple helical molecules which were secreted.	UNIV MELBOURNE,ROYAL CHILDRENS HOSP,DEPT PAEDIAT,ORTHOPAED MOL BIOL RES UNIT,PARKVILLE,VIC 3052,AUSTRALIA	Royal Children's Hospital Melbourne; University of Melbourne			Chan, Danny/C-4203-2009	Chan, Danny/0000-0003-3824-5778; Bateman, John/0000-0001-8542-0730				APTE SS, 1993, MATRIX, V13, P165, DOI 10.1016/S0934-8832(11)80075-2; BATEMAN JF, 1984, BIOCHEM J, V217, P103, DOI 10.1042/bj2170103; BERG RA, 1973, BIOCHEM BIOPH RES CO, V52, P115, DOI 10.1016/0006-291X(73)90961-3; BONAVENTURE J, 1995, HUM GENET, V96, P58, DOI 10.1007/BF00214187; BRASS A, 1992, FEBS LETT, V303, P126, DOI 10.1016/0014-5793(92)80503-9; Byers Peter H., 1993, P317; CHAN D, 1995, J BIOL CHEM, V270, P4558, DOI 10.1074/jbc.270.9.4558; CHAN D, 1995, J BIOL CHEM, V270, P1747, DOI 10.1074/jbc.270.4.1747; CHESSLER SD, 1993, J BIOL CHEM, V268, P18226; DHARMAVARAM RM, 1994, HUM MOL GENET, V3, P507, DOI 10.1093/hmg/3.3.507; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; GRANT WT, 1987, J BIOL CHEM, V262, P9844; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; JACENKO O, 1993, NATURE, V365, P56, DOI 10.1038/365056a0; KIELTY CM, 1985, BIOCHEM J, V227, P545, DOI 10.1042/bj2270545; KWAN APL, 1991, J CELL BIOL, V114, P597, DOI 10.1083/jcb.114.3.597; LAMANDE SR, 1995, J BIOL CHEM, V270, P8642, DOI 10.1074/jbc.270.15.8642; LUVALLE P, 1988, J BIOL CHEM, V263, P18378; MCINTOSH I, 1993, NAT GENET, V4, P219, DOI 10.1038/ng0793-219; MCINTOSH I, 1995, HUM MUTAT, V5, P121, DOI 10.1002/humu.1380050204; MCINTOSH I, 1994, HUM MOL GENET, V3, P303, DOI 10.1093/hmg/3.2.303; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; NERLICH AG, 1992, HISTOCHEMISTRY, V98, P275, DOI 10.1007/BF00270010; REICHENBERGER E, 1992, FEBS LETT, V311, P305, DOI 10.1016/0014-5793(92)81126-7; REICHENBERGER E, 1991, DEV BIOL, V148, P562, DOI 10.1016/0012-1606(91)90274-7; RICH DP, 1990, NATURE, V347, P358, DOI 10.1038/347358a0; ROSATI R, 1994, NAT GENET, V8, P129, DOI 10.1038/ng1094-129; SCHMID TM, 1990, DEV BIOL, V138, P53, DOI 10.1016/0012-1606(90)90176-J; SCHMID TM, 1983, J BIOL CHEM, V258, P9504; THOMAS JT, 1991, BIOCHEM J, V280, P617, DOI 10.1042/bj2800617; WALLIS GA, 1994, AM J HUM GENET, V54, P169	31	46	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13566	13572		10.1074/jbc.271.23.13566	http://dx.doi.org/10.1074/jbc.271.23.13566			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662807	hybrid			2022-12-27	WOS:A1996UP38500041
J	Goodfellow, HR; Sardini, A; Ruetz, S; Callaghan, R; Gros, P; McNaughton, PA; Higgins, CF				Goodfellow, HR; Sardini, A; Ruetz, S; Callaghan, R; Gros, P; McNaughton, PA; Higgins, CF			Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINBLASTINE ACCUMULATION; EXPRESSION SYSTEM; CARCINOMA-CELLS; VACCINIA VIRUS; P388/ADR CELLS; HL60 CELLS; STAUROSPORINE; GENE; IDENTIFICATION; MODULATION	P-glycoprotein (P-gp) is an active transporter that can confer multidrug resistance by pumping cytotoxic drugs out of cells and tumors, P-gp is phosphorylated at several sites in the ''linker'' region, which separates the two halves of the molecule, To examine the role of phosphorylation in drug transport, we mutated P-gp such that it could no longer be phosphorylated by protein kinase C (PRC), When expressed in yeast, the ability of the mutant proteins to confer drug resistance, or to mediate [H-3]vinblastine accumulation in secretory vesicles, was indistinguishable from that of wild type P-gp. A matched pair of mammalian cell lines were generated expressing wild type P-gp and a non-phosphorylatable mutant protein. Mutation of the phosphorylation sites did not alter P-gp expression or its subcellular localization The transport properties of the mutant and wild type proteins were indistinguishable. Thus, phosphorylation of the linker of P-gp by PRC does not affect the rate of drug transport, In fight of these data, the use of agents that alter PRC activity to reverse multidrug resistance in the clinic should be considered with caution.	MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA; JOHN RADCLIFFE HOSP,INST MOLEC MED,NUFFIELD DEPT CLIN BIOCHEM,IMPERIAL CANC RES LABS,OXFORD OX3 9DU,ENGLAND; UNIV LONDON KINGS COLL,DEPT PHYSIOL,LONDON WC2R 2LS,ENGLAND; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3G 1Y6,CANADA	McGill University; University of Oxford; University of London; King's College London; McGill University			Callaghan, Richard/B-7032-2012; Callaghan, Richard/ABG-1638-2020	Callaghan, Richard/0000-0001-6136-3532; Callaghan, Richard/0000-0001-6136-3532; McNaughton, Peter/0000-0003-1946-9610				ABRAHAM I, 1990, EXP CELL RES, V189, P133, DOI 10.1016/0014-4827(90)90265-C; AHMAD S, 1994, BIOCHEMISTRY-US, V33, P10313, DOI 10.1021/bi00200a011; BATES SE, 1992, BIOCHEMISTRY-US, V31, P6366, DOI 10.1021/bi00143a002; BATES SE, 1993, BIOCHEMISTRY-US, V32, P9156, DOI 10.1021/bi00086a022; BLOBE GC, 1993, J BIOL CHEM, V268, P658; CALLAGHAN R, 1993, J BIOL CHEM, V268, P16059; CANOGAUCI DF, 1987, BIOCHEM PHARMACOL, V36, P2115, DOI 10.1016/0006-2952(87)90139-0; CARLSEN SA, 1977, BIOCHIM BIOPHYS ACTA, V467, P238, DOI 10.1016/0005-2736(77)90199-7; CHAMBERS TC, 1990, J BIOL CHEM, V265, P7679; CHAMBERS TC, 1994, BIOCHEM J, V299, P309, DOI 10.1042/bj2990309; CHAMBERS TC, 1993, J BIOL CHEM, V268, P4592; CHAMBERS TC, 1992, MOL PHARMACOL, V41, P1008; CHAUDHARY PM, 1992, ONCOL RES, V4, P281; CHIN KV, 1992, J CELL PHYSIOL, V152, P87, DOI 10.1002/jcp.1041520112; CJHAMBERS TC, 1995, BIOCHEMISTRY-US, V34, P14156; CORNWELL MM, 1986, P NATL ACAD SCI USA, V261, P7762; ELROYSTEIN O, 1989, P NATL ACAD SCI USA, V86, P6126, DOI 10.1073/pnas.86.16.6126; FAN D, 1992, ANTICANCER RES, V12, P661; FINE RL, 1988, P NATL ACAD SCI USA, V85, P582, DOI 10.1073/pnas.85.2.582; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FUJIKI Y, 1982, J CELL BIOL, V93, P97, DOI 10.1083/jcb.93.1.97; GERMANN UA, 1995, J BIOENERG BIOMEMBR, V27, P53, DOI 10.1007/BF02110331; GILL DR, 1992, CELL, V71, P23, DOI 10.1016/0092-8674(92)90263-C; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; HARDY SP, 1995, EMBO J, V14, P68, DOI 10.1002/j.1460-2075.1995.tb06976.x; HIGGINS CF, 1992, TRENDS BIOCHEM SCI, V17, P18, DOI 10.1016/0968-0004(92)90419-A; HIGGINS CF, 1995, CELL, V82, P693, DOI 10.1016/0092-8674(95)90465-4; HOMOLYA L, 1993, J BIOL CHEM, V268, P21493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE SA, 1992, CANCER RES, V52, P3750; LELONG IH, 1994, BIOCHEMISTRY-US, V33, P8921, DOI 10.1021/bi00196a009; LUCKIE DB, 1994, AM J PHYSIOL, V267, pC650, DOI 10.1152/ajpcell.1994.267.2.C650; MA LD, 1991, J BIOL CHEM, V266, P5593; MIYAMOTO K, 1993, J PHARM PHARMACOL, V45, P43, DOI 10.1111/j.2042-7158.1993.tb03677.x; MIYAMOTO KI, 1992, CANCER LETT, V64, P177, DOI 10.1016/0304-3835(92)90079-B; OBRIAN CA, 1989, FEBS LETT, V246, P78, DOI 10.1016/0014-5793(89)80257-1; ORR GA, 1993, J BIOL CHEM, V268, P25054; PALYOOR ST, 1987, BIOCHEM BIOPH RES CO, V148, P718; RIORDAN JR, 1989, SCIENCE, V245, P1066; RUETZ S, 1994, J BIOL CHEM, V269, P12277; SAMPSON KE, 1993, CANCER LETT, V68, P7, DOI 10.1016/0304-3835(93)90213-S; SARDINI A, 1994, J CELL SCI, V107, P3281; SATO W, 1990, BIOCHEM BIOPH RES CO, V173, P1252, DOI 10.1016/S0006-291X(05)80921-0; STAATS J, 1990, J BIOL CHEM, V265, P4084; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; UCHIUMI T, 1993, FEBS LETT, V326, P11, DOI 10.1016/0014-5793(93)81750-T; VALVERDE MA, 1992, NATURE, V355, P830, DOI 10.1038/355830a0; VERNET T, 1987, GENE, V52, P225, DOI 10.1016/0378-1119(87)90049-7; WAKUSAWA S, 1993, J ANTIBIOT, V46, P353, DOI 10.7164/antibiotics.46.353; WAKUSAWA S, 1992, ANTICANCER RES, V12, P2021; WALWORTH NC, 1987, J CELL BIOL, V105, P163, DOI 10.1083/jcb.105.1.163; WU G, 1991, CANCER COMMUN, P181	52	115	118	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13668	13674		10.1074/jbc.271.23.13668	http://dx.doi.org/10.1074/jbc.271.23.13668			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662768	hybrid			2022-12-27	WOS:A1996UP38500056
J	Schreiber, M; Rajarathnam, K; McFadden, G				Schreiber, M; Rajarathnam, K; McFadden, G			Myxoma virus T2 protein, a tumor necrosis factor (TNF) receptor homolog, is secreted as a monomer and dimer that each bind rabbit TNF alpha, but the dimer is a more potent TNF inhibitor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VACCINIA VIRUS; 55-KDA RECEPTOR; GAMMA RECEPTOR; LIGAND-BINDING; EXPRESSION; TYPE-1; CELLS; GENES; IDENTIFICATION; AUGMENTATION	The myxoma virus T2 (M-T2) gene expresses a secreted protein that contains significant sequence similarity to the ligand binding domains of the cellular tumor necrosis factor (TNF) receptors, specifically inhibits the cytolytic activity of rabbit TNF alpha and is an important virulence factor for myxoma virus infection in rabbits, M-T2 protein was overexpressed from vaccinia virus vectors, purified to apparent homogeneity, and found to specifically protect mouse and rabbit cells from lysis by rabbit TNF alpha at molar ratios comparable with the soluble versions of the host tumor necrosis factor receptors. M-T2 secreted from virus-infected cells is detected as both a monomer and a disulfide-linked dimer, both of which were shown by Scatchard analysis to bind rabbit TNF alpha (K-d values of 170 pM and 195 pM, respectively), values that are comparable with the affinities of mammalian TNFs with their receptors. In contrast to the rabbit ligand, M-T2 interacts with mouse TNF alpha with a much lower affinity, K-d of 1.7 nM, and was unable to inhibit the cytolytic activity of this ligand on mouse cells, Although both monomeric and dimeric forms bound rabbit TNF alpha with comparable affinity, the dimeric M-T2 protein was a far more potent inhibitor of rabbit TNF alpha, presumably because it can more effectively prevent dimerization of TNF receptors than can the M-T2 monomer.	UNIV ALBERTA, DEPT BIOCHEM, EDMONTON, AB T6G 2H7, CANADA	University of Alberta								ADERKA D, 1985, CELL IMMUNOL, V92, P218, DOI 10.1016/0008-8749(85)90003-6; AGGARWAL BB, 1992, TUMOR NECROSIS FACTO, P61; ALCAMI A, 1995, IMMUNOL TODAY, V16, P474, DOI 10.1016/0167-5699(95)80030-1; ALCAMI A, 1995, J VIROL, V69, P4633; ALCAMI A, 1992, CELL, V71, P153, DOI 10.1016/0092-8674(92)90274-G; ARMITAGE RJ, 1994, CURR OPIN IMMUNOL, V6, P407, DOI 10.1016/0952-7915(94)90119-8; ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BAZZONI F, 1995, P NATL ACAD SCI USA, V92, P5376, DOI 10.1073/pnas.92.12.5376; BEUTLER B, 1991, PEPTIDE GROWTH FACTO, P39; BUTLER DM, 1994, CYTOKINE, V6, P616, DOI 10.1016/1043-4666(94)90049-3; COLAMONICI OR, 1995, J BIOL CHEM, V270, P15974, DOI 10.1074/jbc.270.27.15974; DAVISON AJ, 1990, NUCLEIC ACIDS RES, V18, P4285, DOI 10.1093/nar/18.14.4285; DEBETS R, 1994, IMMUNOL TODAY, V15, P455, DOI 10.1016/0167-5699(94)90187-2; DECLERCQ W, 1995, CYTOKINE, V7, P701, DOI 10.1006/cyto.1995.0082; FENNER F, 1965, MYXOMATOSIS; FOUNTOULAKIS M, 1990, J BIOL CHEM, V265, P13268; GARFIN DE, 1990, METHOD ENZYMOL, V182, P425; GOODWIN RG, 1991, MOL CELL BIOL, V11, P3020, DOI 10.1128/MCB.11.6.3020; HAAKFRENDSCHO M, 1994, J IMMUNOL, V152, P1347; HALE KK, 1995, CYTOKINE, V7, P26, DOI 10.1006/cyto.1995.1004; Harlow E., 1988, ANTIBODIES LAB MANUA; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HIGUCHI M, 1992, J BIOL CHEM, V267, P20892; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; HU FQ, 1994, VIROLOGY, V204, P343, DOI 10.1006/viro.1994.1539; KOFF WC, 1986, LYMPHOKINE RES, V5, P215; LASTER SM, 1994, SEMIN VIROL, V5, P431, DOI 10.1006/smvy.1994.1049; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LIDBURY BA, 1995, CYTOKINE, V7, P157, DOI 10.1006/cyto.1995.1021; LOETSCHER H, 1991, J BIOL CHEM, V266, P18324; LORENCE RM, 1988, J NATL CANCER I, V80, P1305, DOI 10.1093/jnci/80.16.1305; MACEN JL, 1993, VIROLOGY, V195, P348, DOI 10.1006/viro.1993.1385; MARSTERS SA, 1992, J BIOL CHEM, V267, P5747; MCFADDEN G, 1994, SEMIN VIROL, V5, P421, DOI 10.1006/smvy.1994.1048; MCFADDEN G, 1995, J LEUKOCYTE BIOL, V57, P731, DOI 10.1002/jlb.57.5.731; MCFADDEN G, 1995, VIROCEPTORS VIROKINE; MCFADDEN G, 1994, ENCY VIROLOGY, P1153; MOSSMAN K, 1995, VIROLOGY, V208, P762, DOI 10.1006/viro.1995.1208; MOSSMAN K, 1995, J BIOL CHEM, V270, P3031, DOI 10.1074/jbc.270.7.3031; OLSSON I, 1993, EUR CYTOKINE NETW, V4, P169; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; PENNICA D, 1992, J BIOL CHEM, V267, P21172; PENNICA D, 1992, BIOCHEMISTRY-US, V31, P1134, DOI 10.1021/bi00119a023; PEPPEL K, 1991, J EXP MED, V174, P1483, DOI 10.1084/jem.174.6.1483; PFIZENMAIER K, 1992, TUMOR NECROSIS FACTO, P439; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SAMBHI SK, 1991, P NATL ACAD SCI USA, V88, P4025, DOI 10.1073/pnas.88.9.4025; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SCHREIBER M, 1994, VIROLOGY, V204, P692, DOI 10.1006/viro.1994.1585; SHAKHOV AN, 1990, GENE, V95, P215, DOI 10.1016/0378-1119(90)90364-W; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; SMITH CA, 1995, VIROCEPTORS VIROKINE, P29; SMITH GL, 1994, TRENDS MICROBIOL, V2, P80; SMITH RA, 1992, TUMOR NECROSIS FACTO, P131; SPRIGGS MK, 1992, CELL, V71, P145, DOI 10.1016/0092-8674(92)90273-F; SPRIGGS MK, 1994, VIRUS RES, V33, P1, DOI 10.1016/0168-1702(94)90013-2; SUGARMAN HJ, 1985, SCIENCE, V230, P942; SYMONS JA, 1995, CELL, V81, P551, DOI 10.1016/0092-8674(95)90076-4; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V73, P213, DOI 10.1016/0092-8674(93)90222-C; TARTAGLIA LA, 1993, J BIOL CHEM, V268, P18542; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; TRACEY KJ, 1994, ANNU REV MED, V45, P491, DOI 10.1146/annurev.med.45.1.491; UPTON C, 1992, SCIENCE, V258, P1369, DOI 10.1126/science.1455233; UPTON C, 1991, VIROLOGY, V184, P370, DOI 10.1016/0042-6822(91)90853-4; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WELLS JA, 1994, CURR OPIN CELL BIOL, V6, P163, DOI 10.1016/0955-0674(94)90132-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOLD WSM, 1993, J CELL BIOCHEM, V53, P329, DOI 10.1002/jcb.240530410; WONG GHW, 1992, J IMMUNOL, V149, P3350; WONG GHW, 1986, NATURE, V323, P819, DOI 10.1038/323819a0; [No title captured]	73	61	66	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13333	13341		10.1074/jbc.271.23.13333	http://dx.doi.org/10.1074/jbc.271.23.13333			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662837	hybrid			2022-12-27	WOS:A1996UP38500008
J	FujitaYoshigaki, J; Dohke, Y; HaraYokoyama, M; Kamata, Y; Kozaki, S; Furuyama, S; Sugiya, H				FujitaYoshigaki, J; Dohke, Y; HaraYokoyama, M; Kamata, Y; Kozaki, S; Furuyama, S; Sugiya, H			Vesicle-associated membrane protein 2 is essential for cAMP-regulated exocytosis in rat parotid acinar cells - The inhibition of cAMP-dependent amylase release by botulinum neurotoxin B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; NEUROTRANSMITTER RELEASE; TETANUS TOXIN; KINASE-C; CALCIUM; SYNAPTOBREVIN; SYNAPTOTAGMIN; SECRETION; ANTIBODIES; MACHINERY	Amylase exocytosis of the parotid gland is mediated by intracellular cAMP. To investigate whether cAMP-dependent secretion has a mechanism similar to that of regulated neuroexocytosis, we examined the expression of synaptosome-associated proteins. In rat parotid acinar cells, we found 25 (p25) and 18 kDa (p18) proteins reacted with antibodies against Rab3A and vesicle-associated membrane protein 2 (VAMP-2), respectively. On the other hand, syntaxin 1 and SNAP-25, which interact with VAMP-2 at synapses, were undetectable. Rab3A-like p25 and VAMP-2-like p18 were also expressed in other exocrine acinar cells. The latter was localized at secretory granule membranes, and the former was detected in secretory granule and cytosolic fractions. The antibody against VAMP-2 used in this study did not react with cellubrevin, and p18 was cleaved with botulinum neurotoxin B. Thus, we identified p18 as VAMP-2. Botulinum neurotoxin B inhibited the cAMP-induced amylase release from streptolysin O-permeabilized acinar cells. Therefore, VAMP-2 is required for cAMP-regulated amylase release in rat parotid acinar cells. This is the first report that VAMP-2 is involved in regulated exocytosis that is independent of Ca2+.	UNIV OSAKA PREFECTURE,DEPT AGR,SAKAI,OSAKA 593,JAPAN	Osaka Metropolitan University	FujitaYoshigaki, J (corresponding author), NIHON UNIV,SCH DENT,DEPT PHYSIOL,2-870-1 SAKAE CHO NISHI,MATSUDO,CHIBA 271,JAPAN.		Yoshigaki, Junko/AAE-6702-2020	Fujita-Yoshigaki, Junko/0000-0002-3271-6498				AMMALA C, 1993, NATURE, V363, P356, DOI 10.1038/363356a0; BALDYSWALIGORSKA A, 1987, BIOCHIM BIOPHYS ACTA, V929, P190, DOI 10.1016/0167-4889(87)90175-3; BENNETT MK, 1992, J CELL BIOL, V116, P761, DOI 10.1083/jcb.116.3.761; BENNETT MK, 1993, P NATL ACAD SCI USA, V90, P2559, DOI 10.1073/pnas.90.7.2559; BERNFELD P, 1955, METHOD ENZYMOL, V1, P149, DOI 10.1016/0076-6879(55)01021-5; BERRIDGE MJ, 1985, SCI AM, V253, P142, DOI 10.1038/scientificamerican1085-142; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BLASI J, 1993, EMBO J, V12, P4821, DOI 10.1002/j.1460-2075.1993.tb06171.x; BURGESS GM, 1983, J BIOL CHEM, V258, P5336; BURNHAM DB, 1982, CELL TISSUE RES, V222, P201; Butcher F R, 1980, Adv Cyclic Nucleotide Res, V13, P215; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; GAISANO HY, 1994, J BIOL CHEM, V269, P17062; GALLI T, 1994, J CELL BIOL, V125, P1015, DOI 10.1083/jcb.125.5.1015; GASSER KW, 1990, AM J PHYSIOL, V259, pC413, DOI 10.1152/ajpcell.1990.259.3.C413; JENA BP, 1994, J CELL BIOL, V124, P43, DOI 10.1083/jcb.124.1.43; KOZAKI S, 1974, INFECT IMMUN, V10, P750, DOI 10.1128/IAI.10.4.750-756.1974; LEVEQUE C, 1992, P NATL ACAD SCI USA, V89, P3625, DOI 10.1073/pnas.89.8.3625; LINK E, 1992, BIOCHEM BIOPH RES CO, V189, P1017, DOI 10.1016/0006-291X(92)92305-H; MACRAE MB, 1990, BIOCHEM J, V271, P635, DOI 10.1042/bj2710635; MIZOGUCHI A, 1990, J BIOL CHEM, V265, P11872; MOLLARD GFV, 1990, P NATL ACAD SCI USA, V87, P1988; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OBATA K, 1986, BRAIN RES, V375, P37, DOI 10.1016/0006-8993(86)90956-X; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; POULAIN B, 1993, J NEUROCHEM, V61, P1175, DOI 10.1111/j.1471-4159.1993.tb03640.x; PRENTKI M, 1987, PHYSIOL REV, V67, P1185, DOI 10.1152/physrev.1987.67.4.1185; QUISSELL DO, 1979, P NATL ACAD SCI USA, V76, P2789, DOI 10.1073/pnas.76.6.2789; QUISSELL DO, 1993, BIOL SALIVARY GLANDS, P181; REGAZZI R, 1995, EMBO J, V14, P2723, DOI 10.1002/j.1460-2075.1995.tb07273.x; SCHIAVO G, 1992, NATURE, V359, P832, DOI 10.1038/359832a0; SKEHEL PA, 1995, SCIENCE, V269, P1580, DOI 10.1126/science.7667638; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P319; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUDHOF TC, 1993, CELL, V75, P1; SUGIYA H, 1987, BIOCHEM J, V244, P647, DOI 10.1042/bj2440647; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; TAKUMA T, 1986, BIOCHIM BIOPHYS ACTA, V887, P113, DOI 10.1016/0167-4889(86)90130-8; TRIMBLE WS, 1991, ANNU REV NEUROSCI, V14, P93, DOI 10.1146/annurev.ne.14.030191.000521; YAMASAKI S, 1994, J BIOL CHEM, V269, P12764; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	42	71	75	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13130	13134		10.1074/jbc.271.22.13130	http://dx.doi.org/10.1074/jbc.271.22.13130			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662834	hybrid			2022-12-27	WOS:A1996UN47400068
J	Ahmadian, MR; Wiesmuller, L; Lautwein, A; Bischoff, FR; Wittinghofer, A				Ahmadian, MR; Wiesmuller, L; Lautwein, A; Bischoff, FR; Wittinghofer, A			Structural differences in the minimal catalytic domains of the GTPase-activating proteins p120(GAP) and neurofibromin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; RAS P21 GTPASE; GENE-PRODUCT; TYPE-1 GENE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SIGNALING PROTEINS; MOLECULAR-CLONING; SH3 DOMAINS; GAP	The kinetic properties for the enzymatic stimulation of the GTPase reaction of p21(ras) by the two GTPase-activating proteins (GAPs) p120(GAP) and neurofibromin are different. In order to understand these differences and since crystallization attempts have only been successful with truncated fragments, structure/function requirements of the catalytic core of these proteins were investigated. Differences in size of the minimal catalytic domains of these two proteins mere found as determined by limited proteolysis. The minimal catalytic domain has a molecular mass of 30 kDa in the case of p120(GAP) and of 26 kDa in the case of neurofibromin. Both catalytic domains contain the homology boxes as well as the residues perfectly conserved among all Ras GAPs. The C termini of these fragments are identical, whereas the N-terminal part of the minimal p120(GAP) domain is 47 amino acids longer. These newly identified minimal catalytic fragments were as active in stimulating GTPase activity toward p21(ras) as the corresponding larger fragments GAP-334 and NF1-333 from which they had been generated via proteolytic digestion. Recently it was postulated that a fragment of 91 amino acids from neurofibromin located outside the conserved domain contains catalytic activity. In our hands this protein is unstable and has no catalytic activity. Thus, we believe that we have defined the true minimal domains of p120(GAP) (GAP-273, residues Met(714)-His(986)) and neurofibromin (NF1-230, residues Asp(1248)-Phe(1477)), which can be expressed via LMM fusion vectors in Escherichia coli and isolated in high purity.	MAX PLANCK INST MOL PHYSIOL,ABT STRUKTURELLE BIOL,D-44139 DORTMUND,GERMANY; UNIV HAMBURG,HEINRICH PETTE INST EXPT VIROL & IMMUNOL,D-20251 HAMBURG,GERMANY; DEUTSCH KREBSFORSCHUNGSZENTRUM,D-69009 HEIDELBERG,GERMANY	Max Planck Society; Heinrich Pette Institute; University of Hamburg; Helmholtz Association; German Cancer Research Center (DKFZ)								ANDERSON D, 1990, SCIENCE, V250, P979, DOI 10.1126/science.2173144; BALLESTER R, 1990, CELL, V63, P851, DOI 10.1016/0092-8674(90)90151-4; BASU TN, 1992, NATURE, V356, P713, DOI 10.1038/356713a0; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1993, EMBO J, V12, P1923, DOI 10.1002/j.1460-2075.1993.tb05841.x; BOLLAG G, 1991, NATURE, V351, P576, DOI 10.1038/351576a0; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNBRIDGE GG, 1993, J BIOL CHEM, V268, P10914; BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; CAWTHON RM, 1990, CELL, V62, P193, DOI 10.1016/0092-8674(90)90253-B; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DECLUE JE, 1992, CELL, V69, P265, DOI 10.1016/0092-8674(92)90407-4; DECLUE JE, 1991, MOL CELL BIOL, V11, P2819, DOI 10.1128/MCB.11.5.2819; DUCHESNE M, 1993, SCIENCE, V259, P525, DOI 10.1126/science.7678707; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; Frech M, 1990, SCIENCE, V249, P169, DOI 10.1126/science.2164710; FRIDMAN M, 1994, J BIOL CHEM, V269, P30105; GAUL U, 1992, CELL, V68, P1007, DOI 10.1016/0092-8674(92)90073-L; GAWLER DJ, 1995, ONCOGENE, V10, P817; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; JOHN J, 1989, J BIOL CHEM, V264, P13086; KOCH CA, 1991, SCIENCE, V252, P668, DOI 10.1126/science.1708916; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MARTIN GA, 1990, CELL, V63, P843, DOI 10.1016/0092-8674(90)90150-D; MARTIN GA, 1992, SCIENCE, V255, P192, DOI 10.1126/science.1553544; MAYER BJ, 1993, CELL, V73, P629, DOI 10.1016/0092-8674(93)90244-K; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; MCGLADE J, 1993, EMBO J, V12, P3073, DOI 10.1002/j.1460-2075.1993.tb05976.x; NUREKAMAL MSA, 1992, J BIOL CHEM, V267, P1415; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; POHLNER J, 1992, BIO-TECHNOL, V10, P799, DOI 10.1038/nbt0792-799; SCHULER GD, 1991, PROTEINS, V9, P180, DOI 10.1002/prot.340090304; SCHWEIGHOFFER F, 1992, SCIENCE, V256, P825, DOI 10.1126/science.1317056; SETTLEMAN J, 1992, CELL, V69, P539, DOI 10.1016/0092-8674(92)90454-K; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; TANAKA K, 1990, CELL, V60, P803, DOI 10.1016/0092-8674(90)90094-U; TANAKA K, 1989, MOL CELL BIOL, V9, P757, DOI 10.1128/MCB.9.2.757; TRAHEY M, 1988, SCIENCE, V242, P1697, DOI 10.1126/science.3201259; TRAHEY M, 1987, SCIENCE, V238, P542, DOI 10.1126/science.2821624; TUCKER J, 1986, EMBO J, V5, P1351, DOI 10.1002/j.1460-2075.1986.tb04366.x; VISKOCHIL D, 1990, CELL, V62, P187, DOI 10.1016/0092-8674(90)90252-A; VOGEL KS, 1995, CELL, V82, P733, DOI 10.1016/0092-8674(95)90470-0; VOGEL US, 1988, NATURE, V335, P90, DOI 10.1038/335090a0; WALLACE MR, 1991, NATURE, V353, P864, DOI 10.1038/353864a0; WANG Y, 1991, CELL REGUL, V2, P453, DOI 10.1091/mbc.2.6.453; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; WOLBER V, 1992, BIO-TECHNOL, V10, P900, DOI 10.1038/nbt0892-900; XU GF, 1990, CELL, V63, P835, DOI 10.1016/0092-8674(90)90149-9; XU GF, 1990, CELL, V62, P599, DOI 10.1016/0092-8674(90)90024-9	56	62	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16409	16415		10.1074/jbc.271.27.16409	http://dx.doi.org/10.1074/jbc.271.27.16409			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663212	hybrid			2022-12-27	WOS:A1996UW35200081
J	Das, A; Peterson, GC; Kanner, SB; Frevert, U; Parsons, M				Das, A; Peterson, GC; Kanner, SB; Frevert, U; Parsons, M			A major tyrosine-phosphorylated protein of Trypanosoma brucei is a nucleolar RNA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEIC-ACID BINDING; MOLECULAR-CLONING; POLYMERASE-I; CODING GENES; TRANSCRIPTION; FIBRILLARIN; SEQUENCE; GLYCINE; DOMAIN	We have previously identified a set of tyrosine-phosphorylated proteins with apparent molecular masses of 44-46 kDa as some of the major tyrosine phosphorylated species in the protozoan parasite Trypanosoma brucei. We now show that these molecules, herein named Nopp44/46, are localized in the nucleolus. Using monoclonal antibodies, we have isolated Nopp44/46 cDNA clones from expression libraries. Sequence analysis reveals that the predicted amino acid sequence of the molecule is composed of an N-terminal unique region, an internal acidic region, and C-terminal repeat region. Analysis of the cDNA clones and genomic Southern analysis indicated that Nopp44/46 belongs to a multigene family in which different gene copies are very similar but vary in the number of repeats. Interestingly, the repetitive amino acid sequence moth contains multiple RGG (Arg-Gly-Gly) boxes characteristic of RNA-binding proteins. In vitro binding experiments demonstrated that Nopp44/46 is indeed capable of binding nucleic acids. Competition experiments with different RNA homopolymers demonstrated that Nopp44/46 preferentially binds to poly(U). These studies suggest that Nopp44/46 may play a role in RNA metabolism in trypanosomes and raise the possibility that tyrosine phosphorylation may regulate the process.	SEATTLE BIOMED RES INST,SEATTLE,WA 98109; UNIV WASHINGTON,DEPT PATHOBIOL,SEATTLE,WA 98195; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,SEATTLE,WA 98121; NYU,MED CTR,DEPT MED & MOLEC PARASITOL,NEW YORK,NY 10010	Center for Infectious Disease Research; University of Washington; University of Washington Seattle; Bristol-Myers Squibb; New York University				Parsons, Marilyn/0000-0003-3994-8096	NIAID NIH HHS [AI R01-31077] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031077] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AGABIAN N, 1990, CELL, V61, P1157, DOI 10.1016/0092-8674(90)90674-4; CAPPAI R, 1994, MOL BIOCHEM PARASIT, V64, P353, DOI 10.1016/0166-6851(94)00047-6; DAS A, 1994, J CELL SCI, V107, P3477; FLACH J, 1994, MOL CELL BIOL, V14, P8399, DOI 10.1128/MCB.14.12.8399; GHISOLFI L, 1992, J BIOL CHEM, V267, P2955; HARTSHORNE T, 1993, MOL CELL BIOL, V13, P144, DOI 10.1128/MCB.13.1.144; HEINE MA, 1993, MOL BIOL CELL, V4, P1189, DOI 10.1091/mbc.4.11.1189; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HIROSE T, 1994, MOL GEN GENET, V244, P360, DOI 10.1007/BF00286687; JONG AYS, 1987, MOL CELL BIOL, V7, P2947, DOI 10.1128/MCB.7.8.2947; KILEDJIAN M, 1992, EMBO J, V11, P2656; KOOTER JM, 1984, NUCLEIC ACIDS RES, V12, P9457, DOI 10.1093/nar/12.24.9457; LANHAM SM, 1968, NATURE, V218, P1273, DOI 10.1038/2181273a0; LAPEYRE B, 1987, P NATL ACAD SCI USA, V84, P1472, DOI 10.1073/pnas.84.6.1472; LAPEYRE B, 1990, MOL CELL BIOL, V10, P430, DOI 10.1128/MCB.10.1.430; LIU Q, 1995, MOL CELL BIOL, V15, P2800; MAYRAND SH, 1993, P NATL ACAD SCI USA, V90, P7764, DOI 10.1073/pnas.90.16.7764; MELESE T, 1995, CURR OPIN CELL BIOL, V7, P319, DOI 10.1016/0955-0674(95)80085-9; MERMOUD JE, 1994, EMBO J, V13, P5679, DOI 10.1002/j.1460-2075.1994.tb06906.x; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; OHNO T, 1994, ONCOGENE, V9, P3087; PARSONS M, 1994, MOL BIOCHEM PARASIT, V63, P69, DOI 10.1016/0166-6851(94)90009-4; PERRY KL, 1987, P NATL ACAD SCI USA, V84, P8190, DOI 10.1073/pnas.84.23.8190; PYPE S, 1994, J BIOL CHEM, V269, P31457; RUDENKO G, 1991, EMBO J, V10, P3387, DOI 10.1002/j.1460-2075.1991.tb04903.x; RUDENKO G, 1989, EMBO J, V13, P4259; SAMUELS ME, 1994, MOL CELL BIOL, V14, P4975, DOI 10.1128/MCB.14.7.4975; SHAMOO Y, 1994, BIOCHEMISTRY-US, V33, P8272, DOI 10.1021/bi00193a014; STAURT K, 1984, PARASITOLOGY, V70, P747; SWANSON MS, 1988, MOL CELL BIOL, V8, P2237, DOI 10.1128/MCB.8.5.2237; TAYLOR SJ, 1994, NATURE, V368, P867, DOI 10.1038/368867a0; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L; ZOMERDIJK JCBM, 1991, NATURE, V353, P772, DOI 10.1038/353772a0	33	32	32	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15675	15681		10.1074/jbc.271.26.15675	http://dx.doi.org/10.1074/jbc.271.26.15675			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663171	hybrid			2022-12-27	WOS:A1996UV29900057
J	Schubert, C; Carel, K; DePaolo, D; Leitner, W; Draznin, B				Schubert, C; Carel, K; DePaolo, D; Leitner, W; Draznin, B			Interactions of protein kinase C with insulin signaling - Influence on GAP and SOS activities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTPASE-ACTIVATING PROTEIN; RAT ADIPOCYTES; PHORBOL ESTERS; RECEPTOR; P21RAS; CELLS; STIMULATION; PHOSPHORYLATION; ACID; METABOLISM	In this study, we investigated the influence of the protein kinase C (PKC)-dependent system upon the ability of insulin to stimulate p21(ras)-GTP loading in 3T3-L1 adipocytes, Activation of PRC by 12-0-tetradecanoyl-phorbol-13-acetate (TPA) did not affect the basal amount of p21(ras)-GTP GTP but significantly reduced insulin-induced increases in p21(ras)-GTP. This reduction was due to inhibition of the insulin's ability to stimulate guanine nucleotide exchange activity of Sos in cells incubated with 100 nw TPA for either 30 min or 3 h, TPA had no effect on basal activity of Sos. Depletion of PKC by an 18-h incubation with TPA or inhibition by bisindolylmaleimide resulted in profound inhibition of the insulin-induced p21(ras)-GTP loading. In contrast to PRC activation, removal of PK did not influence Sos activity but resulted in a 2-fold stimulation of GTPase activating protein (GAP), This effect of PB;C depletion is unique to 3T3-L1 adipocytes and was not observed in either 3T3-L1 fibroblasts or Rat-1 fibroblasts. Thus, it appears that in 3T3-L1 adipocytes, PKC has a constitutive inhibitory effect on GAP that permits insulin to activate Sos and p21(ras). Removal of this inhibitory influence activates GAP and reduces insulin-stimulated p21(ras)-GTP loading.	VET AFFAIRS MED CTR,SECT ENDOCRINOL 111H,MED RES SERV,DENVER,CO 80220; VET AFFAIRS MED CTR,DEPT MED,DENVER,CO 80220; UNIV COLORADO,HLTH SCI CTR,DENVER,CO 80220	US Department of Veterans Affairs; Veterans Health Administration (VHA); US Department of Veterans Affairs; Veterans Health Administration (VHA); University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver								BERTI L, 1994, J BIOL CHEM, V269, P3381; BOLLAG GE, 1986, P NATL ACAD SCI USA, V83, P5822, DOI 10.1073/pnas.83.16.5822; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHERQUI G, 1986, ENDOCRINOLOGY, V118, P1759, DOI 10.1210/endo-118-5-1759; CHIN JE, 1993, J BIOL CHEM, V268, P6338; COGHLAN MP, 1994, BIOCHEM J, V303, P893, DOI 10.1042/bj3030893; DANIELSEN AG, 1995, J BIOL CHEM, V270, P21600, DOI 10.1074/jbc.270.37.21600; DePaolo D, 1996, MOL CELL BIOL, V16, P1450; DOWNWARD J, 1990, NATURE, V346, P719, DOI 10.1038/346719a0; DRAZNIN B, 1993, J BIOL CHEM, V268, P19998; FARESE RV, 1988, AM J MED, V85, P36, DOI 10.1016/0002-9343(88)90396-8; FARESE RV, 1984, J BIOL CHEM, V259, P7094; GOLUBIC M, 1991, EMBO J, V10, P2897, DOI 10.1002/j.1460-2075.1991.tb07839.x; HII CST, 1995, J BIOL CHEM, V270, P4201, DOI 10.1074/jbc.270.9.4201; JHUN BH, 1994, J BIOL CHEM, V269, P5699; KIRSCH D, 1985, BIOCHEM BIOPH RES CO, V128, P824, DOI 10.1016/0006-291X(85)90121-4; LANGLOIS J, 1995, ENDOCRINE, V3, P475, DOI 10.1007/BF02738820; LEWIS RE, 1990, BIOCHEMISTRY-US, V29, P1807, DOI 10.1021/bi00459a020; LEWIS RE, 1994, J BIOL CHEM, V269, P26259; LIN F, 1994, FEBS LETT, V352, P389; MEDEMA RH, 1991, J BIOL CHEM, V266, P21186; MEDEMA RH, 1993, MOL CELL BIOL, V13, P155, DOI 10.1128/MCB.13.1.155; MESSINA JL, 1987, ENDOCRINOLOGY, V121, P1227, DOI 10.1210/endo-121-4-1227; MUHLBACHER C, 1988, BIOCHEM J, V249, P865; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; RESNICK RJ, 1994, J BIOL CHEM, V269, P32336; SATOH T, 1992, J BIOL CHEM, V267, P24149; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; STANDAERT ML, 1987, ENDOCRINOLOGY, V121, P941, DOI 10.1210/endo-121-3-941; TAKAYAMA S, 1988, J BIOL CHEM, V263, P3440; TSAI MH, 1989, SCIENCE, V243, P522, DOI 10.1126/science.2536192; VANDEWERVE G, 1985, BIOCHEM J, V225, P523, DOI 10.1042/bj2250523; YU CL, 1990, MOL CELL BIOL, V10, P6683, DOI 10.1128/MCB.10.12.6683	34	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15311	15314		10.1074/jbc.271.26.15311	http://dx.doi.org/10.1074/jbc.271.26.15311			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663173	hybrid			2022-12-27	WOS:A1996UV29900004
J	Dannelly, HK; Roseman, S				Dannelly, HK; Roseman, S			Active site phosphorylation of enzyme I of the bacterial phosphotransferase system by an ATP-dependent kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; SUGAR-TRANSPORT; SALMONELLA-TYPHIMURIUM; ISOCITRATE DEHYDROGENASE; ACETATE KINASE; PYRUVATE; PROTEINS; LYASE; PHOSPHOENOLPYRUVATE; PURIFICATION	Enzyme I (EI) of the bacterial phosphoenolpyruvate: glycose phosphotransferase system (PTS) is autocatalytically phosphorylated by P-enolpyruvate. We report here an ATP-dependent kinase (EI-K) from Escherichia coli that reversibly phosphorylates EI at its active site histidine; ATP and EI-K can therefore replace P-enolpyruvate. EI-K contains a bound cofactor that is lost during purification with concomitant loss of activity. NAD(+) and NADP(+) substitute for the cofactor and restore activity to the apoenzyme, whereas their analogues are inactive. The pyridine nucleotides do not activate EI-K by covalent modification (e.g. ADP-ribosylation), but must be present during the kinase reaction. NADH and NADPH are potent inhibitors of EI-K at all stages of purity, and enzyme activity in a mixture of NAD(+) and NADH depends on the ratio of the two pyridine nucleotides. Inhibition is observed with reduced beta-NMN and alpha-NADH, but neither is as effective as beta-NADH. The reverse reaction, the transfer of the phosphoryl moiety from phospho-EI to ADP, also requires NAD(+) or NADP(+). In the absence of NAD(+) or NADH, [P-32]phospho-EI is hydrolyzed to P-32(i), suggesting that EI-K can act as a phospho-EI phosphatase. EI kinase may serve as a link between PTS-driven sugar transport and the electron transport chain.	JOHNS HOPKINS UNIV,DEPT BIOL,BALTIMORE,MD 21218; JOHNS HOPKINS UNIV,MCCOLLUM PRATT INST,BALTIMORE,MD 21218	Johns Hopkins University; Johns Hopkins University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM038759, R01GM038759] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38759] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN KH, 1990, J BIOL CHEM, V265, P11734; BENESKI DA, 1982, J BIOL CHEM, V257, P4492; BOURRET RB, 1991, ANNU REV BIOCHEM, V60, P401, DOI 10.1146/annurev.bi.60.070191.002153; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CASHEL M, 1969, J CHROMATOGR, V40, P103, DOI 10.1016/S0021-9673(01)96624-5; CHAUVIN F, 1994, J BIOL CHEM, V269, P20263; CHAUVIN F, 1994, J BIOL CHEM, V269, P20270; DANNELLY HK, 1992, P NATL ACAD SCI USA, V89, P11274, DOI 10.1073/pnas.89.23.11274; DANNELLY HK, 1989, BIOCHIMIE, V71, P1095, DOI 10.1016/0300-9084(89)90116-8; DANNELLY HK, 1991, P 91 ANN M AM SOC MI, P238; FOX DK, 1986, J BIOL CHEM, V261, P3487; FOX DK, 1986, J BIOL CHEM, V261, P3498; GARNAK M, 1979, SCIENCE, V203, P1111, DOI 10.1126/science.34215; HESS JF, 1988, CELL, V53, P79, DOI 10.1016/0092-8674(88)90489-8; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LINN TC, 1979, J BIOL CHEM, V254, P1691; MANIATIS T, 1982, MOL CLONING LABORATO, P466; MASON PW, 1981, J BIOL CHEM, V256, P1861; MEADOW ND, 1982, J BIOL CHEM, V257, P4526; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; NEIDHARDT FC, 1987, ESCHERICHIA COLI SAL, P447; NIMMO GA, 1984, EUR J BIOCHEM, V141, P409, DOI 10.1111/j.1432-1033.1984.tb08206.x; PEKALA PH, 1982, PYRIDINE NUCLEOTIDE, P350; POSTMA PW, 1985, MICROBIOL REV, V49, P232, DOI 10.1128/MMBR.49.3.232-269.1985; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; Reed L J, 1981, Curr Top Cell Regul, V18, P95; ROBERTSON EF, 1987, CURR MICROBIOL, V14, P347; ROBERTSON EF, 1988, J BIOL CHEM, V263, P2477; ROBERTSON EF, 1987, ANAL BIOCHEM, V167, P290, DOI 10.1016/0003-2697(87)90166-7; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAIER MH, 1994, MOL MICROBIOL, V13, P755; SNOEP JL, 1992, J GEN MICROBIOL, V138, P2015, DOI 10.1099/00221287-138-10-2015; STOCK JB, 1989, MICROBIOL REV, V53, P450, DOI 10.1128/MMBR.53.4.450-490.1989; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WEIGEL N, 1982, J BIOL CHEM, V257, P4461; WEIGEL N, 1982, J BIOL CHEM, V257, P4477	36	4	4	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15285	15291		10.1074/jbc.271.25.15285	http://dx.doi.org/10.1074/jbc.271.25.15285			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662900				2022-12-27	WOS:A1996UT10600093
J	Thevissen, K; Ghazi, A; DeSamblanx, GW; Brownlee, C; Osborn, RW; Broekaert, WF				Thevissen, K; Ghazi, A; DeSamblanx, GW; Brownlee, C; Osborn, RW; Broekaert, WF			Fungal membrane responses induced by plant defensins and thionins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CULTURED TOBACCO CELLS; ACTIVATED CHANNELS; PYRULARIA THIONIN; CRYSTAL-STRUCTURE; ESCHERICHIA-COLI; INSECT DEFENSIN; MAMMALIAN-CELLS; ION CHANNELS; TIP GROWTH; PEPTIDES	Treatment of hyphae of Neurospora crassa with anti fungal plant defensins, i.e. Rs-AFP2 and Dm-AMP1 isolated from radish and dahlia seed, respectively, induced a rapid K+ efflux, Ca2+ uptake, and alkalinization of the incubation medium, The Rs-AFP2-induced alkalinization of the incubation medium could be inhibited with G-protein inhibitors. alpha-Hordothionin, an antifungal thionin from barley seed, caused a sustained increased Ca2+ uptake at subinhibitory concentrations but only a transient increased uptake at inhibitory concentrations, alpha-Hordothionin also caused increased K+ efflux and alkalinization of the medium, but these fluxes occurred more rapidly compared to those caused by plant defensins. Furthermore, alpha-hordothionin caused permeabilization of fungal hyphae to the non-metabolite alpha aminoisobutyric acid and, in addition, altered the electrical properties of artificial lipid bilayers, consistently leading to rupture of the lipid bilayers, The plant defensins did not form ion permeable pores in artificial membranes and did not exhibit substantial hyphal membrane permeabilization activity, Our results are consistent with the notion that thionins inhibit fungal growth as a result of direct protein-membrane interactions, whereas plant defensins might act via a different, possibly receptor-mediated, mechanism.	KATHOLIEKE UNIV LEUVEN,FA JANSSENS LAB GENET,B-3001 HEVERLEE,BELGIUM; UNIV PARIS 11,URA CNRS 1116,LAB BIOMEMBRANES,F-91405 ORSAY,FRANCE; MARINE BIOL ASSOC UNITED KINGDOM LAB,PLYMOUTH PL1 2PB,DEVON,ENGLAND; ZENECA AGROCHEM,JEALOTTS HILL RES STN,BRACKNELL RG42 6ET,BERKS,ENGLAND	KU Leuven; UDICE-French Research Universities; Universite Paris Saclay; Marine Biological Association United Kingdom			Thevissen, Karin/B-7003-2015	Thevissen, Karin/0000-0003-0275-9072				ATKINSON MM, 1985, PLANT PHYSIOL, V79, P843, DOI 10.1104/pp.79.3.843; BATTEY NH, 1993, NEW PHYTOL, V125, P307, DOI 10.1111/j.1469-8137.1993.tb03883.x; BERRIER C, 1989, FEBS LETT, V259, P27, DOI 10.1016/0014-5793(89)81486-3; BLEIN JP, 1991, PLANT PHYSIOL, V95, P486, DOI 10.1104/pp.95.2.486; BOHLMANN H, 1991, ANNU REV PLANT PHYS, V42, P227, DOI 10.1146/annurev.pp.42.060191.001303; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BONMATIN JM, 1992, J BIOMOL NMR, V2, P235, DOI 10.1007/BF01875319; BOULANGER P, 1988, J BIOL CHEM, V263, P9767; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; BROEKAERT WF, 1990, FEMS MICROBIOL LETT, V69, P55, DOI [10.1111/j.1574-6968.1990.tb04174.x, 10.1016/S0378-1097(98)00477-7]; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; BRUIX M, 1993, BIOCHEMISTRY-US, V32, P715, DOI 10.1021/bi00053a041; Burland T. G., 1984, Mode of action of antifungal agents, P299; CARRASCO L, 1981, EUR J BIOCHEM, V116, P185, DOI 10.1111/j.1432-1033.1981.tb05317.x; COCIANCICH S, 1993, J BIOL CHEM, V268, P19239; EVANS J, 1989, P NATL ACAD SCI USA, V86, P5849, DOI 10.1073/pnas.86.15.5849; FELIX G, 1993, PLANT J, V4, P307, DOI 10.1046/j.1365-313X.1993.04020307.x; FLORACK DEA, 1994, PLANT MOL BIOL, V26, P25, DOI 10.1007/BF00039517; GANZ T, 1994, CURR OPIN IMMUNOL, V6, P584, DOI 10.1016/0952-7915(94)90145-7; Garcia-Olmedo F., 1989, OXFORD SURV PLANT MO, V6, P31; GARRILL A, 1993, EUR J CELL BIOL, V60, P358; GRANADO J, 1995, PLANT PHYSIOL, V107, P485, DOI 10.1104/pp.107.2.485; HILL CP, 1991, SCIENCE, V251, P1481, DOI 10.1126/science.2006422; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOLZ R, 1970, J GEN PHYSIOL, V56, P125, DOI 10.1085/jgp.56.1.125; JACKSON SL, 1993, MICROBIOL REV, V57, P367, DOI 10.1128/MMBR.57.2.367-382.1993; KAGAN BL, 1990, P NATL ACAD SCI USA, V87, P210, DOI 10.1073/pnas.87.1.210; KAZIRO Y, 1991, ANNU REV BIOCHEM, V60, P349, DOI 10.1146/annurev.bi.60.070191.002025; LEHRER RI, 1993, ANNU REV IMMUNOL, V11, P105, DOI 10.1146/annurev.iy.11.040193.000541; Losel D. M., 1990, BIOCH CELL WALLS MEM, P119, DOI DOI 10.1007/978-3-642-74215-6_9; MALHO E, 1995, PLANT CELL, V7, P1173; MALHO R, 1994, PLANT J, V5, P331, DOI 10.1111/j.1365-313X.1994.00331.x; MATHIEU Y, 1991, PLANT J, V1, P333, DOI 10.1046/j.1365-313X.1991.t01-10-00999.x; MILLER AJ, 1990, P NATL ACAD SCI USA, V87, P9348, DOI 10.1073/pnas.87.23.9348; MORENO M, 1994, EUR J BIOCHEM, V223, P135, DOI 10.1111/j.1432-1033.1994.tb18974.x; NURNBERGER T, 1994, CELL, V78, P449, DOI 10.1016/0092-8674(94)90423-5; NURNBERGER T, 1995, P NATL ACAD SCI USA, V92, P2338, DOI 10.1073/pnas.92.6.2338; OKADA T, 1973, AGR BIOL CHEM TOKYO, V37, P2289, DOI 10.1080/00021369.1973.10861004; OSBORN RW, 1995, FEBS LETT, V368, P257, DOI 10.1016/0014-5793(95)00666-W; SCHEEL D, 1991, ADV MOL GENETICS PLA, V1, P373; SLAYMAN CL, 1965, J GEN PHYSIOL, V49, P93, DOI 10.1085/jgp.49.1.93; SLAYMAN CL, 1965, J GEN PHYSIOL, V49, P69, DOI 10.1085/jgp.49.1.69; TEETER MM, 1990, PROTEINS, V8, P118, DOI 10.1002/prot.340080203; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TERRAS FRG, 1995, PLANT CELL, V7, P573, DOI 10.1105/tpc.7.5.573; TERRAS FRG, 1993, PLANT PHYSIOL, V103, P1311, DOI 10.1104/pp.103.4.1311; VERNON LP, 1992, TOXICON, V30, P701, DOI 10.1016/0041-0101(92)90004-O; VIARD MP, 1994, PLANT PHYSIOL, V104, P1245, DOI 10.1104/pp.104.4.1245; WALL F, 1995, MOL MEMBR BIOL, V12, P183	49	246	269	0	21	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15018	15025		10.1074/jbc.271.25.15018	http://dx.doi.org/10.1074/jbc.271.25.15018			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663029				2022-12-27	WOS:A1996UT10600058
J	Yee, MC; Horn, V; Yanofsky, C				Yee, MC; Horn, V; Yanofsky, C			On the role of helix 0 of the tryptophan synthetase alpha chain of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SALMONELLA-TYPHIMURIUM; 3-DIMENSIONAL STRUCTURE; SECONDARY STRUCTURE; BARREL PROTEIN; SYNTHASE-BETA; SUBUNIT; GENES; POLYPEPTIDE; EVOLUTION; MECHANISM	The role of helix 0 of the alpha chain (TrpA) of the tryptophan synthetase alpha(2) beta(2) multi-functional enzyme complex of Escherichia coli was examined by deleting aminoterminal residues 2-6, 2-11, or 2-19 of TrpA, Selected substitutions were also introduced at TrpA positions 2-6, The altered genes encoding these polypeptides were overexpressed from a foreign promoter on a multicopy plasmid and following insertion at their normal chromosomal location, Each deletion polypeptide was functional in vivo, However all appeared to be somewhat more labile and insoluble and less active enzymatically than wild type TrpA, The deletion polypeptides were overproduced and solubilized from cell debris by denaturation and refolding, Several were partially purified and assayed in various reactions in the presence of tryptophan synthetase beta(2) (TrpB), The purified Trp Delta Delta 2-6 and Trp Delta Delta 2-11 deletion polypeptides had low activity in both the indole + serine --> tryptophan reaction and the indoleglycerol phosphate + serine --> tryptophan reaction, Poor activity in each reaction was partly due to reduced association of TrpA with TrpB, The addition of the TrpA ligands, alpha-glycerophosphate or indoleglycerol phosphate, during catalysis of the indole + serine --> tryptophan reaction increased association and activity, These findings suggest that removal of helix 0 of TrpA decreases TrpA-TrpB association as well as the activity of the TrpA active site, Alignment of the TrpA sequences from different species indicates that several lack part or all of helix 0. In some of these polypeptides, extra residues at the carboxyl end may substitute for helix 0.	STANFORD UNIV, DEPT BIOL SCI, STANFORD, CA 94305 USA	Stanford University								BANIK U, 1995, BIOCHEMISTRY-US, V34, P12704, DOI 10.1021/bi00039a029; BURNS DM, 1990, J BIOL CHEM, V265, P2060; BURNS DM, 1989, J BIOL CHEM, V264, P3840; CRAWFORD IP, 1987, PROTEINS, V2, P118, DOI 10.1002/prot.340020206; CRAWFORD IP, 1987, J BIOL CHEM, V262, P239; CRAWFORD IP, 1989, ANNU REV MICROBIOL, V43, P567, DOI 10.1146/annurev.mi.43.100189.003031; CREIGHTON TE, 1966, J BIOL CHEM, V241, P980; CREIGHTON TE, 1970, METHODS ENZYMOLOGY A, V17, P365, DOI DOI 10.1021/ACS.BIOCHEM.8B00167; DRAPEAU GR, 1967, J BIOL CHEM, V242, P5434; GARNIER J, 1978, J MOL BIOL, V120, P97, DOI 10.1016/0022-2836(78)90297-8; GOLDBERG ME, 1966, J MOL BIOL, V21, P71, DOI 10.1016/0022-2836(66)90080-5; HATANAKA M, 1962, ARCH BIOCHEM BIOPHYS, V97, P596, DOI 10.1016/0003-9861(62)90129-7; Hennig M, 1995, STRUCTURE, V3, P1295, DOI 10.1016/S0969-2126(01)00267-2; HYDE CC, 1988, J BIOL CHEM, V263, P17857; JACKSON DA, 1969, J BIOL CHEM, V244, P4539; KIRSCHNER K, 1975, EUR J BIOCHEM, V60, P513, DOI 10.1111/j.1432-1033.1975.tb21030.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANE AN, 1984, EMBO J, V3, P279, DOI 10.1002/j.1460-2075.1984.tb01797.x; LAST RL, 1991, PLANT CELL, V3, P345, DOI 10.1105/tpc.3.4.345; LIM WK, 1991, J BIOL CHEM, V266, P20205; LIM WK, 1991, J BACTERIOL, V173, P1886, DOI 10.1128/jb.173.6.1886-1893.1991; LUGER K, 1989, SCIENCE, V243, P206, DOI 10.1126/science.2643160; Miles E W, 1995, Subcell Biochem, V24, P207; MILES EW, 1987, METHOD ENZYMOL, V142, P398; MILTON DL, 1986, J BIOL CHEM, V261, P6604; NAVON A, 1995, J BIOL CHEM, V270, P4255, DOI 10.1074/jbc.270.9.4255; NICHOLS BP, 1979, P NATL ACAD SCI USA, V76, P5244, DOI 10.1073/pnas.76.10.5244; OGASAHARA K, 1992, J BIOL CHEM, V267, P5222; OHTA N, 1994, CURR GENET, V25, P357, DOI 10.1007/BF00351490; PRIESTLE JP, 1987, P NATL ACAD SCI USA, V84, P5690, DOI 10.1073/pnas.84.16.5690; REARDON D, 1995, FASEB J, V9, P497, DOI 10.1096/fasebj.9.7.7737457; RUVINOV SB, 1995, J BIOL CHEM, V270, P17333, DOI 10.1074/jbc.270.29.17333; SCHNEIDER WP, 1981, P NATL ACAD SCI-BIOL, V78, P2169, DOI 10.1073/pnas.78.4.2169; SKYRZNIA C, 1989, GENE, V81, P83; STERNER R, 1995, EMBO J, V14, P4395, DOI 10.1002/j.1460-2075.1995.tb00118.x; Swift S, 1991, Biotechnol Genet Eng Rev, V9, P229; SWIFT S, 1992, MOL GEN GENET, V233, P129, DOI 10.1007/BF00587570; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; TSUJI T, 1993, BIOCHEMISTRY-US, V32, P5566, DOI 10.1021/bi00072a011; URFER R, 1992, PROTEIN SCI, V1, P31; VIGNAIS ML, 1995, PROTEIN SCI, V4, P994; VOGEL HJ, 1956, J BIOL CHEM, V218, P97; WOEHL EU, 1995, BIOCHEMISTRY-US, V34, P9466, DOI 10.1021/bi00029a023; WRIGHT AD, 1992, PLANT CELL, V4, P711, DOI 10.1105/tpc.4.6.711; YANG XJ, 1993, J BIOL CHEM, V268, P22269; YANOFSKY C, 1987, J BIOL CHEM, V262, P11584; YANOFSKY C, 1960, BACTERIOL REV, V24, P221, DOI 10.1128/MMBR.24.2.221-245.1960; YANOFSKY C, 1984, J BACTERIOL, V158, P1018, DOI 10.1128/JB.158.3.1018-1024.1984; ZALKIN H, 1982, J BIOL CHEM, V257, P1491; ZHAO GP, 1992, J BIOL CHEM, V267, P526; ZHAO GP, 1994, PLANT PHYSIOL, V104, P461, DOI 10.1104/pp.104.2.461	51	8	12	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14754	14763		10.1074/jbc.271.25.14754	http://dx.doi.org/10.1074/jbc.271.25.14754			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662916	hybrid			2022-12-27	WOS:A1996UT10600021
J	Zhang, JS; Pratt, RE				Zhang, JS; Pratt, RE			The AT(2) receptor selectively associates with G(i alpha 2) and G(i alpha 3) in the rat fetus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BINDING REGULATORY PROTEINS; ANGIOTENSIN-II; ADENYLATE-CYCLASE; ALPHA-SUBUNITS; SUBTYPES; EXPRESSION; INHIBITION; CLONING; GI; IDENTIFICATION	The effects of angiotensin II are mediated by a family of seven transmembrane receptors. In the adult, the majority of the receptors are of the AT(1) isoform, which is coupled to heterotrimeric G proteins (either G(q alpha) or G(i alpha)). In contrast, the AT(2) receptor is expressed at low levels in the adult but is the major form expressed in the fetal and neonatal animal. Previous results have failed to show G protein coupling of the AT(2) receptor in the fetus. We now provide evidence that the AT(2) receptor is G protein-coupled. An antibody that binds several G(alpha) subunits immunoselected angiotensin II receptor-G(alpha) complexes. In addition, G(i alpha 1-3) antibody, which recognizes G(i alpha 1), G(i alpha 2) and G(i alpha 3), also co-immunoselect the AT(2) recep tor. Anti-G(i alpha 2) and anti-G(i alpha 3) antibodies were both able to co-immunoselected AT(2) receptor-G(i alpha) complexes, but consistent with the lack of G(i alpha 1) in the fetal extracts, anti-G(i alpha 1), antibodies did not nor did any other G protein-directed antisera. The finding that AT(2) receptor couples to both G(i alpha 2) and G(i alpha 3) raises the possibility that selective interactions between AT(2) receptor and different G proteins may result in specific cellular effects mediated by AT(2) stimulation.	STANFORD UNIV, SCH MED, FALK CARDIOVASC RES CTR, DIV CARDIOVASC MED, STANFORD, CA 94305 USA	Stanford University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042663, P01HL048638] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 48638, HL 42663] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; BAUKAL AJ, 1994, J BIOL CHEM, V269, P24546; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BOTTARI SP, 1991, EUR J PHARM-MOLEC PH, V207, P157, DOI 10.1016/0922-4106(91)90091-U; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; CIUFFO GM, 1993, P NATL ACAD SCI USA, V90, P11009, DOI 10.1073/pnas.90.23.11009; CODINA J, 1991, METHOD ENZYMOL, V195, P177; DUDLEY DT, 1990, MOL PHARMACOL, V38, P370; DZAU VJ, 1991, HYPERTENSION, V18, P100, DOI 10.1161/01.HYP.18.4_Suppl.II100; EDWARDS RM, 1993, J AM SOC NEPHROL, V3, P1643; FEUILLAN PP, 1993, REGUL PEPTIDES, V44, P159, DOI 10.1016/0167-0115(93)90239-5; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; GUPTA SK, 1992, J BIOL CHEM, V267, P7987; GUTOWSKI S, 1991, J BIOL CHEM, V266, P20519; JOHNSON GL, 1994, J CELL BIOCHEM, V54, P415, DOI 10.1002/jcb.240540408; JOHNSON RA, 1991, METHOD ENZYMOL, V195, P177; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOIBUCHI Y, 1993, HYPERTENSION, V21, P1046, DOI 10.1161/01.HYP.21.6.1046; KOIKE G, 1994, BIOCHEM BIOPH RES CO, V203, P1842, DOI 10.1006/bbrc.1994.2402; LYNCH CJ, 1989, J CLIN INVEST, V83, P2050, DOI 10.1172/JCI114116; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MUMBY S, 1988, J BIOL CHEM, V263, P2020; NAKAJIMA M, 1993, BIOCHEM BIOPH RES CO, V197, P393, DOI 10.1006/bbrc.1993.2492; NAKAJIMA M, 1995, P NATL ACAD SCI USA, V92, P10663, DOI 10.1073/pnas.92.23.10663; NEER EJ, 1995, CELL, V80, P249, DOI 10.1016/0092-8674(95)90407-7; OHMURA T, 1992, J EXP MED, V176, P887, DOI 10.1084/jem.176.3.887; POBINER BF, 1991, MOL PHARMACOL, V40, P156; PUCELL AG, 1991, ENDOCRINOLOGY, V128, P1947, DOI 10.1210/endo-128-4-1947; REMAURY A, 1993, BIOCHEM J, V292, P283, DOI 10.1042/bj2920283; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SECHI LA, 1992, CIRC RES, V71, P1482, DOI 10.1161/01.RES.71.6.1482; SENOGLES SE, 1994, J BIOL CHEM, V269, P23120; SHINOHARA H, 1992, J NEUROSCI, V12, P1275; SIEMENS IR, 1994, J NEUROCHEM, V62, P2106; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SUNG CP, 1994, J PHARMACOL EXP THER, V271, P429; TAKAHASI K, 1994, BIOCHEM BIOPH RES CO, V198, P60, DOI 10.1006/bbrc.1994.1009; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; TIAN Y, 1995, AM J PHYSIOL-ENDOC M, V268, pE135, DOI 10.1152/ajpendo.1995.268.1.E135; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUTSUMI K, 1992, MOL PHARMACOL, V41, P290; TSUTSUMI K, 1993, BRAIN RES, V631, P212, DOI 10.1016/0006-8993(93)91537-3; VISWANATHAN M, 1991, BIOCHEM BIOPH RES CO, V179, P1361, DOI 10.1016/0006-291X(91)91723-P; WILLIAMS AG, 1990, BLOOD, V76, P721; WONG PC, 1990, J PHARMACOL EXP THER, V255, P584; YATANI A, 1988, NATURE, V336, P680, DOI 10.1038/336680a0	49	104	106	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15026	15033		10.1074/jbc.271.25.15026	http://dx.doi.org/10.1074/jbc.271.25.15026			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663053	hybrid			2022-12-27	WOS:A1996UT10600059
J	Glerum, DM; Shtanko, A; Tzagoloff, A				Glerum, DM; Shtanko, A; Tzagoloff, A			Characterization of COX17, a yeast gene involved in copper metabolism and assembly of cytochrome oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MITOCHONDRIAL MESSENGER-RNA; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; SUBUNIT-II; PET GENES; PROTEIN; LOCALIZATION; TRANSLATION; EXPRESSION; PRODUCTS	Mutations in the COX17 gene of Saccharomyces cerevisiae cause a respiratory deficiency due to a block. in the production of a functional cytochrome oxidase complex, Because cox17 mutants are able to express both the mitochondrially and nuclearly encoded subunits of cytochrome oxidase, the Cox17p most likely affects some late posttranslational step of the assembly pathway, A fragment of yeast nuclear DNA capable of complementing the mutation has been cloned by transformation of the cox17 mutant with a library of genomic DNA. Subcloning and sequencing of the COX17 gene revealed that it codes for a cysteine-rich protein with a molecular weight of 8,057. Unlike other previously described accessory factors involved in cytochrome oxidase assembly, all of which are components of mitochondria, Cox17p is a cytoplasmic protein, The cytoplasmic location of Cox17p suggested that it might have a function in delivery of a prosthetic group to the holoenzyme. A requirement of Cox17p in providing the copper prosthetic group of cytochrome oxidase is supported by the finding that a cox17 null mutant is rescued by the addition of copper to the growth medium. Evidence is presented indicating that Cox17p is not involved in general copper metabolism in yeast but rather has a more specific function in the delivery of copper to mitochondria.	COLUMBIA UNIV, DEPT BIOL SCI, NEW YORK, NY 10027 USA	Columbia University			Glerum, Moira/AHD-3271-2022		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050187] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM50187, R01 GM050187] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ASKWITH C, 1994, CELL, V76, P403, DOI 10.1016/0092-8674(94)90346-8; Beauchamp Charles, ANAL BIOCHEM, V44, P276, DOI [10.1016/0003-2697(71)90370-8, DOI 10.1016/0003-2697(71)90370-8]; BONNEFOY N, 1994, J MOL BIOL, V239, P201, DOI 10.1006/jmbi.1994.1363; BOTSTEIN D, 1982, MOL BIOL YEAST SACCH, P607; COSTANZO MC, 1986, EMBO J, V5, P3637, DOI 10.1002/j.1460-2075.1986.tb04693.x; DANCIS A, 1994, CELL, V76, P393, DOI 10.1016/0092-8674(94)90345-X; DANCIS A, 1994, J BIOL CHEM, V269, P25660; FAYE G, 1974, J MOL BIOL, V88, P105, DOI 10.1016/0022-2836(74)90304-0; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GLERUM DM, 1995, J BIOL CHEM, V270, P15585, DOI 10.1074/jbc.270.26.15585; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Maniatis T., 1982, MOL CLONING; MAXAM AM, 1977, P NATL ACAD SCI USA, V74, P560, DOI 10.1073/pnas.74.2.560; MCEWEN JE, 1993, CURR GENET, V23, P9, DOI 10.1007/BF00336742; MURTIF VL, 1985, P NATL ACAD SCI USA, V82, P5617, DOI 10.1073/pnas.82.17.5617; MYERS AM, 1985, EMBO J, V4, P2087, DOI 10.1002/j.1460-2075.1985.tb03896.x; NOBREGA MP, 1990, J BIOL CHEM, V265, P14220; PEL HJ, 1992, CURR GENET, V21, P139, DOI 10.1007/BF00318473; POUTRE CG, 1987, GENETICS, V115, P637; RIPMASTER TL, 1992, P NATL ACAD SCI USA, V89, P11131, DOI 10.1073/pnas.89.23.11131; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHMIDT RJ, 1984, MOL BIOL EVOL, V1, P317; SCHULZE M, 1989, MOL GEN GENET, V216, P37, DOI 10.1007/BF00332228; SERAPHIN B, 1988, EMBO J, V7, P1455, DOI 10.1002/j.1460-2075.1988.tb02963.x; SPENO H, 1995, J BIOL CHEM, V270, P25363, DOI 10.1074/jbc.270.43.25363; ten Berge A M, 1974, Mol Gen Genet, V131, P113; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; TZAGOLOFF A, 1993, BIOCHEM MOL BIOL INT, V31, P593; TZAGOLOFF A, 1990, MICROBIOL REV, V54, P211, DOI 10.1128/MMBR.54.3.211-225.1990; TZAGOLOFF A, 1975, J BIOL CHEM, V250, P8228; WEISIGER RA, 1973, J BIOL CHEM, V248, P4793; YUAN DS, 1995, P NATL ACAD SCI USA, V92, P2632, DOI 10.1073/pnas.92.7.2632	37	399	408	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14504	14509		10.1074/jbc.271.24.14504	http://dx.doi.org/10.1074/jbc.271.24.14504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662933	hybrid			2022-12-27	WOS:A1996UQ66000083
J	Mao, ZX; NadalGinard, B				Mao, ZX; NadalGinard, B			Functional and physical interactions between mammalian achaete-scute homolog 1 and myocyte enhancer factor 2A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTORS; DNA-BINDING; REGULATORY ELEMENTS; CARCINOMA-CELLS; GENE; DIFFERENTIATION; EXPRESSION; PROTEIN; IDENTIFICATION; INDUCTION	The mammalian achaete-scute homolog 1 (MASH1) protein is required for the early development of the nervous system. However, the molecular and biochemical mechanism by which MASH1 acts to determine neurogenesis are still unknown. The myocyte enhancer factor 2A (MEF2A) is a MADS transcription factor that is essential for the specification and differentiation of the muscle lineage. Here we show that MEF2A and MASH1 are coordinately induced during the differentiation of the teratocarcinoma cell line P19 along a neuronal lineage and that in transient transfection assays, MEF2A and MASH1 cooperatively activate gene expression, This cooperativity appears to be due to a specific physical interaction between MEF2A and MASH1. Taken together, these findings suggest that MASH1 via a cooperative interaction with MEF2A may regulate the expression of specific genes that are critical for neuronal differentiation.	HARVARD UNIV,SCH MED,DEPT CELL BIOL & PEDIAT,BOSTON,MA 02115	Harvard University; Harvard Medical School	Mao, ZX (corresponding author), HARVARD UNIV,CHILDRENS HOSP,SCH MED,DEPT CARDIOL,DIV NEUROSCI,BOSTON,MA 02115, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [T32NS007009] Funding Source: NIH RePORTER; NINDS NIH HHS [5-T32-NS07009-16] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BREITBART RE, 1993, DEVELOPMENT, V118, P1095; CHANGELIAN PS, 1989, P NATL ACAD SCI USA, V86, P377, DOI 10.1073/pnas.86.1.377; CLARKE AR, 1992, NATURE, V359, P328, DOI 10.1038/359328a0; EDMONDSON DG, 1994, DEVELOPMENT, V120, P1251; GU W, 1993, CELL, V72, P309, DOI 10.1016/0092-8674(93)90110-C; HIRSCH MR, 1990, MOL CELL BIOL, V10, P1959, DOI 10.1128/MCB.10.5.1959; HOBSON GM, 1988, NUCLEIC ACIDS RES, V16, P8925, DOI 10.1093/nar/16.18.8925; JACKS T, 1992, NATURE, V359, P295, DOI 10.1038/359295a0; JAN YN, 1993, CELL, V75, P827, DOI 10.1016/0092-8674(93)90525-U; JOHNSON JE, 1992, DEVELOPMENT, V114, P75; JONESVILLENEUVE EMV, 1983, MOL CELL BIOL, V3, P2271, DOI 10.1128/MCB.3.12.2271; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KAUSHAL S, 1994, SCIENCE, V266, P1236, DOI 10.1126/science.7973707; LEE EYHP, 1992, NATURE, V359, P288, DOI 10.1038/359288a0; LEIFER D, 1993, P NATL ACAD SCI USA, V90, P1546, DOI 10.1073/pnas.90.4.1546; LIPKOWITZ S, 1992, J BIOL CHEM, V267, P21065; LO LC, 1991, GENE DEV, V5, P1524, DOI 10.1101/gad.5.9.1524; LYONS GE, 1995, J NEUROSCI, V15, P5727, DOI 10.1523/jneurosci.15-08-05727.1995; MA PCM, 1994, CELL, V77, P451, DOI 10.1016/0092-8674(94)90159-7; MARTIN JF, 1993, P NATL ACAD SCI USA, V90, P5282, DOI 10.1073/pnas.90.11.5282; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; MCDERMOTT JC, 1993, MOL CELL BIOL, V13, P2564, DOI 10.1128/MCB.13.4.2564; STAINES WA, 1994, NEUROSCIENCE, V58, P735, DOI 10.1016/0306-4522(94)90451-0; SUN XH, 1991, CELL, V64, P459, DOI 10.1016/0092-8674(91)90653-G; YU YT, 1992, GENE DEV, V6, P1783, DOI 10.1101/gad.6.9.1783	26	38	42	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14371	14375		10.1074/jbc.271.24.14371	http://dx.doi.org/10.1074/jbc.271.24.14371			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662987	hybrid			2022-12-27	WOS:A1996UQ66000065
J	Odermatt, A; Kurzydlowski, K; MacLennan, DH				Odermatt, A; Kurzydlowski, K; MacLennan, DH			The V-max of the Ca2+-ATPase of cardiac sarcoplasmic reticulum (SERCA2a) is not altered by Ca2+/Calmodulin dependent phosphorylation or by interaction with phospholamban	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-TRANSPORT; PROTEIN-KINASE; CA-2+ PUMP; MONOCLONAL-ANTIBODY; RYANODINE RECEPTOR; SKELETAL-MUSCLE; CALMODULIN; ATPASE; CA-2+-ATPASE; STIMULATION	Earlier studies (Hawkins, C., Xu, A., and Narayanan, N. (1994) J. Biol. Chem. 269, 31198-31206) have suggested that the V-max of Ca2+ uptake is enhanced up to 2-fold through phosphorylation of Ser(38) in the cardiac Ca2+-ATPase (SERCA2a) by calmodulin-dependent protein kinase (CaM kinase), It is difficult, however, to determine whether stimulation is caused by phosphorylation of the Ca2+-ATPase or by phosphorylation of phospholamban in cardiac microsomes. We have expressed SERCA2a in HEK-293 cells in the presence or absence of phospholamban and measured the effects on Ca2+ uptake activity of phosphorylation of microsomal proteins by CaM kinase or protein kinase A (PKA), We found no effect on the V-max of Ca2+ uptake following phosphorylation by CaM kinase or PKA in either the presence or absence of phospholamban, The K-0.5 for Ca2+ dependence of Ca2+ transport, however, was shifted following phosphorylation by either CaM kinase or PKA in those microsomes containing both SERCA2a and phospholamban, but not in those expressing only SERCA2a. Thus, we cannot confirm earlier reports of stimulation of SERCA2a activity by CaM kinase II phosphorylation of Ser(38). Our studies, however, emphasize the need for adequate controls for measurement of V-max.	UNIV TORONTO, CHARLES H BEST INST, BANTING & BEST DEPT MED RES, TORONTO, ON M5G 1L6, CANADA	University of Toronto				Odermatt, Alex/0000-0002-6820-2712				BRANDL CJ, 1986, CELL, V44, P597, DOI 10.1016/0092-8674(86)90269-2; BRICKEY DA, 1990, BIOCHEM BIOPH RES CO, V173, P578, DOI 10.1016/S0006-291X(05)80074-9; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; BURK SE, 1989, J BIOL CHEM, V264, P18561; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CATTERALL WA, 1991, CELL, V64, P871, DOI 10.1016/0092-8674(91)90309-M; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; CHANG KH, 1992, BIOCHEMISTRY-US, V31, P4074; CHIESI M, 1989, FEBS LETT, V244, P240; FABIATO A, 1988, METHOD ENZYMOL, V157, P378; FUJII J, 1988, FEBS LETT, V277, P51; GASSER JT, 1986, BIOCHEMISTRY-US, V25, P7615, DOI 10.1021/bi00371a052; GUPTA RC, 1988, MEMBRANE BIOCHEM, V7, P73; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HAWKINS C, 1995, MOL CELL BIOCHEM, V142, P131, DOI 10.1007/BF00928934; HIDAKA H, 1981, P NATL ACAD SCI-BIOL, V78, P4354, DOI 10.1073/pnas.78.7.4354; INUI M, 1986, J BIOL CHEM, V261, P1794; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; KAUFMAN RJ, 1989, MOL CELL BIOL, V9, P946, DOI 10.1128/MCB.9.3.946; KIM HW, 1990, J BIOL CHEM, V265, P1702; KINGSTON RE, 1992, CURRENT PROTOCOLS MO; KIRCHBERGER MA, 1982, J BIOL CHEM, V257, P5685; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KRANIAS EG, 1985, J BIOL CHEM, V260, P1006; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LOPASCHUK G, 1980, BIOCHEMISTRY-US, V19, P5603, DOI 10.1021/bi00565a022; LYTTON J, 1988, J BIOL CHEM, V263, P15024; Mac Lennan D H, 1974, Recent Adv Stud Cardiac Struct Metab, V4, P507; MACLENNAN DH, 1985, NATURE, V316, P696, DOI 10.1038/316696a0; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MCINTOSH DB, 1978, J BIOL CHEM, V253, P5140; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SEIFERT J, 1986, BIOCHIM BIOPHYS ACTA, V861, P399, DOI 10.1016/0005-2736(86)90447-5; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P1333; SUZUKI T, 1986, J BIOL CHEM, V261, P7018; TADA M, 1979, J BIOL CHEM, V254, P319; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1982, ANNU REV PHYSIOL, V44, P401, DOI 10.1146/annurev.ph.44.030182.002153; TADA M, 1988, METHOD ENZYMOL, V157, P107; TAKASAGO T, 1991, J BIOCHEM-TOKYO, V109, P163, DOI 10.1093/oxfordjournals.jbchem.a123339; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TOYOFUKU T, 1992, J BIOL CHEM, V267, P14490; TUANA BS, 1984, J BIOL CHEM, V259, P6979; VORHERR T, 1993, PROTEIN SCI, V2, P339; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; XU A, 1993, J BIOL CHEM, V268, P8394; XU ZC, 1989, J BIOL CHEM, V264, P16644; ZAHRADNIKOVA A, 1993, BIOPHYS J, V64, P991, DOI 10.1016/S0006-3495(93)81465-6	52	107	109	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14206	14213		10.1074/jbc.271.24.14206	http://dx.doi.org/10.1074/jbc.271.24.14206			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662932				2022-12-27	WOS:A1996UQ66000042
J	Piedrafita, FJ; Molander, RB; Vansant, G; Orlova, EA; Pfahl, M; Reynolds, WF				Piedrafita, FJ; Molander, RB; Vansant, G; Orlova, EA; Pfahl, M; Reynolds, WF			An Alu element in the myeloperoxidase promoter contains a composite SP1-thyroid hormone-retinoic acid response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ACUTE PROMYELOCYTIC LEUKEMIA; THYROID-HORMONE; GENE-EXPRESSION; MYELOID-LEUKEMIA; RECEPTOR-ALPHA; RAR-ALPHA; SIGNALING PATHWAYS; DNA-BINDING; HL-60 CELLS; X-RECEPTOR	An Alu element preceding the myeloperoxidase gene (MPO) contains four hexamer motifs related to the consensus recognition sequence for nuclear hormone receptors (AGGTCA), arranged as direct repeats with spacing of 2, 4, and 2 nucleotides (DR-2-4-2), Gel shift experiments and transient transfection assays demonstrate that these sequences include binding sites for retinoic acid and thyroid hormone receptors and function in vivo to activate transcription of a chloramphenicol acetyl-transferase reporter gene, The first DR-2 elements of the series do not bind known receptors but do bind the SP1 transcription factor, Two alleles of the MPO gene exist that differ at one position within this element, resulting in one allele with and one without a strong SP1 binding site, The element with the SP1 site activates transcription by 25-fold in transient transfection assays, while the alternative allele confers severalfold less transcriptional activity, Most cases of acute myelocytic leukemia are homozygous for the allele with the SP1 binding site, suggesting this element plays an important role in regulating the MPO gene in myeloid leukemias, This MPO-Alu is a representative of an Alu subclass numbering similar to 400,000 copies, suggesting many genes may be regulated by such elements.	SIDNEY KIMMEL CANC CTR,SAN DIEGO,CA 92121						NATIONAL CENTER FOR RESEARCH RESOURCES [R01RR009118] Funding Source: NIH RePORTER; NCRR NIH HHS [RR09118-09] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AUSTIN GE, 1993, LEUKEMIA, V7, P1145; BAINTON DF, 1971, J EXP MED, V134, P907, DOI 10.1084/jem.134.4.907; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BENNETT JM, 1985, ANN INTERN MED, V103, P620, DOI 10.7326/0003-4819-103-4-620; BRINI AT, 1993, J BIOL CHEM, V268, P1355; BRITTEN RJ, 1988, P NATL ACAD SCI USA, V85, P4770, DOI 10.1073/pnas.85.13.4770; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P5992, DOI 10.1073/pnas.91.13.5992; BRITTEN RJ, 1994, P NATL ACAD SCI USA, V91, P6148, DOI 10.1073/pnas.91.13.6148; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; CHEN Z, 1993, EMBO J, V12, P1161, DOI 10.1002/j.1460-2075.1993.tb05757.x; COLLINS SJ, 1990, MOL CELL BIOL, V10, P2154, DOI 10.1128/MCB.10.5.2154; CONSTANTIN D, 1994, ENVIRON HEALTH PERSP, V102, P161, DOI 10.2307/3431947; DEININGER PL, 1992, TRENDS GENET, V8, P307, DOI 10.1016/0168-9525(92)90262-3; DETHE H, 1991, CELL, V66, P675, DOI 10.1016/0092-8674(91)90113-D; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1474; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAMBOR JE, 1993, MOL CELL BIOL, V13, P7056, DOI 10.1128/MCB.13.11.7056; HASHINAKA K, 1988, BIOCHEMISTRY-US, V27, P5906, DOI 10.1021/bi00416a013; HELLSTRAND K, 1992, J INTERFERON RES, V12, P199, DOI 10.1089/jir.1992.12.199; HERMANN T, 1993, ONCOGENE, V8, P55; HEWITT SM, 1995, J BIOL CHEM, V270, P17908, DOI 10.1074/jbc.270.30.17908; HUANG ME, 1988, BLOOD, V72, P567, DOI 10.1182/blood.V72.2.567.567; HULL MW, 1994, MOL CELL BIOL, V14, P1266, DOI 10.1128/MCB.14.2.1266; KADLUBAR FF, 1992, ENVIRON HEALTH PERSP, V98, P69, DOI 10.2307/3431249; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KAKIZUKA A, 1991, CELL, V66, P663, DOI 10.1016/0092-8674(91)90112-C; KASTNER P, 1992, EMBO J, V11, P629, DOI 10.1002/j.1460-2075.1992.tb05095.x; KLEBANOFF SJ, 1980, ANN INTERN MED, V93, P480, DOI 10.7326/0003-4819-93-3-480; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KLIEWER SA, 1992, NATURE, V358, P771, DOI 10.1038/358771a0; KOEFFLER HP, 1985, BLOOD, V65, P484; KUROKAWA R, 1993, GENE DEV, V7, P1423, DOI 10.1101/gad.7.7b.1423; LANOTTE M, 1991, BLOOD, V77, P1080; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NORRIS J, 1995, J BIOL CHEM, V270, P22777, DOI 10.1074/jbc.270.39.22777; PANDOLFI PP, 1991, ONCOGENE, V6, P1285; PERLMANN T, 1993, GENE DEV, V7, P1411, DOI 10.1101/gad.7.7b.1411; PETRUSKA JM, 1992, CARCINOGENESIS, V13, P1075, DOI 10.1093/carcin/13.7.1075; PFAHL M, 1994, VITAM HORM, V49, P327; PIEDRAFITA FJ, 1994, INDUCIBLE GENE EXPRE, V2, P157; PIEDRAFITA RJ, 1995, MOL ENDOCRINOL, V9, P563; RAMOS CL, 1995, BIOCHEM PHARMACOL, V49, P1079, DOI 10.1016/0006-2952(95)98504-3; ROBERTSON KA, 1992, BLOOD, V80, P1885; SAFFER JD, 1989, MOL CELL BIOL, V9, P355, DOI 10.1128/MCB.9.2.355; SAGOH T, 1988, ARCH BIOCHEM BIOPHYS, V262, P599, DOI 10.1016/0003-9861(88)90411-0; SUTCLIFFE JG, 1984, SCIENCE, V225, P1308, DOI 10.1126/science.6474179; THOREY IS, 1993, MOL CELL BIOL, V13, P6742, DOI 10.1128/MCB.13.11.6742; TOBLER A, 1988, J CELL PHYSIOL, V136, P215, DOI 10.1002/jcp.1041360203; UMESONO K, 1991, CELL, V65, P1255, DOI 10.1016/0092-8674(91)90020-Y; VANRENSBURG CEJ, 1992, MUTAT RES, V265, P255, DOI 10.1016/0027-5107(92)90054-6; VANSANT G, 1995, P NATL ACAD SCI USA, V92, P8229, DOI 10.1073/pnas.92.18.8229; YAMADA M, 1984, J BIOL CHEM, V259, P3021; ZAKI SR, 1989, BLOOD, V74, P2096; ZHANG X, 1991, MOL ENDOCRINOL, V5, P1909, DOI 10.1210/mend-5-12-1909; ZHANG XK, 1993, TRENDS ENDOCRIN MET, V4, P156, DOI 10.1016/1043-2760(93)90105-N; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	59	352	366	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14412	14420		10.1074/jbc.271.24.14412	http://dx.doi.org/10.1074/jbc.271.24.14412			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662930	hybrid			2022-12-27	WOS:A1996UQ66000071
J	Leem, JY; Nishimura, C; Kurata, S; Shimada, I; Kobayashi, A; Natori, S				Leem, JY; Nishimura, C; Kurata, S; Shimada, I; Kobayashi, A; Natori, S			Purification and characterization of N-beta-alanyl-5-S-glutathionyl-3,4-dihydroxyphenylalanine, a novel antibacterial substance of sarcophaga peregrina (flesh fly)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-FREE IMMUNITY; GENE-CLUSTER; MOLECULAR-CLONING; SARCOTOXIN-I; KAPPA-B; PROTEIN; EXPRESSION; HEMOLYMPH; CECROPIA; LARVAE	We purified a novel antibacterial substance from immunized adult Sarcophaga and determined its molecular structure to be N-beta-alanyl-5-S-glutathionyl 3,4-dihydroxyphenylalanine (5-S-GAD), We synthesized 5-S-GAD enzymatically from N-beta-alanyl-3,4-dihydroxyphenylalanine (beta-Ala-Dopa) and reduced glutathione (GSH), The antibacterial activity of 5-S-GAD was found to be due to its production of H2O2. This is a novel antibacterial mechanism as it differs from the mechanisms of known antibacterial peptides, Two possible roles of 5-S-GAD in insect immunity, suppression of bacterial growth and activation of a Rel family transcription factor, are proposed.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								ANDO K, 1988, BIOCHEMISTRY-US, V13, P59; ANDO K, 1987, BIOCHEMISTRY-US, V27, P226; BABA K, 1987, J BIOCHEM-TOKYO, V102, P69, DOI 10.1093/oxfordjournals.jbchem.a122042; BODNARYK RP, 1969, COMP BIOCHEM PHYSIOL, V30, P909, DOI 10.1016/0010-406X(69)90046-2; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; BOMAN HG, 1991, CELL, V65, P205, DOI 10.1016/0092-8674(91)90154-Q; BULET P, 1993, J BIOL CHEM, V268, P14893; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; ISHIKAWA M, 1992, BIOCHEM J, V287, P573, DOI 10.1042/bj2870573; ISHIKAWA T, 1993, STRUCTURE FUNCTION G, P211; ITO S, 1983, BIOCHEM PHARMACOL, V32, P2079, DOI 10.1016/0006-2952(83)90429-X; KANAI A, 1989, FEBS LETT, V258, P199, DOI 10.1016/0014-5793(89)81652-7; KANAI A, 1990, MOL CELL BIOL, V10, P6114, DOI 10.1128/MCB.10.12.6114; KOBAYASHI A, 1993, MOL CELL BIOL, V13, P4049, DOI 10.1128/MCB.13.7.4049; KYLSTEN P, 1990, EMBO J, V9, P217, DOI 10.1002/j.1460-2075.1990.tb08098.x; MATSUMOTO N, 1986, BIOCHEM J, V239, P717, DOI 10.1042/bj2390717; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17117; MATSUYAMA K, 1988, J BIOL CHEM, V263, P17112; MEYER M, 1994, CHEM-BIOL INTERACT, V91, P91, DOI 10.1016/0009-2797(94)90029-9; Natori S., 1987, UCLA (University of California Los Angeles) Symposia on Molecular and Cellular Biology New Series, V49, P369; NATORI S, 1977, J INSECT PHYSIOL, V23, P1169, DOI 10.1016/0022-1910(77)90149-4; OKADA M, 1985, J BIOL CHEM, V260, P7174; OKADA M, 1983, BIOCHEM J, V211, P727, DOI 10.1042/bj2110727; SUGIYAMA H, 1994, J BIOCHEM, V116, P1171, DOI 10.1093/oxfordjournals.jbchem.a124645; SUN SC, 1995, EUR J BIOCHEM, V231, P93, DOI 10.1111/j.1432-1033.1995.0093f.x; SUN SC, 1991, EUR J BIOCHEM, V196, P247, DOI 10.1111/j.1432-1033.1991.tb15811.x; SUN SC, 1992, EUR J BIOCHEM, V204, P885, DOI 10.1111/j.1432-1033.1992.tb16708.x; TAKAHASHI H, 1986, J INSECT PHYSIOL, V32, P771, DOI 10.1016/0022-1910(86)90080-6	29	64	71	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13573	13577		10.1074/jbc.271.23.13573	http://dx.doi.org/10.1074/jbc.271.23.13573			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662858	hybrid			2022-12-27	WOS:A1996UP38500042
J	Takimoto, GS; Hovland, AR; Tasset, DM; Melville, MY; Tung, L; Horwitz, KB				Takimoto, GS; Hovland, AR; Tasset, DM; Melville, MY; Tung, L; Horwitz, KB			Role of phosphorylation on DNA binding and transcriptional functions of human progesterone receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT PROTEIN-KINASE; MOUSE GLUCOCORTICOID RECEPTOR; STEROID-HORMONE RECEPTORS; A-RECEPTORS; B-RECEPTORS; SITES; CAMP; ACTIVATION; LIGAND; IDENTIFICATION	To study the function of human progesterone receptor (hPR) phosphorylation, we have tested four sets of serine to alanine substitution mutants: 10 serine clusters, located in regions common tee both hPR isoforms (the M-series:mutants) were mutated in A-receptors and B-receptors; 6 serine clusters located in the B-upstream segment (BUS; the B-series mutants) were mutated individually and collectively and cloned into B-receptors and into BUS-DBD-NLS, a constitutive transactivator, in which the AF3 function of BUS is fused to the DNA binding domain (DBD) and nuclear localization signal (NLS) of hPR. Transcription by most of the M-series mutants resembles that of wild-type A- or B-receptors. Mutation of 3 sites, Ser(190) at the N terminus of A-receptors, a cluster of serines just upstream of the DBD, or Ser(676) in the hinge region, inhibits A transcription by 20-50% depending on cell or promotes context, These sites lie outside the AF1 activation function. M-series mutants are substrates for a hormone-dependent phosphorylation step, and they all bind well to DNA. Progressive mutation of the B-series clusters leads to the gradual dephosphorylation of BUS, but only the 6-site mutant, involving 10 serine residues, is completely dephosphorylated, These data suggest that in BUS alternate serines are phosphorylated or dephosphorylated at any time. However, even when EUS is completely dephosphorylated, both BUS-DBD-NLS and full-length th S-receptors remain strong transactivators. Mutant B-receptors also do not acquire the dominant negative properties of A-receptors, and they retain the ability to activate transcription in synergy with 8-Br-cAMP and antiprogestins. We conclude that phosphorylation has subtle effects on thee complex transcriptional repertoire that distinguishes the two hPR isoforms and does not influence transactivation mediated by AF1 or AF3, but subserves other functions.	UNIV COLORADO,HLTH SCI CTR,DIV ENDOCRINOL DIABET & METAB,PROGRAM MOLEC BIOL,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT MED,DENVER,CO 80262; UNIV COLORADO,HLTH SCI CTR,DEPT PATHOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Horwitz, Kathryn/0000-0001-7402-6455	NATIONAL CANCER INSTITUTE [R01CA026869, R37CA026869, R01CA055595] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048238] Funding Source: NIH RePORTER; NCI NIH HHS [CA55595, CA26869] Funding Source: Medline; NIDDK NIH HHS [DK48238] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALMLOF T, 1995, J BIOL CHEM, V270, P17535, DOI 10.1074/jbc.270.29.17535; ARNOLD SF, 1995, P NATL ACAD SCI USA, V92, P7475, DOI 10.1073/pnas.92.16.7475; ARNOLD SF, 1995, MOL ENDOCRINOL, V9, P24, DOI 10.1210/me.9.1.24; BAGCHI MK, 1992, P NATL ACAD SCI USA, V89, P2664, DOI 10.1073/pnas.89.7.2664; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BECK CA, 1993, P NATL ACAD SCI USA, V90, P4441, DOI 10.1073/pnas.90.10.4441; BHAT MK, 1994, P NATL ACAD SCI USA, V91, P7927, DOI 10.1073/pnas.91.17.7927; BODWELL JE, 1991, J BIOL CHEM, V266, P7549; CHAUCHEREAU A, 1991, J BIOL CHEM, V266, P18280; CHAUCHEREAU A, 1994, BIOCHEMISTRY-US, V33, P13295, DOI 10.1021/bi00249a016; CHRISTENSEN K, 1991, MOL ENDOCRINOL, V5, P1755, DOI 10.1210/mend-5-11-1755; DENNER LA, 1987, J STEROID BIOCHEM, V27, P235, DOI 10.1016/0022-4731(87)90315-3; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; GILNEUR C, 1989, ONCOGENE, V4, P1247; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GRAHAM ML, 1992, CANCER RES, V52, P593; Higuchi R, 1990, PCR PROTOCOLS GUIDE, P177; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HOECK W, 1990, J BIOL CHEM, V265, P5403; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; KASTNER P, 1990, EMBO J, V9, P1603, DOI 10.1002/j.1460-2075.1990.tb08280.x; KUIPER GGJM, 1993, BIOCHEM J, V291, P95, DOI 10.1042/bj2910095; KUIPER GGJM, 1994, MOL CELL ENDOCRINOL, V100, P103, DOI 10.1016/0303-7207(94)90287-9; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; LIN KH, 1992, P NATL ACAD SCI USA, V89, P7737, DOI 10.1073/pnas.89.16.7737; MASON SA, 1993, J BIOL CHEM, V268, P21501; MCDONNELL DP, 1994, J BIOL CHEM, V269, P11945; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; NAKAO M, 1992, ARCH BIOCHEM BIOPHYS, V298, P340, DOI 10.1016/0003-9861(92)90420-2; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; PINA B, 1990, CELL, V60, P719, DOI 10.1016/0092-8674(90)90087-U; POLETTI A, 1992, GENE, V114, P51, DOI 10.1016/0378-1119(92)90706-U; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RANGARAJAN PN, 1992, MOL ENDOCRINOL, V6, P1451, DOI 10.1210/me.6.9.1451; ROCHETTEEGLY C, 1992, MOL ENDOCRINOL, V6, P2197, DOI 10.1210/me.6.12.2197; SARTORIUS CA, 1994, MOL ENDOCRINOL, V8, P1347, DOI 10.1210/me.8.10.1347; SARTORIUS CA, 1994, CANCER RES, V54, P3868; SARTORIUS CA, 1993, J BIOL CHEM, V268, P9262; SHERIDAN PL, 1989, J BIOL CHEM, V264, P6520; SHERIDAN PL, 1989, J BIOL CHEM, V264, P7054; SUGAWARA A, 1994, J BIOL CHEM, V269, P433; SULLIVAN WP, 1988, J BIOL CHEM, V263, P14717; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TAKIMOTO GS, 1993, TRENDS ENDOCRIN MET, V4, P1, DOI 10.1016/1043-2760(93)90056-K; TAKIMOTO GS, 1991, J STEROID BIOCHEM, V39, P687, DOI 10.1016/0960-0760(91)90368-F; TORA L, 1989, EMBO J, V8, P1981, DOI 10.1002/j.1460-2075.1989.tb03604.x; TUNG L, 1993, MOL ENDOCRINOL, V7, P1256, DOI 10.1210/me.7.10.1256; WEIGEL NL, 1989, ENDOCRINOLOGY, V125, P2494, DOI 10.1210/endo-125-5-2494; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; WOO DDL, 1986, J BIOL CHEM, V261, P460; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	55	59	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13308	13316		10.1074/jbc.271.23.13308	http://dx.doi.org/10.1074/jbc.271.23.13308			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662865	hybrid			2022-12-27	WOS:A1996UP38500005
J	Valnickova, Z; Thogersen, IB; Christensen, S; Chu, CT; Pizzo, SV; Enghild, JJ				Valnickova, Z; Thogersen, IB; Christensen, S; Chu, CT; Pizzo, SV; Enghild, JJ			Activated human plasma carboxypeptidase B is retained in the blood by binding to alpha(2)-macroglobulin and pregnancy zone protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH GLYCOPROTEIN; CARBOXY-TERMINAL LYSINE; ALPHA-2-PLASMIN INHIBITOR; PLASMINOGEN-BINDING; MOLECULAR-CLONING; AFFINITY; ALPHA-2-MACROGLOBULIN; IDENTIFICATION; PURIFICATION; FIBRIN	A 66-kDa glycosylated carboxypeptidase, plasma procarboxypeptidase B (pro-plasma CPB), has recently been identified in human blood (Eaten, D, L,, Malloy, B, E., Tsai, S. P,, Henzel, W,, and Drayna, D, (1991) J. Biol, Chem. 266, 21833-21838), The pro-enzyme binds to plasminogen and the active enzyme is specific for COOH-terminal Lys or Arg residues, These properties implicate a role in the fibrinolytic or coagulation system, However, we show that the molecular mass of the active plasma CPB is approximately 36 kDa, which is below the glomerular filtration limit. Since activated plasma CPB no longer binds plasminogen, the active enzyme may not be retained in the circulation. To investigate this, we performed plasma elimination studies in mice which showed that I-125-plasma CPB remains in the circulation despite its small size, Native polyacrylamide gel electrophoresis of blood samples removed from the mice revealed that plasma CPB migrated as a high molecular weight band, Similar bands were observed in vitro when I-125-plasma CPB was added to plasma from humans and other species, The plasma CPB-binding proteins were purified from human plasma and identified as alpha(2)-macroglobulin (alpha(2)M) and pregnancy zone protein, Only the active enzyme bound to the two alpha-macroglobulins, and the interaction was specific for alpha(2)M in its native conformation, but not its receptor recognized forms, The complex between human alpha(2)M and plasma CPB dissociated during SDS-polyacrylamide gel electrophoresis and transverse urea gel electrophoresis suggesting that the interaction was noncovalent and depended on the tertiary structure of the native alpha(2)M molecule. The catalytic activity of plasma CPB was not significantly affected by its binding to alpha(2)M, The specific binding of plasma CPB to alpha-macroglobulins suggest that these proteins may function as a ''shuttle'' in vivo to modulate the clearance of plasma CPB from the circulatory system.	DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710	Duke University			Chu, Charleen T/B-1601-2008	Chu, Charleen T/0000-0002-5052-8271; Christensen, Soren/0000-0003-2500-0085; Enghild, Jan Johannes/0000-0001-9292-9172	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL024066, R01HL024066, R01HL049542] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL24066, HL49542] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAJZAR L, 1995, J BIOL CHEM, V270, P14477, DOI 10.1074/jbc.270.24.14477; BARRETT AJ, 1973, BIOCHEM J, V133, P709, DOI 10.1042/bj1330709; BORTH W, 1992, FASEB J, V6, P3345, DOI 10.1096/fasebj.6.15.1281457; BURGOS FJ, 1991, BIOCHEMISTRY-US, V30, P4082, DOI 10.1021/bi00230a038; BURY AF, 1981, J CHROMATOGR, V213, P491, DOI 10.1016/S0021-9673(00)80500-2; CHU CT, 1994, LAB INVEST, V71, P792; CLEMMENSEN I, 1986, EUR J BIOCHEM, V156, P327, DOI 10.1111/j.1432-1033.1986.tb09586.x; CLEMMENSEN I, 1981, EUR J BIOCHEM, V120, P105, DOI 10.1111/j.1432-1033.1981.tb05675.x; DEUTSCH DG, 1970, SCIENCE, V170, P1095, DOI 10.1126/science.170.3962.1095; DEVRIENDT K, 1991, BIOCHIM BIOPHYS ACTA, V1088, P95, DOI 10.1016/0167-4781(91)90157-H; EATON DL, 1991, J BIOL CHEM, V266, P21833; ENGHILD JJ, 1994, J BIOL CHEM, V269, P20159; ERDOS EG, 1963, ANN NY ACAD SCI, V104, P222, DOI 10.1111/j.1749-6632.1963.tb17666.x; Goldenberg D.P, 1989, PROTEIN STRUCTURE PR, P225; GONIAS SL, 1992, EXP HEMATOL, V20, P302; HENDRIKS D, 1985, CLIN CHEM, V12, P1936; HIGGINS DL, 1987, BIOCHEMISTRY-US, V26, P7786, DOI 10.1021/bi00398a038; HORTIN GL, 1988, BIOCHEM BIOPH RES CO, V155, P591, DOI 10.1016/S0006-291X(88)80535-7; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; ICHINOSE A, 1984, THROMB RES, V33, P401, DOI 10.1016/0049-3848(84)90079-3; IMBER MJ, 1981, J BIOL CHEM, V256, P8124; LAMARRE J, 1991, LAB INVEST, V65, P3; LENICH C, 1991, THROMB RES, V64, P69, DOI 10.1016/0049-3848(91)90206-C; LIJNEN HR, 1980, J BIOL CHEM, V255, P214; MANWELL C, 1977, BIOCHEM J, V165, P487, DOI 10.1042/bj1650487; MAST AE, 1991, BIOCHEMISTRY-US, V30, P1723, DOI 10.1021/bi00220a039; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; MILES LA, 1991, BIOCHEMISTRY-US, V30, P1682, DOI 10.1021/bi00220a034; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PLUMMER TH, 1981, METHOD ENZYMOL, V80, P442; REECK GR, 1972, BIOCHEMISTRY-US, V21, P3947; SALVESEN G, 1993, METHOD ENZYMOL, V233, P121; SASAKI T, 1986, J BIOCHEM-TOKYO, V99, P1699, DOI 10.1093/oxfordjournals.jbchem.a135645; SAYERS CA, 1980, BIOCHEM J, V189, P255, DOI 10.1042/bj1890255; SKIDGEL RA, 1988, TRENDS PHARMACOL SCI, V9, P299, DOI 10.1016/0165-6147(88)90015-6; SKIDGEL RA, 1995, METHOD ENZYMOL, V248, P653; SOTTRUPJENSEN L, 1984, J BIOL CHEM, V259, P8318; TAN AK, 1995, BIOCHEMISTRY-US, V34, P5811, DOI 10.1021/bi00017a012; TAN FL, 1990, J BIOL CHEM, V265, P13; TRANTHANG C, 1986, EUR J BIOCHEM, V160, P599, DOI 10.1111/j.1432-1033.1986.tb10080.x; TSAI SP, 1992, GENOMICS, V14, P549, DOI 10.1016/S0888-7543(05)80268-X; WANG W, 1994, J BIOL CHEM, V269, P15937; WIMAN B, 1980, BIOCHEM J, V191, P229, DOI 10.1042/bj1910229	43	38	41	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12937	12943		10.1074/jbc.271.22.12937	http://dx.doi.org/10.1074/jbc.271.22.12937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662763	hybrid			2022-12-27	WOS:A1996UN47400041
J	Aharonovitz, O; Granot, Y				Aharonovitz, O; Granot, Y			Stimulation of mitogen-activated protein kinase and Na+/H+ exchanger in human platelets differential effect of phorbol ester and vasopressin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; HUMAN BLOOD-PLATELETS; SMOOTH-MUSCLE CELLS; MAP KINASE; TYROSINE PHOSPHORYLATION; XENOPUS-OOCYTES; INTRACELLULAR PH; OKADAIC ACID; SET-POINT; PHOSPHATASE	Treatment of human platelets with phorbol 12-myris tate 13-acetate (PMA) and arginine vasopressin (AVP) increase the phosphorylation and activation of mitogen-activated protein kinase (MAPK). Electrophoretic retardation of MAPK mobility on SDS polyacrylamide gels was used for determination of MAPK phosphorylation, The activity of MAPK was tested in myelin basic protein (MBP)-containing polyacrylamide gels, In this study we compared the PMA and AVP signal transduction pathways leading to the activation of MAPKs and Na+/H+ exchanger (NHE). Both agonists stimulate MAPK and NHE activities in a similar time frame and concentration dependence, The MAPK and NHE activities induced by PMA were inhibited by staurosporine, a potent inhibitor for protein kinase C (PKC), and by MAPK kinase (MEK) inhibitor, PD98059, but were not affected by the tyrosine kinase inhibitor genistein, In contrast, both AVP-induced MAPK and NHE activities were inhibited by genistein and MEK inhibitor but were not affected by staurosporine, Immunoprecipitation studies demonstrate that PMA, but not AVP, enhances the basal phosphorylation of the NHE-1. In this study, MAPKs are suggested to be a part of converging signaling leading to NHE activation by PKC-dependent and AVP-tyrosine kinase-dependent pathways. We propose that the MAPK activation of the NHE-1 does not involve phosphorylation of this exchanger protein, On the other hand, PKC can lead to phosphorylation and to additional activation of the NHE-1 through a MAPK-independent pathway.	BEN GURION UNIV NEGEV,DEPT LIFE SCI,IL-84105 BEER SHEVA,ISRAEL	Ben Gurion University								AHARONOVITS O, 1992, BIOCHIM BIOPHYS ACTA, V1112, P181, DOI 10.1016/0005-2736(92)90390-8; AKIYAMA T, 1987, J BIOL CHEM, V262, P5592; ALESSI DR, 1993, ONCOGENE, V8, P2015; BIANCHINI L, 1991, J BIOL CHEM, V266, P15406; BOULTON TG, 1990, SCIENCE, V249, P64, DOI 10.1126/science.2164259; DEGROOT PG, 1990, BRIT J HAEMATOL, V75, P308; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; DUFF JL, 1993, J BIOL CHEM, V268, P26037; FORCE T, 1991, J BIOL CHEM, V266, P6650; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRANOT Y, 1990, BIOCHEM BIOPH RES CO, V168, P566, DOI 10.1016/0006-291X(90)92358-7; GRANOT Y, 1993, J BIOL CHEM, V268, P9564; GRINSTEIN S, 1992, J BIOL CHEM, V267, P23823; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V171, P189, DOI 10.1016/0006-291X(90)91375-3; INABA K, 1988, CLIN ENDOCRINOL, V29, P377, DOI 10.1111/j.1365-2265.1988.tb02886.x; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KAPLAN DL, 1994, J BIOL CHEM, V269, P4116; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAZAR DF, 1995, J BIOL CHEM, V270, P20801, DOI 10.1074/jbc.270.35.20801; LIVNE AA, 1991, J HYPERTENS, V9, P1013, DOI 10.1097/00004872-199111000-00006; LIVNE AA, 1992, BIOCHIM BIOPHYS ACTA, V1135, P13, DOI 10.1016/0167-4889(92)90160-D; LIVNE AA, 1991, BIOCHIM BIOPHYS ACTA, V1068, P161, DOI 10.1016/0005-2736(91)90205-M; LIVNE AA, 1991, FEBS LETT, V284, P219, DOI 10.1016/0014-5793(91)80689-Z; NAKASHIMA S, 1994, BIOCHEM BIOPH RES CO, V198, P497, DOI 10.1006/bbrc.1994.1073; NEBREDA AR, 1993, EMBO J, V12, P1979, DOI 10.1002/j.1460-2075.1993.tb05847.x; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PAPKOFF J, 1994, MOL CELL BIOL, V14, P463, DOI 10.1128/MCB.14.1.463; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; POSADA J, 1993, MOL CELL BIOL, V13, P2546, DOI 10.1128/MCB.13.4.2546; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; POUYSSEGUR J, 1994, RENAL PHYSIOL BIOCH, V17, P190; REZAI K, 1994, AM J PHYSIOL-CELL PH, V267, pC1717; ROSSOMANDO AJ, 1991, J BIOL CHEM, V266, P20270; ROZENGURT E, 1986, SCIENCE, V234, P161, DOI 10.1126/science.3018928; SAMIEI M, 1993, BIOCHIM BIOPHYS ACTA, V1176, P287, DOI 10.1016/0167-4889(93)90057-V; SARDET C, 1990, SCIENCE, V247, P723, DOI 10.1126/science.2154036; SARDET C, 1989, CELL, V56, P271, DOI 10.1016/0092-8674(89)90901-X; SARDET C, 1991, J BIOL CHEM, V266, P19166; SAWYER WH, 1984, FED PROC, V43, P87; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; SINNETTSMITH J, 1993, J BIOL CHEM, V268, P14261; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; TAMAOKI T, 1986, BIOCHEM BIOPH RES CO, V135, P397, DOI 10.1016/0006-291X(86)90008-2; WAKABAYASHI S, 1994, J BIOL CHEM, V269, P5583; WARD Y, 1994, NATURE, V367, P651, DOI 10.1038/367651a0; ZHENG CF, 1993, J BIOL CHEM, V268, P16116	47	78	79	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16494	16499		10.1074/jbc.271.28.16494	http://dx.doi.org/10.1074/jbc.271.28.16494			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663100	hybrid			2022-12-27	WOS:A1996UX12600013
J	Kuo, SM; Aronson, PS				Kuo, SM; Aronson, PS			Pathways for oxalate transport in rabbit renal microvillus membrane vesicles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRUSH-BORDER MEMBRANE; BASOLATERAL MEMBRANE; SULFATE TRANSPORT; ANION-EXCHANGE; OH EXCHANGE; ABSORPTION; FORMATE; TUBULE; CORTEX	Recent evidence suggests that apical membrane Cl--oxalate exchange plays a major role in mediating Cl--absorption in the renal proximal tubule. To sustain steady-state Cl- absorption by a mechanism of exchange for intracellular oxalate requires the presence of one or more pathways for recycling oxalate from lumen to cell. Accordingly, we evaluated the mechanisms of oxalate transport in luminal membrane vesicles isolated from the rabbit renal cortex, We found that transport of oxalate by Na+ cotransport is negligible compared to the transport of sulfate, In contrast, we demonstrated that oxalate shares the electroneutral pathway mediating Na+-independent sulfate-carbonate exchange. We also demonstrated the presence of OH--oxalate exchange (indistinguishable from H+-oxalate cotransport). The process of OH--oxalate exchange was electrogenic and partially inhibited by Cl-, indicating that it occurs, at least in part, as a mode of the Cl--oxalate exchanger described previously. An additional component of OH--oxalate exchange was insensitive to inhibition by either Cl- or sulfate, suggesting that it takes place by neither the Cl--oxalate exchanger nor the sulfate-carbonate exchanger, We conclude that multiple anion exchange mechanisms exist by which oxalate can recycle from lumen to cell to sustain Cl- absorption occurring via apical membrane Cl--oxalate exchange in the renal proximal tubule.	YALE UNIV,SCH MED,DEPT MED,NEW HAVEN,CT 06510; YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,NEW HAVEN,CT 06510	Yale University; Yale University					NIDDK NIH HHS [DK-17433] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK017433] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ARONSON PS, 1978, J MEMBRANE BIOL, V42, P81, DOI 10.1007/BF01870395; BASTLEIN C, 1986, AM J PHYSIOL, V250, pF226, DOI 10.1152/ajprenal.1986.250.2.F226; JENNINGS ML, 1988, J GEN PHYSIOL, V92, P161, DOI 10.1085/jgp.92.2.161; KARNISKI LP, 1987, AM J PHYSIOL, V253, pF513, DOI 10.1152/ajprenal.1987.253.3.F513; KUO SM, 1988, J BIOL CHEM, V263, P9710; KUO SM, 1988, FASEB J, V2, pA753; LOW I, 1984, AM J PHYSIOL, V246, pF334, DOI 10.1152/ajprenal.1984.246.3.F334; LUCKE H, 1979, BIOCHEM J, V182, P223; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PRITCHARD JB, 1983, P NATL ACAD SCI-BIOL, V80, P2603, DOI 10.1073/pnas.80.9.2603; PRITCHARD JB, 1987, AM J PHYSIOL, V252, pF346, DOI 10.1152/ajprenal.1987.252.2.F346; SCHNEIDER EG, 1984, J BIOL CHEM, V259, P4591; WANG T, 1992, AM J PHYSIOL, V263, pF37, DOI 10.1152/ajprenal.1992.263.1.F37; WANG T, 1993, AM J PHYSIOL, V264, pF730, DOI 10.1152/ajprenal.1993.264.4.F730; WAREING M, 1994, J PHYSIOL-LONDON, V477, P347, DOI 10.1113/jphysiol.1994.sp020196; YAMAKAWA K, 1990, KIDNEY INT, V37, P1105, DOI 10.1038/ki.1990.92	16	42	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15491	15497		10.1074/jbc.271.26.15491	http://dx.doi.org/10.1074/jbc.271.26.15491			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663096	hybrid			2022-12-27	WOS:A1996UV29900030
J	Ishikawa, T; Bao, JJ; Yamane, Y; Akimaru, K; Frindrich, K; Wright, CD; Kuo, MT				Ishikawa, T; Bao, JJ; Yamane, Y; Akimaru, K; Frindrich, K; Wright, CD; Kuo, MT			Coordinated induction of MRP/GS-X pump and gamma-glutamylcysteine synthetase by heavy metals in human leukemia cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MULTIDRUG RESISTANCE; S-CONJUGATE; CARDIAC TRANSPORT; MDR1 GENE; RAT-HEART; GLUTATHIONE; METABOLISM; LINE; OVEREXPRESSION; LEISHMANIA	We recently reported that GS-X pump activity, as assessed by ATP-dependent transport of the glutathione-platinum complex and leukotriene C-4, and intracellular glutathione (GSH) levels were remarkably enhanced in cis-diamminedichloroplatinum(II) (cisplatin)-resistant human leukemia HL-60 cells (Ishikawa, T,, Wright, C, D,, and Ishizuka, H, (1994) J, Biol, Chem, 269, 29085-29093), Now, using Northern hybridization and RNase protection assay, we provide evidence that the multidrug resistance-associated protein (MRP) gene, which encodes a human GS-X pump, is expressed at higher levels in cisplatin-resistant (HL-60/R-CP) cells than in sensitive cells, whereas amplification of the MRP gene is not detected by Southern hybridization, Culturing HL-60/R-CP cells in cisplatin-free medium resulted in reduced MRP mRNA levels, but these levels could be induced to rise within 30 h by cisplatin and heavy metals such as arsenite, cadmium, and zinc, The increased levels of MRP mRNA were closely related with enhanced activities of ATP-dependent transport of leukotriene C-4 (LTC(4)) in plasma membrane vesicles, The glutathione-platinum (GS-Pt) complex, but not cisplatin, inhibited ATP-dependent LTC(4) transport, suggesting that the MRP/GS-X pump transports both LTC, and the GS-Pt complex, Expression of gamma-glutamylcysteine synthetase in the cisplatin-resistant cells was also co induced within 24 h in response to cisplatin exposure, resulting in a significant increase in cellular GSH level, The resistant cells exposed to cisplatin were cross-resistant to melphalan, chlorambucil, arsenite, and cadmium, These observations suggest that elevated expression of the MRP/GS-X pump and increased GSH biosynthesis together may be important factors in the cellular metabolism and disposition of cisplatin, alkylating agents, and heavy metals.	UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT EXPT PEDIAT, SECT MOL THERAPEUT, HOUSTON, TX 77030 USA; UNIV TEXAS, MD ANDERSON CANCER CTR, DEPT MOLEC PATHOL, SECT EUCARYOT CELL RES, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center; University of Texas System; UTMD Anderson Cancer Center					NATIONAL CANCER INSTITUTE [R01CA060486, R01CA056846] Funding Source: NIH RePORTER; NCI NIH HHS [CA56846, R01 CA60486] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BORST P, 1995, ANNU REV MICROBIOL, V49, P427, DOI 10.1146/annurev.mi.49.100195.002235; CALLAHAN HL, 1991, J BIOL CHEM, V266, P18427; CHAUDHARY PM, 1993, J NATL CANCER I, V85, P632, DOI 10.1093/jnci/85.8.632; CHIN KV, 1990, J BIOL CHEM, V265, P221; CHIN KV, 1990, CELL GROWTH DIFFER, V1, P361; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DELNOMDEDIEU M, 1994, CHEM-BIOL INTERACT, V90, P139, DOI 10.1016/0009-2797(94)90099-X; DEVRIES EGE, 1995, J NATL CANCER I, V87, P537, DOI 10.1093/jnci/87.7.537; FUJII R, 1994, J NATL CANCER I, V86, P1781, DOI 10.1093/jnci/86.23.1781; GIPP JJ, 1992, BIOCHEM BIOPH RES CO, V185, P29, DOI 10.1016/S0006-291X(05)80950-7; GODWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070, DOI 10.1073/pnas.89.7.3070; GOTO S, 1995, CANCER RES, V55, P4297; HOSPERS GAP, 1988, CANCER RES, V48, P6803; HUANG CS, 1993, J BIOL CHEM, V268, P19675; ISHIKAWA T, 1992, TRENDS BIOCHEM SCI, V17, P463, DOI 10.1016/0968-0004(92)90489-V; ISHIKAWA T, 1990, TRENDS BIOCHEM SCI, V15, P219, DOI 10.1016/0968-0004(90)90032-7; ISHIKAWA T, 1995, J NATL CANCER I, V87, P1639, DOI 10.1093/jnci/87.21.1639; ISHIKAWA T, 1994, J BIOL CHEM, V269, P29085; ISHIKAWA T, 1989, J BIOL CHEM, V264, P17343; ISHIKAWA T, 1984, J BIOL CHEM, V259, P3838; ISHIKAWA T, 1993, J BIOL CHEM, V268, P20116; ISHIKAWA T, 1993, STRUCTURE FUNCTION G, P211; ISHIKAWA T, 1996, GLUTATHIONE S TRANSF, P199; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JOHNSON SW, 1994, CANCER RES, V54, P5911; KUROKAWA H, 1995, BIOCHEM BIOPH RES CO, V216, P258, DOI 10.1006/bbrc.1995.2618; LEIER I, 1994, J BIOL CHEM, V269, P27807; MEISTER A, 1988, J BIOL CHEM, V263, P17205; MULCAHY RT, 1994, MOL PHARMACOL, V46, P909; MULCAHY RT, 1995, BIOCHEM BIOPH RES CO, V209, P227, DOI 10.1006/bbrc.1995.1493; MULCAHY RT, 1995, CANCER RES, V55, P4771; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NAREDI P, 1994, CANCER RES, V54, P6464; OUELLETTE M, 1990, EMBO J, V9, P1027, DOI 10.1002/j.1460-2075.1990.tb08206.x; PAPADOPOULOU B, 1994, J BIOL CHEM, V269, P11980; PEI J, 1990, J BIOL CHEM, V265, P14061; PERRIN DD, 1971, BIOCHIM BIOPHYS ACTA, V230, P96, DOI 10.1016/0304-4165(71)90057-2; Sambrook J., 1990, MOL CLONING LAB MANU, V2nd; SEELIG GF, 1984, J BIOL CHEM, V259, P9345; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TEETER LD, 1990, MOL CELL BIOL, V10, P5728, DOI 10.1128/MCB.10.11.5728; TIETZE F, 1969, ANAL BIOCHEM, V27, P502, DOI 10.1016/0003-2697(69)90064-5; WU AL, 1994, MOL CELL BIOL, V14, P5832, DOI 10.1128/MCB.14.9.5832; YAO KS, 1995, CANCER RES, V55, P4367; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690; ZAMAN GJR, 1994, P NATL ACAD SCI USA, V91, P8822, DOI 10.1073/pnas.91.19.8822; ZHENG YW, 1994, J BIOL CHEM, V269, P22593; ZHU QC, 1994, CANCER RES, V54, P4488; ZIJLSTRA JG, 1987, CANCER RES, V47, P1780	51	249	253	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14981	14988		10.1074/jbc.271.25.14981	http://dx.doi.org/10.1074/jbc.271.25.14981			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663001	hybrid			2022-12-27	WOS:A1996UT10600053
J	Karpen, SJ; Sun, AQ; Kudish, B; Hagenbuch, B; Meier, PJ; Ananthanarayanan, M; Suchy, FJ				Karpen, SJ; Sun, AQ; Kudish, B; Hagenbuch, B; Meier, PJ; Ananthanarayanan, M; Suchy, FJ			Multiple factors regulate the rat liver basolateral sodium-dependent bile acid cotransporter gene promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CHOLESTEROL 7-ALPHA-HYDROXYLASE GENE; TYROSINE AMINOTRANSFERASE GENE; DNA-BINDING-PROTEINS; FUNCTIONAL EXPRESSION; SEQUENCE-ANALYSIS; NUCLEAR PROTEINS; ALBUMIN GENE; TRANSCRIPTION; TRANSPORT; SITES	The hepatic uptake of bile acids from the portal circulation is primarily dependent upon a sodium-dependent basolateral membrane transporter, In order to bean to investigate the factors controlling rat liver sodium-dependent bile acid cotransporter (ntcp) gene expression, we isolated approximate to 30 kilobase pairs of rat genomic DNA in three overlapping lambda phage clones, The rat ntcp gene is distributed over 16.5 kilobase pairs as five exons, Primer extension analysis revealed two closely spaced transcription initiation sites, 27 and 41 nucleotides downstream of a TATA sequence, Regulation of transcription was investigated first by transfection of primary rat hepatocytes by a series of 5'-deleted rat ntcp promoter-driven luciferase constructs (from approximate to -6 kilobase pairs to -59 base pairs of upstream sequences, terminating at nucleotide +47), identifying a minimal promoter element: nucleotide -158 to +47, This minimal promoter was active in transfected HepG2, but inactive in NIH3T3, Caco-2, and Madin-Darby canine kidney cells, indicating that the determinants of hepatocyte-specific expression reside within this region, The individual elements within the minimal promoter were investigated via transfection of HepG2 cells by a series of 20 mutant plasmids, each containing a 10-base pair sequential block mutation, Eight mutant constructs profoundly suppressed promoter activity; encompassing sequences from -66 to +4 nt, and +15 to +24 nucleotides, while no other 10-base pair mutation significantly interfered with minimal promoter activity, Deoxyribonuclease I footprint analysis of the minimal promoter revealed three bound regions; -92 to -74 (footprint C), -50 to -37 (footprint B), and -17 to +12 (footprint A), Gel mobility shift assays provided evidence for hepatocyte nuclear factor 1 binding within footprint A and a liver-enriched factor(s) that binds within a novel palindrome in footprint B, These studies indicate that three elements direct the basal and tissue-restricted expression of the rat ntcp promoter; a TATA element, the liver-enriched transcription factor hepatocyte nuclear factor 1, and an unknown liver-enriched factor that binds within a novel palindrome in footprint B.	UNIV ZURICH HOSP,DEPT MED,DIV CLIN PHARMACOL & TOXICOL,CH-8091 ZURICH,SWITZERLAND	University of Zurich; University Zurich Hospital	Karpen, SJ (corresponding author), YALE UNIV,SCH MED,DEPT PEDIAT,333 CEDAR ST,NEW HAVEN,CT 06520, USA.		Hagenbuch, Bruno/M-5294-2016	Hagenbuch, Bruno/0000-0002-2938-8630	NICHD NIH HHS [HD-07388, HD-20632] Funding Source: Medline; NIDDK NIH HHS [DK-02318] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD020632, R37HD020632] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002318] Funding Source: NIH RePORTER	NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANANTHANARAYANAN M, 1994, AM J PHYSIOL-GASTR L, V267, pG637, DOI 10.1152/ajpgi.1994.267.4.G637; Ausubel FM, 1988, MOL REPROD DEV; BANERJEE R, 1989, HEPATOLOGY, V10, P1008, DOI 10.1002/hep.1840100620; BAUMHUETER S, 1989, ANN NY ACAD SCI, V557, P272; BERG JM, 1992, P NATL ACAD SCI USA, V89, P11109, DOI 10.1073/pnas.89.23.11109; BERRY MN, 1969, J CELL BIOL, V43, P506, DOI 10.1083/jcb.43.3.506; BOISCLAIR YR, 1993, J BIOL CHEM, V268, P24892; BOYER JL, 1990, METHOD ENZYMOL, V192, P517; BOYER JL, 1993, P NATL ACAD SCI USA, V90, P435, DOI 10.1073/pnas.90.2.435; BRIGGS MR, 1993, J BIOL CHEM, V268, P14490; CARDINAUX JR, 1994, J BIOL CHEM, V269, P32947; CHIANG JYL, 1994, J BIOL CHEM, V269, P17502; COHN MA, 1995, MAMM GENOME, V6, P60, DOI 10.1007/BF00350902; CRESTANI M, 1993, ARCH BIOCHEM BIOPHYS, V306, P451, DOI 10.1006/abbi.1993.1537; CURRAN T, 1988, CELL, V55, P395, DOI 10.1016/0092-8674(88)90024-4; DARLINGTON GJ, 1987, IN VITRO CELL DEV B, V23, P349; DEVACK C, 1993, EUR J BIOCHEM, V211, P459, DOI 10.1111/j.1432-1033.1993.tb17571.x; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; ETZOLD T, 1993, COMPUT APPL BIOSCI, V9, P49; GHOSH D, 1993, NUCLEIC ACIDS RES, V21, P3117, DOI 10.1093/nar/21.13.3117; GILBERT W, 1987, COLD SPRING HARB SYM, V52, P901, DOI 10.1101/SQB.1987.052.01.098; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; GRANGE T, 1991, NUCLEIC ACIDS RES, V19, P131, DOI 10.1093/nar/19.1.131; HAGENBUCH B, 1991, P NATL ACAD SCI USA, V88, P10629, DOI 10.1073/pnas.88.23.10629; HAGENBUCH B, 1994, J CLIN INVEST, V93, P1326, DOI 10.1172/JCI117091; HARDIKAR W, 1995, J BIOL CHEM, V270, P20841, DOI 10.1074/jbc.270.35.20841; HOFMANN AF, 1991, ANN MED, V23, P169, DOI 10.3109/07853899109148043; HOFMANN AF, 1993, GASTROINTESTINAL DIS, P127; HOPPESEYLER F, 1991, NUCLEIC ACIDS RES, V19, P5080, DOI 10.1093/nar/19.18.5080; JACQUEMIN E, 1994, P NATL ACAD SCI USA, V91, P133, DOI 10.1073/pnas.91.1.133; KARPEN S, 1993, GASTROENTEROLOGY, V104, pA925; KEMLER I, 1990, FASEB J, V4, P144; KUO CJ, 1990, P NATL ACAD SCI USA, V87, P9838, DOI 10.1073/pnas.87.24.9838; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEMAIGRE FP, 1991, MOL CELL BIOL, V11, P1099, DOI 10.1128/MCB.11.2.1099; LIANG D, 1993, HEPATOLOGY, V18, P1162; LICHTSTEINER S, 1989, CELL, V57, P1179, DOI 10.1016/0092-8674(89)90055-X; LICHTSTEINER S, 1987, CELL, V51, P963, DOI 10.1016/0092-8674(87)90583-6; LOCKER J, 1993, GENE TRANSCRIPTION P, P321; MANIATIS T, 1987, SCIENCE, V236, P1237, DOI 10.1126/science.3296191; MENDEL DB, 1991, GENE DEV, V5, P1042, DOI 10.1101/gad.5.6.1042; MOLOWA DT, 1992, BIOCHEMISTRY-US, V31, P2539, DOI 10.1021/bi00124a014; MOUNT SM, 1982, NUCLEIC ACIDS RES, V10, P459, DOI 10.1093/nar/10.2.459; NATHANS J, 1983, CELL, V34, P807, DOI 10.1016/0092-8674(83)90537-8; NATHANSON MH, 1991, HEPATOLOGY, V14, P551, DOI 10.1002/hep.1840140324; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; OLSEN J, 1991, J BIOL CHEM, V266, P18089; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PONDER KP, 1991, HUM GENE THER, V2, P41, DOI 10.1089/hum.1991.2.1-41; RAY BK, 1994, GENE, V147, P253, DOI 10.1016/0378-1119(94)90076-0; RUSSELL DW, 1992, BIOCHEMISTRY-US, V31, P4737, DOI 10.1021/bi00135a001; Sambrook J., 2002, MOL CLONING LAB MANU; SHNEIDER BL, 1995, J CLIN INVEST, V95, P745, DOI 10.1172/JCI117722; SIERRA F, 1993, GENE TRANSCRIPTION P, P125; SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353; STIEGER B, 1994, GASTROENTEROLOGY, V107, P1781, DOI 10.1016/0016-5085(94)90821-4; SUCHY FJ, 1993, SEMIN LIVER DIS, V13, P235, DOI 10.1055/s-2007-1007352; TJIAN R, 1994, CELL, V77, P5, DOI 10.1016/0092-8674(94)90227-5; Tronche F., 1994, LIVER GENE EXPRESSIO, P155; TURK E, 1994, J BIOL CHEM, V269, P15204; TZUNG KW, 1994, GENOMICS, V21, P244, DOI 10.1006/geno.1994.1250; VANDENHOFF MJB, 1994, HISTOCHEM J, V26, P20; VLAHCEVIC ZR, 1991, HEPATOLOGY, V13, P590, DOI 10.1002/hep.1840130331; WANG XD, 1993, J BIOL CHEM, V268, P14497; WEIS L, 1992, FASEB J, V6, P3300, DOI 10.1096/fasebj.6.14.1426767; WINGENDER E, 1994, J BIOTECHNOL, V35, P273, DOI 10.1016/0168-1656(94)90041-8; WONG MH, 1994, J BIOL CHEM, V269, P1340; WU GD, 1994, J BIOL CHEM, V269, P17080	69	111	112	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15211	15221		10.1074/jbc.271.25.15211	http://dx.doi.org/10.1074/jbc.271.25.15211			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662994	hybrid			2022-12-27	WOS:A1996UT10600083
J	Turck, J; Pollock, AS; Lee, LK; Marti, HP; Lovett, DH				Turck, J; Pollock, AS; Lee, LK; Marti, HP; Lovett, DH			Matrix metalloproteinase 2 (gelatinase A) regulates glomerular mesangial cell proliferation and differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEGRADING NEUTRAL PROTEINASE; EXTRACELLULAR-MATRIX; GROWTH-FACTOR; ENZYMATIC-PROPERTIES; FIBROSARCOMA CELLS; TRANSFORMED-CELLS; ENDOTHELIAL-CELLS; GENE-EXPRESSION; IV COLLAGENASE; PURIFICATION	A biologic role for the 72-kDa gelatinase A (matrix metalloproteinase 2; MMP-2), beyond simple extracellular matrix turnover, was evaluated in glomerular mesangial cells, To determine the significance of MMP-2 secretion for the acquisition of the inflammatory phenotype, we reduced the constitutive secretion of MMP-2 by cultured mesangial cells with antisense RNA expressed by an episomally replicating vector or with specific anti-MMP-2 ribozymes expressed by a retroviral transducing vector. The phenotype of the transfected, or retrovirally infected, cells was profoundly altered from the activated state and closely approximated that of quiescent cells in vivo. The prominent differences included a change in the synthesis and organization of the extracellular matrix, loss of activation markers, and a virtually total exit from the cell cycle. Reconstitution with exogenous active, but not latent MMP-2, induced a rapid return to the inflammatory phenotype in vitro. This effect was specific to MMP-2, because the closely related MMP-2 did not reproduce these changes, Furthermore, this pro-inflammatory effect of MMP-2 is dependent upon the active form of the enzyme, which can be produced by an autocatalytic activation process on the mesangial cell plasma membrane. It is concluded that MMP-2 acts directly upon mesangial cells to permit the development of an inflammatory phenotype. Specific inhibition of MMP-2 activity in vivo may represent an alternate means of ameliorating complex inflammatory processes by affecting the phenotype of the synthesizing cells, per se.	VET AFFAIRS MED CTR, MED SERV 111J, DEPT MED, SAN FRANCISCO, CA 94121 USA; UNIV CALIF SAN FRANCISCO, SAN FRANCISCO, CA 94121 USA; UNIV BERN, MED KLIN, CH-3006 BERN, SWITZERLAND	US Department of Veterans Affairs; Veterans Health Administration (VHA); University of California System; University of California San Francisco; University of Bern					NIDDK NIH HHS [P30 DK 47766, DK 39776, DK 31398] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK039776, P30DK047766, R01DK039776, R01DK031398] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AZZAM HS, 1993, J NATL CANCER I, V85, P1758, DOI 10.1093/jnci/85.21.1758; BERGMANN U, 1995, BIOCHEMISTRY-US, V34, P2819, DOI 10.1021/bi00009a011; BORIES D, 1989, CELL, V59, P959, DOI 10.1016/0092-8674(89)90752-6; BRENNER CA, 1989, GENE DEV, V3, P848, DOI 10.1101/gad.3.6.848; BURSTEN SL, 1991, AM J PATHOL, V139, P371; CELIS JE, 1984, LEUKEMIA RES, V8, P143, DOI 10.1016/0145-2126(84)90135-8; CHEN JM, 1987, CELL, V48, P193, DOI 10.1016/0092-8674(87)90423-5; Chen Wen-Tien, 1992, Current Opinion in Cell Biology, V4, P802; CONNOLLY JA, 1988, EXP CELL RES, V174, P461, DOI 10.1016/0014-4827(88)90315-1; COURTOY PJ, 1980, J CELL BIOL, V87, P691, DOI 10.1083/jcb.87.3.691; CRABBE T, 1993, EUR J BIOCHEM, V218, P431, DOI 10.1111/j.1432-1033.1993.tb18393.x; DAVIES M, 1988, BIOCHEM J, V251, P419, DOI 10.1042/bj2510419; DAVIES M, 1992, KIDNEY INT, V41, P671, DOI 10.1038/ki.1992.103; DAVIES M, 1990, KLIN WOCHENSCHR, V68, P1145, DOI 10.1007/BF01798066; DEBENEDETTI A, 1991, NUCLEIC ACIDS RES, V19, P1925, DOI 10.1093/nar/19.8.1925; DOI T, 1992, P NATL ACAD SCI USA, V89, P2873, DOI 10.1073/pnas.89.7.2873; EDWARDS DR, 1987, EMBO J, V6, P1899, DOI 10.1002/j.1460-2075.1987.tb02449.x; ELGER M, 1993, AM J PATHOL, V142, P497; FIRESTEIN GS, 1992, AM J PATHOL, V140, P1309; FLOEGE J, 1992, LAB INVEST, V66, P485; FUNABIKI K, 1990, CLIN NEPHROL, V34, P239; HARALSON MA, 1987, LAB INVEST, V57, P513; HIRT B, 1967, J MOL BIOL, V26, P365, DOI 10.1016/0022-2836(67)90307-5; ISHIMURA E, 1989, AM J PATHOL, V134, P843; JOHNSON RJ, 1991, J CLIN INVEST, V87, P847, DOI 10.1172/JCI115089; KERR LD, 1988, J BIOL CHEM, V263, P16999; KIRCHHEIMER JC, 1987, FASEB J, V1, P125, DOI 10.1096/fasebj.1.2.3038646; KURKI P, 1988, J IMMUNOL METHODS, V109, P49, DOI 10.1016/0022-1759(88)90441-3; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LOVETT DH, 1983, KIDNEY INT, V23, P342, DOI 10.1038/ki.1983.25; LOVETT DH, 1988, KIDNEY INT, V34, P26, DOI 10.1038/ki.1988.141; LOVETT DH, 1992, AM J PATHOL, V141, P85; MARTI HP, 1993, BIOCHEM J, V291, P441, DOI 10.1042/bj2910441; MARTI HP, 1994, AM J PATHOL, V144, P82; MARTIN J, 1989, KIDNEY INT, V36, P790, DOI 10.1038/ki.1989.264; MARTIN J, 1994, KIDNEY INT, V46, P877, DOI 10.1038/ki.1994.345; MCCALL MJ, 1992, P NATL ACAD SCI USA, V89, P5710, DOI 10.1073/pnas.89.13.5710; McMillan JI, 1996, J CLIN INVEST, V97, P1094, DOI 10.1172/JCI118502; MCNAMARA CA, 1993, J CLIN INVEST, V91, P94, DOI 10.1172/JCI116206; MIGNATTI P, 1993, PHYSIOL REV, V73, P161, DOI 10.1152/physrev.1993.73.1.161; MILLER AD, 1993, METHOD ENZYMOL, V217, P581; MONTESANO R, 1990, CELL, V62, P435, DOI 10.1016/0092-8674(90)90009-4; MORODOMI T, 1992, BIOCHEM J, V285, P603, DOI 10.1042/bj2850603; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1989, ANN RHEUM DIS, V48, P645, DOI 10.1136/ard.48.8.645; OKADA Y, 1990, EUR J BIOCHEM, V194, P721, DOI 10.1111/j.1432-1033.1990.tb19462.x; OOMURA A, 1989, VIRCHOWS ARCH A, V415, P151, DOI 10.1007/BF00784353; PEPPER MS, 1993, J CELL BIOL, V122, P673, DOI 10.1083/jcb.122.3.673; POLLOCK AS, 1992, BIOCHEM J, V284, P725, DOI 10.1042/bj2840725; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SCHER W, 1987, LAB INVEST, V57, P607; STERZEL RB, 1982, KLIN WOCHENSCHR, V60, P1077, DOI 10.1007/BF01715838; STERZEL RB, 1988, IMMUNOPATHOLOGY RENA, P137; STRONGIN AY, 1995, J BIOL CHEM, V270, P5331, DOI 10.1074/jbc.270.10.5331; WANG E, 1989, J CELL PHYSIOL, V140, P418, DOI 10.1002/jcp.1041400303; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705; YOSHIOKA K, 1989, KIDNEY INT, V35, P1203, DOI 10.1038/ki.1989.111	57	142	147	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15074	15083		10.1074/jbc.271.25.15074	http://dx.doi.org/10.1074/jbc.271.25.15074			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663054	hybrid			2022-12-27	WOS:A1996UT10600065
J	Welter, JF; Gali, H; Crish, JF; Eckert, RL				Welter, JF; Gali, H; Crish, JF; Eckert, RL			Regulation of human involucrin promoter activity by POU domain proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTION FACTOR SCIP; TRANSGENIC MICE; EXPRESSION; CELLS; GENE; ACTIVATION; BINDS; DIFFERENTIATION; EPIDERMIS; EVOLUTION	POU domain transcription factors are expressed in the epidermis and are thought to be important regulators of keratinocyte gene expression, In the present article we demonstrate that POU transcription factors suppress transcription of the human involucrin (hINV) promoter, Cotransfection of pINV-2473, a construct containing 2473 base pairs of hINV upstream sequence linked to luciferase, with POU homeodomain transcription factors Oct1, Oct2, Brn4, SCIP, Skn1a or Sknli, results in a strong suppression of basal promoter activity, The hINV upstream region includes a consensus POU transcription factor binding site, 5'-ATGCAAAT-3', centered around nucleotide -1277, Although this site interacts with POU factors, assays of promoter activity for a series of progressive 5' end truncations demonstrate that this site is not required for POU factor-dependent transcriptional suppression, Suppression is observed with the shortest truncation construct tested, pINV-41, suggesting that this inhibition may be mediated by effects on TATA box proteins, SCIP mutants that lack transactivation or DNA binding domains were shown to suppress transcription, suggesting that the DNA binding and transactivation domains are not required for suppression, Moreover, cotransfection of the pINV-2473 with pKSM13(+)OCT, which contains a single consensus OCT binding site, results in an increase in basal promoter activity, suggesting that endogenous POU factors suppress hINV promoter activity, In addition to inhibiting basal transcription, POU transcription factors also suppress phorbol ester-stimulated hINV promoter activity, These studies suggest that suppression of hINV promoter activity does not require the amino-terminal segment of the POU factor or direct POU factor interaction with DNA and suggest that the suppression may be via indirect interaction with other proteins in the vicinity of the TATA box, Thus, involucrin joins the ranks of a small set of genes that are regulated by POU factors in an octamer binding site-independent manner.	CASE WESTERN RESERVE UNIV,SCH MED,DEPT PHYSIOL & BIOPHYS,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT DERMATOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT REPROD BIOL,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT BIOCHEM,CLEVELAND,OH 44106; CASE WESTERN RESERVE UNIV,SCH MED,DEPT ONCOL,CLEVELAND,OH 44106; AMER UNIV BEIRUT,DEPT BIOL,BEIRUT,LEBANON	Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; Case Western Reserve University; American University of Beirut					NIAMS NIH HHS [AR39750, AR41456] Funding Source: Medline; NIDDK NIH HHS [DK07678] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R55AR041456, P30AR039750, R01AR041456] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007678] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL VR, 1991, DEV BIOL, V147, P363, DOI 10.1016/0012-1606(91)90294-D; ANDERSEN B, 1993, SCIENCE, V260, P78, DOI 10.1126/science.7682011; ARNOSTI DN, 1993, EMBO J, V12, P157, DOI 10.1002/j.1460-2075.1993.tb05641.x; BAUMRUKER T, 1988, GENE DEV, V2, P1400, DOI 10.1101/gad.2.11.1400; BRUGGEMEIER U, 1991, CELL, V64, P565, DOI 10.1016/0092-8674(91)90240-Y; CARROLL JM, 1993, P NATL ACAD SCI USA, V90, P10270, DOI 10.1073/pnas.90.21.10270; CLERC RG, 1988, GENE DEV, V2, P1570, DOI 10.1101/gad.2.12a.1570; CRISH JF, 1993, DIFFERENTIATION, V53, P191, DOI 10.1111/j.1432-0436.1993.tb00708.x; ECKERT RL, 1993, J INVEST DERMATOL, V100, P613, DOI 10.1111/1523-1747.ep12472288; ECKERT RL, 1989, PHYSIOL REV, V69, P1316, DOI 10.1152/physrev.1989.69.4.1316; ECKERT RL, 1986, CELL, V46, P583, DOI 10.1016/0092-8674(86)90884-6; FAUS I, 1994, MOL CELL BIOL, V14, P3263, DOI 10.1128/MCB.14.5.3263; GERSTER T, 1990, EMBO J, V9, P1635, DOI 10.1002/j.1460-2075.1990.tb08283.x; HARA Y, 1992, P NATL ACAD SCI USA, V89, P3280, DOI 10.1073/pnas.89.8.3280; HE X, 1991, MOL CELL BIOL, V11, P1739, DOI 10.1128/MCB.11.3.1739; KAPILOFF MS, 1991, SCIENCE, V253, P786, DOI 10.1126/science.1652153; LEBOWITZ JH, 1989, GENE DEV, V3, P1625, DOI 10.1101/gad.3.10.1625; MONUKI ES, 1993, MECH DEVELOP, V42, P15, DOI 10.1016/0925-4773(93)90095-F; MONUKI ES, 1990, SCIENCE, V249, P1300, DOI 10.1126/science.1975954; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; MURTHY S, 1993, J STRUCT BIOL, V111, P68, DOI 10.1006/jsbi.1993.1037; NAKSHATRI H, 1995, J BIOL CHEM, V270, P19613, DOI 10.1074/jbc.270.33.19613; NELSON C, 1988, SCIENCE, V239, P1400, DOI 10.1126/science.2831625; POELLINGER L, 1989, NATURE, V337, P573, DOI 10.1038/337573a0; RICE RH, 1979, CELL, V18, P681, DOI 10.1016/0092-8674(79)90123-5; SCHOLER HR, 1991, TRENDS GENET, V7, P323, DOI 10.1016/0168-9525(91)90422-M; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; SUZUKI N, 1990, EMBO J, V9, P3723, DOI 10.1002/j.1460-2075.1990.tb07585.x; TREACY MN, 1992, ANNU REV NEUROSCI, V15, P139, DOI 10.1146/annurev.ne.15.030192.001035; VOSS JW, 1991, GENE DEV, V5, P1309, DOI 10.1101/gad.5.7.1309; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; Welter JF, 1995, ONCOGENE, V11, P2681; WELTER JF, 1995, J BIOL CHEM, V270, P12614, DOI 10.1074/jbc.270.21.12614; YANG XD, 1994, J BIOL CHEM, V269, P10252; YUKAWA K, 1993, GENE, V133, P163; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	37	54	57	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14727	14733		10.1074/jbc.271.25.14727	http://dx.doi.org/10.1074/jbc.271.25.14727			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663077				2022-12-27	WOS:A1996UT10600017
J	Zhang, X; Jeyakumar, M; Bagchi, MK				Zhang, X; Jeyakumar, M; Bagchi, MK			Ligand-dependent cross-talk between steroid and thyroid hormone receptors - Evidence for common transcriptional coactivator(s)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN PROGESTERONE-RECEPTOR; HUMAN GLUCOCORTICOID RECEPTOR; CELL-FREE TRANSCRIPTION; PREINITIATION COMPLEX; ESTROGEN-RECEPTOR; TRANS-ACTIVATION; RETINOIC ACID; MECHANISM; ELEMENT; GENES	Steroid and thyroid hormone receptors exhibit striking structural and functional similarity, suggesting that these nuclear receptors may enhance transcription of target genes by similar mechanisms, To address this issue, we studied transcriptional interference between progesterone and thyroid hormone receptors in vivo and in vitro, We observed that transcriptional interference occurred in a ligand-dependent manner between progesterone receptor-B (PR-B) and thyroid hormone receptor (TR) alpha or beta in transient transfection experiments. Ligand-occupied TR alpha or TR beta, but not the unliganded receptor, strongly suppressed transactivation of a progesterone responsive reporter gene by endogenous PRs in human breast carcinoma T47D cells, Ligand dependent inhibitory cross-talk also occurred between transfected PR-B and TR alpha or TR beta and vice versa in CV1 cells, This phenomenon did not require DNA binding by the ''interfering'' receptor but required it to be hormone-bound, indicating that a transcriptionally active form of the interfering receptor is essential for the interfering effect, To analyze further the mechanism of the ligand-dependent cross talk, we reproduced transcriptional interference between PR and TR in a cell-free transcription system, We observed that the addition of triiodothyronine-bound recombinant TR beta or a ligand binding domain (LED) peptide (145-456) inhibited specifically transcriptional activation of a progesterone-responsive gene by endogenous PRs in nuclear extracts of T47D cells, while the basal level of transcription from a minimal TATA promoter or transcription from an adenovirus major-late promoter remained unaffected. These results indicated that a transactivation function within the LED of the interfering receptor TR beta was likely to interact with a mediator protein(s), termed coactivator, that is distinct from basal transcription factors and is critical for efficient PR-induced transactivation, This concept was reinforced by biochemical evidence that treatment of T47D extracts with immobilized TR beta LED depleted the extract of the coactivator function in a triiodothyronine-dependent manner and markedly impaired progesterone-induced transactivation of progesterone response element-linked genes. Deletion of six amino acids (451-456) in the extreme COOH terminus of TR beta resulted in a receptor that retained the ability to bind thyroid hormone but failed to inhibit progesterone-dependent transcription, Interestingly, these six amino acids are present in a region that is highly conserved among various nuclear hormone receptors and contains a ligand-dependent transactivation function, AF-2. Based on these results, we propose that a limiting coactivator protein(s) interacts with the AF-2 of PR or TR and mediates transactivation by the ligand-bound receptor. This regulatory molecule(s) may therefore serve as a common functional link between the pathways of hormone-inducible gene activation by various members of the nuclear receptor superfamily.	POPULAT COUNCIL, NEW YORK, NY 10021 USA; ROCKEFELLER UNIV, NEW YORK, NY 10021 USA	Population Council; Rockefeller University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK050257] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 50257-01] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAGCHI MK, 1990, NATURE, V345, P547, DOI 10.1038/345547a0; BAGCHI MK, 1990, J BIOL CHEM, V265, P5129; BAGCHI MK, 1988, MOL ENDOCRINOL, V2, P1221, DOI 10.1210/mend-2-12-1221; BANIAHMAD A, 1995, MOL CELL BIOL, V15, P76, DOI 10.1128/MCB.15.1.76; BANIAHMAD A, 1993, P NATL ACAD SCI USA, V90, P8832, DOI 10.1073/pnas.90.19.8832; BARETTINO D, 1994, EMBO J, V13, P3039, DOI 10.1002/j.1460-2075.1994.tb06603.x; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; CAVAILLES V, 1995, EMBO J, V14, P3741, DOI 10.1002/j.1460-2075.1995.tb00044.x; CHIBA H, 1994, NUCLEIC ACIDS RES, V22, P1815, DOI 10.1093/nar/22.10.1815; Chin W.W., 1991, NUCL HORMONE RECEPTO, P79; DANIELIAN PS, 1992, EMBO J, V11, P1025, DOI 10.1002/j.1460-2075.1992.tb05141.x; ELLISTON JF, 1990, MOL CELL BIOL, V10, P6607, DOI 10.1128/MCB.10.12.6607; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FONDELL JD, 1993, GENE DEV, V7, P1400, DOI 10.1101/gad.7.7b.1400; Gill G, 1992, CURR OPIN GENET DEV, V2, P236, DOI 10.1016/S0959-437X(05)80279-5; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1992, FASEB J, V6, P2524, DOI 10.1096/fasebj.6.8.1592204; HALACHMI S, 1994, SCIENCE, V264, P1455, DOI 10.1126/science.8197458; HERBOMEL P, 1984, CELL, V39, P653, DOI 10.1016/0092-8674(84)90472-0; HOFFMANN A, 1991, NUCLEIC ACIDS RES, V19, P6337, DOI 10.1093/nar/19.22.6337; HOLLENBERG SM, 1988, CELL, V55, P899, DOI 10.1016/0092-8674(88)90145-6; HORWITZ KB, 1983, ENDOCRINOLOGY, V113, P2195, DOI 10.1210/endo-113-6-2195; ING NH, 1992, J BIOL CHEM, V267, P17617; JACQ X, 1994, CELL, V79, P107, DOI 10.1016/0092-8674(94)90404-9; KLEINHITPASS L, 1990, CELL, V60, P247, DOI 10.1016/0092-8674(90)90740-6; KWOK RPS, 1994, NATURE, V370, P223, DOI 10.1038/370223a0; LEE JW, 1995, MOL ENDOCRINOL, V9, P243; LEE JW, 1995, NATURE, V374, P91, DOI 10.1038/374091a0; MARKS MS, 1992, EMBO J, V11, P1419, DOI 10.1002/j.1460-2075.1992.tb05187.x; MEYER ME, 1989, CELL, V57, P433, DOI 10.1016/0092-8674(89)90918-5; MEYER ME, 1990, EMBO J, V9, P3923, DOI 10.1002/j.1460-2075.1990.tb07613.x; MUCHARDT C, 1993, EMBO J, V12, P4279, DOI 10.1002/j.1460-2075.1993.tb06112.x; NAGPAL S, 1993, EMBO J, V12, P2349, DOI 10.1002/j.1460-2075.1993.tb05889.x; ONATE SA, 1995, SCIENCE, V270, P1354; PUGH BF, 1990, CELL, V61, P1187, DOI 10.1016/0092-8674(90)90683-6; SAATCIOGLU F, 1993, CELL, V75, P1095, DOI 10.1016/0092-8674(93)90319-L; SADOVSKY Y, 1995, MOL CELL BIOL, V15, P1554; SCHOLER HR, 1991, CELL, V66, P291, DOI 10.1016/0092-8674(91)90619-A; THOMPSON CC, 1989, P NATL ACAD SCI USA, V86, P3494, DOI 10.1073/pnas.86.10.3494; TONG GX, 1995, J BIOL CHEM, V270, P10601, DOI 10.1074/jbc.270.18.10601; TORA L, 1989, CELL, V59, P477, DOI 10.1016/0092-8674(89)90031-7; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1990, J BIOL CHEM, V265, P17055; TSAI SY, 1989, CELL, V57, P443, DOI 10.1016/0092-8674(89)90919-7; UMESONO K, 1988, NATURE, V336, P262, DOI 10.1038/336262a0; VEGETO E, 1992, CELL, V69, P703, DOI 10.1016/0092-8674(92)90234-4; VEGETO E, 1993, MOL ENDOCRINOL, V7, P1244, DOI 10.1210/me.7.10.1244; WEBSTER NJG, 1988, CELL, V54, P199, DOI 10.1016/0092-8674(88)90552-1; YEN PM, 1995, ENDOCRINOLOGY, V136, P440, DOI 10.1210/en.136.2.440; YOSHINAGA SK, 1992, SCIENCE, V258, P1598, DOI 10.1126/science.1360703	50	35	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14825	14833		10.1074/jbc.271.25.14825	http://dx.doi.org/10.1074/jbc.271.25.14825			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662980				2022-12-27	WOS:A1996UT10600031
J	Kimura, EA; Couto, AS; Peres, VJ; Casal, OL; Katzin, AM				Kimura, EA; Couto, AS; Peres, VJ; Casal, OL; Katzin, AM			N-linked glycoproteins are related to schizogony of the intraerythrocytic stage in Plasmodium falciparum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HISTIDINE-RICH PROTEIN; HUMAN-ERYTHROCYTES; MALARIA; SURFACE; BIOSYNTHESIS; ANTIGENS; CELLS; GLYCOSYLATION; MEROZOITES; PARASITE	Although the existence of O-linked oligosaccharide residues in glycoproteins of Plasmodium falciparum has been shown, the existence of N-linked glycoproteins is still a matter of controversy and skepticism. This report demonstrates the unequivocal presence of N-linked glycoproteins in P. falciparum, principally in the ring and young trophozoite stages of the intraerythrocytic cycle. These glycoproteins lose their capacity to bind to concanavalin A-Sepharose after treatment of cultures with tunicamycin under conditions that do not affect protein synthesis. When the glycoproteins were treated with N-Glycanase(R), oligosaccharides were released, It was possible to identify an N-linked glycoprotein of >200 kDa in the ring stage and also N-linked glycoproteins in the range of 200-30 kDa in the trophozoite stage. Treatment of trophozoites with 12 mu M tunicamycin inhibited differentiation to the schizont stage. To our knowledge, this is the first report in the literature unequivocally showing N-linked glycoproteins in trophozoites of P. falciparum as well as their importance for the differentiation of the intraerythrocytic stages of this parasite.	UNIV BUENOS AIRES, FAC CIENCIAS EXACTAS & NAT, DEPT QUIM ORGAN, RA-1428 BUENOS AIRES, DF, ARGENTINA; UNIV SAO PAULO, INST QUIM, DEPT BIOQUIM, BR-05508 SAO PAULO, BRAZIL	University of Buenos Aires; Universidade de Sao Paulo	Kimura, EA (corresponding author), UNIV SAO PAULO, INST CIENCIAS BIOMED, DEPT PARASITOL, AV LINEU PRESTES 1374, BR-05508900 SAO PAULO, SP, BRAZIL.		Katzin, Alejandro/E-9862-2013	Katzin, Alejandro/0000-0002-4782-2162				BLANKEN WM, 1985, ANAL BIOCHEM, V145, P322, DOI 10.1016/0003-2697(85)90369-0; BRAUNBRETON C, 1986, MOL BIOCHEM PARASIT, V20, P33, DOI 10.1016/0166-6851(86)90140-4; DIECKMANN-SCHUPPERT A, 1992, Biochemical Society Transactions, V20, p184S; DIECKMANNSCHUPPERT A, 1992, EUR J BIOCHEM, V205, P815, DOI 10.1111/j.1432-1033.1992.tb16846.x; DIECKMANNSCHUPPERT A, 1994, BBA-GEN SUBJECTS, V1199, P37, DOI 10.1016/0304-4165(94)90093-0; DIECKMANNSCHUPPERT A, 1993, EUR J BIOCHEM, V216, P779, DOI 10.1111/j.1432-1033.1993.tb18198.x; ELBEIN AD, 1987, ANNU REV BIOCHEM, V56, P497, DOI 10.1146/annurev.biochem.56.1.497; ELMENDORF HG, 1994, J CELL BIOL, V124, P449, DOI 10.1083/jcb.124.4.449; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FUNK VA, 1994, MOL BIOCHEM PARASIT, V63, P23, DOI 10.1016/0166-6851(94)90005-1; HALDAR K, 1989, J CELL BIOL, V108, P2183, DOI 10.1083/jcb.108.6.2183; HASELBECK A, 1990, ANAL BIOCHEM, V191, P25, DOI 10.1016/0003-2697(90)90381-I; HOLDER AA, 1985, NATURE, V317, P270, DOI 10.1038/317270a0; HOLDER AA, 1982, J EXP MED, V156, P1528, DOI 10.1084/jem.156.5.1528; HOWARD RF, 1984, MOL BIOCHEM PARASIT, V10, P319, DOI 10.1016/0166-6851(84)90030-6; HOWARD RJ, 1984, MOL BIOCHEM PARASIT, V11, P349, DOI 10.1016/0166-6851(84)90078-1; HOWARD RJ, 1986, J CELL BIOL, V103, P1269, DOI 10.1083/jcb.103.4.1269; KATZIN AM, 1983, BIOCHIM BIOPHYS ACTA, V727, P403, DOI 10.1016/0005-2736(83)90425-X; KATZIN AM, 1991, AM J TROP MED HYG, V45, P453, DOI 10.4269/ajtmh.1991.45.453; KILEJIAN A, 1980, P NATL ACAD SCI-BIOL, V77, P3695, DOI 10.1073/pnas.77.6.3695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON O, 1993, J CELL SCI, V106, P299; Lis H., 1986, LECTINS PROPERTIES F, P293; MALEY F, 1989, ANAL BIOCHEM, V180, P195, DOI 10.1016/0003-2697(89)90115-2; MCBRIDE JS, 1987, MOL BIOCHEM PARASIT, V23, P71, DOI 10.1016/0166-6851(87)90189-7; PASVOL G, 1978, ANN TROP MED PARASIT, V72, P87, DOI 10.1080/00034983.1978.11719283; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; POLOGE LG, 1987, P NATL ACAD SCI USA, V84, P7139, DOI 10.1073/pnas.84.20.7139; RAGGE K, 1990, MOL BIOCHEM PARASIT, V42, P93, DOI 10.1016/0166-6851(90)90116-4; RAMASAMY R, 1987, IMMUNOL CELL BIOL, V65, P147, DOI 10.1038/icb.1987.16; REARICK JI, 1981, J BIOL CHEM, V256, P6255; SCHMIDTULLRICH R, 1986, J EXP MED, V163, P179, DOI 10.1084/jem.163.1.179; SCHWARZ RT, 1987, HOST PARASITIC CELLU, P275; STANLEY P, 1993, CELL SURFACE EXTRACE, P181; THOTAKURA NR, 1987, METHOD ENZYMOL, V138, P350; TRAGER W, 1976, SCIENCE, V193, P673, DOI 10.1126/science.781840; TRETTER V, 1991, EUR J BIOCHEM, V199, P647, DOI 10.1111/j.1432-1033.1991.tb16166.x; UDDIN N, 1992, BIOCH INT, V27, P55; UDEINYA IJ, 1981, PHARMACOLOGY, V23, P165, DOI 10.1159/000137545; VARKI A, 1994, METHOD ENZYMOL, V230, P16; WERNSDORFER WH, 1980, B WORLD HEALTH ORGAN, V58, P341; WILSON ME, 1989, J IMMUNOL, V143, P678; WILSON RJM, 1980, NATURE, V284, P451, DOI 10.1038/284451a0; WRIGHT IG, 1988, PARASITOL TODAY, V4, P214, DOI 10.1016/0169-4758(88)90161-5; ZINGALES B, 1985, MOL BIOCHEM PARASIT, V16, P21, DOI 10.1016/0166-6851(85)90046-5; 1993, WEEKLY EPIDEMIOL REC, V68, P245	46	76	76	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14452	14461		10.1074/jbc.271.24.14452	http://dx.doi.org/10.1074/jbc.271.24.14452			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662869	hybrid			2022-12-27	WOS:A1996UQ66000076
J	Lowman, HB; Slagle, PH; DeForge, LE; Wirth, CM; GilleceCastro, BL; Bourell, JH; Fairbrother, WJ				Lowman, HB; Slagle, PH; DeForge, LE; Wirth, CM; GilleceCastro, BL; Bourell, JH; Fairbrother, WJ			Exchanging interleukin-8 and melanoma growth-stimulating activity receptor binding specificities	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUTROPHIL-ACTIVATING PEPTIDE-2; HIGH-AFFINITY; AMINO TERMINUS; LIGAND; MUTAGENESIS; RESIDUES; FORMS; IL-8	Interleukin-8 (IL-8), a CXC chemokine, is known to bring about chemotaxis and activation of neutrophils through high affinity binding to at least two distinct receptors, receptor A and receptor-B. The IL-8 homolog melanoma growth stimulating activity (MGSA) is also active toward neutrophils. In contrast to IL-8, MGSA binds receptor-B with high affinity and binds receptor-A with similar to 400-fold lower affinity, Using the structure of IL-8 (Clore ct al. (1990) Biochemistry, 29, 1689-1696; Baldwin et al. (1991) Proc. Natl. Acad. Sci. U.S.A. 88, 502-506) and the NMR-determined structure of MGSA (Fairbrother et al. (1994) J. Mel. Biol. 242, 252-270), we designed variants of both IL-8 and MGSA to investigate the basis of specificity for binding of these chemokines to the IL-8 receptors. The most outstanding structural difference between lL-8 and MGSA lies in the loop preceding the first beta-strand, When the corresponding (shorter) loop from MGSA was swapped into IL-8, both receptor-A and receptor-B binding affinities were significantly (>300-fold) reduced, However, with additional mutations that affect packing interactions, an IL-8 variant specific for receptor-B binding was produced. Conversely, when the same loop from IL-8 was swapped into MGSA, receptor-B binding was maintained with only a similar to 30-fold reduction in receptor-A affinity. Again, mutations affecting packing of the loop yielded a MGSA variant with high affinity for both receptors, like IL-8. Finally, we show, through point mutations in a monomeric IL-8 framework, that individual side chain substitutions can affect receptor specificity.	GENENTECH INC,DEPT PROT ENGN,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT BIOANALYT TECHNOL,S SAN FRANCISCO,CA 94080; GENENTECH INC,DEPT PROT CHEM,S SAN FRANCISCO,CA 94080	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech								BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BALDWIN ET, 1991, P NATL ACAD SCI USA, V88, P502, DOI 10.1073/pnas.88.2.502; BERMAN PW, 1993, J CELL BIOCHEM, V52, P183, DOI 10.1002/jcb.240520210; BESEMER J, 1993, CYTOKINE, V5, P512, DOI 10.1016/1043-4666(93)90043-5; BURROWS SD, 1994, BIOCHEMISTRY-US, V33, P12741, DOI 10.1021/bi00209a002; CERRETTI DP, 1993, MOL IMMUNOL, V30, P359; CHANG CN, 1987, GENE, V55, P189, DOI 10.1016/0378-1119(87)90279-4; CLARKLEWIS I, 1991, J BIOL CHEM, V266, P23128; CLARKLEWIS I, 1994, J BIOL CHEM, V269, P16075; CLARKLEWIS I, 1993, P NATL ACAD SCI USA, V90, P3574, DOI 10.1073/pnas.90.8.3574; CLORE GM, 1990, BIOCHEMISTRY-US, V29, P1689, DOI 10.1021/bi00459a004; CLUBB RT, 1994, FEBS LETT, V338, P93, DOI 10.1016/0014-5793(94)80123-1; Dewald B, 1986, Methods Enzymol, V132, P267; FAIRBROTHER WJ, 1994, J MOL BIOL, V242, P252, DOI 10.1006/jmbi.1994.1577; GAYLE RB, 1993, J BIOL CHEM, V268, P7283; HEBERT CA, 1993, J BIOL CHEM, V268, P18549; HEBERT CA, 1991, J BIOL CHEM, V266, P18989; HEBERT CA, 1990, J IMMUNOL, V145, P3033; HESSELGESSER J, 1995, J BIOL CHEM, V270, P11472, DOI 10.1074/jbc.270.19.11472; HOLMES WE, 1991, SCIENCE, V253, P1278, DOI 10.1126/science.1840701; HORUK R, 1993, J BIOL CHEM, V268, P541; KIM KS, 1994, J BIOL CHEM, V269, P32909; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE J, 1992, J BIOL CHEM, V267, P16283; LEONG SR, 1994, J BIOL CHEM, V269, P19343; LOWMAN HB, 1991, BIOCHEMISTRY-US, V30, P10832, DOI 10.1021/bi00109a004; MALKOWSKI MG, 1995, J BIOL CHEM, V270, P7077, DOI 10.1074/jbc.270.13.7077; MOSER B, 1991, J BIOL CHEM, V266, P10666; MOSER B, 1993, J BIOL CHEM, V268, P7125; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; MURPHY PM, 1991, SCIENCE, V253, P1280, DOI 10.1126/science.1891716; PAOLINI JF, 1994, J IMMUNOL, V153, P2704; PETERSEN F, 1994, J IMMUNOL, V152, P2467; PEVERI P, 1988, J EXP MED, V167, P1547, DOI 10.1084/jem.167.5.1547; RAJARATHNAM K, 1994, SCIENCE, V264, P90, DOI 10.1126/science.8140420; RAJARATHNAM K, 1994, BIOCHEMISTRY-US, V33, P6623, DOI 10.1021/bi00187a032; SATOW Y, 1986, J MOL BIOL, V190, P593, DOI 10.1016/0022-2836(86)90245-7; SCHRAUFSTATTER IU, 1995, J BIOL CHEM, V270, P10428, DOI 10.1074/jbc.270.18.10428; SCHRAUFSTATTER IU, 1993, J IMMUNOL, V151, P6418; SCHUMACHER C, 1992, P NATL ACAD SCI USA, V89, P10542, DOI 10.1073/pnas.89.21.10542	41	69	74	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14344	14352		10.1074/jbc.271.24.14344	http://dx.doi.org/10.1074/jbc.271.24.14344			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662882				2022-12-27	WOS:A1996UQ66000062
J	Prins, BA; Weber, MJ; Hu, RM; Pedram, A; Daniels, M; Levin, ER				Prins, BA; Weber, MJ; Hu, RM; Pedram, A; Daniels, M; Levin, ER			Atrial natriuretic peptide inhibits mitogen-activated protein kinase through the clearance receptor - Potential role in the inhibition of astrocyte proliferation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; RAT MESANGIAL CELLS; SIGNAL-TRANSDUCTION; ENDOTHELIAL-CELLS; C-RECEPTOR; PHOSPHORYLATION; CAMP; PATHWAY; GENE	The modulation of the activity of mitogen-activated protein kinase (MAPK) by endogenous growth factors or growth inhibitors provides a potential means of regulating cell proliferation. We determined the effect of the endogenous anti proliferative peptide, atrial natriuretic peptide (ANP), on the ability of MAPK to phosphorylate myelin basic protein. In astrocytes, MAPK activity was significantly stimulated (up to 3-fold) by three known glial mitogens, endothelin-3, platelet-derived growth factor, or phorbol la-myristate 13-acetate. ANP inhibited by 55-70% the ability of each of these mitogens to activate MAPK. The effects of ANP were equipotent to those caused by C-ANP 4-23, a peptide that specifically binds to the natriuretic peptide clearance receptor. Additionally, both natriuretic peptides caused a 70-80% inhibition of the sodium vanadate stimulated MAPK activity, complete inhibition of the okadaic acid stimulated activity, and inhibition of the mitogen-stimulated phosphorylation of MAPK. To understand the potential mechanism by which the natriuretic peptides act, we found that both ANP and C-ANP inhibited the mitogen-stimulated activity of the immediate upstream kinase in the cascade, MAPK kinase (MEK). C-ANP also strongly inhibited the endothelin-3-, platelet-derived growth factor-, and phorbol 12-myristate 13-acetate-induced stimulation of DNA synthesis in the astrocytes, while both okadaic acid and sodium vanadate significantly reversed these anti-proliferative actions. Our results identify ANP as a peptide hormone that inhibits growth factor-stimulated MAPK. These data suggest that the ability of the natriuretic peptides to inhibit MAPK may be important for their anti-growth actions. This effect likely occurs via the inhibition of upstream kinase(s), including MEK, uniquely resulting from ligand binding to the natriuretic peptide clearance receptor.	VET ADM MED CTR,MED SERV 111I,LONG BEACH,CA 90822; UNIV CALIF IRVINE,DEPT MED,IRVINE,CA 92717; UNIV CALIF IRVINE,DEPT PHARMACOL,IRVINE,CA 92717; UNIV VIRGINIA,HLTH SCI CTR,DEPT MICROBIOL,CHARLOTTESVILLE,VA 22908	US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Long Beach Healthcare System; University of California System; University of California Irvine; University of California System; University of California Irvine; University of Virginia			Levin, Ellis/J-5402-2013		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050161] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM047332] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS030521] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50161] Funding Source: Medline; NIGMS NIH HHS [GM47332] Funding Source: Medline; NINDS NIH HHS [NS-30521] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ANANDSRIVASTAVA.MB, 1990, J BIOL CHEM, V265, P8526; ARENANDER AT, 1989, J NEUROSCI RES, V23, P257, DOI 10.1002/jnr.490230303; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; CAHILL PA, 1994, AM J PHYSIOL, V266, pR194, DOI 10.1152/ajpregu.1994.266.1.R194; CAZAUBON S, 1993, BIOCHEM J, V293, P381, DOI 10.1042/bj2930381; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; HER JH, 1993, BIOCHEM J, V296, P25, DOI 10.1042/bj2960025; HU RM, 1994, J CLIN INVEST, V93, P1820, DOI 10.1172/JCI117167; ISHIDA Y, 1992, FEBS LETT, V310, P41, DOI 10.1016/0014-5793(92)81142-9; ITOH H, 1992, HYPERTENSION, V19, P758, DOI 10.1161/01.HYP.19.6.758; KHARBANDA S, 1993, CELL GROWTH DIFFER, V4, P17; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LEVIN E R, 1991, Molecular and Cellular Neuroscience, V2, P189, DOI 10.1016/1044-7431(91)90044-O; LEVIN ER, 1991, AM J PHYSIOL, V261, pR453, DOI 10.1152/ajpregu.1991.261.2.R453; LEVIN ER, 1990, J BIOL CHEM, V265, P10019; LEVIN ER, 1993, AM J PHYSIOL, V264, pE483, DOI 10.1152/ajpendo.1993.264.4.E483; LEVIN ER, 1992, J NEUROCHEM, V58, P659, DOI 10.1111/j.1471-4159.1992.tb09768.x; MAACK T, 1992, ANNU REV PHYSIOL, V54, P11, DOI 10.1146/annurev.physiol.54.1.11; MAACK T, 1987, SCIENCE, V238, P675, DOI 10.1126/science.2823385; OKOLICANY J, 1990, KIDNEY INT, V37, P342; OTTLINGER ME, 1993, J BIOL CHEM, V268, P19173; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; SATOH T, 1992, J BIOL CHEM, V267, P24149; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SIMONSON MS, 1993, J BIOL CHEM, V268, P9347; SUGIMOTO T, 1993, BIOCHEM BIOPH RES CO, V195, P72, DOI 10.1006/bbrc.1993.2011; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WONG SKF, 1992, J CLIN INVEST, V90, P299, DOI 10.1172/JCI115862; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHOU W, 1993, J BIOL CHEM, V268, P23041	34	89	93	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14156	14162		10.1074/jbc.271.24.14156	http://dx.doi.org/10.1074/jbc.271.24.14156			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662898	hybrid			2022-12-27	WOS:A1996UQ66000035
J	Shimazaki, Y; Nishiki, T; Omori, A; Sekiguchi, M; Kamata, Y; Kozaki, S; Takahashi, M				Shimazaki, Y; Nishiki, T; Omori, A; Sekiguchi, M; Kamata, Y; Kozaki, S; Takahashi, M			Phosphorylation of 25-kDa synaptosome-associated protein - Possible involvement in protein kinase C-mediated regulation of neurotransmitter release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LONG-TERM POTENTIATION; PC12 CELLS; IDENTIFICATION; SYNAPTOTAGMIN; ACTIVATION; RECEPTORS; CALCIUM; FAMILY; FUSION	Protein kinase C-mediated phosphorylation of a 25-kDa synaptosome-associated protein (SNAP-25) was examined in living PC12 cells, Phorbol 12-myristate 13 acetate treatment enhanced high potassium-induced [H-3]-norepinephrine release, and a 28-kDa protein recognized by an anti-SNAP-25 antibody was phosphorylated on Ser residues. The molecular size of the phosphorylated band decreased slightly following treatment with Clostridium botulinum type A neurotoxin, whereas the band disappeared after treatment with botulinum type E neurotoxin, indicating that the 28-kDa protein was SNAP-25, A phosphorylation is likely to occur at Ser(187), as this is the only Ser residue located between the cleavage sites of botulinum type A and E neurotoxins, SNAP-25 of PC12 cells was phosphorylated by purified protein kinase C in vitro, and the amount of syntaxin co immunoprecipitated with SNAP-25 was decreased by phosphorylation, These results suggest that the phosphorylation of SNAP-25 may be involved in protein kinase C-mediated regulation of catecholamine release from PC12 cells.	MITSUBISHI KASEI INST LIFE SCI,MACHIDA,TOKYO 194,JAPAN; UNIV OSAKA PREFECTURE,COLL AGR,DEPT VET SCI,SAKAI,OSAKA 593,JAPAN	Osaka Metropolitan University								BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1993, J NEUROSCI, V13, P1701; BINZ T, 1994, J BIOL CHEM, V269, P1617; BLACKSHEAR PJ, 1993, J BIOL CHEM, V268, P1501; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; COGGINS PJ, 1991, J NEUROCHEM, V56, P1095, DOI 10.1111/j.1471-4159.1991.tb11398.x; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HIGASHI H, 1992, J BIOL CHEM, V267, P9831; HUNT JM, 1994, NEURON, V12, P1269, DOI 10.1016/0896-6273(94)90443-X; ISOSAKI M, 1994, JPN J PHARMACOL, V64, P217, DOI 10.1254/jjp.64.217; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KITAMURA M, 1968, BIOCHIM BIOPHYS ACTA, V168, P207, DOI 10.1016/0005-2795(68)90144-X; MALINOW R, 1988, NATURE, V335, P820, DOI 10.1038/335820a0; MILLER RJ, 1985, TRENDS NEUROSCI, V8, P463, DOI 10.1016/0166-2236(85)90169-9; MITSUI K, 1990, FEBS LETT, V268, P157, DOI 10.1016/0014-5793(90)80997-W; MONTECUCCO C, 1994, MOL MICROBIOL, V13, P1, DOI 10.1111/j.1365-2958.1994.tb00396.x; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; Niemann Heiner, 1994, Trends in Cell Biology, V4, P179, DOI 10.1016/0962-8924(94)90203-8; NISHIKI T, 1994, J BIOL CHEM, V269, P10498; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; POZZAN T, 1984, J CELL BIOL, V99, P628, DOI 10.1083/jcb.99.2.628; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SCHELLER RH, 1995, NEURON, V14, P893; SCHIAVO G, 1993, FEBS LETT, V335, P99, DOI 10.1016/0014-5793(93)80448-4; SHOJIKASAI Y, 1992, SCIENCE, V256, P1820, DOI 10.1126/science.256.5065.1820; SHOJIKASAI Y, 1994, FEBS LETT, V353, P315, DOI 10.1016/0014-5793(94)01069-2; SOLLNER T, 1993, CELL, V75, P409, DOI 10.1016/0092-8674(93)90376-2; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; SUGII S, 1975, INFECT IMMUN, V12, P1262, DOI 10.1128/IAI.12.6.1262-1270.1975; TAKAHASHI M, 1989, BIOCHEM BIOPH RES CO, V163, P1182, DOI 10.1016/0006-291X(89)92345-0; TAKAHASHI M, 1991, BRAIN RES, V551, P279, DOI 10.1016/0006-8993(91)90942-O; YOSHIDA A, 1992, J BIOL CHEM, V267, P24925	36	215	222	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14548	14553		10.1074/jbc.271.24.14548	http://dx.doi.org/10.1074/jbc.271.24.14548			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662851	hybrid			2022-12-27	WOS:A1996UQ66000090
J	Gundimeda, U; Chen, ZH; Gopalakrishna, R				Gundimeda, U; Chen, ZH; Gopalakrishna, R			Tamoxifen modulates protein kinase C via oxidative stress in estrogen receptor-negative breast cancer cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ARACHIDONIC-ACID METABOLISM; TUMOR-PROMOTING ACTIVITY; LIPID-PEROXIDATION; MOUSE SKIN; NONSTEROIDAL ANTIESTROGEN; HYDROGEN-PEROXIDE; TISSUE-CULTURE; BINDING-SITES; RAT; ACTIVATION	Nonsteroidal agent tamoxifen (Tam), a therapeutic/chemopreventive agent for breast cancer, inhibits protein kinase C (PKC), which is considered tea be one of its extra-estrogen receptor sites of action, This drug is required at higher (> 100 mu M) concentrations to inhibit PKC in the test tube, whereas it is required at lower (1-10 mu M) concentrations to induce inhibition of cell growth in estrogen receptor-negative cell types, To identify additional mechanisms of action of Tam on PKC and cell growth, studies with MDA-MB-231, an estrogen receptor-negative breast carcinoma cell type, have been carried out, Upon treatment with 5-20 mu M Tam, a cytosol to membrane translocation of PKC occurred within 30 min, which was then followed by a down-regulation of the enzyme within 2 h. A transient generation of Ca2+/lipid-independent activated form of PKC was observed during this period, Rapidly growing cells require nearly 2-3-fold lower concentrations (2-5 mu M) of Tam than do confluent cells to induce changes in PKC, Furthermore, phorbol ester binding observed with intact cells also decreased in Tam-treated cells only under the conditions PKC was inactivated, Unlike phorbol esters, Tam did not directly support the membrane association of PKC. The release of arachidonic acid correlated with the PKC membrane translocation. Studies carried out with [H-3]Tam revealed that Tam partitioned into the membrane, and there was no appreciable covalent association of [3H]Tam with cellular proteins within this limited time period (2 h). Various antioxidants (vitamin E, vitamin C, beta-carotene, catalase, and superoxide dismutase) inhibited all these cellular effects of Tam. Moreover, vitamin E strikingly blocked Tam-induced growth inhibition. To determine whether oxymetabolites of Tam can affect PKC permanently, OH-Tam was tested with purified PKC. In contrast to Tam, which reversibly inhibited PKC, OH-Tam permanently inactivated the enzyme by modifying the catalytic domain at lower concentrations. The vicinal thiols present within this domain were found to be required to induce this inactivation. This effect was partially blocked by various antioxidants. This is the first report showing the role of oxidative stress in mediating the actions of Tam. Taken together these results suggest that Tam, by initially partitioning into the membranes, induces a generation of transmembrane signals and an oxidative stress to elicit the membrane association of PKC, followed by an irreversible activation, and subsequent down-regulation of this enzyme, which, in part, may lead to cell growth inhibition.	UNIV SO CALIF, SCH MED, DEPT CELL & NEUROBIOL, LOS ANGELES, CA 90033 USA	University of Southern California					NATIONAL CANCER INSTITUTE [R01CA062146] Funding Source: NIH RePORTER; NCI NIH HHS [CA62146] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BERTHOIS Y, 1986, P NATL ACAD SCI USA, V83, P2496, DOI 10.1073/pnas.83.8.2496; BHATTACHARYYA B, 1983, BIOCHEM PHARMACOL, V32, P2965, DOI 10.1016/0006-2952(83)90403-3; BIGNON E, 1990, FEBS LETT, V271, P54, DOI 10.1016/0014-5793(90)80370-X; BRUNNER N, 1993, CANCER RES, V53, P3229; CADENAS E, 1990, OXIDATIVE DAMAGE REP, P607; CHAN JKT, 1983, ENDOCRINOLOGY, V113, P2202, DOI 10.1210/endo-113-6-2202; CLARKE R, 1990, J NATL CANCER I, V82, P1702, DOI 10.1093/jnci/82.21.1702; COLLETTA AA, 1990, BRIT J CANCER, V62, P405, DOI 10.1038/bjc.1990.307; COONEY RV, 1992, CARCINOGENESIS, V13, P1107, DOI 10.1093/carcin/13.7.1107; CROXTALL JD, 1994, BIOCHEM PHARMACOL, V47, P197, DOI 10.1016/0006-2952(94)90006-X; DARBRE PD, 1984, CANCER RES, V44, P2790; DAVIES AM, 1995, CARCINOGENESIS, V16, P539, DOI 10.1093/carcin/16.3.539; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DLUGOSZ AA, 1991, CANCER RES, V51, P4677; DOWNES CP, 1981, BIOCHEM J, V198, P133, DOI 10.1042/bj1980133; EDASHIGE K, 1991, CELL STRUCT FUNCT, V16, P273, DOI 10.1247/csf.16.273; FISCHER SM, 1987, CANCER RES, V47, P3174; FRENKEL K, 1987, CARCINOGENESIS, V8, P455, DOI 10.1093/carcin/8.3.455; FURR BJA, 1984, PHARMACOL THERAPEUT, V25, P127, DOI 10.1016/0163-7258(84)90043-3; GOLDSTEIN BD, 1981, CANCER LETT, V11, P257, DOI 10.1016/0304-3835(81)90117-8; GOPALAKRISHNA R, 1995, METHOD ENZYMOL, V252, P132; GOPALAKRISHNA R, 1994, P NATL ACAD SCI USA, V91, P12233, DOI 10.1073/pnas.91.25.12233; GOPALAKRISHNA R, 1992, BIOCHEM BIOPH RES CO, V189, P950, DOI 10.1016/0006-291X(92)92296-A; GOPALAKRISHNA R, 1986, J BIOL CHEM, V261, P6438; GOPALAKRISHNA R, 1992, ANAL BIOCHEM, V206, P24, DOI 10.1016/S0003-2697(05)80006-5; GREENLEE WF, 1981, TOXICOL APPL PHARM, V59, P187, DOI 10.1016/0041-008X(81)90189-7; HAN XL, 1992, CANCER RES, V52, P1360; HENDERSON BE, 1993, SCIENCE, V259, P633, DOI 10.1126/science.8381558; HENNINGS H, 1987, CARCINOGENESIS, V8, P1343, DOI 10.1093/carcin/8.9.1343; HORWITZ KB, 1978, ENDOCRINOLOGY, V103, P1742, DOI 10.1210/endo-103-5-1742; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; ISSANDOU M, 1990, CANCER RES, V50, P5845; Jaken S, 1990, CURR OPIN CELL BIOL, V2, P192, DOI 10.1016/0955-0674(90)90006-Z; JORDAN VC, 1994, BREAST CANCER RES TR, V31, P41, DOI 10.1007/BF00689675; JORDAN VC, 1991, J NATL CANCER I, V83, P492, DOI 10.1093/jnci/83.7.492; KALYANARAMAN B, 1985, ENVIRON HEALTH PERSP, V64, P185, DOI 10.2307/3430009; KARNIK PS, 1994, CANCER RES, V54, P349; KENSLER TW, 1984, ENVIRON MUTAGEN, V6, P593, DOI 10.1002/em.2860060412; KILEY SC, 1992, CARCINOGENESIS, V13, P1997, DOI 10.1093/carcin/13.11.1997; KING CM, 1995, CARCINOGENESIS, V16, P1449, DOI 10.1093/carcin/16.7.1449; KISS Z, 1994, FEBS LETT, V355, P173, DOI 10.1016/0014-5793(94)01200-8; LAM HYP, 1984, BIOCHEM BIOPH RES CO, V118, P27, DOI 10.1016/0006-291X(84)91062-3; LAUGHTON MJ, 1989, BIOCHEM PHARMACOL, V38, P2859, DOI 10.1016/0006-2952(89)90442-5; LIPPMAN M, 1976, CANCER RES, V36, P4595; LIPPMAN ME, 1980, HORMONES CANCER, P3; MANI C, 1991, CANCER RES, V51, P6052; MARKS F, 1991, CARCINOGENESIS, V12, P1491, DOI 10.1093/carcin/12.8.1491; NAKADATE T, 1988, BIOCHEM PHARMACOL, V37, P1541, DOI 10.1016/0006-2952(88)90016-0; NATARAJAN V, 1993, J BIOL CHEM, V268, P930; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBRIAN CA, 1988, J NATL CANCER I, V80, P1628, DOI 10.1093/jnci/80.20.1628; OBRIAN CA, 1985, CANCER RES, V45, P2462; OBRIAN CA, 1986, J NATL CANCER I, V76, P1243; PARR IB, 1987, BIOCHEM PHARMACOL, V36, P1513, DOI 10.1016/0006-2952(87)90119-5; PENTLAND AP, 1992, J BIOL CHEM, V267, P15578; PRYOR WA, 1993, ANN NY ACAD SCI, V686, P12, DOI 10.1111/j.1749-6632.1993.tb39148.x; QUEST AFG, 1992, J BIOL CHEM, V267, P10193; REDDEL RR, 1983, CANCER RES, V43, P4618; ROY D, 1991, CANCER RES, V51, P3882; SALGO MG, 1993, ARCH BIOCHEM BIOPHYS, V304, P123, DOI 10.1006/abbi.1993.1330; SIPE HJ, 1994, CARCINOGENESIS, V15, P2637, DOI 10.1093/carcin/15.11.2637; SKEHAN P, 1990, J NATL CANCER I, V82, P1107, DOI 10.1093/jnci/82.13.1107; SLAGA TJ, 1981, SCIENCE, V213, P1023, DOI 10.1126/science.6791284; STOYANOVSKY DA, 1995, ARCH BIOCHEM BIOPHYS, V317, P315, DOI 10.1006/abbi.1995.1169; SU HD, 1985, BIOCHEM PHARMACOL, V34, P3649; SUDO K, 1983, ENDOCRINOLOGY, V112, P425, DOI 10.1210/endo-112-2-425; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; WATTS CKW, 1984, J BIOL CHEM, V259, P4223; WHITE INH, 1992, CARCINOGENESIS, V13, P2197, DOI 10.1093/carcin/13.12.2197; WILLIAMS GM, 1993, CARCINOGENESIS, V14, P315; WISEMAN H, 1990, FEBS LETT, V263, P192, DOI 10.1016/0014-5793(90)81371-T; YAGER JD, 1991, PREV MED, V20, P27, DOI 10.1016/0091-7435(91)90004-N; YOSHIZAWA S, 1990, CANCER RES, V50, P4974	74	133	138	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13504	13514		10.1074/jbc.271.23.13504	http://dx.doi.org/10.1074/jbc.271.23.13504			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662863	hybrid			2022-12-27	WOS:A1996UP38500032
J	AlRabiee, R; Lee, EJ; Grant, GA				AlRabiee, R; Lee, EJ; Grant, GA			The mechanism of velocity modulated allosteric regulation in D-3-phosphoglycerate dehydrogenase - Cross-linking adjacent regulatory domains with engineered disulfides mimics effector binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article								D-3-Phosphoglycerate dehydrogenase (PGDH) (EC 1.1.1.95) from Escherichia coli is an allosterically regulated enzyme of the V-max type, It is a tetramer of identical subunits and each subunit is made up of three identifiable domains, the cofactor binding domain, the substrate binding domain, and the regulatory domain, Each subunit contacts two other subunits through adjacent cofactor binding domains and through adjacent regulatory domains, L-Serine, the physiological effector, inhibits catalytic activity by apparently tethering regulatory domains from adjacent subunits together through the formation of hydrogen bonds to each subunit, This investigation demonstrates that cross-linking adjacent regulatory domains with engineered disulfides produces catalytic inhibition in the absence of inhibitor in a manner similar to that produced by the inhibitor, The inhibition due to cross-linking can be completely reversed in a concentration dependent manner by dithiothreitol, The active mutant enzyme, containing the engineered cysteines in the reduced state, retains its ability to be inhibited by L-serine, although at a 100-fold higher concentration, Hill plots of the serine inhibition of mutant and native enzyme indicate that the number of interacting sites remains at 2 in the mutant enzyme, The reversible inhibition of enzyme activity that results from tethering adjacent regulatory domains with engineered disulfides suggests that these domains move in some manner relative to one another during the active to inhibited state transition, These observations support the model which predicts that catalytic activity is regulated by the movement of rigid domains about flexible hinges and that effector binding prevents this by locking the regulatory domains in a state that produces an open active site cleft.	WASHINGTON UNIV,SCH MED,DEPT MOLEC BIOL & PHARMACOL,ST LOUIS,MO 63110	Washington University (WUSTL)								CORMACK B, 1991, CURRENT PROTOCOLS MO; CRANKSHAW MW, 1996, CURRENT PROTOCOLS PR; EHRLICH JI, 1994, BIOCHEMISTRY-US, V33, P8890, DOI 10.1021/bi00196a005; Grant GA, 1996, PROTEIN SCI, V5, P34; HURLEY JH, 1993, SCIENCE, V259, P673, DOI 10.1126/science.8430315; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LIU WZ, 1994, BIOCHEMISTRY-US, V33, P10120, DOI 10.1021/bi00199a040; PHILLIPS NFB, 1992, BIOCHEMISTRY-US, V31, P9445, DOI 10.1021/bi00154a017; RODRIGUEZAPARICIO LB, 1989, BIOCHEMISTRY-US, V28, P3070, DOI 10.1021/bi00433a050; SCHRAMM VL, 1974, J BIOL CHEM, V249, P1729; SCHULLER DJ, 1995, NAT STRUCT BIOL, V2, P69, DOI 10.1038/nsb0195-69; SCHULLER DJ, 1989, J BIOL CHEM, V264, P2645; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2090; SUGIMOTO E, 1968, J BIOL CHEM, V243, P2081; TOBEY KL, 1986, J BIOL CHEM, V261, P2179	15	34	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13013	13017		10.1074/jbc.271.22.13013	http://dx.doi.org/10.1074/jbc.271.22.13013			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662776	hybrid			2022-12-27	WOS:A1996UN47400052
J	Florini, JR; Samuel, DS; Ewton, DZ; Kirk, C; Sklar, RM				Florini, JR; Samuel, DS; Ewton, DZ; Kirk, C; Sklar, RM			Stimulation of myogenic differentiation by a Neuregulin, glial growth factor 2 - Are neuregulins the long-sought muscle trophic factors secreted by nerves?	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-INDUCING ACTIVITY; ACETYLCHOLINE-RECEPTOR; GENE; EXPRESSION; LIGAND; ARIA	It has long been known that nerves stimulate growth and maintenance of skeletal muscles in ways not dependent on physical contacts, but numerous attempts to identify and characterize the myotrophic agent(s) secreted by nerves have been unsuccessful. We here suggest that products of the neuregulin gene may be these agents. The neuregulins are a family of proteins made by alternative splicing of a single transcript to give as many as 15 protein products. One member of this family, glial growth factor 2 (rhGGF2) is a very potent stimulator of myogenesis in L6A1 myoblasts, giving a maximal stimulation of cell fusion and creatine kinase elevation at a concentration of 1 ng/ml (18 pM). The stimulation of myogenesis is not rapid, but it is prolonged, continuing over a period of at least 6 days. The effects of rhGGF2 are additive with those of insulin-like growth factor I (IGF-I) or its analog R3-IGF-I, suggesting that the actions of these two myotrophic agents differ in at least one rate-limiting step. We have observed one possible difference; unlike the IGFs, rhGGF2 does not induce elevation of the steady state level of myogenin mRNA.	CAMBRIDGE NEUROSCI,CAMBRIDGE,MA 02139		Florini, JR (corresponding author), SYRACUSE UNIV,DEPT BIOL,130 COLL PL,SYRACUSE,NY 13244, USA.				NHLBI NIH HHS [HL11551] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL011551, R37HL011551] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARBACCI EG, 1995, J BIOL CHEM, V270, P9585, DOI 10.1074/jbc.270.16.9585; BEERLI RR, 1995, MOL CELL BIOL, V15, P6496; BURGESS TL, 1995, J BIOL CHEM, V270, P19188, DOI 10.1074/jbc.270.32.19188; CHENG TC, 1993, SCIENCE, V261, P215, DOI 10.1126/science.8392225; CORFAS G, 1993, J NEUROSCI, V13, P2118; CUSELLADEANGELE.MG, 1992, J CELL BIOL, V268, P14553; DEMEYTS P, 1995, METABOLISM, V44, P2, DOI 10.1016/0026-0495(95)90214-7; EWTON DZ, 1995, J ENDOCRINOL, V144, P539, DOI 10.1677/joe.0.1440539; EWTON DZ, 1994, J CELL PHYSIOL, V161, P277, DOI 10.1002/jcp.1041610212; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; FLORINI JR, 1989, ANAL BIOCHEM, V182, P399, DOI 10.1016/0003-2697(89)90614-3; FLORINI JR, 1991, MOL ENDOCRINOL, V5, P718, DOI 10.1210/mend-5-5-718; Florini JR, 1995, DIABETES REV, V3, P73; GASSMANN M, 1995, NATURE, V378, P390, DOI 10.1038/378390a0; GUTMANN E, 1976, ANNU REV PHYSIOL, V38, P177, DOI 10.1146/annurev.ph.38.030176.001141; HASTY P, 1993, NATURE, V364, P501, DOI 10.1038/364501a0; HO WH, 1995, J BIOL CHEM, V270, P14523, DOI 10.1074/jbc.270.24.14523; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; JO SA, 1995, NATURE, V373, P158, DOI 10.1038/373158a0; KIMURA I, 1981, P JPN ACAD, V51, P200; LEE KF, 1995, NATURE, V378, P394, DOI 10.1038/378394a0; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARKELONIS GJ, 1982, J NEUROCHEM, V39, P315, DOI 10.1111/j.1471-4159.1982.tb03949.x; MARTE BM, 1995, MOL ENDOCRINOL, V9, P14, DOI 10.1210/me.9.1.14; MARTE BM, 1995, ONCOGENE, V10, P167; MARTINOU JC, 1991, P NATL ACAD SCI USA, V88, P7669, DOI 10.1073/pnas.88.17.7669; MEYER D, 1995, NATURE, V378, P386, DOI 10.1038/378386a0; Molkentin JD, 1995, CELL, V83, P1125, DOI 10.1016/0092-8674(95)90139-6; NABESHIMA Y, 1993, NATURE, V364, P532, DOI 10.1038/364532a0; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; SANCHEZ A, 1994, J BIOL CHEM, V269, P1587; SANDROCK AW, 1995, J NEUROSCI, V15, P6124; SASSOON DA, 1988, DEVELOPMENT, V104, P155; Sklar R. M., 1994, Society for Neuroscience Abstracts, V20, P1692; WEN D, 1992, MOL CELL BIOL, V14, P1909	35	54	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12699	12702		10.1074/jbc.271.22.12699	http://dx.doi.org/10.1074/jbc.271.22.12699			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663030	hybrid			2022-12-27	WOS:A1996UN47400004
J	Gedrich, RW; Gilfillan, MC; Duckett, CS; VanDongen, JL; Thompson, CB				Gedrich, RW; Gilfillan, MC; Duckett, CS; VanDongen, JL; Thompson, CB			CD30 contains two binding sites with different specificities for members of the tumor necrosis factor receptor-associated factor family of signal transducing proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REED-STERNBERG CELLS; HODGKINS-DISEASE; MONOCLONAL-ANTIBODY; LYMPHOID-CELLS; KI-1 ANTIGEN; SUBSET; EXPRESSION; ACTIVATION; MOLECULE; DEFINES	CD30 is a member of the tumor necrosis factor (TNF) receptor family of proteins. CD30 can regulate proliferation of lymphocytes and may also play an important role in human immunodeficiency virus replication, However, little is known about CD30 signal transduction. We performed a yeast two-hybrid library screen with the cytoplasmic domain of CD30 and isolated multiple independent cDNAs encoding human tumor necrosis factor receptor-associated factor (TRAF) 1, TRAF2, and GRAF1 (TRAF3). The ability of TRAF1, TRAF2, and CRAF1 to associate with CD30 was confirmed using an in vitro coprecipitation assay, further demonstrating that the interaction was specific and direct. The TRAF-binding domain of CD30 was mapped to the COOH-terminal 36 amino acid residues, which contained two independent binding sites. CRAF1 bound only a single site, which contained the sequence PEQET, whereas TRAF1 and TRAF2 were capable of binding to either the PEQET site or an additional downstream domain. These data indicate that the TRSF protein binding pattern of CD30 differs from other TNF receptor family members and suggest that signaling specificity through TNF receptor family proteins may be achieved through differences in their abilities to bind TRAF proteins.	UNIV CHICAGO,GWEN KNAPP CTR LUPUS & IMMUNOL RES,DEPT MED,CHICAGO,IL 60637; UNIV CHICAGO,COMM IMMUNOL,CHICAGO,IL 60637; UNIV CHICAGO,HOWARD HUGHES MED INST,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637	University of Chicago; University of Chicago; Howard Hughes Medical Institute; University of Chicago				Duckett, Colin/0000-0001-9413-2263	NIAID NIH HHS [P01 AI35294] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [P01AI035294] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREESEN R, 1984, BLOOD, V63, P1299; BANCHEREAU J, 1994, ANNU REV IMMUNOL, V12, P881, DOI 10.1146/annurev.iy.12.040194.004313; BERBERICH I, 1994, J IMMUNOL, V153, P4357; BISWAS P, 1995, IMMUNITY, V2, P587; CHENG GH, 1995, SCIENCE, V267, P1494, DOI 10.1126/science.7533327; CHINNAIYAN AM, 1995, CELL, V81, P505, DOI 10.1016/0092-8674(95)90071-3; CHOI MSK, 1995, EUR J IMMUNOL, V25, P1352, DOI 10.1002/eji.1830250533; CLEVELAND JL, 1995, CELL, V81, P479, DOI 10.1016/0092-8674(95)90068-3; DELPRETE G, 1995, IMMUNOL TODAY, V16, P76, DOI 10.1016/0167-5699(95)80092-1; DELPRETE G, 1995, J EXP MED, V182, P1655, DOI 10.1084/jem.182.6.1655; DELPRETE G, 1995, FASEB J, V9, P81, DOI 10.1096/fasebj.9.1.7821763; DUCKETT CS, 1996, IN PRESS EMBO J; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; DURKOP H, 1992, CELL, V68, P421, DOI 10.1016/0092-8674(92)90180-K; ELLIS TM, 1993, J IMMUNOL, V151, P2380; FALINI B, 1995, BLOOD, V85, P1; FROESE P, 1987, J IMMUNOL, V139, P2081; GRUSS HJ, 1994, BLOOD, V83, P2045; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; Hay BA, 1995, CELL, V83, P1253, DOI 10.1016/0092-8674(95)90150-7; HECHT TT, 1985, J IMMUNOL, V134, P4231; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; HU HM, 1994, J BIOL CHEM, V269, P30069; INUI S, 1990, EUR J IMMUNOL, V20, P1747, DOI 10.1002/eji.1830200819; ISHIDA T, 1995, J IMMUNOL, V155, P5527; IVASHKIV LB, 1995, IMMUNITY, V3, P1, DOI 10.1016/1074-7613(95)90152-3; JOSIMOVICALASEVIC O, 1989, EUR J IMMUNOL, V19, P157, DOI 10.1002/eji.1830190125; KIM YJ, 1993, J IMMUNOL, V151, P1255; LAEGREID A, 1994, J BIOL CHEM, V269, P7785; LEWIS BA, 1995, J VIROL, V69, P1628, DOI 10.1128/JVI.69.3.1628-1636.1995; Liston P, 1996, NATURE, V379, P349, DOI 10.1038/379349a0; MAGGI E, 1995, IMMUNITY, V3, P251, DOI 10.1016/1074-7613(95)90094-2; MANETTI R, 1994, J EXP MED, V180, P2407, DOI 10.1084/jem.180.6.2407; MCDONALD PP, 1995, EUR J IMMUNOL, V25, P2870, DOI 10.1002/eji.1830251024; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; NAWROCKI JF, 1988, J IMMUNOL, V141, P672; PFREUNDSCHUH M, 1988, ANTICANCER RES, V8, P217; REGNIER CH, 1995, J BIOL CHEM, V270, P25715, DOI 10.1074/jbc.270.43.25715; Rothe M, 1995, CELL, V83, P1243, DOI 10.1016/0092-8674(95)90149-3; ROTHE M, 1995, SCIENCE, V269, P1424, DOI 10.1126/science.7544915; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SARMA V, 1995, J BIOL CHEM, V270, P12343, DOI 10.1074/jbc.270.21.12343; SATO T, 1995, FEBS LETT, V358, P113, DOI 10.1016/0014-5793(94)01406-Q; SCHWAB U, 1982, NATURE, V299, P65, DOI 10.1038/299065a0; SCHWARTING R, 1989, BLOOD, V74, P1678; SMITH CA, 1993, CELL, V73, P1349, DOI 10.1016/0092-8674(93)90361-S; SONG HY, 1995, EUR J IMMUNOL, V309, P825; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; STEIN H, 1985, BLOOD, V66, P848; TARTAGLIA LA, 1991, P NATL ACAD SCI USA, V88, P9292, DOI 10.1073/pnas.88.20.9292; TARTAGLIA LA, 1993, J IMMUNOL, V151, P4637; TSUBATA T, 1993, NATURE, V364, P645, DOI 10.1038/364645a0	52	149	152	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12852	12858		10.1074/jbc.271.22.12852	http://dx.doi.org/10.1074/jbc.271.22.12852			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662842	hybrid			2022-12-27	WOS:A1996UN47400027
J	Hartmann, T; Bergsdorf, C; Sandbrink, R; Tienari, PJ; Multhaup, G; Ida, N; Bieger, S; Dyrks, T; Weidemann, A; Masters, CL; Beyreuther, K				Hartmann, T; Bergsdorf, C; Sandbrink, R; Tienari, PJ; Multhaup, G; Ida, N; Bieger, S; Dyrks, T; Weidemann, A; Masters, CL; Beyreuther, K			Alzheimer's disease beta A4 protein release and amyloid precursor protein sorting are regulated by alternative splicing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IDENTIFICATION; LOCALIZATION; BIOGENESIS; EXPRESSION; PEPTIDE; CELLS	We show here that alternative splicing influences the polarized secretion of amyloid precursor protein (APP) as well as the release of its proteolytic 3-4-kDa fragments beta A4 and p3. In Madin-Darby canine kidney II cells stably transfected with various APP isoforms and APP mutants, APPsec was consistently secreted basolaterally. In contrast, Madin-Darby canine kidney II cells transfected with L-APP677, which occurs naturally by alternative splicing of exon 15, secreted this isoform both apically and basolaterally, while maintaining the basolateral sorting of endogenous APPsec. This suggests that the alternative splicing of APP exon 15 modulates the polarized sorting of secretory APP. The same alternative splicing event also decreased the production of beta A4 relative to p3. This is the first example of alternative splicing regulating polarized trafficking of a secretory protein.	UNIV HEIDELBERG,DEPT ANAT & CELL BIOL,D-69120 HEIDELBERG,GERMANY; SCHERING AG,D-13353 BERLIN,GERMANY; UNIV MELBOURNE,DEPT PATHOL,MELBOURNE,VIC 3052,AUSTRALIA	Ruprecht Karls University Heidelberg; Schering AG; University of Melbourne	Hartmann, T (corresponding author), UNIV HEIDELBERG,ZENTRUM MOLEK BIOL,INF 282,D-69120 HEIDELBERG,GERMANY.		Hartmann, Tobias/AAB-8297-2022; Tienari, Pentti J/A-4893-2012	Hartmann, Tobias/0000-0001-7481-6430				CHANAT E, 1993, EMBO J, V12, P2159, DOI 10.1002/j.1460-2075.1993.tb05864.x; DESTROOPER B, 1995, J BIOL CHEM, V270, P4058, DOI 10.1074/jbc.270.8.4058; DYRKS T, 1992, J BIOL CHEM, V267, P18210; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; DYRKS T, 1993, FEBS LETT, V335, P89, DOI 10.1016/0014-5793(93)80446-2; EVIN G, 1994, AMYLOID, V1, P263, DOI 10.3109/13506129409146118; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; HAASS C, 1993, CELL, V75, P1039, DOI 10.1016/0092-8674(93)90312-E; HAASS C, 1993, J BIOL CHEM, V268, P3021; HAASS C, 1995, J CELL BIOL, V128, P537, DOI 10.1083/jcb.128.4.537; HAASS C, 1994, P NATL ACAD SCI USA, V91, P1564, DOI 10.1073/pnas.91.4.1564; HARTMANN T, 1994, NEUROBIOL AGING, V15, P551; HILBICH C, 1993, J BIOL CHEM, V268, P26571; HUNZIKER W, 1989, J CELL BIOL, V109, P3291, DOI 10.1083/jcb.109.6.3291; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; KONIG G, 1992, J BIOL CHEM, V267, P10804; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE ACY, 1995, J BIOL CHEM, V270, P12641; LO ACY, 1994, J BIOL CHEM, V269, P30966; MARUYAMA K, 1994, BIOCHEM BIOPH RES CO, V202, P1517, DOI 10.1006/bbrc.1994.2103; MATTER K, 1994, J CELL BIOL, V126, P991, DOI 10.1083/jcb.126.4.991; MULLER G, 1988, EMBO J, V7, P2723, DOI 10.1002/j.1460-2075.1988.tb03126.x; PANGALOS MN, 1995, J BIOL CHEM, V270, P10388, DOI 10.1074/jbc.270.18.10388; Sandbrink R, 1996, ANN NY ACAD SCI, V777, P281, DOI 10.1111/j.1749-6632.1996.tb34433.x; SANDBRINK R, 1994, J BIOL CHEM, V269, P14227; SANDBRINK R, 1994, J BIOL CHEM, V269, P1510; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SELKOE DJ, 1994, J NEUROPATH EXP NEUR, V53, P438, DOI 10.1097/00005072-199409000-00003; SHIOI J, 1995, J BIOL CHEM, V270, P11839, DOI 10.1074/jbc.270.20.11839; SIMONS K, 1994, CELL BIOL LAB HDB, V1, P225; THINAKARAN G, 1994, J BIOL CHEM, V269, P22099; WASCO W, 1993, NAT GENET, V5, P95, DOI 10.1038/ng0993-95; WEIDEMANN A, 1989, CELL, V57, P115, DOI 10.1016/0092-8674(89)90177-3	33	30	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13208	13214		10.1074/jbc.271.22.13208	http://dx.doi.org/10.1074/jbc.271.22.13208			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662794	hybrid			2022-12-27	WOS:A1996UN47400080
J	Rich, A				Rich, A			The biology of left-handed Z-DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Review							UNWINDING MODIFYING ACTIVITY; MAMMALIAN-CELL NUCLEI; B-Z TRANSITION; BINDING-PROTEINS; HOMOLOGOUS RECOMBINATION; PHYSIOLOGICAL CONDITIONS; TOPOISOMERASE-II; SUPERCOILED DNA; SV40 ENHANCER; SEQUENCES				Rich, A (corresponding author), MIT,DEPT BIOL,77 MASSACHUSETTS AVE,CAMBRIDGE,MA 02139, USA.			Herbert, Alan/0000-0002-0093-1572				APLAN PD, 1989, EMBO J, V8, P2621; ARNDTJOVIN DJ, 1993, BIOCHEMISTRY-US, V32, P4862, DOI 10.1021/bi00069a023; BASS BL, 1988, CELL, V55, P1089, DOI 10.1016/0092-8674(88)90253-X; BASS BL, 1987, CELL, V48, P607, DOI 10.1016/0092-8674(87)90239-X; BASS BL, 1993, RNA WORLD, P383; BECHERT T, 1994, J BIOMOL STRUCT DYN, V12, P605, DOI 10.1080/07391102.1994.10508762; BEHE M, 1981, P NATL ACAD SCI-BIOL, V78, P1619, DOI 10.1073/pnas.78.3.1619; BOEHM T, 1989, EMBO J, V8, P2621, DOI 10.1002/j.1460-2075.1989.tb08402.x; BULLOCK P, 1986, MOL CELL BIOL, V6, P3948, DOI 10.1128/MCB.6.11.3948; ELLISON MJ, 1985, P NATL ACAD SCI USA, V82, P8320, DOI 10.1073/pnas.82.24.8320; ELLISON MJ, 1986, BIOCHEMISTRY-US, V25, P3648, DOI 10.1021/bi00360a026; GARNER MM, 1987, J MOL BIOL, V196, P581, DOI 10.1016/0022-2836(87)90034-9; GLIKIN GC, 1991, NUCLEIC ACIDS RES, V19, P7139, DOI 10.1093/nar/19.25.7139; GRUSKIN EA, 1993, BIOCHEMISTRY-US, V32, P2167, DOI 10.1021/bi00060a007; HANIFORD DB, 1983, NATURE, V302, P632, DOI 10.1038/302632a0; Herbert A, 1996, TRENDS GENET, V12, P6, DOI 10.1016/0168-9525(96)81375-8; HERBERT A, 1995, P NATL ACAD SCI USA, V92, P7550, DOI 10.1073/pnas.92.16.7550; HERBERT AG, 1993, P NATL ACAD SCI USA, V90, P3339, DOI 10.1073/pnas.90.8.3339; HERBERT AG, 1993, NUCLEIC ACIDS RES, V21, P2669, DOI 10.1093/nar/21.11.2669; HERR W, 1986, CELL, V46, P461; HIGUCHI M, 1993, CELL, V75, P1361, DOI 10.1016/0092-8674(93)90622-W; HILL RJ, 1991, J CELL SCI, V99, P675; HO PS, 1986, EMBO J, V5, P2737, DOI 10.1002/j.1460-2075.1986.tb04558.x; JACKSON DA, 1988, J CELL SCI, V90, P365; JACKSON DA, 1985, EMBO J, V4, P913, DOI 10.1002/j.1460-2075.1985.tb03718.x; JAWORSKI A, 1987, SCIENCE, V238, P773, DOI 10.1126/science.3313728; JAWORSKI A, 1991, J BIOL CHEM, V266, P2576; JIANG H, 1991, NUCLEIC ACIDS RES, V19, P6943, DOI 10.1093/nar/19.24.6943; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM U, 1994, P NATL ACAD SCI USA, V91, P11457, DOI 10.1073/pnas.91.24.11457; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; KLYSIK J, 1981, NATURE, V290, P672, DOI 10.1038/290672a0; KRISHNA P, 1990, P NATL ACAD SCI USA, V87, P1292, DOI 10.1073/pnas.87.4.1292; LAFER EM, 1981, P NATL ACAD SCI-BIOL, V78, P3546, DOI 10.1073/pnas.78.6.3546; LAFER EM, 1983, J CLIN INVEST, V71, P314, DOI 10.1172/JCI110771; LAI F, 1995, J BIOL CHEM, V270, P17098, DOI 10.1074/jbc.270.29.17098; LANCILLOTTI F, 1987, P NATL ACAD SCI USA, V84, P1560, DOI 10.1073/pnas.84.6.1560; LIPPS HJ, 1983, CELL, V32, P435, DOI 10.1016/0092-8674(83)90463-4; LIU LF, 1987, P NATL ACAD SCI USA, V84, P7024, DOI 10.1073/pnas.84.20.7024; MARTINEZBALBAS MA, 1994, GENE, V139, P211, DOI 10.1016/0378-1119(94)90757-9; MCLEAN MJ, 1986, P NATL ACAD SCI USA, V83, P5884, DOI 10.1073/pnas.83.16.5884; Melcher T, 1996, NATURE, V379, P460, DOI 10.1038/379460a0; NISHIKURA K, 1991, EMBO J, V10, P3523, DOI 10.1002/j.1460-2075.1991.tb04916.x; NORDHEIM A, 1981, NATURE, V294, P417, DOI 10.1038/294417a0; PALACEK E, 1988, BIOCHEM BIOPH RES CO, V150, P731; PECK LJ, 1982, P NATL ACAD SCI-BIOL, V79, P4560, DOI 10.1073/pnas.79.15.4560; PECK LJ, 1985, CELL, V40, P129, DOI 10.1016/0092-8674(85)90316-2; PECK LJ, 1983, P NATL ACAD SCI-BIOL, V80, P6206, DOI 10.1073/pnas.80.20.6206; POHL FM, 1967, NATURWISSENSCHAFTEN, V54, P616, DOI 10.1007/BF00591426; POHL FM, 1972, J MOL BIOL, V67, P375, DOI 10.1016/0022-2836(72)90457-3; POLSON AG, 1994, EMBO J, V13, P5701, DOI 10.1002/j.1460-2075.1994.tb06908.x; POLSON AG, 1991, BIOCHEMISTRY-US, V30, P11507, DOI 10.1021/bi00113a004; RAHMOUNI AR, 1989, SCIENCE, V246, P358, DOI 10.1126/science.2678475; REBAGLIATI MR, 1987, CELL, V48, P599, DOI 10.1016/0092-8674(87)90238-8; RICH A, 1993, GENE, V135, P99, DOI 10.1016/0378-1119(93)90054-7; ROHNER KJ, 1990, J BIOL CHEM, V265, P19112; SATYANARAYANA K, 1992, IMMUNOGENETICS, V35, P235, DOI 10.1007/BF00166828; SCHROTH GP, 1992, J BIOL CHEM, V267, P11846; SINGLETON CK, 1982, NATURE, V299, P312, DOI 10.1038/299312a0; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STEINMETZ M, 1986, CELL, V44, P895, DOI 10.1016/0092-8674(86)90012-7; TAKEUCHI H, 1994, J MOL BIOL, V236, P610, DOI 10.1006/jmbi.1994.1170; TRECO D, 1986, MOL CELL BIOL, V6, P3934, DOI 10.1128/MCB.6.11.3934; WAGNER RW, 1990, MOL CELL BIOL, V10, P5586, DOI 10.1128/MCB.10.10.5586; WAHLS WP, 1990, MOL CELL BIOL, V10, P785, DOI 10.1128/MCB.10.2.785; WANG AHJ, 1979, NATURE, V282, P680, DOI 10.1038/282680a0; WEINREB A, 1988, P NATL ACAD SCI USA, V85, P529, DOI 10.1073/pnas.85.2.529; WITTIG B, 1989, J CELL BIOL, V108, P755, DOI 10.1083/jcb.108.3.755; WITTIG B, 1992, EMBO J, V11, P4653, DOI 10.1002/j.1460-2075.1992.tb05567.x; WITTIG B, 1991, P NATL ACAD SCI USA, V88, P2259, DOI 10.1073/pnas.88.6.2259; Wolfl S, 1996, P NATL ACAD SCI USA, V93, P3664, DOI 10.1073/pnas.93.8.3664; Wolfl S, 1995, BBA-GENE STRUCT EXPR, V1264, P294, DOI 10.1016/0167-4781(95)00155-7; WOLFL S, 1995, DNA NUCLEOPROTEIN ST, P137; ZACHARIAS W, 1988, BIOCHEMISTRY-US, V27, P2970, DOI 10.1021/bi00408a046; ZENKE M, 1986, EMBO J, V5, P387, DOI 10.1002/j.1460-2075.1986.tb04224.x; ZHENG GX, 1991, J MOL BIOL, V221, P107, DOI 10.1016/0022-2836(91)80208-C	76	23	24	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11595	11598		10.1074/jbc.271.20.11595	http://dx.doi.org/10.1074/jbc.271.20.11595			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662853	hybrid			2022-12-27	WOS:A1996UL25000001
J	Abe, J; Kusuhara, M; Ulevitch, RJ; Berk, BC; Lee, JD				Abe, J; Kusuhara, M; Ulevitch, RJ; Berk, BC; Lee, JD			Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; HYDROGEN-PEROXIDE; ARACHIDONIC-ACID; C-JUN; EXPRESSION; GROWTH; IDENTIFICATION; DOMAIN; ERKS; FOS	Mitogen-activated protein (MAP) kinases are a multigene family activated by many extracellular stimuli. There are three groups of MAP kinases based on their dual phosphorylation motifs, TEY, TPY, and TGY, which are termed extracellular signal regulated protein kinases (ERK1/2), c-Jun N-terminal kinases, and p38, respectively. A new MAP kinase family member termed Big MAP kinase 1 (BMK1) or ERK5 was recently cloned, BMK1 has a TEY sequence similar to ERK1/2 but has unique COOH-terminal and loop-12 domains, To define BMK1 regulation, its activation in cultured rat vascular smooth muscle cells was characterized. Angiotensin II, phorbol ester, platelet-derived growth factor, and tumor necrosis factor-alpha were the strongest stimuli for ERK1/2 but were weak activators of BMK1. In contrast, H2O2 caused concentration-dependent activation of BMK1 but not ERK1/2. Sorbitol activated both BMK1 and ERK1/2. BMK1 activation by H2O2 was calcium-dependent and appeared ubiquitous as shown by stimulation in human skin fibroblasts, human vascular smooth muscle cells, and human umbilical vein endothelial cells, These findings demonstrate that activation of BMK1 is different from ERK1/2 and suggest an important role for BMK1 as a redox-sensitive kinase.	UNIV WASHINGTON, DEPT MED, DIV CARDIOL, SEATTLE, WA 98195 USA; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	University of Washington; University of Washington Seattle; Scripps Research Institute			Ulevitch, Richard J/Q-3393-2017	Berk, Bradford/0000-0002-2767-4115	NHLBI NIH HHS [HL44721, HL49192] Funding Source: Medline; NIGMS NIH HHS [GM37694] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049192, R01HL044721] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM037694] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE J, 1994, CANCER RES, V54, P3407; BAAS AS, 1995, CIRC RES, V77, P29, DOI 10.1161/01.RES.77.1.29; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOGOYEVITCH MA, 1995, J BIOL CHEM, V270, P29710; BOULTON TG, 1991, CELL REGUL, V2, P357, DOI 10.1091/mbc.2.5.357; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRINTON EA, 1986, J BIOL CHEM, V261, P495; CANO E, 1994, MOL CELL BIOL, V14, P7352, DOI 10.1128/MCB.14.11.7352; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; DUFF JL, 1993, J BIOL CHEM, V268, P26037; DUFF JL, 1995, J BIOL CHEM, V270, P7161, DOI 10.1074/jbc.270.13.7161; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; Gimbrone M A Jr, 1976, Prog Hemost Thromb, V3, P1; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUPTA S, 1995, SCIENCE, V267, P389, DOI 10.1126/science.7824938; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; JOSEPHSON RA, 1991, J BIOL CHEM, V266, P2354; KALLUNKI T, 1994, GENE DEV, V8, P2996, DOI 10.1101/gad.8.24.2996; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEE HS, 1993, J BIOL CHEM, V268, P5255; LEE JD, 1995, BIOCHEM BIOPH RES CO, V213, P715, DOI 10.1006/bbrc.1995.2189; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; RAINGEAUD J, 1995, J BIOL CHEM, V270, P7420, DOI 10.1074/jbc.270.13.7420; RAO GN, 1992, CIRC RES, V70, P593, DOI 10.1161/01.RES.70.3.593; RAO GN, 1993, ONCOGENE, V8, P2759; RAO GN, 1993, NUCLEIC ACIDS RES, V21, P1259, DOI 10.1093/nar/21.5.1259; SHIBANUMA M, 1988, ONCOGENE, V3, P17; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; TSENG H, 1995, CIRC RES, V77, P869, DOI 10.1161/01.RES.77.5.869; ZHOU G, 1995, J BIOL CHEM, V270, P12664; ZHU AX, 1994, MOL CELL BIOL, V14, P8202, DOI 10.1128/MCB.14.12.8202	35	372	384	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16586	16590		10.1074/jbc.271.28.16586	http://dx.doi.org/10.1074/jbc.271.28.16586			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663194	hybrid			2022-12-27	WOS:A1996UX12600027
J	Balbin, M; Hannon, GJ; Pendas, AM; Ferrando, AA; Vizoso, F; Fueyo, A; LopezOtin, C				Balbin, M; Hannon, GJ; Pendas, AM; Ferrando, AA; Vizoso, F; Fueyo, A; LopezOtin, C			Functional analysis of a p21(WAF1,CIP1,SDI1) mutant (Arg(94)->trp) identified in a human breast carcinoma - Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SUBUNIT	Human p21 (also known as WAF1, CIP1, or SDI1) is a dual inhibitor of cyclin dependent kinases (CDKs) and the replication factor PCNA, which plays a role as a downstream mediator of the cell-cycle arrest induced by the tumor suppressor p53. To determine whether inactivation of downstream targets of p53 might contribute to cellular transformation, we have examined the integrity of the p21 gene in 36 invasive ductal breast carcinomas. Direct sequence analysis of the polymerase chain reaction-amplified p21 gene revealed a C to T transition in codon 94 that caused the substitution of a tryptophan for an arginine in a tumor specimen. This mutation was not detected in normal DNA extracted from the same patient nor in a polymerase chain reaction-restriction fragment length polymorphism of 50 unrelated individuals, indicating that it corresponds to a tumor specific alteration. Functional analysis of the p21(R94W) protein produced in different eukaryotic and prokaryotic expression systems revealed that this mutation impaired the ability of p21 to inhibit CDKs. By contrast, the R94W mutant was unaltered in its ability to promote cyclin-CDK association as well gs in its ability to bind proliferating cell nuclear antigen, thus leaving its putative functions as kinase activator or as inhibitor of replicative DNA synthesis intact. On the basis of these functional analysis, we propose that the Arg residue at position 94 is important for the CDK inhibitory role of p21.	UNIV OVIEDO,FAC MED,DEPT BIOL FUNC,E-33006 OVIEDO,SPAIN; COLD SPRING HARBOR LAB,HOWARD HUGHES MED INST,COLD SPRING HARBOR,NY 11724; HOSP DE JOVE,SERV CIRUGIA,E-33290 GIJON,SPAIN	University of Oviedo; Cold Spring Harbor Laboratory; Howard Hughes Medical Institute			Balbín, Milagros/I-4206-2015; Pendas, Alberto M/L-1017-2014; Fueyo, Antonio/ABH-3243-2020; López-Otín, Carlos/AAB-2106-2020; Hannon, Gregory/AAB-3568-2019	Balbín, Milagros/0000-0001-5325-0407; Fueyo, Antonio/0000-0002-7121-9398; López-Otín, Carlos/0000-0001-6964-1904; Pendas, Alberto M/0000-0001-9264-3721				BALBIN M, 1993, HUM GENET, V90, P668; BHATIA K, 1995, CANCER RES, V55, P1431; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHEDID M, 1994, ONCOGENE, V9, P3021; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; COX LS, 1995, BIOESSAYS, V17, P501, DOI 10.1002/bies.950170606; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; HALEVY O, 1995, SCIENCE, V267, P1019; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1993, CELL, V75, P805; HIRAMA T, 1995, BLOOD, V86, P841; HUPPI K, 1994, ONCOGENE, V9, P3017; JIANG H, 1994, ONCOGENE, V9, P3389; LEVINE AJ, 1993, ANNU REV BIOCHEM, V62, P623, DOI 10.1146/annurev.bi.62.070193.003203; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI YJ, 1995, ONCOGENE, V10, P599; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MICHIELI P, 1994, CANCER RES, V54, P3391; MIYASHITA T, 1995, CELL, V80, P293; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MOUSSES S, 1995, HUM MOL GENET, V4, P1089, DOI 10.1093/hmg/4.6.1089; NAKANISHI M, 1995, J BIOL CHEM, V270, P17060, DOI 10.1074/jbc.270.29.17060; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PETER M, 1994, CELL, V79, P181, DOI 10.1016/0092-8674(94)90186-4; PINES J, 1995, BIOCHEM J, V308, P697, DOI 10.1042/bj3080697; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHIOHARA M, 1994, BLOOD, V84, P3781, DOI 10.1182/blood.V84.11.3781.bloodjournal84113781; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMITH ML, 1994, SCIENCE, V266, P1375; ULLRICH SJ, 1992, J BIOL CHEM, V267, P15259; VOGELSTEIN B, 1992, CELL, V70, P523, DOI 10.1016/0092-8674(92)90421-8; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; XIONG Y, 1993, GENE DEV, V7, P1572, DOI 10.1101/gad.7.8.1572; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750	47	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15782	15786		10.1074/jbc.271.26.15782	http://dx.doi.org/10.1074/jbc.271.26.15782			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663132	hybrid			2022-12-27	WOS:A1996UV29900072
J	Kurlandsky, SB; Duell, EA; Kang, S; Voorhees, JJ; Fisher, GJ				Kurlandsky, SB; Duell, EA; Kang, S; Voorhees, JJ; Fisher, GJ			Auto-regulation of retinoic acid biosynthesis through regulation of retinol esterification in human keratinocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SKIN KERATINOCYTES; VITAMIN-A; BINDING PROTEIN; RAT-LIVER; ACYLTRANSFERASE ACTIVITY; TERMINAL DIFFERENTIATION; HEPATIC LECITHIN; HUMAN-EPIDERMIS; METABOLISM; MICROSOMES	In this report, we describe an auto-reguIatory loop in human keratinocytes, whereby all-trans retinoic acid (retinoic acid) regulates its own biosynthesis from all-trans retinol (retinol) through regulation of retinol esterification. Retinol esterification activity was low in normal proliferating human keratinocytes, cultured in retinoid-free media. Treatment of keratinocytes with retinoic acid induced retinol esterifying activity (8-fold). Induction of retinol esterifying activity was blocked by either actinomycin D or cycloheximide. Based an substrate specificity and inhibitor sensitivity, lecithin:retinol acyltransferase (LRAT) was identified as the retinoic acid-inducible retinol esterifying enzyme, Induction of LRAT by retinoic acid reduced conversion of retinol to retinoic acid by 50%. This reduction in retinoic acid synthesis resulted from sequestration of retinol as retinyl esters, since inhibition of LRAT restored retinoic acid synthesis to control levels. In normal human skin, undifferentiated keratinocytes, in the lowest cell layer, esterified retinol 4 times greater, than differentiating keratinocytes, in upper cell layers, reflecting an induced state, under conditions of retinol sufficiency, Regulation of LRAT activity by retinoic acid provides a novel mechanism through which retinoic acid can regulate its own level by controlling availability of retinol for conversion to retinoic acid. In human skin in vivo, retinyl esters synthesized in basal keratinocytes could undergo hydrolysis during differentiation and thus serve as a source of retinol for keratinocytes in upper layers of skin.	UNIV MICHIGAN,MED CTR,DEPT DERMATOL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NIAMS NIH HHS [AR07197-19] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [T32AR007197] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ADAMS JC, 1990, CELL, V63, P425, DOI 10.1016/0092-8674(90)90175-E; ANSKIEVICH BJ, 1992, MOL CELL BIOL, V12, P4862; BARRY RJ, 1989, J BIOL CHEM, V264, P9231; BATACSORGO Z, 1993, J EXP MED, V178, P1271, DOI 10.1084/jem.178.4.1271; Blaner William S., 1994, P229; BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUCK J, 1991, SCIENCE, V254, P1654, DOI 10.1126/science.1749937; CHAMBON P, 1995, RECENT PROG HORM RES, V50, P317; CONNOR MJ, 1986, LIFE SCI, V38, P1807, DOI 10.1016/0024-3205(86)90134-7; CREEK KE, 1993, J NUTR, V123, P356, DOI 10.1093/jn/123.suppl_2.356; DEIGNER PS, 1989, SCIENCE, V244, P968, DOI 10.1126/science.2727688; DUELL EA, 1992, J CLIN INVEST, V90, P1269, DOI 10.1172/JCI115990; EPPINGER TM, 1993, J EXP MED, V178, P1995, DOI 10.1084/jem.178.6.1995; FISHER GJ, 1994, J BIOL CHEM, V269, P20629; FISHER GJ, 1988, J INVEST DERMATOL, V91, P142, DOI 10.1111/1523-1747.ep12464387; FROLIK CA, 1984, RETINOIDS, P177; FUCHS E, 1994, CURR OPIN GENET DEV, V4, P725, DOI 10.1016/0959-437X(94)90140-X; GODA T, 1993, BIOCHIM BIOPHYS ACTA, V1168, P153; HERR FM, 1991, J NUTR BIOCHEM, V2, P503, DOI 10.1016/0955-2863(91)90108-H; JONES PH, 1993, CELL, V73, P713, DOI 10.1016/0092-8674(93)90251-K; KANG SW, 1995, J INVEST DERMATOL, V105, P549, DOI 10.1111/1523-1747.ep12323445; KURLANDSKY SB, 1994, J BIOL CHEM, V269, P32821; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; MARCELO CL, 1992, J INVEST DERMATOL, V99, P703, DOI 10.1111/1523-1747.ep12614196; MATSUURA T, 1993, ARCH BIOCHEM BIOPHYS, V301, P221, DOI 10.1006/abbi.1993.1137; ONG DE, 1991, J LIPID RES, V32, P1521; ONG DE, 1988, J BIOL CHEM, V263, P5789; ONG DE, 1994, NUTR REV, V52, pS24; PEMRICK SM, 1994, LEUKEMIA, V8, P1787; PITTELKOW MR, 1986, MAYO CLIN PROC, V61, P771, DOI 10.1016/S0025-6196(12)64815-0; QUICK TC, 1990, BIOCHEMISTRY-US, V29, P11116, DOI 10.1021/bi00502a015; RANDOLPH RK, 1995, ARCH BIOCHEM BIOPHYS, V318, P6, DOI 10.1006/abbi.1995.1197; RANDOLPH RK, 1991, J BIOL CHEM, V266, P16453; RANDOLPH RK, 1991, ARCH BIOCHEM BIOPHYS, V288, P500, DOI 10.1016/0003-9861(91)90227-A; RANDOLPH RK, 1993, J BIOL CHEM, V268, P9198; ROLLMAN O, 1993, BIOCHEM J, V293, P675, DOI 10.1042/bj2930675; ROSS AC, 1990, METHOD ENZYMOL, V189, P442; SAARI JC, 1989, J BIOL CHEM, V264, P8636; SHINGLETON JL, 1989, BIOCHEMISTRY-US, V28, P9647, DOI 10.1021/bi00451a016; SIEGENTHALER G, 1990, BIOCHEM J, V268, P371, DOI 10.1042/bj2680371; TIMMERS AMM, 1986, J LIPID RES, V27, P979; TORMA H, 1990, J INVEST DERMATOL, V94, P132, DOI 10.1111/1523-1747.ep12873990; TORMA H, 1991, SKIN PHARMACOL, V4, P154; WANG XD, 1993, J NUTR, V123, P1277, DOI 10.1093/jn/123.7.1277; YOST RW, 1988, J BIOL CHEM, V263, P18693	46	107	108	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15346	15352		10.1074/jbc.271.26.15346	http://dx.doi.org/10.1074/jbc.271.26.15346			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663081				2022-12-27	WOS:A1996UV29900010
J	Cao, GQ; Goldstein, JL; Brown, MS				Cao, GQ; Goldstein, JL; Brown, MS			Complementation of mutation in acyl-CoA:cholesterol acyltransferase (ACAT) fails to restore sterol regulation in ACAT-defective sterol-resistant hamster cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; LEUCINE ZIPPER PROTEIN; COENZYME-A; TRANSCRIPTION; DEFICIENT	A previously described mutant line of Chinese hamster ovary cells, designated SRD-4, fails to synthesize cholesteryl esters, owing to a deficiency in the activity of acyl-CoA:cholesterol acyltransferase (ACAT). These cells also fail to suppress low density lipoprotein receptors or cholesterol synthesizing enzymes in the presence of 25-hydroxycholesterol. In the current studies we show that SRD-4 cells have three defects: 1) a point mutation in one allele at the ACAT locus that changes codon 265 from Ser to Leu, resulting in an inactive enzyme; 2) a silent allele at the other ACAT locus that does not produce detectable mRNA; and 3) a mutation, as yet undefined, that abolishes the ability of 25-hydroxycholesterol to inhibit the cleavage of both sterol regulatory element binding proteins (SREBP-1 and SREBP-2), Correction of the ACAT deficiency by transfection of a wildtype cDNA failed to restore inhibition of SREBP cleavage by 25-hydroxycholesterol, indicating that the ACAT deficiency and the sterol regulatory defect are caused by independent mutations. These data provide further insight into the interplay between ACAT activation and inhibition of SREBP cleavage by 25-hydroxycholesterol, and they indicate that these two processes can be disrupted independently by mutation.			Cao, GQ (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BROWN MS, 1975, J BIOL CHEM, V250, P4025; CADIGAN KM, 1989, J CELL BIOL, V108, P2201, DOI 10.1083/jcb.108.6.2201; CADIGAN KM, 1988, J BIOL CHEM, V263, P274; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1993, J BIOL CHEM, V268, P20747; CHANG TY, 1983, ENZYMES, P523; CHENG D, 1995, J BIOL CHEM, V270, P685, DOI 10.1074/jbc.270.2.685; DAWSON PA, 1991, J BIOL CHEM, V266, P9128; Ericsson J, 1996, P NATL ACAD SCI USA, V93, P945, DOI 10.1073/pnas.93.2.945; GOLDSTEIN JL, 1977, ANNU REV BIOCHEM, V46, P897, DOI 10.1146/annurev.bi.46.070177.004341; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; HOLLIDAY R, 1991, MUTAT RES, V250, P351, DOI 10.1016/0027-5107(91)90192-Q; HOLLIDAY R, 1990, New Biologist, V2, P719; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; Hua XX, 1996, J BIOL CHEM, V271, P10379, DOI 10.1074/jbc.271.17.10379; HUA XX, 1995, J BIOL CHEM, V270, P29422, DOI 10.1074/jbc.270.49.29422; Lopez JM, 1996, P NATL ACAD SCI USA, V93, P1049, DOI 10.1073/pnas.93.3.1049; METHERALL JE, 1989, J BIOL CHEM, V264, P15634; METHERALL JE, 1991, J BIOL CHEM, V266, P12734; ORITA M, 1989, GENOMICS, V5, P874, DOI 10.1016/0888-7543(89)90129-8; Sambrook J., 2002, MOL CLONING LAB MANU; SATO R, 1994, J BIOL CHEM, V269, P17267; UELMEN PJ, 1995, J BIOL CHEM, V270, P26192, DOI 10.1074/jbc.270.44.26192; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; YANG JX, 1994, GENE DEV, V8, P1910, DOI 10.1101/gad.8.16.1910; YANG JX, 1995, J BIOL CHEM, V270, P12152, DOI 10.1074/jbc.270.20.12152; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	28	47	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14642	14648		10.1074/jbc.271.24.14642	http://dx.doi.org/10.1074/jbc.271.24.14642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662991	hybrid			2022-12-27	WOS:A1996UQ66000104
J	Chen, HF; Campisi, J; Padmanabhan, R				Chen, HF; Campisi, J; Padmanabhan, R			SV40 large T antigen transactivates the human cdc2 promoter by inducing a CCAAT box binding factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE CONTROL; RETINOBLASTOMA GENE-PRODUCT; HUMAN-DIPLOID FIBROBLASTS; E2F TRANSCRIPTION FACTOR; ADENOVIRUS E1A PROTEINS; HUMAN HSP70 PROMOTER; HUMAN MYC PROMOTER; FISSION YEAST; SENESCENT HUMAN; SUSCEPTIBILITY GENE	Cyclin-dependent protein kinases (Cdks) play a key role in the cell division cycle of eukaryotic cells. Cdc2, the first mammalian Cdk that was discovered, is expressed in S phase and functions in the G(2) to M phase transition. By transfecting segments of the human cdc2 promoter linked to a reporter gene into monkey kidney (CV-1) cells, we identified the region containing the Spl, E2F, and two CCAAT box binding sites as essential and sufficient for basal transcription. SV40 large T antigen (SV40-LT) is a viral oncoprotein that transactivates viral and cellular promoters and induces DNA synthesis in quiescent cells. SV40-LT transactivated wild-type cdc2 promoter/reporter constructs in a dose-dependent manner, coinciding with an increase in endogenous cdc2 mRNA. A mutant promoter from which the two CCAAT box motifs were deleted was 8-fold less sensitive to SV40-LT. Activation by SV40-LT did not require its ability to bind the retinoblastoma or p53 tumor suppressor proteins. SV40-LT induced a specific CCAAT box-binding factor (CBF) in CV-1 and COS-7 cells, as judged by gel shift and Southwestern analyses, Similar results were obtained in human fibroblasts expressing a conditional SV40-LT. The SV40-LT-inducible CBF appears to be novel and differs from the CBF that activates heat shock protein 70 gene expression.	UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160; UNIV CALIF BERKELEY,BERKELEY NATL LAB,DEPT CANC BIOL,BERKELEY,CA 94720	University of Kansas; University of Kansas Medical Center; University of California System; University of California Berkeley					NATIONAL CANCER INSTITUTE [R01CA033099] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R37AG009909, R01AG009909, R01AG011658] Funding Source: NIH RePORTER; NCI NIH HHS [CA33099] Funding Source: Medline; NIA NIH HHS [AG11658, AG09909] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AGOFF SN, 1993, SCIENCE, V259, P84, DOI 10.1126/science.8418500; BAGCHI S, 1990, CELL, V62, P659, DOI 10.1016/0092-8674(90)90112-R; BAGCHI S, 1991, CELL, V65, P1063, DOI 10.1016/0092-8674(91)90558-G; BANDARA LR, 1991, NATURE, V351, P494, DOI 10.1038/351494a0; BEACH D, 1982, NATURE, V300, P706, DOI 10.1038/300706a0; BEIJERSBERGEN RL, 1994, GENE DEV, V8, P2680, DOI 10.1101/gad.8.22.2680; BORN TL, 1994, MOL CELL BIOL, V14, P5710, DOI 10.1128/MCB.14.9.5710; Campisi Judith, 1996, P121; CHELLAPPAN S, 1992, P NATL ACAD SCI USA, V89, P4549, DOI 10.1073/pnas.89.10.4549; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; CHEN HF, 1994, VIROLOGY, V205, P364, DOI 10.1006/viro.1994.1654; CHITTENDEN T, 1991, CELL, V65, P1073, DOI 10.1016/0092-8674(91)90559-H; CRAVEN GR, 1965, J BIOL CHEM, V240, P2468; DALTON S, 1992, EMBO J, V11, P1797, DOI 10.1002/j.1460-2075.1992.tb05231.x; DECAPRIO JA, 1988, CELL, V54, P275, DOI 10.1016/0092-8674(88)90559-4; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DIMRI GP, 1994, COLD SPRING HARB SYM, V59, P67, DOI 10.1101/SQB.1994.059.01.010; DRAETTA G, 1988, ONCOGENE, V2, P553; DRAETTA G, 1987, CELL, V50, P319, DOI 10.1016/0092-8674(87)90227-3; DRAETTA G, 1990, TRENDS BIOCHEM SCI, V15, P378, DOI 10.1016/0968-0004(90)90235-4; DURSO G, 1990, SCIENCE, V250, P786, DOI 10.1126/science.2173140; DUTTA A, 1990, GENE DEV, V4, P243, DOI 10.1101/gad.4.2.243; DYSON N, 1989, SCIENCE, V243, P934, DOI 10.1126/science.2537532; DYSON N, 1990, J VIROL, V64, P1353, DOI 10.1128/JVI.64.3.1353-1356.1990; FANG F, 1991, CELL, V66, P731, DOI 10.1016/0092-8674(91)90117-H; GINSBERG D, 1994, GENE DEV, V8, P2665, DOI 10.1101/gad.8.22.2665; GOLDSTEIN S, 1990, SCIENCE, V249, P1129, DOI 10.1126/science.2204114; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GORMAN SD, 1985, J CELL PHYSIOL, V125, P122, DOI 10.1002/jcp.1041250116; Hara E, 1996, DEV GENET, V18, P161; HIEBERT SW, 1989, P NATL ACAD SCI USA, V86, P3594, DOI 10.1073/pnas.86.10.3594; HIJMANS EM, 1995, MOL CELL BIOL, V15, P3082; KREK W, 1989, EMBO J, V8, P3071, DOI 10.1002/j.1460-2075.1989.tb08458.x; KU DH, 1993, J BIOL CHEM, V268, P2255; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDSCHULZ WH, 1988, GENE DEV, V2, P786, DOI 10.1101/gad.2.7.786; LEE MG, 1987, NATURE, V327, P31, DOI 10.1038/327031a0; LEE MG, 1988, NATURE, V333, P676, DOI 10.1038/333676a0; LEES JA, 1993, MOL CELL BIOL, V13, P7813, DOI 10.1128/MCB.13.12.7813; LOEKEN MR, 1989, J BIOL CHEM, V264, P6572; LUDLOW JW, 1989, CELL, V56, P57, DOI 10.1016/0092-8674(89)90983-5; LUM LSY, 1990, MOL CELL BIOL, V10, P6709, DOI 10.1128/MCB.10.12.6709; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MCGOWAN CH, 1990, MOL CELL BIOL, V10, P3847, DOI 10.1128/MCB.10.7.3847; MORAN E, 1987, CELL, V48, P177, DOI 10.1016/0092-8674(87)90418-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MURRAY AW, 1992, NATURE, V359, P599, DOI 10.1038/359599a0; NEVINS JR, 1992, SCIENCE, V258, P424; NURSE P, 1981, NATURE, V292, P558, DOI 10.1038/292558a0; NURSE P, 1990, NATURE, V344, P503, DOI 10.1038/344503a0; NURSE P, 1976, MOL GEN GENET, V146, P167, DOI 10.1007/BF00268085; OSHIMA J, 1993, ONCOGENE, V8, P2987; PAGANO M, 1993, J CELL BIOL, V121, P101, DOI 10.1083/jcb.121.1.101; PANG JH, 1993, J BIOL CHEM, V268, P2909; PEACOCKE M, 1991, J CELL BIOCHEM, V45, P147, DOI 10.1002/jcb.240450205; PHELPS WC, 1988, CELL, V53, P539, DOI 10.1016/0092-8674(88)90570-3; PINES J, 1990, New Biologist, V2, P389; PINES J, 1994, SEMIN CANCER BIOL, V5, P305; REED SI, 1985, P NATL ACAD SCI USA, V82, P4055, DOI 10.1073/pnas.82.12.4055; RIABOWOL K, 1989, CELL, V57, P393, DOI 10.1016/0092-8674(89)90914-8; RICE PW, 1993, J VIROL, V67, P6689, DOI 10.1128/JVI.67.11.6689-6697.1993; RICHTER KH, 1991, CANCER RES, V51, P6010; SAKAMOTO K, 1993, ONCOGENE, V8, P1887; SALA A, 1994, CANCER RES, V54, P1402; Sambrook J., 2002, MOL CLONING LAB MANU; SANTORO C, 1988, NATURE, V334, P218, DOI 10.1038/334218a0; SARDET C, 1995, P NATL ACAD SCI USA, V92, P2403, DOI 10.1073/pnas.92.6.2403; SESHADRI T, 1990, SCIENCE, V247, P205, DOI 10.1126/science.2104680; SHAY JW, 1991, EXP CELL RES, V196, P33, DOI 10.1016/0014-4827(91)90453-2; SHAY JW, 1989, EXP CELL RES, V184, P109, DOI 10.1016/0014-4827(89)90369-8; SHI Y, 1991, CELL, V67, P377, DOI 10.1016/0092-8674(91)90189-6; SHIRODKAR S, 1992, CELL, V68, P157, DOI 10.1016/0092-8674(92)90214-W; SILVA CM, 1987, P NATL ACAD SCI USA, V84, P1744, DOI 10.1073/pnas.84.7.1744; SIMANIS V, 1986, CELL, V45, P261, DOI 10.1016/0092-8674(86)90390-9; STEIN GH, 1991, P NATL ACAD SCI USA, V88, P11012, DOI 10.1073/pnas.88.24.11012; TEVETHIA MJ, 1988, VIROLOGY, V62, P76; THALMEIER K, 1989, GENE DEV, V3, P527, DOI 10.1101/gad.3.4.527; TSAI LH, 1991, NATURE, V353, P174, DOI 10.1038/353174a0; TSUJI Y, 1983, EXP CELL RES, V144, P165, DOI 10.1016/0014-4827(83)90450-0; WANG HGH, 1991, MOL CELL BIOL, V11, P4253, DOI 10.1128/MCB.11.8.4253; WHYTE P, 1988, NATURE, V334, P124, DOI 10.1038/334124a0; WRIGHT WE, 1989, MOL CELL BIOL, V9, P3088, DOI 10.1128/MCB.9.7.3088; YAMAMOTO M, 1994, EXP CELL RES, V210, P94, DOI 10.1006/excr.1994.1014; ZHAO LJ, 1988, CELL, V55, P1005, DOI 10.1016/0092-8674(88)90245-0	84	36	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13959	13967		10.1074/jbc.271.24.13959	http://dx.doi.org/10.1074/jbc.271.24.13959			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662914	hybrid			2022-12-27	WOS:A1996UQ66000008
J	Raney, KD; Carver, TE; Benkovic, SJ				Raney, KD; Carver, TE; Benkovic, SJ			Stoichiometry and DNA unwinding by the bacteriophage T4 41:59 helicase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PROTEIN; PURIFICATION; GENE; INVITRO	The bacteriophage T4 41 protein is a replicative helicase that forms a hexamer in the presence of ATP and associates with the T4 59 protein. The stoichiometry of the 41:59 helicase complex and its mechanism for DNA unwinding have been investigated using steady-state and single-turnover kinetics. A partial duplex DNA fork containing two regions of single-stranded DNA (ssDNA) of 30 nucleotides each, and 30 base pairs served as the substrate, 59 was found to increase the steady-state unwinding rate of the substrate by 200-fold over the rate of 41 alone. Maximum unwinding occurred when 59 and 41 were equimolar, revealing a 1:1 stoichiometry for the complex. Varying 41 while holding 59 constant resulted in sigmoidal kinetics suggesting strong cooperativity for formation of the 41 hexamer and providing a lower limit for hexamer assembly of 65 nM, Substrates were prepared that contained a biotin-streptavidin block in either the leading or lagging strand of the duplex region of the substrate. The first order rate constant for unwinding was reduced only when the block was placed in the lagging strand of the DNA fork, indicating that the helicase interacts primarily with the lagging DNA strand.	PENN STATE UNIV, DEPT CHEM, UNIVERSITY PK, PA 16802 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [F32ES005576] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [F32GM015729] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES05576] Funding Source: Medline; NIGMS NIH HHS [GM15729, GM13306] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS DE, 1995, J MOL BIOL, V247, P404, DOI 10.1006/jmbi.1995.0149; AMARATUNGA M, 1993, BIOCHEMISTRY-US, V32, P6815, DOI 10.1021/bi00078a003; BARRY J, 1994, J BIOL CHEM, V269, P33049; BJORNSON KP, 1994, BIOCHEMISTRY-US, V33, P14306, DOI 10.1021/bi00251a044; BUJALOWSKI W, 1994, J BIOL CHEM, V269, P31350; BURKE RL, 1985, J BIOL CHEM, V260, P1711; CROTHERS DM, 1990, J BIOL CHEM, V265, P7093; DEAN FB, 1992, J BIOL CHEM, V267, P14129; DONG F, 1995, J BIOL CHEM, V270, P7462, DOI 10.1074/jbc.270.13.7462; EGELMAN EH, 1995, P NATL ACAD SCI USA, V92, P3869, DOI 10.1073/pnas.92.9.3869; HINTON DM, 1985, J BIOL CHEM, V260, P2851; HINTON DM, 1987, J BIOL CHEM, V262, P10873; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; Kreuzer K. N., 1994, MOL BIOL BACTERIOP T, P28; LIU CC, 1981, J BIOL CHEM, V256, P2821; MORRICAL SW, 1994, J BIOL CHEM, V269, P33069; Nossal N.G., 1994, MOL BIOL BACTERIOP T, P43; RAMSTEIN J, 1988, P NATL ACAD SCI USA, V85, P7231, DOI 10.1073/pnas.85.19.7231; RANEY KD, 1994, P NATL ACAD SCI USA, V91, P6644, DOI 10.1073/pnas.91.14.6644; RANEY KD, 1995, J BIOL CHEM, V270, P22236, DOI 10.1074/jbc.270.38.22236; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RICHARDSON RW, 1989, J BIOL CHEM, V264, P4725; SALINAS F, 1995, CELL, V82, P111, DOI 10.1016/0092-8674(95)90057-8; SPACCIAPOLI P, 1994, J BIOL CHEM, V269, P447; STASIAK A, 1994, P NATL ACAD SCI USA, V91, P7618, DOI 10.1073/pnas.91.16.7618; TARUMI K, 1995, J BIOL CHEM, V270, P2614, DOI 10.1074/jbc.270.6.2614; TSANEVA IR, 1993, P NATL ACAD SCI USA, V90, P1315, DOI 10.1073/pnas.90.4.1315; VENKATESAN M, 1982, J BIOL CHEM, V257, P2426; WAHLE E, 1989, J BIOL CHEM, V264, P2463; YONESAKI T, 1994, J BIOL CHEM, V269, P1284; YOUNG MC, 1994, J MOL BIOL, V235, P1447, DOI 10.1006/jmbi.1994.1100	31	54	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14074	14081		10.1074/jbc.271.24.14074	http://dx.doi.org/10.1074/jbc.271.24.14074			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662873	hybrid			2022-12-27	WOS:A1996UQ66000024
J	Roth, NJ; Huber, RE				Roth, NJ; Huber, RE			The beta-galactosidase (Escherichia coli) reaction is partly facilitated by interactions of His-540 with the C6 hydroxyl of galactose	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-SPECIFIC MUTAGENESIS; NUCLEOTIDE-SEQUENCE; LACZ GENE; EXPRESSION; BINDING; GLUCURONIDASE; CATALYSIS; CLONING; ENZYME; CDNA	beta-Galactosidases with substitutions for His-540 were only poorly reactive with galactosyl substrates. However, the activity with substrates that were like galactose but did not have a C6 hydroxyl group was not decreased much as a result of such substitutions. The loss of transition state stabilization for galactosyl substrates as a result of substitution was between -15.4 and -22.8 kJ/mol but only between +0.34 and -6.5 for substrates that were identical to galactose but lacked the C6 hydroxyl. These findings indicate that an important function of His-540 is to aid in the stabilization of the transition state by forming a stable interaction with the C6 hydroxyl group. This suggestion was strengthened by the results of competitive inhibition studies showing that L-arabinolactone (a transition state analog inhibitor of beta-galactosidase without a C6 hydroxymethyl group) was bound as well by the substituted enzymes as by wild type, whereas transition state analog inhibitors that contain C6 hydroxyls (L-ribose and D-galactonolactone) were bound much more poorly by the substituted enzymes than by the wild type enzyme. Substrate analog inhibitor studies showed that His-540 was also important for binding interactions with the C6 hydroxyl group of the ground (substrate) state. The activation by Mg2+ was the same for the substituted enzymes as for the wild type, and equilibrium dialysis showed that H540F-beta-galactosidase bound Mg2+ as well as did normal beta-galactosidase. The k(2) and K-s values seem to have the same pH interactions as wild type enzyme, whereas the k(3) interactions are affected differently by pH in the substituted enzymes than in the wild type enzyme. The rate of the ''degalactosylation'' reaction was affected more by substitutions for His-540 than was the rate of the ''galactosylatian'' reaction. All three substituted beta-galactosidases were less stable to heat than was wild type, but H540N-beta-galactosidase was somewhat more stable than the other two substituted enzymes. There were some differences in activity and inhibitory properties that resulted from the different substitutions.			Roth, NJ (corresponding author), UNIV CALGARY,FAC SCI,DIV BIOCHEM,CALGARY,AB T2N 1N4,CANADA.		Roth, Nathan J/K-3894-2013					BULLOCK WO, 1987, BIOTECHNIQUES, V5, P376; BURCHHARDT G, 1991, GENE, V106, P13, DOI 10.1016/0378-1119(91)90560-X; BUVINGER WE, 1985, J BACTERIOL, V163, P850, DOI 10.1128/JB.163.3.850-857.1985; CASE GS, 1973, BIOCHEM J, V133, P99, DOI 10.1042/bj1330099; COHN M, 1957, BACTERIOL REV, V21, P140, DOI 10.1128/MMBR.21.3.140-168.1957; CUPPLES CG, 1990, J BIOL CHEM, V265, P5512; DAVID S, 1992, J BACTERIOL, V174, P4475, DOI 10.1128/JB.174.13.4475-4481.1992; DESCHAVANNE PJ, 1978, J BIOL CHEM, V253, P833; FANNING S, 1994, GENE, V141, P91, DOI 10.1016/0378-1119(94)90133-3; FERSHT A, 1985, ENZYME STRUCTURE MEC, P244; FERSHT AR, 1974, PROC R SOC SER B-BIO, V187, P397, DOI 10.1098/rspb.1974.0084; FERSHT AR, 1987, PROTEIN ENG, P269; FOWLER AV, 1978, J BIOL CHEM, V253, P5521; GALLAGHER P M, 1988, Genomics, V2, P215, DOI 10.1016/0888-7543(88)90005-5; GEBLER JC, 1992, J BIOL CHEM, V267, P11136; Gibson T., 1984, STUDIES EPSTEIN BARR; HANCOCK KR, 1991, J BACTERIOL, V173, P3084, DOI 10.1128/JB.173.10.3084-3095.1991; HUBER RE, 1984, ARCH BIOCHEM BIOPHYS, V234, P151, DOI 10.1016/0003-9861(84)90336-9; HUBER RE, 1976, BIOCHEMISTRY-US, V15, P1994, DOI 10.1021/bi00654a029; HUBER RE, 1987, BIOCHEMISTRY-US, V26, P1526, DOI 10.1021/bi00380a005; HUBER RE, 1979, BIOCHEMISTRY-US, V18, P4090, DOI 10.1021/bi00586a005; JACOBSON RH, 1994, NATURE, V369, P761, DOI 10.1038/369761a0; JEFFERSON RA, 1986, P NATL ACAD SCI USA, V81, P414; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LALEGERIE P, 1982, BIOCHIMIE, V64, P977, DOI 10.1016/S0300-9084(82)80379-9; MCCARTER JD, 1992, BIOCHEM J, V286, P721, DOI 10.1042/bj2860721; MRSHALL P, 1977, J CHEM SOC P2, P1198; NISHIMURA Y, 1986, P NATL ACAD SCI USA, V83, P7292, DOI 10.1073/pnas.83.19.7292; OSHIMA A, 1987, P NATL ACAD SCI USA, V84, P685, DOI 10.1073/pnas.84.3.685; POCH O, 1992, GENE, V118, P55, DOI 10.1016/0378-1119(92)90248-N; Sambrook J., 2002, MOL CLONING LAB MANU; SCHMIDT BF, 1989, J BACTERIOL, V171, P625, DOI 10.1128/jb.171.2.625-635.1989; SCHROEDER CJ, 1991, J GEN MICROBIOL, V137, P369, DOI 10.1099/00221287-137-2-369; STOKES HW, 1985, MOL BIOL EVOL, V2, P469; TENU JP, 1972, EUR J BIOCHEM, V26, P112, DOI 10.1111/j.1432-1033.1972.tb01746.x	36	26	28	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14296	14301		10.1074/jbc.271.24.14296	http://dx.doi.org/10.1074/jbc.271.24.14296			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662937	hybrid			2022-12-27	WOS:A1996UQ66000056
J	Shatwell, KP; Dancis, A; Cross, AR; Klausner, RD; Segal, AW				Shatwell, KP; Dancis, A; Cross, AR; Klausner, RD; Segal, AW			The FRE1 ferric reductase of Saccharomyces cerevisiae is a cytochrome b similar to that of NADPH oxidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; FLAVOCYTOCHROME; PURIFICATION; NEUTROPHILS; PROTEIN	Plasma membrane preparations from strains of the yeast Saccharomyces cerevisiae gave a reduced minus oxidized spectrum characteristic of a b-type cytochrome and very similar to the spectrum of flavocytochrome b(558) of human neutrophils. The magnitude of the signal correlated with the level of ferric reductase activity and the copy number of the FRE1 gene, indicating that the FRE1 protein is a cytochrome b. Sequence similarities with the flavin binding site of flavocytochrome b(558) and other members of the ferredoxin-NADP reductase family, together with increased levels of noncovalently bound FAD and iodonitrotetrazolium violet reductase activity in membranes from a yeast strain overexpressing ferric reductase, suggested that the FRE1 protein may also carry a flavin group. Potentiometric titrations indicated that FRE1, like neutrophil NADPH oxidase, has an unusually low redox potential, in the region of -250 mV, and binds CO.	NICHHD, NIH, BETHESDA, MD 20892 USA; SCRIPPS RES INST, DEPT MOLEC & EXPTL MED, LA JOLLA, CA 92037 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Scripps Research Institute	Shatwell, KP (corresponding author), UCL, DEPT MED, 5 LONDON ST, LONDON WC1E 6JJ, ENGLAND.			Segal, Anthony/0000-0001-7602-9043	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI024838] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24838] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); Wellcome Trust(Wellcome TrustEuropean Commission)		CROSS AR, 1982, BIOCHEM J, V204, P479, DOI 10.1042/bj2040479; CROSS AR, 1995, J BIOL CHEM, V270, P6543, DOI 10.1074/jbc.270.12.6543; CROSS AR, 1995, J BIOL CHEM, V270, P17075, DOI 10.1074/jbc.270.29.17075; CROSS AR, 1994, J BIOL CHEM, V269, P21448; CROSS AR, 1995, J BIOL CHEM, V270, P8194, DOI 10.1074/jbc.270.14.8194; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; HARPER AM, 1984, BIOCHEM J, V219, P519, DOI 10.1042/bj2190519; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1994, METAL IONS FUNGI, V2, P160; MORRIS DL, 1983, METHOD ENZYMOL, V92, P413; PEALING SL, 1992, BIOCHEMISTRY-US, V31, P12132, DOI 10.1021/bi00163a023; PORRA RJ, 1963, BIOCHEM J, V87, P186, DOI 10.1042/bj0870186; ROMAN DG, 1993, MOL CELL BIOL, V13, P4342, DOI 10.1128/MCB.13.7.4342; SCHAFFNE.W, 1973, ANAL BIOCHEM, V56, P502, DOI 10.1016/0003-2697(73)90217-0; SEGAL AW, 1992, BIOCHEM J, V284, P781, DOI 10.1042/bj2840781; SERRANO R, 1988, METHOD ENZYMOL, V157, P533; Stearman R, 1996, SCIENCE, V271, P1552, DOI 10.1126/science.271.5255.1552; TAYLOR WR, 1993, PROTEIN SCI, V2, P1675, DOI 10.1002/pro.5560021013; WIENTJES FB, 1995, CELL BIOL, V6, P357	21	117	120	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14240	14244		10.1074/jbc.271.24.14240	http://dx.doi.org/10.1074/jbc.271.24.14240			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662973				2022-12-27	WOS:A1996UQ66000047
J	VanRollins, M; Kaduce, TL; Fang, X; Knapp, HR; Spector, AA				VanRollins, M; Kaduce, TL; Fang, X; Knapp, HR; Spector, AA			Arachidonic acid diols produced by cytochrome P-450 monooxygenases are incorporated into phospholipids of vascular endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACIDS; 15-HYDROXYEICOSATETRAENOIC ACID; 5,6-EPOXYEICOSATRIENOIC ACID; EPOXYEICOSATRIENOIC ACIDS; EICOSAPENTAENOIC ACID; EPOXYGENASE; METABOLISM; CYCLOOXYGENASE; PHOSPHATIDYLINOSITOL; ESTERIFICATION	Epoxyeicosatrienoic acids (EETs) are synthesized by cytochrome P-450 monooxygenases and released into the blood. When taken up by vascular endothelial and smooth muscle cells, the EETs are primarily esterified to phospholipids or converted to dihydroxyeicosatetraenoic acids (DHETs) and released. In the present studies, radiolabeled 8,9-, 11,12-, and 14,15-DHETs released into the medium from vascular smooth muscle cells were isolated and incubated for 4-16 h with cultured bovine aortic endothelial cells. The uptake ranged from 2 to 50% for the three regioisomers. Hydrolysis of the endothelial lipids and gas chromatographic-mass spectral analyses of the products indicated that all three DHET regioisomers were incorporated intact into phosphatidylcholine and phosphatidylinositol. Similar incubations with EETs confirmed that small amounts of DHETs were also esterified to endothelial phospholipids. These studies indicate that DHETs are incorporated into phospholipids either at the time of EET conversion to DHET or upon release and re-uptake of DHETs. Beside demonstrating for the first time that fatty acid diols are incorporated intact into endothelial lipids, these studies raise the possibility that both EETs and DHETs remain long enough in the vascular wall to produce chronic vasoactive effects.	UNIV IOWA, COLL MED, DEPT INTERNAL MED, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT BIOCHEM, IOWA CITY, IA 52242 USA; UNIV IOWA, COLL MED, DEPT PHARMACOL, IOWA CITY, IA 52242 USA	University of Iowa; University of Iowa; University of Iowa			Spector, Arthur/AAG-9860-2020		NHLBI NIH HHS [HL-49264, HL-48877] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048877, P01HL049264] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALAZY M, 1991, J BIOL CHEM, V266, P23561; BALLOU LR, 1987, P NATL ACAD SCI USA, V84, P6990, DOI 10.1073/pnas.84.20.6990; BERNSTROM K, 1992, J BIOL CHEM, V267, P3686; BRADEN GR, 1991, CLIN RES, V39, pA183; BREZINSKI ME, 1990, P NATL ACAD SCI USA, V87, P6248, DOI 10.1073/pnas.87.16.6248; CAPDEVILA JH, 1992, J BIOL CHEM, V267, P21720; CAPDEVILA JH, 1992, FASEB J, V6, P731, DOI 10.1096/fasebj.6.2.1537463; CARROLL MA, 1993, J BIOL CHEM, V268, P12260; CATELLA F, 1990, P NATL ACAD SCI USA, V87, P5893, DOI 10.1073/pnas.87.15.5893; FANG X, 1995, J LIPID RES, V36, P1236; FOLCH J, 1957, J BIOL CHEM, V226, P497; GIORDANO MJ, 1992, J NEUROCHEM, V58, P374, DOI 10.1111/j.1471-4159.1992.tb09321.x; GOLDSMITH JC, 1981, LAB INVEST, V45, P191; HARDER DR, 1995, J VASC RES, V32, P79, DOI 10.1159/000159080; ISAACSON Y, 1990, CHEM PHYS LIPIDS, V52, P217, DOI 10.1016/0009-3084(90)90117-A; KARARA A, 1992, BIOCHEM BIOPH RES CO, V182, P1320, DOI 10.1016/0006-291X(92)91877-S; KNAPP HR, 1991, CLIN RES, V39, pA185; LEGRAND AB, 1991, J BIOL CHEM, V266, P7570; MADHUN ZT, 1991, J CLIN INVEST, V88, P456, DOI 10.1172/JCI115325; MCGIFF JC, 1991, ANNU REV PHARMACOL, V31, P339, DOI 10.1146/annurev.pa.31.040191.002011; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MURPHY RC, 1993, HDB LIPID RES, V7, P107; OLIW EH, 1994, PROG LIPID RES, V33, P329, DOI 10.1016/0163-7827(94)90029-9; PFISTER SL, 1991, AM J PHYSIOL, V261, pH843, DOI 10.1152/ajpheart.1991.261.3.H843; PRITCHARD KA, 1990, AM J PATHOL, V136, P1383; RICHARDS CF, 1986, BIOCHIM BIOPHYS ACTA, V875, P569, DOI 10.1016/0005-2760(86)90079-2; ROSOLOWSKY M, 1991, ADV PROSTAG THROMB L, V21, P213; ROSOLOWSKY M, 1990, CIRC RES, V66, P608, DOI 10.1161/01.RES.66.3.608; SHEN XY, 1988, BIOCHEMISTRY-US, V27, P996, DOI 10.1021/bi00403a024; SPECTOR AA, 1981, J CLIN INVEST, V68, P1003, DOI 10.1172/JCI110322; SPECTOR AA, 1988, PROG LIPID RES, V27, P271, DOI 10.1016/0163-7827(88)90009-4; SPECTOR AA, 1994, WORLD REV NUTR DIET, V75, P8; STENSON WF, 1983, PROSTAGLANDINS, V26, P253, DOI 10.1016/0090-6980(83)90093-X; STENSON WF, 1979, J CLIN INVEST, V64, P1457, DOI 10.1172/JCI109604; TURK J, 1990, METHOD ENZYMOL, V187, P175; VANROLLINS M, 1995, BBA-LIPID LIPID MET, V1256, P263, DOI 10.1016/0005-2760(95)00029-C; VANROLLINS M, 1993, J LIPID RES, V34, P1931; VANROLLINS M, 1995, J LIPID RES, V36, P952; VANROLLINS M, 1990, LIPIDS, V25, P481, DOI 10.1007/BF02538092; VANROLLINS M, 1989, J LIPID RES, V30, P275; VANROLLINS M, 1982, METHOD ENZYMOL, V86, P518; VANROLLINS M, 1984, J LIPID RES, V25, P507; ZELDIN DC, 1993, J BIOL CHEM, V268, P6402; ZHANG JY, 1992, BIOCHEM BIOPH RES CO, V183, P138, DOI 10.1016/0006-291X(92)91619-2; ZHU Y, 1995, HYPERTENSION, V25, P854, DOI 10.1161/01.HYP.25.4.854	45	72	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14001	14009		10.1074/jbc.271.24.14001	http://dx.doi.org/10.1074/jbc.271.24.14001			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662855	hybrid			2022-12-27	WOS:A1996UQ66000014
J	Baker, RT; Williamson, NA; Wettenhall, REH				Baker, RT; Williamson, NA; Wettenhall, REH			The yeast homolog of mammalian ribosomal protein S30 is expressed from a duplicated gene without a ubiquitin-like protein fusion sequence - Evolutionary implications	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							N-END RULE; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; FUNCTIONAL-ANALYSIS; TRANSFORMATION; CLONING; BIOGENESIS; EXTENSION; ENCODES; VECTORS	In mammals, the 59-residue ribosomal protein S30 (rpS30)is synthesized as a fusion to a 74-residue ubiquitin-like protein, which is cleaved to yield mature rpS30. An artificial fusion of this ubiquitin-like protein to E. coli beta-galactosidase was not cleaved when expressed in yeast (Saccharomyces cerevisiae), indicating that yeast lack this cleaving activity, The yeast rpS30 homolog (yrpS30) was purified and sequenced to reveal a 63-residue protein with 61% sequence identity to mammalian rpS30, Degenerate oligonucleotides based on the yrpS30 sequence were used to isolate full-length yrpS30 cDNAs, Sequence analysis of five cDNA clones revealed that yrpS30 is not synthesized as a fusion to a ubiquitin-like protein but is extended at its N terminus by a single methionine residue, The corresponding gene was identified in the GenBank(TM) data base by sequence alignment and termed RPS30A, The gene consists of two exons separated by a 430-base pair intron, which contains consensus splicing elements, Exon 1 encodes the initiator methionine residue and is preceded by canonical yeast ribosomal protein gene promoter elements, Exon 2 encodes the 62-residue mature yrpS30, Genomic hybridization reveals that the RPS30A gene is duplicated. Disruption of the RPS30A gene is not lethal but confers a slow growth phenotype. Ribosomes in the mutant strains contain an authentic yrpS30 protein, indicating that a functional yrpS30 is expressed from the duplicated gene but that the reduced capacity for yrpS30 synthesis restricted the growth rate. Analysis of avail able DNA sequence data bases reveals that rpS30 is synthesized as a fusion to a ubiquitin-like protein in nematodes and mammals but unfused in yeast, plants, and protazoa.	UNIV MELBOURNE, RUSSELL GRIMWADE SCH BIOCHEM & MOL BIOL, MELBOURNE, VIC 3052, AUSTRALIA	University of Melbourne	Baker, RT (corresponding author), AUSTRALIAN NATL UNIV, JOHN CURTIN SCH MED RES, MOLEC GENET GRP, POB 334, CANBERRA, ACT 2601, AUSTRALIA.		Williamson, Nicholas A/O-9812-2016	Williamson, Nicholas A/0000-0002-2173-3452				ARNASON T, 1994, MOL CELL BIOL, V14, P7876, DOI 10.1128/MCB.14.12.7876; BACHMAIR A, 1986, SCIENCE, V234, P179, DOI 10.1126/science.3018930; BAKER R, 1991, NUCLEIC ACIDS RES, V19, P1945, DOI 10.1093/nar/19.8.1945; BAKER RT, 1994, J BIOL CHEM, V269, P25381; BAKER RT, 1991, P NATL ACAD SCI USA, V88, P1090, DOI 10.1073/pnas.88.4.1090; BAKER RT, 1991, NUCLEIC ACIDS RES, V19, P1035, DOI 10.1093/nar/19.5.1035; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BARTEL B, 1990, EMBO J, V9, P3179, DOI 10.1002/j.1460-2075.1990.tb07516.x; BUTT TR, 1989, P NATL ACAD SCI USA, V86, P2540, DOI 10.1073/pnas.86.8.2540; CHAN YL, 1995, BIOCHEM BIOPH RES CO, V215, P682, DOI 10.1006/bbrc.1995.2518; CHAU V, 1989, SCIENCE, V243, P1576, DOI 10.1126/science.2538923; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ECKER DJ, 1989, J BIOL CHEM, V264, P7715; FINLEY D, 1987, CELL, V48, P1035, DOI 10.1016/0092-8674(87)90711-2; FINLEY D, 1989, NATURE, V338, P394, DOI 10.1038/338394a0; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GUARENTE L, 1982, P NATL ACAD SCI-BIOL, V79, P7410, DOI 10.1073/pnas.79.23.7410; HOFFMAN CS, 1987, GENE, V57, P267, DOI 10.1016/0378-1119(87)90131-4; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; JOHNSON ES, 1992, EMBO J, V11, P497, DOI 10.1002/j.1460-2075.1992.tb05080.x; JOHNSON ES, 1995, J BIOL CHEM, V270, P17442, DOI 10.1074/jbc.270.29.17442; JONES D, 1993, J BIOL CHEM, V268, P19545; KALOGEROPOULOS A, 1995, YEAST, V11, P555, DOI 10.1002/yea.320110605; KAS K, 1992, BIOCHEM BIOPH RES CO, V187, P927, DOI 10.1016/0006-291X(92)91286-Y; LUND PK, 1985, J BIOL CHEM, V260, P7609; MAGER WH, 1990, BIOCHIM BIOPHYS ACTA, V1050, P351, DOI 10.1016/0167-4781(90)90193-6; MICHIELS L, 1993, ONCOGENE, V8, P2537; MORRICE NA, 1994, FEBS LETT, V351, P171, DOI 10.1016/0014-5793(94)00854-X; NICK HP, 1985, ANAL BIOCHEM, V148, P93, DOI 10.1016/0003-2697(85)90632-3; OLVERA J, 1993, J BIOL CHEM, V268, P17967; OZKAYNAK E, 1987, EMBO J, V6, P1429, DOI 10.1002/j.1460-2075.1987.tb02384.x; PAPA FR, 1993, NATURE, V366, P313, DOI 10.1038/366313a0; PLANTA RJ, 1988, TRENDS GENET, V4, P64, DOI 10.1016/0168-9525(88)90042-X; REDMAN KL, 1989, NATURE, V338, P438, DOI 10.1038/338438a0; ROTHSTEIN R, 1991, METHOD ENZYMOL, V194, P281; SABIN EA, 1989, BIO-TECHNOL, V7, P705, DOI 10.1038/nbt0789-705; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SPENCE J, 1995, MOL CELL BIOL, V15, P1265; TEEM JL, 1983, P NATL ACAD SCI-BIOL, V80, P4403, DOI 10.1073/pnas.80.14.4403; TOBIAS JW, 1991, J BIOL CHEM, V266, P12021; VARSHAVSKY A, 1992, CELL, V69, P725, DOI 10.1016/0092-8674(92)90285-K; Warner J R, 1978, Methods Cell Biol, V20, P45, DOI 10.1016/S0091-679X(08)62008-7; WOOLFORD JL, 1991, MOL CELLULAR BIOL YE, V1, P587; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; YOO Y, 1989, J BIOL CHEM, V264, P17078	47	20	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13549	13555		10.1074/jbc.271.23.13549	http://dx.doi.org/10.1074/jbc.271.23.13549			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662789	hybrid			2022-12-27	WOS:A1996UP38500038
J	Janosch, P; Schellerer, M; Seitz, T; Reim, P; Eulitz, M; Brielmeier, M; Kolch, W; Sedivy, JM; Mischak, H				Janosch, P; Schellerer, M; Seitz, T; Reim, P; Eulitz, M; Brielmeier, M; Kolch, W; Sedivy, JM; Mischak, H			Characterization of I kappa B kinases - I kappa B-alpha is not phosphorylated by Raf-1 or protein kinase C isozymes, but is a casein kinase II substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DELTA; CELLS	The NF-kappa B transcription factor is activated by a wide variety of stimuli, including phorbol esters such as 12-O-tetradecanoylphorbol-13-acetate. In its inactive state, NF-kappa B is sequestered in the cytoplasm tethered to an inhibitor protein, I kappa B, Activation comprises the rapid phosphorylation of I kappa B-alpha at N-terminal sites, which presumably marks I kappa B-alpha for proteolytic degradation and leads to release of NF-kappa B into the nucleus, In addition, I kappa B-alpha is constitutively phosphorylated at the C terminus, which may be a prerequisite for proper I kappa B function, Protein kinase C (PKC) is activated by 12-O-tetradecanoylphorbol-13-acetate and has been previously reported to phosphorylate I kappa B-alpha in vitro. As PBC has turned out to constitute a multigene family encoding isozymes with different biological functions, we have reinvestigated I kappa B-alpha phosphorylation by PKC using recombinant PKC isozymes expressed in insect cells, While crude PKC preparations were efficient I kappa B-alpha kinases, highly purified PKC isozymes completely failed to phosphorylate I kappa B-alpha. Biochemical separation of porcine spleen yielded at least two fractions with I kappa B-alpha kinase activity, both of which were devoid of detectable PKC isozymes, One peak contained both Raf-l and casein kinase Il (CKII), Purified Raf-1 does not phosphorylate I kappa B-alpha directly, hut associates with CKII, which efficiently phosphorylates the C terminus of I kappa B-alpha. Two-dimensional phosphopeptide mapping and high pressure liquid chromatography-mass spectroscopy analysis showed that all I kappa B-alpha kinases induced phosphorylation at the same prominent sites in the C terminus. Our results clearly indicate that PRC isozymes alpha, beta, gamma, delta, epsilon, eta, and zeta as well as Raf-1 are not I kappa B-alpha kinases, They furthermore demonstrate that I kappa B-alpha is targeted by several kinases, one of which appears to be CKII.	FORSCHUNGSZENTRUM UMWELT & GESUNDHEIT, INST KLIN MOL BIOL & TUMOR GENET, D-81377 MUNICH, GERMANY; BROWN UNIV, DEPT BIOL MOLEC, PROVIDENCE, RI 02912 USA	Brown University			Mischak, Harald/E-8685-2011; Brielmeier, Markus/M-7352-2014; Kolch, Walter/ABF-2102-2021; Admin, SBI/HGB-2738-2022	Brielmeier, Markus/0000-0002-8715-869X; Kolch, Walter/0000-0001-5777-5016; Mischak, Harald/0000-0003-0323-0306	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM041690] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-R01-41690] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BAEUERLE PA, 1994, ANNU REV IMMUNOL, V12, P141, DOI 10.1146/annurev.immunol.12.1.141; BARROGA CF, 1995, P NATL ACAD SCI USA, V92, P7637, DOI 10.1073/pnas.92.17.7637; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; CHEN ZJ, 1995, GENE DEV, V9, P1586, DOI 10.1101/gad.9.13.1586; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GOSH S, 1990, NATURE, V344, P678; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HATHAWAY GM, 1980, J BIOL CHEM, V255, P8038; HUANG KP, 1991, METHOD ENZYMOL, V200, P241; KAZANIETZ MG, 1993, MOL PHARMACOL, V44, P298; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; LI SF, 1993, P NATL ACAD SCI USA, V90, P9247, DOI 10.1073/pnas.90.20.9247; LOZANO J, 1994, J BIOL CHEM, V269, P19200; McElhinny JA, 1996, MOL CELL BIOL, V16, P899; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; SIEBENLIST U, 1995, INDUCIBLE GENE EXPRE, V1, P93; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; TRAECKNER EBM, 1994, EMBO J, V14, P2876; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	21	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13868	13874		10.1074/jbc.271.23.13868	http://dx.doi.org/10.1074/jbc.271.23.13868			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662925	hybrid			2022-12-27	WOS:A1996UP38500084
J	HaraYokoyama, M; Kukimoto, I; Nishina, H; Kontani, K; Hirabayashi, Y; Irie, F; Sugiya, H; Furuyama, S; Katada, T				HaraYokoyama, M; Kukimoto, I; Nishina, H; Kontani, K; Hirabayashi, Y; Irie, F; Sugiya, H; Furuyama, S; Katada, T			Inhibition of NAD(+) glycohydrolase and ADP-ribosyl cyclase activities of leukocyte cell surface antigen CD38 by gangliosides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN TYROSINE KINASES; HL-60 CELLS; MOLECULE; DIFFERENTIATION; ACTIVATION; COMPLEXES; ACID	We have recently reported that gangliosides act as inhibitors of ADP-ribosyltransferases and NAD(+) glycohydrolases (NADase) of pertussis toxin and the C3 exoenzyme from Clostridium botulinum (Hara-Yokoyama, M., Hirabayashi, Y., Irie, F., Syuto, B., Moriishi, H., Susya, H., and Furuyama, S. (1995) J. Biol. Chem. 270, 8115-8121). Here, we investigated the effect of gangliosides on the enzymatic activity of leukocyte cell surface antigen CD38, which is identified as an ecto-NADase (Kontani, K., Nishina, H., Ohoka, Y., Takahashi, K., and Katada, T. (1993) J. Biol. Chem. 268, 16895-16898). Gangliosides G(M1a) and G(Q1b alpha) inhibited the NADase activity in the immunoprecipitate of anti-CD38 antibody from the membrane extract of retinoic acid-treated human leukemic HL-60 cells. Gangliosides also inhibited the NADase activity of the extracellular domain of CD38 antigen that was deprived of the transmembrane domain and was expressed in Escherichia coli as a fusion protein with maltose-binding protein (MBP-CD38). The order of the inhibitory effect of purified ganglioside species on the NADase activity on MBP-CD38 was as follows: G(Q1b alpha) > G(T1b), G(Q1b) > G(D1a), G(D1b), G(M1a),G(M1b), G(D3), G(M3). G(Q1b alpha) inhibited the NADase of MBP-CD38 in a noncompetitive manner versus NAD(+) with a K-i value of about 0.3 mu M. Neither ceramide nor the oligosaccharide moiety of G(Q1b alpha) had an effect on the NADase activity. G(Q1b alpha) G(T1b), and G(Q1b) also efficiently inhibited the ADP-ribosyl cyclase activity of MBP-CD38. At present, gangliosides are the only endogenous species that can block the enzymatic activity of CD38 antigen. The present results suggest a potential role of gangliosides as inhibitors of the ecto-NADases.	UNIV TOKYO,FAC PHARMACEUT SCI,DEPT PHYSIOL CHEM,BUNKYO KU,TOKYO 113,JAPAN; TOKYO INST TECHNOL,DEPT LIFE SCI,MIDORI KU,YOKOHAMA,KANAGAWA 227,JAPAN; INST PHYS & CHEM RES,FRONTIER RES PROGRAM,LAB GLYCOCELL BIOL,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; Tokyo Institute of Technology; RIKEN	HaraYokoyama, M (corresponding author), NIHON UNIV,SCH DENT,DEPT PHYSIOL,2-870-1 SAKAE CHO NISHI,MATSUDO,CHIBA 271,JAPAN.		Kukimoto, I/I-3995-2019	Kukimoto, I/0000-0001-9080-1642; Hirabayashi, Yoshio/0000-0002-5774-7354				ANDO S, 1992, J BIOCHEM, V111, P287, DOI 10.1093/oxfordjournals.jbchem.a123751; ANDO S, 1989, J BIOL CHEM, V264, P3478; BOHUSLAV J, 1993, EUR J IMMUNOL, V23, P825, DOI 10.1002/eji.1830230409; CINEK T, 1992, J IMMUNOL, V149, P2262; FRA AM, 1994, J BIOL CHEM, V269, P30745; FUNARO A, 1990, J IMMUNOL, V145, P2390; HARAYOKOYAMA M, 1995, J BIOL CHEM, V270, P8115, DOI 10.1074/jbc.270.14.8115; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HIRABAYASHI Y, 1988, J CHROMATOGR, V445, P377, DOI 10.1016/S0021-9673(01)84550-7; HIRABAYASHI Y, 1992, J BIOL CHEM, V267, P12973; HIRATA Y, 1994, FEBS LETT, V356, P244, DOI 10.1016/0014-5793(94)01279-2; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; INAGEDA K, 1995, J BIOCHEM-TOKYO, V117, P125, DOI 10.1093/oxfordjournals.jbchem.a124698; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KAISHO T, 1994, P NATL ACAD SCI USA, V91, P5325, DOI 10.1073/pnas.91.12.5325; KIRKHAM PA, 1994, IMMUNOLOGY, V83, P513; KONTANI K, 1993, J BIOL CHEM, V268, P16895; Kontani K, 1996, J BIOL CHEM, V271, P1534; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; LI Q, 1994, BIOCHEM BIOPH RES CO, V202, P629, DOI 10.1006/bbrc.1994.1974; MAEHAMA T, 1995, J BIOL CHEM, V270, P22747, DOI 10.1074/jbc.270.39.22747; MALAVASI F, 1992, INT J CLIN LAB RES, V22, P73, DOI 10.1007/BF02591400; MUTOH T, 1995, P NATL ACAD SCI USA, V92, P5087, DOI 10.1073/pnas.92.11.5087; NOJIRI H, 1991, J BIOL CHEM, V266, P4531; POWELL LD, 1994, J BIOL CHEM, V269, P10628; SHIMA T, 1969, J BIOL CHEM, V244, P6632; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; STEFANOVA I, 1991, SCIENCE, V254, P1016, DOI 10.1126/science.1719635; SVENNERHOLM L, 1964, J LIPID RES, V5, P145; TAKAHASHI K, 1995, FEBS LETT, V371, P204, DOI 10.1016/0014-5793(95)00914-U; TAKI T, 1986, J BIOL CHEM, V261, P3075; WANG J, 1994, J IMMUNOL, V153, P4048; YAMASHITA Y, 1995, IMMUNOLOGY, V85, P248; YOHE HC, 1976, J BIOL CHEM, V251, P7083; ZHOU QG, 1994, J BIOL CHEM, V269, P1959; ZUPO S, 1994, EUR J IMMUNOL, V24, P1218, DOI 10.1002/eji.1830240532	37	29	30	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12951	12955		10.1074/jbc.271.22.12951	http://dx.doi.org/10.1074/jbc.271.22.12951			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662799	hybrid			2022-12-27	WOS:A1996UN47400043
J	Poon, RYC; Jiang, W; Toyoshima, H; Hunter, T				Poon, RYC; Jiang, W; Toyoshima, H; Hunter, T			Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONIZING-RADIATION; MICE DEFICIENT; P53; APOPTOSIS; PROTEIN; CELLS; INHIBITION; INDUCTION; SUBUNIT; ANTIGEN	The cyclin-dependent kinase (CDK) inhibitor p21 is induced by the tumor suppressor gene product p53 and is thought to be important for the arrest of the cell cycle following DNA damage. Here we have investigated the contribution of p21 in inhibiting different cyclin-CDK complexes that drive different cell cycle transitions following UV irradiation-induced DNA damage in normal human fibroblasts and immortalized rodent fibroblasts. When cells were exposed to a low dose of UV irradiation, both p53 and p21 were induced; the protein kinase activities associated with Cdc2, Cdk2, and Cdk4 were inhibited; and there was a good correlation between their inhibition and binding to p21. p21 alone is likely to be sufficient for the inhibition of Cdk2 because all the cyclin-complexed forms of Cdk2 were associated with p21 after irradiation. In contrast, only a small proportion of Cdk4 and Cdc2 was complexed with p21, although the level of Cdk4 associated with either p21 or p27 was increased after irradiation. Furthermore, recombinant p21 added to an unirradiated cell lysate at the same level as that induced by irradiation damage inhibited only the kinase activity associated with Cdk2. Cdc2 is likely to be inhibited by Thr-14/Tyr-15 phosphorylation after irradiation because Cdc2 was tyrosine-phosphorylated, and recombinant Cdc25 was able to increase its kinase activity significantly. Taken together, these results suggest that different CDKs are inhibited by different mechanisms following UV-induced DNA damage: Cdk2 is inhibited by the elevated level of p21; Cdk4 is inhibited by cooperation of p21 with other CDK inhibitors, like p27, and possibly by phosphorylation; and Cdc2 is inhibited by Thr-14/Tyr-15 phosphorylation. It is likely that these underlying mechanisms that inactivate CDKs are similar for other kinds of DNA damage.	SALK INST BIOL STUDIES,LA JOLLA,CA 92037	Salk Institute				Poon, Randy/0000-0001-5571-6231; Jiang, Wei/0000-0002-2309-9571	NCI NIH HHS [CA39780, CA14195] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R35CA039780, P30CA014195] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		APRELIKOVA O, 1995, J BIOL CHEM, V270, P18195, DOI 10.1074/jbc.270.31.18195; BRUGAROLAS J, 1995, NATURE, V377, P552, DOI 10.1038/377552a0; CHAN FKM, 1995, MOL CELL BIOL, V15, P2682; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DI LEONARDO A, 1994, GENE DEV, V8, P2540, DOI 10.1101/gad.8.21.2540; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DULIC V, 1994, CELL, V76, P1013, DOI 10.1016/0092-8674(94)90379-4; ELDEIRY WS, 1994, CANCER RES, V54, P1169; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8656; GOUBIN F, 1995, ONCOGENE, V10, P2281; GREENBLATT MS, 1994, CANCER RES, V54, P4855; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; GUAN KL, 1994, GENE DEV, V8, P2939, DOI 10.1101/gad.8.24.2939; GUO K, 1995, MOL CELL BIOL, V15, P3823; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; HARPER JW, 1995, MOL BIOL CELL, V6, P387, DOI 10.1091/mbc.6.4.387; HARPER JW, 1993, CELL, V75, P805; HEICHMAN KA, 1994, CELL, V79, P557, DOI 10.1016/0092-8674(94)90541-X; HERZINGER T, 1995, ONCOGENE, V11, P2151; JIANG HP, 1994, ONCOGENE, V9, P3397; KASTAN MB, 1991, CANCER RES, V51, P6304; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KOBAYASHI H, 1991, COLD SH Q B, V56, P437; KUMAGAI A, 1995, MOL BIOL CELL, V6, P199, DOI 10.1091/mbc.6.2.199; LEE MH, 1995, GENE DEV, V9, P639, DOI 10.1101/gad.9.6.639; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI Y, 1994, ONCOGENE, V9, P22621; LOTEM J, 1993, BLOOD, V82, P1092, DOI 10.1182/blood.V82.4.1092.bloodjournal8241092; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; LUO Y, 1995, NATURE, V375, P159, DOI 10.1038/375159a0; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MATSUOKA S, 1995, GENE DEV, V9, P650, DOI 10.1101/gad.9.6.650; MICHIELI P, 1994, CANCER RES, V54, P3391; MISSERO C, 1995, P NATL ACAD SCI USA, V92, P5451, DOI 10.1073/pnas.92.12.5451; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MUSCHEL RJ, 1993, CANCER RES, V53, P1128; NAKANISHI M, 1995, EMBO J, V14, P555, DOI 10.1002/j.1460-2075.1995.tb07031.x; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PONTEN F, 1995, J INVEST DERMATOL, V105, P402, DOI 10.1111/1523-1747.ep12321071; POON RYC, 1995, MOL BIOL CELL, V6, P1197, DOI 10.1091/mbc.6.9.1197; POON RYC, 1994, J CELL SCI, V107, P2789; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; POON RYC, 1995, SCIENCE, V270, P90, DOI 10.1126/science.270.5233.90; QUELLE DE, 1995, CELL, V83, P993; SERRANO M, 1993, NATURE, V366, P704, DOI 10.1038/366704a0; SHEIKH MS, 1994, ONCOGENE, V9, P3407; SHERR CJ, 1995, GENE DEV, V9, P1149, DOI 10.1101/gad.9.10.1149; SHERR CJ, 1994, CELL, V79, P551, DOI 10.1016/0092-8674(94)90540-1; SHIVJI MKK, 1994, CURR BIOL, V4, P1062, DOI 10.1016/S0960-9822(00)00244-X; SMYTHE C, 1992, CELL, V68, P787, DOI 10.1016/0092-8674(92)90153-4; STEINMAN RA, 1994, ONCOGENE, V9, P3389; STRAUSFELD UP, 1994, CURR BIOL, V4, P876, DOI 10.1016/S0960-9822(00)00196-2; TERADA Y, 1995, NATURE, V376, P358, DOI 10.1038/376358a0; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; Tyrrell RM, 1996, BIOESSAYS, V18, P139, DOI 10.1002/bies.950180210; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WALDMAN T, 1995, CANCER RES, V55, P5187; WARBRICK E, 1995, CURR BIOL, V5, P275, DOI 10.1016/S0960-9822(95)00058-3; WASEEM NH, 1990, J CELL SCI, V96, P121; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0; ZHANG H, 1994, GENE DEV, V8, P1750, DOI 10.1101/gad.8.15.1750; ZHANG W, 1995, CANCER RES, V55, P668	71	163	164	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13283	13291		10.1074/jbc.271.22.13283	http://dx.doi.org/10.1074/jbc.271.22.13283			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662825	hybrid			2022-12-27	WOS:A1996UN47400091
J	Gillen, CM; Brill, S; Payne, JA; Forbush, B				Gillen, CM; Brill, S; Payne, JA; Forbush, B			Molecular cloning and functional expression of the K-Cl cotransporter from rabbit, rat, and human - A new member of the cation-chloride cotransporter family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ASCITES TUMOR-CELLS; SHARK RECTAL GLAND; KCL CO-TRANSPORT; SHEEP RED-CELLS; BASOLATERAL MEMBRANE; POTASSIUM-TRANSPORT; MONOCLONAL-ANTIBODIES; VOLUME REGULATION; N-ETHYLMALEIMIDE; BLOOD-CELLS	We report the cloning, sequence analysis, tissue distribution, and functional expression of the K-Cl cotransport protein, KCC1, KCC1 was identified by searching the human expressed sequence tag data base, based on the expectation that it would be distantly related to the Na-K-Cl cotransporter. Rabbit KCC1 (rbKCC1) and rat KCC1 (rtKCC1) were cloned by screening rabbit kidney and rat brain cDNA libraries using homologous cDNA probes, Human KCC1 (hKCC1) was obtained from I.M.A.G.E. clones and in part by reverse transcription-polymerase chain reaction; it exhibits 97% identity with rbKCC1, KCC1 encodes a 1085-residue polypeptide with substantial sequence homology (24-25% identity) to the bumetanide-sensitive Na-K-Cl cotransporter (NKCC or BSC) and the thiazide-sensitive Na-Cl cotransporter (NCC or TSC), Hydropathy analysis of KCC1 indicates structural homology to NKCC, including 12 transmembrane domains, a large extracellular loop with potential N linked glycosylation sites, and cytoplasmic N- and C-terminal regions, Northern blot analysis revealed a ubiquitously expressed 3,8-kilobase transcript. Much of the genomic sequence of hKCC1 is in the data base, and the gene has been previously localized to 16q22.1 (Larsen, F., Solhein, J., Kristensen, T., Kolsto, A. B., and Prydz, H. (1993) Hum. Mel. Genet. 2, 1589-1595), Epitope-tagged rbKCC1 was stably expressed in human embryonic kidney (HEK 293) cells, resulting in production of a similar to 150-kDa glycoprotein. The initial rate of Rb-86 efflux from cells expressing rbKCC1 was more than 7 times greater than efflux from control cells and was inhibited by 2 mM furosemide; Rb-86 efflux was stimulated by cell swelling, Uptake of Rb-86 into rbKCC1 cells after a 15-min pretreatment with 1 mM N-ethylmaleimide was dependent on external chloride but not on external sodium, and was inhibited by furosemide with a K-i of similar to 40 mu M and by bumetanide with a K-i of similar to 60 mu M. These data demonstrate that the KCC1 cDNAs encode a widely expressed K-Cl cotransporter with the characteristics of the K-Cl transporter that has been characterized in red cells.	UNIV CALIF DAVIS,SCH MED,DEPT HUMAN PHYSIOL,DAVIS,CA 95616	University of California System; University of California Davis	Gillen, CM (corresponding author), YALE UNIV,SCH MED,DEPT CELLULAR & MOLEC PHYSIOL,STERLING HALL MED,333 CEDAR ST,NEW HAVEN,CT 06520, USA.				NIDDK NIH HHS [DK47661, DK09219] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK047661, F32DK009219] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AULL F, 1981, BIOCHIM BIOPHYS ACTA, V643, P339, DOI 10.1016/0005-2736(81)90079-1; BAUM M, 1984, J CLIN INVEST, V74, P205, DOI 10.1172/JCI111403; BIANCHINI L, 1988, J EXP BIOL, V137, P303; BIZE I, 1994, AM J PHYSIOL, V266, pC759, DOI 10.1152/ajpcell.1994.266.3.C759; BRUGNARA C, 1985, J CLIN INVEST, V75, P1608, DOI 10.1172/JCI111867; BRUGNARA C, 1989, AM J PHYSIOL, V256, pC994, DOI 10.1152/ajpcell.1989.256.5.C994; CAMERON PL, 1991, J CELL BIOL, V115, P151, DOI 10.1083/jcb.115.1.151; CANESSA M, 1986, FEBS LETT, V200, P197, DOI 10.1016/0014-5793(86)80538-5; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DELPIRE E, 1994, J BIOL CHEM, V269, P25677; DUNHAM PB, 1981, J PHYSIOL-LONDON, V318, P511; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; EVELOFF J, 1987, AM J PHYSIOL, V252, pF883, DOI 10.1152/ajprenal.1987.252.5.F883; FORBUSH B, 1983, J BIOL CHEM, V258, P1787; FRENGEN E, 1995, CYTOGENET CELL GENET, V68, P194, DOI 10.1159/000133912; GAMBA G, 1993, P NATL ACAD SCI USA, V90, P2749, DOI 10.1073/pnas.90.7.2749; GAMBA G, 1994, J BIOL CHEM, V269, P17713; Gillen Christopher M., 1996, Biophysical Journal, V70, pA204; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; GUGGINO WB, 1986, AM J PHYSIOL, V250, pF430, DOI 10.1152/ajprenal.1986.250.3.F430; HAAS M, 1985, J GEN PHYSIOL, V85, P649, DOI 10.1085/jgp.85.5.649; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; Hoffmann EK, 1995, INT REV CYTOL, V161, P173; JENNINGS ML, 1991, J GEN PHYSIOL, V97, P799, DOI 10.1085/jgp.97.4.799; JENNINGS ML, 1990, J GEN PHYSIOL, V95, P1021, DOI 10.1085/jgp.95.6.1021; KAJI DM, 1993, AM J PHYSIOL, V264, pC376, DOI 10.1152/ajpcell.1993.264.2.C376; KRAMHOFT B, 1986, AM J PHYSIOL, V251, pC369, DOI 10.1152/ajpcell.1986.251.3.C369; KREGENOW FM, 1971, J GEN PHYSIOL, V58, P372, DOI 10.1085/jgp.58.4.372; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LARSEN F, 1993, HUM MOL GENET, V2, P1589, DOI 10.1093/hmg/2.10.1589; LARSON M, 1984, J MEMBRANE BIOL, V81, P219, DOI 10.1007/BF01868715; LAUF PK, 1984, AM J PHYSIOL, V246, pC385, DOI 10.1152/ajpcell.1984.246.5.C385; LAUF PK, 1992, AM J PHYSIOL, V263, pC917, DOI 10.1152/ajpcell.1992.263.5.C917; LAUF PK, 1983, J MEMBRANE BIOL, V73, P237, DOI 10.1007/BF01870538; Lennon G, 1996, GENOMICS, V33, P151, DOI 10.1006/geno.1996.0177; LYTLE C, 1992, J BIOL CHEM, V267, P25428; LYTLE C, 1992, J BIOL CHEM, V267, P25438; MCLEAN J, 1986, NUCLEIC ACIDS RES, V14, P9397, DOI 10.1093/nar/14.23.9397; ONEILL WC, 1991, AM J PHYSIOL, V260, pC308, DOI 10.1152/ajpcell.1991.260.2.C308; PAYNE JA, 1995, CURR OPIN CELL BIOL, V7, P493, DOI 10.1016/0955-0674(95)80005-0; PAYNE JA, 1995, J BIOL CHEM, V270, P17977, DOI 10.1074/jbc.270.30.17977; Payne JA, 1996, J BIOL CHEM, V271, P16245, DOI 10.1074/jbc.271.27.16245; PAYNE JA, 1994, P NATL ACAD SCI USA, V91, P4544, DOI 10.1073/pnas.91.10.4544; PERRY PB, 1993, AM J PHYSIOL, V265, pC763, DOI 10.1152/ajpcell.1993.265.3.C763; REAGAN JD, 1995, INSECT BIOCHEM MOLEC, V25, P875, DOI 10.1016/0965-1748(95)00049-2; REUSS L, 1983, NATURE, V305, P723, DOI 10.1038/305723a0; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1995, PROTEIN SCI, V4, P521; SACHS JR, 1993, J GEN PHYSIOL, V102, P551, DOI 10.1085/jgp.102.3.551; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SASAKI S, 1988, J CLIN INVEST, V81, P194, DOI 10.1172/JCI113294; SHINDO T, 1981, J MEMBRANE BIOL, V58, P35, DOI 10.1007/BF01871032; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; XU JC, 1994, P NATL ACAD SCI USA, V91, P2201, DOI 10.1073/pnas.91.6.2201	54	324	334	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16237	16244		10.1074/jbc.271.27.16237	http://dx.doi.org/10.1074/jbc.271.27.16237			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663127	hybrid			2022-12-27	WOS:A1996UW35200056
J	Luthria, DL; Mohammed, BS; Sprecher, H				Luthria, DL; Mohammed, BS; Sprecher, H			Regulation of the biosynthesis of 4,7,10,13,16,19-docosahexaenoic acid	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PEROXISOMAL BETA-OXIDATION; COENZYME-A SYNTHETASE; RAT-LIVER MICROSOMES; ACYL-COA SYNTHETASE; FATTY-ACIDS; CHAIN ELONGATION; PURIFICATION; MITOCHONDRIA; DESATURASE	The synthesis of 4,7,10,13,16,19-docosahexaenoic acid (22:6(n-3)) requires that when 6,9,12,15,18,21-tetracosahexaenoic acid (24:6(n-3)) is produced in the endoplasmic reticulum, it preferentially moves to peroxisomes for one cycle of beta-oxidation rather than serving as a substrate for membrane lipid synthesis. Both 24:6(n-3) and its precursor, 9,12,15,18,21-tetracosapentaenoic acid (24:5(n-3)), were poor substrates for acylation into 1-acyl-sn-glycero-3-phosphocholine (l-acyl-GPC) by rat liver microsomes. When peroxisomes were incubated with 1-C-14- Or 3-C-14-labeled 7,10,13,16,19-docosapentaenoic acid (22:5(n-3)), [1-C-14]22:6(n-3), [3-C-14]24:5(n-3), or [3-C-14]24:6(n-3), only small amounts of acid-soluble radioactivity were produced when double bond removal at positions 4 and 5 was required. When microsomes and l-acyl-GPC were included in incubations, the preferred metabolic fate of acids, with their first double bond at either positions 4 or 5, was to move out of peroxisomes for esterification into the acceptor rather than serving as substrates for continued beta-oxidation. When [1-C-14]22: 6(n-3) or [3-C-14]24:6(n-3) was incubated with peroxisomes, 2-trans-4,7,10,13,16,19-22:7 accumulated. The first cycle of 20:5(n-3) beta-oxidation proceeds through 2-trans-4,8,11,14,17-20:6 and thus requires both Delta(3,5),Delta(2,4)-dienoyl-CoA isomerase and 2,4-dienoyl-CoA reductase. The accumulation of the substrate for 2,4-dienoyl-CoA reductase, as generated from 22:6(n-3), but not from 20: 5(n-3), suggests that this enzyme distinguishes between subtle structural differences. When 22:6(n-3) is produced from 24:6(n-3), its continued degradation is impaired because of low a,4-dienoyl-CoA reductase activity. This slow reaction rate likely contributes to the transport of 22:6(n-3) out of peroxisomes for rapid acylation into l-acyl-GPC by microsomes.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210	University System of Ohio; Ohio State University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048744, R01DK020387] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK20387, DK48744] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BARTLETT K, 1990, BIOCHEM J, V270, P175, DOI 10.1042/bj2700175; BAYKOUSHEVA SP, 1995, FEBS LETT, V367, P198, DOI 10.1016/0014-5793(95)00565-Q; BAYKOUSHEVA SP, 1994, J BIOL CHEM, V269, P18390; BELL RM, 1980, ANNU REV BIOCHEM, V49, P459, DOI 10.1146/annurev.bi.49.070180.002331; BERNERT JT, 1979, BIOCHIM BIOPHYS ACTA, V573, P436, DOI 10.1016/0005-2760(79)90218-2; CHRISTENSEN E, 1993, SCAND J CLIN LA S215, V536, P61; DAS AK, 1992, J BIOL CHEM, V267, P9724; DeMar JC, 1996, J BIOL CHEM, V271, P5007; DOMMES V, 1982, EUR J BIOCHEM, V125, P335, DOI 10.1111/j.1432-1033.1982.tb06688.x; HE XY, 1995, BIOCHEM BIOPH RES CO, V215, P15, DOI 10.1006/bbrc.1995.2428; HORIE S, 1989, ARCH BIOCHEM BIOPHYS, V274, P64, DOI 10.1016/0003-9861(89)90415-3; LAGEWEG W, 1991, EUR J BIOCHEM, V196, P519, DOI 10.1111/j.1432-1033.1991.tb15844.x; LANDS WEM, 1982, J BIOL CHEM, V257, P4968; LUTHRIA DL, 1995, J BIOL CHEM, V270, P13771, DOI 10.1074/jbc.270.23.13771; MANNAERTS GP, 1993, BIOCHIMIE, V75, P147, DOI 10.1016/0300-9084(93)90072-Z; MARTINEZ M, 1989, LIPIDS, V24, P261, DOI 10.1007/BF02535160; MIYAZAWA S, 1985, J BIOCHEM, V98, P723, DOI 10.1093/oxfordjournals.jbchem.a135330; MOHAMMED BS, 1995, ARCH BIOCHEM BIOPHYS, V317, P179, DOI 10.1006/abbi.1995.1151; MOORE SA, 1995, J LIPID RES, V36, P2433; OKAYASU T, 1981, ARCH BIOCHEM BIOPHYS, V206, P21, DOI 10.1016/0003-9861(81)90061-8; OSMUNDSEN H, 1991, BIOCHIM BIOPHYS ACTA, V1085, P141, DOI 10.1016/0005-2760(91)90089-Z; PALOSAARI PM, 1990, J BIOL CHEM, V265, P2446; PHILIPP DP, 1979, J BIOL CHEM, V254, P776; SCHULZ H, 1991, BIOCHIM BIOPHYS ACTA, V1081, P109, DOI 10.1016/0005-2760(91)90015-A; STRITTMATTER P, 1974, P NATL ACAD SCI USA, V71, P4565, DOI 10.1073/pnas.71.11.4565; SUZUKI H, 1990, J BIOL CHEM, V265, P8681; SVENSSON LT, 1995, EUR J BIOCHEM, V230, P813; TANAKA T, 1979, EUR J BIOCHEM, V98, P165, DOI 10.1111/j.1432-1033.1979.tb13173.x; VANCE JE, 1990, J BIOL CHEM, V265, P7248; VOSS A, 1991, J BIOL CHEM, V266, P19995; VOSS A, 1992, BIOCHIM BIOPHYS ACTA, V1127, P33, DOI 10.1016/0005-2760(92)90198-5; YAMADA J, 1994, ARCH BIOCHEM BIOPHYS, V308, P118, DOI 10.1006/abbi.1994.1017	33	69	70	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16020	16025		10.1074/jbc.271.27.16020	http://dx.doi.org/10.1074/jbc.271.27.16020			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663162	hybrid			2022-12-27	WOS:A1996UW35200028
J	Slemmon, JR; Morgan, JI; Fullerton, SM; Danho, W; Hilbush, BS; Wengenack, TM				Slemmon, JR; Morgan, JI; Fullerton, SM; Danho, W; Hilbush, BS; Wengenack, TM			Camstatins are peptide antagonists of calmodulin based upon a conserved structural motif in PEP-19, neurogranin, and neuromodulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BRAIN-SPECIFIC POLYPEPTIDE; BINDING PROTEIN; NERVOUS-SYSTEM; NEURONAL DEATH; ION CHANNELS; KINASE-II; LOCALIZATION; GLUTAMATE; CALCIUM; SUBSTRATE	Unbridled increases in intracellular ionized calcium can result in neuronal damage and death. Since many of the deleterious effects of calcium are mediated by calmodulin, we have sought to identify neuronal proteins that inhibit activation of this ubiquitous protein. PEP-19 is a 7.6-kDa neuron-specific protein, which contains a motif similar to the calmodulin binding domains of neuromodulin (GAP 43) and neurogranin (RC3). Here we show that PEP-19 binds calmodulin in an analogous calcium-independent manner with an apparent R(d) near 1.2 mu M. Furthermore, using the calmodulin-dependent enzyme neuronal nitric oxide synthase, we demonstrate that native PEP-19 is also an antagonist of enzyme activity. Based on the PEP-19 sequence, a series of peptide calmodulin antagonists termed camstatins were synthesized, These analogs define the minimally active domain of PEP-19 and provide a structure/activity relationship for calmodulin antagonism. There was a positive correlation between the binding affinities of the camstatins for calmodulin and their potencies as neuronal nitric oxide synthase inhibitors. Despite the similar IQ motif in PEP-19 and neuromodulin or neurogranin, PEP-19 was not a substrate for protein kinase C. The properties of PEP-19 suggest that it could fulfill a role in calmodulin is present in large excess and is not subject to short neuroprotection.	UNIV ROCHESTER, MED CTR, DEPT NEUROBIOL & ANAT, ROCHESTER, NY 14642 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, DEPT MOLEC SCI, NUTLEY, NJ 07110 USA; HOFFMANN LA ROCHE INC, ROCHE RES CTR, ROCHE INST MOLEC BIOL, NUTLEY, NJ 07110 USA	University of Rochester; Roche Holding; Roche Holding	Slemmon, JR (corresponding author), UNIV ROCHESTER, MED CTR, DEPT BIOCHEM, BOX 607, 601 ELMWOOD AVE, ROCHESTER, NY 14642 USA.		Morgan, James/GRO-2905-2022; Morgan, James/N-8104-2018	Morgan, James/0000-0002-8920-1065; 	NIA NIH HHS [R35 AG09016] Funding Source: Medline; NINDS NIH HHS [R01 NS33299] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS033299] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R35AG009016] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BAIMBRIDGE KG, 1992, TRENDS NEUROSCI, V15, P303, DOI 10.1016/0166-2236(92)90081-I; BARNARD EA, 1992, TRENDS BIOCHEM SCI, V17, P368, DOI 10.1016/0968-0004(92)90002-Q; BAUDIER J, 1991, J BIOL CHEM, V266, P229; BERREBI AS, 1991, J COMP NEUROL, V308, P630, DOI 10.1002/cne.903080409; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; CATTERALL WA, 1988, SCIENCE, V242, P50, DOI 10.1126/science.2459775; CHAPMAN ER, 1991, J BIOL CHEM, V266, P207; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; DAWSON TM, 1995, ANN NEUROL, V37, P115, DOI 10.1002/ana.410370122; DOWD DR, 1991, J BIOL CHEM, V266, P18423; DUNLAP K, 1994, SCIENCE, V266, P828, DOI 10.1126/science.7973643; ESPREAFICO EM, 1992, J CELL BIOL, V119, P1541, DOI 10.1083/jcb.119.6.1541; FAVARON M, 1990, P NATL ACAD SCI USA, V87, P1983, DOI 10.1073/pnas.87.5.1983; FELIPO V, 1993, BRAIN RES, V604, P192, DOI 10.1016/0006-8993(93)90368-W; FIRZLAFF JM, 1991, P NATL ACAD SCI USA, V88, P5187, DOI 10.1073/pnas.88.12.5187; FONG YL, 1989, J BIOL CHEM, V264, P16759; FRIEDMAN LK, 1994, J NEUROSCI, V14, P2697; GERENDASY DD, 1994, J BIOL CHEM, V269, P22420; HANSON PI, 1994, NEURON, V12, P943, DOI 10.1016/0896-6273(94)90306-9; KENNELLY PJ, 1991, J BIOL CHEM, V266, P15555; KIRINO T, 1982, BRAIN RES, V239, P57, DOI 10.1016/0006-8993(82)90833-2; KLEE CB, 1982, ADV PROTEIN CHEM, V35, P213, DOI 10.1016/S0065-3233(08)60470-2; KOPROWSKI H, 1993, P NATL ACAD SCI USA, V90, P3024, DOI 10.1073/pnas.90.7.3024; LANDRY J, 1988, RADIAT RES, V113, P426, DOI 10.2307/3577240; LIU Y, 1989, J BIOL CHEM, V264, P12800; LIU YC, 1990, TRENDS PHARMACOL SCI, V11, P107; MALENKA RC, 1989, NATURE, V340, P554, DOI 10.1038/340554a0; MARTZEN MR, 1995, J NEUROCHEM, V64, P92; MATTSON MP, 1989, BRAIN RES, V490, P110, DOI 10.1016/0006-8993(89)90436-8; MEANS AR, 1991, PHARMACOL THERAPEUT, V50, P255, DOI 10.1016/0163-7258(91)90017-G; MILLER RJ, 1988, TRENDS NEUROSCI, V11, P415, DOI 10.1016/0166-2236(88)90191-9; PIROLLET F, 1992, BIOCHIM BIOPHYS ACTA, V1160, P113, DOI 10.1016/0167-4838(92)90044-E; POLAK KA, 1991, J NEUROSCI, V11, P534; RASMUSSEN CD, 1989, TRENDS NEUROSCI, V12, P433, DOI 10.1016/0166-2236(89)90092-1; REPRESA A, 1990, J NEUROSCI, V10, P3782, DOI 10.1523/JNEUROSCI.10-12-03782.1990; SANGAMESWARAN L, 1989, P NATL ACAD SCI USA, V86, P5651, DOI 10.1073/pnas.86.14.5651; SKENE JHP, 1989, ANNU REV NEUROSCI, V12, P127, DOI 10.1146/annurev.ne.12.030189.001015; SLEMMON JR, 1992, NEUROBIOL AGING, V13, P649, DOI 10.1016/0197-4580(92)90087-E; SLEMMON JR, 1994, BIOCHEMISTRY-US, V33, P5653, DOI 10.1021/bi00184a039; SLEMMON JR, 1994, J NEUROSCI, V14, P2225; SOBUE K, 1981, P NATL ACAD SCI-BIOL, V78, P5652, DOI 10.1073/pnas.78.9.5652; SOBUE K, 1981, BIOCHEM BIOPH RES CO, V100, P1063, DOI 10.1016/0006-291X(81)91931-8; TAYLOR CW, 1992, TRENDS BIOCHEM SCI, V17, P403, DOI 10.1016/0968-0004(92)90009-X; TRUMP B F, 1992, Current Opinion in Cell Biology, V4, P227; VANDERSLUIJS P, 1992, EMBO J, V11, P4379, DOI 10.1002/j.1460-2075.1992.tb05538.x; WATSON JB, 1992, P NATL ACAD SCI USA, V89, P8581, DOI 10.1073/pnas.89.18.8581; WATSON JB, 1990, J NEUROSCI RES, V26, P397, DOI 10.1002/jnr.490260402; WEST MJ, 1994, LANCET, V344, P769, DOI 10.1016/S0140-6736(94)92338-8; ZIAI MR, 1988, J NEUROCHEM, V51, P1771, DOI 10.1111/j.1471-4159.1988.tb01158.x; ZIAI R, 1986, P NATL ACAD SCI USA, V83, P8420, DOI 10.1073/pnas.83.21.8420	51	82	82	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15911	15917		10.1074/jbc.271.27.15911	http://dx.doi.org/10.1074/jbc.271.27.15911			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663125	hybrid			2022-12-27	WOS:A1996UW35200014
J	Strobel, RS; Nagy, AK; Knowles, AF; Buegel, J; Rosenberg, MD				Strobel, RS; Nagy, AK; Knowles, AF; Buegel, J; Rosenberg, MD			Chicken oviductal ecto-ATP-diphosphohydrolase - Purification and characterization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE GELS; BOVINE AORTA; ASSAY; IDENTIFICATION; PHOSPHATE; PROTEINS; ELECTROPHORESIS; SYNAPTOSOMES; LOCALIZATION; MEMBRANES	An ecto-ATP diphosphohydrolase (ATPDase) was purified to homogeneity from vesiculosomes shed from chicken oviduct, First, the ecto-ATPDase-enriched vesiculosomes were concentrated by filtration, differential centrifugation, and exclusion chromatography, Next, the nonionic detergent, Nonidet P-40, was used to extract the ecto-ATPDase from vesiculosomal membranes, and the solubilized enzyme was further purified by ion by ion exchange (DEAE-Bio-Gel) and lentil lectin-Sepharose 4B chromatography, In the final stage, immunoaffinity chromatography was utilized to obtain purified ecto-ATPDase, More than 25,000-fold purification was achieved, Specific activity of the purified enzyme was greater than 800 mu mol/min/mg of protein with MgATP as the substrate, the highest ever reported for an ATPDase, The enzyme also hydrolyzed other nucleoside triphosphates in the presence of magnesium at similar rates and CaATP and MgADP at lower rates, The molecular mass of the purified glycoprotein was 80 kDa as deter mined by SDS-polyacrylamide gel electrophoresis and Western blot analysis, Based on its enzymatic properties, the relationship of the chicken oviduct ecto-ATPDase with other reported ATPDases and ecto-ATPases is discussed.	UNIV MINNESOTA,DEPT GENET & CELL BIOL,ST PAUL,MN 55108; UNIV CALIF LOS ANGELES,DEPT NEUROL & MED,LOS ANGELES,CA; W LOS ANGELES VET AFFAIRS MED CTR,LOS ANGELES,CA 90073; SUNY HLTH SCI CTR,DEPT BIOCHEM & MOLEC BIOL,SYRACUSE,NY 13210	University of Minnesota System; University of Minnesota Twin Cities; University of California System; University of California Los Angeles; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Greater Los Angeles Healthcare System; West Los Angeles VA Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Upstate Medical Center								ANDERSON B, 1974, DEV BIOL, V37, P306, DOI 10.1016/0012-1606(74)90151-1; ANDERSON B, 1976, BIOL REPROD, V14, P253, DOI 10.1095/biolreprod14.3.253; BARBER BH, 1982, J IMMUNOL METHODS, V48, P87, DOI 10.1016/0022-1759(82)90213-7; BEAUDOIN AR, 1986, FEBS LETT, V203, P1, DOI 10.1016/0014-5793(86)81423-5; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; COTE YP, 1991, BIOCHIM BIOPHYS ACTA, V1078, P187, DOI 10.1016/0167-4838(91)99008-G; DAWSON JM, 1986, BIOCHIM BIOPHYS ACTA, V856, P566, DOI 10.1016/0005-2736(86)90148-3; DEBRUYNE I, 1973, ARCH INT PHYSIOL BIO, V81, P963; ERNSTER L, 1962, J CELL BIOL, V15, P563, DOI 10.1083/jcb.15.3.563; ETHEREDGE E, 1971, BIOCHIM BIOPHYS ACTA, V233, P145, DOI 10.1016/0005-2736(71)90367-1; GEFFTER ML, 1977, SOMATIC CELL GENET, V3, P231; GODING JW, 1987, MONOCLONAL ANTIBODIE, P230; HAALAND JE, 1969, NATURE, V223, P1275, DOI 10.1038/2231275a0; HAALAND JE, 1971, BIOCHIM BIOPHYS ACTA, V233, P137, DOI 10.1016/0005-2736(71)90366-X; HEINONEN JK, 1981, ANAL BIOCHEM, V113, P313, DOI 10.1016/0003-2697(81)90082-8; HOCHSTRASSER DF, 1988, ANAL BIOCHEM, V173, P412, DOI 10.1016/0003-2697(88)90208-4; HOWARD IK, 1971, J BIOL CHEM, V246, P1590; HUDSON L, 1980, PRACTICAL IMMUNOLOGY, P220; KETTLUN AM, 1992, PHYTOCHEMISTRY, V31, P3691; KNOWLES AF, 1983, BIOCHIM BIOPHYS ACTA, V731, P88, DOI 10.1016/0005-2736(83)90401-7; KNOWLES AF, 1988, ARCH BIOCHEM BIOPHYS, V263, P264, DOI 10.1016/0003-9861(88)90635-2; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LALIBERTE JF, 1982, J BIOL CHEM, V257, P3869; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LEBEL D, 1980, J BIOL CHEM, V255, P1227; LEE K, 1978, THESIS U MINNESOTA; LEE K, 1980, ENZYME, V25, P276; LIENHARD GE, 1973, J BIOL CHEM, V248, P1121; MAGOCSI M, 1991, BIOCHIM BIOPHYS ACTA, V1070, P163, DOI 10.1016/0005-2736(91)90159-6; MARCUS AJ, 1991, J CLIN INVEST, V88, P1690, DOI 10.1172/JCI115485; MERRIL CR, 1979, P NATL ACAD SCI USA, V76, P4335, DOI 10.1073/pnas.76.9.4335; MOLNAR J, 1961, ARCH BIOCHEM BIOPHYS, V93, P353, DOI 10.1016/0003-9861(61)90278-8; MOODIE FDL, 1991, EUR J BIOCHEM, V202, P1209, DOI 10.1111/j.1432-1033.1991.tb16492.x; NAGY A, 1983, J NEUROCHEM, V40, P226, DOI 10.1111/j.1471-4159.1983.tb12675.x; NAGY AK, 1986, J NEUROCHEM, V47, P976; NIMMO HG, 1982, ANAL BIOCHEM, V121, P17, DOI 10.1016/0003-2697(82)90551-6; PAPAMARCAKI T, 1990, MOL CELL BIOCHEM, V97, P1; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PICHER M, 1993, J BIOL CHEM, V268, P4699; PLESNER L, 1995, INT REV CYTOL, V158, P141; RHEA RP, 1974, FERTIL STERIL, V25, P788; Richardson KC, 1935, PHILOS T ROY SOC B, V225, P149, DOI 10.1098/rstb.1935.0010; ROSENBERG MD, 1980, ENZYME, V25, P276, DOI 10.1159/000459264; ROSENBERG MD, 1977, BIOCHIM BIOPHYS ACTA, V482, P197, DOI 10.1016/0005-2744(77)90366-7; SABBADINI RA, 1989, J BIOENERG BIOMEMBR, V21, P163, DOI 10.1007/BF00812068; SARKIS JJF, 1991, BRAIN RES BULL, V26, P871, DOI 10.1016/0361-9230(91)90251-E; SHUSTER TA, 1983, ENZYME, V30, P1; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; SPIELMAN H, 1974, ANAL BIOCHEM, V59, P462, DOI 10.1016/0003-2697(74)90299-1; STOUT JG, 1994, J BIOCHEM BIOPH METH, V29, P61, DOI 10.1016/0165-022X(94)90057-4; TREUHEIT MJ, 1992, J BIOL CHEM, V267, P11777; VALENZUELA MA, 1989, COMP BIOCHEM PHYS B, V93, P911, DOI 10.1016/0305-0491(89)90066-7; VONK JR, 1977, BIOCHEM PHARMACOL, V27, P397; YAGI K, 1989, EUR J BIOCHEM, V180, P509, DOI 10.1111/j.1432-1033.1989.tb14675.x; YAGI K, 1991, BIOCHEM BIOPH RES CO, V180, P1200, DOI 10.1016/S0006-291X(05)81323-3; YELTON D, 1982, HYBRIDOMA, V1, P1	56	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16323	16331		10.1074/jbc.271.27.16323	http://dx.doi.org/10.1074/jbc.271.27.16323			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663133	hybrid			2022-12-27	WOS:A1996UW35200069
J	Blahos, J; Wenthold, RJ				Blahos, J; Wenthold, RJ			Relationship between N-methyl-D-aspartate receptor NR1 splice variants and NR2 subunits	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; NMDA-RECEPTOR; RAT-BRAIN; IMMUNOCYTOCHEMICAL LOCALIZATION; SYNAPTIC PLASTICITY; NERVOUS-SYSTEM; SOLUBILIZATION; POLYAMINES; INVITRO; CLONING	The N-methyl-D-aspartate (NMDA) subtype of ionotropic glutamate receptor is assembled from one NR1 subunit, expressed in eight splice variants, and four NR2 subunits (NR2A-D). The combination of subunits and splice variants determines the pharmacological and physiological properties of the receptor. In the present study we investigated the relationship between NR1 splice variants and NR2 subunits in rat brain using a series of antibodies selective for the four NR1 cassettes, which vary in the NR1 splice variants, and for NR2A and NR2B. Sodium deoxycholate at pH 9.0 solubilized about 35% of the receptor, which was intact based on co-immunoprecipitation of NR1 and NR2 subunits and chemical cross-linking of the solubilized receptor. The crosslinked product contained three high molecular weight components, M(r) = 603,000, 700,000, and 750,000, which were immunolabeled with antibodies to NR1 and to NR2 subunits. Immunoprecipitation analyses using antibodies selective for NR2A and NR2B showed no preferential assembly between NR2 subunits and NR1 splice variants. There was little co-immunoprecipitation of NR2A and NR2B, suggesting that most NMDA receptor complexes contain only one of these subunits. However, receptor complexes can contain at least two different NR1 splice variants. In developing conditions for the solubilization of intact NMDA receptor complexes, we observed a differential solubilization of NR1 and NR2 subunits. NR2 was nearly insoluble in Triton X-100 in both microsomal and synaptic membrane fractions, while NR1 was readily soluble in the microsomal fraction but insoluble in the synaptic membrane fraction. These results suggest that the NR1 subunit is modified when it is incorporated into the synaptic membrane, possibly by strengthening its interaction with NR2 or another synaptic protein.	NIDCD,NIH,NEUROCHEM LAB,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute on Deafness & Other Communication Disorders (NIDCD)			Blahos, Jaroslav/G-4397-2014; Blahos, Jaroslav/G-8325-2017	Blahos, Jaroslav/0000-0003-3355-1469; Blahos, Jaroslav/0000-0001-9803-0061				AKAZAWA C, 1994, J COMP NEUROL, V347, P150, DOI 10.1002/cne.903470112; BROSE N, 1993, J BIOL CHEM, V268, P22663; BURNASHEV N, 1992, SCIENCE, V257, P1415, DOI 10.1126/science.1382314; BUTLER AL, 1994, J NEUROSCI, V14, P5471; CHAZOT PL, 1994, J BIOL CHEM, V269, P24403; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHO KO, 1992, NEURON, V9, P929, DOI 10.1016/0896-6273(92)90245-9; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.ne.13.030190.001131; COLLINGRIDGE GL, 1987, TRENDS NEUROSCI, V10, P288, DOI 10.1016/0166-2236(87)90175-5; DETOMASO AW, 1994, J CELL BIOL, V127, P55, DOI 10.1083/jcb.127.1.55; DURAND GM, 1992, P NATL ACAD SCI USA, V89, P9359, DOI 10.1073/pnas.89.19.9359; DURAND GM, 1993, P NATL ACAD SCI USA, V90, P6731, DOI 10.1073/pnas.90.14.6731; EHLERS MD, 1995, SCIENCE, V269, P1734, DOI 10.1126/science.7569904; GURD JW, 1973, J NEUROCHEM, V22, P281; HAMMOND C, 1994, TRENDS NEUROSCI, V17, P497, DOI 10.1016/0166-2236(94)90140-6; HOLLMANN M, 1993, NEURON, V10, P943, DOI 10.1016/0896-6273(93)90209-A; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HUNTLEY GW, 1994, J NEUROSCI, V14, P3603; ISHII T, 1993, J BIOL CHEM, V268, P2836; KATSUWADA T, 1992, NATURE, V358, P36; KIRKWOOD A, 1993, SCIENCE, V260, P1518, DOI 10.1126/science.8502997; KORNAU HC, 1995, SCIENCE, V269, P1737, DOI 10.1126/science.7569905; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAURIE DJ, 1994, J NEUROSCI, V14, P3180; LAURIE DJ, 1995, MOL BRAIN RES, V32, P94, DOI 10.1016/0169-328X(95)00067-3; MALENKA RC, 1993, TRENDS NEUROSCI, V16, P521, DOI 10.1016/0166-2236(93)90197-T; MARTIN LJ, 1993, NEUROSCIENCE, V53, P327, DOI 10.1016/0306-4522(93)90199-P; MCKERNAN RM, 1989, J NEUROCHEM, V52, P777, DOI 10.1111/j.1471-4159.1989.tb02522.x; MEGURO H, 1992, NATURE, V357, P70, DOI 10.1038/357070a0; MONAGHAN DT, 1989, ANNU REV PHARMACOL, V29, P365, DOI 10.1146/annurev.pa.29.040189.002053; MONYER H, 1994, NEURON, V12, P529, DOI 10.1016/0896-6273(94)90210-0; MONYER H, 1992, SCIENCE, V256, P1217, DOI 10.1126/science.256.5060.1217; MORIYOSHI K, 1991, NATURE, V354, P31, DOI 10.1038/354031a0; MUSIL LS, 1991, J CELL BIOL, V115, P1357, DOI 10.1083/jcb.115.5.1357; OGITA K, 1990, J NEUROCHEM, V55, P1515, DOI 10.1111/j.1471-4159.1990.tb04933.x; PETRALIA RS, 1992, J COMP NEUROL, V318, P329, DOI 10.1002/cne.903180309; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; STANDAERT DG, 1994, J COMP NEUROL, V343, P1, DOI 10.1002/cne.903430102; SUGIHARA H, 1992, BIOCHEM BIOPH RES CO, V185, P826, DOI 10.1016/0006-291X(92)91701-Q; TOLLE TR, 1995, EUR J NEUROSCI, V7, P1235, DOI 10.1111/j.1460-9568.1995.tb01114.x; TOLLE TR, 1993, J NEUROSCI, V13, P5009, DOI 10.1523/JNEUROSCI.13-12-05009.1993; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VICKERS JC, 1993, J NEUROSCI, V13, P2982; WAFFORD KA, 1993, NEUROREPORT, V4, P1347, DOI 10.1097/00001756-199309150-00015; WANG YH, 1995, J NEUROCHEM, V65, P176; WATANABE M, 1994, J COMP NEUROL, V343, P520, DOI 10.1002/cne.903430403; WENTHOLD RJ, 1994, J BIOL CHEM, V269, P1332; WENTHOLD RJ, 1992, J BIOL CHEM, V267, P501; WILLIAMS K, 1993, NEURON, V10, P267, DOI 10.1016/0896-6273(93)90317-K; ZHENG X, 1994, NEURON, V12, P811; ZUKIN RS, 1995, TRENDS NEUROSCI, V18, P306, DOI 10.1016/0166-2236(95)93920-S	54	132	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15669	15674		10.1074/jbc.271.26.15669	http://dx.doi.org/10.1074/jbc.271.26.15669			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663041	hybrid			2022-12-27	WOS:A1996UV29900056
J	Blobe, GC; Stribling, DS; Fabbro, D; Stabel, S; Hannun, YA				Blobe, GC; Stribling, DS; Fabbro, D; Stabel, S; Hannun, YA			Protein kinase C beta II specifically binds to and is activated by F-actin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SELECTIVE REGULATION; VIMENTIN FILAMENTS; EXPRESSION; PHOSPHORYLATION; ISOENZYMES; ASSOCIATION; TISSUE; FAMILY; ALPHA	The two most closely related isoenzymes of protein kinase C (PRC), PKC beta I and beta II, are distinct but highly homologous isoenzymes derived via alternative splicing of the same gene product. In this study, PKC beta II, but not PKC beta I, translocated to the actin cytoskeleton upon stimulation of cells with phorbol esters. In cells, antibodies to PKC beta II, but not to PKC beta I, co-immunoprecipitated actin. Using an actin-binding co-sedimentation assay, we show in vitro that PKC beta II, but not PKC beta I, binds to actin specifically, This binding was inhibited by peptides based on sequences unique to PKC beta II; thus defining an actin-binding site in PKC beta II that is not present in PKC beta I. The binding of PKC beta II to actin was not inhibited by kinase inhibitors of PKC (sphingosine and staurosporine), suggesting that prior activation and/or substrate phosphorylation are not required for the interaction of PKC beta II with actin. On the other hand, the interaction of PKC beta II with actin resulted in marked enhancement of autophosphorylation of PKC beta II and in an alteration in substrate specificity. These studies serve to define a novel functional domain in the carboxyl-terminal region of PKC beta, which is involved in directing isoenzyme-specific protein-protein interactions, and consequently, isoenzyme-specific functions in vivo.	DUKE UNIV, MED CTR, DIV HEMATOL ONCOL, DEPT MED, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA; CIBA GEIGY LTD, RES DEPT, DIV PHARMACEUT, CH-4002 BASEL, SWITZERLAND; MAX PLANCK GESELL, MAX DELBRUCK LAB, D-50829 COLOGNE, GERMANY	Duke University; Duke University; Novartis; Max Planck Society			Blobe, Gerard/AAJ-5945-2020	Blobe, Gerard/0000-0002-4274-8901	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL043707] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-43707] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADEREM A, 1992, CELL, V71, P713, DOI 10.1016/0092-8674(92)90546-O; Bell R M, 1986, Methods Enzymol, V124, P353; BLOBE GC, 1993, J BIOL CHEM, V268, P658; BLOBE GC, 1993, J BIOL CHEM, V268, P10627; BLOBE GC, 1994, CANCER METAST REV, V13, P411, DOI 10.1007/BF00666107; CHAPLINE C, 1993, J BIOL CHEM, V268, P6858; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; GRAFF JM, 1989, SCIENCE, V246, P503, DOI 10.1126/science.2814478; GREGORIO CC, 1994, J CELL BIOL, V125, P345, DOI 10.1083/jcb.125.2.345; HANNUN YA, 1990, J BIOL CHEM, V265, P2962; INAGAKI M, 1987, NATURE, V328, P649, DOI 10.1038/328649a0; JAKEN S, 1989, J CELL BIOL, V109, P697, DOI 10.1083/jcb.109.2.697; MOCHLYROSEN D, 1990, CELL REGUL, V1, P693, DOI 10.1091/mbc.1.9.693; MOCHLYROSEN D, 1991, P NATL ACAD SCI USA, V88, P3997, DOI 10.1073/pnas.88.9.3997; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NOLAND TA, 1992, BIOCHEM J, V288, P123, DOI 10.1042/bj2880123; ONO Y, 1987, SCIENCE, V236, P1116, DOI 10.1126/science.3576226; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; SPUDICH A, 1992, CELL MOTIL CYTOSKEL, V22, P250, DOI 10.1002/cm.970220405; STABEL S, 1991, METHOD ENZYMOL, V200, P670; STABEL S, 1993, METH NEUROSCI, V18, P154; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; YOSHIDA Y, 1988, J BIOL CHEM, V263, P9868	24	126	130	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15823	15830		10.1074/jbc.271.26.15823	http://dx.doi.org/10.1074/jbc.271.26.15823			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663149	hybrid			2022-12-27	WOS:A1996UV29900078
J	Munnik, T; deVrije, T; Irvine, RF; Musgrave, A				Munnik, T; deVrije, T; Irvine, RF; Musgrave, A			Identification of diacylglycerol pyrophosphate as a novel metabolic product of phosphatidic acid during G-protein activation in plants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; KINASE-C; SUBCELLULAR-LOCALIZATION; CHLAMYDOMONAS-EUGAMETOS; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; NADPH OXIDASE; STIMULATION; CELLS; PHOSPHOINOSITIDES	We provide evidence that phosphatidic acid (PtdOH) formed during signaling in plants is metabolized by a novel pathways. In much of this study, P-32(i)-labeled Chlamydomonas cells were used, and signalling was activated by adding the G-protein activator mastoparan. Within seconds of activation, large amounts of [P-32]Pt-dOH were formed, with peak production at about 4 min, when the level was 5-25-fold higher than the control. As the level of [P-32]PtdOH subsequently decreased, an unknown phospholipid (PLX) increased in radiolabeling; before activation it was barely detectable. The chromatographic properties of PLX resembled those of lyso-PtdOH and CMP . PtdOH but on close inspection were found to be different. PLX was shown to be diacylglycerol pyrophosphate (DGPP), the product of a newly discovered enzyme, phosphatidate kinase, whose in vitro activity was described recently (Wissing, J.B., and Behrbohm, H. (1993) Plant Physiol. 102, 1243-1249). The identity of DGPP was established by co-chromatrography with a standard and by degradation analysis as follows: [P-32]DGPP was deacylated, adn the product mild acid treatment or pyrophosphatase to produce GroP and P-i as the only radioactive products. Since DGPP is the pyrophosphate derivative of PtdOH and is formed as the concentration of PtdOH decreases, we assumed that PtdOH was converted in vivo to DGPP. This was confirmed by showing that during a short labeling protocol while the specific radioactivity of DGPP was increasing, the specific radioactivity of the P-32(i) derived from DGPP as above was higher than that of [P-32]GroP. DGPP was also formed in suspension cultures of tomato and potato cells, and its synthesis was activated by mastoparan. Moreover, it was also found in intact tissues of a number of higher plants, for example, carnation flower petals, vetch roots, leaves of fig-leaved goosefoot, and common persicaria and microspores of rape seed. Our results suggest that DGPP is a common but minor plant lipid that increases in concentration when signaling is activated. Possible functions of DGPP in phospholpase C and D signaling cascades are discussed.	DLO,ATO,AGROTECHNOL RES INST,NL-6700 AA WAGENINGEN,NETHERLANDS; BABRAHAM INST,INOSITIDE LAB,CAMBRIDGE CB2 4AT,ENGLAND	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Munnik, T (corresponding author), UNIV AMSTERDAM,BIOCTR,INST MOLEC CELL BIOL,KRUISLAAN 318,NL-1098 SM AMSTERDAM,NETHERLANDS.		Munnik, Teun/G-8624-2012; Munnik, Teun/N-2778-2019	Munnik, Teun/0000-0002-4919-4913; Munnik, Teun/0000-0002-4919-4913				BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOARDER MR, 1994, TRENDS PHARMACOL SCI, V15, P57, DOI 10.1016/0165-6147(94)90111-2; BOCCKINO SB, 1991, P NATL ACAD SCI USA, V88, P6210, DOI 10.1073/pnas.88.14.6210; BOMAN AL, 1995, TRENDS BIOCHEM SCI, V20, P147, DOI 10.1016/S0968-0004(00)88991-4; CHO MH, 1995, PLANT PHYSIOL, V107, P845, DOI 10.1104/pp.107.3.845; COCKCROFT S, 1992, BIOCHIM BIOPHYS ACTA, V1113, P135, DOI 10.1016/0304-4157(92)90036-A; COTE GG, 1994, BIOESSAYS, V16, P39, DOI 10.1002/bies.950160106; COTE GG, 1993, ANNU REV PLANT PHYS, V44, P333, DOI 10.1146/annurev.pp.44.060193.002001; CUNNINGHAM E, 1995, CURR BIOL, V5, P775, DOI 10.1016/S0960-9822(95)00154-0; DIVECHA N, 1995, CELL, V80, P269, DOI 10.1016/0092-8674(95)90409-3; DROBAK BK, 1994, BIOCHEM BIOPH RES CO, V205, P739, DOI 10.1006/bbrc.1994.2727; DROBAK BK, 1993, PLANT PHYSIOL, V102, P705, DOI 10.1104/pp.102.3.705; DROBAK BK, 1992, BIOCHEM J, V288, P697, DOI 10.1042/bj2880697; EPAND RM, 1992, EUR J BIOCHEM, V208, P327, DOI 10.1111/j.1432-1033.1992.tb17190.x; EXTON JH, 1994, CURR OPIN CELL BIOL, V6, P226, DOI 10.1016/0955-0674(94)90140-6; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; GAMBORG OL, 1968, EXP CELL RES, V50, P151, DOI 10.1016/0014-4827(68)90403-5; GUARINO LA, 1995, CELL, V80, P301, DOI 10.1016/0092-8674(95)90413-1; HA KS, 1994, BIOCHEM J, V303, P55, DOI 10.1042/bj3030055; HA KS, 1993, J CELL BIOL, V123, P178; HASHIZUME T, 1992, BIOCHEM INT, V26, P491; HOEK JB, 1992, FASEB J, V6, P2386, DOI 10.1096/fasebj.6.7.1563591; HORSTMAN DA, 1995, PROTEIN EXPRES PURIF, V6, P278, DOI 10.1006/prep.1995.1036; JACKOWSKI S, 1989, ARCH BIOCHEM BIOPHYS, V268, P516, DOI 10.1016/0003-9861(89)90318-4; JACOB G, 1993, COMP BIOCHEM PHYS B, V106, P895, DOI 10.1016/0305-0491(93)90047-9; JONES GA, 1993, J BIOL CHEM, V268, P20845; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KROLL MH, 1989, J CELL PHYSIOL, V139, P558, DOI 10.1002/jcp.1041390315; LAW GJ, 1994, ANN NY ACAD SCI, V710, P196, DOI 10.1111/j.1749-6632.1994.tb26628.x; LEE MH, 1989, J BIOL CHEM, V264, P14797; LEGENDRE L, 1993, J BIOL CHEM, V268, P24559; LIMATOLA C, 1994, BIOCHEM J, V304, P1001, DOI 10.1042/bj3041001; LISCOVITCH M, 1992, TRENDS BIOCHEM SCI, V17, P393, DOI 10.1016/0968-0004(92)90007-V; LISCOVITCH M, 1989, J BIOL CHEM, V264, P11762; LISCOVITCH M, 1995, CELL, V81, P659, DOI 10.1016/0092-8674(95)90525-1; LISCOVITCH M, 1994, J BIOL CHEM, V269, P21403; LUNDBERG GA, 1992, BIOCHIM BIOPHYS ACTA, V1123, P177, DOI 10.1016/0005-2760(92)90109-9; MARTIN T, 1995, CURR BIOL, V5, P990, DOI 10.1016/S0960-9822(95)00196-5; METZ SA, 1990, BIOCHEM J, V270, P427, DOI 10.1042/bj2700427; MORITZ A, 1992, J BIOL CHEM, V267, P7207; Munnik T, 1995, PLANT CELL, V7, P2197, DOI 10.1105/tpc.7.12.2197; MUNNIK T, 1994, BIOCHEM J, V298, P269, DOI 10.1042/bj2980269; MUNNIK T, 1994, PLANTA, V193, P89, DOI 10.1007/BF00191611; MURASHIGE T, 1962, PHYSIOL PLANTARUM, V15, P473, DOI 10.1111/j.1399-3054.1962.tb08052.x; MUSGRAVE A, 1992, PLANTA, V186, P442, DOI 10.1007/BF00195326; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; QUALLIOTINEMANN D, 1993, J BIOL CHEM, V268, P23843; QUARMBY LM, 1992, J CELL BIOL, V116, P737, DOI 10.1083/jcb.116.3.737; RARA RS, 1990, PHYSIOL REV, V70, P125; ROSS EM, 1994, METHOD ENZYMOL, V237, P26; SCHURING F, 1987, PLANTA, V170, P322, DOI 10.1007/BF00395023; SEIFFERT UB, 1965, BIOCHIM BIOPHYS ACTA, V98, P574, DOI 10.1016/0005-2760(65)90154-2; STASEK JE, 1993, BIOCHEM BIOPH RES CO, V191, P134, DOI 10.1006/bbrc.1993.1194; STEPHENS LR, 1990, BIOCHEM J, V265, P435, DOI 10.1042/bj2650435; THOMAS GMH, 1993, CELL, V74, P919, DOI 10.1016/0092-8674(93)90471-2; VANBLITTERSWIJK WJ, 1993, EMBO J, V12, P2655, DOI 10.1002/j.1460-2075.1993.tb05926.x; VANBLITTERSWIJK WJ, 1994, CURR TOP MEMBR, V40, P413, DOI 10.1016/S0070-2161(08)60990-9; WISSING JB, 1992, PLANT PHYSIOL, V98, P1148, DOI 10.1104/pp.98.3.1148; WISSING JB, 1993, PLANT PHYSIOL, V102, P1243, DOI 10.1104/pp.102.4.1243; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; WISSING JB, 1994, PLANT PHYSIOL, V105, P903, DOI 10.1104/pp.105.3.903; WU L, 1995, NATURE, V373, P216, DOI 10.1038/373216a0; ZHOU D, 1995, J BIOL CHEM, V270, P25549, DOI 10.1074/jbc.270.43.25549	68	118	124	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15708	15715		10.1074/jbc.271.26.15708	http://dx.doi.org/10.1074/jbc.271.26.15708			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663116	hybrid			2022-12-27	WOS:A1996UV29900062
J	Portilla, D; Dai, GH				Portilla, D; Dai, GH			Purification of a novel calcium-independent phospholipase A(2) from rabbit kidney	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC PHOSPHOLIPASE-A2; GLYCEROPHOSPHOLIPIDS; IDENTIFICATION; ACTIVATION; MEMBRANE; PROTEIN; U937	We have recently identified a cytosolic calcium-independent phospholipase A(2) (PLt(2)) that represents the major measurable PLA, activity in rabbit proximal tubules (Portilla, D,, Shah, S, V., Lehman, P, A, and Creer, M, H, (1994) J, Clin. Invest, 93, 1609-1615), We now report the 3200-fold purification of this PLA(2) to homogeneity from rabbit kidney cortex through sequential column chromatography including anion exchange, hydrophobic interaction, Mono Q, hydroxylapatite, phenyl-sepharose, and chromatofocusing fast protein liquid chromatography from rabbit kidney cortex, The purified enzyme had a molecular mass of 28 kDa, possessed a specific activity of 1.2 mu mol/mg min and a neutral pH optimum, and exhibited a preferential hydrolysis toward sn-2 fatty acid from diradylglycerophospholipids. The purified polypeptide hydrolyzed plasmenylcholine > phosphatidylcholine glycerophospholipids and selectively cleaved phospholipids containing arachidonic acid at the sn-2 position in comparison to oleic acid, Antibodies against the purified protein precipitated all of the soluble calcium-independent PLA(2) activity from rabbit kidney cortex, These data altogether suggest that the 28-kDa protein in the kidney represents a novel class of calcium-independent PLA(2).	VET ADM MED CTR,LITTLE ROCK,AR 72205	US Department of Veterans Affairs; Veterans Health Administration (VHA)	Portilla, D (corresponding author), UNIV ARKANSAS MED SCI HOSP,DEPT MED,DIV NEPHROL,4301 W MARKHAM,SLOT 501,LITTLE ROCK,AR 72205, USA.				NIDDK NIH HHS [R29 DK46914] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046914] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACKERMANN EJ, 1995, J BIOL CHEM, V270, P445, DOI 10.1074/jbc.270.1.445; ACKERMANN EJ, 1994, J BIOL CHEM, V269, P9227; CLARK JD, 1990, P NATL ACAD SCI USA, V87, P7708, DOI 10.1073/pnas.87.19.7708; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; Dennis EA, 1983, ENZYMES, P307; FUKUSHIMA T, 1994, LIPIDS, V29, P163, DOI 10.1007/BF02536724; GASSAMADIAGNE A, 1989, J BIOL CHEM, V264, P9470; GROSS RW, 1983, J BIOL CHEM, V258, P5165; HATTORI M, 1994, NATURE, V370, P216, DOI 10.1038/370216a0; HAZEN SL, 1990, J BIOL CHEM, V265, P10622; HAZEN SL, 1991, J BIOL CHEM, V266, P14526; HAZEN SL, 1993, J BIOL CHEM, V268, P9892; HAZEN SL, 1991, J BIOL CHEM, V266, P5629; JAUHIAINEN M, 1986, J BIOL CHEM, V261, P7032; KRAMER RM, 1991, J BIOL CHEM, V266, P5268; PORTILLA D, 1992, AM J PHYSIOL, V262, pF354, DOI 10.1152/ajprenal.1992.262.3.F354; PORTILLA D, 1994, J CLIN INVEST, V93, P1609, DOI 10.1172/JCI117141; PORTILLA D, 1995, KIDNEY INT, V47, P1087, DOI 10.1038/ki.1995.155; SCHONEFELD M, 1994, J AM SOC NEPHROL, V5, P908; TJOELKER LW, 1995, NATURE, V374, P549, DOI 10.1038/374549a0; VERHEIJ HM, 1981, REV PHYSIOL BIOCH P, V91, P91; WAITE M, 1987, HDB LIPID RES, V5; WOLF RA, 1985, J BIOL CHEM, V260, P7295; ZUPAN LA, 1992, J BIOL CHEM, V267, P8707	24	51	56	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15451	15457		10.1074/jbc.271.26.15451	http://dx.doi.org/10.1074/jbc.271.26.15451			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663076	hybrid			2022-12-27	WOS:A1996UV29900025
J	Saito, Y; Maruyama, K; Kawano, H; HaginoYamagishi, K; Kawamura, K; Saido, TC; Kawashima, S				Saito, Y; Maruyama, K; Kawano, H; HaginoYamagishi, K; Kawamura, K; Saido, TC; Kawashima, S			Molecular cloning and characterization of a novel form of neuropeptide gene as a developmentally regulated molecule	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PREPROENKEPHALIN MESSENGER-RNA; ENDOGENOUS OPIOID SYSTEMS; CYCLIC-AMP; SECRETORY PROTEINS; COMPLEMENTARY-DNA; GROWTH CONES; TUMOR-CELLS; EXPRESSION; NEURONS; DIFFERENTIATION	To examine the molecular basis controlling neuronal differentiation, subtraction library construction and differential screening were used to identify cDNAs whose mRNA levels are regulated in mouse NS20Y cells by dibutyryl cyclic AMP treatment, One of them, N27K, whose mRNA increases transiently during both neuronal differentiation in NS20Y cells and development in mouse brain. The deduced amino acid sequence of N27K comprises 212 amino acid residues and is a novel form of a precursor protein for a new neuropeptide nociceptin/ orphanin FQ, which we independently cloned as N23K. That is, the putative protein encoded by N27K is 25 amino acids longer than that encoded by N23R, Using an antibody against a C-terminal peptide of the N27K: protein that recognizes a 27-kDa protein in Western blot analysis, a punctate structure in the perinuclear region and areas near the tip of neurites is visualized in neurally differentiating NS20Y cells, The time of maximal expression correlates with periods of neurite extension, and expression decreases as the neuritic network develops. Immunohistochemistry of tissue sections of the mouse central nervous system revealed that reactivity for the anti-N27K protein antibody can detected in early generated neurons at embryonic day 14, in virtually all immature neurons at postnatal day 1, and in subsets of neurons of discrete brain regions such as the hypothalamus and spinal cord in adults. This remarkable redistribution suggests that N27K may be involved in a process in neurite outgrowth and nervous system development.	TOKYO METROPOLITAN INST MED SCI,DEPT DEV BIOL & CANC PREVENT,BUNKYO KU,TOKYO 113,JAPAN; NATL INST PHYSIOL SCI,NEUROCHEM LAB,OKAZAKI,AICHI 444,JAPAN; KEIO UNIV,SCH MED,DEPT ANAT,SHINJUKU KU,TOKYO 160,JAPAN	Tokyo Metropolitan Institute of Medical Science; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS); Keio University	Saito, Y (corresponding author), TOKYO METROPOLITAN INST MED SCI,DEPT MOLEC BIOL,BUNKYO KU,3-18-22 HONKOMAGOME,TOKYO 113,JAPAN.		Sado, Takaomi/AAN-2759-2021; Saido, Takaomi C/N-5472-2015	Sado, Takaomi/0000-0003-1970-6903; Saido, Takaomi C/0000-0003-1970-6903				AFFOLTER HU, 1985, J BIOL CHEM, V260, P5477; AMANO T, 1972, P NATL ACAD SCI USA, V69, P258, DOI 10.1073/pnas.69.1.258; ANDERSON DJ, 1985, CELL, V42, P649, DOI 10.1016/0092-8674(85)90122-9; BASI GS, 1987, P ACAD NATL SCI US, V77, P1496; Bjorklund A.H.T., 1988, HATLDBOOK CHEM NEURO, V6, P599; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHEN Y, 1994, FEBS LETT, V347, P279, DOI 10.1016/0014-5793(94)00560-5; DEFELIPE C, 1995, SCIENCE, V267, P899, DOI 10.1126/science.7531367; DENISDONINI S, 1989, NATURE, V339, P701, DOI 10.1038/339701a0; FOLKESSON R, 1989, MOL BRAIN RES, V5, P211, DOI 10.1016/0169-328X(89)90037-5; FUKUDA K, 1994, FEBS LETT, V343, P42, DOI 10.1016/0014-5793(94)80603-9; GONZALEZ FA, 1991, J BIOL CHEM, V266, P22159; GORODINSKY A, 1995, J NEUROCHEM, V65, P1481; GROUSE LD, 1980, J BIOL CHEM, V255, P3871; GUILLEMOT F, 1993, CELL, V75, P463, DOI 10.1016/0092-8674(93)90381-Y; HAUSER KF, 1992, DEV BRAIN RES, V70, P291, DOI 10.1016/0165-3806(92)90210-N; HAUSER KF, 1989, J COMP NEUROL, V281, P13, DOI 10.1002/cne.902810103; KARNS LR, 1987, SCIENCE, V236, P597, DOI 10.1126/science.2437653; KAWANO H, 1995, DEV BRAIN RES, V86, P101, DOI 10.1016/0165-3806(95)00018-9; KAWANO H, 1991, J COMP NEUROL, V307, P531, DOI 10.1002/cne.903070402; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KIRSHNER JA, 1986, J NEUROCHEM, V46, P817, DOI 10.1111/j.1471-4159.1986.tb13045.x; KLAR A, 1992, CELL, V69, P95, DOI 10.1016/0092-8674(92)90121-R; KOZAK M, 1987, J MOL BIOL, V196, P947, DOI 10.1016/0022-2836(87)90418-9; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACOWICZ J, 1995, J NEUROCHEM, V64, P34; MARUYAMA K, 1988, P NATL ACAD SCI USA, V85, P3314, DOI 10.1073/pnas.85.10.3314; MARUYAMA K, 1991, BIOCHEM BIOPH RES CO, V178, P291, DOI 10.1016/0006-291X(91)91812-Q; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MCMURRAY CT, 1989, ENDOCRINOLOGY, V124, P49, DOI 10.1210/endo-124-1-49; MEIRI KF, 1986, P NATL ACAD SCI USA, V83, P3537, DOI 10.1073/pnas.83.10.3537; MELNER MH, 1990, EMBO J, V9, P791, DOI 10.1002/j.1460-2075.1990.tb08175.x; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; OBRIEN JS, 1994, P NATL ACAD SCI USA, V91, P9593, DOI 10.1073/pnas.91.20.9593; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; ROSA P, 1985, J CELL BIOL, V101, P1999, DOI 10.1083/jcb.101.5.1999; SAIDO TC, 1992, J BIOCHEM, V111, P81, DOI 10.1093/oxfordjournals.jbchem.a123723; Saito Y, 1995, BIOCHEM BIOPH RES CO, V217, P539, DOI 10.1006/bbrc.1995.2809; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SATO M, 1991, BRAIN RES, V541, P41, DOI 10.1016/0006-8993(91)91071-8; SPRUCE BA, 1990, EMBO J, V9, P1787, DOI 10.1002/j.1460-2075.1990.tb08303.x; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; VILLIJIN MH, 1989, J NEUROCHEM, V53, P1487; WANG JB, 1994, FEBS LETT, V348, P75, DOI 10.1016/0014-5793(94)00557-5; WICK MJ, 1994, MOL BRAIN RES, V27, P37, DOI 10.1016/0169-328X(94)90181-3; WONG GG, 1985, SCIENCE, V228, P810, DOI 10.1126/science.3923623; YOSHIKAWA K, 1988, MOL BRAIN RES, V4, P87, DOI 10.1016/0169-328X(88)90001-0; YOSHIKAWA K, 1986, BIOCHEM BIOPH RES CO, V139, P1, DOI 10.1016/S0006-291X(86)80071-7; ZAGON IS, 1989, BRAIN RES, V490, P14, DOI 10.1016/0006-8993(89)90425-3; ZAGON IS, 1994, MOL BRAIN RES, V21, P85, DOI 10.1016/0169-328X(94)90381-6; ZAGON IS, 1985, SCIENCE, P1049	54	48	52	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15615	15622		10.1074/jbc.271.26.15615	http://dx.doi.org/10.1074/jbc.271.26.15615			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663129	hybrid			2022-12-27	WOS:A1996UV29900048
J	Amara, FM; Entwistle, J; Kuschak, TI; Turley, EA; Wright, JA				Amara, FM; Entwistle, J; Kuschak, TI; Turley, EA; Wright, JA			Transforming growth factor-beta(1) stimulates multiple protein interactions at a unique cis-element in the 3'-untranslated region of the hyaluronan receptor RHAMM mRNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; BINDING-PROTEIN; MAMMALIAN-CELLS; FACTOR-BETA; FIBROBLASTS; EXPRESSION; PROMOTER	The receptor for hyaluronan mediated motility (RHAMMM) gene expression is markedly elevated in fibrosarcomas exposed to transforming growth factor-beta(1) (TGF-beta(1)), The half-life of RHAMM mRNA was increased by 3 fold in cells treated with TGF-beta(1), indicating that growth factor regulation of RHAMM gene expression at least in part involves a posttranscriptional mechanism, Our studies demonstrated that a unique 30-nucleotide (nt) region that has three copies of the sequence, GCU-UGC, was the TGF-beta(1)-responsive region in the 3'-untranslated region (3'-UTR) that mediated message stability, This region interacted specifically with cytoplasmic trans-factors to form multiple protein com plexes of approximately 175, 97, 63, 26, and 17 kDa post-TGF-beta(1) treatment, suggesting a role for these complexes in the mechanism of action of TGF-beta(1)-induced message stabilization, Insertion of the 3'-UTR into the chloramphenicol acetyltransferase gene conferred TGF-beta(1) induced stability of chloramphenicol acetyltransferase-hybrid RNA in stably transfected cells, while the same insert carrying a deletion containing the 30-nt region had no significant effect on mRNA stability, These results provide a model of RHAMM message regulation in which TGF-beta(1)-mediated alteration of RHAMM message stability involves the up-regulation of multiple protein interactions with a 30-nt cis-element stability determinant in the 3'-UTR, This model also suggests that this 30-nt base region functions in cis to destabilize RHAMM mRNA in resting normal cells.	UNIV MANITOBA,MANITOBA INST CELL BIOL,WINNIPEG,MB R3E 0V9,CANADA; UNIV MANITOBA,DEPT BIOCHEM & MOLEC BIOL,WINNIPEG,MB R3E 0V9,CANADA	University of Manitoba; University of Manitoba								AMARA FM, 1993, NUCLEIC ACIDS RES, V21, P4803, DOI 10.1093/nar/21.20.4803; AMARA FM, 1995, NUCLEIC ACIDS RES, V23, P1461, DOI 10.1093/nar/23.9.1461; AMARA FM, 1994, J BIOL CHEM, V269, P6709; BLOSMANIS R, 1987, CANCER RES, V47, P1273; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROWN M, 1987, CELL, V49, P603, DOI 10.1016/0092-8674(87)90536-8; BRUCE AG, 1978, NUCLEIC ACIDS RES, V5, P3665, DOI 10.1093/nar/5.10.3665; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHEN FY, 1994, NUCLEIC ACIDS RES, V22, P4796, DOI 10.1093/nar/22.22.4796; CLERCH LB, 1992, J BIOL CHEM, V267, P2853; EDWARDS DR, 1985, MOL CELL BIOL, V5, P3280, DOI 10.1128/MCB.5.11.3280; EGAN SE, 1987, MOL CELL BIOL, V7, P830, DOI 10.1128/MCB.7.2.830; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; ENTWISTLE J, 1995, IN PRESS GENE AMST; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOUGH NM, 1988, ANAL BIOCHEM, V173, P93, DOI 10.1016/0003-2697(88)90164-9; HALL CL, 1995, CELL, V82, P19, DOI 10.1016/0092-8674(95)90048-9; HARDWICK C, 1992, J CELL BIOL, V117, P1343, DOI 10.1083/jcb.117.6.1343; HURTA RAR, 1995, J CELL BIOCHEM, V57, P543, DOI 10.1002/jcb.240570319; KARTAOKA R, 1993, J BIOL CHEM, V268, P19851; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MANZELLA JM, 1992, J BIOL CHEM, V267, P7077; MATRISIAN LM, 1986, MOL CELL BIOL, V6, P1679, DOI 10.1128/MCB.6.5.1679; PENTTINEN RP, 1988, P NATL ACAD SCI USA, V85, P1105, DOI 10.1073/pnas.85.4.1105; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RONDON IJ, 1991, J BIOL CHEM, V266, P16594; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; SAMUEL SK, 1993, J CELL BIOL, V123, P749, DOI 10.1083/jcb.123.3.749; SCHWARZ LC, 1988, CANCER RES, V48, P6999; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WEISS MI, 1995, MOL CELL BIOL, V15, P2457; WRANA LJ, 1994, NATURE, V340, P341; ZAIDI SHE, 1994, J BIOL CHEM, V269, P24000	35	39	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15279	15284		10.1074/jbc.271.25.15279	http://dx.doi.org/10.1074/jbc.271.25.15279			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663000	hybrid			2022-12-27	WOS:A1996UT10600092
J	MunierLehmann, H; Mauxion, F; Bauer, U; Lobel, P; Hoflack, B				MunierLehmann, H; Mauxion, F; Bauer, U; Lobel, P; Hoflack, B			Re-expression of the mannose 6-phosphate receptors in receptor-deficient fibroblasts - Complementary function of the two mannose 6-phosphate receptors in lysosomal enzyme targeting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II RECEPTOR; BREAST-CANCER CELLS; PHOSPHORYLATED OLIGOSACCHARIDES; BOVINE LIVER; BINDING; CLONING; SEQUENCE; GENE; IDENTIFICATION; GLYCOPROTEINS	We have previously generated primary embryonic fibroblasts lacking either the cation-independent mannose 6-phosphate/insulin-like growth factor II receptor (MPR) or the cation-dependent MPR, two trans-membrane proteins that bind the mannose 6-phosphate (Man-6-P) recognition marker on soluble lysosomal enzymes (Ludwig, T., Munier-Lehmann, H., Bauer, U., Hollinshead, M., Ovitt, C., Lobel, P., and Hoflack, B. (1994) EMBO J, 13, 3430-3437), These two cell types partially missort phosphorylated lysosomal enzymes, Using two dimensional gel electrophoresis, we show here that they secrete, in a large part, different phosphorylated ligands, In order to better understand the sorting function of the MPRs, we have re expressed each MPR in MPR-negative fibroblasts. We show that the MPRs have similar capacities for transporting the bulk of the newly synthesized lysosomal enzymes and that they target individual ligands with various efficiencies, However, high levels of one MPR do not fully compensate for the absence of the other, demonstrating that the two MPRs have complementary targeting functions, perhaps by recognizing different features on lysosomal enzymes, The analysis of the phosphorylated oligosaccharides shows that the ligands missorted in the absence of the cation dependent MPR are slightly but significantly depleted in oligosaccharides with two Man-6-P residues, when compared with those missorted in the absence of the cation independent MPR, While these results could explain some differences between the structure and the sorting function of the two MPRs, they strongly suggest that the reason why cells express two different but related MPRs is to maintain an efficient Man-B-P-dependent targeting process that could be potentially regulated by MPR expression.	EUROPEAN MOLEC BIOL LAB,CELL BIOL PROGRAMME,D-69012 HEIDELBERG,GERMANY; RUTGERS STATE UNIV,CTR ADV BIOTECHNOL & MED,PISCATAWAY,NJ 08854	European Molecular Biology Laboratory (EMBL); Rutgers State University New Brunswick			Munier-Lehmann, Helene/N-9889-2017; HOFLACK, Bernard/AAZ-6668-2020; Munier-Lehmann, Hélène/Q-1867-2019; MAUXION, Fabienne/ABE-3546-2021	Munier-Lehmann, Helene/0000-0001-7579-8561; Munier-Lehmann, Hélène/0000-0001-7579-8561; MAUXION, Fabienne/0000-0003-0554-8211	NIDDK NIH HHS [R01-DK45992] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK045992] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BARLOW DP, 1991, NATURE, V349, P84, DOI 10.1038/349084a0; BRAVO R, 1984, 2 DIMENSIONAL GEL EL, P3; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CAPONY F, 1987, J CELL BIOL, V104, P253, DOI 10.1083/jcb.104.2.253; CHAO HHJ, 1990, EMBO J, V9, P3507, DOI 10.1002/j.1460-2075.1990.tb07559.x; CHEN HJ, 1993, J BIOL CHEM, V268, P2238; CHEN JW, 1985, J CELL BIOL, V101, P85, DOI 10.1083/jcb.101.1.85; DAHMS NM, 1993, J BIOL CHEM, V268, P5457; DAHMS NM, 1989, J BIOL CHEM, V264, P11458; DAHMS NM, 1994, J BIOL CHEM, V269, P3802; DAHMS NM, 1987, CELL, V50, P181, DOI 10.1016/0092-8674(87)90214-5; DECHIARA TM, 1990, NATURE, V345, P78, DOI 10.1038/345078a0; DONG JM, 1990, J BIOL CHEM, V265, P4210; FILSON AJ, 1993, DEVELOPMENT, V118, P731; FISHER HD, 1982, J BIOL CHEM, V257, P9938; GABEL CA, 1983, P NATL ACAD SCI-BIOL, V80, P775, DOI 10.1073/pnas.80.3.775; GAL S, 1986, BIOCHEM BIOPH RES CO, V139, P156, DOI 10.1016/S0006-291X(86)80093-6; HOFLACK B, 1987, J BIOL CHEM, V262, P123; HOFLACK B, 1985, J BIOL CHEM, V260, P2008; JOHNSON KF, 1992, J BIOL CHEM, V267, P17110; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; KOSTER A, 1993, EMBO J, V12, P5219, DOI 10.1002/j.1460-2075.1993.tb06217.x; LAZZARINO D, 1990, J BIOL CHEM, V265, P11864; LOBEL P, 1988, J BIOL CHEM, V263, P2563; LUDWIG T, 1995, TRENDS CELL BIOL, V5, P202, DOI 10.1016/S0962-8924(00)89000-5; LUDWIG T, 1992, J BIOL CHEM, V267, P12211; LUDWIG T, 1993, EMBO J, V12, P5225, DOI 10.1002/j.1460-2075.1993.tb06218.x; LUDWIG T, 1994, EMBO J, V13, P3430, DOI 10.1002/j.1460-2075.1994.tb06648.x; MA ZM, 1991, J BIOL CHEM, V266, P10589; MATHIEU M, 1991, MOL ENDOCRINOL, V5, P815, DOI 10.1210/mend-5-6-815; MATZNER U, 1992, DEVELOPMENT, V114, P965; Mauxion F, 1996, J BIOL CHEM, V271, P2171, DOI 10.1074/jbc.271.4.2171; NEUFELD EF, 1991, ANNU REV BIOCHEM, V60, P257, DOI 10.1146/annurev.biochem.60.1.257; NOLAN CM, 1989, METABOLIC BASIS INHE, P1589; OSHIMA A, 1988, J BIOL CHEM, V263, P2553; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; STEIN M, 1987, BIOL CHEM H-S, V368, P937, DOI 10.1515/bchm3.1987.368.2.937; STEIN M, 1987, EMBO J, V6, P2677, DOI 10.1002/j.1460-2075.1987.tb02559.x; TONG PY, 1989, J BIOL CHEM, V264, P7962; VARKI A, 1983, J BIOL CHEM, V258, P2808; WAHEED A, 1990, EUR J BIOCHEM, V193, P47, DOI 10.1111/j.1432-1033.1990.tb19302.x; WANG ZQ, 1994, NATURE, V372, P464, DOI 10.1038/372464a0; WATANABE H, 1990, P NATL ACAD SCI USA, V87, P8036, DOI 10.1073/pnas.87.20.8036; WESTLUND B, 1991, J BIOL CHEM, V266, P23233	45	50	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15166	15174		10.1074/jbc.271.25.15166	http://dx.doi.org/10.1074/jbc.271.25.15166			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662879	hybrid			2022-12-27	WOS:A1996UT10600077
J	Ornitz, DM; Xu, JS; Colvin, JS; McEwen, DG; MacArthur, CA; Coulier, F; Gao, GX; Goldfarb, M				Ornitz, DM; Xu, JS; Colvin, JS; McEwen, DG; MacArthur, CA; Coulier, F; Gao, GX; Goldfarb, M			Receptor specificity of the fibroblast growth factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING SPECIFICITY; PROTO-ONCOGENE INT-2; MESSENGER-RNA; FGF-RECEPTOR; IMMUNOGLOBULIN DOMAIN; SIGNAL TRANSDUCTION; EXPRESSION PATTERN; CYTOPLASMIC REGION; SKELETAL-MUSCLE; K-SAM	Fibroblast growth factors (FGFs) are essential molecules for mammalian development. The nine known FGF ligands and the four signaling FGF receptors (and their alternatively spliced variants) are expressed in specific spatial and temporal patterns, The activity of this signaling pathway is regulated by ligand binding specificity, heparan sulfate proteoglycans, and the differential signaling capacity of individual FGF receptors. To determine potentially relevant ligand-receptor pairs we have engineered mitogenically responsive cell lines expressing the major splice variants of all the known FGF receptors. We have assayed the mitogenic activity of the nine known FGF ligands on these cell lines. These studies demonstrate that FGF 1 is the only FGF that can activate all FGF receptor splice variants. Using FGF las an internal standard we have determined the relative activity of all the other members of the FGF family. These data should serve as a biochemical foundation for determining developmental, physiological, and patho physiological processes that involve FGF signaling pathways.	WASHINGTON UNIV, SCH MED, DEPT PEDIAT, ST LOUIS, MO 63110 USA; INSERM U119, F-13009 MARSEILLE, FRANCE; COLUMBIA UNIV COLL PHYS & SURG, DEPT BIOCHEM & MOLEC BIOPHYS, NEW YORK, NY 10032 USA; MT SINAI SCH MED, BROOKDALE CTR MOLEC BIOL, NEW YORK, NY 10029 USA	Washington University (WUSTL); Institut National de la Sante et de la Recherche Medicale (Inserm); Columbia University; Icahn School of Medicine at Mount Sinai	Ornitz, DM (corresponding author), WASHINGTON UNIV, SCH MED, DEPT MOLEC BIOL & PHARMACOL, ST LOUIS, MO 63110 USA.		Coulier, François/G-6098-2015	Coulier, François/0000-0002-6288-7773; Ornitz, David/0000-0003-1592-7629	NCI NIH HHS [CA60673] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA060673] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADNANE J, 1991, ONCOGENE, V6, P659; ALARID ET, 1994, P NATL ACAD SCI USA, V91, P1074, DOI 10.1073/pnas.91.3.1074; ASAI T, 1993, MOL BRAIN RES, V17, P174, DOI 10.1016/0169-328X(93)90088-7; AVIVI A, 1993, FEBS LETT, V330, P249, DOI 10.1016/0014-5793(93)80882-U; BASILICO C, 1992, ADV CANCER RES, V59, P115, DOI 10.1016/S0065-230X(08)60305-X; BERNARD O, 1991, P NATL ACAD SCI USA, V88, P7625, DOI 10.1073/pnas.88.17.7625; BOVI PD, 1987, CELL, V50, P729, DOI 10.1016/0092-8674(87)90331-X; CHAMPIONARNAUD P, 1991, ONCOGENE, V6, P979; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; CLEMENTS DA, 1993, ONCOGENE, V8, P1311; COLLINS MKL, 1988, J CELL PHYSIOL, V137, P293, DOI 10.1002/jcp.1041370212; CROSSLEY PH, 1995, DEVELOPMENT, V121, P439; CRUMLEY G, 1991, ONCOGENE, V6, P2255; DANDREA AD, 1991, MOL CELL BIOL, V11, P1980, DOI 10.1128/MCB.11.4.1980; DELAPEYRIERE O, 1993, DEVELOPMENT, V118, P601; DELL KR, 1992, J BIOL CHEM, V267, P21225; DICKSON C, 1984, CELL, V37, P529, DOI 10.1016/0092-8674(84)90383-0; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DRUCKER BJ, 1993, MECH DEVELOP, V40, P155, DOI 10.1016/0925-4773(93)90073-7; DUAN DSR, 1992, J BIOL CHEM, V267, P16076; FINCH PW, 1989, SCIENCE, V245, P752, DOI 10.1126/science.2475908; FLAUMENHAFT R, 1990, J CELL BIOL, V111, P1651, DOI 10.1083/jcb.111.4.1651; FOLKMAN J, 1987, SCIENCE, V235, P442, DOI 10.1126/science.2432664; GAO GX, 1995, EMBO J, V14, P2183, DOI 10.1002/j.1460-2075.1995.tb07212.x; GILBERT E, 1993, MOL CELL BIOL, V13, P5461, DOI 10.1128/MCB.13.9.5461; GOSPODAROWICZ D, 1975, J CELL BIOL, V66, P451, DOI 10.1083/jcb.66.2.451; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATTORI Y, 1990, P NATL ACAD SCI USA, V87, P5983, DOI 10.1073/pnas.87.15.5983; HEBERT JM, 1991, DEVELOPMENT, V112, P407; HEIKINHEIMO M, 1994, MECH DEVELOP, V48, P129, DOI 10.1016/0925-4773(94)90022-1; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; Klagsbrun M, 1989, Prog Growth Factor Res, V1, P207, DOI 10.1016/0955-2235(89)90012-4; KOBRIN MS, 1993, CANCER RES, V53, P4741; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MACARTHUR CA, 1995, DEVELOPMENT, V121, P3603; MANSUKHANI A, 1992, P NATL ACAD SCI USA, V89, P3305, DOI 10.1073/pnas.89.8.3305; MATHEYPREVOT B, 1986, MOL CELL BIOL, V6, P4133, DOI 10.1128/MCB.6.11.4133; MATHIEU M, 1995, J BIOL CHEM, V270, P24197, DOI 10.1074/jbc.270.41.24197; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; NISWANDER L, 1992, DEVELOPMENT, V114, P755; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; ORNITZ DM, 1992, MOL CELL BIOL, V12, P240, DOI 10.1128/MCB.12.1.240; ORNITZ DM, 1995, SCIENCE, V268, P432, DOI 10.1126/science.7536345; ORRURTREGER A, 1993, DEV BIOL, V158, P475, DOI 10.1006/dbio.1993.1205; PALACIOS R, 1985, CELL, V41, P727, DOI 10.1016/S0092-8674(85)80053-2; PANTOLIANO MW, 1994, BIOCHEMISTRY-US, V33, P10229, DOI 10.1021/bi00200a003; PARTANEN J, 1991, EMBO J, V10, P1347, DOI 10.1002/j.1460-2075.1991.tb07654.x; PIZETTE S, 1991, CELL GROWTH DIFFER, V2, P561; REID HH, 1990, P NATL ACAD SCI USA, V87, P1596, DOI 10.1073/pnas.87.4.1596; RUTA M, 1989, P NATL ACAD SCI USA, V86, P8722, DOI 10.1073/pnas.86.22.8722; SAFRAN A, 1990, ONCOGENE, V5, P635; SantosOcampo S, 1996, J BIOL CHEM, V271, P1726, DOI 10.1074/jbc.271.3.1726; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; THOMAS KA, 1987, FASEB J, V1, P434, DOI 10.1096/fasebj.1.6.3315806; VAINIKKA S, 1992, EMBO J, V11, P4273, DOI 10.1002/j.1460-2075.1992.tb05526.x; WANG F, 1995, J BIOL CHEM, V270, P10231, DOI 10.1074/jbc.270.17.10231; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82; WILKINSON DG, 1989, DEVELOPMENT, V105, P131; WILKINSON DG, 1988, EMBO J, V7, P691, DOI 10.1002/j.1460-2075.1988.tb02864.x; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAN GC, 1993, MOL CELL BIOL, V13, P4513, DOI 10.1128/MCB.13.8.4513; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN XI, 1988, MOL CELL BIOL, V8, P3487, DOI 10.1128/MCB.8.8.3487; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	68	1365	1485	1	53	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15292	15297		10.1074/jbc.271.25.15292	http://dx.doi.org/10.1074/jbc.271.25.15292			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663044	hybrid			2022-12-27	WOS:A1996UT10600094
J	Berkhout, TA; Simon, HM; Patel, DD; Bentzen, C; Niesor, E; Jackson, B; Suckling, KE				Berkhout, TA; Simon, HM; Patel, DD; Bentzen, C; Niesor, E; Jackson, B; Suckling, KE			The novel cholesterol-lowering drug SR-12813 inhibits cholesterol synthesis via an increased degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COENZYME-A REDUCTASE; LOW-DENSITY-LIPOPROTEIN; HMG-COA REDUCTASE; HEPATOMA-CELL LINE; MEVALONATE-DERIVED PRODUCT; HEP G2; MESSENGER-RNA; RAT-LIVER; REVERSIBLE PHOSPHORYLATION; REGULATED DEGRADATION	SR-12813 (tetra-ethyl 2-(3,5-di-tert-butyl-4-hydroxy-phenyl)ethenyl-1,1-bisphosphonate) lowers plasma cholesterol in five species, In this paper we investigate the underlying mechanism using Hep G2 cells. SR-12813 inhibited incorporation of tritiated water into cholesterol with an IC50 of 1.2 mu M but had no effect on fatty acid synthesis. Furthermore, SR-12813 reduced cellular 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase activity with an IC50 of 0.85 mu M. The inhibition of HMG-CoA reductase activity was rapid with a T-1/2 of 10 min. After a 16-h incubation with SR-12813, mRNA levels of HMG-CoA reductase and low density lipoprotein (LDL) receptor were increased. The increased expression of LDL receptor translated into a higher LDL uptake, which can explain the primary hypocholesterolemic effect of SR-12813 in vivo. Western blot analysis indicated that the amount of HMG-CoA reductase protein rapidly decreased in the presence of SR-12813. Pulse-chase experiments with [S-35]methionine showed that the T-1/2 of HMG-CoA reductase degradation decreased in the presence of SR-12813 from 90 to 20 min. Pre-incubation with 50 mu M Of lovastatin did not prevent the effects of SR-12813 on HMG-CoA reductase degradation, indicating that the compound does not need mevalonate-derived regulators for its action, It is concluded that SR-12813 inhibits cholesterol synthesis mainly by an enhanced degradation of HMG-CoA reductase.	HAMMERSMITH HOSP,MRC,LIPOPROT TEAM,LONDON W12 0HS,ENGLAND; SYMPHAR RES LABS,CH-1290 VERSOIX,GENEVA,SWITZERLAND	Imperial College London	Berkhout, TA (corresponding author), SMITHKLINE BEECHAM PHARMACEUT,DEPT VASC BIOL,THE FRYTHE,WELWYN GARDEN CIT AL6 9AR,HERTS,ENGLAND.							ALBRIGHTSON CR, 1995, J PHARMACOL EXP THER, V272, P689; BEG ZH, 1987, METABOLISM, V36, P900, DOI 10.1016/0026-0495(87)90101-6; BERKHOUT TA, 1990, BIOCHEM J, V272, P181, DOI 10.1042/bj2720181; BERKHOUT TA, 1994, ATHEROSCLEROSIS, V109, P167; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BRADFUTE DL, 1994, J BIOL CHEM, V269, P6645; CHUN KT, 1992, J BIOL CHEM, V267, P4236; CLARKE PR, 1990, EMBO J, V9, P2439, DOI 10.1002/j.1460-2075.1990.tb07420.x; COHEN LH, 1988, BIOCHEM J, V255, P61, DOI 10.1042/bj2550061; CORRELL CC, 1994, J BIOL CHEM, V269, P633; CORRELL CC, 1994, J BIOL CHEM, V269, P17390; EDWARDS PA, 1983, J BIOL CHEM, V258, P7272; ERICKSON SK, 1986, J LIPID RES, V27, P875; GHERARDI E, 1992, J CELL SCI, V103, P531; GIL G, 1985, CELL, V41, P249, DOI 10.1016/0092-8674(85)90078-9; GILLESPIE JG, 1992, FEBS LETT, V306, P59, DOI 10.1016/0014-5793(92)80837-7; GIRON MD, 1994, P NATL ACAD SCI USA, V91, P6398, DOI 10.1073/pnas.91.14.6398; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GOLDSTEIN JL, 1984, J LIPID RES, V25, P1450; GOLDSTEIN JL, 1990, NATURE, V343, P425, DOI 10.1038/343425a0; HARDEMAN EC, 1983, P NATL ACAD SCI-BIOL, V80, P1516, DOI 10.1073/pnas.80.6.1516; HARWOOD HJ, 1991, J LIPID RES, V32, P1237; INOUE S, 1991, J BIOL CHEM, V266, P13311; JAVITT NB, 1990, FASEB J, V4, P161, DOI 10.1096/fasebj.4.2.2153592; KENNELLY PJ, 1985, J LIPID RES, V26, P903; KITO M, 1995, P JPN ACAD B-PHYS, V71, P189, DOI 10.2183/pjab.71.189; KNIGHT BL, 1988, EUR J BIOCHEM, V178, P555, DOI 10.1111/j.1432-1033.1988.tb14482.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MAYER RJ, 1991, J BIOL CHEM, V266, P20070; MOLOWA DT, 1989, BIOCHEM J, V260, P731, DOI 10.1042/bj2600731; NAKANISHI M, 1988, J BIOL CHEM, V263, P8929; NESS GC, 1985, J BIOL CHEM, V260, P6395; NIESOR E, 1994, ATHEROSCLEROSIS, V109, P167; OMKUMAR RV, 1993, BIOCHIM BIOPHYS ACTA, V1156, P267, DOI 10.1016/0304-4165(93)90041-6; PANINI SR, 1992, J BIOL CHEM, V267, P12647; PARKER RA, 1993, J BIOL CHEM, V268, P11230; PARKER RA, 1989, J BIOL CHEM, V264, P4877; PEFFLEY D, 1985, J BIOL CHEM, V260, P9949; PEFFLEY DM, 1992, SOMAT CELL MOLEC GEN, V18, P19, DOI 10.1007/BF01233446; Rodwell V W, 1976, Adv Lipid Res, V14, P1; ROITELMAN J, 1992, J BIOL CHEM, V267, P25264; SINENSKY M, 1983, J BIOL CHEM, V258, P8547; SUCKLING KE, 1994, ATHEROSCLEROSIS, V109, P166; TRZASKOS JM, 1993, J BIOL CHEM, V268, P22591; TRZASKOS JM, 1987, J BIOL CHEM, V262, P12261; VANDRIEL IR, 1987, J BIOL CHEM, V262, P16127; VONGUNTEN CF, 1989, BIOCHIM BIOPHYS ACTA, V1001, P218, DOI 10.1016/0005-2760(89)90151-3; WILKINS GM, 1994, BBA-LIPID LIPID MET, V1211, P69, DOI 10.1016/0005-2760(94)90140-6	48	37	39	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14376	14382		10.1074/jbc.271.24.14376	http://dx.doi.org/10.1074/jbc.271.24.14376			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662919	hybrid			2022-12-27	WOS:A1996UQ66000066
J	Eguchi, S; Matsumoto, T; Motley, ED; Utsunomiya, H; Inagami, T				Eguchi, S; Matsumoto, T; Motley, ED; Utsunomiya, H; Inagami, T			Identification of an essential signaling cascade for mitogen-activated protein kinase activation by angiotensin II in cultured rat vascular smooth muscle cells - Possible requirement of G(q)-mediated p21(ras) activation coupled to a Ca2+/calmodulin-sensitive tyrosine kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; PHORBOL ESTER; MAP KINASES; CARDIAC FIBROBLASTS; PHOSPHOLIPASE-C; RECEPTOR; PHOSPHORYLATION; TRANSDUCTION; HYPERTROPHY; HYPERPLASIA	In cultured rat vascular smooth muscle cells, angiotensin II (Ang II) induced a rapid increase in mitogen-activated protein kinase (MAPK) activity through the Ang II type 1 receptor, which was insensitive to pertussis toxin but was abolished by the phospholipase C inhibitor, U73122. The Ang II-induced MAPK activation was not affected by the protein kinase C inhibitor, GF109203X, and was only partially impaired by pretreatment with a phorbol ester, whereas both treatments completely prevented MAPR activation by the phorbol ester. Intracellular Ca2+ chelation by TMB-8, but not extracellular Ca2+ chelation or inhibition of Ca2+ influx, abolished Ang II-induced MAPK activation. The calmodulin inhibitor, calmidazolium, and the tyrosine kinase inhibitor, genistein, completely blocked MAPR activation by Ang II as well as by the Ca2+ ionophore A23187. Ang II caused a rapid increase in the binding of GTP to p21(ras), and this was inhibited by genistein, TMB-8, and calmidazolium but not by pertussis toxin or GF109203X These data suggest that Ang II-induced MAPK activation through the Ang II type 1 receptor could be mediated by p21(ras) activation through a currently unidentified tyrosine kinase that lies downstream of G(q)-coupled Ca2+/calmodulin signals.	VANDERBILT UNIV, SCH MED, DEPT BIOCHEM, NASHVILLE, TN 37232 USA; MEHARRY MED COLL, DEPT PHYSIOL, NASHVILLE, TN 37208 USA	Vanderbilt University; Meharry Medical College					NHLBI NIH HHS [HL-14192, HL-35323] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014192, R01HL035323] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKIYAMA T, 1991, METHOD ENZYMOL, V201, P362; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; BAUKAL AJ, 1988, J BIOL CHEM, V263, P6087; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BOOZ GW, 1994, AM J PHYSIOL-CELL PH, V267, pC1308, DOI 10.1152/ajpcell.1994.267.5.C1308; BROCK TA, 1985, J BIOL CHEM, V260, P4158; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; CHAO TSO, 1994, J BIOL CHEM, V269, P7337; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COOK SJ, 1993, EMBO J, V12, P3475, DOI 10.1002/j.1460-2075.1993.tb06022.x; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; EGUCHI S, 1994, ENDOCRINOLOGY, V134, P222, DOI 10.1210/en.134.1.222; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; GEISTERFER AAT, 1988, CIRC RES, V62, P749, DOI 10.1161/01.RES.62.4.749; GIBBONS GH, 1992, J CLIN INVEST, V90, P456, DOI 10.1172/JCI115881; GRIENDLING KK, 1986, J BIOL CHEM, V261, P5901; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HOMMA T, 1992, J BIOL CHEM, V267, P23129; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; HOWE LR, 1993, J BIOL CHEM, V268, P20717; HUCKLE WR, 1990, MOL CELL BIOL, V10, P6290, DOI 10.1128/MCB.10.12.6290; ITOH H, 1984, J BIOCHEM-TOKYO, V96, P1721, DOI 10.1093/oxfordjournals.jbchem.a135004; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAZLAUSKAS A, 1988, J CELL BIOL, V106, P1395, DOI 10.1083/jcb.106.4.1395; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; KRUSE HJ, 1994, J CARDIOVASC PHARM, V24, P328, DOI 10.1097/00005344-199424020-00020; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LANG U, 1989, BIOCHEM J, V259, P477, DOI 10.1042/bj2590477; LASSEGUE B, 1995, MOL PHARMACOL, V48, P601; LEDUC I, 1995, J BIOL CHEM, V270, P4401, DOI 10.1074/jbc.270.9.4401; LEV S, 1995, NATURE, V376, P737, DOI 10.1038/376737a0; LINSEMAN DA, 1995, J BIOL CHEM, V270, P12563, DOI 10.1074/jbc.270.21.12563; MARRERO MB, 1995, J BIOL CHEM, V270, P15734, DOI 10.1074/jbc.270.26.15734; MARRERO MB, 1994, J BIOL CHEM, V269, P10935; MCCORMICK F, 1993, NATURE, V363, P15, DOI 10.1038/363015a0; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAFTILAN AJ, 1990, MOL CELL BIOL, V10, P5536, DOI 10.1128/MCB.10.10.5536; NAFTILAN AJ, 1989, J CLIN INVEST, V83, P1419, DOI 10.1172/JCI114032; NAKANISHI H, 1992, J BIOL CHEM, V267, P16347; NISHIZUKA Y, 1988, NATURE, V334, P661, DOI 10.1038/334661a0; OHNISHI J, 1992, BIOCHEM BIOPH RES CO, V186, P1094, DOI 10.1016/0006-291X(92)90859-J; OWENS GK, 1987, HYPERTENSION, V9, P178, DOI 10.1161/01.HYP.9.2.178; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; POWELL JS, 1989, SCIENCE, V245, P186, DOI 10.1126/science.2526370; SADOSHIMA J, 1995, CIRC RES, V76, P1; SADOSHIMA J, 1993, CIRC RES, V73, P413, DOI 10.1161/01.RES.73.3.413; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SATOH T, 1990, P NATL ACAD SCI USA, V87, P5993, DOI 10.1073/pnas.87.15.5993; SCHORB W, 1993, CIRC RES, V72, P1245, DOI 10.1161/01.RES.72.6.1245; SCHORB W, 1994, J BIOL CHEM, V269, P19626; SEGER R, 1992, J BIOL CHEM, V267, P14373; SHIRAISHI T, 1989, CANCER RES, V49, P2374; SMITH JB, 1986, AM J PHYSIOL, V250, pF759, DOI 10.1152/ajprenal.1986.250.5.F759; SMITH RJ, 1990, J PHARMACOL EXP THER, V253, P688; TAUBMAN MB, 1989, J BIOL CHEM, V264, P526; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSUDA T, 1992, CIRC RES, V71, P620, DOI 10.1161/01.RES.71.3.620; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WEBER H, 1994, J CLIN INVEST, V93, P788, DOI 10.1172/JCI117033; YULE DI, 1992, J BIOL CHEM, V267, P13830	77	262	268	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14169	14175		10.1074/jbc.271.24.14169	http://dx.doi.org/10.1074/jbc.271.24.14169			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662912	hybrid			2022-12-27	WOS:A1996UQ66000037
J	Zhang, ZS; Hocker, M; Koh, TJ; Wang, TC				Zhang, ZS; Hocker, M; Koh, TJ; Wang, TC			The human histidine decarboxylase promoter is regulated by gastrin and phorbol 12-myristate 13-acetate through a downstream cis-acting element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MYRISTATE ACETATE; ENHANCER ELEMENT; GENE; HISTAMINE; IDENTIFICATION; CELLS; INDUCTION; RECEPTOR; MOUSE; FOS	Transcriptional regulation of the human histidine decarboxylase (HDC) gene by gastrin and the phorbol ester phorbol 12-myristate 13 acetate (PMA) was studied using transient transfection of human HDC promoter-luciferase constructs in a human gastric carcinoma cell line (AGS-B) that expresses the human cholecystokinin-B/gastrin receptor, The transcriptional activity of the human HDC promoter was stimulated 3-4-fold by gastrin and 13-fold by PMA, effects that could be blocked by down-regulation or antagonism of protein kinase C. 5'- and 3'-deletion analysis demonstrated that the sequence responsible for gastrin- and PMA-stimulated transactivation (gastrin response element (GAS-RE)) was located in a region (+2 to +24) downstream of the transcriptional start site (+1) in the human HDC promoter and contained a palindrome (5'-CCCTTTAAATAAAGGG-3'). When ligated upstream of the herpes simplex virus 1 thymidine kinase promoter, a single copy of the GAS-RE was sufficient to confer responsiveness to gastrin and PMA, Electrophoretic mobility shift assays with specific competitors and factor-specific antibody supershifts showed that the labeled GAS-RE bound a novel nuclear factor(s). In addition, both gastrin and PMA increased binding of this factor to the GAS-RE, Hence, the palindromic GAS-RE site is sufficient to explain the gastrin/PMA responsiveness of the human HDC promoter and appears to bind a novel transcription factor.	MASSACHUSETTS GEN HOSP, GASTROINTESTINAL UNIT, BOSTON, MA 02114 USA; MASSACHUSETTS GEN HOSP, DEPT MED, BOSTON, MA 02114 USA	Harvard University; Massachusetts General Hospital; Harvard University; Massachusetts General Hospital					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK048077] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK 48077] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ANGEL P, 1987, MOL CELL BIOL, V7, P2256, DOI 10.1128/MCB.7.6.2256; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BALDWIN GS, 1995, J GASTROEN HEPATOL, V10, P215, DOI 10.1111/j.1440-1746.1995.tb01083.x; BARTHOLEYNS J, 1984, CANCER RES, V44, P639; BEAVEN MA, 1982, PHARM HISTAMINE RECE, P101; CHATTON B, 1994, ONCOGENE, V9, P375; CHEW C, 1982, AM J PHYSIOL, V250, pG912; DEGROOT RP, 1993, EMBO J, V12, P3903, DOI 10.1002/j.1460-2075.1993.tb06068.x; DIMALINE R, 1991, FEBS LETT, V281, P20, DOI 10.1016/0014-5793(91)80348-7; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FUJIMOTO K, 1992, J CLIN INVEST, V89, P126, DOI 10.1172/JCI115552; HAKANSON R, 1986, HISTOCHEMISTRY, V86, P5, DOI 10.1007/BF00492340; HAKANSON R, 1991, SCAND J GASTROENTERO, V26, P130, DOI 10.3109/00365529109093190; HASLINGER A, 1985, P NATL ACAD SCI USA, V82, P8572, DOI 10.1073/pnas.82.24.8572; Hocker M, 1996, AM J PHYSIOL-GASTR L, V270, pG619, DOI 10.1152/ajpgi.1996.270.4.G619; HOSODA S, 1985, BIOCHEM PHARMACOL, V34, P4327, DOI 10.1016/0006-2952(85)90293-X; ISHIKAWA E, 1970, J BIOCHEM-TOKYO, V68, P347, DOI 10.1093/oxfordjournals.jbchem.a129365; ITO M, 1993, J BIOL CHEM, V268, P18300; KAHLSON G, 1968, PHYSIOL REV, V48, P155, DOI 10.1152/physrev.1968.48.1.155; KAHLSON G, 1959, NATURE, V184, P1238, DOI 10.1038/1841238a0; KAHLSON G, 1958, J PHYSIOL-LONDON, V144, P337, DOI 10.1113/jphysiol.1958.sp006105; KAHLSON G, 1972, EXPERIENTIA, V28, P993, DOI 10.1007/BF01918636; KAWAI H, 1992, BIOCHIM BIOPHYS ACTA, V1133, P172, DOI 10.1016/0167-4889(92)90066-K; LEE BS, 1995, J BIOL CHEM, V270, P7320, DOI 10.1074/jbc.270.13.7320; LEE YM, 1993, J BIOL CHEM, V268, P8164; MAEYAMA K, 1988, BIOCHEM BIOPH RES CO, V151, P1402, DOI 10.1016/S0006-291X(88)80518-7; MAMUNESATO R, 1990, BIOCHEM PHARMACOL, V40, P1125; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; NOLAN GP, 1994, CELL, V77, P795, DOI 10.1016/0092-8674(94)90126-0; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; RANGACHARI PK, 1992, AM J PHYSIOL, V262, pG1; REHFELD JF, 1994, ADV CANCER RES, V63, P295, DOI 10.1016/S0065-230X(08)60403-0; ROEBUCK KA, 1993, J CLIN INVEST, V92, P1336, DOI 10.1172/JCI116707; SANDVIK AK, 1994, AM J PHYSIOL, V267, pG254, DOI 10.1152/ajpgi.1994.267.2.G254; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P5419; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WANG TC, 1990, J BIOL CHEM, V265, P8908; WATANABE T, 1981, BIOCHEM BIOPH RES CO, V100, P427, DOI 10.1016/S0006-291X(81)80114-3; YAMAUCHI K, 1990, NUCLEIC ACIDS RES, V18, P5891, DOI 10.1093/nar/18.19.5891; YASSIN RR, 1993, PEPTIDES, V14, P1119, DOI 10.1016/0196-9781(93)90164-C; YATSUNAMI K, 1994, J BIOL CHEM, V269, P1554; YATSUNAMI K, 1993, AGENTS ACTIONS, V38, pC155, DOI 10.1007/BF01996445; Zahnow C A, 1991, DNA Seq, V1, P395, DOI 10.3109/10425179109020795	46	41	41	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14188	14197		10.1074/jbc.271.24.14188	http://dx.doi.org/10.1074/jbc.271.24.14188			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662934	hybrid			2022-12-27	WOS:A1996UQ66000040
J	Durick, K; Wu, RY; Gill, GN; Taylor, SS				Durick, K; Wu, RY; Gill, GN; Taylor, SS			Mitogenic signaling by Ret/ptc2 requires association with enigma via a LIM domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RET PROTOONCOGENE; SEQUENCE; PROTEIN; INTERACTS; KINASE	The ret/ptc2 papillary thyroid cancer oncogene, an oncogenic form of the c-Ret receptor tyrosine kinase, is the product of a somatic crossover event fusing the dimerization domain of the type I alpha regulatory subunit of cyclic AMP-dependent protein kinase (RI) with the tyrosine kinase domain of c-Ret. Mitogenic activity of Ret/ptc2 required dimerization via the N terminus of RI and a tyrosine residue located C-terminal to the kinase core of Ret, Tyr-586 (Durick, K., Yao, V. J., Borrello, M. G., Bongarzone, I., Pierotti, M. A. and Taylor, S. S. (1995) J. Biol. Chem. 270, 24642-24645). Using the yeast two-hybrid system, Ret/ptc2 binding proteins were identified, and the sites of interaction with Ret/ptc2 were mapped. The SH2 domains of phospholipase C gamma and Grb10 were both identified, and binding depended on phosphorylation of Tyr-539 and Tyr-429, respectively. These interactions, however, were not required for mitogenic signaling. The second of the three LIM domains in Enigma (Wu, R. Y., and Gill, G. N. (1994) J. Biol. Chem. 269, 25085-25090) was also identified as a Ret/ptc2 binding domain. Enigma, a 455-residue protein, was discovered based on its interaction with the insulin receptor through the C-terminal LIM domain. Although the association with Enigma required Tyr-586 of Ret/ptc2, the interaction was phosphorylation-independent. In contrast to the SH2 interactions, disruption of the interaction with Enigma abolished Ret/ptc2 mitogenic signaling, suggesting that LIM domain recognition of an unphosphorylated tyrosine-based motif is required for Ret signal transduction.	UNIV CALIF SAN DIEGO,DEPT CHEM & BIOCHEM,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT BIOL,LA JOLLA,CA 92093; UNIV CALIF SAN DIEGO,DEPT MED,LA JOLLA,CA 92093	University of California System; University of California San Diego; University of California System; University of California San Diego; University of California System; University of California San Diego					NCI NIH HHS [T32 CA09523] Funding Source: Medline; NIDDK NIH HHS [DK13149] Funding Source: Medline; NATIONAL CANCER INSTITUTE [T32CA009523] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK013149, R37DK013149] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Ausubel FM, 1994, CURRENT PROTOCOLS MO; BONGARZONE I, 1993, MOL CELL BIOL, V13, P358, DOI 10.1128/MCB.13.1.358; BONGARZONE I, 1994, CANCER RES, V54, P2979; BORRELLO MG, 1994, ONCOGENE, V9, P1661; DURICK K, 1995, J BIOL CHEM, V270, P24642, DOI 10.1074/jbc.270.42.24642; EDERY P, 1994, NATURE, V367, P378, DOI 10.1038/367378a0; EMORI Y, 1989, J BIOL CHEM, V264, P21885; ENG C, 1994, HUM MOL GENET, V3, P237, DOI 10.1093/hmg/3.2.237; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HOFSTRA RMW, 1994, NATURE, V367, P375, DOI 10.1038/367375a0; LANZI C, 1992, ONCOGENE, V7, P2189; MULLIGAN LM, 1993, NATURE, V363, P458, DOI 10.1038/363458a0; MULLIGAN LM, 1994, NAT GENET, V6, P70, DOI 10.1038/ng0194-70; OOI J, 1995, ONCOGENE, V10, P1621; PANDEY A, 1995, J BIOL CHEM, V270, P21461, DOI 10.1074/jbc.270.37.21461; ROMEO G, 1994, NATURE, V367, P377, DOI 10.1038/367377a0; SADLER I, 1992, J CELL BIOL, V119, P1573, DOI 10.1083/jcb.119.6.1573; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTORO M, 1994, MOL CELL BIOL, V14, P663, DOI 10.1128/MCB.14.1.663; TAIRA M, 1992, GENE DEV, V6, P356, DOI 10.1101/gad.6.3.356; TAKAHASHI M, 1989, ONCOGENE, V4, P805; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WU RY, 1994, J BIOL CHEM, V269, P25085; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A	26	83	86	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12691	12694		10.1074/jbc.271.22.12691	http://dx.doi.org/10.1074/jbc.271.22.12691			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662982	hybrid			2022-12-27	WOS:A1996UN47400002
J	Kraft, HJ; Mosselman, S; Smits, HA; Hohenstein, P; Piek, E; Chen, Q; Artzt, K; vanZoelen, EJJ				Kraft, HJ; Mosselman, S; Smits, HA; Hohenstein, P; Piek, E; Chen, Q; Artzt, K; vanZoelen, EJJ			Oct-4 regulates alternative platelet-derived growth factor alpha receptor gene promoter in human embryonal carcinoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EARLY MOUSE EMBRYOGENESIS; OCTAMER BINDING-PROTEINS; TRANSCRIPTION FACTORS; POU DOMAIN; KIT GENE; PDGF-A; EXPRESSION; ACID; TERATOCARCINOMA; ACTIVATION	Expression of the platelet-derived growth factor alpha-receptor (PDGF alpha R) gene is tightly controlled in mammalian embryogenesis. A well established model system to study human embryogenesis is the embryonal carcinoma cell line Tera2, We have shown previously that retinoic acid-differentiated Tera2 cells express two PDGF alpha R transcripts of 6.4 kilobase pairs (kb) (encoding the full-length receptor) and 3.0 kb, respectively, whereas in contrast, undifferentiated Tera2 cells express PDFG alpha R transcripts of 1.5 kb and 5.0 kb, Here we show that this switch in PDGF alpha R expression pattern during differentiation of Tera2 cells results from alternative promoter use, In undifferentiated cells, a second promoter is used, which is located in intron 12 of the PDGF alpha R gene, Functional analysis shows that this promoter contains a consensus octamer motif, which can be bound by the POU domain transcription factor Oct-4, Oct-4 is expressed in undifferentiated Tera2 cells but not in retinoic acid-induced differentiated cells, Mutation of the octamer motif decreases promoter activity, while ectopic expression of Oct-4 in differentiated Tera2 cells specifically enhances the activity of this PDGF alpha R promoter, Therefore, we suggest that an important aspect in the maintenance of the undifferentiated state of human embryonal carcinoma cells results from Oct-4 expression, which thereupon activates this PDGF alpha R promoter.	UNIV NIJMEGEN,DEPT CELL BIOL,6525 ED NIJMEGEN,NETHERLANDS; UNIV TEXAS,DEPT ZOOL,AUSTIN,TX 78712	Radboud University Nijmegen; University of Texas System; University of Texas Austin			Hohenstein, Peter/Y-2428-2018	Hohenstein, Peter/0000-0001-8548-4734				AFINK GB, 1995, ONCOGENE, V10, P1667; ANDREWS PW, 1988, BIOCHIM BIOPHYS ACTA, V948, P17, DOI 10.1016/0304-419X(88)90003-0; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Damjanov I, 1991, Recent Results Cancer Res, V123, P1; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; HAMPE A, 1989, ONCOGENE RES, V4, P9; HOSLER BA, 1993, MOL CELL BIOL, V13, P2919, DOI 10.1128/MCB.13.5.2919; JAIN VK, 1991, ANAL BIOCHEM, V199, P119, DOI 10.1016/0003-2697(91)90278-2; JAYE M, 1992, BIOCHIM BIOPHYS ACTA, V1135, P185, DOI 10.1016/0167-4889(92)90136-Y; KITAMI Y, 1995, J CLIN INVEST, V96, P558, DOI 10.1172/JCI118068; LEE KH, 1990, MOL CELL BIOL, V10, P2237, DOI 10.1128/MCB.10.5.2237; MERCOLA M, 1990, DEV BIOL, V138, P114, DOI 10.1016/0012-1606(90)90181-H; MOSSELMAN S, 1994, CANCER RES, V54, P220; NISTER M, 1991, J BIOL CHEM, V266, P16755; OKAMOTO K, 1990, CELL, V60, P461, DOI 10.1016/0092-8674(90)90597-8; ORRURTREGER A, 1992, DEVELOPMENT, V115, P289; PALMIERI SL, 1992, MECH DEVELOP, V39, P181, DOI 10.1016/0925-4773(92)90045-L; PEEK R, 1992, NUCLEIC ACIDS RES, V20, P4865, DOI 10.1093/nar/20.18.4865; PETCH LA, 1990, MOL CELL BIOL, V10, P2973, DOI 10.1128/MCB.10.6.2973; ROSFJORD E, 1994, BIOCHEM BIOPH RES CO, V203, P1795, DOI 10.1006/bbrc.1994.2395; ROSSI P, 1992, DEV BIOL, V152, P203, DOI 10.1016/0012-1606(92)90172-D; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATTEMAN GC, 1992, DEVELOPMENT, V115, P125; SCHOLER HR, 1990, NATURE, V344, P435, DOI 10.1038/344435a0; SCHOLER HR, 1989, EMBO J, V8, P2551, DOI 10.1002/j.1460-2075.1989.tb08393.x; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SMITH EA, 1991, P NATL ACAD SCI USA, V88, P4811, DOI 10.1073/pnas.88.11.4811; STEPHENSON DA, 1991, P NATL ACAD SCI USA, V88, P6, DOI 10.1073/pnas.88.1.6; TANAKA M, 1992, CELL, V68, P755, DOI 10.1016/0092-8674(92)90150-B; VANDENBARK GR, 1992, ONCOGENE, V7, P1259; VANZOELEN EJJ, 1989, DEV BIOL, V133, P272, DOI 10.1016/0012-1606(89)90318-7; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; VU TH, 1989, MOL CELL BIOL, V9, P4563, DOI 10.1128/MCB.9.10.4563; WANG CY, 1994, P NATL ACAD SCI USA, V91, P7061, DOI 10.1073/pnas.91.15.7061; WANG CY, 1990, MOL CELL BIOL, V10, P6781, DOI 10.1128/MCB.10.12.6781; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WEIMA SM, 1988, DIFFERENTIATION, V38, P203, DOI 10.1111/j.1432-0436.1988.tb00214.x; YUAN HB, 1995, GENE DEV, V9, P2635, DOI 10.1101/gad.9.21.2635	39	45	50	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12873	12878		10.1074/jbc.271.22.12873	http://dx.doi.org/10.1074/jbc.271.22.12873			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662786	hybrid, Green Published			2022-12-27	WOS:A1996UN47400030
J	Heinisch, JJ; Boles, E; Timpel, C				Heinisch, JJ; Boles, E; Timpel, C			A yeast phosphofructokinase insensitive to the allosteric activator fructose 2,6-bisphosphate - Glycolysis metabolic regulation allosteric control	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLI SHUTTLE VECTORS; SACCHAROMYCES-CEREVISIAE; RESTRICTION SITES; GENES; MUTANTS; 6-PHOSPHOFRUCTO-2-KINASE; TRANSFORMATION; DUPLICATION; EXPRESSION; SUBUNITS	In this work we used in vitro mutagenesis to modify the allosteric properties of the heterooctameric yeast phosphofructokinase. Specifically, we identified two amino acids involved in the binding of the most potent allosteric activator fructose 2,6-bisphosphate. Thus, Ser(724) was replaced by an aspartate and His(859) by a serine in each of the enzyme subunits. Whereas the substitutions had no drastic effects when introduced only in one of the two types of subunits, kinetic parameters were modified when both subunits carried the mutation. Thus, the enzyme with His(859) --> Ser showed an increase in K-alpha for binding of the activator, whereas the one with Ser(724) --> ASP failed to react to the addition of fructose 2,6-bisphosphate, at all, The enzymes still responded to other allosteric activators, such as AMP. Stabilities of the mutant subunits were not significantly altered in vivo, as judged from Western blot analysis. Phenotypically, strains expressing the mutant PFK genes showed a pronounced effect on the level of intermediary metabolites after growth on glucose, Mutants not responding to the activator at all (Ser(724) --> AsP) also displayed higher generation times on glucose medium. This could be suppressed by increasing the gene dosage of the mutant alleles, These results indicate that fructose 2,6-bisphosphate through its activation of phosphofructokinase plays an important role in regulation of the glycolytic flux.	TH DARMSTADT,INST MIKROBIOL,D-64287 DARMSTADT,GERMANY	Technical University of Darmstadt	Heinisch, JJ (corresponding author), UNIV DUSSELDORF,INST MIKROBIOL,UNIV STR 1,D-40225 DUSSELDORF,GERMANY.		Heinisch, Juergen J./G-3801-2017	Boles, Eckhard/0000-0002-5713-1883				ARVANITIDIS A, 1994, J BIOL CHEM, V269, P8911; AVIGAD G, 1981, BIOCHEM BIOPH RES CO, V102, P985, DOI 10.1016/0006-291X(81)91635-1; BANUELOS M, 1977, J BIOL CHEM, V252, P6394; Barnett JA, 1976, ADV CARBOHYD CHEM, V32, P126; BOLES E, 1993, YEAST, V9, P761, DOI 10.1002/yea.320090710; Boles E, 1996, MOL MICROBIOL, V20, P65, DOI 10.1111/j.1365-2958.1996.tb02489.x; BOLES E, 1993, ARCH MICROBIOL, V160, P324, DOI 10.1007/BF00292085; BREITENBACHSCHMITT I, 1984, MOL GEN GENET, V195, P530, DOI 10.1007/BF00341458; BROACH JR, 1979, GENE, V8, P121, DOI 10.1016/0378-1119(79)90012-X; CIRIACY M, 1979, J BACTERIOL, V139, P152, DOI 10.1128/JB.139.1.152-160.1979; CLIFTON D, 1983, J BIOL CHEM, V258, P9245; CLIFTON D, 1982, BIOCHEMISTRY-US, V21, P1935, DOI 10.1021/bi00537a037; CLIFTON D, 1978, GENETICS, V88, P1; DAVIES SEC, 1992, BIOCHEMISTRY-US, V31, P4729, DOI 10.1021/bi00134a028; DOHMEN RJ, 1991, YEAST, V7, P691, DOI 10.1002/yea.320070704; ESTEVEZ AM, 1995, FEBS LETT, V374, P100, DOI 10.1016/0014-5793(95)01085-S; EVANS PR, 1979, NATURE, V279, P500, DOI 10.1038/279500a0; FRAENKEL DG, 1982, MOL BIOL YEAST SACCH, P1; FRANCOIS J, 1988, EUR J BIOCHEM, V171, P599, DOI 10.1111/j.1432-1033.1988.tb13830.x; Gancedo C., 1989, YEASTS, V3, P205; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; HEINISCH J, 1993, MOL MICROBIOL, V8, P559, DOI 10.1111/j.1365-2958.1993.tb01600.x; HEINISCH J, 1991, FEBS LETT, V289, P77, DOI 10.1016/0014-5793(91)80912-M; HEINISCH J, 1989, GENE, V78, P309; HEINISCH J, 1986, MOL GEN GENET, V202, P75, DOI 10.1007/BF00330520; HEINISCH JJ, 1993, FEBS LETT, V328, P35, DOI 10.1016/0014-5793(93)80960-3; HEINISCH JJ, 1993, BIOTECHNOLOGY, P469; HERS HG, 1982, BIOCHEM J, V206, P1; HILL JE, 1986, YEAST, V2, P163, DOI 10.1002/yea.320020304; KOPPERSCHLAGER G, 1977, EUR J BIOCHEM, V81, P317, DOI 10.1111/j.1432-1033.1977.tb11954.x; KOPPERSCHLAGER G, 1982, ANAL BIOCHEM, V124, P117, DOI 10.1016/0003-2697(82)90228-7; KRETSCHMER M, 1987, BIOCHEM J, V246, P755, DOI 10.1042/bj2460755; KRETSCHMER M, 1991, BIOCHEMISTRY-US, V30, P10663, DOI 10.1021/bi00108a009; LOBO Z, 1982, FEBS LETT, V139, P93, DOI 10.1016/0014-5793(82)80494-8; MARTINEZCOSTA OH, 1994, EUR J BIOCHEM, V226, P1007, DOI 10.1111/j.1432-1033.1994.01007.x; POORMAN RA, 1984, NATURE, V309, P467, DOI 10.1038/309467a0; RABEN N, 1995, AM J HUM GENET, V56, P131; REIBSTEIN D, 1986, BIOCHEMISTRY-US, V25, P219, DOI 10.1021/bi00349a031; ROTHSTEIN RJ, 1983, METHOD ENZYMOL, V101, P202; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHIRMER T, 1990, NATURE, V343, P140, DOI 10.1038/343140a0; Sherman F., 1983, METHODS YEAST GENETI; SOLS A, 1981, CURR TOP CELL REGUL, V19, P77; TIJANE MN, 1980, J BIOL CHEM, V255, P188; Uyeda K, 1979, Adv Enzymol Relat Areas Mol Biol, V48, P193; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	47	40	43	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15928	15933		10.1074/jbc.271.27.15928	http://dx.doi.org/10.1074/jbc.271.27.15928			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663166	hybrid			2022-12-27	WOS:A1996UW35200017
J	Lavoie, CA; Lachance, PED; Sonenberg, N; Lasko, P				Lavoie, CA; Lachance, PED; Sonenberg, N; Lasko, P			Alternatively spliced transcripts from the Drosophila eIF4E gene produce two different cap-binding proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EUKARYOTIC INITIATION FACTOR-4A; MESSENGER-RNA TRANSLATION; MELANOGASTER EMBRYOS; MALIGNANT TRANSFORMATION; ISOZYME FORM; FACTOR 4F; SEQUENCE; PURIFICATION; IDENTIFICATION; YEAST	Eukaryotic initiation factor 4E (eIF4E) is the subunit of eIF4F that binds to the cap structure at the 5' end of messenger RNA and is a critical component for the regulation of translation initiation. Using 7-methyl-GTP-Sepharose affinity chromatography, two distinct cap-binding proteins that migrate on SDS-polyacrylamide gel electrophoresis at approximately 35 kDa were purified from Drosophila adults. Peptide microsequence analysis indicated that these two proteins differ at their amino termini. Analysis of a set of cDNA clones encoding eIF4E led to the conclusion that the two different protein isoforms, which we term eIF4EI and eIF4EII, result from three alternatively spliced transcripts from a single eIF4E gene, which maps to region 67A8-B2 on polytene chromosomes. The three eIF4E transcripts also vary greatly in the lengths of their 5'-UTRs, suggesting the possibility of complex translational control of expression of the two eIF4E isoforms.	MCGILL UNIV,DEPT BIOL,MONTREAL,PQ H3A 1B1,CANADA; MCGILL UNIV,DEPT BIOCHEM,MONTREAL,PQ H3A 1B1,CANADA	McGill University; McGill University			Lasko, Paul/C-6761-2014	Lasko, Paul/0000-0002-4037-3501				ALLEN ML, 1992, J BIOL CHEM, V267, P23232; ALTMANN M, 1989, J BIOL CHEM, V264, P12145; ALTMANN M, 1987, MOL CELL BIOL, V7, P998, DOI 10.1128/MCB.7.3.998; Ashburner M., 2004, DROSOPHILA LAB MANUA, V2nd; BROWN CM, 1994, NUCLEIC ACIDS RES, V22, P3620, DOI 10.1093/nar/22.17.3620; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; BROWNING KS, 1987, J BIOL CHEM, V262, P11228; BROWNING KS, 1992, J BIOL CHEM, V267, P10096; CAVENER DR, 1987, NUCLEIC ACIDS RES, V15, P1353, DOI 10.1093/nar/15.4.1353; CAVENER DR, 1993, ATLAS DROSOPHILA GEN, P359; DUNCAN R, 1987, J BIOL CHEM, V262, P380; DUNCAN RF, 1995, BIOCHEMISTRY-US, V34, P2985, DOI 10.1021/bi00009a030; EDERY I, 1983, J BIOL CHEM, V258, P1398; GOYER C, 1989, J BIOL CHEM, V264, P7603; GOYER C, 1993, MOL CELL BIOL, V13, P4860, DOI 10.1128/MCB.13.8.4860; GRIFO JA, 1983, J BIOL CHEM, V258, P5804; HERNANDEZ G, 1995, BBA-GENE STRUCT EXPR, V1261, P427, DOI 10.1016/0167-4781(95)00039-J; HIREMATH LS, 1985, J BIOL CHEM, V260, P7843; KLEIN PS, 1994, SCIENCE, V265, P803, DOI 10.1126/science.8047887; LAZARISKARATZAS A, 1992, GENE DEV, V6, P1631, DOI 10.1101/gad.6.9.1631; LAZARISKARATZAS A, 1990, NATURE, V345, P544, DOI 10.1038/345544a0; MAROTO FG, 1989, MOL CELL BIOL, V9, P2181, DOI 10.1128/MCB.9.5.2181; MATEU MG, 1987, EUR J BIOCHEM, V162, P221, DOI 10.1111/j.1432-1033.1987.tb10564.x; Merrick WC., 1996, TRANSLATION CONTROL, P31; METZ AM, 1992, NUCLEIC ACIDS RES, V20, P4096, DOI 10.1093/nar/20.15.4096; RYCHLIK W, 1987, P NATL ACAD SCI USA, V84, P945, DOI 10.1073/pnas.84.4.945; RYCHLIK W, 1992, NUCLEIC ACIDS RES, V20, P6415, DOI 10.1093/nar/20.23.6415; Sambrook J., 2002, MOL CLONING LAB MANU; SHATKIN AJ, 1976, CELL, V9, P645, DOI 10.1016/0092-8674(76)90128-8; SMITH M R, 1990, New Biologist, V2, P648; SONENBERG N, 1979, P NATL ACAD SCI USA, V76, P4345, DOI 10.1073/pnas.76.9.4345; Sonenberg N, 1996, TRANSLATIONAL CONTRO, P245; TAHARA SM, 1981, J BIOL CHEM, V256, P7691; WAKIYAMA M, 1995, FEBS LETT, V360, P191, DOI 10.1016/0014-5793(95)00081-J; WEBSTER C, 1991, J BIOL CHEM, V266, P23341; ZAPATA JM, 1994, J BIOL CHEM, V269, P18047	36	28	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16393	16398		10.1074/jbc.271.27.16393	http://dx.doi.org/10.1074/jbc.271.27.16393			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663200	hybrid			2022-12-27	WOS:A1996UW35200079
J	Davidson, JS; McArdle, CA; Davies, P; Elario, R; Flanagan, CA; Millar, RP				Davidson, JS; McArdle, CA; Davies, P; Elario, R; Flanagan, CA; Millar, RP			Asn(102) of the gonadotropin releasing hormone receptor is a critical determinant of potency for agonists containing C-terminal glycinamide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR-CLONING; GNRH RECEPTOR; EXPRESSION; CELLS; SPECIFICITY; ANTAGONISTS; ANALOG; DNA	We demonstrate a critical role for Asn(102) of the human gonadotropin-releasing hormone (GnRH) receptor in the binding of GnRH, Mutation of Asn(102), located at the top of the second transmembrane helix, to Ala resulted in a 225-fold loss of potency for GnRH. Eight GnRH analogs, all containing glycinamide C termini like GnRH, showed similar losses of potency between 95- and 750-foId for the [Ala(102)]GnRHR, compared with wildtype receptor, In contrast, four GnRH analogs that had ethylamide in place of the C-terminal glycinamide residue, showed much smaller decreases in potency between 2.4- and 11-fold, In comparisons of three agonist pairs, differing only at the C terminus, glycinamide derivatives showed an 11-20-fold greater loss of potency for the mutant receptor than their respective ethylamide derivatives, Thus Asn(102) is a critical determinant of potency specifically for ligands with C terminal glycinamide, while ligands with C-terminal ethylamide are less dependent on Asn(102), These findings indicate a role for Asn(102) in the docking of the glycinamide C terminus and are consistent with hydrogen bonding of the Asn(102) side chain with the C-terminal amide moiety, Taken with previous data, they suggest a region of the GnRH receptor formed by the top of helices 2 and 7 as a binding pocket for the C-terminal part of the ligand.	UNIV BRISTOL, DEPT MED, BRISTOL BS2 8HW, AVON, ENGLAND; UNIV CAPE TOWN, SCH MED, ENDOCRINE LAB, DEPT MED, CAPE TOWN 7925, SOUTH AFRICA	University of Bristol; University of Cape Town	Davidson, JS (corresponding author), UNIV CAPE TOWN, SCH MED, DEPT CHEM PATHOL, MRC, REGULATORY PEPTIDES RES UNIT, CAPE TOWN 7925, SOUTH AFRICA.		Flanagan, Colleen/ABG-2109-2020; McArdle, Craig/AAQ-5660-2021	McArdle, Craig/0000-0003-4836-5351; Millar, Robert P/0000-0003-3606-2708; Flanagan, Colleen A./0000-0003-2803-8986				BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; Ballesteros J. A., 1995, RECEPTOR MOL BIOL, V25, P366, DOI [10.1016/S1043-9471(05)80049-7, DOI 10.1016/S1043-9471(05)80049-7]; CHI L, 1993, MOL CELL ENDOCRINOL, V91, pR1, DOI 10.1016/0303-7207(93)90278-R; DAVIDSON J, 1991, MOL CELL ENDOCRINOL, V76, pC33, DOI 10.1016/0303-7207(91)90278-Z; DAVIDSON JS, 1990, ENDOCRINOLOGY, V126, P80, DOI 10.1210/endo-126-1-80; DAVIDSON JS, 1995, MOL CELL ENDOCRINOL, V107, P241, DOI 10.1016/0303-7207(94)03449-4; FLANAGAN CA, 1994, J BIOL CHEM, V269, P22639; FREIDINGER RM, 1980, SCIENCE, V210, P656, DOI 10.1126/science.7001627; FUJINO M, 1972, BIOCHEM BIOPH RES CO, V49, P863, DOI 10.1016/0006-291X(72)90490-1; GETHER U, 1993, J BIOL CHEM, V268, P7893; HSIEH KP, 1992, MOL ENDOCRINOL, V6, P1673, DOI 10.1210/me.6.10.1673; ILLING N, 1993, BIOCHEM BIOPH RES CO, V196, P745, DOI 10.1006/bbrc.1993.2312; KAISER UB, 1992, BIOCHEM BIOPH RES CO, V189, P1645, DOI 10.1016/0006-291X(92)90266-N; KAKAR SS, 1992, BIOCHEM BIOPH RES CO, V189, P289, DOI 10.1016/0006-291X(92)91556-6; KAKAR SS, 1993, DOMEST ANIM ENDOCRIN, V10, P335, DOI 10.1016/0739-7240(93)90037-C; KARTEN MJ, 1986, ENDOCR REV, V7, P44, DOI 10.1210/edrv-7-1-44; Kenakin TP, 1993, PHARM ANAL DRUG RECE, P39; KEOWN WA, 1990, METHOD ENZYMOL, V185, P527, DOI 10.1016/0076-6879(90)85043-N; KUNKEL TA, 1991, METHOD ENZYMOL, V204, P125; LESLIE FM, 1987, PHARMACOL REV, V39, P197; MILLAR RP, 1987, S AFR MED J, V72, P748; MONAHAN MW, 1973, BIOCHEMISTRY-US, V12, P4616, DOI 10.1021/bi00747a012; REINHART J, 1992, J BIOL CHEM, V267, P21281; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SMITH RD, 1992, ANNU REV PHARMACOL, V32, P135; TSE A, 1992, SCIENCE, V255, P462, DOI 10.1126/science.1734523; TSUTSUMI M, 1992, MOL ENDOCRINOL, V6, P1163, DOI 10.1210/me.6.7.1163; ZHOU W, 1994, MOL PHARMACOL, V45, P165; ZHOU W, 1995, J BIOL CHEM, V270, P18853, DOI 10.1074/jbc.270.32.18853	29	83	85	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15510	15514		10.1074/jbc.271.26.15510	http://dx.doi.org/10.1074/jbc.271.26.15510			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663086	Green Published, hybrid			2022-12-27	WOS:A1996UV29900033
J	Komeda, H; Kobayashi, M; Shimizu, S				Komeda, H; Kobayashi, M; Shimizu, S			A novel gene cluster including the Rhodococcus rhodochrous J1 nhlBA genes encoding a low molecular mass nitrile hydratase (L-NHase) induced by its reaction product	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PSEUDOMONAS-CHLORORAPHIS B23; ENANTIOMER-SELECTIVE AMIDASE; NUCLEOTIDE-SEQUENCE; ESCHERICHIA-COLI; STRUCTURAL EVIDENCE; BINDING PROTEIN; DNA-SEQUENCE; EXPRESSION; CLONING; PURIFICATION	The 3.5 kilobases (kb) of the 5'-upstream region from nhlBA encoding a cobalt-containing low molecular mass nitrile hydratase (L-NHase) from Rhodococcus rhodochrous J1 was found to be required for the amide-dependent expression of nhlBA in experiments using a Rhodococcus transformation system. Sequence analysis of the 3,5-kb fragment revealed the presence of two open reading frames (nhlD and nhlC) in this fragment. NhlD has similarity to regulators MerR, CadC, and ArsR. NhlC has similarity to the regulators AmiC, for the expression of an aliphatic amidase from Pseudomonas aeruginosa, and NhhC, for the expression of a high molecular mass nitrile hydratase from R. rhodochrous J1. Assays of NHase activity of transformants carrying nhlD deletion or nhlC deletion mutations suggest a negative regulatory role for nhlD and a positive regulatory role for nhlC in the process of the L-NHase formation. Assays of NHase and amidase activities and Western blot analyses of each Rhodococcus transformant carrying various deletion plasmids, have shown that nhlBA and amdA encoding an amidase, which is located 1.9 kb downstream of nhlBA, were regulated in the same manner. These findings present the genetic evidence for a novel gene cluster controlling the expression of L-NHase, which is induced by the reaction product (amide) in the ''practical microorganism'' R. rhodochrous J1.	KYOTO UNIV,DEPT AGR CHEM,FAC AGR,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University								ASANO Y, 1980, AGR BIOL CHEM TOKYO, V44, P2251, DOI 10.1080/00021369.1980.10864311; BARTEL B, 1994, P NATL ACAD SCI USA, V91, P6649, DOI 10.1073/pnas.91.14.6649; BARTLING D, 1994, P NATL ACAD SCI USA, V91, P6021, DOI 10.1073/pnas.91.13.6021; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAMMAR WJ, 1987, FEBS LETT, V215, P291, DOI 10.1016/0014-5793(87)80164-3; CLARKE PH, 1986, BACTERIA, V10, P71; COHEN SP, 1993, J BACTERIOL, V175, P1484, DOI 10.1128/JB.175.5.1484-1492.1993; DREW R, 1989, J GEN MICROBIOL, V135, P817; DURAN R, 1993, BIOSCI BIOTECH BIOCH, V57, P1323, DOI 10.1271/bbb.57.1323; ENDO G, 1995, J BACTERIOL, V177, P4437, DOI 10.1128/jb.177.15.4437-4441.1995; HASHIMOTO Y, 1992, J GEN MICROBIOL, V138, P1003, DOI 10.1099/00221287-138-5-1003; HOSHINO T, 1989, J BACTERIOL, V171, P6300, DOI 10.1128/jb.171.11.6300-6306.1989; IKEHATA O, 1989, EUR J BIOCHEM, V181, P563, DOI 10.1111/j.1432-1033.1989.tb14761.x; KELLY M, 1962, J GEN MICROBIOL, V27, P305, DOI 10.1099/00221287-27-2-305; KOBAYASHI M, 1995, P NATL ACAD SCI USA, V92, P714, DOI 10.1073/pnas.92.3.714; KOBAYASHI M, 1993, EUR J BIOCHEM, V217, P327, DOI 10.1111/j.1432-1033.1993.tb18250.x; KOBAYASHI M, 1991, BIOCHIM BIOPHYS ACTA, V1129, P23, DOI 10.1016/0167-4781(91)90208-4; KOBAYASHI M, 1993, P NATL ACAD SCI USA, V90, P247, DOI 10.1073/pnas.90.1.247; KOBAYASHI M, 1992, J BIOL CHEM, V267, P20746; KOBAYASHI M, 1992, TRENDS BIOTECHNOL, V10, P402, DOI 10.1016/0167-7799(92)90283-2; KOBAYASHI M, 1994, FEMS MICROBIOL LETT, V120, P217, DOI 10.1016/0378-1097(94)90474-X; Komeda H, 1996, P NATL ACAD SCI USA, V93, P4267, DOI 10.1073/pnas.93.9.4267; MAYAUX JF, 1990, J BACTERIOL, V172, P6764, DOI 10.1128/jb.172.12.6764-6773.1990; MAYAUX JF, 1991, J BACTERIOL, V173, P6694, DOI 10.1128/jb.173.21.6694-6704.1991; NAGASAWA T, 1987, EUR J BIOCHEM, V162, P691, DOI 10.1111/j.1432-1033.1987.tb10692.x; NAGASAWA T, 1988, BIOCHEM BIOPH RES CO, V155, P1008, DOI 10.1016/S0006-291X(88)80597-7; NISHIYAMA M, 1991, J BACTERIOL, V173, P2465, DOI 10.1128/jb.173.8.2465-2472.1991; NUCIFORA G, 1989, P NATL ACAD SCI USA, V86, P3544, DOI 10.1073/pnas.86.10.3544; OHALLORAN TV, 1993, SCIENCE, V261, P715, DOI 10.1126/science.8342038; ROPER DI, 1993, MOL GEN GENET, V237, P241, DOI 10.1007/BF00282806; Sambrook J., 2002, MOL CLONING LAB MANU; SANFRANCISCO MJD, 1990, NUCLEIC ACIDS RES, V18, P619; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEDLMEIER R, 1992, MOL GEN GENET, V236, P76, DOI 10.1007/BF00279645; STOKES HW, 1989, MOL MICROBIOL, V3, P1669, DOI 10.1111/j.1365-2958.1989.tb00153.x; WILSON S, 1991, J BACTERIOL, V173, P4914, DOI 10.1128/jb.173.16.4914-4921.1991; WILSON SA, 1993, EMBO J, V12, P3637, DOI 10.1002/j.1460-2075.1993.tb06037.x; WU JH, 1993, J BIOL CHEM, V268, P52	38	91	95	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15796	15802		10.1074/jbc.271.26.15796	http://dx.doi.org/10.1074/jbc.271.26.15796			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662959	hybrid			2022-12-27	WOS:A1996UV29900074
J	Ungefroren, H; Krull, NB				Ungefroren, H; Krull, NB			Transcriptional regulation of the human biglycan gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; DERMATAN SULFATE PROTEOGLYCAN; VASCULAR SMOOTH-MUSCLE; NUCLEAR FACTOR-I; EXTRACELLULAR-MATRIX; HUMAN FIBROBLASTS; CORE PROTEIN; EXPRESSION; DECORIN; CELLS	The small leucine-rich proteoglycan biglycan is involved in several physiological and pathophysiological processes through the ability of its core protein to interact with other extracellular matrix molecules and transforming growth factor-beta (TGF-beta). To learn more about the regulation of biglycan core protein expression, we have cloned and sequenced 1218 base pairs from the 5'-flanking region of the human biglycan gene, demonstrated functional promoter activity, and investigated the molecular mechanisms through which various agents modulate its transcriptional activity. Sequencing revealed the presence of several cis-acting elements including multiple AP-2 sites and interleukin-6 response elements, a NF-kappa B site, a TGF-beta negative element, and an E-box. The TATA and CAAT box-lacking promoter possesses many features of a growth-related gene, e.g. a GC-rich immediate 5' region, many Sp1 sites, and the use of multiple transcriptional start sites. Transient transfections of the tumor cell lines MG-63, SK-UT-1, and T47D with various biglycan 5'-flanking region-luciferase reporter gene constructs showed that the proximal 78 base pairs are sufficient for full promoter activity. Several agents among them interleukin-6, and tumor necrosis factor-alpha. were capable of altering biglycan promoter activity. However, in MG-63 cells, TGF-beta 1 failed to increase either activity of the biglycan promoter constructs or specific transcription from the endogenous biglycan gene. Since TGF-beta 1 also did not alter the stability of cytoplasmic biglycan mRNA as determined from Northern analysis after inhibition of transcription with 5,6-dichloro-1 beta-D-ribofuranosylbenzimidazole, an as yet unidentified nuclear post-transcriptional mechanism was considered responsible for the TGF-beta effect in this cell type. These results might help to elucidate the molecular pathways leading to pathological alterations of biglycan expression observed in atherosclerosis, glomerulonephritis, and fibrosis.	UNIV HAMBURG,INST ANAT,D-20246 HAMBURG,GERMANY; MED LAB DR HR EBERSOLD,CH-3001 BERN,SWITZERLAND	University of Hamburg								ASUNDI V, 1990, EUR J CELL BIOL, V52, P98; BEAVAN LA, 1993, J BIOL CHEM, V268, P9856; BIANCO P, 1990, J HISTOCHEM CYTOCHEM, V38, P1549, DOI 10.1177/38.11.2212616; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BORDER WA, 1990, KIDNEY INT, V37, P689, DOI 10.1038/ki.1990.35; BREUER B, 1990, BIOCHEM J, V269, P551, DOI 10.1042/bj2690551; CHANDLER LA, 1994, MOL CELL BIOL, V14, P3085, DOI 10.1128/MCB.14.5.3085; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOI I, 1994, CLIN EXP IMMUNOL, V95, P530; DODGE GR, 1990, J BIOL CHEM, V265, P18023; FEDARKO NS, 1992, J CELL PHYSIOL, V151, P215, DOI 10.1002/jcp.1041510202; FISHER LW, 1991, J BIOL CHEM, V266, P14371; FISHER LW, 1989, J BIOL CHEM, V264, P4571; GEERKENS C, 1995, HUM GENET, V96, P44, DOI 10.1007/BF00214185; HATTORI M, 1990, P NATL ACAD SCI USA, V87, P2364, DOI 10.1073/pnas.87.6.2364; HILDEBRAND A, 1994, BIOCHEM J, V302, P527, DOI 10.1042/bj3020527; HOCKE GM, 1992, MOL CELL BIOL, V12, P2282, DOI 10.1128/MCB.12.5.2282; HUTCHINS D, 1994, INT J CANCER, V58, P80, DOI 10.1002/ijc.2910580114; HUTSON JC, 1993, J REPROD IMMUNOL, V23, P63, DOI 10.1016/0165-0378(93)90027-F; IMMENSCHUH S, 1994, J BIOL CHEM, V269, P12654; JARVELAINEN HT, 1991, J BIOL CHEM, V266, P23274; KAHARI VM, 1995, J INVEST DERMATOL, V104, P503, DOI 10.1111/1523-1747.ep12605969; KAHARI VM, 1991, J BIOL CHEM, V266, P10608; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KIMOTO S, 1994, ENDOCRINOLOGY, V135, P2423, DOI 10.1210/en.135.6.2423; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KORNBLIHTT AR, 1983, P NATL ACAD SCI-BIOL, V80, P3218, DOI 10.1073/pnas.80.11.3218; Kresse H, 1994, EXS, V70, P73; KRULL NB, 1993, HEPATOLOGY, V18, P581, DOI 10.1016/0270-9139(93)90359-U; KRUSIUS T, 1986, P NATL ACAD SCI USA, V83, P7683, DOI 10.1073/pnas.83.20.7683; LEWANDOWSKA K, 1987, J CELL BIOL, V105, P1443, DOI 10.1083/jcb.105.3.1443; LI YP, 1993, MOL CELL BIOL, V13, P3714, DOI 10.1128/MCB.13.6.3714; LIN YCA, 1992, J IMMUNOL, V149, P2914; LIU YH, 1994, J BIOL CHEM, V269, P4152; MAATTA A, 1994, BBA-MOL BASIS DIS, V1225, P264, DOI 10.1016/0925-4439(94)90005-1; MAUVIEL A, 1995, J BIOL CHEM, V270, P11692, DOI 10.1074/jbc.270.19.11692; MEYER DH, 1992, HEPATOLOGY, V16, P204, DOI 10.1002/hep.1840160131; NAKAMURA T, 1992, KIDNEY INT, V41, P1213, DOI 10.1038/ki.1992.183; OGATA Y, 1995, EUR J BIOCHEM, V230, P183; OKUDA S, 1990, J CLIN INVEST, V86, P453, DOI 10.1172/JCI114731; RAMASAMY S, 1995, J CELL PHYSIOL, V162, P119, DOI 10.1002/jcp.1041620114; RICCIO A, 1992, MOL CELL BIOL, V12, P1846, DOI 10.1128/MCB.12.4.1846; RICCIOLI A, 1995, P NATL ACAD SCI USA, V92, P5808, DOI 10.1073/pnas.92.13.5808; RIESSEN R, 1994, AM J PATHOL, V144, P962; ROEB E, 1994, FEBS LETT, V349, P45, DOI 10.1016/0014-5793(94)00636-9; ROMARIS M, 1991, BIOCHIM BIOPHYS ACTA, V1093, P229, DOI 10.1016/0167-4889(91)90127-J; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROUGHLEY PJ, 1994, MATRIX BIOL, V14, P51, DOI 10.1016/0945-053X(94)90029-9; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SANTRA M, 1994, J BIOL CHEM, V269, P579; SANTRA M, 1995, P NATL ACAD SCI USA, V92, P7016, DOI 10.1073/pnas.92.15.7016; SCHMIDT G, 1991, BIOCHEM J, V280, P411, DOI 10.1042/bj2800411; SCHOLZEN T, 1994, J BIOL CHEM, V269, P28270; SCHONHERR E, 1993, ARTERIOSCLER THROMB, V13, P1026, DOI 10.1161/01.ATV.13.7.1026; SEHGAL A, 1988, MOL CELL BIOL, V8, P3160, DOI 10.1128/MCB.8.8.3160; SENGER M, 1995, COMPUT METH PROG BIO, V46, P131, DOI 10.1016/0169-2607(94)01610-R; SKINNER MK, 1989, MOL ENDOCRINOL, V3, P625, DOI 10.1210/mend-3-4-625; TAKEUCHI Y, 1995, J CELL PHYSIOL, V162, P315, DOI 10.1002/jcp.1041620303; TOKUNAGA K, 1987, CANCER RES, V47, P5616; UNGEFROREN H, 1995, BIOL REPROD, V52, P1095, DOI 10.1095/biolreprod52.5.1095; VENESSMEEHAN KA, 1994, AM J RESP CELL MOL, V11, P509, DOI 10.1165/ajrcmb.11.5.7946380; WEGROWSKI Y, 1995, GENOMICS, V30, P8, DOI 10.1006/geno.1995.0002; WESTERGRENTHORSSON G, 1991, MATRIX, V11, P177, DOI 10.1016/S0934-8832(11)80156-3; WESTERGRENTHORSSON G, 1993, J CLIN INVEST, V92, P632, DOI 10.1172/JCI116631; WHINNA HC, 1993, J BIOL CHEM, V268, P3920; WRANA JL, 1991, EUR J BIOCHEM, V197, P519, DOI 10.1111/j.1432-1033.1991.tb15940.x; XIE JF, 1994, J IMMUNOL, V153, P378; YAMAGUCHI Y, 1988, NATURE, V336, P244, DOI 10.1038/336244a0; YOUNG MF, 1989, J BIOL CHEM, V264, P450	71	59	60	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15787	15795		10.1074/jbc.271.26.15787	http://dx.doi.org/10.1074/jbc.271.26.15787			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662974				2022-12-27	WOS:A1996UV29900073
J	vandenDobbelsteen, DJ; Nobel, CSI; Schlegel, J; Cotgreave, IA; Orrenius, S; Slater, AFG				vandenDobbelsteen, DJ; Nobel, CSI; Schlegel, J; Cotgreave, IA; Orrenius, S; Slater, AFG			Rapid and specific efflux of reduced glutathione during apoptosis induced by anti-Fas/AP0-1 antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							OXIDATIVE STRESS; LYMPHOID-CELLS; PROTEIN; TRANSPORT; DISULFIDES; INHIBITION; EXPRESSION	Although human JURKAT T lymphocytes induced to undergo apoptosis with anti-Fas/APO-1 antibody were observed to rapidly lose reduced glutathione (GSH), increased concentrations of oxidized products were not detectable, Unexpectedly, the reduced tripeptide was instead quantitatively recovered in the incubation medium of the cells, As GSH loss was blocked by bromosulfophthalein and dibromosulfophthalein, known inhibitors of hepatocyte GSH transport, a specific export rather than nonspecific leakiness through plasma membranes is proposed to be responsible, Apoptosis was de layed when GSH-diethylesters were used to elevate intracellular GSH, although the high capacity of the activated efflux system quickly negated the benefit of this treatment. Stimulation of GSH efflux provides a novel mechanism whereby Fas/APO-1 ligation can deplete GSH. We speculate that it enhances the oxidative tonus of a responding cell without requiring an increase in the production of reactive oxygen species.	KAROLINSKA INST, DIV TOXICOL, INST ENVIRONM MED, S-17177 STOCKHOLM, SWEDEN	Karolinska Institutet			Nobel, Stefan/F-9491-2010	Nobel, Stefan/0000-0003-1671-2291				Akerboom T., 1990, GLUTATHIONE METABOLI, P45; AMEISEN JC, 1995, CELL DEATH DIFFER, V2, P285; BALLATORI N, 1994, J BIOL CHEM, V269, P19731; BALLATORI N, 1985, AM J PHYSIOL, V248, pG238, DOI 10.1152/ajpgi.1985.248.2.G238; BEAVER JP, 1995, EUR J CELL BIOL, V68, P47; BELLOMO G, 1987, BIOCHEM PHARMACOL, V36, P1313, DOI 10.1016/0006-2952(87)90087-6; BROWN DG, 1993, J BIOL CHEM, V268, P3037; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; BUTTKE TM, 1994, IMMUNOL TODAY, V15, P7, DOI 10.1016/0167-5699(94)90018-3; COTGREAVE IA, 1986, J BIOCHEM BIOPH METH, V13, P231, DOI 10.1016/0165-022X(86)90102-8; DETHMERS JK, 1981, P NATL ACAD SCI-BIOL, V78, P7492, DOI 10.1073/pnas.78.12.7492; DOLLE RE, 1994, J MED CHEM, V37, P563, DOI 10.1021/jm00031a003; ECK HP, 1989, BIOL CHEM H-S, V370, P101, DOI 10.1515/bchm3.1989.370.1.101; EISCHEN CM, 1994, J IMMUNOL, V153, P1947; ENARI M, 1995, NATURE, V375, P78, DOI 10.1038/375078a0; FARISS MW, 1987, METHOD ENZYMOL, V143, P101; FERNANDEZCHECA JC, 1993, J BIOL CHEM, V268, P2324; FLORES SC, 1993, P NATL ACAD SCI USA, V90, P7632, DOI 10.1073/pnas.90.16.7632; GARCIARUIZ C, 1995, J BIOL CHEM, V270, P15946, DOI 10.1074/jbc.270.27.15946; GHIBELLI L, 1995, BIOCHEM BIOPH RES CO, V216, P313, DOI 10.1006/bbrc.1995.2626; Gougeon M L, 1995, Cell Death Differ, V2, P1; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P2249, DOI 10.1073/pnas.76.5.2249; HABIG WH, 1974, J BIOL CHEM, V249, P7130; HUG H, 1994, FEBS LETT, V351, P311, DOI 10.1016/0014-5793(94)00852-3; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; KANNAN R, 1995, INVEST OPHTH VIS SCI, V36, P9171; LEVY EJ, 1993, P NATL ACAD SCI USA, V90, P9171, DOI 10.1073/pnas.90.19.9171; LOS M, 1995, NATURE, V375, P81, DOI 10.1038/375081a0; MARTIN SJ, 1995, CELL, V82, P349, DOI 10.1016/0092-8674(95)90422-0; MATSUDA M, 1991, J IMMUNOL, V147, P3837; MEISTER A, 1983, ANNU REV BIOCHEM, V52, P711, DOI 10.1146/annurev.bi.52.070183.003431; MEISTER A, 1994, CANCER RES, V54, pS1969; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; MUSCHEL RJ, 1995, CANCER RES, V55, P995; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; PRUETT SB, 1989, IMMUNOBIOLOGY, V179, P308, DOI 10.1016/S0171-2985(89)80037-3; SATO T, 1995, SCIENCE, V268, P411, DOI 10.1126/science.7536343; Schlegel J, 1996, J BIOL CHEM, V271, P1841, DOI 10.1074/jbc.271.4.1841; SCHUPPE I, 1992, BIOCHEM PHARMACOL, V44, P1757, DOI 10.1016/0006-2952(92)90069-U; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; SLATER AFG, 1995, BIOCHEM J, V306, P771, DOI 10.1042/bj3060771; STAAL FJT, 1992, LANCET, V339, P909, DOI 10.1016/0140-6736(92)90939-Z; SZE G, 1993, AM J PHYSIOL, V265, pG1128, DOI 10.1152/ajpgi.1993.265.6.G1128; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; WEIS M, 1995, EXP CELL RES, V219, P699, DOI 10.1006/excr.1995.1281; WESTENDORP MO, 1995, NATURE, V375, P497, DOI 10.1038/375497a0; WESTENDORP MO, 1995, EMBO J, V14, P546, DOI 10.1002/j.1460-2075.1995.tb07030.x; WHELAN G, 1970, J LAB CLIN MED, V75, P542; Wyllie A H, 1980, Int Rev Cytol, V68, P251; YI JR, 1995, P NATL ACAD SCI USA, V92, P1495, DOI 10.1073/pnas.92.5.1495; YI JR, 1994, J CLIN INVEST, V93, P1841, DOI 10.1172/JCI117170; ZAMAN GJR, 1995, P NATL ACAD SCI USA, V92, P7690, DOI 10.1073/pnas.92.17.7690	55	304	306	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15420	15427		10.1074/jbc.271.26.15420	http://dx.doi.org/10.1074/jbc.271.26.15420			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662848	hybrid			2022-12-27	WOS:A1996UV29900021
J	Balbin, M; LopezOtin, C				Balbin, M; LopezOtin, C			Hormonal regulation of the human pepsinogen C gene in breast cancer cells - Identification of a cis-acting element mediating its induction by androgens, glucocorticoids, and progesterone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROSS CYSTIC-DISEASE; HUMAN RENIN GENE; TRANSCRIPTIONAL REGULATION; PLASMINOGEN-ACTIVATOR; STEROID-HORMONES; APOLIPOPROTEIN-D; INHIBITOR PAI-1; FLUID PROTEINS; RECEPTOR; EXPRESSION	Pepsinogen C is an aspartic proteinase mainly involved in the digestion of proteins in the stomach, which is also synthesized by certain human breast tumors. To examine the possibility that extragastric production of this proteolytic enzyme could be mediated by hormonal factors, we have analyzed pepsinogen C gene expression in human breast cancer cells subjected to different hormonal treatments. Northern blot analyses revealed the expression of pepsinogen C gene by T-47D breast cancer cells after induction with dihydrotestosterone, dexamethasone, and progesterone but not with estradiol, retinoic acid, or ethanol. Reverse transcription-polymerase chain reaction analysis in a series of breast cancer cell lines confirmed the amplification of pepsinogen C mRNA after induction with dihydrotestosterone, in those cells expressing the androgen receptor mRNA. The promoter region of the pepsinogen C gene was functionally characterized by transient expression of a vector containing the promoter region cloned in front of the chloramphenicol acetyltransferase (CAT) reporter gene. CAT activity in T 47D cells was stimulated in the presence of dihydrotestosterone, dexamethasone, and progesterone but not by estradiol. By further deletion mapping of the pepsinogen C promoter, a minimal region (AGAACTattTGTTCC) was identified as being responsible for glucocorticoid, androgen-, and progesterone-regulated gene expression.	UNIV OVIEDO, FAC MED, DEPT BIOL FUNC, E-33006 OVIEDO, SPAIN	University of Oviedo			Balbín, Milagros/I-4206-2015; López-Otín, Carlos/AAB-2106-2020	Balbín, Milagros/0000-0001-5325-0407; López-Otín, Carlos/0000-0001-6964-1904				ALLEGRA JC, 1979, CANCER RES, V39, P1447; AZUMA T, 1992, J BIOL CHEM, V267, P1609; BALBIN M, 1990, BIOCHEM J, V271, P803, DOI 10.1042/bj2710803; BASSET P, 1990, NATURE, V348, P699, DOI 10.1038/348699a0; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BELASZECSI P, 1995, BIOL REPROD, V53, P227, DOI 10.1095/biolreprod53.1.227; BRINKMANN AO, 1989, J STEROID BIOCHEM, V34, P307, DOI 10.1016/0022-4731(89)90098-8; CHAUHAN SS, 1991, CANCER RES, V51, P1478; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DAVIDSON NE, 1989, ONCOGENESIS, V1, P89; DICKSON RB, 1987, ENDOCR REV, V8, P29, DOI 10.1210/edrv-8-1-29; DIEZITZA I, 1993, BRIT J CANCER, V68, P637, DOI 10.1038/bjc.1993.399; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; FABRE S, 1994, J BIOL CHEM, V269, P5857; FOEKENS JA, 1992, CANCER RES, V52, P6101; FOLTMANN B, 1981, ESSAYS BIOCHEM, V17, P52; FREIJE JP, 1991, J BIOL CHEM, V266, P20538; FURIHATA C, 1980, EUR J BIOCHEM, V105, P43, DOI 10.1111/j.1432-1033.1980.tb04472.x; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRONDAHLHANSEN J, 1993, CANCER RES, V53, P2513; HAAGENSEN DE, 1992, BREAST CANCER RES TR, V23, P77, DOI 10.1007/BF01831479; HAYANO T, 1988, J BIOL CHEM, V263, P1382; HOBART PM, 1984, P NATL ACAD SCI-BIOL, V81, P5026, DOI 10.1073/pnas.81.16.5026; ICHINOSE M, 1990, BIOCHEM BIOPH RES CO, V172, P1086, DOI 10.1016/0006-291X(90)91558-A; ISHIHARA T, 1989, J BIOL CHEM, V264, P10193; JANICKE F, 1993, BREAST CANCER RES TR, V24, P195, DOI 10.1007/BF01833260; LOPEZBOADO YS, 1994, BREAST CANCER RES TR, V29, P247, DOI 10.1007/BF00666478; LUBAHN DB, 1989, P NATL ACAD SCI USA, V86, P9534, DOI 10.1073/pnas.86.23.9534; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; LUISI BF, 1991, NATURE, V352, P497, DOI 10.1038/352497a0; MAY FEB, 1988, J BIOL CHEM, V263, P12901; MAZOUJIAN G, 1990, ANN NY ACAD SCI, V586, P188, DOI 10.1111/j.1749-6632.1990.tb17806.x; MIYAZAKI H, 1984, P NATL ACAD SCI-BIOL, V81, P5999, DOI 10.1073/pnas.81.19.5999; MONNE M, 1994, CANCER RES, V54, P6344; MONTEAGUDO C, 1990, AM J PATHOL, V136, P585; MOORE SA, 1995, J MOL BIOL, V247, P466, DOI 10.1006/jmbi.1994.0154; MURTHA P, 1993, BIOCHEMISTRY-US, V32, P6459, DOI 10.1021/bi00076a020; PALS G, 1989, GENOMICS, V4, P137, DOI 10.1016/0888-7543(89)90292-9; POLIMENO L, 1994, DIGEST DIS SCI, V39, P635, DOI 10.1007/BF02088353; REDECKER B, 1991, DNA CELL BIOL, V10, P423, DOI 10.1089/dna.1991.10.423; RIEGMAN PHJ, 1991, MOL ENDOCRINOL, V5, P1921, DOI 10.1210/mend-5-12-1921; ROCHEFORT H, 1987, J CELL BIOCHEM, V35, P17, DOI 10.1002/jcb.240350103; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SAMLOFF IM, 1989, GASTROENTEROLOGY, V96, P586, DOI 10.1016/S0016-5085(89)80054-X; SANCHEZ LM, 1992, J BIOL CHEM, V267, P24725; SANCHEZ LM, 1992, CANCER RES, V52, P95; SANTEN RJ, 1990, ENDOCR REV, V11, P221, DOI 10.1210/edrv-11-2-221; SCHEIDEREIT C, 1986, DNA-J MOLEC CELL BIO, V5, P383, DOI 10.1089/dna.1986.5.383; SCHULE R, 1988, SCIENCE, V242, P1418, DOI 10.1126/science.3201230; SIMARD J, 1992, ENDOCRINOLOGY, V130, P1115, DOI 10.1210/en.130.3.1115; SLOANE BF, 1981, SCIENCE, V212, P1151, DOI 10.1126/science.7233209; SOGAWA K, 1983, J BIOL CHEM, V258, P5306; TAGGART RT, 1989, J BIOL CHEM, V264, P375; TANG J, 1987, J CELL BIOCHEM, V33, P53, DOI 10.1002/jcb.240330106; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; TSAI SY, 1988, CELL, V55, P361, DOI 10.1016/0092-8674(88)90059-1; TSUKADA S, 1994, BIOCHEM BIOPH RES CO, V202, P1, DOI 10.1006/bbrc.1994.1885; VIZOSO F, 1995, J CLIN ONCOL, V13, P54, DOI 10.1200/JCO.1995.13.1.54; WOLF DA, 1992, MOL ENDOCRINOL, V6, P753, DOI 10.1210/me.6.5.753; WU CW, 1994, DIGEST DIS SCI, V39, P2689, DOI 10.1007/BF02087711; YOUNG CYF, 1991, CANCER RES, V51, P3748; YU H, 1994, BREAST CANCER RES TR, V32, P291, DOI 10.1007/BF00666006; ZILLIACUS J, 1995, MOL ENDOCRINOL, V9, P389, DOI 10.1210/me.9.4.389	63	40	40	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15175	15181		10.1074/jbc.271.25.15175	http://dx.doi.org/10.1074/jbc.271.25.15175			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663058	hybrid			2022-12-27	WOS:A1996UT10600078
J	Heding, A; Gill, R; Ogawa, Y; DeMeyts, P; Shymko, RM				Heding, A; Gill, R; Ogawa, Y; DeMeyts, P; Shymko, RM			Biosensor measurement of the binding of insulin-like growth factors I and II and their analogues to the insulin-like growth factor-binding protein-3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSPECIFIC INTERACTION ANALYSIS; HUMAN-SERUM; B-DOMAIN; PURIFICATION; AFFINITY; RECEPTOR; COMPLEX; SUBUNIT; SURFACE; PLASMA	Most insulin-like growth factor (IGF) molecules in the circulation are found in a 150-kDa complex containing IGF-binding protein-3 (IGFBP-3) and an acid-labile subunit, which does not itself bind IGF, Affinities (K-d values) between 0.03 and 0.5 nM have been reported for IGF-I/IGFBP-3 binding, but no kinetic data are available, In this study we measured the high affinity binding of unlabeled IGFs and IGF analogues to recombinant unglycosylated IGFBP-3, using a BIAcore(TM) instrument (Pharmacia Biosensor AB), IGF-I binding showed fast association and slow non-first-order dissociation kinetics, and an equilibrium K-d of 0.23 nM. IGF-II had similar kinetics with slightly higher affinity. Analogues with mutations in the first 3 amino acids of the B-region (des(1-3) IGF-I and long IGF-I) showed 25 and 50 times lower affinity than IGF-I, Replacement of residues 28-37 by Gly-Gly-Gly-Gly or deletion of residues 29-41 in the C-region had little effect on the kinetic parameters, contrasting with the markedly impaired binding of these analogues to the IGF-I receptor, Swapping of the disulfide bridges in IGF-I and the C-region mutants decreased the affinity dramatically for IGFBP-3, primarily by decreasing the association rate. Insulin had approximately 1000 times lower affinity than IGF-I.	HAGEDORN RES LAB,DK-2820 GENTOFTE,DENMARK; UNIV LONDON BIRKBECK COLL,DEPT CRYSTALLOG,LONDON WC1E 7HX,ENGLAND; CELTRIX PHARMACEUT INC,SANTA CLARA,CA 95052	Novo Nordisk; Hagedorn Research Institute; University of London; Birkbeck University London			Gill, Raj/A-5410-2009	De Meyts, Pierre/0000-0001-6214-0824				[Anonymous], 1991, INSULIN LIKE GROWTH; BALLARD FJ, 1987, BIOCHEM BIOPH RES CO, V149, P398, DOI 10.1016/0006-291X(87)90380-9; BAXTER RC, 1989, J BIOL CHEM, V264, P11843; BAXTER RC, 1989, P NATL ACAD SCI USA, V86, P6898, DOI 10.1073/pnas.86.18.6898; BAXTER RC, 1992, J BIOL CHEM, V267, P60; BAYNE ML, 1989, J BIOL CHEM, V264, P11004; BAYNE ML, 1988, J BIOL CHEM, V263, P6233; CASCIERI MA, 1989, MOLECULAR AND CELLULAR BIOLOGY OF INSULIN-LIKE GROWTH FACTORS AND THEIR RECEPTORS, P285; DEVROEDE MA, 1985, P NATL ACAD SCI USA, V82, P3010; ELLIOTT S, 1990, J PROTEIN CHEM, V9, P95, DOI 10.1007/BF01024990; FAGERSTAM LG, 1992, J CHROMATOGR, V597, P397, DOI 10.1016/0021-9673(92)80137-J; FORBES B, 1988, BIOCHEM BIOPH RES CO, V157, P196, DOI 10.1016/S0006-291X(88)80032-9; FURLANETTO RW, 1980, J CLIN ENDOCR METAB, V51, P12, DOI 10.1210/jcem-51-1-12; GULER HP, 1989, ACTA ENDOCRINOL-COP, V121, P753, DOI 10.1530/acta.0.1210753; HEJNAES KR, 1992, PROTEIN ENG, V5, P797, DOI 10.1093/protein/5.8.797; HINTZ RL, 1981, J CLIN ENDOCR METAB, V53, P100, DOI 10.1210/jcem-53-1-100; JOHNSSON B, 1991, ANAL BIOCHEM, V198, P268, DOI 10.1016/0003-2697(91)90424-R; JOSHI S, 1985, BIOCHEMISTRY-US, V24, P4208, DOI 10.1021/bi00336a059; JOSHI S, 1985, BIOCHEM BIOPH RES CO, V133, P423, DOI 10.1016/0006-291X(85)90923-4; KAUFMANN U, 1977, J CLIN ENDOCR METAB, V44, P160, DOI 10.1210/jcem-44-1-160; LEROITH D, 1992, ANN INTERN MED, V116, P854, DOI 10.7326/0003-4819-116-10-854; MARTIN JL, 1986, J BIOL CHEM, V261, P8754; MARTIN JL, 1994, CURR OPIN ENDOCRINOL, V1, P16; MENG H, 1988, J CHROMATOGR, V443, P183, DOI 10.1016/S0021-9673(00)94792-7; MILLER JA, 1993, BIOCHEMISTRY-US, V32, P5203, DOI 10.1021/bi00070a032; PRESS WH, 1986, NUMERICAL RECIPES AR; SOMMER A, 1993, GROWTH REGULAT, V3, P46; SUSSENBACH JS, 1992, GROWTH REGULAT, V2, P1; SZABO L, 1988, BIOCHEM BIOPH RES CO, V151, P207, DOI 10.1016/0006-291X(88)90580-3; TRESSEL TJ, 1991, BIOCHEM BIOPH RES CO, V178, P625, DOI 10.1016/0006-291X(91)90154-Y; WHITE RM, 1981, J CLIN ENDOCR METAB, V53, P49, DOI 10.1210/jcem-53-1-49	31	55	69	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13948	13952		10.1074/jbc.271.24.13948	http://dx.doi.org/10.1074/jbc.271.24.13948			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662901	hybrid			2022-12-27	WOS:A1996UQ66000006
J	Heisler, LM; Feng, GH; Jin, DJ; Gross, CA; Landick, R				Heisler, LM; Feng, GH; Jin, DJ; Gross, CA; Landick, R			Amino acid substitutions in the two largest subunits of Escherichia coli RNA polymerase that suppress a defective rho termination factor affect different parts of the transcription complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-SUBUNIT; RIFAMPICIN-RESISTANT; 3-DIMENSIONAL STRUCTURE; FUNCTIONAL TOPOGRAPHY; REPLICATION CONTROL; CONSERVED REGIONS; TERNARY COMPLEXES; CRYSTAL-STRUCTURE; CHAIN INITIATION; KLENOW FRAGMENT	Among the earliest rpoBC mutations identified are three suppressors of the conditional lethal rho allele, rho201. These three mutations are of particular interest because, unlike rpoB8, they do not increase termination at all rho-dependent and p-independent terminators. rpoB211 and rpoB212 both change Asn-1072 to His in conserved region H of rpoB (beta N1072H), whereas rpoC214 changes Arg-352 to Cys in conserved region C of rpoC (beta'R352C). Both substitutions significantly reduce the overall rate of transcript elongation in vitro relative to wild-type RNA polymerase; however, they probably slow elongation for different reasons. The nucleotide triphosphate concentrations required at the T7 A1 promoter for both abortive trinucleotide synthesis and for promoter escape are much greater for beta N1072H. In contrast, beta'R352C and two adjacent substitutions (beta'G351S and beta'S350F), but not beta N1072H, formed open complexes of greatly reduced stability. The sequence in this region of beta' modestly resembles a region of Escherichia coli DNA polymerase I that contacts the phosphate backbone of DNA in co crystals. Core determinants affecting open complex formation do not reside exclusively in beta', however, since the Rif(r) mutation rpoB2 in beta also dramatically destabilized open complexes. We suggest that the principal defects of the two Rho-suppressing substitutions may differ, perhaps reflecting a greater role of beta region H in nucleoside triphosphate binding and nucleotide addition and of beta' region C in contacts to the DNA strands that could be important for translocation. Although both probably suppress rho201 by slowing RNA chain elongation, these differences may lead to terminator specificity that depends on the rate-limiting step at different sites.	UNIV WISCONSIN, DEPT BACTERIOL, MADISON, WI 53706 USA; WASHINGTON UNIV, DEPT BIOL, ST LOUIS, MO 63130 USA; NCI, MOLEC BIOL LAB, NATL INST HLTH, BETHESDA, MD 20892 USA	University of Wisconsin System; University of Wisconsin Madison; Washington University (WUSTL); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019635] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038660, R37GM038660, R01GM038660] Funding Source: NIH RePORTER; NIAID NIH HHS [AI 19635] Funding Source: Medline; NIGMS NIH HHS [GM 38660] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLISON LA, 1985, CELL, V42, P599, DOI 10.1016/0092-8674(85)90117-5; ARNDT KM, 1988, J MOL BIOL, V202, P271, DOI 10.1016/0022-2836(88)90457-3; BEESE LS, 1993, SCIENCE, V260, P352, DOI 10.1126/science.8469987; BERTRANDBURGGRAF E, 1984, NUCLEIC ACIDS RES, V12, P1697, DOI 10.1093/nar/12.3.1697; BIGGS J, 1985, CELL, V42, P611, DOI 10.1016/0092-8674(85)90118-7; BORUKHOV S, 1991, J BIOL CHEM, V266, P23921; BORUKHOV S, 1993, CELL, V72, P459, DOI 10.1016/0092-8674(93)90121-6; BORUKHOV S, 1991, J BIOL CHEM, V266, P23932; BURGESS RR, 1975, BIOCHEMISTRY-US, V14, P4634, DOI 10.1021/bi00692a011; CAI H, 1987, J BIOL CHEM, V262, P298; CHAMBERLIN MJ, 1979, J BIOL CHEM, V254, P61; CHAMBERLIN MJ, 1995, HARVEY LECT, V88, P1; CHAN CL, 1994, TRANSCRIPTION MECHAN, P297; CHEN CYA, 1987, J BIOL CHEM, V262, P11292; CHENCHIK AA, 1982, MOL BIOL, V16, P34; CLERGET M, 1995, J MOL BIOL, V248, P768, DOI 10.1006/jmbi.1995.0259; DARST SA, 1989, NATURE, V340, P730, DOI 10.1038/340730a0; DARST SA, 1991, CELL, V66, P121, DOI 10.1016/0092-8674(91)90144-N; DAS A, 1978, P NATL ACAD SCI USA, V75, P4828, DOI 10.1073/pnas.75.10.4828; DIECI G, 1995, EMBO J, V14, P3766, DOI 10.1002/j.1460-2075.1995.tb00046.x; DISSINGER S, 1991, J MOL BIOL, V219, P11, DOI 10.1016/0022-2836(91)90853-X; DOMBROSKI AJ, 1992, CELL, V70, P501, DOI 10.1016/0092-8674(92)90174-B; DOWER WJ, 1988, NUCLEIC ACIDS RES, V16, P6127, DOI 10.1093/nar/16.13.6127; ERIE DA, 1992, ANNU REV BIOPH BIOM, V21, P379, DOI 10.1146/annurev.bb.21.060192.002115; FALKENBURG D, 1987, J MOL BIOL, V195, P929, DOI 10.1016/0022-2836(87)90496-7; FENG GH, 1994, J BIOL CHEM, V269, P22282; FISHER RF, 1983, J BIOL CHEM, V258, P8146; GRACHEV MA, 1987, EUR J BIOCHEM, V163, P113, DOI 10.1111/j.1432-1033.1987.tb10743.x; GRACHEV MA, 1989, EUR J BIOCHEM, V180, P577, DOI 10.1111/j.1432-1033.1989.tb14684.x; GRAGEROV AI, 1980, MOL GEN GENET, V180, P399, DOI 10.1007/BF00425854; GROSS C, 1976, J BACTERIOL, V128, P382, DOI 10.1128/JB.128.1.382-389.1976; GUARENTE L, 1979, J MOL BIOL, V129, P295, DOI 10.1016/0022-2836(79)90283-3; GUARENTE LP, 1978, P NATL ACAD SCI USA, V75, P294, DOI 10.1073/pnas.75.1.294; HAGER DA, 1990, BIOCHEMISTRY-US, V29, P7890, DOI 10.1021/bi00486a016; HANNA MM, 1983, P NATL ACAD SCI-BIOL, V80, P4238, DOI 10.1073/pnas.80.14.4238; HEISLER LM, 1993, J BIOL CHEM, V268, P25369; HINKLE DC, 1972, J MOL BIOL, V70, P157, DOI 10.1016/0022-2836(72)90531-1; HINKLE DC, 1972, J MOL BIOL, V70, P209, DOI 10.1016/0022-2836(72)90534-7; HUDSON G, 1988, J MOL BIOL, V200, P45; ITO K, 1993, MOL MICROBIOL, V9, P285, DOI 10.1111/j.1365-2958.1993.tb01690.x; ITO K, 1991, J BACTERIOL, V173, P1492, DOI 10.1128/jb.173.4.1492-1501.1991; JIN DJ, 1988, J MOL BIOL, V202, P245, DOI 10.1016/0022-2836(88)90455-X; JIN DJ, 1991, J BIOL CHEM, V266, P14478; JIN DJ, 1992, P NATL ACAD SCI USA, V89, P1453, DOI 10.1073/pnas.89.4.1453; JIN DJ, 1988, J MOL BIOL, V202, P45, DOI 10.1016/0022-2836(88)90517-7; JIN DJ, 1994, J MOL BIOL, V236, P72, DOI 10.1006/jmbi.1994.1119; KASHLEV M, 1990, SCIENCE, V248, P1006, DOI 10.1126/science.1693014; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KRUMMEL B, 1989, BIOCHEMISTRY-US, V28, P7829, DOI 10.1021/bi00445a045; KRUMMEL B, 1990, THESIS U CALIFORNIA; Kubori T, 1996, J MOL BIOL, V256, P449, DOI 10.1006/jmbi.1996.0100; LANDICK R, 1990, GENE DEV, V4, P1623, DOI 10.1101/gad.4.9.1623; LARIONOV OA, 1990, MOL GEN GENET, V176, P105; LEE DN, 1992, J MOL BIOL, V228, P759, DOI 10.1016/0022-2836(92)90862-E; LEE DN, 1994, J BIOL CHEM, V269, P22293; LEE JY, 1991, P NATL ACAD SCI USA, V88, P6018, DOI 10.1073/pnas.88.14.6018; LEFFERS H, 1989, J MOL BIOL, V206, P1, DOI 10.1016/0022-2836(89)90519-6; LEVIN JR, 1987, J MOL BIOL, V196, P85, DOI 10.1016/0022-2836(87)90512-2; LISITSYN NA, 1984, MOL GEN GENET, V196, P173, DOI 10.1007/BF00334112; LOWE PA, 1979, BIOCHEMISTRY-US, V18, P1344, DOI 10.1021/bi00574a034; MANDEL M, 1970, J MOL BIOL, V53, P159, DOI 10.1016/0022-2836(70)90051-3; MARTIN E, 1992, J BIOL CHEM, V267, P20175; MCCLURE WR, 1978, J BIOL CHEM, V253, P8941; Miller J.H., 1992, SHORT COURSE BACTERI, P150; MUSTAEV A, 1991, J BIOL CHEM, V266, P23927; MUSTAEV A, 1993, J BIOL CHEM, V268, P19185; NOMURA T, 1984, MOL GEN GENET, V193, P8, DOI 10.1007/BF00327407; NUDLER E, 1994, SCIENCE, V265, P793, DOI 10.1126/science.8047884; OKADA M, 1978, NUCLEIC ACIDS RES, V5, P1845, DOI 10.1093/nar/5.6.1845; OLLIS DL, 1985, NATURE, V313, P762, DOI 10.1038/313762a0; PANNY SR, 1974, FEBS LETT, V48, P241, DOI 10.1016/0014-5793(74)80477-1; PATEL DD, 1989, J VIROL, V63, P1076, DOI 10.1128/JVI.63.3.1076-1086.1989; PELLETIER H, 1994, SCIENCE, V264, P1891, DOI 10.1126/science.7516580; PETERSEN SK, 1991, J BACTERIOL, V173, P5200, DOI 10.1128/jb.173.16.5200-5206.1991; PFEFFER SR, 1977, J BIOL CHEM, V252, P5403; PLATT T, 1994, MOL MICROBIOL, V11, P983, DOI 10.1111/j.1365-2958.1994.tb00376.x; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; POLYAKOV A, 1995, CELL, V83, P365, DOI 10.1016/0092-8674(95)90114-0; RASMUSSEN KV, 1983, J BACTERIOL, V154, P443, DOI 10.1128/JB.154.1.443-451.1983; RIVA M, 1990, J BIOL CHEM, V265, P16498; ROBLEDO R, 1991, J MOL BIOL, V220, P613, DOI 10.1016/0022-2836(91)90104-E; SAGITOV V, 1993, J BIOL CHEM, V268, P2195; Sanbrook J., 1989, MOL CLONING LAB MANU; SEVERINOV K, 1993, J BIOL CHEM, V268, P14820; SEVERINOV K, 1995, P NATL ACAD SCI USA, V92, P4591, DOI 10.1073/pnas.92.10.4591; SEVERINOV K, 1995, J BIOL CHEM, V270, P23926, DOI 10.1074/jbc.270.41.23926; Siegel I, 1975, ENZYME KINETICS; SMAGOWICZ WJ, 1978, NUCLEIC ACIDS RES, V5, P1919, DOI 10.1093/nar/5.6.1919; SOUSA R, 1993, NATURE, V364, P593, DOI 10.1038/364593a0; STEITZ TA, 1994, SCIENCE, V266, P2022, DOI 10.1126/science.7528445; STUDIER FW, 1975, J MOL BIOL, V94, P283, DOI 10.1016/0022-2836(75)90083-2; TANAKA M, 1983, MOL GEN GENET, V192, P51, DOI 10.1007/BF00327646; TAVORMINA PL, 1996, IN PRESS J BACTERIOL; THOMPSON NE, 1992, BIOCHEMISTRY-US, V31, P7003, DOI 10.1021/bi00145a019; WANG DG, 1995, CELL, V81, P341, DOI 10.1016/0092-8674(95)90387-9; WEILBAECHER R, 1994, GENE DEV, V8, P2913, DOI 10.1101/gad.8.23.2913; YANOFSKY C, 1981, J BACTERIOL, V145, P1334, DOI 10.1128/JB.145.3.1334-1341.1981; ZAYCHIKOV E, 1995, P NATL ACAD SCI USA, V92, P1739, DOI 10.1073/pnas.92.5.1739; ZILLIG W, 1970, COLD SPRING HARB SYM, V35, P47, DOI 10.1101/SQB.1970.035.01.010	99	19	19	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14572	14583		10.1074/jbc.271.24.14572	http://dx.doi.org/10.1074/jbc.271.24.14572			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662850	hybrid			2022-12-27	WOS:A1996UQ66000094
J	Hidari, KIPJ; Ichikawa, S; Fujita, T; Sakiyama, H; Hirabayashi, Y				Hidari, KIPJ; Ichikawa, S; Fujita, T; Sakiyama, H; Hirabayashi, Y			Complete removal of sphingolipids from the plasma membrane disrupts cell to substratum adhesion of mouse melanoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BALB/C 3T3 CELLS; MONOCLONAL-ANTIBODY; GANGLIOSIDE; MUTANT; MATRIX; GM3; GLYCOSPHINGOLIPIDS; BIOSYNTHESIS; FIBRONECTIN; EXPRESSION	GM-95, a mutant cell line derived from mouse melanoma MEB-4 cells, is deficient in glycosphingolipids (GSLs) due to the lack of ceramide glucosyltransferase-1 activity (Ichikawa, S., Nakajo, N., Sakiyama, H., and Hirabayashi, Y. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 2703-2707). In this study, we examined the involvement of the complex sphingolipids in cell to substratum adhesion. Immunofluorescent and chemical analyses revealed that the complex sphingolipids were significantly concentrated in the detergent-insoluble substrate attachment matrix of both GM-95 and MEB-4 cells. In spite of the absence of GSLs, GM-95 cells retained the ability to adhere to extracellular matrix (ECM) proteins such as fibronectin, collagen, and laminin. When both GM-95 and MEB-4 cells were treated with neutral sphingomyelinase, GM-95 cells were rounded up and detached from all ECM proteins examined. In contrast, neither the morphology nor the adherence of MEB-4 cells was altered. Under this treatment, sphingomyelin (SM) became undetectable in both cells. A similar inhibition was observed upon pretreatment of cells with fumonisin B1 or ISP-1, both of which block the synthesis of ceramide, a common precursor of both GSLs and SM. Stable transfectants expressing GSLs, which were established by transfection of glucosyltransferase-1 cDNA into GM-95 cells, became resistant to neutral sphingomyelinase-mediated rounding up and detachment from ECM proteins. In conclusion, the complex sphingolipids play critical roles in cell to substratum adhesion, and the presence of either GSLs or SM is sufficient for the adhesion.	RIKEN,INST PHYS & CHEM RES,LB CELLULAR GLYCOBIOL,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; SETSUNAN UNIV,FAC PHARMACEUT SCI,HIRAKATA,OSAKA 57301,JAPAN; NATL INST RADIOL SCI,DIV PHYSIOL & PATHOL,CHIBA 260,JAPAN	RIKEN; Setsunan University; National Institutes for Quantum Science & Technology				Hirabayashi, Yoshio/0000-0002-5774-7354				BARLETTA E, 1993, BIOCHEM BIOPH RES CO, V192, P214, DOI 10.1006/bbrc.1993.1402; CHERESH DA, 1984, P NATL ACAD SCI-BIOL, V81, P5767, DOI 10.1073/pnas.81.18.5767; CHERESH DA, 1987, J CELL BIOL, V105, P1163, DOI 10.1083/jcb.105.3.1163; CONFORTI G, 1990, J BIOL CHEM, V265, P4011; FEIZI T, 1985, NATURE, V314, P53, DOI 10.1038/314053a0; GRIFFITHS SL, 1986, J CELL BIOL, V102, P469, DOI 10.1083/jcb.102.2.469; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HANADA K, 1990, J BIOL CHEM, V265, P22137; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANNUN YA, 1994, J BIOL CHEM, V269, P315; HIRABAYASHI Y, 1985, J BIOL CHEM, V260, P3328; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; ICHIKAWA S, 1994, P NATL ACAD SCI USA, V91, P2703, DOI 10.1073/pnas.91.7.2703; ICHIKAWA S, 1996, IN PRESS P NAT AC SC; INGBER DE, 1989, CELL, V58, P803, DOI 10.1016/0092-8674(89)90928-8; Ingber D, 1991, CURR OPIN CELL BIOL, V3, P841, DOI 10.1016/0955-0674(91)90058-7; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; MARGGRAF WD, 1984, BIOCHIM BIOPHYS ACTA, V793, P346, DOI 10.1016/0005-2760(84)90248-0; MIYAKE Y, 1995, BIOCHEM BIOPH RES CO, V211, P396, DOI 10.1006/bbrc.1995.1827; MUGNAI G, 1984, BIOCHEM BIOPH RES CO, V125, P142, DOI 10.1016/S0006-291X(84)80346-0; NOZUE M, 1988, INT J CANCER, V42, P734, DOI 10.1002/ijc.2910420518; OKADA Y, 1984, EXP CELL RES, V155, P448, DOI 10.1016/0014-4827(84)90205-2; SAKIYAMA H, 1987, CELL STRUCT FUNCT, V12, P93, DOI 10.1247/csf.12.93; SCHROEDER JJ, 1994, J BIOL CHEM, V269, P3475; SEUFFERLEIN T, 1994, J BIOL CHEM, V269, P27610; SOUTHERN P J, 1982, Journal of Molecular and Applied Genetics, V1, P327; SYMINGTON BE, 1993, J CELL BIOL, V120, P523, DOI 10.1083/jcb.120.2.523; TSURUOKA T, 1993, J BIOL CHEM, V268, P2211; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; YAMADA KM, 1983, EXP CELL RES, V143, P295, DOI 10.1016/0014-4827(83)90054-X; ZHENG MZ, 1992, BIOCHEM BIOPH RES CO, V186, P1397, DOI 10.1016/S0006-291X(05)81561-X; ZHENG MZ, 1993, J BIOL CHEM, V268, P2217	33	54	54	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14636	14641		10.1074/jbc.271.24.14636	http://dx.doi.org/10.1074/jbc.271.24.14636			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662871	hybrid			2022-12-27	WOS:A1996UQ66000103
J	Jones, SL; Brown, EJ				Jones, SL; Brown, EJ			Fc gamma RII-mediated adhesion and phagocytosis induce L-plastin phosphorylation in human neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							65-KILODALTON PHOSPHOPROTEIN; MONOCLONAL-ANTIBODIES; SIGNAL TRANSDUCTION; IMMUNE-COMPLEXES; ACTIN; CALCIUM; ACTIVATION; RECEPTOR; FIMBRIN; PROTEIN	L-Plastin is a calcium-regulated actin bundling protein expressed in leukocytes and some transformed cells, which is phosphorylated on serine in response to several different leukocyte-activating stimuli. Adhesion to immune complexes induced L-plastin phosphorylation in neutrophils, as did phagocytosis of IgG-opsonized particles, but insoluble immune complexes in suspension were very inefficient activators of L-plastin phosphorylation. Neutrophils express two IgG Fc receptors, the transmembrane Fc gamma RII and the glycan phosphoinositol-linked Fc gamma RIIIB. Use of monoclonal antibodies that distinguished the two Fc receptors demonstrated that Fc gamma RII ligation was 100-fold more potent at signaling L-plastin phosphorylation than occupancy of Fc gamma RIIIB, Depletion of intracellular calcium did not affect Fc gamma RII-activated L-plastin phosphorylation, demonstrating that any potential regulation of plastin function by calcium did not affect its phosphorylation, Adhesion to immune complexes caused L-plastin to localize to podosomes, since it colocalized with actin to discrete, punctate Triton X-100-insoluble sites on the adherent neutrophil surface in a pattern indistinguishable from vinculin and alpha-actinin, Nonetheless, localization to podosomes was not required for L-plastin phosphorylation, since both neutrophils from a patient with leukocyte adhesion deficiency (CD18 deficiency) and neutrophils treated with anti-CD18 F(ab')a, which do not form podosomes upon adhesion to immune complexes, phosphorylated L-plastin normally, Indeed, L-plastin was normally phosphorylated in response to adhesion to immune complexes even when the actin cytoskeleton was disrupted with cytochalasin D. We conclude that efficient Fc gamma RII-mediated phosphorylation of L-plastin requires cell adhesion but does not require IgG-induced rearrangements of the actin cytoskeleton. These data suggest a model in which plastin phosphorylation and localization to the actin cytoskeleton can act as two distinct mechanisms regulating L-plastin functions in neutrophils adherent to immune complexes.	WASHINGTON UNIV,SCH MED,DIV INFECT DIS,ST LOUIS,MO 63110	Washington University (WUSTL)				jones, samuel/0000-0003-3040-8157	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI035811, K11AI001275] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI35811, K11-AI01275] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ADAMS AEM, 1991, NATURE, V354, P404, DOI 10.1038/354404a0; ADAMS AEM, 1995, MOL CELL BIOL, V15, P69, DOI 10.1128/MCB.15.1.69; BARNSTABLE CJ, 1978, CELL, V14, P9, DOI 10.1016/0092-8674(78)90296-9; BLACKBURN WD, 1989, BIOCHEM BIOPH RES CO, V164, P983, DOI 10.1016/0006-291X(89)91766-X; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BRENNAN PJ, 1991, J IMMUNOL, V146, P4282; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; CROCKETTTORABI E, 1990, J IMMUNOL, V145, P3026; DAVIDPFEUTY T, 1980, P NATL ACAD SCI-BIOL, V77, P6687, DOI 10.1073/pnas.77.11.6687; DEARRUDA MV, 1990, J CELL BIOL, V111, P1069, DOI 10.1083/jcb.111.3.1069; EGGLETON P, 1991, BIOCHEM SOC T, V19, P1129, DOI 10.1042/bst0191129; FLEIT HB, 1982, P NATL ACAD SCI-BIOL, V79, P3275, DOI 10.1073/pnas.79.10.3275; GAIDANO G, 1990, LEUKEMIA, V4, P682; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; Greenberg Steven, 1993, P941; GRESHAM HD, 1987, J IMMUNOL, V139, P4159; GRIFFIN FM, 1975, J EXP MED, V142, P1263, DOI 10.1084/jem.142.5.1263; JOHANSSON MW, 1994, J CELL BIOL, V126, P1299, DOI 10.1083/jcb.126.5.1299; KORCHAK HM, 1988, J BIOL CHEM, V263, P11098; KUBLER E, 1993, EMBO J, V12, P2855, DOI 10.1002/j.1460-2075.1993.tb05947.x; LIN CS, 1994, MOL CELL BIOL, V14, P2457, DOI 10.1128/MCB.14.4.2457; LIN CS, 1993, J BIOL CHEM, V268, P2781; LOONEY RJ, 1986, J EXP MED, V163, P826, DOI 10.1084/jem.163.4.826; MATSUSHIMA K, 1987, J IMMUNOL, V139, P3367; MATSUSHIMA K, 1988, BIOCHEMISTRY-US, V27, P3765, DOI 10.1021/bi00410a037; MESSIER JM, 1993, CELL MOTIL CYTOSKEL, V25, P223, DOI 10.1002/cm.970250303; NAMBA Y, 1992, J BIOCHEM-TOKYO, V112, P503, DOI 10.1093/oxfordjournals.jbchem.a123929; OMANN GM, 1987, PHYSIOL REV, V67, P285, DOI 10.1152/physrev.1987.67.1.285; PACAUD M, 1993, BIOCHEMISTRY-US, V32, P3448, DOI 10.1021/bi00064a031; ROMER LH, 1992, COLD SPRING HARB SYM, V57, P193, DOI 10.1101/SQB.1992.057.01.024; ROSALES C, 1992, J BIOL CHEM, V267, P1443; ROSALES C, 1994, P NATL ACAD SCI USA, V91, P3534, DOI 10.1073/pnas.91.9.3534; ROSALES C, 1992, J BIOL CHEM, V267, P5265; SHIBATA M, 1993, J LEUKOCYTE BIOL, V54, P1; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SIGMOND S, 1972, EXP CELL RES, V73, P383; SOUTHWICK FS, 1989, BLOOD, V73, P1973; WRIGHT SD, 1983, P NATL ACAD SCI-BIOL, V80, P5699, DOI 10.1073/pnas.80.18.5699; ZHOU MJ, 1995, J BIOL CHEM, V270, P13553, DOI 10.1074/jbc.270.22.13553; ZHOU MJ, 1994, J CELL BIOL, V125, P1407, DOI 10.1083/jcb.125.6.1407; ZU Y, 1990, BIOCHEMISTRY-US, V29, P1055, DOI 10.1021/bi00456a030	43	55	56	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14623	14630		10.1074/jbc.271.24.14623	http://dx.doi.org/10.1074/jbc.271.24.14623			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663066	hybrid			2022-12-27	WOS:A1996UQ66000101
J	Lewin, TM; Webster, RE				Lewin, TM; Webster, RE			Membrane insertion characteristics of the various transmembrane domains of the Escherichia coli TolQ protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							M13 COAT PROTEIN; PERIPLASMIC PROTEINS; PLASMA-MEMBRANE; SECA-PROTEIN; GENES; TOPOLOGY; EXPORT; TRANSLOCATION; LOCALIZATION; EXPRESSION	The Escherichia coli TolQ protein is a 230-amino acid integral cytoplasmic membrane protein required for the import of group A colicins, for infection by the filamentous phage, and for maintenance of the integrity of the bacterial envelope, TolQ is a polytopic protein with three membrane-spanning regions, The first membrane-spanning region has a 19-residue periplasmic NH2-terminal tail, while the second and third membrane-spanning segments are separated by a short 17-amino acid periplasmic loop. To study the membrane assembly of TolQ, fusions of different membrane-spanning regions were examined for their ability to insert in the absence of functional SecA or the membrane potential, Fusions containing the first membrane-spanning region plus the adjacent cytoplasmic domain and a construct containing the ''hairpin loop,'' formed by the second and third membrane-spanning regions, insert in the absence of functional SecA. The fusion containing the second and third membrane-spanning regions required the membrane potential for insertion while the first membrane-spanning region was able to insert even in the absence of a membrane potential, Taken together, these results suggest that insertion of intact TolQ is not dependent on the Sec system, but does require the membrane potential.	DUKE UNIV,MED CTR,DEPT BIOCHEM,DURHAM,NC 27710	Duke University					NIGMS NIH HHS [GM07184] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007184] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CAO GQ, 1994, J BIOL CHEM, V269, P26898; CAO GQ, 1994, EMBO J, V13, P4662, DOI 10.1002/j.1460-2075.1994.tb06789.x; DATE T, 1980, P NATL ACAD SCI-BIOL, V77, P4669, DOI 10.1073/pnas.77.8.4669; ENGELMAN DM, 1981, CELL, V23, P411, DOI 10.1016/0092-8674(81)90136-7; FOGNINILEFEBVRE N, 1987, MOL GEN GENET, V209, P391, DOI 10.1007/BF00329670; GEBERT JF, 1988, J BIOL CHEM, V263, P16652; GUYCAFFEY JK, 1992, J BACTERIOL, V174, P2460, DOI 10.1128/jb.174.8.2460-2465.1992; HORABIN JI, 1988, J BIOL CHEM, V263, P11575; HORABIN JI, 1986, J MOL BIOL, V188, P403, DOI 10.1016/0022-2836(86)90164-6; ITO K, 1991, MOL MICROBIOL, V5, P2243, DOI 10.1111/j.1365-2958.1991.tb02154.x; KAMPFENKEL K, 1993, J BACTERIOL, V175, P4485, DOI 10.1128/JB.175.14.4485-4491.1993; LAZZARONI JC, 1989, MOL GEN GENET, V218, P460, DOI 10.1007/BF00332410; LEVENGOOD SK, 1989, J BACTERIOL, V171, P6600, DOI 10.1128/jb.171.12.6600-6609.1989; MULLER MM, 1993, J BACTERIOL, V175, P6059, DOI 10.1128/JB.175.18.6059-6061.1993; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; OLIVER DB, 1990, P NATL ACAD SCI USA, V87, P8227, DOI 10.1073/pnas.87.21.8227; ROHRER J, 1990, SCIENCE, V250, P1418, DOI 10.1126/science.2124001; SAIER MH, 1989, MICROBIOL REV, V53, P333, DOI 10.1128/MMBR.53.3.333-366.1989; SCHATZ PJ, 1990, ANNU REV GENET, V24, P215, DOI 10.1146/annurev.ge.24.120190.001243; SCHMIDT MG, 1989, J BACTERIOL, V171, P643, DOI 10.1128/jb.171.2.643-649.1989; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; SUN TP, 1987, J BACTERIOL, V169, P2667, DOI 10.1128/jb.169.6.2667-2674.1987; SWIDERSKY UE, 1992, EUR J BIOCHEM, V207, P803, DOI 10.1111/j.1432-1033.1992.tb17111.x; VIANNEY A, 1994, J BACTERIOL, V176, P822, DOI 10.1128/jb.176.3.822-829.1994; VONHEIJNE G, 1994, FEBS LETT, V346, P69, DOI 10.1016/0014-5793(94)00296-7; WEBSTER RE, 1991, MOL MICROBIOL, V5, P1005, DOI 10.1111/j.1365-2958.1991.tb01873.x; WERNER PK, 1992, J BIOL CHEM, V267, P24523; WHITLEY P, 1994, EMBO J, V13, P4653, DOI 10.1002/j.1460-2075.1994.tb06788.x; WICKNER W, 1991, ANNU REV BIOCHEM, V60, P101, DOI 10.1146/annurev.bi.60.070191.000533; WOLFE PB, 1985, J BIOL CHEM, V260, P1836; YAMATO I, 1992, J BIOCHEM-TOKYO, V111, P444, DOI 10.1093/oxfordjournals.jbchem.a123777; ZIMMERMANN R, 1982, J BIOL CHEM, V257, P6529	34	6	6	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14143	14149		10.1074/jbc.271.24.14143	http://dx.doi.org/10.1074/jbc.271.24.14143			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662905	hybrid			2022-12-27	WOS:A1996UQ66000033
J	Matsuda, M; Ota, S; Tanimura, R; Nakamura, H; Matuoka, K; Takenawa, T; Nagashima, K; Kurata, T				Matsuda, M; Ota, S; Tanimura, R; Nakamura, H; Matuoka, K; Takenawa, T; Nagashima, K; Kurata, T			Interaction between the amino-terminal SH3 domain of CRK and its natural target proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY BINDING; PHOSPHOLIPASE-C; SIMILARITY; RECEPTOR; REGION; SRC	CRK is a human homolog of chichen v-Crk, which is an adaptor protein. The SH2 domain of CRK binds to several tyrosine-phosphorylated proteins, including the epidermal growth factor receptor, p130(Cas), She, and paxillin. The SH3 domain, in turn, binds to cytosolic proteins of 135-145, 160, 180, and 220 kDa. We screened expression libraries by Far Western blotting, using CRK SH3 as a probe, and identified partial cDNA sequences of four distinct proteins, including C3G, DOCK180, EPS15, and clone ST12. The consensus sequence of the CRK SH3 binding sites as deduced from their amino acid sequences was Pro(+3)-Pro(+2)-X(+1)-Leu(0)-Pro(-1)-X(-2)-Lys(-3). The interaction of the CRK SH3 domain with the DOCK180 peptide was examined with an optical biosensor, based on the principles of surface plasmon resonance. A low dissociation constant of the order of 10(-7) resulted from a high association rate constant (k(assoc) = 3 x 10(4)) and low dissociation rate constant (k(assoc) = 3 x 10(-3)). All CRK-binding proteins except clone ST12 also bound to another adaptor protein, Grb2. Mutational analysis revealed that glycine at position +1 of ST12 inhibited the binding to Grb2 while retaining the high affinity binding to CRK SH3. The result suggests that the amino acid at position +1 also contributes to the high affinity binding of the peptides to the SH3 domain of Grb2, but not to that of CRK.	HOKKAIDO UNIV,SCH MED,DEPT PATHOL,KITA KU,SAPPORO,HOKKAIDO 060,JAPAN; PROT ENGN RES INST,SUITA,OSAKA 565,JAPAN; TOKYO METROPOLITAN INST GERONTOL,DEPT BIOSIGNAL RES,ITABASHI KU,TOKYO 173,JAPAN; UNIV TOKYO,INST MED SCI,MINATO KU,TOKYO 108,JAPAN	Hokkaido University; Tokyo Metropolitan Institute of Gerontology; University of Tokyo	Matsuda, M (corresponding author), NATL INST HLTH,DEPT PATHOL,SHINJUKU KU,1-23-1 TOYAMA,TOKYO 162,JAPAN.		Tanimura, Ryuji/GOH-0166-2022; Nakamura, Haruki/O-4028-2014	Tanimura, Ryuji/0000-0002-7865-5686; Matsuda, Michiyuki/0000-0002-5876-9969				BIRGE RB, 1992, J BIOL CHEM, V267, P10588; CHEADLE C, 1994, J BIOL CHEM, V269, P24034; CICCHETTI P, 1992, NATURE, V257, P803; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; FAZIOLI F, 1993, MOL CELL BIOL, V13, P5814, DOI 10.1128/MCB.13.9.5814; FELDER S, 1993, MOL CELL BIOL, V13, P1449, DOI 10.1128/MCB.13.3.1449; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; FELLER SM, 1995, ONCOGENE, V10, P1465; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; GOUT I, 1993, CELL, V75, P25, DOI 10.1016/0092-8674(93)90676-H; Harlow E., 1988, ANTIBODIES LAB MANUA, P27; Hasegawa H, 1996, MOL CELL BIOL, V16, P1770; HEMPSTEAD BL, 1994, MOL CELL BIOL, V14, P1964, DOI 10.1128/MCB.14.3.1964; Ishino Masaho, 1994, Tumor Research, V29, P59; KARLSSON R, 1991, J IMMUNOL METHODS, V145, P229, DOI 10.1016/0022-1759(91)90331-9; KNUDSEN BS, 1995, EMBO J, V14, P2191, DOI 10.1002/j.1460-2075.1995.tb07213.x; KNUDSEN BS, 1994, J BIOL CHEM, V269, P32781; KOHDA D, 1994, STRUCTURE, V2, P1029, DOI 10.1016/S0969-2126(94)00106-5; KURIYAN J, 1993, CURR OPIN STRUC BIOL, V3, P828, DOI 10.1016/0959-440X(93)90145-B; LIM WA, 1994, NATURE, V372, P375, DOI 10.1038/372375a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MAIGNAN S, 1995, SCIENCE, V268, P291, DOI 10.1126/science.7716522; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MATSUDA M, 1994, MOL CELL BIOL, V14, P5495, DOI 10.1128/MCB.14.8.5495; MATSUDA M, 1992, MOL CELL BIOL, V12, P3482, DOI 10.1128/MCB.12.8.3482; MATUOKA K, 1992, P NATL ACAD SCI USA, V89, P9015, DOI 10.1073/pnas.89.19.9015; MAYER BJ, 1988, NATURE, V332, P272, DOI 10.1038/332272a0; Mayer Bruce J., 1993, Trends in Cell Biology, V3, P8, DOI 10.1016/0962-8924(93)90194-6; MIKI H, 1994, J BIOL CHEM, V269, P5489; MUSACCHIO A, 1994, PROG BIOPHYS MOL BIO, V61, P283, DOI 10.1016/0079-6107(94)90003-5; MUSACCHIO A, 1994, NAT STRUCT BIOL, V1, P546, DOI 10.1038/nsb0894-546; NATSUME T, 1994, J BIOL CHEM, V269, P31224; OGAWA S, 1994, ONCOGENE, V9, P1669; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; REICHMAN CT, 1992, CELL GROWTH DIFFER, V3, P451; REN RB, 1994, GENE DEV, V8, P783, DOI 10.1101/gad.8.7.783; REN RB, 1993, SCIENCE, V259, P1157, DOI 10.1126/science.8438166; Ribon V, 1996, MOL CELL BIOL, V16, P45; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SARASTE M, 1994, NAT STRUCT BIOL, V1, P835, DOI 10.1038/nsb1294-835; SASTRY L, 1995, ONCOGENE, V11, P1107; SCHUMACHER C, 1995, J BIOL CHEM, V270, P15341, DOI 10.1074/jbc.270.25.15341; SPARKS AB, 1994, J BIOL CHEM, V269, P23853; STAHL ML, 1988, NATURE, V332, P269, DOI 10.1038/332269a0; TANAKA S, 1993, MOL CELL BIOL, V13, P4409, DOI 10.1128/MCB.13.7.4409; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; TERASAWA H, 1994, NAT STRUCT BIOL, V1, P891, DOI 10.1038/nsb1294-891; VIGUERA AR, 1994, BIOCHEMISTRY-US, V33, P10925, DOI 10.1021/bi00202a011; WU XD, 1995, STRUCTURE, V3, P215, DOI 10.1016/S0969-2126(01)00151-4; YU HT, 1994, NAT STRUCT BIOL, V1, P417, DOI 10.1038/nsb0794-417; YU HT, 1994, CELL, V76, P933, DOI 10.1016/0092-8674(94)90367-0	52	68	75	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14468	14472		10.1074/jbc.271.24.14468	http://dx.doi.org/10.1074/jbc.271.24.14468			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662907	hybrid			2022-12-27	WOS:A1996UQ66000078
J	Lucas, M; Mazzone, T				Lucas, M; Mazzone, T			Cell surface proteoglycans modulate net synthesis and secretion of macrophage apolipoprotein E	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE; CULTURED-CELLS; APOPROTEIN-E; DIFFERENTIATION; INHIBITION; EXPRESS; BINDING; GROWTH	Using a macrophage cell line that constitutively expresses a human apoliprotein E (apoE) cDNA, we have investigated the post-translational metabolism of endogenously produced apoE. Inhibition of lysosomal or cysteine proteases led to significant inhibition of apoE degradation but did not increase apoE secretion, indicating that cellular degradation is not limiting for apoE secretion in macrophages. Treatment of macrophages with inhibitors of proteoglycan synthesis (4-methylum-belliferyl-beta-D-xyloside) or sulfation (sodium chlorate) enhanced the release of apoE from cells and significantly attenuated the increase in secretion produced by incubation with phosphatidylcholine vesicles (PV). These observations suggested that a significant fraction of the apoE retained by cells (and released by incubation with PV) was associated with proteoglycans. Treatment of cells with exogenous heparinase led to a greater than 4-fold increase in apoE secretion and similarly attenuated the response to PV, suggesting that apoE was trapped in an extracellular proteoglycan matrix. This conclusion was confirmed in studies showing that PV could enhance the release of apoE from cells during an incubation at 4 degrees C, but this enhanced release was abolished in proteoglycan-depleted cells. Incubation with lactoferrin at 4 or 37 degrees C produced the existence of a cell surface pool of apoE. Pulse-chase studies showed that the apoE trapped in the proteoglycan matrix was susceptible to rapid cellular degradation such that net synthesis of apoE (secreted plus cell-associated) was increased significantly in proteoglycan-depleted cells compared with control cells as early as 45 min during a chase period.	RUSH MED COLL, DEPT MED, CHICAGO, IL 60612 USA; RUSH MED COLL, DEPT BIOCHEM, CHICAGO, IL 60612 USA	Rush University; Rush University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039653] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 39653] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BATZRI S, 1973, BIOCHIM BIOPHYS ACTA, V298, P1015, DOI 10.1016/0005-2736(73)90408-2; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; DAHAN S, 1994, J CELL BIOL, V127, P1859, DOI 10.1083/jcb.127.6.1859; DENG JT, 1995, J LIPID RES, V36, P2129; EDWARDS IJ, 1995, ARTERIOSCL THROM VAS, V15, P400, DOI 10.1161/01.ATV.15.3.400; HAMILTON RL, 1990, J LIPID RES, V31, P1589; HUMPHRIES DE, 1989, METHOD ENZYMOL, V179, P428; JI ZS, 1994, J BIOL CHEM, V269, P2764; JI ZS, 1993, J BIOL CHEM, V268, P10160; JI ZS, 1994, ARTERIOSCLER THROMB, V14, P2025, DOI 10.1161/01.ATV.14.12.2025; KRUTH HS, 1995, J CELL BIOL, V129, P133, DOI 10.1083/jcb.129.1.133; LASKIN JD, 1991, HEPATOLOGY, V14, P306, DOI 10.1016/0270-9139(91)91420-6; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; MAZZONE T, 1992, J BIOL CHEM, V267, P1081; MAZZONE T, 1994, J LIPID RES, V35, P1345; RAPRAEGER A, 1989, J CELL BIOL, V109, P2509, DOI 10.1083/jcb.109.5.2509; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; REYLAND ME, 1991, J BIOL CHEM, V266, P21099; ROSENFELD ME, 1993, ARTERIOSCLER THROMB, V13, P1382, DOI 10.1161/01.ATV.13.9.1382; SCHLESSINGER J, 1995, CELL, V83, P357, DOI 10.1016/0092-8674(95)90112-4; SHIMADA K, 1987, ARTERIOSCLEROSIS, V7, P627, DOI 10.1161/01.ATV.7.6.627; STAUDERMAN ML, 1993, J LIPID RES, V34, P190; YE SQ, 1993, J BIOL CHEM, V268, P8497; YEAMAN C, 1993, J CELL PHYSIOL, V157, P413, DOI 10.1002/jcp.1041570226	24	58	58	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13454	13460		10.1074/jbc.271.23.13454	http://dx.doi.org/10.1074/jbc.271.23.13454			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662812	hybrid			2022-12-27	WOS:A1996UP38500025
J	Heise, N; Raper, J; Buxbaum, LU; Peranovich, TMS; deAlmeida, MLC				Heise, N; Raper, J; Buxbaum, LU; Peranovich, TMS; deAlmeida, MLC			Identification of complete precursors for the glycosylphosphatidylinositol protein anchors of Trypanosoma cruzi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEINS; MEMBRANE ANCHOR; METACYCLIC TRYPOMASTIGOTES; PHOSPHOLIPASE-C; SACCHAROMYCES-CEREVISIAE; GLYCOLIPID PRECURSORS; RESISTANT GLYCOLIPIDS; BRUCEI; PHOSPHATIDYLINOSITOL; BIOSYNTHESIS	The survival of Trypanosoma cruzi, the causative agent of Chagas' disease, depends vitally on proteins and glycoconjugates that mediate the parasite/host interaction. Since most of these molecules are attached to the membrane by glycosylphosphatidylinositol (GPI), alternative means of chemotherapeutic intervention might emerge from GPI biosynthesis studies. The structure of the major 1G7 antigen GPI has been fully characterized by us (Guther, M. L. S., Cardoso de Almeida, M. L., Yoshida, N., and Ferguson, M. A. J. (1992) J. Biol. Chem. 267, 6820-6828; Heise, N., Cardoso de Almeida, M. L., and Ferguson, M. A. J. (1995) Mel. Biochem. Parasitol. 70, 71-84), and based on its properties we now report the complete precursor glycolipids predicted to be transferred to the nascent protein. Migrating closely to Trypanosoma brucei glycolipid A on TLC, such species, named glycolipids A-like 1 and A-like 2, were labeled with tritiated palmitic acid, myo-inositol, glucosamine, and mannose, but surprisingly only the less polar glycolipid A-like 1 incorporated ethanolamine. The predicted products following nitrous acid deamination and digestion with phospholipases A(2), C, and D confirmed their GPI nature. Evidence that they may represent the anchor transferred to the 1G7 antigen came from the following analyses: (i) alpha-mannosidase treatments indicated that only one mannose was amenable to removal; (ii) their lipid moiety was identified as sn-l-alkyl-a-acylglycerol due to their sensitivity to phospholipase A(2) (PLA(2)), mild base and by direct high performance TLC analysis of the corresponding benzoylated diradylglycerol components; and (iii) both glycolipids incorporated H-3-fatty acid only in the sn-2- and not in the sn-l-alkyl position as previously found in the GPI of the mature 1G7 antigen. Based on the differential [H-3]ethanolamine incorporation pattern and the recent report that an aminoethylphosphonic acid (AEP) replaces ethanolamine phosphate (EtNH(2)-PO4) in the GPI in epimastigote sialoglycoproteins (Previato, J. O., Jones, C., Xavier, M. T., Wait, R., Travassos, L. R., Parodi, A. J., and Mendonca-Previato, L. (1995) J. Biol. Chem. 270, 7241-7250) it is proposed that glycolipid A-like 2 contains AEP and A-like 1 EtNH(2)-PO4. In the in vitro cell-free system both glycolipids were synthesized simultaneously and do not seem to bear a precursor/product relationship. Among the various components synthesized in vitro a glycolipid C-like corresponding to a form of glycolipid A-like 1 acylated on the inositol was also characterized. Phenylmethylsulfonyl fluoride, an inhibitor known to block the addition of ethanolamine phosphate in T. brucei but not in mammalian cells, also inhibits the synthesis of glycolipids A like and C-like in T. cruzi, indicating that the putative trypanosome EtNH(2)-PO4/AEP transferase(s) might represent a potential target for chemotherapy.	UNIV FED SAO PAULO, ESCOLA PAULISTA MED, DEPT MICROBIOL IMMUNOL & PARASITOL, BR-04023062 SAO PAULO, SP, BRAZIL; JOHNS HOPKINS UNIV, SCH MED, DEPT BIOL CHEM, BALTIMORE, MD 21205 USA	Universidade Federal de Sao Paulo (UNIFESP); Johns Hopkins University			Heise, Norton/I-4098-2013	Heise, Norton/0000-0003-0154-7406; Raper, Jayne/0000-0002-8723-9748				ABUIN G, 1994, MEM I OSWALDO CRUZ, V89, P90; ADROHER FJ, 1988, CELL DIFFER DEV, V22, P165, DOI 10.1016/0045-6039(88)90029-2; ARAGUTH MF, 1988, PARASITE IMMUNOL, V10, P707, DOI 10.1111/j.1365-3024.1988.tb00256.x; ARAYA JE, 1994, MOL BIOCHEM PARASIT, V65, P161, DOI 10.1016/0166-6851(94)90124-4; BARRY RJ, 1988, BIOCHEM BIOPH RES CO, V153, P177, DOI 10.1016/S0006-291X(88)81205-1; BECKER GW, 1980, J BACTERIOL, V142, P747, DOI 10.1128/JB.142.3.747-754.1980; BERTELLI MSM, 1977, J PARASITOL, V63, P434, DOI 10.2307/3279994; BERTELLO LE, 1995, BIOCHEM J, V310, P255, DOI 10.1042/bj3100255; BLANK ML, 1984, J CHROMATOGR, V298, P473, DOI 10.1016/S0021-9673(01)92744-X; BONALDO MC, 1988, J CELL BIOL, V106, P1349, DOI 10.1083/jcb.106.4.1349; BUTIKOFER P, 1990, J BIOL CHEM, V265, P18983; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; CamargO E. P., 1964, Revista do Instituto de Medicina Tropical de Sao Paulo, V6, P93; Cardoso de Almeida M. Lucia, 1993, Biological Research, V26, P285; CONTRERAS VT, 1985, MOL BIOCHEM PARASIT, V16, P315, DOI 10.1016/0166-6851(85)90073-8; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; COUTO AS, 1993, EUR J BIOCHEM, V217, P597, DOI 10.1111/j.1432-1033.1993.tb18282.x; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; DEALMEIDA IC, 1994, BIOCHEM J, V304, P793; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; DEALMEIDA MLC, 1988, BIOCHEM BIOPH RES CO, V150, P476; DELEDERKREMER RM, 1993, EUR J BIOCHEM, V218, P929, DOI 10.1111/j.1432-1033.1993.tb18449.x; DELEDERKREMER RM, 1991, J BIOL CHEM, V266, P23670; DOERING T L, 1990, Methods (Orlando), V1, P288, DOI 10.1016/S1046-2023(05)80330-5; ENGLUND PT, 1993, ANNU REV BIOCHEM, V62, P121, DOI 10.1146/annurev.bi.62.070193.001005; FERGUSON MAJ, 1984, J BIOL CHEM, V259, P3011; Fernandes J. F., 1976, Revista do Instituto de Medicina Tropical de Sao Paulo, V18, P130; GOLGHER DB, 1993, MOL BIOCHEM PARASIT, V60, P249, DOI 10.1016/0166-6851(93)90136-L; GONCALVES MF, 1991, EXP PARASITOL, V72, P43, DOI 10.1016/0014-4894(91)90119-H; GONZALEZ J, 1991, INFECT IMMUN, V59, P863; GRACE TDC, 1962, NATURE, V195, P788, DOI 10.1038/195788a0; GUTHER MLS, 1994, J BIOL CHEM, V269, P18694; GUTHER MLS, 1995, EMBO J, V14, P3080, DOI 10.1002/j.1460-2075.1995.tb07311.x; GUTHER MLS, 1992, J BIOL CHEM, V267, P6820; HEISE N, 1994, BRAZ J MED BIOL RES, V27, P233; HEISE N, 1995, MOL BIOCHEM PARASIT, V70, P71, DOI 10.1016/0166-6851(95)00009-P; HEISE N, 1995, THESIS U FEDERAL SAO; KRAKOW JL, 1986, J BIOL CHEM, V261, P2147; KRAKOW JL, 1989, MOL BIOCHEM PARASIT, V36, P263, DOI 10.1016/0166-6851(89)90174-6; Krettli A. U., 1984, Memorias do Instituto Oswaldo Cruz, V79, P157, DOI 10.1590/S0074-02761984000500027; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANHAM SM, 1970, EXP PARASITOL, V28, P521, DOI 10.1016/0014-4894(70)90120-7; MARKWELL MAK, 1978, BIOCHEMISTRY-US, V17, P4807, DOI 10.1021/bi00615a031; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MASTERSON WJ, 1991, EMBO J, V10, P2041, DOI 10.1002/j.1460-2075.1991.tb07734.x; MASTERSON WJ, 1990, CELL, V62, P73, DOI 10.1016/0092-8674(90)90241-6; MAYOR S, 1990, J BIOL CHEM, V265, P6164; MAYOR S, 1990, J BIOL CHEM, V265, P6174; MCCONVILLE MJ, 1993, BIOCHEM J, V294, P305, DOI 10.1042/bj2940305; MENON AK, 1992, J BIOL CHEM, V267, P15277; MENON AK, 1988, J BIOL CHEM, V263, P1970; PAN CT, 1971, J PROTOZOOL, V18, P556, DOI 10.1111/j.1550-7408.1971.tb03375.x; PREVIATO JO, 1995, J BIOL CHEM, V270, P7241, DOI 10.1074/jbc.270.13.7241; PREVIATO JO, 1990, J BIOL CHEM, V265, P2518; RAMIREZ MI, 1993, INFECT IMMUN, V61, P3636, DOI 10.1128/IAI.61.9.3636-3641.1993; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; ROSENBERRY TL, 1991, CELL BIOL INT REP, V15, P1133, DOI 10.1016/0309-1651(91)90060-V; RUIZ RD, 1993, PARASITE IMMUNOL, V15, P121, DOI 10.1111/j.1365-3024.1993.tb00591.x; SCHENKMAN S, 1993, MOL BIOCHEM PARASIT, V59, P293, DOI 10.1016/0166-6851(93)90227-O; SCHENKMAN S, 1988, MOL BIOCHEM PARASIT, V29, P141, DOI 10.1016/0166-6851(88)90069-2; SERRANO AA, 1995, J BIOL CHEM, V270, P27244, DOI 10.1074/jbc.270.45.27244; SINGH BN, 1994, J BIOL CHEM, V269, P21972; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STAMBUK BU, 1994, BRAZ J MED BIOL RES, V27, P383; SULLIVAN JJ, 1982, T ROY SOC TROP MED H, V76, P300, DOI 10.1016/0035-9203(82)90173-0; TEIXEIRA MMG, 1986, MOL BIOCHEM PARASIT, V18, P271, DOI 10.1016/0166-6851(86)90085-X; WARD J, 1987, MOL BIOCHEM PARASIT, V23, P1, DOI 10.1016/0166-6851(87)90180-0; YOSHIDA N, 1983, INFECT IMMUN, V40, P836, DOI 10.1128/IAI.40.2.836-839.1983; YOSHIDA N, 1989, INFECT IMMUN, V57, P1663, DOI 10.1128/IAI.57.6.1663-1667.1989; ZINGALES B, 1985, CURR TOP MICROBIOL, V117, P129	70	46	46	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16877	16887		10.1074/jbc.271.28.16877	http://dx.doi.org/10.1074/jbc.271.28.16877			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663209	hybrid			2022-12-27	WOS:A1996UX12600070
J	Reaven, E; Tsai, L; Azhar, S				Reaven, E; Tsai, L; Azhar, S			Intracellular events in the ''selective'' transport of lipoprotein-derived cholesteryl esters	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-DENSITY-LIPOPROTEIN; EGG PHOSPHATIDYLCHOLINE VESICLES; OVARY PLASMA-MEMBRANES; LUTEINIZED OVARY; INTERMEDIATE FILAMENTS; RICH LIPOPROTEINS; GOLGI-COMPLEX; ANIMAL-CELLS; OKADAIC ACID; BREFELDIN-A	The current study utilizes human, apoE-free high density lipoprotein reconstituted with a highly specific fluorescent-cholesteryl ester probe to define the initial steps and regulatory sites associated with the ''selective'' uptake and intracellular itinerary of lipoprotein-derived cholesteryl esters. Bt(2)cAMP-stimulated ovarian granulosa cells were used as the experimental model, and both morphological and biochemical fluorescence data were obtained. The data show that cholesteryl ester provided through the selective pathway is a process which begins with a temperature-independent transfer of cholesteryl ester to the cell's plasma membrane. Thereafter transfer of the lipid proceeds rapidly and accumulates prominently in a perinuclear region (presumed to be the Golgi/membrane sorting compartment) and in lipid storage droplets of the cells. The data suggest that lipid transfer proteins (or other small soluble proteins) are not required for the intracellular transport of the cholesteryl esters, nor is an intact Golgi complex or an intact cell cytoskeleton (although the transfer is less efficient in the presence of certain microtubule-disrupting agents). The intracellular transfer of the cholesteryl esters is also somewhat dependent on an energy source in that a glucose-deficient culture medium or a combination of metabolic inhibitors reduces the efficiency of the transfer. A protein-mediated event may be required for cholesteryl ester internalization from the plasma membrane, in that N-ethylmaleimide dramatically blocks the internalization phase of the selective uptake process. Taken together these data suggest that the selective pathway is a factor-dependent, energy-requiring cholesteryl ester transport system, in which lipoprotein-donated cholesteryl esters probably flow through vesicles or intracellular membrane sheets and their connections, rather than through the cell cytosol.	STANFORD UNIV,SCH MED,DEPT MED,PALO ALTO,CA 94304	Stanford University	Reaven, E (corresponding author), VET AFFAIRS PALO ALTO HLTH CARE SYST,GRECC 182B,3801 MIRANDA AVE,PALO ALTO,CA 94304, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R56HL033881, R01HL033881] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 33881] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Acton S, 1996, SCIENCE, V271, P518, DOI 10.1126/science.271.5248.518; ALLAN D, 1993, PROG LIPID RES, V32, P195, DOI 10.1016/0163-7827(93)90015-O; AZHAR S, 1989, J LIPID RES, V30, P1799; AZHAR S, 1988, J LIPID RES, V29, P869; AZHAR S, 1990, BIOCHIM BIOPHYS ACTA, V1047, P148, DOI 10.1016/0005-2760(90)90041-U; AZHAR S, 1994, J LIPID RES, V35, P1161; BACALLAO R, 1994, J CELL SCI, V107, P3301; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN RE, 1992, BIOCHIM BIOPHYS ACTA, V1113, P375, DOI 10.1016/0304-4157(92)90007-W; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRIDER BP, 1994, J BIOL CHEM, V269, P17379; DAWIDOWICZ EA, 1987, CURR TOP MEMBR TRANS, V29, P175; DELAMATRE JG, 1991, J CELL PHYSIOL, V146, P18, DOI 10.1002/jcp.1041460104; DURHAM HD, 1983, MUSCLE NERVE, V6, P631, DOI 10.1002/mus.880060903; ECKERT BS, 1986, CELL MOTIL CYTOSKEL, V6, P15, DOI 10.1002/cm.970060104; ESPARISOGANDO A, 1994, AM J PHYSIOL, V267, pC166, DOI 10.1152/ajpcell.1994.267.1.C166; FEDER TJ, 1994, J CELL PHYSIOL, V158, P7, DOI 10.1002/jcp.1041580103; FIELDING CJ, 1995, BIOCHEMISTRY-US, V34, P14237, DOI 10.1021/bi00043a031; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; GLASS C, 1983, P NATL ACAD SCI-BIOL, V80, P5435, DOI 10.1073/pnas.80.17.5435; GWYNNE JT, 1982, ENDOCR REV, V3, P299, DOI 10.1210/edrv-3-3-299; GWYNNE JT, 1989, J BIOL CHEM, V264, P8141; HAMILTON JA, 1983, J BIOL CHEM, V258, P2821; HAMILTON JA, 1982, J BIOL CHEM, V257, P7318; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOEKSTRA D, 1992, BIOCHIM BIOPHYS ACTA, V1113, P277, DOI 10.1016/0304-4157(92)90002-R; JACKLE S, 1993, HEPATOLOGY, V17, P455, DOI 10.1016/0270-9139(93)90058-U; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAPELLER R, 1995, J BIOL CHEM, V270, P25985, DOI 10.1074/jbc.270.43.25985; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KHOO JC, 1995, J LIPID RES, V36, P593; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEBLOND L, 1993, J BIOL CHEM, V268, P1670; LEITERSDORF E, 1986, BIOCHIM BIOPHYS ACTA, V878, P320, DOI 10.1016/0005-2760(86)90239-0; LI QT, 1992, J LIPID RES, V33, P503; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1995, J BIOL CHEM, V270, P15443, DOI 10.1074/jbc.270.26.15443; MAHLEY RW, 1983, BIOCHIM BIOPHYS ACTA, V737, P197, DOI 10.1016/0304-4157(83)90001-1; MARTIN OC, 1994, J CELL BIOL, V125, P769, DOI 10.1083/jcb.125.4.769; MILLER SG, 1991, J CELL BIOL, V112, P39, DOI 10.1083/jcb.112.1.39; MOESTRUP SK, 1994, BBA-REV BIOMEMBRANES, V1197, P197, DOI 10.1016/0304-4157(94)90005-1; MOREAU P, 1994, BBA-REV BIOMEMBRANES, V1197, P257; MORGAN A, 1995, TRENDS CELL BIOL, V5, P335, DOI 10.1016/S0962-8924(00)89059-5; MOSS J, 1995, J BIOL CHEM, V270, P12327, DOI 10.1074/jbc.270.21.12327; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; Pagano RE, 1990, CURR OPIN CELL BIOL, V2, P652, DOI 10.1016/0955-0674(90)90107-P; PAGANO RE, 1991, J CELL BIOL, V113, P1267, DOI 10.1083/jcb.113.6.1267; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P146, DOI 10.1016/0968-0004(87)90071-5; Pedersen R.C., 1988, BIOL CHOLESTEROL, P39; PELHAM HRB, 1991, CELL, V67, P449, DOI 10.1016/0092-8674(91)90517-3; PETERS JM, 1990, EMBO J, V9, P1757, DOI 10.1002/j.1460-2075.1990.tb08300.x; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITTMAN RC, 1987, J BIOL CHEM, V262, P2443; PITTMAN RC, 1987, J BIOL CHEM, V262, P2435; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; REAVEN E, 1989, J LIPID RES, V30, P1551; REAVEN E, 1995, J LIPID RES, V36, P1602; REAVEN E, 1988, ARTERIOSCLEROSIS, V8, P298, DOI 10.1161/01.ATV.8.3.298; REAVEN E, 1986, J CLIN INVEST, V77, P1971, DOI 10.1172/JCI112526; REAVEN E, 1984, J CLIN INVEST, V74, P1384, DOI 10.1172/JCI111549; REAVEN E, 1990, J BIOL CHEM, V265, P19100; REAVEN EP, 1980, J CELL BIOL, V84, P28, DOI 10.1083/jcb.84.1.28; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUETZ S, 1994, CELL, V77, P1071, DOI 10.1016/0092-8674(94)90446-4; SCHLIWA M, 1982, J CELL BIOL, V92, P79, DOI 10.1083/jcb.92.1.79; SHI XY, 1992, BIOCHEMISTRY-US, V31, P3230, DOI 10.1021/bi00127a026; SPARROW CP, 1990, BIOCHIM BIOPHYS ACTA, V1043, P203, DOI 10.1016/0005-2760(90)90297-B; SPECTOR I, 1983, SCIENCE, V219, P493, DOI 10.1126/science.6681676; STONE DK, 1988, KIDNEY INT, V33, P767, DOI 10.1038/ki.1988.65; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SZTUL E, 1993, J BIOL CHEM, V268, P1876; TAGAYA M, 1993, J BIOL CHEM, V268, P2662; THYBERG J, 1992, J CELL SCI, V103, P1167; TOCANNE JF, 1994, PROG LIPID RES, V33, P203, DOI 10.1016/0163-7827(94)90027-2; TROTTER PJ, 1994, BBA-LIPID LIPID MET, V1213, P241, DOI 10.1016/0005-2760(94)00073-5; TURNER JR, 1989, J CELL BIOL, V109, P2081, DOI 10.1083/jcb.109.5.2081; UL M, 1995, TRENDS BIOCHEM SCI, V20, P303; URBANI L, 1990, J BIOL CHEM, V265, P1919; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; WHITEHEART SW, 1995, TRENDS CELL BIOL, V5, P64, DOI 10.1016/S0962-8924(00)88948-5; YAHARA I, 1982, J CELL BIOL, V92, P69, DOI 10.1083/jcb.92.1.69	81	99	99	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16208	16217		10.1074/jbc.271.27.16208	http://dx.doi.org/10.1074/jbc.271.27.16208			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663101	hybrid			2022-12-27	WOS:A1996UW35200053
J	Butikofer, P; Boschung, M; Brodbeck, U; Menon, AK				Butikofer, P; Boschung, M; Brodbeck, U; Menon, AK			Phosphatidylinositol hydrolysis by Trypanosoma brucei glycosylphosphatidylinositol phospholipase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VARIANT SURFACE GLYCOPROTEIN; BACILLUS-CEREUS; CROSSREACTING DETERMINANTS; AFRICAN TRYPANOSOMES; MEMBRANE-PROTEINS; PURIFICATION; RELEASE; ANCHOR; GLYCAN; ANTIGENS	Detergent-solubilized glycosylphosphatidylinositol (GPI)-anchored structures can be cleaved by C-type phospholipases isolated from peanuts and bloodstream cells of the African trypanosome, Trypanosoma brucei. The two enzymes differ in their reported ability to hydrolyze phosphatidylinositol (PI); while the peanut enzyme readily hydrolyzes PI in vitro, the T. brucei enzyme was reported to be virtually inactive against PI and consequently named GPI-specific phospholipase C (GPI-PLC). In this paper, we describe experiments in which we reinvestigated the substrate specificity of T. brucei GPI-PLC by incubating the purified enzyme with Triton X-100/PI-mixed micelles and by studying PI hydrolysis. We found that PI hydrolysis occurred in a detergent-dependent fashion over the range of concentrations tested (5 mu M to 1 mM PI). At 5 mu M PI, hydrolysis was maximal at 0.005% Triton X-100, whereas at 1 mM PI, maximal hydrolysis required 0.05% Triton X-100. Hydrolysis of both PI and GPI was strongly affected by the presence of phospholipids. Endogenous PI was hydrolyzed during osmotic and detergent lysis of trypanosomes under conditions used to obtain quantitative hydrolysis of the GPI-anchored trypanosome variant surface glycoprotein. PI hydrolysis in the lysates was inhibited by sodium p-chloromercuriphenyIsulfonate but unaffected by EGTA, consistent with the proposal that hydrolysis is due to GPI-PLC. These results suggest that the function of T. brucei GPI-PLC may be to regulate PI as well as (or instead of) GPI levels.	UNIV WISCONSIN, DEPT BIOCHEM, MADISON, WI 53706 USA	University of Wisconsin System; University of Wisconsin Madison	Butikofer, P (corresponding author), UNIV BERN, INST BIOCHEM & MOLEC BIOL, BUHLSTR 28, CH-3012 BERN, SWITZERLAND.			Menon, Anant Kumar/0000-0001-6924-2698	NIAID NIH HHS [AI28858] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI028858] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BARBET AF, 1978, P NATL ACAD SCI USA, V75, P1989, DOI 10.1073/pnas.75.4.1989; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORDIER C, 1981, J BIOL CHEM, V256, P1604; BRAUNBRETON C, 1992, EXP PARASITOL, V74, P452, DOI 10.1016/0014-4894(92)90207-Q; BRODBECK U, 1994, BRAZ J MED BIOL RES, V27, P369; BRODBECK U, 1981, MEMBRANE PROTEINS LA, P85; BULOW R, 1989, J CELL SCI, V93, P233; BULOW R, 1986, J BIOL CHEM, V261, P1918; BUTIKOFER P, 1995, ANAL BIOCHEM, V229, P125, DOI 10.1006/abio.1995.1388; BUTIKOFER P, 1993, J BIOL CHEM, V268, P17794; BUTIKOFER P, 1990, J BIOL CHEM, V265, P16035; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1995, J BIOL CHEM, V270, P18711, DOI 10.1074/jbc.270.32.18711; CARRINGTON M, 1991, CELL BIOL INT REP, V15, P1101, DOI 10.1016/0309-1651(91)90058-Q; CROSS GAM, 1979, NATURE, V277, P310, DOI 10.1038/277310a0; CROSS GAM, 1984, J CELL BIOCHEM, V24, P79, DOI 10.1002/jcb.240240107; DEALMEIDA MLC, 1983, NATURE, V302, P349, DOI 10.1038/302349a0; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1988, SCIENCE, V239, P753, DOI 10.1126/science.3340856; FERGUSON MAJ, 1994, PARASITOL TODAY, V10, P48, DOI 10.1016/0169-4758(94)90392-1; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4963; Field M. C., 1992, LIPID MODIFICATION P, P155; FOUCHIER F, 1990, BIOCHEM J, V269, P321, DOI 10.1042/bj2690321; FOX JA, 1987, P NATL ACAD SCI USA, V84, P2663, DOI 10.1073/pnas.84.9.2663; FOX JA, 1986, J BIOL CHEM, V261, P5767; GRIFFITH OH, 1991, METHOD ENZYMOL, V197, P493; HEINZ DW, 1995, EMBO J, V14, P3855, DOI 10.1002/j.1460-2075.1995.tb00057.x; HENDERSON LE, 1979, ANAL BIOCHEM, V93, P153, DOI 10.1016/S0003-2697(79)80129-3; HERELD D, 1986, J BIOL CHEM, V261, P3813; HERELD D, 1988, POST TRANSLATIONAL M, P9; HIGGINS JA, 1989, BIOCHEM J, V259, P913, DOI 10.1042/bj2590913; HIROSE S, 1995, METHOD ENZYMOL, V250, P582; HOENER MC, 1992, EUR J BIOCHEM, V206, P747, DOI 10.1111/j.1432-1033.1992.tb16981.x; HUANG KS, 1991, METHOD ENZYMOL, V197, P567; Ikezawa H, 1981, METHODS ENZYMOLOGY C, P731, DOI [10.1016/0076-6879(81)71086-3, DOI 10.1016/0076-6879(81)71086-3]; JACKSON DG, 1985, J BIOL CHEM, V260, P5179; KUPPE A, 1989, J BACTERIOL, V171, P6077, DOI 10.1128/jb.171.11.6077-6083.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Low M G, 1981, Methods Enzymol, V71 Pt C, P741; LOW MG, 1988, J IMMUNOL METHODS, V113, P101, DOI 10.1016/0022-1759(88)90386-9; LOW MG, 1986, TRENDS BIOCHEM SCI, V11, P212, DOI 10.1016/0968-0004(86)90009-5; MELLORS A, 1989, PARASITOL TODAY, V5, P239, DOI 10.1016/0169-4758(89)90255-X; MENSAWILMOT K, 1994, J CELL BIOL, V124, P935, DOI 10.1083/jcb.124.6.935; MENSAWILMOT K, 1992, MOL BIOCHEM PARASIT, V56, P311, DOI 10.1016/0166-6851(92)90180-R; MORRIS JC, 1995, J BIOL CHEM, V270, P2517, DOI 10.1074/jbc.270.6.2853; PATNAIK PK, 1993, MOL BIOCHEM PARASIT, V58, P97, DOI 10.1016/0166-6851(93)90094-E; RHEE SG, 1989, SCIENCE, V244, P546, DOI 10.1126/science.2541501; ROUSER G, 1970, LIPIDS, V5, P494, DOI 10.1007/BF02531316; SALTIEL AR, 1987, J BIOL CHEM, V262, P1116; SCHENKMAN S, 1988, MOL BIOCHEM PARASIT, V29, P141, DOI 10.1016/0166-6851(88)90069-2; STIEGER S, 1991, BIOCHIMIE, V73, P1179, DOI 10.1016/0300-9084(91)90002-I; TAKENAWA T, 1991, METHOD ENZYMOL, V197, P511; VIDUGIRIENE J, 1995, METHOD ENZYMOL, V250, P513; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; WEBB H, 1994, BRAZ J MED BIOL RES, V27, P349; ZAMZE SE, 1988, EUR J BIOCHEM, V176, P527, DOI 10.1111/j.1432-1033.1988.tb14310.x; ZIEGELBAUER K, 1993, BIOCHEMISTRY-US, V32, P3737, DOI 10.1021/bi00065a028	58	37	37	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15533	15541						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663180	hybrid			2022-12-27	WOS:A1996UV29900037
J	Rai, SS; Wolff, J				Rai, SS; Wolff, J			Localization of the vinblastine-binding site on beta-tubulin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VINCA ALKALOIDS; MICROTUBULES INVITRO; TAXOL BINDS; COLCHICINE; PODOPHYLLOTOXIN; POLYMERIZATION; IDENTIFICATION; HYDROLYSIS	A fluorescent vinblastine derivative, vinblastine-4'-anthranilate, has been shown to inhibit polymerization of rat brain tubulin (IC50 = 4.8 mu M). Binding of the drug to tubulin increases fluorescence intensity, causes a small emission blue shift, and has a quantum yield of 0.037. Fluorescence increases as a function of drug concentration, with a high affinity site and an undetermined number of lower affinity sites. Photolabeling, by exciting the fluorescent drug-tubulin complex at the absorption maximum of anthranilate, yields a covalent adduct confined to beta-tubulin. Its formation is specific in that it is blocked by maytansine or vinblastine, Tryptic hydrolysis identifies a single fluorescent beta-peptide coinciding with residues 175-213. The interactions between various ligands at this central portion of beta-tubulin are discussed.	NIDDK,BIOCHEM PHARMACOL LAB,NIH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)								BENSCH KG, 1969, J CELL BIOL, V40, P95, DOI 10.1083/jcb.40.1.95; BHATTACH.B, 1974, P NATL ACAD SCI USA, V71, P2627, DOI 10.1073/pnas.71.7.2627; BHATTACHARYYA B, 1976, P NATL ACAD SCI USA, V73, P2375, DOI 10.1073/pnas.73.7.2375; BHATTACHARYYA B, 1977, FEBS LETT, V75, P159, DOI 10.1016/0014-5793(77)80075-6; BHATTACHARYYA B, 1975, ARCH BIOCHEM BIOPHYS, V167, P264, DOI 10.1016/0003-9861(75)90462-2; CARLIER MF, 1983, BIOCHEMISTRY-US, V22, P4814, DOI 10.1021/bi00289a031; CORTESE F, 1977, J BIOL CHEM, V252, P1134; DAVIDPFEUTY T, 1979, J BIOL CHEM, V254, P1696; Dustin P., 1984, MICROTUBULES; GARLAND D, 1975, ANN NY ACAD SCI, V253, P232, DOI 10.1111/j.1749-6632.1975.tb19202.x; HAMEL E, 1984, BIOCHEMISTRY-US, V23, P4173, DOI 10.1021/bi00313a026; Hamel E., 2018, MICROTUBULE PROTEINS, P89, DOI [10.1201/9781351074643-4, DOI 10.1201/9781351074643-4]; HIMES RH, 1991, PHARMACOL THERAPEUT, V51, P257, DOI 10.1016/0163-7258(91)90081-V; HIRATSUKA T, 1976, BIOCHIM BIOPHYS ACTA, V453, P293, DOI 10.1016/0005-2795(76)90277-4; KRALOVIC RC, 1977, EXP CELL RES, V106, P205, DOI 10.1016/0014-4827(77)90257-9; LIN CM, 1981, J BIOL CHEM, V256, P9242; LUDUENA RF, 1991, PHARMACOL THERAPEUT, V49, P133, DOI 10.1016/0163-7258(91)90027-J; MANDELBAUMSHAVIT F, 1976, BIOCHEM BIOPH RES CO, V72, P47, DOI 10.1016/0006-291X(76)90958-X; MANFREDI JJ, 1984, PHARMACOL THERAPEUT, V25, P83, DOI 10.1016/0163-7258(84)90025-1; MANFREDI JJ, 1982, J CELL BIOL, V94, P688, DOI 10.1083/jcb.94.3.688; MAS MT, 1985, BIOCHEMISTRY-US, V24, P1634, DOI 10.1021/bi00328a011; MORGAN JL, 1983, J BIOL CHEM, V258, P3127; NASIOULAS G, 1990, EUR J BIOCHEM, V192, P69, DOI 10.1111/j.1432-1033.1990.tb19196.x; PARNESS J, 1981, J CELL BIOL, V91, P479, DOI 10.1083/jcb.91.2.479; PFEFFER TA, 1976, J CELL BIOL, V69, P599, DOI 10.1083/jcb.69.3.599; PRAKASH V, 1992, ARCH BIOCHEM BIOPHYS, V295, P137, DOI 10.1016/0003-9861(92)90499-M; RAI SS, 1993, ARCH BIOCHEM BIOPHYS, V306, P133, DOI 10.1006/abbi.1993.1490; RAO S, 1994, J BIOL CHEM, V269, P3132; RAO S, 1995, J BIOL CHEM, V270, P20235, DOI 10.1074/jbc.270.35.20235; SACKETT DL, 1995, BIOCHEMISTRY-US, V34, P7010, DOI 10.1021/bi00021a012; SACKETT DL, 1993, BIOCHEMISTRY-US, V32, P13560, DOI 10.1021/bi00212a023; SACKETT DL, 1992, PROTEIN EXPRES PURIF, V2, P390; SAFA AR, 1987, BIOCHEMISTRY-US, V26, P97, DOI 10.1021/bi00375a014; SAWADA T, 1993, BIOCHEM PHARMACOL, V45, P1387; SENGUPTA S, 1995, BIOCHEMISTRY-US, V34, P11889, DOI 10.1021/bi00037a029; SHIVANNA BD, 1993, J BIOL CHEM, V268, P127; TOSO RJ, 1993, BIOCHEMISTRY-US, V32, P1285, DOI 10.1021/bi00056a013; UPPULURI S, 1993, P NATL ACAD SCI USA, V90, P11598, DOI 10.1073/pnas.90.24.11598; WARFIELD RK, 1974, SCIENCE, V186, P1219, DOI 10.1126/science.186.4170.1219; WILSON L, 1982, J MOL BIOL, V159, P125, DOI 10.1016/0022-2836(82)90035-3; WILSON L, 1970, BIOCHEMISTRY-US, V9, P4999, DOI 10.1021/bi00827a026; WOLFF J, 1991, P NATL ACAD SCI USA, V88, P2820, DOI 10.1073/pnas.88.7.2820	42	152	162	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14707	14711		10.1074/jbc.271.25.14707	http://dx.doi.org/10.1074/jbc.271.25.14707			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663038	hybrid			2022-12-27	WOS:A1996UT10600013
J	Zhou, DJ; Clarke, P; Wang, JF; Chen, SA				Zhou, DJ; Clarke, P; Wang, JF; Chen, SA			Identification of a promoter that controls aromatase expression in human breast cancer and adipose stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-P450 GENE-EXPRESSION; TISSUE-SPECIFIC EXPRESSION; MAMMALIAN-CELLS; TUMOR TISSUES; GROWTH; ESTROGEN; ADENOSINE-3',5'-MONOPHOSPHATE; TRANSCRIPTION; ELEMENTS; BINDING	Aromatase, a cytochrome P450, catalyzes three consecutive hydroxylation reactions converting C19 androgens to aromatic C18 estrogens, In this study, the regulatory properties of a 696-base pair region, that contains the promoter II and is situated immediately upstream of exon II of the human aromatase gene, were investigated, Chloramphenicol acetyltransferase (CAT) functional studies with DNA segments derived from this genomic region and primer extension analysis revealed the presence of a second promoter which is functional in adipose stromal cells and in breast cancer cells. Detailed DNase-l footprinting analysis, DNA mobility shift assays, and CAT functional studies of this genomic region were performed and led to the identification of a segment (B1) that could act as a promoter (probably promoter 1.3) in adipose stromal and breast cancer cells, The study revealed further that the B1 region could be divided into two domains which were designated RE1 and RE2, RE1 was found to have the promoter activity, and RE2 was found to regulate the promoter activity of RE1, but in different manners in MCF-7 cells (as an example of breast cancer cells) and in adipose stromal cells. RE2 was found to function as a positive regulatory element in MCF-7 cells and as a negative regulatory element in adipose stromal cells, respectively. DNA mobility shift and W-cross-linking experiments with BrUrd-substituted B1 fragment and nuclear extracts isolated from two types of cells were performed, The experiments identified DNA-bound proteins with molecular masses around 50 kDa. These findings serve as the basis for further examination of the regulatory mechanism of aromatase expression in human breast cancer and adipose stromal cells.	BECKMAN RES INST CITY HOPE,DIV IMMUNOL,DUARTE,CA 91010	City of Hope; Beckman Research Institute of City of Hope					NCI NIH HHS [CA 33572, CA 44735] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA033572, R01CA044735] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BATES SE, 1988, MOL ENDOCRINOL, V2, P543, DOI 10.1210/mend-2-6-543; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRADLOW HL, 1982, CANCER RES, V42, P3382; BULUN SE, 1993, J CLIN ENDOCR METAB, V77, P1622, DOI 10.1210/jc.77.6.1622; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; FITZPATRICK SL, 1994, MOL ENDOCRINOL, V8, P1309, DOI 10.1210/me.8.10.1309; FITZPATRICK SL, 1993, MOL ENDOCRINOL, V7, P341, DOI 10.1210/me.7.3.341; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; HARADA N, 1992, BIOCHEM BIOPH RES CO, V189, P1001, DOI 10.1016/0006-291X(92)92303-F; HARADA N, 1993, P NATL ACAD SCI USA, V90, P11312, DOI 10.1073/pnas.90.23.11312; JAMES V H T, 1987, Steroids, V50, P269, DOI 10.1016/0039-128X(83)90077-6; KILLINGER D W, 1987, Steroids, V50, P61, DOI 10.1016/0039-128X(83)90062-4; KINGSTON RE, 1992, CURRENT PROTOCOLS MO, V1; KINGSTON RE, 1991, CURRENT PROTOCOLS MO; KITAWAKI J, 1992, J STEROID BIOCHEM, V42, P267, DOI 10.1016/0960-0760(92)90129-7; LIPPMAN ME, 1986, J STEROID BIOCHEM, V24, P147, DOI 10.1016/0022-4731(86)90044-0; MAHENDROO MS, 1993, J BIOL CHEM, V268, P19463; MAHENDROO MS, 1991, J BIOL CHEM, V266, P11276; Maxam A M, 1980, Methods Enzymol, V65, P499; MEANS GD, 1991, MOL ENDOCRINOL, V5, P2005, DOI 10.1210/mend-5-12-2005; MENDELSON CR, 1986, ENDOCRINOLOGY, V118, P968, DOI 10.1210/endo-118-3-968; MICHAEL MD, 1995, J BIOL CHEM, V270, P13561, DOI 10.1074/jbc.270.22.13561; MILLER W R, 1987, Steroids, V50, P537, DOI 10.1016/0039-128X(87)90037-7; REED MJ, 1989, INT J CANCER, V44, P233, DOI 10.1002/ijc.2910440208; REED MJ, 1994, BREAST CANCER RES TR, V30, P7, DOI 10.1007/BF00682737; ROSENTHAL N, 1987, METHOD ENZYMOL, V152, P705; SANTNER SJ, 1993, J STEROID BIOCHEM, V44, P611, DOI 10.1016/0960-0760(93)90267-Z; SELDEN RF, 1991, CURRENT PROTOCOLS MO; SINGH H, 1986, NATURE, V319, P154, DOI 10.1038/319154a0; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; TODA K, 1994, J BIOL CHEM, V269, P8099; WANG JF, 1992, MOL ENDOCRINOL, V6, P1479, DOI 10.1210/me.6.9.1479; YUE W, 1994, CANCER RES, V54, P5092; ZHAO Y, 1995, MOL ENDOCRINOL, V9, P340, DOI 10.1210/me.9.3.340; ZHOU D, 1990, CANCER RES, V50, P6949	35	42	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15194	15202		10.1074/jbc.271.25.15194	http://dx.doi.org/10.1074/jbc.271.25.15194			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662988	Green Published			2022-12-27	WOS:A1996UT10600081
J	Chen, PF; Tsai, AL; Berka, V; Wu, KK				Chen, PF; Tsai, AL; Berka, V; Wu, KK			Endothelial nitric-oxide synthase - Evidence for bidomain structure and successful reconstitution of catalytic activity from two separate domains generated by a baculovirus expression system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							L-ARGININE; PURIFICATION; BRAIN; HEME; FLAVOPROTEIN; HEMOPROTEIN; ENZYME; CYTOCHROME-P-450BM-3; IDENTIFICATION; CALMODULIN	A baculovirus system was used to express the oxygenase and reductase domains of human endothelial nitric-oxide synthase (ecNOS) as distinct proteins. The oxygenase domain (residues 1-491) was expressed using a vector containing a His(6) tag at the N terminus. The purified oxygenase domain had an apparent molecular mass of similar to 54 kDa, and retained the ability to bind L-arginine and form the ferrous CO complex. The purified reductase domain (residues 492-1244) had an apparent molecular mass of similar to 82 kDa and retained the ability to catalyze NADPH-dependent cytochrome c reduction, which was enhanced 10-fold by the presence of Ca2+/calmodulin. Both purified domains exhibited immunoreactivity to rabbit anti-ecNOS IgG. The NOS activity was successfully reconstituted by mixing the two domains. These results demonstrate for the first time that the two domains of ecNOS are catalytically intact and can be reconstituted in vitro.	UNIV TEXAS, HLTH SCI CTR, VASC BIOL RES CTR, HOUSTON, TX 77030 USA; UNIV TEXAS, HLTH SCI CTR, DEPT INTERNAL MED, DIV HEMATOL, HOUSTON, TX 77030 USA	University of Texas System; University of Texas Health Science Center Houston; University of Texas System; University of Texas Health Science Center Houston			Wu, Kenneth Kun-Yu/B-1070-2010		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL050675] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P50NS023327] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-50675] Funding Source: Medline; NIGMS NIH HHS [GM-44911] Funding Source: Medline; NINDS NIH HHS [NS-23327] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABUSOUD HM, 1993, P NATL ACAD SCI USA, V90, P10769, DOI 10.1073/pnas.90.22.10769; ASSEFFA A, 1989, ARCH BIOCHEM BIOPHYS, V274, P481, DOI 10.1016/0003-9861(89)90461-X; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BODDUPALLI SS, 1992, J BIOL CHEM, V267, P10375; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BREDT DS, 1990, P NATL ACAD SCI USA, V87, P682, DOI 10.1073/pnas.87.2.682; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; CHEN PF, 1995, BIOCHEM BIOPH RES CO, V215, P1119, DOI 10.1006/bbrc.1995.2579; CHEN PF, 1994, J BIOL CHEM, V269, P25062; CULLEN BR, 1987, METHOD ENZYMOL, V152, P8125; FORSTERMANN U, 1991, BIOCHEM PHARMACOL, V42, P1849, DOI 10.1016/0006-2952(91)90581-O; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P801, DOI 10.1021/bi00003a013; GHOSH DK, 1995, BIOCHEMISTRY-US, V34, P11316, DOI 10.1021/bi00036a003; HAUGEN DA, 1976, J BIOL CHEM, V251, P7929; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HEVEL JM, 1991, J BIOL CHEM, V266, P22789; KLATT P, 1992, BIOCHEM J, V288, P15, DOI 10.1042/bj2880015; KLATT P, 1992, J BIOL CHEM, V267, P11374; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MCMILLAN K, 1992, P NATL ACAD SCI USA, V89, P11141, DOI 10.1073/pnas.89.23.11141; MCMILLAN K, 1993, BIOCHEMISTRY-US, V32, P9875, DOI 10.1021/bi00089a001; MCMILLAN K, 1995, BIOCHEMISTRY-US, V34, P3683; NARHI LO, 1987, J BIOL CHEM, V262, P6683; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NISHIMURA JS, 1995, BIOCHEM BIOPH RES CO, V210, P288, DOI 10.1006/bbrc.1995.1659; OLKEN NM, 1991, BIOCHEM BIOPH RES CO, V177, P828, DOI 10.1016/0006-291X(91)91864-9; POLLOCK JS, 1991, P NATL ACAD SCI USA, V88, P10480, DOI 10.1073/pnas.88.23.10480; REIF DW, 1995, ARCH BIOCHEM BIOPHYS, V320, P170, DOI 10.1006/abbi.1995.1356; RENAUD JP, 1993, BIOCHEM BIOPH RES CO, V192, P53, DOI 10.1006/bbrc.1993.1380; ROMAN LJ, 1995, P NATL ACAD SCI USA, V92, P8428, DOI 10.1073/pnas.92.18.8428; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHMIDT HHHW, 1992, BIOCHEMISTRY-US, V31, P3243, DOI 10.1021/bi00127a028; SHETA EA, 1994, J BIOL CHEM, V269, P15147; STUEHR DJ, 1991, P NATL ACAD SCI USA, V88, P7773, DOI 10.1073/pnas.88.17.7773; STUEHR DJ, 1991, J BIOL CHEM, V266, P6259; STUEHR DJ, 1992, J BIOL CHEM, V267, P20547; STUEHR DJ, 1992, ADV ENZYMOL REALT AR, V65, P287; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WHITE KA, 1992, BIOCHEMISTRY-US, V31, P6627, DOI 10.1021/bi00144a001; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522	42	95	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14631	14635		10.1074/jbc.271.24.14631	http://dx.doi.org/10.1074/jbc.271.24.14631			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663033	hybrid			2022-12-27	WOS:A1996UQ66000102
J	Coustry, F; Maity, SN; Sinha, S; deCrombrugghe, B				Coustry, F; Maity, SN; Sinha, S; deCrombrugghe, B			The transcriptional activity of the CCAAT-binding factor CBF is mediated by two distinct activation domains, one in the CBF-B subunit and the other in the CBF-C subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; SEQUENCE IDENTITY; COLLAGEN PROMOTER; DNA-BINDING; YEAST HAP2; PROTEINS; COMPLEX; CELLS	CBF-A, CBF-B, and CBF-C together form the heterotrimeric mammalian CCAAT-binding factor, CBF, which binds to DNA to form a CBF-DNA complex. Here we examined the transcription activation function of CBF in an in vitro reconstituted system using the three purified recombinant CBF subunits expressed in Escherichia coli, Two of the subunits, CBF-A and CBF-C, were coexpressed and purified as a CBF-A/CBF-C complex. Addition of the three wild-type recombinant CBF subunits to EL4 cell nuclear extracts depleted of CBF stimulated transcription 5-20-fold from pro alpha 2(1) collagen promoters and 10-fold from the Rous sarcoma virus long terminal repeat, Two CBF deletion mutants, one containing full-length CBF-A and CBF-C and a CBF-B lacking the NH2-terminal residues 1-224, and the other containing full- length CBF-A and CBF-B and a CBF-C lacking the COOH-terminal residues 114-309, also stimulated transcription from these promoters, but the level of activation was reduced to half that obtained with the full-length CBF subunits, In contrast, a CBF deletion mutant protein containing full-length CBF-A and deleted forms of both CBF-B and CBF-C showed very little transcription activation from these promoters, Hence, this study demonstrates that the heterotrimeric CBF protein consists of two transcription activation domains, one present in CBF-B and the other in CBF-C, and that the two domains act additively in the in vitro assay, The activation domains of both CBF-B and CBF-C, which are rich in glutamine and hydrophobic residues, showed amino acid sequence similarities with each other and with the glutamine-rich activation domain of transcription factor Sp1.	UNIV TEXAS, MD ANDERSON CANC CTR, DEPT MOLEC GENET, HOUSTON, TX 77030 USA	University of Texas System; UTMD Anderson Cancer Center				Maity, Sankar/0000-0002-2387-6545	NATIONAL CANCER INSTITUTE [R01CA049515, P30CA016672] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR043660] Funding Source: NIH RePORTER; NCI NIH HHS [CA 16672-21, CA 49515] Funding Source: Medline; NIAMS NIH HHS [AR 43660] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P2685, DOI 10.1093/nar/23.14.2685; BUCHER P, 1990, J MOL BIOL, V212, P563, DOI 10.1016/0022-2836(90)90223-9; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHODOSH LA, 1988, CELL, V53, P11, DOI 10.1016/0092-8674(88)90483-7; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; COUSTRY F, 1995, J BIOL CHEM, V270, P468, DOI 10.1074/jbc.270.1.468; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DORN A, 1987, CELL, V50, P863, DOI 10.1016/0092-8674(87)90513-7; FERRERI K, 1994, P NATL ACAD SCI USA, V91, P210; GILL G, 1994, P NATL ACAD SCI USA, V91, P192, DOI 10.1073/pnas.91.1.192; GOLDBERG H, 1992, J BIOL CHEM, V267, P19622; GONZALEZ GA, 1991, MOL CELL BIOL, V11, P1306, DOI 10.1128/MCB.11.3.1306; HAHN S, 1988, SCIENCE, V240, P317, DOI 10.1126/science.2832951; JACKSON SM, 1995, J BIOL CHEM, V270, P21445, DOI 10.1074/jbc.270.37.21445; LIWEBER M, 1994, J IMMUNOL, V153, P4122; MAIRE P, 1989, SCIENCE, V244, P343, DOI 10.1126/science.2711183; MAITY SN, 1990, P NATL ACAD SCI USA, V87, P5378, DOI 10.1073/pnas.87.14.5378; MAITY SN, 1988, SCIENCE, V241, P582, DOI 10.1126/science.3399893; MAITY SN, 1992, J BIOL CHEM, V267, P8286; MAITY SN, 1992, J BIOL CHEM, V267, P16574; MARTIN KJ, 1990, NATURE, V346, P147, DOI 10.1038/346147a0; MCNABB DS, 1995, GENE DEV, V9, P47, DOI 10.1101/gad.9.1.47; MUDRYJ M, 1988, NUCLEIC ACIDS RES, V16, P7513, DOI 10.1093/nar/16.15.7513; OLESEN JT, 1990, GENE DEV, V4, P1714, DOI 10.1101/gad.4.10.1714; ROY B, 1995, MOL CELL BIOL, V15, P2263; SADOWSKI I, 1988, NATURE, V335, P563, DOI 10.1038/335563a0; Sinha S, 1996, MOL CELL BIOL, V16, P328; SINHA S, 1995, P NATL ACAD SCI USA, V92, P1624, DOI 10.1073/pnas.92.5.1624; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; VUORIO T, 1990, J BIOL CHEM, V265, P22480; WOOD WM, 1989, J BIOL CHEM, V264, P14840; WRIGHT KL, 1994, EMBO J, V13, P4042, DOI 10.1002/j.1460-2075.1994.tb06721.x	32	69	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14485	14491		10.1074/jbc.271.24.14485	http://dx.doi.org/10.1074/jbc.271.24.14485			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662945	hybrid			2022-12-27	WOS:A1996UQ66000080
J	Wang, S; McLeod, RS; Gordon, DA; Yao, ZM				Wang, S; McLeod, RS; Gordon, DA; Yao, ZM			The microsomal triglyceride transfer protein facilitates assembly and secretion of apolipoprotein B-containing lipoproteins and decreases cotranslational degradation of apolipoprotein B in transfected COS-7 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; PAUSE TRANSFER; TRANSLOCATION; SEQUENCE; ABETALIPOPROTEINEMIA; LINE	We studied the role of microsomal triglyceride transfer protein (MTP) in the synthesis, secretion, and cotranslational degradation of apolipoprotein (apo) B using nonhepatic COS-7 cells that expressed C-terminally truncated forms of apoB (from apoB15 to apoB94) with or without the large subunit of human MTP, With the exception of apoB15 and apoB18, secretion of all of the apoB forms was stimulated by expression of MTP, even though a small amount of short apoB forms (less than or equal to apoB48) could be secreted by cells transfected with apoB alone, The majority of the apoB protein, including apoB72 and apoB94, was secreted as high density lipoprotein (1.08-1.17 g/ml). Pulse chase experiments revealed that the secretion efficiency of apoB94 and apoB72 was low (ranging from 2 to 12%), The failure to secrete buoyant lipoproteins and the low secretion efficiency were associated with insufficient lipid synthesis by the cells, The incorporation of [H-3]oleate into cellular triglyceride and phosphatidylcholine by COS cells over a 2-h period was 28 and 38%, respectively, of that by rat hepatoma (McA-RH7777) cells, In addition to the desired full-length apoB, cells transfected with large constructs (greater than or equal to apoB60) also produced smaller species with a size of similar to 220 kDa (designated B48-like protein), Coexpression with MTP decreased formation of the B48-like proteins by 40-60%, The reduction in B48-like protein formation was specific to MTP expression; coexpression with other proteins (e.g. apoA-I or apoB15) did not alter E48-like protein production, Kinetic analysis suggested that B48-like proteins were produced concurrently (cotranslational) with the full-length apoB94 and apoB72 and were not products of post-translational degradation, Although some of the B48-like proteins might be derived from truncated species (similar to 7 kb in size) of apoB mRNA that were found in cells transfected with large apoB constructs, MTP coexpression did not affect the relative levels of the aberrant 7-kb RNA with respect to the full-length mRNA, However, coexpression of MTP decreased the accessibility of apoB to exogenous trypsin by 2-fold for apoB72 and by 10-fold for apoB94 in isolated microsomes, Thus, the reduced E48-like protein formation by MTP may be a consequence of attenuated cotranslational degradation during apoB translocation across the ER membrane, Formation of B48-like proteins was insensitive to N-acetyl-leucyl-leucyl-norleucinal, a cysteine protease inhibitor known to block post-translational degradation of apoB, These results indicate that MTP facilitates the assembly and secretion of lipoproteins containing apoB and also attenuates the formation of E48-like proteins, probably by assisting apoB translocation across the ER membrane.	UNIV OTTAWA,INST HEART,DEPT BIOCHEM,OTTAWA,ON K1Y 4E9,CANADA; BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT METAB DIS,PRINCETON,NJ 08543	University of Ottawa; University of Ottawa Heart Institute; Bristol-Myers Squibb	Wang, S (corresponding author), UNIV OTTAWA,INST HEART,LIPOPROT & ATHEROSCLEROSIS GRP,DEPT PATHOL & LAB MED,1053 CARLING AVE,OTTAWA,ON K1Y 4E9,CANADA.		McLeod, Roger/F-8014-2015	McLeod, Roger/0000-0002-6740-5569				ADELI K, 1994, J BIOL CHEM, V269, P9166; BLACKHART BD, 1990, J BIOL CHEM, V265, P8358; BOREN J, 1992, J BIOL CHEM, V267, P9858; BOREN J, 1994, J BIOL CHEM, V269, P25879; CHUCK SL, 1993, J BIOL CHEM, V268, P22794; CHUCK SL, 1992, CELL, V68, P9, DOI 10.1016/0092-8674(92)90202-N; CHUCK SL, 1990, NATURE, V346, P382, DOI 10.1038/346382a0; DIXON JL, 1993, J LIPID RES, V34, P167; DU EZ, 1994, J BIOL CHEM, V269, P24169; FAZIO S, 1995, ARTERIOSCL THROM VAS, V15, P593, DOI 10.1161/01.ATV.15.5.593; GINSBERG HN, 1995, CIRCULATION S1, V92, P1; GORDON DA, 1995, TRENDS CELL BIOL, V5, P317, DOI 10.1016/S0962-8924(00)89054-6; GORDON DA, 1994, P NATL ACAD SCI USA, V91, P7628, DOI 10.1073/pnas.91.16.7628; Gregg Richard E., 1994, Current Opinion in Lipidology, V5, P81, DOI 10.1097/00041433-199404000-00003; HEINEMANN T, 1994, J LIPID RES, V35, P2200; HERSCOVITZ H, 1995, P NATL ACAD SCI USA, V92, P659, DOI 10.1073/pnas.92.3.659; HUSSAIN MM, 1995, ARTERIOSCL THROM VAS, V15, P485, DOI 10.1161/01.ATV.15.4.485; JOHNSON DF, 1993, CIRCULATION S, V88, P1; KNOTT TJ, 1986, NATURE, V323, P734, DOI 10.1038/323734a0; LEIPER JM, 1994, J BIOL CHEM, V269, P21951; LIN MCM, 1995, J LIPID RES, V36, P1073; MARCEL YL, 1984, J BIOL CHEM, V259, P6952; MCLEOD RS, 1994, BIOCHEM J, V302, P641, DOI 10.1042/bj3020641; MCLEOD RS, 1994, J BIOL CHEM, V269, P2852; MILNE RW, 1983, ARTERIOSCLEROSIS, V3, P23, DOI 10.1161/01.ATV.3.1.23; PEASE RJ, 1995, J BIOL CHEM, V270, P7261, DOI 10.1074/jbc.270.13.7261; PEASE RJ, 1991, NATURE, V353, P448, DOI 10.1038/353448a0; RUSINOL AE, 1995, J BIOL CHEM, V270, P13318, DOI 10.1074/jbc.270.22.13318; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SELBY SL, 1988, ARTERIOSCLER THROMB, V15, P1900; SHARP D, 1993, NATURE, V365, P65, DOI 10.1038/365065a0; SPRING DJ, 1992, J BIOL CHEM, V267, P14839; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WANG HX, 1994, J BIOL CHEM, V269, P18514; WETTERAU JR, 1992, SCIENCE, V258, P999; YAMANAKA S, 1994, J BIOL CHEM, V269, P21725; YAO ZM, 1994, BBA-LIPID LIPID MET, V1212, P152, DOI 10.1016/0005-2760(94)90249-6; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YAO ZM, 1992, J BIOL CHEM, V267, P1175	40	90	90	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14124	14133		10.1074/jbc.271.24.14124	http://dx.doi.org/10.1074/jbc.271.24.14124			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662886	hybrid			2022-12-27	WOS:A1996UQ66000031
J	Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ				Fredericks, ZL; Pitcher, JA; Lefkowitz, RJ			Identification of the G protein-coupled receptor kinase phosphorylation sites in the human beta(2)-adrenergic receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; BETA-2-ADRENERGIC RECEPTOR; RHODOPSIN KINASE; ADENYLATE-CYCLASE; BOVINE RHODOPSIN; GAMMA-SUBUNITS; DESENSITIZATION; MECHANISM; AGONIST	Rapid desensitization of G protein-coupled receptors is mediated, at least in part, by their phosphorylation by the G protein-coupled receptor kinases (GRKs), However, only in the case of rhodopsin have the actual sites of receptor phosphorylation been unambiguously determined, Although previous studies have implicated the cytoplasmic tail of the beta(2)-adrenergic receptor (beta(2)AR) as the site of GRK-mediated phosphorylation, the identities of the phosphorylated residues were unknown, Here we report the identification of the sites of GRK2- and GRK5-mediated beta(2)AR phosphorylation. The phosphorylation sites of both serine/threonine kinases reside exclusively in a 40-amino acid peptide located at the extreme carboxyl terminus of the beta(2)AR. Of the seven phosphorylatable residues within this peptide, sin are phosphorylated by GRK5 (Thr-384, Thr-393, Ser-396, Ser-401, Ser-407, and Ser-411) and four are phosphorylated by GRK2 (Thr-384, Ser-396, Ser-401, and Ser-407) at equivalent phosphorylation stoichiometries (similar to 1.0 mol P-i/mol receptor), In addition to the GRK5-specific phosphorylation of Thr-393 and Ser-411, differences in the distribution of phosphate between sites are observed for GRK2 and GRK5. Increasing the stoichiometry of GRK2-mediated beta(2)AR phosphorylation from similar to 1.0 to 5.0 mol P-i/mol receptor increases the stoichiometry of phosphorylation of Thr-384, Ser-396, Ser-401, and Ser-407 rather than increasing the number of phosphoacceptor sites. The location of multiple GRK2 and GRB5 phosphoacceptor sites at the extreme carboxyl terminus of the beta(2)AR is highly reminiscent of GRK1-mediated phosphorylation of rhodopsin.	DUKE UNIV,MED CTR,DEPT MED,HOWARD HUGHES MED INST,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT BIOCHEM,HOWARD HUGHES MED INST,DURHAM,NC 27710	Duke University; Howard Hughes Medical Institute; Duke University; Howard Hughes Medical Institute			Lefkowitz, Robert/AAW-2649-2021; Pitcher, Julie/ABH-2078-2020		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATON BR, 1984, BIOCHEMISTRY-US, V23, P1737, DOI 10.1021/bi00303a024; BENOVIC JL, 1984, BIOCHEMISTRY-US, V23, P4510, DOI 10.1021/bi00315a002; BOUVIER M, 1988, NATURE, V333, P370, DOI 10.1038/333370a0; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CERIONE RA, 1983, NATURE, V306, P562, DOI 10.1038/306562a0; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; EASON MG, 1995, J BIOL CHEM, V270, P4681, DOI 10.1074/jbc.270.9.4681; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; HAUSDORFF WP, 1991, P NATL ACAD SCI USA, V88, P2979, DOI 10.1073/pnas.88.8.2979; INGLESE J, 1993, J BIOL CHEM, V268, P23735; MCDOWELL JH, 1993, BIOCHEMISTRY-US, V32, P4968, DOI 10.1021/bi00069a036; OHGURO H, 1993, BIOCHEMISTRY-US, V32, P5718, DOI 10.1021/bi00072a030; OHGURO H, 1995, J BIOL CHEM, V270, P14259, DOI 10.1074/jbc.270.24.14259; OHGURO H, 1994, BIOCHEMISTRY-US, V33, P1023, DOI 10.1021/bi00170a022; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALCZEWSKI K, 1989, BIOCHEMISTRY-US, V28, P8764, DOI 10.1021/bi00448a013; PALCZEWSKI K, 1991, J BIOL CHEM, V266, P12949; PALCZEWSKI K, 1995, J BIOL CHEM, V270, P15294, DOI 10.1074/jbc.270.25.15294; PAPAC DI, 1993, BIOCHEMISTRY-US, V32, P5930, DOI 10.1021/bi00074a002; PITCHER JA, 1995, J BIOL CHEM, V270, P11707, DOI 10.1074/jbc.270.20.11707; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; PULLEN N, 1994, BIOCHEMISTRY-US, V33, P14536, DOI 10.1021/bi00252a021; SAMAMA P, 1993, J BIOL CHEM, V268, P4625; STRASSER RH, 1986, P NATL ACAD SCI USA, V83, P6362, DOI 10.1073/pnas.83.17.6362; WILDEN U, 1982, BIOCHEMISTRY-US, V21, P3014, DOI 10.1021/bi00541a032	29	197	200	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13796	13803		10.1074/jbc.271.23.13796	http://dx.doi.org/10.1074/jbc.271.23.13796			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662852	hybrid			2022-12-27	WOS:A1996UP38500074
J	Harte, MT; Hildebrand, JD; Burnham, MR; Bouton, AH; Parsons, JT				Harte, MT; Hildebrand, JD; Burnham, MR; Bouton, AH; Parsons, JT			p130(Cas), a substrate associated with v-Src and v-Crk, localizes to focal adhesions and binds to focal adhesion kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; EXTRACELLULAR-MATRIX; CELL-ADHESION; PHOSPHORYLATION; PP125(FAK); TRANSFORMATION; IDENTIFICATION; CYTOSKELETON; EXPRESSION; PP125FAK	p130(Cas) (crk associated substrate) has the structural characteristics of an adapter protein, containing multiple consensus SH2 binding sites, an SH3 domain, and a proline-rich domain, The structure of p130(Cas) suggests that it may act to provide a framework for protein-protein interactions; however, as yet, its functional role in cells is unknown, In this report we show that p130(Cas) is localized to focal adhesions, We demonstrate that p130(Cas) associates both in, vitro and in vive with pp125(FAK) (focal adhesion kinase), a kinase implicated in signaling by the integrin family of cell adhesion receptors, p130(Cas) also associates with pp41/43(FRNK) (ppl25(FAK)-related non-kinase), an autonomously expressed form of pp125(FAK) composed of only the C-terminal noncatalytic domain, We show that the association of p130(Cas) with pp125(Fak) and pp41/43(FRNK) is direct, and is mediated by the binding of the SH3 domain of p130(Cas) to a proline-rich sequence present in both the C terminus of pp125(FAK) and in pp41/43(FRNK). In agreement with recent studies we show that p130(Cas) is tyrosine-phosphorylated upon integrin mediated cell adhesion,The association of p130(Cas) with pp125(FAK), a kinase which is activated upon cell adhesion, is likely to be functionally important in integrin mediated signal transduction.	UNIV VIRGINIA, HLTH SCI CTR, DEPT MICROBIOL, CHARLOTTESVILLE, VA 22908 USA; UNIV VIRGINIA, HLTH SCI CTR, CTR CANC, CHARLOTTESVILLE, VA 22908 USA	University of Virginia; University of Virginia					NATIONAL CANCER INSTITUTE [R37CA029243, R01CA029243] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40042, CA 29243] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AUVINEN M, 1995, MOL CELL BIOL, V15, P6513; BERGMAN M, 1995, MOL CELL BIOL, V15, P711; BOCKHOLT SM, 1993, J BIOL CHEM, V268, P14565; BOUDREAU N, 1995, TRENDS CELL BIOL, V5, P1, DOI 10.1016/S0962-8924(00)88924-2; BURNHAM MR, 1996, IN PRESS ONCOGENE, V12; BURRIDGE K, 1992, J CELL BIOL, V119, P893, DOI 10.1083/jcb.119.4.893; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; FENG SB, 1994, SCIENCE, V266, P1241, DOI 10.1126/science.7526465; GUAN JL, 1992, NATURE, V358, P690, DOI 10.1038/358690a0; HANKS SK, 1992, P NATL ACAD SCI USA, V89, P8487, DOI 10.1073/pnas.89.18.8487; HILDEBRAND JD, 1993, J CELL BIOL, V123, P993, DOI 10.1083/jcb.123.4.993; HILDEBRAND JD, 1995, MOL BIOL CELL, V6, P637, DOI 10.1091/mbc.6.6.637; HILDEBRAND JD, 1996, IN PRESS MOL CELL BI, V16; HYNES RO, 1987, CELL, V48, P549, DOI 10.1016/0092-8674(87)90233-9; Ishino M, 1995, ONCOGENE, V11, P2331; KAELIN WG, 1992, CELL, V70, P351, DOI 10.1016/0092-8674(92)90108-O; KANNER SB, 1991, EMBO J, V10, P1689, DOI 10.1002/j.1460-2075.1991.tb07693.x; KANNER SB, 1989, J IMMUNOL METHODS, V120, P115, DOI 10.1016/0022-1759(89)90296-2; KORNBERG L, 1992, J BIOL CHEM, V267, P23439; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; LO SH, 1994, CANCER METAST REV, V13, P9, DOI 10.1007/BF00690415; LO SH, 1994, J CELL BIOL, V125, P1067, DOI 10.1083/jcb.125.5.1067; MATSUDA M, 1990, SCIENCE, V248, P1537, DOI 10.1126/science.1694307; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NOJIMA Y, 1995, J BIOL CHEM, V270, P15398, DOI 10.1074/jbc.270.25.15398; PATCH LA, 1995, J CELL SCI, V108, P1371; POLTE TR, 1995, P NATL ACAD SCI USA, V92, P10678, DOI 10.1073/pnas.92.23.10678; REYNOLDS AB, 1989, MOL CELL BIOL, V9, P629, DOI 10.1128/MCB.9.2.629; RICHARDSON A, 1995, BIOESSAYS, V17, P229, DOI 10.1002/bies.950170309; ROHRSCHNEIDER LR, 1980, P NATL ACAD SCI-BIOL, V77, P3514, DOI 10.1073/pnas.77.6.3514; RUOSLAHTI E, 1994, CELL, V77, P477, DOI 10.1016/0092-8674(94)90209-7; SAKAI R, 1994, EMBO J, V13, P3748, DOI 10.1002/j.1460-2075.1994.tb06684.x; SCHALLER MD, 1993, MOL CELL BIOL, V13, P785, DOI 10.1128/MCB.13.2.785; SCHALLER MD, 1994, MOL CELL BIOL, V14, P1680, DOI 10.1128/MCB.14.3.1680; SCHALLER MD, 1992, P NATL ACAD SCI USA, V89, P5192, DOI 10.1073/pnas.89.11.5192; SCHWARTZ M A, 1992, Trends in Cell Biology, V2, P304, DOI 10.1016/0962-8924(92)90120-C; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; VUORI K, 1995, J BIOL CHEM, V270, P22259, DOI 10.1074/jbc.270.38.22259; WOODS A, 1992, J CELL SCI, V101, P277; WU H, 1991, MOL CELL BIOL, V11, P5113, DOI 10.1128/MCB.11.10.5113	43	314	317	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13649	13655		10.1074/jbc.271.23.13649	http://dx.doi.org/10.1074/jbc.271.23.13649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662921	hybrid			2022-12-27	WOS:A1996UP38500053
J	Hsu, KT; Storch, J				Hsu, KT; Storch, J			Fatty acid transfer from liver and intestinal fatty acid-binding proteins to membranes occurs by different mechanisms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-LIVER; ESCHERICHIA-COLI; RETINOL-BINDING; PURIFICATION; REFINEMENT; RESOLUTION; EXPRESSION; TRANSPORT; LIGAND; HEART	Intestinal absorptive cells contain high levels of expression of two homologous fatty acid-binding proteins (FABP), liver FABP (L-FABP), and intestinal FABP (I-FABP). Both bind long chain fatty acids with relatively high affinity, The functional distinction, if any, between these two proteins remains unknown, It is often hypothesized that FABP are important in intracellular transport of fatty acids. To assess whether fatty acid transport properties might differ between the two enterocyte FABPs, we examined the rate and mechanism of transfer of fluorescent anthroyloxy fatty acids (AOFA) from these proteins to model membranes using a resonance energy transfer assay, The results show that the absolute rate of AOFA transfer from I-FABP is faster than from L-FABP. Moreover, the apparent mechanism of fatty acid transfer is different between the two proteins. The rate of AOFA transfer from I-FABP is independent of ionic strength, directly dependent on the concentration of acceptor membrane vesicles, and dramatically regulated by the lipid composition of the membranes, These data strongly suggest that fatty acid transfer from I-FABP to membranes occurs by direct collisional interaction of the protein with the phospholipid bilayer, In contrast, the characteristics of fatty acid transfer from L-FABP are consistent with an aqueous diffusion-mediated process, Thus the two enterocyte FABPs may perform different functions within the intestinal absorptive cell in the regulation of fatty acid transport and utilization. It is hypothesized that L-FABP may act as a cytosolic buffer for fatty acids, maintaining the unbound fatty acid concentration, whereas I-FABP may be involved in the uptake and/or specific targeting of fatty acid to subcellular membrane sites.			Hsu, KT (corresponding author), RUTGERS STATE UNIV,COOK COLL,DEPT NUTR SCI,NEW BRUNSWICK,NJ 08903, USA.			Storch, Judith/0000-0001-5482-1777	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK038389, R01DK038389] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK38389, R01 DK038389] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALPERS DH, 1984, P NATL ACAD SCI-BIOL, V81, P313, DOI 10.1073/pnas.81.2.313; BAIER LJ, 1995, J CLIN INVEST, V95, P1281, DOI 10.1172/JCI117778; BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BASS NM, 1988, INT REV CYTOL, V111, P143, DOI 10.1016/S0074-7696(08)61733-7; BASS NM, 1985, J BIOL CHEM, V260, P1432; BASS NM, 1985, CHEM PHYS LIPIDS, V38, P95, DOI 10.1016/0009-3084(85)90060-X; CAREY MC, 1983, ANNU REV PHYSIOL, V45, P651, DOI 10.1146/annurev.ph.45.030183.003251; CHARLTON SC, 1982, BIOCHEMISTRY-US, V21, P4023, DOI 10.1021/bi00260a018; CISTOLA DP, 1989, J BIOL CHEM, V264, P2700; COWAN SW, 1993, J MOL BIOL, V230, P1225, DOI 10.1006/jmbi.1993.1238; GANGL A, 1975, J CLIN INVEST, V55, P803, DOI 10.1172/JCI107991; GLATZ JFC, 1985, BIOCHIM BIOPHYS ACTA, V837, P57, DOI 10.1016/0005-2760(85)90085-2; GLATZ JFC, 1983, ANAL BIOCHEM, V132, P89, DOI 10.1016/0003-2697(83)90429-3; Gomori G, 1942, J LAB CLIN MED, V27, P955; GORDON JI, 1982, BIOCHEMISTRY-US, V21, P5424, DOI 10.1021/bi00265a007; Herr FM, 1996, BIOCHEMISTRY-US, V35, P1296, DOI 10.1021/bi952204b; Huang C, 1974, Methods Enzymol, V32, P485; JAKOBY MG, 1993, BIOCHEMISTRY-US, V32, P872, DOI 10.1021/bi00054a019; KAIKAUS RM, 1990, EXPERIENTIA, V46, P617, DOI 10.1007/BF01939701; KANDA T, 1990, BIOCHEM BIOPH RES CO, V168, P1053, DOI 10.1016/0006-291X(90)91136-G; KIM HK, 1992, J BIOL CHEM, V267, P20051; KIM HK, 1992, J BIOL CHEM, V267, P77; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LONG FA, 1952, CHEM REV, V51, P119, DOI 10.1021/cr60158a004; LOWE JB, 1987, J BIOL CHEM, V262, P5931; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNZER MA, 1977, J BIOL CHEM, V252, P5483; LUXON BA, 1993, AM J PHYSIOL, V265, pG831, DOI 10.1152/ajpgi.1993.265.5.G831; MATARESE V, 1989, PROG LIPID RES, V28, P245, DOI 10.1016/0163-7827(89)90001-5; MUGA A, 1993, BIOCHIM BIOPHYS ACTA, V1162, P291, DOI 10.1016/0167-4838(93)90293-Z; NEMECZ G, 1991, J BIOL CHEM, V266, P17112; NEMECZ G, 1991, ARCH BIOCHEM BIOPHYS, V286, P300, DOI 10.1016/0003-9861(91)90044-J; OCKNER RK, 1982, J BIOL CHEM, V257, P7872; OCKNER RK, 1974, J CLIN INVEST, V54, P326, DOI 10.1172/JCI107768; RICHIERI GV, 1992, J BIOL CHEM, V267, P23495; RICHIERI GV, 1994, J BIOL CHEM, V269, P23918; ROSEMAN MA, 1980, BIOCHEMISTRY-US, V19, P439, DOI 10.1021/bi00544a006; ROSING J, 1988, BIOCHEMISTRY-US, V27, P9048, DOI 10.1021/bi00425a025; SACCHETTINI JC, 1989, J MOL BIOL, V208, P327, DOI 10.1016/0022-2836(89)90392-6; SACCHETTINI JC, 1988, J BIOL CHEM, V263, P5815; SCAPIN G, 1992, J BIOL CHEM, V267, P4253; STEWART JM, 1991, BIOCHEM J, V275, P569, DOI 10.1042/bj2750569; STORCH J, 1993, MOL CELL BIOCHEM, V123, P45, DOI 10.1007/BF01076474; STORCH J, 1990, J BIOL CHEM, V265, P7827; STORCH J, 1986, BIOCHEMISTRY-US, V25, P1717, DOI 10.1021/bi00355a041; STORCH J, 1989, J BIOL CHEM, V264, P8708; SWEETSER DA, 1987, ANNU REV NUTR, V7, P337, DOI 10.1146/annurev.nu.07.070187.002005; TAKAHASHI K, 1983, EUR J BIOCHEM, V136, P589, DOI 10.1111/j.1432-1033.1983.tb07781.x; TIPPING E, 1981, BIOCHEM J, V195, P441, DOI 10.1042/bj1950441; VEERKAMP JH, 1991, BIOCHIM BIOPHYS ACTA, V1081, P1, DOI 10.1016/0005-2760(91)90244-C; WOOTAN MG, 1994, J BIOL CHEM, V269, P10517; WOOTAN MG, 1993, BIOCHEMISTRY-US, V32, P3622; WORRALL AF, 1991, BIOCHEM J, V278, P365, DOI 10.1042/bj2780365; XU ZH, 1993, J BIOL CHEM, V268, P7874; XU ZH, 1991, J BIOL CHEM, V266, P14367; ZANOTTI G, 1994, BIOCHEM J, V301, P459, DOI 10.1042/bj3010459; ZANOTTI G, 1992, J BIOL CHEM, V267, P18541	57	165	170	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13317	13323		10.1074/jbc.271.23.13317	http://dx.doi.org/10.1074/jbc.271.23.13317			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662836	hybrid			2022-12-27	WOS:A1996UP38500006
J	Junius, FK; ODonoghue, SI; Nilges, M; Weiss, AS; King, GF				Junius, FK; ODonoghue, SI; Nilges, M; Weiss, AS; King, GF			High resolution NMR solution structure of the leucine zipper domain of the c-Jun homodimer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-RAY STRUCTURE; COILED COILS; 3-DIMENSIONAL STRUCTURES; GCN4; PROTEINS; DNA; RECOGNITION; COMPLEX; REGION	The solution structure of the c-Jun leucine zipper domain has been determined to high resolution using a new calculation protocol designed to handle highly ambiguous sets of interproton distance restraints, The domain comprises a coiled coil of parallel alpha-helices in which most of the hydrophobic residues are buried at the highly symmetrical dimer interface; this Interface extends over 10 helical turns and is the most elongated protein domain solved to date using MMR methods, The backbone fold is very similar to that seen in crystal structures of the GCN4 and Jun-Fos leucine zippers; however, in contrast with these crystal structures, the Jun leucine zipper dimer appears to be devoid of favorable intermolecular electrostatic interactions, A polar asparagine residue, located at the dimer interface, forms the sole point of asymmetry in the structure; furthermore, the side chain of this residue is disordered due to motional averaging, This residue, which is highly conserved in the leucine zipper family of transcription factors, provides a destabilizing influence that is likely to facilitate the rapid exchange of zipper strands in vivo.	UNIV SYDNEY,DEPT BIOCHEM,SYDNEY,NSW 2006,AUSTRALIA; EUROPEAN MOLEC BIOL LAB,D-69012 HEIDELBERG,GERMANY	University of Sydney; European Molecular Biology Laboratory (EMBL)			Weiss, Anthony S/F-8103-2010; Nilges, Michael/E-4803-2011; King, Glenn F/J-5059-2012; Weiss, Anthony S/GYV-0157-2022; O'Donoghue, Sean/A-9522-2012	Weiss, Anthony S/0000-0002-8106-4836; Nilges, Michael/0000-0002-1451-8092; King, Glenn F/0000-0002-2308-2200; O'Donoghue, Sean/0000-0001-9520-6623				Angel P. E., 1994, FOS JUN FAMILIES TRA; BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BENEDETTI E, 1992, BIOPOLYMERS, V32, P453, DOI 10.1002/bip.360320424; BLAKE DJ, 1995, TRENDS BIOCHEM SCI, V20, P133, DOI 10.1016/S0968-0004(00)88986-0; BRUNGER AT, 1993, XPLOR USER MANUAL VE; BURGERING MJM, 1993, FEBS LETT, V330, P105, DOI 10.1016/0014-5793(93)80929-O; CRICK FHC, 1953, ACTA CRYSTALLOGR, V6, P689, DOI 10.1107/S0365110X53001964; ELLENBERGER TE, 1992, CELL, V71, P1223, DOI 10.1016/S0092-8674(05)80070-4; FERREDAMARE AR, 1993, NATURE, V363, P38, DOI 10.1038/363038a0; GLOVER JNM, 1995, NATURE, V373, P257, DOI 10.1038/373257a0; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HURST HC, 1994, PROTEIN PROFILE, V1, P123; JOHN M, 1994, J BIOL CHEM, V269, P16247; JUNIUS FK, 1993, EUR J BIOCHEM, V214, P415, DOI 10.1111/j.1432-1033.1993.tb17937.x; JUNIUS FK, 1995, BIOCHEMISTRY-US, V34, P6164, DOI 10.1021/bi00018a020; KONIG P, 1993, J MOL BIOL, V233, P139, DOI 10.1006/jmbi.1993.1490; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LUMB KJ, 1995, SCIENCE, V268, P436, DOI 10.1126/science.7716550; Lumb KJ, 1996, SCIENCE, V271, P1137, DOI 10.1126/science.271.5252.1137; LUMB KJ, 1995, BIOCHEMISTRY-US, V34, P8642, DOI 10.1021/bi00027a013; Mackay JP, 1996, BIOCHEMISTRY-US, V35, P4867, DOI 10.1021/bi952761y; MCLACHLAN AD, 1975, J MOL BIOL, V98, P293, DOI 10.1016/S0022-2836(75)80119-7; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; NILGES M, 1993, PROTEINS, V17, P297, DOI 10.1002/prot.340170307; NILGES M, 1991, PROTEIN ENG, V4, P649, DOI 10.1093/protein/4.6.649; NILGES M, 1988, FEBS LETT, V229, P317, DOI 10.1016/0014-5793(88)81148-7; ODONOGHUE SI, 1993, PROTEIN ENG, V6, P557, DOI 10.1093/protein/6.6.557; ODONOGHUE SI, 1996, IN PRESS J BIOMOL NM; OSHEA EK, 1991, SCIENCE, V254, P539, DOI 10.1126/science.1948029; OSHEA EK, 1992, CELL, V68, P699, DOI 10.1016/0092-8674(92)90145-3; PATEL LR, 1994, P NATL ACAD SCI USA, V91, P7360, DOI 10.1073/pnas.91.15.7360; RILEY LG, 1994, EUR J BIOCHEM, V219, P877, DOI 10.1111/j.1432-1033.1994.tb18569.x; SEO J, 1993, PROTEINS, V15, P223, DOI 10.1002/prot.340150302; SIPPL MJ, 1993, PROTEINS, V17, P355, DOI 10.1002/prot.340170404; WENDT H, 1995, BIOCHEMISTRY-US, V34, P4097, DOI 10.1021/bi00012a028; ZHAO DQ, 1994, J MOL BIOL, V239, P601, DOI 10.1006/jmbi.1994.1402; ZHOU NE, 1994, PROTEIN ENG, V7, P1365, DOI 10.1093/protein/7.11.1365	39	85	89	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13663	13667		10.1074/jbc.271.23.13663	http://dx.doi.org/10.1074/jbc.271.23.13663			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662824	hybrid			2022-12-27	WOS:A1996UP38500055
J	Pieper, RO; Patel, S; Ting, SA; Futscher, BW; Costello, JF				Pieper, RO; Patel, S; Ting, SA; Futscher, BW; Costello, JF			Methylation of CpG island transcription factor binding sites is unnecessary for aberrant silencing of the human MGMT gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA METHYLATION; O6-METHYLGUANINE-DNA METHYLTRANSFERASE; CHROMOSOME INACTIVATION; CYTOSINE METHYLATION; CHROMATIN STRUCTURE; KINASE GENE; HPRT GENE; EXPRESSION; PROMOTER; MARKERS	Aberrant transcriptional inactivation of the non-X-linked human O-6-methylguanine DNA methyltransferase (MGMT) gene has been associated with loss of open chromatin structure and increases in cytosine methylation in the Sp1-binding region of the 5'-CpG island of the gene, To examine the necessity of these events for gene silencing, we]save isolated and characterized a subline of human MGMT+ T98G glioma cells, The subline, T98Gs, does not express MGMT activity or MGMT mRNA, and exhibits no in vivo DNA-protein interactions at Sp1-like binding sites in the MGMT 5'-CpG island. While the MGMT CPG island is less accessible to exogenously added restriction enzymes in T98Gs nuclei than in T98G nuclei, it is similarly methylated in both T98G and T98Gs cell lines 5' and 3' to the transcription factor binding sites, and similarly unmethylated in the region encompassing the binding sites, Inappropriate transcriptional inactivation of MGMT, therefore, does not require methylation of transcription factor binding sites within the 5'-CpG island. Rather, MGMT gene silencing and transcription factor exclusion from T98Gs MGMT CpG island binding sites is most closely associated with condensed chromatin structure, which is in turns indirectly influenced by distant sites of methylation.	LOYOLA UNIV,DEPT PHARMACOL,DIV HEMATOL ONCOL,MAYWOOD,IL 60153; LOYOLA UNIV,PROGRAM MOLEC BIOL,MAYWOOD,IL 60153; UNIV ARIZONA,ARIZONA CANC CTR,TUCSON,AZ 85724; LUDWIG INST CANC RES,SAN DIEGO,CA 92093	Loyola University Chicago; Loyola University Chicago; Arizona Center Cancer Care; University of Arizona; Ludwig Institute for Cancer Research	Pieper, RO (corresponding author), LOYOLA UNIV,MED CTR,DEPT MED,DIV HEMATOL ONCOL,2160 S 1ST AVE,MAYWOOD,IL 60153, USA.				NATIONAL CANCER INSTITUTE [R29CA055064, R01CA055064] Funding Source: NIH RePORTER; NCI NIH HHS [CA55064] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BIRD AP, 1987, TRENDS GENET, V3, P342, DOI 10.1016/0168-9525(87)90294-0; BUSCHHAUSEN G, 1987, P NATL ACAD SCI USA, V84, P1177, DOI 10.1073/pnas.84.5.1177; CARLSON M, 1994, CURR OPIN CELL BIOL, V6, P396, DOI 10.1016/0955-0674(94)90032-9; COSTELLO JF, 1994, J BIOL CHEM, V269, P17228; COSTELLO JF, 1994, MOL CELL BIOL, V14, P6515, DOI 10.1128/MCB.14.10.6515; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; Futscher B W, 1989, Cancer Commun, V1, P65; GARDINERGARDEN M, 1987, J MOL BIOL, V196, P261, DOI 10.1016/0022-2836(87)90689-9; HANSEN RS, 1988, MOL CELL BIOL, V8, P4692, DOI 10.1128/MCB.8.11.4692; HARRINGTON MA, 1988, P NATL ACAD SCI USA, V85, P2066, DOI 10.1073/pnas.85.7.2066; HARRIS LC, 1991, NUCLEIC ACIDS RES, V19, P6163, DOI 10.1093/nar/19.22.6163; HERMAN JG, 1994, P NATL ACAD SCI USA, V91, P9700, DOI 10.1073/pnas.91.21.9700; HOLLER M, 1988, GENE DEV, V2, P1127, DOI 10.1101/gad.2.9.1127; HORNSTRA IK, 1994, MOL CELL BIOL, V14, P1419, DOI 10.1128/MCB.14.2.1419; ISSA JPJ, 1994, NAT GENET, V7, P536, DOI 10.1038/ng0894-536; KASS SU, 1993, MOL CELL BIOL, V13, P7372, DOI 10.1128/MCB.13.12.7372; KESHET I, 1986, CELL, V44, P535, DOI 10.1016/0092-8674(86)90263-1; KING BL, 1994, AM J PATHOL, V144, P486; KOVESDI I, 1987, P NATL ACAD SCI USA, V84, P2180, DOI 10.1073/pnas.84.8.2180; KROES RA, 1995, CARCINOGENESIS, V16, P2255, DOI 10.1093/carcin/16.9.2255; KWIATKOWSKI DJ, 1992, GENOMICS, V12, P229, DOI 10.1016/0888-7543(92)90370-8; LARSEN F, 1992, GENOMICS, V13, P1095, DOI 10.1016/0888-7543(92)90024-M; LEE WH, 1994, P NATL ACAD SCI USA, V91, P11733, DOI 10.1073/pnas.91.24.11733; LEE YW, 1995, MOL CELL BIOL, V15, P2547; LOCK LF, 1987, CELL, V48, P39, DOI 10.1016/0092-8674(87)90353-9; LOCK LF, 1986, MOL CELL BIOL, V6, P914, DOI 10.1128/MCB.6.3.914; Maxam A M, 1980, Methods Enzymol, V65, P499; MCGREW MJ, 1993, BIOTECHNIQUES, V15, P722; MEEHAN RR, 1989, CELL, V58, P499, DOI 10.1016/0092-8674(89)90430-3; MEEHAN RR, 1992, NUCLEIC ACIDS RES, V20, P5085, DOI 10.1093/nar/20.19.5085; NAKATSU Y, 1993, MUTAT RES, V293, P119, DOI 10.1016/0921-8777(93)90063-M; PEGG AE, 1990, CANCER RES, V50, P6119; PFEIFER GP, 1990, GENE DEV, V4, P1277, DOI 10.1101/gad.4.8.1277; PFIEFER GP, 1989, SCIENCE, V246, P810; PIEPER RO, 1991, CANCER COMMUN, V3, P241, DOI 10.3727/095535491820873092; RIDEOUT WM, 1994, MOL CELL BIOL, V14, P6143, DOI 10.1128/MCB.14.9.6143; SELKER EU, 1990, TRENDS BIOCHEM SCI, V15, P103, DOI 10.1016/0968-0004(90)90193-F; SINGERSAM J, 1990, MOL CELL BIOL, V10, P4987, DOI 10.1128/MCB.10.9.4987; TETER B, 1994, J NEUROSCI RES, V39, P680, DOI 10.1002/jnr.490390609; VONWRONSKI MA, 1994, CARCINOGENESIS, V15, P577, DOI 10.1093/carcin/15.4.577; WATT F, 1988, GENE DEV, V2, P1136, DOI 10.1101/gad.2.9.1136; WU SW, 1987, CANCER RES, V47, P6229	42	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13916	13924		10.1074/jbc.271.23.13916	http://dx.doi.org/10.1074/jbc.271.23.13916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662860	hybrid			2022-12-27	WOS:A1996UP38500091
J	Bai, WL; Weigel, NL				Bai, WL; Weigel, NL			Phosphorylation of Ser(211) in the chicken progesterone receptor modulates its transcriptional activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STEROID-HORMONE RECEPTORS; DNA-BINDING DOMAIN; VITAMIN-D RECEPTOR; CASEIN KINASE-II; GLUCOCORTICOID RECEPTOR; ESTROGEN-RECEPTOR; DEPENDENT PHOSPHORYLATION; PROTEIN-KINASE; ACTIVATION; SITE	The chicken progesterone receptor has been shown to be phosphorylated in vivo at four major sites. Previous studies have shown that mutation of one of the hormone-dependent phosphorylation sites, Ser(530), to alanine decreases the transcriptional activity of the receptor under conditions where ligand is limited. Here, we present evidence for the functional significance of another phosphorylation site, Ser(211). Mutation of Set-211 to alanine results in a decrease in the transcriptional activity of the receptor and affects the phosphorylation-dependent decrease in mobility of the receptor in SDS-polyacrylamide gel electrophoresis. The degree of reduction in transcriptional activity is dependent on both the cell type and the reporters used in the studies but is independent of hormone concentration, suggesting that phosphorylation at Ser(211) regulates the activity of the receptor through a mechanism distinct from Ser(530) phosphorylation.	BAYLOR COLL MED, DEPT CELL BIOL, HOUSTON, TX 77030 USA	Baylor College of Medicine			Bai, Wenlong/A-8977-2013	Bai, Wenlong/0000-0002-9536-0556	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [P30HD007495, R01HD022061] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [F32DK009151] Funding Source: NIH RePORTER; NICHD NIH HHS [HD22061, HD-07495] Funding Source: Medline; NIDDK NIH HHS [F32 DK009151, 1F32 DK09151-01] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALI S, 1993, EMBO J, V12, P1153, DOI 10.1002/j.1460-2075.1993.tb05756.x; ALLGOOD VE, 1993, J BIOL CHEM, V268, P20870; ARNOLD SF, 1994, MOL ENDOCRINOL, V8, P1208, DOI 10.1210/me.8.9.1208; Bai Wenlong, 1995, V51, P289; BAI WL, 1994, MOL ENDOCRINOL, V8, P1465, DOI 10.1210/me.8.11.1465; BAILLY A, 1986, EMBO J, V5, P3235, DOI 10.1002/j.1460-2075.1986.tb04634.x; BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BECK CA, 1992, MOL ENDOCRINOL, V6, P607, DOI 10.1210/me.6.4.607; BOCQUEL MT, 1989, NUCLEIC ACIDS RES, V17, P2581, DOI 10.1093/nar/17.7.2581; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; BRADSHAW MS, 1988, MOL ENDOCRINOL, V2, P1286, DOI 10.1210/mend-2-12-1286; BRIAN S, 1988, GENE, V67, P271; CARSONJURICA MA, 1990, J STEROID BIOCHEM, V34, P1; CASTORIA G, 1993, BIOCHEMISTRY-US, V32, P1740, DOI 10.1021/bi00058a007; DAVIS IJ, 1994, MOL CELL BIOL, V14, P3469, DOI 10.1128/MCB.14.5.3469; DAYANI N, 1990, BIOCHEMISTRY-US, V29, P2691, DOI 10.1021/bi00463a011; DENNER LA, 1990, J BIOL CHEM, V265, P16548; DENNER LA, 1989, ENDOCRINOLOGY, V125, P3051, DOI 10.1210/endo-125-6-3051; DENNER LA, 1990, SCIENCE, V250, P1740, DOI 10.1126/science.2176746; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GLINEUR C, 1989, ONCOGENE, V4, P1247; GREEN S, 1988, TRENDS GENET, V4, P309, DOI 10.1016/0168-9525(88)90108-4; GRONEMEYER H, 1987, EMBO J, V6, P3985, DOI 10.1002/j.1460-2075.1987.tb02741.x; GRONEMEYER H, 1991, ANNU REV GENET, V25, P89, DOI 10.1146/annurev.ge.25.120191.000513; HILLIARD GM, 1994, BIOCHEMISTRY-US, V33, P4300, DOI 10.1021/bi00180a026; HIRATA Y, 1993, J BIOL CHEM, V268, P24808; HSIEH JC, 1991, P NATL ACAD SCI USA, V88, P9315, DOI 10.1073/pnas.88.20.9315; HSU SC, 1992, EMBO J, V11, P3457, DOI 10.1002/j.1460-2075.1992.tb05425.x; JEWELL CM, 1995, ENDOCRINE SOC, P423; JOEL PB, 1995, MOL ENDOCRINOL, V9, P1041, DOI 10.1210/me.9.8.1041; JURUTKA PW, 1993, J BIOL CHEM, V268, P6791; KATO S, 1995, SCIENCE, V270, P1491, DOI 10.1126/science.270.5241.1491; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LEGOFF P, 1994, J BIOL CHEM, V269, P4458; MASON SA, 1993, J BIOL CHEM, V268, P21501; MORENO S, 1990, CELL, V61, P549, DOI 10.1016/0092-8674(90)90463-O; MULKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; OLEASERRANO N, 1985, EUR J CANCER CLIN ON, V21, P965, DOI 10.1016/0277-5379(85)90116-6; OMALLEY B, 1990, MOL ENDOCRINOL, V4, P363, DOI 10.1210/mend-4-3-363; OMALLEY BW, 1992, MOL ENDOCRINOL, V6, P1359, DOI 10.1210/me.6.9.1359; OMALLEY BW, 1991, RECENT PROG HORM RES, V47, P1; ORTI E, 1992, ENDOCR REV, V13, P105, DOI 10.1210/er.13.1.105; POLETTI A, 1993, BIOCHEMISTRY-US, V32, P9563, DOI 10.1021/bi00088a007; POLETTI A, 1993, MOL ENDOCRINOL, V7, P241, DOI 10.1210/me.7.2.241; POWER RF, 1991, SCIENCE, V254, P1636, DOI 10.1126/science.1749936; RAYMOURE WJ, 1985, NATURE, V314, P745, DOI 10.1038/314745a0; TAKIMOTO GS, 1992, P NATL ACAD SCI USA, V89, P3050, DOI 10.1073/pnas.89.7.3050; TSAI MJ, 1994, ANNU REV BIOCHEM, V63, P451, DOI 10.1146/annurev.bi.63.070194.002315; WEIGEL NL, 1989, ENDOCRINOLOGY, V125, P2494, DOI 10.1210/endo-125-5-2494; WEIGEL NL, 1992, MOL ENDOCRINOL, V6, P8, DOI 10.1210/me.6.1.8; WEIGEL NL, 1993, ADV PROT PHOSPHAT, V7, P237; WEIGEL NL, 1994, MECH STEROID HORMONE, P93; WEIGEL NL, 1990, RECEPTOR PURIFICATIO, P259; ZHANG Y, 1994, ENDOCRINE SOC, P630; ZHANG YX, 1994, MOL ENDOCRINOL, V8, P577, DOI 10.1210/me.8.5.577; ZHANG YX, 1994, J BIOL CHEM, V269, P31034; ZHANG YX, 1995, MOL ENDOCRINOL, V9, P1029, DOI 10.1210/me.9.8.1029	57	32	33	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12801	12806		10.1074/jbc.271.22.12801	http://dx.doi.org/10.1074/jbc.271.22.12801			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662804	hybrid			2022-12-27	WOS:A1996UN47400019
J	Crawley, JB; Williams, LM; Mander, T; Brennan, FM; Foxwell, BMJ				Crawley, JB; Williams, LM; Mander, T; Brennan, FM; Foxwell, BMJ			Interleukin-10 stimulation of phosphatidylinositol 3-kinase and p70 S6 kinase is required for the proliferative but not the antiinflammatory effects of the cytokine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IL-10; CELLS; ACTIVATION; RAPAMYCIN; RECEPTORS; PROTEIN; 3,4,5-TRISPHOSPHATE; PHOSPHORYLATION; LYMPHOCYTES; EXPRESSION	Interleukin-10 (IL-10) is a powerful suppressor of the proinflammatory monokine production by lipopolysaccharide-stimulated monocytes as well as a T- and B-cell growth cofactor, The signal transduction cascades initiated by IL-10 ligation to its cognate receptor remain to be elucidated, Here, we demonstrate that in both primary monocytes and the D36 cell line, IL-10 rapidly and transiently stimulated phosphatidylinositol 5-kinase activity associated with the p85 subunit of the enzyme, IL-10 also activated p70 S6 kinase in both cell types, The activation of both of these kinases was sensitive to wortmannin, an inhibitor of phosphatidylinositol 3-kinase, The activation of p70 S6 kinase was also inhibited by the immunosuppressive drug rapamycin. Both rapamycin and wortmannin inhibited the IL-10-induced proliferation of D36 cells but in contrast had no effect on the antiinflammatory effects of the cytokine on lipopolysaccharide-stimulated monocytes, Similar results on D36 proliferation and lipopolysaccharide stimulated monocyte inhibition by IL-10 were obtained with another phosphatidylinositol 3-kinase inhibitor, LY294002, This suggests that the activation of phosphatidylinositol 3-kinase and p70 S6 kinase is involved in the proliferative functions of IL-10 and that other as yet uncharacterized pathways affect the suppressive effects on monocytes, indicating that multiple and distinct signaling pathways mediate the various pleiotropic activities of IL-10. Furthermore, these findings suggest that it may be possible in the future to modulate the antiinflammatory effects of IL-10 for therapeutic benefit without disrupting other functions of the cytokine.	KENNEDY INST,SUNLEY DIV,LONDON W6 8LW,ENGLAND; XENOVA LTD,SLOUGH SL1 4EQ,BERKS,ENGLAND	University of Oxford								ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; AUGUSTINE JA, 1991, MOL CELL BIOL, V11, P4431, DOI 10.1128/MCB.11.9.4431; BROWN EJ, 1994, NATURE, V369, P756, DOI 10.1038/369756a0; BROWN EJ, 1995, NATURE, V377, P441, DOI 10.1038/377441a0; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; BUTLER DM, 1994, EUR CYTOKINE NETW, V5, P441; CALVO V, 1994, EUR J IMMUNOL, V24, P2664, DOI 10.1002/eji.1830241115; CASSATELLA MA, 1993, J EXP MED, V178, P2207, DOI 10.1084/jem.178.6.2207; CHUI M, 1994, P NATL ACAD SCI USA, V91, P12574; CHUNG J, 1992, CELL, V69, P1227, DOI 10.1016/0092-8674(92)90643-Q; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; DADI H, 1994, BLOOD, V84, P1579; DING L, 1993, J IMMUNOL, V151, P1224; DUMONT FJ, 1990, J IMMUNOL, V144, P251; ENGELBERTS I, 1991, LYMPHOKINE CYTOK RES, V10, P69; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; FIORENTINO DF, 1991, J IMMUNOL, V147, P3815; FLUCKIGER AC, 1993, J EXP MED, V178, P1473, DOI 10.1084/jem.178.5.1473; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FUKUI Y, 1989, MOL CELL BIOL, V9, P1651, DOI 10.1128/MCB.9.4.1651; HARA K, 1995, BIOCHEM BIOPH RES CO, V208, P735, DOI 10.1006/bbrc.1995.1399; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HURME M, 1994, IMMUNOL LETT, V42, P129, DOI 10.1016/0165-2478(94)90075-2; JOYCE DA, 1994, EUR J IMMUNOL, V24, P2699, DOI 10.1002/eji.1830241119; KANAI F, 1993, BIOCHEM BIOPH RES CO, V195, P762, DOI 10.1006/bbrc.1993.2111; KHARBANDA S, 1995, J BIOL CHEM, V270, P18871, DOI 10.1074/jbc.270.32.18871; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LEHMANN J, 1994, J IMMUNOL, V153, P165; LEVY Y, 1994, J CLIN INVEST, V93, P424, DOI 10.1172/JCI116977; MACNEIL IA, 1990, J IMMUNOL, V145, P4167; MALEFYT RD, 1991, J EXP MED, V174, P1209; MALEFYT RD, 1991, J EXP MED, V174, P915; MERIDA I, 1991, J IMMUNOL, V147, P2202; MIYAZAKI T, 1995, CELL, V81, P223, DOI 10.1016/0092-8674(95)90332-1; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; MOWER DA, 1994, J IMMUNOL, V152, P4832; MYERS MG, 1994, J BIOL CHEM, V269, P28783; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; PAGES F, 1994, NATURE, V369, P327, DOI 10.1038/369327a0; PAI SY, 1994, EUR J IMMUNOL, V24, P2364, DOI 10.1002/eji.1830241016; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SABATINI DM, 1994, CELL, V78, P35, DOI 10.1016/0092-8674(94)90570-3; SCHLAAK JF, 1994, J IMMUNOL METHODS, V168, P49, DOI 10.1016/0022-1759(94)90208-9; TAGA K, 1993, INT IMMUNOL, V5, P1599, DOI 10.1093/intimm/5.12.1599; TAYLORFISHWICK DA, 1993, TRANSPLANTATION, V56, P368, DOI 10.1097/00007890-199308000-00023; THOMPSONSNIPES LA, 1991, J EXP MED, V173, P507, DOI 10.1084/jem.173.2.507; VENTIKARAMAN AR, 1994, EUR J IMMUNOL, V24, P2168; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; YANO H, 1993, J BIOL CHEM, V268, P25846	54	84	88	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16357	16362		10.1074/jbc.271.27.16357	http://dx.doi.org/10.1074/jbc.271.27.16357			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663063	hybrid			2022-12-27	WOS:A1996UW35200074
J	Dodig, M; Kronenberg, MS; Bedalov, A; Kream, BE; Gronowicz, G; Clark, SH; Mack, K; Liu, YH; Maxon, R; Pan, ZZ; Upholt, WB; Rowe, DW; Lichtler, AC				Dodig, M; Kronenberg, MS; Bedalov, A; Kream, BE; Gronowicz, G; Clark, SH; Mack, K; Liu, YH; Maxon, R; Pan, ZZ; Upholt, WB; Rowe, DW; Lichtler, AC			Identification of a TAAT-containing motif required for high level expression of the COL1A1 promoter in differentiated osteoblasts of transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-1(I) COLLAGEN PROMOTER; MESSENGER-RNA LEVELS; FETAL-RAT CALVARIA; GROWTH FACTOR-BETA; NUCLEAR FACTOR-I; PARATHYROID-HORMONE; INSITU HYBRIDIZATION; CELL REPLICATION; MC3T3-E1 CELLS; DNA-SEQUENCES	Our previous studies have shown that the 49-base pair region of promoter DNA between -1719 and -1670 base pairs is necessary for transcription of the rat COL1A1 gene in transgenic mouse calvariae, In this study, we further define this element to the 13-base pair region between -1683 and -1670. This element contains a TAAT motif that binds homeodomain-containing proteins, Site-directed mutagenesis of this element in the context of a COL1A1-chloramphenicol acetyltransferase construct extending to -3518 base pairs decreased the ratio of reporter gene activity in calvariae to tendon from 3:1 to 1:1, suggesting a preferential effect on activity in calvariae, Moreover, chloramphenicol acetyltransferase-specific immunofluorescence microscopy of transgenic calvariae showed that the mutation preferentially reduced levels of chloramphenicol acetyltransferase-protein in differentiated osteoblasts, Gel mobility shift assays demonstrate that differentiated osteoblasts contain a nuclear factor that binds to this site, This binding activity is not present in undifferentiated osteoblasts, Ne show that Msx2, a homeodomain protein, binds to this motif; however, Northern blot analysis revealed that Msx2 mRNA is present in undifferentiated bone cells but not in fully differentiated osteoblasts, In addition, cotransfection studies in ROS 17/2.8 osteosarcoma cells using an Msx2 expression vector showed that Msx2 inhibits a COL1A1 promoter-chloramphenicol acetyltransferase construct, Our results suggest that high COL1A1 expression in bone is mediated by a protein that is induced during osteoblast differentiation. This protein may contain a homeodomain; however, it is distinct from homeodomain proteins reported previously to be present in bone.	UNIV CONNECTICUT,CTR HLTH,DEPT PEDIAT,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT ORTHOPAED SURG,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT BIOSTRUCT & FUNCT,FARMINGTON,CT 06030; UNIV CONNECTICUT,CTR HLTH,DEPT MED,DIV RHEUMAT DIS,FARMINGTON,CT 06030; DEPT VET AFFAIRS MED CTR,NEWINGTON,CT 06111; UNIV SO CALIF,SCH MED,KENNETH R NORRIS HOSP & INST,DEPT BIOCHEM & MOLEC BIOL,LOS ANGELES,CA 90033	University of Connecticut; University of Connecticut; University of Connecticut; University of Connecticut; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Connecticut Healthcare System; University of Southern California			Pan, Zhong-Zong/B-6964-2012	Gronowicz, Gloria/0000-0001-7158-3598	NIAMS NIH HHS [AR29850, AR38933, AR29983] Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR029983, R01AR029850, P01AR038933] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BEDALOV A, 1995, J BONE MINER RES, V10, P1443; BELL JR, 1993, GENOMICS, V16, P123, DOI 10.1006/geno.1993.1149; BIRNBAUM RS, 1994, ENDOCRINOLOGY, V135, P223, DOI 10.1210/en.135.1.223; BOGDANOVIC Z, 1994, J BONE MINER RES, V9, P285; CATRON KM, 1993, MOL CELL BIOL, V13, P2354, DOI 10.1128/MCB.13.4.2354; CELESTE AJ, 1986, EMBO J, V5, P1885, DOI 10.1002/j.1460-2075.1986.tb04440.x; CHEN JK, 1991, MATRIX, V11, P133, DOI 10.1016/S0934-8832(11)80217-9; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CSERJESI P, 1992, DEVELOPMENT, V115, P1087; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DUCY P, 1995, MOL CELL BIOL, V15, P1858; ECAROTCHARRIER B, 1983, J CELL BIOL, V96, P639, DOI 10.1083/jcb.96.3.639; GENOVESE C, 1984, BIOCHEMISTRY-US, V23, P6210, DOI 10.1021/bi00320a049; GOLDRING MB, 1987, J BIOL CHEM, V262, P16724; HARRISON JR, 1990, MOL ENDOCRINOL, V4, P184, DOI 10.1210/mend-4-2-184; HEINRICHS AAJ, 1995, J CELL BIOCHEM, V57, P90, DOI 10.1002/jcb.240570110; HOCK JM, 1988, ENDOCRINOLOGY, V122, P254, DOI 10.1210/endo-122-1-254; HOCK JM, 1990, ENDOCRINOLOGY, V126, P421, DOI 10.1210/endo-126-1-421; HODGKINSON JE, 1993, BIOCHIM BIOPHYS ACTA, V1174, P11, DOI 10.1016/0167-4781(93)90086-S; HOFFMANN HM, 1994, P NATL ACAD SCI USA, V91, P12887, DOI 10.1073/pnas.91.26.12887; HOGAN B, 1986, MANIPULATING MOUSE E; KARSENTY G, 1988, J BIOL CHEM, V263, P13909; KREAM BE, 1986, ENDOCRINOLOGY, V119, P1922, DOI 10.1210/endo-119-5-1922; KREAM BE, 1980, P NATL ACAD SCI-BIOL, V77, P5654, DOI 10.1073/pnas.77.10.5654; KREAM BE, 1993, MOL ENDOCRINOL, V7, P399, DOI 10.1210/me.7.3.399; KREBSBACH PH, 1993, MOL CELL BIOL, V13, P5168, DOI 10.1128/MCB.13.9.5168; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; MONAGHAN AP, 1991, DEVELOPMENT, V112, P1053; NEHLS MC, 1991, MOL CELL BIOL, V11, P4065, DOI 10.1128/MCB.11.8.4065; NEHLS MC, 1992, DNA CELL BIOL, V11, P443, DOI 10.1089/dna.1992.11.443; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PAGE KM, 1982, THEORY PRACTICE HIST, P324; PAVLIN D, 1992, J CELL BIOL, V116, P227, DOI 10.1083/jcb.116.1.227; POON RYC, 1993, EMBO J, V12, P3123, DOI 10.1002/j.1460-2075.1993.tb05981.x; PRYWES R, 1986, CELL, V47, P777, DOI 10.1016/0092-8674(86)90520-9; QUARLES LD, 1992, J BONE MINER RES, V7, P683; RAISZ LG, 1983, NEW ENGL J MED, V309, P83, DOI 10.1056/NEJM198307143090206; RIPPE RA, 1989, MOL CELL BIOL, V9, P2224, DOI 10.1128/MCB.9.5.2224; ROSSERT J, 1995, J CELL BIOL, V129, P1421, DOI 10.1083/jcb.129.5.1421; ROSSI P, 1988, CELL, V52, P405, DOI 10.1016/S0092-8674(88)80033-3; ROSSOUW CMS, 1987, J BIOL CHEM, V262, P15151; ROWE DW, 1982, J BIOL CHEM, V257, P8009; Sambrook J., 2002, MOL CLONING LAB MANU; SHAPIRO DJ, 1988, DNA-J MOLEC CELL BIO, V7, P47, DOI 10.1089/dna.1988.7.47; SLACK JL, 1991, MOL CELL BIOL, V11, P2066, DOI 10.1128/MCB.11.4.2066; SOKOLOV BP, 1995, J BIOL CHEM, V270, P9622, DOI 10.1074/jbc.270.16.9622; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P1484, DOI 10.1210/me.8.11.1484; TOWLER DA, 1994, MOL ENDOCRINOL, V8, P614, DOI 10.1210/me.8.5.614; WEINREB M, 1990, J BONE MINER RES, V5, P831; WONG G, 1974, NATURE, V252, P713, DOI 10.1038/252713a0	50	82	82	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16422	16429		10.1074/jbc.271.27.16422	http://dx.doi.org/10.1074/jbc.271.27.16422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663211	hybrid			2022-12-27	WOS:A1996UW35200083
J	Lortat-Jacob, H; Baltzer, F; Grimaud, JA				Lortat-Jacob, H; Baltzer, F; Grimaud, JA			Heparin decreases the blood clearance of interferon-gamma and increases its activity by limiting the processing of its carboxyl-terminal sequence	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR; IMMUNE INTERFERON; CELL-SURFACE; BINDING; SULFATE; RECEPTOR; PARAMETERS; CYTOKINES	Interferon-gamma (IFN-gamma) binds with high affinity to heparan sulfate and heparin molecules through its carboxyl-terminal domain, In vivo, IFN-gamma is eliminated from the bloodstream with a half-life (t(1/2)) of 1.1 min, due to binding to heparan sulfate, Unbound IFN-gamma is cleaved rapidly at the carboxyl-terminal side, a process that removes at least 18 amino acids and inactivates the cytokine. When bound to heparin, the plasma clearance of IFN-gamma is decreased greatly (t(1/2) = 99 min), and the area under the curve obtained with IFN-gamma alone represented only 15% of that obtained with injected IFN-gamma bound to heparin, Furthermore, the binding of heparin to IFN-gamma limits the extent of its carboxyl-terminal domain degradation to less than 10 amino acids. Importantly, this process increases the cytokine activity by as much as 600%. These data demonstrate that the blood clearance of the cytokine is a non-receptor-mediated process and that in vivo the local concentration of heparan sulfate/heparin-like molecules regulates IFN-gamma activity by a unique mechanism involving a controlled processing of its carboxyl-terminal sequence.			Lortat-Jacob, H (corresponding author), INST PASTEUR, CNRS URA 1459, AVE T GARNIER, F-69365 LYON 7, FRANCE.							ARAI K, 1990, ANNU REV BIOCHEM, V59, P783, DOI 10.1146/annurev.biochem.59.1.783; BERG K, 1990, APMIS, V98, P156, DOI 10.1111/j.1699-0463.1990.tb01016.x; COUSIN MA, 1992, HYBRIDOMA, V11, P561, DOI 10.1089/hyb.1992.11.561; DOBELI H, 1988, J BIOTECHNOL, V7, P199, DOI 10.1016/0168-1656(88)90052-1; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FLAUMENHAFT R, 1992, MOL BIOL CELL, V3, P1057, DOI 10.1091/mbc.3.10.1057; Flaumenhaft R, 1991, CURR OPIN CELL BIOL, V3, P817, DOI 10.1016/0955-0674(91)90055-4; GONIAS SL, 1989, J INTERFERON RES, V9, P517, DOI 10.1089/jir.1989.9.517; GORDON MY, 1987, NATURE, V326, P403, DOI 10.1038/326403a0; GUTTERMAN JU, 1984, CANCER RES, V44, P4164; HORNER AA, 1990, BIOCHEM J, V266, P553; KATO Y, 1994, HEPATOLOGY, V20, P417; LORTAT-JACOB H, 1991, FEBS LETT, V280, P152, DOI 10.1016/0014-5793(91)80225-R; LORTAT-JACOB H, 1991, J CLIN INVEST, V87, P878, DOI 10.1172/JCI115093; LORTAT-JACOB H, 1992, BIOCHIM BIOPHYS ACTA, V1117, P126, DOI 10.1016/0304-4165(92)90069-7; LORTAT-JACOB H, 1995, BIOCHEM J, V310, P497, DOI 10.1042/bj3100497; LORTATJACOB H, 1996, IN PRESS CYTOKINE; LUSTER AD, 1995, J EXP MED, V182, P219, DOI 10.1084/jem.182.1.219; MIYAJIMA A, 1992, ANNU REV IMMUNOL, V10, P295, DOI 10.1146/annurev.immunol.10.1.295; MORDENTI J, 1992, PHARMACEUT RES, V9, P17, DOI 10.1023/A:1018915307554; NARITA M, 1995, J BIOL CHEM, V270, P24800, DOI 10.1074/jbc.270.42.24800; NATHAN C, 1991, J CELL BIOL, V113, P981, DOI 10.1083/jcb.113.5.981; PROTHERO JW, 1980, COMP BIOCHEM PHYS A, V67, P649, DOI 10.1016/0300-9629(80)90255-8; RINDERKNECHT E, 1984, J BIOL CHEM, V259, P6790; ROBERTS R, 1988, NATURE, V332, P376, DOI 10.1038/332376a0; SCHEIN CH, 1995, BIOCHEM J, V307, P123, DOI 10.1042/bj3070123; TRINCHIERI G, 1985, IMMUNOL TODAY, V6, P131, DOI 10.1016/0167-5699(85)90080-5; WAGNER JG, 1976, J PHARMACOKINET BIOP, V4, P443, DOI 10.1007/BF01062831; WETZEL R, 1990, PROTEIN ENG, V3, P611, DOI 10.1093/protein/3.7.611; WIETZERBIN J, 1986, J IMMUNOL, V136, P2451; YANAGISHITA M, 1992, J BIOL CHEM, V267, P9451; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W	32	104	104	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16139	16143		10.1074/jbc.271.27.16139	http://dx.doi.org/10.1074/jbc.271.27.16139			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663206	hybrid			2022-12-27	WOS:A1996UW35200044
J	Barr, DP; Gunther, MR; Deterding, LJ; Tomer, KB; Mason, RP				Barr, DP; Gunther, MR; Deterding, LJ; Tomer, KB; Mason, RP			ESR spin-trapping of a protein-derived tyrosyl radical from the reaction of cytochrome c with hydrogen peroxide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIPID-PEROXIDATION; HYDROPEROXIDE; RESONANCE; METMYOGLOBIN; CATALASE; TYR-151; DAMAGE; HEART	The reaction of horse heart cytochrome c with hydrogen peroxide was investigated using the ESR spin-trapping technique and the nitroso spin traps 3,5-dibromo-4-nitrosobenzenesulfonic acid (DBNBS) and 2-methyl-2-nitrosopropane (MNP). The ESR spectra obtained using both spin traps were typical of an immobilized nitroxide and indicated that the adduct was a macromolecule, The intensity of the ESR spectrum corresponding to the DBNBS/(.)cytochrome c radical adduct was greatly enhanced by performing the reaction under anaerobic conditions, which suggested that the spin trap was competing with O-2 for reaction with the radical site(s), Nonspecific proteolysis of either the DBNBS or the MNP adducts revealed isotropic three-line spectra, In addition, a high resolution ESR spectrum for the protease-treated MNP cytochrome c-derived protein radical adduct was obtained. The superhyperfine couplings detected in this spectra were identical to those detected from an authentic MNP/tyrosyl adduct, Carbon-13 labeling of the aromatic ring positions of tyrosine yielded additional hyperfine coupling, demonstrating that the radical site was definitely located on the ring of tyrosine, Mass spectrometry detected as many as four DBNBS/(.)cytochrome c-derived adducts from the reaction of cytochrome with H2O2, Thus, it would appear four radical sites are formed during the reaction, at least one of which is tyrosine.			Barr, DP (corresponding author), NIEHS, MOLEC BIOPHYS LAB, NIH, POB 12233, RES TRIANGLE PK, NC 27709 USA.		Tomer, Kenneth B/E-8018-2013; Mason, Ronald P/G-5967-2019	Mason, Ronald P/0000-0002-1859-9109				Barr DP, 1996, CHEM RES TOXICOL, V9, P318, DOI 10.1021/tx9501501; Brigellius R., 1985, OXIDATIVE STRESS, P243; CHANCE B, 1979, PHYSIOL REV, V59, P527, DOI 10.1152/physrev.1979.59.3.527; CHOE YS, 1994, ARCH BIOCHEM BIOPHYS, V314, P126, DOI 10.1006/abbi.1994.1420; DAVIES MJ, 1991, FREE RADICAL RES COM, V15, P111, DOI 10.3109/10715769109049131; DICKERSON RE, 1971, J BIOL CHEM, V246, P1511; DULING DR, 1994, J MAGN RESON SER B, V104, P105, DOI 10.1006/jmrb.1994.1062; DYER C, 1979, BIOCHIM BIOPHYS ACTA, V579, P253, DOI 10.1016/0005-2795(79)90053-9; FLAHERTY JT, 1988, FREE RADICAL BIO MED, V5, P409, DOI 10.1016/0891-5849(88)90115-3; FLORENCE TM, 1985, J INORG BIOCHEM, V23, P131, DOI 10.1016/0162-0134(85)83017-8; GALARIS D, 1990, ARCH BIOCHEM BIOPHYS, V281, P163, DOI 10.1016/0003-9861(90)90427-Z; GEORGE P, 1952, BIOCHEM J, V52, P511, DOI 10.1042/bj0520511; GIBSON JF, 1958, NATURE, V181, P1398, DOI 10.1038/1811398a0; GUNTHER MR, 1995, J BIOL CHEM, V270, P16075, DOI 10.1074/jbc.270.27.16075; HIRAMOTO K, 1994, FREE RADICAL RES, V21, P341, DOI 10.3109/10715769409056586; HOFFMAN BM, 1981, J BIOL CHEM, V256, P6556; JANSSEN YMW, 1993, LAB INVEST, V69, P261; KANNER J, 1985, ARCH BIOCHEM BIOPHYS, V237, P314, DOI 10.1016/0003-9861(85)90282-6; Kappus H., 1985, OXIDATIVE STRESS, V40, P273, DOI [DOI 10.1016/B978-0-12-642760-8.50016-8, 10.1016/B978-0-12-642760-8.50016-8]; KARAS M, 1991, MASS SPECTROM REV, V10, P335, DOI 10.1002/mas.1280100503; KAUR H, 1981, J CHEM SOC CHEM COMM, P142, DOI 10.1039/c39810000142; KELMAN DJ, 1994, J BIOL CHEM, V269, P7458; KING NK, 1967, BIOCHIM BIOPHYS ACTA, V133, P65; KING NK, 1963, J BIOL CHEM, V238, P1520; LION Y, 1982, PHOTOCHEM PHOTOBIOL, V35, P53, DOI 10.1111/j.1751-1097.1982.tb03810.x; LION Y, 1982, PHOTOCHEM PHOTOBIOL, V35, P43, DOI 10.1111/j.1751-1097.1982.tb03809.x; MAIORINO M, 1994, FREE RADICAL BIO MED, V16, P661, DOI 10.1016/0891-5849(94)90067-1; MIKI H, 1989, ARCH BIOCHEM BIOPHYS, V275, P354, DOI 10.1016/0003-9861(89)90382-2; MILLER DM, 1990, FREE RADICAL BIO MED, V8, P95, DOI 10.1016/0891-5849(90)90148-C; OMalley PJ, 1995, BBA-BIOENERGETICS, V1232, P175, DOI 10.1016/0005-2728(95)00102-6; OSHEROFF N, 1980, J BIOL CHEM, V255, P1689; RADI R, 1993, FREE RADICAL BIO MED, V15, P653, DOI 10.1016/0891-5849(93)90169-U; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P112, DOI 10.1016/0003-9861(91)90171-E; RADI R, 1991, ARCH BIOCHEM BIOPHYS, V288, P118, DOI 10.1016/0003-9861(91)90172-F; RADI R, 1993, ARCH BIOCHEM BIOPHYS, V300, P409, DOI 10.1006/abbi.1993.1055; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; ROUBAL WT, 1966, ARCH BIOCHEM BIOPHYS, V113, P150, DOI 10.1016/0003-9861(66)90168-8; TAPPEL AL, 1953, FOOD RES, V18, P560; TEW D, 1988, J BIOL CHEM, V263, P17880; TURRENS JF, 1988, FEBS LETT, V227, P43, DOI 10.1016/0014-5793(88)81410-8; WUTHRICH K, 1971, BIOCHIM BIOPHYS ACTA, V253, P98, DOI 10.1016/0005-2728(71)90237-4	41	131	133	0	14	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15498	15503		10.1074/jbc.271.26.15498	http://dx.doi.org/10.1074/jbc.271.26.15498			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663160	hybrid			2022-12-27	WOS:A1996UV29900031
J	Duan, WR; Linzer, DIH; Gibori, G				Duan, WR; Linzer, DIH; Gibori, G			Cloning and characterization of an ovarian-specific protein that associates with the short form of the prolactin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUTEINIZING-HORMONE; LUTEAL CELL; RAT OVARY; EXPRESSION; ALPHA-2-MACROGLOBULIN; PREGNANCY; ESTRADIOL; LIVER	Prolactin (PRL) is essential for progesterone biosynthesis and luteal cell hypertrophy of the rat corpus luteum during pregnancy. Both the long and short form of the PRL receptor have been identified in the corpus luteum of pregnant rat. The long form has been shown to transduce PRL signal in other cells, whereas no information is available on the role of the short form, especially in the corpus luteum. In the present study, we have cloned a rat ovarian specific phosphoprotein, FRAP (PRL Receptor Associated Protein), which has no significant homology to other known proteins, We have demonstrated that this protein is immunoprecipitated by anti-PRL receptor and anti-phosphotyrosine antibodies. To determine whether FRAP associates with either the long or the short form of the PRL receptor, fusion proteins with glutathione S-transferase containing the cytoplasmic domain of the long or short form of the PRL receptor were produced, purified, and incubated with luteal proteins. Our results indicate that FRAP preferentially binds to the short form of the PRL receptor. Thus, the long form and short forms of the PRL receptor may signal through distinct pathways. These data provide evidence for the involvement of a novel protein in PRL signal transduction and suggest that FRAP may contribute to the luteotropic effects of PRL on the corpus luteum during pregnancy.	UNIV ILLINOIS, DEPT PHYSIOL & BIOPHYS, CHICAGO, IL 60612 USA; NORTHWESTERN UNIV, DEPT BIOCHEM MOLEC BIOL & CELL BIOL, EVANSTON, IL 60208 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; Northwestern University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [P01HD021921] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD011119, R37HD011119] Funding Source: NIH RePORTER; NICHD NIH HHS [HD-11119, HD21921] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALBARRACIN CT, 1994, J BIOL CHEM, V269, P7772; ALBARRACIN CT, 1994, ENDOCRINOLOGY, V134, P2453, DOI 10.1210/en.134.6.2453; ALI S, 1991, J BIOL CHEM, V266, P20110; ALI S, 1992, MOL ENDOCRINOL, V6, P1242, DOI 10.1210/me.6.8.1242; BASURAY R, 1983, BIOL REPROD, V28, P551, DOI 10.1095/biolreprod28.3.551; BERLANGA JJ, 1995, MOL ENDOCRINOL, V9, P1461, DOI 10.1210/me.9.11.1461; BOUTIN JM, 1988, CELL, V53, P69, DOI 10.1016/0092-8674(88)90488-6; CLARKE DL, 1993, ENDOCRINOLOGY, V133, P2594, DOI 10.1210/en.133.6.2594; CLARKE DL, 1994, OVARIAN CELL INTERAC, P110; CLEVENGER CV, 1995, J BIOL CHEM, V270, P13246, DOI 10.1074/jbc.270.22.13246; CLEVENGER CV, 1994, MOL ENDOCRINOL, V8, P674, DOI 10.1210/me.8.6.674; CLEVENGER CV, 1994, J BIOL CHEM, V269, P5559; DAJEE M, 1995, BIOL REPROD S, V52, pA353; DAS R, 1995, MOL ENDOCRINOL, V9, P1750, DOI 10.1210/me.9.12.1750; DAVID M, 1994, P NATL ACAD SCI USA, V91, P7174, DOI 10.1073/pnas.91.15.7174; DAVIS JA, 1989, MOL ENDOCRINOL, V3, P674, DOI 10.1210/mend-3-4-674; DAVIS S, 1993, SCIENCE, V260, P1805, DOI 10.1126/science.8390097; DUSANTERFOURT I, 1994, EMBO J, V13, P2583, DOI 10.1002/j.1460-2075.1994.tb06548.x; ERWIN RA, 1995, ENDOCRINOLOGY, V136, P3512, DOI 10.1210/en.136.8.3512; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GADDYKURTEN D, 1989, ENDOCRINOLOGY, V125, P2985; GADDYKURTEN D, 1991, MOL ENDOCRINOL, V5, P1280, DOI 10.1210/mend-5-9-1280; GIBORI G, 1988, RECENT PROG HORM RES, V44, P377; GIBORI G, 1979, BIOL REPROD, V21, P419, DOI 10.1095/biolreprod21.2.419; GIBORI G, 1978, ENDOCRINOLOGY, V102, P767, DOI 10.1210/endo-102-3-767; GIBORI G, 1978, ENDOCRINOLOGY, V102, P1176, DOI 10.1210/endo-102-4-1176; Gibori G., 1993, OVARY, P261; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEBRUN JJ, 1994, J BIOL CHEM, V269, P14021; LEGENDRE N, 1993, PRACTICAL GUIDE PROT, P74; LESUEUR L, 1991, P NATL ACAD SCI USA, V88, P824, DOI 10.1073/pnas.88.3.824; MACDONALD GJ, 1971, P SOC EXP BIOL MED, V136, P687; MCLEAN MP, 1990, ENDOCRINOLOGY, V126, P1796, DOI 10.1210/endo-126-4-1796; NAGANO M, 1994, J BIOL CHEM, V269, P13337; Nisson P E, 1991, PCR Methods Appl, V1, P120; ONEAL KD, 1994, J BIOL CHEM, V269, P26076; PARMER TG, 1992, ENDOCRINOLOGY, V131, P2213, DOI 10.1210/en.131.5.2213; RUI H, 1994, J BIOL CHEM, V269, P5364; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGALOFF DL, 1990, MOL ENDOCRINOL, V4, P1856, DOI 10.1210/mend-4-12-1856; SHIROTA M, 1990, MOL ENDOCRINOL, V4, P1136, DOI 10.1210/mend-4-8-1136; SHUAL K, 1993, NATURE, V366, P580, DOI 10.1038/366580a0; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STANDKE GJR, 1994, MOL ENDOCRINOL, V8, P469, DOI 10.1210/me.8.4.469; WAKAO H, 1994, EMBO J, V13, P2182, DOI 10.1002/j.1460-2075.1994.tb06495.x; ZHANG R, 1990, BIOCHEM BIOPH RES CO, V168, P415, DOI 10.1016/0006-291X(90)92337-Y; ZHONG L, 1995, BIOL REPROD S, V52, pA379	50	66	67	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15602	15607		10.1074/jbc.271.26.15602	http://dx.doi.org/10.1074/jbc.271.26.15602			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663045	hybrid			2022-12-27	WOS:A1996UV29900046
J	Lenormand, P; McMahon, M; Pouyssegur, J				Lenormand, P; McMahon, M; Pouyssegur, J			Oncogenic Raf-1 activates p70 S6 kinase via a mitogen-activated protein kinase-independent pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; GROWTH-FACTORS; INHIBITION; PHOSPHORYLATION; FIBROBLASTS; PHOSPHATASE; P42(MAPK); P44(MAPK); ENCODES; INDUCE	Cell proliferation requires the co-ordinate triggering of several protein kinases of Ser/Thr specificity such as p70 S6 kinase (S6K), which phosphorylates the ribosomal S6 protein and thus increases translation of mRNAs with polypyrimidine tracts. The multiplicity of signaling pathways leading to p70 S6K activation are not fully elucidated, However, several reports have indicated that the activation of p70 S6K is independent of mitogen activated protein kinase (MAPK) activation, Interestingly, we and others have shown that constitutive activation of the MAPK pathway promotes cell proliferation, suggesting that this cascade is able to activate p70 S6K, a key step to trigger cell cycle entry, In this report we demonstrate that transfection of constitutively active mitogen activated protein kinase kinase 1 in CCL 39 cells leads to activation of p70 S6K. Furthermore, we have established a cell line that stably expresses Delta Raf-1:ER, an estradiol-regulated form of oncogenic Raf-1. The addition of estradiol to these cells was sufficient to elicit rapid activation of mitogen-activated protein kinase kinase 1, MAPK, and p70 S6K. Surprisingly, the activation of p70 S6K is not mediated by MAPK because blocking MAPK activation by expression of the phosphatase MKP-1 did not prevent p70 S6K activation by Delta Raf-1:ER, In conclusion, we have demonstrated that activation of p70 S6K by Delta Raf-1:ER is mediated by a new MAPK-independent pathway. This pathway is resistant to low nanomolar concentrations of wortmannin, indicating that it does not involve membrane-bound phosphatidylinositol-trisphosphate kinase activation.	DNAX RES INST MOLEC & CELLULAR BIOL INC, RES INST, PALO ALTO, CA 94304 USA	Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Lenormand, P (corresponding author), UNIV NICE, CTR BIOCHIM, CNRS UMR 135, PARC VALROSE, F-06108 NICE 02, FRANCE.		McMahon, Martin/L-3303-2013; Lenormand, Philippe/N-5996-2018	McMahon, Martin/0000-0003-2812-1042; 				ALESSI DR, 1994, EMBO J, V13, P1610, DOI 10.1002/j.1460-2075.1994.tb06424.x; BALLOU LM, 1991, NATURE, V349, P848; BLENIS J, 1984, J VIROL, V50, P966, DOI 10.1128/JVI.50.3.966-969.1984; BLENIS J, 1991, CELL GROWTH DIFFER, V2, P279; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUNET A, 1994, ONCOGENE, V9, P3379; BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CHEATHAM B, 1994, MOL CELL BIOL, V14, P4902, DOI 10.1128/MCB.14.7.4902; CHEATHAM L, 1995, P NATL ACAD SCI USA, V92, P11696, DOI 10.1073/pnas.92.25.11696; CHOU MM, 1995, CURR OPIN CELL BIOL, V7, P806, DOI 10.1016/0955-0674(95)80064-6; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK SG, 1992, NATURE, V356, P340, DOI 10.1038/356340a0; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; GALAKTIONOV K, 1995, GENE DEV, V9, P1046, DOI 10.1101/gad.9.9.1046; HIPSKIND RA, 1994, MOL CELL BIOL, V14, P6219, DOI 10.1128/MCB.14.9.6219; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; JEFFERIES HBJ, 1994, P NATL ACAD SCI USA, V91, P4441, DOI 10.1073/pnas.91.10.4441; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KARNITZ LM, 1995, MOL CELL BIOL, V15, P3049; KEYSE SM, 1992, NATURE, V359, P644, DOI 10.1038/359644a0; KOLODZIEJ PA, 1991, METHOD ENZYMOL, V194, P508; KREIS TE, 1986, EMBO J, V5, P931, DOI 10.1002/j.1460-2075.1986.tb04306.x; KUO CJ, 1992, NATURE, V358, P70, DOI 10.1038/358070a0; L'Allemain Gilles, 1994, Progress in Growth Factor Research, V5, P291, DOI 10.1016/0955-2235(94)90011-6; LANE HA, 1993, NATURE, V363, P170, DOI 10.1038/363170a0; LANE HA, 1991, METHOD ENZYMOL, V200, P268; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LI S, 1993, P NATL ACAD SCI USA, V90, P2947; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MCCARTHY SA, 1995, GENE DEV, V9, P1953, DOI 10.1101/gad.9.16.1953; MELOCHE S, 1992, MOL BIOL CELL, V3, P63, DOI 10.1091/mbc.3.1.63; MING XF, 1994, NATURE, V371, P426, DOI 10.1038/371426a0; MONFAR M, 1995, MOL CELL BIOL, V15, P326, DOI 10.1128/MCB.15.1.326; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; POSADA J, 1992, SCIENCE, V255, P212, DOI 10.1126/science.1313186; PRICE DJ, 1992, SCIENCE, V257, P973, DOI 10.1126/science.1380182; REINHARD C, 1992, P NATL ACAD SCI USA, V89, P4052, DOI 10.1073/pnas.89.9.4052; SAKAUE M, 1995, MOL CELL BIOL, V15, P379, DOI 10.1128/MCB.15.1.379; SAMUELS ML, 1994, MOL CELL BIOL, V14, P7855, DOI 10.1128/MCB.14.12.7855; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; SUN H, 1993, CELL, V75, P487, DOI 10.1016/0092-8674(93)90383-2; SUTHERLAND C, 1995, J BIOL CHEM, V270, P15501, DOI 10.1074/jbc.270.26.15501; THOMAS G, 1993, BIOCHEM SOC T, V21, P901, DOI 10.1042/bst0210901; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744; WENG QP, 1995, MOL CELL BIOL, V15, P2333	50	82	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15762	15768		10.1074/jbc.271.26.15762	http://dx.doi.org/10.1074/jbc.271.26.15762			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663120	hybrid			2022-12-27	WOS:A1996UV29900069
J	Maru, Y; Afar, DE; Witte, ON; Shibuya, M				Maru, Y; Afar, DE; Witte, ON; Shibuya, M			The dimerization property of glutathione S-transferase partially reactivates Bcr-Abl lacking the oligomerization domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYROSINE KINASE-ACTIVITY; PHILADELPHIA-CHROMOSOME; ONCOGENE PRODUCT; C-ABL; TRANSFORMATION; PROTEIN; EXON; CELLS	Bcr-Abl oncoproteins are responsible for the pathogenesis of human leukemias with a reciprocal chromosome translocation t(9;22). The amino-terminal Bcr sequence has a potential to form a homotetramer (tetramer domain), and destructions of the tetramer domain cause a complete loss of biological activities in Bcr-Abl. Here we show that Bcr-Abl in which the tetramer domain is replaced with glutathione S-transferase (GST) with a dimerizing ability (GST/Bcr-Abl-(Delta 1-160)) can no longer induce an interleukin-3 (IL-3) independence in Ba/F3 cells or transform mouse bone marrow cells but still retains by 30-40% the ability to transform Rat1 cells, Compared with the wild type Bcr-Abl, autophosphorylation of GST/Bcr-Abl-(Delta 1-160) in vivo was reduced by more than 50%. The Grb-2 binding to GST/Bcr-Abl-(Delta 1-160) was 50% reduced in Rat1 cells and undetectable in Ba/F3 cells. In Rat1 cells expressing GST/Bcr-Abl-(Delta 1-160), phosphotyrosine contents of p62 and She were 70% decreased.	UNIV CALIF LOS ANGELES, HOWARD HUGHES MED INST, LOS ANGELES, CA 90024 USA	Howard Hughes Medical Institute; University of California System; University of California Los Angeles	Maru, Y (corresponding author), UNIV TOKYO, INST MED SCI, DEPT GENET, MINATO KU, 4-6-1 SHIROKANEDAI, TOKYO 108, JAPAN.							CAMPBELL ML, 1990, ONCOGENE, V5, P773; DALEY GQ, 1988, P NATL ACAD SCI USA, V85, P9312, DOI 10.1073/pnas.85.23.9312; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GOGA A, 1993, MOL CELL BIOL, V13, P4967, DOI 10.1128/MCB.13.8.4967; GOLUB TR, 1994, CELL, V77, P307, DOI 10.1016/0092-8674(94)90322-0; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; JI XH, 1992, BIOCHEMISTRY-US, V31, P10169, DOI 10.1021/bi00157a004; KONOPKA JB, 1985, MOL CELL BIOL, V5, P3116, DOI 10.1128/MCB.5.11.3116; LIFSHITZ B, 1988, ONCOGENE, V2, P113; LUGO TG, 1990, SCIENCE, V247, P1079, DOI 10.1126/science.2408149; MARU Y, 1995, MOL CELL BIOL, V15, P835; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MARU Y, 1993, BRIS MYER C, V15, P123; MATUOKA K, 1993, EMBO J, V12, P3467, DOI 10.1002/j.1460-2075.1993.tb06021.x; MCLAUGHLIN J, 1987, P NATL ACAD SCI USA, V84, P6558, DOI 10.1073/pnas.84.18.6558; MCWHIRTER JR, 1993, MOL CELL BIOL, V13, P7587, DOI 10.1128/MCB.13.12.7587; MUI ALF, 1995, EMBO J, V14, P1166, DOI 10.1002/j.1460-2075.1995.tb07100.x; MULLER AJ, 1991, MOL CELL BIOL, V11, P1785, DOI 10.1128/MCB.11.4.1785; NICHOLS GL, 1994, BLOOD, V84, P2912; PARKER MW, 1990, J MOL BIOL, V213, P221, DOI 10.1016/S0022-2836(05)80183-4; PENDERGAST AM, 1993, MOL CELL BIOL, V13, P1728, DOI 10.1128/MCB.13.3.1728; PENDERGAST AM, 1989, ONCOGENE, V4, P759; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PENDERGAST AM, 1991, CELL, V66, P161, DOI 10.1016/0092-8674(91)90148-R; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; TENHOEVE J, 1994, CANCER RES, V54, P2563; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; WONG G, 1992, CELL, V69, P551, DOI 10.1016/0092-8674(92)90455-L	28	80	82	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15353	15357		10.1074/jbc.271.26.15353	http://dx.doi.org/10.1074/jbc.271.26.15353			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663064	hybrid			2022-12-27	WOS:A1996UV29900011
J	Park, PW; Rosenbloom, J; Abrams, WR; Rosenbloom, J; Mecham, RP				Park, PW; Rosenbloom, J; Abrams, WR; Rosenbloom, J; Mecham, RP			Molecular cloning and expression of the gene for elastin-binding protein (ebpS) in Staphylococcus aureus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; LAMININ RECEPTORS; HEPARAN-SULFATE; SEQUENCE; ADHESION; COLLAGEN; SIGNAL	Interactions between staphylococci and components of the extracellular matrix mediate attachment of the bacteria to host tissues and organs and define an important mechanism leading to colonization, invasion, and formation of metastatic abscesses. We have previously demonstrated a specific binding interaction between Staphylococcus aureus and elastin, one of the major protein components of the extracellular matrix. Available evidence suggests that this association is mediated by a 25-kDa elastin-binding protein on the surface of S. aureus (EbpS). To study the molecular structure and function of EbpS, the gene encoding EbpS was cloned, sequenced, and expressed in Escherichia coli. DNA sequence data indicate that the ebpS open reading frame consists of 606 base pairs and encodes a novel polypeptide with a predicted molecular mass of 23,345 daltons and pI of 4.9. A polyclonal antibody raised against recombinant EbpS interacted with the native 25-kDa cell surface EbpS and inhibited staphylococcal elastin binding. Furthermore, recombinant EbpS bound specifically to immobilized elastin and inhibited binding of S. aureus to elastin. A degradation product of recombinant EbpS lacking the first 59 amino acids of the molecule and a C-terminal fragment of CNBr-cleaved recombinant EbpS, however, did not interact with elastin. Together, these results confirm that EbpS is the cell surface molecule mediating binding of S. aureus to elastin. The inability of truncated forms of recombinant EbpS to bind to elastin suggests that the elastin binding site in EbpS is contained in the first 59 amino acids of the molecule.	UNIV WASHINGTON,SCH MED,DEPT CELL BIOL,ST LOUIS,MO 63110; UNIV WASHINGTON,SCH MED,DEPT MED,ST LOUIS,MO 63110; UNIV PENN,SCH DENT MED,DEPT ANAT & HISTOL,PHILADELPHIA,PA 19104	Washington University (WUSTL); Washington University (WUSTL); University of Pennsylvania			Abrams, William R/A-5782-2008	Park, Pyong Woo/0000-0002-7979-4979	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL026499, R01HL041926] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR020553] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 41926, HL 26499] Funding Source: Medline; NIAMS NIH HHS [AR 20553] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BADDOUR LM, 1994, INFECT IMMUN, V62, P2143, DOI 10.1128/IAI.62.6.2143-2148.1994; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; BUSBY S, 1994, CELL, V79, P743, DOI 10.1016/0092-8674(94)90063-9; CLARKE VA, 1995, J BIOL CHEM, V270, P8805, DOI 10.1074/jbc.270.15.8805; COURTNEY HS, 1994, INFECT IMMUN, V62, P3937, DOI 10.1128/IAI.62.9.3937-3946.1994; FATH MJ, 1993, MICROBIOL REV, V57, P995, DOI 10.1128/MMBR.57.4.995-1017.1993; FINLAY BB, 1989, MICROBIOL REV, V53, P210, DOI 10.1128/MMBR.53.2.210-230.1989; HAAS TA, 1994, CURR OPIN CELL BIOL, V6, P656, DOI 10.1016/0955-0674(94)90091-4; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KRIVAN HC, 1988, P NATL ACAD SCI USA, V85, P6157, DOI 10.1073/pnas.85.16.6157; KUUSELA P, 1978, NATURE, V276, P718, DOI 10.1038/276718a0; LANCEFIELD RC, 1962, J IMMUNOL, V89, P307; LIANG OD, 1992, INFECT IMMUN, V60, P899, DOI 10.1128/IAI.60.3.899-906.1992; LIOTTA LA, 1991, CELL, V64, P327, DOI 10.1016/0092-8674(91)90642-C; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOBB RR, 1994, J CLIN INVEST, V94, P1722, DOI 10.1172/JCI117519; LOPES JD, 1985, SCIENCE, V229, P275, DOI 10.1126/science.3160113; LOTTENBERG R, 1992, J BACTERIOL, V174, P5204, DOI 10.1128/JB.174.16.5204-5210.1992; Lottenberg Richard, 1994, Trends in Microbiology, V2, P20, DOI 10.1016/0966-842X(94)90340-9; MCDEVITT D, 1994, MOL MICROBIOL, V11, P237, DOI 10.1111/j.1365-2958.1994.tb00304.x; MCGAVIN MJ, 1993, J BIOL CHEM, V268, P23946; MCKINNEY MM, 1987, J IMMUNOL METHODS, V96, P271, DOI 10.1016/0022-1759(87)90324-3; MECHAM RP, 1991, ANNU REV CELL BIOL, V7, P71, DOI 10.1146/annurev.cb.07.110191.000443; MORAN CP, 1982, MOL GEN GENET, V186, P339, DOI 10.1007/BF00729452; OZ MC, 1989, J VASC SURG, V10, P439; PARK PW, 1991, J BIOL CHEM, V266, P23399; PATTI JM, 1994, ANNU REV MICROBIOL, V48, P585, DOI 10.1146/annurev.mi.48.100194.003101; PATTI JM, 1995, J BIOL CHEM, V270, P12005, DOI 10.1074/jbc.270.20.12005; PATTI JM, 1994, INFECT IMMUN, V62, P152, DOI 10.1128/IAI.62.1.152-161.1994; RAGHOW R, 1994, FASEB J, V8, P823, DOI 10.1096/fasebj.8.11.8070631; ROBERTS DD, 1990, AM J RESP CELL MOL, V3, P181, DOI 10.1165/ajrcmb/3.3.181; ROSENBLOOM J, 1993, FASEB J, V7, P1208, DOI 10.1096/fasebj.7.13.8405806; SCHNEEWIND O, 1995, SCIENCE, V268, P103, DOI 10.1126/science.7701329; SCHNEEWIND O, 1992, CELL, V70, P267, DOI 10.1016/0092-8674(92)90101-H; SELA S, 1993, MOL MICROBIOL, V10, P1049, DOI 10.1111/j.1365-2958.1993.tb00975.x; SHEAGREN JN, 1984, NEW ENGL J MED, V310, P1368, DOI 10.1056/NEJM198405243102107; SIGNAS C, 1989, P NATL ACAD SCI USA, V86, P699, DOI 10.1073/pnas.86.2.699; SJOBRING U, 1992, INFECT IMMUN, V60, P3601; SPEZIALE P, 1986, J BACTERIOL, V167, P77, DOI 10.1128/jb.167.1.77-81.1986; SWITALSKI LM, 1993, MOL MICROBIOL, V7, P99, DOI 10.1111/j.1365-2958.1993.tb01101.x; TAKESHITA S, 1987, GENE, V61, P63, DOI 10.1016/0378-1119(87)90365-9; TALAY SR, 1994, MOL MICROBIOL, V13, P531, DOI 10.1111/j.1365-2958.1994.tb00448.x; WALDVOGEL FA, 1980, NEW ENGL J MED, V303, P360, DOI 10.1056/NEJM198008143030703; WRENN DS, 1986, BIOCHEMISTRY-US, V25, P5172, DOI 10.1021/bi00366a028; YAMADA KM, 1991, J BIOL CHEM, V266, P12809; YOTHER J, 1994, J BACTERIOL, V176, P2976, DOI 10.1128/JB.176.10.2976-2985.1994	47	71	75	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15803	15809		10.1074/jbc.271.26.15803	http://dx.doi.org/10.1074/jbc.271.26.15803			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663124	hybrid			2022-12-27	WOS:A1996UV29900075
J	Banno, Y; Nakashima, S; Ohzawa, M; Nozawa, Y				Banno, Y; Nakashima, S; Ohzawa, M; Nozawa, Y			Differential translocation of phospholipase C isozymes to integrin-mediated cytoskeletal complexes in thrombin stimulated human platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; TYROSINE PHOSPHORYLATION; MEMBRANE SKELETON; AGGREGATION; PP60C-SRC; ASSOCIATION; PP60(C-SRC); ACTIVATION; C-GAMMA-1; PROTEIN	To investigate a role of phospholipase C (PLC) isozymes in the integrin alpha(IIb)beta(3)-mediated signaling, their location was examined in thrombin-activated human platelets, revealing different regulation of their translocation to the cytoskeleton (CSK). In resting platelets, the major PLCs such as PLC beta 2, PLC beta 3a (155 kDa), and PLC gamma 2 and the minor PLCs (PLC beta 1 and PLC gamma 1) were located in the Triton X-100-soluble (Tx . Sol) fraction and the membrane skeleton, whereas PLC beta 3b (140 kDa) was present only in Tx . Sol fraction when examined by Western immunoblotting, Thrombin stimulation caused a rapid and transient translocation of PLC beta 3a and PLC beta 3b and a slower accumulation of PLC beta 2 and PLC gamma 2 in the reorganized CSK. The translocation to CSK of both PLC beta 3a and PLC beta 3b, but not PLC beta 2, was dependent on integrin alpha(IIb)beta(3)-mediated aggregation, Furthermore, an actin polymerization inhibitor, genistein, abolished the CSK association of alpha(IIb)beta(3), PLC beta 3a, and PLC beta 3b. In the genistein pretreated platelets, pp60(c-src), G(q), and protein kinase C alpha were no longer able to associate with CSK, In contrast, these agents had no or marginal inhibitory effects on the CSK association of PLC beta 2 and G(i2). The late diacylglycerol generation induced by thrombin stimulation was significantly reduced by the genistein treatment, These results suggest that the inte grin alpha(IIb)beta 3-mediated cytoskeletal association of PLC beta 3 is regulated by protein tyrosine kinase and also that the activation of the relocated PLC may play a role in the late platelet-to-platelet aggregation in thrombin-stimulated human platelets.	GIFU UNIV, SCH MED, DEPT BIOCHEM, GIFU 500, JAPAN	Gifu University								BANNO Y, 1994, FEBS LETT, V340, P185, DOI 10.1016/0014-5793(94)80134-7; BANNO Y, 1995, J BIOL CHEM, V270, P4318, DOI 10.1074/jbc.270.9.4318; BLAKE RA, 1994, FEBS LETT, V353, P212, DOI 10.1016/0014-5793(94)01037-4; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, TRENDS BIOCHEM SCI, V19, P464, DOI 10.1016/0968-0004(94)90131-7; CLARK EA, 1993, MOL CELL BIOL, V13, P1863, DOI 10.1128/MCB.13.3.1863; DANIEL JL, 1994, BIOCHEM J, V302, P617, DOI 10.1042/bj3020617; DASH D, 1995, J BIOL CHEM, V270, P17321, DOI 10.1074/jbc.270.29.17321; EARNEST JP, 1995, J BIOL CHEM, V270, P27259, DOI 10.1074/jbc.270.45.27259; EZUMI Y, 1995, J BIOL CHEM, V270, P11927, DOI 10.1074/jbc.270.20.11927; FOX JEB, 1993, ADV EXP MED BIOL, V344, P175; FOX JEB, 1993, J CELL BIOL, V120, P1501, DOI 10.1083/jcb.120.6.1501; FOX JEB, 1988, J CELL BIOL, V106, P1525, DOI 10.1083/jcb.106.5.1525; FOX JEB, 1993, J BIOL CHEM, V268, P25973; GOLDEN A, 1990, J CELL BIOL, V111, P3117, DOI 10.1083/jcb.111.6.3117; GRONDIN P, 1991, J BIOL CHEM, V266, P15705; GUINEBAULT C, 1995, J CELL BIOL, V129, P831, DOI 10.1083/jcb.129.3.831; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; HASEN CA, 1994, J CELL BIOL, V126, P811; HORVATH AR, 1992, EMBO J, V11, P855, DOI 10.1002/j.1460-2075.1992.tb05123.x; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; KANNER SB, 1993, P NATL ACAD SCI USA, V90, P7099, DOI 10.1073/pnas.90.15.7099; KOVACSOVICS TJ, 1995, J BIOL CHEM, V270, P11358, DOI 10.1074/jbc.270.19.11358; MIYAMOTO S, 1995, J CELL BIOL, V131, P791, DOI 10.1083/jcb.131.3.791; NAKASHIMA S, 1991, BIOCHEM J, V275, P355, DOI 10.1042/bj2750355; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; ODA A, 1992, J BIOL CHEM, V267, P20075; PUMIGLIA KM, 1993, BIOCHEM J, V294, P253, DOI 10.1042/bj2940253; RIDLEY AJ, 1994, EMBO J, V13, P2600, DOI 10.1002/j.1460-2075.1994.tb06550.x; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; SCHOENWAELDER SM, 1994, J BIOL CHEM, V269, P32479; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SORIANO P, 1991, CELL, V64, P693, DOI 10.1016/0092-8674(91)90499-O; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TORTI M, 1994, P NATL ACAD SCI USA, V91, P4239, DOI 10.1073/pnas.91.10.4239; YAMAGUCHI A, 1990, BIOCHIM BIOPHYS ACTA, V1054, P8, DOI 10.1016/0167-4889(90)90198-M; YANO S, 1994, J BIOCHEM, V116, P778, DOI 10.1093/oxfordjournals.jbchem.a124596; ZHANG J, 1992, J BIOL CHEM, V267, P4686	39	36	36	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14989	14994		10.1074/jbc.271.25.14989	http://dx.doi.org/10.1074/jbc.271.25.14989			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663010	hybrid			2022-12-27	WOS:A1996UT10600054
J	Prudovsky, IA; Savion, N; LaVallee, TM; Maciag, T				Prudovsky, IA; Savion, N; LaVallee, TM; Maciag, T			The nuclear trafficking of extracellular fibroblast growth factor (FGF)-1 correlates with the perinuclear association of the FGF receptor-1 alpha isoforms but not the FGF receptor-1 beta isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-I; TYROSINE PHOSPHORYLATION; CELL-CYCLE; 3T3 CELLS; BINDING; FORMS; EXPRESSION; CLONING; BFGF; TRANSLOCATION	The alternatively spliced fibroblast growth factor receptor (FGFR)-1 isoforms, FGFR-1 alpha and FGFR-1 beta, are characterized by the presence of either three or two Ig-like loops in the extracellular domain and are differentially expressed during embryonic development and tumor progression, We have previously shown that in cells irreversibly committed to DNA synthesis by FGF-1, approximately 15% of cell surface FGFR-1 traffics to a perinuclear locale as a structurally intact and functional tyrosine kinase (Prudovsky, I., Savion, N., Zhan, X., Friesel, R., Xu, J., Hou, J., McKeehan, W, L., and Maciag, T. (1994) J. Biol, Chem. 269, 31720-31724). In order to define the structural requirement for association of FGFR-1 with the nucleus, the expression and trafficking of FGFR-1 in FGFR-1 alpha and FGFR-1 beta L6 myoblast transfectants was studied, Although FGFR-1 alpha was expressed as p145 and p125 forms, FGFR-1 beta was expressed as p120 and p100 forms in the L6 myoblast transfectants. Tunicamycin and N-glyconase experiments suggest that these forms of FGFR-1 alpha and FGFR-1 beta are the result of differential glycosylation. However, only the p145 form of FGFR-1 alpha and the p120 form of FGFR-1 beta were able to bind FGF-1 and activate tyrosine phosphorylation. Pulse-chase analysis of FGFR-1 biosynthesis suggests that the p125 and p100 proteins are the precursor forms of p145 FGFR-1 alpha and p120 FGFR-1 beta, respectively, Because ligand chase analysis demonstrated that FGFR-1 beta L6 myoblast transfectants exhibited a reduced efficiency of nuclear translocation of exogenous FGF-1 when compared with FGFR-1 alpha transfectants, the intracellular trafficking of the FGFR-1 alpha and FGFR-1 beta isoforms was studied using an in vitro kinase assay to amplify immunoprecipitated FGFR-1, Indeed, the appearance of the FGFR-1 alpha but not FGFR-1 beta isoform in the nuclear fraction of L6 myoblast transfectants suggests that the distal Ig-like loop in FGFR-1 alpha mediates the differential nuclear association of FGFR-1 alpha as a structurally intact and functional tyrosine kinase. Further, the FGFR-1 beta L6 myoblast transfectants but not the FGFR-1 alpha myoblast transfectants exhibited a pronounced morphologic change in response to exogenous FGF-1. Because this phenotype change involves the induction of a rounded cellular shape, it is possible that the FGFR-1 alpha and FGFR-1 beta may ultimately exhibit differential trafficking to adhesion sites.	AMER RED CROSS,HOLLAND LAB,DEPT MOLEC BIOL,ROCKVILLE,MD 20855	American Red Cross			Savion, Naphtali/K-1013-2019; Prudovsky, Igor/GVU-1521-2022	Savion, Naphtali/0000-0001-8899-0624	NHLBI NIH HHS [HL32348, HL35627] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL035627, R01HL032348] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ACLAND P, 1990, NATURE, V343, P662, DOI 10.1038/343662a0; AVIEZER D, 1994, J BIOL CHEM, V269, P114; BALDIN V, 1990, EMBO J, V9, P1511, DOI 10.1002/j.1460-2075.1990.tb08269.x; BOUCHE G, 1987, P NATL ACAD SCI USA, V84, P6770, DOI 10.1073/pnas.84.19.6770; BUGLER B, 1991, MOL CELL BIOL, V11, P573, DOI 10.1128/MCB.11.1.573; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEON HG, 1994, P NATL ACAD SCI USA, V91, P989, DOI 10.1073/pnas.91.3.989; COBB BS, 1994, MOL CELL BIOL, V14, P147, DOI 10.1128/MCB.14.1.147; EDELMAN GM, 1991, ANNU REV BIOCHEM, V60, P155, DOI 10.1146/annurev.bi.60.070191.001103; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FLORKIEWICZ RZ, 1989, P NATL ACAD SCI USA, V86, P3978, DOI 10.1073/pnas.86.11.3978; FOROUGH R, 1993, J BIOL CHEM, V268, P2960; FRIEDMAN S, 1994, BIOCHEM BIOPH RES CO, V198, P1203, DOI 10.1006/bbrc.1994.1170; FRIESEL R, 1989, MOL CELL BIOL, V9, P1857, DOI 10.1128/MCB.9.5.1857; FRIESEL R, 1991, MOL CELL BIOL, V11, P2481, DOI 10.1128/MCB.11.5.2481; FRIESEL RE, 1995, FASEB J, V9, P919, DOI 10.1096/fasebj.9.10.7542215; GERACE L, 1995, CELL, V82, P341, DOI 10.1016/0092-8674(95)90420-4; GUALANDRIS A, 1994, J CELL PHYSIOL, V161, P149, DOI 10.1002/jcp.1041610118; HAWKER JR, 1993, IN VITRO CELL DEV-AN, V30, P653; HOU JZ, 1991, SCIENCE, V251, P665, DOI 10.1126/science.1846977; HOWELL BW, 1994, MOL CELL BIOL, V14, P5402, DOI 10.1128/MCB.14.8.5402; HYNES RO, 1992, CELL, V68, P303, DOI 10.1016/0092-8674(92)90472-O; IMAMURA T, 1990, SCIENCE, V249, P1567, DOI 10.1126/science.1699274; JANS DA, 1994, FASEB J, V8, P841, DOI 10.1096/fasebj.8.11.8070633; JAYE M, 1986, SCIENCE, V233, P541, DOI 10.1126/science.3523756; JOHNSON DE, 1990, MOL CELL BIOL, V10, P4728, DOI 10.1128/MCB.10.9.4728; JOHNSON DE, 1991, MOL CELL BIOL, V11, P4627, DOI 10.1128/MCB.11.9.4627; Johnston CL, 1995, J BIOL CHEM, V270, P30643, DOI 10.1074/jbc.270.51.30643; KAN MK, 1993, SCIENCE, V259, P1918, DOI 10.1126/science.8456318; KAPLAN KB, 1995, GENE DEV, V9, P1505, DOI 10.1101/gad.9.12.1505; KIEFER P, 1995, MOL CELL BIOL, V15, P4364; KIEFER P, 1994, EMBO J, V13, P4126, DOI 10.1002/j.1460-2075.1994.tb06730.x; LEE PL, 1989, SCIENCE, V245, P57, DOI 10.1126/science.2544996; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MASON IJ, 1994, CELL, V78, P547, DOI 10.1016/0092-8674(94)90520-7; MOROIANU J, 1994, BIOCHEMISTRY-US, V33, P12535, DOI 10.1021/bi00208a001; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; OLWIN BB, 1989, J CELL BIOCHEM, V39, P443, DOI 10.1002/jcb.240390410; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; PRUDOVSKY I, 1994, J BIOL CHEM, V269, P31720; QUARTO N, 1991, CELL REGUL, V2, P699, DOI 10.1091/mbc.2.9.699; QUARTO N, 1991, J CELL PHYSIOL, V147, P311, DOI 10.1002/jcp.1041470217; RAPRAEGER AC, 1991, SCIENCE, V252, P1705, DOI 10.1126/science.1646484; ROBINSON ML, 1995, DEVELOPMENT, V121, P505; ROGHANI M, 1994, J BIOL CHEM, V269, P3976; RUOSLAHTI E, 1988, ANNU REV CELL BIOL, V4, P229, DOI 10.1146/annurev.cb.04.110188.001305; SANO H, 1990, J CELL BIOL, V110, P1417, DOI 10.1083/jcb.110.4.1417; SHI DL, 1994, DEV BIOL, V164, P173, DOI 10.1006/dbio.1994.1189; STACHOWIAK MK, 1994, J CELL BIOL, V127, P203, DOI 10.1083/jcb.127.1.203; WIEDLOCHA A, 1994, CELL, V76, P1039, DOI 10.1016/0092-8674(94)90381-6; WILLIAMS EJ, 1994, NEURON, V13, P583, DOI 10.1016/0896-6273(94)90027-2; WU H, 1993, J CELL BIOL, V120, P1417, DOI 10.1083/jcb.120.6.1417; XU JM, 1992, J BIOL CHEM, V267, P17792; YAFFE D, 1968, P NATL ACAD SCI USA, V61, P477, DOI 10.1073/pnas.61.2.477; YAMAGUCHI F, 1994, P NATL ACAD SCI USA, V91, P484, DOI 10.1073/pnas.91.2.484; YAYON A, 1991, CELL, V64, P841, DOI 10.1016/0092-8674(91)90512-W; ZHAN X, 1993, J BIOL CHEM, V268, P24427; ZHAN X, 1993, J BIOL CHEM, V268, P9611; ZHAN X, 1994, J BIOL CHEM, V269, P20221; ZIMMER Y, 1993, J BIOL CHEM, V268, P7899	62	66	66	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14198	14205		10.1074/jbc.271.24.14198	http://dx.doi.org/10.1074/jbc.271.24.14198			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662999	hybrid			2022-12-27	WOS:A1996UQ66000041
J	Jain, N; Mahendran, R; Philp, R; Guy, GR; Tan, YH; Cao, X				Jain, N; Mahendran, R; Philp, R; Guy, GR; Tan, YH; Cao, X			Casein kinase II associates with Egr-1 and acts as a negative modulator of its DNA binding and transcription activities in NIH 3T3 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-S-TRANSFERASE; TUMOR SUPPRESSOR PROTEIN; SERUM RESPONSE FACTOR; GENE-PRODUCT; ESCHERICHIA-COLI; GROWTH; PHOSPHORYLATION; EXPRESSION; DIFFERENTIATION; SUBUNIT	Although the activation domains within early growth response gene protein 1 (Egr-1) have been mapped, little is known of the kinases which phosphorylate Egr-1 and how phosphorylation correlates with the transcriptional activity of Egr-1. In this study we report that casein kinase II (CKII) co-immunoprecipitates with Egr-1 from NIH 3T3 cell lysates. The association of Egr-1 and CKII requires the C terminus of Egr-1 and CKII phosphorylates Egr-1 in vitro. The in vitro phosphorylation of Egr-1 by CKII and that induced by serum in vivo was compared by examining the CNBr-digested fragments of the phosphorylated Egr-1, CKII strongly phosphorylates fragments 7 and 10 which cover part of the activation/nuclear localization and DNA binding domains of Egr-1. CKII also phosphorylates, albeit weakly, fragments 5 and 8 which cover part of activation domain and the entire repression domain of Egr-1, respectively. Strong phosphorylation on fragment 10 as well as fragment 5 was also observed in Egr-1 immunoprecipitated from serum-induced, P-32-labeled cells. CKII phosphorylation of Egr-1 resulted in a decrease of its DNA binding as well as its transcriptional activities.	NATL UNIV SINGAPORE, INST MOLEC & CELL BIOL, SIGNAL TRANSDUCT LAB, SINGAPORE 119260, SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Mahendran, Ratha/B-3827-2012					BOYLE WJ, 1991, METHOD ENZYMOL, V201, P110; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CAO XM, 1993, J BIOL CHEM, V268, P16949; CAO XM, 1992, J BIOL CHEM, V267, P12991; CARDENAS ME, 1993, J CELL SCI, V104, P533; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DOHROWOLSKA G, 1991, BIOCHIM BIOPHYS ACTA, V1129, P139; FILHOL O, 1992, J BIOL CHEM, V267, P20577; GASHLER AL, 1993, MOL CELL BIOL, V13, P4556, DOI 10.1128/MCB.13.8.4556; GUAN KL, 1991, ANAL BIOCHEM, V192, P262, DOI 10.1016/0003-2697(91)90534-Z; HELLERHARRISON RA, 1991, J BIOL CHEM, V266, P14435; HILL CS, 1995, CELL, V80, P199, DOI 10.1016/0092-8674(95)90403-4; HUANG RP, 1994, BIOCHEM BIOPH RES CO, V200, P1271, DOI 10.1006/bbrc.1994.1588; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JIN YJ, 1993, P NATL ACAD SCI USA, V90, P7769, DOI 10.1073/pnas.90.16.7769; KAMPS MP, 1991, METHOD ENZYMOL, V201, P21; KIKKAWA U, 1992, MOL CELL BIOL, V12, P5711, DOI 10.1128/MCB.12.12.5711; KUENZEL EA, 1985, P NATL ACAD SCI USA, V82, P737, DOI 10.1073/pnas.82.3.737; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMAIRE P, 1988, P NATL ACAD SCI USA, V85, P4691, DOI 10.1073/pnas.85.13.4691; LIM RW, 1987, ONCOGENE, V1, P263; LIN AN, 1992, CELL, V70, P777, DOI 10.1016/0092-8674(92)90311-Y; LUDEMANN R, 1993, J BIOL CHEM, V268, P17413; LUSCHER B, 1994, EUR J BIOCHEM, V220, P521, DOI 10.1111/j.1432-1033.1994.tb18651.x; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MADDEN SL, 1991, SCIENCE, V253, P1550, DOI 10.1126/science.1654597; MANAK JR, 1993, ONCOGENE, V8, P703; MANAK JR, 1990, GENE DEV, V4, P955, DOI 10.1101/gad.4.6.955; MEEK DW, 1990, EMBO J, V9, P3253, DOI 10.1002/j.1460-2075.1990.tb07524.x; MEGGIO F, 1994, CELL MOL BIOL RES, V40, P401; MILBRANDT J, 1987, SCIENCE, V238, P797, DOI 10.1126/science.3672127; NGUYEN HQ, 1993, CELL, V72, P197, DOI 10.1016/0092-8674(93)90660-I; RUDNICKI MA, 1990, DEV BIOL, V138, P348, DOI 10.1016/0012-1606(90)90202-T; RUSSO MW, 1993, MOL CELL BIOL, V13, P6858, DOI 10.1128/MCB.13.11.6858; SAIKI RK, 1988, SCIENCE, V239, P487, DOI 10.1126/science.2448875; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; STIGARE J, 1993, MOL CELL BIOCHEM, V129, P77, DOI 10.1007/BF00926578; SUKHATME VP, 1990, J AM SOC NEPHROL, V1, P859; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATT PM, 1994, BIOCHEM J, V303, P681, DOI 10.1042/bj3030681	44	43	45	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13530	13536		10.1074/jbc.271.23.13530	http://dx.doi.org/10.1074/jbc.271.23.13530			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662759	hybrid			2022-12-27	WOS:A1996UP38500035
J	Mechling, DE; Gambee, JE; Morris, NP; Sakai, LY; Keene, DR; Mayne, R; Bachinger, HP				Mechling, DE; Gambee, JE; Morris, NP; Sakai, LY; Keene, DR; Mayne, R; Bachinger, HP			Type IX collagen NC1 domain peptides can trimerize in vitro without forming a triple helix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CONSTRUCTION; MUTATIONS; XII	Synthetic peptides of the three chains of type IX collagen consisting of the carboxyl-terminal end of the COL1 domain and the complete NC1 domain were characterized by circular dichroism spectroscopy and analyzed for their ability to assemble into trimers, In vitro association and oxidation result in disulfide-linked oligomers as shown by molecular sieve chromatography and SDS-polyacrylamide electrophoresis, Whereas the individual peptides show a tendency to self-associate, when an equimolar amount of the three peptides was oxidized, a heterotrimer of the three chains was observed, This heterotrimer is recognized by a monoclonal antibody against the disulfide-linked NC1 domain of chicken type IX collagen, indicating the correct formation of the disulfide bonds, Circular dichroism measurements show that under the association conditions used, a triple helix does not form between the chains, These results indicate that these peptides contain all the necessary information for chain selection and assembly.	SHRINERS HOSP CRIPPLED CHILDRENS,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT BIOCHEM & MOLEC BIOL,PORTLAND,OR 97201; UNIV ALABAMA,DEPT CELL BIOL,BIRMINGHAM,AL 35294	Oregon Health & Science University; University of Alabama System; University of Alabama Birmingham					NEI NIH HHS [EY09908] Funding Source: Medline; NIAMS NIH HHS [AR30481] Funding Source: Medline; NATIONAL EYE INSTITUTE [R01EY009908] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R37AR030481, R01AR030481] Funding Source: NIH RePORTER	NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BACHINGER HP, 1993, AM J MED GENET, V45, P152, DOI 10.1002/ajmg.1320450204; BREWTON RG, 1995, GENOMICS, V30, P329, DOI 10.1006/geno.1995.9870; BREWTON RG, 1992, EUR J BIOCHEM, V205, P443, DOI 10.1111/j.1432-1033.1992.tb16798.x; BREWTON RG, 1994, EXTRACELLULAR MATRIX, P129; COMPTON LA, 1987, J BIOL CHEM, V262, P13039; DOEGE KJ, 1986, J BIOL CHEM, V261, P8924; ELIMA K, 1992, BIOCHIM BIOPHYS ACTA, V1130, P78, DOI 10.1016/0167-4781(92)90465-C; ENGEL J, 1991, ANNU REV BIOPHYS BIO, V20, P137, DOI 10.1146/annurev.biophys.20.1.137; EYRE DR, 1995, J RHEUMATOL, V22, P82; FASSLER R, 1994, P NATL ACAD SCI USA, V91, P5070, DOI 10.1073/pnas.91.11.5070; FESSLER JH, 1978, ANNU REV BIOCHEM, V47, P129, DOI 10.1146/annurev.bi.47.070178.001021; HEIDEMANN E, 1982, ADV POLYM SCI, V43, P143; HWANG C, 1992, SCIENCE, V257, P1496, DOI 10.1126/science.1523409; LABOURDETTE L, 1993, FEBS LETT, V320, P211, DOI 10.1016/0014-5793(93)80588-L; LAMBERT N, 1983, BIOCHEM J, V213, P213; LEES JF, 1994, J BIOL CHEM, V269, P24354; LOZANO G, 1985, P NATL ACAD SCI USA, V82, P4050, DOI 10.1073/pnas.82.12.4050; MAZZORANA M, 1993, J BIOL CHEM, V268, P3029; MIDDLETON RB, 1993, BIOCHEM J, V296, P511, DOI 10.1042/bj2960511; MORRIS NP, 1987, J BIOL CHEM, V262, P11345; MURAGAKI Y, 1990, EUR J BIOCHEM, V192, P703, DOI 10.1111/j.1432-1033.1990.tb19279.x; NINOMIYA Y, 1985, BIOCHEMISTRY-US, V24, P4223, DOI 10.1021/bi00336a061; Prockop D.J., 1976, BIOCH COLLAGENS, P163; RIES A, 1995, J BIOL CHEM, V270, P23790, DOI 10.1074/jbc.270.40.23790; SAKAI LY, 1994, METHOD ENZYMOL, V245, P29; SAKAI LY, 1986, J CELL BIOL, V103, P2499, DOI 10.1083/jcb.103.6.2499; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHMID FX, 1993, ADV PROTEIN CHEM, V44, P25, DOI 10.1016/S0065-3233(08)60563-X; SHAW LM, 1991, TRENDS BIOCHEM SCI, V16, P191, DOI 10.1016/0968-0004(91)90074-6; STEINMANN B, 1991, J BIOL CHEM, V266, P1299; WATT SL, 1992, J BIOL CHEM, V267, P20093	31	29	31	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13781	13785		10.1074/jbc.271.23.13781	http://dx.doi.org/10.1074/jbc.271.23.13781			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662808	hybrid			2022-12-27	WOS:A1996UP38500072
J	Robb, L; Hilton, DJ; Willson, TA; Begley, CG				Robb, L; Hilton, DJ; Willson, TA; Begley, CG			Structural analysis of the gene encoding the murine interleukin-11 receptor alpha-chain and a related locus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COLONY-STIMULATING FACTOR; TRANSCRIPTION FACTORS; EXPRESSION; CYTOKINE; FAMILY; ORGANIZATION; CLONING; CELLS	In this study the gene for the murine interleukin-11 receptor alpha chain (IL-11R alpha) has been characterized, The gene spans 9 kilobase pairs of DNA, and the organization of its 14 exons conforms to the pattern observed for other members of the hematopoietin receptor family. Analysis of the 5' end of the cDNA using 5' RACE showed that the first two exons, designated exons Ba and Ib, are spliced to form alternate transcripts. Transcripts initiating from exon lib were not found in adult tissues but were present in embryonic stem cells. S1 nuclease and 5' rapid amplification of cDNA ends assays demonstrated multiple major and minor sites of transcription initiation for each exon. The putative promoter regions of both exons lacked TATA boxes, although potential recognition sites for several transcription factors including Spl, AP1, and AP2 were present. A comparison of the murine and human IL-11R alpha revealed that the 5' sequence upstream of the major site of transcription initiation site for exon lib is highly conserved, Northern analysis showed that IL-11R alpha is expressed in many adult murine tissues. A second IL-11R alpha-like locus containing a sequence homologous to exons 2-13 was also identified.	ROYAL MELBOURNE HOSP,ROTARY BONE MARROW RES INST,MELBOURNE,VIC 3050,AUSTRALIA	Royal Melbourne Hospital	Robb, L (corresponding author), ROYAL MELBOURNE HOSP,WALTER & ELIZA HALL INST MED RES,COOPERAT CTR CELLULAR GROWTH FACTORS,MELBOURNE,VIC 3050,AUSTRALIA.		Hilton, Douglas J/C-7250-2013	Hilton, Douglas J/0000-0002-7698-2392				ALEXANDER WS, 1995, ONCOGENE, V10, P795; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHEREL M, 1995, BLOOD, V86, P2534; Davis S, 1993, CURR OPIN CELL BIOL, V5, P281, DOI 10.1016/0955-0674(93)90117-9; DU XX, 1994, BLOOD, V83, P2023; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HEANEY ML, 1993, BLOOD, V82, P1945, DOI 10.1182/blood.V82.7.1945.bloodjournal8271945; HILTON DJ, 1992, TRENDS BIOCHEM SCI, V17, P72, DOI 10.1016/0968-0004(92)90505-4; HILTON DJ, 1994, EMBO J, V13, P4765, DOI 10.1002/j.1460-2075.1994.tb06802.x; KISHIMOTO T, 1992, SCIENCE, V258, P593, DOI 10.1126/science.1411569; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KORN R, 1992, MECH DEVELOP, V39, P95, DOI 10.1016/0925-4773(92)90029-J; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; Nandurkar HH, 1996, ONCOGENE, V12, P585; NEUHAUS H, 1994, DEV BIOL, V166, P521; ORKIN SH, 1992, BLOOD, V80, P575; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; PAUL SR, 1990, P NATL ACAD SCI USA, V87, P7512, DOI 10.1073/pnas.87.19.7512; PIECHACZYK M, 1984, NUCLEIC ACIDS RES, V12, P6951, DOI 10.1093/nar/12.18.6951; ROSE TM, 1991, P NATL ACAD SCI USA, V88, P8641, DOI 10.1073/pnas.88.19.8641; SETO Y, 1992, J IMMUNOL, V148, P259; SHAPIRO MB, 1987, NUCLEIC ACIDS RES, V15, P7155, DOI 10.1093/nar/15.17.7155; Tuypens T, 1992, Eur Cytokine Netw, V3, P451; VanLeuven F, 1996, GENOMICS, V31, P65, DOI 10.1006/geno.1996.0010; Wrighton N, 1992, GROWTH FACTORS, V6, P103, DOI 10.3109/08977199209011014; YANG YC, 1992, BIOFACTORS, V4, P15	30	35	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13754	13761		10.1074/jbc.271.23.13754	http://dx.doi.org/10.1074/jbc.271.23.13754			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662802	hybrid			2022-12-27	WOS:A1996UP38500068
J	Hemmann, U; Gerhartz, C; Heesel, B; Sasse, J; Kurapkat, G; Grotzinger, J; Wollmer, A; Zhong, Z; Darnell, JE; Graeve, L; Heinrich, PC; Horn, F				Hemmann, U; Gerhartz, C; Heesel, B; Sasse, J; Kurapkat, G; Grotzinger, J; Wollmer, A; Zhong, Z; Darnell, JE; Graeve, L; Heinrich, PC; Horn, F			Differential activation of acute phase response factor/Stat3 and Stat1 via the cytoplasmic domain of the interleukin 6 signal transducer gp130 .2. Src homology SH2 domains define the specificity of STAT factor activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; TRANSCRIPTION FACTOR; INTERFERON-GAMMA; BINDING; PHOSPHORYLATION; ASSOCIATION; ALPHA/BETA; EXPRESSION; RECEPTOR; PATHWAY	Distinct yet overlapping sets of STAT transcription factors are activated by different cytokines. One example is the differential activation of acute phase response factor (APRF, also called Stat3) and Stat1 by interleukin 6 and interferon-gamma. Interleukin 6 activates both factors while, at least in human cells, interferon-gamma recruits only Stat1. Stat1 activation by interferon-gamma is mediated through a cytosolic tyrosine motif, Y440, of the interferon-gamma receptor. In an accompanying paper (Gerhartz, C., Heesel, B., Sasse, J., Hemmann, U., Landgraf, C., Schneider-Mergener, J., Horn, F., Heinrich, P. C., and Graeve, L. (1996) J. Biol. Chem. 271, 12991-12998), we demonstrated that two tyrosine motifs within the cytoplasmic part of the interleukin 6 signal transducer gp130 specifically mediate APRF activation while two others can recruit both APRF and Stat1. By expressing a series of Stat1/APRF domain swap mutants in COS-7 cells, we now determined which domains of Stat1 and APRF are involved in the specific recognition of phosphotyrosine motifs. Our data demonstrate that the SH2 domain is the sole determinant of specific STAT factor recruitment. Furthermore, the SH2 domain of Stat1 is able to recognize two unrelated types of phosphotyrosine motifs, one represented by the interferon-gamma receptor Y440DKPH peptide, and the other by two gp130 YXPQ motifs. By molecular modeling, we propose three dimensional model structures of the Stat1 and APRF SH2 domains which allow us to explain the different binding preferences of these factors and to predict amino acids crucial for specific peptide recognition.	RHEIN WESTFAL TH AACHEN,INST BIOCHEM,D-52057 AACHEN,GERMANY; ROCKEFELLER UNIV,MOLEC CELL BIOL LAB,NEW YORK,NY 10021	RWTH Aachen University; Rockefeller University								AKIRA S, 1994, CELL, V77, P63, DOI 10.1016/0092-8674(94)90235-6; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; CALDENHOVEN E, 1994, J BIOL CHEM, V269, P21146; CAMPBELL GS, 1995, J BIOL CHEM, V270, P3974, DOI 10.1074/jbc.270.8.3974; COFFER P, 1995, ONCOGENE, V10, P985; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; DITTRICH E, 1994, J BIOL CHEM, V269, P19014; FU XY, 1992, CELL, V70, P323, DOI 10.1016/0092-8674(92)90106-M; FUJII H, 1995, P NATL ACAD SCI USA, V92, P5482, DOI 10.1073/pnas.92.12.5482; Gerhartz C, 1996, J BIOL CHEM, V271, P12991, DOI 10.1074/jbc.271.22.12991; GREENLUND AC, 1994, EMBO J, V13, P1591, DOI 10.1002/j.1460-2075.1994.tb06422.x; GREENLUND AC, 1995, IMMUNITY, V2, P677, DOI 10.1016/1074-7613(95)90012-8; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HEIM MH, 1995, SCIENCE, V267, P1347, DOI 10.1126/science.7871432; HEMMI S, 1994, CELL, V76, P803, DOI 10.1016/0092-8674(94)90355-7; HIBI M, 1990, CELL, V63, P1149, DOI 10.1016/0092-8674(90)90411-7; HORVATH CM, 1995, GENE DEV, V9, P984, DOI 10.1101/gad.9.8.984; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEUNG S, 1995, MOL CELL BIOL, V15, P1312; LITTICKEN C, 1994, SCIENCE, V263, P89; MAYER BJ, 1992, MOL CELL BIOL, V12, P609, DOI 10.1128/MCB.12.2.609; MULLER M, 1993, NATURE, V366, P129, DOI 10.1038/366129a0; MURAKAMI M, 1993, SCIENCE, V260, P1808, DOI 10.1126/science.8511589; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PASCAL SM, 1994, CELL, V77, P461, DOI 10.1016/0092-8674(94)90160-0; SCHINDLER C, 1992, P NATL ACAD SCI USA, V89, P7836, DOI 10.1073/pnas.89.16.7836; SCHINDLER C, 1992, SCIENCE, V257, P809, DOI 10.1126/science.1496401; SEIDEL HM, 1995, P NATL ACAD SCI USA, V92, P3041, DOI 10.1073/pnas.92.7.3041; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; SHUAI K, 1993, SCIENCE, V261, P1744, DOI 10.1126/science.7690989; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; VELAZQUEZ L, 1992, CELL, V70, P313, DOI 10.1016/0092-8674(92)90105-L; VRIEND G, 1990, J MOL GRAPHICS, V8, P52, DOI 10.1016/0263-7855(90)80070-V; WAGNER BJ, 1990, EMBO J, V9, P4477, DOI 10.1002/j.1460-2075.1990.tb07898.x; WAKAO H, 1995, EMBO J, V14, P2527, DOI 10.1002/j.1460-2075.1995.tb07250.x; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WANG YD, 1995, J BIOL CHEM, V270, P7021, DOI 10.1074/jbc.270.13.7021; WATLING D, 1993, NATURE, V366, P166, DOI 10.1038/366166a0; WEGENKA UM, 1994, MOL CELL BIOL, V14, P3186, DOI 10.1128/MCB.14.5.3186; WEGENKA UM, 1993, MOL CELL BIOL, V13, P276, DOI 10.1128/MCB.13.1.276; YAMASAKI K, 1988, SCIENCE, V241, P825, DOI 10.1126/science.3136546; YUAN JP, 1994, MOL CELL BIOL, V14, P1657, DOI 10.1128/MCB.14.3.1657; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321; ZHONG Z, 1994, SCIENCE, V264, P95, DOI 10.1126/science.8140422; Ziemiecki Andrew, 1994, Trends in Cell Biology, V4, P207, DOI 10.1016/0962-8924(94)90143-0; ZVELEBIL MJJM, 1995, PROTEIN ENG, V8, P527, DOI 10.1093/protein/8.6.527	56	143	146	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12999	13007		10.1074/jbc.271.22.12999	http://dx.doi.org/10.1074/jbc.271.22.12999			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662795	hybrid			2022-12-27	WOS:A1996UN47400050
J	Ishizuka, T; Oshiba, A; Sakata, N; Terada, N; Johnson, GL; Gelfand, EW				Ishizuka, T; Oshiba, A; Sakata, N; Terada, N; Johnson, GL; Gelfand, EW			Aggregation of the Fc epsilon RI on mast cells stimulates c-Jun amino-terminal kinase activity - A response inhibited by Wortmannin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AFFINITY IGE RECEPTOR; PROTEIN-KINASE; TYROSINE PHOSPHORYLATION; ANTIGEN RECEPTOR; PHOSPHATIDYLINOSITOL 3-KINASE; SIGNAL TRANSDUCTION; ACTIVATION DOMAIN; TRANSFECTED CELLS; RBL-2H3 CELLS; MAP KINASE	Aggregation of the high-affinity Fc receptors for immunoglobulin E (IgE) (Fc epsilon RI) on the surface of mast cells initiates intracellular signal transduction pathways including the tyrosine phosphorylation of cellular proteins, phosphoinositide hydrolysis, an increase in intracellular calcium, and protein kinase C activation. These signals are believed to be involved in the exocytic release of inflammatory mediators such as vasoactive amines, cytokines, and lipid metabolites. However, the downstream consequences of these early activation events are not well defined. One exception is the activation of the extracellular signal-regulated kinases/mitogen-activated protein kinases. One member of the mitogen-activated protein kinase superfamily, designated c-Jun amino-terminal kinase (JNK), has been recently identified. JNK is activated following dual phosphorylation at a Thr-Pro-Tyr motif in response to diverse stimuli including tumor necrosis factor-alpha, heat shock, or ultraviolet irradiation. We found that JNK was strongly activated by antigen cross-linking in a mouse mast cell line passively sensitized with ovalbumin-specific IgE. Anti-mouse IgE antibody also activated JNK. MEK kinase 1 (MEKK1) which activates the JNK activator, JNK kinase (JNKK), was similarly activated by antigen stimulation. JNK but not p42(erk2) activation induced by antigen was significantly inhibited in the presence of wortmannin, a known inhibitor of phosphatidylinositol 3-kinase. These results indicate that in response to the aggregation of Fc epsilon RI on mast cells, phosphatidylinositol 3-kinase activation is involved in the stimulation of the MEKK1, JNKK, JNK pathway.	NATL JEWISH CTR IMMUNOL & RESP MED,DEPT PEDIAT,DIV BASIC SCI,DENVER,CO 80206; NATL JEWISH CTR IMMUNOL & RESP MED,PROGRAM MOL SIGNAL TRANSDUCT,DENVER,CO 80206	National Jewish Health; National Jewish Health					NIAID NIH HHS [AI HL-36577] Funding Source: Medline; NIDDK NIH HHS [DK-37871] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALVAREZ E, 1991, J BIOL CHEM, V266, P15277; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BEAVEN MA, 1984, J BIOL CHEM, V259, P7137; BENHAMOU M, 1990, P NATL ACAD SCI USA, V87, P5327, DOI 10.1073/pnas.87.14.5327; BLANK U, 1989, NATURE, V337, P187, DOI 10.1038/337187a0; BOULTON TG, 1991, CELL, V65, P663, DOI 10.1016/0092-8674(91)90098-J; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; EISEMAN E, 1992, NATURE, V355, P78; GALLI SJ, 1993, NEW ENGL J MED, V328, P257; GALLI SJ, 1982, J CELL BIOL, V95, P435, DOI 10.1083/jcb.95.2.435; GOTTSCHALK LR, 1993, J EXP MED, V178, P1681, DOI 10.1084/jem.178.5.1681; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; HUTCHCROFT JE, 1992, P NATL ACAD SCI USA, V89, P9107, DOI 10.1073/pnas.89.19.9107; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; KAWAKAMI T, 1992, J IMMUNOL, V148, P3513; KAWAKAMI Y, 1994, MOL CELL BIOL, V14, P5108, DOI 10.1128/MCB.14.8.5108; KAYE RE, 1992, P NATL ACAD SCI USA, V89, P8542, DOI 10.1073/pnas.89.18.8542; KIMURA K, 1994, J BIOL CHEM, V269, P18961; KOTANI K, 1994, EMBO J, V13, P2313, DOI 10.1002/j.1460-2075.1994.tb06515.x; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LIN LL, 1993, CELL, V72, P269, DOI 10.1016/0092-8674(93)90666-E; MARAIS R, 1993, CELL, V73, P381, DOI 10.1016/0092-8674(93)90237-K; MINDEN A, 1995, CELL, V81, P1147, DOI 10.1016/S0092-8674(05)80019-4; MINDEN A, 1994, SCIENCE, V266, P1719, DOI 10.1126/science.7992057; MUKHOPADHYAY NK, 1992, J BIOL CHEM, V267, P3325; NABEL G, 1981, NATURE, V291, P332, DOI 10.1038/291332a0; NINOMIYA N, 1994, J BIOL CHEM, V269, P22732; OFFERMANNS S, 1994, J IMMUNOL, V152, P250; OKADA T, 1994, J BIOL CHEM, V269, P3563; OKADA T, 1994, J BIOL CHEM, V269, P3568; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; OZAWA K, 1993, J BIOL CHEM, V268, P1749; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; PLAUT M, 1989, NATURE, V339, P64, DOI 10.1038/339064a0; RA C, 1989, J BIOL CHEM, V264, P15323; RAZIN E, 1983, J EXP MED, V157, P189, DOI 10.1084/jem.157.1.189; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; ROONEY JW, 1995, IMMUNITY, V2, P473, DOI 10.1016/1074-7613(95)90028-4; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SAMELSON LE, 1992, J BIOL CHEM, V267, P24913; SANTINI F, 1993, J BIOL CHEM, V268, P22716; SHIUE L, 1995, MOL CELL BIOL, V15, P272, DOI 10.1128/MCB.15.1.272; SU B, 1994, CELL, V77, P727, DOI 10.1016/0092-8674(94)90056-6; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; WHITE KN, 1988, J IMMUNOL, V141, P942; WODNARFILIPOWICZ A, 1989, NATURE, V339, P150, DOI 10.1038/339150a0; YANO H, 1993, J BIOL CHEM, V268, P25846	52	70	70	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12762	12766		10.1074/jbc.271.22.12762	http://dx.doi.org/10.1074/jbc.271.22.12762			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662803	hybrid			2022-12-27	WOS:A1996UN47400013
J	Dawson, SJ; Morris, PJ; Latchman, DS				Dawson, SJ; Morris, PJ; Latchman, DS			A single amino acid change converts an inhibitory transcription factor into an activator	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMAIN PROTEIN; HOMEO DOMAIN; CELL-LINES; NEURONS; DIFFERENTIATION; ELEMENTS; DISTINCT	The closely related POU family transcription factors Brn-3a and Brn-3b differ in their functional activity with Brn-3a activating several target promoters, which are repressed by Brn-3b. Brn-3b also prevents promoter activation by Brn-3a. Here we have altered a single isoleucine residue in the POU homeodomain of Brn-3b to the valine residue found at the equivalent position in Brn-3a. This change not only abolishes the ability of Brn-3b to repress basal and Brn-3a-stimulated promoter activity but also converts it to an activator of similar potency to Brn-3a. Hence a single amino acid difference determines the difference between an activator and a repressor in the Brn-3 family.	UCL, SCH MED, MED MOLEC BIOL UNIT, DEPT MOLEC PATHOL, LONDON W1P 6DB, ENGLAND	University of London; University College London; UCL Medical School				Dawson, Sally/0000-0002-4421-2043				ABKEN H, 1992, NUCLEIC ACIDS RES, V20, P3527, DOI 10.1093/nar/20.13.3527; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BudhramMahadeo V, 1996, J BIOL CHEM, V271, P9108, DOI 10.1074/jbc.271.15.9108; BUDHRAMMAHADEO V, 1995, J BIOL CHEM, V270, P2853, DOI 10.1074/jbc.270.6.2853; BUDHRAMMAHADEO V, 1994, NUCLEIC ACIDS RES, V22, P3092, DOI 10.1093/nar/22.15.3092; Dawson SJ, 1996, BIOCHEM J, V314, P439, DOI 10.1042/bj3140439; DESAI C, 1988, NATURE, V336, P638, DOI 10.1038/336638a0; FEDTSOVA NG, 1995, MECH DEVELOP, V53, P291, DOI 10.1016/0925-4773(95)00435-1; FINNEY M, 1988, CELL, V55, P757, DOI 10.1016/0092-8674(88)90132-8; GERRERO MR, 1993, P NATL ACAD SCI USA, V90, P10841, DOI 10.1073/pnas.90.22.10841; GORMAN C, 1985, DNA CLONING PRACTICA, V2, P143; KLEMM JD, 1994, CELL, V77, P21, DOI 10.1016/0092-8674(94)90231-3; LAI JS, 1992, GENE DEV, V6, P2058, DOI 10.1101/gad.6.11.2058; LILLYCROP KA, 1992, NUCLEIC ACIDS RES, V20, P5093, DOI 10.1093/nar/20.19.5093; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MACPHERSON I, 1962, VIROLOGY, V16, P147, DOI 10.1016/0042-6822(62)90290-8; MORRIS PJ, 1994, MOL CELL BIOL, V14, P6907, DOI 10.1128/MCB.14.10.6907; NINKINA NN, 1993, NUCLEIC ACIDS RES, V21, P3175, DOI 10.1093/nar/21.14.3175; POMERANTZ JL, 1992, GENE DEV, V6, P2047, DOI 10.1101/gad.6.11.2047; SUBURO AM, 1992, NEUROSCIENCE, V46, P881, DOI 10.1016/0306-4522(92)90191-4; THEIL T, 1993, NUCLEIC ACIDS RES, V21, P5921, DOI 10.1093/nar/21.25.5921; THEIL T, 1994, CYTOGENET CELL GENET, V66, P267, DOI 10.1159/000133709; TURNER EE, 1994, NEURON, V12, P205, DOI 10.1016/0896-6273(94)90164-3; VERRIJZER CP, 1993, BIOCHIM BIOPHYS ACTA, V1173, P1, DOI 10.1016/0167-4781(93)90237-8; Wegner M, 1993, CURR OPIN CELL BIOL, V5, P488, DOI 10.1016/0955-0674(93)90015-I; WOOD JN, 1990, P ROY SOC B-BIOL SCI, V241, P187, DOI 10.1098/rspb.1990.0084; XI H, 1989, NATURE, V340, P35, DOI 10.1038/340035a0	27	29	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11631	11633		10.1074/jbc.271.20.11631	http://dx.doi.org/10.1074/jbc.271.20.11631			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662774	hybrid			2022-12-27	WOS:A1996UL25000010
J	Genazzani, AA; Empson, RM; Galione, A				Genazzani, AA; Empson, RM; Galione, A			Unique inactivation properties of NAADP-sensitive Ca2+ release	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-ADP-RIBOSE; INDUCED CALCIUM-RELEASE; SEA-URCHIN EGGS; INOSITOL TRISPHOSPHATE; FERTILIZATION; RECEPTORS; STORES	Ca2+ mobilization from intracellular stores constitutes an important mechanism for generating cytoplasmic Ca2+ signals. Inositol trisphosphate (InsP(3)) and ryanodine receptors are the two families of intracellular Ca2+ release channels that have been identified, which may be regulated by separate intracellular messengers, InsP(3) and cyclic adenosine 5'-diphosphate ribose, respectively. A third molecule, nicotinic acid adenine dinucleotide phosphate (NAADP), has recently been recognized as a potent Ca2+ releasing agent in sea urchin eggs and microsomes. We now report that non-releasing concentrations of NAADP fully and irreversibly inactivate the NAADP-sensitive Ca2+ release mechanism. This phenomenon occurred both in intact sea urchin eggs and in homogenates and is not shared by either InsP(3) or cyclic adenosine 5'-diphosphate ribose, The novel properties of this Ca2+ release mechanism, giving a one-shot Ca2+ release, may be suited to irreversible cellular events.			Genazzani, AA (corresponding author), UNIV OXFORD,DEPT PHARMACOL,S PARKS RD,OXFORD OX1 3QT,ENGLAND.		Galione, Antony/E-5884-2011; Genazzani, Armando/AAI-8280-2020	Galione, Antony/0000-0002-4132-7646; Genazzani, Armando/0000-0003-1923-7430; Empson, Ruth/0000-0002-0415-6083				Aarhus R, 1995, J BIOL CHEM, V270, P30327, DOI 10.1074/jbc.270.51.30327; BOOTMAN M, 1994, CURR BIOL, V4, P169, DOI 10.1016/S0960-9822(94)00041-2; BOYD ND, 1987, J PHYSIOL-LONDON, V389, P45, DOI 10.1113/jphysiol.1987.sp016646; CHINI EN, 1995, J BIOL CHEM, V270, P3216, DOI 10.1074/jbc.270.7.3216; CHINI EN, 1995, BIOCHEM BIOPH RES CO, V209, P167, DOI 10.1006/bbrc.1995.1485; CLAPPER DL, 1985, J BIOL CHEM, V260, P3947; CLAPPER DL, 1987, J BIOL CHEM, V262, P9561; DARGIE PJ, 1990, CELL REGUL, V1, P279, DOI 10.1091/mbc.1.3.279; EHRLICH BE, 1994, TRENDS PHARMACOL SCI, V15, P145, DOI 10.1016/0165-6147(94)90074-4; FINCH EA, 1991, SCIENCE, V252, P443, DOI 10.1126/science.2017683; GALIONE A, 1993, SCIENCE, V261, P348, DOI 10.1126/science.8392748; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GENAZZANI AA, 1996, BIOCHEM J, V315, P715; HAJNOCZKY G, 1994, NATURE, V370, P474, DOI 10.1038/370474a0; LEE HC, 1995, J BIOL CHEM, V270, P2152, DOI 10.1074/jbc.270.5.2152; LEE HC, 1993, SCIENCE, V261, P352, DOI 10.1126/science.8392749; OEKEN HJ, 1986, EUR J BIOCHEM, V156, P661, DOI 10.1111/j.1432-1033.1986.tb09629.x; PerezTerzic CM, 1995, BIOCHEM J, V312, P955, DOI 10.1042/bj3120955; POENIE M, 1990, CELL CALCIUM, V11, P85, DOI 10.1016/0143-4160(90)90062-Y; ROSALES C, 1992, J BIOL CHEM, V267, P1443; SPEDDING M, 1992, PHARMACOL REV, V44, P363; WALSETH TF, 1993, BIOCHIM BIOPHYS ACTA, V1178, P235, DOI 10.1016/0167-4889(93)90199-Y	23	146	147	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11599	11602		10.1074/jbc.271.20.11599	http://dx.doi.org/10.1074/jbc.271.20.11599			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662773	hybrid			2022-12-27	WOS:A1996UL25000002
J	Redpath, NT; Price, NT; Proud, CG				Redpath, NT; Price, NT; Proud, CG			Cloning and expression of cDNA encoding protein synthesis elongation factor-2 kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR-II EF-2; MR 100,000 SUBSTRATE; RABBIT RETICULOCYTES; ENDOTHELIAL-CELLS; MAMMALIAN-TISSUES; PHOSPHORYLATION; IDENTIFICATION; TRANSLATION; PURIFICATION; ACTIVATION	A cDNA from rat skeletal muscle encoding calcium/calmodulin-dependent eukaryotic elongation factor-2 kinase (eEF-2K) has been cloned and sequenced, and the amino acid sequence of the protein has been deduced. The kinase is composed of 724 amino acids and has a predicted molecular mass of 81,499 Da. The cDNA was judged to be full-length, as the protein, expressed in rabbit reticulocyte lysate or wheat germ extract, migrated upon SDS-PAGE with the same apparent molecular weight as the purified kinase and possessed eEF-2K activity, eEF-2K contains all of the 12 catalytic subdomains present in the majority of protein kinases, but they are atypical and display only limited homology with other kinases. A putative calmodulin-binding domain is present C-terminal to the catalytic domain as is a putative pseudosubstrate sequence. Two antipeptide antibodies raised against sequences derived from a partial rabbit cDNA clone, cross-reacted with purified eEF-2K, and one also immunoprecipitated eEF-2K activity from cell extracts. Northern blot analysis demonstrated that eEF-2K mRNA is expressed in a number of different tissues and that it may exist in multiple forms.	UNIV BRISTOL,SCH MED SCI,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND; UNIV KENT,DEPT BIOSCI,CANTERBURY CT2 7NJ,KENT,ENGLAND	University of Bristol; University of Kent	Redpath, NT (corresponding author), UNIV LEICESTER,DEPT BIOCHEM,UNIV RD,LEICESTER LE1 7RH,LEICS,ENGLAND.			Proud, Christopher/0000-0003-0704-6442	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BANERJEE P, 1990, P NATL ACAD SCI USA, V87, P8550, DOI 10.1073/pnas.87.21.8550; BEELER JF, 1994, MOL CELL BIOL, V14, P982, DOI 10.1128/MCB.14.2.982; BRICKEY DA, 1994, J BIOL CHEM, V269, P29047; CARLBERG U, 1990, EUR J BIOCHEM, V191, P639, DOI 10.1111/j.1432-1033.1990.tb19169.x; CHEN JJ, 1991, P NATL ACAD SCI USA, V88, P7729, DOI 10.1073/pnas.88.17.7729; CRADDOCK BL, 1995, BIOCHEM J, V309, P1009, DOI 10.1042/bj3091009; DEMOLLE D, 1990, MOL PHARMACOL, V37, P827; HANKS SK, 1995, PROTEIN KINASE FAC 1; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; HINCKE MT, 1992, BIOCHEM J, V282, P877, DOI 10.1042/bj2820877; KOIZUMI S, 1989, FEBS LETT, V253, P55, DOI 10.1016/0014-5793(89)80928-7; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; KREUGER JK, 1995, J BIOL CHEM, V270, P16848; MACKIE KP, 1989, J BIOL CHEM, V264, P1748; MARU Y, 1991, CELL, V67, P459, DOI 10.1016/0092-8674(91)90521-Y; MITSUI K, 1993, J BIOL CHEM, V268, P13422; NAIRN AC, 1985, P NATL ACAD SCI USA, V82, P7939, DOI 10.1073/pnas.82.23.7939; NAIRN AC, 1987, J BIOL CHEM, V262, P17299; ONEIL KT, 1990, TRENDS BIOCHEM SCI, V15, P59, DOI 10.1016/0968-0004(90)90177-D; OVCHINNIKOV LP, 1990, FEBS LETT, V275, P509; PALFREY HC, 1983, FEBS LETT, V157, P183, DOI 10.1016/0014-5793(83)81142-9; PALFREY HC, 1987, J BIOL CHEM, V262, P9785; PRICE NT, 1994, BBA-GENE STRUCT EXPR, V1217, P207, DOI 10.1016/0167-4781(94)90037-X; PRICE NT, 1991, FEBS LETT, V282, P253, DOI 10.1016/0014-5793(91)80489-P; PROUD CG, 1994, MOL BIOL REP, V19, P161, DOI 10.1007/BF00986958; REDPATH NT, 1993, BIOCHEM J, V293, P31, DOI 10.1042/bj2930031; REDPATH NT, 1993, EUR J BIOCHEM, V212, P511, DOI 10.1111/j.1432-1033.1993.tb17688.x; REDPATH NT, 1989, BIOCHEM J, V262, P69, DOI 10.1042/bj2620069; REDPATH NT, 1993, EUR J BIOCHEM, V213, P689, DOI 10.1111/j.1432-1033.1993.tb17809.x; REDPATH NT, 1994, BBA-MOL CELL RES, V1220, P147, DOI 10.1016/0167-4889(94)90130-9; RYAZANOV AG, 1988, NATURE, V334, P170, DOI 10.1038/334170a0; RYAZANOV AG, 1987, FEBS LETT, V214, P331, DOI 10.1016/0014-5793(87)80081-9; RYAZANOV AG, 1989, FEBS LETT, V251, P187, DOI 10.1016/0014-5793(89)81452-8; SMAILOV SK, 1993, FEBS LETT, V321, P219, DOI 10.1016/0014-5793(93)80112-8; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; VANREGENMORTEL MHV, 1988, LABORATORY TECHNIQUE, V19, P95; WELSH GI, 1994, BIOCHEM J, V303, P15, DOI 10.1042/bj3030015; WILSON R, 1994, NATURE, V368, P32, DOI 10.1038/368032a0; YOKOKURA H, 1995, J BIOL CHEM, V270, P23851, DOI 10.1074/jbc.270.40.23851	40	60	67	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17547	17554		10.1074/jbc.271.29.17547	http://dx.doi.org/10.1074/jbc.271.29.17547			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663182	hybrid			2022-12-27	WOS:A1996UX94300085
J	Maru, I; Ohta, Y; Murata, K; Tsukada, Y				Maru, I; Ohta, Y; Murata, K; Tsukada, Y			Molecular cloning and identification of N-acyl-D-glucosamine 2-epimerase from porcine kidney as a renin-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER MOTIF; HOG KIDNEY; RNBP; PURIFICATION; GENE	N-Acetylneuraminic acid (NeuAc) is an important molecule in biological recognition systems, NeuAc is known to be biosynthesized either from UDP-N-acetyl-D-glucosamine by an action of UDP-N-acetyl-D-glucosamine 2-epimerase or from N-acetyl-D-glucosamine by N-acyl-D-glucosamine 2-epimerase (GlcNAc 2-epimerase), However, the physiological function of the GlcNAc a epimerase in NeuAc biosynthesis has not been fully evaluated, To clarify the role of GlcNAc 2-epimerase in NeuAc biosynthesis, the enzyme and its gene were isolated from porcine kidney cortex, Escherichia coli cells transformed with the gene expressed the GlcNAc 2-epimerase having the same properties as those of the GlcNAc 2-epimerase from porcine kidney. Sequence analysis indicated that the gene was capable of synthesizing a 46.5-kDa protein (402 amino acids) with a conserved leucine zipper motif, Homology search for the cloned gene revealed that the GlcNAc 2-epimerase was identical with renin-binding protein (RnBP) in porcine kidney (Inoue, H., Fukui, K., Takahashi, S., and Miyake, Y. (1990) J. Biol. Chem. 265, 6556-6561) (identity: 99.6% in nucleotide sequence, 99.0% in amino acid sequence), That GlcNAc 2-epimerase is a RnBP was confirmed by its ability to bind porcine kidney renin and mask its protease activity, These findings provide unequivocal evidence that the enzyme GlcNAc 2-epimerase is a Rnp.	KYOTO UNIV,FOOD SCI RES INST,UJI,KYOTO 611,JAPAN; MARUKIN SHOYA CO LTD,KYOTO RES LABS,UJI,KYOTO 611,JAPAN	Kyoto University								BOYD GW, 1974, CIRC RES, V35, P426, DOI 10.1161/01.RES.35.3.426; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DATTA A, 1970, BIOCHEMISTRY-US, V9, P3363, DOI 10.1021/bi00819a011; EDMAN P, 1950, ACTA CHEM SCAND, V4, P283, DOI 10.3891/acta.chem.scand.04-0283; FARANDA S, 1995, GENE, V155, P237, DOI 10.1016/0378-1119(94)00810-F; GHOSH S, 1965, J BIOL CHEM, V240, P1531; GINSBURG V, 1964, ADV ENZYMOL REL S BI, V26, P35; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HONDA S, 1989, ANAL BIOCHEM, V180, P351, DOI 10.1016/0003-2697(89)90444-2; INAGAMI T, 1977, J BIOL CHEM, V252, P2978; INOUE H, 1991, J BIOCHEM-TOKYO, V110, P493, DOI 10.1093/oxfordjournals.jbchem.a123609; INOUE H, 1990, J BIOL CHEM, V265, P6556; INOUE H, 1991, J BIOL CHEM, V266, P11896; KLEMM P, 1982, EUR J BIOCHEM, V124, P339; KONDO M, 1991, ELECTROPHORESIS, V12, P685, DOI 10.1002/elps.1150120918; KORNFELD S, 1964, P NATL ACAD SCI USA, V52, P371, DOI 10.1073/pnas.52.2.371; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LECKIE BJ, 1975, CIRC RES, V36, P513, DOI 10.1161/01.RES.36.4.513; McGuire E. J., 1976, BIOL ROLES SIALIC AC, P123; MURAKAMI K, 1980, BIOMED RES-TOKYO, V1, P476, DOI 10.2220/biomedres.1.476; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SHAUER R, 1982, ADV CARBOHYD CHEM BI, V40, P131; TADA M, 1992, J BIOCHEM, V112, P175, DOI 10.1093/oxfordjournals.jbchem.a123874; TAKAHASHI S, 1983, J BIOCHEM, V93, P1583, DOI 10.1093/oxfordjournals.jbchem.a134297; TAKAHASHI S, 1992, J BIOL CHEM, V267, P13007; TAKAHASHI S, 1983, J BIOCHEM-TOKYO, V93, P265, DOI 10.1093/oxfordjournals.jbchem.a134162; TRIBIOLI C, 1994, HUM MOL GENET, V3, P1061, DOI 10.1093/hmg/3.7.1061; VANRINSUM J, 1983, BIOCHEM J, V210, P21, DOI 10.1042/bj2100021; WARREN L, 1972, GLYCOPROTEINS, P1097	30	104	115	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16294	16299		10.1074/jbc.271.27.16294	http://dx.doi.org/10.1074/jbc.271.27.16294			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663114	hybrid			2022-12-27	WOS:A1996UW35200065
J	Yancey, PG; Rodriqueza, WV; Kilsdonk, EPC; Stoudt, GW; Johnson, WJ; Phillips, MC; Rothblat, GH				Yancey, PG; Rodriqueza, WV; Kilsdonk, EPC; Stoudt, GW; Johnson, WJ; Phillips, MC; Rothblat, GH			Cellular cholesterol effect mediated by cyclodextrins - Demonstration of kinetic pools and mechanism of efflux	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-A-I; DENSITY-LIPOPROTEINS; LIPID-COMPOSITION; PLASMA-MEMBRANE; PHYSICAL STATE; CELLS; FIBROBLASTS; TRANSPORT; EXCHANGE; RECEPTOR	In this study, we compared the kinetics of cholesterol efflux from cells with 2-hydroxypropyl-beta-cyclodextrins and with discoidal high density lipoprotein (HDL) particles to probe the mechanisms governing the remarkably rapid rates of cyclodextrin-mediated efflux. The rate of cholesterol efflux was enhanced by shaking cells growing in a monolayer and further enhanced by placing cells in suspension to achieve maximal efflux rates, The extent of efflux was dependent on cyclodextrin concentration, and maximal efflux was observed at concentrations >50 mM. For several cell types, biexponential kinetics of cellular cholesterol efflux were observed, indicating the existence of two kinetic pools of cholesterol: a fast pool (half-time (t(1/2)) similar to 19-23 s) and a slow pool with t(1/2) of 15-30 min. Two distinct kinetic pools of cholesterol were also observed with model membranes (large unilamellar cholesterol-containing vesicles), implying that the cellular pools are in the plasma membrane, Cellular cholesterol content was altered by incubating cells with solutions of cyclodextrins complexed with increasing levels of cholesterol. The number of kinetic pools was unaffected by raising the cellular cholesterol content, but the size of the fast pool increased, After depleting cells of the fast pool of cholesterol, this pool was completely restored after a 40-min recovery period. The temperature dependence of cyclodextrin-mediated cholesterol efflux from cells and model membranes was compared; the activation energies were 7 kcal/mol and 2 kcal/mol, respectively. The equivalent activation energy observed with apo-HDL-phospholipid acceptor particles was 20 kcal/mol, It seems that cyclodextrin molecules are substantially more efficient than phospholipid accepters, because cholesterol molecules desorbing from a membrane surface can diffuse directly into the hydrophobic core of a cyclodextrin molecule without having to desorb completely into the aqueous phase before being sequestered by the acceptor.	MED COLL PENN & HAHNEMANN UNIV,DEPT BIOCHEM,PHILADELPHIA,PA 19129	Drexel University			Yancey, Patricia/ABB-5856-2021	Phillips, Michael/0000-0002-7147-8007	NHLBI NIH HHS [HL22633, HL07443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007443, P01HL022633] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADELMAN SJ, 1984, J BIOL CHEM, V259, P3844; BAR LK, 1989, BIOCHIM BIOPHYS ACTA, V983, P109, DOI 10.1016/0005-2736(89)90386-6; BELLINI F, 1984, BIOCHIM BIOPHYS ACTA, V777, P209, DOI 10.1016/0005-2736(84)90422-X; BRASAEMLE DL, 1988, J LIPID RES, V29, P481; CHANG WJ, 1992, J CELL BIOL, V118, P63, DOI 10.1083/jcb.118.1.63; CHONG PLG, 1994, P NATL ACAD SCI USA, V91, P10069, DOI 10.1073/pnas.91.21.10069; DAVIDSON WS, 1994, J BIOL CHEM, V269, P22975; DAVIDSON WS, 1995, J BIOL CHEM, V270, P17106, DOI 10.1074/jbc.270.29.17106; DAVIDSON WS, 1995, J BIOL CHEM, V270, P5882, DOI 10.1074/jbc.270.11.5882; DECAPRIO J, 1992, J LIPID RES, V33, P441; DELAMATRE J, 1986, BIOCHIM BIOPHYS ACTA, V875, P419, DOI 10.1016/0005-2760(86)90061-5; DEMEL RA, 1977, BIOCHIM BIOPHYS ACTA, V465, P1, DOI 10.1016/0005-2736(77)90350-9; DUCHENE D, 1990, 5 INT S CYCL PAR FRA; ELYANDOUZI E, 1994, BIOCHEMISTRY-US, V33, P2329, DOI 10.1021/bi00174a046; ELYANDOUZI EH, 1993, BIOCHEMISTRY-US, V32, P2047, DOI 10.1021/bi00059a023; FIELDING CJ, 1995, J LIPID RES, V36, P211; FIELDING PE, 1995, BIOCHEMISTRY-US, V34, P14288, DOI 10.1021/bi00044a004; FRIJLINK HW, 1991, PHARMACEUT RES, V8, P9, DOI 10.1023/A:1015861719134; GLOMSET JA, 1968, J LIPID RES, V9, P155; Hatch F T, 1968, Adv Lipid Res, V6, P1; IRIE T, 1992, J PHARM SCI, V81, P521, DOI 10.1002/jps.2600810609; ISHIKAWA TT, 1974, J LIPID RES, V15, P286; JOHNSON WJ, 1991, BIOCHIM BIOPHYS ACTA, V1085, P273, DOI 10.1016/0005-2760(91)90132-2; KAVECANSKY J, 1994, BIOCHEMISTRY-US, V33, P2880, DOI 10.1021/bi00176a018; KILSDONK EPC, 1995, J BIOL CHEM, V270, P17250, DOI 10.1074/jbc.270.29.17250; KLANSEK JJ, 1995, J LIPID RES, V36, P2261; LANGE Y, 1983, J BIOL CHEM, V258, P5130; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUAN P, 1995, BIOCHEMISTRY-US, V34, P9874, DOI 10.1021/bi00031a008; LUNDKATZ S, 1982, BIOCHEMISTRY-US, V21, P2964, DOI 10.1021/bi00541a025; MAHLBERG FH, 1991, J BIOL CHEM, V266, P19930; MAHLBERG FH, 1992, J BIOL CHEM, V267, P4541; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCINTOSH TJ, 1995, BIOCHEMISTRY-US, V34, P8520, DOI 10.1021/bi00027a002; PHILLIPS MC, 1980, ATHEROSCLEROSIS, V36, P409, DOI 10.1016/0021-9150(80)90220-8; PHILLIPS MC, 1987, BIOCHIM BIOPHYS ACTA, V906, P223, DOI 10.1016/0304-4157(87)90013-X; PITHA J, 1988, LIFE SCI, V43, P493, DOI 10.1016/0024-3205(88)90150-6; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; ROSS AC, 1984, J BIOL CHEM, V259, P815; ROTHBERG KG, 1990, J CELL BIOL, V111, P2931, DOI 10.1083/jcb.111.6.2931; Rothblat G H, 1986, Methods Enzymol, V129, P628; ROTHBLAT GH, 1982, J BIOL CHEM, V257, P4775; ROTHBLAT GH, 1992, J LIPID RES, V33, P1091; SCHROEDER, 1995, MOL MEMBR BIOL, V12, P113; SCHROEDER F, 1991, P SOC EXP BIOL MED, V196, P235; SCHROEDER F, 1990, ADV CHOLESTEROL RES, P48; SLOTTE JP, 1995, BBA-BIOMEMBRANES, V1235, P419, DOI 10.1016/0005-2736(95)80031-A; SMART EJ, 1994, J CELL BIOL, V127, P1185, DOI 10.1083/jcb.127.5.1185; SOKOLOFF L, 1974, P SOC EXP BIOL MED, V146, P1166; WOODFORD JK, 1993, BIOCHIM BIOPHYS ACTA, V1145, P257, DOI 10.1016/0005-2736(93)90297-D; YANCEY PG, 1995, BIOCHEMISTRY-US, V34, P7955, DOI 10.1021/bi00024a021; YANDOUZI EHE, 1992, BIOCHEMISTRY-US, V31, P547; 1992, SIGMA TECHNICAL B, V7	54	392	396	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16026	16034		10.1074/jbc.271.27.16026	http://dx.doi.org/10.1074/jbc.271.27.16026			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663188	hybrid			2022-12-27	WOS:A1996UW35200029
J	Cruse, WBT; Saludjian, P; Leroux, Y; Leger, G; ElManouni, D; Prange, T				Cruse, WBT; Saludjian, P; Leroux, Y; Leger, G; ElManouni, D; Prange, T			A continuous transition from A-DNA to B-DNA in the 1:1 complex between nogalamycin and the hexamer dCCCGGG	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTITUMOR DRUG NOGALAMYCIN; ORDERED WATER-STRUCTURE; CRYSTAL-STRUCTURE; MOLECULAR-STRUCTURE; DAUNOMYCIN; BINDING; PSEUDOROTATION; RESOLUTION; REFINEMENT; DODECAMER	The antibiotic nogalamycin, a drug with high specificity for TG and CG steps in double-stranded DNA, has been crystallized as a 1:1 complex with the hexamer d(CCCGGG). The antibiotic is inserted at the central CG step of the duplex, with the two sugars oriented in the same direction and with strong interactions with the DNA within the grooves, The amino-glucose residue makes an integral part of a well defined major groove hydration network with van der Waals contacts and several strong hydrogen bonds to the duplex, The nogalose residue resides in the minor groove, making primarily van der Waals contacts, The single site allows an accurate molecular description of the intercalation, without perturbations from end effects observed previously, The local unwinding induced by nogalamycin is completely relaxed 2 base pairs away from the intercalation site. The two strands of the DNA show a continuous deformation from the A to the B form: 1) the cytosines toward the 5' end of the nogalomycin site in each strand have c3'-endo conformations while 5 guanosines toward the 3' ends have c2'-endo conformations; 2) within each strand, the phosphate-phosphate distances increase in a continuous manner from 5.7 Angstrom (A-form) to 7.1 Angstrom (B-form).	UNIV PARIS 11,LURE,F-91405 ORSAY,FRANCE	UDICE-French Research Universities; Universite Paris Saclay	Cruse, WBT (corresponding author), UFR BIOMED,URA 1430 CNRS,74 RUE M CACHIN,F-93012 BOBIGNY,FRANCE.		Prangé, Thierry/AAA-4009-2022	Prangé, Thierry/0000-0002-7129-7396				ALTONA C, 1972, J AM CHEM SOC, V94, P8205, DOI 10.1021/ja00778a043; [Anonymous], 1994, ACTA CRYSTALLOGR D, V50, P760; ARORA SK, 1983, J AM CHEM SOC, V105, P1328, DOI 10.1021/ja00343a042; BAEYENS KJ, 1995, NAT STRUCT BIOL, V2, P56, DOI 10.1038/nsb0195-56; BERMAN HM, 1978, P NATL ACAD SCI USA, V75, P828, DOI 10.1073/pnas.75.2.828; BERMAN HM, 1979, BIOPOLYMERS, V18, P2405, DOI 10.1002/bip.1979.360181004; BRUNGER AT, 1988, XPLOR MANUAL; CASTELLANO EE, 1992, J APPL CRYSTALLOGR, V25, P281, DOI 10.1107/S0021889891012773; DICKERSON RE, 1992, METHOD ENZYMOL, V211, P67; DICKERSON RE, 1993, NEWHEL 93 PROGRAM; DOUCET J, 1989, NATURE, V337, P190, DOI 10.1038/337190a0; DREW HR, 1981, J MOL BIOL, V151, P535, DOI 10.1016/0022-2836(81)90009-7; FOURME R, 1992, REV SCI INSTRUM, V63, P982, DOI 10.1063/1.1143716; FOX KR, 1986, BIOCHEMISTRY-US, V25, P4349, DOI 10.1021/bi00363a026; FREDERICK CA, 1990, BIOCHEMISTRY-US, V29, P2538, DOI 10.1021/bi00462a016; GAO YG, 1990, BIOCHEMISTRY-US, V29, P10307, DOI 10.1021/bi00497a004; HEIDELBERGER C, 1975, ANNU REV BIOCHEM, V44, P79, DOI 10.1146/annurev.bi.44.070175.000455; ISLAM SA, 1985, J MED CHEM, V28, P857, DOI 10.1021/jm00145a003; KENNARD O, 1986, J BIOMOL STRUCT DYN, V3, P623, DOI 10.1080/07391102.1986.10508452; KOPKA ML, 1983, J MOL BIOL, V163, P129, DOI 10.1016/0022-2836(83)90033-5; LESLIE A, 1994, MOSFLM USER GUIDE MO; LI LH, 1979, CANCER RES, V39, P4816; MCCALL M, 1985, J MOL BIOL, V183, P385, DOI 10.1016/0022-2836(85)90009-9; MOORE MH, 1989, J MOL BIOL, V206, P693, DOI 10.1016/0022-2836(89)90577-9; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NUNN CM, 1991, J MOL BIOL, V222, P167, DOI 10.1016/0022-2836(91)90203-I; SAENGER W, 1983, PRINCIPLES NUCLEIC A, P350; SHAKKED Z, 1989, NATURE, V342, P456, DOI 10.1038/342456a0; VANHOUTE LPA, 1993, BIOCHEMISTRY-US, V32, P1667, DOI 10.1021/bi00057a034; WAKELIN LPG, 1980, J MOL BIOL, V144, P183, DOI 10.1016/0022-2836(80)90032-7; WANG AHJ, 1987, BIOCHEMISTRY-US, V26, P1152, DOI 10.1021/bi00378a025; WESTHOF E, 1985, BIOCHIMIE, V67, P811, DOI 10.1016/S0300-9084(85)80172-3; WESTHOF E, 1980, J AM CHEM SOC, V102, P1493, DOI 10.1021/ja00525a004; WESTHOF E, 1985, J MOL BIOL, V184, P119, DOI 10.1016/0022-2836(85)90048-8; WESTHOF E, 1990, WATER SCI REV, V5, P24; WILLIAMS LD, 1990, P NATL ACAD SCI USA, V87, P2225, DOI 10.1073/pnas.87.6.2225	36	18	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15558	15567		10.1074/jbc.271.26.15558	http://dx.doi.org/10.1074/jbc.271.26.15558			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662899	hybrid			2022-12-27	WOS:A1996UV29900040
J	Kubo, Y; Miyashita, T; Kubokawa, K				Kubo, Y; Miyashita, T; Kubokawa, K			A weakly inward rectifying potassium channel of the salmon brain - Glutamate 179 in the second transmembrane domain is insufficient for strong rectification	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GUINEA-PIG HEART; EGG CELL-MEMBRANE; ANOMALOUS RECTIFICATION; FUNCTIONAL EXPRESSION; VENTRICULAR CELLS; MAGNESIUM BLOCK; INTERNAL MG-2+; K+-CHANNEL; CONDUCTANCE; RECTIFIER	A cDNA encoding for a weakly inward rectifying K+ channel (sWIRK: salmon weakly inward rectifying K+ channel) was isolated from the masu salmon brain by expression cloning. The sWIRK channel exhibited the highest similarity with members of the ROMK1 subfamily, BIR(10)/K-AB-2 (70% amino acid identity) and ROMK1 (46%). An ATP binding motif which is characteristic of this subfamily was also conserved. The sWIRK: RNA was detected in the brain, but not in the heart, kidney, skeletal muscle, liver, testis, and ovary. In the brain, the expression was observed in the ependymoglial cells on the surface of the ventricles as well as in the small peri-neuronal glia-like cells in the midbrain and the medulla. When compared with the strong inward rectifier IRK1 channel, the sWIRK channel showed a much weaker inward rectification property, and the activation kinetics upon hyperpolarization was slower and less voltage-dependent. The slope conductance of the single channel inward current was 37 pS (140 mM K-o(+)), and outward current channel events were also observed. The weak rectification of sWIRK is significant in that it has a negatively charged residue (glutamate) in the M2 region which is reported to cause strong inward rectification. By introducing a point mutation to remove this negative charge (glutamine), the sWIRK E179Q mutant channel lost its inward rectification property completely, and the single channel property (45 pS; 140 mM K-o(+)) was ohmic up to highly depolarized potential, even in the presence of the physiological cytoplasmic blockers such as Mg2+ and polyamines.	UNIV TOKYO,OCEAN RES INST,DEPT BIOL MOLEC,TOKYO 164,JAPAN	University of Tokyo	Kubo, Y (corresponding author), TOKYO METROPOLITAN INST NEUROSCI,DEPT NEUROPHYSIOL,MUSASHIDAI 2-6,FUCHU,TOKYO 183,JAPAN.			Kubo, Yoshihiro/0000-0001-6707-0837				ASHFORD MLJ, 1994, NATURE, V370, P456, DOI 10.1038/370456a0; Barres B A, 1991, Curr Opin Neurobiol, V1, P354, DOI 10.1016/0959-4388(91)90052-9; BARRES BA, 1990, ANNU REV NEUROSCI, V13, P441, DOI 10.1146/annurev.neuro.13.1.441; BARRES BA, 1988, GLIA, V1, P10, DOI 10.1002/glia.440010104; BOND CT, 1994, RECEPTOR CHANNEL, V2, P183; COHEN IS, 1989, BIOPHYS J, V55, P197, DOI 10.1016/S0006-3495(89)82792-4; DASCAL N, 1993, P NATL ACAD SCI USA, V90, P10235, DOI 10.1073/pnas.90.21.10235; FAKLER B, 1995, CELL, V80, P149, DOI 10.1016/0092-8674(95)90459-X; FICKER E, 1994, SCIENCE, V266, P1068, DOI 10.1126/science.7973666; HAGIWARA S, 1974, J MEMBRANE BIOL, V18, P61, DOI 10.1007/BF01870103; HAGIWARA S, 1977, J GEN PHYSIOL, V70, P269, DOI 10.1085/jgp.70.3.269; HAGIWARA S, 1976, J GEN PHYSIOL, V67, P621, DOI 10.1085/jgp.67.6.621; HIGGINS DG, 1988, GENE, V73, P237, DOI 10.1016/0378-1119(88)90330-7; HILLE B, 1978, J GEN PHYSIOL, V72, P409, DOI 10.1085/jgp.72.4.409; Hille B., 1992, IONIC CHANNELS EXCIT; HO K, 1993, NATURE, V362, P31, DOI 10.1038/362031a0; INAGAKI N, 1995, SCIENCE, V270, P1166, DOI 10.1126/science.270.5239.1166; INAGAKI N, 1995, J BIOL CHEM, V270, P5691, DOI 10.1074/jbc.270.11.5691; ISHIHARA K, 1994, J MEMBRANE BIOL, V142, P55; KATZ B, 1949, ARCH SCI PHYSL, V2, P285; KOYAMA H, 1994, FEBS LETT, V341, P303, DOI 10.1016/0014-5793(94)80478-8; KRAPIVINSKY G, 1995, NATURE, V374, P135, DOI 10.1038/374135a0; KUBO Y, 1993, NATURE, V362, P127, DOI 10.1038/362127a0; KUBO Y, 1993, NATURE, V364, P802, DOI 10.1038/364802a0; KUBO Y, 1996, IN PRESS RECEPTORS C; KUBOTA Y, 1994, ENVIRON PLANN B, V21, P109, DOI 10.1068/b210109; LESAGE F, 1994, FEBS LETT, V353, P37, DOI 10.1016/0014-5793(94)01007-2; LEWIS DL, 1991, FEBS LETT, V290, P17, DOI 10.1016/0014-5793(91)81215-T; LOPATIN AN, 1994, NATURE, V372, P366, DOI 10.1038/372366a0; LU Z, 1994, NATURE, V371, P243, DOI 10.1038/371243a0; MATSUDA H, 1991, J PHYSIOL-LONDON, V435, P83, DOI 10.1113/jphysiol.1991.sp018499; MATSUDA H, 1987, NATURE, V325, P156, DOI 10.1038/325156a0; MATSUDA H, 1988, J PHYSIOL-LONDON, V397, P237, DOI 10.1113/jphysiol.1988.sp016998; MAYER ML, 1983, J PHYSIOL-LONDON, V340, P19, DOI 10.1113/jphysiol.1983.sp014747; MCKINNEY LC, 1988, J MEMBRANE BIOL, V103, P41, DOI 10.1007/BF01871931; MIHARA S, 1987, J PHYSIOL-LONDON, V390, P335, DOI 10.1113/jphysiol.1987.sp016704; MORISHIGE KI, 1994, FEBS LETT, V346, P251, DOI 10.1016/0014-5793(94)00483-8; NEWMAN EA, 1984, SCIENCE, V225, P1174, DOI 10.1126/science.6474173; OKAMOTO H, 1976, J PHYSIOL-LONDON, V254, P607, DOI 10.1113/jphysiol.1976.sp011249; SAKMANN B, 1984, J PHYSIOL-LONDON, V347, P641, DOI 10.1113/jphysiol.1984.sp015088; SHUCK ME, 1994, J BIOL CHEM, V269, P24261; SILVER MR, 1990, J GEN PHYSIOL, V96, P109, DOI 10.1085/jgp.96.1.109; SONTHEIMER H, 1994, GLIA, V11, P156, DOI 10.1002/glia.440110210; STANDEN NB, 1978, J PHYSIOL-LONDON, V280, P169, DOI 10.1113/jphysiol.1978.sp012379; STANFIELD PR, 1994, J PHYSIOL-LONDON, V478, P1; STANFIELD PR, 1994, J PHYSIOL-LONDON, V475, P1; TAKUMI T, 1995, J BIOL CHEM, V270, P16339, DOI 10.1074/jbc.270.27.16339; VANDENBERG CA, 1987, P NATL ACAD SCI USA, V84, P2560, DOI 10.1073/pnas.84.8.2560; WIBLE BA, 1994, NATURE, V371, P246, DOI 10.1038/371246a0; YANG J, 1995, NEURON, V14, P1047, DOI 10.1016/0896-6273(95)90343-7; YANO H, 1994, MOL PHARMACOL, V45, P854	51	26	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15729	15735		10.1074/jbc.271.26.15729	http://dx.doi.org/10.1074/jbc.271.26.15729			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663136				2022-12-27	WOS:A1996UV29900065
J	Netto, LES; Chae, HZ; Kang, SW; Rhee, SG; Stadtman, ER				Netto, LES; Chae, HZ; Kang, SW; Rhee, SG; Stadtman, ER			Removal of hydrogen peroxide by thiol-specific antioxidant enzyme (TSA) is involved with its antioxidant properties - TSA possesses thiol peroxidase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SACCHAROMYCES-CEREVISIAE; OXIDATION; PROTEIN	The thiol-specific antioxidant protein (TSA) protects glutamine synthetase from inactivation by a metal-catalyzed oxidation (MCO) system comprised of dithiothreitol (DTT)/Fe3+/O-2 but not by the ascorbate/Fe3+/O-2 MCO system. The removal of sulfur-centered radicals or H2O2 has been proposed as the protective mechanism of TSA. Like catalase, TSA prevents the initiation of the rapid O-2 uptake phase during MCO of DTT but causes only partial inhibition when added after the reaction is well into the propagation phase. Stoichiometric studies showed that the antioxidant property of TSA is, at least in part, due to its ability to catalyze the destruction of H2O2 by the overall reaction 2 RSH + H2O2 --> RSSR + H2O. Results of kinetic studies demonstrate that the removal of H2O2 by TSA correlates with its ability to protect glutamine synthetase from inactivation. In the presence of thioredoxin, TSA is more active, whereas C170S (an active mutant of TSA in which cysteine 170 was replaced by a serine) and open reading frame 6 (a human antioxidant protein homologous to TSA with only one conserved cysteine residue) are only slightly affected. The thiol specificity of the protective activity of TSA derives from the fact that the oxidized form of TSA can be converted back to its sulfhydryl form by treatment with thiols but not by ascorbate.	NHLBI,NIH,BIOCHEM LAB,BETHESDA,MD 20892; NHLBI,NIH,LAB CELL SIGNALLING,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI); National Institutes of Health (NIH) - USA; NIH National Heart Lung & Blood Institute (NHLBI)			Netto, Luis/A-3783-2008	Netto, Luis/0000-0002-4250-9177				AMSTAD P, 1991, BIOCHEMISTRY-US, V30, P9305, DOI 10.1021/bi00102a024; CHAE HZ, 1993, J BIOL CHEM, V268, P16815; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7017, DOI 10.1073/pnas.91.15.7017; CHAE HZ, 1994, J BIOL CHEM, V269, P27670; CHAE HZ, 1994, P NATL ACAD SCI USA, V91, P7022, DOI 10.1073/pnas.91.15.7022; CLELAND WW, 1964, BIOCHEMISTRY-US, V3, P480, DOI 10.1021/bi00892a002; GIULIVI C, 1993, J BIOL CHEM, V268, P8752; GUIBAULT GG, 1968, ANAL CHEM, V40, P1256; Halliwell B., 1989, FREE RADICAL BIO MED, P86; HARMAN LS, 1986, J BIOL CHEM, V261, P1642; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; JACOBSON FS, 1989, J BIOL CHEM, V264, P1488; JOCELYN PC, 1972, BIOCH SH GROUP, P79; KIM IH, 1989, P NATL ACAD SCI USA, V86, P6018, DOI 10.1073/pnas.86.16.6018; KIM KW, 1988, J BIOL CHEM, V263, P4704; KWON SJ, 1994, BIOCHEM BIOPH RES CO, V201, P8, DOI 10.1006/bbrc.1994.1662; LIM YS, 1993, BIOCHEM BIOPH RES CO, V192, P273, DOI 10.1006/bbrc.1993.1410; NETTO LES, 1994, FASEB J, V8, pA1412; POOLE LB, 1989, J BIOL CHEM, V264, P12330; RHEE SG, 1985, METHOD ENZYMOL, V113, P213; RIDDLES PW, 1983, METHOD ENZYMOL, V91, P49; ROBINSON J, 1970, ANAL BIOCHEM, V20, P525; Schonbaum G. R., 1976, ENZYMES, V13, P363, DOI [10.1016/S1874-6047(08)60245-0, DOI 10.1016/S1874-6047(08)60245-0]; STADTMAN ER, 1990, P NATL ACAD SCI USA, V87, P384, DOI 10.1073/pnas.87.1.384; STADTMAN ER, 1990, FREE RADICAL BIO MED, V9, P315, DOI 10.1016/0891-5849(90)90006-5; YIM MB, 1994, J BIOL CHEM, V269, P1621	26	196	203	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15315	15321		10.1074/jbc.271.26.15315	http://dx.doi.org/10.1074/jbc.271.26.15315			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663080	hybrid			2022-12-27	WOS:A1996UV29900005
J	Ng, JY; Marians, KJ				Ng, JY; Marians, KJ			The ordered assembly of the phi X174-type primosome .2. Preservation of primosome composition from assembly through replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI CHROMOSOME; DNA-REPLICATION; INITIATION SIGNALS; SITE SELECTION; PROTEIN-I; STRAND; INVITRO; REGION; PURIFICATION; ASSOCIATION	Gel filtration chromatography was used to isolate both preprimosomal and primosomal complexes formed on single-stranded DNA-binding protein-coated phi X174 DNA by the combination of PriA, PriB, PriC, DnaT, DnaB, DnaC, and DnaG, The presence and relative amounts of primosomal proteins in these complexes were determined by Western blotting, Protein-DNA complexes isolated (i) after assembly in the presence of 10 mu M ATP, (ii) after preprimosome movement in the presence of 1 mM ATP, (iii) after priming in the presence of the four ribonucleoside triphosphates, or (iv) after complementary strand DNA replication in the presence of the DNA polymerase III holoenzyme all had the same protein composition; preprimosomes contained PriA, PriB, PriC, DnaT, and DnaB, whereas primosomes included DnaG, The stable association of DnaG with the protein-DNA complex could be attributed partially to its ability to remain bound to the primers synthesized, In the absence of PriC, the efficiencies of priming and replication were reduced by one-third and one-half, respectively, even though PriC was not required for the formation of stable protein-DNA complexes on a 304-nucleotide-long single strand of DNA containing a primosome assembly site (Ng, J. Y., and Marians, K. J. (1996) J. Biol. Chem, 271, 15642-15648), We hypothesize that maintenance of the primosome on the replicated DNA may provide a mechanism to allow primosomes to participate in the resolution of recombination intermediates and intermediates formed during double strand break repair by permitting the re-establishment of a replication fork.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Ng, JY (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM034557, R01GM034557] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM34557] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1993, J BIOL CHEM, V268, P19204; ALLEN GC, 1991, J BIOL CHEM, V266, P22096; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5281; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; FRANCKE B, 1971, VIROLOGY, V44, P168, DOI 10.1016/0042-6822(71)90163-2; FRIED M, 1981, NUCLEIC ACIDS RES, V9, P6505, DOI 10.1093/nar/9.23.6505; HIASA H, 1994, J BIOL CHEM, V269, P26959; HIASA H, 1989, FEBS LETT, V246, P21, DOI 10.1016/0014-5793(89)80245-5; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LEE MS, 1989, J BIOL CHEM, V264, P14531; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; LOW RL, 1981, P NATL ACAD SCI-BIOL, V78, P1436, DOI 10.1073/pnas.78.3.1436; LOW RL, 1982, J BIOL CHEM, V257, P6242; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1982, J BIOL CHEM, V257, P5665; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1986, P NATL ACAD SCI USA, V83, P1256, DOI 10.1073/pnas.83.5.1256; MASAI H, 1988, J BIOL CHEM, V263, P15083; MINDEN JS, 1985, J BIOL CHEM, V260, P9316; MOK M, 1987, J BIOL CHEM, V262, P2304; Ng JY, 1996, J BIOL CHEM, V271, P15642, DOI 10.1074/jbc.271.26.15642; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; OGAWA T, 1983, J BIOL CHEM, V258, P3353; PRATT D, 1968, J MOL BIOL, V181, P37; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; STUITJE AR, 1984, NUCLEIC ACIDS RES, V12, P3321, DOI 10.1093/nar/12.7.3321; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WU CA, 1992, J BIOL CHEM, V267, P4030	35	55	68	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15649	15655		10.1074/jbc.271.26.15649	http://dx.doi.org/10.1074/jbc.271.26.15649			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663105	hybrid			2022-12-27	WOS:A1996UV29900053
J	Favre, CJ; Schrenzel, J; Jacquet, J; Lew, DP; Krause, KH				Favre, CJ; Schrenzel, J; Jacquet, J; Lew, DP; Krause, KH			Highly supralinear feedback inhibition of Ca2+ uptake by the Ca2+ load of intracellular stores	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM; ENDOPLASMIC-RETICULUM; CA-2+ TRANSPORT; CALCIUM-PUMP; CA-2+-ATPASE; PROTEINS; MEMBRANE; ATPASES; STATE; CELLS	Net Ca2+ uptake into intracellular Ca2+ stores of homogenized cells is transient, even when the extravesicular Ca2+ concentration is kept constant. To study the mechanism underlying the phenomenon, we have investigated Ca-45(2+) uptake by HL-60 cell homogenates. The initial rate of Ca2+ uptake as well as the final amount of stored Ca2+ were a function of the extravesicular Ca2+ concentration. However, Ca2+ uptake stopped independently of the extravesicular Ca2+ concentration after approximately 10 min. Studies using Ca2+-ATPase inhibitors demonstrated that the transient nature of the net uptake was not due to Ca2+ efflux. Monovalent cat ion ionophores did not influence the Ca2+ uptake curves, excluding a relevant involvement of pH and membrane potential. Together with the observation of a continued Ca2+ uptake in the presence of the intralumenal Ca2+ chelator oxalate, these results strongly suggest a feedback inhibition of Ca2+ uptake by the Ca2+ load of intracellular stores. The concentration-inhibition relationship between the Ca2+ load and the rate of Ca2+ uptake was highly supralinear (slope factor greater than or equal to 4). IC50 and maximum of the dose-inhibition curve, but not the slope factor were a function of the extravesicular free Ca2+ concentration. A series of three logistic equations derived from our data allowed an appropriate description of the behavior of Ca2+ uptake. Our results suggest, in addition to its well known activation by cytosolic Ca2+ concentration, a highly supralinear feedback inhibition of Ca2+ uptake by the Ca2+ load of intracellular stores. The steepness of the feedback inhibition might have a profound effect on spatial and temporal behavior of the Ca2+ signal.	UNIV GENEVA,HOP CANTONAL,DIV INFECT DIS,CH-1211 GENEVA 14,SWITZERLAND; CTR MED UNIV GENEVA,SICMU,CH-1211 GENEVA 14,SWITZERLAND	University of Geneva; University of Geneva			Schrenzel, Jacques/AAC-5685-2021; Krause, Karl-Heinz/E-8030-2011; Schrenzel, Jacques/P-8525-2017	Schrenzel, Jacques/0000-0001-5464-7764; Krause, Karl-Heinz/0000-0002-9033-6768; Schrenzel, Jacques/0000-0001-5464-7764				CAMPBELL AM, 1991, J BIOL CHEM, V266, P16050; DACOSTA AG, 1994, BBA-BIOMEMBRANES, V1189, P181, DOI 10.1016/0005-2736(94)90064-7; DEMAUREX N, 1992, J BIOL CHEM, V267, P2318; FAVRE CJ, 1994, BIOCHEM J, V302, P155, DOI 10.1042/bj3020155; FAVRE CJ, 1996, IN PRESS BIOCH J, V313; FORGE V, 1995, J BIOL CHEM, V270, P18271, DOI 10.1074/jbc.270.31.18271; GILL DL, 1985, J BIOL CHEM, V260, P9289; GOMEZFERNANDEZ JC, 1994, BIOCHEM SOC T, V22, P826, DOI 10.1042/bst0220826; HEEGAARD CW, 1990, J BIOL CHEM, V265, P12020; HEILMANN C, 1983, BIOCHEM BIOPH RES CO, V114, P584, DOI 10.1016/0006-291X(83)90820-3; INESI G, 1989, J BIOL CHEM, V264, P5929; INESI G, 1992, J BIOENERG BIOMEMBR, V24, P271; JORGENSEN PL, 1988, J MEMBRANE BIOL, V103, P95, DOI 10.1007/BF01870942; MACER DRJ, 1988, J CELL SCI, V91, P61; MADEIRA VMC, 1982, CELL CALCIUM, V3, P62; MCINTOSH DB, 1988, J BIOL CHEM, V263, P12220; MISSIAEN L, 1993, BIOCHEM BIOPH RES CO, V193, P6, DOI 10.1006/bbrc.1993.1582; MOORE GA, 1987, FEBS LETT, V224, P331, DOI 10.1016/0014-5793(87)80479-9; PEDERSEN PL, 1987, TRENDS BIOCHEM SCI, V12, P186, DOI 10.1016/0968-0004(87)90090-9; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SMITH PM, 1994, BIOCHEM J, V299, P37, DOI 10.1042/bj2990037; TAYLOR KA, 1986, J MOL BIOL, V187, P417, DOI 10.1016/0022-2836(86)90442-0; THASTRUP O, 1990, P NATL ACAD SCI USA, V87, P2466, DOI 10.1073/pnas.87.7.2466; THOMAS D, 1994, METHOD CELL BIOL, V40, P65; TOYOSHIMA C, 1993, NATURE, V362, P469, DOI 10.1038/362469a0; YU X, 1995, J BIOL CHEM, V270, P4361, DOI 10.1074/jbc.270.9.4361	26	40	40	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14925	14930		10.1074/jbc.271.25.14925	http://dx.doi.org/10.1074/jbc.271.25.14925			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662967	hybrid			2022-12-27	WOS:A1996UT10600045
J	KrijnseLocker, J; Schleich, S; Rodriguez, D; Goud, B; Snijder, EJ; Griffiths, G				KrijnseLocker, J; Schleich, S; Rodriguez, D; Goud, B; Snijder, EJ; Griffiths, G			The role of a 21-kDa viral membrane protein in the assembly of vaccinia virus from the intermediate compartment	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL ENDOMEMBRANE SYSTEM; ENDOPLASMIC-RETICULUM; GOLGI-APPARATUS; CIS ELEMENT; PRE-GOLGI; GLYCOPROTEIN; TRANSPORT; GENE; CELL; ER	We have recently provided morphological evidence that a key event in the assembly of vaccinia virus is the formation of a novel cisternal domain of the intermediate compartment (IC) between the endoplasmic reticulum and the Golgi complex (Sodeik, B., Doms, R. W., Ericsson, M., Hiller, G., Machamer, C. E., van't Hof, W., van Meer, G., Moss, B., and Griffiths, G. (1993) J. Cell Biol. 121, 521-541). This tightly apposed cisternal domain incompletely surrounds the spherical immature virus that matures into the first of the two distinct infectious forms of vaccinia, the intracellular mature virus (IMV). In this study we describe the characterization of an abundant membrane protein of the IMV, the gene product of A17L, a 21-kDa protein that has recently been shown to be essential for the formation of the viral mem branes (Rodriguez, D., Esteban, M., and Rodriguez, J. R. (1995) J. Virol. 69, 4640-4648). Upon translation in vitro, p21 associated with rough microsomal membranes in a co-translational manner. Using NH2- and COOH-terminal specific antibodies, we show that both in vitro as well as in vivo, p21 adopts a topology where the NH, and COOH termini are cytoplasmically orientated. Immuno cytochemical experiments demonstrated that p21 is a component of the inner of the two cisternal membranes of the immature virus as well as of membranes of the IC, identified using antibodies against Rab1. Taken together, these data provide the first molecular evidence in support of our assembly model; they show that an essential membrane protein of the IMV inserts into the rough endoplasmic reticulum, but gets efficiently targeted to the IC and membranes of the viral factory.	EUROPEAN MOLEC BIOL LAB, CELL BIOL PROGRAM, D-69118 HEIDELBERG, GERMANY; UNIV AUTONOMA MADRID, CTR NACL BIOTECNOL, E-28049 MADRID, SPAIN; INST PASTEUR, UNITE GENET SOMAT, F-75231 PARIS 05, FRANCE	European Molecular Biology Laboratory (EMBL); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Locker, Jacomine Krijnse/AAX-1185-2020; Locker, Jacomine Krijnse/E-1009-2016; Goud, Bruno/GWC-4807-2022; Snijder, Eric J./E-6073-2018; Rodriguez, Dolores/ABF-9855-2020	Snijder, Eric J./0000-0003-3297-2309; Rodriguez, Dolores/0000-0001-6365-4501				ARIDOR M, 1995, J CELL BIOL, V131, P875, DOI 10.1083/jcb.131.4.875; BALCH WE, 1986, J BIOL CHEM, V261, P4681; BALDICK CJ, 1987, VIROLOGY, V156, P138, DOI 10.1016/0042-6822(87)90444-2; BECKERS CJM, 1990, J BIOL CHEM, V265, P18298; BEYER EC, 1990, J MEMBRANE BIOL, V116, P187, DOI 10.1007/BF01868459; BLASCO R, 1991, J VIROL, V65, P5910, DOI 10.1128/JVI.65.11.5910-5920.1991; CAIRNS J, 1960, VIROLOGY, V11, P603, DOI 10.1016/0042-6822(60)90103-3; CLAUDE A, 1970, J CELL BIOL, V47, P745, DOI 10.1083/jcb.47.3.745; CLERMONT Y, 1994, ANAT REC, V240, P469, DOI 10.1002/ar.1092400405; Dales S, 1981, Virol Monogr, V18, P1; DALES S, 1963, J CELL BIOL, V18, P51, DOI 10.1083/jcb.18.1.51; DUPREE P, 1993, EMBO J, V12, P1597, DOI 10.1002/j.1460-2075.1993.tb05804.x; ERICSSON M, 1995, J VIROL, V69, P7072, DOI 10.1128/JVI.69.11.7072-7086.1995; FRIEDLANDER M, 1985, NATURE, V318, P338, DOI 10.1038/318338a0; FUERST TR, 1986, P NATL ACAD SCI USA, V83, P8122, DOI 10.1073/pnas.83.21.8122; FURUSE M, 1993, J CELL BIOL, V123, P1777, DOI 10.1083/jcb.123.6.1777; GARON CF, 1971, VIROLOGY, V46, P233, DOI 10.1016/0042-6822(71)90026-2; GOEBEL SJ, 1990, VIROLOGY, V179, P247, DOI 10.1016/0042-6822(90)90294-2; Griffiths G, 1992, Semin Cell Biol, V3, P367, DOI 10.1016/1043-4682(92)90022-N; GRIFFITHS G, 1995, J CELL SCI, V108, P2839; GRIFFITHS G, 1994, J CELL BIOL, V127, P1557, DOI 10.1083/jcb.127.6.1557; GRIFFITHS G, 1993, FINE STRUCTURE IMMUN; HARTMANN E, 1989, P NATL ACAD SCI USA, V86, P5786, DOI 10.1073/pnas.86.15.5786; HAURI H-P, 1992, Current Opinion in Cell Biology, V4, P600, DOI 10.1016/0955-0674(92)90078-Q; HOBMAN TC, 1992, J CELL BIOL, V118, P795, DOI 10.1083/jcb.118.4.795; ICHIHASHI Y, 1994, VIROLOGY, V202, P834, DOI 10.1006/viro.1994.1405; KRIJNSELOCKER J, 1994, J CELL BIOL, V124, P55, DOI 10.1083/jcb.124.1.55; Kutay Ulrike, 1993, Trends in Cell Biology, V3, P72, DOI 10.1016/0962-8924(93)90066-A; LINDSEY JD, 1985, J NEUROSCI, V5, P3124; LINDSEY JD, 1985, J NEUROSCI, V5, P3111; LOCKER JK, 1992, J BIOL CHEM, V267, P21911; LOCKER JK, 1995, MOL BIOL CELL, V6, P1315; MAA JS, 1987, J VIROL, V61, P3910, DOI 10.1128/JVI.61.12.3910-3919.1987; Mohandas AR, 1995, VIROLOGY, V214, P494, DOI 10.1006/viro.1995.0060; MORGAN, 1976, SCIENCE, V193, P591, DOI 10.1126/science.959819; MOSS B, 1969, NATURE, V224, P1280, DOI 10.1038/2241280a0; MOSS B, 1990, P2079; NILES EG, 1988, J VIROL, V62, P3772, DOI 10.1128/JVI.62.10.3772-3778.1988; OPSTELTEN DJE, 1995, J CELL BIOL, V131, P339, DOI 10.1083/jcb.131.2.339; PAABO S, 1986, EMBO J, V5, P1921, DOI 10.1002/j.1460-2075.1986.tb04445.x; PELHAM HRB, 1994, CELL, V79, P1125, DOI 10.1016/0092-8674(94)90002-7; Pfeiffer Steve E., 1993, Trends in Cell Biology, V3, P191, DOI 10.1016/0962-8924(93)90213-K; POPOT JL, 1991, J MEMBRANE BIOL, V120, P233, DOI 10.1007/BF01868534; RAPOPORT TA, 1986, CRC CR REV BIOCH MOL, V20, P73, DOI 10.3109/10409238609115901; REXACH MF, 1991, J CELL BIOL, V114, P219, DOI 10.1083/jcb.114.2.219; RODRIGUEZ D, 1993, J VIROL, V67, P3435, DOI 10.1128/JVI.67.6.3435-3440.1993; RODRIGUEZ D, 1995, J VIROL, V69, P4640; ROOS N, 1996, IN PRESS EMBO J; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROTTIER P, 1985, J BIOL CHEM, V260, P4648; ROTTIER P, 1984, P NATL ACAD SCI-BIOL, V81, P1421, DOI 10.1073/pnas.81.5.1421; SABATINI DD, 1982, J CELL BIOL, V92, P1, DOI 10.1083/jcb.92.1.1; SARASTE J, 1984, CELL, V38, P535, DOI 10.1016/0092-8674(84)90508-7; SARASTE J, 1995, J CELL SCI, V108, P1541; SARASTE J, 1991, J CELL SCI, V100, P415; SCHMELZ M, 1994, J VIROL, V68, P130, DOI 10.1128/JVI.68.1.130-147.1994; SESSO A, 1994, J CELL SCI, V107, P517; SODEIK B, 1995, J VIROL, V69, P3560, DOI 10.1128/JVI.69.6.3560-3574.1995; SODEIK B, 1994, J VIROL, V68, P1103, DOI 10.1128/JVI.68.2.1103-1114.1994; SODEIK B, 1993, J CELL BIOL, V121, P521, DOI 10.1083/jcb.121.3.521; STINCHCOMBE JC, 1995, J CELL BIOL, V131, P1387, DOI 10.1083/jcb.131.6.1387; TARTAGLIA J, 1986, VIROLOGY, V150, P45, DOI 10.1016/0042-6822(86)90264-3; VONHEIJNE G, 1988, EUR J BIOCHEM, V174, P671; WHITEHEAD SS, 1994, VIROLOGY, V200, P154, DOI 10.1006/viro.1994.1174; WICKNER WT, 1985, SCIENCE, V230, P400, DOI 10.1126/science.4048938; Wilton S, 1995, VIROLOGY, V214, P503, DOI 10.1006/viro.1995.0061	66	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14950	14958		10.1074/jbc.271.25.14950	http://dx.doi.org/10.1074/jbc.271.25.14950			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662995	hybrid			2022-12-27	WOS:A1996UT10600049
J	Shi, WX; Chammas, R; Varki, A				Shi, WX; Chammas, R; Varki, A			Linkage-specific action of endogenous sialic acid O-acetyltransferase in Chinese hamster ovary cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GALACTOSIDE ALPHA-2,6-SIALYLTRANSFERASE; N-LINKED OLIGOSACCHARIDES; HUMAN-MELANOMA CELLS; DE-ORTHO-ACETYLATION; RAT-LIVER; MAACKIA-AMURENSIS; GOLGI-APPARATUS; GD3 GANGLIOSIDE; EXPRESSION; GENE	9-O-Acetylation of sialic acids shows cell type-specific and developmentally regulated expression in various systems, In a given cell type, O-acetylation can also be specific to a particular type of glycoconjugate. It is assumed that this regulation is achieved by control of expression of specific 9-O-acetyltransferases. However, it has been difficult to test this hypothesis, as these enzymes have so far proven intractable to purification or molecular cloning, During a cloning attempt, we discovered that while polyoma T antigen-positive Chinese hamster ovary cells (CHO-Tag cells) do not normally express cell surface 9-O-acetylation, they do so when transiently transfected with a cDNA encoding the lactosamine-specific alpha 2-6-sialyltransferase (Gal beta 1-4Glc-NAc:alpha 2-6 sialyltransferase (ST6Gal I); formerly ST6N), This phenomenon is reproducible by stable expression of ST6Gal I in parental CHO cells, but not upon transfection of the competing lactosamine specific (alpha 2-3-sialyltransferase (Gal beta 1-(3)4GlcNAc:alpha 23-sialyltransferase (ST6Gal III) formerly ST3N) into either cell type, Further analyses of stably transfected parental CHO-K1 cells indicated that expression of the STGGa1 I gene causes selective 9-O-acetylation of alpha 2-6-linked sialic acid residues on N-linked oligosaccharides, In a similar manner, while the alpha 2-3 linked sialic acid residue of the endogenous G(M3) ganglioside of CHO cells is not O-acetylated, transfection of an alpha 2-8-sialyltransferase (G(M3):alpha 2-8-sialyltransferase (ST8Sia I); formerly G(D3) synthase) caused expression of 9-O-acetylation of the alpha 2-8-linked sialic acid residues of newly synthesized G(D3). These data indicate either that linkage-specific sialic acid O-acetyltransferase(s) are constitutively expressed in CHO cells or that expression of these enzymes is secondarily induced upon expression of certain sialyltransferases. The former explanation is supported by a low level of background 9-O-acetylation found in parental CHO-K1 cells and by the finding that O-acetylation is not induced when the ST6Gal I or ST8Sia I cDNAs are overexpressed in SV40 T antigen-expressing primate (COS) cells, Taken together, these results indicate that expression of sialic acid 9-O-acetylation can be regulated by the action of specific sialyltransferases that alter the predominant linkage of the terminal sialic acids found on specific classes of glycoconjugates.	UNIV CALIF SAN DIEGO,SCH MED,CTR CANC,GLYCOBIOL PROGRAM,DIV CELLULAR & MOL MED,LA JOLLA,CA 92093	University of California System; University of California San Diego			Chammas, Roger/A-8004-2011	Chammas, Roger/0000-0003-0342-8726	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER; NCI NIH HHS [P01-CA5869] Funding Source: Medline; NIGMS NIH HHS [R01-GM32373] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AASHEIM HC, 1993, EUR J BIOCHEM, V213, P467, DOI 10.1111/j.1432-1033.1993.tb17783.x; BLUM AS, 1987, P NATL ACAD SCI USA, V84, P8716, DOI 10.1073/pnas.84.23.8716; BUTOR C, 1993, J BIOL CHEM, V268, P10197; CHANG ML, 1995, GLYCOBIOLOGY, V5, P319, DOI 10.1093/glycob/5.3.319; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; DIAZ S, 1989, J BIOL CHEM, V264, P19416; DO SI, 1990, J BIOL CHEM, V265, P114; ERIKSTEIN BK, 1992, EUR J IMMUNOL, V22, P1149, DOI 10.1002/eji.1830220507; FURUKAWA K, 1990, ARCH BIOCHEM BIOPHYS, V281, P70, DOI 10.1016/0003-9861(90)90414-T; GILLESPIE W, 1992, J BIOL CHEM, V267, P21004; HANASAKI K, 1994, J BIOL CHEM, V269, P10637; HANASAKI K, 1995, J BIOL CHEM, V270, P7533, DOI 10.1074/jbc.270.13.7533; HANASAKI K, 1995, J BIOL CHEM, V270, P7543, DOI 10.1074/jbc.270.13.7543; HARAGUCHI M, 1994, P NATL ACAD SCI USA, V91, P10455, DOI 10.1073/pnas.91.22.10455; HarduinLepers A, 1995, GLYCOBIOLOGY, V5, P741, DOI 10.1093/glycob/5.8.741; HAYES BK, 1993, J BIOL CHEM, V268, P16155; HIGA HH, 1989, J BIOL CHEM, V264, P19427; HOKKE CH, 1995, EUR J BIOCHEM, V228, P981, DOI 10.1111/j.1432-1033.1995.tb20350.x; KAMERLING JP, 1987, EUR J BIOCHEM, V162, P601, DOI 10.1111/j.1432-1033.1987.tb10681.x; KELM S, 1994, GLYCOCONJUGATE J, V11, P576, DOI 10.1007/BF00731309; KITAGAWA H, 1994, J BIOL CHEM, V269, P1394; KITAGAWA H, 1994, J BIOL CHEM, V269, P17872; KLEIN A, 1994, P NATL ACAD SCI USA, V91, P7782, DOI 10.1073/pnas.91.16.7782; KNIBBS RN, 1991, J BIOL CHEM, V266, P83; KNIEP B, 1993, BLOOD, V82, P1776; KUROSAWA N, 1994, J BIOL CHEM, V269, P19048; KUROSAWA N, 1994, J BIOL CHEM, V269, P1432; LANCE P, 1989, BIOCHEM BIOPH RES CO, V164, P225, DOI 10.1016/0006-291X(89)91706-3; LAU JTY, 1992, GLYCONCONJUGATES COM, P499; LEE EU, 1989, J BIOL CHEM, V264, P13848; LEE YC, 1994, J BIOL CHEM, V269, P10028; LEMARER N, 1992, GLYCOBIOLOGY, V2, P49, DOI 10.1093/glycob/2.1.49; LUTZ MS, 1994, J BIOL CHEM, V269, P29227; MANZI AE, 1990, ANAL BIOCHEM, V188, P20, DOI 10.1016/0003-2697(90)90523-C; MANZI AE, 1990, J BIOL CHEM, V265, P8094; MANZI AE, 1990, J BIOL CHEM, V265, P13091; MATTOX S, 1992, ANAL BIOCHEM, V206, P430, DOI 10.1016/0003-2697(92)90389-O; MENGELING BJ, 1991, ANAL BIOCHEM, V199, P286, DOI 10.1016/0003-2697(91)90103-Z; MOSTAFAPOUR MK, 1993, ARCH BIOCHEM BIOPHYS, V303, P255, DOI 10.1006/abbi.1993.1280; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; OHANLON TP, 1989, J BIOL CHEM, V264, P17389; PAHLSSON P, 1994, GLYCOCONJUGATE J, V11, P43, DOI 10.1007/BF00732431; PATON MC, 1986, NATURE, V324, P459; PAULSON JC, 1984, EUR J BIOCHEM, V140, P523, DOI 10.1111/j.1432-1033.1984.tb08133.x; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; POWELL LD, 1994, J BIOL CHEM, V269, P10628; REUTER G, 1983, EUR J BIOCHEM, V134, P139, DOI 10.1111/j.1432-1033.1983.tb07542.x; REUTER G, 1990, BIOCHEM BIOPH RES CO, V94, P567; SANAI Y, 1990, J BIOCHEM-TOKYO, V107, P740, DOI 10.1093/oxfordjournals.jbchem.a123118; SARRIS AH, 1979, J BIOL CHEM, V254, P6724; SASAKI K, 1994, J BIOL CHEM, V269, P15950; SCHAUER R, 1987, METHOD ENZYMOL, V138, P611; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SCHUZHENNINGER R, 1989, EUR J BIOCHEM, V185, P327, DOI 10.1111/j.1432-1033.1989.tb15119.x; SHAH S, 1992, J BIOL CHEM, V267, P10652; SHIBUYA N, 1987, J BIOL CHEM, V262, P1596; SHIGETA S, 1994, CARBOHYD RES, V264, P111, DOI 10.1016/0008-6215(94)00192-8; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; SJOBERG ER, 1993, J BIOL CHEM, V268, P10185; STAMENKOVIC I, 1991, CELL, V66, P1133, DOI 10.1016/0092-8674(91)90036-X; TROY FA, 1992, GLYCOBIOLOGY, V2, P5, DOI 10.1093/glycob/2.1.5; VARKI A, 1994, METHOD ENZYMOL, V230, P16; VARKI A, 1984, ANAL BIOCHEM, V137, P236, DOI 10.1016/0003-2697(84)90377-4; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; Varki A, 1994, Subcell Biochem, V22, P71; VERTINOBELL A, 1994, DEV BIOL, V165, P126, DOI 10.1006/dbio.1994.1240; WANG WC, 1988, J BIOL CHEM, V263, P4576; WANG XC, 1993, J BIOL CHEM, V268, P4355; WANG XC, 1989, J BIOL CHEM, V264, P1854; WARNOCK DE, 1994, P NATL ACAD SCI USA, V91, P2708, DOI 10.1073/pnas.91.7.2708; WEIS FMB, 1990, J BIOL CHEM, V265, P12059; YAMASHIRO S, 1995, GLYCOCONJUGATE J, V12, P894, DOI 10.1007/BF00731251; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343	74	49	51	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15130	15138		10.1074/jbc.271.25.15130	http://dx.doi.org/10.1074/jbc.271.25.15130			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662976	hybrid			2022-12-27	WOS:A1996UT10600072
J	Urata, Y; Yamamoto, H; Goto, S; Tsushima, H; Akazawa, S; Yamashita, S; Nagataki, S; Kondo, T				Urata, Y; Yamamoto, H; Goto, S; Tsushima, H; Akazawa, S; Yamashita, S; Nagataki, S; Kondo, T			Long exposure to high glucose concentration impairs the responsive expression of gamma-glutamylcysteine synthetase by interleukin-1 beta and tumor necrosis factor-alpha in mouse endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NF-KAPPA-B; TRANSCRIPTION FACTOR; OXYGEN RADICALS; GLUTATHIONE; TOXICITY; MECHANISMS; INHIBITION; TRANSPORT; RECEPTOR; SUBUNIT	To elucidate the pathological metabolism of glutathione synthesis in diabetic endothelial cells, we studied the expression of gamma-glutamylcysteine synthetase (gamma-GCS) using a mouse vascular endothelial cell line. Exposing normoglycemic endothelial cells to tumor necrosis factor-alpha (TNF-alpha) or interleukin-1 beta (IL-1 beta) increased the activity and the mRNA expression of gamma-GCS, The addition of inhibitors for nuclear factor kappa B (NF-kappa B) to the cells caused a loss of the gamma-GCS mRNA expression in response to TNF-alpha. A shift of the concentration of glucose in the medium from 5.5 to 28 mM glucose and a following incubation for 7 days decreased the expression of gamma-GCS mRNA. These cells showed no apparent responses of gamma-GCS mRNA or the activity of NF-kappa B to TNF-alpha or IL-beta. Increase in the GSH concentration of the cells treated with 28 mM glucose restored the expression of gamma-GCS mRNA and its response to TNF-alpha or IL-beta, suggesting that redox regulation is involved in the expression of gamma-GCS. In summary, the expression of gamma-GCS is regulated by TNF-alpha or IL-1 beta in endothelial cells mediated by NF-kappa B stimulation, and impairment of the regulation of gamma-GCS in hyperglycemic cells may be a cause of medical complications that develop in diabetes mellitus.	NAGASAKI UNIV, SCH MED, INST ATOM DIS, DEPT PATHOL BIOCHEM, NAGASAKI 852, JAPAN; NAGASAKI UNIV, SCH MED, INST ATOM DIS, DEPT CELLULAR PHYSIOL, NAGASAKI 852, JAPAN; NAGASAKI UNIV, SCH MED, DEPT MED 1, NAGASAKI 852, JAPAN	Nagasaki University; Nagasaki University; Nagasaki University			Yamashita, Shunichi/GVS-9508-2022	Yamashita, Shunichi/0000-0001-6399-6261; nagataki, shigenobu/0000-0002-9974-3554				BAEUERLE PA, 1991, BIOCHIM BIOPHYS ACTA, V1072, P63, DOI 10.1016/0304-419X(91)90007-8; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BARBU V, 1989, NUCLEIC ACIDS RES, V17, P7115, DOI 10.1093/nar/17.17.7115; BEUTLER E, 1986, CLIN CHIM ACTA, V158, P115, DOI 10.1016/0009-8981(86)90122-1; Beutler E, 1984, RED CELL METABOLISM, P77; CAULEY K, 1994, P NATL ACAD SCI USA, V91, P390, DOI 10.1073/pnas.91.1.390; DINARELLO CA, 1991, BLOOD, V77, P1627; FINCO TS, 1994, P NATL ACAD SCI USA, V91, P11884, DOI 10.1073/pnas.91.25.11884; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; Galter Dagmar, 1994, European Journal of Biochemistry, V221, P639; GHOSH S, 1990, CELL, V62, P1019, DOI 10.1016/0092-8674(90)90276-K; GOLDWIN AK, 1992, P NATL ACAD SCI USA, V89, P3070; GOTO S, 1995, CANCER RES, V55, P4297; HALLIWELL B, 1984, LANCET, V1, P1396; HAMANAKA R, 1992, J BIOL CHEM, V267, P13160; HAYASHI T, 1993, J BIOL CHEM, V268, P11380; HOSODA C, 1995, ENDOCR J, V42, P341, DOI 10.1507/endocrj.42.341; ISHII Y, 1992, J CLIN INVEST, V89, P794, DOI 10.1172/JCI115658; JOSHIBARVE SS, 1993, J BIOL CHEM, V268, P18018; KALEBIC T, 1991, P NATL ACAD SCI USA, V88, P986, DOI 10.1073/pnas.88.3.986; KASAI H, 1986, CARCINOGENESIS, V7, P1849, DOI 10.1093/carcin/7.11.1849; KASHIWAGI A, 1994, DIABETOLOGIA, V37, P264, DOI 10.1007/BF00398053; KONDO T, 1993, J BIOL CHEM, V268, P20366; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; MANDRUPPOULSEN T, 1987, J IMMUNOL, V139, P4077; MANJI SS, 1995, J BIOL CHEM, V270, P8958, DOI 10.1074/jbc.270.15.8958; MARCHO Z, 1991, AM J RESP CELL MOL, V5, P556, DOI 10.1165/ajrcmb/5.6.556; MEISTER A, 1985, METHOD ENZYMOL, V113, P571; MURAMATSU M, 1974, EXP CELL RES, V88, P345, DOI 10.1016/0014-4827(74)90250-X; NAKAYAMA K, 1992, MOL CELL BIOL, V12, P1736, DOI 10.1128/MCB.12.4.1736; REDINBAUGH MG, 1986, ANAL BIOCHEM, V153, P267, DOI 10.1016/0003-2697(86)90091-6; RICHMAN PG, 1975, J BIOL CHEM, V250, P1422; RUBEN SM, 1991, SCIENCE, V251, P1490, DOI 10.1126/science.2006423; SAMBROOK J, 1989, MOL CLONING LAB MANU, P7; SEN R, 1986, CELL, V46, P705, DOI 10.1016/0092-8674(86)90346-6; STOCKER R, 1985, P NATL ACAD SCI USA, V82, P548, DOI 10.1073/pnas.82.2.548; STYLIANOU E, 1992, J BIOL CHEM, V267, P15836; TAGAMI S, 1992, METABOLISM, V41, P1053, DOI 10.1016/0026-0495(92)90285-I; TOLENADO MB, 1990, P NATL ACAD SCI USA, V88, P4328; TROCINO AT, 1995, DIABETES, V44, P1; TSAN MF, 1991, J APPL PHYSIOL, V71, P688, DOI 10.1152/jappl.1991.71.2.688; VILCEK J, 1991, J BIOL CHEM, V266, P7313; VISNER GA, 1990, J BIOL CHEM, V265, P2856; WU GY, 1992, J BIOL CHEM, V267, P12436; YAN N, 1990, J BIOL CHEM, V265, P1588	45	131	133	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15146	15152		10.1074/jbc.271.25.15146	http://dx.doi.org/10.1074/jbc.271.25.15146			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662965	hybrid			2022-12-27	WOS:A1996UT10600074
J	Ames, GFL; Liu, CE; Joshi, AK; Nikaido, K				Ames, GFL; Liu, CE; Joshi, AK; Nikaido, K			Liganded and unliganded receptors interact with equal affinity with the membrane complex of periplasmic permeases, a subfamily of traffic ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ORNITHINE-BINDING PROTEIN; HISTIDINE PERMEASE; SALMONELLA-TYPHIMURIUM; TRANSPORT-SYSTEMS; ESCHERICHIA-COLI; CYSTIC-FIBROSIS; MULTIDRUG-RESISTANCE; BACTERIAL TRANSPORT; ACTIVE-TRANSPORT; ATP HYDROLYSIS	The histidine-binding protein, HisJ, is the soluble receptor for the periplasmic histidine permease of Salmonella typhimurium, The receptor binds the substrate in the periplasm, interacts with the membrane-bound complex, transmits a transmembrane signal to hydrolyze ATP, and releases the ligand for translocation, HisJ, like other periplasmic receptors, has two lobes that are apart in the unliganded structure (open conformation) and drawn close together in the liganded structure (closed conformation), burying deeply the ligand, Such receptors are postulated to interact with the membrane bound complex with high affinity in their liganded con formation, and, upon substrate translocation, to undergo a reduction in affinity and therefore be released, Here we show that in contrast to the current postulate, liganded and unliganded receptors have equal affinity for the membrane-bound complex, The affinity is measured both by chemical cross-linking and co-sedimentation procedures, An ATPase activity assay is also used to demonstrate the interaction of unliganded receptor with the membrane-bound complex, These findings support a new model for the transport mechanism, in which the soluble receptor functions independently of the commonly accepted high-low affinity switch.			Ames, GFL (corresponding author), UNIV CALIF BERKELEY, DEPT MOLEC & CELL BIOL, DIV BIOCHEM & MOLEC BIOL, BERKELEY, CA 94720 USA.				NIDDK NIH HHS [DK-12121] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK012121, R37DK012121] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AMES BN, 1952, J AM CHEM SOC, V74, P252; AMES GF, 1990, FEMS MICROBIOL LETT, V75, P429, DOI 10.1016/S0168-6445(05)80008-7; AMES GF, 1964, ARCH BIOCHEM BIOPHYS, V104, P1, DOI 10.1016/S0003-9861(64)80028-X; AMES GFL, 1972, J BIOL CHEM, V247, P4309; AMES GFL, 1986, ANNU REV BIOCHEM, V55, P397, DOI 10.1146/annurev.biochem.55.1.397; BISHOP L, 1989, P NATL ACAD SCI USA, V86, P6953, DOI 10.1073/pnas.86.18.6953; BOEDTKER H, 1967, BIOCHEMISTRY-US, V6, P2718, DOI 10.1021/bi00861a011; BOHL E, 1995, J THEOR BIOL, V172, P83, DOI 10.1006/jtbi.1995.0006; BRASS JM, 1986, J BACTERIOL, V165, P787, DOI 10.1128/jb.165.3.787-795.1986; BROWN EM, 1993, NATURE, V366, P575, DOI 10.1038/366575a0; CANTOR CR, 1980, BIOPHYSICAL CHEM, P943; CHIFFLET S, 1988, ANAL BIOCHEM, V168, P1, DOI 10.1016/0003-2697(88)90002-4; DAVIDSON AL, 1992, P NATL ACAD SCI USA, V89, P2360, DOI 10.1073/pnas.89.6.2360; DOIGE CA, 1993, ANNU REV MICROBIOL, V47, P291, DOI 10.1146/annurev.micro.47.1.291; EASLEY CW, 1969, BIOCHIM BIOPHYS ACTA, V175, P211, DOI 10.1016/0005-2795(69)90161-5; FERROLUZZIAMES G, 1976, P NATL ACAD SCI USA, V73, P1877, DOI 10.1073/pnas.73.6.1877; FLOCCO MM, 1994, J BIOL CHEM, V269, P8931; GHINEA N, 1989, J BIOL CHEM, V264, P4755; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HOBOT JA, 1984, J BACTERIOL, V160, P143, DOI 10.1128/JB.160.1.143-152.1984; HOBSON AC, 1984, P NATL ACAD SCI-BIOL, V81, P7333, DOI 10.1073/pnas.81.23.7333; HUANG ZJ, 1995, SCIENCE, V267, P1169, DOI 10.1126/science.7855598; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JACKSON V, 1978, CELL, V15, P945, DOI 10.1016/0092-8674(78)90278-7; KERPPOLA RE, 1991, J BIOL CHEM, V266, P9857; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; MILLER DM, 1983, J BIOL CHEM, V258, P3665; NIKAIDO K, 1992, J BIOL CHEM, V267, P20706; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PETRONILLI V, 1991, J BIOL CHEM, V266, P16293; PROSSNITZ E, 1988, J BIOL CHEM, V263, P17917; PROSSNITZ E, 1989, J BIOL CHEM, V264, P5006; PROSSNITZ E, 1989, THESIS U CALIFORNIA; QUIOCHO FA, 1990, PHILOS T R SOC B, V326, P341, DOI 10.1098/rstb.1990.0016; ROTH JR, 1970, METHODS ENZYMOL    A, V17, P3; SHARFF AJ, 1992, BIOCHEMISTRY-US, V31, P10657, DOI 10.1021/bi00159a003; SHILTON BH, 1995, PROTEIN SCI, V4, P1346, DOI 10.1002/pro.5560040710; SHYAMALA V, 1991, J BIOL CHEM, V266, P18714; SILHAVY TJ, 1975, P NATL ACAD SCI USA, V72, P2120, DOI 10.1073/pnas.72.6.2120; SPEISER DM, 1991, J BACTERIOL, V173, P1444, DOI 10.1128/jb.173.4.1444-1451.1991; SPEISER DM, 1989, THESIS U CALIFORNIA; STERN MJ, 1986, THESIS U CALIFORNIA; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; WALMSLEY AR, 1992, BIOCHEMISTRY-US, V31, P11175, DOI 10.1021/bi00160a031; WILLIS RC, 1974, J BIOL CHEM, V249, P6926; WOLF A, 1994, J BIOL CHEM, V269, P23051	48	70	70	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14264	14270		10.1074/jbc.271.24.14264	http://dx.doi.org/10.1074/jbc.271.24.14264			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662800	hybrid			2022-12-27	WOS:A1996UQ66000051
J	Ponzetto, C; Zhen, Z; Audero, E; Maina, F; Bardelli, A; Basile, ML; Giordano, S; Narsimhan, R; Comoglio, P				Ponzetto, C; Zhen, Z; Audero, E; Maina, F; Bardelli, A; Basile, ML; Giordano, S; Narsimhan, R; Comoglio, P			Specific uncoupling of GRB2 from the met receptor - Differential effects on transformation and motility	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR SCATTER FACTOR; GROWTH-FACTOR RECEPTOR; TYROSINE KINASE; PHOSPHATIDYLINOSITOL 3-KINASE; C-MET; PROTEIN	The biological effects of hepatocyte growth factor/scatter scatter factor are mediated by autophosphorylation of its receptor, the Met tyrosine kinase, on two carboxyl-terminal tyrosines. These phosphotyrosines (Y(1349)VHVNATY(1356)VNV) are multifunctional docking sites for several effecters. Grb2, the adaptor for the Res guanyl-nucleotide exchanger SOS, binds to Tyr(1356) in the <YV(N)under bar V> motif. By site-directed mutagenesis we either abrogated or duplicated the Grb2 consensus, without interfering with the other effecters. Loss of the Link with Grb2 severely impaired transformation. The same mutation, however, had no effect on the ''scattering'' response, indicating that the level of signal which can be reached by Grb2-independent routes is permissive for motility. Duplication of the Grb2 binding site enhanced transformation and left motility unchanged. Thus, two Met-mediated biological responses, motility and growth, can be dissociated on the basis of their differential requirement for a direct link with Ras.	UNIV TURIN,DEPT BIOMED SCI & HUMAN ONCOL,I-10126 TURIN,ITALY; LUDWIG INST CANC RES,LONDON W1P 8BT,ENGLAND	University of Turin; Ludwig Institute for Cancer Research			Maina, Flavio/J-9962-2019; Giordano, Silvia/J-9858-2018; BARDELLI, Alberto/J-9721-2018	Maina, Flavio/0000-0001-6100-4695; Giordano, Silvia/0000-0003-1854-1086; Comoglio, Paolo/0000-0002-7056-5328; BARDELLI, Alberto/0000-0003-1647-5070; Audero, Enrica/0000-0002-6138-244X				BASU T, 1994, ONCOGENE, V9, P3483; BLADT F, 1995, NATURE, V376, P768, DOI 10.1038/376768a0; DOWNWARD J, 1995, CELL, V83, P631; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIXMAN ED, 1995, ONCOGENE, V10, P237; GHERARDI E, 1991, CANCER CELL-MON REV, V3, P227; GIORDANO S, 1989, NATURE, V339, P155, DOI 10.1038/339155a0; GONZATTIHACES M, 1988, P NATL ACAD SCI USA, V85, P21, DOI 10.1073/pnas.85.1.21; GRAZIANI A, 1991, J BIOL CHEM, V266, P22087; HARTMANN G, 1994, J BIOL CHEM, V269, P21936; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; MARTINZANCA D, 1989, MOL CELL BIOL, V9, P24, DOI 10.1128/MCB.9.1.24; MEYER S, 1994, MOL CELL BIOL, V14, P3253, DOI 10.1128/MCB.14.5.3253; NAGAFUCHI A, 1988, EMBO J, V7, P3679, DOI 10.1002/j.1460-2075.1988.tb03249.x; PELICCI G, 1995, ONCOGENE, V10, P1631; PONZETTO C, 1993, MOL CELL BIOL, V13, P4600, DOI 10.1128/MCB.13.8.4600; PONZETTO C, 1991, ONCOGENE, V6, P553; PONZETTO C, 1994, CELL, V77, P261, DOI 10.1016/0092-8674(94)90318-2; PRAT M, 1991, MOL CELL BIOL, V11, P5954, DOI 10.1128/MCB.11.12.5954; RIDLEY AJ, 1995, MOL CELL BIOL, V15, P1110; RODRIGUES GA, 1993, MOL CELL BIOL, V13, P6711, DOI 10.1128/MCB.13.11.6711; ROYAL I, 1995, J BIOL CHEM, V270, P27780, DOI 10.1074/jbc.270.46.27780; SCHMIDT C, 1995, NATURE, V373, P699, DOI 10.1038/373699a0; SOLER C, 1994, J BIOL CHEM, V269, P12320; SONGYANG Z, 1993, CELL, V72, P1; STOKER M, 1987, NATURE, V327, P239, DOI 10.1038/327239a0; UEHARA Y, 1995, NATURE, V373, P702, DOI 10.1038/373702a0; WEIDNER KM, 1995, P NATL ACAD SCI USA, V92, P2597, DOI 10.1073/pnas.92.7.2597; ZHU H, 1994, J BIOL CHEM, V269, P29943	29	144	154	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14119	14123		10.1074/jbc.271.24.14119	http://dx.doi.org/10.1074/jbc.271.24.14119			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662889	hybrid			2022-12-27	WOS:A1996UQ66000030
J	Seabra, MC				Seabra, MC			Nucleotide dependence of Rab geranylgeranylation - Rab escort protein interacts preferentially with GDP-bound Rab	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; CHOROIDEREMIA GENE; ALPHA-SUBUNIT; CDNA CLONING; COMPONENT-A; SMG P25A; TRANSFERASE; PURIFICATION; GERANYLGERANYLTRANSFERASE; ISOPRENYLATION	Geranylgeranylation of Rab GTPases is an essential post-translational modification that enables Rabs to associate with intracellular membranes where they regulate exocytic and endocytic pathways. Geranylgeranylation is initiated by formation of a stable complex between newly synthesized Rab proteins and Rab escort protein (REP). The complex is recognized by Rab geranylgeranyl (GG) transferase, which transfers two GG groups to Rabs. The geranylgeranylated Rabs regulate vesicular movement by oscillating between an inactive GDP-bound form and an active GTP-bound form. In this study, I show that the kinetics of geranylgeranylation is influenced by the nucleotide status of nascent Rab. GDP-bound Rab is geranylgeranylated with 10-50 fold higher affinity than GTP-bound Rab (or GTP analog-bound Rab), as indicated by the apparent K-m of the reaction. In vitro REP Rab binding assays demonstrate that REP forms a stable complex only with the GDP-bound form of Rab but not the GTP-bound form, suggesting that the apparent K-m effect in the prenylation reaction is due to a discrimination between the two different nucleotide-bound forms of Rab by REP. Inasmuch as Rabs are likely GTP-bound after synthesis and REP does not possess GTPase-activating protein activity, these results raise the possibility that a Rab GTPase-activating protein enhances the REP Rab interaction prior to prenylation.			Seabra, MC (corresponding author), UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235, USA.		Seabra, Miguel/AAC-3099-2019; Seabra, Miguel C/M-3280-2013	Seabra, Miguel C/0000-0002-6404-4892	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL020948] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL20948] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALEXANDROV K, 1994, EMBO J, V13, P5262, DOI 10.1002/j.1460-2075.1994.tb06860.x; ANDRES DA, 1993, CELL, V73, P1091, DOI 10.1016/0092-8674(93)90639-8; ARAKI S, 1990, J BIOL CHEM, V265, P13007; ARMSTRONG SA, 1995, METHOD ENZYMOL, V257, P30; ARMSTRONG SA, 1993, J BIOL CHEM, V268, P12221; BERANGER F, 1994, J BIOL CHEM, V269, P13637; BOURNE HR, 1991, NATURE, V349, P117, DOI 10.1038/349117a0; BURSTEIN ES, 1991, J BIOL CHEM, V266, P2689; CASEY PJ, 1995, SCIENCE, V268, P221, DOI 10.1126/science.7716512; Casey PJ, 1996, J BIOL CHEM, V271, P5289, DOI 10.1074/jbc.271.10.5289; CREMERS FPM, 1990, NATURE, V347, P674, DOI 10.1038/347674a0; CREMERS FPM, 1994, J BIOL CHEM, V269, P2111; Cremers Frans P. M., 1992, Human Molecular Genetics, V1, P71, DOI 10.1093/hmg/1.2.71; FARNSWORTH CC, 1994, P NATL ACAD SCI USA, V91, P11963, DOI 10.1073/pnas.91.25.11963; FARNSWORTH CC, 1991, P NATL ACAD SCI USA, V88, P6196, DOI 10.1073/pnas.88.14.6196; FUJIMURA K, 1994, J BIOL CHEM, V269, P9205; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; HORIUCHI H, 1995, J BIOL CHEM, V270, P11257, DOI 10.1074/jbc.270.19.11257; JOHN J, 1990, BIOCHEMISTRY-US, V29, P6058, DOI 10.1021/bi00477a025; MILLIGAN G, 1995, TRENDS BIOCHEM SCI, V20, P181, DOI 10.1016/S0968-0004(00)89004-0; MOOMAW JF, 1992, J BIOL CHEM, V267, P17438; MOORES SL, 1991, J BIOL CHEM, V266, P14603; NUOFFER C, 1994, ANNU REV BIOCHEM, V63, P949, DOI 10.1146/annurev.bi.63.070194.004505; PFEFFER SR, 1995, J BIOL CHEM, V270, P17057, DOI 10.1074/jbc.270.29.17057; REISS Y, 1990, CELL, V62, P81, DOI 10.1016/0092-8674(90)90242-7; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; SANFORD JC, 1995, J BIOL CHEM, V270, P26904, DOI 10.1074/jbc.270.45.26904; SANFORD JC, 1995, MOL BIOL CELL, V6, P71, DOI 10.1091/mbc.6.1.71; SANFORD JC, 1993, J BIOL CHEM, V268, P23773; SASAKI T, 1990, J BIOL CHEM, V265, P2333; SCHIEDEL AC, 1995, FEBS LETT, V376, P113, DOI 10.1016/0014-5793(95)01258-0; SEABRA MC, 1992, CELL, V70, P1049, DOI 10.1016/0092-8674(92)90253-9; SEABRA MC, 1991, CELL, V65, P429, DOI 10.1016/0092-8674(91)90460-G; SEABRA MC, 1993, SCIENCE, V259, P377, DOI 10.1126/science.8380507; SEABRA MC, 1995, J BIOL CHEM, V270, P24420, DOI 10.1074/jbc.270.41.24420; SEABRA MC, 1992, J BIOL CHEM, V267, P14497; SHAPIRO AD, 1993, J BIOL CHEM, V268, P2925; Shen F, 1996, J BIOL CHEM, V271, P3692; SMELAND TE, 1994, P NATL ACAD SCI USA, V91, P10712, DOI 10.1073/pnas.91.22.10712; SOLDATI T, 1994, NATURE, V369, P76, DOI 10.1038/369076a0; TAN TJ, 1991, FEBS LETT, V291, P322, DOI 10.1016/0014-5793(91)81312-V; TAVITIAN A, 1992, METHOD ENZYMOL, V219, P387; ULLRICH O, 1994, NATURE, V368, P157, DOI 10.1038/368157a0; WALDHERR M, 1993, NAT GENET, V3, P193, DOI 10.1038/ng0393-193; WILSON AL, 1993, J BIOL CHEM, V268, P14561; YOKOYAMA K, 1993, J BIOL CHEM, V268, P4055; Zerial M, 1993, CURR OPIN CELL BIOL, V5, P613, DOI 10.1016/0955-0674(93)90130-I	47	47	48	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14398	14404		10.1074/jbc.271.24.14398	http://dx.doi.org/10.1074/jbc.271.24.14398			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662963	hybrid			2022-12-27	WOS:A1996UQ66000069
J	TsaiMorris, CH; Buczko, E; Geng, Y; GamboaPinto, A; Dufau, ML				TsaiMorris, CH; Buczko, E; Geng, Y; GamboaPinto, A; Dufau, ML			The genomic structure of the rat corticotropin releasing factor receptor - A member of the Class II G protein-coupled receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; FUNCTIONAL EXPRESSION; SIGNAL-TRANSDUCTION; LEYDIG-CELLS; HORMONE; GENE; PEPTIDE; CDNA; VARIANTS; BINDING	Isolation and structural characterization of the rat corticotropin releasing factor receptor (CRFR) gene was performed to determine the exon/intron organization of the coding region and the potential for splice variants, The CRFR gene contains 13 exons and 12 introns, and the positions of the exon/intron junctions are similar to those of other Class II G protein-coupled receptor genes including the parathyroid hormone and glucagon receptors, The promoter resides within 593 base pairs of the initiation codon and the major transcriptional start site at nucleotide -238. This domain does not possess a TATA box but contains multiple Spl and AP-2 sites upstream and downstream of the major transcriptional start site, Intron junctions were identified in the extracellular, transmembrane (TM), and cytoplasmic (C) domains of the CRFR, giving the potential for differential signal transduction by splice variants, CRFR cDNAs derived from rat Leydig cell mRNA included the pituitary Form A, which spans exons 1-13, and two splice variants with deletion of exon 3 or exons 7, 11, and 12, An evolutionary link between the intronless TM/C module of the glycoprotein hormone receptors and the intron-containing TM/C module of the CRFR is suggested by the common position of the luteinizing hormone receptor Form D alternate acceptor splice site and the CRFR intron 12.	NICHHD, SECT MOL ENDOCRINOL, ENDOCRINOL & REPROD RES BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)				Tsai Morris, Chon Hwa/0000-0002-8113-0979; Gamboa-Pinto, Antonio/0000-0002-0236-6132				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; BUGGY JJ, 1995, J BIOL CHEM, V270, P7474, DOI 10.1074/jbc.270.13.7474; BURBACH JPH, 1992, EUR J PHARM-MOLEC PH, V227, P1, DOI 10.1016/0922-4106(92)90136-J; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; DOHLMAN HG, 1987, J BIOL CHEM, V262, P14282; IMAGAWA M, 1987, CELL, V51, P251, DOI 10.1016/0092-8674(87)90152-8; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JELINEK LJ, 1993, SCIENCE, V259, P1614, DOI 10.1126/science.8384375; JOURNOT L, 1995, BIOCHEM SOC T, V23, P133, DOI 10.1042/bst0230133; KONG XF, 1994, BIOCHEM BIOPH RES CO, V200, P1290, DOI 10.1006/bbrc.1994.1591; KOO YB, 1991, ENDOCRINOLOGY, V128, P2297, DOI 10.1210/endo-128-5-2297; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LOOSFELT H, 1989, SCIENCE, V245, P525, DOI 10.1126/science.2502844; MAGET B, 1994, FEBS LETT, V351, P271, DOI 10.1016/0014-5793(94)00875-2; PERRIN MH, 1993, ENDOCRINOLOGY, V133, P3058, DOI 10.1210/en.133.6.3058; ROSS PC, 1994, BIOCHEM BIOPH RES CO, V205, P1836, DOI 10.1006/bbrc.1994.2884; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; SVOBODA M, 1993, BIOCHEM BIOPH RES CO, V191, P479, DOI 10.1006/bbrc.1993.1243; TSAIMORRIS CH, 1990, J BIOL CHEM, V265, P19385; TSAIMORRIS CH, 1991, J BIOL CHEM, V266, P11355; TSAIMORRIS CH, 1993, J BIOL CHEM, V268, P4447; ULISSE S, 1990, J BIOL CHEM, V265, P1964; ULISSE S, 1989, J BIOL CHEM, V264, P2156; VALE W, 1981, SCIENCE, V213, P1394, DOI 10.1126/science.6267699; VITA N, 1993, FEBS LETT, V335, P1, DOI 10.1016/0014-5793(93)80427-V; WHEELER MB, 1993, ENDOCRINOLOGY, V133, P57, DOI 10.1210/en.133.1.57; WOODSON SA, 1989, CELL, V57, P335, DOI 10.1016/0092-8674(89)90971-9; XIONG YT, 1995, ENDOCRINOLOGY, V136, P1828, DOI 10.1210/en.136.5.1828	28	55	57	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14519	14525		10.1074/jbc.271.24.14519	http://dx.doi.org/10.1074/jbc.271.24.14519			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662941	hybrid			2022-12-27	WOS:A1996UQ66000086
J	Xie, WW; Kaetzel, MA; Bruzik, KS; Dedman, JR; Shears, SB; Nelson, DJ				Xie, WW; Kaetzel, MA; Bruzik, KS; Dedman, JR; Shears, SB; Nelson, DJ			Inositol 3,4,5,6-tetrakisphosphate inhibits the calmodulin-dependent protein kinase II-activated chloride conductance in T84 colonic epithelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYSTIC-FIBROSIS; AIRWAY EPITHELIA; BINDING PROTEIN; ACINAR-CELLS; LINE T84; CALCIUM; CHANNELS; STIMULATION; PHOSPHATES; SECRETION	The mechanism by which inositol 3,4,5,6-tetrakisphosphate (Ins(3,4,5,6)P-4) regulates chloride (Cl-) secretion was evaluated in the colonic epithelial cell line T84 using whole cell voltage clamp techniques. Our studies focused on the calcium-dependent chloride conductance (gCl(Ca)) that was activated either by mobilizing intracellular calcium (Ca-i) stores with thapsigargin or by introduction of the autonomous, autophosphorylated calmodulin-dependent protein kinase II (CaMKII) into the cell via the patch pipette. Basal concentrations of Ins(3,4,5,6)P-4 (1 mu M) present in the pipette solution had no significant effect on Cl- current; however, as the concentration of the polyphosphate was increased there was a corresponding reduction in anion current, with near complete inhibition at 8-10 mu M Ins(3,4,5,6)P-4. Corresponding levels are found in cells after sustained receptor-dependent activation of phospholipase C. The Ins(3,4,5,6)P-4-induced inhibition of gCl(Ca) was isomer specific; neither Ins(1,3,4,5)P-4, Ins(1,3,4,6)P-4, Ins(1,4,5,6)P-4, nor Ins(1,3,4,5,6)P-5 induced current inhibition at concentrations of up to 100 mu M. Annexin TV also plays an inhibitory role in modulating gCl(Ca) in T84 cells. When 2 mu M annexin IV was present in the pipette solution, a concentration that by itself has no effect on gCl(Ca), the potency of Ins(3,4,5,6)P-4 was approximately doubled. The combination of Ins(3,4,5,6)P-4 and annexin TV did not alter the in vitro activity of CaMKII. These data demonstrate that Ins(3,4,5,6)P-4 is an additional cellular signal that participates in the control of salt and fluid secretion, pH balance, osmoregulation, and other physiological activities that depend upon gCl(Ca) activation. Ins(3,4,5,6)P-4 metabolism and action should also be taken into account when designing treatment strategies for cystic fibrosis.	UNIV CHICAGO,DEPT NEUROL,CHICAGO,IL 60637; UNIV ILLINOIS,COLL PHARM,DEPT MED CHEM & PHARMACOGNOSY,CHICAGO,IL 60612; UNIV CINCINNATI,COLL MED,DEPT CELLULAR & MOLEC PHYSIOL,CINCINNATI,OH 45267; NIEHS,CELLULAR & MOLEC PHARMACOL LAB,NIH,RES TRIANGLE PK,NC 27709	University of Chicago; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; University of Cincinnati; National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Shears, Stephen B/C-6335-2019	Shears, Stephen B/0000-0001-7309-8916	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046433] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM036823] Funding Source: NIH RePORTER; NIDDK NIH HHS [R01 DK46433] Funding Source: Medline; NIGMS NIH HHS [R01 GM36823] Funding Source: Medline; PHS HHS [R01 41470] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ANDERSON MP, 1991, P NATL ACAD SCI USA, V88, P6003, DOI 10.1073/pnas.88.14.6003; BOUCHER RC, 1989, J CLIN INVEST, V84, P1424, DOI 10.1172/JCI114316; BRUZIK KS, 1989, CARBOHYD RES, V195, P67, DOI 10.1016/0008-6215(89)85089-X; CHAN HC, 1994, J BIOL CHEM, V269, P32464; CHAN HC, 1992, J BIOL CHEM, V267, P8411; CHAN HC, 1992, SCIENCE, V257, P669, DOI 10.1126/science.1379742; CHAO AC, 1994, BRIT J PHARMACOL, V112, P169, DOI 10.1111/j.1476-5381.1994.tb13047.x; CLARKE LL, 1994, P NATL ACAD SCI USA, V91, P479, DOI 10.1073/pnas.91.2.479; DESAI T, 1992, CARBOHYD RES, V228, P65, DOI 10.1016/S0008-6215(00)90549-4; GRUBB BR, 1994, AM J PHYSIOL, V266, pC1478, DOI 10.1152/ajpcell.1994.266.5.C1478; HAAS M, 1994, AM J PHYSIOL-CELL PH, V267, pC869, DOI 10.1152/ajpcell.1994.267.4.C869; HAMILL OP, 1981, PFLUG ARCH EUR J PHY, V391, P85, DOI 10.1007/BF00656997; HAUSSINGER D, 1992, TRENDS PHARMACOL SCI, V13, P371, DOI 10.1016/0165-6147(92)90114-L; KAETZEL MA, 1994, J BIOL CHEM, V269, P5297; KAETZEL MA, 1989, J BIOL CHEM, V264, P14463; KAETZEL MA, 1987, J BIOL CHEM, V262, P1818; KNOWLES MR, 1991, NEW ENGL J MED, V325, P533, DOI 10.1056/NEJM199108223250802; KNOWLES MR, 1995, CHEST, V107, P715; KORN SJ, 1991, J PHYSIOL-LONDON, V439, P423, DOI 10.1113/jphysiol.1991.sp018674; MASON SJ, 1991, BRIT J PHARMACOL, V103, P1649, DOI 10.1111/j.1476-5381.1991.tb09842.x; MENNITI FS, 1993, TRENDS BIOCHEM SCI, V18, P53, DOI 10.1016/0968-0004(93)90053-P; MENNITI FS, 1990, J BIOL CHEM, V265, P11167; NAUNTOFTE B, 1992, AM J PHYSIOL, V263, pG823, DOI 10.1152/ajpgi.1992.263.6.G823; NISHIMOTO I, 1991, NEURON, V6, P547, DOI 10.1016/0896-6273(91)90057-7; PAPP Z, 1995, J PHYSIOL-LONDON, V483, P319, DOI 10.1113/jphysiol.1995.sp020588; PETERSEN OH, 1992, J PHYSIOL-LONDON, V488, P1; PIETRUSIEWICZ KM, 1992, TETRAHEDRON, V48, P5523, DOI 10.1016/S0040-4020(01)88305-8; PIETRUSIEWICZ KM, 1994, TETRAHEDRON, V50, P573; RAYNAL P, 1994, BBA-REV BIOMEMBRANES, V1197, P63, DOI 10.1016/0304-4157(94)90019-1; SEATON BA, 1990, J BIOL CHEM, V265, P4567; Shears Stephen B., 1992, Advances in Second Messenger and Phosphoprotein Research, V26, P63; STREB H, 1983, NATURE, V306, P67, DOI 10.1038/306067a0; VAJANAPHANICH M, 1994, NATURE, V371, P711, DOI 10.1038/371711a0; WAGNER JA, 1991, NATURE, V349, P793, DOI 10.1038/349793a0; WORRELL RT, 1989, AM J PHYSIOL, V256, pC1111, DOI 10.1152/ajpcell.1989.256.6.C1111; WORRELL RT, 1991, AM J PHYSIOL, V260, pC877, DOI 10.1152/ajpcell.1991.260.4.C877	36	104	106	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14092	14097		10.1074/jbc.271.24.14092	http://dx.doi.org/10.1074/jbc.271.24.14092			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662902	hybrid			2022-12-27	WOS:A1996UQ66000026
J	Missbach, M; Jagher, B; Sigg, I; Nayeri, S; Carlberg, C; Wiesenberg, I				Missbach, M; Jagher, B; Sigg, I; Nayeri, S; Carlberg, C; Wiesenberg, I			Thiazolidine diones, specific ligands of the nuclear receptor retinoid Z receptor retinoid acid receptor-related orphan receptor alpha with potent antiarthritic activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ADJUVANT ARTHRITIS; BREAST-CANCER-CELLS; MELATONIN; CULTURE; MCF-7	Rat adjuvant arthritis is a chronic T cell-dependent autoimmune disease with many similarities to rheumatoid arthritis. We have identified a class of thiazolidine diones with high potency in suppressing chronic inflammation and joint destruction in this experimental model. The lead compound CGP 52608 (1-(3-allyl-4-oxothiazolidine-2-ylidene)-4- methylthiosemicarbazone) exhibits antiarthritic activity at dailyoral doses between 0.01 and 1 mg/kg and was shown to specifically activate the retinoid Z receptor/retinoid acid receptor-related orphan receptor alpha (RZR/ROR alpha) in low nanomolar concentrations, This receptor is a novel member of the superfamily of ligand-inducible transcription factors, and we have recently identified the pineal gland hormone melatonin as a natural ligand. Structure-activity relationship studies with 13 closely related analogues of CGP 52608 revealed a striking correlation between RZR/ROR alpha activation and antiarthritic activity. We therefore suggest that nuclear signaling via RZR/ROR alpha is a key mechanism in mediating the antiarthritic effects of these thiazolidine diones and may open a novel therapeutic approach for the treatment of rheumatoid arthritis and other autoimmune diseases. The existence of a nuclear melatonin receptor may lead to a better understanding of the immunomodulatory actions of melatonin.	CIBA GEIGY AG, PHARMA FORSCH, CH-4002 BASEL, SWITZERLAND; HOP CANTONAL UNIV GENEVA, DERMATOL CLIN, CH-1211 GENEVA 14, SWITZERLAND	Novartis; University of Geneva			Carlberg, Carsten/C-9075-2011	Carlberg, Carsten/0000-0003-2633-0684				ACUNACASTROVIEJO D, 1994, J PINEAL RES, V16, P100, DOI 10.1111/j.1600-079X.1994.tb00089.x; ARMSTRONG SM, 1993, PHARMACOL BIOCHEM BE, V46, P45, DOI 10.1016/0091-3057(93)90315-K; BECKERANDRE M, 1993, BIOCHEM BIOPH RES CO, V194, P1371, DOI 10.1006/bbrc.1993.1976; BECKERANDRE M, 1994, J BIOL CHEM, V269, P28531; BILLINGHAM MEJ, 1983, PHARMACOL THERAPEUT, V21, P389, DOI 10.1016/0163-7258(83)90062-1; BUCK J, 1993, J EXP MED, V178, P675, DOI 10.1084/jem.178.2.675; CARLBERG C, 1994, MOL ENDOCRINOL, V8, P757, DOI 10.1210/me.8.6.757; CARLBERG C, 1995, J PINEAL RES, V18, P171, DOI 10.1111/j.1600-079X.1995.tb00157.x; CARLBERG C, 1993, NATURE, V361, P657, DOI 10.1038/361657a0; CARLBERG C, 1993, BIOCHEM J, V295, P343, DOI 10.1042/bj2950343; COS S, 1991, J PINEAL RES, V10, P36, DOI 10.1111/j.1600-079X.1991.tb00007.x; DEPREUX P, 1994, J MED CHEM, V37, P3231, DOI 10.1021/jm00046a006; EBISAWA T, 1994, P NATL ACAD SCI USA, V91, P6133, DOI 10.1073/pnas.91.13.6133; FEIGE U, 1992, Patent No. 508955; GEIGER T, 1992, CLIN EXP RHEUMATOL, V10, P467; GEISSLER JF, 1990, J BIOL CHEM, V265, P22255; GIGUERE V, 1994, GENE DEV, V8, P538, DOI 10.1101/gad.8.5.538; HAGAN RM, 1995, TRENDS PHARMACOL SCI, V16, P81, DOI 10.1016/S0165-6147(00)88985-3; HILL SM, 1988, CANCER RES, V48, P6121; HIROSE T, 1994, BIOCHEM BIOPH RES CO, V205, P1976, DOI 10.1006/bbrc.1994.2902; IP MM, 1983, 13 INT C CHEM VIENN, V16, P192; JORDAN VC, 1979, EUR J CANCER, V15, P755, DOI 10.1016/0014-2964(79)90150-6; KLIEWER SA, 1995, CELL, V83, P813, DOI 10.1016/0092-8674(95)90194-9; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEHMANN JM, 1995, J BIOL CHEM, V270, P12953, DOI 10.1074/jbc.270.22.12953; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LEWIS AJ, 1985, HDB INFLAMMATION, V5, P371; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MENENDEZPELAEZ A, 1993, J CELL BIOCHEM, V53, P373, DOI 10.1002/jcb.240530415; MISSBACH, 1993, Patent No. 573392; MISSBACH M, 1995, Patent No. 9514685; MORGAN PJ, 1994, NEUROCHEM INT, V24, P101, DOI 10.1016/0197-0186(94)90100-7; ORTIZ MA, 1995, MOL ENDOCRINOL, V9, P1679, DOI 10.1210/me.9.12.1679; POTHIER F, 1992, DNA CELL BIOL, V11, P83, DOI 10.1089/dna.1992.11.83; REITER RJ, 1993, EXPERIENTIA, V49, P654, DOI 10.1007/BF01923947; REPPERT SM, 1994, NEURON, V13, P1177, DOI 10.1016/0896-6273(94)90055-8; ROSEN J, 1995, J MED CHEM, V38, P4855, DOI 10.1021/jm00025a001; SCHEINMAN RI, 1995, SCIENCE, V270, P283, DOI 10.1126/science.270.5234.283; SCHIEWECK K, 1983, 13 INT C CHEM VIENN, V16, P66; SCHMIDTRUPPIN KH, 1976, ONCOLOGY, V33, P229, DOI 10.1159/000225152; SCHMIDTRUPPIN KH, 1973, EXPERIENTIA, V29, P823, DOI 10.1007/BF01946310; SCHRADER M, 1994, J BIOL CHEM, V269, P5501; SCHRADER M, 1994, J BIOL CHEM, V269, P6444; SCHRADER M, 1994, J MOL ENDOCRINOL, V12, P327, DOI 10.1677/jme.0.0120327; STEINHILBER D, 1995, J BIOL CHEM, V270, P7037, DOI 10.1074/jbc.270.13.7037; VITTE PA, 1988, J PINEAL RES, V5, P437, DOI 10.1111/j.1600-079X.1988.tb00787.x; WIESENBERG I, 1995, NUCLEIC ACIDS RES, V23, P327, DOI 10.1093/nar/23.3.327; WIESENBERG I, 1989, CLIN EXP IMMUNOL, V78, P245; Yu H. L., 2020, ARXIV PREPRINT ARXIV	49	89	95	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13515	13522		10.1074/jbc.271.23.13515	http://dx.doi.org/10.1074/jbc.271.23.13515			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662835	hybrid			2022-12-27	WOS:A1996UP38500033
J	Potaman, VN; Ussery, DW; Sinden, RR				Potaman, VN; Ussery, DW; Sinden, RR			Formation of a combined H-DNA/open TATA box structure in the promoter sequence of the human Na,K-ATPase alpha 2 gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-MYC GENE; KI-RAS PROMOTER; NON-B-DNA; TRANSCRIPTION INITIATION; INTRAMOLECULAR TRIPLEX; 5'-FLANKING REGION; EXPRESSION; CONFORMATION; ELEMENT; SITES	Structural variation of DNA within the promoter of the human Na,K-ATPase alpha 2 gene, which contains a 35-base pair (bp) homopyrimidine homopurine (Py . Pu) tract adjacent to a TATA box has been studied. The Py . Pu tract contains a 26-bp quasi-mirror repeat sequence with a potential for intramolecular triplex formation. As analyzed by two-dimensional agarose gel electrophoresis, a plasmid containing 151 bp of the pro meter sequence including the 35-bp Py . Pu tract undergoes structural transitions under moderately acidic pH. Chemical probing with chloroacetaldehyde, dimethyl sulfate, and potassium permanganate is consistent with the formation of tripler DNA within the Py . Pu tract at native superhelical density as isolated from Escherichia coli. Chemical probing was used to determine a supercoil dependence for the formation of this combined unwound structure, At the superhelical density sufficient to locally unwind DNA, an H-y3 isomer of intermolecular tripler likely forms, However, at higher superhelical tension an H-y5 structure forms in the Py . Pu tract, and with increasing supercoiling the local DNA unwinding extends into the abutting TATA box. The H-y5/open TATA box combination structure might be favorable at higher superhelical densities since it relaxes more supercoils, The possible involvement of the H-y5/open TATA box structure in transcription is discussed.			Potaman, VN (corresponding author), TEXAS A&M UNIV,INST BIOCHEM & BIOTECHNOL,2121 W HOLCOMBE BLVD,HOUSTON,TX 77030, USA.		Ussery, David/J-2026-2019; Sinden, Richard/AAE-3086-2019	Ussery, David/0000-0003-3632-5512; 				BEHE MJ, 1995, NUCLEIC ACIDS RES, V23, P689, DOI 10.1093/nar/23.4.689; BELOTSERKOVSKII BP, 1990, NUCLEIC ACIDS RES, V18, P6621, DOI 10.1093/nar/18.22.6621; BIRNBOIM HC, 1979, EUR J BIOCHEM, V98, P301, DOI 10.1111/j.1432-1033.1979.tb13189.x; BOLES TC, 1987, BIOCHEMISTRY-US, V26, P367, DOI 10.1021/bi00376a006; BOWATER R, 1992, METHOD ENZYMOL, V212, P105; Bucher P, 1991, DNA Seq, V1, P157, DOI 10.3109/10425179109020767; CHEN AH, 1993, GENE, V128, P211, DOI 10.1016/0378-1119(93)90565-K; CHRISTOPHE D, 1985, NUCLEIC ACIDS RES, V13, P5127, DOI 10.1093/nar/13.14.5127; CHUNG YT, 1990, MOL CELL BIOL, V10, P206, DOI 10.1128/MCB.10.1.206; CLARK SP, 1990, NUCLEIC ACIDS RES, V18, P5119, DOI 10.1093/nar/18.17.5119; DAVIS TL, 1989, P NATL ACAD SCI USA, V86, P9682, DOI 10.1073/pnas.86.24.9682; DAYN A, 1992, P NATL ACAD SCI USA, V89, P11406, DOI 10.1073/pnas.89.23.11406; FIRULLI AB, 1994, ARCH BIOCHEM BIOPHYS, V310, P236, DOI 10.1006/abbi.1994.1162; FOSSELLA JA, 1993, NUCLEIC ACIDS RES, V21, P4511, DOI 10.1093/nar/21.19.4511; FRANKKAMENETSKII MD, 1995, ANNU REV BIOCHEM, V64, P65, DOI 10.1146/annurev.bi.64.070195.000433; GILMOUR DS, 1989, SCIENCE, V245, P1487, DOI 10.1126/science.2781290; GLASER RL, 1990, J MOL BIOL, V211, P751, DOI 10.1016/0022-2836(90)90075-W; HOFFMAN EK, 1990, P NATL ACAD SCI USA, V87, P2705, DOI 10.1073/pnas.87.7.2705; HTUN H, 1984, P NATL ACAD SCI-BIOL, V81, P7288, DOI 10.1073/pnas.81.23.7288; HTUN H, 1988, SCIENCE, V241, P1791, DOI 10.1126/science.3175620; HTUN H, 1989, SCIENCE, V243, P1571, DOI 10.1126/science.2648571; JOHNSON AC, 1988, MOL CELL BIOL, V8, P4174, DOI 10.1128/MCB.8.10.4174; KANG S, 1992, J BIOL CHEM, V267, P20889; KINNIBURGH AJ, 1989, NUCLEIC ACIDS RES, V17, P7771, DOI 10.1093/nar/17.19.7771; KLYSIK J, 1995, J MOL BIOL, V245, P499, DOI 10.1006/jmbi.1994.0041; KOCHEL TJ, 1988, BIOTECHNIQUES, V6, P532; KOHWI Y, 1991, GENE DEV, V5, P2547, DOI 10.1101/gad.5.12b.2547; KOHWISHIGEMATSU T, 1992, METHOD ENZYMOL, V212, P155; LAFYATIS R, 1991, NUCLEIC ACIDS RES, V16, P6419; LARSEN A, 1982, CELL, V29, P609, DOI 10.1016/0092-8674(82)90177-5; LEE JS, 1984, NUCLEIC ACIDS RES, V12, P6603, DOI 10.1093/nar/12.16.6603; LEROY JL, 1994, NUCLEIC ACIDS RES, V22, P1600, DOI 10.1093/nar/22.9.1600; LINGREL JB, 1992, J BIOENERG BIOMEMBR, V24, P263; LYAMICHEV VI, 1986, J BIOMOL STRUCT DYN, V3, P667, DOI 10.1080/07391102.1986.10508454; LYAMICHEV VI, 1985, J BIOMOL STRUCT DYN, V3, P327, DOI 10.1080/07391102.1985.10508420; MANOR H, 1988, J MOL EVOL, V27, P96, DOI 10.1007/BF02138367; MANZINI G, 1994, NUCLEIC ACIDS RES, V22, P4634, DOI 10.1093/nar/22.22.4634; MAVROTHALASSITIS GJ, 1990, P NATL ACAD SCI USA, V87, P1047, DOI 10.1073/pnas.87.3.1047; MIRKIN SM, 1994, ANNU REV BIOPH BIOM, V23, P541, DOI 10.1146/annurev.bb.23.060194.002545; PARVIN JD, 1993, CELL, V73, P533, DOI 10.1016/0092-8674(93)90140-L; PATHAK BG, 1990, GENOMICS, V8, P641, DOI 10.1016/0888-7543(90)90250-X; PEI D, 1991, SCIENCE, V253, P1408, DOI 10.1126/science.1716784; PESTOV DG, 1991, NUCLEIC ACIDS RES, V19, P6527, DOI 10.1093/nar/19.23.6527; POSTEL EH, 1989, MOL CELL BIOL, V9, P5123, DOI 10.1128/MCB.9.11.5123; POTAMAN VN, 1995, BIOCHEMISTRY-US, V34, P14885, DOI 10.1021/bi00045a033; RAGHU G, 1994, NUCLEIC ACIDS RES, V22, P3271, DOI 10.1093/nar/22.16.3271; ROBERTS RW, 1991, P NATL ACAD SCI USA, V88, P9397, DOI 10.1073/pnas.88.21.9397; ROEDER RG, 1991, TRENDS BIOCHEM SCI, V16, P402, DOI 10.1016/0968-0004(91)90164-Q; SANTRA M, 1994, J BIOL CHEM, V269, P579; SASSEDWIGHT S, 1989, J BIOL CHEM, V264, P8074; SCHON E, 1983, CELL, V35, P837, DOI 10.1016/0092-8674(83)90116-2; SCHROTH GP, 1995, NUCLEIC ACIDS RES, V23, P1977, DOI 10.1093/nar/23.11.1977; SHIMIZU M, 1994, J MOL BIOL, V235, P185, DOI 10.1016/S0022-2836(05)80025-7; SHULL MM, 1989, J BIOL CHEM, V264, P17532; SHULL MM, 1990, GENOMICS, V6, P451, DOI 10.1016/0888-7543(90)90475-A; SIEGFRIED E, 1986, NUCLEIC ACIDS RES, V14, P9125; SINDEN RR, 1994, DNA STRUCTURE FUNCTI, P217; Soyfer V. N., 1995, TRIPLE HELICAL NUCL; TRIPATHI J, 1991, J BIOMOL STRUCT DYN, V9, P387, DOI 10.1080/07391102.1991.10507919; ULRICH MJ, 1992, J BIOL CHEM, V267, P18649; USDIN K, 1989, J BIOL CHEM, V264, P20736; USSERY DW, 1993, BIOCHEMISTRY-US, V32, P6206, DOI 10.1021/bi00075a013; WONG AKC, 1990, CHROMOSOMA, V99, P344, DOI 10.1007/BF01731722	63	19	19	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13441	13447		10.1074/jbc.271.23.13441	http://dx.doi.org/10.1074/jbc.271.23.13441			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662935	hybrid			2022-12-27	WOS:A1996UP38500023
J	Chaudhary, LR; Avioli, LV				Chaudhary, LR; Avioli, LV			Regulation of interleukin-8 gene expression by interleukin-1 beta, osteotropic hormones, and protein kinase inhibitors in normal human bone marrow stromal cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; OSTEOBLAST-LIKE CELLS; ARACHIDONIC-ACID METABOLISM; 3' UNTRANSLATED REGION; MESSENGER-RNA; C-FOS; HUMAN-FIBROBLASTS; BINDING-PROTEIN; FACTOR ACTIVATE; FACTOR-ALPHA	Interleukin-8 (IL-8), a potent neutrophil chemotactic peptide that elicits pleiotropic biological effects is secreted in large amounts by normal human osteoblastic and bone marrow osteoprogenitor stromal (HEMS) cells in response to IL-1 beta and tumor necrosis factor-alpha, In the present study we investigated the regulation of IL-8 gene expression by IL-1 beta, osteotropic hormones, and protein kinase inhibitors in primary cultures of HEMS cells, The treatment of HEMS cells with IL-1 beta increased the steady-state levels of IL-8 mRNA in a dose and time-dependent fashion and was detectable within 1 h, reached maximal by 4 h, and remained elevated at 24 h, whereas parathyroid hormone (10(-7) and 10(-8) M) had no effect on IL-8 mRNA, Both synthetic and natural glucocorticoids dexamethasone (10(-7)-10(-10) M) and hydrocortisone (10(-6)-10(-8) M) inhibited IL-1 beta-stimulated IL-8 mRNA expression, The suppressive effect of dexamethasone on IL-1 beta-induced IL-8 mRNA was not observed in the presence of cycloheximide (5 mu g/ml), indicating that the dexamethasone-mediated repression of IL-8 gene expression also depends on new protein synthesis, Experiments with actinomycin D demonstrated that IL-8 mRNA is long-lived and that glucocorticoids down-regulate IL 8 gene expression mainly by decreasing the mRNA stability in normal HEMS cells. Furthermore, as determined by nuclear run-on analysis, IL-1 beta increased the rate of transcription of IL-8 gene and dexamethasone did not affect the IL-1 beta-induced transcription of IL-8. 1-(5-Isoquinolinesulfonyl)-2-methylpiperazine, HCl (50 mu M) and staurosporine (1 mu M), potent inhibitors of protein kinase C, and genistein (100 mu M), a specific protein tyrosine kinase inhibitor blocked IL-1 beta-induced IL-8 gene expression, Because curcumin (20 mu M), an inhibitor of c-jun/AP-1 and protein kinases, also blocked IL-1 beta stimulated IL-8 gene expression implicating c-JUN/AP-1 and protein phosphorylation in the induction of PL-8 gene expression by IL-1 beta, we conclude that the regulation of IL-8 mRNA by IL-1 beta is mediated via protein kinase-dependent signal transduction pathways, Our accumulated results have demonstrated that glucocorticoid suppression of IL-1 beta-induced IL-8 mRNA occurs at the levels of post-transcription (mRNA stability) and protein synthesis.			Chaudhary, LR (corresponding author), WASHINGTON UNIV, JEWISH HOSP ST LOUIS, SCH MED, DEPT INTERNAL MED, DIV BONE & MINERAL DIS, ST LOUIS, MO 63110 USA.				NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR032087, T32AR007033] Funding Source: NIH RePORTER; NIAMS NIH HHS [T32 AR07033, P01 AR32087] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		AMMON HPT, 1993, J ETHNOPHARMACOL, V38, P113, DOI 10.1016/0378-8741(93)90005-P; BAGGIOLINI M, 1989, J CLIN INVEST, V84, P1045, DOI 10.1172/JCI114265; BAGGIOLINI M, 1992, FEBS LETT, V307, P97, DOI 10.1016/0014-5793(92)80909-Z; BENAYAHU D, 1989, J CELL PHYSIOL, V140, P1, DOI 10.1002/jcp.1041400102; BIRCH MA, 1993, J BONE MINER RES, V8, P1155; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CHAUDHARY LR, 1994, CALCIFIED TISSUE INT, V55, P16, DOI 10.1007/BF00310163; CHAUDHARY LR, 1992, ENDOCRINOLOGY, V130, P2528, DOI 10.1210/en.130.5.2528; CHEN Y, 1994, J BONE MINER RES  S1, V9, P368; CHENG SL, 1994, ENDOCRINOLOGY, V134, P277, DOI 10.1210/en.134.1.277; CONNEY AH, 1991, ADV ENZYME REGUL, V31, P385, DOI 10.1016/0065-2571(91)90025-H; EDWARDS DR, 1992, EMBO J, V11, P2415, DOI 10.1002/j.1460-2075.1992.tb05306.x; FARBER JM, 1990, P NATL ACAD SCI USA, V87, P5238, DOI 10.1073/pnas.87.14.5238; FUJITA T, 1990, ANN NY ACAD SCI, V587, P371, DOI 10.1111/j.1749-6632.1990.tb00178.x; FULLER K, 1995, J IMMUNOL, V154, P6065; GIRASOLE G, 1992, J CLIN INVEST, V89, P883, DOI 10.1172/JCI115668; GOWEN M, 1990, ENDOCRINOLOGY, V126, P1250, DOI 10.1210/endo-126-2-1250; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; GREENBERG ME, 1994, CURRENT PROTOCOLS MO, V1; GUY GR, 1991, J BIOL CHEM, V266, P14343; HANAZAWA S, 1993, J BIOL CHEM, V268, P9526; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HUANG TS, 1991, P NATL ACAD SCI USA, V88, P5292, DOI 10.1073/pnas.88.12.5292; KAMALIA N, 1992, BLOOD, V79, P320; KAUSHANSKY K, 1987, BLOOD CELLS, V13, P3; KEETING PE, 1991, J BONE MINER RES, V6, P827; KOVACS EJ, 1986, J IMMUNOL, V137, P3649; LEBOY PS, 1991, J CELL PHYSIOL, V146, P370, DOI 10.1002/jcp.1041460306; LIN GF, 1994, J BIOL CHEM, V269, P77; LIN JX, 1987, J BIOL CHEM, V262, P11908; LIU JY, 1993, CARCINOGENESIS, V14, P857, DOI 10.1093/carcin/14.5.857; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MASURE S, 1991, EUR J BIOCHEM, V198, P391, DOI 10.1111/j.1432-1033.1991.tb16027.x; Matsushima K, 1989, Cytokine, V1, P2, DOI 10.1016/1043-4666(89)91043-0; MATSUSHIMA K, 1988, J EXP MED, V167, P1883, DOI 10.1084/jem.167.6.1883; MITCHELL RL, 1986, CELL, V45, P497, DOI 10.1016/0092-8674(86)90281-3; Muegge K, 1990, Cytokine, V2, P1, DOI 10.1016/1043-4666(90)90036-S; Mukaida N, 1992, Cytokines, V4, P41; MUKAIDA N, 1990, J BIOL CHEM, V265, P21128; MUKAIDA N, 1989, J IMMUNOL, V143, P1366; MUKAIDA N, 1992, MICROBIOL IMMUNOL, V36, P773, DOI 10.1111/j.1348-0421.1992.tb02080.x; MUNOZ E, 1991, J IMMUNOL, V146, P136; NIJWEIDE PJ, 1986, PHYSIOL REV, V66, P855, DOI 10.1152/physrev.1986.66.4.855; OWEN M, 1988, CIBA F SYMP, V136, P42; Owen M., 1985, BONE MINERAL RES ANN, V1, P1; PACIFICI R, 1987, P NATL ACAD SCI USA, V84, P4616, DOI 10.1073/pnas.84.13.4616; PACIFICI R, 1991, J CLIN INVEST, V87, P221, DOI 10.1172/JCI114975; PACIFICI R, 1989, P NATL ACAD SCI USA, V86, P2398, DOI 10.1073/pnas.86.7.2398; PEPPEL K, 1991, J EXP MED, V173, P349, DOI 10.1084/jem.173.2.349; PFEILSCHIFTER J, 1989, J BONE MINER RES, V4, P113, DOI 10.1002/jbmr.5650040116; RAO CV, 1993, CARCINOGENESIS, V14, P2219, DOI 10.1093/carcin/14.11.2219; SAKLATVALA J, 1993, FEBS LETT, V334, P189, DOI 10.1016/0014-5793(93)81709-9; Sambrook J, 1989, MOL CLONING LAB MANN; SHALHOUB V, 1992, J CELL BIOCHEM, V50, P425, DOI 10.1002/jcb.240500411; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHIROO M, 1990, Cytokine, V2, P13, DOI 10.1016/1043-4666(90)90038-U; SIMMONS DJ, 1991, CALCIFIED TISSUE INT, V48, P326, DOI 10.1007/BF02556152; THOMSON BM, 1987, J IMMUNOL, V138, P775; TOBLER A, 1992, BLOOD, V79, P45; WLODARSKI KH, 1990, CLIN ORTHOP RELAT R, P276; WONG MM, 1990, J BONE MINER RES, V5, P803	61	77	83	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16591	16596		10.1074/jbc.271.28.16591	http://dx.doi.org/10.1074/jbc.271.28.16591			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663179	hybrid			2022-12-27	WOS:A1996UX12600028
J	Hwang, JR; Moncollin, V; Vermeulen, W; Seroz, T; vanVuuren, H; Hoeijmakers, JHJ; Egly, JM				Hwang, JR; Moncollin, V; Vermeulen, W; Seroz, T; vanVuuren, H; Hoeijmakers, JHJ; Egly, JM			A 3'->5'XPB helicase defect in repair/transcription factor TFIIH of xeroderma pigmentosum group B affects both DNA repair and transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INITIATION; COMPONENT; ATPASE; YEAST; BTF2	XPB is a subunit of the basal transcription factor TFIIH, which is also involved in nucleotide excision repair (NER) and potentially in cell cycle regulation. A frameshift mutation in the 3'-end of the XPB gene is responsible for a concurrence of two disorders: xeroderma pigmentosum (XP) and Cockayne's syndrome (CS). We have isolated TFIIH from cells derived hom a patient (XP11BE) who carries this frameshift mutation (TFIIHmut) and from the mother of this patient (TFIIHwt) to determine the biochemical consequences of the mutation. Although identical in composition and stoichiometry to TFIIHwt, TFFIIHmut shows a reduced 3' --> 5' XPB helicase activity. A decrease in helicase and DNA-dependent ATPase activities was also observed with the mutated recombinant XPB protein. The XPB mutation causes a severe NER defect. In addition, we provide evidence for a decrease in basal transcription activity in vitro. The latter defect may provide an explanation for many of the XP and CS symptoms that are difficult to rationalize based solely on an NER defect. Thus, this work presents the first detailed analysis of a naturally occurring mutation in a basal transcription factor and supports the concept that the combined XP/CS clinical entity is actually the result of a combined transcription/repair deficiency.	INST GENET & BIOL MOL & CELLULAIRE,CNRS,INSERM,F-67404 ILLKIRCH GRAFFENS,FRANCE; ERASMUS UNIV ROTTERDAM,CTR GENET MED,DEPT CELL BIOL & GENET,3000 DR ROTTERDAM,NETHERLANDS	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); Erasmus University Rotterdam			MONCOLLIN, Vincent/R-1941-2017; Hoeijmakers, Jan/AAX-6972-2021; Vermeulen, Wim/W-8708-2019	MONCOLLIN, Vincent/0000-0002-4163-0231; Vermeulen, Wim/0000-0003-3616-734X				ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; BOOTSMA D, 1993, NATURE, V363, P114, DOI 10.1038/363114a0; CHALUT C, 1994, PROTEIN EXPRES PURIF, V5, P458, DOI 10.1006/prep.1994.1065; CLEAVER JE, 1994, METABOLIC BASIS INHE, V3, P4393; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CONAWAY RC, 1989, P NATL ACAD SCI USA, V86, P7356, DOI 10.1073/pnas.86.19.7356; DRAPKIN R, 1994, CELL, V77, P9, DOI 10.1016/0092-8674(94)90228-3; FEAVER WJ, 1993, CELL, V75, P1379, DOI 10.1016/0092-8674(93)90624-Y; FISCHER L, 1992, SCIENCE, V257, P1392, DOI 10.1126/science.1529339; FISHER RP, 1994, CELL, V78, P713, DOI 10.1016/0092-8674(94)90535-5; FRIEDBERG EC, 1995, DNA REPAIR; GERARD M, 1991, J BIOL CHEM, V266, P20940; GIL G, 1992, CURR OPIN GENE DEV, V2, P236; GUZDER SN, 1995, J BIOL CHEM, V270, P12973, DOI 10.1074/jbc.270.22.12973; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HOEIJMAKERS JHJ, 1994, EUR J CANCER, V30A, P1912, DOI 10.1016/0959-8049(94)00381-E; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; HUMBERT S, 1994, EMBO J, V13, P2393, DOI 10.1002/j.1460-2075.1994.tb06523.x; MA LB, 1994, MOL CELL BIOL, V14, P4126, DOI 10.1128/MCB.14.6.4126; MU D, 1995, J BIOL CHEM, V270, P2415, DOI 10.1074/jbc.270.6.2415; OHKUMA Y, 1994, NATURE, V368, P160, DOI 10.1038/368160a0; ROY R, 1994, J BIOL CHEM, V269, P9826; ROY R, 1994, CELL, V79, P1093, DOI 10.1016/0092-8674(94)90039-6; SCHAEFFER L, 1993, SCIENCE, V260, P58, DOI 10.1126/science.8465201; SCHAEFFER L, 1994, EMBO J, V13, P2388, DOI 10.1002/j.1460-2075.1994.tb06522.x; SERIZAWA H, 1993, J BIOL CHEM, V268, P17300; SEROZ T, 1995, CURR OPIN GENET DEV, V5, P217, DOI 10.1016/0959-437X(95)80011-5; SUNG P, 1993, NATURE, V365, P852, DOI 10.1038/365852a0; TASSAN JP, 1994, J CELL BIOL, V127, P467, DOI 10.1083/jcb.127.2.467; VANVUUREN AJ, 1993, EMBO J, V12, P3693, DOI 10.1002/j.1460-2075.1993.tb06044.x; VANVUUREN AJ, 1994, EMBO J, V13, P1645, DOI 10.1002/j.1460-2075.1994.tb06428.x; VERMEULEN W, 1994, COLD SPRING HARB SYM, V59, P317, DOI 10.1101/SQB.1994.059.01.036; WANG XW, 1995, NAT GENET, V10, P188, DOI 10.1038/ng0695-188; WANG ZG, 1995, MOL CELL BIOL, V15, P2288; WEEDA G, 1990, CELL, V62, P77; XIAO H, 1994, MOL CELL BIOL, V14, P7013, DOI 10.1128/MCB.14.10.7013; YOON H, 1992, GENE DEV, V6, P2463, DOI 10.1101/gad.6.12b.2463; ZAWEL L, 1992, Current Opinion in Cell Biology, V4, P488, DOI 10.1016/0955-0674(92)90016-6	38	72	73	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15898	15904		10.1074/jbc.271.27.15898	http://dx.doi.org/10.1074/jbc.271.27.15898			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663148	hybrid, Green Published			2022-12-27	WOS:A1996UW35200012
J	Murray, EW; Pihl, C; Morcos, A; Brown, CB				Murray, EW; Pihl, C; Morcos, A; Brown, CB			Ligand-independent cell surface expression of the human soluble granulocyte-macrophage colony-stimulating factor receptor alpha subunit depends on co-expression of the membrane-associated receptor beta subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GM-CSF RECEPTOR; HUMAN MYELOID CELLS; SIGNAL-TRANSDUCTION; FUNCTIONAL RECEPTORS; HEMATOPOIETIC-CELLS; CYTOPLASMIC DOMAINS; HUMAN INTERLEUKIN-5; MOLECULAR-CLONING; GROWTH-FACTORS; RECONSTITUTION	The hematopoietic cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates its activity through binding to cell surface receptors, The receptor for GM-CSF belongs to a superfamily of cytokine receptors characterized by a conserved extracellular motif. The high affinity GM-CSF receptor (GMR) consists of two transmembrane anchored subunits; a ligand binding alpha subunit (transmembrane GMR alpha) and a signal transducing beta subunit (GMR beta), both of which belong to the cytokine receptor superfamily, The human GM-CSF receptor alpha subunit also exists in a soluble form (sol-GMR alpha), which antagonizes GM-CSF activity in vitro, We directly tested the potential for solGMR alpha to interact with GMR beta in vitro, Our experiments demonstrated that exogenous solGMR alpha, even in the presence of GM-CSF, does not interact with GMR beta on the cell surface, However, when solGMR alpha and GMR beta are co expressed in baby hamster kidney cells, solGMR alpha is retained on the cell surface and forms a functional intermediate affinity GM-CSF binding complex (K-d = 331 pM). In addition, the cell surface expression of solGMR alpha is independent of the presence of GM-CSF as demonstrated using flow cytometry, Cells expressing only solGMR alpha do not show cell surface retention or form functional GM-CSF cell surface binding complexes. Sequencing of our GMR beta clone revealed a nucleotide substitution (A --> C) resulting in the substitution of Ala for Glu at position 9 from the amino terminus of the mature GMR beta peptide. Because the GMR beta (A --> C) clone is capable of forming functional high affinity receptors with transmembrane GMR alpha (K-d = 64 pM), we feel that the cell surface retention of solGMR alpha is independent of the GMR beta mutation, We suggest that the co-expression and interaction of solGMR alpha and GMR beta represents a previously unrecognized GM-CSF receptor complex and a novel, ligand-independent mechanism of cytokine receptor assembly.	UNIV CALGARY,HLTH SCI CTR,DEPT MED,CANC BIOL RES GRP,CALGARY,AB T2N 4N1,CANADA	University of Calgary; University of Manitoba; Children's Hospital Research Institute of Manitoba				Murray, Elizabeth/0000-0003-3087-7578				ASHWORTH A, 1990, NUCLEIC ACIDS RES, V18, P7178, DOI 10.1093/nar/18.23.7178; BALDWIN GC, 1991, BLOOD, V78, P609, DOI 10.1182/blood.V78.3.609.bloodjournal783609; BALDWIN GC, 1989, BLOOD, V73, P1033; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROWN CB, 1995, BLOOD, V85, P1488, DOI 10.1182/blood.V85.6.1488.bloodjournal8561488; CANNISTRA SA, 1990, J BIOL CHEM, V265, P12656; CHIBA S, 1990, CELL REGUL, V1, P327, DOI 10.1091/mbc.1.4.327; CROSIER KE, 1991, P NATL ACAD SCI USA, V88, P7744, DOI 10.1073/pnas.88.17.7744; DAVIS S, 1993, SCIENCE, V259, P1736, DOI 10.1126/science.7681218; DAVIS S, 1991, SCIENCE, V253, P59, DOI 10.1126/science.1648265; DIPERSIO J, 1988, J BIOL CHEM, V263, P1834; EDER M, 1994, J BIOL CHEM, V269, P30173; FAIRBAIRN LJ, 1993, CELL, V74, P823, DOI 10.1016/0092-8674(93)90462-Y; GASSON JC, 1986, P NATL ACAD SCI USA, V83, P669, DOI 10.1073/pnas.83.3.669; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; Heaney ML, 1996, BLOOD, V87, P847, DOI 10.1182/blood.V87.3.847.bloodjournal873847; HEANEY ML, 1995, P NATL ACAD SCI USA, V92, P2365, DOI 10.1073/pnas.92.6.2365; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; KITAMURA T, 1991, P NATL ACAD SCI USA, V88, P5082, DOI 10.1073/pnas.88.12.5082; KITAMURA T, 1992, BLOOD, V80, P84; LEARY AG, 1992, P NATL ACAD SCI USA, V89, P4013, DOI 10.1073/pnas.89.9.4013; METCALF D, 1990, P NATL ACAD SCI USA, V87, P4670, DOI 10.1073/pnas.87.12.4670; METCALF D, 1989, NATURE, V339, P27, DOI 10.1038/339027a0; MINTY A, 1986, MOL CELL BIOL, V6, P2125, DOI 10.1128/MCB.6.6.2125; MIYAJIMA A, 1993, BLOOD, V82, P1960; NAKAGAWA Y, 1994, J BIOL CHEM, V269, P10905; NICOLA NA, 1987, IMMUNOL TODAY, V8, P134, DOI 10.1016/0167-5699(87)90140-X; NICOLA NA, 1989, ANNU REV BIOCHEM, V58, P45; PARK LS, 1992, P NATL ACAD SCI USA, V89, P4295, DOI 10.1073/pnas.89.10.4295; RAINES MA, 1991, P NATL ACAD SCI USA, V88, P8203, DOI 10.1073/pnas.88.18.8203; RONCO LV, 1994, J BIOL CHEM, V269, P277; SAKAMAKI K, 1992, EMBO J, V11, P3541, DOI 10.1002/j.1460-2075.1992.tb05437.x; SIEFF CA, 1985, SCIENCE, V230, P1171, DOI 10.1126/science.3877981; SYMONS JA, 1990, FEBS LETT, V272, P133, DOI 10.1016/0014-5793(90)80466-V; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; TAKAKI S, 1993, J EXP MED, V177, P1523, DOI 10.1084/jem.177.6.1523; TAVERNIER J, 1992, P NATL ACAD SCI USA, V89, P7041, DOI 10.1073/pnas.89.15.7041; TAVERNIER J, 1991, CELL, V66, P1175, DOI 10.1016/0092-8674(91)90040-6; TOMONAGA M, 1986, BLOOD, V67, P31; WEISS M, 1993, BLOOD, V82, P3298; WILLIAMS WV, 1994, ARTHRITIS RHEUM, V37, P1468, DOI 10.1002/art.1780371010; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x	43	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15330	15335		10.1074/jbc.271.26.15330	http://dx.doi.org/10.1074/jbc.271.26.15330			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663062	hybrid			2022-12-27	WOS:A1996UV29900007
J	Markiewicz, S; Bosselut, R; LeDeist, F; deVillartay, JP; Hivroz, C; Ghysdael, J; Fischer, A; deSaintBasile, G				Markiewicz, S; Bosselut, R; LeDeist, F; deVillartay, JP; Hivroz, C; Ghysdael, J; Fischer, A; deSaintBasile, G			Tissue-specific activity of the gamma c chain gene promoter depends upon an Ets binding site and is regulated by GA-binding protein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; LONG TERMINAL REPEAT; FUNCTIONAL COMPONENT; IL-2 RECEPTOR; INTERLEUKIN-2; DNA; LYMPHOCYTES; EXPRESSION; DOMAIN; IDENTIFICATION	The gamma c chain is a subunit of multiple cytokine receptors (interleukin (IL)-2, IL-4, IL-7, IL-9, and IL-15), the expression of which is restricted to hematopoietic lineages, A defect in gamma c leads to the X-linked severe combined immunodeficiency characterized by a block in T cell differentiation. In order to better characterize the human gamma c promoter and define the minimal tissue-specific promoter region, progressive 5'-deletion constructs of a segment extending 1053 base pairs upstream of the major transcription start site were generated and tested for promoter activity in various hematopoietic and nonhematopoietic cell types, The -1053/+34 construct allowed promoter activity only in cells of hematopoietic origin, and tissue specificity was conserved in all other constructs tested, The region downstream of -90 appeared critical for basal promoter activity. It contains two potential Ets binding sites conserved in the murine gamma c promoter gene, one of which was found essential for functional promoter activity as determined by mutational analysis, The functional Ets binding site was found to bind Ets family proteins, principally GA-binding protein and Elf-1 and could be transactivated by GABP alpha and -beta synergistically. These results indicate that, as already reported for the IL2R beta promoter, GA-binding protein is an essential component of gamma c basal promoter activity, Although GABP expression is not restricted to the hematopoietic lineage, its interaction with other specific factors may contribute to the tissue-specific expression of the gamma c gene.	HOP NECKER ENFANTS MALAD,INSERM U429,F-75743 PARIS 15,FRANCE; CTR UNIV ORSAY,SECT RECH,INST CURIE,CNRS UMR 146,F-91405 ORSAY,FRANCE	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; PSL Research University Paris; UNICANCER; Institut Curie; Universite Paris Saclay			Hivroz, Claire/H-2711-2014; GHYSDAEL, Jacques/F-3377-2013; de villartay, jeanpierre/H-9353-2017; de Saint Basile, Genevieve/G-9731-2017	Hivroz, Claire/0000-0002-6794-2890; de villartay, jeanpierre/0000-0001-5987-0463; de Saint Basile, Genevieve/0000-0002-1913-5269				Ammann AJ, 1989, IMMUNOLOGIC DISORDER, P257; BAILLY RA, 1994, MOL CELL BIOL, V14, P3230, DOI 10.1128/MCB.14.5.3230; BHAT NK, 1994, CHALLENGES MODERN ME, P63; BOSCO MC, 1994, BLOOD, V83, P2995, DOI 10.1182/blood.V83.10.2995.2995; BOSSELUT R, 1993, NUCLEIC ACIDS RES, V21, P5184, DOI 10.1093/nar/21.22.5184; BOSSELUT R, 1990, EMBO J, V9, P3137, DOI 10.1002/j.1460-2075.1990.tb07511.x; BOTTINGER EP, 1994, MOL CELL BIOL, V14, P2604; BOULUKOS KE, 1989, MOL CELL BIOL, V9, P5718, DOI 10.1128/MCB.9.12.5718; DISANTO JP, 1994, EUR J IMMUNOL, V24, P3014, DOI 10.1002/eji.1830241214; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; DUPREZ V, 1985, P NATL ACAD SCI USA, V82, P6932, DOI 10.1073/pnas.82.20.6932; GHYSDAEL J, 1986, P NATL ACAD SCI USA, V83, P1714, DOI 10.1073/pnas.83.6.1714; GIRI JG, 1994, EMBO J, V13, P2822, DOI 10.1002/j.1460-2075.1994.tb06576.x; GOLDBERG Y, 1988, EMBO J, V7, P2425, DOI 10.1002/j.1460-2075.1988.tb03088.x; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GOUGEON ML, 1990, J IMMUNOL, V145, P2873; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HAN JH, 1987, BIOCHEMISTRY-US, V26, P1617, DOI 10.1021/bi00380a020; ISHII N, 1994, INT IMMUNOL, V6, P1273, DOI 10.1093/intimm/6.8.1273; ISHII N, 1994, J IMMUNOL, V153, P1310; KIMURA Y, 1995, INT IMMUNOL, V7, P115, DOI 10.1093/intimm/7.1.115; KONDO M, 1994, EUR J IMMUNOL, V24, P2026, DOI 10.1002/eji.1830240914; KONDO M, 1994, SCIENCE, V263, P1453, DOI 10.1126/science.8128231; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LIN JX, 1993, MOL CELL BIOL, V13, P6201, DOI 10.1128/MCB.13.10.6201; MACLEOD K, 1992, TRENDS BIOCHEM SCI, V17, P251, DOI 10.1016/0968-0004(92)90404-W; NIZETIC D, 1991, P NATL ACAD SCI USA, V88, P3233, DOI 10.1073/pnas.88.8.3233; NOGUCHI M, 1993, CELL, V73, P147, DOI 10.1016/0092-8674(93)90167-O; NOGUCHI M, 1993, J BIOL CHEM, V268, P13601; NOGUCHI M, 1993, SCIENCE, V262, P1877, DOI 10.1126/science.8266077; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; NYE JA, 1992, GENE DEV, V6, P975, DOI 10.1101/gad.6.6.975; OHBO K, 1995, J BIOL CHEM, V270, P7479, DOI 10.1074/jbc.270.13.7479; POTTER H, 1984, P NATL ACAD SCI-BIOL, V81, P7161, DOI 10.1073/pnas.81.22.7161; ROMANOSPICA V, 1994, INT J ONCOL, V4, P521; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TESHIGAWARA K, 1987, J EXP MED, V165, P223, DOI 10.1084/jem.165.1.223; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; THOMPSON CC, 1991, SCIENCE, V253, P762, DOI 10.1126/science.1876833; VIRBASIUS JV, 1993, GENE DEV, V7, P880	42	23	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14849	14855		10.1074/jbc.271.25.14849	http://dx.doi.org/10.1074/jbc.271.25.14849			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663060	hybrid			2022-12-27	WOS:A1996UT10600034
J	Pratico, D; Smyth, EM; Violi, F; FitzGerald, GA				Pratico, D; Smyth, EM; Violi, F; FitzGerald, GA			Local amplification of platelet function by 8-epi prostaglandin F-2 alpha is not mediated by thromboxane receptor isoforms	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGGREGATION; 8-EPI-PROSTAGLANDIN-F2-ALPHA; F2-ISOPROSTANE; ANTAGONIST; ACTIVATION; AGONIST; INVIVO; RAT	8-epi-Prostaglandin (PG) F-2 alpha may be formed by cyclooxygenases 1 and 2 or by a free radical catalyzed process as an isoprostane. Concentrations of 8-epi-PGF(2 alpha) in the range 1 nM to 1 mu M induce a dose-dependent increase in platelet shape change, in calcium release from intracellular stores [Ca2+](i) and in inositol phosphates; it also causes irreversible platelet aggregation, dependent on thromboxane generation, when incubated with subthreshold concentrations of ADP, thrombin, collagen, and arachidonic acid, Much higher concentrations of 8-epi-PGF(2 alpha) (10-20 mu M) alone induce weak, reversible aggregation. Although these effects are prevented by pharmacological thromboxane receptor antagonists, they are unlikely to be mediated by thromboxane receptors, Thus, 8-epi-PGF(2 alpha) does not compete for binding at the stably expressed placental or endothelial isoforms of the thromboxane receptor or for binding of thromboxane ligands to human platelets, Furthermore, the response to 8-epi PGF(2 alpha) exhibits structural specificity versus 8-epi PGF(3 alpha) and PGF(2 alpha). Concentrations in the range that evoke its effects on platelets do not desensitize the aggregation response stimulated by thromboxane or PGH(2) analogs, Unlike primary prostaglandins, which are rapidly metabolized to inactive products, 8-epi PGF(2 alpha) circulates in plasma, However, the systemic concentrations found in healthy volunteers (median 48 pmol/liter) and in patients with hepatic cirrhosis (median 147 pmol/liter), a syndrome of oxidant stress in vivo, fall well below those which modulate platelet function. 8-Epi PGF(2 alpha) may amplify the response to platelet agonists in syndromes where oxidant stress and platelet activation coincide, Despite blockade by thromboxane antagonists, 8-epi PGF(2 alpha) does not activate either of the thromboxane receptor isoforms described in platelets, Activation of a distinct receptor would be consistent with the enzymatic formation of 8-epi PGF(2 alpha) by cyclooxygenases. However, incidental activation of such a receptor by systemic concentrations of 8-epi PGF(2 alpha) is unlikely to occur, even in syndromes of excessive free radical generation in vivo.	UNIV PENN,CTR EXPTL THERAPEUT,PHILADELPHIA,PA 19104; UNIV ROMA LA SAPIENZA,MED CLIN 1,ROME,ITALY	University of Pennsylvania; Sapienza University Rome			Violi, Francesco/K-1509-2016; Pratico, Domenico/ABA-9590-2020; FitzGerald, Garret A/A-4222-2010	Violi, Francesco/0000-0002-6610-7068; 	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054500] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 54500] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BANERJEE M, 1992, AM J PHYSIOL, V263, pH660, DOI 10.1152/ajpheart.1992.263.3.H660; BHAGWAT SS, 1985, NATURE, V315, P511, DOI 10.1038/315511a0; COLLER BS, 1985, J CLIN INVEST, V76, P101, DOI 10.1172/JCI111931; DELANTY N, 1996, IN PRESS CIRCUALTION; DELANTY N, IN PRESS BR J CLIN P; DORN GW, 1990, J BIOL CHEM, V265, P4240; FOURCADE O, 1995, CELL, V80, P919, DOI 10.1016/0092-8674(95)90295-3; FUKUNAGA M, 1993, AM J PHYSIOL, V264, pC1619, DOI 10.1152/ajpcell.1993.264.6.C1619; FURCI L, 1991, J PHARMACOL EXP THER, V258, P74; Habib A, 1996, J INVEST MED, V44, pA263; HARRISON KA, 1995, J BIOL CHEM, V270, P17273, DOI 10.1074/jbc.270.29.17273; HIRATA M, 1991, NATURE, V349, P617, DOI 10.1038/349617a0; HIRATA T, 1995, THROMB HAEMOSTASIS, V73, pA60; KINSELLA BT, 1994, ANN NY ACAD SCI, V714, P270, DOI 10.1111/j.1749-6632.1994.tb12054.x; LANEUVILLE O, 1994, J PHARMACOL EXP THER, V271, P927; LAPETINA EG, 1987, METHOD ENZYMOL, V141, P176; LEFKOWITZ RJ, 1991, NATURE, V351, P353, DOI 10.1038/351353a0; LONGMIRE AW, 1994, PROSTAGLANDINS, V48, P247, DOI 10.1016/0090-6980(94)90011-6; MAIS DE, 1985, J PHARMACOL EXP THER, V233, P418; MAYEUX PR, 1988, BIOCHEM BIOPH RES CO, V157, P733, DOI 10.1016/S0006-291X(88)80311-5; Meagher EA, 1996, J INVEST MED, V44, pA300; MORROW JD, 1990, P NATL ACAD SCI USA, V87, P9383, DOI 10.1073/pnas.87.23.9383; MORROW JD, 1994, J BIOL CHEM, V269, P4317; MORROW JD, 1992, PROSTAGLANDINS, V44, P155, DOI 10.1016/0090-6980(92)90077-7; NAMBA T, 1993, NATURE, V365, P166, DOI 10.1038/365166a0; NEGISHI M, 1993, J BIOL CHEM, V268, P9517; NUSING RM, 1993, J BIOL CHEM, V268, P25253; OCONNOR DE, 1984, J AM CHEM SOC, V106, P3577, DOI 10.1021/ja00324a028; OGLETREE ML, 1985, J PHARMACOL EXP THER, V234, P435; PRATICO D, 1992, J LAB CLIN MED, V119, P364; PRATICO D, 1995, J BIOL CHEM, V270, P9800, DOI 10.1074/jbc.270.17.9800; Pratico D., 1995, Blood, V86, p509A; Pratico D, 1996, J INVEST MED, V44, pA301; RAYCHOWDHURY MK, 1994, J BIOL CHEM, V269, P19256; REILLY IAG, 1987, BLOOD, V69, P180; REILLY M, 1996, IN PRESS CIRCULATION; TAKAHARA K, 1990, J BIOL CHEM, V265, P6836; TAKAHASHI K, 1992, J CLIN INVEST, V90, P136, DOI 10.1172/JCI115826; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94; WATSON SP, 1986, J BIOL CHEM, V261, P5368; YIN K, 1994, J PHARMACOL EXP THER, V270, P1192	41	178	182	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14916	14924		10.1074/jbc.271.25.14916	http://dx.doi.org/10.1074/jbc.271.25.14916			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663015	hybrid			2022-12-27	WOS:A1996UT10600044
J	Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Clarke, DM; Riordan, JR				Seibert, FS; Linsdell, P; Loo, TW; Hanrahan, JW; Clarke, DM; Riordan, JR			Disease-associated mutations in the fourth cytoplasmic loop of cystic fibrosis transmembrane conductance regulator compromise biosynthetic processing and chloride channel activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR GENE; PHOSPHORYLATION; IDENTIFICATION; DOMAINS; CELLS; POPULATION; MEMBRANE; SITES; DNA	A cluster of 18 point mutations in exon 17b of the cystic fibrosis transmembrane conductance regulator (CFTR) gene has been detected in patients with cystic fibrosis. These mutations cause single amino acid substitutions in the most C-terminal cytoplasmic loop (CL4, residues 1035-1102) of the CFTR chloride channel, Heterologous expression of the mutants showed that 12 produced only core-glycosylated CFTR, which was retained in the endoplasmic reticulum; the other six mutants matured and reached the cell surface, In some cases substitution of one member of pairs of adjacent residues resulted in misprocessing, whereas the other did not, Thus, the secondary structure of CL4 may contribute crucially to the proper folding of the entire CFTR molecule, Cyclic AMP stimulated iodide efflux was not detected from cells expressing the misprocessed variants but was from the other six, indicating that their mutations cause relatively subtle channel defects. Consistent with this, these latter mutations generally are present in patients who are pancreatic-sufficient, while the processing mutants are mostly from patients who are pancreatic-insufficient. Single-channel patch-clamp analysis demonstrated that the processed mutants had the same ohmic conductance as wild-type CFTR, but a lower open probability, generally due to an increase in channel mean closed time and a reduction in mean open time, This suggests that mutations in CL4 do not affect pore properties of CFTR, but disrupt the mechanism of channel gating.	MAYO CLIN SCOTTSDALE,MAYO FDN,DEPT BIOCHEM & MOLEC BIOL,SCOTTSDALE,AZ 85259; MAYO CLIN SCOTTSDALE,MAYO FDN,SC JOHNSON MED RES CTR,SCOTTSDALE,AZ 85259; UNIV TORONTO,MRC,GRP MEMBRANE BIOL,DEPT MED,TORONTO,ON M5S 1A8,CANADA; UNIV TORONTO,MRC,GRP MEMBRANE BIOL,DEPT BIOCHEM,TORONTO,ON M5S 1A8,CANADA; MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA	Mayo Clinic; Mayo Clinic Phoenix; Mayo Clinic; Mayo Clinic Phoenix; SC Johnson & Son; University of Toronto; University of Toronto; McGill University			Hanrahan, John/AGG-1926-2022; Clarke, David M./A-1112-2008	Hanrahan, John/0000-0001-9080-2039; Clarke, David M./0000-0003-4335-7184; Loo, Tip W/0000-0003-2108-0188; Linsdell, Paul/0000-0001-6257-6273				ANDERSON MP, 1992, SCIENCE, V257, P1701, DOI 10.1126/science.1382316; ANDERSON MP, 1991, CELL, V67, P775, DOI 10.1016/0092-8674(91)90072-7; BOZON D, 1994, HUM MUTAT, V3, P330, DOI 10.1002/humu.1380030329; CASALS T, 1995, HUM GENET, V95, P205; CHANG XB, 1993, J BIOL CHEM, V268, P11304; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHENG SH, 1990, CELL, V63, P827, DOI 10.1016/0092-8674(90)90148-8; CHENG SH, 1991, CELL, V66, P1027, DOI 10.1016/0092-8674(91)90446-6; DIAMOND G, 1991, J BIOL CHEM, V266, P22761; FANAN P, 1992, GENOMICS, V13, P770; FEREC C, 1992, NAT GENET, V1, P188, DOI 10.1038/ng0692-188; FEREC C, 1993, HUM MOL GENET, V2, P1557, DOI 10.1093/hmg/2.10.1557; GHANEM N, 1994, GENOMICS, V21, P434, DOI 10.1006/geno.1994.1290; GRAY MA, 1988, J MEMBRANE BIOL, V105, P131, DOI 10.1007/BF02009166; GREGORY RJ, 1991, MOL CELL BIOL, V11, P3886, DOI 10.1128/MCB.11.8.3886; GUNDERSON KL, 1994, J BIOL CHEM, V269, P19349; HANRAHAN JW, 1995, SOC GEN PHY, V50, P125; HANRAHAN JW, 1996, IN PRESS J EXP ZOOL, V275; Higuchi R., 1990, RECOMBINANT PCR PCR, P177; HWANG TC, 1994, P NATL ACAD SCI USA, V91, P4698, DOI 10.1073/pnas.91.11.4698; LOO TW, 1994, J BIOL CHEM, V269, P28683; LUKACS GL, 1994, EMBO J, V13, P6076, DOI 10.1002/j.1460-2075.1994.tb06954.x; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MATHEWS CJ, 1995, 9 ANN N AM CYST FIBR; MERCIER B, 1993, GENOMICS, V16, P296, DOI 10.1006/geno.1993.1183; PIND S, 1994, J BIOL CHEM, V269, P12784; RIORDAN JR, 1989, SCIENCE, V245, P1066; SAVOV A, 1994, HUM MOL GENET, V3, P57; SHEPPARD DN, 1993, NATURE, V362, P160, DOI 10.1038/362160a0; TABCHARANI JA, 1993, NATURE, V366, P79, DOI 10.1038/366079a0; TABCHARANI JA, 1991, NATURE, V352, P628, DOI 10.1038/352628a0; VENGLARIK CJ, 1994, J GEN PHYSIOL, V104, P123, DOI 10.1085/jgp.104.1.123; WELSH MJ, 1992, NEURON, V8, P821, DOI 10.1016/0896-6273(92)90196-K; WELSH MJ, 1993, CELL, V73, P1251, DOI 10.1016/0092-8674(93)90353-R; WINTER MC, 1994, BIOPHYS J, V66, P1398, DOI 10.1016/S0006-3495(94)80930-0; XIE JX, 1995, J BIOL CHEM, V270, P28084; ZIELENSKI J, 1995, HUM MUTAT, V5, P43, DOI 10.1002/humu.1380050106; ZIELENSKI J, 1993, AM J HUM GENET, V52, P609	38	106	107	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15139	15145		10.1074/jbc.271.25.15139	http://dx.doi.org/10.1074/jbc.271.25.15139			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662892	hybrid			2022-12-27	WOS:A1996UT10600073
J	Waring, JD; Haq, R; Tamai, K; Sabourin, LA; Ikeda, JE; Korneluk, RG				Waring, JD; Haq, R; Tamai, K; Sabourin, LA; Ikeda, JE; Korneluk, RG			Investigation of myotonic dystrophy kinase isoform translocation and membrane association	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UNSTABLE CTG REPEAT; TRIPLET REPEAT; MESSENGER-RNA; PROTEIN; GENE; EXPANSION; SEQUENCE; REGION	Myotonic dystrophy is caused by the expansion of a CTG repeat found in the 3'-untranslated region of the myotonic dystrophy kinase. The mechanism of disease and the role of the kinase are currently obscure. Here we begin the investigation of domain structure/function correlations to aid in determining its normal function. Expressed full-length protein and protein truncated before a C terminal hydrophobic domain were compared. In vitro, signal peptide function and protection of kinase by microsomal membranes were absent; thus, it is not translocated, as previously proposed. However, full-length kinase expressed in insect cells was found in fractions enriched for membranes and decorated mitochondria. The truncated form was found primarily in the cytosol. The kinase was present as two self-associated, disulfide-linked complexes, The majority of full-length kinase was found in the larger of the two complexes, while almost all of the truncated form was found in the smaller. Thus, the C-terminal region confers a higher order of self-association. Furthermore, full-length kinase expressed in COS-1 cells was present as high molecular weight complex, while the truncated form was present as monomer species. These experiments indicate that the myotonic dystrophy kinase is not membrane-integrated but that it may have a molecular organization which favors peripheral association with membranes.	CHILDRENS HOSP EASTERN ONTARIO,GENET MOLEC LAB,OTTAWA,ON K1H 8L1,CANADA; TOKAI UNIV,SCH MED,GENOSPHERE PROJECT,ISEHARA,KANAGAWA 25911,JAPAN; UNIV OTTAWA,DEPT MICROBIOL & IMMUNOL,OTTAWA,ON K1H 8M5,CANADA	University of Ottawa; Children's Hospital of Eastern Ontario; Tokai University; University of Ottawa			Tamai, Katsuyuki/F-4743-2013	Tamai, Katsuyuki/0000-0003-4094-3911				BARCELO JM, 1993, HUM MOL GENET, V2, P705, DOI 10.1093/hmg/2.6.705; BLOBEL G, 1966, SCIENCE, V154, P1662, DOI 10.1126/science.154.3757.1662; BREWSTER BS, 1993, BIOCHEM BIOPH RES CO, V194, P1256, DOI 10.1006/bbrc.1993.1958; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; CARRERA AC, 1993, P NATL ACAD SCI USA, V90, P442, DOI 10.1073/pnas.90.2.442; DUNNE PW, 1994, BIOCHEMISTRY-US, V33, P10809, DOI 10.1021/bi00201a031; ETONGUEMAYER P, 1994, BIOCHEM BIOPH RES CO, V199, P89, DOI 10.1006/bbrc.1994.1198; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; HARLEY HG, 1993, AM J HUM GENET, V52, P1164; Harper P.S., 1989, MYOTONIC DYSTROPHY; HERRERA GA, 1989, ULTRASTRUCT PATHOL, V13, P485, DOI 10.3109/01913128909074532; HERSHBERGER PA, 1994, J VIROL, V68, P3467, DOI 10.1128/JVI.68.6.3467-3477.1994; HOFFMANRADVANYI H, 1993, HUM MOL GENET, V2, P1263; JANSEN G, 1992, NAT GENET, V1, P261, DOI 10.1038/ng0792-261; KOGA R, 1994, BIOCHEM BIOPH RES CO, V202, P577, DOI 10.1006/bbrc.1994.1967; KRAHE R, 1995, GENOMICS, V28, P1, DOI 10.1006/geno.1995.1099; MAEDA M, 1995, J BIOL CHEM, V270, P20246, DOI 10.1074/jbc.270.35.20246; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MAHADEVAN MS, 1993, HUM MOL GENET, V2, P299, DOI 10.1093/hmg/2.3.299; Moore DD, 1995, GLOB MOB SURV; MOUNSEY JP, 1995, J CLIN INVEST, V95, P2379, DOI 10.1172/JCI117931; SABOURI LA, 1993, NAT GENET, V4, P233, DOI 10.1038/ng0793-233; SASAGAWA N, 1994, FEBS LETT, V351, P22, DOI 10.1016/0014-5793(94)00808-6; TANEJA KL, 1995, J CELL BIOL, V128, P995, DOI 10.1083/jcb.128.6.995; TSILFIDIS C, 1992, NAT GENET, V1, P192, DOI 10.1038/ng0692-192; VANDERVEN PFM, 1993, HUM MOL GENET, V2, P1889; WANG JZ, 1995, HUM MOL GENET, V4, P599, DOI 10.1093/hmg/4.4.599; WHITING EJ, 1995, HUM MOL GENET, V4, P1063, DOI 10.1093/hmg/4.6.1063	30	22	22	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15187	15193		10.1074/jbc.271.25.15187	http://dx.doi.org/10.1074/jbc.271.25.15187			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663097	hybrid			2022-12-27	WOS:A1996UT10600080
J	Giuffre, A; DItri, E; Giannini, S; Brunori, M; UbbinkKok, T; Konings, WN; Antonini, G				Giuffre, A; DItri, E; Giannini, S; Brunori, M; UbbinkKok, T; Konings, WN; Antonini, G			The caa(3) terminal oxidase of Bacillus stearothermophilus - Transient spectroscopy of electron transfer and ligand binding	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; THERMOPHILIC BACTERIUM PS3; FACULTATIVE ALKALOPHILIC BACILLUS; ESCHERICHIA-COLI; KINETICS; FEATURES; AERATION; OXYGEN	The thermophilic bacterium Bacillus stearothermophilus possesses a caa(3)-type terminal oxidase, which was previously purified (De Vrij, W., Heyne, R. I. HL, and Konings, W. N. (1989) Ear. J. Biochem. 178, 763-770). We have carried out extensive kinetic experiments on the purified enzyme by stopped-flow time-resolved optical spectroscopy combined with singular value decomposition analysis. The results indicate a striking similarity of behavior between this enzyme and the electrostatic complex between mammalian cytochrome c and cytochrome c oxidase. CO binding to fully reduced caa(3) occurs with a second order rate constant (k = 7.8 x 10(4) M(-1) S-1) and an activation energy (E* = 6.1 kcal mol(-1)) similar to those reported for beef heart cytochrome c oxidase. Dithionite reduces cytochrome a with bimolecular kinetics, while cytochrome a(3) (and Cu-B) is reduced via intramolecular electron transfer. When the fully reduced enzyme is mixed with O-2, cytochrome a(3), and cytochrome c are rapidly oxidized, whereas cytochrome a remains largely reduced in the first few milliseconds. When cyanide-bound caa(3) is mixed with ascorbate plus TMPD, cytochrome c and cytochrome a are synchronously reduced; the value of the second order rate constant (k = 3 x 10(5) M(-1) S-1 at 30 degrees C) suggests that cytochrome c is the electron entry site. Steady-state experiments indicate that cytochrome a has a redox potential higher than cytochrome c. The data from the reaction with O-2 reveal a remarkable similarity in the kinetic, equilibrium, and optical properties of caa(3) and the electrostatic complex cytochrome c/cytochrome c oxidase.	UNIV ROMA LA SAPIENZA,DEPT BIOCHEM SCI,I-00185 ROME,ITALY; UNIV ROMA LA SAPIENZA,CNR,CTR MOLEC BIOL,I-00185 ROME,ITALY; UNIV GRONINGEN,GRONINGEN BIOMOL SCI & BIOTECHNOL INST,DEPT MICROBIOL,9750 AA HAREN,NETHERLANDS; UNIV LAQUILA,DEPT PURE & APPL BIOL,I-67010 LAQUILA,ITALY	Sapienza University Rome; Consiglio Nazionale delle Ricerche (CNR); Sapienza University Rome; University of Groningen; University of L'Aquila			Konings, Wilhelmus N./C-7063-2013; Giuffrè, Alessandro/K-4341-2015	Giuffrè, Alessandro/0000-0001-5301-0681; Antonini, Giovanni/0000-0002-2115-8961; Brunori, Maurizio/0000-0002-7795-1635				BICKAR D, 1986, J BIOL CHEM, V261, P4461; DEVRIJ W, 1989, EUR J BIOCHEM, V178, P763; ELFERINK MGL, 1993, EUR J BIOCHEM, V214, P917, DOI 10.1111/j.1432-1033.1993.tb17995.x; ELFERINK MGL, 1995, BBA-BIOENERGETICS, V1230, P31, DOI 10.1016/0005-2728(95)00028-H; FEE JA, 1993, J BIOENERG BIOMEMBR, V25, P103, DOI 10.1007/BF00762852; GIBSON QH, 1963, BIOCHEM J, V86, P541, DOI 10.1042/bj0860541; GIUFFRE A, 1994, J BIOL CHEM, V269, P31006; HENNING W, 1995, BIOCHEM J, V309, P279, DOI 10.1042/bj3090279; HENRY ER, 1992, METHOD ENZYMOL, V210, P129; HILL BC, 1991, J BIOL CHEM, V266, P2219; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; MALATESTA F, 1995, BIOPHYS CHEM, V54, P1, DOI 10.1016/0301-4622(94)00117-3; MALATESTA F, 1990, P NATL ACAD SCI USA, V87, P7410, DOI 10.1073/pnas.87.19.7410; Malatesta F, 1996, BIOCHEM J, V315, P909, DOI 10.1042/bj3150909; MUNTYAN MS, 1993, FEBS LETT, V327, P351, DOI 10.1016/0014-5793(93)81019-V; NICHOLLS P, 1984, BIOCHIM BIOPHYS ACTA, V767, P240, DOI 10.1016/0005-2728(84)90193-2; ORII Y, 1991, J BIOL CHEM, V266, P14310; PUUSTINEN A, 1991, P NATL ACAD SCI USA, V88, P6122, DOI 10.1073/pnas.88.14.6122; QUIRK PG, 1993, J BIOL CHEM, V268, P678; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SONE N, 1986, METHOD ENZYMOL, V126, P145; SONE N, 1991, J BIOCHEM-TOKYO, V110, P1016, DOI 10.1093/oxfordjournals.jbchem.a123671; SONE N, 1983, J BIOCHEM-TOKYO, V93, P1329, DOI 10.1093/oxfordjournals.jbchem.a134267; SONE N, 1994, BIOCHEMISTRY-US, V33, P849, DOI 10.1021/bi00170a001; SONE N, 1991, FEBS LETT, V288, P154, DOI 10.1016/0014-5793(91)81024-3; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; WILSON MT, 1994, J BIOL CHEM, V269, P24114; WOODRUFF WH, 1991, P NATL ACAD SCI USA, V88, P2588, DOI 10.1073/pnas.88.6.2588; YUMOTO I, 1993, J BIOCHEM-TOKYO, V114, P88, DOI 10.1093/oxfordjournals.jbchem.a124145	29	5	5	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13987	13992		10.1074/jbc.271.24.13987	http://dx.doi.org/10.1074/jbc.271.24.13987			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662862	hybrid			2022-12-27	WOS:A1996UQ66000012
J	McGuire, V; Alexander, S				McGuire, V; Alexander, S			PsB multiprotein complex of Dictyostelium discoideum - Demonstration of cellulose binding activity and order of protein subunit assembly	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE COAT PROTEINS; CRYSTALLINE CELLULOSE; EXTRACELLULAR-MATRIX; LECTIN EXPRESSION; PRESTALK CELLS; ADHESION; DIFFERENTIATION; GLYCOPROTEINS; ORGANIZATION; PRESPORE	The differentiated spores of Dictyostelium are surrounded by an extracellular matrix, the spore coat, which protects them from environmental factors allowing them to remain viable for extended periods of time. This presumably is a major evolutionary advantage. This unique extracellular matrix is composed of cellulose and glycoproteins. Previous work has shown that some of these spore coat glycoproteins exist as a preassembled multiprotein complex (the PsB multiprotein complex) which is stored in the prespore vesicles (Watson, N., McGuire, V., and Alexander, S (1994) J. Cell Sci. 107, 2567-2579), Later in development, the complex is synchronously secreted from the prespore vesicles and incorporated into the spore coat, We now have shown that the PsB complex has a specific in vitro cellulose binding activity, The analysis of mutants lacking individual subunits of the PsB complex revealed the relative order of assembly of the subunit proteins and demonstrated that the protein subunits must be assembled for cellulose binding activity, These results provide a biochemical explanation for the localization of this multiprotein complex in the spore coat.	UNIV MISSOURI, DIV BIOL SCI, COLUMBIA, MO 65211 USA	University of Missouri System; University of Missouri Columbia								ALEXANDER S, 1988, DIFFERENTIATION, V38, P82, DOI 10.1111/j.1432-0436.1988.tb00201.x; ALEXANDER S, 1991, MOL CELL BIOL, V11, P3171, DOI 10.1128/MCB.11.6.3171; ALEXANDER S, 1992, DIFFERENTIATION, V51, P149, DOI 10.1111/j.1432-0436.1992.tb00691.x; ALEXANDER S, 1990, DEV GENET, V11, P418, DOI 10.1002/dvg.1020110515; ALEXANDER S, 1983, DIFFERENTIATION, V24, P209, DOI 10.1111/j.1432-0436.1983.tb01321.x; BLANTON RL, 1993, DEVELOPMENT, V119, P703; BLUSCH J, 1995, DIFFERENTIATION, V58, P253, DOI 10.1046/j.1432-0436.1995.5840253.x; CARPITA NC, 1993, PLANT J, V3, P1, DOI 10.1111/j.1365-313X.1993.tb00007.x; CASSAB GI, 1988, ANNU REV PLANT PHYS, V39, P321, DOI 10.1146/annurev.pp.39.060188.001541; CHAMPION A, 1995, MICROBIOL-UK, V141, P785, DOI 10.1099/13500872-141-4-785; CHAMPION A, 1991, J GEN MICROBIOL, V137, P2431, DOI 10.1099/00221287-137-10-2431; Creighton TE, 1983, PROTEINS STRUCTURES; DEVINE KM, 1982, P NATL ACAD SCI-BIOL, V79, P7361, DOI 10.1073/pnas.79.23.7361; DEVINE KM, 1983, DEV BIOL, V99, P437, DOI 10.1016/0012-1606(83)90293-2; EBERT DL, 1989, J CELL BIOL, V109, P1445, DOI 10.1083/jcb.109.4.1445; EDELMAN GM, 1986, ANNU REV CELL BIOL, V2, P81, DOI 10.1146/annurev.cb.02.110186.000501; EKBLOM P, 1986, ANNU REV CELL BIOL, V2, P27, DOI 10.1146/annurev.cb.02.110186.000331; ERDOS GW, 1989, EXP MYCOL, V13, P169, DOI 10.1016/0147-5975(89)90022-4; ERDOS GW, 1973, P NATL ACAD SCI USA, V70, P1828, DOI 10.1073/pnas.70.6.1828; FIEDLER K, 1995, CELL, V81, P309, DOI 10.1016/0092-8674(95)90380-1; FIRTEL RA, 1995, GENE DEV, V9, P1427, DOI 10.1101/gad.9.12.1427; FOSNAUGH K, 1994, DEV BIOL, V166, P823, DOI 10.1006/dbio.1994.1362; FREEZE H, 1978, BIOCHIM BIOPHYS ACTA, V539, P529, DOI 10.1016/0304-4165(78)90086-7; FREEZE H, 1977, DEV BIOL, V56, P184, DOI 10.1016/0012-1606(77)90161-0; FREEZE H, 1977, J BIOL CHEM, V252, P820; FREEZE HH, 1989, J BIOL CHEM, V264, P19278; GEHIN A, 1995, RES MICROBIOL, V146, P251, DOI 10.1016/0923-2508(96)80281-6; GILKES NR, 1992, J BIOL CHEM, V267, P6743; GOLDSTEIN MA, 1994, J BACTERIOL, V176, P7328, DOI 10.1128/JB.176.23.7328-7334.1994; GONZALEZYANES B, 1989, DEV BIOL, V133, P576, DOI 10.1016/0012-1606(89)90060-2; GRANT WN, 1983, EMBO J, V2, P935, DOI 10.1002/j.1460-2075.1983.tb01524.x; GUNAGYYI X, 1995, BIOCHEMISTRY-US, V34, P6993; HEMMES DE, 1972, J ULTRA MOL STRUCT R, V41, P406, DOI 10.1016/S0022-5320(72)90047-0; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KUSPA A, 1994, METH MOL G, V3, P3; LINDER M, 1995, PROTEIN SCI, V4, P1056, DOI 10.1002/pro.5560040604; LOOMIS WF, 1988, ISI ATLAS-IMMUNOL, V1, P25; MATTER K, 1994, CURR OPIN CELL BIOL, V6, P545, DOI 10.1016/0955-0674(94)90075-2; MCROBBIE SJ, 1988, DEVELOPMENT, V104, P275; MURRAY BA, 1983, MOL CELL BIOL, V3, P863, DOI 10.1128/MCB.3.5.863; NEWELL PC, 1969, J BACTERIOL, V100, P763, DOI 10.1128/JB.100.2.763-768.1969; OKANO T, 1989, CELLULOSE WOOD CHEM, P53; PROCHIANTZ A, 1995, BIOESSAYS, V17, P39, DOI 10.1002/bies.950170109; RAMALINGAM R, 1992, J BACTERIOL, V174, P7834, DOI 10.1128/JB.174.23.7834-7837.1992; RICHARDSON DL, 1992, GENE DEV, V6, P1058, DOI 10.1101/gad.6.6.1058; ROSEN SD, 1973, P NATL ACAD SCI USA, V70, P2554, DOI 10.1073/pnas.70.9.2554; RUOSLAHTI E, 1991, CELL, V64, P867, DOI 10.1016/0092-8674(91)90308-L; SAXENA IM, 1994, J BACTERIOL, V176, P5735, DOI 10.1128/JB.176.18.5735-5752.1994; SHARON N, 1993, TRENDS BIOCHEM SCI, V18, P221, DOI 10.1016/0968-0004(93)90193-Q; SHOSEYOV O, 1990, P NATL ACAD SCI USA, V87, P2192, DOI 10.1073/pnas.87.6.2192; SHOSEYOV O, 1992, P NATL ACAD SCI USA, V89, P3483, DOI 10.1073/pnas.89.8.3483; SMITH E, 1989, GENETICS, V122, P59; SOLL DR, 1987, METHOD CELL BIOL, V28, P413; STAHLBERG J, 1988, EUR J BIOCHEM, V173, P179, DOI 10.1111/j.1432-1033.1988.tb13982.x; SUSSMAN M, 1987, METHOD CELL BIOL, V28, P9; SUSSMAN M, 1976, ANNU REV PLANT PHYS, V27, P229, DOI 10.1146/annurev.pp.27.060176.001305; SUSSMAN M, 1978, DIFFERENTIATION, V10, P1, DOI 10.1111/j.1432-0436.1978.tb00938.x; VARNER JE, 1989, CELL, V56, P231, DOI 10.1016/0092-8674(89)90896-9; WALLACE JS, 1984, CELL DIFFER DEV, V14, P205, DOI 10.1016/0045-6039(84)90047-2; Watson J. D., 1987, MOL BIOL GENE; WATSON N, 1993, J BIOL CHEM, V268, P22634; WATSON N, 1994, J CELL SCI, V107, P2567; WATSON N, 1994, THESIS U MISSOURI; WEST CM, 1985, J BIOL CHEM, V260, P3803; WEST CM, 1990, DEV GENET, V11, P492, DOI 10.1002/dvg.1020110526; WEST CM, 1986, MOL CELL BIOCHEM, V72, P121; WILLIAMS KL, 1993, NATO ADV SCI INST SE, V259, P345; WU L, 1995, DEV BIOL, V171, P149, DOI 10.1006/dbio.1995.1267; Zhou-Chou Ti, 1995, Developmental Biology, V168, P332, DOI 10.1006/dbio.1995.1084	69	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14596	14603		10.1074/jbc.271.24.14596	http://dx.doi.org/10.1074/jbc.271.24.14596			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662961	hybrid			2022-12-27	WOS:A1996UQ66000097
J	Wood, IC; Roopra, A; Buckley, NJ				Wood, IC; Roopra, A; Buckley, NJ			Neural specific expression of the m4 muscarinic acetylcholine receptor gene is mediated by a RE1/NRSE-type silencing element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CHANNEL GENE; SYNAPSIN-I GENE; BINDING-PROPERTIES; RABBIT LUNG; RAT-BRAIN; PROMOTER; CELLS; IDENTIFICATION; FAMILY; HEART	Muscarinic receptor genes are members of the G-protein receptor superfamily that, with the inclusion of the odorant receptors, is believed to contain over a thousand members, Each member of this superfamily, which has been studied to date, appears to have a distinct pattern of expression, but little work has been done on the regulation of these complex expression patterns, We have recently isolated the rat m4 muscarinic receptor gene and identified a genomic 1520-nucleotide sequence that appeared capable of directing cell-specific expression (Wood, I, C., Roopra, A., Harrington, C., and Buckley, N. J. (1995) J, Biol, Chem. 270, 30933-30940), In the present study we have constructed a set of deletion promoter constructs to more closely define the DNA elements that are responsible for m4 gene expression, We have found that deletion of a RE1/NRSE silencer element between nucleotides -574 and -550, similar to that found in other neural specific genes, results in activation of reporter expression in non-m4-expressing cells. Gel mobility shift analysis has shown that a protein present in nonexpressing cells is capable of binding to this element and is probably the recently identified neural silencer, REST/NRSF, Of the constitutively active proximal promoter only a tandem Sp-l site appears to recruit DNA binding proteins that are present in all cells tested, This represents the first report documenting the role of this silencer in regulating expression of a member of the G-protein receptor family.			Wood, IC (corresponding author), UCL, WELLCOME LAB MOLEC PHARMACOL, LONDON WC1E 6BT, ENGLAND.		Buckley, Noel J/B-9675-2012; Wood, Ian/AAK-9423-2021	Buckley, Noel J/0000-0003-1152-0653; Wood, Ian/0000-0003-1886-2533	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BONNER TI, 1987, SCIENCE, V237, P527, DOI 10.1126/science.3037705; BONNER TI, 1988, NEURON, V1, P403, DOI 10.1016/0896-6273(88)90190-0; Brown D. A., 1995, MOL B INT U, P165; BUCKLEY NJ, 1989, MOL PHARMACOL, V35, P469; BUCKLEY NJ, 1988, J NEUROSCI, V8, P4646; CHONG JHA, 1995, CELL, V80, P949, DOI 10.1016/0092-8674(95)90298-8; DENT CL, 1993, TRANSCRIPTION FACTOR, P1; HASSALL CJS, 1993, NEUROSCIENCE, V56, P1041, DOI 10.1016/0306-4522(93)90149-A; HOWLAND DS, 1991, MOL BRAIN RES, V11, P345, DOI 10.1016/0169-328X(91)90044-X; ISHIGURO H, 1993, J BIOL CHEM, V268, P17987; KALLUNKI P, 1995, J BIOL CHEM, V270, P21291, DOI 10.1074/jbc.270.36.21291; KLARSFELD A, 1991, EMBO J, V10, P625, DOI 10.1002/j.1460-2075.1991.tb07990.x; KRANER SD, 1992, NEURON, V9, P37, DOI 10.1016/0896-6273(92)90218-3; KUBO T, 1986, NATURE, V323, P411, DOI 10.1038/323411a0; LAZARENO S, 1990, MOL PHARMACOL, V38, P805; LI LA, 1993, P NATL ACAD SCI USA, V90, P1460, DOI 10.1073/pnas.90.4.1460; MAK JCW, 1993, LIFE SCI, V53, P1501, DOI 10.1016/0024-3205(93)90624-C; MAUE RA, 1990, NEURON, V4, P223, DOI 10.1016/0896-6273(90)90097-Y; Mieda M, 1996, J BIOL CHEM, V271, P5177; MORI N, 1990, NEURON, V4, P583, DOI 10.1016/0896-6273(90)90116-W; MORI N, 1992, NEURON, V9, P45, DOI 10.1016/0896-6273(92)90219-4; PATHAK BG, 1994, NUCLEIC ACIDS RES, V22, P4748, DOI 10.1093/nar/22.22.4748; PERALTA EG, 1987, EMBO J, V6, P3923, DOI 10.1002/j.1460-2075.1987.tb02733.x; Sambrook J., 2002, MOL CLONING LAB MANU; Schoch S, 1996, J BIOL CHEM, V271, P3317, DOI 10.1074/jbc.271.6.3317; SCHOENHERR CJ, 1995, SCIENCE, V267, P1360, DOI 10.1126/science.7871435; VINSON CR, 1988, GENE DEV, V2, P801, DOI 10.1101/gad.2.7.801; Wood IC, 1995, J BIOL CHEM, V270, P30933, DOI 10.1074/jbc.270.52.30933; WOOD IC, 1995, FORME, V5, P29; ZOPF D, 1990, NUCLEIC ACIDS RES, V18, P521, DOI 10.1093/nar/18.3.521	30	84	85	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14221	14225		10.1074/jbc.271.24.14221	http://dx.doi.org/10.1074/jbc.271.24.14221			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662964	hybrid			2022-12-27	WOS:A1996UQ66000044
J	Carman, GM; Zeimetz, GM				Carman, GM; Zeimetz, GM			Regulation of phospholipid biosynthesis in the yeast Saccharomyces cerevisiae	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLETHANOLAMINE METHYLATION PATHWAY; DEPENDENT PROTEIN-KINASE; PHOSPHATIDYLSERINE SYNTHASE ACTIVITY; PHOSPHATIDATE PHOSPHATASE-ACTIVITY; CDP-DIACYLGLYCEROL SYNTHASE; PHOSPHATIDYLINOSITOL SYNTHASE; COORDINATE REGULATION; NUCLEOTIDE-SEQUENCE; STRUCTURAL GENE; SN-1,2-DIACYLGLYCEROL CHOLINEPHOSPHOTRANSFERASE				Carman, GM (corresponding author), RUTGERS STATE UNIV,COOK COLL,NEW JERSEY AGR EXPT STN,DEPT FOOD SCI,NEW BRUNSWICK,NJ 08903, USA.				NIGMS NIH HHS [GM-28140, GM-35655, GM-50679] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050679, R37GM028140, R01GM028140, R01GM035655] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMBROZIAK J, 1994, J BIOL CHEM, V269, P15344; ATKINSON K, 1980, J BIOL CHEM, V255, P6653; ATKINSON KD, 1980, J BACTERIOL, V141, P558, DOI 10.1128/JB.141.2.558-564.1980; BACHHAWAT N, 1995, J BIOL CHEM, V270, P25087, DOI 10.1074/jbc.270.42.25087; BAELEE M, 1990, J BIOL CHEM, V265, P7221; BAELEE MS, 1984, J BIOL CHEM, V259, P857; BAILIS AM, 1992, NUCLEIC ACIDS RES, V20, P1411, DOI 10.1093/nar/20.6.1411; BAILIS AM, 1987, MOL CELL BIOL, V7, P167, DOI 10.1128/MCB.7.1.167; BECKER GW, 1977, J BIOL CHEM, V252, P8684; BELUNIS CJ, 1988, J BIOL CHEM, V263, P18897; BUXEDA RJ, 1993, J BIOL CHEM, V268, P6248; BUXEDA RJ, 1991, J BIOL CHEM, V266, P13859; CARMAN GM, 1989, ANNU REV BIOCHEM, V58, P635, DOI 10.1146/annurev.biochem.58.1.635; CARMAN GM, 1989, PHOSPHATIDYLCHOLINE, P165; CARSON MA, 1984, J BIOL CHEM, V259, P6267; CARSON MA, 1982, J BIOL CHEM, V257, P8115; CLANCEY CJ, 1993, J BIOL CHEM, V268, P24580; CULBERTSON MR, 1976, J BACTERIOL, V126, P243, DOI 10.1128/JB.126.1.243-250.1976; DEANJOHNSON M, 1989, J BIOL CHEM, V264, P1274; DONAHUE TF, 1981, J BIOL CHEM, V256, P7077; FISCHL AS, 1986, J BIOL CHEM, V261, P3178; FISCHL AS, 1983, J BACTERIOL, V154, P304, DOI 10.1128/JB.154.1.304-311.1983; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FLANAGAN CA, 1992, J BIOL CHEM, V267, P24117; GAYNOR PM, 1991, BIOCHIM BIOPHYS ACTA, V1090, P326, DOI 10.1016/0167-4781(91)90197-T; Greenberg ML, 1996, MICROBIOL REV, V60, P1; GREENBERG ML, 1982, GENETICS, V100, P19; GREENBERG ML, 1983, J BACTERIOL, V153, P791, DOI 10.1128/JB.153.2.791-799.1983; GREENBERG ML, 1982, MOL GEN GENET, V186, P157, DOI 10.1007/BF00331845; Henry S. A., 1982, MOL BIOL YEAST SACCH, P101; HENRY SA, 1977, J BACTERIOL, V130, P472, DOI 10.1128/JB.130.1.472-484.1977; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HIRSCH JP, 1986, MOL CELL BIOL, V6, P3320, DOI 10.1128/MCB.6.10.3320; HJELMSTAD RH, 1988, J BIOL CHEM, V263, P19748; HJELMSTAD RH, 1987, J BIOL CHEM, V262, P3909; HJELMSTAD RH, 1991, J BIOL CHEM, V266, P5094; HJELMSTAD RH, 1990, J BIOL CHEM, V265, P1755; HOLLAND KM, 1988, J BACTERIOL, V170, P828, DOI 10.1128/jb.170.2.828-833.1988; HOMANN MJ, 1985, J BACTERIOL, V163, P1265, DOI 10.1128/JB.163.3.1265-1266.1985; HOSAKA K, 1990, J BACTERIOL, V172, P2005, DOI 10.1128/jb.172.4.2005-2012.1990; HOSAKA K, 1989, J BIOL CHEM, V264, P2053; HOSAKA K, 1984, BIOCHIM BIOPHYS ACTA, V796, P110; HOSAKA K, 1987, EUR J BIOCHEM, V162, P7, DOI 10.1111/j.1432-1033.1987.tb10533.x; KATO H, 1989, J BIOL CHEM, V264, P3116; KELLEY MJ, 1988, J BIOL CHEM, V263, P18078; KELLEY MJ, 1987, J BIOL CHEM, V262, P14563; KELLEY MJ, 1989, THESIS RUTGERS U; Kennedy E. P., 1986, LIPIDS MEMBRANES PRE, P171; KENNEDY EP, 1956, J BIOL CHEM, V222, P193; KINNEY AJ, 1988, P NATL ACAD SCI USA, V85, P7962, DOI 10.1073/pnas.85.21.7962; KINNEY AJ, 1990, J BACTERIOL, V172, P1133, DOI 10.1128/jb.172.2.1133-1136.1990; KIYONO K, 1987, J BIOCHEM-TOKYO, V102, P1089, DOI 10.1093/oxfordjournals.jbchem.a122147; KLIG LS, 1984, P NATL ACAD SCI-BIOL, V81, P3816, DOI 10.1073/pnas.81.12.3816; KLIG LS, 1985, J BACTERIOL, V162, P1135, DOI 10.1128/JB.162.3.1135-1141.1985; KLIG LS, 1988, J BACTERIOL, V170, P1878, DOI 10.1128/jb.170.4.1878-1886.1988; KO JS, 1994, J BACTERIOL, V176, P5181, DOI 10.1128/jb.176.16.5181-5183.1994; KODAKI T, 1987, J BIOL CHEM, V262, P15428; KODAKI T, 1989, EUR J BIOCHEM, V185, P243, DOI 10.1111/j.1432-1033.1989.tb15109.x; LAI K, 1994, J BIOL CHEM, V269, P2245; LAMPING E, 1991, J BACTERIOL, V173, P6432, DOI 10.1128/jb.173.20.6432-6437.1991; LETTS VA, 1985, J BACTERIOL, V163, P560, DOI 10.1128/JB.163.2.560-567.1985; LETTS VA, 1983, P NATL ACAD SCI-BIOL, V80, P7279, DOI 10.1073/pnas.80.23.7279; LIN YP, 1989, J BIOL CHEM, V264, P8641; LOPES JM, 1991, NUCLEIC ACIDS RES, V19, P1687, DOI 10.1093/nar/19.7.1687; MCDONOUGH VM, 1995, J BIOL CHEM, V270, P18774, DOI 10.1074/jbc.270.32.18774; MCGEE TP, 1994, J CELL BIOL, V124, P273, DOI 10.1083/jcb.124.3.273; MCGRAW P, 1989, GENETICS, V122, P317; MCMASTER CR, 1994, J BIOL CHEM, V269, P14776; MCMASTER CR, 1994, J BIOL CHEM, V269, P28010; MORASH SC, 1994, J BIOL CHEM, V269, P28769; MORLOCK KR, 1991, J BIOL CHEM, V266, P3586; MORLOCK KR, 1988, J BACTERIOL, V170, P3561, DOI 10.1128/jb.170.8.3561-3566.1988; NICKELS JT, 1994, J BIOL CHEM, V269, P11018; NICKELS JT, 1992, J BIOL CHEM, V267, P16297; NIKAWA J, 1987, EUR J BIOCHEM, V167, P7, DOI 10.1111/j.1432-1033.1987.tb13297.x; NIKAWA J, 1990, J BIOL CHEM, V265, P15996; NIKAWA J, 1984, EUR J BIOCHEM, V143, P251, DOI 10.1111/j.1432-1033.1984.tb08366.x; NIKAWA J, 1987, J BIOL CHEM, V262, P4876; NIKAWA J, 1983, EUR J BIOCHEM, V131, P223, DOI 10.1111/j.1432-1033.1983.tb07253.x; NIKAWA J, 1993, MOL MICROBIOL, V10, P955, DOI 10.1111/j.1365-2958.1993.tb00967.x; NIKAWA J, 1981, BIOCHIM BIOPHYS ACTA, V665, P420, DOI 10.1016/0005-2760(81)90254-X; NIKAWA JI, 1982, EUR J BIOCHEM, V125, P445, DOI 10.1111/j.1432-1033.1982.tb06703.x; NIKOLOFF DM, 1994, J BIOL CHEM, V269, P7402; OVERMEYER JH, 1991, ARCH BIOCHEM BIOPHYS, V290, P511, DOI 10.1016/0003-9861(91)90574-3; PALTAUF F, 1992, MOL CELLULAR BIOL YE, P415; POOLE MA, 1986, J BACTERIOL, V168, P668, DOI 10.1128/jb.168.2.668-672.1986; QUINLAN JJ, 1992, J BIOL CHEM, V267, P18013; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; Shen HF, 1996, J BIOL CHEM, V271, P789, DOI 10.1074/jbc.271.2.789; SUMMERS EF, 1988, GENETICS, V120, P909; TALWALKAR RT, 1973, BIOCHIM BIOPHYS ACTA, V306, P412, DOI 10.1016/0005-2760(73)90180-X; TAYLOR FR, 1979, BIOCHIM BIOPHYS ACTA, V575, P204, DOI 10.1016/0005-2760(79)90022-5; TROTTER PJ, 1995, J BIOL CHEM, V270, P6071, DOI 10.1074/jbc.270.11.6071; TROTTER PJ, 1995, J BIOL CHEM, V270, P6062, DOI 10.1074/jbc.270.11.6062; TROTTER PJ, 1993, J BIOL CHEM, V268, P21416; TSUKAGOSHI Y, 1987, EUR J BIOCHEM, V169, P477, DOI 10.1111/j.1432-1033.1987.tb13635.x; WAECHTER CJ, 1973, ARCH BIOCHEM BIOPHYS, V158, P401, DOI 10.1016/0003-9861(73)90637-1; WISSING JB, 1993, FEBS LETT, V315, P95, DOI 10.1016/0014-5793(93)81141-L; Wu WI, 1996, J BIOL CHEM, V271, P1868, DOI 10.1074/jbc.271.4.1868; WU WI, 1995, J BIOL CHEM, V270, P13171, DOI 10.1074/jbc.270.22.13171; WU WI, 1994, J BIOL CHEM, V269, P29495; WU WI, 1993, J BIOL CHEM, V268, P13830; Wu WI, 1996, BIOCHEMISTRY-US, V35, P3790, DOI 10.1021/bi952808f; YAMASHITA S, 1980, EUR J BIOCHEM, V104, P611, DOI 10.1111/j.1432-1033.1980.tb04465.x; YAMASHITA S, 1982, EUR J BIOCHEM, V128, P589	105	142	145	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13293	13296		10.1074/jbc.271.23.13293	http://dx.doi.org/10.1074/jbc.271.23.13293			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663192	hybrid			2022-12-27	WOS:A1996UP38500001
J	Wu, YY; Bradshaw, RA				Wu, YY; Bradshaw, RA			Synergistic induction of neurite outgrowth by nerve growth factor or epidermal growth factor and interleukin-6 in PC12 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHEOCHROMOCYTOMA CELLS; GAP-43; GENE	Native PC12 cells respond differentially to nerve growth factor (NGF) but not interkeukin-6 (IL-6); PC12-E2 cells, a stable variant, respond to both stimuli (and more rapidly to NGF). Neither responds to epidermal growth factor (EGF), NGF primarily induces the RAS/extracellular signal-regulated kinase (ERK) pathway and IL-6 activates a JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) response. EGF also stimulates RAS/ERK but in a transient manner. When either cell type is treated with combinations of NGF, EGF, and IL-6, at concentrations that produce modest or no response, a substantial augmentation of neurite outgrowth is observed. With PC12-E2 cells, a subthreshold concentration of IL-6 increases NGF response by similar to-3-fold after 1-2 days; the increase with EGF is more pronounced. Native PC12 cells show even greater synergistic effects with NGF and IL-6. The most dramatic effect was observed with low levels of EGF, where IL-6 increased the percentage of responsive cells from zero to similar to 60% after 3 days. In addition, two neural specific transcripts, GAP-43 and SCG-10, are synergistically increased by the combinations of growth factors. Importantly, IL-6 does not enhance ERK phosphorylation in the presence of either NGF or EGF. In contrast, NGF and EGF, in the presence or absence of IL-6, cause mobility shifts of Stat3 that are consistent with serine phosphorylations. Although these modifications do not lead to activation and translocation by themselves, in the presence of the tyrosine phosphorylation induced by IL-6, they may play a role in the synergistic responses. These observations suggest a differentially regulated two-stage mechanism for the differentiative response of PC12 cells to NGF.	UNIV CALIF IRVINE,COLL MED,DEPT BIOL CHEM,IRVINE,CA 92717	University of California System; University of California Irvine			Bradshaw, Ralph A/K-1515-2013		NIA NIH HHS [AG09735] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [R01AG009735] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALTIN JG, 1991, J BIOL CHEM, V266, P5401; BASI GS, 1987, CELL, V49, P785, DOI 10.1016/0092-8674(87)90616-7; BOULTON TG, 1995, P NATL ACAD SCI USA, V92, P6915, DOI 10.1073/pnas.92.15.6915; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; Decker SJ, 1995, J BIOL CHEM, V270, P30841, DOI 10.1074/jbc.270.52.30841; DOBASHI Y, 1995, J BIOL CHEM, V270, P23031, DOI 10.1074/jbc.270.39.23031; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FEDEROFF HJ, 1988, J BIOL CHEM, V263, P19290; Glass David J., 1993, Trends in Cell Biology, V3, P262, DOI 10.1016/0962-8924(93)90054-5; GLOWACKA D, 1990, J NEUROSCI RES, V25, P453, DOI 10.1002/jnr.490250403; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Greene LA., 1982, ADV CELL NEUROBIOL, V3, P373, DOI [10.1016/B978-0-12-008303-9.50016-5, DOI 10.1016/B978-0-12-008303-9.50016-5]; GUSCHIN D, 1995, EMBO J, V14, P1421, DOI 10.1002/j.1460-2075.1995.tb07128.x; HONDERMARCK H, 1994, P NATL ACAD SCI USA, V91, P9377, DOI 10.1073/pnas.91.20.9377; HOPKINS SJ, 1995, TRENDS NEUROSCI, V18, P83; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; Ihle JN, 1996, CELL, V84, P331, DOI 10.1016/S0092-8674(00)81277-5; Leaman DW, 1996, MOL CELL BIOL, V16, P369; LOTAN M, 1994, FASEB J, V8, P1026, DOI 10.1096/fasebj.8.13.7926367; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MITSUMOTO H, 1994, SCIENCE, V265, P1107, DOI 10.1126/science.8066451; MURPHY PG, 1995, J NEUROSCI, V15, P5130; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; PENG X, 1995, NEURON, V15, P3395; RAFFIONI S, 1995, J BIOL CHEM, V270, P7568, DOI 10.1074/jbc.270.13.7568; ROTHWELL NJ, 1995, TRENDS NEUROSCI, V18, P130, DOI 10.1016/0166-2236(95)93890-A; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; STAHL N, 1994, SCIENCE, V263, P92, DOI 10.1126/science.8272873; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; STEIN R, 1988, DEV BIOL, V127, P316, DOI 10.1016/0012-1606(88)90318-1; TENG KK, 1995, J BIOL CHEM, V270, P20677, DOI 10.1074/jbc.270.35.20677; VAILLANCOURT RR, 1995, MOL CELL BIOL, V15, P3644; WEN ZL, 1995, CELL, V82, P241, DOI 10.1016/0092-8674(95)90311-9; WILDER RL, 1995, ANNU REV IMMUNOL, V13, P307; WU YY, 1995, J CELL PHYSIOL, V164, P522, DOI 10.1002/jcp.1041640310; WU YY, 1993, J CELL BIOL, V121, P409, DOI 10.1083/jcb.121.2.409; Wu YY, 1996, J BIOL CHEM, V271, P13023, DOI 10.1074/jbc.271.22.13023; YAN GZ, 1995, J NEUROSCI, V15, P6200; ZHANG XK, 1995, SCIENCE, V267, P1990, DOI 10.1126/science.7701321	41	69	74	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13033	13039		10.1074/jbc.271.22.13033	http://dx.doi.org/10.1074/jbc.271.22.13033			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662831	hybrid			2022-12-27	WOS:A1996UN47400055
J	Muller, K; Gombert, FO; Manning, U; Grossmuller, F; Graff, P; Zaegel, H; Zuber, JF; Freuler, F; Tschopp, C; Baumann, G				Muller, K; Gombert, FO; Manning, U; Grossmuller, F; Graff, P; Zaegel, H; Zuber, JF; Freuler, F; Tschopp, C; Baumann, G			Rapid identification of phosphopeptide ligands for SH2 domains - Screening of peptide libraries by fluorescence-activated bead sorting	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR RECEPTOR; SRC HOMOLOGY-2 DOMAIN; SIGNAL-TRANSDUCTION; TYROSINE KINASES; ADAPTER PROTEIN; BINDING; GRB2; RAS; PHOSPHATASE; AFFINITY	A method for the identification of high-affinity ligands to SH2 domains by fluorescence-activated bead sorting (FABS) was established, Recombinant SH2 domains, expressed as glutathione S-transferase (GST) fusion proteins, were incubated with a phosphotyrosine (Y*) containing peptide library, 6.4 x 10(5) individual peptides of nine amino acids in length (EPX(6)Y*X(19)X(7)X(19)X(7)X(6)) were each displayed on beads, Phosphopeptide interaction of a given SH2 domain was monitored by binding of fluorescein isothiocyanate-labeled antibodies directed against GST. High-fluorescence beads were isolated by flow cytometric sorting, Subsequent pool sequencing of the selected beads revealed a distinct pattern of phosphotyrosine-containing motifs for each individual SH2 domain: the SH2 domain of the adapter protein Grb2 predominantly selected beads with the sequence Y*ENDP, whereas the C-terminal SH2 domain of the tyrosine kinase Syk, selected Y*EELD, each motif representing the most frequently found residues C-terminal to the phosphotyrosine, For deconvolution studies, soluble phosphopeptides comprising variations of the Grb2 motifs were resynthesized and analyzed by surface plasmon resonance.	SANDOZ PHARMA LTD, PRECLIN RES, CH-4002 BASEL, SWITZERLAND	Novartis; Sandoz				GOMBERT, Frank Otto/0000-0002-7507-697X				BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BAUMANN G, 1994, EUR J IMMUNOL, V24, P1799, DOI 10.1002/eji.1830240812; BENNETT AM, 1994, P NATL ACAD SCI USA, V91, P7335, DOI 10.1073/pnas.91.15.7335; BOOKER GW, 1992, NATURE, V358, P684, DOI 10.1038/358684a0; BU JY, 1995, P NATL ACAD SCI USA, V92, P5106, DOI 10.1073/pnas.92.11.5106; CAMBIER JC, 1994, ANNU REV IMMUNOL, V12, P457, DOI 10.1146/annurev.immunol.12.1.457; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; CUSSAC D, 1994, EMBO J, V13, P4011, DOI 10.1002/j.1460-2075.1994.tb06717.x; DEFRANCO AL, 1995, CURR OPIN CELL BIOL, V7, P163, DOI 10.1016/0955-0674(95)80024-7; ECK MJ, 1993, NATURE, V362, P87, DOI 10.1038/362087a0; FANTL WJ, 1992, CELL, V69, P413, DOI 10.1016/0092-8674(92)90444-H; FIXMAN ED, 1995, ONCOGENE, V10, P237; FURKA A, 1991, INT J PEPT PROT RES, V37, P487, DOI 10.1111/j.1399-3011.1991.tb00765.x; HELLBERG S, 1987, J MED CHEM, V30, P1126, DOI 10.1021/jm00390a003; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; LADBURY JE, 1995, P NATL ACAD SCI USA, V92, P3199, DOI 10.1073/pnas.92.8.3199; LAM KS, 1991, NATURE, V354, P82, DOI 10.1038/354082a0; LAW CL, 1994, J BIOL CHEM, V269, P12310; LEE CH, 1994, STRUCTURE, V2, P423, DOI 10.1016/S0969-2126(00)00044-7; LEMMON MA, 1994, BIOCHEMISTRY-US, V33, P5070, DOI 10.1021/bi00183a010; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; MARENGERE LEM, 1994, NATURE, V369, P502, DOI 10.1038/369502a0; MULLER W, 1992, FLOW CYTOMETRY CELL, P27; NEEDELS MC, 1993, P NATL ACAD SCI USA, V90, P10700, DOI 10.1073/pnas.90.22.10700; OHLMEYER MHJ, 1993, P NATL ACAD SCI USA, V90, P10922, DOI 10.1073/pnas.90.23.10922; OVERDUIN M, 1992, CELL, V70, P697, DOI 10.1016/0092-8674(92)90437-H; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PAWSON T, 1992, CELL, V71, P359, DOI 10.1016/0092-8674(92)90504-6; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PENDERGAST AM, 1993, CELL, V75, P175, DOI 10.1016/S0092-8674(05)80094-7; PUIL L, 1994, EMBO J, V13, P764, DOI 10.1002/j.1460-2075.1994.tb06319.x; RUSSELL RB, 1992, FEBS LETT, V304, P15, DOI 10.1016/0014-5793(92)80579-6; SCHLAEPFER DD, 1994, NATURE, V372, P786; SIERKE SL, 1993, BIOCHEM BIOPH RES CO, V191, P45, DOI 10.1006/bbrc.1993.1182; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; STEVANOVIC S, 1993, ANAL BIOCHEM, V212, P212, DOI 10.1006/abio.1993.1314; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WAKSMAN G, 1992, NATURE, V358, P646, DOI 10.1038/358646a0; WIENANDS J, 1995, INT IMMUNOL, V7, P1701, DOI 10.1093/intimm/7.11.1701; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	42	61	63	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16500	16505						6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663178				2022-12-27	WOS:A1996UX12600014
J	Romagnolo, B; Cluzeaud, F; Lambert, M; Colnot, S; Porteu, A; Molina, T; Tomasset, M; Vandewalle, A; Kahn, A; Perret, C				Romagnolo, B; Cluzeaud, F; Lambert, M; Colnot, S; Porteu, A; Molina, T; Tomasset, M; Vandewalle, A; Kahn, A; Perret, C			Tissue-specific and hormonal regulation of Calbindin-D9K fusion genes in transgenic mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; VITAMIN-D; RAT UTERUS; MESSENGER-RNA; TRANSCRIPTIONAL REGULATION; INSITU DETECTION; GUT EPITHELIUM; YOLK-SAC; EXPRESSION; ESTROGEN	The rat Calbindin-D9K (CaBP9K) gene is mainly expressed in intestine, uterus, and lung and is regulated in a complex tissue specific manner. To analyze the role of potential regulatory elements, previously defined by DNaseI hypersensivity, we made transgenic mice containing truncated rat CaBP9K fusion gene with simian virus 40 large T antigen and the chloramphenicol acetyltransferase as reporter genes. The transgenes contained CaBP9K promoter fragments with 5' end points at -4400, -1011, and -117 base pairs (bp), whereas the 3' end points was at +365 bp. Northern blot analysis of T antigen expression and chloramphenicol acetyltransferase enzyme-linked immunosorbent assay indicated that a positive element, probably the distal intestine-specific DNaseI HS, necessary to target the expression of the transgene in the intestine, is present between -4400 and -1011 bp. The cephalo-caudal gradient of expression of the transgene along the small intestine was similar to those of the endogenous gene, but an ectopic expression of the transgene was observed in the colon. The -1011 transgene was expressed in epithelial alveolar cells of the lung, in renal proximal tubule cells, and in uterine myometrium, as judged from immunocytochemical, histological, and Northern blot analyses. The shortest, -117 construct was only expressed in uterine myometrium, and it was under a strict estrogen dependence like the endogenous gene. Finally,res ness to vitamin D in the duodenum was observed with the largest, -4400 construct, Thus, different tissues utilize distinct cis-acting elements to direct and regulate the expression of the rat CaBP9K gene.	UNIV PARIS 05,INST COCHIN GENET MOLEC,INSERM U129,F-75014 PARIS,FRANCE; HOP ROBERT DEBRE,INSERM U120,F-75019 PARIS,FRANCE; LAB UNIV RECH HISTOPATHOL,F-75006 PARIS,FRANCE; UNIV PARIS 07,INST FEDERAT RECH,INSERM U246,F-75780 PARIS 18,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Robert-Debre - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite; Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite			Colnot, Sabine/A-9169-2008; Perret-Mayeux, Christine/L-3297-2017; Romagnolo, Béatrice/D-5017-2017; Molina, Thierry/ABA-5214-2020	Colnot, Sabine/0000-0002-3949-9107; Romagnolo, Béatrice/0000-0001-8772-3604; Molina, Thierry/0000-0002-3929-9754; perret, christine/0000-0003-4710-7051				ARMBRECHT HJ, 1989, ENDOCRINOLOGY, V125, P2950, DOI 10.1210/endo-125-6-2950; BERGER U, 1988, J CLIN ENDOCR METAB, V67, P607, DOI 10.1210/jcem-67-3-607; BONIFER C, 1990, EMBO J, V9, P2843, DOI 10.1002/j.1460-2075.1990.tb07473.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROOKS AR, 1994, MOL CELL BIOL, V14, P2243, DOI 10.1128/MCB.14.4.2243; BRUNS MEH, 1985, ANAT REC, V213, P514, DOI 10.1002/ar.1092130406; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHRISTAKOS S, 1991, ENDOCR REV, V10, P3; COHN SM, 1992, J CELL BIOL, V119, P27, DOI 10.1083/jcb.119.1.27; CROSSMAN MW, 1994, J CELL BIOL, V126, P1547, DOI 10.1083/jcb.126.6.1547; CUIF MH, 1992, MOL CELL BIOL, V12, P4852, DOI 10.1128/MCB.12.11.4852; DARWISH H, 1991, J BIOL CHEM, V266, P551; DARWISH HM, 1992, P NATL ACAD SCI USA, V89, P603, DOI 10.1073/pnas.89.2.603; DELORME AC, 1983, ENDOCRINOLOGY, V113, P1340, DOI 10.1210/endo-113-4-1340; DUPRET JM, 1992, ENDOCRINOLOGY, V131, P2643, DOI 10.1210/en.131.6.2643; DUPRET JM, 1987, J BIOL CHEM, V262, P16553; GALLAGHER JC, 1979, J CLIN INVEST, V64, P729, DOI 10.1172/JCI109516; GANSS R, 1994, EMBO J, V13, P3083, DOI 10.1002/j.1460-2075.1994.tb06607.x; GARLAND C, 1985, LANCET, V1, P307, DOI 10.1016/S0140-6736(85)91082-7; GARLAND CF, 1991, AM J CLIN NUTR, V54, P193; GLASS CK, 1994, ENDOCR REV, V15, P391, DOI 10.1210/er.15.3.391; GODBOUT R, 1988, GENE DEV, V2, P949, DOI 10.1101/gad.2.8.949; LHORSET F, 1994, ENDOCRINOLOGY, V134, P11, DOI 10.1210/en.134.1.11; LHORSET F, 1993, ENDOCRINOLOGY, V132, P489, DOI 10.1210/en.132.2.489; LI H, 1991, ENDOCRINOLOGY, V128, P2844, DOI 10.1210/endo-128-6-2844; LI S, 1994, MOL ENDOCRINOL, V8, P1328, DOI 10.1210/me.8.10.1328; MARKOWITZ AJ, 1993, AM J PHYSIOL, V265, pG526, DOI 10.1152/ajpgi.1993.265.3.G526; MATHIEU CL, 1989, P NATL ACAD SCI USA, V86, P3433, DOI 10.1073/pnas.86.9.3433; PERRET C, 1991, GENE, V108, P227, DOI 10.1016/0378-1119(91)90438-H; PERRET C, 1985, EUR J BIOCHEM, V150, P211, DOI 10.1111/j.1432-1033.1985.tb09009.x; PERRET C, 1988, EUR J BIOCHEM, V172, P43, DOI 10.1111/j.1432-1033.1988.tb13853.x; PINKERT CA, 1987, GENE DEV, V1, P268, DOI 10.1101/gad.1.3.268; ROTTMAN JN, 1993, J BIOL CHEM, V268, P11994; SAMBROOK J, 1993, MOL CLONING LAB MANU; SANDGREN ME, 1991, BIOCHEM BIOPH RES CO, V181, P611, DOI 10.1016/0006-291X(91)91234-4; SCHREINER DS, 1983, ACTA ANAT, V117, P1; THOMASSET M, 1982, AM J PHYSIOL, V243, pE483, DOI 10.1152/ajpendo.1982.243.6.E483; THOMASSET M, 1996, EUR J BIOCHEM, V236, P778; WADA L, 1992, AM J PHYSIOL, V235, pE338; WAREMBOURG M, 1986, J HISTOCHEM CYTOCHEM, V34, P277, DOI 10.1177/34.2.3753716; WAREMBOURG M, 1987, CELL TISSUE RES, V247, P51, DOI 10.1007/BF00216546; WIKENHEISER KA, 1992, CANCER RES, V52, P5342	42	31	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16820	16826		10.1074/jbc.271.28.16820	http://dx.doi.org/10.1074/jbc.271.28.16820			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663193	hybrid			2022-12-27	WOS:A1996UX12600062
J	Grondin, B; Bazinet, M; Aubry, M				Grondin, B; Bazinet, M; Aubry, M			The KRAB zinc finger gene ZNF74 encodes an RNA-binding protein tightly associated with the nuclear matrix	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARDIO-FACIAL SYNDROME; TUMOR SUPPRESSOR WT1; PRE-MESSENGER-RNA; DIGEORGE-SYNDROME; TRANSCRIPTION FACTOR; XENOPUS OOCYTES; DELETIONS; DOMAINS; FAMILY; TFIIIA	We previously cloned ZNF74, a developmentally expressed zinc finger gene commonly deleted in DiGeorge syndrome. Here, the intron/exon organization of the human gene and the functional properties of the expressed protein are presented. This zinc finger gene from the transcription factor IIIA/Kruppel family contains three exons. A truncated Kruppel-associated box (KRAB) located at the N terminus of the predicted 64-kDa zinc finger protein is encoded by exon 2. The remainder of the protein including the zinc finger domain as well as the 3'-untranslated region (UTR) is encoded by exon 3. Both 5'-UTR (exon 1) and 3'-UTR contain repetitive Alu elements. In vitro translation of a cDNA encoding the entire ZNF74 coding region produced a 63-kDa protein as determined on sodium dodecyl sulfate-polyacrylamide gel. A bacterially expressed fusion protein shown to bind tightly to (65)zinc was used to test the nucleic acid binding properties of ZNF74. By RNA binding assays, ZNF74 was found to bind specifically to poly(U) and poly(G) RNA homopolymers. The restricted binding to these homopolymers and not to poly(A) and poly(C) suggested that ZNF74 displays RNA sequence preferences. RNA binding was mediated by the zinc finger domain. Immunofluorescence studies on transfected cells revealed ZNF74 nuclear localization. The labeling pattern observed in the nuclei clearly excluded the nucleoli. The zinc finger region lacks a classical nuclear localization signal but was found to be responsible for nuclear targeting, Subcellular and in situ sequential fractionations further showed that ZNF74 is associated with the nuclear matrix. The RNA binding properties of this protein and its tight association with the nuclear matrix, a subnuclear compartment involved in DNA replication as well as RNA synthesis and processing, suggest a role for ZNF74 in RNA metabolism.	UNIV MONTREAL, INST RECH CLIN MONTREAL, MONTREAL, PQ H2W 1R7, CANADA	Institut de Recherche Clinique de Montreal (IRCM); Universite de Montreal								ANDREAZZOLI M, 1993, NUCLEIC ACIDS RES, V21, P4218, DOI 10.1093/nar/21.18.4218; ASCOLI CA, 1991, J CELL BIOL, V112, P785, DOI 10.1083/jcb.112.5.785; AUBRY M, 1993, HUM MOL GENET, V2, P1583, DOI 10.1093/hmg/2.10.1583; BARDWELL VJ, 1994, GENE DEV, V8, P1664, DOI 10.1101/gad.8.14.1664; BELLEFROID EJ, 1991, P NATL ACAD SCI USA, V88, P3608, DOI 10.1073/pnas.88.9.3608; BELLEFROID EJ, 1993, EMBO J, V12, P1363, DOI 10.1002/j.1460-2075.1993.tb05781.x; BISOTTO S, 1995, J CELL SCI, V108, P1873; BOULIKAS T, 1994, J CELL BIOCHEM, V55, P32, DOI 10.1002/jcb.240550106; Boulikas Teni, 1993, Critical Reviews in Eukaryotic Gene Expression, V3, P193; BREEUWER M, 1990, CELL, V60, P999, DOI 10.1016/0092-8674(90)90348-I; BUDARF ML, 1995, NAT GENET, V10, P269, DOI 10.1038/ng0795-269; BURN J, 1993, J MED GENET, V30, P822, DOI 10.1136/jmg.30.10.822; CHANG KS, 1995, BLOOD, V85, P3646, DOI 10.1182/blood.V85.12.3646.bloodjournal85123646; CHOWDHURY K, 1987, CELL, V48, P771, DOI 10.1016/0092-8674(87)90074-2; COCKERILL PN, 1986, CELL, V44, P273, DOI 10.1016/0092-8674(86)90761-0; COLBEREGARAPIN F, 1983, DEV BIOLOGICALS, V55, P267; DEMCZUK S, 1995, HUM MOL GENET, V4, P551, DOI 10.1093/hmg/4.4.551; DESHAZER D, 1994, BIOTECHNIQUES, V17, P288; DRISCOLL DA, 1992, AM J MED GENET, V44, P261, DOI 10.1002/ajmg.1320440237; DRUMMOND IA, 1992, SCIENCE, V257, P674, DOI 10.1126/science.1323141; DYCK JA, 1994, CELL, V76, P333, DOI 10.1016/0092-8674(94)90340-9; FABRE E, 1994, CURR OPIN CELL BIOL, V6, P335, DOI 10.1016/0955-0674(94)90023-X; FIBISON WJ, 1990, AM J HUM GENET, V46, P888; FISCHER U, 1994, J CELL BIOL, V125, P971, DOI 10.1083/jcb.125.5.971; GASHLER AL, 1992, P NATL ACAD SCI USA, V89, P10984, DOI 10.1073/pnas.89.22.10984; GLOVER TW, 1995, NAT GENET, V10, P257, DOI 10.1038/ng0795-257; GREENBERG F, 1988, AM J HUM GENET, V43, P605; GUDDAT U, 1990, CELL, V60, P619, DOI 10.1016/0092-8674(90)90665-2; GUIOCHONMANTEL A, 1994, P NATL ACAD SCI USA, V91, P7179, DOI 10.1073/pnas.91.15.7179; HAGEN G, 1994, EMBO J, V13, P3843, DOI 10.1002/j.1460-2075.1994.tb06695.x; HALFORD S, 1993, HUM MOL GENET, V2, P1577, DOI 10.1093/hmg/2.10.1577; HALFORD S, 1993, HUM MOL GENET, V2, P2099, DOI 10.1093/hmg/2.12.2099; HAMM J, 1990, CELL, V62, P569, DOI 10.1016/0092-8674(90)90021-6; HE DC, 1990, J CELL BIOL, V110, P569, DOI 10.1083/jcb.110.3.569; HEISTERKAMP N, 1995, GENOMICS, V29, P451, DOI 10.1006/geno.1995.9982; HOZAK P, 1995, J CELL SCI, V108, P635; HOZAK P, 1993, CELL, V73, P361, DOI 10.1016/0092-8674(93)90235-I; JACKSON DA, 1993, EMBO J, V12, P1059, DOI 10.1002/j.1460-2075.1993.tb05747.x; KALNINS A, 1983, EMBO J, V2, P593, DOI 10.1002/j.1460-2075.1983.tb01468.x; KAPELNER SN, 1994, BIOTECHNIQUES, V17, P64; KARAYIORGOU P, 1995, P NATL ACAD SCI USA, V92, P7612, DOI 10.1073/pnas.92.17.7612; KLOCKE B, 1994, BBA-GENE STRUCT EXPR, V1217, P81; KLUG A, 1995, FASEB J, V9, P597, DOI 10.1096/fasebj.9.8.7768350; KNOCHEL W, 1989, P NATL ACAD SCI USA, V86, P6097, DOI 10.1073/pnas.86.16.6097; KOSTER M, 1991, EMBO J, V10, P3087, DOI 10.1002/j.1460-2075.1991.tb07861.x; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KURAHASHI H, 1995, HUM MOL GENET, V4, P541, DOI 10.1093/hmg/4.4.541; LACASSE EC, 1995, NUCLEIC ACIDS RES, V23, P1647, DOI 10.1093/nar/23.10.1647; MAKOWSKI GS, 1991, BIOL TRACE ELEM RES, V29, P93, DOI 10.1007/BF03032687; Maniatis T., 1982, MOL CLONING; MARGOLIN JF, 1994, P NATL ACAD SCI USA, V91, P4509, DOI 10.1073/pnas.91.10.4509; MARINEAU C, 1992, NUCLEIC ACIDS RES, V20, P1430, DOI 10.1093/nar/20.6.1430; MCBRYANT SJ, 1995, J MOL BIOL, V248, P44, DOI 10.1006/jmbi.1995.0201; MILLER J, 1985, EMBO J, V4, P1609, DOI 10.1002/j.1460-2075.1985.tb03825.x; MOLNAR G, 1994, MOL CELL BIOL, V14, P5242, DOI 10.1128/MCB.14.8.5242; NICKERSON JA, 1992, J CELL BIOL, V116, P977, DOI 10.1083/jcb.116.4.977; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; NUMOTO M, 1993, NUCLEIC ACIDS RES, V21, P3767, DOI 10.1093/nar/21.16.3767; PELHAM HRB, 1980, P NATL ACAD SCI-BIOL, V77, P4170, DOI 10.1073/pnas.77.7.4170; PENGUE G, 1994, NUCLEIC ACIDS RES, V22, P2908, DOI 10.1093/nar/22.15.2908; PENMAN S, 1995, P NATL ACAD SCI USA, V92, P5251, DOI 10.1073/pnas.92.12.5251; PIELER T, 1994, MOL BIOL REP, V20, P1, DOI 10.1007/BF00999848; PREDKI PF, 1995, CELL, V80, P41, DOI 10.1016/0092-8674(95)90449-2; RIGGS P, 1994, CURRENT PROTOCOLS MO; ROSATI M, 1991, NUCLEIC ACIDS RES, V19, P5661, DOI 10.1093/nar/19.20.5661; SCAMBLER PJ, 1992, LANCET, V339, P1138, DOI 10.1016/0140-6736(92)90734-K; SCHUH R, 1986, CELL, V47, P1025, DOI 10.1016/0092-8674(86)90817-2; SILVER PA, 1991, CELL, V64, P489, DOI 10.1016/0092-8674(91)90233-O; SIOMI H, 1995, J CELL BIOL, V129, P551, DOI 10.1083/jcb.129.3.551; SPECTOR DL, 1991, EMBO J, V10, P3467, DOI 10.1002/j.1460-2075.1991.tb04911.x; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; THEUNISSEN O, 1992, CELL, V71, P679, DOI 10.1016/0092-8674(92)90601-8; VANWIJK I, 1992, MECH DEVELOP, V39, P63, DOI 10.1016/0925-4773(92)90026-G; VINCENT A, 1986, NUCLEIC ACIDS RES, V14, P4385, DOI 10.1093/nar/14.11.4385; VISSING H, 1995, FEBS LETT, V369, P153, DOI 10.1016/0014-5793(95)00728-R; WAN KM, 1994, P NATL ACAD SCI USA, V91, P594, DOI 10.1073/pnas.91.2.594; WANG J, 1991, P NATL ACAD SCI USA, V88, P7391, DOI 10.1073/pnas.88.16.7391; WANSINK DG, 1993, J CELL BIOL, V122, P283, DOI 10.1083/jcb.122.2.283; WEIS K, 1994, CELL, V76, P345, DOI 10.1016/0092-8674(94)90341-7; WILSON DI, 1992, LANCET, V340, P573, DOI 10.1016/0140-6736(92)92107-Q; WILSON DI, 1991, BRIT HEART J, V66, P308; WILSON DI, 1993, J MED GENET, V30, P852, DOI 10.1136/jmg.30.10.852; WITZGALL R, 1993, MOL CELL BIOL, V13, P1933, DOI 10.1128/MCB.13.3.1933; WITZGALL R, 1994, P NATL ACAD SCI USA, V91, P4514, DOI 10.1073/pnas.91.10.4514; ZAHS KR, 1993, GLIA, V7, P121, DOI 10.1002/glia.440070202; ZANG WQ, 1995, J MOL BIOL, V245, P549, DOI 10.1006/jmbi.1994.0045	86	59	65	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15458	15467		10.1074/jbc.271.26.15458	http://dx.doi.org/10.1074/jbc.271.26.15458			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663113	hybrid			2022-12-27	WOS:A1996UV29900026
J	Hoffmann, JS; Pillaire, MJ; GarciaEstefania, D; Lapalu, S; Villani, G				Hoffmann, JS; Pillaire, MJ; GarciaEstefania, D; Lapalu, S; Villani, G			In vitro bypass replication of the cisplatin-d(GpG) lesion by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase is highly mutagenic	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN CELL-EXTRACTS; FRAMESHIFT MUTAGENESIS; ANGSTROM RESOLUTION; CRYSTAL-STRUCTURE; STRANDED-DNA; INVITRO; FIDELITY; CIS-DIAMMINEDICHLOROPLATINUM(II); MISALIGNMENT; SPECIFICITY	Eukaryotic DNA polymerase beta and the reverse transcriptases are the most inaccurate of the known DNA polymerases. We report here mutagenic replication in vitro past intrastrand N(7)G-N(7)G chelates of the cis-diamminedichloroplatinum(II), the major DNA adduct of the antitumor agent cisplatin by calf thymus DNA polymerase beta and human immunodeficiency virus type I reverse transcriptase (42% and 26% mutations, respectively). The most frequent modifications generated by both enzymes were one-base frameshift deletions. Only one mutational hot spot opposite the platinated guanines was observed with human immunodeficiency virus type I reverse transcriptase, while two hot spots were generated by DNA polymerase beta, one at the base situated 5' to the lesion and the other situated 4-6 nucleotides 5' to the adduct. An unusual mutagenic event, tandem replication of a 12-base pair sequence, was observed with DNA polymerase beta. The mutational spectra of the two DNA polymerases suggest that template slip page occurred with higher frequency in the presence of the more distributive DNA polymerase beta.	ECOLE NORMALE SUPER LYON,F-69364 LYON 07,FRANCE	Ecole Normale Superieure de Lyon (ENS de LYON)	Hoffmann, JS (corresponding author), CNRS,INST PHARMACOL & BIOL STRUCT,205 ROUTE NARBONNE,F-31077 TOULOUSE,FRANCE.		Hoffmann, Jean-Sebastien/O-9183-2014; Pillaire, Marie-Jeanne/P-1579-2014	Hoffmann, Jean-Sebastien/0000-0003-2222-354X; Pillaire, Marie-Jeanne/0000-0001-6866-7416				BEBENEK K, 1993, J BIOL CHEM, V268, P10324; BEBENEK K, 1995, J BIOL CHEM, V270, P19516, DOI 10.1074/jbc.270.33.19516; BEBENEK K, 1989, J BIOL CHEM, V264, P16948; BELGUISEVALLADIER P, 1994, J MOL BIOL, V236, P151, DOI 10.1006/jmbi.1994.1125; BOYER JC, 1992, P NATL ACAD SCI USA, V89, P6919, DOI 10.1073/pnas.89.15.6919; CALSOU P, 1992, NUCLEIC ACIDS RES, V20, P6363, DOI 10.1093/nar/20.23.6363; CHANG LMS, 1973, J BIOL CHEM, V248, P3789; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; GREENE MH, 1992, J NATL CANCER I, V84, P306, DOI 10.1093/jnci/84.5.306; HERMAN F, 1990, EUR J BIOCHEM, V194, P119, DOI 10.1111/j.1432-1033.1990.tb19435.x; HOFFMANN JS, 1989, J BIOL CHEM, V264, P15130; HOFFMANN JS, 1995, P NATL ACAD SCI USA, V92, P5356, DOI 10.1073/pnas.92.12.5356; HUANG JC, 1994, P NATL ACAD SCI USA, V91, P10394, DOI 10.1073/pnas.91.22.10394; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; HUBER HE, 1989, J BIOL CHEM, V264, P4669; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JI JP, 1992, BIOCHEMISTRY-US, V31, P954, DOI 10.1021/bi00119a002; KADYK LC, 1993, GENETICS, V133, P469; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; KUNKEL TA, 1985, J BIOL CHEM, V260, P2866; KUNKEL TA, 1986, J BIOL CHEM, V261, P3581; KUNKEL TA, 1986, J BIOL CHEM, V261, P160; KUNKEL TA, 1990, BIOCHEMISTRY-US, V29, P8003, DOI 10.1021/bi00487a001; LAMBERT IB, 1992, P NATL ACAD SCI USA, V89, P1310, DOI 10.1073/pnas.89.4.1310; LOEHRER PJ, 1984, ANN INTERN MED, V100, P704, DOI 10.7326/0003-4819-100-5-704; NAEGELI H, 1994, BIOESSAYS, V16, P1; ODAY CL, 1992, NUCLEIC ACIDS RES, V20, P5403, DOI 10.1093/nar/20.20.5403; PERRINO FW, 1989, P NATL ACAD SCI USA, V86, P8343, DOI 10.1073/pnas.86.21.8343; PILLAIRE MJ, 1994, NUCLEIC ACIDS RES, V22, P2519, DOI 10.1093/nar/22.13.2519; PRESTON BD, 1988, SCIENCE, V242, P1168, DOI 10.1126/science.2460924; REARDON JE, 1993, J BIOL CHEM, V268, P8743; RIPLEY LS, 1990, ANNU REV GENET, V24, P189, DOI 10.1146/annurev.ge.24.120190.001201; ROBERTS JD, 1989, MOL CELL BIOL, V9, P469, DOI 10.1128/MCB.9.2.469; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SAWAYA MR, 1994, SCIENCE, V264, P1930, DOI 10.1126/science.7516581; SHERMAN SE, 1987, CHEM REV, V87, P1153, DOI 10.1021/cr00081a013; SINGHAL RK, 1993, J BIOL CHEM, V268, P15906; SPIVAK G, 1992, BIOCHEMISTRY-US, V31, P6794, DOI 10.1021/bi00144a021; SZYMKOWSKI DE, 1992, P NATL ACAD SCI USA, V89, P10772, DOI 10.1073/pnas.89.22.10772; WANG CI, 1992, BIOCHEMISTRY-US, V31, P3671, DOI 10.1021/bi00129a016; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513	41	54	58	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15386	15392		10.1074/jbc.271.26.15386	http://dx.doi.org/10.1074/jbc.271.26.15386			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663082	hybrid			2022-12-27	WOS:A1996UV29900016
J	Godde, JS; Wolffe, AP				Godde, JS; Wolffe, AP			Nucleosome assembly on CTG triplet repeats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RNA POLYMERASE-II; MYOTONIC-DYSTROPHY; HISTONE OCTAMER; MESSENGER-RNA; CORE PARTICLE; 5S RNA; DNA; GENE; TRANSCRIPTION; INITIATION	Expansion of CTG repeat sequences is associated with several human genetic diseases. We have examined the consequences of CTG repeat expansion for nucleosome assembly and positioning. Short CTG repeats are found within the most favored DNA sequences yet defined for nucleosome assembly. We find that as few as six CTG repeats will facilitate nucleosome assembly to a similar extent as the 50 or more repeats found in disease genes. Thus an increase in nucleosome stability on expansion of existing triplet repeats is unlikely to explain the acquisition of the disease phenotype. However, the CTG repeat sequence is efficiently wrapped around the histone octamer, preferring to associate with histones at the nucleosomal dyad. Thus short segments CTG; repeat sequence will facilitate the assembly of a stable positioned nucleosome which might contribute to the expansion phenomenon and the functional organization of chromatin.			Godde, JS (corresponding author), NICHHD,MOLEC EMBRYOL LAB,NIH,BETHESDA,MD 20892, USA.							ARENTS G, 1993, P NATL ACAD SCI USA, V90, P10489, DOI 10.1073/pnas.90.22.10489; BATES G, 1994, BIOESSAYS, V16, P277, DOI 10.1002/bies.950160411; BROOK JD, 1992, CELL, V68, P799, DOI 10.1016/0092-8674(92)90154-5; BURRIGHT EN, 1995, CELL, V82, P937, DOI 10.1016/0092-8674(95)90273-2; CAMERINIOTERO RD, 1976, CELL, V8, P333, DOI 10.1016/0092-8674(76)90145-8; CARANGO P, 1993, GENOMICS, V18, P340, DOI 10.1006/geno.1993.1474; Chastain PD, 1995, BIOCHEMISTRY-US, V34, P16125, DOI 10.1021/bi00049a027; DONG F, 1991, P NATL ACAD SCI USA, V88, P10596, DOI 10.1073/pnas.88.23.10596; DONG F, 1990, P NATL ACAD SCI USA, V87, P5724, DOI 10.1073/pnas.87.15.5724; DREW HR, 1985, J MOL BIOL, V186, P773, DOI 10.1016/0022-2836(85)90396-1; FITZGERALD PC, 1985, J BIOL CHEM, V260, P5318; FU YH, 1992, SCIENCE, V255, P1256, DOI 10.1126/science.1546326; FU YH, 1993, SCIENCE, V260, P235, DOI 10.1126/science.8469976; GACY AM, 1995, CELL, V81, P533; GODDE JS, 1995, NUCLEIC ACIDS RES, V23, P4557, DOI 10.1093/nar/23.22.4557; HARLEY HG, 1992, NATURE, V355, P545, DOI 10.1038/355545a0; HAYES JJ, 1991, BIOCHEMISTRY-US, V30, P8434, DOI 10.1021/bi00098a022; HAYES JJ, 1990, P NATL ACAD SCI USA, V87, P7405, DOI 10.1073/pnas.87.19.7405; HAYES JJ, 1991, P NATL ACAD SCI USA, V88, P6829, DOI 10.1073/pnas.88.15.6829; HOFMANNRADVANYI H, 1993, HUM MOL GENET, V2, P1263, DOI 10.1093/hmg/2.8.1263; HOGAN ME, 1987, NATURE, V328, P554, DOI 10.1038/328554a0; IMAGAWA M, 1995, J BIOL CHEM, V270, P20898, DOI 10.1074/jbc.270.36.20898; IZBAN MG, 1991, GENE DEV, V5, P683, DOI 10.1101/gad.5.4.683; KNEZETIC JA, 1986, CELL, V45, P95, DOI 10.1016/0092-8674(86)90541-6; KOHWI Y, 1995, NUCLEIC ACIDS RES, V21, P5651; KOIDE R, 1994, NAT GENET, V6, P9, DOI 10.1038/ng0194-9; LASPADA AR, 1991, NATURE, V352, P77, DOI 10.1038/352077a0; LORCH Y, 1987, CELL, V49, P203, DOI 10.1016/0092-8674(87)90561-7; MAHADEVAN M, 1992, SCIENCE, V255, P1253, DOI 10.1126/science.1546325; MARCHUK D, 1991, NUCLEIC ACIDS RES, V19, P1154, DOI 10.1093/nar/19.5.1154; MEERSSEMAN G, 1991, J MOL BIOL, V220, P89, DOI 10.1016/0022-2836(91)90383-H; MORSE RH, 1988, CELL, V54, P285, DOI 10.1016/0092-8674(88)90190-0; NAGAFUCHI S, 1994, NAT GENET, V6, P14, DOI 10.1038/ng0194-14; NAGAFUCHI S, 1994, NAT GENET, V8, P177, DOI 10.1038/ng1094-177; NOLL M, 1974, NUCLEIC ACIDS RES, V1, P1573, DOI 10.1093/nar/1.11.1573; ONEILL TE, 1992, J MOL BIOL, V223, P67, DOI 10.1016/0022-2836(92)90716-W; ORR HT, 1993, NAT GENET, V4, P221, DOI 10.1038/ng0793-221; OTTEN AD, 1995, P NATL ACAD SCI USA, V92, P5465, DOI 10.1073/pnas.92.12.5465; PERRY M, 1985, J MOL BIOL, V185, P479, DOI 10.1016/0022-2836(85)90065-8; PRUSS D, 1993, BIOCHEMISTRY-US, V32, P6810, DOI 10.1021/bi00078a002; PRUSS D, 1994, P NATL ACAD SCI USA, V91, P5913, DOI 10.1073/pnas.91.13.5913; PRUSS D, 1995, BIOESSAYS, V17, P161, DOI 10.1002/bies.950170211; RHODES D, 1985, EMBO J, V4, P3473, DOI 10.1002/j.1460-2075.1985.tb04106.x; RICHMOND TJ, 1984, NATURE, V311, P532, DOI 10.1038/311532a0; ROTH SY, 1990, MOL CELL BIOL, V10, P2247, DOI 10.1128/MCB.10.5.2247; SATCHWELL SC, 1986, J MOL BIOL, V191, P659, DOI 10.1016/0022-2836(86)90452-3; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; SHRADER TE, 1989, P NATL ACAD SCI USA, V86, P7418, DOI 10.1073/pnas.86.19.7418; SHRADER TE, 1990, J MOL BIOL, V216, P69, DOI 10.1016/S0022-2836(05)80061-0; STRAKA C, 1991, EMBO J, V10, P361, DOI 10.1002/j.1460-2075.1991.tb07957.x; TATCHELL K, 1977, BIOCHEMISTRY-US, V16, P5295, DOI 10.1021/bi00643a021; VERDIN E, 1993, EMBO J, V12, P3249, DOI 10.1002/j.1460-2075.1993.tb05994.x; WANG YH, 1995, GENOMICS, V25, P570, DOI 10.1016/0888-7543(95)80061-P; WANG YH, 1994, SCIENCE, V265, P669, DOI 10.1126/science.8036515; Wolffe A., 1995, CHROMATIN STRUCTURE; WOLFFE AP, 1989, P NATL ACAD SCI USA, V86, P9817, DOI 10.1073/pnas.86.24.9817; WOLFFE AP, 1986, CELL, V44, P381, DOI 10.1016/0092-8674(86)90459-9; WOLFFE AP, 1993, METH MOL G, V2, P314; WORKMAN JL, 1987, CELL, V51, P613, DOI 10.1016/0092-8674(87)90130-9; YANOYANAGISAWA H, 1995, NUCLEIC ACIDS RES, V23, P2654, DOI 10.1093/nar/23.14.2654; YU A, 1995, NUCLEIC ACIDS RES, V23, P4055, DOI 10.1093/nar/23.20.4055; 1993, CELL, V72, P971	62	95	97	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15222	15229		10.1074/jbc.271.25.15222	http://dx.doi.org/10.1074/jbc.271.25.15222			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663027	hybrid			2022-12-27	WOS:A1996UT10600084
J	Kazzaz, JA; Xu, J; Palaia, TA; Mantell, L; Fein, AM; Horowitz, S				Kazzaz, JA; Xu, J; Palaia, TA; Mantell, L; Fein, AM; Horowitz, S			Cellular oxygen toxicity - Oxidant injury without apoptosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HAMSTER OVARY CELLS; HYDROGEN-PEROXIDE; NORMOBARIC HYPEROXIA; DEATH; DAMAGE	All forms of aerobic life are faced with the threat of oxidation from molecular oxygen (O-2) and have evolved antioxidant defenses to cope with this potential problem, However, cellular antioxidants can become overwhelmed by oxidative insults, including supraphysiologic concentrations of O-2 (hyperoxia), Oxidative cell injury involves the modification of cellular macromole cules by reactive oxygen intermediates (ROI), often leading to cell death, O-2 therapy, which is a widely used component of life-saving intensive care, can cause lung injury, It is generally thought that hyperoxia injures cells by virtue of the accumulation of toxic levels of ROI, including H2O2 and the superoxide anion (O-2(-)), which are not adequately scavenged by endogenous antioxidant defenses, These oxidants are cytotoxic and have been shown to kill cells via apoptosis, or programmed cell death, If hyperoxia-induced cell death is a result of increased ROI, then O-2 toxicity should kill cells via ap optosis, We studied cultured epithelial cells in 95% O-2 and assayed apoptosis using a DNA-binding fluorescent dye, in situ end-labeling of DNA, and electron microscopy, Using all approaches we found that hyperoxia kills cells via necrosis, not apoptosis, In contrast, lethal concentrations of either H2O2 or O-2(-) cause apoptosis, Paradoxically, apoptosis is a prominent event in the lungs of animals injured by breathing 100% O-2. These data indicate that O-2 toxicity is somewhat distinct from other forms of oxidative injury and suggest that apoptosis in vivo is not a direct effect of O-2.	SUNY STONY BROOK,WINTHROP UNIV HOSP,SCH MED,CARDIOPULM RES INST,MINEOLA,NY 11501; SUNY STONY BROOK,WINTHROP UNIV HOSP,SCH MED,DEPT MED NEPHROL,MINEOLA,NY 11501	State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; Winthrop University Hospital								ALBRECHT H, 1994, FEBS LETT, V351, P45, DOI 10.1016/0014-5793(94)00817-5; BORTNER CD, 1995, TRENDS CELL BIOL, V5, P21, DOI 10.1016/S0962-8924(00)88932-1; BOWDEN DH, 1994, EXP LUNG RES, V20, P251, DOI 10.3109/01902149409064386; CAPPELLETTI G, 1994, CELL BIOL TOXICOL, V10, P255, DOI 10.1007/BF00756765; CHRISTIE NA, 1994, ARCH BIOCHEM BIOPHYS, V313, P131, DOI 10.1006/abbi.1994.1369; CLEMENT A, 1992, J CLIN INVEST, V90, P1812, DOI 10.1172/JCI116056; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; FAVIER A, 1994, CHEM-BIOL INTERACT, V91, P165, DOI 10.1016/0009-2797(94)90037-X; FORREST VJ, 1994, FREE RADICAL BIO MED, V16, P675, DOI 10.1016/0891-5849(94)90182-1; FUKUDA Y, 1992, TOXICOLOGY, V74, P185, DOI 10.1016/0300-483X(92)90138-5; GARDNER PR, 1994, P NATL ACAD SCI USA, V91, P12248, DOI 10.1073/pnas.91.25.12248; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; GILLE JJP, 1989, MUTAT RES, V214, P89, DOI 10.1016/0027-5107(89)90201-7; GILLE JJP, 1992, MUTAT RES, V275, P405, DOI 10.1016/0921-8734(92)90043-O; GILLE JJP, 1989, MUTAT RES, V219, P17, DOI 10.1016/0921-8734(89)90037-4; GILLE JJP, 1994, CARCINOGENESIS, V15, P2695, DOI 10.1093/carcin/15.12.2695; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOLLAN S, 1995, HAEMATOLOGIA, V26, P177; ISCHIROPOULOS H, 1995, FEBS LETT, V364, P279, DOI 10.1016/0014-5793(95)00307-U; IWATA M, 1994, J AM SOC NEPHROL, V5, P1307; JANSSEN YMW, 1993, LAB INVEST, V69, P261; JONES GRN, 1992, PHYSIOL CHEM PHYS ME, V24, P169; KAZZAZ JA, 1995, AM J RESP CRIT CARE, V151, pA547; MIESEL R, 1995, INFLAMMATION, V19, P379, DOI 10.1007/BF01534394; Morris A H, 1994, New Horiz, V2, P19; PIEDBOEUF B, 1994, AM J RESP CELL MOL, V10, P123, DOI 10.1165/ajrcmb.10.2.8110467; PIERCE GB, 1991, DIFFERENTIATION, V46, P181, DOI 10.1111/j.1432-0436.1991.tb00880.x; QUINLAN T, 1994, ENVIRON HEALTH PERSP, V102, P79, DOI 10.2307/3431823; RICHTER C, 1995, BBA-MOL BASIS DIS, V1271, P67, DOI 10.1016/0925-4439(95)00012-S; SANDSTROM PA, 1993, AIDS RES HUM RETROV, V9, P1107, DOI 10.1089/aid.1993.9.1107; SCHACTER E, 1994, FREE RADICAL BIO MED, V17, P429; SCHOONEN WGEJ, 1990, J BIOL CHEM, V265, P11118; SLATER AFG, 1995, BBA-MOL BASIS DIS, V1271, P59, DOI 10.1016/0925-4439(95)00010-2; SPITZ DR, 1992, ARCH BIOCHEM BIOPHYS, V292, P221, DOI 10.1016/0003-9861(92)90071-4; STOGNER SW, 1992, ANN PHARMACOTHER, V26, P1554, DOI 10.1177/106002809202601214; TORNUSCIOLO DRZ, 1995, BIOTECHNIQUES, V19, P800; UEDA N, 1992, J CLIN INVEST, V90, P2593, DOI 10.1172/JCI116154; WAGNER BA, 1994, BIOCHEMISTRY-US, V33, P4449, DOI 10.1021/bi00181a003; YUAN H, 1995, COMP BIOCHEM PHYS B, V110, P145, DOI 10.1016/0305-0491(94)00137-J; ZAMZAMI N, 1995, J EXP MED, V182, P367, DOI 10.1084/jem.182.2.367	40	239	249	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15182	15186		10.1074/jbc.271.25.15182	http://dx.doi.org/10.1074/jbc.271.25.15182			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662947	hybrid			2022-12-27	WOS:A1996UT10600079
J	Tsao, TS; Burcelin, R; Charron, MJ				Tsao, TS; Burcelin, R; Charron, MJ			Regulation of hexokinase II gene expression by glucose flux in skeletal muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WHITE ADIPOSE-TISSUE; MESSENGER-RNA; TRANSGENIC MICE; INSULIN; RAT; TRANSPORT; TRANSCRIPTION; PROTEIN; CELLS	The in vivo studies of transcriptional regulation by glucose, in general, have yielded ambiguous interpretations due to the closed loop relationship between insulin and glucose. Insulin cannot be held as a constant since elevated glucose levels will elicit a corresponding rise in insulin and current animal models of insulinopenia are associated with a plethora of counter regulatory hormone responses. One potential solution to increase intracellular glucose flux without a further increase in insulin was achieved by transgenic overexpression of the insulin-sensitive glucose transporter, GLUT4, in specific skeletal muscles (previously described in Tsao, T.-S., Burcelin, R., Katz, E. B., Huang, L., and Charron, M. J. (1996) Diabetes 45, 28-36). Using these MLC GLUT4 transgenic mice as a model, we investigated the effects of increased glucose flux on hexokinase II (HK II) gene expression in skeletal muscle. Under conditions where blood glucose levels were normal and insulin levels decreased by 36%, HK II mRNA level was reduced in non-GLUT4-overexpressing tissues (i.e. heart and adipose tissue) of 2-4-month-old male MLC-GLUT4 transgenic mice. This reduction in HK II mRNA was prevented in skeletal muscle, where overexpression of GLUT4 caused a 2.5-fold increase in basal and insulin-stimulated glucose uptake. The levels of HK II mRNA in heart, muscle, and adipose tissue are paralleled by HK II enzymatic activity. In conclusion: 1) due to relative mild insulinopenia, HK II expression is decreased in non-GLUT4-overexpressing tissues of MLC-GLUT4 mice compared to age/sex-matched controls, and 2) GLUT4-mediated increase in cellular glucose flux can prevent the decrease in HK II expression (in GLUT4-overexpressing tissues) as a result of relative mild insulinopenia. Indeed, during the process of aging, the return of circulating insulin levels of MLC-GLUT4 mice to normal levels is associated with the normalization of HK II expression in all tissues of MLC GLUT4 and age/sex-matched control mice. We propose that: 1) glucose flux has an amplifying effect on the ability of insulin to stimulate skeletal muscle HK II gene expression and 2) insulin-dependent glucose flux may be a potential mechanism by which HK II gene expression is regulated by sensitivity to insulin.	YESHIVA UNIV ALBERT EINSTEIN COLL MED, DEPT BIOCHEM, BRONX, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine				Tsao, Tsu-Shuen/0000-0002-1041-9687	NATIONAL CANCER INSTITUTE [K04CA001330] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P60DK020541, P30DK020541] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007491] Funding Source: NIH RePORTER; NCI NIH HHS [5P30CA1330] Funding Source: Medline; NIDDK NIH HHS [DK20541-17] Funding Source: Medline; NIGMS NIH HHS [5T32GM07491] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BELL GI, 1990, DIABETES CARE, V13, P198, DOI 10.2337/diacare.13.3.198; BERNSTEIN RS, 1973, DIABETES, V22, P913, DOI 10.2337/diab.22.12.913; BRAITHWAITE SS, 1995, DIABETES, V44, P43, DOI 10.2337/diabetes.44.1.43; BURCELIN R, 1993, AM J PHYSIOL, V265, pE392, DOI 10.1152/ajpendo.1993.265.3.E392; CHARRON MJ, 1989, P NATL ACAD SCI USA, V86, P2535, DOI 10.1073/pnas.86.8.2535; DECAUX JF, 1989, J BIOL CHEM, V264, P11584; DECAUX JF, 1991, J BIOL CHEM, V266, P3432; FERRE P, 1985, BIOCHEM J, V228, P103, DOI 10.1042/bj2280103; FINK RI, 1983, J CLIN INVEST, V71, P1523, DOI 10.1172/JCI110908; FOUFELLE F, 1992, J BIOL CHEM, V267, P20543; GORDON JW, 1993, METHOD ENZYMOL, V225, P747; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GOTO Y, 1992, DIABETES, V41, P339, DOI 10.2337/diabetes.41.3.339; GULVE EA, 1993, AM J PHYSIOL, V264, pE319, DOI 10.1152/ajpendo.1993.264.3.E319; KATZ A, 1991, AM J PHYSIOL, V260, pE411, DOI 10.1152/ajpendo.1991.260.3.E411; KATZEN HM, 1965, P NATL ACAD SCI USA, V54, P1218, DOI 10.1073/pnas.54.4.1218; KATZEN HM, 1968, ANN NY ACAD SCI, V151, P351, DOI 10.1111/j.1749-6632.1968.tb11900.x; KATZEN HM, 1970, J BIOL CHEM, V245, P4081; KUBO K, 1986, AM J PHYSIOL, V250, pE100, DOI 10.1152/ajpendo.1986.250.1.E100; MANDARINO LJ, 1995, AM J PHYSIOL-ENDOC M, V269, pE701; MUECKLER M, 1994, EUR J BIOCHEM, V219, P713, DOI 10.1111/j.1432-1033.1994.tb18550.x; ODOHERTY RM, 1994, AM J PHYSIOL, V266, pE171; OSAWA H, 1995, DIABETES, V44, P1426, DOI 10.2337/diabetes.44.12.1426; PESSIN JE, 1992, ANNU REV PHYSIOL, V54, P911, DOI 10.1146/annurev.ph.54.030192.004403; POSTIC C, 1993, DIABETES, V42, P922, DOI 10.2337/diabetes.42.6.922; POSTIC C, 1994, AM J PHYSIOL, V266, pE548, DOI 10.1152/ajpendo.1994.266.4.E548; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REN JM, 1993, J BIOL CHEM, V268, P16113; ROSENTHAL N, 1989, P NATL ACAD SCI USA, V86, P7780, DOI 10.1073/pnas.86.20.7780; SCHIMKE TR, 1968, ANN NY ACAD SCI, V151, P332, DOI 10.1111/j.1749-6632.1968.tb11899.x; SOMOGYI M, 1945, J BIOL CHEM, V160, P69; TORDJMAN KM, 1990, BIOCHEM J, V271, P201, DOI 10.1042/bj2710201; Tsao TS, 1996, DIABETES, V45, P28, DOI 10.2337/diabetes.45.1.28; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; Vestergaard H, 1995, J CLIN INVEST, V96, P2639, DOI 10.1172/JCI118329; WALKER PS, 1990, J BIOL CHEM, V265, P1516	37	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14959	14963		10.1074/jbc.271.25.14959	http://dx.doi.org/10.1074/jbc.271.25.14959			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663067	hybrid			2022-12-27	WOS:A1996UT10600050
J	Adam, D; Wiegmann, K; AdamKlages, S; Ruff, A; Kronke, M				Adam, D; Wiegmann, K; AdamKlages, S; Ruff, A; Kronke, M			A novel cytoplasmic domain of the p55 tumor necrosis factor receptor initiates the neutral sphingomyelinase pathway	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR TNF RECEPTOR; NF-KAPPA-B; ACTIVATION; CELLS; KINASE	The human p55 tumor necrosis factor (TNF) receptor (TR55) initiates at least two independent signaling cascades. The acidic sphingomyelinase (A-SMase) pathway involves a phosphatidylcholine-specific phospholipase C, an endosomal A-SMase, and controls expression of multiple TNF-responsive genes through induction of transcription factors such as NF-kappa B. The neutral sphingomyelinase (N-SMase) pathway comprises a membrane-bound N-SMase, proline-directed protein kinases, as well as phospholipase A(2) and appears critical for the inflammatory responses induced by TNF. While the domain of TR55 that induces A-SMase is probably identical to the death domain, the exact location and extent of a putative N-SMase activation domain are still unknown. Structure-function analysis of TR55 deletion mutants revealed a novel region of 11 amino acids at position 309-319 that is both necessary and sufficient for activation of N-SMase. The N-SMase activation domain is distinct from the death domain and incapable of induction of A-SMase, NF-kappa B, and cytotoxicity. Taken together, our results suggest that a functionally independent region of TR55 is responsible for selectively initiating the N-SMase pathway that couples to an important inflammatory signaling cascade.			Adam, D (corresponding author), CHRISTIAN ALBRECHTS UNIV KIEL, INST IMMUNOL, D-24105 KIEL, GERMANY.		Adam-Klages, Sabine/E-9761-2010; Adam, Dieter/E-9763-2010	Adam, Dieter/0000-0002-5668-5032				BELKA C, 1995, EMBO J, V14, P1156, DOI 10.1002/j.1460-2075.1995.tb07099.x; BEUTLER B, 1988, ANNU REV BIOCHEM, V57, P505, DOI 10.1146/annurev.bi.57.070188.002445; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BOLDIN MP, 1995, FEBS LETT, V367, P39, DOI 10.1016/0014-5793(95)00534-G; BRAKEBUSCH C, 1992, EMBO J, V11, P943, DOI 10.1002/j.1460-2075.1992.tb05133.x; Chinnaiyan AM, 1996, J BIOL CHEM, V271, P4961; CIFONE MG, 1995, EMBO J, V14, P5859, DOI 10.1002/j.1460-2075.1995.tb00274.x; DARNAY BG, 1995, J BIOL CHEM, V270, P14867, DOI 10.1074/jbc.270.25.14867; DAS DVM, 1984, BIOCHIM BIOPHYS ACTA, V777, P339; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; FIERS W, 1991, FEBS LETT, V285, P199, DOI 10.1016/0014-5793(91)80803-B; GOEDDEL DV, 1986, COLD SPRING HARB SYM, V51, P597, DOI 10.1101/SQB.1986.051.01.072; GULBINS E, 1995, IMMUNITY, V2, P341, DOI 10.1016/1074-7613(95)90142-6; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; Hsu HL, 1996, CELL, V84, P299, DOI 10.1016/S0092-8674(00)80984-8; KARASUYAMA H, 1988, EUR J IMMUNOL, V18, P97, DOI 10.1002/eji.1830180115; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; Kronke M, 1992, Immunol Ser, V56, P189; KRUPPA G, 1992, J IMMUNOL, V148, P3152; LIU J, 1994, J BIOL CHEM, V269, P3047; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MACHLEIDT T, 1994, J BIOL CHEM, V269, P13760; MATHIAS S, 1993, SCIENCE, V259, P519, DOI 10.1126/science.8424175; MIZUSHIMA S, 1990, NUCLEIC ACIDS RES, V18, P5322, DOI 10.1093/nar/18.17.5322; MULLER G, 1995, EMBO J, V14, P1961, DOI 10.1002/j.1460-2075.1995.tb07188.x; QUINTERN LE, 1991, METHOD ENZYMOL, V197, P536; RAINES MA, 1993, J BIOL CHEM, V268, P14572; ROTHE J, 1992, IMMUNOL RES, V11, P81, DOI 10.1007/BF02918612; SCHUTZE S, 1992, CELL, V71, P765, DOI 10.1016/0092-8674(92)90553-O; SONG HY, 1995, J BIOL CHEM, V270, P3574, DOI 10.1074/jbc.270.8.3574; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1992, J BIOL CHEM, V267, P4304; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; THOMA B, 1990, J EXP MED, V172, P1019, DOI 10.1084/jem.172.4.1019; VIETOR I, 1993, J BIOL CHEM, V268, P18994; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5; WIEGMANN K, 1992, J BIOL CHEM, V267, P17997; WOLFF RA, 1994, J BIOL CHEM, V269, P19605; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	40	129	134	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14617	14622		10.1074/jbc.271.24.14617	http://dx.doi.org/10.1074/jbc.271.24.14617			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663014	hybrid			2022-12-27	WOS:A1996UQ66000100
J	Gardner, AM; Johnson, GL				Gardner, AM; Johnson, GL			Fibroblast growth factor-2 suppression of tumor necrosis factor alpha-mediated apoptosis requires Ras and the activation of mitogen-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL-TRANSDUCTION PATHWAY; C-MYC; GENE-EXPRESSION; CELL-DEATH; MOLECULAR-CLONING; FACTOR RECEPTOR; MAP KINASE; PHOSPHORYLATION; DOMAIN; DIFFERENTIATION	Treatment of L929 cells with tumor necrosis factor a (TNF alpha) activates a programmed cell death pathway resulting in apoptosis. We investigated the intracellular signaling pathways activated in L929 cells by TNF alpha. TNF alpha robustly activates Jun kinase (JNK), a member of the mitogen-activated protein kinase (MAPK) family, In addition, p42(MAPK) is activated, but a 10-fold greater concentration of TNF alpha was required for substantial MAPK activation than was needed for maximal JNK stimulation, Simultaneous treatment of L929 cells with fibroblast growth factor (FGF-2) significantly reduced the apoptotic response to TNF alpha. FGF-2 substantially activated the Raf/MEK/MAPK (where MER is mitogen-activated protein kinase kinase) pathway but did not affect TNF alpha activation of JNK. These results indicate that although JNK may play an important role in transmitting the TNF alpha signal from the cell surface to the nucleus, activation of the JNK pathway is not sufficient to induce apoptosis. Expression of dominant-negative Asn-17 Ras in L929 cells diminished the FGF-2 stimulation of p42(MAPK) and eliminated the protective effect of FGF-2, Asn-17 Ras expression did not affect JNK activity and had no effect on TNF alpha activation of JNK, Pharmacological inhibition of MEK-1 activity by incubation of cells with the compound PD 098059 blocked p42(MAPK) activation and FGF-2 protection against apoptosis. Interestingly, activated Val-12 Ras expression substantially enhanced TNF alpha-mediated apoptosis in L929 cells, but Val-12 Ras did not constitutively activate MAPK in L929 cells and FGF-2 partially protected Val-12 Ras-expressing cells from TNF alpha-mediated apoptosis. Our data indicate that activation of the MAPK pathway mediates an FGF-2 protective effect against apoptosis and highlights the important role that integration of multiple intracellular signaling pathways plays in the regulation of cell growth and death.	UNIV COLORADO,SCH MED,DEPT PHARMACOL,DENVER,CO 80262	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Gardner, AM (corresponding author), NATL JEWISH CTR IMMUNOL & RESP MED,DIV BASIC SCI,1400 JACKSON ST,K1007,DENVER,CO 80206, USA.			Gardner, Anne/0000-0001-7095-772X	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK037871, R01DK048845] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM030324, R01GM030324] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK37871, DK48845] Funding Source: Medline; NIGMS NIH HHS [GM30324] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; Ausubel F.M., 1994, CURRENT PROTOCOLS MO, V1; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CORTEZ D, 1995, MOL CELL BIOL, V15, P5531; CREWS CM, 1992, P NATL ACAD SCI USA, V89, P8205, DOI 10.1073/pnas.89.17.8205; CREWS CM, 1992, SCIENCE, V258, P478, DOI 10.1126/science.1411546; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DEVARY Y, 1992, CELL, V71, P1081, DOI 10.1016/S0092-8674(05)80058-3; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; FANIDI A, 1992, NATURE, V359, P554, DOI 10.1038/359554a0; FEIG LA, 1988, MOL CELL BIOL, V8, P3235, DOI 10.1128/MCB.8.8.3235; FERNANDEZ A, 1994, ONCOGENE, V9, P2009; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; FESHEL K, 1991, AM J PATHOL, V139, P251; FINTER NB, 1969, J GEN VIROL, V5, P419, DOI 10.1099/0022-1317-5-3-419; FRUTH ME, 1982, J VIROL, V43, P294; GALLEGO C, 1992, P NATL ACAD SCI USA, V89, P7355, DOI 10.1073/pnas.89.16.7355; GARDNER AM, 1994, METHOD ENZYMOL, V238, P258; GOGA A, 1995, CELL, V82, P981, DOI 10.1016/0092-8674(95)90277-5; GREEN DR, 1994, CURR OPIN IMMUNOL, V6, P476, DOI 10.1016/0952-7915(94)90130-9; GUPTA S, 1993, P NATL ACAD SCI USA, V90, P3216, DOI 10.1073/pnas.90.8.3216; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HEASLEY LE, 1994, AM J PHYSIOL, V267, pF366, DOI 10.1152/ajprenal.1994.267.3.F366; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HELLER RA, 1992, CELL, V70, P47; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; ITOH N, 1993, J BIOL CHEM, V268, P10932; JANICKE RU, 1994, MOL CELL BIOL, V14, P5661; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; KIM MY, 1991, J BIOL CHEM, V266, P484; KINOSHITA T, 1995, EMBO J, V14, P266, DOI 10.1002/j.1460-2075.1995.tb07000.x; KLEFSTROM J, 1994, EMBO J, V13, P5442, DOI 10.1002/j.1460-2075.1994.tb06879.x; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; KULL FC, 1985, P NATL ACAD SCI USA, V82, P5756, DOI 10.1073/pnas.82.17.5756; KYPRIANOU N, 1991, J NATL CANCER I, V83, P346, DOI 10.1093/jnci/83.5.346; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LARRICK JW, 1990, FASEB J, V4, P3215, DOI 10.1096/fasebj.4.14.2172061; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MILLER SC, 1988, MOL CELL BIOL, V8, P2295, DOI 10.1128/MCB.8.6.2295; MINDEN A, 1994, MOL CELL BIOL, V14, P6683, DOI 10.1128/MCB.14.10.6683; NAKIELNY S, 1992, EMBO J, V11, P2123, DOI 10.1002/j.1460-2075.1992.tb05271.x; OPPENHEIM RW, 1991, ANNU REV NEUROSCI, V14, P453, DOI 10.1146/annurev.ne.14.030191.002321; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; RAFF MC, 1992, NATURE, V356, P297; REDDY EP, 1982, NATURE, V300, P149, DOI 10.1038/300149a0; Sakata N, 1995, J BIOL CHEM, V270, P30823, DOI 10.1074/jbc.270.51.30823; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SEGER R, 1992, J BIOL CHEM, V267, P14373; SETH A, 1991, J BIOL CHEM, V266, P23521; SHI YF, 1992, SCIENCE, V257, P212, DOI 10.1126/science.1378649; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; TAPAROWSKY E, 1982, NATURE, V300, P149; TARTAGLIA LA, 1992, IMMUNOL TODAY, V13, P151, DOI 10.1016/0167-5699(92)90116-O; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; TOBIN CJ, 1982, NATURE, V300, P143; TORTI FM, 1985, SCIENCE, V229, P867, DOI 10.1126/science.3839597; TRACEY KJ, 1986, SCIENCE, V234, P470, DOI 10.1126/science.3764421; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TRINCHIERI G, 1986, J EXP MED, V164, P1206, DOI 10.1084/jem.164.4.1206; VANLINT J, 1992, J BIOL CHEM, V267, P25916; VIETOR I, 1993, J BIOL CHEM, V268, P18994; VILCEK J, 1986, J EXP MED, V163, P632, DOI 10.1084/jem.163.3.632; WESTWICK JK, 1994, J BIOL CHEM, V269, P26396; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; YAO RJ, 1995, SCIENCE, V267, P2003, DOI 10.1126/science.7701324	69	204	206	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14560	14566		10.1074/jbc.271.24.14560	http://dx.doi.org/10.1074/jbc.271.24.14560			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662985	hybrid			2022-12-27	WOS:A1996UQ66000092
J	Miyazaki, T; Kanou, Y; Murata, Y; Ohmori, S; Niwa, T; Maeda, K; Yamamura, H; Seo, H				Miyazaki, T; Kanou, Y; Murata, Y; Ohmori, S; Niwa, T; Maeda, K; Yamamura, H; Seo, H			Molecular cloning of a novel thyroid hormone-responsive gene, ZAKI-4, in human skin fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYMERASE CHAIN-REACTION; DIFFERENTIAL DISPLAY; RESISTANCE; RNA; CELLS; MUTANT	Utilizing a method called ''differential display of mRNAs by means of polymerase chain reaction'', the cDNA fragment of a thyroid hormone-responsive gene ZAKI-4 was cloned from cultured human skin fibroblasts, Northern blot analysis revealed that there were two ZAKI-4 mRNA species (3.4 and 1.4 kilobases (kb)), and they were up-regulated by a physiological concentration of triiodothyronine (T-3). This T-3 effect was abolished by the treatment with cycloheximide, indicating the possibility that gene ZAKI-4 is regulated by T-3 in an indirect fashion, through an intermediate product of T-3, rather directly by T-3 itself, No effect of T-3 on ZAKI-4 mRNA stability suggested that T-3 induces the mRNA at the transcriptional level. Rapid amplification of cDNA ends confirmed the presence of two mRNA species. ZAKI-4 mRNA was detected in heart, brain, liver, and skeletal muscle but not in placenta, lung, kidney and pancreas. In skin fibroblasts and skeletal muscle, 3,4-kb mRNA was the major species, whereas 1.4-kb mRNA was dominant in heart, brain, and liver. The sequence analysis suggested that the two mRNA species arise from alternative polyadenylation and code a single protein of 192 amino acids. No homologous protein sequence was found in a data base. Elucidation of the function of ZAKI-4 gene product will provide new insights into an important role of T-3 in various organs.	NAGOYA UNIV,DEPT ENDOCRINOL & METAB,DIV MOL & CELLULAR ADAPTAT,ENVIRONM MED RES INST,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,DEPT TERATOL & GENET,DIV MOL & CELLULAR ADAPTAT,ENVIRONM MED RES INST,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; NAGOYA UNIV,BRANCH HOSP,DEPT INTERNAL MED,NAGOYA,AICHI 461,JAPAN	Nagoya University; Nagoya University; Nagoya University								ADAMS MD, 1993, NAT GENET, V4, P373, DOI 10.1038/ng0893-373; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BARNES WM, 1994, P NATL ACAD SCI USA, V91, P2216, DOI 10.1073/pnas.91.6.2216; CHAIT A, 1982, J CLIN ENDOCR METAB, V54, P767, DOI 10.1210/jcem-54-4-767; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANNIES PS, 1977, ENDOCRINOLOGY, V101, P1151, DOI 10.1210/endo-101-4-1151; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; HAYASHI Y, 1993, J CLIN ENDOCR METAB, V76, P64, DOI 10.1210/jc.76.1.64; ICHIKAWA K, 1986, METABOLISM, V35, P861, DOI 10.1016/0026-0495(86)90229-5; KLANN RC, 1993, J CLIN ENDOCR METAB, V77, P969, DOI 10.1210/jc.77.4.969; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LIANG P, 1992, SCIENCE, V257, P967, DOI 10.1126/science.1354393; LIANG P, 1992, CANCER RES, V52, P6966; MIYAZAKI T, 1995, AM J NEPHROL, V15, P48, DOI 10.1159/000168801; MURATA Y, 1983, J CLIN ENDOCR METAB, V57, P1233, DOI 10.1210/jcem-57-6-1233; MURATA Y, 1987, J CLIN ENDOCR METAB, V64, P334, DOI 10.1210/jcem-64-2-334; RALPH D, 1993, P NATL ACAD SCI USA, V90, P10710, DOI 10.1073/pnas.90.22.10710; REFETOFF S, 1993, ENDOCR REV, V14, P348, DOI 10.1210/er.14.3.348; SAKURAI A, 1993, CLIN ENDOCRINOL, V38, P29, DOI 10.1111/j.1365-2265.1993.tb00969.x; SEO H, 1977, ENDOCRINOLOGY, V100, P216, DOI 10.1210/endo-100-1-216; SMITH TJ, 1982, J CLIN INVEST, V70, P1066, DOI 10.1172/JCI110694; SOBIEZCZYK S, 1988, ENDOCRINOLOGY S, V122, pT24; TRENTMANN SM, 1995, SCIENCE, V267, P1186, DOI 10.1126/science.7855603; WELSH J, 1992, NUCLEIC ACIDS RES, V20, P4965, DOI 10.1093/nar/20.19.4965	24	68	73	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14567	14571		10.1074/jbc.271.24.14567	http://dx.doi.org/10.1074/jbc.271.24.14567			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662924	hybrid			2022-12-27	WOS:A1996UQ66000093
J	Guimaraes, MJ; Bazan, JF; Castagnola, J; Diaz, S; Copeland, NG; Gilbert, DJ; Jenkins, NA; Varki, A; Zlotnik, A				Guimaraes, MJ; Bazan, JF; Castagnola, J; Diaz, S; Copeland, NG; Gilbert, DJ; Jenkins, NA; Varki, A; Zlotnik, A			Molecular cloning and characterization of lysosomal sialic acid O-acetylesterase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DE-ORTHO-ACETYLATION; INFLUENZA-C VIRUS; COLONY-STIMULATING FACTOR; RAT-LIVER; CELL; GROWTH; IDENTIFICATION; PROLIFERATION; PURIFICATION; LYMPHOCYTES	O-Acetylation and de-O-acetylation of sialic acids have been implicated in the regulation of a variety of biological phenomena, including endogenous lectin recognition, tumor antigenicity, virus binding, and complement activation. Applying a strategy designed to identify genes preferentially expressed in active sites of embryonic hematopoiesis, we isolated a novel cDNA from the pluripotent hematopoietic cell line FDCP-mixA4 whose open reading frame contained sequences homologous to peptide fragments of a lysosomal sialic acid O-acetylesterase (Use) previously purified from rat liver, but with no evident similarity to endoplasmic reticulum-derived acetylesterases. The expressed Lse protein exhibits sialic-acid O-acetylesterase activity that is not attributable to a typical serine esterase active site, Lse expression is spatially and temporally restricted during embryogenesis, and its mRNA levels correlate with differences in O-acetylesterase activity described in adult tissues and blood cell. types, Using interspecific backcross analysis, we further mapped the Ise gene to the central region of mouse chromosome 9, This constitutes the first report on the molecular cloning of a sialic acid specific O-acetylesterase in vertebrates and suggests novel roles for the 9-O-acetyl modification of sialic acids during the development and differentiation of mammalian organisms.	UNIV CALIF SAN DIEGO, CTR CANC, GLYCOBIOL PROGRAM, LA JOLLA, CA 92093 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA	University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick	Guimaraes, MJ (corresponding author), DNAX RES INST MOLEC & CELLULAR BIOL INC, 901 CALIF AVE, PALO ALTO, CA 94304 USA.		Zlotnik, Albert/C-3791-2011; Bazan, J. Fernando/B-4562-2010	Guimaraes, M. Jorge/0000-0002-1588-7391	NCI NIH HHS [N01-CO-4600] Funding Source: Medline; NIGMS NIH HHS [R01GM32373] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032373] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1994, NAT GENET, V6, P119, DOI 10.1038/ng0294-119; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARNOLD LW, 1983, J IMMUNOL, V131, P2064; BAUER SR, 1986, J IMMUNOL, V136, P4695; Bazan JF, 1996, PROTEINS, V24, P1; BENSON DA, 1994, NUCLEIC ACIDS RES, V22, P3441, DOI 10.1093/nar/22.17.3441; BOGUSKI MS, 1995, TRENDS BIOCHEM SCI, V20, P295, DOI 10.1016/S0968-0004(00)89051-9; Bork P, 1996, METHOD ENZYMOL, V266, P162; BORK P, 1994, CURR OPIN STRUC BIOL, V4, P393, DOI 10.1016/S0959-440X(94)90109-0; BOURETTE RP, 1993, BLOOD, V81, P2511; BRANDEN CI, 1980, Q REV BIOPHYS, V13, P317, DOI 10.1017/S0033583500001712; BRENNER S, 1988, NATURE, V334, P528, DOI 10.1038/334528a0; BUTOR C, 1993, J BIOL CHEM, V268, P10207; BUTOR C, 1995, J CELL SCI, V108, P2213; CHERESH DA, 1984, SCIENCE, V225, P844, DOI 10.1126/science.6206564; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; DEIBEL MR, 1988, LYMPHOKINE RES, V7, P469; DIAZ S, 1989, J BIOL CHEM, V264, P19416; EVERSON MP, 1989, BLOOD, V74, P1472; FORD AM, 1992, BLOOD, V79, P1962, DOI 10.1182/blood.V79.8.1962.bloodjournal7981962; FUJINO E, 1995, J BACTERIOL, V177, P5169, DOI 10.1128/jb.177.17.5169-5175.1995; Green EL, 1981, GENETICS PROBABILITY, P77; GUIMARAES MJ, 1995, DEVELOPMENT, V121, P3335; GUIMARAES MJ, 1995, NUCLEIC ACIDS RES, V23, P1832, DOI 10.1093/nar/23.10.1832; HANSEN JE, 1995, BIOCHEM J, V308, P801, DOI 10.1042/bj3080801; HAYES BK, 1989, J BIOL CHEM, V264, P19443; HERRLER G, 1985, EMBO J, V4, P1503, DOI 10.1002/j.1460-2075.1985.tb03809.x; HERRLER G, 1991, ADV VIRUS RES, V40, P213; HIGA HH, 1989, J BIOL CHEM, V264, P19435; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HUNT P, 1987, CELL, V48, P997, DOI 10.1016/0092-8674(87)90708-2; KAMERLING JP, 1982, BIOCHIM BIOPHYS ACTA, V714, P351, DOI 10.1016/0304-4165(82)90344-0; KIM KJ, 1986, IMMUNOLOGY, V59, P15; KNIEP B, 1995, J BIOL CHEM, V270, P30173; KORNFELD S, 1992, ANNU REV BIOCHEM, V61, P307, DOI 10.1146/annurev.bi.61.070192.001515; LAWSON DM, 1994, BIOCHEMISTRY-US, V33, P9382, DOI 10.1021/bi00198a003; LEDERER JA, 1994, J IMMUNOL, V152, P77; MACNEIL I, 1993, J IMMUNOL, V151, P6913; MARKS PA, 1978, ANNU REV BIOCHEM, V47, P419, DOI 10.1146/annurev.bi.47.070178.002223; OLLIS DL, 1992, PROTEIN ENG, V5, P197, DOI 10.1093/protein/5.3.197; RENNICK D, 1989, J IMMUNOL, V142, P161; ROST B, 1996, IN PRESS ANN REV BIO, V25; ROTH J, 1993, HISTOCHEM J, V25, P687; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHAUER R, 1991, Glycobiology, V1, P449, DOI 10.1093/glycob/1.5.449; SCHAUER R, 1989, J BIOCHEM-TOKYO, V106, P143, DOI 10.1093/oxfordjournals.jbchem.a122804; SCHAUER R, 1988, BIOCHIMIE, V70, P1511, DOI 10.1016/0300-9084(88)90288-X; Schauer R., 1982, CELL BIOL MONOGRAPHS, V10; SJOBERG ER, 1994, J CELL BIOL, V126, P549, DOI 10.1083/jcb.126.2.549; UNDEM BJ, 1990, J BIOL CHEM, V265, P6750; VALLETTE F, 1989, NUCLEIC ACIDS RES, V17, P723, DOI 10.1093/nar/17.2.723; VARKI A, 1980, J EXP MED, V152, P532, DOI 10.1084/jem.152.3.532; VARKI A, 1991, CELL, V65, P65, DOI 10.1016/0092-8674(91)90408-Q; VARKI A, 1992, GLYCOBIOLOGY, V2, P25, DOI 10.1093/glycob/2.1.25; VARKI A, 1993, GLYCOBIOLOGY, V3, P97, DOI 10.1093/glycob/3.2.97; VLASAK R, 1989, J VIROL, V63, P2056, DOI 10.1128/JVI.63.5.2056-2062.1989; VLASAK R, 1988, P NATL ACAD SCI USA, V85, P4526, DOI 10.1073/pnas.85.12.4526; WATSON J, 1979, J EXP MED, V150, P1510, DOI 10.1084/jem.150.6.1510; WEST AH, 1995, J MOL BIOL, V250, P276, DOI 10.1006/jmbi.1995.0376; WILKIE TM, 1993, GENOMICS, V18, P175, DOI 10.1006/geno.1993.1452; WORLEY KC, 1995, GENOME RES, V5, P173, DOI 10.1101/gr.5.2.173; ZIMMER G, 1994, GLYCOBIOLOGY, V4, P343, DOI 10.1093/glycob/4.3.343; ZVELEBIL MJJM, 1988, PROTEIN ENG, V2, P127, DOI 10.1093/protein/2.2.127	63	23	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13697	13705		10.1074/jbc.271.23.13697	http://dx.doi.org/10.1074/jbc.271.23.13697			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662838				2022-12-27	WOS:A1996UP38500061
J	Eason, MG; Liggett, SB				Eason, MG; Liggett, SB			Chimeric mutagenesis of putative G-protein coupling domains of the alpha(2A)-adrenergic receptor - Localization of two redundant and fully competent G(1) coupling domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-ADRENERGIC-RECEPTOR; HUMAN ALPHA-2-ADRENERGIC RECEPTOR; HUMAN BETA-2-ADRENERGIC RECEPTOR; 3RD INTRACELLULAR LOOP; HAMSTER OVARY CELLS; ALPHA(2)-ADRENERGIC RECEPTOR; ADENYLATE-CYCLASE; CYTOPLASMIC DOMAINS; AMINO-ACIDS; EXPRESSION	We have investigated potential G(i) and G(s) coupling domains within the intracellular regions of the alpha(2A)AR subtype using a series of nine chimeric mutations. The second intracellular loop (ICL2, amino acids 133-149) and the amino- and carboxyl-terminal regions of the third intracellular loop (ICL3, amino acids 218-235 and 355-371, respectively) of the cloned human alpha(2A)AR were substituted with the analogous sequence from either the G(s)-coupled beta(2)AR or the G(i)-coupled serotonin type 1A receptor (5-HT(1A)R). Mutant and wild type alpha(2A)AR were stably expressed in Chinese hamster ovary cells and functional coupling of each receptor to G(i) and G(s) was assessed in membrane adenylyl cyclase assays. Substitution of 5-HT(1A)R sequence into ICL2 ablated coupling to G(s) but not to G(i), whereas substitution of beta(2)AR sequence significantly depressed coupling to G(i) but not to G(s). Thus, the ICL2 of the alpha(2A)AR contains elements essential for both signaling pathways. Substitution of either the amino- or carboxyl-terminal. segments of ICL3 with 5-HT(1A)R sequence ablated agonist stimulation of adenylyl cyclase activity (without affecting inhibition), suggesting that both domains are necessary for alpha(2A)AR coupling to G(s). In contrast, individual substitution of beta(2)AR sequence into ICL3 amino or carboxyl termini had no appreciable effect on G(i) coupling. Concomitant substitution of beta(2)AR sequence into both regions substantially impaired G(i) coupling, implying that each is capable of independently supporting functional coupling. Substitution of 5-HT(1A)R at either locus had no effect on G(i) coupling. Thus, for G(s) coupling, these two domains within ICL3 are both required for functional coupling. However, for G(i) coupling, the alpha(2A)AR appears to have two distinct regions within ICL3 that are capable of supporting G(i) coupling independently. There has been no previous elucidation of a receptor having redundant, fully competent domains for coupling to a single class of G-protein. Such duplicity of functional domains within alpha(2)AR may suggest strong evolutionary pressure to maintain G(i) coupling.	UNIV CINCINNATI,COLL MED,DEPT PULM MED,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT MOLEC GENET,CINCINNATI,OH 45267; UNIV CINCINNATI,COLL MED,DEPT PHARMACOL,CINCINNATI,OH 45267	University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati; University System of Ohio; University of Cincinnati			liggett, stephen b/E-7453-2012	Liggett, Stephen B./0000-0002-0128-3669	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL053436, P01HL041496] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL53436, HL41496] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERKOWITZ DE, 1994, ANESTHESIOLOGY, V81, P1235, DOI 10.1097/00000542-199411000-00018; CHABRE O, 1994, J BIOL CHEM, V269, P5730; CHEUNG AH, 1992, MOL PHARMACOL, V41, P1061; CHEUNG AH, 1991, FEBS LETT, V279, P277, DOI 10.1016/0014-5793(91)80167-2; CHEUNG AH, 1990, MOL PHARMACOL, V37, P775; COTECCHIA S, 1990, J BIOL CHEM, V265, P63; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DALMAN HM, 1991, J BIOL CHEM, V266, P11025; DELEAN A, 1981, MOL PHARMACOL, V21, P5; DUMAN RS, 1986, J NEUROCHEM, V47, P800; DUZIC E, 1992, J BIOL CHEM, V267, P24045; EASON MG, 1993, MOL PHARMACOL, V44, P70; EASON MG, 1992, J BIOL CHEM, V267, P15795; EASON MG, 1995, J BIOL CHEM, V270, P24753, DOI 10.1074/jbc.270.42.24753; EASON MG, 1994, MOL PHARMACOL, V45, P696; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; FRASER CM, 1989, J BIOL CHEM, V264, P11754; GUAN XM, 1995, MOL PHARMACOL, V48, P492; HAUSDORFF WP, 1990, J BIOL CHEM, V265, P1388; HAUSDORFF WP, 1989, J BIOL CHEM, V264, P12657; IKEZU T, 1992, FEBS LETT, V311, P29, DOI 10.1016/0014-5793(92)81359-T; JANSSON CC, 1994, EUR J PHARM-MOLEC PH, V266, P165, DOI 10.1016/0922-4106(94)90106-6; JONES SB, 1991, MOL PHARMACOL, V39, P239; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; KOBILKA BK, 1987, SCIENCE, V238, P650, DOI 10.1126/science.2823383; KOSUGI S, 1994, MOL ENDOCRINOL, V8, P498, DOI 10.1210/me.8.4.498; KOSUGI S, 1994, FEBS LETT, V356, P291, DOI 10.1016/0014-5793(94)01286-5; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LECHLEITER J, 1990, EMBO J, V9, P4381, DOI 10.1002/j.1460-2075.1990.tb07888.x; LEEUWEN DH, 1995, MOL PHARMACOL, V48, P344; LIGGETT SB, 1992, J BIOL CHEM, V267, P4740; LIGGETT SB, 1991, J BIOL CHEM, V266, P4816; LIMBIRD LE, 1985, RECEPTORS, V2, P281; LOMASNEY JW, 1991, BIOCHIM BIOPHYS ACTA, V1095, P127, DOI 10.1016/0167-4889(91)90075-9; LOMASNEY JW, 1990, P NATL ACAD SCI USA, V87, P5094, DOI 10.1073/pnas.87.13.5094; ODOWD BF, 1988, J BIOL CHEM, V263, P15985; OKAMOTO T, 1992, J BIOL CHEM, V267, P8342; PEPPERL DJ, 1993, MOL PHARMACOL, V44, P802; RAYMOND JR, 1993, BIOCHEMISTRY-US, V32, P11064, DOI 10.1021/bi00092a016; REGAN JW, 1988, P NATL ACAD SCI USA, V85, P6301, DOI 10.1073/pnas.85.17.6301; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SCHEININ M, 1994, MOL BRAIN RES, V21, P133, DOI 10.1016/0169-328X(94)90386-7; SMITH PK, 1985, ANAL BIOCHEM, V150, P76, DOI 10.1016/0003-2697(85)90442-7; ULLRICH S, 1984, J BIOL CHEM, V259, P4111; WESS J, 1990, MOL PHARMACOL, V38, P517; WONG SKF, 1990, J BIOL CHEM, V265, P6219; YAMADA M, 1994, MOL PHARMACOL, V46, P470; ZENG DW, 1991, MOL BRAIN RES, V10, P219, DOI 10.1016/0169-328X(91)90064-5	49	79	83	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12826	12832		10.1074/jbc.271.22.12826	http://dx.doi.org/10.1074/jbc.271.22.12826			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662784	hybrid			2022-12-27	WOS:A1996UN47400023
J	He, WM; Craparo, A; Zhu, YY; ONeill, TJ; Wang, LM; Pierce, JH; Gustafson, TA				He, WM; Craparo, A; Zhu, YY; ONeill, TJ; Wang, LM; Pierce, JH; Gustafson, TA			Interaction of insulin receptor substrate-2 (IRS-2) with the insulin and insulin-like growth factor I receptors - Evidence for two distinct phosphotyrosine-dependent interaction domains within IRS-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIGNAL TRANSDUCTION; HEMATOPOIETIC-CELLS; PROTEIN; SHC; PHOSPHORYLATION; SITES; ACIDS	Insulin receptor substrate 2 (IRS-2) has recently been shown to be a substrate of the insulin receptor (IR), In this study we utilize the yeast two-hybrid system and assays of in vitro interaction to demonstrate that IRS-2 interacts directly with the IR and the insulin-like growth factor I receptor, We show that, like IRS-1, the region of IRS-2 that contains the putative phosphotyrosine binding and SAIN elements (188-591) is sufficient for receptor interaction and that this interaction is dependent upon the NPX(p)Y (where (p)Y is phosphotyrosine) motifs within the juxtamembrane domains of the receptors, In addition to this amino-terminal NPX(p)Y-binding domain, an additional domain of strong interaction was identified in the central region of IRS-2 and was localized between amino acids 591 and 733, This interaction was found to be dependent upon receptor phosphorylation but was NPX(p)Y-independent, This region does not appear to have either an SH2 or a phosphotyrosine binding domain, Both of the interactions could also be demonstrated in vitro using IRS-2 glutathione S-transferase fusion proteins, We conclude that IRS-2, unlike IRS-1, can interact with tyrosine phosphorylated receptors such as the IR and insulin-like growth factor I receptor via multiple independent binding motifs, Our findings suggest the existence of a previously unidentified phosphotyrosine dependent binding domain within the central region of IRS-2.	UNIV MARYLAND,SCH MED,DEPT PHYSIOL,BALTIMORE,MD 21201; UNIV MARYLAND,SCH MED,PROGRAM MOLEC & CELLULAR BIOL,BALTIMORE,MD 21201; NCI,CELLULAR & MOLEC BIOL LAB,NIH,BETHESDA,MD 20892	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK044093] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM008181] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44093] Funding Source: Medline; NIGMS NIH HHS [GM08181] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARAKI E, 1994, NATURE, V372, P186, DOI 10.1038/372186a0; Ausubel F.M., 1993, CURRENT PROTOCOLS MO; BACKER JM, 1993, J BIOL CHEM, V268, P8204; BECKER AB, 1990, ANNU REV MED, V41, P99; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; CHUANG LM, 1993, P NATL ACAD SCI USA, V90, P5172, DOI 10.1073/pnas.90.11.5172; CRAPARO A, 1995, J BIOL CHEM, V270, P15639, DOI 10.1074/jbc.270.26.15639; EBINA Y, 1985, CELL, V40, P747, DOI 10.1016/0092-8674(85)90334-4; GIORGETTI S, 1994, EUR J BIOCHEM, V223, P195, DOI 10.1111/j.1432-1033.1994.tb18983.x; GOLEMIS EA, 1992, MOL CELL BIOL, V12, P3006, DOI 10.1128/MCB.12.7.3006; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; GUTHRIE C, 1992, METHOD ENZYMOL, V194, P1; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HARA K, 1994, P NATL ACAD SCI USA, V91, P7415, DOI 10.1073/pnas.91.16.7415; HE WM, 1995, J BIOL CHEM, V270, P23258, DOI 10.1074/jbc.270.40.23258; KAHN CR, 1993, RECENT PROG HORM RES, V48, P291; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; Miller J.H., 1972, EXPT MOL GENETICS; OKADA T, 1994, J BIOL CHEM, V269, P3568; ONEILL TJ, 1994, MOL CELL BIOL, V14, P6433, DOI 10.1128/MCB.14.10.6433; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRONK GJ, 1994, MOL CELL BIOL, V14, P1575, DOI 10.1128/MCB.14.3.1575; PRONK GJ, 1993, J BIOL CHEM, V268, P5748; PRUETT W, 1995, MOL CELL BIOL, V15, P1778; QUON MJ, 1994, J BIOL CHEM, V269, P27920; RON D, 1992, BIOTECHNIQUES, V13, P866; ROSE DW, 1994, P NATL ACAD SCI USA, V91, P797, DOI 10.1073/pnas.91.2.797; SASAOKA T, 1994, J BIOL CHEM, V269, P10734; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SKOLNIK EY, 1993, EMBO J, V12, P1929, DOI 10.1002/j.1460-2075.1993.tb05842.x; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; TAMEMOTO H, 1994, NATURE, V372, P182, DOI 10.1038/372182a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; WANG LM, 1992, EMBO J, V11, P4899, DOI 10.1002/j.1460-2075.1992.tb05596.x; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZERVOS AS, 1993, CELL, V72, P223, DOI 10.1016/0092-8674(93)90662-A; ZHANG B, 1991, J BIOL CHEM, V266, P990	45	125	126	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11641	11645		10.1074/jbc.271.20.11641	http://dx.doi.org/10.1074/jbc.271.20.11641			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662806	hybrid			2022-12-27	WOS:A1996UL25000012
J	OBryan, JP; Martin, CB; Songyang, Z; Cantley, LC; Der, CJ				OBryan, JP; Martin, CB; Songyang, Z; Cantley, LC; Der, CJ			Binding specificity and mutational analysis of the phosphotyrosine binding domain of the brain-specific adaptor protein ShcC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SH2 DOMAIN	She proteins (hereafter referred to as ShcA) represent major substrates of tyrosine phosphorylation by a wide variety of growth factors and cytokines, We have recently described a novel ShcA-like protein, ShcC, which like ShcA contains an NH2-terminal phosphotyrosine binding domain (PTB), a central effector region (CH1) and a COOH-terminal Src homology 2 domain (SH2). Both the SH2 and PTB domains of ShcC bind a similar profile of proteins as the comparable regions of ShcA. In an effort to define the functional differences or similarities between ShcA and ShcC, we have further characterized the PTB domain of ShcC. Using a degenerate phosphopeptide library screen, we show that the PTB domain of ShcC preferentially binds the sequence His-hydrophobic-Asn/hydrophobic-Asn-Pro-Ser/Thr-Tyr(P). This sequence is similar to the binding site for the ShcA PTB domain, suggesting that these two proteins may have overlapping specificities. In addition, random mutagenesis of the ShcC PTB domain has identified several amino acids important for PTB function (Gly(32), Glu(63), Ala(136), Gly(139), and Asp(140)). Mutation of these amino acids dramatically reduces the affinity of the ShcC PTB domain for the activated epidermal growth factor receptor in vitro.	HARVARD UNIV, SCH MED, BOSTON, MA 02115 USA; BETH ISRAEL HOSP, DEPT MED, BOSTON, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	OBryan, JP (corresponding author), UNIV N CAROLINA, DEPT PHARMACOL, CB 7365, CHAPEL HILL, NC 27599 USA.		Cantley, Lewis C/D-1800-2014	Cantley, Lewis C/0000-0002-1298-7653; Der, Channing/0000-0002-7751-2747; O'Bryan, John/0000-0001-5386-1080	NCI NIH HHS [CA42978, CA55008, CA63071] Funding Source: Medline; NIGMS NIH HHS [R01 GM056203] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA055008, R01CA063071, R01CA042978] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056203] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BATZER AG, 1995, MOL CELL BIOL, V15, P4403; BATZER AG, 1994, MOL CELL BIOL, V14, P5192, DOI 10.1128/MCB.14.8.5192; BLAIKIE P, 1994, J BIOL CHEM, V269, P32031; BORK P, 1995, CELL, V80, P693, DOI 10.1016/0092-8674(95)90347-X; CAMPBELL KS, 1994, P NATL ACAD SCI USA, V91, P6344, DOI 10.1073/pnas.91.14.6344; DILWORTH SM, 1994, NATURE, V367, P87, DOI 10.1038/367087a0; FEIG LA, 1987, MOL ENDOCRINOL, V1, P127, DOI 10.1210/mend-1-2-127; Fridell YWC, 1996, MOL CELL BIOL, V16, P135; GOTOH N, 1994, P NATL ACAD SCI USA, V91, P167, DOI 10.1073/pnas.91.1.167; GUSTAFSON TA, 1995, MOL CELL BIOL, V15, P2500; KAVANAUGH WM, 1995, SCIENCE, V268, P1177, DOI 10.1126/science.7539155; KAVANAUGH WM, 1994, SCIENCE, V266, P1862, DOI 10.1126/science.7527937; LI NX, 1994, ONCOGENE, V9, P3457; MARENGERE LEM, 1992, J BIOL CHEM, V267, P22779; OBryan JP, 1996, P NATL ACAD SCI USA, V93, P2729, DOI 10.1073/pnas.93.7.2729; OKABAYASHI Y, 1994, J BIOL CHEM, V269, P18674; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; QUILLIAM LA, 1994, MOL CELL BIOL, V14, P1113, DOI 10.1128/MCB.14.2.1113; RAMEH LE, 1995, CELL, V83, P821, DOI 10.1016/0092-8674(95)90195-7; SOLER C, 1994, ONCOGENE, V9, P2207; SONGYANG Z, 1995, J BIOL CHEM, V270, P14863, DOI 10.1074/jbc.270.25.14863; SONGYANG Z, 1994, MOL CELL BIOL, V14, P2777, DOI 10.1128/MCB.14.4.2777; vanderGeer P, 1996, P NATL ACAD SCI USA, V93, P963, DOI 10.1073/pnas.93.3.963; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WOLF G, 1995, J BIOL CHEM, V270, P27407, DOI 10.1074/jbc.270.46.27407; Yajnik V, 1996, J BIOL CHEM, V271, P1813, DOI 10.1074/jbc.271.4.1813; ZHOU MM, 1995, P NATL ACAD SCI USA, V92, P7784, DOI 10.1073/pnas.92.17.7784; ZHOU SY, 1993, CELL, V72, P767, DOI 10.1016/0092-8674(93)90404-E	29	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11787	11791		10.1074/jbc.271.20.11787	http://dx.doi.org/10.1074/jbc.271.20.11787			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662772	hybrid			2022-12-27	WOS:A1996UL25000034
J	DeStefano, JJ				DeStefano, JJ			Interaction of human immunodeficiency virus nucleocapsid protein with a structure mimicking a replication intermediate - Effects on stability, reverse transcriptase binding, and strand transfer	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PRIMER TRANSFER-RNA; GENETIC-RECOMBINATION; RIBONUCLEASE H; ZINC-FINGERS; HIV-1; TYPE-1; GENOMES; ENDONUCLEASE; POLYMERASE; TEMPLATES	The interaction of human immunodeficiency virus (HIV) nucleocapsid protein (NCp) with a substrate closely mimicking a retrovirus replication intermediate was studied. The heteroduplex substrate consisted of a DNA and RNA of 80 and 63 nucleotides, respectively. The nucleotides at the 3' end of the DNA were complementary to those at the 3' end of the RNA such that a hybrid region of 30 base pairs could form. HIV-reverse transcriptase (RT) extended the DNA and cleaved the RNA strand of the substrate, The rates of extension and cleavage were significantly decreased when the substrate was prebound with NCp before HIV-RT addition. In assays assessing the integrity of the substrate by measuring release of the DNA strand from the heteroduplex, prebinding with NCp protected the substrate when HIV-RT was added, a result consistent with resistance to RT-mediated cleavage. In contrast, NCp significantly decreased the thermal stability of the substrate as judged by incubation of the substrate at various temperatures, In strand transfer assays, a 189-nucleotide RNA (acceptor) with an internal region complementary to all 80 nucleotides of the substrate DNA was incubated with the substrate in the presence or absence of NCp, Nucleocapsid protein stimulated strand transfer in which the substrate RNA was displaced upon binding of the DNA to the acceptor. Results are discussed with respect to the role of NCp in retroviral recombination.			DeStefano, JJ (corresponding author), UNIV MARYLAND,DEPT MICROBIOL,BLDG 231,COLLEGE PK,MD 20742, USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM051140, R01GM051140] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM51140-01, R29 GM051140] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLAIN B, 1994, EMBO J, V13, P973, DOI 10.1002/j.1460-2075.1994.tb06342.x; BARAT C, 1989, EMBO J, V8, P3279, DOI 10.1002/j.1460-2075.1989.tb08488.x; BIETH E, 1990, NUCLEIC ACIDS RES, V18, P119, DOI 10.1093/nar/18.1.119; CLAVEL F, 1989, J VIROL, V63, P1455, DOI 10.1128/JVI.63.3.1455-1459.1989; COFFIN JM, 1979, J GEN VIROL, V42, P1, DOI 10.1099/0022-1317-42-1-1; CORNILLE F, 1990, INT J PEPT PROT RES, V36, P551; DELAHUNTY MD, 1992, BIOCHEMISTRY-US, V31, P6461, DOI 10.1021/bi00143a015; DEROCQUIGNY H, 1992, P NATL ACAD SCI USA, V89, P6472, DOI 10.1073/pnas.89.14.6472; DESTEFANO JJ, 1995, ARCH VIROL, V140, P1775, DOI 10.1007/BF01384341; DESTEFANO JJ, 1994, J BIOL CHEM, V269, P161; DESTEFANO JJ, 1994, NUCLEIC ACIDS RES, V22, P3793, DOI 10.1093/nar/22.18.3793; DESTEFANO JJ, 1992, J VIROL, V66, P6370, DOI 10.1128/JVI.66.11.6370-6378.1992; DESTEFANO JJ, 1991, J BIOL CHEM, V266, P24295; DICKSON C, 1985, RNA TUMOR VIRUSES, V1, P513; FU TB, 1992, J VIROL, V66, P4271, DOI 10.1128/JVI.66.7.4271-4278.1992; FURFINE ES, 1991, J BIOL CHEM, V266, P406; GOODRICH DW, 1990, P NATL ACAD SCI USA, V87, P2052, DOI 10.1073/pnas.87.6.2052; GOPALAKRISHNAN V, 1992, P NATL ACAD SCI USA, V89, P10763, DOI 10.1073/pnas.89.22.10763; HANSEN J, 1987, J BIOL CHEM, V262, P12393; HENDERSON LE, 1992, J VIROL, V66, P1856, DOI 10.1128/JVI.66.4.1856-1865.1992; HU WS, 1990, P NATL ACAD SCI USA, V87, P1556, DOI 10.1073/pnas.87.4.1556; HUBER HE, 1989, J BIOL CHEM, V264, P4669; KARPEL RL, 1987, J BIOL CHEM, V262, P4961; KHAN R, 1992, J BIOL CHEM, V267, P6689; KOLSTAEDT LA, 1992, SCIENCE, V256, P1783; PELISKA JA, 1994, BIOCHEMISTRY-US, V33, P13817, DOI 10.1021/bi00250a036; PELISKA JA, 1992, SCIENCE, V258, P1112, DOI 10.1126/science.1279806; PRATS AC, 1991, NUCLEIC ACIDS RES, V19, P3533, DOI 10.1093/nar/19.13.3533; PRATS AC, 1988, EMBO J, V7, P1777, DOI 10.1002/j.1460-2075.1988.tb03008.x; PRIEL E, 1995, FEBS LETT, V362, P59, DOI 10.1016/0014-5793(95)00208-Q; RODRIGUEZRODRIGUEZ L, 1995, J BIOL CHEM, V270, P15005, DOI 10.1074/jbc.270.25.15005; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ O, 1990, EMBO J, V9, P1171, DOI 10.1002/j.1460-2075.1990.tb08224.x; STARNES MC, 1989, J BIOL CHEM, V264, P7073; SUROVOY A, 1993, J MOL BIOL, V229, P94, DOI 10.1006/jmbi.1993.1011; TEMIN HM, 1993, P NATL ACAD SCI USA, V90, P6900, DOI 10.1073/pnas.90.15.6900; TSUCHIHASHI Z, 1993, SCIENCE, V262, P99, DOI 10.1126/science.7692597; VARMUS H, 1984, RNA TUMOR VIRUSES, P369; VARTANIAN JP, 1991, J VIROL, V65, P1779, DOI 10.1128/JVI.65.4.1779-1788.1991; VERONESE FD, 1986, SCIENCE, V231, P1289, DOI 10.1126/science.2418504; WOHRL BM, 1990, BIOCHEMISTRY-US, V29, P10141, DOI 10.1021/bi00496a001; YOU JC, 1994, J BIOL CHEM, V269, P31491	42	43	43	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16350	16356						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663119				2022-12-27	WOS:A1996UW35200073
J	Etter, A; Cully, DF; Schaeffer, JM; Liu, KK; Arena, JP				Etter, A; Cully, DF; Schaeffer, JM; Liu, KK; Arena, JP			An amino acid substitution in the pore region of a glutamate-gated chloride channel enables the coupling of ligand binding to channel gating	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INHIBITORY GLYCINE RECEPTOR; CAENORHABDITIS-ELEGANS RNA; XENOPUS-OOCYTES; MUSCLE-FIBERS; BETA-SUBUNIT; EXPRESSION; AVERMECTIN; RESISTANCE; MECHANISM; NEURONS	Many of the subunits of ligand-gated ion channels respond poorly, if at all, when expressed as homomeric channels in Xenopus oocytes, This lack of a ligand response has been thought to result from poor surface expression, poor assembly, or lack of an agonist binding domain. The Caenorhabditis elegans glutamate-gated chloride channel subunit GluCl beta responds to glutamate as a homomeric channel while the GluCl alpha subunit is insensitive. A chimera between GluCl alpha and GluCl beta was used to suggest that major determinants for glutamate binding are present on the GluCl alpha N terminus, Amino acid substitutions in the presumed pore of GluCl alpha conferred direct glutamate gating indicating that GluCl alpha is deficient in coupling of ligand binding to channel gating. Heteromeric channels of GluCl alpha+beta may differ from the prototypic muscle nicotinic acetylcholine receptor in that they have the potential to bind ligand to all of the subunits forming the channel.	MERCK RES LABS,DEPT CELL BIOCHEM & PHYSIOL,RAHWAY,NJ 07065; MERCK RES LABS,DEPT MOLEC BIOL & GENET,RAHWAY,NJ 07065	Merck & Company; Merck & Company								ARENA JP, 1995, J PARASITOL, V81, P286, DOI 10.2307/3283936; ARENA JP, 1992, MOL BRAIN RES, V15, P339, DOI 10.1016/0169-328X(92)90127-W; ARENA JP, 1991, MOL PHARMACOL, V40, P368; BERTRAND D, 1995, NEUROSCIENCES, V7, P75; BLAIR LAC, 1988, SCIENCE, V242, P577, DOI 10.1126/science.2845583; BORMANN J, 1993, EMBO J, V12, P3729, DOI 10.1002/j.1460-2075.1993.tb06050.x; BORMANN J, 1987, J PHYSIOL-LONDON, V385, P243, DOI 10.1113/jphysiol.1987.sp016493; Campbell WW, 1989, IVERMECTIN ABAMECTIN; COCKCROFT VB, 1990, PROTEINS, V8, P386, DOI 10.1002/prot.340080412; CULLCANDY SG, 1976, J PHYSIOL-LONDON, V255, P449, DOI 10.1113/jphysiol.1976.sp011289; CULLY DF, 1994, NATURE, V371, P707, DOI 10.1038/371707a0; DALRISON MK, 1995, NEUROSCIENCES, V7, P115; DUDEL J, 1989, BRAIN RES, V481, P215, DOI 10.1016/0006-8993(89)90796-8; EISELE JL, 1993, NATURE, V366, P479, DOI 10.1038/366479a0; FFRENCHCONSTANT RH, 1993, NATURE, V363, P449, DOI 10.1038/363449a0; FILATOV GN, 1995, MOL PHARMACOL, V48, P379; Goldman DE, 1943, J GEN PHYSIOL, V27, P37, DOI 10.1085/jgp.27.1.37; GRENNINGLOH G, 1990, NEURON, V4, P963, DOI 10.1016/0896-6273(90)90149-A; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HODGKIN AL, 1949, J PHYSIOL-LONDON, V108, P37, DOI 10.1113/jphysiol.1949.sp004310; Karlin A, 1993, Curr Opin Neurobiol, V3, P299, DOI 10.1016/0959-4388(93)90121-E; KUHSE J, 1995, CURR OPIN NEUROBIOL, V5, P318, DOI 10.1016/0959-4388(95)80044-1; LABARCA C, 1995, NATURE, V376, P514, DOI 10.1038/376514a0; LEA T J, 1973, Comparative and General Pharmacology, V4, P351, DOI 10.1016/0010-4035(73)90046-3; NEWLAND CF, 1992, J PHYSIOL-LONDON, V447, P191, DOI 10.1113/jphysiol.1992.sp018998; PRIBILLA I, 1992, EMBO J, V11, P4305, DOI 10.1002/j.1460-2075.1992.tb05529.x; PRITCHETT DB, 1988, SCIENCE, V242, P1306, DOI 10.1126/science.2848320; SCHREIBMAYER W, 1994, PFLUG ARCH EUR J PHY, V426, P453, DOI 10.1007/BF00388310; UNWIN N, 1993, J MOL BIOL, V229, P1101, DOI 10.1006/jmbi.1993.1107; ZHANG HG, 1994, J PHYSIOL-LONDON, V479, P65, DOI 10.1113/jphysiol.1994.sp020278	30	41	42	2	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16035	16039		10.1074/jbc.271.27.16035	http://dx.doi.org/10.1074/jbc.271.27.16035			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663156	hybrid			2022-12-27	WOS:A1996UW35200030
J	Habib, GM; Barrios, R; Shi, ZZ; Lieberman, MW				Habib, GM; Barrios, R; Shi, ZZ; Lieberman, MW			Four distinct membrane-bound dipeptidase RNAs are differentially expressed and show discordant regulation with gamma-glutamyl transpeptidase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN RENAL DIPEPTIDASE; TRANSFERASE TRANSPEPTIDASE; DEHYDROPEPTIDASE-I; MOLECULAR-CLONING; GLUTATHIONE; TRANSPORT; STEP; CDNA; DNA	Membrane-bound dipeptidase (MBD) participates in the degradation of glutathione by cleaving the cysteinylglycine bond of cystinyl bisglycine (oxidized cysteinylglycine) following removal of a gamma-glutamyl group by gamma-glutamyl transpeptidase (GGT). In the mouse, MBD RNA is most abundant in small intestine, kidney, and lung and is represented by four distinct RNA species, These are generated by transcription from two promoters located 6 kilobases apart in the 5' flanking region of the gene and by the use of two different poly(A) addition sites, Promoter I is used primarily in small intestine and kidney, whereas promoter II is most active in lung and kidney, We found a discordance in the expected co-expression of MBD and GGT; as expected, MBD and GGT are both expressed at high levels in the kidney and small intestine, However, in the lung, MBD is expressed at high levels, whereas GGT is almost undetectable, The reverse is true in the seminal vesicles and fetal liver. Thus, although both enzymes may function in concert to metabolize glutathione in kidney and small intestine, in other tissues they appear to act independently, suggesting that they have independent roles in other biological processes.	BAYLOR COLL MED,DEPT PATHOL,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT CELL BIOL,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine								ADACHI H, 1993, BIOCHIM BIOPHYS ACTA, V1163, P42, DOI 10.1016/0167-4838(93)90276-W; AN SZ, 1994, BBA-MOL BASIS DIS, V1226, P337, DOI 10.1016/0925-4439(94)90046-9; ANDERSON ME, 1980, BIOCHEM BIOPH RES CO, V96, P848, DOI 10.1016/0006-291X(80)91433-3; CHISHOLM D, 1989, BIOTECHNIQUES, V7, P21; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Curthoys N. P., 1990, GLUTATHIONE METABOLI, P217; GONZALEZ J, 1990, GLUTATHIONE METABOLI, P295; GRIFFITH OW, 1979, P NATL ACAD SCI USA, V76, P268, DOI 10.1073/pnas.76.1.268; HABIB GM, 1995, J BIOL CHEM, V270, P13711, DOI 10.1074/jbc.270.23.13711; HANNIGAN MH, 1993, BIOCHEMISTRY-US, V32, P6302; HIKIDA M, 1992, ANTIMICROB AGENTS CH, V36, P481, DOI 10.1128/AAC.36.2.481; HUBER M, 1988, GLUTATHIONE CONJUGAT, P449; KENGAKU M, 1993, MOL BRAIN RES, V18, P71, DOI 10.1016/0169-328X(93)90174-N; KENNY AJ, 1987, MAMMALIAN ECTOENZYME, P329; KEPPLER D, 1992, REV PHYSIOL BIOCH P, V121, P1, DOI 10.1007/BFb0033192; KEYNAN S, 1994, FEBS LETT, V349, P50, DOI 10.1016/0014-5793(94)00637-7; KOZAK EM, 1982, J BIOL CHEM, V257, P6322; KROPP H, 1982, ANTIMICROB AGENTS CH, V22, P62, DOI 10.1128/AAC.22.1.62; LAPERCHE Y, 1986, P NATL ACAD SCI USA, V83, P937, DOI 10.1073/pnas.83.4.937; LIEBERMAN MW, 1995, AM J PATHOL, V147, P1175; Meister A., 1995, METABOLIC BASIS INHE, P1461; RACHED E, 1990, BIOCHEM J, V271, P755, DOI 10.1042/bj2710755; RUTENBURG AM, 1969, J HISTOCHEM CYTOCHEM, V17, P517, DOI 10.1177/17.8.517; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1163, P234, DOI 10.1016/0167-4838(93)90157-M; SATOH S, 1993, BIOCHIM BIOPHYS ACTA, V1172, P181, DOI 10.1016/0167-4781(93)90289-P; SCHAFFNER DL, 1993, AM J PATHOL, V142, P1051; SEPULVEDA AR, 1994, J BIOL CHEM, V269, P10699; TODA K, 1994, MOL ENDOCRINOL, V8, P210, DOI 10.1210/me.8.2.210; TURNER AJ, 1990, MOL CELL BIOL MEMBRA, P129	29	27	29	2	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16273	16280		10.1074/jbc.271.27.16273	http://dx.doi.org/10.1074/jbc.271.27.16273			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663190	hybrid			2022-12-27	WOS:A1996UW35200062
J	Manuel, RC; Czerwinski, EW; Lloyd, RS				Manuel, RC; Czerwinski, EW; Lloyd, RS			Identification of the structural and functional domains of MutY, an Escherichia coli DNA mismatch repair enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							G-A MISPAIRS; ENDONUCLEASE-III; FPG PROTEIN; ZINC-FINGER; GLYCOSYLASE; T4-ENDONUCLEASE-V; MECHANISM; DYNAMICS; TERMINUS; DUPLEX	The linear amino acid sequences of the Escherichia coli DNA repair proteins, MutY and endonuclease III, show significant homology, even though these enzymes recognize entirely different substrates, In this study, proteolysis and molecular modeling of MutY were used to elucidate its domain organization, Proteolysis by trypsin cleaved the enzyme into 26- and 13-kDa fragments, NH2-terminal sequencing showed that the pig domain begins at Gln(226), indicating that the COOH-terminal portion of MutY, absent in endonuclease III, is organized as a separate domain, The large p26 domain is almost equivalent to the size of endonuclease III. Binding activity of the p26 domain to a DNA substrate containing an A . G mismatch was comparable with that of the intact enzyme. In vitro studies show that the p26 domain retains adenine glycosylase and AP lyase activity on DNA containing undamaged adenine opposite guanine or 8-oxo-7,8-dihydro-2'-deoxyguanine. Although the activity was somewhat reduced, the above results show that the critical amino acid residues involved in substrate binding and catalysis are present in this domain. The structure predicted by molecular modeling indicates that the region of MutY (Met(1)-Trp(216)), which is homologous to endonuclease III exhibits a two domain structure, even though this portion is resistant to proteolysis by trypsin.	UNIV TEXAS,MED BRANCH,SEALY CTR MOL SCI,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,SEALY CTR STRUCT BIOL,GALVESTON,TX 77555; UNIV TEXAS,MED BRANCH,DEPT HUMAN BIOL CHEM & GENET,GALVESTON,TX 77555	University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston; University of Texas System; University of Texas Medical Branch Galveston				Lloyd, R. Stephen/0000-0001-7273-372X	NIEHS NIH HHS [ES04091, ES06676] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [P30ES006676, R01ES004091] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		AU KG, 1989, P NATL ACAD SCI USA, V86, P8877, DOI 10.1073/pnas.86.22.8877; BAILLY V, 1987, BIOCHEM J, V242, P565, DOI 10.1042/bj2420565; BAILLY V, 1989, BIOCHEM J, V262, P581, DOI 10.1042/bj2620581; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNGER AT, 1992, X PLOR MANUAL VERSIO; DODSON ML, 1993, BIOCHEMISTRY-US, V32, P8284, DOI 10.1021/bi00083a032; DODSON ML, 1994, J BIOL CHEM, V269, P32709; GAO XL, 1988, J AM CHEM SOC, V110, P5178, DOI 10.1021/ja00223a045; GERLT JA, 1993, NUCLEASES, V2, P263; KOW YW, 1987, BIOCHEMISTRY-US, V26, P8200, DOI 10.1021/bi00399a027; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LATHAM KA, 1995, BIOCHEMISTRY-US, V34, P8796, DOI 10.1021/bi00027a031; LI Y, 1995, BIOCHEMISTRY-US, V34, P10056, DOI 10.1021/bi00031a030; LIPSCOMB LA, 1995, P NATL ACAD SCI USA, V92, P719, DOI 10.1073/pnas.92.3.719; LU AL, 1995, J BIOL CHEM, V270, P23582, DOI 10.1074/jbc.270.40.23582; LU AL, 1988, CELL, V54, P805, DOI 10.1016/S0092-8674(88)91109-9; MANUEL RC, 1995, J BIOL CHEM, V270, P2652, DOI 10.1074/jbc.270.6.2652; MAZUMDER A, 1989, J AM CHEM SOC, V111, P8029, DOI 10.1021/ja00202a062; MCAULEYHECHT KE, 1994, BIOCHEMISTRY-US, V33, P10266, DOI 10.1021/bi00200a006; MCGOLDRICK JP, 1995, MOL CELL BIOL, V15, P989; MICHAELS ML, 1990, NUCLEIC ACIDS RES, V18, P3841, DOI 10.1093/nar/18.13.3841; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; NGHIEM Y, 1988, P NATL ACAD SCI USA, V85, P2709, DOI 10.1073/pnas.85.8.2709; NIKONOWICZ EP, 1991, BIOCHEMISTRY-US, V30, P1323, DOI 10.1021/bi00219a024; NIKONOWICZ EP, 1992, J AM CHEM SOC, V114, P7494, DOI 10.1021/ja00045a024; OCONNOR TR, 1993, J BIOL CHEM, V268, P9063; PATEL DJ, 1984, BIOCHEMISTRY-US, V23, P3207, DOI 10.1021/bi00309a015; PAVLOV YI, 1994, BIOCHEMISTRY-US, V33, P4695, DOI 10.1021/bi00181a029; PIERSEN CE, 1995, J BIOL CHEM, V270, P23475, DOI 10.1074/jbc.270.40.23475; SACK JS, 1988, J MOL GRAPHICS, V6, P224, DOI 10.1016/S0263-7855(98)80040-4; SALI A, 1993, J MOL BIOL, V234, P779, DOI 10.1006/jmbi.1993.1626; SCHROCK RD, 1991, J BIOL CHEM, V266, P17631; SCHROCK RD, 1993, J BIOL CHEM, V268, P880; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; TCHOU J, 1993, MUTAT RES, V299, P277, DOI 10.1016/0165-1218(93)90104-L; TCHOU J, 1995, J BIOL CHEM, V270, P11671, DOI 10.1074/jbc.270.19.11671; TCHOU J, 1993, J BIOL CHEM, V268, P26738; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; TSAIWU JJ, 1992, P NATL ACAD SCI USA, V89, P8779, DOI 10.1073/pnas.89.18.8779; XING DX, 1995, BIOCHEMISTRY-US, V34, P2537, DOI 10.1021/bi00008a018	40	70	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16218	16226		10.1074/jbc.271.27.16218	http://dx.doi.org/10.1074/jbc.271.27.16218			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663135	hybrid			2022-12-27	WOS:A1996UW35200054
J	Tullius, MV; Munson, RS; Wang, J; Gibson, BW				Tullius, MV; Munson, RS; Wang, J; Gibson, BW			Purification, cloning, and expression of a cytidine 5'-monophosphate N-acetylneuraminic acid synthetase from Haemophilus ducreyi	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI K1; HEMOPHILUS-DUCREYI; NEISSERIA-GONORRHOEAE; ANOMERIC SPECIFICITY; MUCOSAL PATHOGENS; HUMAN-SERUM; LIPOPOLYSACCHARIDE; CELLS; LIPOOLIGOSACCHARIDES; CYTIDYLYLTRANSFERASE	An N-acetylneuraminic acid cytidylyltransferase (EC 2.7.7.43) (CMP-NeuAc synthetase) was isolated from a Haemophilus ducreyi strain 35000 cell lysate and partially characterized. The enzyme catalyzes the reaction of CTP and NeuAc to form CMP-NeuAc, which is the nucleotide sugar donor used by sialyltransferases. Previous studies have shown that the outer membrane lipooligosaccharides of H. ducreyi contain terminal sialic acid attached to N-acetyllactosamine and that this modification is likely important to its pathogenesis. Therefore, to investigate the role of sialic acid in a. ducreyi pathogenesis, the gene encoding the CMP-NeuAc synthetase was cloned using degenerate oligonucleotide probes derived from NH2-terminal sequence data, and the nucleotide sequence was determined. The derived amino acid sequence of the CMP-NeuAc synthetase gene has homology to other CMP-NeuAc synthetases and to a lesser extent to CMP-2-keto-3-deoxy-D-manno-octulosonic acid synthetases, The gene was cloned into a T7 expression vector, the protein expressed in Escherichia coli, and purified to apparent homogeneity by anion exchange, Green 19 dye, and hydrophobic interaction chromatography. The final step yielded 20 mg of pure protein/liter of culture, The protein has a predicted molecular mass of 25440.6 Pa, which was confirmed by electrospray mass spectrometry (M(expt) = 25439.9 +/- 1.4 Pa). The enzyme appears to exist as a dimer by size exclusion chromatography. In contrast to other bacterial CMP-NeuAc synthetases, the H. ducreyi enzyme exhibited a different substrate specificity, being capable of also using N-glycolylneuraminic acid as a substrate.	UNIV CALIF SAN FRANCISCO, SCH PHARM, DEPT PHARMACEUT CHEM, SAN FRANCISCO, CA 94143 USA; OHIO STATE UNIV, CHILDRENS HOSP, RES FDN, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, DEPT PEDIAT, COLUMBUS, OH 43205 USA; OHIO STATE UNIV, DEPT MED MICROBIOL & IMMUNOL, COLUMBUS, OH 43205 USA	University of California System; University of California San Francisco; University System of Ohio; Ohio State University; Nationwide Childrens Hospital; Research Institute at Nationwide Children's Hospital; University System of Ohio; Ohio State University; University System of Ohio; Ohio State University			Munson, Jr, Robert/E-3710-2011	Munson, Jr, Robert/0000-0002-3204-3019	NIAID NIH HHS [AI 34967, AI 31254] Funding Source: Medline; NIGMS NIH HHS [GM 07175] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031254, R01AI034967] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBRITTON WL, 1989, MICROBIOL REV, V53, P377, DOI 10.1128/MMBR.53.4.377-389.1989; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AMBROSE MG, 1992, BIOCHEMISTRY-US, V31, P775, DOI 10.1021/bi00118a019; BARNES WM, 1987, METHOD ENZYMOL, V152, P538; BITTERSUERMANN D, 1993, POLYSIALIC ACID MICR, P11; BORK P, 1995, PROTEINS, V22, P259, DOI 10.1002/prot.340220306; BRAMLEY J, 1995, MICROB PATHOGENESIS, V18, P187, DOI 10.1016/S0882-4010(95)90040-3; BRENTJENS RJ, 1994, MICROB PATHOGENESIS, V16, P243, DOI 10.1006/mpat.1994.1025; CAMPAGNARI AA, 1990, MICROB PATHOGENESIS, V8, P353, DOI 10.1016/0882-4010(90)90094-7; CAMPAGNARI AA, 1991, INFECT IMMUN, V59, P2601, DOI 10.1128/IAI.59.8.2601-2608.1991; Centers for Disease Control and Prevention (CDC), 1995, MMWR Morb Mortal Wkly Rep, V44, P573; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; ELKINS C, 1992, MOL MICROBIOL, V6, P2617, DOI 10.1111/j.1365-2958.1992.tb01439.x; FLOOD JM, 1993, J INFECT DIS, V167, P1106, DOI 10.1093/infdis/167.5.1106; GANGULI S, 1994, J BACTERIOL, V176, P4583, DOI 10.1128/JB.176.15.4583-4589.1994; HAFT RF, 1994, J BACTERIOL, V176, P7372, DOI 10.1128/JB.176.23.7372-7374.1994; Jann K., 1985, The virulence of Escherichia coli, P157; JENNINGS HJ, 1984, PURE APPL CHEM, V56, P893, DOI 10.1351/pac198456070893; JESSAMINE PG, 1990, MED CLIN N AM, V74, P1417, DOI 10.1016/S0025-7125(16)30488-6; JOHNSON AP, 1988, J INFECTION, V17, P99, DOI 10.1016/S0163-4453(88)91487-9; KEAN E L, 1991, Glycobiology, V1, P441, DOI 10.1093/glycob/1.5.441; KNAPP JS, 1993, ANTIMICROB AGENTS CH, V37, P1552, DOI 10.1128/AAC.37.7.1552; KOHLBRENNER WE, 1987, J BIOL CHEM, V262, P4534; KOHLBRENNER WE, 1985, J BIOL CHEM, V260, P4695; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAGERGARD T, 1992, MICROB PATHOGENESIS, V13, P203, DOI 10.1016/0882-4010(92)90021-F; LAGERGARD T, 1993, MICROB PATHOGENESIS, V14, P417, DOI 10.1006/mpat.1993.1041; LAMMEL CJ, 1993, J INFECT DIS, V167, P642, DOI 10.1093/infdis/167.3.642; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MANDRELL RE, 1993, MICROB PATHOGENESIS, V14, P307, DOI 10.1006/mpat.1993.1030; MANDRELL RE, 1993, IMMUNOBIOLOGY, V187, P382, DOI 10.1016/S0171-2985(11)80352-9; MANDRELL RE, 1992, INFECT IMMUN, V60, P1322, DOI 10.1128/IAI.60.4.1322-1328.1992; Melaugh W, 1996, J BACTERIOL, V178, P564, DOI 10.1128/jb.178.2.564-570.1996; MELAUGH W, 1994, BIOCHEMISTRY-US, V33, P13070, DOI 10.1021/bi00248a016; ODUMERU JA, 1985, INFECT IMMUN, V50, P495, DOI 10.1128/IAI.50.2.495-499.1985; ODUMERU JA, 1987, J MED MICROBIOL, V23, P155, DOI 10.1099/00222615-23-2-155; Palmer KL, 1995, MOL MICROBIOL, V18, P821, DOI 10.1111/j.1365-2958.1995.18050821.x; PARSONS NJ, 1988, MICROB PATHOGENESIS, V5, P303, DOI 10.1016/0882-4010(88)90103-9; PETRIE CR, 1983, ANAL BIOCHEM, V131, P153, DOI 10.1016/0003-2697(83)90147-1; PORAT N, 1995, INFECT IMMUN, V63, P2164, DOI 10.1128/IAI.63.6.2164-2172.1995; REST RF, 1992, INFECT IMMUN, V60, P989, DOI 10.1128/IAI.60.3.989-997.1992; RODRIGUEZAPARICIO LB, 1992, J BIOL CHEM, V267, P9257; RODRIGUEZAPARICIO LB, 1995, BIOCHEM J, V308, P501, DOI 10.1042/bj3080501; SCHAUER R, 1985, TRENDS BIOCHEM SCI, V10, P357, DOI 10.1016/0968-0004(85)90112-4; SCHMID GP, 1990, REV INFECT DIS, V12, pS580; SCHULTE J M, 1992, Morbidity and Mortality Weekly Report, V41, P57; SMITH RF, 1990, P NATL ACAD SCI USA, V87, P118, DOI 10.1073/pnas.87.1.118; SMITHWHITE BJ, 1992, J MOL EVOL, V34, P449, DOI 10.1007/BF00162999; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; THORSON JS, 1994, J BACTERIOL, V176, P1840, DOI 10.1128/jb.176.7.1840-1849.1994; TIMMIS KN, 1985, CURR TOP MICROBIOL, V118, P197; TOTTEN PA, 1994, INFECT IMMUN, V62, P5632, DOI 10.1128/IAI.62.12.5632-5640.1994; VAN DE, 1994, ANTIMICROB AGENTS CH, V38, P1647; VANN WF, 1987, J BIOL CHEM, V262, P17556; VANN WF, 1993, POLYSIALIC ACID MICR, P125; VIMR ER, 1992, J BACTERIOL, V174, P5127, DOI 10.1128/JB.174.15.5127-5131.1992; WANG RF, 1991, GENE, V100, P195, DOI 10.1016/0378-1119(91)90366-J; WARREN L, 1962, BIOCHEM BIOPH RES CO, V7, P433, DOI 10.1016/0006-291X(62)90330-3; ZAPATA G, 1989, J BIOL CHEM, V264, P14769; ZAPATA G, 1995, GLYCOCONJ J, V12, P519	60	50	51	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15373	15380		10.1074/jbc.271.26.15373	http://dx.doi.org/10.1074/jbc.271.26.15373			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663048	hybrid			2022-12-27	WOS:A1996UV29900014
J	Verghese, MW; Kneisler, TB; Boucheron, JA				Verghese, MW; Kneisler, TB; Boucheron, JA			P-2U agonists induce chemotaxis and actin polymerization in human neutrophils and differentiated HL60 cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHOLIPASE-C; PURINERGIC RECEPTOR; NUCLEOTIDES; ACTIVATION; LEUKOCYTES; ELEVATION; CALCIUM; CAMP; ATP	Human neutrophils or HL60 cells express P-2U receptors and respond to micromolar concentrations of ATP, adenosine 5'-O-(thiotriphosphate) (ATP gamma S), or UTP with immediate increases in intracellular Ca2+ through activation of phosphoinositide phospholipase C (Cowen, D. S., Lazarus, H, M,, Shurin, S. B,, Stoll, S, E., and Dubyak, G. R, (1989) J. Clin. Invest, 83, 1651-1660). P-2U agonists reportedly induce limited enzyme secretion and enhance the respiratory burst in response to chemotactic factors, We demonstrate here that P-2U agonists are chemotactic for neutrophils or differentiated HL60 cells. Rhodamine phalloidin staining indicates that ATP gamma S treatment induces actin polymerization and shape changes similar to those seen when these cells are treated with chemotactic peptide fMet-Leu-Phe. Although undifferentiated HL60 cells fail to mount a rise in Ca2+ when challenged with fMet-Leu-Phe, they increase Ca2+ in response to P-2U agonists, However, functional expression of phospholipase C-coupled receptors is not sufficient for chemotaxis since HL60 cell migration in response to these agonists or to fMet-Leu-Phe occurs only after exposure to differentiating agents such as BT(2)cAMP, In addition to the well known G protein-linked receptors for lipid or peptide chemotactic factors, neutrophils apparently also can utilize G protein-linked purino/pyrimidino receptors to recognize nucleotides as chemoattractants. High concentrations of ATP and UTP generated at sites of platelet aggregation and tissue injury could thus be important mediators of inflammation.	GLAXO WELLCOME INC,DEPT CELL BIOL,RES TRIANGLE PK,NC 27709; ARMED FORCES RADIOBIOL RES INST,DEPT RADIAT PATHOPHYSIOL & TOXICOL,BETHESDA,MD 20889	GlaxoSmithKline; United States Department of Defense								AXTELL RA, 1990, BLOOD, V75, P1324; BOYER JL, 1989, J BIOL CHEM, V264, P884; CHAPLINSKI TJ, 1982, J CLIN INVEST, V70, P953, DOI 10.1172/JCI110707; COCKCROFT S, 1989, BIOCHEM J, V263, P715, DOI 10.1042/bj2630715; COOPER CL, 1989, J BIOL CHEM, V264, P6202; COWEN DS, 1989, J CLIN INVEST, V83, P1651, DOI 10.1172/JCI114064; COWEN DS, 1990, J BIOL CHEM, V265, P16181; DEVREOTES PN, 1988, ANNU REV CELL BIOL, V4, P649, DOI 10.1146/annurev.cb.04.110188.003245; ERB L, 1993, P NATL ACAD SCI USA, V90, P10449, DOI 10.1073/pnas.90.22.10449; GORDON JL, 1986, BIOCHEM J, V233, P309, DOI 10.1042/bj2330309; HARVATH L, 1991, J IMMUNOL, V146, P224; OKAJIMA F, 1987, J BIOL CHEM, V262, P13483; PARR CE, 1994, P NATL ACAD SCI USA, V91, P3275, DOI 10.1073/pnas.91.8.3275; PIROTTON S, 1993, CELL SIGNAL, V5, P1, DOI 10.1016/0898-6568(93)90002-4; REIBMAN J, 1991, P NATL ACAD SCI USA, V88, P6805, DOI 10.1073/pnas.88.15.6805; SEIFERT R, 1989, TRENDS PHARMACOL SCI, V10, P365, DOI 10.1016/0165-6147(89)90009-6; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; XIE MS, 1991, J CLIN INVEST, V88, P45, DOI 10.1172/JCI115303	19	69	69	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15597	15601		10.1074/jbc.271.26.15597	http://dx.doi.org/10.1074/jbc.271.26.15597			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663069	hybrid			2022-12-27	WOS:A1996UV29900045
J	Johnson, RM; Buck, S; Chiu, CH; Schneider, H; Sampaio, I; Gage, DA; Shen, TL; Schneider, MPC; Muniz, JA; Gumucio, DL; Goodman, M				Johnson, RM; Buck, S; Chiu, CH; Schneider, H; Sampaio, I; Gage, DA; Shen, TL; Schneider, MPC; Muniz, JA; Gumucio, DL; Goodman, M			Fetal globin expression in new world monkeys	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHYLOGENETIC FOOTPRINTING REVEALS; EPSILON-GLOBIN; NUCLEOTIDE-SEQUENCES; GAMMA; GENES; HEMOGLOBIN; PRIMATES; CAPUCHIN; CHAINS	Reverse phase chromatography of the globin chains of adult, newborn, and fetal erythrocytes from three species of New World monkeys (Cebus apella, Aotus azarae, and Callithrix jacchus) representing three of the seven platyrrhine clades showed that gamma-globin expression was fetal in these animals, The globins were identified by a combination of chemical sequencing and mass spectro metric analysis, Since gamma-globin expression is fetal in the other major simian branch, the catarrhines, but embryonic in prosimian primates and nonprimate placental mammals, the evolution of fetal recruitment can now be assigned to the period between the simian-prosimian divergence (55 million years ago) and the platyrrhine-catarrhine divergence (35 million years ago), The gamma-globin gene underwent tandem duplication during the same evolutionary epoch, in accord with a model that suggests that the downstream duplicated gamma-gene (gamma 2) was free to acquire the mutations necessary for fetal recruitment, Mass spectrometric analysis of tryptic digests of the gamma-globins verified the amino acid sequences deduced from genomic sequencing, Detailed analysis of high performance liquid chromatography and matrix-assisted laser desorption/ionization mass spectrometry data showed that gamma 2-globin in Cebus was expressed to a far greater extent than gamma 1-globin, supporting inferences drawn from a study of the promoter sequences, A ''pre-gamma''-globin was observed in C. apella and shown to be primarily the glutathionyl adduct, The other species, A. azarae and C. jacchus, also express only one gamma-globin polypeptide. This work provides biochemical evidence of an evolutionary trend in the platyrrhines to alter the duplicated gamma-globin gene locus so that only one gamma-globin polypeptide is expressed.	WAYNE STATE UNIV,SCH MED,DEPT ANAT & CELL BIOL,DETROIT,MI 48201; MICHIGAN STATE UNIV,DEPT BIOCHEM,MASS SPECT FACIL,E LANSING,MI 48824; UNIV MICHIGAN,DEPT ANAT & CELL BIOL,ANN ARBOR,MI 48109; UNIV FED PARA,DEPT GENET,BELEM,PARA,BRAZIL; CTR NACL PRIMATAS,ANANINDEUA,PARA,BRAZIL	Wayne State University; Michigan State University; University of Michigan System; University of Michigan; Universidade Federal do Para	Johnson, RM (corresponding author), WAYNE STATE UNIV,SCH MED,DEPT BIOCHEM,540 E CANFIELD,DETROIT,MI 48201, USA.		SAMPAIO, IRACILDA/J-6514-2012; Schneider, Horacio/J-7131-2012	SAMPAIO, IRACILDA/0000-0002-2137-4656; Schneider, Horacio/0000-0002-5987-6395	NCRR NIH HHS [RR-00480] Funding Source: Medline; NHLBI NIH HHS [HL-33940] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR000480] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL033940] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALLEN DW, 1961, J CLIN INVEST, V40, P454, DOI 10.1172/JCI104273; BIRCHMEIER W, 1973, BIOCHEMISTRY-US, V12, P3667, DOI 10.1021/bi00743a015; BOYER SH, 1969, ANN NY ACAD SCI, V165, P360, DOI 10.1111/j.1749-6632.1969.tb27806.x; BOYER SH, 1970, BIOCH GENET, V5, P405; Bunn HF, 1986, HEMOGLOBIN MOL GENET; CHIU CH, 1996, IN PRESS P NATL ACAD; DESIMONE J, 1979, BLOOD, V53, P19, DOI 10.1182/blood.V53.1.19.19; FITCH DHA, 1991, P NATL ACAD SCI USA, V88, P7396, DOI 10.1073/pnas.88.16.7396; FITCH DHA, 1990, J BIOL CHEM, V265, P781; GOODMAN M, 1996, IN PRESS GENE FAMILI; GROSVELD F, 1993, COLD SPRING HARB SYM, V58, P7, DOI 10.1101/SQB.1993.058.01.004; GUMUCIO DL, 1992, MOL CELL BIOL, V12, P4919, DOI 10.1128/MCB.12.11.4919; GUMUCIO DL, 1994, J BIOL CHEM, V269, P15371; GUMUCIO DL, 1993, P NATL ACAD SCI USA, V90, P6018, DOI 10.1073/pnas.90.13.6018; HARADA ML, 1995, MOL PHYLOGENET EVOL, V4, P331, DOI 10.1006/mpev.1995.1029; HAYASAKA K, 1992, J MOL BIOL, V224, P875, DOI 10.1016/0022-2836(92)90568-5; HAYASAKA K, 1993, GENOMICS, V18, P20, DOI 10.1006/geno.1993.1422; HUISHMAN TH, 1966, J LAB CLIN MED, V67, P355; HUISMAN THJ, 1973, BIOCHEM GENET, V10, P309, DOI 10.1007/BF00485708; HUISMAN THJ, 1986, HEMOGLOBINOPATHIES, P1; MATSUDA G, 1973, H-S Z PHYSIOL CHEM, V354, P1513; MEIRELES CMM, 1995, P NATL ACAD SCI USA, V92, P2607, DOI 10.1073/pnas.92.7.2607; MYERS RM, 1986, SCIENCE, V232, P613, DOI 10.1126/science.3457470; NUTE PE, 1971, COMP BIOCHEM PHYSIOL, V39, P797, DOI 10.1016/0305-0491(71)90104-0; SCHNEIDER H, 1993, MOL PHYLOGENET EVOL, V2, P225, DOI 10.1006/mpev.1993.1022; SCHROEDER WA, 1986, HEMOGLOBIN, V10, P239, DOI 10.3109/03630268609042845; SHELTON JB, 1984, J LIQ CHROMATOGR, V7, P1969, DOI 10.1080/01483918408068849; SLIGHTOM JL, 1988, J BIOL CHEM, V262, P7472; SPRITZ RA, 1988, MOL BIOL EVOL, V5, P21; TAGLE DA, 1988, J MOL BIOL, V203, P439, DOI 10.1016/0022-2836(88)90011-3; TANIOKA Y, 1986, BIOL CHEM H-S, V367, P147, DOI 10.1515/bchm3.1986.367.1.147	31	21	21	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14684	14691		10.1074/jbc.271.25.14684	http://dx.doi.org/10.1074/jbc.271.25.14684			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663037	hybrid			2022-12-27	WOS:A1996UT10600010
J	Mukhija, S; Erni, B				Mukhija, S; Erni, B			Purification by Ni2+ affinity chromatography, and functional reconstitution of the transporter for N-acetylglucosamine of Escherichia coli	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL PHOSPHOTRANSFERASE SYSTEM; MEMBRANE-BOUND ENZYMES; SALMONELLA-TYPHIMURIUM; GLUCOSE-TRANSPORTER; CHITIN UTILIZATION; MARINE-BACTERIA; SUGAR-TRANSPORT; KLEBSIELLA-PNEUMONIAE; STREPTOCOCCUS-LACTIS; VIBRIO-FURNISSII	The N-acetyl-D-glucosamine transporter (IIGlcNAc) Of the bacterial phosphotransferase system couples vectorial translocation to phosphorylation of the transported GlcNAc, IIGlcNAc of Escherichia coli containing a carboxyl-terminal affinity tag of six histidines was purified by Ni2+ chelate affinity chromatography. 4 mg of purified protein was obtained from 10 g (wet weight) of cells. Purified IIGlcNAc was reconstituted into phospholipid vesicles by detergent dialysis and freeze/thaw sonication. IIGlcNAc was Oriented randomly in the vesicles as inferred from protein phosphorylation studies. Import and subsequent phosphorylation of GlcNAc were measured with proteoliposomes preloaded with enzyme I, histidine-containing phosphocarrier protein, and phosphoenolpyruvate. Uptake and phosphorylation occurred in a 1:1 ratio, Active extrusion of GlcNAc entrapped in vesicles was also measured by the addition of enzyme I, histidine-containing phosphocarrier protein, and phosphoenolpyruvate to the outside of the vesicles. The K-m for vectorial phosphorylation and non-vectorial phosphorylation were 66.6 +/- 8.2 mu m and 750 +/- 19.6 mu m, respectively, Non-vectorial phosphorylation was faster than vectorial phosphorylation with k(cat) 15.8 +/- 0.9 s(-1) and 6.2 +/- 0.7 s(-1), respectively. Using exactly the same conditions, the purified transporters for mannose (IIAB(Man), IICMan, IIDMan) and glucose (IICBGlc, IIA(Glc)) were also reconstituted for comparison. Although the vectorial transport activities of IICBA(GlcNAc) and IICBGlc IIA(Glc) are inhibited by non vectorial phosphorylation, no such effect was observed with the IIAB(Man) IICMan IIDMan complex, This suggests that the molecular mechanisms underlying solute transport and phosphorylation are different for different transporters of the phosphotransferase system.	UNIV BERN, INST BIOCHEM, CH-3012 BERN, SWITZERLAND	University of Bern								BASSLER BL, 1991, J BIOL CHEM, V266, P24268; BASSLER BL, 1991, J BIOL CHEM, V266, P24276; BUHR A, 1993, J BIOL CHEM, V268, P11599; BUHR A, 1994, J BIOL CHEM, V269, P23437; DORSCHUG M, 1984, EUR J BIOCHEM, V144, P113, DOI 10.1111/j.1432-1033.1984.tb08438.x; ELFERINK MGL, 1990, J BACTERIOL, V172, P7119, DOI 10.1128/jb.172.12.7119-7125.1990; ERNI B, 1985, J BIOL CHEM, V260, P5495; ERNI B, 1989, FEMS MICROBIOL LETT, V63, P13, DOI 10.1016/0168-6445(89)90004-1; ERNI B, 1982, J BIOL CHEM, V257, P13726; HUBER F, 1996, THESIS U BERN BERN; HUMMEL U, 1992, PROTEIN SCI, V1, P356; JACOBSON GR, 1979, J BIOL CHEM, V254, P249; KUNDIG W, 1964, P NATL ACAD SCI USA, V52, P1067, DOI 10.1073/pnas.52.4.1067; KUNDIG W, 1971, J BIOL CHEM, V246, P1407; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LENGELER J, 1981, MOL GEN GENET, V183, P163, DOI 10.1007/BF00270156; LENGELER JW, 1994, BBA-BIOENERGETICS, V1188, P1, DOI 10.1016/0005-2728(94)90017-5; LEVY D, 1990, J BIOL CHEM, V265, P19524; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LIAO DI, 1991, BIOCHEMISTRY-US, V30, P9583, DOI 10.1021/bi00104a004; MAC Q, 1995, J BIOL CHEM, V270, P5258; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MEADOW ND, 1990, ANNU REV BIOCHEM, V59, P497, DOI 10.1146/annurev.biochem.59.1.497; MEADOW ND, 1987, J BACTERIOL, V169, P4893, DOI 10.1128/jb.169.11.4893-4900.1987; MEINS M, 1993, J BIOL CHEM, V268, P11604; NUNN RS, 1996, IN PRESS J MOL BIOL; NUOFFER C, 1988, J BIOL CHEM, V263, P6647; PERHAM RN, 1991, BIOCHEMISTRY-US, V30, P8501, DOI 10.1021/bi00099a001; PERI GK, 1991, BIOCH CELL BIOL, V68, P123; PERI KG, 1988, BIOCHEMISTRY-US, V27, P6054, DOI 10.1021/bi00416a034; PHILIPPOT J, 1983, BIOCHIM BIOPHYS ACTA, V734, P137, DOI 10.1016/0005-2736(83)90111-6; PLUMBRIDGE J, 1993, MOL MICROBIOL, V10, P973, DOI 10.1111/j.1365-2958.1993.tb00969.x; PLUMBRIDGE J, 1991, J MOL BIOL, V217, P661, DOI 10.1016/0022-2836(91)90524-A; PLUMBRIDGE JA, 1990, J BACTERIOL, V172, P2728, DOI 10.1128/jb.172.5.2728-2735.1990; POSTMA PW, 1993, MICROBIOL REV, V57, P543, DOI 10.1128/MMBR.57.3.543-594.1993; RACKER E, 1979, ARCH BIOCHEM BIOPHYS, V198, P470, DOI 10.1016/0003-9861(79)90521-6; ROGERS MJ, 1988, GENE, V62, P197; ROOSSIEN FF, 1983, BIOCHIM BIOPHYS ACTA, V760, P185, DOI 10.1016/0304-4165(83)90141-1; SAIER MH, 1994, MOL MICROBIOL, V13, P755; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; THOMPSON J, 1985, J BACTERIOL, V162, P224, DOI 10.1128/JB.162.1.224-234.1985; THOMPSON J, 1985, J BACTERIOL, V162, P217, DOI 10.1128/JB.162.1.217-223.1985; VANDERVLAG J, 1995, MOL GEN GENET, V248, P236, DOI 10.1007/BF02190806; VOGLER AP, 1988, MOL GEN GENET, V213, P175, DOI 10.1007/BF00333417; VOGLER AP, 1989, MOL GEN GENET, V219, P97, DOI 10.1007/BF00261163; VOGLER AP, 1988, MOL MICROBIOL, V2, P719, DOI 10.1111/j.1365-2958.1988.tb00082.x; WAEBER U, 1993, FEBS LETT, V324, P109, DOI 10.1016/0014-5793(93)81542-8; WAYGOOD EB, 1984, J CELL BIOCHEM, V25, P139, DOI 10.1002/jcb.240250304; WEIGEL N, 1982, J BIOL CHEM, V257, P4499; WEIGEL N, 1982, J BIOL CHEM, V257, P4477; YU C, 1991, J BIOL CHEM, V266, P24260	51	18	19	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14819	14824		10.1074/jbc.271.25.14819	http://dx.doi.org/10.1074/jbc.271.25.14819			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662917	hybrid			2022-12-27	WOS:A1996UT10600030
J	Varlamov, O; Leiter, EH; Fricker, L				Varlamov, O; Leiter, EH; Fricker, L			Induced and spontaneous mutations at Ser(202) of carboxypeptidase E - Effect on enzyme expression, activity, and intracellular routing	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEUROPEPTIDE-PROCESSING ENZYME; MOLECULAR-CLONING; SEQUENCE-ANALYSIS; CRYSTAL-STRUCTURE; ATT-20 CELLS; CDNA; IDENTIFICATION; PURIFICATION; DEGRADATION; RESOLUTION	Carboxypeptidase E (CPE) is involved in peptide processing in the brain and various neuroendocrine tissues. In mice homozygous for the Cpe(fat) mutation, the virtual absence of CPE activity in islets of Langerhans and pituitary was associated with a missense mutation effecting a Ser(202) to Pro shift (Naggert, J. K., Fricker, L. D., Varlamov, O., Nishina, P. M., Rouille, Y., Steiner, D. F., Carroll, R. J., Paigen, B. J., and Leiter, E. H. (1995) Not. Genet. 10, 135-142). To examine the importance of Ser(202) in CPE function, several mutations in this position were generated (pro(202), Ala(202), Gly(202), and Phe(202)). When the mutant proteins were expressed in a Baculovirus system, both Phe(202) and Pro(202)CPE were enzymatically inactive, were unable to bind to a substrate affinity column, and were not secreted from Sf9 cells. In contrast, Ala(202)CPE or Gly(202)CPE exhibited enzymatic properties similar to those of wild-type CPE and were secreted from Sf9 cells. When expressed in AtT-20 cells, a mouse pituitary-derived cell line, CPE with pro(202) and Phe(202) were not secreted. Pulse-chase analysis with [S-35]Met indicated that Pro(202)CPE Wag degraded in AtT-20 cells within several hours. This degradative process was blocked by incubation at 15 degrees C but not by brefeldin A or by lysoso-motrophic drugs. Pulse-chase analysis using dispersed pituitary cells from C57BLKS/Lt-Cpe(fat)/Cpe(fat) mutant mice shows similar results; Pro(202)-CPE produced in these cells was not secreted but rather was degraded within 5 h. Immunofluorescence analysis of epitope-tagged CPE revealed Ser(202)CPE to be present primarily in secretory vesicles, whereas pro(202)CPE was localized to the endoplasmic reticulum and not the secretory vesicle-like structures. These results support the previous finding that Cpe(fat)/Cpe(fat) mice are defective in CPE activity because of the point mutation producing the Ser(202) to Pro substitution. Furthermore, these results are consistent with a model that Ser(202) is important for the intracellular folding of CPE.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; JACKSON LAB,BAR HARBOR,ME 04609	Yeshiva University; Albert Einstein College of Medicine; Jackson Laboratory					NATIONAL INSTITUTE ON DRUG ABUSE [R01DA004494, K02DA000194] Funding Source: NIH RePORTER; NIDA NIH HHS [DA-00194, DA-04494] Funding Source: Medline	NATIONAL INSTITUTE ON DRUG ABUSE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission); NIDA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA))		ADELI K, 1994, J BIOL CHEM, V269, P9166; [Anonymous], 1995, METH NEUROSCI; Bennett HPJ, 1991, PEPTIDE BIOSYNTHESIS, P111; BRADSHAW RA, 1969, P NATL ACAD SCI USA, V63, P1389, DOI 10.1073/pnas.63.4.1389; CLAUSER E, 1988, J BIOL CHEM, V263, P17837; DAVIDSON HW, 1987, BIOCHEM J, V245, P575, DOI 10.1042/bj2450575; EATON DL, 1991, J BIOL CHEM, V266, P21833; FRICKER LD, 1986, NATURE, V323, P461, DOI 10.1038/323461a0; FRICKER LD, 1990, J BIOL CHEM, V265, P2476; FRICKER LD, 1983, J BIOL CHEM, V258, P950; FRICKER LD, 1988, ANNU REV PHYSIOL, V50, P309, DOI 10.1146/annurev.ph.50.030188.001521; FRICKER LD, 1993, J NEUROCHEM, V61, P1404, DOI 10.1111/j.1471-4159.1993.tb13634.x; FRICKER LD, 1989, MOL ENDOCRINOL, V3, P666, DOI 10.1210/mend-3-4-666; FRICKER LD, 1991, PEPTIDE BIOSYNTHESIS, P199; GARDNER AM, 1993, J BIOL CHEM, V268, P25940; GEBHARD W, 1989, EUR J BIOCHEM, V178, P603, DOI 10.1111/j.1432-1033.1989.tb14488.x; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HE GP, 1995, NATURE, V378, P92, DOI 10.1038/378092a0; HORNBY PJ, 1993, NEUROENDOCRINOLOGY, V58, P555, DOI 10.1159/000126590; HOSAKA M, 1991, J BIOL CHEM, V266, P12127; KUROKI K, 1995, J BIOL CHEM, V270, P15022, DOI 10.1074/jbc.270.25.15022; LIPPINCOTTSCHWARTZ J, 1988, CELL, V54, P209, DOI 10.1016/0092-8674(88)90553-3; MANSER E, 1990, BIOCHEM J, V267, P517, DOI 10.1042/bj2670517; MITRA A, 1994, J BIOL CHEM, V269, P19876; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; REES DC, 1983, J MOL BIOL, V168, P367, DOI 10.1016/S0022-2836(83)80024-2; REYNOLDS DS, 1989, P NATL ACAD SCI USA, V86, P9480, DOI 10.1073/pnas.86.23.9480; ROTH WW, 1991, MOL CELL ENDOCRINOL, V78, P171, DOI 10.1016/0303-7207(91)90120-H; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAFER MKH, 1993, J NEUROSCI, V13, P1258; SCHMID MF, 1976, J MOL BIOL, V103, P175, DOI 10.1016/0022-2836(76)90058-9; SEIDAH NG, 1990, DNA CELL BIOL, V9, P415, DOI 10.1089/dna.1990.9.415; SETTLE SH, 1995, P NATL ACAD SCI USA, V92, P9470, DOI 10.1073/pnas.92.21.9470; SMEEKENS SP, 1990, J BIOL CHEM, V265, P2997; SONG LX, 1995, J BIOL CHEM, V270, P7963, DOI 10.1074/jbc.270.14.7963; SONG LX, 1995, J BIOL CHEM, V270, P25007, DOI 10.1074/jbc.270.42.25007; SONG LX, 1995, J NEUROCHEM, V65, P444; TAN FL, 1989, J BIOL CHEM, V264, P13165; TEPLYAKOV A, 1992, EUR J BIOCHEM, V208, P281, DOI 10.1111/j.1432-1033.1992.tb17184.x; TITANI K, 1975, P NATL ACAD SCI USA, V72, P1666, DOI 10.1073/pnas.72.5.1666; Varlamov O, 1996, J BIOL CHEM, V271, P6077, DOI 10.1074/jbc.271.11.6077; YAMASHITA Y, 1994, J VIROL, V68, P7933, DOI 10.1128/JVI.68.12.7933-7943.1994; YUN HY, 1995, J BIOL CHEM, V270, P15412, DOI 10.1074/jbc.270.25.15412; ZHENG M, 1994, J NEUROSCI, V14, P4656; ZHU X, 1996, IN PRESS P NATL ACAD	45	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13981	13986		10.1074/jbc.271.24.13981	http://dx.doi.org/10.1074/jbc.271.24.13981			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662840	hybrid			2022-12-27	WOS:A1996UQ66000011
J	McKenzie, FR; Pouyssegur, J				McKenzie, FR; Pouyssegur, J			cAMP-mediated growth inhibition in fibroblasts is not mediated via mitogen-activated protein (MAP) kinase (ERK) inhibition - cAMP-dependent protein kinase induces a temporal shift in growth factor-stimulated MAP kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC-AMP; HAMSTER FIBROBLASTS; SIGNAL-TRANSDUCTION; DNA-SYNTHESIS; PHOSPHORYLATION; PATHWAY; RAF; CELLS; PROLIFERATION; P42(MAPK)	Growth factors stimulate fibroblast cell division by activating the recently identified mitogen-activated protein kinase (MAP kinase) signaling cascade. In contrast to our previous work (Kahan, K., Seuwen, K., 13369-13375), several reports have suggested that an elevation in intracellular cAMP blocks cell proliferation by attenuating MAP kinase activation. Hence we re-examined the effect of a long term increase in intracellular cAMP and therefore cAMP-dependent protein kinase (PKA) activation on the MAP kinase cascade in CCL39 fibroblasts. The concomitant addition of cAMP-elevating agents prostaglandin E, (PGE(1)) and IBMX did not inhibit the mitogen-mediated activation of p44 MAP kinase. However, a 5-min PGE(1)/IBMX pretreatment abolished the MAP kinase response, in a manner correlating with the extent of PKA activity. This inhibition was temporal in nature, and while modifying the time course of growth factor-mediated p44 MAP kinase, activation did not diminish the magnitude of the response. Thus the major peak of MAP kinase activity normally present 5 min after alpha-thrombin addition was now evident at 10 min in the presence of PGE(1)/IBMX. CCL39 cell proliferation could reflect either a reduction in the number of cells entering the cell cycle or a delay in the time required to go through the cycle. Bromodeoxyuridine labeling experiments revealed that the cAMP-mediated inhibition of DNA synthesis in CCL39 cell was not due to a delay in S phase entry, but was due to a reduction in the number of cells entering S phase. Thus we conclude that although PKA activation may slightly modify the time course of MAP kinase activation in response to mitogens in CCL39 cells, the PKA-mediated inhibition of cell division occurs through modulation of an intracellular target, distinct from the p42/p44 MAP kinase cascade.			McKenzie, FR (corresponding author), CTR BIOCHIM,CNRS,PARC VALROSE,F-06108 NICE,FRANCE.							ALALAWI N, 1995, MOL CELL BIOL, V15, P1162; BARLAT I, 1995, ONCOGENE, V11, P1309; Berra E, 1995, EMBO J, V14, P6157, DOI 10.1002/j.1460-2075.1995.tb00306.x; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRONDELLO JM, 1995, ONCOGENE, V10, P1895; BRUGGEMANN A, 1993, NATURE, V365, P445, DOI 10.1038/365445a0; BRUNET A, 1994, ONCOGENE, V9, P3379; BURGERING BMT, 1993, EMBO J, V12, P4211, DOI 10.1002/j.1460-2075.1993.tb06105.x; BURGERING BMT, 1995, TRENDS BIOCHEM SCI, V20, P18, DOI 10.1016/S0968-0004(00)88944-6; BURK RR, 1968, NATURE, V219, P1272, DOI 10.1038/2191272a0; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHEN JH, 1994, SCIENCE, V263, P1278, DOI 10.1126/science.8122111; COHEN P, 1992, TRENDS BIOCHEM SCI, V17, P408, DOI 10.1016/0968-0004(92)90010-7; COOK SJ, 1993, SCIENCE, V262, P1069, DOI 10.1126/science.7694367; CREWS CM, 1992, CELL GROWTH DIFFER, V3, P135; DENT P, 1995, SCIENCE, V268, P1902, DOI 10.1126/science.7604263; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DIFRANCESCO D, 1991, NATURE, V351, P145, DOI 10.1038/351145a0; DUMONT JE, 1989, TRENDS BIOCHEM SCI, V14, P67, DOI 10.1016/0968-0004(89)90046-7; FANTL WJ, 1994, NATURE, V371, P612, DOI 10.1038/371612a0; FAURE M, 1994, J BIOL CHEM, V269, P7851; FREED E, 1994, SCIENCE, V265, P1713, DOI 10.1126/science.8085158; FRODIN M, 1994, J BIOL CHEM, V269, P6207; FU H, 1994, SCIENCE, V266, P126, DOI 10.1126/science.7939632; GRAVES LM, 1993, P NATL ACAD SCI USA, V90, P10300, DOI 10.1073/pnas.90.21.10300; GUY HR, 1991, SCIENCE, V254, P730, DOI 10.1126/science.1658932; HAFNER S, 1994, MOL CELL BIOL, V14, P6696; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; HAYSTEAD CMM, 1994, J BIOL CHEM, V269, P12804; HORDIJK PL, 1994, J BIOL CHEM, V269, P3534; HOWE LR, 1992, CELL, V71, P335, DOI 10.1016/0092-8674(92)90361-F; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAHAN C, 1992, J BIOL CHEM, V267, P13369; KUPPERMAN E, 1993, MOL CELL BIOL, V13, P4477, DOI 10.1128/MCB.13.8.4477; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAMY F, 1993, J BIOL CHEM, V268, P8398; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LANGECARTER CA, 1993, SCIENCE, V260, P315, DOI 10.1126/science.8385802; LENORMAND P, 1993, J CELL BIOL, V122, P1079, DOI 10.1083/jcb.122.5.1079; LOEVERS SJ, 1994, NATURE, V369, P411; MAGNALDO I, 1989, FEBS LETT, V245, P65, DOI 10.1016/0014-5793(89)80193-0; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; MOODIE SA, 1994, TRENDS GENET, V10, P44, DOI 10.1016/0168-9525(94)90147-3; MORRISON DK, 1993, J BIOL CHEM, V268, P17309; NAKAMURA T, 1987, NATURE, V325, P442, DOI 10.1038/325442a0; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PAGES G, 1994, EMBO J, V13, P3003, DOI 10.1002/j.1460-2075.1994.tb06599.x; PASTAN IH, 1975, ANNU REV BIOCHEM, V44, P491, DOI 10.1146/annurev.bi.44.070175.002423; PERALDI P, 1995, FEBS LETT, V357, P290, DOI 10.1016/0014-5793(94)01376-C; PIPER RC, 1993, J BIOL CHEM, V268, P16557; REUTER CWM, 1995, J BIOL CHEM, V270, P7644, DOI 10.1074/jbc.270.13.7644; ROGERS KV, 1990, P NATL ACAD SCI USA, V87, P8975, DOI 10.1073/pnas.87.22.8975; ROSKOSKI R, 1983, METHOD ENZYMOL, V99, P3; SAUNIER B, 1995, J BIOL CHEM, V270, P3693, DOI 10.1074/jbc.270.8.3693; SEUWEN K, 1990, J BIOL CHEM, V265, P22292; SEVETSON BR, 1993, P NATL ACAD SCI USA, V90, P10305, DOI 10.1073/pnas.90.21.10305; SUTHERLAND EW, 1957, J AM CHEM SOC, V79, P3608, DOI 10.1021/ja01570a087; VAILLANCOURT RR, 1994, MOL CELL BIOL, V14, P6522, DOI 10.1128/MCB.14.10.6522; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WALSH DA, 1990, CRC CRIT REV BIOCH, P43; WANG YZ, 1992, BIOCHEM J, V287, P589, DOI 10.1042/bj2870589; WU J, 1993, SCIENCE, V262, P1065, DOI 10.1126/science.7694366; ZHENG CF, 1994, BIOCHEMISTRY-US, V33, P5595, DOI 10.1021/bi00184a031; ZHONG Y, 1995, NATURE, V375, P588, DOI 10.1038/375588a0	68	92	92	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13476	13483		10.1074/jbc.271.23.13476	http://dx.doi.org/10.1074/jbc.271.23.13476			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662790				2022-12-27	WOS:A1996UP38500028
J	Pinkus, R; Weiner, LM; Daniel, V				Pinkus, R; Weiner, LM; Daniel, V			Role of oxidants and antioxidants in the induction of AP-1, NF-kappa B, and glutathione S-transferase gene expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YA-SUBUNIT GENE; ELECTROPHILE-RESPONSIVE ELEMENT; INDUCIBLE EXPRESSION; TRANSCRIPTION FACTOR; BUTYLATED HYDROXYANISOLE; SUPEROXIDE-DISMUTASE; RADICAL FORMATION; INTACT-CELLS; ACTIVATION; JUN	Transcription factors AP-1 and NF-kappa B have been implicated in the inducible expression of a variety of genes in response to oxidative stress. Recently, based on the observation that butylated hydroxyanisole (BHA) and pyrrolidine dithiocarbamate (PDTC) induce AP-1 binding activity and AP-1-dependent gene expression and assuming that these compounds exert an antioxidant effect, it was claimed that AP-1 is an antioxidant-responsive factor. To determine whether AP-1 can be responsive to both oxidant and antioxidant, we examined the nature of BHA and PDTC inducing activity. Using EPR spectroscopy to detect semiquinone radicals, we demonstrate the autoxidation of BHA metabolite tert-butylhydroquinone (TBHQ) to tert-butylquinone. The kinetics of TBHQ-mediated generations of (OH)-O-. radicals were monitored in intact hepatoma HepG2 cells by EPR spin trapping technique. Exogenous catalase inhibited the rate and amount of (OH)-O-. radical formation and the induction of AP-1-mediated glutathione S-transferase (GST) Ya gene expression by BHA and TBHQ, thus indicating the intermediate formation of H2O2 in the metabolism of these chemicals. Furthermore, we show that the induction of AP-1 and NF-kappa B activities and GST Ya gene expression by BHA and TBHQ is due to a pro-oxidant activity, since this induction was inhibited by thiol compounds N-acetyl cysteine and GSH. The present findings do not support the notion that the induction of AP-1 by BHA, TBHQ, or PDTC is an antioxidant response and demonstrate that both AP-1 and NF-kappa B activities are induced by oxygen radicals.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL; WEIZMANN INST SCI, DEPT ORGAN CHEM, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science; Weizmann Institute of Science			Lev, Weiner/GZK-4484-2022					ADCOCK IM, 1994, BIOCHEM BIOPH RES CO, V199, P1518, DOI 10.1006/bbrc.1994.1403; ANGEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129, DOI 10.1016/0304-419X(91)90011-9; ASHWORTH P, 1975, MOL PHYS, V30, P313, DOI 10.1080/00268977500101961; BAEUERLE PA, 1988, SCIENCE, V242, P540, DOI 10.1126/science.3140380; BELLOMO G, 1990, METHOD ENZYMOL, V186, P627; BERGELSON S, 1994, ONCOGENE, V9, P565; BERGELSON S, 1994, CANCER RES, V54, P36; BOYNE AF, 1972, ANAL BIOCHEM, V46, P639, DOI 10.1016/0003-2697(72)90335-1; BUETTNER GR, 1987, FREE RADICAL BIO MED, V3, P259, DOI 10.1016/S0891-5849(87)80033-3; BUETTNER GR, 1990, METHOD ENZYMOL, V186, P127; CERUTTI PA, 1985, SCIENCE, V227, P375, DOI 10.1126/science.2981433; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DANIEL V, 1993, CRIT REV BIOCHEM MOL, V28, P173, DOI 10.3109/10409239309086794; DANIEL V, 1989, DNA-J MOLEC CELL BIO, V8, P399, DOI 10.1089/dna.1.1989.8.399; DANIEL V, 1993, STRUCTURE FUNCTION G, P129; DENEKE SM, 1979, J PHARMACOL EXP THER, V208, P377; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; DIKALOV SI, 1992, BIOCHEMISTRY-US, V31, P8947, DOI 10.1021/bi00152a034; FORMAN HJ, 1980, J PHARMACOL EXP THER, V212, P452; FRIDOVICH I, 1978, SCIENCE, V201, P875, DOI 10.1126/science.210504; FRILING RS, 1990, P NATL ACAD SCI USA, V87, P6258, DOI 10.1073/pnas.87.16.6258; FRILING RS, 1992, P NATL ACAD SCI USA, V89, P668, DOI 10.1073/pnas.89.2.668; GOLDSTEIN BD, 1979, BIOCHEM PHARMACOL, V28, P27, DOI 10.1016/0006-2952(79)90265-X; GRIFFITH OW, 1980, ANAL BIOCHEM, V106, P207, DOI 10.1016/0003-2697(80)90139-6; ISRAEL N, 1992, J IMMUNOL, V149, P3386; KAHL R, 1989, TOXICOLOGY, V59, P179, DOI 10.1016/0300-483X(89)90056-5; KHRAMTSOV VV, 1989, ANAL BIOCHEM, V182, P58, DOI 10.1016/0003-2697(89)90718-5; LAUTIER D, 1992, CARCINOGENESIS, V13, P227, DOI 10.1093/carcin/13.2.227; MEISTER A, 1991, PHARMACOL THERAPEUT, V51, P155, DOI 10.1016/0163-7258(91)90076-X; MEYER M, 1993, EMBO J, V12, P2005, DOI 10.1002/j.1460-2075.1993.tb05850.x; MIHM S, 1991, AIDS, V5, P497, DOI 10.1097/00002030-199105000-00004; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MORIMOTO K, 1991, CARCINOGENESIS, V12, P703, DOI 10.1093/carcin/12.4.703; NGUYEN T, 1994, J BIOL CHEM, V269, P13656; NOBEL CSI, 1995, J BIOL CHEM, V270, P26202, DOI 10.1074/jbc.270.44.26202; OLLINGER K, 1990, CHEM-BIOL INTERACT, V73, P53, DOI 10.1016/0009-2797(90)90108-Y; PEDERSEN JA, 1985, CRC HDB EPR SPECTRA, P69; PINKUS R, 1993, BIOCHEM J, V290, P637, DOI 10.1042/bj2900637; PINKUS R, 1995, BIOCHEMISTRY-US, V34, P81, DOI 10.1021/bi00001a010; POWIS G, 1989, FREE RADICAL BIO MED, V6, P63, DOI 10.1016/0891-5849(89)90162-7; PUGA A, 1992, DNA CELL BIOL, V11, P269, DOI 10.1089/dna.1992.11.269; SCHENK H, 1994, P NATL ACAD SCI USA, V91, P1672, DOI 10.1073/pnas.91.5.1672; SCHILDERMAN PAEL, 1993, CARCINOGENESIS, V14, P347, DOI 10.1093/carcin/14.3.347; SCHMIDT KN, 1995, CHEM BIOL, V2, P13, DOI 10.1016/1074-5521(95)90076-4; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHRECK R, 1992, J EXP MED, V175, P1181, DOI 10.1084/jem.175.5.1181; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SCHULZEOSTHOFF K, 1993, EMBO J, V12, P3095, DOI 10.1002/j.1460-2075.1993.tb05978.x; SHERMAN ML, 1990, P NATL ACAD SCI USA, V87, P5663, DOI 10.1073/pnas.87.15.5663; SHI MM, 1994, J BIOL CHEM, V269, P26512; Sies, 1991, OXIDATIVE STRESS OXI, P245; SIES H, 1991, AM J MED, V91, pS31, DOI 10.1016/0002-9343(91)90281-2; STAAL FJT, 1990, P NATL ACAD SCI USA, V87, P9943, DOI 10.1073/pnas.87.24.9943; STEENKEN S, 1979, J PHYS CHEM-US, V83, P595, DOI 10.1021/j100468a008; TAYLOR KL, 1987, BIOCHEM PHARMACOL, V36, P141, DOI 10.1016/0006-2952(87)90391-1; WEINER LM, 1994, METHOD ENZYMOL, V233, P92; WEINER LM, 1995, METHOD ENZYMOL, V251, P87, DOI 10.1016/0076-6879(95)51113-X; WILFORD JH, 1985, J ELECTROANAL CHEM, V190, P271, DOI 10.1016/0022-0728(85)80094-2; YOSHIOKA K, 1995, P NATL ACAD SCI USA, V92, P4972, DOI 10.1073/pnas.92.11.4972; ZIEGLER DM, 1991, OXIDATIVE STRESS OXI, P85	60	425	434	2	23	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13422	13429		10.1074/jbc.271.23.13422	http://dx.doi.org/10.1074/jbc.271.23.13422			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662787				2022-12-27	WOS:A1996UP38500020
J	Yoshida, H; Kinoshita, K; Ashida, M				Yoshida, H; Kinoshita, K; Ashida, M			Purification of a peptidoglycan recognition protein from hemolymph of the silkworm, Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROPHENOLOXIDASE ACTIVATING SYSTEM; BACTERIAL-CELL WALLS; MURAMYL PEPTIDES; BINDING-PROTEIN; FREE IMMUNITY; AMINO-ACID; PLASMA; BETA-1,3-GLUCAN; LECTIN; LARVAE	A method was developed far obtaining a homogeneous silkworm hemolymph protein (peptidoglycan recognition protein, PGRP) which has affinity for peptidoglycan and the ability to trigger the prophenoloxidase cascade upon its binding to peptidoglycan. The purified PGRP had a molecular mass of about 19 kDa and is composed of a single polypeptide with an isoelectric point of 6.5. It bound to peptidoglycan in the absence of divalent cation, whereas its binding to beta 1,3-glucan and chitin was not detected. N-Acetyl-D-glucosaminyl-(beta 1-4)-N-acetylmuramyl-L-alanyl-D-isoglutamine did not inhibit purified PGRP to bind Insoluble peptidoglycan, but fragmented soluble peptidoglycan did. PGRP seemed to require peptidoglycan as a possible ligand to keep its glycan portion consisting of at least two or more of the repeating unit. PGRP did not have any detectable lysozyme activity, and its amino acid composition and amino-terminal sequence of 20 amino acid residues were shown to be different from those of silkworm lysozyme, PGRP seems to be a hitherto unknown protein. In the absence of PGRP, the prophenoloxidase cascade in the plasma fraction of hemolymph could not be triggered by peptidoglycan, indicating that some type of activity, capable of activating the cascade, is generated upon their binding. However, the exact nature of this activity is not yet known. The purified PGRP bound to peptidoglycan did not hydrolyze significantly any of the 26 commercially available peptidyl-7-amino-4-methylcoumarins, substrates for various proteases.	HOKKAIDO UNIV, INST LOW TEMP SCI, SAPPORO, HOKKAIDO 060, JAPAN	Hokkaido University								AMANAI K, 1990, COMP BIOCHEM PHYS B, V97, P471, DOI 10.1016/0305-0491(90)90146-K; ARAKI Y, 1972, J BIOL CHEM, V247, P6312; ASHIDA M, 1983, BIOCHEM BIOPH RES CO, V113, P562, DOI 10.1016/0006-291X(83)91762-X; ASHIDA M, 1994, INSECT BIOCHEM MOLEC, V24, P1037, DOI 10.1016/0965-1748(94)90141-4; Ashida M., 1990, P239; ASHIDA M, 1995, P NATL ACAD SCI USA, V92, P10698, DOI 10.1073/pnas.92.23.10698; ASHIDA M, 1981, INSECT BIOCHEM, V11, P57, DOI 10.1016/0020-1790(81)90041-X; ASHIDA M, 1988, INSECT BIOCHEM, V18, P11, DOI 10.1016/0020-1790(88)90031-5; BOMAN HG, 1991, EUR J BIOCHEM, V201, P23, DOI 10.1111/j.1432-1033.1991.tb16252.x; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; CERENIUS L, 1994, J BIOL CHEM, V269, P29462; DUNN PE, 1994, ANN NY ACAD SCI, V712, P117, DOI 10.1111/j.1749-6632.1994.tb33567.x; DUNN PE, 1986, ANNU REV ENTOMOL, V31, P321, DOI 10.1146/annurev.en.31.010186.001541; DUVIC B, 1990, J BIOL CHEM, V265, P9327; DZIARSKI R, 1994, J BIOL CHEM, V269, P2100; DZIARSKI R, 1991, J BIOL CHEM, V266, P4719; DZIARSKI R, 1994, J BIOL CHEM, V269, P20431; ENGSTROM A, 1985, EMBO J, V4, P2119, DOI 10.1002/j.1460-2075.1985.tb03901.x; HEWICK RM, 1981, J BIOL CHEM, V256, P7990; IKETANI M, 1993, INSECT BIOCHEM MOLEC, V23, P913, DOI 10.1016/0965-1748(93)90108-5; JANEWAY CA, 1989, COLD SPRING HARB SYM, V54, P1; JOHANSSON MW, 1989, PARASITOL TODAY, V5, P171, DOI 10.1016/0169-4758(89)90139-7; JOMORI T, 1991, J BIOL CHEM, V266, P13318; KIJIMOTOOCHIAI S, 1985, ANAL BIOCHEM, V147, P222, DOI 10.1016/0003-2697(85)90031-4; KOJIMA K, 1979, ANAL BIOCHEM, V100, P43, DOI 10.1016/0003-2697(79)90106-4; KOMANO H, 1985, DEV COMP IMMUNOL, V9, P31, DOI 10.1016/0145-305X(85)90057-6; KOTANI E, 1995, BBA-GENE STRUCT EXPR, V1260, P245, DOI 10.1016/0167-4781(94)00202-E; KOTANI S, 1986, FASEB J, V45, P2534; Lackie A.M., 1988, Advances in Insect Physiology, V21, P85, DOI 10.1016/S0065-2806(08)60123-X; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUNT MR, 1960, BIOCHIM BIOPHYS ACTA, V44, P371, DOI 10.1016/0006-3002(60)91581-X; MUTA T, 1991, J BIOL CHEM, V266, P6554; NAPPI AJ, 1993, PIGM CELL RES, V6, P117, DOI 10.1111/j.1600-0749.1993.tb00590.x; OCHIAI M, 1988, J BIOL CHEM, V263, P12056; PENDLAND JC, 1986, DEV COMP IMMUNOL, V10, P477, DOI 10.1016/0145-305X(86)90169-2; RATCLIFFE NA, 1984, SCIENCE, V226, P557, DOI 10.1126/science.226.4674.557; SAMAKOVLIS C, 1992, BIOCHEM BIOPH RES CO, V188, P1169, DOI 10.1016/0006-291X(92)91354-S; SCHMIDT O, 1993, DEV COMP IMMUNOL, V17, P195, DOI 10.1016/0145-305X(93)90038-R; SILVERMAN DHS, 1986, J IMMUNOL, V136, P2195; SIMPSON RJ, 1976, J BIOL CHEM, V251, P1936; SODERHALL K, 1988, INSECT BIOCHEM, V18, P323, DOI 10.1016/0020-1790(88)90045-5; SUN SC, 1990, SCIENCE, V250, P1729, DOI 10.1126/science.2270488; TAKLE GB, 1986, J CELL SCI, V85, P85; ULEVITCH RJ, 1993, ADV IMMUNOL, V53, P267, DOI 10.1016/S0065-2776(08)60502-7; VASTA GR, 1994, ANN NY ACAD SCI, V712, P55, DOI 10.1111/j.1749-6632.1994.tb33562.x; Vey A., 1986, P89; Wrigley C.W., 1971, METHOD ENZYMOL, V22, P559; YOSHIDA H, 1986, BIOCHEM BIOPH RES CO, V141, P1177, DOI 10.1016/S0006-291X(86)80168-1; YOSHIDA H, 1986, INSECT BIOCHEM, V16, P539, DOI 10.1016/0020-1790(86)90031-4; YPHANTIS DA, 1964, BIOCHEMISTRY-US, V3, P297, DOI 10.1021/bi00891a003	51	384	424	2	36	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS		1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13854	13860		10.1074/jbc.271.23.13854	http://dx.doi.org/10.1074/jbc.271.23.13854			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662762	hybrid			2022-12-27	WOS:A1996UP38500082
J	Yoshimura, M; Ihara, Y; Matsuzawa, Y; Taniguchi, N				Yoshimura, M; Ihara, Y; Matsuzawa, Y; Taniguchi, N			Aberrant glycosylation of E-cadherin enhances cell-cell binding to suppress metastasis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							UDP-N-ACETYLGLUCOSAMINE; OLIGOSACCHARIDES; PURIFICATION; EXPRESSION; CDNA	Introduction of the beta 1-4 N-acetylglucosaminyltransferase (GnT-III) gene was reported to suppress metastasis in highly metastatic B16-hm murine melanoma cells (Yoshimura, M., Nishikawa, A., Ihara, Y., Taniguchi, S., and Taniguchi, N. (1995) Proc, Natl. Acad, Sci. U. S. A. 92, 8754-8758), In this study, the effect of GnT-III gene transfer on E-cadherin was studied, since E-cadherin acts as a suppressor of metastasis. E-cadherin expression at cell-cell contacts of B16-hm cells expressing high GnT-III activity was greater than controls without affecting transcription, Lectin blotting showed that E-cadherin from GnT-III transfectants was glycosylated by ectopically expressed GnT-III, The glycosylated E-cadherin exhibited the delayed turnover and the decreased release from cell surface, as compared with the native E-cadherin, resulting in the elevated expression at the cell-cell border of GnT-III transfectants. Furthermore, cell-cell aggregation was enhanced in GnT-III transfectants, indicating that the glycosylated E-cadherin is biologically functional, These results suggest that the glycosylated E-cadherin contributes to the suppression of metastasis by the introduction of GnT-III gene into melanoma cells.	OSAKA UNIV,SCH MED,DEPT BIOCHEM,SUITA,OSAKA 565,JAPAN; OSAKA UNIV,SCH MED,DEPT INTERNAL MED 2,SUITA,OSAKA 565,JAPAN	Osaka University; Osaka University			Taniguchi, Naoyuki/A-7086-2016; Taniguchi, Naoyuki/I-4182-2014	Taniguchi, Naoyuki/0000-0001-5889-5968				CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; DEMETRIOU M, 1995, J CELL BIOL, V130, P383, DOI 10.1083/jcb.130.2.383; DENNIS JW, 1987, SCIENCE, V236, P582, DOI 10.1126/science.2953071; DWEK RA, 1995, SCIENCE, V269, P1234, DOI 10.1126/science.7652569; FERNANDES B, 1991, CANCER RES, V51, P718; FUJII S, 1990, J BIOL CHEM, V265, P6009; GU JG, 1993, J BIOCHEM, V113, P614, DOI 10.1093/oxfordjournals.jbchem.a124091; HART IR, 1992, LANCET, V339, P1453, DOI 10.1016/0140-6736(92)92039-I; JIANG WG, 1995, CANCER RES, V55, P5043; MIYOSHI E, 1995, J BIOL CHEM, V270, P28311; NAGAFUCHI A, 1987, NATURE, V329, P341, DOI 10.1038/329341a0; NISHIKAWA A, 1992, J BIOL CHEM, V267, P18199; ODA T, 1994, P NATL ACAD SCI USA, V91, P1858, DOI 10.1073/pnas.91.5.1858; SAITOH O, 1992, J BIOL CHEM, V267, P5700; SCHACHTER H, 1986, BIOCHEM CELL BIOL, V64, P163, DOI 10.1139/o86-026; SCHEIFFELE P, 1995, NATURE, V378, P96, DOI 10.1038/378096a0; Takeichi M, 1993, CURR OPIN CELL BIOL, V5, P806, DOI 10.1016/0955-0674(93)90029-P; TANIGUCHI N, 1995, GLYCOCONJUGATE J, V12, P733, DOI 10.1007/BF00731232; WYSS DF, 1995, SCIENCE, V269, P1273, DOI 10.1126/science.7544493; YAMASHITA K, 1983, J BIOL CHEM, V258, P4753; YOSHIMURA M, 1995, P NATL ACAD SCI USA, V92, P8754, DOI 10.1073/pnas.92.19.8754; YOUSEFI S, 1991, J BIOL CHEM, V266, P1772	22	173	177	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13811	13815		10.1074/jbc.271.23.13811	http://dx.doi.org/10.1074/jbc.271.23.13811			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662832				2022-12-27	WOS:A1996UP38500076
J	Feng, XH; Derynck, R				Feng, XH; Derynck, R			Ligand-independent activation of transforming growth factor (TGF) beta signaling pathways by heteromeric cytoplasmic domains of TGF-beta receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SERINE THREONINE KINASE; II RECEPTOR; ACTIVIN RECEPTOR; EXPRESSION CLONING; IDENTIFICATION; COMPLEX	Transforming growth factor beta (TGF-beta) transduces signals through two related serine/threonine kinase receptors, the type I and type II receptors, which have the ability to interact with each other. In the heteromeric complex, the type II receptor is the primary determinant of ligand binding and phosphorylates the cytoplasmic domain of the type I receptor. Using a chimeric receptor strategy, we and others have shown previously that a functional TGF-beta receptor complex requires heteromerization of both extracellular and intracellular domains of type I and type II receptors. In the current study, we show that overexpression of two receptors carrying a heteromeric combination of cytoplasmic domains resulted in ligand-independent responses, fur ther supporting the functional requirement of the two heterologous cytoplasmic domains in TGF-beta signaling. Furthermore, coexpression of only the cytoplasmic domains of both the type I and II receptors or tethering the type II to the type I cytoplasmic domain activated TGF-beta responses in a ligand-independent manner. In cotransfected COS-1 cells, both cytoplasmic domains are associated with each other. Our results indicate that the cytoplasmic domains of the type I and type II TGF-beta receptors physically and functionally interact with each other in the heteromeric complex.	UNIV CALIF SAN FRANCISCO,DEPT GROWTH & DEV,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT ANAT,PROGRAM CELL & DEV BIOL,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco					NCI NIH HHS [CA63101] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA063101] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ATTISANO L, 1992, CELL, V68, P97, DOI 10.1016/0092-8674(92)90209-U; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, J BIOL CHEM, V269, P14861; CHEN F, 1995, P NATL ACAD SCI USA, V92, P1565, DOI 10.1073/pnas.92.5.1565; CHEN RH, 1995, J BIOL CHEM, V270, P12235, DOI 10.1074/jbc.270.20.12235; CHEN RH, 1994, J BIOL CHEM, V269, P22868; DERYNCK R, 1994, TRENDS BIOCHEM SCI, V19, P548, DOI 10.1016/0968-0004(94)90059-0; Derynck R, 1994, CYTOKINE HDB, P319; EBNER R, 1993, SCIENCE, V262, P900, DOI 10.1126/science.8235612; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; FENG XH, 1995, J BIOL CHEM, V270, P24237, DOI 10.1074/jbc.270.41.24237; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; HE WW, 1993, DEV DYNAM, V196, P133, DOI 10.1002/aja.1001960207; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KEETON MR, 1991, J BIOL CHEM, V266, P23048; KINGSLEY DM, 1994, GENE DEV, V8, P133, DOI 10.1101/gad.8.2.133; LILLIEN L, 1995, NATURE, V377, P158, DOI 10.1038/377158a0; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; MATHEWS LS, 1992, SCIENCE, V255, P1702, DOI 10.1126/science.1313188; MATHEWS LS, 1991, CELL, V65, P973, DOI 10.1016/0092-8674(91)90549-E; MIETTINEN PJ, 1994, J CELL BIOL, V127, P2021, DOI 10.1083/jcb.127.6.2021; NEUHOLD LA, 1993, CELL, V74, P1033, DOI 10.1016/0092-8674(93)90725-6; OKADOME T, 1994, J BIOL CHEM, V269, P30753; RODRIGUEZ C, 1995, J BIOL CHEM, V270, P15919, DOI 10.1074/jbc.270.27.15919; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; TENDIJKE P, 1994, J BIOL CHEM, V269, P16985; TENDIJKE P, 1993, ONCOGENE, V8, P2879; VELU TJ, 1989, J CELL BIOCHEM, V39, P153, DOI 10.1002/jcb.240390207; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0; YAMASHITA H, 1994, J BIOL CHEM, V269, P20172	35	90	94	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13123	13129		10.1074/jbc.271.22.13123	http://dx.doi.org/10.1074/jbc.271.22.13123			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662796	hybrid			2022-12-27	WOS:A1996UN47400067
J	Pitt, RM; Marsters, SA; Ruppert, S; Donahue, CJ; Moore, A; Ashkenazi, A				Pitt, RM; Marsters, SA; Ruppert, S; Donahue, CJ; Moore, A; Ashkenazi, A			Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FACTOR RECEPTOR; CELL-DEATH; EXPRESSION; RESOLUTION; CLONING; SURFACE	Cytokines in the tumor necrosis factor (TNF) family regulate development and function of the immune system. We have isolated a new member of this family, designated Apo-2 ligand (Apo-2L), via an expressed sequence tag. Apo-2L is a 281-amino acid protein, related most closely to Fas/Apo-1 ligand. Transfected Apo-2L is expressed at the cell surface with its C terminus exposed, indicating a type II transmembrane protein topology. Like Fas/Apo-1 ligand and TNF, the C-terminal extracellular region of Apo-2L (amino acids 114-281) exhibits a homotrimeric subunit structure. Soluble Apo-2L induces extensive apoptosis in lymphoid as well as non-lymphoid tumor cell lines. The effect of Apo-2L is not inhibited by soluble Fas/Apo-1 and TNF receptors; moreover, expression of human Fas/Apo-1 in mouse fibroblasts, which confers sensitivity to induction of apoptosis by agonistic anti-Fas/Apo-1 antibody, does not confer sensitivity to Apo-2L. Hence, Apo-2L acts via a receptor which is distinct from Fas/Apo-1 and TNF receptors. These results suggest that, along with other family members such as Fas/Apo-1 ligand and TNF, Apo-2L may serve as an extracellular signal that triggers programmed cell death.	GENENTECH INC, DEPT MOLEC ONCOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT MOLEC BIOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT IMMUNOL, S SAN FRANCISCO, CA 94080 USA; GENENTECH INC, DEPT CELL BIOL, S SAN FRANCISCO, CA 94080 USA	Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech; Roche Holding; Genentech			Ashkenazi, Avi/ABG-2712-2020	Ashkenazi, Avi/0000-0002-6890-4589				ASHKENAZI A, 1991, P NATL ACAD SCI USA, V88, P10535, DOI 10.1073/pnas.88.23.10535; BEUTLER B, 1994, SCIENCE, V264, P667, DOI 10.1126/science.8171316; COHEN JJ, 1991, ADV IMMUNOL, V50, P55; DANIEL PT, 1994, J IMMUNOL, V152, P5624; DARZYNKIEWICZ Z, 1994, METHOD CELL BIOL, V41, P15; DHEIN J, 1995, NATURE, V373, P438, DOI 10.1038/373438a0; ECK MJ, 1992, J BIOL CHEM, V267, P2119; ECK MJ, 1989, J BIOL CHEM, V264, P17595; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FADOK VA, 1992, J IMMUNOL, V148, P2207; GRUSS HJ, 1995, BLOOD, V85, P3378, DOI 10.1182/blood.V85.12.3378.bloodjournal85123378; HOWARD OMZ, 1993, P NATL ACAD SCI USA, V90, P2335, DOI 10.1073/pnas.90.6.2335; KOOPMAN G, 1994, BLOOD, V84, P1415, DOI 10.1182/blood.V84.5.1415.1415; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KRAMMER PH, 1994, CURR OPIN IMMUNOL, V6, P279, DOI 10.1016/0952-7915(94)90102-3; MOORE A, 1995, CYTOTECHNOLOGY, V17, P1, DOI 10.1007/BF00749215; NAGATA S, 1995, SCIENCE, V267, P1449, DOI 10.1126/science.7533326; O'Reilly D.R., 1994, BACULOVIRUS EXPRESSI; RAFF MC, 1992, NATURE, V356, P397, DOI 10.1038/356397a0; RUPPERT S, 1993, NATURE, V362, P175, DOI 10.1038/362175a0; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHERWOOD SW, 1995, METHOD CELL BIOL, V46, P77; SMITH CA, 1994, CELL, V76, P959, DOI 10.1016/0092-8674(94)90372-7; STELLER H, 1995, SCIENCE, V267, P1445, DOI 10.1126/science.7878463; YONEHARA S, 1989, J EXP MED, V169, P1747, DOI 10.1084/jem.169.5.1747; ZHENG LX, 1995, NATURE, V377, P348, DOI 10.1038/377348a0	26	1565	1790	0	26	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12687	12690		10.1074/jbc.271.22.12687	http://dx.doi.org/10.1074/jbc.271.22.12687			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663110	hybrid			2022-12-27	WOS:A1996UN47400001
J	Flint, DH				Flint, DH			Escherichia coli contains a protein that is homologous in function and N-terminal sequence to the protein encoded by the nifS gene of Azotobacter vinelandii and that can participate in the synthesis of the Fe-S cluster of dihydroxy-acid dehydratase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOSYNTHESIS; SULFUR	In this paper, I report the purification of a protein from Escherichia coli that is very similar in sequence, molecular weight, and the reactions it can catalyze to the protein encoded by the Azotobacter vinelandii nifS gene. This E. coli protein contains pyridoxal phosphate as a cofactor and catalyzes the removal of sulfur from cysteine to form alanine and S-0. When dithiothreitol is present along with cysteine, the S-0 formed is reduced to S2-. This protein has a reactive sulfhydryl group that is essential for activity. As isolated, this sulfhydryl group appears to be in a disulfide linkage with the sulfhydryl group from the phosphopantetheine moiety of the acyl carrier protein. The purified E. coli protein can mobilize the sulfur from cysteine and contribute it to the formation of a [4Fe-4S] cluster on the apoprotein off. coli dihydroxy-acid dehydratase. A mechanism is proposed for the early stages of the synthesis of Fe-S clusters using this protein and sulfur in the S-0 oxidation state.			Flint, DH (corresponding author), DUPONT CO INC, CENT RES & DEV, EXPTL STN, POB 89328, WILMINGTON, DE 19880 USA.							BENYON J, 1987, J BACTERIOL, V169, P4024; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CERLETTI P, 1986, TRENDS BIOCHEM SCI, V11, P369, DOI 10.1016/0968-0004(86)90206-9; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1988, J BIOL CHEM, V263, P3558; Flint DH, 1996, J BIOL CHEM, V271, P16053, DOI 10.1074/jbc.271.27.16053; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KREDICH NM, 1972, J BIOL CHEM, V247, P7157; LEONGMORGENTHAL.PM, 1993, J BACTERIOL, V175, P1433; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TOOHEY JI, 1989, BIOCHEM J, V264, P625, DOI 10.1042/bj2640625; VANAMAN TC, 1968, J BIOL CHEM, V243, P6420; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723; ZHENG LM, 1994, BIOCHEMISTRY-US, V33, P4714, DOI 10.1021/bi00181a031	20	184	203	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16068	16074						7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663056				2022-12-27	WOS:A1996UW35200034
J	Chen, HM; Zhang, P; Radomska, HS; Hetherington, CJ; Zhang, DE; Tenen, DG				Chen, HM; Zhang, P; Radomska, HS; Hetherington, CJ; Zhang, DE; Tenen, DG			Octamer binding factors and their coactivator can activate the murine PU.1 (spi-1) promoter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMUNOGLOBULIN GENE-EXPRESSION; TRANSCRIPTION FACTOR; CELL-LINES; REGULATES EXPRESSION; HEMATOPOIETIC-CELLS; PUTATIVE ONCOGENE; PROTEIN-BINDING; CD11B PROMOTER; ETS ONCOGENE; CHAIN GENE	PU.1 (spi-1), a member of the Ets transcription factor family, is predominantly expressed in myeloid and B cells, activates many B cell and myeloid genes, and is critical for development of both of these lineages. Our previous studies (Chen, H. M., Ray-Gallet, D., Zhang, P., Hetherington, C. J., Gonzalez, D. A., Zhang, D.-E., Moreau-Gachelin, F., and Tenen, D. G. (1995) Oncogene 11, 1549-1560) demonstrate that the PU.1 promoter directs cell type-specific reporter gene expression in myeloid cell lines, and that PU.1 activates its own promoter in an autoregulatory loop. Here we show that the murine PU.1 promoter is also specifically and highly functional in B cell lines as well. Oct-1 and Oct-2 can bind specifically to a site at base pair -55 in vitro, and this site is specifically protected in B cells in vivo. We also demonstrate that two other sites contribute to promoter activity in B cells; an Spl binding site adjacent to the octamer site, and the PU.1 autoregulatory site. Finally, we show that the B cell coactivator OBF-1/Bob1/OCA-B is only expressed in B cells and not in myeloid cells, and that OBF-1/Bob1/OCA-B can transactivate the PU.1 promoter in HeLa and myeloid cells. This B cell restricted coactivator may be responsible for the B cell specific expression of PU.1 mediated by the octamer site.	HARVARD UNIV, SCH MED,BETH ISRAEL HOSP,DEPT MED, DIV HEMATOL ONCOL, BOSTON, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School				Tenen, Daniel/0000-0002-6423-3888	NATIONAL CANCER INSTITUTE [R01CA041456, R29CA059589] Funding Source: NIH RePORTER; NCI NIH HHS [CA59589, CA41456] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		CHEN HM, 1995, BLOOD, V85, P2918, DOI 10.1182/blood.V85.10.2918.bloodjournal85102918; CHEN HM, 1993, J BIOL CHEM, V268, P8230; CHEN HM, 1995, ONCOGENE, V11, P1549; CHEN JH, 1993, ONCOGENE, V8, P3375; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; COCKERILL PN, 1990, MOL CELL BIOL, V10, P1293, DOI 10.1128/MCB.10.3.1293; CORCORAN LM, 1993, GENE DEV, V7, P570, DOI 10.1101/gad.7.4.570; DELGADO MD, 1994, ONCOGENE, V9, P1723; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; ECKHARDT LA, 1992, FASEB J, V6, P2553, DOI 10.1096/fasebj.6.8.1592208; EISENBEIS CF, 1993, MOL CELL BIOL, V13, P6452, DOI 10.1128/MCB.13.10.6452; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GALSON DL, 1993, MOL CELL BIOL, V13, P2929, DOI 10.1128/MCB.13.5.2929; GSTAIGER M, 1995, NATURE, V373, P360, DOI 10.1038/373360a0; HAGEMEIER C, 1993, P NATL ACAD SCI USA, V90, P1580, DOI 10.1073/pnas.90.4.1580; HERR W, 1988, GENE DEV, V2, P1513, DOI 10.1101/gad.2.12a.1513; HROMAS R, 1993, BLOOD, V82, P2998; HUANG CC, 1974, J NATL CANCER I, V53, P655, DOI 10.1093/jnci/53.3.655; JANSON L, 1990, P NATL ACAD SCI USA, V87, P4732, DOI 10.1073/pnas.87.12.4732; JOHANNSEN E, 1995, J VIROL, V69, P253, DOI 10.1128/JVI.69.1.253-262.1995; JUNKER S, 1990, CELL, V61, P467, DOI 10.1016/0092-8674(90)90528-M; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KIM KJ, 1979, J IMMUNOL, V122, P549; KLEIN G, 1974, P NATL ACAD SCI USA, V71, P3283, DOI 10.1073/pnas.71.8.3283; KLEMPNAUER KH, 1989, GENE DEV, V3, P1582, DOI 10.1101/gad.3.10.1582; KLEMSZ MJ, 1990, CELL, V61, P113, DOI 10.1016/0092-8674(90)90219-5; LAUX G, 1994, EMBO J, V13, P5624, DOI 10.1002/j.1460-2075.1994.tb06900.x; LUO Y, 1992, CELL, V71, P231, DOI 10.1016/0092-8674(92)90352-D; LUO Y, 1995, MOL CELL BIOL, V15, P4115; MOREAUGACHELIN F, 1989, ONCOGENE, V4, P1449; MOREAUGACHELIN F, 1994, BBA-REV CANCER, V1198, P149, DOI 10.1016/0304-419X(94)90011-6; MOREAUGACHELIN F, 1988, NATURE, V331, P277, DOI 10.1038/331277a0; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; MULLER MM, 1988, NATURE, V336, P544, DOI 10.1038/336544a0; NELSEN B, 1993, SCIENCE, V261, P82, DOI 10.1126/science.8316859; NUCHPRAYOON I, 1994, MOL CELL BIOL, V14, P5558, DOI 10.1128/MCB.14.8.5558; OMORI SA, 1993, P NATL ACAD SCI USA, V90, P11723, DOI 10.1073/pnas.90.24.11723; PAHL HL, 1991, EXP HEMATOL, V19, P1038; PAHL HL, 1993, J BIOL CHEM, V268, P5014; PALACIOS R, 1987, EMBO J, V6, P3687, DOI 10.1002/j.1460-2075.1987.tb02702.x; PAUL R, 1991, J VIROL, V65, P464, DOI 10.1128/JVI.65.1.464-467.1991; PFISTERER P, 1994, EMBO J, V13, P1654, DOI 10.1002/j.1460-2075.1994.tb06429.x; PONGUBALA JMR, 1992, MOL CELL BIOL, V12, P368, DOI 10.1128/MCB.12.1.368; RADOMSKA HS, 1994, IMMUNITY, V1, P623, DOI 10.1016/1074-7613(94)90034-5; RAY D, 1990, ONCOGENE, V5, P663; RAYGALLET D, 1995, ONCOGENE, V11, P303; ROSENBERG HF, 1990, BIOTECHNIQUES, V8, P384; SCHEIDEREIT C, 1988, NATURE, V336, P551, DOI 10.1038/336551a0; SCHOLER HR, 1989, EMBO J, V8, P2543, DOI 10.1002/j.1460-2075.1989.tb08392.x; SCHUETZE S, 1993, MOL CELL BIOL, V13, P5670, DOI 10.1128/MCB.13.9.5670; SCHWARZENBACH H, 1995, J BIOL CHEM, V270, P898, DOI 10.1074/jbc.270.2.898; SCOTT EW, 1994, SCIENCE, V265, P1573, DOI 10.1126/science.8079170; SEGIL N, 1991, SCIENCE, V254, P1814, DOI 10.1126/science.1684878; SHIN MK, 1993, GENE DEV, V7, P2006, DOI 10.1101/gad.7.10.2006; STAUDT LM, 1986, NATURE, V323, P640, DOI 10.1038/323640a0; STAUDT LM, 1988, SCIENCE, V241, P577, DOI 10.1126/science.3399892; STAUDT LM, 1991, ANNU REV IMMUNOL, V9, P373; STRUBIN M, 1995, CELL, V80, P497, DOI 10.1016/0092-8674(95)90500-6; STURM RA, 1988, GENE DEV, V2, P1582, DOI 10.1101/gad.2.12a.1582; TANAKA M, 1990, CELL, V60, P375, DOI 10.1016/0092-8674(90)90589-7; TORCZYNSKI RM, 1985, DNA-J MOLEC CELL BIO, V4, P283, DOI 10.1089/dna.1985.4.283; TSAI SF, 1991, GENE DEV, V5, P919, DOI 10.1101/gad.5.6.919; VOSO MT, 1994, P NATL ACAD SCI USA, V91, P7932, DOI 10.1073/pnas.91.17.7932; WEINTRAUB SJ, 1995, NATURE, V375, P812, DOI 10.1038/375812a0; WIRTH T, 1987, NATURE, V329, P174, DOI 10.1038/329174a0; YU H, 1989, CELL, V58, P441, DOI 10.1016/0092-8674(89)90425-X; ZARET KS, 1990, P NATL ACAD SCI USA, V87, P5469, DOI 10.1073/pnas.87.14.5469; Zhang DE, 1996, CURR TOP MICROBIOL, V211, P137; ZHANG DE, 1994, J BIOL CHEM, V269, P11425; ZHANG DE, 1994, MOL CELL BIOL, V14, P8085, DOI 10.1128/MCB.14.12.8085; ZIEGLERHEITBROCK HWL, 1988, INT J CANCER, V41, P456, DOI 10.1002/ijc.2910410324; ZWILLING S, 1994, NUCLEIC ACIDS RES, V22, P1655, DOI 10.1093/nar/22.9.1655	72	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15743	15752		10.1074/jbc.271.26.15743	http://dx.doi.org/10.1074/jbc.271.26.15743			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663022	hybrid			2022-12-27	WOS:A1996UV29900067
J	Huang, XC; Richards, EM; Sumners, C				Huang, XC; Richards, EM; Sumners, C			Mitogen-activated protein kinases in rat brain neuronal cultures are activated by angiotensin II type 1 receptors and inhibited by angiotensin II type 2 receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SMOOTH-MUSCLE CELLS; FOS GENE-EXPRESSION; SENSITIVE METHOD; MAP KINASE; SUBTYPES; CLONING; PHOSPHORYLATION; STIMULATION; MECHANISMS; PATHWAYS	Neurons cultured from neonatal rat hypothalamus and brainstem contain many angiotensin II (Ang II) type 2 (AT(2)) receptors, and we previously determined that activation of these sites elicited a stimulation of serine/threonine phosphatase 2A (PP2A). Here, we have investigated the effects of Ang II on neuronal mitogen-activated protein (MAP) kinases, potential targets for PP2A. Using in-gel kinase assays and immunoprecipitation analyses we have shown that Ang II (10 nM(-1) mu M) elicits significant increases in p44(MAPK) (Erk1) and p42(MAPK) (Erk2) activities in cultured neurons, mediated via Ang II type 1 (AT(1)) receptors. This stimulatory effect of Ang II on Erk1 and Erk2 activities was potentiated by blockade of AT(2) receptors with (S)-1-[4-(dimethylamino)-3-methylphenyl]methyl-5-(diphenylacetyl)-4,5,6,7-tetrahydro-1H-imidazo[4,5-C]pyridine-6-carboxylic acid (PD 123319, 1 mu M). Furthermore, the AT(2) receptor agonist N-alpha-nicotinoyl-Tyr-Lys-(N-alpha CBZ-Arg)-His-Pro-Ile-OH (CGP42112A) (10-50 nM) caused significant decreases in neuronal Erk1 and Erk2 activities, which were abolished by PD 123319 (1 mu M) and by the PP2A inhibitor okadaic acid (3 nM). This indicates that AT(1) and AT(2) receptors have opposite actions on Erb1 and Erk2 activities in neonatal neurons. Since MAP kinases are involved in the regulation of growth/differentiation and apoptosis, our data may provide an intracellular basis for modulatory effects of Ang II receptors on these processes.	UNIV FLORIDA, DEPT PHYSIOL, COLL MED, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida				Sumners, Colin/0000-0002-9689-2255	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS019441] Funding Source: NIH RePORTER; NINDS NIH HHS [NS-19441] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Ahn Natalie G., 1992, Current Opinion in Cell Biology, V4, P992, DOI 10.1016/0955-0674(92)90131-U; ALBEROLAILA J, 1995, NATURE, V373, P620, DOI 10.1038/373620a0; ANDERSON NG, 1990, NATURE, V343, P651, DOI 10.1038/343651a0; BERNSTEIN KE, 1993, AM J KIDNEY DIS, V22, P745, DOI 10.1016/S0272-6386(12)80441-0; BOTTARI SP, 1993, FRONT NEUROENDOCRIN, V14, P123, DOI 10.1006/frne.1993.1005; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLARKE PR, 1994, CURR BIOL, V4, P647, DOI 10.1016/S0960-9822(00)00144-5; COHEN P, 1990, TRENDS BIOCHEM SCI, V15, P98, DOI 10.1016/0968-0004(90)90192-E; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DUFF JL, 1992, BIOCHEM BIOPH RES CO, V188, P257, DOI 10.1016/0006-291X(92)92378-B; FAURE M, 1994, J BIOL CHEM, V269, P7851; GOTOH Y, 1990, EUR J BIOCHEM, V193, P661, DOI 10.1111/j.1432-1033.1990.tb19384.x; GRADY EF, 1991, J CLIN INVEST, V88, P921, DOI 10.1172/JCI115395; HEIN L, 1995, NATURE, V377, P744, DOI 10.1038/377744a0; HUANG XC, 1995, J NEUROCHEM, V65, P2131; ICHIKI T, 1995, NATURE, V377, P748, DOI 10.1038/377748a0; JANIAK P, 1992, HYPERTENSION, V20, P737, DOI 10.1161/01.HYP.20.6.737; JESSUS C, 1989, BIOCHEM J, V260, P45, DOI 10.1042/bj2600045; KAMBAYASHI Y, 1993, J BIOL CHEM, V268, P24543; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANG J, 1994, AM J PHYSIOL-CELL PH, V267, pC1389, DOI 10.1152/ajpcell.1994.267.5.C1389; KANG J, 1992, BRAIN RES, V580, P317, DOI 10.1016/0006-8993(92)90960-H; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KRUG LM, 1992, HYPERTENSION, V20, P144, DOI 10.1161/01.HYP.20.2.144; LEBRUN CJ, 1995, NEUROSCIENCE, V65, P93, DOI 10.1016/0306-4522(94)00482-K; LYALL F, 1992, J HYPERTENS, V10, P1463, DOI 10.1097/00004872-199210120-00005; MARRERO MB, 1995, NATURE, V375, P247, DOI 10.1038/375247a0; MILLAN MA, 1991, PEPTIDES, V12, P723, DOI 10.1016/0196-9781(91)90125-9; MOLLOY CJ, 1993, J BIOL CHEM, V268, P7338; MORGAN JI, 1990, PROG BRAIN RES, V86, P287; MUKOYAMA M, 1993, J BIOL CHEM, V268, P24539; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; NAHMIAS C, 1995, BIOCHEM J, V306, P87, DOI 10.1042/bj3060087; PAGES G, 1993, P NATL ACAD SCI USA, V90, P8319, DOI 10.1073/pnas.90.18.8319; PRATT RE, 1993, CELLULAR MOL BIOL RE, P471; QIU MS, 1992, NEURON, V9, P705, DOI 10.1016/0896-6273(92)90033-A; RAIZADA MK, 1993, AM J PHYSIOL, V265, pC1046, DOI 10.1152/ajpcell.1993.265.4.C1046; SADOSHIMA J, 1993, CIRC RES, V73, P424, DOI 10.1161/01.RES.73.3.424; SADOSHIMA J, 1995, CIRC RES, V76, P1; SASAKI K, 1991, NATURE, V351, P230, DOI 10.1038/351230a0; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; SPIEGEL AM, 1992, ENDOCR REV, V13, P536, DOI 10.1210/er.13.3.536; STOLL M, 1995, J CLIN INVEST, V95, P651, DOI 10.1172/JCI117710; SUMNERS C, 1991, P NATL ACAD SCI USA, V88, P7567, DOI 10.1073/pnas.88.17.7567; SUMNERS C, 1994, FRONT NEUROENDOCRIN, V15, P203; TIMMERMANS PBMWM, 1993, PHARMACOL REV, V45, P205; TSUTSUMI K, 1991, AM J PHYSIOL, V261, pR209, DOI 10.1152/ajpregu.1991.261.1.R209; XIA ZG, 1995, SCIENCE, V270, P1326, DOI 10.1126/science.270.5240.1326; Yamada T, 1996, P NATL ACAD SCI USA, V93, P156, DOI 10.1073/pnas.93.1.156	50	160	164	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15635	15641		10.1074/jbc.271.26.15635	http://dx.doi.org/10.1074/jbc.271.26.15635			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663175	hybrid			2022-12-27	WOS:A1996UV29900051
J	Seksek, O; Biwersi, J; Verkman, AS				Seksek, O; Biwersi, J; Verkman, AS			Evidence against defective trans-Golgi acidification in cystic fibrosis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CFTR; FIBROBLASTS; GLYCOPROTEINS; GLANDS; CELLS	Defective organelle acidification has been proposed as a unifying hypothesis to explain the pleiotropic cellular abnormalities associated with cystic fibrosis. To test whether cystic fibrosis transmembrane conductance regulator (CFTR) participates in trans-Golgi pH regulation, intraluminal trans-Golgi pH was measured in stably transfected Swiss 3T3 fibroblasts (expressing CFTR or Delta F508-CFTR) and CFTR-expressing and nonexpressing epithelial cells. trans-Golgi pH was measured by ratio-imaging confocal microscopy using a liposome injection procedure to label the lumen of trans-Golgi with fluid phase fluorescein and rhodamine chromophores (Seksek, O., Biwersi, J., and Verkman, A. S. (1995) J. Biol. Chem. 270, 4967-4970). Selective labeling of trans-Golgi was confirmed by colocalization of the delivered fluid phase fluorophores with N-(6-[(7-nitrobenzo-2-oxa-1,3-diazol-4-yl)amino]caproyl)-sphingosine. In unstimulated fibroblasts in HCO3--free buffer, trans-Golgi pH was 6.25 +/- 0.04 (mean +/- S.E.; n = 80, vector control), 6.30 +/- 0.03 (n = 74, CFTR) and 6.23 +/- 0.06 (n = 60, Delta F508) (not significant). After stimulation of plasma membrane Cl- conductance by 8-(4-chlorophenylthio)-cAMP (CPT-cAMP), trans-Golgi pH was 6.42 +/- 0.07 (n = 22, control), 6.47 +/- 0.07 (n = 20, CFTR), and 6.35 +/- 0.07 (n = 22, Delta F508) (not significant). Similarly, significant pH differences were not found for control versus CFTR expressing cells in 25 mM HCO3- buffer. In epithelial cells, which do not express CFTR, trans-Golgi pH was (in 25 mM HCO3-) 6.36 +/- 0.04 (n = 33) and 6.34 +/- 0.08 (n = 23, CPT-cAMP) in MDCK cells and 6.25 +/- 0.04 (n = 18) and 6.24 +/- 0.06 (n = 15, CPT-cAMP) in SK-MES-1 cells. In Calu-3 cells, which natively express CFTR, trans-Golgi pH was (in 25 mM HCO3-) 6.19 +/- 0.05 (n = 25) and 6.17 +/- 0.08 (n = 23, CPT-cAMP). To test whether CFTR expression affects pH in the endosomal compartment in HCO3- buffer, pH was measured by ratio imaging in individual endosomes labeled with fluorescein-rhodamine dextrans. Comparing control and CFTR expressing fibroblasts, average endosome pH (range, 5.40-5.53 after 10 min; 4.79-4.89, 30 min) differed by <0.13 unit, both before and after cAMP stimulation. These results indicate that CFTR expression and activation do not influence pH in the trans-Golgi and endosomal compartments, providing direct evidence against the defective acidification hypothesis.	UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT MED, SAN FRANCISCO, CA 94143 USA; UNIV CALIF SAN FRANCISCO, CARDIOVASC RES INST, DEPT PHYSIOL, SAN FRANCISCO, CA 94143 USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco			Seksek, Olivier/AAO-1837-2020	Seksek, Olivier/0000-0002-3053-3022	NHLBI NIH HHS [HL42368] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL042368] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSON MP, 1991, SCIENCE, V251, P679, DOI 10.1126/science.1704151; BARASCH J, 1991, NATURE, V352, P70, DOI 10.1038/352070a0; Barasch Jonathan, 1993, P191; BIWERSI J, 1994, AM J PHYSIOL, V266, pC149, DOI 10.1152/ajpcell.1994.266.1.C149; BIWERSI J, 1995, PEDIAT PULMONOL, V12, P179; BRADBURY NA, 1992, SCIENCE, V256, P530, DOI 10.1126/science.1373908; BRADBURY NA, 1994, J BIOL CHEM, V269, P8296; CANTIELLO HF, 1994, J BIOL CHEM, V269, P11224; CARROLL TP, 1993, CELL PHYSIOL BIOCHEM, V3, P388, DOI 10.1159/000154700; CHAO AC, 1989, BIOPHYS J, V56, P1071, DOI 10.1016/S0006-3495(89)82755-9; CRAWFORD I, 1991, P NATL ACAD SCI USA, V88, P9262, DOI 10.1073/pnas.88.20.9262; DOSANJH A, 1994, AM J PHYSIOL, V266, pC360, DOI 10.1152/ajpcell.1994.266.2.C360; DUNN KW, 1994, J BIOL CHEM, V269, P5336; FINKBEINER WE, 1993, AM J RESP CELL MOL, V9, P547, DOI 10.1165/ajrcmb/9.5.547; HASEGAWA H, 1992, SCIENCE, V258, P1477, DOI 10.1126/science.1279809; HAWS C, 1994, AM J PHYSIOL, V266, pL502, DOI 10.1152/ajplung.1994.266.5.L502; IMUNDO L, 1995, P NATL ACAD SCI USA, V92, P3019, DOI 10.1073/pnas.92.7.3019; KRIVAN HC, 1988, ARCH BIOCHEM BIOPHYS, V260, P493, DOI 10.1016/0003-9861(88)90473-0; LUKACS GL, 1992, J BIOL CHEM, V267, P14568; MOLINARI A, 1994, INT J CANCER, V59, P789, DOI 10.1002/ijc.2910590614; PAGANO RE, 1989, J CELL BIOL, V109, P2067, DOI 10.1083/jcb.109.5.2067; PASYK EA, 1995, J BIOL CHEM, V270, P12347, DOI 10.1074/jbc.270.21.12347; PAULSON JC, 1978, J BIOL CHEM, V253, P5617; POULSEN JH, 1994, P NATL ACAD SCI USA, V91, P5340, DOI 10.1073/pnas.91.12.5340; QUINTON PM, 1990, FASEB J, V4, P2709, DOI 10.1096/fasebj.4.10.2197151; RIORDAN JR, 1993, ANNU REV PHYSIOL, V55, P609, DOI 10.1146/annurev.ph.55.030193.003141; SCANLIN TF, 1985, PEDIATR RES, V19, P368, DOI 10.1203/00006450-198519040-00011; SCHWIEBERT EM, 1995, CELL, V81, P1063, DOI 10.1016/S0092-8674(05)80011-X; SEKSEK O, 1995, J BIOL CHEM, V270, P4967, DOI 10.1074/jbc.270.10.4967; SHEN RQ, 1994, AM J PHYSIOL, V266, pL493, DOI 10.1152/ajplung.1994.266.5.L493; SMITH JJ, 1992, J CLIN INVEST, V89, P1148, DOI 10.1172/JCI115696; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; WEBSTER P, 1994, AM J PHYSIOL, V267, pC340, DOI 10.1152/ajpcell.1994.267.2.C340; YAMAYA M, 1991, AM J PHYSIOL, V261, pL491, DOI 10.1152/ajplung.1991.261.6.L491; ZEN K, 1992, J CELL BIOL, V119, P99, DOI 10.1083/jcb.119.1.99	35	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15542	15548		10.1074/jbc.271.26.15542	http://dx.doi.org/10.1074/jbc.271.26.15542			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663158	hybrid			2022-12-27	WOS:A1996UV29900038
J	Sayeski, PP; Kudlow, JE				Sayeski, PP; Kudlow, JE			Glucose metabolism to glucosamine is necessary for glucose stimulation of transforming growth factor-alpha gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PORE COMPLEX GLYCOPROTEINS; SMOOTH-MUSCLE CELLS; HEXOSAMINE BIOSYNTHESIS; O-GLCNAC; EXPRESSION; GLYCOSYLATION; NUCLEAR; ATHEROSCLEROSIS; PATHWAY	Transforming growth factor-alpha (TGF alpha) gene transcription can be increased when arterial smooth muscle cells are exposed to supraphysiological concentrations of glucose, and this effect of glucose can be mimicked by glucosamine. To determine whether the metabolism of glucose to glucosamine is required for this glucose effect, the rate-limiting step in glucose metabolism to glucosamine through the enzyme glutamine:fructose-6-phosphate amidotransferase (GFAT) was blocked using pharmacological and antisense strategies. We found that blockage of GFAT activity or expression significantly blunted the glucose-induced increase of TGF alpha expression, Blockage of GFAT also resulted in a decreased RL2 signal on intracellular proteins as detected by Western blotting and indirect immunofluorescence. The RL2 monoclonal antibody recognizes an epitope on proteins that contain N-acetylglucosamine and thus is a measure of protein glycosylation. Conversely, treatment of the cells with glucose and glucosamine resulted in an increase in the RL2 epitope on intracellular proteins. These results indicate that the metabolism of glucose to glucosamine is necessary for the transcriptional stimulation of TGF alpha expression in vascular smooth muscle cells by glucose, Furthermore, the level of glycosylation of some intracellular proteins can be modulated in response to physiological changes in the extracellular glucose concentration and the net activity of GFAT.	UNIV ALABAMA, DEPT MED, DIV ENDOCRINOL & METAB, BIRMINGHAM, AL 35294 USA; UNIV ALABAMA, DEPT PHYSIOL, BIRMINGHAM, AL 35294 USA	University of Alabama System; University of Alabama Birmingham; University of Alabama System; University of Alabama Birmingham					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK043652] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK43652] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEKESI JG, 1969, J BIOL CHEM, V244, P5663; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CHOU TY, 1995, J BIOL CHEM, V270, P18961, DOI 10.1074/jbc.270.32.18961; DANIELS MC, 1993, MOL ENDOCRINOL, V7, P1041, DOI 10.1210/me.7.8.1041; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GUNNING P, 1983, MOL CELL BIOL, V3, P787, DOI 10.1128/MCB.3.5.787; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HALTIWANGER RS, 1992, BIOCHEM SOC T, V20, P264, DOI 10.1042/bst0200264; HART GW, 1989, ANNU REV BIOCHEM, V58, P841; HOLLENBERG MD, 1994, LIFE SCI, V54, P223, DOI 10.1016/0024-3205(94)00811-6; HOLT GD, 1987, J CELL BIOL, V104, P1157, DOI 10.1083/jcb.104.5.1157; JACKSON SP, 1988, CELL, V55, P125, DOI 10.1016/0092-8674(88)90015-3; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KELLY WG, 1993, J BIOL CHEM, V268, P10416; KLAGSBRUN M, 1989, ARTERIOSCLEROSIS, V9, P269, DOI 10.1161/01.ATV.9.3.269; KORNFELD R, 1967, J BIOL CHEM, V242, P3135; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LORENZI M, 1992, DIABETES METAB REV, V8, P85, DOI 10.1002/dmr.5610080202; MARSHALL S, 1991, J BIOL CHEM, V266, P4706; MCCLAIN DA, 1992, P NATL ACAD SCI USA, V89, P8150, DOI 10.1073/pnas.89.17.8150; MCKNIGHT GL, 1992, J BIOL CHEM, V267, P25208; MUELLER SG, 1990, MOL CELL BIOL, V10, P4596, DOI 10.1128/MCB.10.9.4596; NABELL LM, 1994, CELL GROWTH DIFFER, V5, P87; RAJA RH, 1991, MOL ENDOCRINOL, V5, P514, DOI 10.1210/mend-5-4-514; REASON AJ, 1992, J BIOL CHEM, V267, P16911; ROOS MD, 1986, AM J PHYSIOL, V270, pC803; ROQUEMORE EP, 1994, METHOD ENZYMOL, V230, P443; ROSS R, 1973, SCIENCE, V180, P1332, DOI 10.1126/science.180.4093.1332; SAYESKI PP, 1994, GENE, V140, P289, DOI 10.1016/0378-1119(94)90560-6; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; SHIN TH, 1992, MOL CELL BIOL, V12, P3998, DOI 10.1128/MCB.12.9.3998; SNOW CM, 1987, J CELL BIOL, V104, P1143, DOI 10.1083/jcb.104.5.1143	32	137	144	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15237	15243		10.1074/jbc.271.25.15237	http://dx.doi.org/10.1074/jbc.271.25.15237			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663078	hybrid			2022-12-27	WOS:A1996UT10600086
J	Ohnishi, T; Wang, XJ; Ohnishi, K; Matsumoto, H; Takahashi, A				Ohnishi, T; Wang, XJ; Ohnishi, K; Matsumoto, H; Takahashi, A			p53-dependent induction of WAF1 by heat treatment in human glioblastoma cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							P53	Induction of WAF1 expression was investigated after heat treatment (44 degrees C, 30 min) in two human glioblastoma cell lines with the wild-type or a mutant p53 gene. WAF1 accumulation was induced by heat treatment in A-172 cells carrying the wild-type p53 gene but not in T98G cells carrying the mutant p53 gene. We examined whether this phenomenon was due to the induction of WAF1 expression. Northern blot analysis showed that heat treatment not only activated WAF1 but also upregulated p53 expression only in A-172 cells carrying the wild-type p53 gene. Gel mobility shift assay indicated an increase in p53 DNA binding activity after heat treatment. These findings suggest that the WAF1 expression is heat inducible in human glioblastoma cells and that this induction may be due to signal transduction mediated by p53 in response to heat stress.	NARA MED UNIV,DEPT PHYSIOL,KASHIHARA,NARA 634,JAPAN	Nara Medical University	Ohnishi, T (corresponding author), NARA MED UNIV,DEPT BIOL,840 SHIJO CHO,KASHIHARA,NARA 634,JAPAN.			Takahashi, Akihisa/0000-0002-9960-2153				AGARWAL ML, 1995, P NATL ACAD SCI USA, V92, P8493, DOI 10.1073/pnas.92.18.8493; AKASHI M, 1995, J BIOL CHEM, V270, P19181, DOI 10.1074/jbc.270.32.19181; BAE IS, 1995, CANCER RES, V55, P2387; DEFFIE A, 1993, MOL CELL BIOL, V13, P3415, DOI 10.1128/MCB.13.6.3415; DUTTA A, 1993, NATURE, V365, P79, DOI 10.1038/365079a0; ELDEIRY WS, 1992, NAT GENET, V1, P45, DOI 10.1038/ng0492-45; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; KASTAN MB, 1991, CANCER RES, V51, P6304; LI CY, 1995, J BIOL CHEM, V270, P4971, DOI 10.1074/jbc.270.10.4971; MATSUMOTO H, 1994, CANCER LETT, V87, P39, DOI 10.1016/0304-3835(94)90407-3; MATSUMOTO H, 1995, CANCER LETT, V92, P127, DOI 10.1016/0304-3835(95)03769-S; MICHIELI P, 1994, CANCER RES, V54, P3391; NAMBA H, 1995, CANCER RES, V55, P2075; NODA A, 1994, EXP CELL RES, V211, P90, DOI 10.1006/excr.1994.1063; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEINMAN RA, 1994, ONCOGENE, V9, P3389; SUGANO T, 1995, JPN J CANCER RES, V86, P415, DOI 10.1111/j.1349-7006.1995.tb03072.x; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; XIONG Y, 1993, NATURE, V366, P701, DOI 10.1038/366701a0	20	95	101	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14510	14513		10.1074/jbc.271.24.14510	http://dx.doi.org/10.1074/jbc.271.24.14510			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662996	hybrid			2022-12-27	WOS:A1996UQ66000084
J	Homma, K; Matsushita, T; Natori, S				Homma, K; Matsushita, T; Natori, S			Purification, characterization, and cDNA cloning of a novel growth factor from the conditioned medium of NIH-Sape-4, an embryonic cell line of Sarcophaga peregrina (flesh fly)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DROSOPHILA EGF RECEPTOR; FACTOR-BETA FAMILY; GENE; PROTEIN; HOMOLOG; ESTABLISHMENT; POLARITY; PATTERN; DPP; RNA	A growth factor from the conditioned medium of NIH-Sape-4, an embryonic cell line of the flesh fly, was purified to homogeneity. This growth factor, termed IDGF, stimulated the proliferation of NIH-Sape-4 cells in an autocrine manner; it was a homodimer of a protein with a molecular mass of 52 kDa, and its specific activity was comparable with those of mammalian growth factors, Immunoblotting experiments revealed that unfertilized mature eggs of the flesh fly contained this growth factor, a certain level of which was maintained throughout embryonic development, Analysis of cDNA for this growth factor showed that this factor is a novel protein consisting of 553 amino acid residues, No significant sequence similarity was found between this factor and other proteins except atrial gland granule-specific antigen of Aplysia californica.	UNIV TOKYO,FAC PHARMACEUT SCI,BUNKYO KU,TOKYO 113,JAPAN	University of Tokyo								AHMED SA, 1994, J IMMUNOL METHODS, V170, P211, DOI 10.1016/0022-1759(94)90396-4; BRAND AH, 1994, GENE DEV, V8, P629, DOI 10.1101/gad.8.5.629; BRUMMEL TJ, 1994, CELL, V78, P251, DOI 10.1016/0092-8674(94)90295-X; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERGUSON EL, 1992, CELL, V71, P451, DOI 10.1016/0092-8674(92)90514-D; GOODE S, 1992, DEVELOPMENT, V116, P177; HEBERLEIN U, 1993, CELL, V75, P913, DOI 10.1016/0092-8674(93)90535-X; HELDIN CH, 1981, BIOCHEM J, V193, P907, DOI 10.1042/bj1930907; HENIKOFF S, 1987, METHOD ENZYMOL, V155, P156; HOMMA K, 1994, J BIOL CHEM, V269, P15258; KOMANO H, 1991, FEBS LETT, V289, P167, DOI 10.1016/0014-5793(91)81061-C; KOMANO H, 1987, BIOCHEM J, V248, P217, DOI 10.1042/bj2480217; KURAMA T, 1995, EUR J BIOCHEM, V228, P229, DOI 10.1111/j.1432-1033.1995.tb20254.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMKE GE, 1984, J NEUROSCI, V4, P75; LIVNEH E, 1985, CELL, V40, P599, DOI 10.1016/0092-8674(85)90208-9; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCCAULEY R, 1973, MOL CELL BIOCHEM, V1, P73, DOI 10.1007/BF01659940; MITSUHAS.J, 1964, CONTRIB BOYCE THOMPS, V22, P435; NAKANISHIMATSUI M, 1995, EUR J BIOCHEM, V230, P396, DOI 10.1111/j.1432-1033.1995.0396h.x; NELLEN D, 1994, CELL, V78, P225, DOI 10.1016/0092-8674(94)90293-3; NEUMANSILBERBERG FS, 1993, CELL, V75, P165, DOI 10.1016/S0092-8674(05)80093-5; PADGETT RW, 1987, NATURE, V325, P81, DOI 10.1038/325081a0; PAGE B, 1993, INT J ONCOL, V3, P473; PANGANIBAN GEF, 1990, MOL CELL BIOL, V10, P2669, DOI 10.1128/MCB.10.6.2669; PENTON A, 1994, CELL, V78, P239, DOI 10.1016/0092-8674(94)90294-1; RAZ E, 1993, GENE DEV, V7, P1937, DOI 10.1101/gad.7.10.1937; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SGARAMELLA V, 1972, J MOL BIOL, V72, P427, DOI 10.1016/0022-2836(72)90155-6; SOSSIN WS, 1989, J BIOL CHEM, V264, P16933; STAEHLINGHAMPTON K, 1994, NATURE, V372, P783; TAKAHASHI M, 1980, DEV GROWTH DIFFER, V22, P11; THOMAS KA, 1984, P NATL ACAD SCI-BIOL, V81, P357, DOI 10.1073/pnas.81.2.357; XIE T, 1994, SCIENCE, V263, P1756, DOI 10.1126/science.8134837	34	56	58	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13770	13775		10.1074/jbc.271.23.13770	http://dx.doi.org/10.1074/jbc.271.23.13770			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662793	hybrid			2022-12-27	WOS:A1996UP38500070
J	Ravichandran, V; Chawla, A; Roche, PA				Ravichandran, V; Chawla, A; Roche, PA			Identification of a novel syntaxin- and synaptobrevin/VAMP-binding protein, SNAP-23, expressed in non-neuronal tissues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SYNAPTOSOMAL-ASSOCIATED PROTEIN; RECEPTORS; TRANSPORT; SUBSTRATE; FUSION	The specificity of vesicular transport is regulated, in part, by the interaction of a vesicle-associated membrane protein termed synaptobrevin/VAMP with a target compartment membrane protein termed syntaxin. These proteins, together with SNAP-25 (synaptosome associated protein of 25 kDa), form a complex which serves as a binding site for the general membrane fusion machinery, Synaptobrevin/VAMP and syntaxin are ubiquitously expressed proteins and are believed to be involved in vesicular transport in mast (if not all) cells. However, SNAP-25 is present almost exclusively in the brain, suggesting that a ubiquitously expressed homolog of SNAP-25 exists to facilitate transport vesicle/target membrane fusion in other tissues, Using the yeast two-hybrid system, we have identified a 23-kDa protein from human B lymphocytes (termed SNAP-23) that binds tightly to multiple syntaxins and synaptobrevins/VAMPs in vitro. SNAP-23 is 59% identical with SNAP-25. Unlike SNAP-25, SNAP-23 was expressed in all tissues examined, These findings suggest that SNAP-23 is an essential component of the high affinity receptor for the general membrane fusion machinery and an important regulator of transport vesicle docking and fusion in all mammalian cells.	NIH,NCI,EXPTL IMMUNOL BRANCH,BETHESDA,MD 20892	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)				Roche, Paul/0000-0002-8949-9172				BARK IC, 1994, GENE, V139, P291, DOI 10.1016/0378-1119(94)90773-0; BARK IC, 1995, P NATL ACAD SCI USA, V92, P1510, DOI 10.1073/pnas.92.5.1510; BENNETT MK, 1993, CELL, V74, P863, DOI 10.1016/0092-8674(93)90466-4; BENNETT MK, 1994, ANNU REV BIOCHEM, V63, P63, DOI 10.1146/annurev.bi.63.070194.000431; BLASI J, 1993, NATURE, V365, P160, DOI 10.1038/365160a0; BRUMELL JH, 1995, J IMMUNOL, V155, P5750; CALAKOS N, 1994, SCIENCE, V263, P1146, DOI 10.1126/science.8108733; CHAPMAN ER, 1994, J BIOL CHEM, V269, P27427; FERRONOVICK S, 1994, NATURE, V370, P191, DOI 10.1038/370191a0; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; HATA Y, 1995, J BIOL CHEM, V270, P13022, DOI 10.1074/jbc.270.22.13022; HAYASHI T, 1994, EMBO J, V13, P5051, DOI 10.1002/j.1460-2075.1994.tb06834.x; HESS DT, 1992, J NEUROSCI, V12, P4634; JAHN R, 1994, ANNU REV NEUROSCI, V17, P219, DOI 10.1146/annurev.ne.17.030194.001251; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI H, 1994, GENE, V143, P303; MCMAHON HT, 1995, J BIOL CHEM, V270, P2213, DOI 10.1074/jbc.270.5.2213; MCMAHON HT, 1993, NATURE, V364, P346, DOI 10.1038/364346a0; OHO C, 1995, NEUROSCI LETT, V186, P208, DOI 10.1016/0304-3940(95)11317-P; OSENSAND A, 1993, NATURE, V364, P445, DOI 10.1038/364445a0; OYLER GA, 1989, J CELL BIOL, V109, P3039, DOI 10.1083/jcb.109.6.3039; PEVSNER J, 1994, NEURON, V13, P353, DOI 10.1016/0896-6273(94)90352-2; Rossetto O, 1996, J CELL BIOL, V132, P167, DOI 10.1083/jcb.132.1.167; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SADOUL K, 1995, J CELL BIOL, V128, P1019, DOI 10.1083/jcb.128.6.1019; SOLLNER T, 1993, NATURE, V362, P318, DOI 10.1038/362318a0; VOLCHUK A, 1994, BIOCHEM J, V304, P139, DOI 10.1042/bj3040139	27	279	287	0	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13300	13303		10.1074/jbc.271.23.13300	http://dx.doi.org/10.1074/jbc.271.23.13300			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663154	hybrid			2022-12-27	WOS:A1996UP38500003
J	Cassell, M; Tobacman, LS				Cassell, M; Tobacman, LS			Opposite effects of myosin subfragment 1 on binding of cardiac troponin and tropomyosin to the thin filament	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MUSCLE-CONTRACTION; COOPERATIVE BINDING; F-ACTIN; HEAVY-MEROMYOSIN; COMPLEX; MOLECULES	To better understand the regulation of striated muscle contraction, the effects of myosin subfragment 1 (S-1) on the actin binding of cardiac troponin and tropomyosin were investigated, Troponin's affinity for actin-tropomyosin was 4-fold stronger in the absence than in the presence of myosin S-1. CaCl2 had no effect on troponin binding to the thin filament in the presence of myosin S-1, The binding curve was weakly cooperative, implying interactions between adjacent troponin molecules, Myosin S-1 increased (40-200-fold) the affinity of tropomyosin for the thin filament, an effect opposite to the effect of myosin on troponin, This effect was highly cooperative and occurred in the presence of ADP or in the absence of nucleotide; Myosin altered the effect of ionic conditions on tropomyosin-actin binding, consistent with tropomyosin binding to a different site on F-actin in the presence of myosin. The results indicate that troponin-tropomyosin and strongly binding myosin crossbridges do not compete for an F-actin binding site, Although repositioning of troponin-tropomyosin on the actin filament may be sterically required for tight myosin-actin binding, a myosin-induced conformational change in actin provides a better explanation for the complex effects of myosin on thin filament assembly.	UNIV IOWA,DEPT INTERNAL MED,IOWA CITY,IA 52246; UNIV IOWA,DEPT BIOCHEM,IOWA CITY,IA 52246	University of Iowa; University of Iowa								BUTTERS CA, 1993, J BIOL CHEM, V268, P15565; CHALOVICH JM, 1992, PHARMACOL THERAPEUT, V55, P95, DOI 10.1016/0163-7258(92)90013-P; DAHIYA R, 1994, J BIOL CHEM, V269, P29457; EATON BL, 1976, SCIENCE, V192, P1337, DOI 10.1126/science.131972; EBASHI S, 1969, Quarterly Reviews of Biophysics, V2, P351; FISHER D, 1995, J BIOL CHEM, V270, P25455, DOI 10.1074/jbc.270.43.25455; Geeves M A, 1995, Biophys J, V68, p194S; GREENE LE, 1980, P NATL ACAD SCI-BIOL, V77, P2616, DOI 10.1073/pnas.77.5.2616; GREENE LE, 1981, BIOCHEMISTRY-US, V20, P2120, DOI 10.1021/bi00511a008; Haselgrove J. C., 1972, COLD SPRING HARB SYM, V37, P341; HILL LE, 1992, J BIOL CHEM, V267, P16106; Hill T. L., 1985, COOPERATIVITY THEORY; HOLMES KC, 1995, BIOPHYS J, V68, pS2; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; Huynh Q, 1996, BIOPHYS J, V70, P1447, DOI 10.1016/S0006-3495(96)79704-7; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; LEAVIS PC, 1984, CRC CR REV BIOCH MOL, V16, P235, DOI 10.3109/10409238409108717; LORENZ M, 1995, J MOL BIOL, V246, P108, DOI 10.1006/jmbi.1994.0070; MCGHEE JD, 1974, J MOL BIOL, V86, P469, DOI 10.1016/0022-2836(74)90031-X; MEHEGAN JP, 1991, J BIOL CHEM, V266, P966; NAGASHIMA H, 1982, J MOL BIOL, V155, P409, DOI 10.1016/0022-2836(82)90479-X; PARRY DAD, 1973, J MOL BIOL, V75, P33, DOI 10.1016/0022-2836(73)90527-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; SZCZESNA D, 1989, BIOL CHEM H-S, V370, P399, DOI 10.1515/bchm3.1989.370.1.399; TOBACMAN LS, 1986, BIOCHEMISTRY-US, V25, P798, DOI 10.1021/bi00352a010; TOBACMAN LS, 1987, J BIOL CHEM, V262, P4059; Tobacman LS, 1996, ANNU REV PHYSIOL, V58, P447, DOI 10.1146/annurev.physiol.58.1.447; TOBACMAN LS, 1990, J BIOL CHEM, V265, P931; TRYBUS KM, 1980, P NATL ACAD SCI-BIOL, V77, P7209, DOI 10.1073/pnas.77.12.7209; WEEDS AG, 1975, NATURE, V257, P54, DOI 10.1038/257054a0; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; WILLADSEN KA, 1992, J BIOL CHEM, V267, P23746; WILLIAMS DL, 1983, BIOCHEMISTRY-US, V22, P2770, DOI 10.1021/bi00280a027; YANG YZ, 1979, J BIOL CHEM, V254, P2084	35	48	48	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12867	12872		10.1074/jbc.271.22.12867	http://dx.doi.org/10.1074/jbc.271.22.12867			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662810	hybrid			2022-12-27	WOS:A1996UN47400029
J	Joseph, DE; Paul, CC; Baumann, MA; GomezCambronero, J				Joseph, DE; Paul, CC; Baumann, MA; GomezCambronero, J			S6 kinase p90(rsk) in granulocyte-macrophage colony-stimulating factor-stimulated proliferative and mature hematopoietic cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBOSOMAL-PROTEIN S6; TYROSINE PHOSPHORYLATION; HUMAN-NEUTROPHILS; MAP KINASE; RAPID PHOSPHORYLATION; SWISS 3T3-CELLS; GM-CSF; ACTIVATION; INTERLEUKIN-3; EXPRESSION	The ribosomal S6 kinase p90(rsk) was studied in mature and proliferating hemopoietic cells in response to the human cytokine granulocyte-macrophage colony-stimulating factor (GM-CSF). In neutrophils, GM-CSF induced time-dependent electrophoretic mobility shifts in immunoreactive p90(rsk) Although these shifts suggested changes in the phosphorylation status of the molecule, a kinase assay with whole cell lysates detected minimal (1.5-fold) increments in enzymatic activity. Only immunoprecipitation followed by immune complex kinase assay or in-gel kinase assay performed against the RSK substrate RRLSSLRA evidenced an increase in p90(rsk) activity (SR-fold). p90(rsk) was also detected in the GMCSF-dependent erythroleukemia cell line TF-1. Normally cultured, cytokine-supplemented cells did not respond to further GM-CSF stimulation. However, the activity of p90(rsk) in cytokine-starved cells increased dramatically in response to short term CRI-CSF challenge. This effect was readily observable in total cell lysates (6.6-fold increase over controls) and was paralleled by changes in mitogen-activated protein kinase activity (a substrate of p90(rsk)). Thus, p90(rsk) is present in mature hemopoietic cells, but the extent of the enzymatic response to GM-CSF is significantly lower than that seen in proliferative cells.	WRIGHT STATE UNIV,SCH MED,DEPT PHYSIOL,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DEPT BIOPHYS,DAYTON,OH 45435; WRIGHT STATE UNIV,SCH MED,DEPT MED,DAYTON,OH 45435; VET AFFAIRS MED CTR,RES SERV,DAYTON,OH 45428	University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; University System of Ohio; Wright State University Dayton; US Department of Veterans Affairs; Veterans Health Administration (VHA); Case Western Reserve University; Louis Stokes Cleveland Veterans Affairs Medical Center				Gomez-Cambronero, Julian/0000-0002-7581-9227				AHN NG, 1990, J BIOL CHEM, V265, P11487; AHN NG, 1990, J BIOL CHEM, V265, P11495; ALCORTA DA, 1989, MOL CELL BIOL, V9, P3850, DOI 10.1128/MCB.9.9.3850; BAXTER GT, 1992, BIOCHEMISTRY-US, V31, P10950, DOI 10.1021/bi00160a002; BERKOW RL, 1989, BIOCHIM BIOPHYS ACTA, V997, P292, DOI 10.1016/0167-4838(89)90200-8; BLENIS J, 1986, EMBO J, V5, P3441, DOI 10.1002/j.1460-2075.1986.tb04667.x; CALVO V, 1992, EUR J IMMUNOL, V22, P457, DOI 10.1002/eji.1830220225; CANNISTRA SA, 1988, SEMIN HEMATOL, V25, P173; CARROLL MP, 1990, J BIOL CHEM, V265, P19812; CLARK SC, 1987, SCIENCE, V236, P1229, DOI 10.1126/science.3296190; COLOTTA F, 1987, J EXP MED, V165, P1224, DOI 10.1084/jem.165.4.1224; COREY S, 1993, EMBO J, V12, P2681, DOI 10.1002/j.1460-2075.1993.tb05929.x; DENT P, 1990, NATURE, V348, P302, DOI 10.1038/348302a0; ENGLISH D, 1974, J IMMUNOL METHODS, V5, P249, DOI 10.1016/0022-1759(74)90109-4; ERIKSON E, 1986, J BIOL CHEM, V261, P350; ERIKSON RL, 1991, J BIOL CHEM, V266, P6007; GEARING DP, 1989, EMBO J, V8, P3667, DOI 10.1002/j.1460-2075.1989.tb08541.x; GOLDE DW, 1988, INFLAMMATION BASIC P, P253; GOMEZCAMBRONERO J, 1995, J INTERF CYTOK RES, V15, P877, DOI 10.1089/jir.1995.15.877; GOMEZCAMBRONERO J, 1991, J BIOL CHEM, V266, P6240; GOMEZCAMBRONERO J, 1991, ADV EXP MED BIOL, V314, P35; GOMEZCAMBRONERO J, 1992, P NATL ACAD SCI USA, V89, P7551, DOI 10.1073/pnas.89.16.7551; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HANAZONO Y, 1993, EMBO J, V12, P1641, DOI 10.1002/j.1460-2075.1993.tb05809.x; HUANG CK, 1990, BIOCHEM J, V269, P431, DOI 10.1042/bj2690431; HUANG CK, 1994, J LEUKOCYTE BIOL, V55, P430, DOI 10.1002/jlb.55.4.430; JOHNSON GM, 1995, J LEUKOCYTE BIOL, V57, P692, DOI 10.1002/jlb.57.4.692; KAMESHITA I, 1989, ANAL BIOCHEM, V183, P139, DOI 10.1016/0003-2697(89)90181-4; KANAKURA Y, 1991, BLOOD, V77, P243; KITAMURA T, 1989, J CELL PHYSIOL, V140, P323, DOI 10.1002/jcp.1041400219; KYRIAKIS JM, 1990, J BIOL CHEM, V265, P17355; MCCOLL SR, 1989, BLOOD, V73, P588; METCALF D, 1985, SCIENCE, V229, P16, DOI 10.1126/science.2990035; NACCACHE PH, 1990, BLOOD, V76, P2098; NASMITH PE, 1989, BIOCHEM J, V257, P893, DOI 10.1042/bj2570893; OKUDA K, 1992, BLOOD, V79, P2880; PELECH S, 1986, P NATL ACAD SCI USA, V383, P5968; RAINES MA, 1992, BLOOD, V79, P3350; RAY LB, 1988, J BIOL CHEM, V263, P12721; STURGILL TW, 1988, NATURE, V334, P715, DOI 10.1038/334715a0; STURGILL TW, 1991, BIOCHIM BIOPHYS ACTA, V1092, P350, DOI 10.1016/S0167-4889(97)90012-4; SWEET LJ, 1990, MOL CELL BIOL, V10, P2413, DOI 10.1128/MCB.10.5.2413; THOMAS G, 1992, CELL, V68, P3, DOI 10.1016/0092-8674(92)90199-M; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; TORRES M, 1993, J IMMUNOL, V150, P1563; WOOL IG, 1979, ANNU REV BIOCHEM, V48, P719, DOI 10.1146/annurev.bi.48.070179.003443	46	28	28	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13088	13093		10.1074/jbc.271.22.13088	http://dx.doi.org/10.1074/jbc.271.22.13088			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662788	hybrid			2022-12-27	WOS:A1996UN47400062
J	Bennett, EP; Hassan, H; Clausen, H				Bennett, EP; Hassan, H; Clausen, H			cDNA cloning and expression of a novel human UDP-N-acetyl-alpha-D-galactosamine - Polypeptide N-acetylgalactosaminyltransferase, GalNAc-T3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							O-GLYCOSYLATION; GENE FAMILY; PROTEIN; ENZYME; GALACTOSYLTRANSFERASE; GLYCOSYLTRANSFERASES; ANTIGEN; MEMBER	The glycosylation of serine and threonine residues during mucin-type O-linked protein glycosylation is carried out by a family of UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases (GalNAc-transferase). Previously two members, GalNAc-T1 and -T2, have been isolated and the genes cloned and characterized, Here we report the cDNA cloning and expression of a novel GalNAc-transferase termed GalNAc-T3. The gene was isolated and cloned based on the identification of a GalNAc-transferase motif (61 amino acids) that is shared between GalNAc-T1 and -T2 as well as a homologous Caenorhabditis elegans gene, The cDNA sequence has a 633-amino acid coding region indicating a protein of 72.5 kDa with a type II domain structure, The overall amino acid sequence similarity with GalNAc-T1 and -T2 is approximately 45%; 12 cysteine residues that are shared between GalNAc-T1 and -T2 are also found in GalNAcT3, GalNAc-T3 was expressed as a soluble protein without the hydrophobic transmembrane domain in insect cells using a Baculo-virus vector, and the expressed GalNAc-transferase activity showed substrate specificity different from that previously reported for GalNAc-T1 and -T2, Northern analysis of human organs revealed a very restricted expression pattern of GalNAc-T3.	FAC HLTH SCI, SCH DENT, DK-2200 COPENHAGEN N, DENMARK				clausen, henrik/AAD-8016-2021; Bennett, Eric/AAG-6120-2020	Bennett, Eric/0000-0002-4976-0647; Clausen, Henrik/0000-0002-0915-5055				BENNETT EP, 1995, BIOCHEM BIOPH RES CO, V206, P318, DOI 10.1006/bbrc.1995.1044; BIERHUIZEN MFA, 1993, GENE DEV, V7, P468, DOI 10.1101/gad.7.3.468; CLAUSEN H, 1994, ALFRED BENZON SYMP S, V36, P297; DATTA AK, 1995, J BIOL CHEM, V270, P1497, DOI 10.1074/jbc.270.4.1497; DRICKAMER K, 1993, GLYCOBIOLOGY, V3, P2, DOI 10.1093/glycob/3.1.2; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; GOOLEY AA, 1994, GLYCOBIOLOGY, V4, P413, DOI 10.1093/glycob/4.4.413; GRUNNET N, 1994, VOX SANG, V67, P210, DOI 10.1111/j.1423-0410.1994.tb01662.x; HAGEN FK, 1995, GLYCOCONJUGATE J, V12, P901, DOI 10.1007/BF00731252; HAGEN FK, 1993, J BIOL CHEM, V268, P18960; HANSEN JE, 1994, PROTEIN STRUCTURE BY DISTANCE ANALYSIS, P247; HENION TR, 1994, GLYCOBIOLOGY, V4, P193, DOI 10.1093/glycob/4.2.193; HOMA FL, 1993, J BIOL CHEM, V268, P12609; IMMERVOLL T, 1995, YEAST, V11, P1345, DOI 10.1002/yea.320111403; JOZIASSE DH, 1992, J BIOL CHEM, V267, P5534; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KLEENE R, 1993, BIOCHIM BIOPHYS ACTA, V1154, P283, DOI 10.1016/0304-4157(93)90003-7; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LIVINGSTON BD, 1993, J BIOL CHEM, V268, P11504; LUSSIER M, 1995, J BIOL CHEM, V270, P2770, DOI 10.1074/jbc.270.6.2770; NARA K, 1994, P NATL ACAD SCI USA, V91, P7952, DOI 10.1073/pnas.91.17.7952; PAREKH RB, 1994, ADV DRUG DELIVER REV, V13, P251, DOI 10.1016/0169-409X(94)90014-0; PAULSON JC, 1989, J BIOL CHEM, V264, P17615; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHACHTER H, 1994, MOL GLYCOBIOLOGY, P88; SMITH PL, 1994, J BIOL CHEM, V269, P15162; SORENSEN T, 1995, J BIOL CHEM, V270, P24166, DOI 10.1074/jbc.270.41.24166; STRAHLBOLSINGER S, 1993, P NATL ACAD SCI USA, V90, P8164, DOI 10.1073/pnas.90.17.8164; WANG Y, 1994, BIOCHEM BIOPH RES CO, V204, P701, DOI 10.1006/bbrc.1994.2516; WANG YC, 1992, J BIOL CHEM, V267, P2728; WHITE T, 1995, J BIOL CHEM, V270, P24156, DOI 10.1074/jbc.270.41.24156	32	204	215	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 19	1996	271	29					17006	17012		10.1074/jbc.271.29.17006	http://dx.doi.org/10.1074/jbc.271.29.17006			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX943	8663203	hybrid			2022-12-27	WOS:A1996UX94300007
J	Miyamoto, K; Segawa, H; Tatsumi, S; Katai, K; Yamamoto, H; Taketani, Y; Haga, H; Morita, K; Takeda, E				Miyamoto, K; Segawa, H; Tatsumi, S; Katai, K; Yamamoto, H; Taketani, Y; Haga, H; Morita, K; Takeda, E			Effects of truncation of the COOH-terminal region of a Na+-independent neutral and basic amino acid transporter on amino acid transport in Xenopus oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXPRESSION CLONING; HEAVY-CHAIN; RAT-KIDNEY; CDNA; 4F2; STIMULATION; CYSTINE; ANTIGEN; SYSTEM	To determine the role of a neutral and basic amino acid transporter (NEAT) in amino acid transport, we microinjected several COOH-terminal deletion mutants of NEAT cRNA into Xenopus oocytes and measured transport activity for arginine, leucine, and cystine in the presence and absence of sodium, Wild type NEAT significantly stimulated the uptake of all three amino acids 10-20-fold compared with controls, On the other hand, no mutant, except a Delta 511-685 mutant, stimulated the uptake of these amino acids, The Delta 511-685 mutant significantly increased the uptake of arginine. In the presence of sodium, the Delta 511-685 mutant also increased the uptake of leucine, The Delta 511-685 mutant did not stimulate cystine uptake in the presence or absence of sodium, The stimulation of arginine uptake by the Delta 511-685 mutant was inhibited by a 100-fold excess of unlabeled leucine in the presence of sodium, Inhibition of L-arginine uptake by L-homoserine was seen only in the presence of sodium, and an increase in the inhibition of L-arginine uptake by L-histidine was seen when the extracellular pH was decreased, Furthermore, an inward current in oocytes injected with the Delta 511-685 mutant was recorded electrophysiologically when basic amino acids were applied, Homoserine was also taken up, but sodium was necessary for their transport, These properties of the Delta 511-685 mutant correspond to those of the y(+) amino acid transporter, If NEAT is a component of the b(0,+)-like amino acid transport system, it is unlikely that a mutant protein (Delta 511-685) is able to stimulate an endogenous y(+)-like transport system, These results suggest that NEAT functions as a activator of the amino acid transport system in Xenopus oocytes.			Miyamoto, K (corresponding author), UNIV TOKUSHIMA,SCH MED,DEPT CLIN NUTR,KURAMOTO CHO 3,TOKUSHIMA 770,JAPAN.			Tatsumi, Sawako/0000-0002-4862-2955				AGARWAL K, 1991, BIOCHEMISTRY-US, V30, P7842, DOI 10.1021/bi00245a026; AHMED A, 1995, J BIOL CHEM, V270, P8482, DOI 10.1074/jbc.270.15.8482; BERTRAN J, 1993, J BIOL CHEM, V268, P14842; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5601, DOI 10.1073/pnas.89.12.5601; BERTRAN J, 1992, P NATL ACAD SCI USA, V89, P5606, DOI 10.1073/pnas.89.12.5606; BUSH AE, 1994, J BIOL CHEM, V269, P25581; CALONGE MJ, 1995, HUM GENET, V95, P633; CALONGE MJ, 1995, P NATL ACAD SCI USA, V92, P9667, DOI 10.1073/pnas.92.21.9667; CALONGE MT, 1994, NAT GENET, V6, P420, DOI 10.1038/ng0494-420; COADY MJ, 1994, FEBS LETT, V356, P174, DOI 10.1016/0014-5793(94)01262-8; HAYNES BF, 1981, J IMMUNOL, V126, P1409; HERMLER ME, 1982, J IMMUNOL, V129, P623; Hisano S, 1996, BRAIN RES, V710, P299, DOI 10.1016/0006-8993(95)01442-X; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; MCKUSICK VA, 1994, MENDELIAN INHERITANC, P1750; MIYAMOTO K, 1995, BIOCHEM J, V310, P951, DOI 10.1042/bj3100951; MIYAMOTO K, 1994, BIOCHEM J, V303, P877, DOI 10.1042/bj3030877; MIYAMOTO KI, 1995, BIOCHEM J, V305, P81, DOI 10.1042/bj3050081; MOSCKOVITZ R, 1994, FASEB J, V8, P1069, DOI 10.1096/fasebj.8.13.7926373; PRAS E, 1995, AM J HUM GENET, V56, P1297; PRAS E, 1994, NAT GENET, V6, P415, DOI 10.1038/ng0494-415; REBECCA WS, 1993, J CLIN NVEST, V91, P1959; SEGAL S, 1989, METABOLIC BASIS INHE, P2479; SILBERNAGL S, 1988, PHYSIOL REV, V68, P911, DOI 10.1152/physrev.1988.68.3.911; TATE SS, 1992, P NATL ACAD SCI USA, V89, P1, DOI 10.1073/pnas.89.1.1; VANWINKLE LJ, 1993, BIOCHIM BIOPHYS ACTA, V1154, P157, DOI 10.1016/0304-4157(93)90009-D; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WELLS RG, 1992, J BIOL CHEM, V267, P15285; WELLS RG, 1992, P NATL ACAD SCI USA, V89, P5596, DOI 10.1073/pnas.89.12.5596	29	28	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16758	16763		10.1074/jbc.271.28.16758	http://dx.doi.org/10.1074/jbc.271.28.16758			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663184	hybrid			2022-12-27	WOS:A1996UX12600054
J	Mendoza, JA; DelCampo, G				Mendoza, JA; DelCampo, G			Ligand-induced conformational changes of GroEL are dependent on the bound substrate polypeptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR CHAPERONE; ESCHERICHIA-COLI; PROTEIN; ATP; PURIFICATION; CARBOXYLASE; HYDROLYSIS; RHODANESE; MUTATION; CYCLE	Ligand-induced conformational changes of GroEL alone and with bound rhodanese, citrate synthase, or dihydrofolate reductase were studied by limited proteolysis. Similar digestion patterns of GroEL, with or without bound substrate polypeptide, were obtained in the absence and presence of the chaperonin ligands, K+, Mg2+, or ATP. The rates of formation and degradation of the six produced proteolytic fragments were significantly different, however. Strikingly, only with Mg2+/ATP or K+/Mg2+/ATP an additional fragment of approximately 25 kDa was generated during digestion of GroEL alone or with bound rhodanese or dihydrofolate reductase, but not with bound citrate synthase. Most of the trypsin-sensitive sites in GroEL were localized in the flexible apical domain, which contains the putative polypeptide-binding region. Our data indicate that subtle structural changes in the trypsin-sensitive regions of GroEL occur as a result of the binding of the chaperonin ligands, However, these structural changes are influenced by the GroEL substrate polypeptides.			Mendoza, JA (corresponding author), CALIF STATE UNIV,DEPT CHEM,SAN MARCOS,CA 92096, USA.							AZEM A, 1994, BIOCHEMISTRY-US, V33, P6671, DOI 10.1021/bi00187a037; BANEYX F, 1992, J BIOL CHEM, V267, P11637; BRAIG K, 1994, NATURE, V371, P578, DOI 10.1038/371578a0; BUCHNER J, 1991, BIOCHEMISTRY-US, V30, P1586, DOI 10.1021/bi00220a020; CHANDRASEKHAR GN, 1986, J BIOL CHEM, V261, P2414; CREIGHTON TE, 1991, NATURE, V352, P17, DOI 10.1038/352017a0; ERLANGER BF, 1961, ARCH BIOCHEM BIOPHYS, V95, P271, DOI 10.1016/0003-9861(61)90145-X; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FISHER MT, 1992, BIOCHEMISTRY-US, V31, P3955, DOI 10.1021/bi00131a010; Georgopoulos C, 1990, Semin Cell Biol, V1, P19; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gibbons DL, 1996, J BIOL CHEM, V271, P238, DOI 10.1074/jbc.271.1.238; GOLOUBINOFF P, 1989, NATURE, V342, P884, DOI 10.1038/342884a0; GOROVITS B, 1995, J BIOL CHEM, V270, P2061, DOI 10.1074/jbc.270.5.2061; HANSEN JE, 1994, J BIOL CHEM, V269, P6286; HANSEN JE, 1993, J BIOL CHEM, V268, P21632; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRIX RW, 1979, J MOL BIOL, V129, P375, DOI 10.1016/0022-2836(79)90502-3; HOROVITZ A, 1993, J MOL BIOL, V231, P58, DOI 10.1006/jmbi.1993.1256; HOROWITZ PM, 1995, J BIOL CHEM, V270, P1535, DOI 10.1074/jbc.270.4.1535; HOROWITZ PM, 1978, ANAL BIOCHEM, V86, P751, DOI 10.1016/0003-2697(78)90803-5; JACKSON GS, 1993, BIOCHEMISTRY-US, V32, P2554, DOI 10.1021/bi00061a013; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANGER T, 1992, EMBO J, V11, P4757, DOI 10.1002/j.1460-2075.1992.tb05581.x; LORIMER GH, 1993, PHILOS T R SOC B, V339, P297, DOI 10.1098/rstb.1993.0028; MARTIN J, 1993, NATURE, V366, P228, DOI 10.1038/366228a0; MENDOZA JA, 1991, J BIOL CHEM, V266, P13044; MENDOZA JA, 1994, J BIOL CHEM, V269, P25963; MENDOZA JA, 1991, J BIOL CHEM, V266, P16973; Ploegman J.H., 1978, NATURE, V273, P1245; SCHMIDT M, 1994, J BIOL CHEM, V269, P10304; SEALE JW, 1995, BIOCHEMISTRY-US, V34, P7443, DOI 10.1021/bi00022a018; SMITH KE, 1995, J BIOL CHEM, V270, P21517, DOI 10.1074/jbc.270.37.21517; SORBO BH, 1953, ACTA CHEM SCAND, V7, P1129, DOI 10.3891/acta.chem.scand.07-1129; TODD MJ, 1994, SCIENCE, V265, P659, DOI 10.1126/science.7913555; VIITANEN PV, 1990, BIOCHEMISTRY-US, V29, P5665, DOI 10.1021/bi00476a003; VIITANEN PV, 1991, BIOCHEMISTRY-US, V30, P9716, DOI 10.1021/bi00104a021; WEDRYCHOWSKI A, 1986, ANAL BIOCHEM, V159, P323, DOI 10.1016/0003-2697(86)90349-0	39	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16344	16349		10.1074/jbc.271.27.16344	http://dx.doi.org/10.1074/jbc.271.27.16344			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663187	hybrid			2022-12-27	WOS:A1996UW35200072
J	Coburn, GA; Mackie, GA				Coburn, GA; Mackie, GA			Differential sensitivities of portions of the mRNA for ribosomal protein S20 to 3'-exonucleases dependent on oligoadenylation and RNA secondary structure	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; MESSENGER-RNA; RIBONUCLEASE-E; POLYNUCLEOTIDE PHOSPHORYLASE; PCNB GENE; DECAY; AMS; CLEAVAGE; DEGRADATION; OVEREXPRESSION	The 5'-exonucleolytic decay of the mRNA for ribosomal protein S20 has been reconstituted in vitro using purified RNase II and crude extracts enriched for polynucleotide phosphorylase (PNPase) activity. We show that RNase II can catalyze the degradation of the 5' two-thirds of the S20 mRNA and that prior oligoadenylation of the 3' termini of truncated S20 mRNA substrates can significantly stimulate the initiation of degradation by RNase II. The intact S20 mRNA is, however, insensitive to attack by RNase II and polyadenylation of its 3'-end cannot overcome the natural resistance of the S20 mRNA to RNase II. Complete degradation of either the entire S20 mRNA without prior endonucleolytic cleavage or the 3'-terminal 147-residue fragment is de pendent on both oligoadenylation and PNPase activity. Moreover, this process can take place in the absence of RNase E activity. Our data point to the importance of oligoadenylation in facilitating 3'-exonucleolytic activity and indicate that there are alternative degradative pathways. The implications for mRNA decay are discussed.	UNIV BRITISH COLUMBIA,DEPT BIOCHEM & MOLEC BIOL,VANCOUVER,BC V6T 1Z3,CANADA	University of British Columbia								BABITZKE P, 1991, P NATL ACAD SCI USA, V88, P1, DOI 10.1073/pnas.88.1.1; BABITZKE P, 1993, J BACTERIOL, V175, P229, DOI 10.1128/JB.175.1.229-239.1993; BELASCO JG, 1988, GENE, V72, P15, DOI 10.1016/0378-1119(88)90123-0; BRENNAN CA, 1987, CELL, V48, P945, DOI 10.1016/0092-8674(87)90703-3; CAO GJ, 1992, P NATL ACAD SCI USA, V89, P10380, DOI 10.1073/pnas.89.21.10380; CARPOUSIS AJ, 1994, CELL, V76, P889, DOI 10.1016/0092-8674(94)90363-8; CAUSTON H, 1994, MOL MICROBIOL, V14, P731, DOI 10.1111/j.1365-2958.1994.tb01310.x; Coburn GA, 1996, J BIOL CHEM, V271, P1048, DOI 10.1074/jbc.271.2.1048; COHEN SN, 1995, CELL, V80, P829, DOI 10.1016/0092-8674(95)90284-8; CORMACK RS, 1993, P NATL ACAD SCI USA, V90, P9006, DOI 10.1073/pnas.90.19.9006; DONOVAN WP, 1986, P NATL ACAD SCI USA, V83, P120, DOI 10.1073/pnas.83.1.120; DOTTIN RP, 1983, P NATL ACAD SCI USA, V70, P1078; GOLDBLUM K, 1981, J BACTERIOL, V146, P128, DOI 10.1128/JB.146.1.128-132.1981; JAHNSDORF E, 1995, P NATL ACAD SCI USA, V92, P3973; LITTAUER UZ, 1982, ENZYMES, V15, P517; MACKIE GA, 1992, J BIOL CHEM, V267, P1054; MACKIE GA, 1989, J BACTERIOL, V171, P4112, DOI 10.1128/JB.171.8.4112-4120.1989; MACKIE GA, 1993, J MOL BIOL, V234, P998, DOI 10.1006/jmbi.1993.1654; MACKIE GA, 1991, J BACTERIOL, V173, P2488, DOI 10.1128/jb.173.8.2488-2497.1991; MASTERS M, 1993, J BACTERIOL, V175, P4405, DOI 10.1128/JB.175.14.4405-4413.1993; MCLAREN RS, 1991, J MOL BIOL, V221, P81, DOI 10.1016/0022-2836(91)90806-H; MELEFORS O, 1991, MOL MICROBIOL, V5, P857, DOI 10.1111/j.1365-2958.1991.tb00759.x; MOTT JE, 1985, EMBO J, V4, P1887, DOI 10.1002/j.1460-2075.1985.tb03865.x; MUDD EA, 1990, MOL MICROBIOL, V4, P2127, DOI 10.1111/j.1365-2958.1990.tb00574.x; OHARA EB, 1995, P NATL ACAD SCI USA, V92, P1807, DOI 10.1073/pnas.92.6.1807; PEPE CM, 1994, MOL MICROBIOL, V13, P1133, DOI 10.1111/j.1365-2958.1994.tb00504.x; PY B, 1994, MOL MICROBIOL, V14, P717, DOI 10.1111/j.1365-2958.1994.tb01309.x; RAPAPORT LR, 1994, J BACTERIOL, V176, P992, DOI 10.1128/JB.176.4.992-998.1994; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; TAKIFF HE, 1989, J BACTERIOL, V171, P2581, DOI 10.1128/jb.171.5.2581-2590.1989; XU FF, 1995, NATURE, V374, P180, DOI 10.1038/374180a0; XU FF, 1993, P NATL ACAD SCI USA, V90, P6756, DOI 10.1073/pnas.90.14.6756; ZHU LQ, 1990, J BACTERIOL, V172, P3146, DOI 10.1128/jb.172.6.3146-3151.1990	33	65	65	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15776	15781		10.1074/jbc.271.26.15776	http://dx.doi.org/10.1074/jbc.271.26.15776			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663115	hybrid			2022-12-27	WOS:A1996UV29900071
J	Gamm, DM; Baude, EJ; Uhler, MD				Gamm, DM; Baude, EJ; Uhler, MD			The major catalytic subunit isoforms of cAMP-dependent protein kinase have distinct biochemical properties in vitro and in vivo	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-STABLE INHIBITOR; I REGULATORY SUBUNIT; CYCLIC-AMP; MOLECULAR-CLONING; KINETIC MECHANISM; SKELETAL-MUSCLE; PEPTIDE INHIBITOR; CRYSTAL-STRUCTURE; GENE-EXPRESSION; MOUSE-BRAIN	Two isoforms of the catalytic subunit of cAMP-dependent protein kinase, C alpha and C beta 1, are known to be widely expressed in mammals, Although much is known about the structure and function of C alpha, few studies have addressed the possibility of a distinct role for the C beta proteins, The present study is a detailed comparison of the biochemical properties of these two isoforms, which were initially expressed in Escherichia coli and purified to homogeneity, C beta 1 demonstrated higher K-m values for some peptide substrates than did C alpha but C beta 1 was insensitive to substrate inhibition, a phenomenon that was observed with C alpha at substrate concentrations above 100 mu M. C alpha and C beta l displayed distinct IC50 values for the a and beta isoforms of the protein kinase inhibitor, protein kinase inhibitor (5-24) peptide, and the type II alpha regulatory subunit (RII alpha), Of particular interest, purified type II holoenzyme containing C beta 1 exhibited a B-fold lower K-alpha value for cAMP (13 nM) than did type II holoenzyme containing C alpha (63 nM), This latter result was extended to in vivo conditions by employing a transcriptional activation assay, In these experiments, luciferase reporter activity in COS-l cells expressing RII alpha(2)C beta 1(2) holoenzyme was half-maximal at 12-fold lower concentrations of 8-(4-chlorophenylthio)-cAMP and 5-fold lower concentrations of forskolin than in COS-1 cells expressing RII alpha(2)Ca(2) holoenzyme. These results provide evidence that type II holoenzyme formed with C beta 1 is preferentially activated by cAMP in vivo and suggest that activation of the holoenzyme is determined in part by interactions between the regulatory and catalytic subunits that have not been described previously.	UNIV MICHIGAN, DEPT BIOL CHEM, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, NEUROSCI PROGRAM, ANN ARBOR, MI 48104 USA; UNIV MICHIGAN, MENTAL HLTH RES INST, ANN ARBOR, MI 48104 USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM038788, R01GM038788] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM38788] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ADAMS JA, 1992, BIOCHEMISTRY-US, V31, P8516, DOI 10.1021/bi00151a019; ADAVANI SR, 1987, EUR J BIOCHEM, V167, P221, DOI 10.1111/j.1432-1033.1987.tb13326.x; Ausubel FM, 1994, CURRENT PROTOCOLS MO; BAUDE EJ, 1994, J BIOL CHEM, V269, P2316; BAUDE EJ, 1994, J BIOL CHEM, V269, P18128; BEEBE SJ, 1990, MOL ENDOCRINOL, V4, P465, DOI 10.1210/mend-4-3-465; BRANDON EP, 1995, P NATL ACAD SCI USA, V92, P8851, DOI 10.1073/pnas.92.19.8851; BREGMAN DB, 1989, J BIOL CHEM, V264, P4648; CADD G, 1989, NEURON, V3, P71, DOI 10.1016/0896-6273(89)90116-5; CADD GG, 1990, J BIOL CHEM, V265, P19502; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CLEGG CH, 1988, P NATL ACAD SCI USA, V85, P3703, DOI 10.1073/pnas.85.11.3703; CLEGG CH, 1992, BIOCHEMISTRY-US, V31, P3720, DOI 10.1021/bi00129a023; Cohen P, 1978, Curr Top Cell Regul, V14, P117; COLBRAN JL, 1992, BIOCHEM CELL BIOL, V70, P1277, DOI 10.1139/o92-174; COOK PF, 1982, BIOCHEMISTRY-US, V21, P5794, DOI 10.1021/bi00266a011; DOSKELAND SO, 1993, BIOCHIM BIOPHYS ACTA, V1178, P249, DOI 10.1016/0167-4889(93)90201-Y; FRANCIS SH, 1994, ANNU REV PHYSIOL, V56, P237, DOI 10.1146/annurev.ph.56.030194.001321; GAMM DM, 1995, J BIOL CHEM, V270, P7227, DOI 10.1074/jbc.270.13.7227; GJERTSEN BT, 1995, BBA-MOL CELL RES, V1269, P187, DOI 10.1016/0167-4889(95)00117-B; GLASS DB, 1986, J BIOL CHEM, V261, P2166; GOSSE ME, 1994, BIOCHEM J, V297, P79, DOI 10.1042/bj2970079; GRIECO D, 1994, P NATL ACAD SCI USA, V91, P9896, DOI 10.1073/pnas.91.21.9896; GROVE JR, 1989, J BIOL CHEM, V264, P19506; Huang YY, 1995, CELL, V83, P1211, DOI 10.1016/0092-8674(95)90146-9; HUGGENVIK JI, 1991, MOL ENDOCRINOL, V5, P921, DOI 10.1210/mend-5-7-921; JAHNSEN T, 1986, J BIOL CHEM, V261, P2352; KEMP BE, 1977, J BIOL CHEM, V252, P4888; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; KOMALAVILAS P, 1994, J BIOL CHEM, V269, P8701; KONG CT, 1988, BIOCHEMISTRY-US, V27, P4795, DOI 10.1021/bi00413a032; Krebs E G, 1972, Curr Top Cell Regul, V5, P99; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVITAN IB, 1994, ANNU REV PHYSIOL, V56, P193, DOI 10.1146/annurev.ph.56.030194.001205; Lineweaver H, 1934, J AM CHEM SOC, V56, P658, DOI 10.1021/ja01318a036; MATTEN W, 1994, MOL CELL BIOL, V14, P4419, DOI 10.1128/MCB.14.7.4419; MAURER RA, 1989, J BIOL CHEM, V264, P6870; MCDONALD RA, 1995, P NATL ACAD SCI USA, V92, P7560, DOI 10.1073/pnas.92.16.7560; MELLON PL, 1989, P NATL ACAD SCI USA, V86, P4887, DOI 10.1073/pnas.86.13.4887; MERRIL CR, 1984, METHOD ENZYMOL, V104, P441; MONTMINY MR, 1990, TRENDS NEUROSCI, V13, P184, DOI 10.1016/0166-2236(90)90045-C; OLSEN SR, 1989, J BIOL CHEM, V264, P18662; ROESLER WJ, 1988, J BIOL CHEM, V263, P9063; ROSENMUND C, 1994, NATURE, V368, P853, DOI 10.1038/368853a0; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SCOTT JD, 1986, P NATL ACAD SCI USA, V83, P1613, DOI 10.1073/pnas.83.6.1613; SCOTT JD, 1994, MOL ENDOCRINOL, V8, P5, DOI 10.1210/me.8.1.5; SCOTT JD, 1987, P NATL ACAD SCI USA, V84, P5192, DOI 10.1073/pnas.84.15.5192; SHOWERS MO, 1986, J BIOL CHEM, V261, P6288; SLICE LW, 1989, J BIOL CHEM, V264, P20940; SOLBERG R, 1994, EXP CELL RES, V214, P595, DOI 10.1006/excr.1994.1297; SUZUKI T, 1994, INT J BIOCHEM, V26, P735; TASKEN K, 1993, J BIOL CHEM, V268, P21276; UHLER MD, 1986, J BIOL CHEM, V261, P5360; UHLER MD, 1987, J BIOL CHEM, V262, P15202; UHLER MD, 1986, P NATL ACAD SCI USA, V83, P1300, DOI 10.1073/pnas.83.5.1300; VANPATTEN SM, 1991, P NATL ACAD SCI USA, V88, P5383, DOI 10.1073/pnas.88.12.5383; WALSH D A, 1992, Current Opinion in Cell Biology, V4, P241, DOI 10.1016/0955-0674(92)90039-F; Walsh D.A., 2018, PEPT PROT PHOSPH, P43; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3682; WHITEHOUSE S, 1983, J BIOL CHEM, V258, P3693; WIEMANN S, 1991, J BIOL CHEM, V266, P5940; YANG SM, 1995, BIOCHEMISTRY-US, V34, P6267, DOI 10.1021/bi00019a002; YONEMOTO WM, 1991, METHOD ENZYMOL, V200, P581; ZHENG JH, 1993, BIOCHEMISTRY-US, V32, P2154, DOI 10.1021/bi00060a005; ZI M, 1996, P NATL ACAD SCI USA, V93, P1571	70	77	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15736	15742		10.1074/jbc.271.26.15736	http://dx.doi.org/10.1074/jbc.271.26.15736			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662989	hybrid			2022-12-27	WOS:A1996UV29900066
J	Kim, JH; Krahn, JM; Tomchick, DR; Smith, JL; Zalkin, H				Kim, JH; Krahn, JM; Tomchick, DR; Smith, JL; Zalkin, H			Structure and function of the glutamine phosphoribosylpyrophosphate amidotransferase glutamine site and communication with the phosphoribosylpyrophosphate site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; NUCLEOTIDE-SEQUENCE; AMINO-ACID; SYNTHETASE; CYSTEINE; CLONING; PURIFICATION; MUTAGENESIS; PURF	Glutamine phosphoribosylpyrophosphate (PRPP) amidotransferase from Escherichia coli exhibits a basal PRPP-independent glutaminase activity having a k(cat)/K-m that is 0.3% of fully active enzyme, Binding of PRPP activates the enzyme by a structural change that lowers the K-m for glutamine 100-fold and couples glutamine hydrolysis to synthesis of 5-phosphoribosylamine. By analysis of the x-ray structure of the glutamine site containing bound 6-diazo-5-oxonorleucine, a glutamine affinity analog, and by site-directed mutagenesis we have identified residues important for glutamine binding, catalysis, and coupling with PRPP, Tyr(74) is a key residue in the coupling between the sites for glutamine in the NH2-terminal domain and PRPP in the COOH-terminal domain, Arg(73) and Asp(127) have roles in glutamine binding, The x-ray structure indicates that there are no amino acid side chains sufficiently close to Cys(1) to participate as a proton acceptor in formation of the thiolate needed for nucleophilic attack on the carboxamide of glutamine, nor as a general acid for amide nitrogen transfer, Based on the x-ray model of the glutamine site and analysis of a mutant enzyme we propose that the free NH2 terminus of Cys(1) functions as the proton acceptor and donor. The results indicate that the side chain of As-101 and the backbone nitrogen of Gly(102) function to stabilize a tetrahedral oxyanion resulting from attack. of Cys(1) on the glutamine carboxamide. Cys(1), Arg(73), Asn(101), Gly(102), and Asp(127) are conserved in the NH2-terminal domain of a subfamily of amidotransferases that includes asparagine synthetase, glucosamine 6-phosphate synthase, and glutamate synthase, implying a common function in the four enzymes. Tyr(74), On the other hand, is conserved only in glutamine PRPP amidotransferase sequences consistent with a specific role in interdomain coupling. The catalytic framework of key glutamine site residues supports the assignment of glutamine PRPP amidotransferase to a recently described Ntn (NH2-terminal nucleophile) hydrolase family of enzymes.	PURDUE UNIV,DEPT SCI BIOL,W LAFAYETTE,IN 47907	Purdue University System; Purdue University; Purdue University West Lafayette Campus	Kim, JH (corresponding author), PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907, USA.		Tomchick, Diana/HGV-2018-2022	Tomchick, Diana/0000-0002-7529-4643	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK042303, R37DK042303] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM024658, R01GM024658] Funding Source: NIH RePORTER; NIDDK NIH HHS [R37 DK042303, DK42303] Funding Source: Medline; NIGMS NIH HHS [GM24658] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BACON D, 1988, J MOL GRAPHICS, V6, P219, DOI 10.1016/S0263-7855(98)80030-1; BADET B, 1987, BIOCHEMISTRY-US, V26, P1940, DOI 10.1021/bi00381a023; BOEHLEIN SK, 1994, J BIOL CHEM, V269, P26789; BRANNIGAN JA, 1995, NATURE, V378, P416, DOI 10.1038/378416a0; BRAYTON KA, 1994, J BIOL CHEM, V269, P5313; BRUNGER AT, 1992, X PLOR VERSION 3 0 M; CLARK DV, 1994, GENETICS, V136, P547; DUGGLEBY HJ, 1995, NATURE, V373, P264, DOI 10.1038/373264a0; EGON A, 1988, GENE, V69, P301; GU ZM, 1992, GENE, V119, P123, DOI 10.1016/0378-1119(92)90076-2; HIREL PH, 1989, P NATL ACAD SCI USA, V86, P8247, DOI 10.1073/pnas.86.21.8247; ITO T, 1994, PLANT MOL BIOL, V26, P529, DOI 10.1007/BF00039565; IWAHANA H, 1993, J BIOL CHEM, V268, P7225; KIM JH, 1995, J BIOL CHEM, V270, P17394, DOI 10.1074/jbc.270.29.17394; KIM JH, 1995, PLANT J, V7, P77, DOI 10.1046/j.1365-313X.1995.07010077.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LUDIN KM, 1994, CURR GENET, V25, P465, DOI 10.1007/BF00351787; MANTSALA P, 1984, J BIOL CHEM, V259, P8478; MANTSALA P, 1984, J BIOL CHEM, V259, P4230; MEI B, 1989, J BIOL CHEM, V264, P16613; MERRITT EA, 1994, ACTA CRYSTALLOGR D, V50, P869, DOI 10.1107/S0907444994006396; MESSENGER LJ, 1979, J BIOL CHEM, V254, P3382; Miller J. H., 1972, EXPT MOL GENETICS, P431; OINONEN C, 1995, NAT STRUCT BIOL, V2, P1102, DOI 10.1038/nsb1295-1102; OLIVER G, 1987, GENE, V60, P1, DOI 10.1016/0378-1119(87)90207-1; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; SCHENDEL FJ, 1988, BIOCHEMISTRY-US, V27, P2614, DOI 10.1021/bi00407a052; SHEN Y, 1990, BIOCHEMISTRY-US, V29, P218, DOI 10.1021/bi00453a030; Smith JL, 1995, BIOCHEM SOC T, V23, P894, DOI 10.1042/bst0230894; SMITH JL, 1994, SCIENCE, V264, P1427, DOI 10.1126/science.8197456; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; Tesmer JG, 1996, NAT STRUCT BIOL, V3, P74, DOI 10.1038/nsb0196-74; TSO JY, 1982, J BIOL CHEM, V257, P3525; VANHEEKE G, 1989, J BIOL CHEM, V264, P19475; Zalkin H, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P203; ZHOU GC, 1990, J BIOL CHEM, V265, P21152; ZHOU GC, 1993, J BIOL CHEM, V268, P10471; ZHOU GC, 1994, J BIOL CHEM, V269, P6784	39	81	86	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15549	15557		10.1074/jbc.271.26.15549	http://dx.doi.org/10.1074/jbc.271.26.15549			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663035	hybrid			2022-12-27	WOS:A1996UV29900039
J	Navazo, MDP; Daviet, L; Savill, J; Ren, Y; Leung, LLK; McGregor, JL				Navazo, MDP; Daviet, L; Savill, J; Ren, Y; Leung, LLK; McGregor, JL			Identification of a domain (155-183) on CD36 implicated in the phagocytosis of apoptotic neutrophils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IV CD36; MONOCLONAL-ANTIBODY; VITRONECTIN RECEPTOR; SIGNAL TRANSDUCTION; THROMBOSPONDIN; BINDING; PLATELETS; ERYTHROCYTES; INFLAMMATION; RECOGNITION	Clearance of apoptotic neutrophils by macrophages is a crucial event following the resolution of acute inflammation. CD36, together with alpha(v) beta(3), has been identified as one of the adhesion molecules on the surface of macrophages implicated in the clearance of polymorphonuclear leukocytes. The domain on CD36 implicated in the phagocytosis of aged neutrophils remains to be elucidated. In this study, COS cells transfected with human CD36 cDNA had a significantly higher capacity to phagocytose human apoptotic neutrophils compared with murine CD36 cDNA. Moreover, monoclonal antibodies 10/5 or OKM5 (epitopes identified on amino acids 155-183) but not monoclonal antibody 13/10 (epitope identified on amino acids 30-76) inhibited phagocytosis of apoptotic neutrophils by COS cells transfected by human CD36. Swapping the human CD36 155-183 domain fi om human to murine CD36 (human-murine CD36 chimera) imparted to murine CD3B-transfected COS cells an increased capacity to phagocytose apoptotic neutrophils. Conversely, when the murine domain 155-185 was inserted in human CD36, a decreased phagocytic capacity was observed. In addition, a synthetic peptide (155-169) but not its scrambled form significantly inhibited phagocytosis. These results identify for the first time a functional domain encompassing amino acids 155-183 on human CD36 implicated in the recognition and phagocytosis of apoptotic neutrophils.	QUEENS MED CTR,DEPT RENAL & INFLAMMATORY DIS,NOTTINGHAM NG2 UH,ENGLAND; STANFORD UNIV,SCH MED,DIV HAEMATOL,STANFORD,CA 94305	Stanford University	Navazo, MDP (corresponding author), RTH LAENNEC,FAC MED,INSERM U331,RUE GUILLAUME PARADIN,F-69372 LYON,FRANCE.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL042943] Funding Source: NIH RePORTER; NHLBI NIH HHS [1R01-HL42943] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); Wellcome Trust(Wellcome TrustEuropean Commission)		AIKEN ML, 1990, BLOOD, V76, P2501; AKBAR AN, 1994, J EXP MED, V180, P1943, DOI 10.1084/jem.180.5.1943; ARMESILLA AL, 1994, J BIOL CHEM, V269, P18985; ASCH AS, 1987, J CLIN INVEST, V79, P1054, DOI 10.1172/JCI112918; ASCH AS, 1993, SCIENCE, V262, P1436, DOI 10.1126/science.7504322; DAVIET L, 1995, BIOCHEM J, V305, P221, DOI 10.1042/bj3050221; DAVIET L, 1995, THROMB HAEMOSTASIS, V73, P543; DAVIET L, 1995, THROMB HAEMOSTASIS, V73, P1141; DECHAVANNE M, 1987, THROMB HAEMOSTASIS, V57, P106; Dransfield Ian, 1993, Tissue Antigens, V42, P416; ENDEMANN G, 1993, J BIOL CHEM, V268, P11811; FADOK VA, 1993, J IMMUNOL, V151, P4274; GREENWALT DE, 1992, BLOOD, V80, P1105; HASLETT C, 1992, CLIN SCI, V83, P639, DOI 10.1042/cs0830639; HUANG MM, 1991, P NATL ACAD SCI USA, V88, P7844, DOI 10.1073/pnas.88.17.7844; HUH HY, 1995, J BIOL CHEM, V270, P6267, DOI 10.1074/jbc.270.11.6267; LEUNG LLK, 1992, J BIOL CHEM, V267, P18244; Navazo MDP, 1995, BLOOD, V86, P1490; OCKENHOUSE CF, 1989, J CLIN INVEST, V84, P468, DOI 10.1172/JCI114188; OQUENDO P, 1989, CELL, V58, P95, DOI 10.1016/0092-8674(89)90406-6; PARMENTIER S, 1991, BLOOD, V77, P1734; PEARCE SFA, 1995, J BIOL CHEM, V270, P2981, DOI 10.1074/jbc.270.7.2981; REN Y, 1995, J EXP MED, V181, P1857, DOI 10.1084/jem.181.5.1857; SAVILL J, 1994, EUR J CLIN INVEST, V24, P715, DOI 10.1111/j.1365-2362.1994.tb01067.x; SAVILL J, 1992, J CLIN INVEST, V90, P1513, DOI 10.1172/JCI116019; SAVILL J, 1995, J AM SOC NEPHROL, V6, P852; SAVILL J, 1990, NATURE, V343, P170, DOI 10.1038/343170a0; SAVILL JS, 1989, J CLIN INVEST, V83, P865, DOI 10.1172/JCI113970; SCHUEPP BJ, 1991, BIOCHEM BIOPH RES CO, V175, P263, DOI 10.1016/S0006-291X(05)81229-X; SILVERSTEIN RL, 1989, J CLIN INVEST, V84, P546, DOI 10.1172/JCI114197; TANDON NN, 1989, J BIOL CHEM, V264, P7576	31	72	73	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15381	15385		10.1074/jbc.271.26.15381	http://dx.doi.org/10.1074/jbc.271.26.15381			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663130	hybrid			2022-12-27	WOS:A1996UV29900015
J	Yao, PM; Buhler, JM; dOrtho, MP; Lebargy, F; Delclaux, C; Harf, A; Lafuma, C				Yao, PM; Buhler, JM; dOrtho, MP; Lebargy, F; Delclaux, C; Harf, A; Lafuma, C			Expression of matrix metalloproteinase gelatinases A and B by cultured epithelial cells from human bronchial explants	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IV COLLAGENASE; HUMAN KERATINOCYTES; 72-KDA GELATINASE; TISSUE INHIBITOR; MACROPHAGES; INJURY; DIFFERENTIATION; IDENTIFICATION; MORPHOGENESIS; REGENERATION	To investigate the role of human bronchial epithelial cells (HBECs) in the maintenance and remodeling of the extracellular matrix, we evaluated the expression by HBECs of 72- and 92-kDa gelatinases under basal conditions and after exposure to bacterial lipopolysaccharides (LPS). Confluent HBECs from explants were cultured in plastic dishes coated with type I and III collagens, Gelatin zymography of HBEC-conditioned media showed constitutive major 92-kDa and minor 72-kDa gelatinases recognized by specific human antibodies and totally inhibited by the metalloproteinase inhibitor EDTA. The identification of the two matrix metaIloproteinases was confirmed by quantitative reverse transcription-polymerase chain reaction, Identical patterns of gelatinase expression were observed with repetitive primary cultures issued from the same explants, Zymography showed that exposure of HBECs to LPS induced 2- and 20-fold increases in 92-kDa gelatinase production and activation, respectively, as well as a smaller increase in activated 68-kDa gelatinase. With [H-3]gelatin substrate, elevated metallogelatinolytic activity (138 mu g of hydrolyzed gelatin/48 h/10(6) cells) was also observed, whereas no activity was detected in the absence of LPS. A human epithelial cell line (16HBE14o(-)) exhibited the same basal profile of gelatinase activity, but this profile remained unchanged after exposure to LPS, Quantitative reverse transcription-polymerase chain reaction demonstrated only minimal changes in 92-kDa mRNA levels in response to LPS, but the half-life of 92-kDa gelatinase mRNA was increased with exposure to EPS, In contrast, concomitant slight increases in 72-kDa gelatinase protein and mRNA were found, suggesting that the control mechanisms regulating the expression of 92- and 72-kDa gelatinases by HBECs in response to LPS are divergent. All these data allowed us to propose that HBECs may be actively involved in the physiological and physiopathological remodeling of the airway basement membrane.	FAC MED,INSERM U296,F-94010 CRETEIL,FRANCE; FAC MED,DEPT PHYSIOL,F-94010 CRETEIL,FRANCE; CEA SACLAY,DEPT BIOL CELLULAIRE & MOLEC,F-91191 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); CEA; UDICE-French Research Universities; Universite Paris Saclay								BAEZASQUIBAN A, 1991, IN VITRO CELL DEV B, V27, P453; BENALI R, 1993, AM J PHYSIOL, V264, pL183, DOI 10.1152/ajplung.1993.264.2.L183; CANETESOLER R, 1994, AM J PATHOL, V144, P518; CAWSTON TE, 1979, ANAL BIOCHEM, V99, P340, DOI 10.1016/S0003-2697(79)80017-2; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIER IE, 1988, J BIOL CHEM, V263, P6579; CRABBE T, 1994, FEBS LETT, V345, P14, DOI 10.1016/0014-5793(94)00412-9; DORTHO MP, 1994, AM J PHYSIOL, V266, pL209, DOI 10.1152/ajplung.1994.266.3.L209; DUFOUR S, 1986, BIOL CELL, V58, P1; EVANS MJ, 1986, AM J PATHOL, V123, P126; FRIDMAN R, 1993, BIOCHEM J, V289, P411, DOI 10.1042/bj2890411; FRIDMAN R, 1992, J BIOL CHEM, V267, P15398; HAMAMOTO S, 1988, CELL DIFFER DEV, V22, P191, DOI 10.1016/0045-6039(88)90011-5; HIBBS MS, 1987, J CLIN INVEST, V80, P1644, DOI 10.1172/JCI113253; JEFFERY PK, 1992, EUR RESPIR J, V5, P93; JONES R, 1973, BRIT J EXP PATHOL, V54, P229; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAFUMA C, 1994, J INVEST DERMATOL, V102, P945, DOI 10.1111/1523-1747.ep12384118; LANE BP, 1974, P SOC EXP BIOL MED, V145, P1139; LEHTOVIRTA J, 1994, BBA-PROTEIN STRUCT M, V1206, P83, DOI 10.1016/0167-4838(94)90075-2; LEPPERT D, 1995, J IMMUNOL, V154, P4379; MacDougall JR, 1995, CANCER METAST REV, V14, P351, DOI 10.1007/BF00690603; MCDOWELL EM, 1987, AM J PATHOL, V129, P511; MOLL UM, 1990, CANCER RES, V50, P6162; MONTGOMERY AMP, 1993, BIOCHIM BIOPHYS ACTA, V1176, P265, DOI 10.1016/0167-4889(93)90054-S; RAY JM, 1994, EUR RESPIR J, V7, P2062; RIES C, 1994, BLOOD, V83, P3638; SAARIALHOKERE UK, 1993, J BIOL CHEM, V268, P17354; SALO T, 1991, J BIOL CHEM, V266, P11436; SALO T, 1994, LAB INVEST, V70, P176; SATO H, 1994, NATURE, V370, P61, DOI 10.1038/370061a0; SHOJI S, 1989, AM J RESP CELL MOL, V1, P13, DOI 10.1165/ajrcmb/1.1.13; SIBILLE Y, 1990, AM REV RESPIR DIS, V141, P471, DOI 10.1164/ajrccm/141.2.471; SNIDER GL, 1984, AM REV RESPIR DIS, V129, P155; STAHLEBACKDAHL M, 1994, J CLIN INVEST, V93, P2022, DOI 10.1172/JCI117196; STETLERSTEVENSON WG, 1989, J BIOL CHEM, V264, P1353; STONER GD, 1981, IN VITRO CELL DEV B, V17, P577; SUZANNE M, 1995, FEBS LETT, V361, P61; TALHOUK RS, 1992, J CELL BIOL, V118, P1271, DOI 10.1083/jcb.118.5.1271; TEZUKA K, 1994, J BIOL CHEM, V269, P15006; TOURNIER JM, 1994, J BIOL CHEM, V269, P25454; TOURNIER JM, 1990, AM REV RESPIR DIS, V141, P1280, DOI 10.1164/ajrccm/141.5_Pt_1.1280; WANG AM, 1989, P NATL ACAD SCI USA, V86, P9717, DOI 10.1073/pnas.86.24.9717; WILHELM SM, 1989, J BIOL CHEM, V264, P17213; WOODLEY DT, 1986, J INVEST DERMATOL, V86, P418, DOI 10.1111/1523-1747.ep12285689; WUCHERPFENNIG AL, 1994, J BONE MINER RES, V9, P549; YASUMITSU H, 1992, J BIOCHEM-TOKYO, V111, P74, DOI 10.1093/oxfordjournals.jbchem.a123721	47	97	100	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15580	15589		10.1074/jbc.271.26.15580	http://dx.doi.org/10.1074/jbc.271.26.15580			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663061	hybrid			2022-12-27	WOS:A1996UV29900043
J	Chen, AC; Gudas, LJ				Chen, AC; Gudas, LJ			An analysis of retinoic acid-induced gene expression and metabolism in AB1 embryonic stem cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F9 TERATOCARCINOMA CELLS; ACUTE PROMYELOCYTIC LEUKEMIA; ACTIVATOR MESSENGER-RNA; BINDING-PROTEIN CRABP; MOUSE MELANOMA-CELLS; ALL-TRANS; CARCINOMA-CELLS; MOLECULAR-CLONING; INVIVO METABOLISM; THYROID-HORMONE	Murine embryonic stem cells such as the AB1 cell line undergo differentiation in the presence of retinoic acid (RA) into an extraembryonic epithelial cell type. This results in the activation of genes such as Hoxa-1, Hoxb-1, laminin, collagen IV(alpha 1), tissue plasminogen activator, RAR beta, and CRABPII, The CRABPI gene is regulated in an unusual fashion; CRABPI message and protein levels are induced at low concentrations of RA, but induction is diminished at higher concentrations. AB1 cells take up RA rapidly from the medium, and the addition of low, exogenous concentrations of RA to the culture medium results in very high intracellular RA concentrations, For example, AB1 stem cells cultured in 5 nM [H-3]RA have an internal [H-3]RA concentration of 1-2 mu M within the first hour. AB1 cells also metabolize [H-3]RA to more polar RA derivatives, The half-life of RA in AB1 cells not previously exposed to RA is about 2-2.5 h versus 40-45 min in cells cultured for 2-3 days in 1 mu M exogenous RA. Thus, the enzyme(s) which metabolize RA are induced or activated by RA, Furthermore, the local concentration of RA required to elicit some biological responses may be higher than previously thought.	CORNELL UNIV,COLL MED,DEPT PHARMACOL,NEW YORK,NY 10021	Cornell University					EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [F32HD007560] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [R01CA043796] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA43796] Funding Source: Medline; NICHD NIH HHS [HD07560] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ANDREWS PW, 1984, DEV BIOL, V103, P285, DOI 10.1016/0012-1606(84)90316-6; Armstrong Robert B., 1994, P545; ASTROM A, 1994, J BIOL CHEM, V269, P22334; BARUA AB, 1991, BIOCHEM J, V277, P527, DOI 10.1042/bj2770527; BHAT PV, 1987, BIOCHIM BIOPHYS ACTA, V922, P18, DOI 10.1016/0005-2760(87)90240-2; Blaner William S., 1994, P229; Bloom W., 1975, TXB HISTOLOGY; BOYLAN JF, 1991, J CELL BIOL, V112, P965, DOI 10.1083/jcb.112.5.965; BOYLAN JF, 1992, J BIOL CHEM, V267, P21486; BRADLEY A, 1984, NATURE, V309, P255, DOI 10.1038/309255a0; BUGGE TH, 1992, EMBO J, V11, P1409, DOI 10.1002/j.1460-2075.1992.tb05186.x; CASTAIGNE S, 1990, BLOOD, V76, P1704; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOMIENNE C, 1990, BLOOD, V76, P1710; DAVIS AC, 1993, GENE DEV, V7, P671, DOI 10.1101/gad.7.4.671; DENCKER L, 1990, DEVELOPMENT, V110, P343; DETHE H, 1990, NATURE, V343, P177, DOI 10.1038/343177a0; DOETSCHMAN TC, 1985, J EMBRYOL EXP MORPH, V87, P27; DOLLE P, 1990, DEVELOPMENT, V110, P1133; DURAND B, 1992, CELL, V71, P73, DOI 10.1016/0092-8674(92)90267-G; EICHELE G, 1989, TRENDS GENET, V5, P246, DOI 10.1016/0168-9525(89)90096-6; FEINBERG AP, 1984, ANAL BIOCHEM, V137, P266; FIORELLA PD, 1991, J BIOL CHEM, V266, P16572; FIORELLA PD, 1994, J BIOL CHEM, V269, P10538; FIORELLA PD, 1993, J BIOL CHEM, V268, P21545; FROLIK CA, 1980, J BIOL CHEM, V255, P8057; FUCHS E, 1981, CELL, V25, P617, DOI 10.1016/0092-8674(81)90169-0; GIGUERE V, 1990, P NATL ACAD SCI USA, V87, P6233, DOI 10.1073/pnas.87.16.6233; GRIPPO JF, 1987, J BIOL CHEM, V262, P4492; GUBLER ML, 1985, J BIOL CHEM, V260, P9552; GUDAS LJ, 1991, SEMIN DEV BIOL, V2, P171; Gudas Lorraine J., 1994, P443; HEYMAN RA, 1992, CELL, V68, P397, DOI 10.1016/0092-8674(92)90479-V; HILL DL, 1992, ANNU REV NUTR, V12, P161, DOI 10.1146/annurev.nu.12.070192.001113; Hofmann Clementine, 1994, P387; Hong Waun Ki, 1994, P597; HONG WK, 1990, NEW ENGL J MED, V323, P795, DOI 10.1056/NEJM199009203231205; HOSLER BA, 1989, MOL CELL BIOL, V9, P5623, DOI 10.1128/MCB.9.12.5623; HU L, 1990, MOL CELL BIOL, V10, P391, DOI 10.1128/MCB.10.1.391; JETTEN AM, 1990, INT J CANCER, V45, P195, DOI 10.1002/ijc.2910450135; JETTEN AM, 1979, EXP CELL RES, V119, P289, DOI 10.1016/0014-4827(79)90356-2; JONESVILLENEUVE EMV, 1982, J CELL BIOL, V94, P253, DOI 10.1083/jcb.94.2.253; KEITH C, 1983, J CELL BIOL, V97, P1918, DOI 10.1083/jcb.97.6.1918; KOSA K, 1995, CANCER RES, V55, P4850; LAMMER EJ, 1985, NEW ENGL J MED, V313, P837, DOI 10.1056/NEJM198510033131401; LANGSTON AW, 1992, MECH DEVELOP, V38, P217, DOI 10.1016/0925-4773(92)90055-O; LAROSA GJ, 1988, P NATL ACAD SCI USA, V85, P329, DOI 10.1073/pnas.85.2.329; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; LOTAN R, 1981, J CELL PHYSIOL, V106, P179, DOI 10.1002/jcp.1041060203; MACGREGOR TM, 1992, J BIOL CHEM, V267, P7777; Mangelsdorf David J., 1994, P319; MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X; MARTINI R, 1993, ARCH BIOCHEM BIOPHYS, V303, P57, DOI 10.1006/abbi.1993.1255; MATZUK MM, 1995, NATURE, V374, P354, DOI 10.1038/374354a0; MATZUK MM, 1995, NATURE, V374, P360, DOI 10.1038/374360a0; MATZUK MM, 1995, NATURE, V374, P356, DOI 10.1038/374356a0; MCCLEAN SW, 1982, CLIN CHEM, V28, P693; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; MUMMERY CL, 1990, DEV BIOL, V142, P406, DOI 10.1016/0012-1606(90)90362-M; Ong David E., 1994, P283; Peck Gary L., 1994, P631; PEREZCASTRO AV, 1989, P NATL ACAD SCI USA, V86, P8813, DOI 10.1073/pnas.86.22.8813; RAMIREZSOLIS R, 1993, CELL, V73, P279, DOI 10.1016/0092-8674(93)90229-J; REYNOLDS NJ, 1993, J PHARMACOL EXP THER, V266, P1636; RICKLES RJ, 1988, J BIOL CHEM, V263, P1563; RICKLES RJ, 1988, FEBS LETT, V229, P100, DOI 10.1016/0014-5793(88)80806-8; ROBERTS ES, 1992, MOL PHARMACOL, V41, P427; ROGERS MB, 1991, DEVELOPMENT, V113, P815; RUBERTE E, 1991, DEVELOPMENT, V111, P45; RUBERTE E, 1993, DEVELOPMENT, V118, P267; RUBERTE E, 1992, DEVELOPMENT, V115, P973; SHIKONE T, 1994, MOL ENDOCRINOL, V8, P983, DOI 10.1210/me.8.8.983; SIEGENTHALER G, 1992, BIOCHEM J, V287, P383, DOI 10.1042/bj2870383; SIEGENTHALER G, 1987, EUR J BIOCHEM, V166, P209, DOI 10.1111/j.1432-1033.1987.tb13503.x; SIMEONE A, 1990, NATURE, V346, P763, DOI 10.1038/346763a0; SIMEONE A, 1991, MECH DEVELOP, V33, P215, DOI 10.1016/0925-4773(91)90029-6; SMITH WC, 1991, EMBO J, V10, P2223, DOI 10.1002/j.1460-2075.1991.tb07758.x; SPIEGELMAN BM, 1983, J BIOL CHEM, V258, P83; SPORN MB, 1983, CANCER RES, V43, P3034; STONER CM, 1989, CANCER RES, V49, P1497; STRICKLAND S, 1978, CELL, V15, P393, DOI 10.1016/0092-8674(78)90008-9; SULIK KK, 1988, DEVELOPMENT, V103, P213; VAESSEN MJ, 1990, DEVELOPMENT, V110, P371; Vanden Bossche H, 1988, Skin Pharmacol, V1, P176; VANWAUWE J, 1994, BIOCHEM PHARMACOL, V47, P737, DOI 10.1016/0006-2952(94)90137-6; VANWAUWE JP, 1990, J PHARMACOL EXP THER, V252, P365; VANWAUWE JP, 1988, J PHARMACOL EXP THER, V245, P718; VASIOS GW, 1989, P NATL ACAD SCI USA, V86, P9099, DOI 10.1073/pnas.86.23.9099; WANG SY, 1990, J BIOL CHEM, V265, P15818; WANG SY, 1992, J BIOL CHEM, V267, P15362; WANG SY, 1983, P NATL ACAD SCI-BIOL, V80, P5880, DOI 10.1073/pnas.80.19.5880; WARRELL RP, 1993, NEW ENGL J MED, V329, P177, DOI 10.1056/NEJM199307153290307; WEI LN, 1989, MOL ENDOCRINOL, V3, P454, DOI 10.1210/mend-3-3-454; WEI LN, 1990, DNA CELL BIOL, V9, P471, DOI 10.1089/dna.1990.9.471; WILLIAMS JB, 1985, P NATL ACAD SCI USA, V82, P4658, DOI 10.1073/pnas.82.14.4658; WILLIAMS RL, 1988, NATURE, V336, P684, DOI 10.1038/336684a0; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZHANG XK, 1992, NATURE, V355, P441, DOI 10.1038/355441a0	99	43	43	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14971	14980		10.1074/jbc.271.25.14971	http://dx.doi.org/10.1074/jbc.271.25.14971			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663043	hybrid			2022-12-27	WOS:A1996UT10600052
J	Holtmann, MH; Ganguli, S; Hadac, EM; Dolu, V; Miller, LJ				Holtmann, MH; Ganguli, S; Hadac, EM; Dolu, V; Miller, LJ			Multiple extracellular loop domains contribute critical determinants for agonist binding and activation of the secretin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASOACTIVE INTESTINAL POLYPEPTIDE; EXPRESSION; MUTAGENESIS	Distinct themes exist for ligand-binding domains of G protein coupled receptors, The secretin receptor is prototypic of a recently described family in this superfamily which binds moderate-sized peptides possessing a diffuse pharmacophore. We recently demonstrated the importance of the N terminus and first loop of this receptor for secretin binding (Holtmann, M. H., Hadac, E. M., and Miller, L. J. (1995) J. Biol. Chem. 270:14394-14398), Here, we extend those findings to define another receptor domain important for agonist recognition and to focus on critical determinants within each of these domains, Extending the secretin-vasoactive intestinal polypeptide (VIP) chimeric receptor approach, we confirmed and refined the critical importance of the N terminus and the need to complement this with other domains of the secretin receptor, There was redundancy in the complementary determinants required, with the second extracellular loop able to compensate for the absence of the first loop, The first 10 residues of the N terminus of the secretin receptor were critical, Sequential segmental and site replacements permitted focusing on the His(189)-Lys(190) sequence at the C terminus of the first extracellular loop, and on four residues (phe(257), Leu(258), Asn(260), and Thr(261)) in the N-terminal half of the second loop as providing critical determinants, All receptor constructs which expressed sensitive cAMP responses to secretin (EC(50) <5 nM) bound this peptide with high affinity. Of note, one construct dissociated high affinity binding of secretin from its biological responsiveness, providing a clue to the conformational ''switch'' that activates this receptor.	MAYO CLIN & MAYO FDN,CTR BASIC RES DIGEST DIS,ROCHESTER,MN 55905	Mayo Clinic					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK046577, R01DK046577] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK46577] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BODANSZKY M, 1978, J MED CHEM, V21, P1171, DOI 10.1021/jm00209a018; BODANSZKY M, 1977, GASTROENTEROLOGY, V72, P801; COUGHLIN SR, 1994, CURR OPIN CELL BIOL, V6, P191, DOI 10.1016/0955-0674(94)90135-X; COUVINEAU A, 1995, BIOCHEM BIOPH RES CO, V206, P246, DOI 10.1006/bbrc.1995.1034; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; HOUSSAMI S, 1994, ENDOCRINOLOGY, V135, P183, DOI 10.1210/en.135.1.183; ISHIHARA T, 1992, NEURON, V8, P811, DOI 10.1016/0896-6273(92)90101-I; ISHIHARA T, 1991, EMBO J, V10, P1635, DOI 10.1002/j.1460-2075.1991.tb07686.x; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KOLAKOWSKI LF, 1994, RECEPTOR CHANNEL, V2, P1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; ULRICH CD, 1993, GASTROENTEROLOGY, V105, P1534, DOI 10.1016/0016-5085(93)90162-6	17	88	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14944	14949		10.1074/jbc.271.25.14944	http://dx.doi.org/10.1074/jbc.271.25.14944			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663161	hybrid			2022-12-27	WOS:A1996UT10600048
J	Beers, MF				Beers, MF			Inhibition of cellular processing of surfactant protein C by drugs affecting intracellular pH gradients	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LUNG LAMELLAR BODIES; PULMONARY SURFACTANT; II CELLS; RAT LUNG; HYDROPHOBIC PROTEINS; NILE RED; LOCALIZATION; DEGRADATION; EXPRESSION; SECRETION	Surfactant protein C (SP-C) is a hydrophobic protein synthesized and secreted exclusively by alveolar type LI cells through proteolysis of a 21-kDa propeptide (SPC21) to produce the 3.7-kDa surface active form. Previous studies from this laboratory have demonstrated that early processing of proSP-C involves extensive intracellular proteolysis of the COOH terminus of proSP-C-21 in subcellular compartments, which include the acidic type II cell-specific subcellular organelle, the lamellar body. (Beers, M. F., Kim, C. Y., Dodia, C., and Fisher, A. B. (1994) J. Biol. Chem. 269, 20318-20328). The role of intracellular pH gradients in SP-C processing was studied in freshly isolated rat type II cells. Using vital fluorescence microscopy, the pH indicator acridine orange (AO) identified intense fluorescence staining of acidic cytoplasmic vesicles within fresh type II cells. The AO vesicular staining pattern was similar in cells labeled with the lamellar body marker phosphine 3R and the phospholipid dye nile red. AO fluorescence was quenched by the addition of a membrane-permeable weak base, methylamine. Immunoprecipitation of cell lysates with anti-proSP-C antisera following pulse-chase labeling (0-2 h) with S-35-Translabel demonstrated rapid synthesis of S-35-proSP-C-21 with a time-dependent appearance of 16- and 6-kDa intermediates (SP-C-16 and SP-C-6). Tricine polyacrylamide gel electrophoresis analysis of organic extracts of cell lysates showed time-dependent appearance of mature SP-C-3.7. The addition of 5 mM methylamine significantly blocked the post-translational processing of proSP-C resulting in disruption of normal precursor-product relationships and inhibition of SP-C-3.7 formation. Methylamine-treated cells exhibited slow accumulation of SP-C-16 and SP-C-6, a persistence of SP-C-21, and an absence of SP-C-3.7 for the duration of the chase period. The lysosomotropic agent chloroquine, the proton ionophore monensin, and bafilomycin A(1), a specific vacuolar H+-ATPase inhibitor, each caused inhibition of proSP-C processing in a similar manner. These results demonstrate that normal posttranslational proteolysis of proSP-C occurs in acidic intracellular compartments, which include the lamellar body, and that complete processing to SP-C-3.7 is dependent upon maintenance of transmembrane pH gradients by a vacuolar H+-ATPase.	HOSP UNIV PENN,DEPT MED,DIV PULM & CRIT CARE,PHILADELPHIA,PA 19104	University of Pennsylvania	Beers, MF (corresponding author), UNIV PENN,SCH MED,INST ENVIRONM MED,1 JOHN MORGAN BLDG,36TH & HAMILTON WALK,PHILADELPHIA,PA 19104, USA.				NHLBI NIH HHS [HL-02869] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002869] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALLARD PL, 1995, J PEDIATR, V96, P1046; BARITUSSIO A, 1992, AM J PHYSIOL, V263, pL607, DOI 10.1152/ajplung.1992.263.5.L607; BEERS MF, 1994, AM J RESP CELL MOL, V11, P240, DOI 10.1165/ajrcmb.11.2.8049085; Beers MF, 1995, AM J PHYSIOL-LUNG C, V269, pL744, DOI 10.1152/ajplung.1995.269.6.L744; BEERS MF, 1992, AM J PHYSIOL, V263, pL151, DOI 10.1152/ajplung.1992.263.2.L151; BEERS MF, 1982, ANN NY ACAD SCI, V402, P116, DOI 10.1111/j.1749-6632.1982.tb25736.x; BEERS MF, 1994, J BIOL CHEM, V269, P20318; BEERS MF, 1992, AM J RESP CELL MOL, V7, P368, DOI 10.1165/ajrcmb/7.4.368; BIDANI A, 1995, J LEUKOCYTE BIOL, V57, P275, DOI 10.1002/jlb.57.2.275; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BRESLIN JS, 1992, AM J PHYSIOL, V262, pL699, DOI 10.1152/ajplung.1992.262.6.L699; BROWN WJ, 1992, HISTOCHEMISTRY, V97, P349, DOI 10.1007/BF00270037; CHANDER A, 1986, J BIOL CHEM, V261, P6126; CHANDER A, 1992, BIOCHIM BIOPHYS ACTA, V1123, P198, DOI 10.1016/0005-2760(92)90112-9; CHANDER A, 1989, AM J PHYSIOL, V257, pL354, DOI 10.1152/ajplung.1989.257.6.L354; DEMELLO DE, 1994, J PEDIATR-US, V125, P43, DOI 10.1016/S0022-3476(94)70119-9; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; FISHER JH, 1989, BIOCHIM BIOPHYS ACTA, V995, P225, DOI 10.1016/0167-4838(89)90040-X; GLASSER SW, 1988, J BIOL CHEM, V263, P9; GREENSPAN P, 1985, J CELL BIOL, V100, P965, DOI 10.1083/jcb.100.3.965; HAWGOOD S, 1989, AM J PHYSIOL, V257, pL13, DOI 10.1152/ajplung.1989.257.2.L13; LOH YP, 1984, ANNU REV NEUROSCI, V7, P189, DOI 10.1146/annurev.ne.07.030184.001201; MASON RJ, 1977, AM REV RESPIR DIS, V115, P1015; MATHIALAGAN N, 1990, BIOCHIM BIOPHYS ACTA, V1045, P121, DOI 10.1016/0005-2760(90)90140-S; NOGEE LM, 1993, NEW ENGL J MED, V328, P406, DOI 10.1056/NEJM199302113280606; OOSTERLAKENDIJKSTERHUIS MA, 1991, BIOCHEM J, V274, P115, DOI 10.1042/bj2740115; ORCI L, 1986, J CELL BIOL, V103, P2273, DOI 10.1083/jcb.103.6.2273; PHELPS DS, 1991, EXP LUNG RES, V17, P985, DOI 10.3109/01902149109064330; PHIZACKERLEY PJR, 1979, BIOCHEM J, V183, P731, DOI 10.1042/bj1830731; QANBAR R, 1994, ANAL BIOCHEM, V216, P262, DOI 10.1006/abio.1994.1040; RADONS J, 1994, BIOCHEM J, V302, P581, DOI 10.1042/bj3020581; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; VOORHOUT WF, 1993, MICROSC RES TECHNIQ, V26, P366, DOI 10.1002/jemt.1070260504; VORBROKER DK, 1995, AM J PHYSIOL-LUNG C, V268, pL647, DOI 10.1152/ajplung.1995.268.4.L647; VORBROKER DK, 1992, BIOCHIM BIOPHYS ACTA, V1105, P161, DOI 10.1016/0005-2736(92)90175-L; Vorbroker DK, 1995, AM J PHYSIOL-LUNG C, V269, pL727, DOI 10.1152/ajplung.1995.269.6.L727; WEAVER TE, 1989, AM J PHYSIOL, V257, pL100, DOI 10.1152/ajplung.1989.257.2.L100; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEAVER TE, 1992, AM J PHYSIOL, V263, pL95, DOI 10.1152/ajplung.1992.263.1.L95; WIBO M, 1974, J CELL BIOL, V63, P430, DOI 10.1083/jcb.63.2.430; XIE XS, 1986, J BIOL CHEM, V261, P2492; YOUNG SL, 1989, J APPL PHYSIOL, V66, P1336, DOI 10.1152/jappl.1989.66.3.1336	44	63	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14361	14370		10.1074/jbc.271.24.14361	http://dx.doi.org/10.1074/jbc.271.24.14361			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662952	hybrid			2022-12-27	WOS:A1996UQ66000064
J	Ikuta, T; Papayannopoulou, T; Stamatoyannopoulos, G; Kan, YW				Ikuta, T; Papayannopoulou, T; Stamatoyannopoulos, G; Kan, YW			Globin gene switching - In vivo protein-DNA interactions of the human beta-globin locus in erythroid cells expressing the fetal or the adult globin gene program	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DOMINANT CONTROL REGION; HUMAN GAMMA-GLOBIN; K562 ERYTHROLEUKEMIA-CELLS; HIGH-LEVEL EXPRESSION; TRANSCRIPTION FACTOR; TRANSGENIC MICE; HYPERSENSITIVE SITE; MINIMAL REQUIREMENTS; CHROMATIN STRUCTURE; ACTIVATION REGION	To characterize the protein-DNA interactions important for the developmental control of the human beta-globin locus, we analyzed by in vivo dimethyl sulfate footprinting erythroid cells expressing either the fetal or the adult globin developmental program, In the locus control region (LCR) of the beta-globin locus, in vivo footprints on NF-EB (or AP-1) and GATA-1 motifs remained the same regardless of whether the fetal or the adult globin genes are expressed. In contrast, in vivo footprints on GT (CACCC) motifs differed between the cells expressing the fetal or the adult globin program, In promoter regions, the actively transcribed genes demonstrated extensive and consistent footprints over the ca nonical elements, such as CACCC and CCAAT motifs, The adult globin expressing cells displayed more extensive footprints than the fetal globin expressing cells in the 3' regulatory sequences of both the (A) gamma- and the beta-globin genes, suggesting a role of these 3' elements in beta-globin gene expression, Our results suggest that the bulk of protein-DNA interactions that underlies the developmental control of globin genes takes place in the gamma- and beta-globin gene promoters, and that GT motifs of the beta-globin locus LCR may play a role in the developmental regulation of human beta-globin gene expression, perhaps by increasing the probability of interaction of the LCR holocomplex with the fetal or the adult globin gene.	UNIV CALIF SAN FRANCISCO,DEPT LAB MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,HOWARD HUGHES MED INST,SAN FRANCISCO,CA 94143; UNIV WASHINGTON,DIV MED GENET,SEATTLE,WA 98195	University of California System; University of California San Francisco; Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of Washington; University of Washington Seattle					NIDDK NIH HHS [DK45365, DK30852, DK16666] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R56DK045365, R01DK045365, R37DK045365, R01DK016666, R37DK016666, R01DK030852, R37DK030852] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDREWS NC, 1993, NATURE, V362, P722, DOI 10.1038/362722a0; ANTONIOU M, 1990, GENE DEV, V4, P1007, DOI 10.1101/gad.4.6.1007; BALTA G, 1994, BLOOD, V83, P3727; BIEKER JJ, 1995, MOL CELL BIOL, V15, P852; BODINE DM, 1987, EMBO J, V6, P2997, DOI 10.1002/j.1460-2075.1987.tb02605.x; BOHMANN D, 1987, SCIENCE, V238, P1386, DOI 10.1126/science.2825349; CHAN JY, 1993, P NATL ACAD SCI USA, V90, P11371, DOI 10.1073/pnas.90.23.11371; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLIS P, 1990, EMBO J, V9, P233, DOI 10.1002/j.1460-2075.1990.tb08100.x; CUNNINGHAM JM, 1994, BLOOD, V84, P1298; DEBOER E, 1988, EMBO J, V7, P4203, DOI 10.1002/j.1460-2075.1988.tb03317.x; DIERKS P, 1983, CELL, V32, P695, DOI 10.1016/0092-8674(83)90055-7; DONZE D, 1995, J BIOL CHEM, V270, P1955, DOI 10.1074/jbc.270.4.1955; EVANS T, 1988, P NATL ACAD SCI USA, V85, P5976, DOI 10.1073/pnas.85.16.5976; FIERING S, 1995, GENE DEV, V9, P2203, DOI 10.1101/gad.9.18.2203; FORRESTER WC, 1987, NUCLEIC ACIDS RES, V15, P10159, DOI 10.1093/nar/15.24.10159; FORRESTER WC, 1986, P NATL ACAD SCI USA, V83, P1359, DOI 10.1073/pnas.83.5.1359; FORRESTER WC, 1990, GENE DEV, V4, P1637, DOI 10.1101/gad.4.10.1637; FRASER P, 1990, NUCLEIC ACIDS RES, V18, P3503, DOI 10.1093/nar/18.12.3503; FRASER P, 1993, GENE DEV, V7, P106, DOI 10.1101/gad.7.1.106; GILBERT W, 1976, CONTROL RIBOSOME SYN, P139; GROSVELD F, 1987, CELL, V51, P975, DOI 10.1016/0092-8674(87)90584-8; GUMUCIO DL, 1988, MOL CELL BIOL, V8, P5310, DOI 10.1128/MCB.8.12.5310; HUG BA, 1992, NUCLEIC ACIDS RES, V20, P5771, DOI 10.1093/nar/20.21.5771; IKUTA T, 1991, P NATL ACAD SCI USA, V88, P10188, DOI 10.1073/pnas.88.22.10188; JANE SM, 1992, EMBO J, V11, P2961, DOI 10.1002/j.1460-2075.1992.tb05366.x; KARA CJ, 1991, SCIENCE, V252, P709, DOI 10.1126/science.1902592; KARLSSON S, 1985, ANNU REV BIOCHEM, V54, P1071; KATAOKA K, 1995, MOL CELL BIOL, V15, P2180; KOTKOW KJ, 1995, MOL CELL BIOL, V15, P4640; LONERGAN M, 1993, MOL CELL BIOL, V13, P6629, DOI 10.1128/MCB.13.11.6629; LOWREY CH, 1992, P NATL ACAD SCI USA, V89, P1143, DOI 10.1073/pnas.89.3.1143; Maxam A M, 1980, Methods Enzymol, V65, P499; MCDONAGH KT, 1991, J BIOL CHEM, V266, P11965; MILLER IJ, 1993, MOL CELL BIOL, V13, P2776, DOI 10.1128/MCB.13.5.2776; MILLER JL, 1993, BLOOD, V82, P1900; MOI P, 1994, P NATL ACAD SCI USA, V91, P9926, DOI 10.1073/pnas.91.21.9926; MUELLER PR, 1989, SCIENCE, V246, P780, DOI 10.1126/science.2814500; ONEILL D, 1990, NUCLEIC ACIDS RES, V18, P1977, DOI 10.1093/nar/18.8.1977; ORKIN SH, 1984, ANNU REV GENET, V18, P131; ORKIN SH, 1990, CELL, V63, P665, DOI 10.1016/0092-8674(90)90133-Y; ORKIN SH, 1995, EUR J BIOCHEM, V231, P271, DOI 10.1111/j.1432-1033.1995.tb20697.x; PAPAYANNOPOULOU T, 1986, CELL, V46, P469, DOI 10.1016/0092-8674(86)90667-7; PETERSON KR, 1996, IN PRESS P NATL ACAD; PHILIPSEN S, 1993, EMBO J, V12, P1077, DOI 10.1002/j.1460-2075.1993.tb05749.x; PHILIPSEN S, 1990, EMBO J, V9, P2159, DOI 10.1002/j.1460-2075.1990.tb07385.x; PRUZINA S, 1991, NUCLEIC ACIDS RES, V19, P1413, DOI 10.1093/nar/19.7.1413; PURUCKER M, 1990, NUCLEIC ACIDS RES, V18, P7407, DOI 10.1093/nar/18.24.7407; RAICH N, 1990, SCIENCE, V250, P1147, DOI 10.1126/science.2251502; RAICH N, 1995, EMBO J, V14, P801, DOI 10.1002/j.1460-2075.1995.tb07058.x; REDDY PMS, 1994, J BIOL CHEM, V269, P8287; REDDY PMS, 1991, P NATL ACAD SCI USA, V88, P8676, DOI 10.1073/pnas.88.19.8676; RYAN TM, 1989, GENE DEV, V3, P314, DOI 10.1101/gad.3.3.314; Sambrook J., 2002, MOL CLONING LAB MANU; SHIVDASANI RA, 1995, P NATL ACAD SCI USA, V92, P8690, DOI 10.1073/pnas.92.19.8690; STAMATOYANNOPOU.G, 1987, MOL BASIS BLOOD DISE, P66; STARCK J, 1994, BLOOD, V84, P1656; STRAUSS EC, 1992, P NATL ACAD SCI USA, V89, P5809, DOI 10.1073/pnas.89.13.5809; TALBOT D, 1990, EMBO J, V9, P2169, DOI 10.1002/j.1460-2075.1990.tb07386.x; TOWNES TM, 1985, EMBO J, V4, P1715, DOI 10.1002/j.1460-2075.1985.tb03841.x; TRUDEL M, 1987, GENE DEV, V1, P954, DOI 10.1101/gad.1.9.954; TUAN D, 1985, P NATL ACAD SCI USA, V82, P6384, DOI 10.1073/pnas.82.19.6384; ULRICH MJ, 1990, BLOOD, V75, P990; WALL L, 1988, GENE DEV, V2, P1089, DOI 10.1101/gad.2.9.1089	64	32	32	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14082	14091		10.1074/jbc.271.24.14082	http://dx.doi.org/10.1074/jbc.271.24.14082			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662960				2022-12-27	WOS:A1996UQ66000025
J	Kinet, S; Goffin, V; Mainfroid, V; Martial, JA				Kinet, S; Goffin, V; Mainfroid, V; Martial, JA			Characterization of lactogen receptor-binding site 1 of human prolactin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; ALANINE-SCANNING MUTAGENESIS; METHIONYL BOVINE PROLACTIN; BIOLOGICAL PROPERTIES; RATIONAL DESIGN; FAMILY; ERYTHROPOIETIN; PURIFICATION; ANTAGONISTS; BIOACTIVITY	Prolactin (PRL) binds to two molecules of PRL receptor (PRLR) through two regions referred to as binding sites 1 and 2. Although binding site 1 has been generally assigned to the pocket delimited by helix 1, helix 4, and the second half of loop 1, the residues involved in receptor binding have not yet all been precisely identified. In an earlier alanine-scanning mutational study, we identified three major binding determinants in loop 1 of human PRL (hPRL) (Goffin, V., Norman, M. & Martial, J. A. (1992) Mol. Endocrinol. 6, 1381-1392). Here we focus on the two other regions that form binding site 1, namely helices 1 and 4. Putative binding residues, selected on the basis of a three-dimensional model of hPRL constructed in this laboratory, were mutated to alanine, and recombinant hPRL mutants produced in Escherichia coli were tested for their ability to bind to the PRLR and to stimulate Nb2 cell. proliferation. We thus identified nine single mutations (three in helix 1 and six in helix 4) whose effect was to reduce both binding and mitogenic activity by more than half as compared with wild-type hPRL, indicating the functional involvement of the corresponding residues. Adding these to the three binding determinants identified in loop 1, we now propose a complete picture of PRLR-binding site 1 of hPRL. As we earlier hypothesized, the binding site 1 determinants of hPRL differ from those of human growth hormone, a hPRL homolog.	UNIV LIEGE,LAB MOLEC BIOL & GENET ENGN,B-4000 SART,BELGIUM	University of Liege			GOFFIN, Vincent/G-3322-2013	GOFFIN, Vincent/0000-0002-8021-3086; kinet, sandrina/0000-0003-0699-108X				ABDELMEGUID SS, 1987, P NATL ACAD SCI USA, V84, P6434, DOI 10.1073/pnas.84.18.6434; BAZAN JF, 1989, BIOCHEM BIOPH RES CO, V164, P788, DOI 10.1016/0006-291X(89)91528-3; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHEN YH, 1972, BIOCHEMISTRY-US, V11, P4120, DOI 10.1021/bi00772a015; Clarke W.C., 1980, Hormonal Proteins and Peptides, V8, P105; CLARKSON T, 1995, SCIENCE, V267, P383; COOKE NE, 1981, J BIOL CHEM, V256, P4007; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; CUNNINGHAM BC, 1991, P NATL ACAD SCI USA, V88, P3407, DOI 10.1073/pnas.88.8.3407; CUNNINGHAM BC, 1993, J MOL BIOL, V234, P554, DOI 10.1006/jmbi.1993.1611; CUNNINGHAM BC, 1990, SCIENCE, V250, P1709, DOI 10.1126/science.2270485; CUNNINGHAM BC, 1989, SCIENCE, V243, P1330, DOI 10.1126/science.2466339; CUNNINGHAM BC, 1989, SCIENCE, V244, P1081, DOI 10.1126/science.2471267; DEMCHUK E, 1994, PROTEIN SCI, V3, P920; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; FUH G, 1995, J BIOL CHEM, V270, P13133, DOI 10.1074/jbc.270.22.13133; FUH G, 1993, J BIOL CHEM, V268, P5376; FUH G, 1992, SCIENCE, V256, P1677, DOI 10.1126/science.256.5064.1677; FUKUNAGA R, 1990, J BIOL CHEM, V265, P14008; GOFFIN V, 1994, J BIOL CHEM, V269, P32598; GOFFIN V, 1992, MOL ENDOCRINOL, V6, P1381, DOI 10.1210/me.6.9.1381; GOFFIN V, 1993, EUR J BIOCHEM, V214, P483, DOI 10.1111/j.1432-1033.1993.tb17945.x; GOFFIN V, 1996, PROTEIN ENG, V8, P1215; GOUT PW, 1980, CANCER RES, V40, P2433; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; KELLY PA, 1993, RECENT PROG HORM RES, V48, P123; KELLY PA, 1991, ENDOCR REV, V12, P235, DOI 10.1210/edrv-12-3-235; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KOSSIAKOFF AA, 1994, PROTEIN SCI, V3, P1697, DOI 10.1002/pro.5560031008; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRUSE N, 1993, EMBO J, V12, P5121, DOI 10.1002/j.1460-2075.1993.tb06207.x; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LUCK DN, 1991, MOL ENDOCRINOL, V5, P1880, DOI 10.1210/mend-5-12-1880; LUCK DN, 1989, MOL ENDOCRINOL, V3, P822, DOI 10.1210/mend-3-5-822; LUCK DN, 1990, MOL ENDOCRINOL, V4, P1011, DOI 10.1210/mend-4-7-1011; MILLER WL, 1983, ENDOCR REV, V4, P97, DOI 10.1210/edrv-4-2-97; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLL CS, 1986, ENDOCR REV, V7, P169, DOI 10.1210/edrv-7-2-169; PARIS N, 1990, BIOTECHNOL APPL BIOC, V12, P436; RUI H, 1994, ENDOCRINOLOGY, V135, P1299, DOI 10.1210/en.135.4.1299; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SHIU RPC, 1983, ENDOCRINOLOGY, V113, P159, DOI 10.1210/endo-113-1-159; SOMERS W, 1994, NATURE, V372, P478, DOI 10.1038/372478a0; SPRANG SR, 1993, CURR OPIN STRUC BIOL, V3, P815, DOI 10.1016/0959-440X(93)90144-A; STAHL N, 1993, CELL, V74, P587, DOI 10.1016/0092-8674(93)90506-L; TAGA T, 1993, FASEB J, V7, P3387; TANAKA T, 1980, J CLIN ENDOCR METAB, V51, P1058, DOI 10.1210/jcem-51-5-1058; Wallis M., 1988, Hormones and their actions. Part II. Specific actions of protein hormones., P265; WATOWICH SS, 1994, MOL CELL BIOL, V14, P3535, DOI 10.1128/MCB.14.6.3535; WATOWICH SS, 1992, P NATL ACAD SCI USA, V89, P2140, DOI 10.1073/pnas.89.6.2140	50	25	27	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14353	14360		10.1074/jbc.271.24.14353	http://dx.doi.org/10.1074/jbc.271.24.14353			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662911	hybrid			2022-12-27	WOS:A1996UQ66000063
J	Leung, CL; Liem, RKH				Leung, CL; Liem, RKH			Characterization of interactions between the neurofilament triplet proteins by the yeast two-hybrid system	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NEURONAL INTERMEDIATE FILAMENTS; NF-M; INVITRO; EXPRESSION; VIMENTIN; CELLS; FIBROBLASTS; SUBUNITS; BIOLOGY	In the adult axon, the neurofilaments (NFs) are heteropolymers formed from the low (NFL), middle (NFM), and high (NFH) molecular weight neurofilament triplet proteins (NFTPs). All three proteins have the basic intermediate filament protein tripartite structure, which consists of a short amino-terminal head region, an alpha-helical rod region of similar to 310 amino acids, and a carboxyl-terminal tail region of variable length. lit vitro polymerization studies have shown that only NFL can assemble into homopolymeric 10-nm filaments. The assembly of intermediate filaments, including the NFs, begins with the formation of a coiled-coil dimer involving the alpha-helical rod domains of two molecules. In order to determine whether homodimers or heterodimers of NFTPs are the preferred intermediates in the assembly of NFs, we have used the yeast two-hybrid system to study the interactions between the different NFTPs. By monitoring the activity of the lacZ reporter gene product, we are able to show that the interactions of Nn with NFL, NFM, or NFH are stronger than the interactions of NFM with NFM or NFH and the interaction of NFH with NFH. These results imply that NFM and NFH are more likely to form heterodimers with Nn than homodimers and are consistent with the inability of NFM and NFH to self-polymerize in vitro and in vivo.	COLUMBIA UNIV COLL PHYS & SURG,DEPT PATHOL,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT BIOCHEM & MOLEC BIOPHYS,NEW YORK,NY 10032; COLUMBIA UNIV COLL PHYS & SURG,DEPT ANAT & CELL BIOL,NEW YORK,NY 10032	Columbia University; Columbia University; Columbia University					NATIONAL EYE INSTITUTE [T32EY007105] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015182] Funding Source: NIH RePORTER; NEI NIH HHS [EY07105] Funding Source: Medline; NIA NIH HHS [AG00189] Funding Source: Medline; NINDS NIH HHS [NS15182] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		CHIN SSM, 1989, EUR J CELL BIOL, V50, P475; CHIN SSM, 1991, J CELL SCI, V99, P335; CHIN SSM, 1990, J NEUROSCI, V10, P3714; CHING GY, 1993, J CELL BIOL, V122, P1323, DOI 10.1083/jcb.122.6.1323; COHLBERG JA, 1995, J BIOL CHEM, V270, P9334, DOI 10.1074/jbc.270.16.9334; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FLIEGNER KH, 1991, INT REV CYTOL, V131, P109, DOI 10.1016/S0074-7696(08)62018-5; GEISLER N, 1981, J MOL BIOL, V151, P565, DOI 10.1016/0022-2836(81)90011-5; HISANAGA S, 1990, J MOL BIOL, V211, P871, DOI 10.1016/0022-2836(90)90080-6; LEE MK, 1993, J CELL BIOL, V122, P1337, DOI 10.1083/jcb.122.6.1337; LEE MK, 1994, CURR OPIN CELL BIOL, V6, P34, DOI 10.1016/0955-0674(94)90113-9; LIEM RKH, 1982, BIOCHEMISTRY-US, V21, P3221, DOI 10.1021/bi00256a029; Meng JJ, 1996, J BIOL CHEM, V271, P1599, DOI 10.1074/jbc.271.3.1599; Miller J.H., 1972, EXPT MOL GENETICS; MONTEIRO MJ, 1989, J CELL BIOL, V108, P579, DOI 10.1083/jcb.108.2.579; MULLIGAN L, 1991, J STRUCT BIOL, V106, P145, DOI 10.1016/1047-8477(91)90084-A; NAPOLITANO EW, 1987, J NEUROSCI, V7, P2590; QUINLAN RA, 1986, J MOL BIOL, V192, P233; Sambrook J., 2002, MOL CLONING LAB MANU; STEINERT PM, 1988, ANNU REV BIOCHEM, V57, P593, DOI 10.1146/annurev.bi.57.070188.003113; STEINERT PM, 1981, P NATL ACAD SCI-BIOL, V78, P3692, DOI 10.1073/pnas.78.6.3692; VANDENHEUVEL RMM, 1987, J CELL SCI, V88, P475	22	32	33	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14041	14044		10.1074/jbc.271.24.14041	http://dx.doi.org/10.1074/jbc.271.24.14041			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663004	hybrid			2022-12-27	WOS:A1996UQ66000019
J	Su, JY; Erikson, E; Maller, JL				Su, JY; Erikson, E; Maller, JL			Cloning and characterization of a novel serine/threonine protein kinase expressed in early Xenopus embryos	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CATALYTIC SUBUNIT; TYROSINE PHOSPHORYLATION; CONSERVED FEATURES; CRYSTAL-STRUCTURE; YEAST; MITOSIS; GENE; IDENTIFICATION; INHIBITOR; SEQUENCE	We have cloned from a Xenopus ovary cDNA library a novel protein kinase gene whose expression peaks in the oocyte and unfertilized egg, beans to decrease gradually after fertilization, and disappears during the gastrulation stage of embryogenesis. The cloned gene, termed XEEK1 (for Xenopus egg and embryo kinase), encodes a protein with a predicted molecular mass of 49 kDa. Bacterially expressed XEEK1 migrates at 57 kDa upon polyacrylamide gel electrophoresis analysis, and a XEEK1-specific antibody recognizes a protein of 57 kDa in Xenopus oocyte and egg extracts. The XEEK1 kinase domain shares 35% identity (similar to 65% similarity) with the yeast SNF1 kinase and related kinases. However, expression of XEEK1 does not complement a snf1 deletion mutation in yeast, which suggests that it is probably not a Xenopus homolog of SNF1. Recombinant XEEK1 protein autophosphorylates on threonine residues in vitro in a reaction that prefers Mn2+ to Mg2+ ions. Site directed mutagenesis of the conserved lysine residue (Lys-81) within the kinase domain to isoleucine totally abolishes kinase activity, and threonine 192 has been identified as the autophosphorylation site. This site is distinct from the conserved threonine (Thr-215 in XEEK1) present in the protein kinase activation loop that is the site of autophosphorylation for many protein kinases. XEEK1 is a substrate for the cyclic AMP-dependent protein kinase both in vitro and in vivo, suggesting a possible mode of regulation of XEEK1. An immunoprecipitate of oocyte/egg extracts with anti-YEEK1 serum contains a protein of -155 kDa that may be a substrate and/or a regulatory component of the kinase.	UNIV COLORADO, SCH MED, HOWARD HUGHES MED INST, DENVER, CO 80262 USA; UNIV COLORADO, SCH MED, DEPT PHARMACOL, DENVER, CO 80262 USA	Howard Hughes Medical Institute; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM026743] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM26743] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALDERSON A, 1991, P NATL ACAD SCI USA, V88, P8602, DOI 10.1073/pnas.88.19.8602; Beavo J A, 1974, Methods Enzymol, V38, P299; BOOHER RN, 1993, EMBO J, V12, P3417, DOI 10.1002/j.1460-2075.1993.tb06016.x; BOSSEMEYER D, 1993, EMBO J, V12, P849, DOI 10.1002/j.1460-2075.1993.tb05725.x; CAMPBELL SD, 1995, MOL BIOL CELL, V6, P1333, DOI 10.1091/mbc.6.10.1333; CARLING D, 1994, J BIOL CHEM, V269, P11422; CARLSON M, 1981, GENETICS, V98, P25; CELENZA JL, 1986, SCIENCE, V233, P1175, DOI 10.1126/science.3526554; CREWS CM, 1991, P NATL ACAD SCI USA, V88, P8845, DOI 10.1073/pnas.88.19.8845; DEBONDT HL, 1993, NATURE, V363, P595, DOI 10.1038/363595a0; ENOCH T, 1991, CELL, V65, P921, DOI 10.1016/0092-8674(91)90542-7; ERIKSON E, 1989, J BIOL CHEM, V264, P13711; GABRIELLI BG, 1992, J BIOL CHEM, V267, P18040; GOULD KL, 1989, NATURE, V342, P39, DOI 10.1038/342039a0; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; HANKS SK, 1991, METHOD ENZYMOL, V200, P38; Harlow E., 1988, ANTIBODIES LAB MANUA; JEFFREY PD, 1995, NATURE, V376, P313, DOI 10.1038/376313a0; KAMPS MP, 1989, ANAL BIOCHEM, V176, P22, DOI 10.1016/0003-2697(89)90266-2; KNIGHTON DR, 1991, SCIENCE, V253, P407, DOI 10.1126/science.1862342; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LUNDGREN K, 1991, CELL, V64, P1111, DOI 10.1016/0092-8674(91)90266-2; MITCHELHILL KI, 1994, J BIOL CHEM, V269, P2361; MUELLER PR, 1995, MOL BIOL CELL, V6, P119, DOI 10.1091/mbc.6.1.119; MUELLER PR, 1995, SCIENCE, V270, P86, DOI 10.1126/science.270.5233.86; MURANAKA T, 1994, MOL CELL BIOL, V14, P2958, DOI 10.1128/MCB.14.5.2958; MURRAY AW, 1991, METHOD CELL BIOL, V36, P581; Nieuwkoop P. D., 1975, NORMAL TABLE XENOPUS; OLMSTED JB, 1981, J BIOL CHEM, V256, P1955; PIPPIN J, 1994, BIOTECHNIQUES, V16, P676; RUSSELL P, 1987, CELL, V49, P559, DOI 10.1016/0092-8674(87)90458-2; SADLER SE, 1982, J BIOL CHEM, V257, P355; SAMBROOK J, 1989, MOL CLO NING LAB MAN; SHOJI S, 1979, J BIOL CHEM, V254, P6211; SPEVAK W, 1993, MOL CELL BIOL, V13, P4953, DOI 10.1128/MCB.13.8.4953; STEELE RE, 1989, J BIOL CHEM, V264, P10649; STEINBERG RA, 1993, MOL CELL BIOL, V13, P2332, DOI 10.1128/MCB.13.4.2332; SU JY, 1995, MOL GEN GENET, V246, P387, DOI 10.1007/BF00288613; SU JY, 1994, GENE, V145, P155, DOI 10.1016/0378-1119(94)90343-3; THOMAS J, 1991, J BIOL CHEM, V266, P10906; WOODS A, 1994, J BIOL CHEM, V269, P19509	42	75	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14430	14437		10.1074/jbc.271.24.14430	http://dx.doi.org/10.1074/jbc.271.24.14430			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662877	hybrid			2022-12-27	WOS:A1996UQ66000073
J	Aggeler, R; Capaldi, RA				Aggeler, R; Capaldi, RA			Nucleotide-dependent movement of the epsilon subunit between alpha and beta subunits in the Escherichia coli F1F0-type ATPase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							F1 ADENOSINE-TRIPHOSPHATASE; CRYOELECTRON MICROSCOPY; GAMMA-SUBUNIT; TRANSLOCATING ATPASE; ELECTRON-MICROSCOPY; CATALYTIC SITES; CROSS-LINKING; SYNTHASE; CHLOROPLASTS; F1-ATPASE	Mutants of ECF(1)-ATPase were generated, containing cysteine residues in one or more of the following positions: alpha Ser-411, beta Glu-381, and epsilon Ser-108, after which disulfide bridges could be created by CuCl2 induced oxidation in high yield between alpha and epsilon, beta and epsilon, alpha and gamma, beta and gamma (endogenous Cys-87), and alpha and beta. All of these cross-links lead to inhibition of ATP hydrolysis activity. In the two double mutants, containing a cysteine in epsilon Ser-108 along with either the DELSEED region of beta (Glu-381) or the homologous region in alpha (Ser-411), there was a clear nucleotide dependence of the cross-link formation with the epsilon subunit. In beta E381C/epsilon S108C the beta-epsilon cross-link was obtained preferentially with Mg2+ and ADP + P-i (addition of MgCl2 + ATP) was present, while the alpha-epsilon cross-link product was strongly favored in the alpha S411C/epsilon S108C mutant in the Mg2+ ATP state (addition of MgCl2 + 5'-adenylyl-beta,gamma-imidodiphosphate). In the triple mutant alpha S411C/beta E381C/epsilon S108C, the epsilon subunit bound to the beta subunit in Mg2+-ADP and to the alpha subunit in Mg2+-ATP, indicating a significant movement of this subunit. The gamma cross-linked to the beta subunit in higher yield in Mg2+-ATP than in Mg(2+)-ADP, and when possible, i.e. in the triple mutant, always preferred the interaction with the beta over the alpha subunit.	UNIV OREGON,INST MOLEC BIOL,EUGENE,OR 97403	University of Oregon					NHLBI NIH HHS [HL24526] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024526] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1993, J BIOL CHEM, V268, P14576; AGGELER R, 1993, J BIOL CHEM, V268, P20831; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AGGELER R, 1992, BIOCHEMISTRY-US, V31, P2956, DOI 10.1021/bi00126a016; AGGELER R, 1987, BIOCHEMISTRY-US, V26, P7107, DOI 10.1021/bi00396a036; Battey, 1986, BASIC METHODS MOL BI; BECKERS G, 1992, BIOCHIM BIOPHYS ACTA, V1101, P97, DOI 10.1016/0167-4838(92)90473-Q; BOEKEMA EJ, 1992, BIOCHIM BIOPHYS ACTA, V1098, P131, DOI 10.1016/S0005-2728(05)80328-7; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CAPALDI RA, 1994, TRENDS BIOCHEM SCI, V19, P284, DOI 10.1016/0968-0004(94)90006-X; CAPALDI RA, 1995, T BIOCH SOC, V23, P767; DALLMANN HG, 1992, J BIOL CHEM, V267, P18953; DOWNER NW, 1976, BIOCHEMISTRY-US, V15, P2930, DOI 10.1021/bi00658a036; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; DUNN SD, 1982, J BIOL CHEM, V257, P7354; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4717, DOI 10.1021/bi00437a031; GOGOL EP, 1987, FEBS LETT, V219, P274, DOI 10.1016/0014-5793(87)80234-X; GOGOL EP, 1990, P NATL ACAD SCI USA, V87, P9585, DOI 10.1073/pnas.87.24.9585; GOGOL EP, 1989, BIOCHEMISTRY-US, V28, P4709, DOI 10.1021/bi00437a030; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOTSCHER HR, 1984, BIOCHEMISTRY-US, V23, P4134, DOI 10.1021/bi00313a019; LUCKEN U, 1990, BIOCHEMISTRY-US, V29, P5339; Maniatis T., 1982, MOL CLONING; MENDELHARTVIG J, 1991, BIOCHEMISTRY-US, V30, P1278, DOI 10.1021/bi00219a017; SENIOR AE, 1988, PHYSIOL REV, V68, P177, DOI 10.1152/physrev.1988.68.1.177; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; TURINA P, 1994, J BIOL CHEM, V269, P13465; WILKENS S, 1994, BIOL CHEM H-S, V375, P43; ZHANG Y, 1995, J BIOL CHEM, V270, P24609, DOI 10.1074/jbc.270.41.24609	31	96	98	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13888	13891		10.1074/jbc.271.23.13888	http://dx.doi.org/10.1074/jbc.271.23.13888			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662953	hybrid			2022-12-27	WOS:A1996UP38500087
J	Carver, RS; Sliwkowski, MX; Sitaric, S; Russell, WE				Carver, RS; Sliwkowski, MX; Sitaric, S; Russell, WE			Insulin regulates heregulin binding and ErbB3 expression in rat hepatocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL GROWTH-FACTOR; FACTOR-ALPHA; DNA-SYNTHESIS; LIVER-REGENERATION; PRIMARY CULTURES; FACTOR-BETA; LIGAND; DIFFERENTIATION; RECEPTOR; CELLS	The heregulin-ErbB system of ligands and receptors are newly described epidermal growth factor (EGF) and EGF receptor-related proteins that regulate growth, differentiation, and gene expression in numerous cell types, This study describes a receptor for heregulin beta-1 (HRG beta 1) on cultured rat hepatocytes and an inhibitory influence of insulin on HRG beta 1 binding. HRG beta 1 (30 nM) stimulated DNA synthesis 2-fold and was not augmented by insulin as is the case with EGF receptor ligands, A labeled peptide corresponding to the EGF domain of HRG beta 1 bound to a single population of 19,600 +/- 1,800 binding sites/cell with a K-d of 360 +/- 22 PM. Cross-linking experiments showed binding of HRG beta 1 to ErbB3 but not ErbB2 or ErbB4. HRG beta 1 induced phosphorylation of ErbB3 and decreased ErbB3 protein levels, suggesting that HRG beta 1 activates signaling through the ErbB3 receptor and influences receptor trafficking, Following plating, [I-125]HRG beta 1 binding and ErbB3 protein levels increased 8- and 3-fold, respectively, over the first 12 h in culture, These increases required de novo protein synthesis and were inhibited with 50 nM insulin resulting in 3500 binding sites with a K-d of 265 PM. These data suggest that the heregulin-ErbB system can regulate liver functions and may be linked to the metabolic and nutritional status of the animal.	VANDERBILT UNIV, DEPT PEDIAT, NASHVILLE, TN 37232 USA; VANDERBILT UNIV, DEPT CELL BIOL, NASHVILLE, TN 37232 USA; VANDERBILT CANC CTR, NASHVILLE, TN 37232 USA; GENENTECH INC, DEPT PROT CHEM, SAN FRANCISCO, CA 94080 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Roche Holding; Genentech			Russell, William/A-7307-2009		NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK044557] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK44557] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ALIMANDI M, 1995, ONCOGENE, V10, P1813; BACUS SS, 1993, CANCER RES, V53, P5251; BACUS SS, 1992, CELL GROWTH DIFFER, V3, P401; Bucher N L, 1975, Adv Enzyme Regul, V13, P281; BUCHER NLR, 1975, P NATL ACAD SCI USA, V72, P1157, DOI 10.1073/pnas.72.3.1157; BUCHER NLR, 1990, LIVER BILIARY DIS, P258; CARRAWAY KL, 1994, J BIOL CHEM, V269, P14303; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DONG Z, 1995, NEURON, V15, P585, DOI 10.1016/0896-6273(95)90147-7; DUNN WA, 1984, J CELL BIOL, V98, P2148, DOI 10.1083/jcb.98.6.2148; EARP HS, 1995, BREAST CANCER RES TR, V35, P115, DOI 10.1007/BF00694752; EVARTS RP, 1992, MOL CARCINOGEN, V5, P25, DOI 10.1002/mc.2940050107; FALLS DL, 1993, CELL, V72, P801, DOI 10.1016/0092-8674(93)90407-H; Fausto N, 1991, Prog Growth Factor Res, V3, P219, DOI 10.1016/0955-2235(91)90008-R; GEBHARDT R, 1988, SCAND J GASTROENTERO, V23, P8, DOI 10.3109/00365528809095909; GRAUSPORTA D, 1995, MOL CELL BIOL, V15, P1182; GUY PM, 1994, P NATL ACAD SCI USA, V91, P8132, DOI 10.1073/pnas.91.17.8132; HELMAN A, 1984, AM J PHYSIOL, V246, pE544, DOI 10.1152/ajpendo.1984.246.6.E544; HOLMES WE, 1992, SCIENCE, V256, P1205, DOI 10.1126/science.256.5060.1205; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; HYNES NE, 1994, BBA-REV CANCER, V1198, P165, DOI 10.1016/0304-419X(94)90012-4; KREAMER BL, 1986, IN VITRO CELL DEV B, V22, P201; LEVI ADO, 1995, J NEUROSCI, V15, P1329; MARCHIONNI MA, 1993, NATURE, V362, P312, DOI 10.1038/362312a0; MARTE BM, 1995, ONCOGENE, V10, P167; MCGOWAN JA, 1981, J CELL PHYSIOL, V108, P353, DOI 10.1002/jcp.1041080309; MEAD JE, 1989, P NATL ACAD SCI USA, V86, P1558, DOI 10.1073/pnas.86.5.1558; MICHALOPOULOS GK, 1994, J GASTROENTEROL, V29, P23; MORIARITY DM, 1980, ARCH BIOCHEM BIOPHYS, V203, P506, DOI 10.1016/0003-9861(80)90208-8; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; PELES E, 1993, BIOESSAYS, V15, P815, DOI 10.1002/bies.950151207; PELES E, 1992, CELL, V69, P205, DOI 10.1016/0092-8674(92)90131-U; PIETRAS RJ, 1995, ONCOGENE, V10, P2435; PINKASKRAMARSKI R, 1994, P NATL ACAD SCI USA, V91, P9387, DOI 10.1073/pnas.91.20.9387; RAM TG, 1995, J CELL PHYSIOL, V163, P589, DOI 10.1002/jcp.1041630320; RANA B, 1994, MOL CELL BIOL, V14, P5858, DOI 10.1128/MCB.14.9.5858; RICHARDS GM, 1974, ANAL BIOCHEM, V57, P369, DOI 10.1016/0003-2697(74)90091-8; RICHMAN RA, 1976, P NATL ACAD SCI USA, V73, P3589, DOI 10.1073/pnas.73.10.3589; RIESE DJ, 1995, MOL CELL BIOL, V15, P5770; RUSSELL WE, 1993, ENDOCRINOLOGY, V133, P1731, DOI 10.1210/en.133.4.1731; RUSSELL WE, 1988, J CELL PHYSIOL, V135, P253, DOI 10.1002/jcp.1041350212; RUSSELL WE, 1994, REGULATION LIVER GRO, P11; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SHAH NM, 1994, CELL, V77, P349, DOI 10.1016/0092-8674(94)90150-3; SHIOTA K, 1986, BIOCHEM INT, V13, P893; SHOYAB M, 1989, SCIENCE, V243, P1074, DOI 10.1126/science.2466334; SLIWKOWSKI MX, 1994, J BIOL CHEM, V269, P14661; SOLTOFF SP, 1994, MOL CELL BIOL, V14, P3550, DOI 10.1128/MCB.14.6.3550; STROMBLAD S, 1993, EXP CELL RES, V204, P321, DOI 10.1006/excr.1993.1039; TZAHAR E, 1994, J BIOL CHEM, V269, P25226; WALLASCH C, 1995, EMBO J, V14, P4267, DOI 10.1002/j.1460-2075.1995.tb00101.x; WEBBER EM, 1993, HEPATOLOGY, V18, P1422, DOI 10.1016/0270-9139(93)90234-E; WEN DZ, 1992, CELL, V69, P559, DOI 10.1016/0092-8674(92)90456-M	53	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13491	13496		10.1074/jbc.271.23.13491	http://dx.doi.org/10.1074/jbc.271.23.13491			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662847	hybrid			2022-12-27	WOS:A1996UP38500030
J	Durrer, P; Galli, C; Hoenke, S; Corti, C; Gluck, R; Vorherr, T; Brunner, J				Durrer, P; Galli, C; Hoenke, S; Corti, C; Gluck, R; Vorherr, T; Brunner, J			H+-induced membrane insertion of influenza virus hemagglutinin involves the HA2 amino-terminal fusion peptide but not the coiled coil region	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM DODECYL-SULFATE; POLYACRYLAMIDE-GEL-ELECTROPHORESIS; CONFORMATIONAL CHANGE; PROTEINS; GLYCOPROTEIN; ECTODOMAIN; SUBUNIT	Fusion of influenza virus with target membranes is induced by acid and involves complex changes in the viral envelope protein hemagglutinin (HA), In a first, kinetically distinct step, the HA polypeptide chain 2 (HA2) is inserted into the target membrane bilayer, Using hydrophobic photolabeling with the phospholipid analogue 1-O-hexadecanoyl-2-O-[9-[[[2-[I-125] iodo-4-(trifluoromethyl-3H-diazirin-3-yl)benzyl] oxy]carbonyl]nonanoyl]-sn-glycero-3-phosphocholine, we identified the segment within HA2 that interacts with the membrane. The sole part of the HA2 ectodomain that was labeled with the membrane-restricted reagent is the NH2-terminal fusion peptide (residues 1-22). No labeling occurred within the long coiled coil region generated during the acid induced conformational transition (Bullough, P. A., Hughson, F. M., Skehel, J. J., and Wiley, D. C. (1994) Nature 371, 37-43). These data strongly suggest that the coiled coil region of HA2 does not insert into the lipid bilayer, This conclusion is at variance with the recent suggestion (Yu, Y. G., King, D. S., and Shin, Y.-K. (1994) Science 266, 274-276) that the coiled coil of HA may splay apart and insert into the target membrane, providing a mechanism by which the viral and the target membrane may come in close apposition.	ETH ZENTRUM,BIOCHEM LAB 2,CH-8092 ZURICH,SWITZERLAND; SWISS SERUM & VACCINE INST,POB 2707,CH-3021 BERN,SWITZERLAND; HOFFMANN LA ROCHE AG,CH-4002 BASEL,SWITZERLAND	Swiss Federal Institutes of Technology Domain; ETH Zurich; Roche Holding								BALL EH, 1986, ANAL BIOCHEM, V155, P23, DOI 10.1016/0003-2697(86)90218-6; BRUNNER J, 1991, BIOCHEMISTRY-US, V30, P2432, DOI 10.1021/bi00223a019; BULLOUGH PA, 1994, NATURE, V371, P37, DOI 10.1038/371037a0; CARR CM, 1993, CELL, V73, P823, DOI 10.1016/0092-8674(93)90260-W; DURRER P, 1995, J BIOL CHEM, V270, P17575, DOI 10.1074/jbc.270.29.17575; GAUDIN Y, 1995, J GEN VIROL, V76, P1541, DOI 10.1099/0022-1317-76-7-1541; GERHARD W, 1976, J EXP MED, V144, P985, DOI 10.1084/jem.144.4.985; HARTER C, 1989, J BIOL CHEM, V264, P6459; HARTER C, 1988, BIOCHEMISTRY-US, V27, P1856, DOI 10.1021/bi00406a010; HOPE MJ, 1985, BIOCHIM BIOPHYS ACTA, V812, P55, DOI 10.1016/0005-2736(85)90521-8; HUGHSON FM, 1995, CURR BIOL, V5, P265, DOI 10.1016/S0960-9822(95)00057-1; KONIGSBERG WH, 1983, METHOD ENZYMOL, V91, P254; LAURIERE M, 1993, ANAL BIOCHEM, V212, P206, DOI 10.1006/abio.1993.1313; Ohnishi Shun-Ichi, 1988, Curr Top Membr Transp, V32, P257, DOI 10.1016/S0070-2161(08)60137-9; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; STEGMANN T, 1989, ANNU REV BIOPHYS BIO, V18, P187, DOI 10.1146/annurev.bb.18.060189.001155; STEGMANN T, 1991, J BIOL CHEM, V266, P18404; TATULIAN SA, 1995, EMBO J, V14, P5514, DOI 10.1002/j.1460-2075.1995.tb00238.x; TSURUDOME M, 1992, J BIOL CHEM, V267, P20225; WEBER T, 1994, J BIOL CHEM, V269, P18353; WEBER T, 1995, J AM CHEM SOC, V117, P3084, DOI 10.1021/ja00116a013; WHARTON SA, 1995, EMBO J, V14, P240, DOI 10.1002/j.1460-2075.1995.tb06997.x; WHITE JM, 1992, SCIENCE, V258, P917, DOI 10.1126/science.1439803; WILEY DC, 1987, ANNU REV BIOCHEM, V56, P365, DOI 10.1146/annurev.bi.56.070187.002053; WILSON IA, 1981, NATURE, V289, P366, DOI 10.1038/289366a0; YU YG, 1994, SCIENCE, V266, P274, DOI 10.1126/science.7939662; ZIMMERBERG J, 1993, ANNU REV BIOPH BIOM, V22, P433, DOI 10.1146/annurev.bb.22.060193.002245	28	166	172	0	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13417	13421		10.1074/jbc.271.23.13417	http://dx.doi.org/10.1074/jbc.271.23.13417			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662770	hybrid			2022-12-27	WOS:A1996UP38500019
J	Esmon, CT; Lollar, P				Esmon, CT; Lollar, P			Involvement of thrombin anion-binding exosites 1 and 2 in the activation of factor V and factor VIII	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-V; HUMAN ALPHA-THROMBIN; PORCINE FACTOR-VIII; VONWILLEBRAND-FACTOR; SUBUNIT STRUCTURE; PROTHROMBIN FRAGMENT-2; PHOSPHOLIPID-VESICLES; COMPLETE CDNA; ACTIVE-SITE; LIGHT CHAIN	The role of anion-binding exosites of thrombin in the activation of factor V and factor VIII was studied using thrombin Arg(93) --> Ala, Arg(97) --> Ala, and Arg(101) --> Ala (thrombin RA), a recombinant exosite 2 defective mutant and a synthetic M-acetylated dodecapeptide, Ac-Asn-Gly-Asp-Phe-Glu-Glu-Ile-Pro-Glu-Glu-Tyr-O-SO4-Leu (hirugen), which competitively inhibits binding of macromolecules to exosite 1. The catalytic efficiency of the activation of factor VIII or of the first step of factor V activations by thrombin RA was approximately 10% that of wild-type thrombin. The overall rate of conversion to factor Va was not influenced by the mutation. in contrast to factor V, the slow activation of factor VIII by thrombin RA was associated with a decreased rate of cleavage at all three proteolytic sites (Arg(372), Arg(740), and Arg(1689)). Hirugen inhibited factor V and factor VIII activation, These results indicate that both anion-binding exosites of thrombin are involved in the recognition of factor V and factor VIII.	UNIV OKLAHOMA,OKLAHOMA MED RES FDN,HOWARD HUGHES MED INST,DEPT PATHOL,RES LABS,HLTH SCI CTR,OKLAHOMA CITY,OK 73104; HOWARD HUGHES MED INST,OKLAHOMA CITY,OK 73104; EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322	Howard Hughes Medical Institute; Oklahoma Medical Research Foundation; University of Oklahoma System; University of Oklahoma Health Sciences Center; Howard Hughes Medical Institute; Emory University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL030340, R01HL040921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL40921, R37 HL30340] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANDERSSON LO, 1981, BIOCHEM J, V200, P161, DOI 10.1042/bj2000161; ARNI RK, 1993, BIOCHEMISTRY-US, V32, P4727, DOI 10.1021/bi00069a006; BARENHOLZ Y, 1977, BIOCHEMISTRY-US, V16, P2806, DOI 10.1021/bi00631a035; BARROW RT, 1994, J BIOL CHEM, V269, P593; BOCK PE, 1992, J BIOL CHEM, V267, P14974; CHOPEK MW, 1986, BIOCHEMISTRY-US, V25, P3146, DOI 10.1021/bi00359a012; CHURCH FC, 1989, J BIOL CHEM, V264, P18419; CHURCH WR, 1984, P NATL ACAD SCI-BIOL, V81, P6934, DOI 10.1073/pnas.81.22.6934; CURTIS JE, 1994, J BIOL CHEM, V269, P6246; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; EATON D, 1986, BIOCHEMISTRY-US, V25, P505, DOI 10.1021/bi00350a035; ESMON CT, 1979, J BIOL CHEM, V254, P964; ESMON CT, 1995, FASEB J, V9, P946, DOI 10.1096/fasebj.9.10.7615164; ESMON CT, 1982, J BIOL CHEM, V257, P7944; FAY PJ, 1991, J BIOL CHEM, V266, P8957; FENTON JW, 1977, J BIOL CHEM, V252, P3587; GUINTO ER, 1992, J BIOL CHEM, V267, P2971; HILLEUBANKS DC, 1990, J BIOL CHEM, V265, P17854; HILLEUBANKS DC, 1989, P NATL ACAD SCI USA, V86, P6508, DOI 10.1073/pnas.86.17.6508; HOGG PJ, 1989, P NATL ACAD SCI USA, V86, P3619, DOI 10.1073/pnas.86.10.3619; HOGG PJ, 1990, J BIOL CHEM, V265, P241; HORTIN GL, 1990, BLOOD, V76, P946; JENNY RJ, 1987, P NATL ACAD SCI USA, V84, P4846, DOI 10.1073/pnas.84.14.4846; KANE WH, 1988, BLOOD, V71, P539; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAJMANOVICH A, 1981, BIOCHIM BIOPHYS ACTA, V678, P132, DOI 10.1016/0304-4165(81)90056-8; LIU LW, 1994, J BIOL CHEM, V269, P11807; LOLLAR P, 1988, J BIOL CHEM, V263, P10451; LOLLAR P, 1984, BLOOD, V63, P1303; LOLLAR P, 1989, BIOCHEMISTRY-US, V28, P666, DOI 10.1021/bi00428a038; LOLLAR P, 1988, BLOOD, V71, P137; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MICHNICK DA, 1994, J BIOL CHEM, V269, P20095; NASKI MC, 1990, J BIOL CHEM, V265, P13484; NESHEIM ME, 1979, J BIOL CHEM, V254, P508; OBRIEN DP, 1992, BIOCHEMISTRY-US, V31, P2805, DOI 10.1021/bi00125a022; OFOSU FA, 1991, HAEMOSTASIS, V21, P240; PITTMAN DD, 1994, BIOCHEMISTRY-US, V33, P6952, DOI 10.1021/bi00188a026; PITTMAN DD, 1992, BIOCHEMISTRY-US, V31, P3315, DOI 10.1021/bi00128a003; PITTMAN DD, 1993, BLOOD, V81, P2925; PITTMAN DD, 1988, P NATL ACAD SCI USA, V85, P2429, DOI 10.1073/pnas.85.8.2429; PRIESTLE JP, 1993, PROTEIN SCI, V2, P1630, DOI 10.1002/pro.5560021009; REGAN LM, 1995, J BIOL CHEM, V270, P8546, DOI 10.1074/jbc.270.15.8546; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SCHOEN P, 1987, J BIOL CHEM, V262, P11268; SHEEHAN JP, 1994, P NATL ACAD SCI USA, V91, P5518, DOI 10.1073/pnas.91.12.5518; SHEEHAN JP, 1994, J BIOL CHEM, V269, P32747; SKRZYPCZAKJANKUN E, 1991, J MOL BIOL, V221, P1379; STUBBS MT, 1992, EUR J BIOCHEM, V206, P187, DOI 10.1111/j.1432-1033.1992.tb16916.x; STUBBS MT, 1993, THROMB RES, V69, P1, DOI 10.1016/0049-3848(93)90002-6; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; THARAKAN J, 1990, VOX SANG, V58, P21, DOI 10.1111/j.1423-0410.1990.tb02050.x; TSIANG M, 1995, J BIOL CHEM, V270, P16854, DOI 10.1074/jbc.270.28.16854; TULINSKY A, 1993, BLOOD COAGUL FIBRIN, V4, P305, DOI 10.1097/00001721-199304000-00012; VEHAR GA, 1984, NATURE, V312, P337, DOI 10.1038/312337a0; VIJAYALAKSHMI J, 1994, PROTEIN SCI, V3, P2254, DOI 10.1002/pro.5560031211; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; YE J, 1994, J BIOL CHEM, V269, P17965	59	100	102	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13882	13887		10.1074/jbc.271.23.13882	http://dx.doi.org/10.1074/jbc.271.23.13882			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662922	hybrid			2022-12-27	WOS:A1996UP38500086
J	GravesWoodward, KL; Weller, SK				GravesWoodward, KL; Weller, SK			Replacement of Gly(815) in helicase motif V alters the single-stranded DNA-dependent ATPase activity of the herpes simplex virus type 1 helicase-primase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ESCHERICHIA-COLI; PUTATIVE HELICASES; EXCISION REPAIR; GENE-PRODUCTS; PROTEIN; REPLICATION; UL5; OVEREXPRESSION; IDENTIFICATION; RECOMBINATION	Herpes simplex virus type 1 encodes a helicase-primase complex composed of the products of the UL5, UL52, and UL8 genes, A subcomplex consisting of the UL5 and UL52 proteins purified from insect cells also displays ATPase, helicase, and primase activities, UL5 contains six motifs conserved in superfamily I of known and/or putative helicase proteins, Consistent with the ability to hydrolyze ATP, motifs I and II resemble a nucleotide binding site, Although the role of the other four motifs is not known, single amino acid substitutions created in conserved residues in all six motifs abolish the ability of UL5 to support viral DNA replication in vivo (Zhu, L., and Weller, S. K. (1992) J. Virol, 66, 469-479). In one such mutation, a highly conserved glycine in motif V (Gly(815)) is replaced with an alanine, Although the UL5(G815A) protein does not support viral DNA replication in vivo, the purified UL5(G815A). 52 subcomplex retains primase and helicase activities and supports strand displacement DNA synthesis on a preformed replication fork in the presence of the other HSV-1 replication proteins, The major difference between the wildtype and variant protein is that the UL5(G815A). 52 subcomplex displays an increased K-m for single-stranded DNA and decreased K-cat for single-stranded DNA-dependent ATPase activity, Several hypotheses for the role of motif V in the function of the UL5 helicase in HSV-I DNA replication are considered, This is the first report of a biochemical analysis of a motif V variant in any member of helicase superfamily I.	UNIV CONNECTICUT, CTR HLTH, DEPT MICROBIOL, FARMINGTON, CT 06030 USA	University of Connecticut			Weller, Sandra/N-3979-2013	Weller, Sandra/0000-0002-4519-6276	NIAID NIH HHS [AI21747] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI021747, R01AI021747] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAILIS AM, 1995, MOL CELL BIOL, V15, P3998; CALDER JM, 1990, NUCLEIC ACIDS RES, V18, P3573, DOI 10.1093/nar/18.12.3573; CHALLBERG MD, 1986, P NATL ACAD SCI USA, V83, P9094, DOI 10.1073/pnas.83.23.9094; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CRUTE JJ, 1991, J BIOL CHEM, V266, P21252; CRUTE JJ, 1989, J BIOL CHEM, V264, P19266; CRUTE JJ, 1988, NUCLEIC ACIDS RES, V16, P6585, DOI 10.1093/nar/16.14.6585; CRUTE JJ, 1989, P NATL ACAD SCI USA, V86, P2186, DOI 10.1073/pnas.86.7.2186; DEBYSER Z, 1994, CELL, V77, P157, DOI 10.1016/0092-8674(94)90243-7; DODSON MS, 1989, J BIOL CHEM, V264, P20835; DODSON MS, 1991, P NATL ACAD SCI USA, V88, P1105, DOI 10.1073/pnas.88.4.1105; DRACHEVA S, 1995, J BIOL CHEM, V270, P14148, DOI 10.1074/jbc.270.23.14148; EARNSHAW DL, 1994, BIOCHEM BIOPH RES CO, V199, P1333, DOI 10.1006/bbrc.1994.1377; *GEN COMP GROUP, 1994, VERS 8; GORBALENYA AE, 1989, NUCLEIC ACIDS RES, V17, P4713, DOI 10.1093/nar/17.12.4713; GORBALENYA AE, 1988, NUCLEIC ACIDS RES, V16, P7734, DOI 10.1093/nar/16.15.7734; GORBALENYA AE, 1988, FEBS LETT, V235, P16, DOI 10.1016/0014-5793(88)81226-2; GORBALENYA AE, 1988, NATURE, V333, P22, DOI 10.1038/333022a0; ILYINA TV, 1992, J MOL EVOL, V34, P351, DOI 10.1007/BF00160243; KLINEDINST DK, 1994, J VIROL, V68, P3693, DOI 10.1128/JVI.68.6.3693-3701.1994; LAHAYE A, 1993, J BIOL CHEM, V268, P26155; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LIVINGSTONE C, 1989, NUCLEIC ACIDS RES, V17, P2366, DOI 10.1093/nar/17.6.2366; LOHMAN TM, 1992, MOL MICROBIOL, V6, P5, DOI 10.1111/j.1365-2958.1992.tb00831.x; LOHMAN TM, 1993, J BIOL CHEM, V268, P2269; Lukonis CJ, 1996, J VIROL, V70, P1751, DOI 10.1128/JVI.70.3.1751-1758.1996; MATSON SW, 1991, PROG NUCLEIC ACID RE, V40, P289; MATSON SW, 1990, ANNU REV BIOCHEM, V59, P289, DOI 10.1146/annurev.bi.59.070190.001445; MATSON SW, 1983, J BIOL CHEM, V258, P4017; MOOLENAAR GF, 1994, J MOL BIOL, V240, P294, DOI 10.1006/jmbi.1994.1447; OLIVO PD, 1990, HERPESVIRUS TRANSCRI, P137; PATEL SS, 1994, BIOCHEMISTRY-US, V33, P7857, DOI 10.1021/bi00191a013; SEELEY TW, 1989, P NATL ACAD SCI USA, V86, P6577, DOI 10.1073/pnas.86.17.6577; SHERMAN G, 1992, J VIROL, V66, P4884, DOI 10.1128/JVI.66.8.4884-4892.1992; SUNG P, 1988, EMBO J, V7, P3263, DOI 10.1002/j.1460-2075.1988.tb03193.x; TENNEY DJ, 1995, J BIOL CHEM, V270, P9129, DOI 10.1074/jbc.270.16.9129; THIAGALINGAM S, 1991, J BIOL CHEM, V266, P11395; THOMMES P, 1992, CHROMOSOMA, V101, P467, DOI 10.1007/BF00352468; WALKER JE, 1982, EMBO J, V1, P945, DOI 10.1002/j.1460-2075.1982.tb01276.x; WELLER SK, 1995, IMPLICATIONS DNA PRO, P189; WELLER SK, 1988, CANCER CELL, V6, P53; WELLER SK, 1990, HERPESVIRUS TRANSCRI, P105; ZHU L, 1992, J VIROL, V66, P469, DOI 10.1128/JVI.66.1.469-479.1992; ZHU L, 1988, VIROLOGY, V166, P366, DOI 10.1016/0042-6822(88)90507-7	45	25	25	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13629	13635		10.1074/jbc.271.23.13629	http://dx.doi.org/10.1074/jbc.271.23.13629			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662872	hybrid			2022-12-27	WOS:A1996UP38500050
J	Hirako, Y; Usukura, J; Nishizawa, Y; Owaribe, K				Hirako, Y; Usukura, J; Nishizawa, Y; Owaribe, K			Demonstration of the molecular shape of BP180, a 180-kDa bullous pemphigoid antigen and its potential for trimer formation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BASEMENT-MEMBRANE ADHESION; IMMUNOELECTRON MICROSCOPY; INTEGRIN ALPHA-6-BETA-4; ANCHORING FILAMENTS; EPITHELIAL-CELLS; HEMIDESMOSOMES; COMPONENT; PROTEINS; AUTOANTIBODIES; EXPRESSION	The 180-kDa bullous pemphigoid antigen (BP180) is a hemidesmosomal transmembrane glycoprotein comprising interrupted collagen domains in its extracellular part, BP180 is also termed type XVII collagen, But the question of whether it actually takes a collagen-like triple helical conformation in. vivo has remained unanswered, Using a monoclonal antibody, we found that a sub-population of BP180 localizes at the lateral surfaces of corneal basal cells and cultured cells, in addition to the basal surface, This subpopulation of BP180 could be solubilized by 0.5% Triton X-100 and, among examined cell lines, was found to be most abundant in BMGE+H, a bovine mammary gland epithelial cell line, The Triton soluble fraction of BMGE+H cells was used for characterization, On sucrose gradient centrifugation, the soluble BP180 demonstrated a value of approximately 7 S, and chemical cross-linking experiments revealed a trimer form, The calculated frictional ratio, f/f(0) = 2.8, suggests an asymmetric configuration, For further characterization, we purified the soluble BP180 by immunoaffinity column chromatography using an anti-BP180 monoclonal antibody, Rotary shadowing images of the purified BP180 showed a quaver-like molecule consisting of a globular head, a central rod, and a flexible tail, With regard to the primary structure and species comparisons, the central rod, 60-70 nm in length, probably corresponds to the largest collagenous region, forming a collagen-like triple helix, in human form, The globular head and the flexible tail seem to correspond to the cytoplasmic and the interrupted collagenous region, respectively, of the extracellular portions, In conclusion, the present demonstration of the entire configuration of BP180, with a collagen-like trimer in its extracellular part, suggests that BP180 is one of the major components of anchoring filaments.	NAGOYA UNIV, SCH SCI, DEPT BIOL MOLEC, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN; NAGOYA UNIV, SCH MED, DEPT ANAT, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN	Nagoya University; Nagoya University	Hirako, Y (corresponding author), NAGOYA UNIV, GRAD SCH HUMAN INFORMAT, UNIT BIOSYST, CHIKUSA KU, NAGOYA, AICHI 46401, JAPAN.			Usukura, Jiro/0000-0003-2286-5403				AMAGAI M, 1990, J INVEST DERMATOL, V95, P252, DOI 10.1111/1523-1747.ep12484863; BERNARD P, 1990, J INVEST DERMATOL, V94, P630, DOI 10.1111/1523-1747.ep12876206; DOMLOGEHULTSCH N, 1992, J CLIN INVEST, V90, P1628, DOI 10.1172/JCI116033; ELLISON J, 1984, J CELL SCI, V72, P163; Garrod DR, 1993, CURR OPIN CELL BIOL, V5, P30, DOI 10.1016/S0955-0674(05)80005-5; GIUDICE GJ, 1992, J INVEST DERMATOL, V99, P243, DOI 10.1111/1523-1747.ep12616580; GUO LF, 1995, CELL, V81, P233, DOI 10.1016/0092-8674(95)90333-X; HIEDA Y, 1992, J CELL BIOL, V116, P1497, DOI 10.1083/jcb.116.6.1497; HOPKINSON SB, 1992, J INVEST DERMATOL, V99, P264, DOI 10.1111/1523-1747.ep12616615; HOPKINSON SB, 1995, J CELL BIOL, V130, P117, DOI 10.1083/jcb.130.1.117; JONES JCR, 1994, EXP CELL RES, V213, P1, DOI 10.1006/excr.1994.1166; JONES JCR, 1991, CELL REGUL, V2, P427, DOI 10.1091/mbc.2.6.427; JONKMAN MF, 1995, J CLIN INVEST, V95, P1345, DOI 10.1172/JCI117785; KATZ SI, 1984, CIBA F SYMP, V108, P243; KITAJIMA Y, 1988, CANCER RES, V48, P964; KITAJIMA Y, 1992, EXP CELL RES, V203, P17, DOI 10.1016/0014-4827(92)90034-6; Kitajima Y, 1995, EPITHELIAL CELL BIOL, V4, P70; KITAJIMA Y, 1994, JOURNAL OF DERMATOLOGY, VOL 21, NO 11, NOVEMBER 1994, P838, DOI 10.1111/j.1346-8138.1994.tb03299.x; KLATTE DH, 1989, J CELL BIOL, V109, P3377, DOI 10.1083/jcb.109.6.3377; KURPAKUS MA, 1991, J CELL BIOL, V115, P1737, DOI 10.1083/jcb.115.6.1737; LABIB RS, 1986, J IMMUNOL, V136, P1231; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LI KH, 1993, J BIOL CHEM, V268, P8825; LIU Z, 1993, J CLIN INVEST, V92, P2480, DOI 10.1172/JCI116856; MARINKOVICH MP, 1993, LAB INVEST, V69, P295; MCGRATH JA, 1995, NAT GENET, V11, P83, DOI 10.1038/ng0995-83; NIESSEN CM, 1994, EXP CELL RES, V211, P360, DOI 10.1006/excr.1994.1099; NISHIZAWA Y, 1993, J BIOCHEM-TOKYO, V113, P493, DOI 10.1093/oxfordjournals.jbchem.a124072; OWARIBE K, 1991, EXP CELL RES, V192, P622, DOI 10.1016/0014-4827(91)90084-8; ROUSSELLE P, 1991, J CELL BIOL, V114, P567, DOI 10.1083/jcb.114.3.567; SAWAMURA D, 1991, J BIOL CHEM, V266, P17784; SCHMID E, 1983, J CELL BIOL, V96, P37, DOI 10.1083/jcb.96.1.37; SONNENBERG A, 1991, J CELL BIOL, V113, P907, DOI 10.1083/jcb.113.4.907; SPINARDI L, 1995, J CELL BIOL, V129, P473, DOI 10.1083/jcb.129.2.473; STANLEY JR, 1988, J CLIN INVEST, V82, P1864, DOI 10.1172/JCI113803; STANLEY JR, 1993, ADV IMMUNOL, V53, P291, DOI 10.1016/S0065-2776(08)60503-9; STEPP MA, 1990, P NATL ACAD SCI USA, V87, P8970, DOI 10.1073/pnas.87.22.8970; UEMATSU J, 1994, J BIOCHEM-TOKYO, V115, P469, DOI 10.1093/oxfordjournals.jbchem.a124361; VERRANDO P, 1987, EXP CELL RES, V170, P116, DOI 10.1016/0014-4827(87)90121-2	40	110	111	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13739	13745		10.1074/jbc.271.23.13739	http://dx.doi.org/10.1074/jbc.271.23.13739			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662839				2022-12-27	WOS:A1996UP38500066
J	Huang, LX; Scrutton, NS; Hille, R				Huang, LX; Scrutton, NS; Hille, R			Reaction of the C30A mutant of trimethylamine dehydrogenase with diethylmethylamine	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRAMOLECULAR ELECTRON-TRANSFER; COVALENTLY BOUND COENZYME; DIMETHYLAMINE DEHYDROGENASE; BACTERIUM W3A1; FLAVOPROTEIN; IDENTIFICATION; SUBSTRATE; FLAVINS	The role played by the 6-S-cysteinyl-FMN bond of trimethylamine dehydrogenase in the reductive half-reaction of the enzyme has been studied by following the reaction of the slow substrate diethylmethylamine with a C30A mutant of the enzyme lacking the covalent flavin attachment to the polypeptide. Removal of the 6-S-cysteinyl-FMN bond diminishes the limiting rate for the first of the three observed kinetic phases of the reaction by a factor of 6, but has no effect on the rate constants for the two subsequent kinetic phases. The flavin in the C30A-enzyme recovered from the reaction of the C30A enzyme with excess substrate is found to have been converted to the 6-hydroxy derivative, rendering the enzyme inactive, The noncovalently bound FMN of the C30A mutant enzyme is also converted to 6-hydroxy-FMN and rendered inactive upon reduction with excess trimethylamine, but not by reduction with dithionite, even at high pH or in the presence of the effector tetramethylammonium chloride, These results suggest that one significant role of the 6-S-cysteinyl-FMN bond is to prevent the inactivation of the enzyme during catalysis. A reaction mechanism is proposed whereby OH- attacks C-6 of a flavin-substrate covalent adduct in the course of steady-state turnover to form 6-hydroxy-FMN.	OHIO STATE UNIV,DEPT MED BIOCHEM,COLUMBUS,OH 43210; UNIV LEICESTER,DEPT BIOCHEM,LEICESTER LE1 7RH,LEICS,ENGLAND	University System of Ohio; Ohio State University; University of Leicester								BELLAMY HD, 1989, J BIOL CHEM, V264, P11887; Bevington P. R., 1969, DATA REDUCTION ERROR, P235; DUPLESSIS ER, 1994, BIOCHEM MOL BIOL INT, V32, P195; HILL CL, 1977, P NATL ACAD SCI USA, V74, P547, DOI 10.1073/pnas.74.2.547; HUANG L, 1995, J BIOL CHEM, V270, P23956; KASPRZAK AA, 1983, BIOCHEM J, V211, P535, DOI 10.1042/bj2110535; KENNEY WC, 1978, FEBS LETT, V85, P137, DOI 10.1016/0014-5793(78)81265-4; LEHMAN TC, 1990, BIOCHEMISTRY-US, V29, P10594, DOI 10.1021/bi00499a004; LEHMAN TC, 1990, ANAL BIOCHEM, V186, P280, DOI 10.1016/0003-2697(90)90080-S; LIM LW, 1988, J BIOL CHEM, V263, P3075; LIM LW, 1982, J MOL BIOL, V162, P869, DOI 10.1016/0022-2836(82)90551-4; LIM LW, 1986, J BIOL CHEM, V261, P5140; MASSEY V, 1986, BIOCHEMISTRY-US, V25, P8103, DOI 10.1021/bi00372a046; MASSEY V, 1991, J BIOL CHEM, V266, P8281; Massey V., 1970, PYRIDINE NUCLEOTIDE, P393; Massey V, 1980, BIOCHEM SOC T, V8, P246, DOI 10.1042/bst0080246; MAYHEW SG, 1974, EUR J BIOCHEM, V44, P579, DOI 10.1111/j.1432-1033.1974.tb03515.x; NAGY J, 1979, J BIOL CHEM, V254, P2684; PACKMAN LC, 1995, J BIOL CHEM, V270, P13186, DOI 10.1074/jbc.270.22.13186; ROHLFS RJ, 1994, J BIOL CHEM, V269, P30869; ROHLFS RJ, 1995, J BIOL CHEM, V270, P22196, DOI 10.1074/jbc.270.38.22196; ROHLFS RJ, 1991, J BIOL CHEM, V266, P15244; SCHOLLNHAMMER G, 1974, EUR J BIOCHEM, V44, P561, DOI 10.1111/j.1432-1033.1974.tb03514.x; SCRUTTON NS, 1994, J BIOL CHEM, V269, P13942; SINGER TP, 1980, FLAVINS FLAVOPROTEIN, P277; STEENKAMP DJ, 1982, BIOCHEM J, V207, P241, DOI 10.1042/bj2070241; STEENKAMP DJ, 1978, BIOCHEM J, V169, P361, DOI 10.1042/bj1690361; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P4086; STEENKAMP DJ, 1978, J BIOL CHEM, V253, P2818; STEENKAMP DJ, 1978, MECHANISMS OXIDIZING, P127; STRICKLAND S, 1975, J BIOL CHEM, V250, P4048	31	15	15	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13401	13406		10.1074/jbc.271.23.13401	http://dx.doi.org/10.1074/jbc.271.23.13401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662829	hybrid			2022-12-27	WOS:A1996UP38500017
J	Turchi, JJ; Henkels, K				Turchi, JJ; Henkels, K			Human Ku autoantigen binds cisplatin-damaged DNA but fails to stimulate human DNA-activated protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ANTICANCER DRUG CIS-DIAMMINEDICHLOROPLATINUM(II); OVARIAN-CANCER; HUMAN P53; SITE; PHOSPHORYLATION; SENSITIVITY; REQUIREMENT; RESISTANCE; INHIBITION; MECHANISM	We have identified a series of proteins based on an affinity for cisplatin-damaged DNA, One protein termed DRP-1 has been purified to homogeneity and was isolated as two distinct complexes, The first complex is a heterodimer of 83- and 68-kDa subunits, while the second complex is a heterotrimer of 350-, 83-, and 68-kDa subunits in a 1:1:1 ratio, The 83- and 68-kDa subunits in each complex are identical, The 83-kDa subunit of DRP-1 was identified as the p80 subunit of Ku autoantigen by N-terminal protein sequence analysis and reactivity with a monoclonal antibody directed against human Ku p80 subunit. The 68-kDa subunit of DRP-1 crossreacted with monoclonal antisera raised against the Ku autoantigen p70 subunit, The 350-kDa subunit was identified as DNA-PKcs, the catalytic subunit of the human DNA-activated protein kinase, DNA-PK, DRP-1/Ku DNA binding was assessed in mobility shift assays and competition binding assays using cisplatin-damaged DNA, Results indicate that DNA binding was essentially unaffected by cisplatin-DNA adducts in the presence or absence of DNA-PKcs, DNA-PK activity was only stimulated with undamaged DNA, despite the ability of Ku to bind to cisplatin-damaged DNA. The lack of DNA-PR stimulation by cisplatin-damaged DNA correlated with the extent of cisplatin-DNA adduct formation, These results demonstrate that Ku can bind cisplatin-damaged DNA but fails to activate DNA-PR, These results are discussed with respect to the repair of cisplatin-DNA adducts and the role of DNA-PK in coordinating DNA repair processes.			Turchi, JJ (corresponding author), WRIGHT STATE UNIV, DEPT BIOCHEM & MOLEC BIOL, SCH MED, 3640 COLONEL GLENN HIGHWAY, DAYTON, OH 45435 USA.		Turchi, John J/B-5807-2015	Turchi, John J/0000-0001-5375-2992	NATIONAL CANCER INSTITUTE [R29CA064374] Funding Source: NIH RePORTER; NCI NIH HHS [CA64374] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Anderson Carl W., 1992, Critical Reviews in Eukaryotic Gene Expression, V2, P283; ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BELLON SF, 1990, BIOPHYS CHEM, V35, P179, DOI 10.1016/0301-4622(90)80007-T; BELLON SF, 1991, BIOCHEMISTRY-US, V30, P8026, DOI 10.1021/bi00246a021; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; BROWN SJ, 1993, SCIENCE, V261, P603, DOI 10.1126/science.8342024; BRUHN SL, 1992, P NATL ACAD SCI USA, V89, P2307, DOI 10.1073/pnas.89.6.2307; BRUSH GS, 1994, P NATL ACAD SCI USA, V91, P12520, DOI 10.1073/pnas.91.26.12520; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; CHU G, 1994, J BIOL CHEM, V269, P787; CLUGSTON CK, 1992, CANCER RES, V52, P6375; COMESS KM, 1992, BIOCHEMISTRY-US, V31, P3975, DOI 10.1021/bi00131a013; COVERLEY D, 1991, NATURE, V349, P538, DOI 10.1038/349538a0; DEMARCQ C, 1994, CELL GROWTH DIFFER, V5, P983; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; EVANS DL, 1994, CANCER RES, V54, P1596; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FISCELLA M, 1993, ONCOGENE, V8, P1519; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HUANG HF, 1995, SCIENCE, V270, P1842, DOI 10.1126/science.270.5243.1842; HUANG L, 1993, BIOCHEMISTRY-US, V32, P841, DOI 10.1021/bi00054a015; HUGHES EN, 1992, J BIOL CHEM, V267, P13520; IIJIMA S, 1992, EUR J BIOCHEM, V206, P595, DOI 10.1111/j.1432-1033.1992.tb16964.x; JOHNSON SW, 1994, BIOCHEM PHARMACOL, V47, P689, DOI 10.1016/0006-2952(94)90132-5; JONES SL, 1994, INT J CANCER, V59, P388, DOI 10.1002/ijc.2910590317; JONES SL, 1994, BIOCHEM PHARMACOL, V48, P1662, DOI 10.1016/0006-2952(94)90213-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEESMILLER SP, 1992, MOL CELL BIOL, V12, P5041, DOI 10.1128/MCB.12.11.5041; MASUDA H, 1988, CANCER RES, V48, P5713; MOROZOV VE, 1994, J BIOL CHEM, V269, P16664; MORRISSEY JH, 1981, ANAL BIOCHEM, V117, P307, DOI 10.1016/0003-2697(81)90783-1; ORMEROD MG, 1994, BRIT J CANCER, V69, P93, DOI 10.1038/bjc.1994.14; ORMEROD MG, 1994, EXP CELL RES, V211, P231, DOI 10.1006/excr.1994.1082; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAN ZQ, 1994, P NATL ACAD SCI USA, V91, P8343, DOI 10.1073/pnas.91.18.8343; PAN ZQ, 1995, P NATL ACAD SCI USA, V92, P4636, DOI 10.1073/pnas.92.10.4636; PENEFSKY HS, 1977, J BIOL CHEM, V252, P2891; PEREZ RP, 1993, CANCER, V71, P1571, DOI 10.1002/cncr.2820710424; PIL PM, 1992, SCIENCE, V256, P234, DOI 10.1126/science.1566071; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; Sambrook J., 2002, MOL CLONING LAB MANU; SIBGHATULLAH, 1989, NUCLEIC ACIDS RES, V17, P4471, DOI 10.1093/nar/17.12.4471; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TAKAHARA PM, 1995, NATURE, V377, P649, DOI 10.1038/377649a0; Turchi JJ, 1996, BIOCHEMISTRY-US, V35, P2992, DOI 10.1021/bi951843j; USHAY HM, 1981, BIOCHEMISTRY-US, V20, P3744, DOI 10.1021/bi00516a012; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; YANG DZ, 1995, BIOCHEMISTRY-US, V34, P12912, DOI 10.1021/bi00039a054	52	51	53	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13861	13867		10.1074/jbc.271.23.13861	http://dx.doi.org/10.1074/jbc.271.23.13861			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662830	hybrid			2022-12-27	WOS:A1996UP38500083
J	Morrison, P; Saltiel, AR; Rosner, MR				Morrison, P; Saltiel, AR; Rosner, MR			Role of mitogen-activated protein kinase kinase in regulation of the epidermal growth factor receptor by protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-INDUCED INTERNALIZATION; SIGNAL TRANSDUCTION; PHOSPHORYLATION; THREONINE-654; PHOSPHATASE; BINDING; MUTANTS; SITES	The epidermal growth factor receptor (EGFR) is regulated by at least two mechanisms involving protein kinase C (PKC), inhibition of EGF binding and inhibition of EGF-stimulated tyrosine kinase activity. In this study we investigated whether mitogen-activated protein kinase (MAPK) mediates the inhibitory effects of PKC on EGFR binding or kinase activity by pretreating NIH3T3 and Chinese hamster ovary cells expressing the EGFR with PD98059, an inhibitor of MAPK/extracellular signal-regulated kinase kinase (MEK). We also determined whether substitution of cysteine for threonine at residue 669, the site of MAPK phosphorylation of the EGFR, alters the inhibition of kinase activity by PKC. The results indicate that 1) PKC down-regulates EGFR tyrosine kinase activity by an MEK-dependent mechanism presumably involving MAPK; 2) the inhibition by PKC is not a direct result of phosphorylation of the EGFR by PKC or MAPK; 3) activation of MAPK is not sufficient to regulate EGFR kinase activity; and 4) PKC-mediated down-regulation of EGF binding and EGFR kinase activity occur by different mechanisms. These data are consistent with a model for regulation of the EGFR by other receptors whereby their activation of PKC, in conjunction with MAPK, results in the phosphorylation of a protein(s) that modulates EGFR kinase activity.	UNIV CHICAGO,BEN MAY INST,CHICAGO,IL 60637; UNIV CHICAGO,DEPT PHARMACOL & PHYSIOL SCI,CHICAGO,IL 60637; UNIV CHICAGO,DEPT MOLEC GENET & CELL BIOL,CHICAGO,IL 60637; WARNER LAMBERT PARKE DAVIS,DIV PHARMACEUT RES,DEPT SIGNAL TRANSDUCT,ANN ARBOR,MI 48105	University of Chicago; University of Chicago; University of Chicago; Pfizer			Saltiel, Alan/L-3632-2019	Saltiel, Alan/0000-0002-9726-9828	NCI NIH HHS [CA35541] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA035541] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALESSI DR, 1995, J BIOL CHEM, V270, P27489, DOI 10.1074/jbc.270.46.27489; CASTAGNINO P, 1995, ONCOGENE, V10, P723; CHAO TSO, 1992, J BIOL CHEM, V267, P19876; COCHET C, 1991, J BIOL CHEM, V266, P637; COUNTAWAY JL, 1990, J BIOL CHEM, V265, P3407; DECKER SJ, 1990, J BIOL CHEM, V265, P7009; DOWNWARD J, 1985, J BIOL CHEM, V260, P14358; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FOWLER KJ, 1995, P NATL ACAD SCI USA, V92, P1465, DOI 10.1073/pnas.92.5.1465; FRIEDMAN B, 1989, P NATL ACAD SCI USA, V86, P812, DOI 10.1073/pnas.86.3.812; GRISWOLDPRENNER I, 1993, J BIOL CHEM, V268, P27489; HEISERMANN GJ, 1990, J BIOL CHEM, V265, P12820; HONEGGER A, 1988, EMBO J, V7, P3053, DOI 10.1002/j.1460-2075.1988.tb03170.x; LUND KA, 1990, J BIOL CHEM, V265, P20517; MATTHEWS RJ, 1992, MOL CELL BIOL, V12, P2396, DOI 10.1128/MCB.12.5.2396; MOOLENAAR WH, 1988, EMBO J, V7, P707, DOI 10.1002/j.1460-2075.1988.tb02866.x; MORRISON P, 1993, J BIOL CHEM, V268, P15536; PANG L, 1995, J BIOL CHEM, V270, P13585, DOI 10.1074/jbc.270.23.13585; Sambrook J., 2002, MOL CLONING LAB MANU; SUN H, 1995, P NATL ACAD SCI USA, V92, P2229, DOI 10.1073/pnas.92.6.2229; TAKISHIMA K, 1991, P NATL ACAD SCI USA, V88, P2520, DOI 10.1073/pnas.88.6.2520; TOMIC S, 1995, J BIOL CHEM, V270, P21277, DOI 10.1074/jbc.270.36.21277; ULLRICH A, 1990, CELL, V61, P203, DOI 10.1016/0092-8674(90)90801-K; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WALTON KM, 1993, ANNU REV BIOCHEM, V62, P101; WATTENBERG EV, 1989, J BIOL CHEM, V264, P14668; ZHAO ZH, 1994, P NATL ACAD SCI USA, V91, P5007, DOI 10.1073/pnas.91.11.5007	28	48	48	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12891	12896		10.1074/jbc.271.22.12891	http://dx.doi.org/10.1074/jbc.271.22.12891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662819	hybrid			2022-12-27	WOS:A1996UN47400033
J	Singh, N; Liang, LN; Tykocinski, ML; Tartakoff, AM				Singh, N; Liang, LN; Tykocinski, ML; Tartakoff, AM			A novel class of cell surface glycolipids of mammalian cells - Free glycosyl phosphatidylinositols	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PAROXYSMAL-NOCTURNAL HEMOGLOBINURIA; GLYCOINOSITOL PHOSPHOLIPID ANCHOR; HUMAN-ERYTHROCYTE ACETYLCHOLINESTERASE; MEMBRANE ANCHOR; TRYPANOSOMA-BRUCEI; SACCHAROMYCES-CEREVISIAE; INTRACELLULAR-TRANSPORT; THY-1 GLYCOPROTEIN; HEPATOMA-CELLS; MDCK CELLS	Glycosyl phosphatidylinositol (GPI) lipids function as anchors of membrane proteins, and free GPI units serve as intermediates along the path of GPI-anchor biosynthesis, By using in vivo cell surface biotinylation, we show that free GPIs: 1) can exit the rough endoplasmic reticulum and are present on the surface of a murine EL-4 T-lymphoma and a human carcinoma cell (HeLa), 2) arrive at the cell surface in a time and temperature-dependent fashion, and 3) are built on a base-labile glycerol backbone, unlike GPI anchors of surface proteins of the same cells, The free GPIs described in this study may serve as a source of hormone sensitive phosphoinositol glycans. The absence of free GPIs from the cell surface may also account for the growth advantage of blood cells in paroxysmal nocturnal hemoglobinuria.	CASE WESTERN RESERVE UNIV, INST PATHOL, CLEVELAND, OH 44106 USA; CASE WESTERN RESERVE UNIV, CELL BIOL PROGRAM, CLEVELAND, OH 44106 USA	Case Western Reserve University; Case Western Reserve University					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P01DK038181] Funding Source: NIH RePORTER; NIDDK NIH HHS [P01-DK38181] Funding Source: Medline; PHS HHS [1 F32 D07612] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		BALLOU CE, 1963, J BIOL CHEM, V238, P69; BANGS JD, 1985, P NATL ACAD SCI USA, V82, P3207, DOI 10.1073/pnas.82.10.3207; BESSLER M, 1994, LANCET, V343, P951, DOI 10.1016/S0140-6736(94)90068-X; BROWN D, 1993, CURR OPIN IMMUNOL, V5, P349, DOI 10.1016/0952-7915(93)90052-T; BUXBAUM LU, 1994, J BIOL CHEM, V269, P30212; CONZELMANN A, 1992, EMBO J, V11, P457, DOI 10.1002/j.1460-2075.1992.tb05075.x; CONZELMANN A, 1987, BIOCHEM J, V246, P605, DOI 10.1042/bj2460605; COSTELLO LC, 1992, J BIOL CHEM, V267, P8599; CROSS GAM, 1990, ANNU REV CELL BIOL, V6, P1, DOI 10.1146/annurev.cb.06.110190.000245; CURATOLO W, 1987, BIOCHIM BIOPHYS ACTA, V906, P137, DOI 10.1016/0304-4157(87)90009-8; DEEG MA, 1992, J BIOL CHEM, V267, P18581; DEEG MA, 1992, J BIOL CHEM, V267, P18573; DEVINE DV, 1987, J CLIN INVEST, V79, P314, DOI 10.1172/JCI112802; DOERING TL, 1989, J BIOL CHEM, V264, P11168; FANKHAUSER C, 1993, J BIOL CHEM, V268, P26365; FERGUSON MAJ, 1985, J BIOL CHEM, V260, P4547; FERGUSON MAJ, 1986, J BIOL CHEM, V261, P356; HAKOMORI SI, 1993, ADV LIPID RES, V25, P147; HAKOMORI SI, 1990, J BIOL CHEM, V265, P18713; HANADA K, 1992, J BIOL CHEM, V267, P23527; HIROSE S, 1991, P NATL ACAD SCI USA, V88, P3762, DOI 10.1073/pnas.88.9.3762; HIROSE S, 1992, J BIOL CHEM, V267, P16968; HOMANS SW, 1988, NATURE, V333, P269, DOI 10.1038/333269a0; Issitt PD, 1985, APPL BLOOD GROUP SER; KAMITANI T, 1992, J BIOL CHEM, V267, P24611; KAPLAN MR, 1985, J CELL BIOL, V101, P441, DOI 10.1083/jcb.101.2.441; KOJIMA N, 1991, J BIOL CHEM, V266, P17552; LAZAR DF, 1994, P NATL ACAD SCI USA, V91, P9665, DOI 10.1073/pnas.91.21.9665; LEMANSKY P, 1991, MOL CELL BIOL, V11, P3879, DOI 10.1128/MCB.11.8.3879; LISANTI MP, 1990, P NATL ACAD SCI USA, V87, P7419, DOI 10.1073/pnas.87.19.7419; LOW MG, 1988, SCIENCE, V239, P268, DOI 10.1126/science.3276003; MASTERSON WJ, 1989, CELL, V56, P793, DOI 10.1016/0092-8674(89)90684-3; MATO JM, 1987, J BIOL CHEM, V262, P2131; MCCONVILLE MJ, 1990, J BIOL CHEM, V265, P19611; MCCONVILLE MJ, 1993, J BIOL CHEM, V268, P15595; MCNEELY TB, 1989, BIOCHEM J, V259, P601, DOI 10.1042/bj2590601; MENON AK, 1993, EMBO J, V12, P1907, DOI 10.1002/j.1460-2075.1993.tb05839.x; MENON AK, 1988, J BIOL CHEM, V263, P1970; MENON AK, 1990, EMBO J, V9, P4249, DOI 10.1002/j.1460-2075.1990.tb07873.x; PARPAL S, 1995, J CELL BIOL, V131, P125, DOI 10.1083/jcb.131.1.125; PROUDFOOT L, 1995, BIOCHEM J, V308, P45, DOI 10.1042/bj3080045; PUOTI A, 1992, J BIOL CHEM, V267, P22673; REPRESA J, 1991, P NATL ACAD SCI USA, V88, P8016, DOI 10.1073/pnas.88.18.8016; ROBERTS WL, 1988, J BIOL CHEM, V263, P18766; RODRIGUEZBOULAN E, 1989, METHOD CELL BIOL, V32, P37; SARGIACOMO M, 1993, J CELL BIOL, V122, P789, DOI 10.1083/jcb.122.4.789; SCHOFIELD L, 1993, J EXP MED, V177, P145, DOI 10.1084/jem.177.1.145; SCHWARZMANN G, 1990, BIOCHEMISTRY-US, V29, P10865, DOI 10.1021/bi00501a001; SHIAO YJ, 1993, J BIOL CHEM, V268, P26085; SINGH N, 1991, MOL CELL BIOL, V11, P391, DOI 10.1128/MCB.11.1.391; SINGH N, 1994, MOL CELL BIOL, V14, P21, DOI 10.1128/MCB.14.1.21; SIPOS G, 1994, EMBO J, V13, P2789, DOI 10.1002/j.1460-2075.1994.tb06572.x; STAHL N, 1992, BIOCHEMISTRY-US, V31, P5043, DOI 10.1021/bi00136a600; SUGIYAMA E, 1991, J BIOL CHEM, V266, P12119; TAKEDA J, 1993, CELL, V73, P703, DOI 10.1016/0092-8674(93)90250-T; TARTAKOFF AM, 1992, TRENDS BIOCHEM SCI, V17, P470, DOI 10.1016/0968-0004(92)90491-Q; TARTAKOFF AM, 1986, EMBO J, V5, P1477, DOI 10.1002/j.1460-2075.1986.tb04385.x; TURCO SJ, 1992, ANNU REV MICROBIOL, V46, P65, DOI 10.1146/annurev.mi.46.100192.000433; UEDA E, 1993, J BIOL CHEM, V268, P9998; URAKAZE M, 1992, J BIOL CHEM, V267, P6459; Van Meer Gerrit, 1992, Trends in Cell Biology, V2, P332; VANTHOF W, 1995, J BIOL CHEM, V270, P24150; VIDUGIRIENE J, 1993, J CELL BIOL, V121, P987, DOI 10.1083/jcb.121.5.987; VIDUGIRIENE J, 1994, J CELL BIOL, V127, P333, DOI 10.1083/jcb.127.2.333; WALTER EI, 1990, J IMMUNOL, V144, P1030; ZURZOLO C, 1994, EMBO J, V13, P42, DOI 10.1002/j.1460-2075.1994.tb06233.x	66	45	45	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12879	12884		10.1074/jbc.271.22.12879	http://dx.doi.org/10.1074/jbc.271.22.12879			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663031	hybrid			2022-12-27	WOS:A1996UN47400031
J	Chroneos, ZC; Abdolrasulnia, R; Whitsett, JA; Rice, WR; Shepherd, VL				Chroneos, ZC; Abdolrasulnia, R; Whitsett, JA; Rice, WR; Shepherd, VL			Purification of a cell-surface receptor for surfactant protein A	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALVEOLAR MACROPHAGES; APOPROTEIN SP-A; II CELLS; PULMONARY SURFACTANT; HIGH-AFFINITY; PHOSPHOLIPID SECRETION; MANNOSE RECEPTOR; BINDING PROTEINS; PHAGOCYTOSIS; EXPRESSION	In the present report we have characterized the binding of surfactant protein A (SP-A) to bone marrow-derived macrophages, U937 cells, alveolar macrophages, and type II epithelial cells. The binding of SP-A to all cell types is Ca2+-dependent and trypsin-sensitive, but type II cells express distinct Ca2+-independent binding sites. The binding of SP A to macrophages is independent of known cell surface carbohydrate-specific receptors and of glycoconjugate binding sites on the surface of the cells and is distinct from binding to Clq receptors. Based on ligand blot analysis, both type II cells and macrophages express a 210-kDa SP-A-binding protein. The 210-kDa protein was purified to apparent homogeneity from U937 macrophage membranes using affinity chromatography with noncovalently immobilized surfactant protein A, and was purified from rat lung by differential detergent and salt extraction of isolated rat lung membranes. Polyclonal antibodies against the rat lung SP-A-binding protein inhibit binding of SP-A to both type II cells and macrophages, indicating that the 210-kDa protein is expressed on the cell surface. The polyclonal antibodies also block the SP-A-mediated inhibition of phospholipid secretion by type II cells, indicating that the 210-kDa protein is a functional cell-surface receptor on type II cells. In a separate report we have determined that antibodies to the SP-A receptor block the SP-A-mediated uptake of Mycobacterium bovis, indicating that the macrophage SP-A receptor is involved in SP-A-mediated clearance of pathogens.	VANDERBILT UNIV,DEPT BIOCHEM,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT MED,NASHVILLE,TN 37232; VANDERBILT UNIV,DEPT PATHOL,NASHVILLE,TN 37232; DEPT VET AFFAIRS MED CTR,NASHVILLE,TN 37203	Vanderbilt University; Vanderbilt University; Vanderbilt University; US Department of Veterans Affairs; Veterans Health Administration (VHA); VA Tennessee Valley Healthcare System	Chroneos, ZC (corresponding author), CHILDRENS HOSP,MED CTR,DIV PULM BIOL,CINCINNATI,OH 45229, USA.			, Zissis/0000-0002-9841-7917	NHLBI NIH HHS [HL-28623, 5P50 HL14214-23] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL014214, R01HL028623] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARVIEUX J, 1984, BIOCHEM J, V218, P547, DOI 10.1042/bj2180547; BLAU H, 1994, AM J PHYSIOL, V266, pL148, DOI 10.1152/ajplung.1994.266.2.L148; CHILDS RA, 1992, J BIOL CHEM, V267, P9972; Chroneos Z, 1995, AM J PHYSIOL-LUNG C, V269, pL721, DOI 10.1152/ajplung.1995.269.6.L721; DOBBS LG, 1987, P NATL ACAD SCI USA, V84, P1010, DOI 10.1073/pnas.84.4.1010; DOBBS LG, 1986, AM REV RESPIR DIS, V134, P141; DRANOFF G, 1994, SCIENCE, V264, P713, DOI 10.1126/science.8171324; EGGLETON P, 1995, J CLIN INVEST, V95, P1569, DOI 10.1172/JCI117830; ERDEI A, 1988, BIOCHEM J, V255, P493; GEERTSMA MF, 1994, AM J PHYSIOL-LUNG C, V267, pL578, DOI 10.1152/ajplung.1994.267.5.L578; GRIESE M, 1991, AM J PHYSIOL, V261, pL434, DOI 10.1152/ajplung.1991.261.6.L434; GUAN E, 1991, J BIOL CHEM, V266, P20345; GUSTAFSON S, 1991, BIOCHIM BIOPHYS ACTA, V1091, P36, DOI 10.1016/0167-4889(91)90218-M; KHOOR A, 1993, J HISTOCHEM CYTOCHEM, V41, P1311, DOI 10.1177/41.9.8354874; KLOTZ IM, 1986, INTRO BIOMOLECULAR E, P103; KREMLEV SG, 1994, AM J PHYSIOL-LUNG C, V267, pL712, DOI 10.1152/ajplung.1994.267.6.L712; KRIEGER M, 1992, TRENDS BIOCHEM SCI, V17, P141, DOI 10.1016/0968-0004(92)90322-Z; KUROKI Y, 1994, J BIOL CHEM, V269, P29793; KUROKI Y, 1988, J BIOL CHEM, V263, P3388; KUROKI Y, 1988, J BIOL CHEM, V263, P17596; KUROKI Y, 1988, P NATL ACAD SCI USA, V85, P5566, DOI 10.1073/pnas.85.15.5566; MALHOTRA R, 1992, EUR J IMMUNOL, V22, P1437, DOI 10.1002/eji.1830220616; MALHOTRA R, 1990, J EXP MED, V172, P955, DOI 10.1084/jem.172.3.955; MANZKEINKE H, 1991, EXP CELL RES, V192, P597, DOI 10.1016/0014-4827(91)90081-5; MANZKEINKE H, 1992, EUR J CELL BIOL, V57, P95; MCCORMACK FX, 1994, J BIOL CHEM, V269, P5833; MCCORMACK FX, 1994, J BIOL CHEM, V269, P29801; MCNEELY TB, 1994, AM J RESP CELL MOL, V11, P114, DOI 10.1165/ajrcmb.11.1.8018334; MCNEELY TB, 1993, J INFECT DIS, V167, P91, DOI 10.1093/infdis/167.1.91; PISON U, 1992, AM J PHYSIOL, V262, pL412, DOI 10.1152/ajplung.1992.262.4.L412; RICE WR, 1987, J APPL PHYSIOL, V63, P692, DOI 10.1152/jappl.1987.63.2.692; RICE WR, 1986, BRIT J PHARMACOL, V89, P485, DOI 10.1111/j.1476-5381.1986.tb11148.x; ROONEY SA, 1994, FASEB J, V8, P957, DOI 10.1096/fasebj.8.12.8088461; ROSS GF, 1987, BIOCHIM BIOPHYS ACTA, V911, P294, DOI 10.1016/0167-4838(87)90070-7; RYAN RM, 1989, J HISTOCHEM CYTOCHEM, V37, P429, DOI 10.1177/37.4.2926121; SHEPHERD VL, 1985, J BIOL CHEM, V260, P160; SHEPHERD VL, 1984, J BIOL CHEM, V259, P2257; SHEPHERD VL, 1990, J IMMUNOL, V145, P1530; SHIPP MA, 1993, BLOOD, V82, P1052, DOI 10.1182/blood.V82.4.1052.bloodjournal8241052; STAHL PD, 1992, CURR OPIN IMMUNOL, V4, P49, DOI 10.1016/0952-7915(92)90123-V; STEVENS PA, 1995, BIOCHEM J, V308, P77, DOI 10.1042/bj3080077; STRAYER DS, 1993, J BIOL CHEM, V268, P18679; SUWABE A, 1991, AM J RESP CELL MOL, V4, P264, DOI 10.1165/ajrcmb/4.3.264; TENNER AJ, 1989, J BIOL CHEM, V264, P13923; THORKELSSON T, 1992, J HISTOCHEM CYTOCHEM, V40, P643, DOI 10.1177/40.5.1573247; TOWNSEND R, 1981, BIOCHEM J, V194, P209, DOI 10.1042/bj1940209; TSIBILAYR EC, 1983, J HISTOCHEM CYTOCHEM, V31, P1298; VANIWAARDEN F, 1990, AM J RESP CELL MOL, V2, P91, DOI 10.1165/ajrcmb/2.1.91; VANIWAARDEN JF, 1991, AM J PHYSIOL, V261, pL204, DOI 10.1152/ajplung.1991.261.2.L204; WEAVER TE, 1991, BIOCHEM J, V273, P249, DOI 10.1042/bj2730249; WEIKERT L, 1996, AM REV RESPIR DIS, V153, pA130; WEISSBACH S, 1994, AM J PHYSIOL-LUNG C, V267, pL660, DOI 10.1152/ajplung.1994.267.6.L660; WHITSETT JA, 1985, J BIOL CHEM, V260, P5273; WHITSETT JA, 1985, EXP LUNG RES, V9, P135; WINTERGERST E, 1989, EUR J CELL BIOL, V50, P291; WRIGHT JR, 1993, AM J PHYSIOL, V264, pL338, DOI 10.1152/ajplung.1993.264.4.L338; WRIGHT JR, 1987, J BIOL CHEM, V262, P2888; WRIGHT JR, 1989, P NATL ACAD SCI USA, V86, P5410, DOI 10.1073/pnas.86.14.5410; ZIMMERMAN PE, 1992, J CLIN INVEST, V89, P143, DOI 10.1172/JCI115554	59	161	164	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16375	16383		10.1074/jbc.271.27.16375	http://dx.doi.org/10.1074/jbc.271.27.16375			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663107	hybrid			2022-12-27	WOS:A1996UW35200077
J	Hebert, TE; Moffett, S; Morello, JP; Loisel, TP; Bichet, DG; Barret, C; Bouvier, M				Hebert, TE; Moffett, S; Morello, JP; Loisel, TP; Bichet, DG; Barret, C; Bouvier, M			A peptide derived from a beta(2)-adrenergic receptor transmembrane domain inhibits both receptor dimerization and activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-LINKED RECEPTORS; GROWTH-FACTOR RECEPTOR; PIG CEREBRAL-CORTEX; ADRENERGIC-RECEPTORS; SIGNAL-TRANSDUCTION; LIGAND-BINDING; BETA-2-ADRENERGIC RECEPTOR; MUSCARINIC RECEPTORS; COUPLED RECEPTORS; H-3 HISTAMINE	One of the assumptions of the mobile receptor hypothesis as it relates to G protein-coupled receptors is that the stoichiometry of receptor, G protein, and effector is 1:1:1 (Bourne, H. R,, Sanders, D, A, and McCormick, F, (1990) Nature 348, 125-132), Many studies on the cooperativity of agonist binding are incompatible with this notion and have suggested that both G proteins and their associated receptors can be oligomeric. However, a clear physical demonstration that G protein-coupled receptors can indeed interact as dimers and that such interactions may have functional consequences was lacking, Here, using differential epitope tagging we demonstrate that beta(2)-adrenergic receptors do form SDS-resistant homodimers and that transmembrane domain VI of the receptor may represent part of an interface for receptor dimerization, The functional importance of dimerization is supported by the observation that a peptide derived from this domain that inhibits dimerization also inhibits beta-adrenergic agonist-promoted stimulation of adenylyl cyclase activity. Moreover, agonist stimulation was found to stabilize the dimeric state of the receptor, while inverse agonists favored the monomeric species, which suggests that interconversion between monomeric and dimeric forms may be important for biological activity.	UNIV MONTREAL,DEPT BIOCHIM,MONTREAL,PQ H3C 3J7,CANADA; UNIV MONTREAL,GRP RECH SYST NERVEUX AUTONOME,MONTREAL,PQ H3C 3J7,CANADA; HOP SACRE COEUR,CTR RECH,MONTREAL,PQ H4J 1C5,CANADA; UNIV MONTREAL,DEPT MED,MONTREAL,PQ H4J 1C5,CANADA	Universite de Montreal; Universite de Montreal; Universite de Montreal; Universite de Montreal			Bouvier, Michel/H-2758-2014	Bouvier, Michel/0000-0003-1128-0100; BICHET, DANIEL-G/0000-0003-2856-6850				ALBLAS J, 1995, J BIOL CHEM, V270, P8944, DOI 10.1074/jbc.270.15.8944; ALI H, 1994, J BIOL CHEM, V269, P24557; AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; AVISSAR S, 1983, P NATL ACAD SCI-BIOL, V80, P156, DOI 10.1073/pnas.80.1.156; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BICHET DG, 1994, AM J HUM GENET, V55, P278; BIEMANN HP, 1994, BIOCHEMISTRY-US, V33, P629, DOI 10.1021/bi00169a002; BISHAYEE S, 1989, J BIOL CHEM, V264, P11699; BORMANN BJ, 1989, J BIOL CHEM, V264, P4033; BOURNE HR, 1990, NATURE, V348, P125, DOI 10.1038/348125a0; BOUVIER M, 1988, MOL PHARMACOL, V33, P133; CHIDIAC P, 1994, MOL PHARMACOL, V45, P490; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DANNER M, 1993, EUR J BIOCHEM, V215, P653, DOI 10.1111/j.1432-1033.1993.tb18076.x; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FURTHMAYR H, 1976, BIOCHEMISTRY-US, V15, P1137, DOI 10.1021/bi00650a028; GARAVITO RM, 1983, J MOL BIOL, V164, P315; GETHER U, 1995, J BIOL CHEM, V270, P28268; GIANNINI E, 1995, J BIOL CHEM, V270, P19166, DOI 10.1074/jbc.270.32.19166; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HAMILTON KK, 1993, J BIOL CHEM, V268, P3632; HARRIS HW, 1996, KIDNEY, V1, P516; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HELDIN CH, 1989, J BIOL CHEM, V264, P8905; HERBERG JT, 1985, J BIOL CHEM, V259, P9285; HIRSCHBERG BT, 1994, J BIOL CHEM, V269, P26127; IBARRONDO J, 1995, P NATL ACAD SCI USA, V92, P8413, DOI 10.1073/pnas.92.18.8413; KENAKIN T, 1995, TRENDS PHARMACOL SCI, V16, P256, DOI 10.1016/S0165-6147(00)89037-9; KIM SH, 1994, PROTEIN SCI, V3, P159; KOBILKA B, 1992, ANNU REV NEUROSCI, V15, P87, DOI 10.1146/annurev.ne.15.030192.000511; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMMON MA, 1992, J BIOL CHEM, V267, P7683; LEMMON MA, 1994, NAT STRUCT BIOL, V1, P157, DOI 10.1038/nsb0394-157; LEMMON MA, 1992, BIOCHEMISTRY-US, V31, P12719, DOI 10.1021/bi00166a002; LONG DG, 1992, BIOCHEMISTRY-US, V31, P9904, DOI 10.1021/bi00156a007; MAGGIO R, 1993, P NATL ACAD SCI USA, V90, P3103, DOI 10.1073/pnas.90.7.3103; MATTERA R, 1985, J BIOL CHEM, V260, P7410; MILLIGAN DL, 1991, SCIENCE, V254, P1651, DOI 10.1126/science.1661030; MILLIGAN G, 1995, TRENDS PHARMACOL SCI, V16, P10, DOI 10.1016/S0165-6147(00)88963-4; MIXON MB, 1995, SCIENCE, V270, P954, DOI 10.1126/science.270.5238.954; MOFFETT S, 1993, EMBO J, V12, P349, DOI 10.1002/j.1460-2075.1993.tb05663.x; MONNOT C, 1993, J BIOL CHEM, V271, P1507; MOUILLAC B, 1992, J BIOL CHEM, V267, P21733; NEUBIG RR, 1994, FASEB J, V8, P939, DOI 10.1096/fasebj.8.12.8088459; NG GYK, 1994, J NEUROCHEM, V63, P1589; NG GYK, 1994, EUR J PHARM-MOLEC PH, V267, P7, DOI 10.1016/0922-4106(94)90219-4; NG GYK, 1993, BIOCHEMISTRY-US, V32, P11727, DOI 10.1021/bi00094a032; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; PETERSON GL, 1986, BIOCHEMISTRY-US, V25, P3189, DOI 10.1021/bi00359a017; PICKERING DS, 1993, J NEUROCHEM, V61, P85, DOI 10.1111/j.1471-4159.1993.tb03540.x; POTTER LT, 1991, MOL PHARMACOL, V39, P211; RODBELL M, 1992, CURR TOP CELL REGUL, V32, P1; SALHANY JM, 1990, J BIOL CHEM, V265, P17688; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; SAMAMA P, 1994, MOL PHARMACOL, V45, P390; SCHATZ G, 1983, CELL, V32, P316, DOI 10.1016/0092-8674(83)90450-6; SCHREURS J, 1995, J NEUROCHEM, V64, P1622; SEEMAN P, 1994, TRENDS PHARMACOL SCI, V15, P264, DOI 10.1016/0165-6147(94)90323-9; SEIFERT RA, 1989, J BIOL CHEM, V264, P8771; SHORR RGL, 1981, J BIOL CHEM, V256, P5820; SINKINS WG, 1993, MOL PHARMACOL, V43, P583; SINKINS WG, 1993, MOL PHARMACOL, V43, P569; SOROKIN A, 1994, J BIOL CHEM, V269, P9752; Stewart JM, 1984, SOLID PHASE PEPTIDE; STOCK JB, 1991, ANNU REV BIOPHYS BIO, V20, P109, DOI 10.1146/annurev.bb.20.060191.000545; STRANGE PG, 1994, TRENDS PHARMACOL SCI, V15, P317, DOI 10.1016/0165-6147(94)90020-5; STROSBERG AD, 1993, PROTEIN SCI, V2, P1198, DOI 10.1002/pro.5560020802; TOBKES N, 1985, BIOCHEMISTRY-US, V24, P1915, DOI 10.1021/bi00329a017; TSCHOPP J, 1984, J BIOL CHEM, V259, P1922; TSCHOPP J, 1982, NATURE, V298, P534, DOI 10.1038/298534a0; VASUDEVAN S, 1995, EUR J BIOCHEM, V227, P466, DOI 10.1111/j.1432-1033.1995.tb20411.x; VENTER JC, 1983, TRENDS PHARMACOL SCI, V4, P256; WESSLINGRESNICK M, 1987, J BIOL CHEM, V262, P3697; WILLARDSON BM, 1993, J BIOL CHEM, V268, P6371; WREGGETT KA, 1995, J BIOL CHEM, V270, P22488, DOI 10.1074/jbc.270.38.22488; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1443, DOI 10.1021/bi00379a035; YARDEN Y, 1987, BIOCHEMISTRY-US, V26, P1434, DOI 10.1021/bi00379a034	78	639	655	1	25	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16384	16392		10.1074/jbc.271.27.16384	http://dx.doi.org/10.1074/jbc.271.27.16384			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663163	hybrid			2022-12-27	WOS:A1996UW35200078
J	Wang, XS; Penzes, P; Napoli, JL				Wang, XS; Penzes, P; Napoli, JL			Cloning of a cDNA encoding an aldehyde dehydrogenase and its expression in Escherichia coli - Recognition of retinal as substrate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LIGAND-BINDING PROPERTIES; MOUSE-LIVER; ACID; OXIDATION; RAT; IDENTIFICATION; BIOSYNTHESIS; DIVERSITY; CATALYZE; PROTEIN	The biosynthesis of the hormone retinoic acid from retinol (vitamin A) involves two sequential steps, catalyzed by retinol dehydrogenases and retinal dehydrogenases, respectively. This report describes the cloning of a cDNA encoding a heretofore unknown aldehyde dehydrogenase from a rat testis library and its expression in Escherichia coli, This enzyme has been designated retinal dehydrogenase, type II, RalDH(II). The deduced amino acid sequence of RalDH(II) had the highest identity with mammalian aldehyde dehydrogenases that feature low K-m values (mu M) for retinal: human ALDH1 (72.2%), rat retinal dehydrogenase, type I (71.5%), bovine retina (72.7%), and mouse AHD-2 (71.5%). RalDH(II) expressed in E. coli recognizes as substrates free retinal, with a K-m of similar to 0.7 mu M, and cellular retinol-binding protein-bound retinal, with a K-m of similar to 0.2 mu M. RalDH(II) also can utilize as substrate retinal generated in situ by microsomal retinol dehydrogenases, from the physiologically most abundant substrate: retinol bound to cellular retinol-binding protein. Rat testis expresses RalDH(II) mRNA most abundantly, followed by (relative to testis): lung (6.7%), brain (6.3%), heart (5.2%), liver (4.4%), and kidney (2.7%). RalDH(II) does not recognize citral, benzaldehyde, acetaldehyde, and propanal efficiently as substrates, but does metabolize octanal and decanal efficiently. These data support a function for RalDH(II) in the pathway of retinoic acid biogenesis.	SUNY BUFFALO, SCH MED & BIOMED SCI, DEPT BIOCHEM, BUFFALO, NY 14214 USA	State University of New York (SUNY) System; State University of New York (SUNY) Buffalo			Penzes, Peter/L-3987-2016	Penzes, Peter/0000-0001-5449-1640	NATIONAL INSTITUTE ON AGING [R01AG013566] Funding Source: NIH RePORTER; NIA NIH HHS [AG 13566] Funding Source: Medline	NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BOERMAN MHEM, 1995, BIOCHEMISTRY-US, V34, P7027, DOI 10.1021/bi00021a014; Boerman MHEM, 1996, J BIOL CHEM, V271, P5610, DOI 10.1074/jbc.271.10.5610; Chai XY, 1996, GENE, V169, P219, DOI 10.1016/0378-1119(95)00833-0; CHAI XY, 1995, J BIOL CHEM, V270, P3900, DOI 10.1074/jbc.270.8.3900; CHAI XY, 1995, J BIOL CHEM, V270, P28408, DOI 10.1074/jbc.270.47.28408; CHEN M, 1994, MOL PHARMACOL, V46, P88; CHYTIL F, 1990, Critical Reviews in Eukaryotic Gene Expression, V1, P61; DOCKHAM PA, 1992, BIOCHEM PHARMACOL, V43, P2453, DOI 10.1016/0006-2952(92)90326-E; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; FESUS L, 1991, EUR J CELL BIOL, V56, P170; GIGUERE V, 1994, ENDOCR REV, V15, P61, DOI 10.1210/er.15.1.61; GODBOUT R, 1992, EXP EYE RES, V54, P297, DOI 10.1016/S0014-4835(05)80219-2; GOSS GD, 1992, CRIT REV CL LAB SCI, V29, P185, DOI 10.3109/10408369209114600; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; Leatherbarrow R.J, 1987, ENZFITTER NONLINEAR; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LEID M, 1992, TRENDS BIOCHEM SCI, V17, P427, DOI 10.1016/0968-0004(92)90014-Z; LEVIN MS, 1988, J BIOL CHEM, V263, P17715; LI E, 1991, J BIOL CHEM, V266, P3622; LOHNES D, 1992, J CELL SCI, P69; NAPOLI JL, 1995, J STEROID BIOCHEM, V53, P497, DOI 10.1016/0960-0760(95)00096-I; NAPOLI JL, 1993, J NUTR, V123, P362, DOI 10.1093/jn/123.suppl_2.362; NAPOLI JL, 1990, BIOCHIM BIOPHYS ACTA, V1034, P228, DOI 10.1016/0304-4165(90)90081-7; NAPOLI JL, 1990, METHOD ENZYMOL, V189, P470; NAPOLI JL, 1990, CHEM BIOL SYNTHETIC, P229; POSCH KC, 1992, J BIOL CHEM, V267, P19676; POSCH KC, 1991, BIOCHEMISTRY-US, V30, P6224, DOI 10.1021/bi00239a021; RONGNOPARUT P, 1991, GENE, V101, P261, DOI 10.1016/0378-1119(91)90421-7; SAARI JC, 1995, VISUAL NEUROSCI, V12, P263, DOI 10.1017/S095252380000794X; SATRE MA, 1989, DEV BIOL, V133, P529, DOI 10.1016/0012-1606(89)90055-9; WOLF G, 1984, PHYSIOL REV, V64, P874; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794	34	143	145	1	7	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16288	16293		10.1074/jbc.271.27.16288	http://dx.doi.org/10.1074/jbc.271.27.16288			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663198	hybrid			2022-12-27	WOS:A1996UW35200064
J	Carmen, AA; Rundlett, SE; Grunstein, M				Carmen, AA; Rundlett, SE; Grunstein, M			HDA1 and HDA3 are components of a yeast histone deacetylase (HDA) complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERNAL NUCLEAR MATRIX; GENE-EXPRESSION; ZEA-MAYS; ACETYLATION; INVIVO; TRANSCRIPTION; NUCLEOSOMES; CEREVISIAE; CHROMATIN; MARKER	Histone acetylation is maintained through the action of histone acetyltransferases and deacetylases and has been correlated with increased gene activity. To investigate the functional role of these enzymes in the regulation of transcription, we have purified from Saccharomyces cerevisiae two histone deacetylase activities, HDA and HDB, with molecular masses of similar to 350 and 600 kDa, respectively. In vitro, the HDA activity deacetylates all four core histones, has a preference for histone H3, and is strongly inhibited by trichostatin A (a specific inhibitor of histone deacetylases). HDB is considerably less sensitive to trichostatin A. We report the extensive purification of the HDA activity and the identification of peptides (p75, p73, p72, and p71) whose presence correlates with deacetylase activity on native polyacrylamide gels. An antibody to p75 immunoprecipitates peptides with molecular masses similar to those in the 350-kDa complex. Additionally, antibodies to p75 and p71 specifically precipitate histone deacetylase activity and coimmunoprecipitate each other. Gene disruptions of p75 (HDA1) or p71 (HDA3) cause the loss of the 350-kDa (but not the 600-kDa) activity from our chromatography profiles. These data argue strongly that HDA1 and HDA3 are subunits of the HDA complex, which is structurally distinct from the second, HDB complex.	UNIV CALIF LOS ANGELES,SCH MED,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,INST MOLEC BIOL,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles					NATIONAL CANCER INSTITUTE [T32CA009056] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R37GM023674, R01GM023674, R01GM042421] Funding Source: NIH RePORTER; NCI NIH HHS [2T32CA-09056] Funding Source: Medline; NIGMS NIH HHS [GM23674, GM42421] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALANSO WR, 1986, BIOCHIM BIOPHYS ACTA, V866, P161; ALLEGRA P, 1987, J MOL BIOL, V196, P379, DOI 10.1016/0022-2836(87)90698-X; BONE JR, 1994, GENE DEV, V8, P96, DOI 10.1101/gad.8.1.96; BRAUNSTEIN M, 1993, GENE DEV, V7, P592, DOI 10.1101/gad.7.4.592; Brownell JE, 1996, CELL, V84, P843, DOI 10.1016/S0092-8674(00)81063-6; BROWNELL JE, 1995, P NATL ACAD SCI USA, V92, P6364, DOI 10.1073/pnas.92.14.6364; CLARKE DJ, 1993, BIOCHEM J, V294, P557, DOI 10.1042/bj2940557; DAVIE JR, 1981, NUCLEIC ACIDS RES, V9, P3205, DOI 10.1093/nar/9.13.3205; DELPINO MMS, 1994, BIOCHEM J, V303, P723, DOI 10.1042/bj3030723; DURRIN LK, 1991, CELL, V65, P1023, DOI 10.1016/0092-8674(91)90554-C; GEORGIEVA EI, 1991, J BIOL CHEM, V266, P18751; GRABHER A, 1994, BIOCHEMISTRY-US, V33, P14887, DOI 10.1021/bi00253a028; GRUNSTEIN M, 1990, ANNU REV CELL BIOL, V6, P643, DOI 10.1146/annurev.cellbio.6.1.643; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HEBBES TR, 1992, NUCLEIC ACIDS RES, V20, P1017, DOI 10.1093/nar/20.5.1017; HENDZEL MJ, 1991, J BIOL CHEM, V266, P21936; HENDZEL MJ, 1992, BIOCHIM BIOPHYS ACTA, V1130, P307, DOI 10.1016/0167-4781(92)90443-4; JEPPESEN P, 1993, CELL, V74, P281, DOI 10.1016/0092-8674(93)90419-Q; KIEFF S, 1995, J BIOL CHEM, V270, P24674; LOPEZRODAS G, 1989, J BIOL CHEM, V264, P19028; LOPEZRODAS G, 1992, FEBS LETT, V296, P82, DOI 10.1016/0014-5793(92)80408-9; LOPEZRODAS G, 1991, J BIOL CHEM, V266, P18745; LORCH Y, 1988, CELL, V55, P743, DOI 10.1016/0092-8674(88)90128-6; MARVIN KW, 1990, J BIOL CHEM, V265, P19839; NELSON DA, 1982, J BIOL CHEM, V257, P1565; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; SOBEL RE, 1994, J BIOL CHEM, V269, P18576; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; SUN JM, 1992, BIOCHEM CELL BIOL, V70, P822, DOI 10.1139/o92-125; THORNE AW, 1990, EUR J BIOCHEM, V193, P701, DOI 10.1111/j.1432-1033.1990.tb19390.x; TURNER BM, 1992, CELL, V69, P375, DOI 10.1016/0092-8674(92)90417-B; TURNER BM, 1991, J CELL SCI, V99, P13; YOSHIDA M, 1990, J BIOL CHEM, V265, P17174; YOSHIDA M, 1995, BIOESSAYS, V17, P423, DOI 10.1002/bies.950170510; ZHANG DE, 1988, BIOCHEM J, V250, P233, DOI 10.1042/bj2500233; Zweidler A, 1978, Methods Cell Biol, V17, P223, DOI 10.1016/S0091-679X(08)61145-0	36	172	186	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15837	15844		10.1074/jbc.271.26.15837	http://dx.doi.org/10.1074/jbc.271.26.15837			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663039	hybrid			2022-12-27	WOS:A1996UV29900080
J	Gierse, JK; McDonald, JJ; Hauser, SD; Rangwala, SH; Koboldt, CM; Seibert, K				Gierse, JK; McDonald, JJ; Hauser, SD; Rangwala, SH; Koboldt, CM; Seibert, K			A single amino acid difference between cyclooxygenase-1 (COX-1) and -2 (COX-2) reverses the selectivity of COX-2 specific inhibitors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPEROXIDE SYNTHASE CYCLOOXYGENASE; PROSTAGLANDIN SYNTHASE; MESSENGER-RNA; EXPRESSION	Nonsteroidal anti-inflammatory drugs (NSAIDs) currently available for clinical use inhibit both COX-1 and COX-2. This suggests that clinically useful NSAIDs inhibit pro-inflammatory prostaglandins (PGs) derived from the activity of COX-2, as well as PGs in tissues like the stomach and kidney (via COX-1), A new class of compounds has recently been developed (SC-58125) that have a high degree of selectivity for the inducible form of cyxlooxygenase (COX-2) over the constitutive form (COX-1). This unique class of compounds exhibit a time-dependent irreversible inhibition of COX-2, while re versibly inhibiting COX-1. The molecular basis of this selectivity was probed by site-directed mutagenesis of the active site of COX-2. The sequence differences in the active site were determined by amino acid replacement of the COX-2 sequences based on the known crystal structure of COX-1, which revealed a single amino acid difference in the active site (valine 509 to isoleucine) and a series of differences at the mouth of the active site. Mutants with the single amino acid substitution in the active site and a combination of three changes in the mouth of the active site were made in human COX-2, expressed in insect cells and purified. The single amino acid change of valine 509 to isoleucine confers selectivity of COX-2 inhibitors in the class of SC-58125 and others of the same class (SC-236, NS-398), while commonly used NSAIDs such as indomethacin showed no change in selectivity. Substitutions of COX-1 sequences in COX-2 at the mouth of the active site of COX-2 did not change the selectivity of SC-58125. This indicates that the single amino acid substitution of isoleucine at position 509 for a valine is sufficient to confer COX-2 selectivity in this example of a diaryl-heterocycle COX inhibitor.			Gierse, JK (corresponding author), MONSANTO SEARLE,SEARLE RES & DEV,700 CHESTERFIELD PKWY N,AA21,CHESTERFIELD,MO 63198, USA.							BAIROCH A, 1994, NUCLEIC ACIDS RES, V22, P3578; BARNETT J, 1994, BBA-PROTEIN STRUCT M, V1209, P130, DOI 10.1016/0167-4838(94)90148-1; COPELAND RA, 1994, P NATL ACAD SCI USA, V91, P11202, DOI 10.1073/pnas.91.23.11202; FU JY, 1990, J BIOL CHEM, V265, P16737; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; HAYNES RC, 1990, GOODMAN GILMANS PHAR, V8, P1431; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; JONES DA, 1993, J BIOL CHEM, V268, P9049; KENNEDY BP, 1993, BIOCHEM BIOPH RES CO, V197, P494, DOI 10.1006/bbrc.1993.2506; KUJUBU DA, 1991, J BIOL CHEM, V266, P12866; KULMACZ RJ, 1995, J BIOL CHEM, V270, P24019, DOI 10.1074/jbc.270.41.24019; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; MEADE EA, 1993, J BIOL CHEM, V268, P6610; MERLIE JP, 1988, J BIOL CHEM, V263, P3550; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; ONEILL GP, 1994, MOL PHARMACOL, V45, P245; OTTO JC, 1994, J BIOL CHEM, V269, P19868; PICOT D, 1994, NATURE, V367, P243, DOI 10.1038/367243a0; RAZ A, 1988, J BIOL CHEM, V263, P3022; SANO H, 1992, J CLIN INVEST, V89, P97, DOI 10.1172/JCI115591; SEBOLDT RJ, 1990, P NATL ACAD SCI USA, V87, P6971; TAKAHASHI Y, 1992, BIOCHEM BIOPH RES CO, V182, P443; THOMPSON JD, 1994, NUCLEIC ACIDS RES, V22, P4673, DOI 10.1093/nar/22.22.4673; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	25	345	358	1	24	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15810	15814		10.1074/jbc.271.26.15810	http://dx.doi.org/10.1074/jbc.271.26.15810			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663121	hybrid			2022-12-27	WOS:A1996UV29900076
J	Ng, JY; Marians, KJ				Ng, JY; Marians, KJ			The ordered assembly of the phi X174-type primosome .1. Isolation and identification of intermediate protein-DNA complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REPLICATION FACTOR-Y; ESCHERICHIA-COLI PROTEIN; GENE-PRODUCT; HELICASE; STRAND; PURIFICATION; MECHANISM; ASSOCIATION; DIRECTION; MUTATION	The phi X-type primosome was discovered during the resolution and reconstitution in vitro of the complementary strand DNA replication step of the phi X174 viral life cycle, This multienzyme bidirectional helicase-primase complex can provide the DNA unwinding and Okazaki fragment-priming functions at the replication fork and has been implicated in cellular DNA replication, repair, and recombination. We have used gel mobility shift assays and enhanced chemiluminescence Western analysis to isolate and identify the pathway of primosome assembly at a primosome assembly site (PAS) on a 300-nucleotide-long single-stranded DNA fragment. The first three steps do not require ATP and are as follows: (i) PriA recognition and binding to the PAS, (ii) stabilization of the PriA-PAS complex by the addition of PriB, and (iii) formation of a PriA-PriB-DnaT-PAS complex. Subsequent formation of the preprimosome involves the ATP-dependent transfer of DnaB from a DnaB-DnaC complex to the PriA-PriB-DnaT-PAS complex. The final preprimosomal complex contains PriA, PriB, DnaT, and DnaB but not DnaC. A transient interaction between the preprimosome and DnaG generates the five-protein primosome. As described in an accompanying article (Ng, J. Y., and Marians, K. J. (1996) J. Biol. Chem. 271, 15649-15655), when assembled on intact phi X174 phage DNA, the primosome also contains PriC.	MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center	Ng, JY (corresponding author), CORNELL UNIV,GRAD SCH MED SCI,GRAD PROGRAM MOLEC BIOL,NEW YORK,NY 10021, USA.				NIGMS NIH HHS [GM34557] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM034557, R37GM034557] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALLEN GC, 1993, J BIOL CHEM, V268, P19204; ALLEN GC, 1993, CELL, V74, P813; ARAI K, 1981, J BIOL CHEM, V256, P5260; ARAI K, 1981, P NATL ACAD SCI-BIOL, V78, P69, DOI 10.1073/pnas.78.1.69; ARAI K, 1981, J BIOL CHEM, V256, P5273; ARAI K, 1981, J BIOL CHEM, V256, P5253; ARAI K, 1981, J BIOL CHEM, V256, P5281; ARAI KI, 1981, P NATL ACAD SCI-BIOL, V78, P707, DOI 10.1073/pnas.78.2.707; ASAI T, 1994, J BACTERIOL, V176, P1807, DOI 10.1128/jb.176.7.1807-1812.1994; GREENBAUM JH, 1984, J BIOL CHEM, V259, P2594; KOBORI JA, 1982, J BIOL CHEM, V257, P13770; Kogoma T, 1996, J BACTERIOL, V178, P1258, DOI 10.1128/jb.178.5.1258-1264.1996; LARK CA, 1978, J BACTERIOL, V136, P1008, DOI 10.1128/JB.136.3.1008-1017.1978; LARK KG, 1978, CSHSQB, V43, P537; LASKEN RS, 1988, J BIOL CHEM, V263, P5512; LEBOWITZ JH, 1986, J BIOL CHEM, V261, P4738; LEE EH, 1991, P NATL ACAD SCI USA, V88, P3029, DOI 10.1073/pnas.88.8.3029; LEE MS, 1989, J BIOL CHEM, V264, P14531; LEE MS, 1987, P NATL ACAD SCI USA, V84, P8345, DOI 10.1073/pnas.84.23.8345; Liu J, 1996, J BIOL CHEM, V271, P15656, DOI 10.1074/jbc.271.26.15656; LOW RL, 1981, P NATL ACAD SCI-BIOL, V78, P1436, DOI 10.1073/pnas.78.3.1436; LOW RL, 1982, J BIOL CHEM, V257, P6242; MARIANS KJ, 1984, CRC CR REV BIOCH MOL, V17, P153, DOI 10.3109/10409238409113604; Marians KJ, 1995, METHOD ENZYMOL, V262, P507; MARIANS KJ, 1982, J BIOL CHEM, V257, P5656; MASAI H, 1994, EMBO J, V13, P5338, DOI 10.1002/j.1460-2075.1994.tb06868.x; MASAI H, 1986, P NATL ACAD SCI USA, V83, P1256, DOI 10.1073/pnas.83.5.1256; MASAI H, 1988, J BIOL CHEM, V263, P15083; MOK M, 1987, J BIOL CHEM, V262, P2304; Ng JY, 1996, J BIOL CHEM, V271, P15649, DOI 10.1074/jbc.271.26.15649; NURSE P, 1991, J BACTERIOL, V173, P6686, DOI 10.1128/jb.173.21.6686-6693.1991; REHAKRANTZ LJ, 1978, J BIOL CHEM, V253, P4043; RIGGS AD, 1970, J MOL BIOL, V48, P67, DOI 10.1016/0022-2836(70)90219-6; Sandler SJ, 1996, MOL MICROBIOL, V19, P871, DOI 10.1046/j.1365-2958.1996.429959.x; Sandler SJ, 1996, GENETICS, V143, P5; SHLOMAI J, 1980, P NATL ACAD SCI-BIOL, V77, P799, DOI 10.1073/pnas.77.2.799; TOUGU K, 1994, J BIOL CHEM, V269, P4675; WAHLE E, 1989, J BIOL CHEM, V264, P2469; WAHLE E, 1989, J BIOL CHEM, V264, P2463; WEINER JH, 1976, P NATL ACAD SCI USA, V73, P752, DOI 10.1073/pnas.73.3.752; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P921, DOI 10.1073/pnas.72.3.921; WICKNER S, 1974, P NATL ACAD SCI USA, V71, P4120, DOI 10.1073/pnas.71.10.4120; WICKNER S, 1975, P NATL ACAD SCI USA, V72, P3342, DOI 10.1073/pnas.72.9.3342; WICKNER S, 1978, SINGLE STRANDED DNA, P255; WONG I, 1992, SCIENCE, V256, P350, DOI 10.1126/science.256.5055.350; WU CA, 1992, J BIOL CHEM, V267, P4030; ZAVITZ KH, 1991, MOL MICROBIOL, V5, P2869, DOI 10.1111/j.1365-2958.1991.tb01846.x	47	88	101	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15642	15648		10.1074/jbc.271.26.15642	http://dx.doi.org/10.1074/jbc.271.26.15642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663104	hybrid			2022-12-27	WOS:A1996UV29900052
J	Qadri, I; Ferrari, ME; Siddiqui, A				Qadri, I; Ferrari, ME; Siddiqui, A			The hepatitis B virus transactivator protein, HBx, interacts with single-stranded DNA (ssDNA) - Biochemical characterizations of the HBx-ssDNA interactions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							X-GENE PRODUCT; BINDING-PROPERTIES; ESCHERICHIA-COLI; TRANS-ACTIVATION; VIRAL ENHANCERS; U6 GENES; REPLICATION; TRANSCRIPTION; PURIFICATION; SPECIFICITY	Human hepatitis B virus X protein, HBx, is widely acknowledged as a transcriptional transactivator. While HBx has been shown to increase gene expression in trans, it is generally believed that it does not bind double-stranded DNA. Using several experimental approaches, we show that HBx interacts with single-stranded DNA in a manner that is not sequence-specific. Various heterologous single-stranded DNA (ssDNA) oligonucleotides were able to compete in HBx-ssDNA interactions in gel shift assays. Escherichia coli non-sequence-specific, single-stranded DNA binding protein, E. coli SSB, displaced the HBx-ssDNA interactions, confirming the ability of HBx to interact with single-stranded DNA in a non-sequence-specific manner. We have further characterized the HBx-ssDNA interactions under various biochemical conditions. These include the effects of mono- and divalent cations, the effect of cardiolipin and heparin, pH and temperature dependence, and variations in the incubation time. HBx bound more tightly to d(pyrimidines)(25) than to d(purines)(25), a property that is characteristic of other single-stranded DNA-binding proteins (SSBs). Collectively the results presented here provide the first evidence of HBx's interaction with ssDNA. The biochemical parameters of these interactions were similar to those of known viral and cellular SSBs.	UNIV COLORADO, DEPT MICROBIOL, PROGRAM MOLEC BIOL, HLTH SCI CTR, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOCHEM, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT BIOPHYS, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA; UNIV COLORADO, HLTH SCI CTR, DEPT GENET, PROGRAM MOLEC BIOL, DENVER, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver				Qadri, Ishtiaq/0000-0003-4334-0585				BEASLEY RP, 1981, LANCET, V2, P1129; BENN J, 1994, P NATL ACAD SCI USA, V91, P10350, DOI 10.1073/pnas.91.22.10350; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CHALLBERG MD, 1989, ANNU REV BIOCHEM, V58, P671; CHEONG JH, 1995, EMBO J, V14, P143, DOI 10.1002/j.1460-2075.1995.tb06984.x; COLGROVE R, 1989, J VIROL, V63, P4019, DOI 10.1128/JVI.63.9.4019-4026.1989; CONAWAY RC, 1993, ANNU REV BIOCHEM, V62, P161; CROSS JC, 1993, P NATL ACAD SCI USA, V90, P8078, DOI 10.1073/pnas.90.17.8078; DUNCAN R, 1994, GENE DEV, V8, P465, DOI 10.1101/gad.8.4.465; HANG X, 1995, J VIROL, V69, P3924, DOI 10.1128/JVI.69.6.3924-3928.1995; HAVIV I, 1995, MOL CELL BIOL, V15, P1079; HOEIJMAKERS JHJ, 1993, TRENDS GENET, V9, P211, DOI 10.1016/0168-9525(93)90121-W; HU KQ, 1990, P NATL ACAD SCI USA, V87, P721; JAMEEL S, 1990, J VIROL, V64, P3963, DOI 10.1128/JVI.64.8.3963-3966.1990; KEKULE AS, 1993, NATURE, V361, P742, DOI 10.1038/361742a0; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE TH, 1995, J VIROL, V69, P1107, DOI 10.1128/JVI.69.2.1107-1114.1995; LOHMAN TM, 1994, ANNU REV BIOCHEM, V63, P527, DOI 10.1146/annurev.biochem.63.1.527; MAGUIRE HF, 1991, SCIENCE, V252, P842, DOI 10.1126/science.1827531; MUKHERJEE R, 1990, NUCLEIC ACIDS RES, V18, P5713, DOI 10.1093/nar/18.19.5713; NAKAJIMA N, 1988, MOL CELL BIOL, V8, P4028, DOI 10.1128/MCB.8.10.4028; NASAL M, 1993, TRENDS MICROBIOL, V6, P222; NATOLI G, 1994, MOL CELL BIOL, V14, P989, DOI 10.1128/MCB.14.2.989; OLIVO PD, 1988, P NATL ACAD SCI USA, V85, P5414, DOI 10.1073/pnas.85.15.5414; QADRI I, 1995, P NATL ACAD SCI USA, V92, P1003, DOI 10.1073/pnas.92.4.1003; RECORD MT, 1978, Q REV BIOPHYS, V11, P103, DOI 10.1017/S003358350000202X; RECORD MT, 1976, J MOL BIOL, V107, P145, DOI 10.1016/S0022-2836(76)80023-X; ROSSNER MT, 1992, J MED VIROL, V36, P101, DOI 10.1002/jmv.1890360207; SETO E, 1991, J VIROL, V65, P2351, DOI 10.1128/JVI.65.5.2351-2356.1991; SIDDIQUI A, 1989, VIROLOGY, V169, P479, DOI 10.1016/0042-6822(89)90177-3; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; SPANDAU DF, 1988, J VIROL, V62, P427, DOI 10.1128/JVI.62.2.427-434.1988; STAHL H, 1986, EMBO J, V5, P1939, DOI 10.1002/j.1460-2075.1986.tb04447.x; TWU JS, 1987, J VIROL, V61, P3448, DOI 10.1128/JVI.61.11.3448-3453.1987; WALDSCHMIDT R, 1992, J BIOL CHEM, V267, P16359; WANANDI I, 1993, J BIOL CHEM, V268, P6629; WANG XW, 1994, P NATL ACAD SCI USA, V91, P2230, DOI 10.1073/pnas.91.6.2230; WILLIAMS JS, 1995, P NATL ACAD SCI USA, V92, P3819, DOI 10.1073/pnas.92.9.3819; YAGIL G, 1991, CRIT REV BIOCHEM MOL, V26, P475, DOI 10.3109/10409239109086791; ZAHM P, 1988, ONCOGENE, V3, P169	40	34	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15443	15450		10.1074/jbc.271.26.15443	http://dx.doi.org/10.1074/jbc.271.26.15443			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663128	hybrid			2022-12-27	WOS:A1996UV29900024
J	Fass, SH; Engels, JW				Fass, SH; Engels, JW			Influence of specific signal peptide mutations on the expression and secretion of the alpha-amylase inhibitor tendamistat in Streptomyces lividans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							POLYACRYLAMIDE-GEL ELECTROPHORESIS; ENDOPLASMIC-RETICULUM MEMBRANE; CHARGED AMINO-ACIDS; ESCHERICHIA-COLI; RECOGNITION PARTICLE; PROTEIN TRANSLOCATION; NUCLEOTIDE-SEQUENCE; PRESECRETORY PROTEINS; EFFICIENT SECRETION; POSITIVE CHARGE	The Streptomyces alpha-amylase inhibitor tendamistat is secreted by a signal peptide with an amino-terminal charge of +3. To elucidate the influence of the charged residues on protein secretion in Streptomyces, the amino-terminal charge was varied from +6 to neutral net charge. The effects of charge variation were analyzed in combination with three Streptomyces promoters and two transcriptional terminators, Introduction of additional positive charges significantly decreased the amount of secreted tendamistat. On the contrary, a charge reduction to +2 resulted in the doubling of inhibitor production. After exclusion of transcriptional effects, the observed alterations of inhibitor secretion by the mutants with a charge of +6 to +2 were attributed to a modulation of precursor synthesis, Furthermore, a tight coupling of synthesis and export was stated, Charge reduction to +1 or neutral charge generally reduced the yield of secreted tendamistat, yet remarkable differences were found for mutants with identical net charge. Elimination of the positive charge at a defined position resulted in the release of tendamistat precursor protein, which suggested a specific uncoupling of synthesis and translocation.	UNIV FRANKFURT,INST ORGAN CHEM,D-60439 FRANKFURT,GERMANY	Goethe University Frankfurt			Engels, Joachim W/A-9224-2012					AKITA M, 1990, J BIOL CHEM, V265, P8164; ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; ANNE J, 1993, FEMS MICROBIOL LETT, V114, P121, DOI 10.1016/0378-1097(93)90507-X; ARKOWITZ RA, 1994, BBA-REV BIOMEMBRANES, V1197, P311; BENDER E, 1989, THESIS JW GOETHE U F; BENSON SA, 1987, J BACTERIOL, V169, P4686, DOI 10.1128/jb.169.10.4686-4691.1987; BERCHTOLD H, 1993, NATURE, V365, P126, DOI 10.1038/365126a0; BERGMEYER HU, 1970, METHODEN ENZYMATISCH, V1, P394; BERNAN V, 1985, GENE, V37, P101, DOI 10.1016/0378-1119(85)90262-8; BERNSTEIN HD, 1993, P NATL ACAD SCI USA, V90, P5229, DOI 10.1073/pnas.90.11.5229; BIBB MJ, 1985, GENE, V38, P215, DOI 10.1016/0378-1119(85)90220-3; BORCHERT TV, 1991, J BACTERIOL, V173, P276, DOI 10.1128/jb.173.1.276-282.1991; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; Brawner M, 1991, Curr Opin Biotechnol, V2, P674, DOI 10.1016/0958-1669(91)90033-2; BURNETT WV, 1987, NUCLEIC ACIDS RES, V15, P3926, DOI 10.1093/nar/15.9.3926; CHEN M, 1994, J BACTERIOL, V176, P5796, DOI 10.1128/JB.176.18.5796-5801.1994; CHURCH GM, 1984, P NATL ACAD SCI-BIOL, V81, P1991, DOI 10.1073/pnas.81.7.1991; COLEMAN J, 1985, CELL, V43, P351, DOI 10.1016/0092-8674(85)90040-6; CONNOLLY T, 1993, J CELL BIOL, V123, P799, DOI 10.1083/jcb.123.4.799; DOBBERSTEIN B, 1994, NATURE, V367, P599, DOI 10.1038/367599a0; ENGELS JW, 1992, TRANSGENESIS, P31; GENNITY J, 1990, J BIOENERG BIOMEMBR, V22, P233, DOI 10.1007/BF00763167; GIERASCH LM, 1989, BIOCHEMISTRY-US, V28, P923, DOI 10.1021/bi00429a001; GILMORE R, 1993, CELL, V75, P589, DOI 10.1016/0092-8674(93)90476-7; HALL MN, 1983, EMBO J, V2, P15, DOI 10.1002/j.1460-2075.1983.tb01373.x; HARTMANN E, 1994, NATURE, V367, P654, DOI 10.1038/367654a0; Hopwood D.A., 1985, GENETIC MANIPULATION; HSU LM, 1984, J MOL BIOL, V178, P509, DOI 10.1016/0022-2836(84)90236-5; IBRAHIMI IM, 1986, EUR J BIOCHEM, V155, P571, DOI 10.1111/j.1432-1033.1986.tb09526.x; INOUYE M, 1980, CRC CR REV BIOCH MOL, V7, P339, DOI 10.3109/10409238009105465; INOUYE S, 1982, P NATL ACAD SCI-BIOL, V79, P3438, DOI 10.1073/pnas.79.11.3438; JONES JD, 1990, J BIOENERG BIOMEMBR, V22, P213, DOI 10.1007/BF00763166; JUNGNICKEL B, 1994, FEBS LETT, V346, P73, DOI 10.1016/0014-5793(94)00367-X; KATZ E, 1983, J GEN MICROBIOL, V129, P2703; KIM H, 1994, MOL MICROBIOL, V11, P819, DOI 10.1111/j.1365-2958.1994.tb00360.x; KOLLER KP, 1989, J BACTERIOL, V171, P4953, DOI 10.1128/jb.171.9.4953-4957.1989; KOLLER KP, 1984, 3RD P EUR C BIOT MUN, V3, P273; KRAMER W, 1984, NUCLEIC ACIDS RES, V12, P9441, DOI 10.1093/nar/12.24.9441; LEHNHARDT S, 1988, J BIOL CHEM, V263, P10300; LONG CM, 1987, J BACTERIOL, V169, P5745, DOI 10.1128/jb.169.12.5745-5754.1987; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUIRINK J, 1992, NATURE, V359, P741, DOI 10.1038/359741a0; LUIRINK J, 1994, EMBO J, V13, P2289, DOI 10.1002/j.1460-2075.1994.tb06511.x; MILLER JD, 1994, NATURE, V367, P657, DOI 10.1038/367657a0; NILSSON IM, 1990, CELL, V62, P1135, DOI 10.1016/0092-8674(90)90390-Z; NUNNARI J, 1992, Current Opinion in Cell Biology, V4, P573, DOI 10.1016/0955-0674(92)90074-M; OKUN MM, 1992, J BIOL CHEM, V267, P11476; PHOENIX DA, 1993, J BIOL CHEM, V268, P17069; PLOUG M, 1989, ANAL BIOCHEM, V181, P33, DOI 10.1016/0003-2697(89)90390-4; PUGSLEY AP, 1993, MICROBIOL REV, V57, P50, DOI 10.1128/MMBR.57.1.50-108.1993; PULIDO D, 1987, NUCLEIC ACIDS RES, V15, P4227, DOI 10.1093/nar/15.10.4227; PUZISS JW, 1992, J BACTERIOL, V174, P92, DOI 10.1128/jb.174.1.92-101.1992; RAPOPORT TA, 1992, SCIENCE, V258, P931, DOI 10.1126/science.1332192; RAPOPORT TA, 1991, NATURE, V349, P107, DOI 10.1038/349107a0; RIBES V, 1990, CELL, V63, P591, DOI 10.1016/0092-8674(90)90454-M; ROMISCH K, 1989, NATURE, V340, P478, DOI 10.1038/340478a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SCHLENSTEDT G, 1992, J BIOL CHEM, V267, P24328; SCHMITTJOHN T, 1992, APPL MICROBIOL BIOT, V36, P493; SIMONEN M, 1993, MICROBIOL REV, V57, P109, DOI 10.1128/MMBR.57.1.109-137.1993; TANJI Y, 1991, J BACTERIOL, V173, P1997, DOI 10.1128/jb.173.6.1997-2005.1991; VERTESY L, 1984, EUR J BIOCHEM, V141, P505, DOI 10.1111/j.1432-1033.1984.tb08221.x; VLASUK GP, 1983, J BIOL CHEM, V258, P7141; VONHEIJNE G, 1989, FEBS LETT, V244, P439, DOI 10.1016/0014-5793(89)80579-4; VONHEIJNE G, 1986, EMBO J, V5, P3021, DOI 10.1002/j.1460-2075.1986.tb04601.x; WOLIN SL, 1993, J CELL BIOL, V121, P1211, DOI 10.1083/jcb.121.6.1211; WRIGHT F, 1992, GENE, V113, P55, DOI 10.1016/0378-1119(92)90669-G; YAMAMOTO Y, 1987, BIOCHEM BIOPH RES CO, V149, P431, DOI 10.1016/0006-291X(87)90385-8	69	16	17	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15244	15252						9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662986				2022-12-27	WOS:A1996UT10600087
J	Hirschberg, K; Zisling, R; vanEchtenDeckert, G; Futerman, AH				Hirschberg, K; Zisling, R; vanEchtenDeckert, G; Futerman, AH			Ganglioside synthesis during the development of neuronal polarity - Major changes occur during axonogenesis and axon elongation, but not during dendrite growth or synaptogenesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CEREBELLAR GRANULE CELLS; HIPPOCAMPAL-NEURONS; BRAIN GANGLIOSIDES; RAT-LIVER; CULTURE; BIOSYNTHESIS; DIFFERENTIATION; NEURITOGENESIS; SPHINGOLIPIDS; LOCALIZATION	Changes in the levels and types of gangliosides occur during neuronal differentiation and development, but no studies have correlated these changes with defined events in neuronal morphogenesis. Here, we have analyzed the relationship between ganglioside synthesis and the development of axons and dendrites in polarized neurons, using hippocampal neurons cultured in such a way that axons and dendrites are generated by a defined sequence of events and in which there is virtu ally no contamination by glial cells, Neurons were la beled with [4,5-H-3]dihydrosphingosine, which was rapidly incorporated into cells and metabolized to H-3-labeled glycosphingolipids, The rate of H-3-labeled glycosphingolipid synthesis was directly proportional to the initial rate of [4,5-H-3]dihydrosphingosilae uptake and was linear versus time for up to 9 h of incubation, The major changes in H-3-labeled ganglioside synthesis occurred during the period of axonogenesis and rapid axon growth, During axonogenesis, there was a significant increase in the synthesis of complex gangliosides (i.e. G(m1), G(D1a), G(D1b), and G(T1b)) with a corresponding reduction in the synthesis of glucosylceramide and ganglioside G(D3). During the stage of rapid axon growth, the ratio of a- to b-series gangliosides increased significantly, However, during dendritogenesis, dendrite growth, and synaptogenesis, there was little change in ganglioside synthesis, with a small and gradual increase in the ratio of a- to b-series gangliosides and an increase in the synthesis of gangliosides G(D1a) and G(T1b). These results indicate that despite major changes in neuronal morphology and functionality as neurons mature, changes in ganglioside synthesis are restricted to early stages of neuronal development, namely axonogenesis and rapid axon elongation.	WEIZMANN INST SCI, DEPT MEMBRANE RES & BIOPHYS, IL-76100 REHOVOT, ISRAEL; UNIV BONN, INST ORGAN CHEM & BIOCHEM, D-53121 BONN, GERMANY	Weizmann Institute of Science; University of Bonn			Hirschberg, Koret/AAF-4566-2019	Futerman, Anthony/0000-0003-0013-0115				ARIGA T, 1995, BIOCHEMISTRY-US, V34, P11500, DOI 10.1021/bi00036a024; BANKER GA, 1977, BRAIN RES, V126, P397, DOI 10.1016/0006-8993(77)90594-7; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CACERES A, 1986, J NEUROSCI, V6, P714; CRAIG AM, 1994, ANNU REV NEUROSCI, V17, P267, DOI 10.1146/annurev.ne.17.030194.001411; DOTTI CG, 1988, J NEUROSCI, V8, P1454; DOTTI CG, 1991, J CELL SCI, P75; FLETCHER TL, 1991, J NEUROSCI, V11, P1617; FURUYA S, 1994, J BIOL CHEM, V269, P32418; FUTERMAN AH, 1994, CURR TOP MEMBR, V40, P93, DOI 10.1016/S0070-2161(08)60978-8; GOSLIN K, 1988, NATURE, V336, P672, DOI 10.1038/336672a0; Goslin K., 1991, CULTURING NERVE CELL, P251; HAREL R, 1993, J BIOL CHEM, V268, P14476; HIRSCHBERG K, 1993, BIOCHEM J, V290, P751, DOI 10.1042/bj2900751; LEDEEN RW, 1989, NEUROBIOLOGY GLYCOCO, P43; LEDEEN RW, 1992, TRENDS GLYCOSCI GLYC, V4, P174; MANDON EC, 1992, J BIOL CHEM, V267, P11144; MERRILL AH, 1992, METHOD ENZYMOL, V209, P427; OHSAWA T, 1989, MECH AGEING DEV, V50, P169, DOI 10.1016/0047-6374(89)90012-2; POHLENTZ G, 1988, P NATL ACAD SCI USA, V85, P7044, DOI 10.1073/pnas.85.19.7044; Radin N S, 1981, Methods Enzymol, V72, P673; RIBONI L, 1990, NEUROCHEM RES, V15, P1175, DOI 10.1007/BF01208577; RIBONI L, 1995, J BIOL CHEM, V270, P26868, DOI 10.1074/jbc.270.45.26868; ROSENBERG A, 1992, J BIOL CHEM, V267, P10607; ROSENBERG A, 1989, J NEUROSCI RES, V24, P531, DOI 10.1002/jnr.490240411; ROTHER J, 1992, BIOCHEM BIOPH RES CO, V189, P14, DOI 10.1016/0006-291X(92)91518-U; SCHWARZ A, 1995, J BIOL CHEM, V270, P10990, DOI 10.1074/jbc.270.18.10990; SCHWARZMANN G, 1987, METHOD ENZYMOL, V138, P319; SIEGEL DA, 1994, J NEUROCHEM, V62, P1852; SVENNERHOLM L, 1963, J NEUROCHEM, V10, P613, DOI 10.1111/j.1471-4159.1963.tb08933.x; SVENNERHOLM L, 1989, BIOCHIM BIOPHYS ACTA, V1005, P109, DOI 10.1016/0005-2760(89)90175-6; VALSECCHI M, 1993, J NEUROCHEM, V60, P193, DOI 10.1111/j.1471-4159.1993.tb05837.x; VANECHTEN G, 1993, J BIOL CHEM, V268, P5341; VANECHTEN G, 1989, J NEUROCHEM, V52, P207; VANECHTEN G, 1990, EUR J CELL BIOL, V51, P135; WANG E, 1991, J BIOL CHEM, V266, P14486; WILLIAMS MA, 1980, J NEUROCHEM, V35, P266, DOI 10.1111/j.1471-4159.1980.tb12515.x; Yu R.K., 1989, NEUROBIOLOGY GLYCOCO, P1; YU RK, 1988, J NEUROCHEM, V50, P1825, DOI 10.1111/j.1471-4159.1988.tb02484.x	39	68	69	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14876	14882		10.1074/jbc.271.25.14876	http://dx.doi.org/10.1074/jbc.271.25.14876			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663007				2022-12-27	WOS:A1996UT10600038
J	Kogure, K; Yamamoto, K; Majima, E; Shinohara, Y; Yamashita, K; Terada, H				Kogure, K; Yamamoto, K; Majima, E; Shinohara, Y; Yamashita, K; Terada, H			Alteration of enzyme function of the type II hexokinase C-terminal half on replacements of restricted regions by corresponding regions of glucokinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT-BRAIN HEXOKINASE; AMINO-ACID-SEQUENCE; CLONED CDNA; TUMOR-CELLS; GLUCOSE PHOSPHORYLATION; LIVER GLUCOKINASE; BOUND HEXOKINASE; SITE; BINDING; HALVES	To know the structural properties responsible for the enzymic activity of the 50-kDa C-terminal half of type II hexokinase (HKII-C) derived from rat hepatoma cell line AH130, we constructed cDNAs of HKII-C and its recombinants in which restricted regions containing highly conserved sequences, referred to as regions 2 and 3, were replaced by the corresponding regions of glucokinase. nase. The binding domains of ATP and glucose were proposed to exist in these regions, respectively, Then, the HKII-C and chimera HKII-Cs were overexpressed in Escherichia coli BL21(DE3)pLysS. They all exhibited hexokinase activity, and their activities were inhibited by glucose-8-phosphate (Glc-6-P) competitively for ATP and uncompetitively for glucose. The replacement of region 2 of HKII-C by the corresponding region of glucokinase increased the affinity for glucose and decreased the affinity for Glc-6-P, but it did not significantly affect the affinity for ATP. In contrast, the replacement of region 3 did not cause an appreciable change in hexokinase activity. These findings suggest that region 2 is associated with the binding of ATP and Glc-6-P, and that the latter binding site is located close to the ATP binding site. In addition, region 2 was suggested to be directly related with the binding of glucose and other hexoses.	UNIV TOKUSHIMA,FAC PHARMACEUT SCI,TOKUSHIMA 770,JAPAN	Tokushima University								ANDREONE TL, 1989, J BIOL CHEM, V264, P363; ARORA KK, 1990, J BIOL CHEM, V265, P6481; ARORA KK, 1993, J BIOL CHEM, V268, P18259; ARORA KK, 1988, J BIOL CHEM, V263, P17422; ARORA KK, 1991, J BIOL CHEM, V266, P5359; ARORA KK, 1993, ARCH BIOCHEM BIOPHYS, V304, P515, DOI 10.1006/abbi.1993.1384; BENNETT WS, 1980, J MOL BIOL, V140, P211, DOI 10.1016/0022-2836(80)90103-5; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BUSTAMANTE E, 1981, J BIOL CHEM, V256, P8699; BUSTAMANTE E, 1980, BIOCHEMISTRY-US, V19, P4972, DOI 10.1021/bi00563a006; EASTERBY JS, 1983, METHOD ENZYMOL, V90, P11; GREGORIOU M, 1983, EUR J BIOCHEM, V134, P283, DOI 10.1111/j.1432-1033.1983.tb07563.x; GROSSBARD L, 1966, J BIOL CHEM, V241, P3546; ICHIHARA J, 1995, BBA-GENE STRUCT EXPR, V1260, P365, DOI 10.1016/0167-4781(94)00226-S; KOGURE K, 1993, J BIOL CHEM, V268, P8422; LANGE AJ, 1991, BIOCHEM J, V277, P159, DOI 10.1042/bj2770159; MAGNANI M, 1992, BIOCHEM J, V285, P193, DOI 10.1042/bj2850193; MAJIMA E, 1993, J BIOL CHEM, V268, P22181; MATHUPALA SP, 1995, J BIOL CHEM, V270, P16918, DOI 10.1074/jbc.270.28.16918; NISHI S, 1988, BIOCHEM BIOPH RES CO, V157, P937, DOI 10.1016/S0006-291X(88)80964-1; POLAKIS PG, 1985, ARCH BIOCHEM BIOPHYS, V236, P328, DOI 10.1016/0003-9861(85)90633-2; PRELLER A, 1992, ARCH BIOCHEM BIOPHYS, V294, P482, DOI 10.1016/0003-9861(92)90715-9; PRINTZ RL, 1993, J BIOL CHEM, V268, P5209; REMPEL A, 1994, BIOCHEM J, V303, P269, DOI 10.1042/bj3030269; SCHWAB DA, 1989, P NATL ACAD SCI USA, V86, P2563, DOI 10.1073/pnas.86.8.2563; SCHWAB DA, 1991, ARCH BIOCHEM BIOPHYS, V285, P365, DOI 10.1016/0003-9861(91)90373-Q; SCHWAB DA, 1988, J BIOL CHEM, V263, P3220; SHINOHARA Y, 1991, FEBS LETT, V291, P55, DOI 10.1016/0014-5793(91)81102-E; SHINOHARA Y, 1994, CANCER LETT, V82, P27, DOI 10.1016/0304-3835(94)90142-2; SMITH AD, 1991, ARCH BIOCHEM BIOPHYS, V287, P359, DOI 10.1016/0003-9861(91)90490-A; STORER AC, 1976, BIOCHEM J, V159, P7, DOI 10.1042/bj1590007; THELEN AP, 1991, ARCH BIOCHEM BIOPHYS, V286, P645, DOI 10.1016/0003-9861(91)90094-Y; TSAI HJ, 1995, ARCH BIOCHEM BIOPHYS, V316, P206, DOI 10.1006/abbi.1995.1029; URETA T, 1982, COMP BIOCHEM PHYS B, V71, P549, DOI 10.1016/0305-0491(82)90461-8; WEINHOUSE S, 1972, CANCER RES, V32, P2007; WHITE TK, 1990, ARCH BIOCHEM BIOPHYS, V277, P26, DOI 10.1016/0003-9861(90)90545-A; WHITE TK, 1989, ARCH BIOCHEM BIOPHYS, V274, P375, DOI 10.1016/0003-9861(89)90451-7; WILSON JE, 1984, REGULATION CARBOHYDR, V1, P45; XIE GC, 1988, ARCH BIOCHEM BIOPHYS, V267, P803, DOI 10.1016/0003-9861(88)90090-2; [No title captured]	40	10	10	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15230	15236		10.1074/jbc.271.25.15230	http://dx.doi.org/10.1074/jbc.271.25.15230			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662949	hybrid			2022-12-27	WOS:A1996UT10600085
J	Pang, YP; Cusack, B; Groshan, K; Richelson, E				Pang, YP; Cusack, B; Groshan, K; Richelson, E			Proposed ligand binding site of the transmembrane receptor for neurotensin(8-13)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLASTOMA CLONE N1E-115; CYCLIC-GMP FORMATION; HUMAN-BRAIN; AROMATIC INTERACTIONS; ATOMIC-STRUCTURE; ANTAGONIST; PROTEIN; EXPRESSION; AFFINITY; ACETYLCHOLINESTERASE	We report here the first proposed ligand binding site of the transmembrane receptor for neurotensin (8-13) in human and rat, the corresponding bound conformation of the peptide ligand, and site directed mutagenesis studies that support the binding site model, These three-dimensional structures were generated by using a heuristic approach in conjunction with experimental data. The proposed neurotensin(8-13) binding site is primarily composed of eight residues (i.e., Phe(326), Ile(329), Trp(334), Phe(337), Tyr(339), Phe(341), Tyr(342), and Tyr(344) in the human receptor; Phe(331), Ile(334), Trp(339), Phe(342), Phe(344), Phe(346), Tyr(347), and Tyr(349) in the rat receptor) located in the third extracellular loop, The seven aromatic residues form an aromatic pocket on the extracellular surface of the neurotensin receptor to accommodate its ligands apparently by cation-pi, pi-pi, and hydrogen bonding interactions, The neurotensin(8-13) ligand adopts a compact conformation at the proposed binding site, In the bound conformation of neurotensin(8-13), the backbone of Arg(9)-Pro(10)-Tyr(11)-Ile(12) forms the proline type I turn, and the hydroxy group of Tyr(11) interacts with the two guanidinium groups of Arg(8) and Arg(9). These guanidinium groups are curled toward the hydroxy group so that they interact electrostatically with the hydroxy group, and that the guanidinium group of Arg(9) forms an intra-hydrogen bond with the hydroxy group. The proposed three-dimensional structure may not only provide a basis for rationalizing mutations of the neurotensin receptor gene but also offer insights into understanding the binding of many neurotensin analogs, biological functions of the neurotensin receptors, and structural elements for species specificity of the neurotensin receptors, and may expedite developing nonpeptidic neurotensin mimetics for the potential treatment of the neuropsychiatric diseases.			Pang, YP (corresponding author), MAYO FDN MED EDUC & RES,4500 SAN PABLO RD,JACKSONVILLE,FL 32224, USA.		Richelson, Elliott/A-9407-2012; Cusack, Bernadette/D-4606-2013	Pang, Yuan-Ping/0000-0003-0838-2560	NIMH NIH HHS [MH27692-18A2] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH027692] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		Botto J. M., 1995, Society for Neuroscience Abstracts, V21, P1013; BURLEY SK, 1985, SCIENCE, V229, P23, DOI 10.1126/science.3892686; BURLEY SK, 1986, FEBS LETT, V203, P139, DOI 10.1016/0014-5793(86)80730-X; CORNELL WD, 1995, J AM CHEM SOC, V117, P5179, DOI 10.1021/ja00124a002; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; Cusack B, 1996, J BIOL CHEM, V271, P15054, DOI 10.1074/jbc.271.25.15054; CUSACK B, 1993, MOL PHARMACOL, V44, P1036; CUSACK B, 1993, J RECEPTOR RES, V13, P123, DOI 10.3109/10799899309073650; CUSACK B, 1995, J BIOL CHEM, V270, P18359, DOI 10.1074/jbc.270.31.18359; DEAKYNE CA, 1985, J AM CHEM SOC, V107, P474; DELEAN A, 1982, MOL PHARMACOL, V21, P5; ENGELMAN DM, 1986, ANNU REV BIOPHYS BIO, V15, P321, DOI 10.1146/annurev.bb.15.060186.001541; FONG TM, 1992, J BIOL CHEM, V267, P25664; GARCIALOPEZ MT, 1992, PEPTIDES, P623; *GEN COMP GROUP IC, 1992, GCG VERS 7 2 GEN COM; GILBERT JA, 1989, BIOCHEM PHARMACOL, V38, P3377, DOI 10.1016/0006-2952(89)90637-0; GILBERT JA, 1986, BIOCHEM PHARMACOL, V35, P391, DOI 10.1016/0006-2952(86)90210-8; GRAHAM FL, 1973, VIROLOGY, V54, P536, DOI 10.1016/0042-6822(73)90163-3; GULLY D, 1993, P NATL ACAD SCI USA, V90, P65, DOI 10.1073/pnas.90.1.65; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; HENDERSON R, 1990, BIOCHEM SOC T, V18, P844, DOI 10.1042/bst0180844; HUANG ZW, 1994, P NATL ACAD SCI USA, V91, P7139, DOI 10.1073/pnas.91.15.7139; HUNTER CA, 1990, J AM CHEM SOC, V112, P5525, DOI 10.1021/ja00170a016; Johnson S., 1995, Society for Neuroscience Abstracts, V21, P1597; KANBA KS, 1986, J NEUROCHEM, V46, P946, DOI 10.1111/j.1471-4159.1986.tb13061.x; KANBA KS, 1988, J NEUROCHEM, V50, P131, DOI 10.1111/j.1471-4159.1988.tb13239.x; KITABGI P, 1989, NEUROCHEM INT, V14, P111, DOI 10.1016/0197-0186(89)90110-1; KOZIKOWSKI AP, 1995, J CHEM SOC PERK T 1, P1615, DOI 10.1039/p19950001615; KYLE DJ, 1994, J MED CHEM, V37, P1347, DOI 10.1021/jm00035a015; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LABBEJULLIE C, 1995, MOL PHARMACOL, V47, P1050; LAZARUS LH, 1977, J BIOL CHEM, V252, P7180; LOWRY OH, 1951, J BIOL CHEM, V193, P265; *MOL SIM INC, 1994, QUANTA MOL SI INC; MORBECK DE, 1993, METHODS COMPANION ME, V6, P191; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NORDVALL G, 1993, J MED CHEM, V36, P967, DOI 10.1021/jm00060a003; PANG YP, 1994, J COMPUT AID MOL DES, V8, P433, DOI 10.1007/BF00125377; PANG YP, 1994, J COMPUT AID MOL DES, V8, P669, DOI 10.1007/BF00124014; PEARLMAN DA, 1995, COMPUT PHYS COMMUN, V91, P1, DOI 10.1016/0010-4655(95)00041-D; PFENNING MA, 1990, METHODS NEUROTRANSMI, P147; PONDER JW, 1987, J MOL BIOL, V193, P775, DOI 10.1016/0022-2836(87)90358-5; SEFLER AM, 1995, J MED CHEM, V38, P249, DOI 10.1021/jm00002a006; SNIDER RM, 1992, BIOORG MED CHEM LETT, V2, P1535, DOI 10.1016/S0960-894X(00)80423-0; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TRUMPPKALLMEYER S, 1992, J MED CHEM, V35, P3448, DOI 10.1021/jm00097a002; VANDUYNE GD, 1991, SCIENCE, V252, P839, DOI 10.1126/science.1709302; VERDONK ML, 1993, J COMPUT AID MOL DES, V7, P173, DOI 10.1007/BF00126443; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WAKSMAN G, 1993, CELL, V72, P779, DOI 10.1016/0092-8674(93)90405-F; WATSON M, 1993, MAYO CLIN PROC, V68, P1043, DOI 10.1016/S0025-6196(12)60896-9; YAMADA M, 1994, MOL PHARMACOL, V46, P470	53	67	71	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15060	15068		10.1074/jbc.271.25.15060	http://dx.doi.org/10.1074/jbc.271.25.15060			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663052	hybrid			2022-12-27	WOS:A1996UT10600063
J	Reddy, LG; Jones, LR; Pace, RC; Stokes, DL				Reddy, LG; Jones, LR; Pace, RC; Stokes, DL			Purified, reconstituted cardiac Ca2+-ATPase is regulated by phospholamban but not by direct phosphorylation with Ca2+/calmodulin-dependent protein kinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SARCOPLASMIC-RETICULUM CA2+-ATPASE; BETA-ADRENERGIC STIMULATION; CALCIUM-TRANSPORT; CA-2+ PUMP; DEPENDENT PHOSPHORYLATION; CA2+ UPTAKE; ATPASE; PURIFICATION; MUSCLE; MECHANISM	Regulation of calcium transport by sarcoplasmic reticulum provides increased cardiac contractility in response to beta-adrenergic stimulation. This is due to phosphorylation of phospholamban by cAMP-dependent protein kinase or by calcium/calmodulin-dependent protein kinase, which activates the calcium pump (Ca2+-ATPase), Recently, direct phosphorylation of Ca2+-ATPase by calcium/calmodulin-dependent protein kinase has been proposed to provide additional regulation. To investigate these effects in detail, we have purified Ca2+-ATPase from cardiac sarcoplasmic reticulum using affinity chromatography and reconstituted it with purified, recombinant phospholamban, The resulting proteoliposomes had high rates of calcium transport, which was tightly coupled to ATP hydrolysis (similar to 1.7 calcium ions transported per ATP molecule hydro lyzed). Co-reconstitution with phospholamban suppressed both calcium uptake and ATPase activities by similar to 50%, and this suppression was fully relieved by a phospholamban monoclonal antibody or by phosphorylation either with cAMP-dependent protein kinase or with calcium/calmodulin-dependent protein kinase, These effects were consistent with a change in the apparent calcium affinity of Ca2+-ATPase and not with a change in V-max. Neither the purified, reconstituted cardiac Ca2+-ATPase nor the Ca2+-ATPase in longitudinal cardiac sarcoplasmic reticulum vesicles was a substrate for calcium/calmodulin-dependent protein kinase, and accordingly, we found no effect of calcium/calmodulin-dependent protein kinase phosphorylation on V-max for calcium transport.	INDIANA UNIV,SCH MED,KRANNERT INST CARDIOL,DEPT MED,INDIANAPOLIS,IN 46202; UNIV MINNESOTA,DEPT BIOCHEM,MINNEAPOLIS,MN 55455; NYU,MED CTR,SKIRBALL INST BIOMOL MED,NEW YORK,NY 10016	Indiana University System; Indiana University-Purdue University Indianapolis; University of Minnesota System; University of Minnesota Twin Cities; New York University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL048807, R01HL028556] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48807, HL28556, HL06308] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ADAMS PD, 1995, NAT STRUCT BIOL, V2, P154, DOI 10.1038/nsb0295-154; ALSHAWI MK, 1993, J BIOL CHEM, V268, P4197; ANDERSEN JP, 1989, BIOCHIM BIOPHYS ACTA, V988, P47, DOI 10.1016/0304-4157(89)90003-8; ARKIN IT, 1994, EMBO J, V13, P4757, DOI 10.1002/j.1460-2075.1994.tb06801.x; BIDLACK JM, 1982, J BIOL CHEM, V257, P4501; BRIGGS FN, 1992, J BIOL CHEM, V267, P26056; CANTILINA T, 1993, J BIOL CHEM, V268, P17018; CHAMBERLAIN BK, 1983, J BIOL CHEM, V258, P6602; COLYER J, 1993, CARDIOVASC RES, V27, P1766, DOI 10.1093/cvr/27.10.1766; EDES I, 1989, MEMBRANE BIOCHEM, V7, P175; FABIATO A, 1979, J PHYSIOL-PARIS, V75, P463; FUJII J, 1990, FEBS LETT, V273, P232, DOI 10.1016/0014-5793(90)81092-3; HAWKINS C, 1994, J BIOL CHEM, V269, P31198; HIDALGO C, 1978, J BIOL CHEM, V253, P6879; HUGHES G, 1994, BIOCHEM J, V303, P511, DOI 10.1042/bj3030511; INUI M, 1986, J BIOL CHEM, V261, P1794; JAKAB G, 1988, BIOCHEMISTRY-US, V27, P3799, DOI 10.1021/bi00410a042; JAMES P, 1989, NATURE, V342, P90, DOI 10.1038/342090a0; JONES LR, 1977, J BIOL CHEM, V252, P3315; JONES LR, 1981, BIOCHIM BIOPHYS ACTA, V641, P242, DOI 10.1016/0005-2736(81)90588-5; JONES LR, 1981, J BIOL CHEM, V256, P1809; KIM HW, 1990, J BIOL CHEM, V265, P1702; KIRCHBERGER MA, 1982, J BIOL CHEM, V257, P5685; KIRCHBERGER MA, 1986, BIOCHEMISTRY-US, V25, P5484, DOI 10.1021/bi00367a021; KOVACS RJ, 1988, J BIOL CHEM, V263, P18364; LEPEUCH CJ, 1979, BIOCHEMISTRY-US, V18, P5150, DOI 10.1021/bi00590a019; LEVITSKY DO, 1976, BIOCHIM BIOPHYS ACTA, V443, P468, DOI 10.1016/0005-2787(76)90510-4; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LINDEMANN JP, 1983, J BIOL CHEM, V258, P464; LUO WS, 1994, CIRC RES, V75, P401, DOI 10.1161/01.RES.75.3.401; MARTONOSI A, 1964, J BIOL CHEM, V239, P648; MOLLER JV, 1980, J BIOL CHEM, V255, P1912; MORRIS GL, 1991, J BIOL CHEM, V266, P11270; NAKAMURA J, 1983, J BIOL CHEM, V258, P5079; PLANK B, 1983, BIOCHIM BIOPHYS ACTA, V732, P99, DOI 10.1016/0005-2736(83)90191-8; PORZIO MA, 1977, BIOCHIM BIOPHYS ACTA, V490, P27, DOI 10.1016/0005-2795(77)90102-7; REDDY LG, 1995, J BIOL CHEM, V270, P9390, DOI 10.1074/jbc.270.16.9390; SASAKI T, 1992, J BIOL CHEM, V267, P1674; SHAM JSK, 1991, AM J PHYSIOL, V261, pH1344, DOI 10.1152/ajpheart.1991.261.4.H1344; Simmerman HKB, 1996, J BIOL CHEM, V271, P5941, DOI 10.1074/jbc.271.10.5941; SIMMERMAN HKB, 1986, J BIOL CHEM, V261, P3333; STOKES DL, 1990, BIOPHYS J, V57, P1, DOI 10.1016/S0006-3495(90)82501-7; SZYMANSKA G, 1990, MEMBRANE BIOCHEM, V9, P1; TADA M, 1983, J MOL CELL CARDIOL, V15, P335, DOI 10.1016/0022-2828(83)91345-7; TADA M, 1989, BIOESSAYS, V10, P157, DOI 10.1002/bies.950100505; TATULIAN SA, 1995, BIOCHEMISTRY-US, V34, P4448, DOI 10.1021/bi00013a038; TOYOFUKU T, 1994, J BIOL CHEM, V269, P3088; TOYOFUKU T, 1994, J BIOL CHEM, V269, P26492; TOYOFUKU T, 1993, J BIOL CHEM, V268, P2809; VANVELDHOVEN PP, 1987, ANAL BIOCHEM, V161, P45, DOI 10.1016/0003-2697(87)90649-X; VANWINKLE WB, 1978, J BIOL CHEM, V253, P8671; VOSS J, 1994, BIOPHYS J, V67, P190, DOI 10.1016/S0006-3495(94)80469-2; WARREN GB, 1974, P NATL ACAD SCI USA, V71, P622, DOI 10.1073/pnas.71.3.622; WEGENER AD, 1984, J BIOL CHEM, V259, P1834; WEGENER AD, 1989, J BIOL CHEM, V264, P11468; WITCHER DR, 1991, J BIOL CHEM, V266, P11144; YAO Q, 1993, BIOPHYS J, V64, pA305	57	91	93	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14964	14970		10.1074/jbc.271.25.14964	http://dx.doi.org/10.1074/jbc.271.25.14964			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663079	hybrid			2022-12-27	WOS:A1996UT10600051
J	White, SL; Low, RB				White, SL; Low, RB			Identification of promoter elements involved in cell-specific regulation of rat smooth muscle myosin heavy chain gene transcription	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-FOS; VASCULAR DEVELOPMENT; ISOFORM DIVERSITY; SKELETAL-MUSCLES; SILENCER ELEMENT; BINDING FACTOR; CDNA CLONING; ACTIN; EXPRESSION; PROTEIN	In order to identify cis-acting regulatory elements involved in smooth muscle cell-specific gene regulation, we have cloned a 4.7-kilobase pair fragment of the pro meter for the rat smooth muscle myosin heavy chain, a protein expressed in differentiated smooth muscle cells, Sequence analysis of a 1.7-kilobase pair portion of this clone reveals potential binding sites for known transcription factors, A comparison of the primary sequence between the rat and rabbit smooth muscle myosin heavy chain promoters reveals numerous conserved consensus binding sites. Transient transfection analysis of promoter deletion constructs in rat aorta and tracheal smooth muscle cells, L8 myoblast cells, and rat pulmonary aorta endothelial cells suggests that a region of the promoter located between -1,249 and -1,317 base pairs is important for the restriction of gene expression to smooth muscle cells. Electrophoretic mobility shift analysis of a highly conserved region located between -1,317 and -1,085 base pairs reveals specific DNA-protein complexes formed in smooth muscle cell extracts, which can be competed with an oligonucleotide containing a nuclear factor 1 binding site.			White, SL (corresponding author), UNIV VERMONT,DEPT PHYSIOL & MOLEC BIOPHYS,GIVEN MED BLDG,RM E201,BURLINGTON,VT 05405, USA.							AIKAWA M, 1993, CIRC RES, V73, P1000, DOI 10.1161/01.RES.73.6.1000; BABIJ P, 1989, J MOL BIOL, V210, P673, DOI 10.1016/0022-2836(89)90142-3; BABIJ P, 1992, AM J PHYSIOL, V262, pC607, DOI 10.1152/ajpcell.1992.262.3.C607; BABIJ P, 1993, AM J PHYSIOL, V265, pL127, DOI 10.1152/ajplung.1993.265.2.L127; BABIJ P, 1991, P NATL ACAD SCI USA, V88, P10676, DOI 10.1073/pnas.88.23.10676; BABIJ P, 1993, NUCLEIC ACIDS RES, V21, P1467, DOI 10.1093/nar/21.6.1467; BARANY M, 1967, J GEN PHYSIOL, V50, P197, DOI 10.1085/jgp.50.6.197; BLACKWELL TK, 1990, SCIENCE, V250, P1104, DOI 10.1126/science.2174572; BLANK RS, 1992, J BIOL CHEM, V267, P984; BOCHATONPIALLAT ML, 1992, DIFFERENTIATION, V49, P175, DOI 10.1111/j.1432-0436.1992.tb00665.x; BOXER LM, 1989, MOL CELL BIOL, V9, P515, DOI 10.1128/MCB.9.2.515; BREATHNACH R, 1981, ANNU REV BIOCHEM, V50, P349, DOI 10.1146/annurev.bi.50.070181.002025; CHAMLEY JH, 1974, EXP CELL RES, V84, P105, DOI 10.1016/0014-4827(74)90385-1; CHAMLEYCAMPBELL J, 1979, PHYSIOL REV, V59, P1, DOI 10.1152/physrev.1979.59.1.1; DARBY I, 1990, LAB INVEST, V63, P21; FAISST S, 1992, NUCLEIC ACIDS RES, V20, P3, DOI 10.1093/nar/20.1.3; GOSSETT LA, 1989, MOL CELL BIOL, V9, P5022, DOI 10.1128/MCB.9.11.5022; GUERIN SL, 1993, EUR J BIOCHEM, V213, P399, DOI 10.1111/j.1432-1033.1993.tb17774.x; JONES KA, 1987, CELL, V48, P79, DOI 10.1016/0092-8674(87)90358-8; KALLMEIR R, 1985, J BIOL CHEM, V270, P30949; KATOH Y, 1994, J BIOL CHEM, V269, P30538; KELLEY CA, 1993, J BIOL CHEM, V268, P12848; KOCHER O, 1991, LAB INVEST, V65, P459; KUROO M, 1991, J BIOL CHEM, V266, P3768; LADIAS JAA, 1992, J BIOL CHEM, V267, P15849; LILLY B, 1995, SCIENCE, V267, P688, DOI 10.1126/science.7839146; MCQUINN T, 1995, VASCULAR SMOOTH MUSC, P226; MIANO JM, 1994, CIRC RES, V75, P803, DOI 10.1161/01.RES.75.5.803; MIN BH, 1990, J BIOL CHEM, V265, P16667; NAGAI R, 1989, J BIOL CHEM, V264, P9734; OWENS GK, 1995, PHYSIOL REV, V75, P487; REIDY MA, 1992, ARCH PATHOL LAB MED, V116, P1276; ROVNER AS, 1986, J BIOL CHEM, V261, P4740; ROY RJ, 1992, NUCLEIC ACIDS RES, V20, P401, DOI 10.1093/nar/20.3.401; RUZICKA D, 1988, J CELL BIOL, V107, P2525; RYAN US, 1978, TISSUE CELL, V10, P535, DOI 10.1016/S0040-8166(16)30347-0; RYAN US, 1986, J TISSUE CULTURE MET, V10, P3; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHWARTZ SM, 1986, CIRC RES, V58, P427, DOI 10.1161/01.RES.58.4.427; SHIMIZU RT, 1995, J BIOL CHEM, V270, P7631, DOI 10.1074/jbc.270.13.7631; SWYNGHEDAUW B, 1986, PHYSIOL REV, V66, P710, DOI 10.1152/physrev.1986.66.3.710; THYBERG J, 1990, ARTERIOSCLEROSIS, V10, P966, DOI 10.1161/01.ATV.10.6.966; TREISMAN R, 1986, CELL, V46, P567, DOI 10.1016/0092-8674(86)90882-2; WALSH K, 1989, MOL CELL BIOL, V9, P2191, DOI 10.1128/MCB.9.5.2191; WHITE S, 1993, AM J PHYSIOL, V264, pC1252, DOI 10.1152/ajpcell.1993.264.5.C1252; WOODCOCKMITCHELL J, 1988, DIFFERENTIATION, V39, P161, DOI 10.1111/j.1432-0436.1988.tb00091.x	46	47	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15008	15017		10.1074/jbc.271.25.15008	http://dx.doi.org/10.1074/jbc.271.25.15008			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663099	hybrid			2022-12-27	WOS:A1996UT10600057
J	Moore, AN; Waxham, MN; Dash, PK				Moore, AN; Waxham, MN; Dash, PK			Neuronal activity increases the phosphorylation of the transcription factor cAMP response element-binding protein (CREB) in rat hippocampus and cortex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IMMEDIATE EARLY GENES; NUCLEAR FACTOR CREB; C-FOS; CYCLIC-AMP; RECEPTOR ACTIVATION; SYNAPTIC PLASTICITY; INDUCED SEIZURES; MESSENGER-RNA; SPINAL-CORD; KINASE-II	Activity-mediated gene expression is thought to play an important role in many forms of neuronal plasticities. We have used pentylenetetrazol-induced seizure that produces synchronous and sustained neuronal activity as a model to examine the mechanism(s) of gene activation. The transcription factor CREB (Ca2+/cAMP response element-binding protein) is thought to be necessary for long-term memory formation both in invertebrates and vertebrates. When phosphorylated on Ser(133) either by cAMP-dependent protein kinase and/or Ca2+/calmodulin-dependent protein kinases, CREB increases transcription of genes containing the CRE (cAMP response element) sequence. Using an antibody that detects Ser(133)-phosphorylated CREB protein, we show that CREB phosphorylation is maximal between 3 and 8 min after the onset of seizure activity and declines slowly both in the hippocampus and the cortex. The total amount of CREB protein did not change at the time points examined. The increased phosphorylation of CREB protein is preceded by an increase in the amount of cAMP, suggestive of cAMP-dependent protein kinase activation, in the hippocampus and activation of Ca2+/calmodulin-dependent protein kinases in the cortex. Subsequent to CREE phosphorylation, the expression of the CRE-containing gene, c-fos, and the AP-1 complexes (heterodimers of Fos and Jun family members) is increased. These findings support the role of CREB-mediated gene expression in activity-dependent neuronal plasticities.	UNIV TEXAS,HLTH SCI CTR,DEPT NEUROBIOL & ANAT,HOUSTON,TX 77225	University of Texas System; University of Texas Health Science Center Houston				Waxham, M. Neal/0000-0003-4801-1190	NIMH NIH HHS [MH49962] Funding Source: Medline; NINDS NIH HHS [NS01509] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [K04NS001509] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADAMS SR, 1991, NATURE, V349, P694, DOI 10.1038/349694a0; ALBERINI CM, 1994, CELL, V76, P1099, DOI 10.1016/0092-8674(94)90386-7; ANKARCRONA M, 1995, NEURON, V15, P961, DOI 10.1016/0896-6273(95)90186-8; ANOKHIN KV, 1991, BRAIN RES, V544, P101, DOI 10.1016/0006-8993(91)90890-8; ARONOWSKI J, 1992, J NEUROCHEM, V58, P1743, DOI 10.1111/j.1471-4159.1992.tb10049.x; BACSKAI BJ, 1995, NEURON, V14, P19, DOI 10.1016/0896-6273(95)90237-6; BEAR MF, 1990, J NEUROSCI, V10, P909; BENARI Y, 1990, TRENDS NEUROSCI, V13, P312, DOI 10.1016/0166-2236(90)90135-W; BOURTCHULADZE R, 1994, CELL, V79, P59, DOI 10.1016/0092-8674(94)90400-6; BROWNING RA, 1990, EPILEPSY RES, V6, P1, DOI 10.1016/0920-1211(90)90002-D; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CHETKOVICH DM, 1991, P NATL ACAD SCI USA, V88, P6467, DOI 10.1073/pnas.88.15.6467; CHRIVIA JC, 1993, NATURE, V365, P855, DOI 10.1038/365855a0; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLE AJ, 1989, NATURE, V340, P474, DOI 10.1038/340474a0; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; COTMAN CW, 1984, SCIENCE, V225, P1287, DOI 10.1126/science.6382610; CURRAN T, 1987, ONCOGENE, V2, P79; DASH PK, 1995, J NEUROSCI, V15, P2030, DOI 10.1523/JNEUROSCI.15-03-02030.1995; DASH PK, 1990, NATURE, V345, P718, DOI 10.1038/345718a0; DASH PK, 1991, P NATL ACAD SCI USA, V88, P5061, DOI 10.1073/pnas.88.11.5061; DASH PK, 1993, CELL MOL BIOL, V39, P35; DEUTSCH PJ, 1988, J BIOL CHEM, V263, P18466; DICHTER MA, 1987, SCIENCE, V237, P157, DOI 10.1126/science.3037700; DRAGUNOW M, 1987, NATURE, V329, P441, DOI 10.1038/329441a0; ENSLEN H, 1994, J BIOL CHEM, V269, P15520; FIELDS RD, 1991, J NEUROSCI, V11, P134; GHOSH A, 1995, SCIENCE, V268, P239, DOI 10.1126/science.7716515; GINTY DD, 1993, SCIENCE, V260, P238, DOI 10.1126/science.8097062; GOELET P, 1986, NATURE, V322, P419, DOI 10.1038/322419a0; GONZALEZ GA, 1989, NATURE, V337, P749, DOI 10.1038/337749a0; GREENOUGH WT, 1988, TRENDS NEUROSCI, V11, P142, DOI 10.1016/0166-2236(88)90139-7; HAGIWARA M, 1992, CELL, V70, P105, DOI 10.1016/0092-8674(92)90537-M; HANSON PI, 1992, ANNU REV BIOCHEM, V61, P559, DOI 10.1146/annurev.bi.61.070192.003015; HANSON PI, 1992, J BIOL CHEM, V267, P17216; Harlow E., 1988, ANTIBODIES LAB MANUA; HASHIMOTO Y, 1987, J BIOL CHEM, V262, P8051; HERDEGEN T, 1993, J COMP NEUROL, V333, P271, DOI 10.1002/cne.903330212; HOFFLER JP, 1988, SCIENCE, V242, P1430; HUNT SP, 1987, NATURE, V328, P632, DOI 10.1038/328632a0; HYMAN SE, 1988, MOL CELL BIOL, V8, P4225, DOI 10.1128/MCB.8.10.4225; KEELY SL, 1975, J BIOL CHEM, V250, P4832; KIM KS, 1993, J BIOL CHEM, V268, P15689; KOLB SJ, 1995, J NEUROCHEM, V64, P2147; KONRADI C, 1994, J NEUROSCI, V14, P5623; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LUNDBLAD JR, 1995, NATURE, V374, P85, DOI 10.1038/374085a0; MATHEWS RP, 1994, MOL CELL BIOL, V14, P6107; MCNAUGHTON BL, 1983, NEUROBIOLOGY HIPPOCA, P233; MELLO CV, 1992, P NATL ACAD SCI USA, V89, P6818, DOI 10.1073/pnas.89.15.6818; MEYER T, 1992, SCIENCE, V256, P1199, DOI 10.1126/science.256.5060.1199; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MOLLOY SS, 1991, P NATL ACAD SCI USA, V88, P4756, DOI 10.1073/pnas.88.11.4756; MONTMINY MR, 1986, P NATL ACAD SCI USA, V83, P6682, DOI 10.1073/pnas.83.18.6682; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; MURPHY TH, 1991, NEURON, V7, P625, DOI 10.1016/0896-6273(91)90375-A; OCORR KA, 1991, NEURON, V6, P907, DOI 10.1016/0896-6273(91)90231-N; QIAN Z, 1993, NATURE, V361, P453, DOI 10.1038/361453a0; ROSE SPR, 1991, TRENDS NEUROSCI, V14, P390, DOI 10.1016/0166-2236(91)90027-R; SAGAR SM, 1988, SCIENCE, V240, P1328, DOI 10.1126/science.3131879; SANNA E, 1995, MOL PHARMACOL, V47, P213; SHENG M, 1991, SCIENCE, V252, P1427, DOI 10.1126/science.1646483; SHENG M, 1990, NEURON, V4, P477, DOI 10.1016/0896-6273(90)90106-P; SONNENBERG JL, 1989, NEURON, V4, P477; SUN PQ, 1994, GENE DEV, V8, P2527, DOI 10.1101/gad.8.21.2527; TOKUMITSU H, 1994, J BIOL CHEM, V269, P28640; WAXHAM MN, 1989, J BIOL CHEM, V264, P7477; White J D, 1987, Brain Res, V427, P21; WISDEN W, 1990, NEURON, V4, P603, DOI 10.1016/0896-6273(90)90118-Y; XIA ZG, 1991, NEURON, V6, P431, DOI 10.1016/0896-6273(91)90251-T; YAMAMOTO KK, 1988, NATURE, V334, P494, DOI 10.1038/334494a0; YIN JCP, 1995, CELL, V81, P107, DOI 10.1016/0092-8674(95)90375-5; YIN JCP, 1994, CELL, V79, P49, DOI 10.1016/0092-8674(94)90399-9	73	125	126	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14214	14220		10.1074/jbc.271.24.14214	http://dx.doi.org/10.1074/jbc.271.24.14214			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662977	hybrid			2022-12-27	WOS:A1996UQ66000043
J	Obin, MS; JahngenHodge, J; Nowell, T; Taylor, A				Obin, MS; JahngenHodge, J; Nowell, T; Taylor, A			Ubiquitinylation and ubiquitin-dependent proteolysis in vertebrate photoreceptors (rod outer segments) - Evidence for ubiquitinylation of G(t) and rhodopsin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBOXYL-TERMINAL HYDROLASE; RETINITIS-PIGMENTOSA; PROTEIN BREAKDOWN; SYSTEM; PURIFICATION; DEGRADATION; RESOLUTION; PATHWAY; CHAINS; PHOTOTRANSDUCTION	In corroboration of the hypothesized regulation of phototransduction proteins by the ubiquitin-dependent pathway, we identified free ubiquitin (8 kDa) and ubiquitin-protein conjugates (50 to >200 kDa; pi 5.3-6.8 by two-dimensional electrophoresis) in bovine rod outer segments (ROS). A 38-kDa ubiquitinylated protein and transducin (G(t)) were eluted together from light-adapted ROS membranes with GTP. When ROS were dark-adapted, this 38-kDa ubiquitinylated species and G, were readily solubilized in buffer lacking GTP, These data are consistent with ubiquitinylation of G(t) and corroborate previous cell-free experiments identifying G(t) as a substrate for ubiquitin-dependent proteolysis (Obin, M. S,, Nowell, T,, and Taylor, A. (1994) Biochem. Biophys. Res, Commun. 200, 1169-1176). Evidence for ubiquitinylation of rhodopsin (36 kDa), the (photo)receptor coupled to G(t), included (i) the presence in ROS membranes ''stripped'' of peripheral membrane proteins of numerous ubiquitin-protein conjugates, including two whose masses (44 and 50 kDa) are consistent with mono- and diubiquitinylated rhodopsin; (ii) catalysis by permeabilized ROS of I-125-labeled ubiquitin-protein conjugates whose masses (42, 50, and 58 kDa) suggest a ''ladder'' of mono-, di-, and triubiquitinylated rhodopsin; (iii) parallel mobility shifts on SDS-polyacrylamide gels of rhodopsin and these I-125-labeled ubiquitin-protein conjugates; and (iv) generation of enhanced levels of I-125-labeled ubiquitin-protein conjugates when stripped, detergent-solubilized ROS membranes (95% rhodopsin) were incubated with reticulocyte lysate. A functional ubiquitin-dependent pathway in ROS is demonstrated by the presence of (i) the ubiquitin-activating enzyme (El); (ii) four ubiquitin carrier proteins (E2(14K), E2(20K), E2(25K), and E2(35K)) and pronounced activity of E2(14K), an enzyme required for ''N-end rule'' proteolysis; (iii) ATP-dependent 26 S proteasome activity that rapidly degrades high mass I-125-labeled ubiquitin-ROS protein conjugates; and (iv) distinct ubiquitin C-terminal isopeptidase/hydrolase activities, including potent ubiquitin-aldehyde-insensitive activity directed at high mass ubiquitinylated moieties, Considered together, the data support a novel role for the ubiquitin-dependent pathway in the regulation of mammalian phototransduction protein levels and/or activities and provide the first identification of a non-calpain proteolytic system in photoreceptors.	TUFTS UNIV, USDA, JMHNRCA, LAB NUTR & VIS RES, BOSTON, MA 02111 USA	Tufts University; United States Department of Agriculture (USDA)					PHS HHS [8566] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		AZARIAN SM, 1995, J BIOL CHEM, V270, P24375, DOI 10.1074/jbc.270.41.24375; BIZZI A, 1991, BRAIN RES, V548, P292, DOI 10.1016/0006-8993(91)91135-N; Bok D., 1979, RETINAL PIGMENT EPIT, P148; BONFANTI L, 1992, J COMP NEUROL, V322, P35, DOI 10.1002/cne.903220104; CHABRE M, 1989, EUR J BIOCHEM, V179, P255, DOI 10.1111/j.1432-1033.1989.tb14549.x; CHEN ZJ, 1990, J BIOL CHEM, V265, P21835; CIECHANOVER A, 1978, BIOCHEM BIOPH RES CO, V81, P1100, DOI 10.1016/0006-291X(78)91249-4; CIECHANOVER A, 1994, FASEB J, V8, P182, DOI 10.1096/fasebj.8.2.8119489; DRYJA TP, 1991, P NATL ACAD SCI USA, V88, P9370, DOI 10.1073/pnas.88.20.9370; DUBIEL W, 1993, FEBS LETT, V323, P276, DOI 10.1016/0014-5793(93)81356-5; DUNTEN RL, 1989, J BIOL CHEM, V264, P16739; FAIN GL, 1993, EXP EYE RES, V57, P335, DOI 10.1006/exer.1993.1132; FARBER DB, 1988, EXP EYE RES, V46, P363, DOI 10.1016/S0014-4835(88)80026-5; FEENEY L, 1973, INVEST OPHTH VISUAL, V12, P635; FINLEY D, 1991, ANNU REV CELL BIOL, V7, P25, DOI 10.1146/annurev.cb.07.110191.000325; GONDA DK, 1989, J BIOL CHEM, V264, P16700; HAAS AL, 1995, J BIOL CHEM, V270, P9407, DOI 10.1074/jbc.270.16.9407; HAAS AL, 1988, J BIOL CHEM, V263, P13258; HAAS AL, 1988, UBIQUITIN, P173; HADARI T, 1992, J BIOL CHEM, V267, P719; HALDEMAN MT, 1995, J BIOL CHEM, V270, P9507, DOI 10.1074/jbc.270.16.9507; HARA S, 1983, EXP EYE RES, V36, P799, DOI 10.1016/0014-4835(83)90034-9; HARGRAVE PA, 1992, FASEB J, V6, P2323, DOI 10.1096/fasebj.6.6.1544542; HARGRAVE PA, 1994, REGULATION CELLULAR, P25; HERSHKO A, 1980, P NATL ACAD SCI-BIOL, V77, P1783, DOI 10.1073/pnas.77.4.1783; HERSHKO A, 1983, J BIOL CHEM, V258, P8206; HERSHKO A, 1987, P NATL ACAD SCI USA, V84, P1829, DOI 10.1073/pnas.84.7.1829; HERSHKO A, 1992, ANNU REV BIOCHEM, V61, P761, DOI 10.1146/annurev.bi.61.070192.003553; HOU D, 1994, J BIOL CHEM, V269, P14244; HOUGH R, 1986, J BIOL CHEM, V261, P2391; HUANG HV, 1973, FEBS LETT, V37, P285, DOI 10.1016/0014-5793(73)80479-X; HUANG LL, 1995, EXP EYE RES, V61, P45, DOI 10.1016/S0014-4835(95)80057-3; JOHNSTON NL, 1991, BIOCHEMISTRY-US, V30, P7514, DOI 10.1021/bi00244a021; KAWAMURA S, 1993, J BIOL CHEM, V268, P14579; KLEMPERER NS, 1989, BIOCHEMISTRY-US, V28, P6035, DOI 10.1021/bi00440a047; KOCH KW, 1988, NATURE, V334, P64, DOI 10.1038/334064a0; KOLESNIKOV SS, 1995, NATURE, V376, P85, DOI 10.1038/376085a0; KOLLING R, 1994, EMBO J, V13, P3261, DOI 10.1002/j.1460-2075.1994.tb06627.x; KORNITZER D, 1994, EMBO J, V13, P6021, DOI 10.1002/j.1460-2075.1994.tb06948.x; Koutalos Y, 1993, Curr Opin Neurobiol, V3, P513, DOI 10.1016/0959-4388(93)90049-5; KUHN H, 1980, NATURE, V283, P587, DOI 10.1038/283587a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE RH, 1992, J BIOL CHEM, V267, P25104; LOETSCHER P, 1991, J BIOL CHEM, V266, P11213; MA CP, 1994, J BIOL CHEM, V269, P3539; MADURA K, 1994, SCIENCE, V265, P1454, DOI 10.1126/science.8073290; MCLAUGHLIN ME, 1993, NAT GENET, V4, P130, DOI 10.1038/ng0693-130; MOLDAY RS, 1983, BIOCHEMISTRY-US, V22, P653, DOI 10.1021/bi00272a020; MOLDAY RS, 1987, INVEST OPHTH VIS SCI, V28, P50; MOLDAY RS, 1993, METH NEUROSCI, V15, P131; MURA CV, 1993, CURR EYE RES, V12, P1081, DOI 10.3109/02713689309033506; NAASH M, 1991, J NEUROSCI RES, V30, P433, DOI 10.1002/jnr.490300220; NAASH M, 1990, THESIS BAYLOR COLL M; NAASH M, 1991, INVEST OPHTHALMOL  S, V31, P293; OBIN M, 1995, CURR EYE RES, V14, P751, DOI 10.3109/02713689508995796; OBIN M, 1994, BIOCHEM BIOPH RES CO, V200, P1169, DOI 10.1006/bbrc.1994.1574; OFARRELL PZ, 1977, CELL, V12, P1133, DOI 10.1016/0092-8674(77)90176-3; PAPERMASTER DS, 1995, INVEST OPHTH VIS SCI, V36, P977; PETERS JM, 1994, TRENDS BIOCHEM SCI, V19, P377, DOI 10.1016/0968-0004(94)90115-5; PICKART CM, 1985, J BIOL CHEM, V260, P1573; PORTERACAILLIAU C, 1994, P NATL ACAD SCI USA, V91, P974, DOI 10.1073/pnas.91.3.974; RECHSTEINER M, 1991, CELL, V66, P615, DOI 10.1016/0092-8674(91)90104-7; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; Rose I. A., 1988, UBIQUITIN, P135; SALESSE C, 1984, ANAL BIOCHEM, V142, P258, DOI 10.1016/0003-2697(84)90462-7; SEMPLEROWLAND SL, 1991, ELECTROPHORESIS, V12, P307, DOI 10.1002/elps.1150120414; SHANG F, 1995, BIOCHEM J, V307, P297, DOI 10.1042/bj3070297; SHANKLIN J, 1987, P NATL ACAD SCI USA, V84, P359, DOI 10.1073/pnas.84.2.359; STRADER CD, 1995, FASEB J, V9, P745, DOI 10.1096/fasebj.9.9.7601339; SUNG CH, 1993, J BIOL CHEM, V268, P26645; TREIER M, 1994, CELL, V78, P787, DOI 10.1016/S0092-8674(94)90502-9; VANNOCKER S, 1993, J BIOL CHEM, V268, P24766; WEISS ER, 1994, BIOCHEMISTRY-US, V33, P7587, DOI 10.1021/bi00190a011; WIEBEL FF, 1992, NATURE, V359, P73, DOI 10.1038/359073a0; WILKINSON KD, 1989, SCIENCE, V246, P670, DOI 10.1126/science.2530630; WING SS, 1995, BIOCHEM J, V305, P125, DOI 10.1042/bj3050125; WITT PL, 1987, BIOCHEMISTRY-US, V26, P1769, DOI 10.1021/bi00380a040; WOO SK, 1995, J BIOL CHEM, V270, P18766, DOI 10.1074/jbc.270.32.18766; YARFITZ S, 1994, J BIOL CHEM, V269, P14329	80	73	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14473	14484		10.1074/jbc.271.24.14473	http://dx.doi.org/10.1074/jbc.271.24.14473			12	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662797	hybrid			2022-12-27	WOS:A1996UQ66000079
J	Schubart, UK; Yu, JH; Amat, JA; Wang, ZQ; Hoffmann, MK; Edelmann, W				Schubart, UK; Yu, JH; Amat, JA; Wang, ZQ; Hoffmann, MK; Edelmann, W			Normal development of mice lacking metablastin (P19), a phosphoprotein implicated in cell cycle regulation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STAGE-SPECIFIC EXPRESSION; NEURON-ENRICHED PHOSPHOPROTEIN; MULTIPLE SIGNAL-TRANSDUCTION; HAMSTER INSULINOMA CELLS; DEPENDENT PROTEIN-KINASE; NUCLEOTIDE-SEQUENCE; GENE FAMILY; PHYLOGENETIC CONSERVATION; RAPID PHOSPHORYLATION; DISTINCT PATTERNS	Metablastin, also called pig, stathmin, prosolin, Lap18, and oncoprotein18, is a highly conserved cytosolic protein that undergoes extracellular factor- and cell cycle-regulated serine phosphorylation and developmentally regulated expression in mammals. It has been implicated in a variety of cellular functions including growth and differentiation, and recent evidence suggests an involvement in cell cycle control. To explore its potential role in mammalian development, we have disrupted the gene encoding metablastin by gene targeting in mice. The metablastin null mutants have no overt phenotype regarding development, growth rate, behavior, T cell maturation, or fertility and do not exhibit an increased predisposition to tumors. SCG10, a protein closely related in structure to metablastin, shows no compensatory up-regulation in metablastin(-/-) mice. Although the data suggest that metablastin is not essential for mammalian development, the knockout mice should prove valuable in exploring the role of this protein in cell cycle regulation.	ALBERT EINSTEIN COLL MED,DEPT MOLEC PHARMACOL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT NEUROL,BRONX,NY 10461; ALBERT EINSTEIN COLL MED,DEPT MOLEC GENET,BRONX,NY 10461; NEW YORK MED COLL,DEPT IMMUNOL,VALHALLA,NY 10595	Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; Yeshiva University; Albert Einstein College of Medicine; New York Medical College	Schubart, UK (corresponding author), ALBERT EINSTEIN COLL MED,DEPT MED,1300 MORRIS PK AVE,BRONX,NY 10461, USA.				NINDS NIH HHS [R01 NS26333] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS026333] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ADRA CN, 1987, GENE, V60, P65, DOI 10.1016/0378-1119(87)90214-9; AMAT JA, 1991, DEV BRAIN RES, V60, P205, DOI 10.1016/0165-3806(91)90049-O; AMAT JA, 1990, MOL REPROD DEV, V26, P383, DOI 10.1002/mrd.1080260414; BECK E, 1982, GENE, V19, P327, DOI 10.1016/0378-1119(82)90023-3; Belmont LD, 1996, CELL, V84, P623, DOI 10.1016/S0092-8674(00)81037-5; BERETTA L, 1995, EUR J BIOCHEM, V227, P388, DOI 10.1111/j.1432-1033.1995.tb20401.x; BERETTA L, 1993, J BIOL CHEM, V268, P20076; BRATTSAND G, 1993, LEUKEMIA, V7, P569; BRATTSAND G, 1994, EUR J BIOCHEM, V220, P359, DOI 10.1111/j.1432-1033.1994.tb18632.x; COOPER HL, 1989, J IMMUNOL, V143, P956; COOPER HL, 1991, J IMMUNOL, V146, P3689; COOPER HL, 1990, J IMMUNOL, V145, P1205; CROSS SM, 1995, SCIENCE, V267, P1353, DOI 10.1126/science.7871434; DANNECKER G, 1991, J IMMUNOL, V146, P2083; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; DOYE V, 1989, J BIOL CHEM, V264, P12134; DOYE V, 1990, J BIOL CHEM, V265, P11650; FERRARI AC, 1990, GENE CHROMOSOME CANC, V2, P125, DOI 10.1002/gcc.2870020208; FEUERSTEIN N, 1983, J BIOL CHEM, V258, P786; FODDE R, 1994, P NATL ACAD SCI USA, V91, P8969, DOI 10.1073/pnas.91.19.8969; GULLBERG M, 1990, J BIOL CHEM, V265, P17499; HANASH SM, 1988, J BIOL CHEM, V263, P12813; JOHNSON WEB, 1995, FEBS LETT, V364, P309; KOPPEL J, 1993, FEBS LETT, V331, P65, DOI 10.1016/0014-5793(93)80298-9; KOPPEL J, 1990, J BIOL CHEM, V265, P3703; LABDON JE, 1992, J BIOL CHEM, V267, P3506; LARSSON N, 1995, J BIOL CHEM, V270, P14175, DOI 10.1074/jbc.270.23.14175; LUO XN, 1994, J BIOL CHEM, V269, P10312; LUO XN, 1991, J BIOL CHEM, V266, P21004; MARKLUND U, 1993, J BIOL CHEM, V268, P15039; MARKLUND U, 1993, J BIOL CHEM, V268, P25671; MARKLUND U, 1994, EUR J BIOCHEM, V225, P53, DOI 10.1111/j.1432-1033.1994.00053.x; MARKLUND U, 1994, J BIOL CHEM, V269, P30628; MAUCUER A, 1990, FEBS LETT, V264, P275, DOI 10.1016/0014-5793(90)80266-L; MAUCUER A, 1993, J BIOL CHEM, V268, P16420; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MELHEM RF, 1991, BIOCHEM BIOPH RES CO, V179, P1649, DOI 10.1016/0006-291X(91)91764-4; MELHEM RF, 1991, J BIOL CHEM, V266, P17747; MOCK BA, 1993, MAMM GENOME, V4, P461, DOI 10.1007/BF00296823; OKAZAKI T, 1993, GENOMICS, V18, P360, DOI 10.1006/geno.1993.1477; OKAZAKI T, 1993, FEBS LETT, V336, P8, DOI 10.1016/0014-5793(93)81598-T; PASMANTIER R, 1986, ENDOCRINOLOGY, V119, P1229, DOI 10.1210/endo-119-3-1229; Robertson EJ, 1987, TERATOCARCINOMAS EMB, P71; ROOS G, 1993, LEUKEMIA, V7, P1538; Sambrook J., 2002, MOL CLONING LAB MANU; SCHUBART UK, 1982, J BIOL CHEM, V257, P2231; SCHUBART UK, 1992, DIFFERENTIATION, V51, P21, DOI 10.1111/j.1432-0436.1992.tb00676.x; SCHUBART UK, 1988, J BIOL CHEM, V263, P12156; SCHUBART UK, 1986, ENDOCRINOLOGY, V119, P1741, DOI 10.1210/endo-119-4-1741; SCHUBART UK, 1989, DNA-J MOLEC CELL BIO, V8, P389, DOI 10.1089/dna.1.1989.8.389; SCHUBART UK, 1987, J BIOL CHEM, V262, P11871; SOBEL A, 1983, J BIOL CHEM, V258, P312; SOBEL A, 1989, J BIOL CHEM, V264, P3765; SOBEL A, 1991, TRENDS BIOCHEM SCI, V16, P301, DOI 10.1016/0968-0004(91)90123-D; STEIN R, 1988, NEURON, V1, P463, DOI 10.1016/0896-6273(88)90177-8; STRAHLER JR, 1992, J IMMUNOL, V149, P1191; STRAHLER JR, 1992, BIOCHEM BIOPH RES CO, V185, P197, DOI 10.1016/S0006-291X(05)80975-1; THOMAS KR, 1992, MOL CELL BIOL, V12, P2919, DOI 10.1128/MCB.12.7.2919; ZHU XX, 1989, J BIOL CHEM, V264, P14556	60	79	80	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14062	14066		10.1074/jbc.271.24.14062	http://dx.doi.org/10.1074/jbc.271.24.14062			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662897	hybrid			2022-12-27	WOS:A1996UQ66000022
J	Takahashi, Y; Yamaguchi, M; Hirose, F; Cotterill, S; Kobayashi, J; Miyajima, S; Matsukage, A				Takahashi, Y; Yamaguchi, M; Hirose, F; Cotterill, S; Kobayashi, J; Miyajima, S; Matsukage, A			DNA replication-related elements cooperate to enhance promoter activity of the Drosophila DNA polymerase a 73-kDa subunit gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL NUCLEAR ANTIGEN; SACCHAROMYCES-CEREVISIAE; TRANSCRIPTION FACTOR; PRIMASE COMPLEX; ALPHA-PRIMASE; BUDDING YEAST; EXPRESSION; PROTEIN; MELANOGASTER; CYCLE	An analysis was carried out on the promoter region of the Drosophila DNA polymerase alpha 73-kDa subunit gene and the factor(s) activating the promoter. Transcription initiation sites were newly identified in the region downstream of the previously determined sites. Full promoter activity resided within the region from -285 to +129 base pairs with respect to the newly determined major site. Within this region, we found three sequences identical or similar to the DNA replication-related element (DRE), 5'-TATCGATA, which is known as a common promoter-activating element for the Drosophila DNA polymerase a 180-kDa subunit gene and the proliferating cell nuclear antigen gene. These sites were located at positions -77 to -70 (DRE alpha-I), -44 to -37 (DRE alpha-Il), and +3 to +10 (DRE alpha-LZI). Footprinting analysis using the recombinant DRE-binding factor (DREF) or Kc cell nuclear extract demonstrated that DREF can bind to all three DRE-related sites. Introduction of mutation in even one of the three DRE-related sequences caused extensive reductions of the promoter activity and also the DREF-binding activity of the promoter-containing fragment. The results indicate that the three DREF-binding sites cooperate to enhance promoter activity of the DNA polymerase alpha 73-kDa subunit gene.	AICHI CANC CTR,RES INST,CELL BIOL LAB,CHIKUSA KU,NAGOYA,AICHI 464,JAPAN; MIE UNIV,FAC ENGN,LAB MOL BIOENGN,TSU,MIE 514,JAPAN; MARIE CURIE RES INST,OXTED RH8 OTL,SURREY,ENGLAND	Aichi Cancer Center; Mie University				Yamaguchi, Masamitsu/0000-0002-6321-9750				ARAKI H, 1992, EMBO J, V11, P733, DOI 10.1002/j.1460-2075.1992.tb05106.x; BAMBARA RA, 1991, BIOCHIM BIOPHYS ACTA, V1088, P11, DOI 10.1016/0167-4781(91)90147-E; BLAKE MC, 1989, MOL CELL BIOL, V9, P4994, DOI 10.1128/MCB.9.11.4994; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COTTERILL S, 1992, NUCLEIC ACIDS RES, V20, P4325, DOI 10.1093/nar/20.16.4325; CROSS DP, 1978, J EMBRYOL EXP MORPH, V45, P161; DEGREGORI J, 1995, MOL CELL BIOL, V15, P4215; DINOCERA PP, 1983, P NATL ACAD SCI-BIOL, V80, P7095; DIRICK L, 1992, NATURE, V357, P508, DOI 10.1038/357508a0; DYNLACHT BD, 1994, P NATL ACAD SCI USA, V91, P6359, DOI 10.1073/pnas.91.14.6359; ECHALIER G, 1970, IN VITRO CELL DEV B, V6, P162; HAO XF, 1995, J CELL SCI, V108, P2945; HIROSE F, 1991, NUCLEIC ACIDS RES, V19, P4991, DOI 10.1093/nar/19.18.4991; Hirose F, 1996, J BIOL CHEM, V271, P3930; HIROSE F, 1993, J BIOL CHEM, V268, P2092; LI R, 1993, P NATL ACAD SCI USA, V90, P3554; LINN S, 1991, CELL, V66, P185, DOI 10.1016/0092-8674(91)90608-2; LOWNDES NF, 1992, NATURE, V357, P505, DOI 10.1038/357505a0; LOWNDES NF, 1991, NATURE, V350, P247, DOI 10.1038/350247a0; MIYAZAWA H, 1993, J BIOL CHEM, V268, P8111; MORRISON A, 1990, CELL, V62, P1143, DOI 10.1016/0092-8674(90)90391-Q; NEVINS JR, 1992, SCIENCE, V258, P424; OHTANI K, 1994, MOL CELL BIOL, V14, P1603, DOI 10.1128/MCB.14.3.1603; PEARSON BE, 1991, MOL CELL BIOL, V11, P2296; PURNELL BA, 1994, GENE DEV, V8, P830, DOI 10.1101/gad.8.7.830; SLANSKY JE, 1993, MOL CELL BIOL, V13, P1610, DOI 10.1128/MCB.13.3.1610; TSURIMOTO T, 1990, NATURE, V346, P534, DOI 10.1038/346534a0; WANG TSF, 1991, ANNU REV BIOCHEM, V60, P513, DOI 10.1146/annurev.biochem.60.1.513; WONG SW, 1986, J BIOL CHEM, V261, P7958; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YAMAGUCHI M, 1991, MOL CELL BIOL, V11, P4909, DOI 10.1128/MCB.11.10.4909; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P15808, DOI 10.1074/jbc.270.26.15808; YAMAGUCHI M, 1995, J BIOL CHEM, V270, P25159, DOI 10.1074/jbc.270.42.25159; Yamaguchi M, 1996, GENES CELLS, V1, P47, DOI 10.1046/j.1365-2443.1996.03003.x; YAMAGUCHI M, 1988, NUCLEIC ACIDS RES, V16, P8773, DOI 10.1093/nar/16.18.8773	35	52	52	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14541	14547		10.1074/jbc.271.24.14541	http://dx.doi.org/10.1074/jbc.271.24.14541			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662923	hybrid			2022-12-27	WOS:A1996UQ66000089
J	Faiman, GA; Levy, R; Anglister, J; Horovitz, A				Faiman, GA; Levy, R; Anglister, J; Horovitz, A			Contribution of arginine residues in the RP135 peptide derived from the V3 loop of gp120 to its interaction with the Fv fragment of the 0.5 beta HIV-1 neutralizing antibody	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-IMMUNODEFICIENCY-VIRUS; MONOCLONAL-ANTIBODY; ESCHERICHIA-COLI; PROTEIN; EXPRESSION; ANTIGEN; COOPERATIVITY; CHIMPANZEES; DETERMINANT; SEQUENCE	The construction, expression, and purification of an active Fv fragment of the 0.5 beta monoclonal human immunodeficiency virus type 1 (HIV-1) neutralizing antibody is reported, The interaction between the Fv fragment and the RP135 peptide derived from the V3 loop of gp120 from HIV-1(IIIB) was studied by varying the salt concentration and by mutating arginine residues in the peptide, The mutations R4A, R8A and R11A (which correspond to residues 311, 315, and 318 in gp120 of HIV-1(IIIB)) reduce the binding free energy by 0.22 (+/- 0.20), 4.32 (+/- 0.16), and 1.58 (+/- 0.17) kcal mol(-1), respectively. The salt-dependent components of their contributions to binding are 0.02 (+/- 0.22), -0.55 (+/- 0.18), and -0.97 (+/- 0.19) kcal mol(-1), respectively. The magnitudes of the mutational effects and the extent of shielding by 1 M NaCl suggest that Arg-8 is involved in a buried salt bridge in the peptide-Fv fragment complex, whereas Arg-11 is involved in a more solvent-exposed electrostatic interaction.	WEIZMANN INST SCI, DEPT BIOL STRUCT, IL-76100 REHOVOT, ISRAEL	Weizmann Institute of Science								ANDERSON DE, 1990, BIOCHEMISTRY-US, V29, P2403, DOI 10.1021/bi00461a025; BETTER M, 1988, SCIENCE, V240, P1041, DOI 10.1126/science.3285471; BIRD RE, 1988, SCIENCE, V242, P423, DOI 10.1126/science.3140379; EMINI EA, 1992, NATURE, V355, P728, DOI 10.1038/355728a0; GHIARA JB, 1994, SCIENCE, V264, P82, DOI 10.1126/science.7511253; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GOUDSMIT J, 1988, P NATL ACAD SCI USA, V85, P4478, DOI 10.1073/pnas.85.12.4478; HOROVITZ A, 1990, J MOL BIOL, V214, P613, DOI 10.1016/0022-2836(90)90275-Q; HOROVITZ A, 1990, J MOL BIOL, V216, P1031, DOI 10.1016/S0022-2836(99)80018-7; HUSTON JS, 1988, P NATL ACAD SCI USA, V85, P5879, DOI 10.1073/pnas.85.16.5879; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAROSA GJ, 1990, SCIENCE, V249, P932, DOI 10.1126/science.2392685; MARASCO WA, 1993, P NATL ACAD SCI USA, V90, P7889, DOI 10.1073/pnas.90.16.7889; MATSUSHITA S, 1988, J VIROL, V62, P2107, DOI 10.1128/JVI.62.6.2107-2114.1988; MATSUSHITA S, 1992, AIDS RES HUM RETROV, V8, P1107, DOI 10.1089/aid.1992.8.1107; MEAD DA, 1986, PROTEIN ENG, V1, P67, DOI 10.1093/protein/1.1.67; NOVOTNY J, 1992, PROG BIOPHYS MOL BIO, V58, P203, DOI 10.1016/0079-6107(92)90006-R; OKADA T, 1994, AIDS RES HUM RETROV, V10, P803, DOI 10.1089/aid.1994.10.803; ORLANDI R, 1989, P NATL ACAD SCI USA, V86, P3833, DOI 10.1073/pnas.86.10.3833; PALKER TJ, 1988, P NATL ACAD SCI USA, V85, P1932, DOI 10.1073/pnas.85.6.1932; RIECHMANN L, 1991, FEBS LETT, V287, P185, DOI 10.1016/0014-5793(91)80047-7; RIECHMANN L, 1988, J MOL BIOL, V203, P825, DOI 10.1016/0022-2836(88)90214-8; RINI JM, 1993, P NATL ACAD SCI USA, V90, P6325, DOI 10.1073/pnas.90.13.6325; SAYERS JR, 1988, NUCLEIC ACIDS RES, V16, P791, DOI 10.1093/nar/16.3.791; SKERRA A, 1993, CURR OPIN IMMUNOL, V5, P256, DOI 10.1016/0952-7915(93)90014-J; SKERRA A, 1988, SCIENCE, V240, P1038, DOI 10.1126/science.3285470; SKINNER MA, 1988, AIDS RES HUM RETROV, V4, P187, DOI 10.1089/aid.1988.4.187; SNYDER SL, 1975, ANAL BIOCHEM, V64, P284, DOI 10.1016/0003-2697(75)90431-5; WINTER G, 1991, NATURE, V349, P293, DOI 10.1038/349293a0; ZVI A, 1992, BIOCHEMISTRY-US, V31, P6972, DOI 10.1021/bi00145a015; ZVI A, 1995, EUR J BIOCHEM, V229, P178, DOI 10.1111/j.1432-1033.1995.tb20453.x	31	16	16	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13829	13833		10.1074/jbc.271.23.13829	http://dx.doi.org/10.1074/jbc.271.23.13829			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662780	hybrid			2022-12-27	WOS:A1996UP38500079
J	Follesa, P; Ticku, MK				Follesa, P; Ticku, MK			Chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptor polypeptide subunits in mouse cortical neurons in culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IONOPHORE COMPLEX; BRAIN	The goal of this study was to determine whether chronic ethanol-mediated up-regulation of the N-methyl-D-aspartate receptors (NMDAR) was associated with an augmentation of the NMDAR polypeptide subunits in the mammalian cortical neurons. The results show that chronic ethanol treatment produced an increase in the R1 and R2B polypeptide subunits. The R2A subunit was not expressed in these neurons. Chronic NMDAR antagonist ((+)-3-2-(carboxypiperazin-4-yl)propyl-1-phosphonic acid (CPP)) treatment also increased the R1 and R2B polypeptide subunits. A similar increase was observed when ethanol and CPP were used in combination. Binding studies using [H-3]MK-801 ((+)-5-methyl-10,11-dihydro -5H-dibenzo[a,d]cyclophenptan-5,10-imine maleate), a noncompetitive NMDAR antagonist, confirmed that concomitant exposure of ethanol and CPP up-regulated the NMDAR. Our results demonstrate for the first time that chronic ethanol treatment increased the NMDA receptor polypeptide subunit synthesis and that it was associated with an increase in [H-3]MK-801 binding sites.	UNIV TEXAS,HLTH SCI CTR,DEPT PHARMACOL,SAN ANTONIO,TX 78284	University of Texas System; University of Texas Health San Antonio			Follesa, Paolo/K-5416-2015	Follesa, Paolo/0000-0003-4857-476X	NIAAA NIH HHS [AA10552] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R01AA010552] Funding Source: NIH RePORTER	NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		Follesa P, 1996, J NEUROSCI, V16, P2172; FOLLESA P, 1995, MOL BRAIN RES, V29, P99, DOI 10.1016/0169-328X(94)00235-7; GODFREY EW, 1975, BRAIN RES, V90, P1, DOI 10.1016/0006-8993(75)90679-4; GULYA K, 1991, BRAIN RES, V547, P129; HU XJ, 1995, MOL BRAIN RES, V30, P347, DOI 10.1016/0169-328X(95)00019-O; Hu XJ, 1996, MOL BRAIN RES, V36, P211, DOI 10.1016/0169-328X(95)00223-F; KRANZLER HR, 1995, HDB EXP PHARM, V114, P75; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOVINGER DM, 1989, SCIENCE, V243, P1721, DOI 10.1126/science.2467382; MASOOD K, 1994, MOL PHARMACOL, V45, P324; MHATRE MC, 1992, MOL PHARMACOL, V42, P415; SANNA E, 1993, ALCOHOL CLIN EXP RES, V17, P115, DOI 10.1111/j.1530-0277.1993.tb00735.x; SHENG M, 1994, NATURE, V368, P144, DOI 10.1038/368144a0; SNELL LD, 1993, BRAIN RES, V602, P91, DOI 10.1016/0006-8993(93)90246-J; TREVISAN L, 1994, J NEUROCHEM, V62, P1635; WILLIAMS K, 1992, MOL PHARMACOL, V42, P147; ZHONG J, 1994, MOL PHARMACOL, V45, P846	17	124	126	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13297	13299		10.1074/jbc.271.23.13297	http://dx.doi.org/10.1074/jbc.271.23.13297			3	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663153	hybrid			2022-12-27	WOS:A1996UP38500002
J	Lokuta, MA; Maher, J; Noe, KH; Pitha, PM; Shin, ML; Shin, HS				Lokuta, MA; Maher, J; Noe, KH; Pitha, PM; Shin, ML; Shin, HS			Mechanisms of murine RANTES chemokine gene induction by Newcastle disease virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INFLAMMATORY PROTEIN 1-ALPHA; TRANSCRIPTION FACTOR; CYTOKINE RANTES; CHROMOSOMAL-PROTEINS; INTERFERON; ACTIVATION; EXPRESSION; CELLS; DNA; IDENTIFICATION	We have previously defined the lipopolysaccharide (LPS)-responsive element (LRE) in the promoters of murine RANTES (regulated on activation normal T-cell expressed) (MuRantes) and murine IP-10/crg-2, chemokines which have potent chemotactic properties for inflammatory cells including monocytes and T lymphocytes. In the present work, we studied the transcriptional mechanism of MuRantes gene induction by virus and compared it with that of LPS in an effort to understand the host responses to virus and bacterial toxins at the molecular level, MuRantes mRNA expression is induced by Newcastle disease virus (NDV) and LPS in the RAW 264.7 macrophage cell line and peritoneal macrophages of LPS-responsive C3HeB/FeJ mice. Tn LPS-hyporesponsive C3H/HeJ mice, only NDV induces this chemokine gene, indicating that the pathways of transcriptional activation by NDV and LPS are not identical. Using a transient transfection assay, the minimal virus-responsive element (VRE) was localized between nt -175 and -116. The VRE contains previously defined LRE motif 1 (TCAYRCTT) and motif 3 ((T/A)GRTT-TCA(G/C)TTT), which were shown to also be important for initiation of transcription by virus. NDV-stimulated nuclear extracts were tested for trans activating factors able to bind the VRE, The chromosomal protein HMG-I(C) was shown to bind the 3'-A-T-rich domains of the VRE, and the presence of HMG-I(C) was demonstrated in the VRE-protein complex formed with nuclear extracts from NDV-stimulated, but not unstimulated cells. These findings demonstrate the role of HMG-I(C) in activation of MuRantes promoter by NDV.	UNIV MARYLAND,SCH MED,DEPT PATHOL,BALTIMORE,MD 21201; JOHNS HOPKINS UNIV,SCH MED,DEPT MOLEC BIOL & GENET,BALTIMORE,MD 21205	University System of Maryland; University of Maryland Baltimore; Johns Hopkins University					NCI NIH HHS [R01 CA1411320] Funding Source: Medline; NIAID NIH HHS [R01 AI19622] Funding Source: Medline; NINDS NIH HHS [R01 NS 15662] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA014113] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI019622] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015662] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABDELHAFIZ HAM, 1993, ONCOGENE, V8, P1161; AU WC, 1992, NUCLEIC ACIDS RES, V20, P2877, DOI 10.1093/nar/20.11.2877; AZNAR C, 1990, Cytokine, V2, P259, DOI 10.1016/1043-4666(90)90026-P; BUSTIN M, 1990, BIOCHIM BIOPHYS ACTA, V1049, P231, DOI 10.1016/0167-4781(90)90092-G; CHATTON B, 1993, MOL CELL BIOL, V13, P561, DOI 10.1128/MCB.13.1.561; CHELLAPPAN SP, 1991, CELL, V65, P1053, DOI 10.1016/0092-8674(91)90557-F; Drysdale B E, 1986, Methods Enzymol, V132, P549; DU W, 1993, CELL, V74, P887, DOI 10.1016/0092-8674(93)90468-6; EINCK L, 1985, EXP CELL RES, V156, P295, DOI 10.1016/0014-4827(85)90539-7; ELTON TS, 1987, BIOCHEM BIOPH RES CO, V143, P260, DOI 10.1016/0006-291X(87)90659-0; Fisher SN, 1995, BRAIN BEHAV IMMUN, V9, P331, DOI 10.1006/brbi.1995.1031; FISHER SN, 1994, J IMMUNOL, V153, P3210; Galinski M.S., 1991, PARAMYXOVIRUSES, P41; GIANCOTTI V, 1991, EUR J BIOCHEM, V198, P211, DOI 10.1111/j.1432-1033.1991.tb16003.x; GIESE K, 1992, CELL, V69, P185, DOI 10.1016/0092-8674(92)90129-Z; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIDAKA H, 1984, BIOCHEMISTRY-US, V23, P5036, DOI 10.1021/bi00316a032; LAMB P, 1991, TRENDS BIOCHEM SCI, V16, P417, DOI 10.1016/0968-0004(91)90167-T; LIEBERMAN AP, 1989, P NATL ACAD SCI USA, V86, P6348, DOI 10.1073/pnas.86.16.6348; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIU F, 1990, CELL, V61, P1217, DOI 10.1016/0092-8674(90)90686-9; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; MANFIOLETTI G, 1991, NUCLEIC ACIDS RES, V19, P6793, DOI 10.1093/nar/19.24.6793; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MEURER R, 1993, J EXP MED, V178, P1913, DOI 10.1084/jem.178.6.1913; Nagai Y, 1989, Prog Vet Microbiol Immunol, V5, P16; NELSON PJ, 1993, J IMMUNOL, V151, P2601; OHNO S, 1983, NUCLEIC ACIDS RES, V11, P5403, DOI 10.1093/nar/11.16.5403; RAJ NBK, 1991, J BIOL CHEM, V266, P11360; RATHANASWAMI P, 1993, J BIOL CHEM, V268, P5834; ROSENSTREICH DL, 1985, CELLULAR BIOL ENDOTO, P82; ROT A, 1992, J EXP MED, V176, P1489, DOI 10.1084/jem.176.6.1489; ROULSTON A, 1993, J VIROL, V67, P5235, DOI 10.1128/JVI.67.9.5235-5246.1993; RUS HG, 1992, J IMMUNOL, V148, P928; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, NATURE, V347, P669, DOI 10.1038/347669a0; SHIN HS, 1994, MOL CELL BIOL, V14, P2914, DOI 10.1128/MCB.14.5.2914; SHIN ML, 1993, NEUROBIOLOGY CYTOK B, P16; STARR DB, 1991, CELL, V67, P1231, DOI 10.1016/0092-8674(91)90299-E; STEIN B, 1993, EMBO J, V12, P3879, DOI 10.1002/j.1460-2075.1993.tb06066.x; TANAKA N, 1992, ADV IMMUNOL, V52, P263, DOI 10.1016/S0065-2776(08)60877-9; TANIGUCHI T, 1988, ANNU REV IMMUNOL, V6, P439, DOI 10.1146/annurev.iy.06.040188.002255; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VANGURI P, 1994, J IMMUNOL, V152, P1411; VANGURI P, 1990, J BIOL CHEM, V265, P15049; WOLF G, 1993, KIDNEY INT, V44, P795, DOI 10.1038/ki.1993.314; ZAWATZKY R, 1991, PATHOBIOLOGY, V59, P232, DOI 10.1159/000163652	49	32	32	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13731	13738		10.1074/jbc.271.23.13731	http://dx.doi.org/10.1074/jbc.271.23.13731			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662857	hybrid			2022-12-27	WOS:A1996UP38500065
J	Martin, M; Czajkowski, C; Karlin, A				Martin, M; Czajkowski, C; Karlin, A			The contributions of aspartyl residues in the acetylcholine receptor gamma and delta subunits to the binding of agonists and competitive antagonists	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; TORPEDO-CALIFORNICA; LIGAND-BINDING; AMINO-ACIDS; AFFINITY; IDENTIFICATION; DISULFIDE; OOCYTES	The acetylcholine (ACh) receptors in muscle have the composition alpha(2) beta gamma delta and contain two ACh binding sites. One is formed between an alpha subunit and the gamma subunit, and the other is formed between an alpha subunit and the delta subunit, Among the residues in the ACh binding sites are alpha Cys-192 and alpha Cys-193. The negatively charged delta Asp-180 is at an appropriate distance from alpha Cys-192/193 also to be in the ACh binding site and to interact electrostatically with the positively charged ammonium group common to agonists and competitive antagonists. Mutation to Asn of either delta Asp-180 or the aligned residue in the gamma subunit, gamma Asp-174, decreased the affinities of three agonists, acetylcholine, tetramethylammonium, and succinyldicholine 170-560-fold. By contrast, these mutations decreased the affinities of three competitive antagonists, (+)-tubocurarine, hexamethonium, and dihydro-beta-erythroidine, only 2-15-fold. Agonists, but not antagonists, promote the transitions of the receptor from the resting state to the higher affinity active and desensitized states, and the greater effects of the mutations of gamma Asp-174 and delta Asp-180 on the apparent affinities of agonists could reflect the involvement of these residues in the conformational changes of the receptor corresponding to its transitions to higher affinity states. In these transitions, one possibility is that gamma Asp-174 and delta Asp-180 move closer to bound agonist.	COLUMBIA UNIV COLL PHYS & SURG, CTR MOL RECOGNIT, NEW YORK, NY 10032 USA	Columbia University				KARLIN, ARTHUR/0000-0002-4813-752X	NINDS NIH HHS [NS07258, NS07065] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ABRAMSON SN, 1989, J BIOL CHEM, V264, P12666; AKABAS MH, 1994, NEURON, V13, P919, DOI 10.1016/0896-6273(94)90257-7; AKABAS MH, 1992, SCIENCE, V258, P307, DOI 10.1126/science.1384130; BERTRAND D, 1992, P NATL ACAD SCI USA, V89, P1261, DOI 10.1073/pnas.89.4.1261; BLOUNT P, 1989, NEURON, V3, P349, DOI 10.1016/0896-6273(89)90259-6; CHEN J, 1995, BIOPHYS J, V69, P849, DOI 10.1016/S0006-3495(95)79959-3; CHIARA DC, 1992, FASEB J, V6, pA106; COHEN JB, 1991, J BIOL CHEM, V266, P23354; CORRINGER PJ, 1995, J BIOL CHEM, V270, P11749, DOI 10.1074/jbc.270.20.11749; CZAJKOWSKI C, 1991, J BIOL CHEM, V266, P22603; CZAJKOWSKI C, 1995, J BIOL CHEM, V270, P3160, DOI 10.1074/jbc.270.7.3160; CZAJKOWSKI C, 1993, P NATL ACAD SCI USA, V90, P6285, DOI 10.1073/pnas.90.13.6285; DAMLE VN, 1978, BIOCHEMISTRY-US, V17, P2039, DOI 10.1021/bi00604a002; DENNIS M, 1988, BIOCHEMISTRY-US, V27, P2346, DOI 10.1021/bi00407a016; DOUGHERTY DA, 1990, SCIENCE, V250, P1558, DOI 10.1126/science.2274786; DOWDING AJ, 1987, BIOCHEMISTRY-US, V26, P6372, DOI 10.1021/bi00394a010; GALZI JL, 1991, P NATL ACAD SCI USA, V88, P5051, DOI 10.1073/pnas.88.11.5051; GALZI JL, 1991, FEBS LETT, V294, P198, DOI 10.1016/0014-5793(91)80668-S; GALZI JL, 1990, J BIOL CHEM, V265, P10430; KAO PN, 1984, J BIOL CHEM, V259, P1662; KAO PN, 1986, J BIOL CHEM, V261, P8085; KARLIN A, 1968, P NATL ACAD SCI USA, V60, P668, DOI 10.1073/pnas.60.2.668; KARLIN A, 1969, J GEN PHYSIOL, V54, pS245; KATZ B, 1957, J PHYSIOL-LONDON, V138, P63, DOI 10.1113/jphysiol.1957.sp005838; KREIENKAMP HJ, 1995, NEURON, V14, P635, DOI 10.1016/0896-6273(95)90320-8; KUIPERS OP, 1991, NUCLEIC ACIDS RES, V19, P4558, DOI 10.1093/nar/19.16.4558; KULLBERG R, 1990, P NATL ACAD SCI USA, V87, P2067, DOI 10.1073/pnas.87.6.2067; KUROSAKI T, 1987, FEBS LETT, V214, P253, DOI 10.1016/0014-5793(87)80065-0; LINDSTROM J, 1979, BIOCHEMISTRY-US, V18, P4465, DOI 10.1021/bi00588a003; LIU Y, 1993, J PHYSIOL-LONDON, V470, P349, DOI 10.1113/jphysiol.1993.sp019862; MIDDLETON RE, 1991, BIOCHEMISTRY-US, V30, P6987, DOI 10.1021/bi00242a026; MISHINA M, 1986, NATURE, V321, P406, DOI 10.1038/321406a0; MISHINA M, 1985, NATURE, V313, P364, DOI 10.1038/313364a0; NELSON RM, 1989, ANAL BIOCHEM, V180, P147, DOI 10.1016/0003-2697(89)90103-6; NEUBIG RR, 1979, BIOCHEMISTRY-US, V18, P5464, DOI 10.1021/bi00591a032; OLEARY ME, 1994, AM J PHYSIOL, V266, pC648, DOI 10.1152/ajpcell.1994.266.3.C648; OLEARY ME, 1992, J BIOL CHEM, V267, P8360; PEDERSEN SE, 1990, P NATL ACAD SCI USA, V87, P2785, DOI 10.1073/pnas.87.7.2785; RAFTERY MA, 1980, SCIENCE, V208, P1454, DOI 10.1126/science.7384786; REYNOLDS JA, 1978, BIOCHEMISTRY-US, V17, P2035, DOI 10.1021/bi00604a001; SINE SM, 1991, J BIOL CHEM, V266, P19369; SINE SM, 1994, J BIOL CHEM, V269, P8808; TOMASELLI GF, 1991, BIOPHYS J, V60, P721, DOI 10.1016/S0006-3495(91)82102-6; UNWIN N, 1995, NATURE, V373, P37, DOI 10.1038/373037a0; Zhang Y., 1995, Society for Neuroscience Abstracts, V21, P1582	45	55	55	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13497	13503		10.1074/jbc.271.23.13497	http://dx.doi.org/10.1074/jbc.271.23.13497			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662820	hybrid			2022-12-27	WOS:A1996UP38500031
J	Molz, L; Chen, YW; Hirano, M; Williams, LT				Molz, L; Chen, YW; Hirano, M; Williams, LT			Cpk is a novel class of Drosophila PtdIns 3-kinase containing a C2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GROWTH-FACTOR RECEPTORS; PHOSPHATIDYLINOSITOL 3-KINASE; SH2 DOMAINS; SACCHAROMYCES-CEREVISIAE; ACTIVATED NEUTROPHILS; BOVINE BRAIN; BINDING; COMPLEX; SUBUNIT	We report the identification of a novel class of phosphatidylinositol (PtdIns) 3-kinases whose members contain C-terminal C2 domains. We have isolated Drosophila and murine genes (termed cpk and cpk-m respectively) by polymerase chain reaction amplification of cDNA libraries with degenerate primers corresponding to conserved regions of PtdIns kinases. The amino acid sequences of Cpk and Cpk-m are most similar to that of p110, a family of PtdIns 3-kinases that mediates the responses of cells to mitogenic stimuli. The Cpk and Cpk-m sequences are similar to a large, central region of p110, but differ from p110 at their N and C termini. The N termini of the Cpk proteins do not contain any recognizable protein motif, while the C termini contain ''C2 domains,'' a feature unique among PtdIns kinases. Cpk has an intrinsic PtdIns kinase activity and can phosphorylate PtdIns and PtdIns-4-P, but not PtdIns(4,5)P-2, at the D3 position of the inositol ring. Cpk is the first PtdIns 3-kinase identified with this particular substrate specificity, We have identified two potential Cpk-binding proteins, p90 and p190, and have determined that both Cpk and p190 may be tyrosine phosphorylated. This finding suggests that Cpk function may be regulated by tyrosine kinases.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco								AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; BROWN NH, 1988, J MOL BIOL, V203, P425, DOI 10.1016/0022-2836(88)90010-1; CARPENTER CL, 1990, BIOCHEMISTRY-US, V29, P11147, DOI 10.1021/bi00503a001; CARPENTER CL, 1990, J BIOL CHEM, V265, P19704; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; FLANAGAN CA, 1993, SCIENCE, V262, P1444, DOI 10.1126/science.8248783; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FRY MJ, 1992, BIOCHEM J, V288, P383, DOI 10.1042/bj2880383; GEPPERT M, 1991, J BIOL CHEM, V266, P13548; Harlow E., 1988, ANTIBODIES LAB MANUA; Herman Paul K., 1992, Trends in Cell Biology, V2, P363, DOI 10.1016/0962-8924(92)90048-R; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HOLT KH, 1994, MOL CELL BIOL, V14, P42, DOI 10.1128/MCB.14.1.42; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1992, MOL CELL BIOL, V12, P981, DOI 10.1128/MCB.12.3.981; HU QJ, 1995, SCIENCE, V268, P100, DOI 10.1126/science.7701328; JESSUS C, 1992, CELL, V68, P323, DOI 10.1016/0092-8674(92)90473-P; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KAPLAN DR, 1987, CELL, V50, P1021, DOI 10.1016/0092-8674(87)90168-1; KLIPPEL A, 1992, MOL CELL BIOL, V12, P1451, DOI 10.1128/MCB.12.4.1451; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; KUNZ J, 1993, CELL, V73, P585, DOI 10.1016/0092-8674(93)90144-F; LISCOVITCH M, 1994, CELL, V77, P329, DOI 10.1016/0092-8674(94)90148-1; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; MATTHIAS P, 1989, NUCLEIC ACIDS RES, V17, P6418, DOI 10.1093/nar/17.15.6418; MCGLADE CJ, 1992, MOL CELL BIOL, V12, P991, DOI 10.1128/MCB.12.3.991; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MORGAN SJ, 1990, EUR J BIOCHEM, V191, P761, DOI 10.1111/j.1432-1033.1990.tb19185.x; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; REEDIJK M, 1992, EMBO J, V11, P1365, DOI 10.1002/j.1460-2075.1992.tb05181.x; Sambrook J., 2002, MOL CLONING LAB MANU; SCHAEFFER E, 1989, CELL, V57, P403, DOI 10.1016/0092-8674(89)90915-X; SCHU PV, 1993, SCIENCE, V260, P88, DOI 10.1126/science.8385367; SHIBASAKI F, 1991, J BIOL CHEM, V266, P8108; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STEPHENS LR, 1991, NATURE, V351, P33, DOI 10.1038/351033a0; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; TOKER A, 1994, J BIOL CHEM, V269, P32358; TRAYNORKAPLAN AE, 1988, NATURE, V334, P353, DOI 10.1038/334353a0; TRAYNORKAPLAN AE, 1989, J BIOL CHEM, V264, P15668; TYERS M, 1992, EMBO J, V11, P1773, DOI 10.1002/j.1460-2075.1992.tb05229.x; VOLINIA S, 1994, GENOMICS, V24, P472, DOI 10.1006/geno.1994.1655; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALSH JP, 1991, P NATL ACAD SCI USA, V88, P9184, DOI 10.1073/pnas.88.20.9184; WHITMAN M, 1988, NATURE, V332, P644, DOI 10.1038/332644a0; WOSCHOLSKI R, 1994, FEBS LETT, V342, P109, DOI 10.1016/0014-5793(94)80482-6; YOAKIM M, 1992, J VIROL, V66, P5485, DOI 10.1128/JVI.66.9.5485-5491.1992; YONEZAWA K, 1992, J BIOL CHEM, V267, P25958; ZHANG JZ, 1994, CELL, V78, P751, DOI 10.1016/S0092-8674(94)90442-1; ZHOU KM, 1995, MOL CELL BIOL, V15, P5645	56	55	64	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13892	13899		10.1074/jbc.271.23.13892	http://dx.doi.org/10.1074/jbc.271.23.13892			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662856	hybrid			2022-12-27	WOS:A1996UP38500088
J	Li, JX; Zhu, ZX; Bao, ZH				Li, JX; Zhu, ZX; Bao, ZH			Role of MacMARCKS in integrin-dependent macrophage spreading and tyrosine phosphorylation of paxillin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; MEDIATED PHAGOCYTOSIS; HUMAN-NEUTROPHILS; HUMAN-MONOCYTES; CELL-ADHESION; ACTIVATION; MARCKS; FIBROBLASTS; MODULATION; MECHANISMS	The cellular function of the MARCKS family of protein kinase C substrates is unknown, In this report, we present evidence that indicates a role for MacMARCKS, a member of the MARCKS family, in the integrin-dependent signal transduction pathways in macrophages, Using a dominant negative mutant of MacMARCKS, we showed that MacMARCKS participates in several integrirm-dependent macrophage functions, including the phorbol ester-stimulated macrophage spreading, a process involving multiple integrins, The dominant negative mutant also blocks macrophage spreading on immune complex-coated surfaces, a process again requiring beta(2) integrin, More direct evidence of the role of MacMARCKS in the integrin-dependent pathway is the ablation of macrophage binding to complement iC3b-coated sheep erythrocytes by MacMARCKS mutant, suggesting an effect of this mutant on the avidity of complement receptor 3, a member of the beta(2) integrin family, To further evaluate the possible mechanism of MacMARCKS function, the integrin-dependent tyrosine phosphorylation of paxillin was examined, Concomitant with the inhibition of macrophage spreading and rosette formation, MacMARCKS mutant also inhibits integrin-dependent tyrosine phosphorylation of paxillin, Furthermore, immunofluorescent microscopy data showed that MacMARCKS and paxillin colocalize in the membrane ruffles at the leading edge of the spreading cells, providing a potential site and opportunity for MacMARCKS to participate in the regulation of integrin-dependent tyrosine phosphorylation of paxillin, Together, these data strongly suggest that MacMARCKS plays a role in integrin-dependent signal transduction pathways in macrophages.			Li, JX (corresponding author), UNIV TENNESSEE,COLL MED,DEPT MICROBIOL & IMMUNOL,858 MADISON AVE,MEMPHIS,TN 38163, USA.							ANDERSON DC, 1987, ANNU REV MED, V38, P175, DOI 10.1146/annurev.med.38.1.175; BIRGE RB, 1993, MOL CELL BIOL, V13, P4648, DOI 10.1128/MCB.13.8.4648; BLACKSHEAR PJ, 1992, J BIOL CHEM, V267, P13540; BROWN EJ, 1988, J CLIN INVEST, V81, P365, DOI 10.1172/JCI113328; BUYON JP, 1988, J IMMUNOL, V140, P3156; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; DUSTIN ML, 1989, NATURE, V341, P619, DOI 10.1038/341619a0; FUORTES M, 1994, J CELL BIOL, V127, P1477, DOI 10.1083/jcb.127.5.1477; GRAHAM IL, 1993, J CELL BIOL, V120, P1509, DOI 10.1083/jcb.120.6.1509; GRAHAM IL, 1994, J CELL BIOL, V127, P1139, DOI 10.1083/jcb.127.4.1139; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; GRESHAM HD, 1991, J CLIN INVEST, V88, P588, DOI 10.1172/JCI115343; HARTWIG JH, 1992, NATURE, V356, P618, DOI 10.1038/356618a0; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; KIM JY, 1994, BIOPHYS J, V67, P227, DOI 10.1016/S0006-3495(94)80473-4; LI JX, 1992, CELL, V70, P791, DOI 10.1016/0092-8674(92)90312-Z; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MINOGUCHI K, 1994, MOL IMMUNOL, V31, P519; MIYAMOTO S, 1995, SCIENCE, V267, P883, DOI 10.1126/science.7846531; NATHAN C, 1989, J CELL BIOL, V109, P1341, DOI 10.1083/jcb.109.3.1341; PETTY HR, 1989, BIOCHIM BIOPHYS ACTA, V1012, P284, DOI 10.1016/0167-4889(89)90110-9; PHAIREWASHINGTON L, 1980, J CELL BIOL, V86, P634, DOI 10.1083/jcb.86.2.634; PHILLIPS WD, 1991, SCIENCE, V251, P568, DOI 10.1126/science.1703661; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; ROSALES C, 1995, J LEUKOCYTE BIOL, V57, P189, DOI 10.1002/jlb.57.2.189; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; SPRINGER TA, 1990, NATURE, V346, P425, DOI 10.1038/346425a0; TURNER CE, 1990, J CELL BIOL, V111, P1059, DOI 10.1083/jcb.111.3.1059; TURNER CE, 1994, J CELL SCI, V107, P1583; TURNER CE, 1994, BIOESSAYS, V16, P47, DOI 10.1002/bies.950160107; UMEKAGE T, 1991, FEBS LETT, V286, P147, DOI 10.1016/0014-5793(91)80961-2; VUORI K, 1993, J BIOL CHEM, V268, P21459; WALLIS WJ, 1986, BLOOD, V67, P1007; WALLIS WJ, 1985, J IMMUNOL, V135, P2323; WENG ZG, 1993, J BIOL CHEM, V268, P14956; WOODS A, 1992, J CELL SCI, V101, P277; Wright S D, 1986, Methods Enzymol, V132, P204; WRIGHT SD, 1982, J EXP MED, V156, P1149, DOI 10.1084/jem.156.4.1149; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; ZHELEZNYAK A, 1992, J BIOL CHEM, V267, P12042; ZHU ZX, 1995, J BIOL CHEM, V270, P17652, DOI 10.1074/jbc.270.30.17652	43	45	46	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12985	12990		10.1074/jbc.271.22.12985	http://dx.doi.org/10.1074/jbc.271.22.12985			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662782	hybrid			2022-12-27	WOS:A1996UN47400048
J	Malcolm, KC; Elliott, CM; Exton, JH				Malcolm, KC; Elliott, CM; Exton, JH			Evidence for Rho-mediated agonist stimulation of phospholipase D in Rat1 fibroblasts - Effects of Clostridium botulinum C3 exoenzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GTP-BINDING PROTEIN; SWISS 3T3 CELLS; ADP-RIBOSYLATION; LYSOPHOSPHATIDIC-ACID; GENE-PRODUCT; PHOSPHATIDYLCHOLINE HYDROLYSIS; SIGNALING PATHWAYS; KINASE-C; ACTIVATION; MEMBRANE	Small GTP-binding proteins of the Rho family are implicated in the in vitro regulation of phosphatidylcholine hydrolysis by phospholipase D (PLD), However, their role in agonist-stimulated PLD activity in whole cells is not clear. The ribosyltransferase C3 from Clostridium botulinum modifies Rho proteins and inhibits their function. When introduced into rat1 fibroblasts by scrape-loading, C3 inhibited PLD activity stimulated by lysophosphatidic acid (LPA), endothelin-1, or phorbol ester. Neither the time course nor agonist dose response for LPA-stimulated PLD activity was altered in C3-treated cells. In contrast to the effects of C3 on PLD activity, agonist-stimulated phosphatidylinositol-phospholipase C activity was not altered in C3-treated cells, Surprisingly, C3 treatment led to a decrease in the amount of RhoA protein, indicating that the loss of PLD activity in response to agonist was partly due to the loss of Rho proteins. As described previously, C3 treatment led to the inhibition of LPA-stimulated actin filament formation. However, disruption of actin filaments with cytochalasin D caused only a minor inhibition of LPA-stimulated PLD activity. Interestingly, stimulation of cells with LPA caused a rapid enrichment of RhoA in the particulate fraction of cell lysates. These data support an in vivo role for RhoA in agonist-stimulated PLD activity that is separate from its role in actin fiber formation.	VANDERBILT UNIV,SCH MED,HOWARD HUGHES MED INST,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT MOLEC PHYSIOL & BIOPHYS,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,DEPT PHARMACOL,NASHVILLE,TN 37232	Howard Hughes Medical Institute; Vanderbilt University; Vanderbilt University; Vanderbilt University								AKTORIES K, 1995, METHOD ENZYMOL, V256, P184; Amano M, 1996, SCIENCE, V271, P648, DOI 10.1126/science.271.5249.648; AVRAHAM H, 1989, MOL CELL BIOL, V9, P2058, DOI 10.1128/MCB.9.5.2058; BALBOA MA, 1995, J BIOL CHEM, V270, P29843; BERRIDGE MJ, 1983, BIOCHEM J, V212, P473, DOI 10.1042/bj2120473; BILLAH MM, 1990, BIOCHEM J, V269, P281, DOI 10.1042/bj2690281; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BOKOCH GM, 1994, J BIOL CHEM, V269, P31674; BOWMAN EP, 1993, J BIOL CHEM, V268, P21509; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; CONRICODE KM, 1992, J BIOL CHEM, V267, P7199; DILLON ST, 1995, INFECT IMMUN, V63, P1421, DOI 10.1128/IAI.63.4.1421-1426.1995; DUBYAK GR, 1993, BIOCHEM J, V292, P121, DOI 10.1042/bj2920121; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; HORDIJK PL, 1994, J BIOL CHEM, V269, P645; HOULE MG, 1995, J BIOL CHEM, V270, P22795, DOI 10.1074/jbc.270.39.22795; INOUE H, 1995, BIOCHEM BIOPH RES CO, V210, P542, DOI 10.1006/bbrc.1995.1694; JIANG H, 1995, NATURE, V378, P409, DOI 10.1038/378409a0; KUMAGAI N, 1993, J BIOL CHEM, V268, P24535; KUMAGAI N, 1995, FEBS LETT, V366, P11, DOI 10.1016/0014-5793(95)00478-R; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; KWAK JY, 1995, J BIOL CHEM, V270, P27093, DOI 10.1074/jbc.270.45.27093; LAMBETH JD, 1995, J BIOL CHEM, V270, P2431, DOI 10.1074/jbc.270.6.2431; LEONARD D, 1992, J BIOL CHEM, V267, P22860; LEUNG T, 1995, J BIOL CHEM, V270, P29051, DOI 10.1074/jbc.270.49.29051; MACNULTY EE, 1992, J BIOL CHEM, V267, P2149; MALCOLM KC, 1994, J BIOL CHEM, V269, P25951; MARTIN TW, 1989, J BIOL CHEM, V264, P8847; MCNEIL PL, 1984, J CELL BIOL, V98, P1556, DOI 10.1083/jcb.98.4.1556; MORII N, 1992, J BIOL CHEM, V267, P20921; NOBES CD, 1995, CELL, V81, P53, DOI 10.1016/0092-8674(95)90370-4; OHGUCHI K, 1995, BIOCHEM BIOPH RES CO, V211, P306, DOI 10.1006/bbrc.1995.1811; OLSON MF, 1995, SCIENCE, V269, P1270, DOI 10.1126/science.7652575; OLSON SC, 1991, J BIOL CHEM, V266, P17236; PLEVIN R, 1991, BIOCHEM J, V280, P609, DOI 10.1042/bj2800609; PRICE BD, 1989, J BIOL CHEM, V264, P16638; QIAN Z, 1989, J BIOL CHEM, V264, P21720; QIU RG, 1995, NATURE, V374, P457, DOI 10.1038/374457a0; RIDLEY AJ, 1992, CELL, V70, P389, DOI 10.1016/0092-8674(92)90163-7; RODEN RBS, 1993, CELL GROWTH DIFFER, V4, P957; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; SIDDIQI AR, 1995, J BIOL CHEM, V270, P8466, DOI 10.1074/jbc.270.15.8466; SINGER WD, 1995, J BIOL CHEM, V270, P14944, DOI 10.1074/jbc.270.25.14944; VANCORVEN EJ, 1989, CELL, V59, P45, DOI 10.1016/0092-8674(89)90868-4; VANDERBEND RL, 1992, BIOCHEM J, V285, P235, DOI 10.1042/bj2850235; Watanabe G, 1996, SCIENCE, V271, P645, DOI 10.1126/science.271.5249.645; YAMAMOTO M, 1993, ONCOGENE, V8, P1449; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZHANG J, 1993, J BIOL CHEM, V268, P22251	51	136	136	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13135	13139		10.1074/jbc.271.22.13135	http://dx.doi.org/10.1074/jbc.271.22.13135			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662844	hybrid			2022-12-27	WOS:A1996UN47400069
J	Niviere, V; Fieschi, F; Decout, JL; Fontecave, M				Niviere, V; Fieschi, F; Decout, JL; Fontecave, M			Is the NAD(P)H:flavin oxidoreductase from Escherichia coli a member of the ferredoxin-NADP(+) reductase family? Evidence for the catalytic role of serine 49 residue	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NADPH-SULFITE REDUCTASE; AMINO-ACID SEQUENCE; FLAVIN REDUCTASE; NADPH-CYTOCHROME-P-450 REDUCTASE; IDENTIFICATION; MUTAGENESIS; ENZYME; DOMAIN; LIVER; GENE	The NAD(P)H:flavin oxidoreductase from Escherichia coli, Fre, is a monomer of 26.1 kDa which catalyzes the reduction of free flavins by NADPH or NADH. The flavin reductase Fre is the prototype of a new class of flavin reductases able to transfer electrons with no prosthetic group. It has been suggested that the flavin reductase could belong to the ferredoxin-NADP(+) reductase (FNR) family, on the basis of limited sequence homologies. A sequence, conserved within the ferredoxin-NADP(+) reductase family and present in the flavin reductase, is important for recognition of the isoalloxazine ring, Within this sequence, we have mutated serine 49 of the flavin reductase into alanine or threonine. k(cat) value of the S49A mutant was 35-fold lower than k(cat) of the wildtype enzyme. Determination of real K-d values for NADPH and lumichrome, a flavin analog, showed that recognition of the flavin is strongly affected by the S49A mutation, whereas affinity for the nicotinamide cofactor is only weakly modified. This suggests that serine 49 is involved in the binding of the isoalloxazine ring. Moreover, the K-d value for 5-deazariboflavin, in which the N-5 position of the isoalloxazine ring has been changed to a carbon atom, is not affected by the serine 49 to alanine mutation. This is consistent with the concept that the N-5 position is the main site for serine 49-flavin interaction. In the ferredoxin-NADP(+) reductase family, the equivalent serine residue, which has been shown to be essential for activity, is hydrogen-bonded to the N-5 of the FAD cofactor. Taken together, these data provide the first experimental support to the hypothesis that the flavin reductase Fre may belong to the ferredoxin-NADP(+) reductase family.	UNIV GRENOBLE 1, CNRS, UMR C5616, ETUD DYNAM & STRUCT SELECT LAB, F-38041 GRENOBLE 9, FRANCE	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA)			Fieschi, Franck/W-2748-2019	FIESCHI, Franck/0000-0003-1194-8107; Niviere, Vincent/0000-0002-5132-457X				ALIVERTI A, 1995, BIOCHEMISTRY-US, V34, P8371, DOI 10.1021/bi00026a019; ANDREWS SC, 1992, FEBS LETT, V302, P247, DOI 10.1016/0014-5793(92)80452-M; ASHTON WT, 1978, J HETEROCYCLIC CHEM, V15, P489, DOI 10.1002/jhet.5570150324; BLANC V, 1995, J BACTERIOL, V177, P5206, DOI 10.1128/jb.177.18.5206-5214.1995; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BREDT DS, 1991, NATURE, V351, P714, DOI 10.1038/351714a0; BRUNS CM, 1995, J MOL BIOL, V247, P125, DOI 10.1006/jmbi.1994.0127; CORRELL CC, 1992, SCIENCE, V258, P1604, DOI 10.1126/science.1280857; COVES J, 1993, J BIOL CHEM, V268, P18604; COVES J, 1993, EUR J BIOCHEM, V211, P635, DOI 10.1111/j.1432-1033.1993.tb17591.x; DALZIEL K, 1973, ENZYMES, V11, P2; DWIVEDI UN, 1994, J BIOL CHEM, V269, P13785; Fieschi F, 1995, J BIOL CHEM, V270, P30392, DOI 10.1074/jbc.270.51.30392; Fieschi F, 1996, EUR J BIOCHEM, V237, P870, DOI 10.1111/j.1432-1033.1996.0870p.x; FONTECAVE M, 1987, J BIOL CHEM, V262, P12325; FONTECAVE M, 1994, BIOMETALS, V7, P3; GAUDU P, 1994, J BIOL CHEM, V269, P8182; HANIU M, 1989, BIOCHEMISTRY-US, V28, P8639, DOI 10.1021/bi00447a054; KARPLUS PA, 1991, SCIENCE, V251, P60, DOI 10.1126/science.1986412; KARPLUS PA, 1984, BIOCHEMISTRY-US, V23, P6576, DOI 10.1021/bi00321a046; KENDREW SG, 1995, J BIOL CHEM, V270, P17339, DOI 10.1074/jbc.270.29.17339; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LU GG, 1995, J MOL BIOL, V248, P931, DOI 10.1006/jmbi.1995.0273; MEIGHEN EA, 1991, MICROBIOL REV, V55, P123, DOI 10.1128/MMBR.55.1.123-142.1991; NISHIDA H, 1995, BIOCHEMISTRY-US, V34, P2763, DOI 10.1021/bi00009a004; OSTROWSKI J, 1989, J BIOL CHEM, V264, P15796; PLAPP BV, 1995, METHOD ENZYMOL, V249, P91; QUANDT KS, 1994, P NATL ACAD SCI USA, V91, P9322, DOI 10.1073/pnas.91.20.9322; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SPECTOR T, 1981, BIOCHEM PHARMACOL, V30, P1, DOI 10.1016/0006-2952(81)90277-X; SPYROU G, 1991, J BACTERIOL, V173, P3673, DOI 10.1128/JB.173.12.3673-3679.1991; TOMATSU S, 1989, GENE, V80, P353; YUBISUI T, 1979, J BIOCHEM, V85, P719; ZENNO S, 1994, J BACTERIOL, V176, P3536, DOI 10.1128/JB.176.12.3536-3543.1994; ZENNO S, 1994, J BACTERIOL, V176, P3544, DOI 10.1128/JB.176.12.3544-3551.1994	36	30	30	1	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16656	16661		10.1074/jbc.271.28.16656	http://dx.doi.org/10.1074/jbc.271.28.16656			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663185	hybrid			2022-12-27	WOS:A1996UX12600038
J	Brosnan, JT; Brosnan, ME; Charron, R; Nissim, I				Brosnan, JT; Brosnan, ME; Charron, R; Nissim, I			A mass isotopomer study of urea and glutamine synthesis from N-15-labeled ammonia in the perfused rat liver	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CARBAMOYL-PHOSPHATE SYNTHETASE; TERM METABOLIC-FATE; CHROMATOGRAPHY; N-15; SPECTROMETRY; BIOSYNTHESIS; UREAGENESIS; INSITU; CYCLE; CELLS	This study examines the incorporation of N-15 from (NH4Cl)-N-15 into urea and glutamine, predicts the pattern of isotopomers produced as a function of the N-15 enrich ment of the relevant precursor pools, and presents a means of determining the isotopic enrichment of these pools, Rat livers were perfused, in the nonrecirculating mode, with 0.3 mM (NH4Cl)-N-15, and the isotopomers of urea and of glutamine produced were determined by gas chromatography-mass spectrometry methodology, Three different nitrogen mass isotopomers of urea were found, containing no, one, or two atoms of N-15. Four glutamine isotopomers were found, containing no N-15, one atom of N-15 in either the amino or amide position, or two N-15 atoms, A mathematical relationship was deduced that predicts that the relative proportions of the urea isotopomers depends not only on the relative enrichment of N-15 in the two precursor pools of urea nitrogen (mitochondrial ammonia and cytoplasmic aspartate) but on their absolute enrichment, This relationship was validated in experiments in which the isotopic enrichment of the substrate, (NH4Cl)-N-15, was varied, The proportions of the urea isotopomers produced can be predicted if one knows the N-15 enrichment in the two precursor pools, We found that when the N-15 enrichment of citrulline and aspartate in the perfusate were used as proxies for that in the mitochondrial ammonia and cytoplasmic aspartate pools we could accurately predict the relative proportion of the three isotopomers. The production of the four nitrogen isotopomers of glutamine could be used to determine the N-15 enrichment in the two precursor pools of glutamine nitrogen, the cytoplasmic ammonia and glutamate pools of the perivenous hepatocytes.	MEM UNIV NEWFOUNDLAND,DEPT MATH & STAT,ST JOHNS,NF A1C 5S7,CANADA; CHILDRENS HOSP PHILADELPHIA,ABRAMSON PEDIAT RES CTR,PHILADELPHIA,PA 19104	Memorial University Newfoundland; University of Pennsylvania; Childrens Hospital of Philadelphia	Brosnan, JT (corresponding author), MEM UNIV NEWFOUNDLAND,DEPT BIOCHEM,ST JOHNS,NF A1B 3X9,CANADA.				NIDDK NIH HHS [DK-39348] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039348] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ANDERSON LW, 1987, ANAL BIOCHEM, V163, P358, DOI 10.1016/0003-2697(87)90236-3; BROSNAN JT, 1970, BIOCHEM J, V117, P91, DOI 10.1042/bj1170091; BROSNAN JT, 1976, UREA CYCLE, P443; COHEN NS, 1985, BIOCHEM J, V229, P205, DOI 10.1042/bj2290205; COOPER AJL, 1987, J BIOL CHEM, V262, P1073; COOPER AJL, 1988, J BIOL CHEM, V263, P12268; GEBHARDT R, 1983, EMBO J, V2, P567, DOI 10.1002/j.1460-2075.1983.tb01464.x; GEISSLER A, 1992, BIOCHEM J, V287, P813, DOI 10.1042/bj2870813; GEYER JW, 1971, ANAL BIOCHEM, V39, P412, DOI 10.1016/0003-2697(71)90431-3; HAUSSINGER D, 1983, EUR J BIOCHEM, V133, P269, DOI 10.1111/j.1432-1033.1983.tb07458.x; HELLERSTEIN MK, 1992, AM J PHYSIOL, V263, pE988; HELLERSTEIN MK, 1991, J BIOL CHEM, V266, P10920; Jacobs M. H., 1940, Cold Spring Harbor Symposia on Quantitative Biology, V8, P30; JONES BN, 1983, J CHROMATOGR, V266, P471, DOI 10.1016/S0021-9673(01)90918-5; JONES ME, 1980, ANNU REV BIOCHEM, V49, P253, DOI 10.1146/annurev.bi.49.070180.001345; KELLEHER JK, 1994, AM J PHYSIOL, V266, pE384, DOI 10.1152/ajpendo.1994.266.3.E384; KELLEHER JK, 1992, AM J PHYSIOL, V262, pE118, DOI 10.1152/ajpendo.1992.262.1.E118; KHARROUBI AT, 1992, AM J PHYSIOL, V263, pE667, DOI 10.1152/ajpendo.1992.263.4.E667; KIRSTEN E, 1963, BIOCHEM Z, V337, P312; KUO FC, 1991, P NATL ACAD SCI USA, V88, P9468, DOI 10.1073/pnas.88.21.9468; LOBLEY GE, 1995, BRIT J NUTR, V73, P667, DOI 10.1079/BJN19950072; LUO QJ, 1995, EUR J BIOCHEM, V228, P912, DOI 10.1111/j.1432-1033.1995.0912m.x; MEIJER AJ, 1985, FEBS LETT, V191, P249, DOI 10.1016/0014-5793(85)80018-1; NEESE RA, 1993, AM J PHYSIOL, V264, pE136, DOI 10.1152/ajpendo.1993.264.1.E136; NISSIM I, 1984, ANAL BIOCHEM, V143, P14, DOI 10.1016/0003-2697(84)90550-5; NISSIM I, 1993, J AM SOC NEPHROL, V3, P1416; NISSIM I, 1985, J BIOL CHEM, V260, P3955; NISSIM I, 1992, ARCH BIOCHEM BIOPHYS, V292, P393, DOI 10.1016/0003-9861(92)90008-K; PAUSCH J, 1985, EUR J BIOCHEM, V150, P189, DOI 10.1111/j.1432-1033.1985.tb09006.x; Sies H, 1978, Methods Enzymol, V52, P48; WATFORD M, 1983, FASEB J, V7, P1468; WETTSTEIN M, 1994, HEPATOLOGY, V19, P641, DOI 10.1002/hep.1840190315; WOLFE RR, 1992, RADIOACTIVE STABLE I, P49	33	44	44	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16199	16207		10.1074/jbc.271.27.16199	http://dx.doi.org/10.1074/jbc.271.27.16199			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663091	hybrid			2022-12-27	WOS:A1996UW35200052
J	UtsunomiyaTate, N; Endou, H; Kanai, Y				UtsunomiyaTate, N; Endou, H; Kanai, Y			Cloning and functional characterization of a system ASC-like Na+-dependent neutral amino acid transporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTAMATE TRANSPORTER; HIGH-AFFINITY; NEUROTRANSMITTER TRANSPORTERS; RAT HEPATOCYTES; EXPRESSION; PROTEIN; BRAIN; CDNA; SIMILARITY; SUBSTRATE	A cDNA was isolated from mouse testis which encodes a Na+-dependent neutral amino acid transporter. The encoded protein, designated ASCT2, showed amino acid sequence similarity to the mammalian glutamate transporters (40-44% identity), Na+-dependent neutral amino acid transporter ASCT1 (57% identity; Arriza, J. L., Kavanaugh, M. P., Fairman, W. A., Wu, Y.-N., Murdoch, G. H., North, R. A., and Amara, S. G. (1993) J. Biol. Chem. 268, 15329-15332; Shafqat, S., Tamarappoo, B. K., Kilberg, M. S., Puranam, R. S., McNamara, J. O., Guadano-Ferraz, A., and Fremeau, T., Jr. (1993) J. Biol. Chem. 268, 15351-15355) and a mouse adipocyte differentiation associated gene product AAAT (94% identity; Liao, K., and Lane, D. (1995) Biochem. Biophys. Res. Commun. 208, 1008-1015). When expressed in Xenopus laevis oocytes, ASCT2 exhibited Na+-dependent uptakes of neutral amino acids such as L-alanine, L-serine, L-threo nine, L-cysteine, and L-glutamine at high affinity with K-m values around 20 mu m. L-Methionine, L-leucine, L-glycine, and L-valine were also transported by ASCT2 but with lower affinity. The substrate selectivity of ASCT2 was typical of amino acid transport system ASC, which prefers neutral amino acids without bulky or branched side chains. ASCT2 also transported L-glutamate at low affinity (K-m = 1.6 mM). L-Glutamate transport was enhanced by lowering extracellular pH, suggesting that L-glutamate was transported as protonated form. In contrast to electrogenic transport of glutamate transporters and the other ASC isoform ASCT1, ASCT2-mediated amino acid transport was electroneutral. Na+ dependence of L-alanine uptake fits to the Michaelis-Menten equation, suggesting a single Na+ cotransported with one amino acid, which was distinct from glutamate transporters coupled to two Na+. Northern blot hybridization revealed that ASCT2 was mainly expressed in kidney, large intestine, lung, skeletal muscle, testis, and adipose tissue. Functional characterization of ASCT2 provided fruitful information on the properties of substrate binding sites and the mechanisms of transport of Na+-dependent neutral and acidic amino acid trans porter family, which would facilitate the structure-function analyses based on the comparison of the primary structures of ASCT2 and the other members of the family.	KYORIN UNIV,SCH MED,DEPT PHARMACOL & TOXICOL,MITAKA,TOKYO 181,JAPAN	Kyorin University								AMARA SG, 1993, ANNU REV NEUROSCI, V16, P73, DOI 10.1146/annurev.ne.16.030193.000445; ARRIZA JL, 1993, J BIOL CHEM, V268, P15329; ARRIZA JL, 1994, J NEUROSCI, V14, P5559; BOUVIER M, 1992, NATURE, V360, P471, DOI 10.1038/360471a0; BUSSOLATI O, 1992, J BIOL CHEM, V267, P8330; CASADO M, 1993, J BIOL CHEM, V268, P27313; Chou P Y, 1978, Adv Enzymol Relat Areas Mol Biol, V47, P45; CHRISTENSEN HN, 1967, J BIOL CHEM, V242, P5237; CHRISTENSEN HN, 1990, PHYSIOL REV, V70, P43, DOI 10.1152/physrev.1990.70.1.43; CHRISTENSEN HN, 1965, J BIOL CHEM, V240, P3609; DANBOLT NC, 1992, NEUROSCIENCE, V51, P259; FAIRMAN WA, 1995, NATURE, V375, P599, DOI 10.1038/375599a0; GAZZOLA GC, 1981, J BIOL CHEM, V256, P6054; HANDLOGTEN ME, 1981, J BIOL CHEM, V256, P7905; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEDIGER MA, 1994, J EXP BIOL, V196, P15; KANAI Y, 1995, J BIOL CHEM, V270, P16561, DOI 10.1074/jbc.270.28.16561; KANAI Y, 1992, AM J PHYSIOL, V263, pF1087, DOI 10.1152/ajprenal.1992.263.6.F1087; KANAI Y, 1993, FASEB J, V7, P1450, DOI 10.1096/fasebj.7.15.7903261; KANAI Y, 1994, J BIOL CHEM, V269, P20599; KANAI Y, 1994, J CLIN INVEST, V93, P397, DOI 10.1172/JCI116972; KANAI Y, 1993, TRENDS NEUROSCI, V16, P365, DOI 10.1016/0166-2236(93)90094-3; KANAI Y, 1992, NATURE, V360, P467, DOI 10.1038/360467a0; KANNER BI, 1987, CRIT REV BIOCHEM MOL, V22, P1, DOI 10.3109/10409238709082546; KILBERG MS, 1979, BIOCHEM BIOPH RES CO, V88, P744, DOI 10.1016/0006-291X(79)92110-7; KIM JW, 1991, NATURE, V352, P725, DOI 10.1038/352725a0; KIMELBERG HK, 1989, J NEUROSCI, V9, P1141; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LEE WS, 1994, J BIOL CHEM, V269, P10202; LERNER J, 1987, COMP BIOCHEM PHYS B, V87, P443, DOI 10.1016/0305-0491(87)90035-6; LIAO K, 1995, BIOCHEM BIOPH RES CO, V208, P1008, DOI 10.1006/bbrc.1995.1434; PINES G, 1992, NATURE, V360, P464, DOI 10.1038/360464a0; ROTHSTEIN JD, 1994, NEURON, V13, P713, DOI 10.1016/0896-6273(94)90038-8; SHAFQAT S, 1993, J BIOL CHEM, V268, P15351; SILBERNAGL S, 1979, KLIN WOCHENSCHR, V57, P1009, DOI 10.1007/BF01479986; STEVENS BR, 1984, ANNU REV PHYSIOL, V46, P417; STEVENS BR, 1992, AM J PHYSIOL, V263, pR458, DOI 10.1152/ajpregu.1992.263.3.R458; STORCK T, 1992, P NATL ACAD SCI USA, V89, P10955, DOI 10.1073/pnas.89.22.10955; UCHIDA S, 1992, P NATL ACAD SCI USA, V89, P8230, DOI 10.1073/pnas.89.17.8230; VADGAMA JV, 1984, J BIOL CHEM, V259, P3648; WELLS RG, 1992, AM J PHYSIOL, V263, pF459, DOI 10.1152/ajprenal.1992.263.3.F459; YAMAUCHI A, 1992, J BIOL CHEM, V267, P649	43	408	424	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14883	14890		10.1074/jbc.271.25.14883	http://dx.doi.org/10.1074/jbc.271.25.14883			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662767	hybrid			2022-12-27	WOS:A1996UT10600039
J	Hsu, MH; Chirala, SS; Wakil, SJ				Hsu, MH; Chirala, SS; Wakil, SJ			Human fatty-acid synthase gene - Evidence for the presence of two promoters and their functional interaction	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; TRANSCRIPTIONAL INTERFERENCE; MOLECULAR-CLONING; LIVER; EXPRESSION; ENZYME; TERMINATION; SEQUENCES; REGION	We have isolated and sequenced a genomic clone coding for the first three exons and the 5'-flanking region of the human fatty-acid synthase gene, The translation initiation site, ATG, is located in exon II. Primer extension and S1 nuclease analyses showed the presence of three transcription initiation (Ti) sites: Ti I, Ti II, and Ti III, The Ti I site is mapped to the beginning of the untranslated exon I and preceded by a promoter with recognizable TATA and CAAT boxes. The Ti II and Ti III sites are located in intron I, at 60 and 49 nucleotides upstream of the translation initiation site ATG in exon II , respectively, These two Ti sites are preceded by four putative Sp1 boxes, but lack TATA and CAAT boxes, Analysis of luciferase reporter gene expression in transient transfection assays confirmed the existence of two promoters, A 200-base pair 5'-flanking region, which has strong promoter activity comparable with that of the CMV promoter, is considered human fatty-acid synthase promoter I. In a wild-type human fatty-acid synthase-luciferase construct, in which promoter I and intron I are present in their natural configuration, the reporter gene activity is only 1% of that of promoter I. Deletion analysis showed the existence of promoter II, which is located in intron I immediately upstream of the Ti II site. The strength of promoter II is approximately 1/15th of that of promoter I in transient transfection assays, Further analysis of reporter gene constructs showed that promoter II inhibited the reporter gene activity of the wildtype construct that contained promoter I and intron I and that the spatial separation of the two promoters is important for this inhibition, A model is proposed based on the possibility that the assembly of transcription complexes on promoter HP creates a ''roadblock'' and reduces the overall expression of the fatty-acid synthase gene by interfering with the progression of transcription from promoter I.	BAYLOR COLL MED, VERNA & MARRS MCLEAN DEPT BIOCHEM, HOUSTON, TX 77030 USA	Baylor College of Medicine					NIGMS NIH HHS [GM-19091] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AMY CM, 1990, BIOCHEM J, V271, P675, DOI 10.1042/bj2710675; AMY CM, 1992, P NATL ACAD SCI USA, V89, P1105, DOI 10.1073/pnas.89.3.1105; BACK DW, 1986, J BIOL CHEM, V261, P4190; Beck K F, 1992, DNA Seq, V2, P359, DOI 10.3109/10425179209020817; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BERK AJ, 1977, CELL, V12, P721, DOI 10.1016/0092-8674(77)90272-0; BRIGGS MR, 1986, SCIENCE, V234, P47, DOI 10.1126/science.3529394; CHALBOS D, 1991, J BIOL CHEM, V266, P8220; CHIRALA SS, 1992, P NATL ACAD SCI USA, V89, P10232, DOI 10.1073/pnas.89.21.10232; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CULLEN BR, 1984, NATURE, V307, P241, DOI 10.1038/307241a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GOODRIDGE AG, 1984, ARCH BIOCHEM BIOPHYS, V230, P82, DOI 10.1016/0003-9861(84)90088-2; HA J, 1994, EUR J BIOCHEM, V219, P297, DOI 10.1111/j.1432-1033.1994.tb19941.x; HILLGARTNER F, 1995, PHYSIOL REV, V75, P47, DOI 10.1152/physrev.1995.75.1.47; HOFFMANN GE, 1980, BIOCHIM BIOPHYS ACTA, V620, P151, DOI 10.1016/0005-2760(80)90194-0; HUNT CR, 1986, P NATL ACAD SCI USA, V83, P3786, DOI 10.1073/pnas.83.11.3786; IRITANI N, 1992, J NUTR, V122, P28, DOI 10.1093/jn/122.1.28; IRNIGER S, 1992, NUCLEIC ACIDS RES, V20, P4733, DOI 10.1093/nar/20.18.4733; JAYAKUMAR A, 1995, P NATL ACAD SCI USA, V92, P8695, DOI 10.1073/pnas.92.19.8695; JAYAKUMAR A, 1994, GENOMICS, V23, P420, DOI 10.1006/geno.1994.1518; KAMEDA K, 1995, MOL CELL BIOCHEM, V144, P105, DOI 10.1007/BF00944388; KAMEDA K, 1991, J BIOL CHEM, V266, P419; KASTURI R, 1988, BIOCHEMISTRY-US, V27, P7778, DOI 10.1021/bi00420a029; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; Maniatis T., 1982, MOL CLONING; Miller JH, 1972, EXPT MOL GENETICS, P403; MOHAMED AH, 1988, J BIOL CHEM, V263, P12315; MONACO L, 1994, J BIOL CHEM, V269, P347; MORRIS SM, 1982, J BIOL CHEM, V257, P3225; MOUSTAID N, 1991, J BIOL CHEM, V266, P18550; MOUSTAID N, 1994, J BIOL CHEM, V269, P5629; NORDEEN SK, 1988, BIOTECHNIQUES, V6, P454; PONCZ M, 1982, P NATL ACAD SCI-BIOL, V79, P4298, DOI 10.1073/pnas.79.14.4298; PROUDFOOT NJ, 1986, NATURE, V322, P562, DOI 10.1038/322562a0; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SEMENKOVICH CF, 1993, J BIOL CHEM, V268, P6961; SHRAGO E, 1969, J BIOL CHEM, V244, P2761; Soncini M, 1995, J BIOL CHEM, V270, P30339, DOI 10.1074/jbc.270.51.30339; STAPLETON SR, 1990, J BIOL CHEM, V265, P18442; TAE HJ, 1994, J BIOL CHEM, V269, P10475; TOWLE HC, 1995, J BIOL CHEM, V270, P23235, DOI 10.1074/jbc.270.40.23235; WAKIL SJ, 1983, ANNU REV BIOCHEM, V52, P537, DOI 10.1146/annurev.bi.52.070183.002541; WAKIL SJ, 1989, BIOCHEMISTRY-US, V28, P4523, DOI 10.1021/bi00437a001; WANG D, 1995, J BIOL CHEM, V270, P28716, DOI 10.1074/jbc.270.48.28716; WOLF SS, 1994, BIOCHEM BIOPH RES CO, V203, P943, DOI 10.1006/bbrc.1994.2273; ZELEWSKI M, 1990, COMP BIOCHEM PHYS B, V95, P469, DOI 10.1016/0305-0491(90)90004-D	48	43	44	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13584	13592		10.1074/jbc.271.23.13584	http://dx.doi.org/10.1074/jbc.271.23.13584			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662758	hybrid			2022-12-27	WOS:A1996UP38500044
J	Thorner, PS; Zheng, KQ; Kalluri, R; Jacobs, R; Hudson, BG				Thorner, PS; Zheng, KQ; Kalluri, R; Jacobs, R; Hudson, BG			Coordinate gene expression of the alpha 3, alpha 4, and alpha 5 chains of collagen type IV - Evidence from a canine model of X-linked nephritis with a COL4A5 gene mutation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SAMOYED HEREDITARY GLOMERULOPATHY; BASEMENT-MEMBRANE COLLAGEN; COMMON PROMOTER REGION; AMINO-ACID-SEQUENCE; ALPORT SYNDROME; NC1 DOMAIN; BIDIRECTIONAL PROMOTER; GOODPASTURE ANTIGEN; MOLECULAR-GENETICS; MESSENGER-RNA	Canine X-linked hereditary nephritis is an animal model for human X-linked hereditary nephritis with a premature stop codon in the alpha 5(IV) gene of collagen type IV. We used this model to examine the other alpha(IV) chains at the mRNA and protein level in the kidney, since in human X-linked hereditary nephritis, the alpha 3(IV) and alpha 4(IV) chains are often absent from the glomerular basement membrane, although both are encoded by autosomal genes, cDNA probes for the alpha 1(IV)-alpha 6(IV) chains were generated from normal dog kidney using the polymerase chain reaction, Sequences were greater than or equal to 88% identical at the DNA level and greater than or equal to 92% identical at the protein level to the respective human alpha(IV) chains, By Northern analysis, transcripts for the alpha 1(IV), alpha 2(IV), and alpha 6(IV) chains were detected at comparable levels in both normal and affected male dog kidney RNA, As previously shown, the transcript for the alpha 5(IV) chain was reduced to similar to 10% of normal. Unexpectedly, the alpha 3(IV) and alpha 4(IV) transcripts were both decreased greater than or equal to 77% in affected male dog kidney, suggesting a mechanism coordinating the expression of these three basement membrane components, The NC1 domain of collagen type IV isolated from normal dog glomeruli was positive for the alpha 3(IV), alpha 4(IV), and alpha 5(IV) chains by Western blotting, In contrast, in the NC1 domain isolated from affected dog glomeruli, these three chains were not detectable, except for a trace of alpha 3(IV) dimer. In X-linked hereditary nephritis, the absence of the alpha 3(IV) and alpha 4(IV) chains from glomerular basement membrane may reflect factors acting at the transcriptional and/or translational level in addition to the protein assembly level.	UNIV TORONTO,TORONTO,ON M5G 1X8,CANADA; UNIV KANSAS,MED CTR,DEPT BIOCHEM & MOLEC BIOL,KANSAS CITY,KS 66160; UNIV GUELPH,GUELPH,ON N1G 2W1,CANADA; ONTARIO VET COLL,DEPT PATHOL,GUELPH,ON N1G 2W1,CANADA	University of Toronto; University of Kansas; University of Kansas Medical Center; University of Guelph	Thorner, PS (corresponding author), HOSP SICK CHILDREN,DEPT PATHOL,555 UNIV AVE,TORONTO,ON M5G 1X8,CANADA.		Kalluri, Raghu/E-2677-2015	Kalluri, Raghu/0000-0002-2190-547X; Hudson, Billy/0000-0002-5420-4100	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R37DK018381, R01DK018381] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18381] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BAUMAL R, 1991, AM J PATHOL, V139, P751; BRAZEL D, 1987, EUR J BIOCHEM, V168, P529, DOI 10.1111/j.1432-1033.1987.tb13450.x; BURBELO PD, 1991, J BIOL CHEM, V266, P22297; BURBELO PD, 1990, J BIOL CHEM, V265, P4839; BURBELO PD, 1988, P NATL ACAD SCI USA, V85, P9679, DOI 10.1073/pnas.85.24.9679; DING J, 1995, J AM SOC NEPHROL, V5, P1714; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; FEINGOLD J, 1985, KIDNEY INT, V27, P672, DOI 10.1038/ki.1985.63; FISCHER G, 1993, BIOCHEM J, V292, P687, DOI 10.1042/bj2920687; FISCHER G, 1990, BIOCHEMISTRY-US, V29, P2205, DOI 10.1021/bi00461a001; GRIFFIN CA, 1987, P NATL ACAD SCI USA, V84, P512, DOI 10.1073/pnas.84.2.512; GRUNFELD JP, 1985, KIDNEY INT, V27, P83, DOI 10.1038/ki.1985.14; GUNWAR S, 1991, J BIOL CHEM, V266, P15318; GUO CY, 1993, KIDNEY INT, V44, P1316, DOI 10.1038/ki.1993.384; Habib R, 1982, Kidney Int Suppl, V11, pS20; HEIKKILA P, 1993, J BIOL CHEM, V268, P24677; HEMMINGSEN SM, 1988, NATURE, V333, P330, DOI 10.1038/333330a0; HILAL L, 1993, NAT GENET, V5, P287, DOI 10.1038/ng1193-287; HOSTIKKA SL, 1988, J BIOL CHEM, V263, P19488; HOSTIKKA SL, 1990, P NATL ACAD SCI USA, V87, P1606, DOI 10.1073/pnas.87.4.1606; HUDSON BG, 1992, KIDNEY INT, V42, P179, DOI 10.1038/ki.1992.276; HUDSON BG, 1993, J BIOL CHEM, V268, P26033; INNIS MA, 1990, PCR PROTOCOLS GUIDE, P30; JANSEN B, 1986, J LAB CLIN MED, V107, P551; JANSEN B, 1986, AM J PATHOL, V125, P536; KALLURI R, 1994, KIDNEY INT, V45, P721, DOI 10.1038/ki.1994.96; KLEPPEL MM, 1987, J CLIN INVEST, V80, P263, DOI 10.1172/JCI113057; KUIVANIEMI H, 1991, FASEB J, V5, P2052, DOI 10.1096/fasebj.5.7.2010058; LEINONEN A, 1994, J BIOL CHEM, V269, P26172; LEMMINK HH, 1994, HUM MOL GENET, V3, P1269, DOI 10.1093/hmg/3.8.1269; LEMMINK HH, 1994, HUM MOL GENET, V3, P313; MARIYAMA M, 1994, J BIOL CHEM, V269, P23013; MARIYAMA M, 1992, J BIOL CHEM, V267, P1253; MINER JH, 1994, J CELL BIOL, V127, P879, DOI 10.1083/jcb.127.3.879; MOCHIZUKI T, 1994, NAT GENET, V8, P77, DOI 10.1038/ng0994-77; MORRISON KE, 1991, J BIOL CHEM, V266, P34; MORRISON KE, 1991, AM J HUM GENET, V49, P545; NEILSON EG, 1993, J BIOL CHEM, V268, P8402; NONOMIYA Y, 1995, J CELL BIOL, V130, P1219; OBERBAUMER I, 1985, EUR J BIOCHEM, V147, P212; OOHASHI T, 1994, J BIOL CHEM, V269, P7520; PEISSEL B, 1995, J CLIN INVEST, V96, P1948, DOI 10.1172/JCI118241; POSCHL E, 1988, EMBO J, V7, P2687, DOI 10.1002/j.1460-2075.1988.tb03122.x; REEDERS ST, 1992, KIDNEY INT, V42, P783, DOI 10.1038/ki.1992.348; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; SAMBROOK J, 1989, MOL CLONING LABORATO, P60; SCHMID SR, 1992, MOL MICROBIOL, V6, P283, DOI 10.1111/j.1365-2958.1992.tb01470.x; SCHMIDT C, 1993, BIOCHIM BIOPHYS ACTA, V1174, P1, DOI 10.1016/0167-4781(93)90085-R; SPEAR GS, 1972, AM J PATHOL, V69, P213; SPRANGER J, 1994, EUR J PEDIATR, V153, P56, DOI 10.1007/BF01959208; STOVER ML, 1993, J CLIN INVEST, V92, P1994, DOI 10.1172/JCI116794; SUGIMOTO M, 1993, FEBS LETT, V330, P122, DOI 10.1016/0014-5793(93)80256-T; TANAKA S, 1993, J BIOL CHEM, V268, P8862; THORNER P, 1989, KIDNEY INT, V35, P843, DOI 10.1038/ki.1989.62; THORNER P, 1987, LAB INVEST, V56, P435; THORNER PS, 1992, VIRCHOWS ARCH A, V421, P467, DOI 10.1007/BF01606875; TRYGGVASON K, 1993, KIDNEY INT, V43, P38, DOI 10.1038/ki.1993.8; URLAUB G, 1989, MOL CELL BIOL, V9, P2868, DOI 10.1128/MCB.9.7.2868; WILLING MC, 1992, AM J HUM GENET, V51, P508; YOSHIOKA K, 1994, AM J PATHOL, V144, P986; ZHENG KQ, 1994, P NATL ACAD SCI USA, V91, P3989, DOI 10.1073/pnas.91.9.3989; ZHOU J, 1994, J BIOL CHEM, V269, P13193; ZHOU J, 1993, SCIENCE, V261, P1167, DOI 10.1126/science.8356449; ZHOU J, 1993, KIDNEY INT, V43, P722, DOI 10.1038/ki.1993.103; ZHOU J, 1992, J BIOL CHEM, V267, P12475	65	55	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13821	13828		10.1074/jbc.271.23.13821	http://dx.doi.org/10.1074/jbc.271.23.13821			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662866	hybrid			2022-12-27	WOS:A1996UP38500078
J	Chun, JS; Ha, MJ; Jacobson, BS				Chun, JS; Ha, MJ; Jacobson, BS			Differential translocation of protein kinase C epsilon during HeLa cell adhesion to a gelatin substratum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EXTRACELLULAR-MATRIX; ARACHIDONIC-ACID; TYROSINE PHOSPHORYLATION; SIGNAL TRANSDUCTION; PLASMA-MEMBRANE; ACTIVATION; RECEPTOR; CYTOSKELETON; FIBRONECTIN; INTEGRINS	The spreading of HeLa cells, following attachment to a collagen or gelatin substratum, requires the activation of protein kinase C (PKC). Membrane-bound PKC was previously shown to be activated during cell attachment and in response to the activation of a series of lipid second messengers turned on by the ligation of beta 1-integrin collagen receptors. HeLa cells express the alpha, gamma, epsilon, zeta, lambda, and iota isozymes of PKC as determined by Western blotting with specific antibodies. Only PKC epsilon redistributed from the cytosol to the membrane during cell adhesion. Most of the PKC epsilon in cells that were in suspension was in the cytosolic fraction. During cell attachment to a gelatin matrix, all of the PKC epsilon moved out of the cytosol, with most going to the membrane fraction. After the cells became fully spread, PKC epsilon began to reappear in the cytosol. Translocation of PKC epsilon was not observed during the adhesion of cells to culture dishes where cells nonspecifically attach but do not spread, The conventional PKC alpha and -gamma isozymes were translocated from the cytosol to the membrane only when phorbol ester was present at a concentration that increases the rate and extent of cell spreading. Under normal conditions, i.e. in the absence of phorbol ester, PKC epsilon appears to be the PKC isozyme responsible for the regulation of HeLa cell adhesion to the extracellular matrix.	UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003; KYUNGPOOK NATL UNIV,DEPT BIOL,TAEGU 702701,SOUTH KOREA; AJOU UNIV,INST MED SCI,MED GENET LAB,SUWON 441749,SOUTH KOREA; UNIV MASSACHUSETTS,DEPT BIOCHEM & MOLEC BIOL,AMHERST,MA 01003	University of Massachusetts System; University of Massachusetts Amherst; Kyungpook National University; Ajou University; University of Massachusetts System; University of Massachusetts Amherst					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM029127] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM-29127] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALBELDA SM, 1990, FASEB J, V4, P2868, DOI 10.1096/fasebj.4.11.2199285; AUER KL, 1995, MOL BIOL CELL, V6, P1305, DOI 10.1091/mbc.6.10.1305; BURRIDGE K, 1988, ANNU REV CELL BIOL, V4, P487, DOI 10.1146/annurev.cb.04.110188.002415; CHEN QM, 1994, J BIOL CHEM, V269, P26602; CHUN JS, 1993, MOL BIOL CELL, V4, P271; CHUN JS, 1992, MOL BIOL CELL, V3, P481, DOI 10.1091/mbc.3.5.481; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CYBULSKY AV, 1993, AM J PHYSIOL, V264, pC323, DOI 10.1152/ajpcell.1993.264.2.C323; DANILOV YN, 1989, J CELL BIOL, V108, P1925, DOI 10.1083/jcb.108.5.1925; FRAZIER WA, 1984, CELL MEMBR METH REV, V2, P1; GOODNIGHT J, 1994, ADV CANCER RES, V64, P159, DOI 10.1016/S0065-230X(08)60838-6; GROSSI IM, 1989, CANCER RES, V49, P1029; HEIDENREICH KA, 1990, J BIOL CHEM, V265, P15076; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; JULIANO RL, 1993, J CELL BIOL, V120, P577, DOI 10.1083/jcb.120.3.577; KAPRONBRAS C, 1993, J BIOL CHEM, V268, P20701; KORNBERG LJ, 1991, P NATL ACAD SCI USA, V88, P8392, DOI 10.1073/pnas.88.19.8392; LU ML, 1992, J CELL SCI, V101, P873; MCNAMEE HP, 1993, J CELL BIOL, V121, P673, DOI 10.1083/jcb.121.3.673; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OHMICHI M, 1993, BIOCHEM J, V295, P767, DOI 10.1042/bj2950767; PATTON WF, 1989, J CELL SCI, V92, P85; SCHLAEPFER DD, 1994, NATURE, V372, P786; SCHWARTZ MA, 1993, J CELL BIOL, V120, P1003, DOI 10.1083/jcb.120.4.1003; SHAW LM, 1990, J CELL BIOL, V110, P2167, DOI 10.1083/jcb.110.6.2167; VUORI K, 1993, J BIOL CHEM, V268, P21459; ZHU XY, 1995, MOL BIOL CELL, V6, P273, DOI 10.1091/mbc.6.3.273	27	82	84	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13008	13012		10.1074/jbc.271.22.13008	http://dx.doi.org/10.1074/jbc.271.22.13008			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662811	hybrid			2022-12-27	WOS:A1996UN47400051
J	Yamin, TT; Ayala, JM; Miller, DK				Yamin, TT; Ayala, JM; Miller, DK			Activation of the native 45-kDa precursor form of interleukin-1-converting enzyme	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-1-BETA-CONVERTING ENZYME; SEQUENCE; PROTEASE	Active interleukin-1 beta-converting enzyme (ICE) is composed of 20- and 10-kDa polypeptides (p20 and p10) derived from the processing of a cytosolic 45-kDa precursor protein (p45). The cleavage and activation of the native p45 ICE precursor have been characterized by use of specific inhibitors and antibodies recognizing various regions of ICE, The processing of p45 in vitro in THP.1 monocytic cell cytoplasmic extracts is inhibited only by protease inhibitors that inhibit ICE and not by inhibitors of other protease classes. The addition of L-742,395, a biotinylated irreversible ICE inhibitor, to these extracts labels only p45 and simultaneously inhibits p45 processing, demonstrating that the p45 has catalytic activity. Following a cleavage of p45 at a site that becomes the COOH terminus of p20, a more active intermediate is formed which migrates on SDS-polyacrylamide gel electrophoresis with an molecular mass of 35 kDa (ED(50) of similar to 0.1 mu M L-742,395 labeling versus 5 mu M for p45), This new more active ICE form serves both as an intermediate enzyme to cleave p45 as well as a substrate for the formation of the final active ICE (ED(50) of 1 nM L-742,395 labeling of p20 and for p22, an NH2-terminally extended form of p20), While initial cleavage of p45 can be found at the sites corresponding to both the NH2 termini of p22 and p20, these fragments cannot be labeled by L-742,395 and are hence inactive, p45 is not processed at the site corresponding to the NH2 terminus of the p10. Less than 50% of the p45 is cleaved down to active p20 or p22 ICE as determined by band shift on SDS-polyacrylamide gel electrophoresis of the biotinylated fragments, indicating that the in vitro activation is highly inefficient. The ICE fragmentation occurs by an intermolecular process and is highly dilution sensitive. Cleavage of p45 by exogenous p20/p10 ICE differs from that of the endogenous p45 cleavage activity in that the p20/p10 activity is more salt sensitive, and it produces a different pattern of cleavage fragments, principally 35- and 12-kDa fragments, These results indicate that the nature of the ICE activity changes as p45 is processed down to the p20/p10 form of the enzyme.	MERCK RES LABS,DEPT INFLAMMAT RES,RAHWAY,NJ 07065	Merck & Company								ALNEMRI ES, 1995, J BIOL CHEM, V270, P4312, DOI 10.1074/jbc.270.9.4312; AURON PE, 1984, P NATL ACAD SCI-BIOL, V81, P7907, DOI 10.1073/pnas.81.24.7907; AYALA JM, 1994, J IMMUNOL, V153, P2592; BLACK RA, 1989, FEBS LETT, V247, P386, DOI 10.1016/0014-5793(89)81376-6; CAMERON P, 1985, J EXP MED, V162, P790, DOI 10.1084/jem.162.3.790; CASANO FJ, 1994, GENOMICS, V20, P474, DOI 10.1006/geno.1994.1203; CERRETTI DP, 1994, GENOMICS, V20, P468, DOI 10.1006/geno.1994.1202; DINARELLO CA, 1991, BLOOD, V77, P1627; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; FLETCHER DS, 1995, J INTERF CYTOK RES, V15, P243, DOI 10.1089/jir.1995.15.243; HORVITZ HR, 1995, J CELL BIOCH B, V19, P261; HOWARD AD, 1995, J IMMUNOL, V154, P2321; KOSTURA MJ, 1989, P NATL ACAD SCI USA, V86, P5227, DOI 10.1073/pnas.86.14.5227; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; KUMAR S, 1994, GENE DEV, V8, P1613, DOI 10.1101/gad.8.14.1613; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; MARCH CJ, 1985, NATURE, V315, P641, DOI 10.1038/315641a0; MILLER BE, 1995, J IMMUNOL, V154, P1331; MILLER DK, 1993, J BIOL CHEM, V268, P18062; MUNDAY NA, 1995, J BIOL CHEM, V270, P15870, DOI 10.1074/jbc.270.26.15870; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAMAGE P, 1995, J BIOL CHEM, V270, P9378, DOI 10.1074/jbc.270.16.9378; ROLANDO AM, 1994, J CELL BIOCHEM, V18, P147; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1994, BIOCHEMISTRY-US, V33, P3934, DOI 10.1021/bi00179a020; THORNBERRY NA, 1994, METHOD ENZYMOL, V244, P615; WALKER NPC, 1994, CELL, V78, P343, DOI 10.1016/0092-8674(94)90303-4; WANG L, 1994, CELL, V78, P739, DOI 10.1016/S0092-8674(94)90422-7; WANG XM, 1994, GENE, V145, P273; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; YUAN JY, 1993, CELL, V75, P641, DOI 10.1016/0092-8674(93)90485-9	33	152	156	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13273	13282		10.1074/jbc.271.22.13273	http://dx.doi.org/10.1074/jbc.271.22.13273			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662843	hybrid			2022-12-27	WOS:A1996UN47400090
J	Negrete, HO; Rivers, RL; Gough, AH; Colombini, M; Zeidel, ML				Negrete, HO; Rivers, RL; Gough, AH; Colombini, M; Zeidel, ML			Individual leaflets of a membrane bilayer can independently regulate permeability	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NONELECTROLYTE PERMEABILITIES; WATER PERMEABILITY; LIPID-MEMBRANES; CELL-MEMBRANE; MDCK CELLS; CHOLESTEROL; MONOLAYERS; TRANSPORT; KIDNEY; DOMAIN	Water rapidly crosses most membranes, but only slowly crosses apical membranes of barrier epithelia such as bladder and kidney collecting duct, a feature essential to barrier function. How apical membrane structure reduces permeabilities remains unclear, Cell plasma membranes contain two leaflets of distinct lipid composition; the role of this bilayer asymmetry in membrane permeability is unclear, To determine how asymmetry of leaflet composition affects membrane permeability, effects on bilayer permeation of reducing single leaflet permeability were determined using two approaches: formation of asymmetric bilayers in an Ussing chamber, with only one of two leaflets containing cholesterol sulfate, and stabilization of the external leaflet of unilamellar vesicles with praeseodymium (Pr3+). In both systems, permeability measurements showed that each leaflet acts as an independent resistor of water permeation, These results show that a single bilayer leaflet can act as the barrier to permeation and provide direct evidence that segregation of lipids to create a low permeability exofacial leaflet may act to reduce the permeability of barrier epithelial apical membranes.	UNIV PITTSBURGH,MED CTR,LAB EPITHELIAL CELL BIOL,RENAL ELECTROLYTE DIV,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,CTR LIGHT MICROSCOPE IMAGING & BIOTECHNOL,PITTSBURGH,PA 15213; CARNEGIE MELLON UNIV,DEPT BIOL SCI,PITTSBURGH,PA 15213; UNIV MARYLAND,DEPT ZOOL,COLLEGE PK,MD 20742	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Carnegie Mellon University; Carnegie Mellon University; University System of Maryland; University of Maryland College Park			Gough, Albert/K-2490-2019; Colombini, Marco/A-1540-2014	Gough, Albert/0000-0001-6456-0195; 				COLOMBINI M, 1987, METHOD ENZYMOL, V148, P465; FETTIPLACE R, 1980, PHYSIOL REV, V60, P510, DOI 10.1152/physrev.1980.60.2.510; GENZ A, 1986, EUR BIOPHYS J BIOPHY, V13, P323, DOI 10.1007/BF00265668; GROSSMAN EB, 1992, AM J PHYSIOL, V262, pC1109, DOI 10.1152/ajpcell.1992.262.5.C1109; HOLZ R, 1970, J GEN PHYSIOL, V56, P125, DOI 10.1085/jgp.56.1.125; HUNT GR, 1978, BIOCHIM BIOPHYS ACTA, V507, P242, DOI 10.1016/0005-2736(78)90420-0; KIKERI D, 1989, NATURE, V339, P478, DOI 10.1038/339478a0; LANDE MB, 1994, AM J PHYSIOL, V267, pC367, DOI 10.1152/ajpcell.1994.267.2.C367; LANDE MB, 1995, J GEN PHYSIOL, V106, P67, DOI 10.1085/jgp.106.1.67; LANGE Y, 1984, BIOCHIM BIOPHYS ACTA, V769, P551, DOI 10.1016/0005-2736(84)90053-1; LANGE Y, 1989, J BIOL CHEM, V264, P3786; LEGRIMELLEC C, 1992, KIDNEY INT, V42, P825, DOI 10.1038/ki.1992.357; MONTAL M, 1981, Q REV BIOPHYS, V14, P1, DOI 10.1017/S0033583500002079; MONTAL M, 1972, P NATL ACAD SCI USA, V69, P3561, DOI 10.1073/pnas.69.12.3561; PRENNER E, 1993, ARCH BIOCHEM BIOPHYS, V305, P473, DOI 10.1006/abbi.1993.1449; PRIVER NA, 1993, BIOCHEMISTRY-US, V32, P2459, DOI 10.1021/bi00061a002; RODRIGUEZA WV, 1995, BIOCHEMISTRY-US, V34, P6208, DOI 10.1021/bi00018a025; SCHMIDT CF, 1978, NATURE, V271, P775, DOI 10.1038/271775a0; SILLERUD LO, 1982, BIOCHEMISTRY-US, V21, P1756, DOI 10.1021/bi00537a009; SIMONS K, 1988, BIOCHEMISTRY-US, V27, P6197, DOI 10.1021/bi00417a001; STRANGE K, 1987, J MEMBRANE BIOL, V96, P27, DOI 10.1007/BF01869332; VAN MEER G, 1987, J CELL BIOL, V105, P1623, DOI 10.1083/jcb.105.4.1623; VAN MEER G, 1986, EMBO J, V5, P1455, DOI 10.1002/j.1460-2075.1986.tb04382.x; VAN MEER G, 1982, EMBO J, V1, P847, DOI 10.1002/j.1460-2075.1982.tb01258.x; ZACHOWSKI A, 1989, NATURE, V340, P75, DOI 10.1038/340075a0; ZACHOWSKI A, 1989, COMMENTS MOL CELL BI, V6, P63; ZEIDEL ML, 1993, SEMIN NEPHROL, V13, P155; ZEIDEL ML, 1995, KIDNEY, P516	28	48	48	0	17	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11627	11630		10.1074/jbc.271.20.11627	http://dx.doi.org/10.1074/jbc.271.20.11627			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662821	hybrid			2022-12-27	WOS:A1996UL25000009
J	Caput, D; Laurent, P; Kaghad, M; Lelias, JM; Lefort, S; Vita, N; Ferrara, P				Caput, D; Laurent, P; Kaghad, M; Lelias, JM; Lefort, S; Vita, N; Ferrara, P			Cloning and characterization of a specific interleukin (IL)-13 binding protein structurally related to the IL-5 receptor alpha chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HIGH-AFFINITY; IGE SYNTHESIS; GAMMA-CHAIN; EXPRESSION; COMPONENT; IGG4	Interleukin-13 (IL-13) is a cytokine secreted by activated T lymphocytes that shares many, but not all, biological activities with IL-4. These overlapping activities are probably due to the existence of common receptor components, Two proteins have been described as constituents of the IL-4 receptor, a similar to 140-kDa glycoprotein (IL-4R) and the gamma chain (gamma c) of the IL-2 receptor, but neither of these proteins binds IL-13, We have cloned a cDNA encoding an IL-13 binding protein (IL-13R) from the Caki-1 human renal carcinoma cell line. The cloned cDNA encodes a 380-amino acid protein with two consensus patterns characteristic of the hematopoietic cytokine receptor family and a short cytoplasmic tail, The IL-13R shows homology with the IL-5 receptor, and to a lesser extent, with the prolactin receptor, COS-7 cells transfected with the IL-13R cDNA bind IL-13 with high affinity but do not bind IL-4, COS-7 cells co transfected with the cloned IL-13R cDNA and IL-CR cDNA resulted in the reconstitution of a small number of receptors that recognized both IL-4 and IL-13, Reverse transcription-polymerase chain reaction analysis detected the receptor transcript only in cell lines known to bind IL-13.	SANOFI RECH,F-31676 LABEGE,FRANCE	Sanofi-Aventis; Sanofi France								AVERSA G, 1993, J EXP MED, V178, P2213, DOI 10.1084/jem.178.6.2213; CAPUT D, 1986, P NATL ACAD SCI USA, V83, P1670, DOI 10.1073/pnas.83.6.1670; CORNELIS S, 1995, EUR J IMMUNOL, V25, P1857, DOI 10.1002/eji.1830250710; GALIZZI JP, 1990, J BIOL CHEM, V265, P439; GIRI J, 1993, EMBO J, V14, P3654; Honjo T, 1991, Curr Biol, V1, P201, DOI 10.1016/0960-9822(91)90055-2; IDZERDA RL, 1990, J EXP MED, V171, P861, DOI 10.1084/jem.171.3.861; KEEGAN AD, 1995, P NATL ACAD SCI USA, V92, P7681, DOI 10.1073/pnas.92.17.7681; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; KONDO M, 1993, SCIENCE, V262, P1874, DOI 10.1126/science.8266076; KRUSE N, 1992, EMBO J, V11, P3237, DOI 10.1002/j.1460-2075.1992.tb05401.x; LEFORT S, 1995, FEBS LETT, V366, P122, DOI 10.1016/0014-5793(95)00512-8; MATTHEWS DJ, 1995, BLOOD, V85, P38, DOI 10.1182/blood.V85.1.38.bloodjournal85138; MCKENZIE ANJ, 1993, P NATL ACAD SCI USA, V90, P3735, DOI 10.1073/pnas.90.8.3735; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; OBIRI NI, 1995, J BIOL CHEM, V270, P8797, DOI 10.1074/jbc.270.15.8797; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; RUSSELL SM, 1993, SCIENCE, V262, P1880, DOI 10.1126/science.8266078; VITA N, 1995, J BIOL CHEM, V270, P3512, DOI 10.1074/jbc.270.8.3512; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WANG LM, 1995, BLOOD, V86, P4218, DOI 10.1182/blood.V86.11.4218.bloodjournal86114218; ZURAWSKI G, 1994, IMMUNOL TODAY, V15, P19, DOI 10.1016/0167-5699(94)90021-3; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x; ZURAWSKI SM, 1995, J BIOL CHEM, V270, P13869, DOI 10.1074/jbc.270.23.13869	25	250	284	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16921	16926		10.1074/jbc.271.28.16921	http://dx.doi.org/10.1074/jbc.271.28.16921			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663118	hybrid			2022-12-27	WOS:A1996UX12600075
J	Neumann, A; Wohlfarth, G; Diekert, G				Neumann, A; Wohlfarth, G; Diekert, G			Purification and characterization of tetrachloroethene reductive dehalogenase from Dehalospirillum multivorans	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; QUANTITATION; IRON	Tetrachloroethene reductive dehalogenase from the tetrachloroethene-utilizing anaerobe, Dehalospirillum multivorans, was purified approximately 100-fold to apparent homogeneity. The purified dehalogenase catalyzed the reductive dechlorination of tetrachloroethene (PCE) to trichloroethene and of trichloroethene to cis-1,2-dichloroethene with reduced methyl viologen as the electron donor at a specific activity of 2.6 microkatal/mg. The apparent K-m values for tetrachloroethene and trichloroethene were 0.20 and 0.24 mM, respectively. The apparent molecular mass of the native enzyme was determined by gel filtration to be 58 kDa. Sodium dodecyl sulfate-gel electrophoresis revealed a single protein band with a molecular mass of 57 kDa. One mol of dehalogenase contained 1.0 mol of corrinoid, 9.8 mol of iron, and 8.0 mol of acid-labile sulfur. The pH optimum was about 8.0. The enzyme had a temperature optimum of 42 degrees C. It was slightly oxygen-sensitive and was ther molabile above 50 degrees C. The dechlorination of PCE was stimulated by ammonium ions. Chlorinated methanes severely inhibited PCE dehalogenase activity.	UNIV STUTTGART,INST MIKROBIOL,DEPT MICROBIOL,D-70550 STUTTGART,GERMANY	University of Stuttgart				Neumann, Anke/0000-0002-9969-7586				BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; FETZNER S, 1994, MICROBIOL REV, V58, P641, DOI 10.1128/MMBR.58.4.641-685.1994; FISCHER R, 1992, ARCH MICROBIOL, V158, P208, DOI 10.1007/BF00290817; FISH WW, 1988, METHOD ENZYMOL, V158, P357, DOI 10.1016/0076-6879(88)58067-9; HARDER SR, 1989, BIOCHEMISTRY-US, V28, P9080, DOI 10.1021/bi00449a019; HOLLIGER C, 1994, ANTON LEEUW INT J G, V66, P239, DOI 10.1007/BF00871642; JANSSEN DB, 1994, ANNU REV MICROBIOL, V48, P163, DOI 10.1146/annurev.mi.48.100194.001115; NEUMANN A, 1994, ARCH MICROBIOL, V162, P295, DOI 10.1007/s002030050141; NEUMANN A, 1995, ARCH MICROBIOL, V163, P276, DOI 10.1007/BF00393380; NI SS, 1995, J BACTERIOL, V177, P5135, DOI 10.1128/jb.177.17.5135-5139.1995; NICHOLLS DG, 1992, BIOENERGETICS, V2, P76; Rabinowitz J C, 1978, Methods Enzymol, V53, P275; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; SCHOLZMURAMATSU H, 1995, ARCH MICROBIOL, V163, P48, DOI 10.1007/BF00262203; SCOPES RK, 1974, ANAL BIOCHEM, V59, P277, DOI 10.1016/0003-2697(74)90034-7; ZEHNDER AJB, 1976, SCIENCE, V194, P1165, DOI 10.1126/science.793008	16	168	174	0	39	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16515	16519		10.1074/jbc.271.28.16515	http://dx.doi.org/10.1074/jbc.271.28.16515			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663199				2022-12-27	WOS:A1996UX12600017
J	Odani, N; Negishi, M; Takahashi, S; Kitano, Y; Kozutsumi, Y; Ichikawa, A				Odani, N; Negishi, M; Takahashi, S; Kitano, Y; Kozutsumi, Y; Ichikawa, A			Regulation of BiP gene expression by cyclopentenone prostaglandins through unfolded protein response element	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTRACELLULAR GLUTATHIONE; ANTIPROLIFERATIVE ACTIVITY; CELLS; 9-DEOXY-DELTA-9,DELTA-12(E)-PROSTAGLANDIN-D2	Delta(12)-Prostaglandin (PG) J(2), a cyclopentenone prostaglandin, plays a role in various stress responses, BiP, a stress-inducible chaperone protein, is implicated in protein folding and translocation in endoplasmic reticulum and induced in the condition of accumulation of unfolded proteins, Here, we examined the effect of Delta(12)-PGJ(2) on the expression of the BiP gene, Delta(12)-PGJ(2) markedly stimulated the expression of the BiP gene in a time- and concentration-dependent manner in HeLa cells, This stimulation was specific for cyclopentenone PGs among various PGs. Cycloheximide pretreatment completely inhibited the Delta(12)-PGJ(2)-induced expression of the BiP gene, suggesting that the effects on nascent protein synthesis are involved in the signaling mechanism, Delta(12)-PGJ(2) markedly stimulated the promoter activity of the 5'-flanking region of the BiP gene through the unfolded protein response element. Furthermore, Delta(12)-PGJ(2) stimulated the enhancer activity of the 3'-half of the unfolded protein response element, and this stimulation required three nucleotides within this region, Gel mobility shift assay demonstrated that this region was occupied with two specific nuclear protein factors with different mobilities in the control cells, and Delta(12)-PGJ(2) induced the dissociation of the protein-DNA complex with lower mobility, These findings indicate that Delta(12)-PGJ(2) stimulates the expression of BiP gene through the 3'-half of the unfolded protein response element.	KYOTO UNIV, FAC PHARMACEUT SCI, DEPT PHYSIOL CHEM, SAKYO KU, KYOTO 606, JAPAN; KYOTO UNIV, FAC PHARMACEUT SCI, DEPT BIOCHEM, SAKYO KU, KYOTO 606, JAPAN	Kyoto University; Kyoto University								AMICI C, 1992, P NATL ACAD SCI USA, V89, P6227, DOI 10.1073/pnas.89.14.6227; ATSMON J, 1990, CANCER RES, V50, P1879; ATSMON J, 1990, BIOCHEMISTRY-US, V29, P3760, DOI 10.1021/bi00467a023; BROCK TG, 1994, J BIOL CHEM, V269, P22059; CAGEN LM, 1976, J BIOL CHEM, V251, P6550; FUKUSHIMA M, 1992, PROSTAG LEUKOTR ESS, V47, P1, DOI 10.1016/0952-3278(92)90178-L; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; KOHNO K, 1993, MOL CELL BIOL, V13, P877, DOI 10.1128/MCB.13.2.877; KOIZUMI T, 1995, J BIOL CHEM, V270, P21779, DOI 10.1074/jbc.270.37.21779; KOIZUMI T, 1993, BIOCHEM PHARMACOL, V45, P2457, DOI 10.1016/0006-2952(93)90227-N; KOIZUMI T, 1992, BIOCHEM PHARMACOL, V44, P1597; KOZUTSUMI Y, 1989, J CELL SCI, P115; LI WW, 1994, MOL CELL BIOL, V14, P5533, DOI 10.1128/MCB.14.8.5533; MCKNIGHT SL, 1980, NUCLEIC ACIDS RES, V8, P5949, DOI 10.1093/nar/8.24.5949; MORI K, 1992, EMBO J, V11, P2583, DOI 10.1002/j.1460-2075.1992.tb05323.x; NEEDLEMAN P, 1986, ANNU REV BIOCHEM, V55, P69, DOI 10.1146/annurev.biochem.55.1.69; NEGISHI M, 1995, J LIPID MEDIAT CELL, V12, P443, DOI 10.1016/0929-7855(95)00029-P; NOYORI R, 1993, SCIENCE, V259, P44, DOI 10.1126/science.8418493; PARKER J, 1992, BIOCHEM PHARMACOL, V43, P1053, DOI 10.1016/0006-2952(92)90612-M; REINBOTHE S, 1994, P NATL ACAD SCI USA, V91, P7012, DOI 10.1073/pnas.91.15.7012; RESENDEZ E, 1988, MOL CELL BIOL, V8, P4579, DOI 10.1128/MCB.8.10.4579; RUTHERFORD SL, 1994, CELL, V79, P1129, DOI 10.1016/0092-8674(94)90003-5; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SANTORO MG, 1989, P NATL ACAD SCI USA, V86, P8407, DOI 10.1073/pnas.86.21.8407; Shamu Caroline E., 1994, Trends in Cell Biology, V4, P56, DOI 10.1016/0962-8924(94)90011-6; TING J, 1988, DNA-J MOLEC CELL BIO, V7, P275, DOI 10.1089/dna.1988.7.275	26	28	28	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16609	16613		10.1074/jbc.271.28.16609	http://dx.doi.org/10.1074/jbc.271.28.16609			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663202	hybrid			2022-12-27	WOS:A1996UX12600031
J	Yamasaki, M; Miyake, A; Tagashira, S; Itoh, N				Yamasaki, M; Miyake, A; Tagashira, S; Itoh, N			Structure and expression of the rat mRNA encoding a novel member of the fibroblast growth factor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SEQUENCE; CLONING	We isolated the cDNA encoding a novel member of the fibroblast growth factor (FGF) family from rat embryos by homology-based polymerase chain reaction. The FGF-related cDNA encodes a protein of 215 amino acids (similar to 24 kDa), which has a conserved similar to 120 amino acid core with similar to 30-60% amino acid sequence identity with the FGF family, This protein with a hydrophobic amino terminus appears to be a secreted protein. The cDNA was translated in a coupled in vitro transcription-translation system. The molecular mass of the translation product was observed to be similar to 26 kDa. The expression of the FGF-related mRNA in the rat embryo and adult tissues was determined by Northern analysis and in situ hybridization. The mRNA was expressed in several discrete regions of the embryo. In adult tissues, the mRNA was preferentially expressed in the lung. The expression profile of the FGF-related mRNA was different from those of other FGF family mRNAs. As this protein is the 10th documented protein related to FGFs, we tentatively term this protein FGF-10.	KYOTO UNIV,FAC PHARMACEUT SCI,DEPT BIOCHEM GENET,SAKYO KU,KYOTO 60601,JAPAN	Kyoto University				Yamasaki, Masahiro/0000-0002-5296-4974				AARONSON SA, 1991, ANN NY ACAD SCI, V638, P62, DOI 10.1111/j.1749-6632.1991.tb49018.x; BAIRD A, 1991, CANCER CELL-MON REV, V3, P239; BURGESS WH, 1989, ANNU REV BIOCHEM, V58, P575, DOI 10.1146/annurev.bi.58.070189.003043; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COULIER F, 1991, ANN NY ACAD SCI, V638, P53, DOI 10.1111/j.1749-6632.1991.tb49017.x; DICKSON C, 1991, ANN NY ACAD SCI, V638, P18, DOI 10.1111/j.1749-6632.1991.tb49014.x; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GOLDFARB M, 1991, ANN NY ACAD SCI, V638, P38, DOI 10.1111/j.1749-6632.1991.tb49016.x; MASON IJ, 1994, MECH DEVELOP, V45, P15, DOI 10.1016/0925-4773(94)90050-7; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOORE R, 1986, EMBO J, V5, P919, DOI 10.1002/j.1460-2075.1986.tb04304.x; TANAKA A, 1992, P NATL ACAD SCI USA, V89, P8928, DOI 10.1073/pnas.89.19.8928; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; YAZAKI N, 1993, BIOCHIM BIOPHYS ACTA, V1172, P37, DOI 10.1016/0167-4781(93)90266-G; YOSHIDA T, 1991, ANN NY ACAD SCI, V638, P27, DOI 10.1111/j.1749-6632.1991.tb49015.x	15	256	284	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15918	15921		10.1074/jbc.271.27.15918	http://dx.doi.org/10.1074/jbc.271.27.15918			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663172	hybrid			2022-12-27	WOS:A1996UW35200015
J	Grune, T; Reinheckel, T; Davies, KJA				Grune, T; Reinheckel, T; Davies, KJA			Degradation of oxidized proteins in K562 human hematopoietic cells by proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT SKELETAL-MUSCLE; RED BLOOD-CELLS; MULTICATALYTIC PROTEINASE; MAMMALIAN-CELLS; GLUTAMINE-SYNTHETASE; HUMAN-ERYTHROCYTES; YEAST PROTEASOME; PURIFICATION; UBIQUITIN; COMPLEX	Exposure to various forms of oxidative stress (H2O2 and O-2(radical ion)) significantly increased the intracellular degradation of both ''short-lived'' and ''long-lived'' cellular proteins in the human hematopoietic cell line K562. Oxidatively modified hemoglobin and superoxide dismutase used as purified proteolytic substrates were also selectively degraded by K562 cell lysates, but exposure of these protein substrates to very high hydrogen peroxide concentrations actually decreased their proteolytic susceptibility, Our studies found little or no change in the overall capacity of cells and cell lysates to degrade ''foreign'' oxidized proteins after treatment of K562 cells with hydrogen peroxide or paraquat, a finding supported by proteasome Western blots and unchanged capacity of cell lysates to degrade the fluorogenic peptide succinyl-leucine leucine-valine-tyrosine coumarin-7 amide. Six days of daily treatment of K562 cells with an antisense oligodeoxynucleotide directed against the initiation codon region of the human proteasome C2 subunit gene dramatically depressed hydrogen peroxide-induced degradation of metabolically radiolabeled intracellular proteins, The actual amount of proteasome in antisense-treated K562 cells was also severely depressed, as revealed by Western blots and by measurements of the degradation of the fluorogenic peptide succinyl-leucine-leucine-valine-tyrosine-4-methylcoumarin-7-amide. The degradation of oxidatively modified foreign protein substrates was also markedly depressed in lysates prepared from K562 cells treated with the proteasome C2 antisense dideoxynucleotide, The inhibitor profile for the degradation of H2O2-modified hemoglobin by R562 cell lysates was consistent with a major role for the ATP-independent 20 S ''core'' proteasome complex, We conclude that proteasome, probably the 20 S core proteasome complex, is primarily responsible for the selective degradation of oxidatively damaged proteins in human hematopoietic cells, Since ''oxidative marking'' of cellular proteins by lipoxygenase has been proposed as an important step in red blood cell maturation, it is important to determine which protease or proteases could recognize and degrade such modified substrates, Our results provide evidence that proteasome can, indeed, conduct such selective degradation and appears to be the major cellular protease capable of fulfilling such a role in maturation.	UNIV SO CALIF,ANDRUS GERONTOL CTR,LOS ANGELES,CA 90089; ALBANY MED COLL,DEPT BIOCHEM & MOLEC BIOL,ALBANY,NY 12208	University of Southern California; Albany Medical College			Reinheckel, Thomas/AAL-9761-2021	Reinheckel, Thomas/0000-0001-9866-9105; Grune, Tilman/0000-0003-4775-9973; Davies, Kelvin/0000-0001-7790-3003	NIEHS NIH HHS [ES-03598] Funding Source: Medline; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES003598, R56ES003598, R23ES003598] Funding Source: NIH RePORTER	NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ARRIGO AP, 1988, NATURE, V331, P192, DOI 10.1038/331192a0; BAUMEISTER W, 1988, FEBS LETT, V241, P239, DOI 10.1016/0014-5793(88)81069-X; CERVERA J, 1988, FASEB J, V2, P2591, DOI 10.1096/fasebj.2.10.2898411; DAHLMANN B, 1983, FEBS LETT, V160, P243, DOI 10.1016/0014-5793(83)80975-2; DAHLMANN B, 1988, BIOCHEM J, V255, P750; DAHLMANN B, 1985, BIOCHEM J, V228, P171, DOI 10.1042/bj2280171; DAVIES KJA, 1987, J BIOL CHEM, V262, P9895; DAVIES KJA, 1993, BIOCHEM SOC T, V21, P346, DOI 10.1042/bst0210346; DEAN RT, 1993, TRENDS BIOCHEM SCI, V18, P437, DOI 10.1016/0968-0004(93)90145-D; DEMARTINO GN, 1979, J BIOL CHEM, V254, P3712; DUBIEL W, 1987, BIOMED BIOCHIM ACTA, V46, P565; FAGAN JM, 1986, J BIOL CHEM, V261, P5705; FALKENBURG PE, 1988, NATURE, V331, P190, DOI 10.1038/331190a0; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V63, P1578; GRUNE T, 1995, J BIOL CHEM, V270, P2344, DOI 10.1074/jbc.270.5.2344; HEINEMEYER W, 1993, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; HIPKISS AR, 1983, BIOMED BIOCHIM ACTA, V42, pS212; HOUGH R, 1987, J BIOL CHEM, V262, P8303; ISHIURA S, 1985, FEBS LETT, V189, P119, DOI 10.1016/0014-5793(85)80854-1; JENTOFT N, 1979, J BIOL CHEM, V254, P4359; MATTHEWS W, 1989, P NATL ACAD SCI USA, V86, P2597, DOI 10.1073/pnas.86.8.2597; MCGUIRE MJ, 1989, BIOCHIM BIOPHYS ACTA, V995, P181, DOI 10.1016/0167-4838(89)90078-2; MCGUIRE MJ, 1986, BIOCHIM BIOPHYS ACTA, V873, P279, DOI 10.1016/0167-4838(86)90055-5; NAKAMURA K, 1984, P NATL ACAD SCI-BIOL, V81, P2011, DOI 10.1073/pnas.81.7.2011; PACIFICI RE, 1993, J BIOL CHEM, V268, P15405; PACIFICI RE, 1989, FREE RADICAL BIO MED, V7, P521, DOI 10.1016/0891-5849(89)90028-2; PACIFICI RE, 1990, METHOD ENZYMOL, V186, P485; PICKART CM, 1988, J BIOL CHEM, V263, P12028; RAY K, 1985, P NATL ACAD SCI USA, V82, P7545, DOI 10.1073/pnas.82.22.7545; RIEDER RF, 1985, J BIOL CHEM, V260, P2015; RIVETT AJ, 1989, ARCH BIOCHEM BIOPHYS, V268, P1, DOI 10.1016/0003-9861(89)90558-4; RIVETT AJ, 1993, BIOCHEM J, V291, P1; ROCK KL, 1994, CELL, V78, P761, DOI 10.1016/S0092-8674(94)90462-6; SALO DC, 1990, J BIOL CHEM, V265, P11919; SAVORY PJ, 1993, BIOCHEM J, V296, P601, DOI 10.1042/bj2960601; SHIMBARA N, 1992, J BIOL CHEM, V267, P18100; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; VINITSKY A, 1994, J BIOL CHEM, V269, P29860; WOLFF SP, 1986, BIOCHEM J, V234, P399, DOI 10.1042/bj2340399	41	292	295	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15504	15509		10.1074/jbc.271.26.15504	http://dx.doi.org/10.1074/jbc.271.26.15504			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663134	hybrid			2022-12-27	WOS:A1996UV29900032
J	Arnet, UA; McMillan, A; Dinerman, JL; Ballermann, B; Lowenstein, CJ				Arnet, UA; McMillan, A; Dinerman, JL; Ballermann, B; Lowenstein, CJ			Regulation of endothelial nitric-oxide synthase during hypoxia	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; MOLECULAR-CLONING; CELL; RNA; VASODILATATION; LOCALIZATION; MESSENGER; RELEASE; DNA	The mechanism by which nitric-oxide (NO) production increases during hypoxia is unknown, To explore the effect of hypoxia upon endothelial nitric-oxide synthase (ecNOS) activity and expression, we exposed bovine aortic endothelial cells (BAEC) to hypoxia (1% O-2) for 0-24 h and measured levels of ecNOS mRNA, protein, and activity, The amount of ecNOS mRNA increases to more than twice the basal level after 6 h of hypoxia, Incubation of BAEC with actinomycin D during hypoxia prevents this increase, demonstrating that higher levels of mRNA observed during hypoxia are due to increased synthesis, not to increased stability of ecNOS mRNA, Levels of ecNOS protein increase throughout 24 h of hypoxia to more than twice normoxic levels. Although ecNOS expression increases within 2 h of hypoxia, total activity remains unchanged, To explore the transcriptional regulation of ecNOS, we constructed a reporter plasmid containing the ecNOS promoter region upstream of the luc gene and transfected this reporter plasmid into BAEC. In this system, hypoxia induces a linear increase over time in the expression of luciferase driven by the ecNOS promoter, It is concluded that hypoxia induces an increase in transcription of ecNOS in endothelial cells, activating the regulatory region of ecNOS by undefined transcription factors.	JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV CARDIOL, BALTIMORE, MD 21205 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT MED, DIV NEPHROL, BALTIMORE, MD 21205 USA	Johns Hopkins University; Johns Hopkins University			Ballermann, Barbara J/G-5349-2016	Ballermann, Barbara J/0000-0002-8220-6381; Lowenstein, Charles/0000-0003-0485-7514	NHLBI NIH HHS [HL52315] Funding Source: Medline; PHS HHS [K1102451] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL052315] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ARROYO CM, 1990, BIOCHEM BIOPH RES CO, V170, P1177, DOI 10.1016/0006-291X(90)90517-Q; BREDT DS, 1989, P NATL ACAD SCI USA, V86, P9030, DOI 10.1073/pnas.86.22.9030; BROWN IP, 1993, AM J PHYSIOL, V264, pH821, DOI 10.1152/ajpheart.1993.264.3.H821; BUGA GM, 1991, HYPERTENSION, V17, P187, DOI 10.1161/01.HYP.17.2.187; BUSCONI L, 1993, J BIOL CHEM, V268, P8410; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; FORD PC, 1993, FEBS LETT, V326, P1, DOI 10.1016/0014-5793(93)81748-O; GOETZ RM, 1994, BIOCHEM BIOPH RES CO, V205, P905, DOI 10.1006/bbrc.1994.2750; GREENBERG B, 1993, AM J PHYSIOL, V265, pH1712, DOI 10.1152/ajpheart.1993.265.5.H1712; HAMPL V, 1995, EUR RESPIR J, V8, P515; HARLOW E, 1988, ANTIBODIES LABORATOR, P72; HISHIKAWA K, 1995, FEBS LETT, V360, P291, DOI 10.1016/0014-5793(95)00124-R; IGNARRO LJ, 1993, THROMB HAEMOSTASIS, V70, P148; IGNARRO LJ, 1990, ANNU REV PHARMACOL, V30, P535, DOI 10.1146/annurev.pa.30.040190.002535; Isozumi Kazuo, 1994, Keio Journal of Medicine, V43, P31; JOANNIDES R, 1995, CIRCULATION, V91, P1314, DOI 10.1161/01.CIR.91.5.1314; KILBOURN RG, 1990, J NATL CANCER I, V82, P772, DOI 10.1093/jnci/82.9.772; KOLLER A, 1994, AM J PHYSIOL, V267, pH326, DOI 10.1152/ajpheart.1994.267.1.H326; KORENAGA R, 1994, BIOCHEM BIOPH RES CO, V198, P213, DOI 10.1006/bbrc.1994.1030; KOZNIEWSKA E, 1992, J CEREBR BLOOD F MET, V12, P311; KUCHAN MJ, 1994, AM J PHYSIOL, V266, pC628, DOI 10.1152/ajpcell.1994.266.3.C628; LAMAS S, 1992, P NATL ACAD SCI USA, V89, P6348, DOI 10.1073/pnas.89.14.6348; LOWENSTEIN CJ, 1992, CELL, V70, P705, DOI 10.1016/0092-8674(92)90301-R; LUSCHER TF, 1993, AM J HYPERTENS, V6, pS283; Maniatis T., 1989, MOL CLONING LAB MAN; MARLETTA M A, 1990, Biofactors, V2, P219; MARLETTA MA, 1994, CELL, V78, P927, DOI 10.1016/0092-8674(94)90268-2; MARLETTA MA, 1993, J BIOL CHEM, V268, P12231; MARSDEN PA, 1992, FEBS LETT, V307, P287, DOI 10.1016/0014-5793(92)80697-F; MARSDEN PA, 1993, J BIOL CHEM, V268, P17478; MCPHERSON RW, 1994, AM J PHYSIOL, V266, pH476, DOI 10.1152/ajpheart.1994.266.2.H476; MCQUILLAN LP, 1994, AM J PHYSIOL-HEART C, V267, pH1921; MONCADA S, 1991, PHARMACOL REV, V43, P109; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; NISHIDA K, 1992, J CLIN INVEST, V90, P2092, DOI 10.1172/JCI116092; NORIS M, 1995, CIRC RES, V76, P536, DOI 10.1161/01.RES.76.4.536; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; POHL U, 1989, AM J PHYSIOL, V256, pH1595, DOI 10.1152/ajpheart.1989.256.6.H1595; ROBINSON LJ, 1995, J BIOL CHEM, V270, P995, DOI 10.1074/jbc.270.3.995; ROBINSON LJ, 1994, GENOMICS, V19, P350, DOI 10.1006/geno.1994.1068; Schwartz SE, 1983, TRACE ATMOSPHERIC CO, P1; SHAUL PW, 1994, AM J RESP CELL MOL, V11, P432, DOI 10.1165/ajrcmb.11.4.7522486; SHAUL PW, 1992, AM J PHYSIOL, V262, pH355, DOI 10.1152/ajpheart.1992.262.2.H355; SHAUL PW, 1995, AM J RESP CELL MOL, V13, P167, DOI 10.1165/ajrcmb.13.2.7542896; SUN M, 1992, LIFE SCI, V50, P555, DOI 10.1016/0024-3205(92)90367-X; UCHIDA K, 1992, AM J PHYSIOL, V263, pC200, DOI 10.1152/ajpcell.1992.263.1.C200; VANBUREN GA, 1992, AM J OBSTET GYNECOL, V167, P828, DOI 10.1016/S0002-9378(11)91597-X; WEINER CP, 1994, P NATL ACAD SCI USA, V91, P5212, DOI 10.1073/pnas.91.11.5212; YOSHIZUMI M, 1993, CIRC RES, V73, P205, DOI 10.1161/01.RES.73.1.205	51	166	172	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15069	15073		10.1074/jbc.271.25.15069	http://dx.doi.org/10.1074/jbc.271.25.15069			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663208	hybrid			2022-12-27	WOS:A1996UT10600064
J	Banecki, B; Liberek, K; Wall, D; Wawrzynow, A; Georgopoulos, C; Bertoli, E; Tanfani, F; Zylicz, M				Banecki, B; Liberek, K; Wall, D; Wawrzynow, A; Georgopoulos, C; Bertoli, E; Tanfani, F; Zylicz, M			Structure-function analysis of the zinc finger region of the DnaJ molecular chaperone	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI-DNAJ; NUCLEOTIDE-SEQUENCE; REPLICATION; BINDING; PURIFICATION; INITIATION; HOMOLOGS; GENE	DnaJ is a molecular chaperone, which not only binds to its various protein substrates, but can also activate the DnaK cochaperone to bind to its various protein substrates as well. DnaJ is a modular protein, which contains a putative zinc finger motif of unknown function. Quantitation of the released Zn(II) ions, upon challenge with p-hydroxymercuriphenylsulfonic acid, and by atomic absorption showed that two Zn(II) ions interact with each monomer of DnaJ. Following the release of Zn(II) ions, the free cysteine residues probably form disulfide bridge(s), which contribute to overcoming the destabilizing effect of losing Zn(II). Supporting this view, infrared and circular dichroism studies show that the DnaJ secondary structure is largely unaffected by the release of Zn(II). Moreover, infrared spectra recorded at different temperatures, as well as scanning calorimetry, show that the Zn(II) ions help to stabilize DnaJ's tertiary structure. An internal 57 amino acid deletion of the cysteine-reach region did not noticeably affect the affinity of this mutant protein, DnaJ Delta 144-200, to bind DnaK nor its ability to stimulate DnaK's ATPase activity. However, the DnaJ Delta 144-200 was unable to induce DnaK to a conformation required for the stabilization of the DnaK-substrate complex. Additionally, the DnaJ Delta 144-200 mutant protein alone was unimpaired in its ability to interact with its sigma(32) transcription factor substrate, but exhibited reduced affinity toward its P1 RepA and lambda P substrates. Finally, these in vitro results correlate well with the in vivo observed partial inhibition of bacteriophage A growth in a DnaJ Delta 144-200 mutant background.	UNIV GDANSK,DEPT BIOL MOLEC,DIV BIOPHYS,PL-80822 GDANSK,POLAND; CTR MED UNIV GENEVA,DEPT BIOCHIM MED,CH-1211 GENEVA 4,SWITZERLAND; UNIV ANCONA,SCH MED,INST BIOCHEM,I-60100 ANCONA,ITALY	Fahrenheit Universities; University of Gdansk; University of Geneva; Marche Polytechnic University			Tanfani, Fabio/F-1441-2010; Liberek, Krzysztof/F-5812-2011	Zylicz, Alicja/0000-0003-4174-3073; Liberek, Krzysztof/0000-0002-7532-9279; Tanfani, Fabio/0000-0001-7685-4692; Wall, Daniel/0000-0002-0273-1371				ALFANO C, 1989, J BIOL CHEM, V264, P10709; Banecki B, 1996, J BIOL CHEM, V271, P6137, DOI 10.1074/jbc.271.11.6137; BANECKI B, 1992, J BIOL CHEM, V267, P25051; BARDWELL JCA, 1986, J BIOL CHEM, V261, P1782; BERG JM, 1990, J BIOL CHEM, V265, P6513; BLUME A, 1988, BIOCHEMISTRY-US, V27, P8239, DOI 10.1021/bi00421a038; BYLER DM, 1986, BIOPOLYMERS, V25, P469, DOI 10.1002/bip.360250307; CAPLAN AJ, 1993, MOL BIOL CELL, V4, P555, DOI 10.1091/mbc.4.6.555; CASAL HL, 1988, BIOCHIM BIOPHYS ACTA, V957, P11, DOI 10.1016/0167-4838(88)90152-5; CYR DM, 1994, TRENDS BIOCHEM SCI, V19, P176, DOI 10.1016/0968-0004(94)90281-X; GIEDROC DP, 1987, BIOCHEMISTRY-US, V26, P5251, DOI 10.1021/bi00391a007; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; HENDRICK JP, 1993, P NATL ACAD SCI USA, V90, P10216, DOI 10.1073/pnas.90.21.10216; HUNT JB, 1984, J BIOL CHEM, V259, P4793; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1993, P NATL ACAD SCI USA, V90, P11019, DOI 10.1073/pnas.90.23.11019; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; MCCARTY JS, 1995, J MOL BIOL, V249, P126, DOI 10.1006/jmbi.1995.0284; ODAKA M, 1994, J BIOCHEM-TOKYO, V115, P789, DOI 10.1093/oxfordjournals.jbchem.a124410; OHKI M, 1986, J BIOL CHEM, V261, P1778; QIU HW, 1994, J BIOL CHEM, V269, P2773; SAZABO A, 1996, EMBO J, V15, P408; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SEHL LC, 1990, J BIOL CHEM, V265, P5482; SILVER PA, 1993, CELL, V74, P5, DOI 10.1016/0092-8674(93)90287-Z; SZABO A, 1994, P NATL ACAD SCI USA, V91, P10345, DOI 10.1073/pnas.91.22.10345; SZYPERSKI T, 1994, P NATL ACAD SCI USA, V91, P11343, DOI 10.1073/pnas.91.24.11343; WALL D, 1994, J BIOL CHEM, V269, P5446; WALL D, 1995, J BIOL CHEM, V270, P2139, DOI 10.1074/jbc.270.5.2139; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19300, DOI 10.1074/jbc.270.33.19300; WICKNER S, 1992, P NATL ACAD SCI USA, V89, P10345, DOI 10.1073/pnas.89.21.10345; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; ZYLICZ M, 1989, EMBO J, V8, P1601, DOI 10.1002/j.1460-2075.1989.tb03544.x; ZYLICZ M, 1993, PHILOS T ROY SOC B, V339, P271, DOI 10.1098/rstb.1993.0025; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591; [No title captured]	40	130	133	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14840	14848		10.1074/jbc.271.25.14840	http://dx.doi.org/10.1074/jbc.271.25.14840			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662861	hybrid			2022-12-27	WOS:A1996UT10600033
J	Avent, ND; Liu, W; Warner, KM; Mawby, WJ; Jones, JW; Ridgwell, K; Tanner, MJA				Avent, ND; Liu, W; Warner, KM; Mawby, WJ; Jones, JW; Ridgwell, K; Tanner, MJA			Immunochemical analysis of the human erythrocyte Rh polypeptides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BLOOD-GROUP SYSTEM; RED-CELL MEMBRANE; MOLECULAR-CLONING; RHO(D) ANTIGEN; PROTEINS; IDENTIFICATION; LOCALIZATION; GLYCOPROTEIN; EXPRESSION; RH(D)	We have used rabbit polyclonal antisera raised against synthetic peptides complementary to different domains of the Rh polypeptides and Rh glycoprotein to examine the topography and organization of these proteins in the human erythrocyte membrane, Previously unrecognized exofacial protease sites have been identified on Rh CcEe, D proteins, and Rh glycoprotein. The Rh D protein has two specific bromelain cleavage sites located within the first and sixth predicted external domains, with the site of cleavage localized in the sixth domain to lie between residues 353 and 354. All Rh polypeptide species were found to be susceptible to cleavage with trypsin and subtilisin within the first external domain of these proteins, The Rh glycoprotein has two bromelain cleavage sites within the first external domain, These flank the single N-glycosylation site (Asn(37)), with the cleavage site toward the C-terminal side of this residue being between residues 39 and 40, Bromelain treatment was found to deglycosylate the Rh glycoprotein, Immunoprecipitation experiments have revealed that anti-C, -c,E, -e, and -D immune complexes are reactive with antisera raised against the fourth predicted external loop of the Rh proteins and the C-terminal domain, These data indicate that the hypothesis that suggests Rh C/c antigens are expressed on truncated Rh polypeptides by a mechanism of alternate splicing is incorrect and support the hypothesis that Rh Cc and Ee antigens are expressed on a single polypeptide chain.	BRISTOL INST TRANSFUS SCI,BRISTOL BS10 5ND,AVON,ENGLAND; UNIV W ENGLAND,FAC SCI APPL,BRISTOL BS16 1QY,AVON,ENGLAND; UNIV BRISTOL,DEPT BIOCHEM,BRISTOL BS8 1TD,AVON,ENGLAND	University of West England; University of Bristol	Avent, ND (corresponding author), INT BLOOD GRP REFERENCE LAB,SOUTHMEAD RD,BRISTOL BS10 5ND,AVON,ENGLAND.							ARCE MA, 1993, BLOOD, V82, P651; AVENT ND, 1990, BIOCHEM J, V271, P821, DOI 10.1042/bj2710821; AVENT ND, 1992, J BIOL CHEM, V267, P15134; AVENT ND, 1988, BIOCHEM J, V256, P1043, DOI 10.1042/bj2561043; BLANCHARD D, 1988, BLOOD, V72, P1424; CARTRON JP, 1994, BLOOD REV, V8, P199, DOI 10.1016/0268-960X(94)90108-2; CHERIFZAHAR B, 1990, P NATL ACAD SCI USA, V87, P6243, DOI 10.1073/pnas.87.16.6243; CherifZahar B, 1996, NAT GENET, V12, P168, DOI 10.1038/ng0296-168; Daniels G., 1995, HUMAN BLOOD GROUPS, P257; DEVETTEN MP, 1988, J BIOL CHEM, V263, P18193; EYERS SAC, 1994, J BIOL CHEM, V269, P6417; GAHMBERG CG, 1983, EMBO J, V2, P223, DOI 10.1002/j.1460-2075.1983.tb01409.x; GAHMBERG CG, 1982, FEBS LETT, V140, P93, DOI 10.1016/0014-5793(82)80528-0; HARTELSCHENK S, 1992, J BIOL CHEM, V267, P5569; HERMAND P, 1993, BLOOD, V82, P669; HUGHESJONES NC, 1971, VOX SANG, V21, P210, DOI 10.1111/j.1423-0410.1971.tb00578.x; KAJII E, 1993, HUM GENET, V91, P157; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEVANKIM C, 1992, P NATL ACAD SCI USA, V89, P10925, DOI 10.1073/pnas.89.22.10925; LEVANKIM C, 1992, BLOOD, V80, P1074; MALLINSON G, 1986, BIOCHEM J, V234, P649, DOI 10.1042/bj2340649; Mollison PL, 1993, BLOOD TRANSFUSION CL, P543; MOORE S, 1982, NATURE, V295, P529, DOI 10.1038/295529a0; MOORE S, 1987, BIOCHEM J, V244, P735, DOI 10.1042/bj2440735; MOURO I, 1993, NAT GENET, V5, P62, DOI 10.1038/ng0993-62; RIDGWELL K, 1992, BIOCHEM J, V287, P223, DOI 10.1042/bj2870223; RIDGWELL K, 1994, J BIOL CHEM, V269, P6410; SCHAGGER H, 1987, ANAL BIOCHEM, V166, P368, DOI 10.1016/0003-2697(87)90587-2; SKOV F, 1977, VOX SANG, V33, P170, DOI 10.1111/j.1423-0410.1977.tb02249.x; Smythe JS, 1996, BLOOD, V87, P2968, DOI 10.1182/blood.V87.7.2968.bloodjournal8772968; SUYAMA K, 1992, BLOOD, V79, P808	31	46	50	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14233	14239		10.1074/jbc.271.24.14233	http://dx.doi.org/10.1074/jbc.271.24.14233			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663003	hybrid			2022-12-27	WOS:A1996UQ66000046
J	Han, ZY; Johnston, C; Reeves, WH; Carter, T; Wyche, JH; Hendrickson, EA				Han, ZY; Johnston, C; Reeves, WH; Carter, T; Wyche, JH; Hendrickson, EA			Characterization of a Ku86 variant protein that results in altered DNA binding and diminished DNA-dependent protein kinase activity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STRAND BREAK REPAIR; HAMSTER OVARY CELLS; V(D)J RECOMBINATION; IONIZING-RADIATION; SCID MUTATION; ANTIGENIC DETERMINANTS; MOUSE THYMOCYTES; MUTANTS; AUTOANTIGEN; MECHANISMS	Three proteins known to play a critical role in mammalian DNA double strand break repair and lymphoid V(D)J recombination are the autoantigens Ku86 and Ku70 and a 465-kDa serine/threonine protein kinase catalytic subunit (DNA-PKcs). These proteins physically associate to form a complex (DNA . PK) with DNA-dependent protein kinase activity. In this study, we demonstrate using electrophoretic mobility shift assays (EMSAs) that the nuclear DNA end-binding activity of Ku is altered in the human promyelocytic leukemic HL-60 cell line. Western blot and EMSA supershift analyses revealed that HL-60 cells expressed both full-length and variant Ku86 proteins. However, a combined EMSA and immunoanalysis revealed that the Ru heterodimers complexed with DNA in HL-60 cells contained only the variant Ku86 proteins. Finally, UV cross-linking experiments and DNA . PK assays demonstrated that the Ku complexes containing variant Ku86 had a greatly reduced ability to interact with DNA-PKcs and that consequently HL-60 cells had severely diminished DNA . PK activity. These data provide important insights into the interaction between Ku and DNA-PKcs and into the role of DNA . PK in DNA double-strand break repair.	BROWN UNIV, DEPT MOLEC BIOL CELL BIOL & BIOCHEM, PROVIDENCE, RI 02912 USA; UNIV N CAROLINA, DEPT MED & MICROBIOL IMMUNOL, THRUSTON ARTHRIT RES CTR, CHAPEL HILL, NC USA; UNIV N CAROLINA, UNC LINEBERGER COMPREHENS CANC CTR, CHAPEL HILL, NC USA; ST JOHNS UNIV, DEPT BIOL SCI, JAMAICA, NY 11439 USA	Brown University; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Saint John's University					NIAID NIH HHS [K23 AI079394, AI35763] Funding Source: Medline; NIAMS NIH HHS [AR40391] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [K23AI079394, R01AI035763] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR040391] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Anderson Carl W., 1994, Seminars in Cell Biology, V5, P427, DOI 10.1006/scel.1994.1050; BIEDERMANN KA, 1991, P NATL ACAD SCI USA, V88, P1394, DOI 10.1073/pnas.88.4.1394; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOUBNOV NV, 1995, P NATL ACAD SCI USA, V92, P890, DOI 10.1073/pnas.92.3.890; CAI QQ, 1994, CYTOGENET CELL GENET, V65, P221, DOI 10.1159/000133635; CAO QP, 1994, BIOCHEMISTRY-US, V33, P8548, DOI 10.1021/bi00194a021; CARTER T, 1990, MOL CELL BIOL, V10, P6460, DOI 10.1128/MCB.10.12.6460; CHOU CH, 1992, J EXP MED, V175, P1677, DOI 10.1084/jem.175.6.1677; DEVRIES E, 1989, J MOL BIOL, V208, P65, DOI 10.1016/0022-2836(89)90088-0; DVIR A, 1992, P NATL ACAD SCI USA, V89, P11920, DOI 10.1073/pnas.89.24.11920; Errami A, 1996, MOL CELL BIOL, V16, P1519; EVANS HH, 1993, RADIAT RES, V134, P307, DOI 10.2307/3578190; FALZON M, 1993, J BIOL CHEM, V268, P10546; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; FRANKENBERGSCHWAGER M, 1990, INT J RADIAT BIOL, V58, P569, DOI 10.1080/09553009014551931; FULOP GM, 1990, NATURE, V347, P479, DOI 10.1038/347479a0; GETTS RC, 1994, J BIOL CHEM, V269, P15981; GOTTLIEB TM, 1994, TRENDS BIOCHEM SCI, V19, P500, DOI 10.1016/0968-0004(94)90138-4; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; Han ZY, 1996, CANCER RES, V56, P1621; HARTLEY KO, 1995, CELL, V82, P849, DOI 10.1016/0092-8674(95)90482-4; HE DM, 1996, IN PRESS MUTAT RES; HENDRICKSON EA, 1993, AM J PATHOL, V143, P1511; HENDRICKSON EA, 1991, P NATL ACAD SCI USA, V88, P4061, DOI 10.1073/pnas.88.10.4061; JACKSON SP, 1995, TRENDS BIOCHEM SCI, V20, P412, DOI 10.1016/S0968-0004(00)89090-8; JEGGO PA, 1992, P NATL ACAD SCI USA, V89, P6423, DOI 10.1073/pnas.89.14.6423; KAN ZY, 1995, MOL CELL BIOL, V15, P5849; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; KLAR AJS, 1984, COLD SPRING HARB SYM, V49, P77, DOI 10.1101/SQB.1984.049.01.011; KONNOSATO S, 1993, BIOCHEM MOL BIOL INT, V31, P113; LEE SE, 1995, MUTAT RES-DNA REPAIR, V336, P279, DOI 10.1016/0921-8777(95)00002-2; LEESMILLER SP, 1990, MOL CELL BIOL, V10, P6472, DOI 10.1128/MCB.10.12.6472; LEESMILLER SP, 1995, SCIENCE, V267, P1183, DOI 10.1126/science.7855602; LEWIS SM, 1994, ADV IMMUNOL, V56, P27, DOI 10.1016/S0065-2776(08)60450-2; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIMORI T, 1986, J BIOL CHEM, V261, P375; PAILLARD S, 1991, NUCLEIC ACIDS RES, V19, P5619, DOI 10.1093/nar/19.20.5619; PAILLARD S, 1993, PROTEINS, V15, P330, DOI 10.1002/prot.340150310; PERGOLA F, 1993, MOL CELL BIOL, V13, P3464, DOI 10.1128/MCB.13.6.3464; PETERSON SR, 1995, P NATL ACAD SCI USA, V92, P3171, DOI 10.1073/pnas.92.8.3171; POLTORATSKY VP, 1995, J IMMUNOL, V155, P4529; PORGES AJ, 1990, J IMMUNOL, V145, P4222; PRICE A, 1993, SEMIN CANCER BIOL, V4, P61; RATHMELL WK, 1994, P NATL ACAD SCI USA, V91, P7623, DOI 10.1073/pnas.91.16.7623; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; ROTH DB, 1992, CELL, V69, P41, DOI 10.1016/0092-8674(92)90117-U; ROTH DB, 1992, CELL, V70, P983, DOI 10.1016/0092-8674(92)90248-B; SCHLISSEL M, 1993, GENE DEV, V7, P2520, DOI 10.1101/gad.7.12b.2520; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SUWA A, 1994, P NATL ACAD SCI USA, V91, P6904, DOI 10.1073/pnas.91.15.6904; TACCIOLI GE, 1994, J BIOL CHEM, V269, P7439; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973; THOMPSON LH, 1995, IN PRESS MUTAT RES; TROELSTRA C, 1994, CURR BIOL, V4, P1149, DOI 10.1016/S0960-9822(00)00260-8; TUTEJA N, 1994, EMBO J, V13, P4991, DOI 10.1002/j.1460-2075.1994.tb06826.x; VANGENT DC, 1995, CELL, V81, P925, DOI 10.1016/0092-8674(95)90012-8; WANG JS, 1993, MOL BIOL REP, V18, P15, DOI 10.1007/BF01006891; WANG JS, 1994, FEBS LETT, V351, P219, DOI 10.1016/0014-5793(94)00863-9; WANG JS, 1994, J CELL SCI, V107, P3223; WARD JF, 1988, PROG NUCLEIC ACID RE, V35, P95, DOI 10.1016/S0079-6603(08)60611-X; WEAVER DT, 1995, TRENDS GENET, V11, P388, DOI 10.1016/S0168-9525(00)89121-0; WEIBEZAHN KF, 1985, MUTAT RES, V145, P177, DOI 10.1016/0167-8817(85)90025-2; ZDZIENICKA MZ, 1995, MUTAT RES-DNA REPAIR, V336, P203, DOI 10.1016/0921-8777(95)00003-3; ZDZIENICKA MZ, 1988, MUTAT RES, V194, P239; ZHANG WW, 1992, BIOCHEM BIOPH RES CO, V186, P574, DOI 10.1016/S0006-291X(05)80847-2	67	46	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14098	14104		10.1074/jbc.271.24.14098	http://dx.doi.org/10.1074/jbc.271.24.14098			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662896	Green Published, hybrid			2022-12-27	WOS:A1996UQ66000027
J	Liang, F; Jasin, M				Liang, F; Jasin, M			Ku80-deficient cells exhibit excess degradation of extrachromosomal DNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE; RECOMBINATION; REPAIR; MUTANTS; ANTIGEN; DEFECT	Mammalian cells possess a protein complex, termed DNA-PII, which binds to DNA double strand breaks in vitro. The complex consists of the heterodimeric Ru autoantigen and a DNA-dependent protein kinase, DNA-PKcs. Cell lines that are deficient for components of this complex are sensitive to ionizing radiation and have impaired V(D)J recombination, a site-specific recombination process. We have tested these cell lines for their ability to repair double strand breaks in transfected DNA. The xrs-6 cell line, which is deficient for the 80-kDa subunit of the Ru autoantigen, exhibited reduced stability of transfected DNA. Prior to obvious reductions in DNA stability, the levels of homologous recombination and DNA end joining were unaffected. However, the recovery of end joining products with precisely joined ends was reduced, with a concomitant increase in products containing deletions. Unlike the Ku80-deficient cells, no reduction in DNA stability was detected in DNA-PKcs-deficient scid cells. Scid cells also exhibited normal levels of homologous recombination and DNA end joining. These experiments implicate the Ru autoantigen, but not DNA-PKcs, in a direct role in protecting DNA ends from degradation.	MEM SLOAN KETTERING CANC CTR,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021; MEM SLOAN KETTERING CANC CTR,PROGRAM MOLEC BIOL,NEW YORK,NY 10021; CORNELL UNIV,GRAD SCH MED SCI,NEW YORK,NY 10021	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; Cornell University								ANDERSON CW, 1993, TRENDS BIOCHEM SCI, V18, P433, DOI 10.1016/0968-0004(93)90144-C; BLUNT T, 1995, CELL, V80, P813, DOI 10.1016/0092-8674(95)90360-7; BOSMA MJ, 1991, ANNU REV IMMUNOL, V9, P323, DOI 10.1146/annurev.iy.09.040191.001543; BUHLER B, 1995, IMMUNOGENETICS, V42, P181; CHANG C, 1993, CANCER RES, V53, P1244; CHOULIKA A, 1995, MOL CELL BIOL, V15, P1968; DANSKA JS, 1994, SCIENCE, V266, P450, DOI 10.1126/science.7524150; FINNIE NJ, 1995, P NATL ACAD SCI USA, V92, P320, DOI 10.1073/pnas.92.1.320; GODWIN AR, 1994, P NATL ACAD SCI USA, V91, P12554, DOI 10.1073/pnas.91.26.12554; GOTTLIEB TM, 1993, CELL, V72, P131, DOI 10.1016/0092-8674(93)90057-W; HAMILTON AA, 1987, MOL CELL BIOL, V7, P1409, DOI 10.1128/MCB.7.4.1409; HARRINGTON J, 1992, MOL CELL BIOL, V12, P4758, DOI 10.1128/MCB.12.10.4758; Jasin M, 1996, TRENDS GENET, V12, P224, DOI 10.1016/0168-9525(96)10019-6; KEMP LM, 1984, MUTAT RES, V132, P189, DOI 10.1016/0167-8817(84)90037-3; KIRCHGESSNER CU, 1995, SCIENCE, V267, P1178, DOI 10.1126/science.7855601; LIANG F, 1995, J BIOL CHEM, V270, P23838, DOI 10.1074/jbc.270.40.23838; LUKACSOVICH T, 1994, NUCLEIC ACIDS RES, V22, P5649, DOI 10.1093/nar/22.25.5649; Maniatis T., 1982, MOL CLONING; MCBLANE JF, 1995, CELL, V83, P387, DOI 10.1016/0092-8674(95)90116-7; MIMORI T, 1986, J BIOL CHEM, V261, P2274; MIMORI T, 1986, J BIOL CHEM, V261, P375; MOORE PD, 1986, MUTAT RES, V160, P149, DOI 10.1016/0027-5107(86)90038-2; MOROZOV VE, 1994, J BIOL CHEM, V269, P16684; PHILLIPS JW, 1994, MOL CELL BIOL, V14, P5794, DOI 10.1128/MCB.14.9.5794; RATHMELL WK, 1994, MOL CELL BIOL, V14, P4741, DOI 10.1128/MCB.14.7.4741; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROUET P, 1994, MOL CELL BIOL, V14, P8096, DOI 10.1128/MCB.14.12.8096; ROUET P, 1994, P NATL ACAD SCI USA, V91, P6064, DOI 10.1073/pnas.91.13.6064; SMIDER V, 1994, SCIENCE, V266, P288, DOI 10.1126/science.7939667; SMITHRAVIN J, 1989, INT J RADIAT BIOL, V56, P951, DOI 10.1080/09553008914552411; SUBRAMANI S, 1988, GENETIC RECOMBINATIO, P549; TACCIOLI GE, 1994, SCIENCE, V265, P1442, DOI 10.1126/science.8073286; TACCIOLI GE, 1993, SCIENCE, V260, P207, DOI 10.1126/science.8469973	33	139	140	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14405	14411		10.1074/jbc.271.24.14405	http://dx.doi.org/10.1074/jbc.271.24.14405			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662903	hybrid			2022-12-27	WOS:A1996UQ66000070
J	Sciorra, VA; Daniel, LW				Sciorra, VA; Daniel, LW			Phospholipase D-derived products in the regulation of 12-O-tetradecanoylphorbol-13-acetate-stimulated prostaglandin synthesis in Madin-Darby canine kidney cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; STIMULATED HUMAN FIBROBLASTS; ARACHIDONIC-ACID METABOLISM; HUMAN-NEUTROPHILS; PHOSPHATIDYLCHOLINE HYDROLYSIS; PHOSPHATIDIC-ACID; SUPEROXIDE GENERATION; DEPENDENT ACTIVATION; SIGNAL TRANSDUCTION; CHEMOTACTIC PEPTIDE	Madin-Darby canine kidney (MDCK) cells stimulated with 12-O-tetradecanoylphorbol-13-acetate (TPA) in the presence of ethanol synthesize phosphatidylethanol (PEt) instead of phosphatidic acid (PA) and diglyceride (DG). We have used ethanol to block the production of phospholipase D (PLD)-derived PA and DG (from PA hydrolysis) to study their role in signal transduction. In MDCK cells, TPA-stimulated prostaglandin E(2) (PGE(2)) synthesis was inhibited by ethanol at concentrations which inhibit PA and DG formation. In addition, TPA elicited a prolonged increase in PGE(2) synthesis that is dependent upon continuous activation of PLD. The TPA-stimulated translocation of protein kinase C alpha (PKC alpha) from cytosol to membrane was unaffected by ethanol. This suggests that PLD derived products act downstream of PKC in TPA-stimulated prostaglandin synthesis. The calcium ionophore, A23187, did not activate PLD, and PGE(2) synthesis in response to A23187 was unaffected by ethanol. TPA increased prostaglandin endoperoxide H synthase (PGHS) activity and increased the amount of immunodetectable prostaglandin endoperoxide H synthase 2 (PGHS-2). A23187 did not induce PGHS-2 and A23187-stimulated PGE(2) synthesis appears to be due to the constitutively expressed PGHS-1. Blocking the formation of PLD-derived products, PA and DG, inhibited the induction of PGHS-2 by TPA. These results indicate that prolonged PGE(2) synthesis in response to TPA is due to the continuous induction of PGHS-2, which is dependent upon PLD activation, In contrast, induction of PGHS-2 by epidermal growth factor was not affected by ethanol. Epidermal growth factor did not induce PKC alpha translocation nor activate PLD. Taken together, these data suggest that PLD-derived PA or DG act as second messengers in the induction of PGHS-2 by PKC-dependent pathways. The demonstration that inhibition of TPA-induced PA formation inhibits Raf-l translocation in MDCK cells (Ghosh, S., Strum, J. C., Sciorra, V. A., Daniel, L. W., and Bell, R. M. (1996) J. Biol. Chem, 271, 8472-8480) suggests that PA is the active PLD metabolite in TPA-stimulated signaling.	WAKE FOREST UNIV,BOWMAN GRAY SCH MED,DEPT BIOCHEM,WINSTON SALEM,NC 27157	Wake Forest University; Wake Forest Baptist Medical Center					NATIONAL CANCER INSTITUTE [R01CA043297, P30CA012197] Funding Source: NIH RePORTER; NCI NIH HHS [CA-43297, CA-48955, CA-12197] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ADAMS PD, 1991, FEBS LETT, V290, P77, DOI 10.1016/0014-5793(91)81230-6; AGWU DE, 1991, J IMMUNOL, V146, P3895; AGWU DE, 1991, J CLIN INVEST, V88, P531, DOI 10.1172/JCI115336; AGWU DE, 1989, J BIOL CHEM, V264, P1405; BALBOA MA, 1994, J BIOL CHEM, V269, P10511; BALSINDE J, 1994, BBA-LIPID LIPID MET, V1210, P195, DOI 10.1016/0005-2760(94)90121-X; BASS DA, 1988, J BIOL CHEM, V263, P19610; BAULDRY SA, 1988, J BIOL CHEM, V263, P16787; BAULDRY SA, 1992, J BIOL CHEM, V267, P25141; BEAUDRY GA, 1985, ARCH BIOCHEM BIOPHYS, V239, P242, DOI 10.1016/0003-9861(85)90832-X; BESTERMAN JM, 1986, P NATL ACAD SCI USA, V83, P6785, DOI 10.1073/pnas.83.18.6785; BILLAH MM, 1989, J BIOL CHEM, V264, P9069; BILLAH MM, 1989, J BIOL CHEM, V264, P17069; BILLAH MM, 1991, BIOCHEM SOC T, V19, P324, DOI 10.1042/bst0190324; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BOCCKINO SB, 1987, FEBS LETT, V225, P201, DOI 10.1016/0014-5793(87)81157-2; BOCCKINO SB, 1987, J BIOL CHEM, V262, P15309; BONSER RW, 1989, BIOCHEM J, V264, P617, DOI 10.1042/bj2640617; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURGERING BMT, 1993, MOL CELL BIOL, V13, P7248, DOI 10.1128/MCB.13.12.7248; COOK SJ, 1992, BIOCHEM J, V268, P10534; DANIEL LW, 1984, BIOCHIM BIOPHYS ACTA, V792, P33, DOI 10.1016/0005-2760(84)90279-0; DANIEL LW, 1993, J BIOL CHEM, V268, P21519; DANIEL LW, 1986, J BIOL CHEM, V261, P9128; DIEZ E, 1987, BIOCHIM BIOPHYS ACTA, V921, P82, DOI 10.1016/0005-2760(87)90173-1; EXTON JH, 1994, BBA-LIPID LIPID MET, V1212, P26, DOI 10.1016/0005-2760(94)90186-4; EXTON JH, 1990, J BIOL CHEM, V265, P1; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; FERNANDEZ B, 1994, J BIOL CHEM, V269, P26711; FLOWER RJ, 1976, BIOCHEM PHARMACOL, V25, P285, DOI 10.1016/0006-2952(76)90216-1; Ghosh S, 1996, J BIOL CHEM, V271, P8472, DOI 10.1074/jbc.271.14.8472; GODSON C, 1993, J BIOL CHEM, V268, P11946; HEMLER M, 1976, J BIOL CHEM, V251, P5575; HERSCHMAN HR, 1994, CANCER METAST REV, V13, P241, DOI 10.1007/BF00666095; HUANG CF, 1990, J BIOL CHEM, V265, P14858; IRVING HR, 1987, J BIOL CHEM, V262, P3440; JACKSON BA, 1993, BIOCHEM BIOPH RES CO, V197, P1465, DOI 10.1006/bbrc.1993.2642; KHAN WA, 1994, J BIOL CHEM, V269, P9729; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEACH KL, 1991, J BIOL CHEM, V266, P3215; LISCOVITCH M, 1991, BIOCHEM SOC T, V19, P402, DOI 10.1042/bst0190402; MARTIN TFJ, 1990, J BIOL CHEM, V265, P7623; MARTIN TW, 1988, BIOCHEM BIOPH RES CO, V157, P1271, DOI 10.1016/S0006-291X(88)81012-X; MARTINSON EA, 1990, J BIOL CHEM, V265, P22282; MCNAMARA MJG, 1948, BIOCHEM BIOPH RES CO, V122, P824; MOOLENAAR WH, 1992, REV PHYSIOL BIOCH P, V119, P47; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; OLSON SC, 1990, FEBS LETT, V272, P19, DOI 10.1016/0014-5793(90)80439-P; OSULLIVAN MG, 1992, J BIOL CHEM, V267, P14547; PAI JK, 1988, BIOCHEM BIOPH RES CO, V150, P355, DOI 10.1016/0006-291X(88)90528-1; PAI JK, 1987, CARCINOGENESIS, V8, P173, DOI 10.1093/carcin/8.1.173; PARKER J, 1987, J BIOL CHEM, V262, P5385; PIKE LJ, 1987, J BIOL CHEM, V262, P1644; PILBEAM CC, 1993, J BIOL CHEM, V268, P25643; REINHOLD SL, 1990, FASEB J, V4, P208, DOI 10.1096/fasebj.4.2.2105252; RUBIN R, 1988, BIOCHEM BIOPH RES CO, V156, P1090, DOI 10.1016/S0006-291X(88)80744-7; SAMET JM, 1995, J BIOL CHEM, V270, P8044, DOI 10.1074/jbc.270.14.8044; SCHULZE S, 1991, J EXP MED, V174, P1975; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; Simmons D.L., 1991, PROSTAGLANDINS LEUKO, P67; SMITH CJ, 1993, BIOCHEM BIOPH RES CO, V192, P787, DOI 10.1006/bbrc.1993.1483; SMITH WL, 1994, ANN NY ACAD SCI, V714, P136, DOI 10.1111/j.1749-6632.1994.tb12037.x; SMITH WL, 1991, PHARMACOL THERAPEUT, V49, P153, DOI 10.1016/0163-7258(91)90054-P; SMITH WL, 1992, AM J PHYSIOL, V263, pF181; TYAGI SR, 1989, J BIOL CHEM, V264, P12977; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10344; VANBLITTERSWIJK WJ, 1991, J BIOL CHEM, V266, P10337; WRIGHT TM, 1990, BIOCHEM J, V267, P501, DOI 10.1042/bj2670501; XIE WL, 1995, J BIOL CHEM, V270, P27622, DOI 10.1074/jbc.270.46.27622; YEO EJ, 1995, J BIOL CHEM, V270, P3980, DOI 10.1074/jbc.270.8.3980; ZYGLEWSKA T, 1993, J LAB CLIN MED, V122, P542	73	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14226	14232		10.1074/jbc.271.24.14226	http://dx.doi.org/10.1074/jbc.271.24.14226			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663019	hybrid			2022-12-27	WOS:A1996UQ66000045
J	Cook, JR; Cleary, CM; Mariano, TM; Izotova, L; Pestka, S				Cook, JR; Cleary, CM; Mariano, TM; Izotova, L; Pestka, S			Differential responsiveness of a splice variant of the human type I interferon receptor to interferons	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUKOCYTE INTERFERONS; GAMMA RECEPTOR; HUMAN-CELLS; BINDING; ALPHA; RECOMBINANT; GENE; PURIFICATION; EXPRESSION; CLONING	Chinese hamster ovary cells containing the yeast artificial chromosome F136C5 (alpha YAC) respond to all type I human interferons including IFN-alpha A, IFN-beta, and IFN-omega. The alpha YAC contains at least two genes encoding interferon-alpha receptor (IFN-alpha R) chains that are required for response to type I human interferons: Hu-IFN-alpha R1 and Hu-IFN-alpha R2. Ne previously isolated a splice variant of the Hu-IFN-alpha R1 chain designated Hu-IFN-alpha R1s. Chinese hamster ovary cells containing a disrupted alpha YAC, which contains a deletion in the human IFNAR1 gene, were transfected with expression vectors for the Hu IFN-alpha R1 and Hu-IFN-alpha R1s chains, With these cells, two type I interferons have been identified which can interact with the splice valiant (Hu-IFN-alpha R1s) and with the Hu IFN-alpha R1 chains: Hu-IFN-alpha A and IFN-omega. Two other type I interferons, Hu-IFN-alpha B2 and Hu-IFN-alpha F, are capable of signaling through the Hu-IFN-alpha R1 chain only and cannot utilize the splice variant Hu-IFN-alpha R1s. Hu-IFN-alpha R1 and Hu-IFN-alpha R1s differ in that the latter is missing a single subdomain of the receptor extracellular domain encoded by exons 4 and 5 of the IFNAR1 gene. These results therefore indicate that different type I interferons require different subdomains of the Hu-IFN-alpha R1 receptor chain, and that the splice variant chain (Hu-IFN-alpha R1s) is functional.	UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT MOLEC GENET & MICROBIOL,PISCATAWAY,NJ 08854	Rutgers State University New Brunswick; Rutgers State University Medical Center					NATIONAL CANCER INSTITUTE [R01CA046465, R01CA052363] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI036450] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA52363, R01 CA46465] Funding Source: Medline; NIAID NIH HHS [R01 AI/GM36450] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BAZAN JF, 1990, CELL, V61, P753, DOI 10.1016/0092-8674(90)90182-E; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; Cleary Cathleen M., 1992, Journal of Interferon Research, V12, pS220; CLEARY CM, 1994, J BIOL CHEM, V269, P18747; CLEARY CM, 1995, THESIS RUTGERS U PIS; COOK JR, 1994, J BIOL CHEM, V269, P7013; COOK JR, 1993, GENET ANAL-BIOMOL E, V10, P109, DOI 10.1016/1050-3862(93)90033-F; COOK JR, 1992, P NATL ACAD SCI USA, V89, P11317, DOI 10.1073/pnas.89.23.11317; EMANUEL SL, 1995, GENE, V155, P167, DOI 10.1016/0378-1119(94)00852-J; EMANUEL SL, 1995, THESIS U MED DENT NE; EMANUEL SL, 1995, PHARM TECHNOL, V19, P22; EVINGER M, 1981, ARCH BIOCHEM BIOPHYS, V210, P319, DOI 10.1016/0003-9861(81)90195-8; Familletti P C, 1981, Methods Enzymol, V78, P387; FISH EN, 1983, BIOCHEM BIOPH RES CO, V112, P537, DOI 10.1016/0006-291X(83)91498-5; FLORES I, 1991, J BIOL CHEM, V266, P19875; JUNG V, 1991, THESIS RUTGERS U PIS; LANGER JA, 1986, METHOD ENZYMOL, V119, P305; LANGER JA, 1990, SOMAT CELL MOLEC GEN, V16, P321; LI BL, 1989, P NATL ACAD SCI USA, V86, P558, DOI 10.1073/pnas.86.2.558; LUTFALLA G, 1993, GENOMICS, V16, P366, DOI 10.1006/geno.1993.1199; LUTFALLA G, 1992, J BIOL CHEM, V267, P2802; MANIATIS T, 1982, MOL CLONING LABORATO, P63; MARIANO TM, 1992, INTERFERON PRINCIPLE, P129; MIKI T, 1991, P NATL ACAD SCI USA, V88, P5167, DOI 10.1073/pnas.88.12.5167; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MOSCHERA JA, 1986, METHOD ENZYMOL, V119, P177; NOVICK D, 1994, CELL, V77, P391, DOI 10.1016/0092-8674(94)90154-6; ORTALDO JR, 1984, P NATL ACAD SCI-BIOL, V81, P4926, DOI 10.1073/pnas.81.15.4926; PESTKA S, 1986, METHOD ENZYMOL, V119, P3; REHBERG E, 1982, J BIOL CHEM, V257, P1497; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SOH J, 1993, P NATL ACAD SCI USA, V90, P8737, DOI 10.1073/pnas.90.18.8737; SOH J, 1994, CELL, V76, P793, DOI 10.1016/0092-8674(94)90354-9; SOH JM, 1994, J BIOL CHEM, V269, P18102; SOMMER B, 1991, CELL, V67, P11, DOI 10.1016/0092-8674(91)90568-J; STAEHELIN T, 1981, J BIOL CHEM, V256, P9750; UZE G, 1990, CELL, V60, P225, DOI 10.1016/0092-8674(90)90738-Z; WANG PY, 1994, J INTERFERON RES, V14, P41, DOI 10.1089/jir.1994.14.41; WERNER S, 1992, MOL CELL BIOL, V12, P82, DOI 10.1128/MCB.12.1.82	39	59	66	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13448	13453		10.1074/jbc.271.23.13448	http://dx.doi.org/10.1074/jbc.271.23.13448			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662801	hybrid			2022-12-27	WOS:A1996UP38500024
J	Hofhaus, G; Johns, DR; Hurko, O; Attardi, G; Chomyn, A				Hofhaus, G; Johns, DR; Hurko, O; Attardi, G; Chomyn, A			Respiration and growth defects in transmitochondrial cell lines carrying the 11778 mutation associated with Leber's hereditary optic neuropathy	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C OXIDASE; COMPLEX-I; NADH DEHYDROGENASE; MITOCHONDRIAL NADH; HUMAN MTDNA; HELA-CELLS; LACKING; GENE; NEURORETINOPATHY; FIBROBLASTS	Mitochondrial DNA from two genetically unrelated patients carrying the mutation at position 11778 that causes Leber's hereditary optic neuropathy has been transferred with mitochondria into human mtDNA-less rho(0)206 cells. As analyzed in several transmitochondrial cell lines thus obtained, the mutation, which is in the gene encoding subunit ND4 of the respiratory chain NADH dehydrogenase (ND), did not affect the synthesis, size, or stability of ND4, nor its incorporation into the enzyme complex, However, NADH dehydrogenase-dependent respiration, as measured in digitonin-permeabilized cells, was specifically decreased by approximately 40% in cells carrying the mutation, This decrease, which was significant at the 99.99% confidence level, was correlated with a significantly reduced ability of the mutant cells to grow in a medium containing galactose instead of glucose, indicating a clear impairment in their oxidative phosphorylation capacity. On the contrary, no decrease in rotenone-sensitive NADH dehydrogenase activity, using a water-soluble ubiquinone analogue as electron acceptor, was detected in disrupted mitochondrial membranes. This is the first cellular model exhibiting in a foreign nuclear background mitochondrial DNA-linked biochemical defects underlying the optic neuropathy phenotype.	CALTECH, DIV BIOL, PASADENA, CA 91125 USA; HARVARD UNIV, BETH ISRAEL HOSP, SCH MED, DEPT NEUROL, BOSTON, MA 02215 USA; JOHNS HOPKINS UNIV, SCH MED, DEPT NEUROL, BALTIMORE, MD 21206 USA	California Institute of Technology; Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Johns Hopkins University					NATIONAL EYE INSTITUTE [R01EY010864] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR038231] Funding Source: NIH RePORTER; NEI NIH HHS [EY 10864] Funding Source: Medline; NIAMS NIH HHS [AR NS 38231] Funding Source: Medline; NIGMS NIH HHS [GM 11726] Funding Source: Medline	NATIONAL EYE INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NEI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ATTARDI B, 1969, J MOL BIOL, V44, P47, DOI 10.1016/0022-2836(69)90404-5; BENECKE R, 1992, ANN NEUROL, V32, P683, DOI 10.1002/ana.410320512; BONNER WM, 1974, EUR J BIOCHEM, V46, P83, DOI 10.1111/j.1432-1033.1974.tb03599.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWN MD, 1992, GENETICS, V130, P163; BU XD, 1991, P NATL ACAD SCI USA, V88, P8198, DOI 10.1073/pnas.88.18.8198; CHOMYN A, 1994, AM J HUM GENET, V54, P966; Chomyn A, 1996, Methods Enzymol, V264, P197, DOI 10.1016/S0076-6879(96)64020-8; CHOMYN A, 1986, SCIENCE, V234, P614, DOI 10.1126/science.3764430; CHOMYN A, 1991, MOL CELL BIOL, V11, P2236, DOI 10.1128/MCB.11.4.2236; CHU EHY, 1972, P NATL ACAD SCI USA, V69, P3459, DOI 10.1073/pnas.69.11.3459; CLEETER MWJ, 1985, BIOCHEM J, V227, P467, DOI 10.1042/bj2270467; DAY CE, 1982, SOMAT CELL GENET, V8, P691, DOI 10.1007/BF01543012; DONNELLY M, 1976, J CELL PHYSIOL, V89, P39, DOI 10.1002/jcp.1040890105; ESPOSTI MD, 1994, FEBS LETT, V352, P375, DOI 10.1016/0014-5793(94)00971-6; ESTORNELL E, 1993, FEBS LETT, V332, P127, DOI 10.1016/0014-5793(93)80498-J; FEINBERG AP, 1983, ANAL BIOCHEM, V132, P6, DOI 10.1016/0003-2697(83)90418-9; GRANGER DL, 1982, J CELL BIOL, V95, P527, DOI 10.1083/jcb.95.2.527; GUAN MX, 1996, IN PRESS HUM MOL GEN; HARDING AE, 1995, AM J HUM GENET, V57, P77; HAYASHI JI, 1991, P NATL ACAD SCI USA, V88, P10614, DOI 10.1073/pnas.88.23.10614; Hofhaus G, 1996, Methods Enzymol, V264, P476, DOI 10.1016/S0076-6879(96)64043-9; HOFHAUS G, 1993, EMBO J, V12, P3043, DOI 10.1002/j.1460-2075.1993.tb05973.x; HOWELL N, 1991, AM J HUM GENET, V48, P935; HOWELL N, 1991, AM J HUM GENET, V49, P939; HUOPONEN K, 1991, AM J HUM GENET, V48, P1147; JOHNS DR, 1993, AM J HUM GENET, V53, P916; JOHNS DR, 1992, BIOCHEM BIOPH RES CO, V187, P1551, DOI 10.1016/0006-291X(92)90479-5; JOHNS DR, 1991, BIOCHEM BIOPH RES CO, V181, P1358, DOI 10.1016/0006-291X(91)92088-2; JUN AS, 1994, P NATL ACAD SCI USA, V91, P6206, DOI 10.1073/pnas.91.13.6206; KING MP, 1989, SCIENCE, V246, P500, DOI 10.1126/science.2814477; LARSSON NG, 1991, ANN NEUROL, V30, P701, DOI 10.1002/ana.410300511; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MAJANDER A, 1991, FEBS LETT, V292, P289, DOI 10.1016/0014-5793(91)80886-8; MARIOTTINI P, 1986, J BIOL CHEM, V261, P3355; MASON TL, 1973, J BIOL CHEM, V248, P1346; NEWMAN NJ, 1993, ARCH NEUROL-CHICAGO, V50, P540, DOI 10.1001/archneur.1993.00540050082021; REITZER LJ, 1979, J BIOL CHEM, V254, P2669; ROBINSON BH, 1992, BIOCHEM MED METAB B, V48, P122, DOI 10.1016/0885-4505(92)90056-5; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; STORRIE B, 1972, J MOL BIOL, V71, P177, DOI 10.1016/0022-2836(72)90345-2; SUMEGI B, 1984, J BIOL CHEM, V259, P5040; VERGANI L, 1995, BIOCHEM BIOPH RES CO, V210, P880, DOI 10.1006/bbrc.1995.1740; WALLACE DC, 1994, P NATL ACAD SCI USA, V91, P8739, DOI 10.1073/pnas.91.19.8739; WALLACE DC, 1988, SCIENCE, V242, P1427, DOI 10.1126/science.3201231; YONEDA M, 1992, P NATL ACAD SCI USA, V89, P11164, DOI 10.1073/pnas.89.23.11164	46	131	136	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13155	13161		10.1074/jbc.271.22.13155	http://dx.doi.org/10.1074/jbc.271.22.13155			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662757	Green Accepted, hybrid			2022-12-27	WOS:A1996UN47400072
J	Peraldi, P; Hotamisligil, GS; Buurman, WA; White, MF; Spiegelman, BM				Peraldi, P; Hotamisligil, GS; Buurman, WA; White, MF; Spiegelman, BM			Tumor necrosis factor (TNF)-alpha inhibits insulin signaling through stimulation of the p55 TNF receptor and activation of sphingomyelinase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEMATOPOIETIC-CELLS; FACTOR-ALPHA; EXPRESSION; PHOSPHORYLATION; MONOCYTOGENES; RESISTANCE; ADIPOCYTES; INFECTION	Tumor necrosis factor (TNF)alpha plays a central role in the state of insulin resistance associated with obesity. It has previously been shown that one important mechanism by which TNF-alpha interferes with insulin signaling is through the serine phosphorylation of insulin receptor substrate-1 (IRS-1), which can then function as an inhibitor of the tyrosine kinase activity of the insulin receptor (IR), However, the receptors and the signaling pathway used by TNF-alpha that mediate the inhibition of IR activity are unknown. We show here that human TNF-alpha, which binds only to the murine p55 TNF receptor (TNFR), is as effective at inhibiting insulin-dependent tyrosine phosphorylation of IR and IRS-1 in adipocytes and myeloid 32D cells as murine TNF-alpha, which binds to both p55 TNFR and p75 TNFR. Likewise, antibodies that are specific agonists for p55 TNFR or p75 TNFR demonstrate that stimulation of p55 TNFR is sufficient to inhibit insulin signaling, though a small effect can also be seen with antibodies to p75 TNFR. Exogenous sphingomyelinase and ceramides, known to be formed by activat- ion of p55 TNFR, inhibit IR and IRS-1 tyrosine phosphorylation and convert IRS-1 into an inhibitor of IR tyrosine kinase in vitro. Myeloid 32D cells expressing LR and IRS-1 are sensitive to this inhibition, but cells expressing IR and IRS-2 are resistant, pointing to an important difference in the biological function between IRS-1 and IRS-2. These data strongly suggest that TNF-alpha inhibits insulin signaling via stimulation of p55 TNFR and sphingomyelinase activity, which results in the production of an inhibitory form of IRS-1.	HARVARD UNIV,SCH MED,DANA FARBER CANC INST,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT CELL BIOL,BOSTON,MA 02115; HARVARD UNIV,SCH PUBL HLTH,DEPT NUTR,BOSTON,MA 02115; UNIV LIMBURG,DEPT SURG,6200 MD MAASTRICHT,NETHERLANDS; HARVARD UNIV,SCH MED,JOSLIN DIABET CTR,BOSTON,MA 02115; HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Hasselt University; Maastricht University; Harvard University; Harvard Medical School; Joslin Diabetes Center, Inc.; Harvard University; Harvard Medical School			Peraldi, Pascal/O-4592-2016	Peraldi, Pascal/0000-0003-0205-9252				BENNETT PH, 1990, DIABETES MELLITUS TH, P357; DEHERREROS AG, 1989, J BIOL CHEM, V264, P19994; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; ERICKSON SL, 1994, NATURE, V372, P560, DOI 10.1038/372560a0; FEINSTEIN R, 1993, J BIOL CHEM, V268, P26055; HAMANN A, 1995, DIABETES, V44, P1266, DOI 10.2337/diabetes.44.11.1266; HELLER RA, 1994, J CELL BIOL, V126, P5, DOI 10.1083/jcb.126.1.5; HOFMANN C, 1994, ENDOCRINOLOGY, V134, P264, DOI 10.1210/en.134.1.264; HOTAMISLIGIL GS, 1994, DIABETES, V43, P1271, DOI 10.2337/diabetes.43.11.1271; Hotamisligil GS, 1996, SCIENCE, V271, P665, DOI 10.1126/science.271.5249.665; HOTAMISLIGIL GS, 1993, SCIENCE, V259, P87, DOI 10.1126/science.7678183; HOTAMISLIGIL GS, 1994, P NATL ACAD SCI USA, V91, P4854, DOI 10.1073/pnas.91.11.4854; HOTAMISLIGIL GS, 1995, J CLIN INVEST, V95, P2409, DOI 10.1172/JCI117936; HOTAMISLIGIL GS, 1994, J CLIN INVEST, V94, P1543, DOI 10.1172/JCI117495; HSU HL, 1995, CELL, V81, P495, DOI 10.1016/0092-8674(95)90070-5; JOSEPH C, 1993, J BIOL CHEM, V269, P3047; KANETY H, 1995, J BIOL CHEM, V270, P23780, DOI 10.1074/jbc.270.40.23780; KERN PA, 1995, J CLIN INVEST, V95, P2111, DOI 10.1172/JCI117899; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; LEWIS M, 1991, P NATL ACAD SCI USA, V88, P2830, DOI 10.1073/pnas.88.7.2830; LOZANO J, 1994, J BIOL CHEM, V269, P19200; MOSIALOS G, 1995, CELL, V80, P389, DOI 10.1016/0092-8674(95)90489-1; MULLER G, 1995, EMBO J, V14, P1156; Olefsky JM, 1990, DIABETES MELLITUS TH, P121; PALEOLOG EM, 1994, BLOOD, V84, P2578; PATTI ME, 1995, J BIOL CHEM, V270, P24670, DOI 10.1074/jbc.270.42.24670; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE M, 1994, CELL, V78, P681, DOI 10.1016/0092-8674(94)90532-0; SAAD MJA, 1992, J CLIN INVEST, V90, P1839, DOI 10.1172/JCI116060; Saghizadeh M, 1996, J CLIN INVEST, V97, P1111, DOI 10.1172/JCI118504; Shepherd Peter R., 1993, P253; SONG H, 1994, J BIOL CHEM, V270, P3574; STANGER BZ, 1995, CELL, V81, P513, DOI 10.1016/0092-8674(95)90072-1; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; THIES RS, 1990, DIABETES, V39, P250, DOI 10.2337/diabetes.39.2.250; VANDENABEELE P, 1995, TRENDS CELL BIOL, V5, P392, DOI 10.1016/S0962-8924(00)89088-1; WANG LM, 1993, SCIENCE, V261, P1591, DOI 10.1126/science.8372354; WANG LM, 1993, P NATL ACAD SCI USA, V90, P4032, DOI 10.1073/pnas.90.9.4032; WHITE MF, 1994, J BIOL CHEM, V269, P1; YAO B, 1995, NATURE, V378, P307, DOI 10.1038/378307a0	41	336	347	0	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13018	13022		10.1074/jbc.271.22.13018	http://dx.doi.org/10.1074/jbc.271.22.13018			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662983	Green Published, hybrid			2022-12-27	WOS:A1996UN47400053
J	Burns, EL; Nicholas, RA; Price, EM				Burns, EL; Nicholas, RA; Price, EM			Random mutagenesis of the sheep Na,K-ATPase alpha 1 subunit generating the ouabain-resistant mutant L793P	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; MUTATION; BINDING; ENZYME; CELLS; DNA	The polymerase chain reaction was used to randomly mutagenize a cDNA cassette encoding amino acids 691-946 of the sheep Na,K-ATPase alpha subunit, The mutagenized cassettes were used to replace the wild type region in the full-length cDNA, and pools of mutants were transfected into HeLa cells, After the generation of resistant cells via selection in 0.5 mu M ouabain, polymerase chain reaction was used to amplify the mutagenized cassette from the genomic DNA of the stable transfectants, Sequence analysis of the polymerase chain reaction product revealed three amino acid substitutions: I729V, L793P, and K836R, Subsequent site-directed mutagenesis experiments showed that only L793P was important for resistance, To elucidate the role of L793 in ouabain inhibition, additional mutations at this position were prepared. L793A and L793I mutants were constructed and expressed in HeLa cells, Only L793A survived selection using ouabain, which suggested that resistance is not due to the specific substitution of leucine with proline. To explore the mechanism of resistance, apparent affinities of the L793P mutant for sodium and potassium were compared to the wild-type HeLa pump, Although the apparent affinities were comparable for sodium, the mutant had a a-fold higher apparent affinity for potassium, This suggests that the mechanism of ouabain insensitivity of L793P is due to a perturbation in the region of the enzyme that may include the K+ binding site.	UNIV MISSOURI, DEPT VET BIOMED SCI, COLUMBIA, MO 65211 USA; UNIV MISSOURI, DALTON CARDIOVASC RES CTR, COLUMBIA, MO 65211 USA; UNIV N CAROLINA, DEPT PHARMACOL, CHAPEL HILL, NC 27599 USA	University of Missouri System; University of Missouri Columbia; University of Missouri System; University of Missouri Columbia; University of North Carolina; University of North Carolina Chapel Hill					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL046469] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01HL46469] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARYSTARKHOVA E, 1992, J BIOL CHEM, V267, P13694; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Brown A., 1982, ATP ATPASE DETERMINA, P223; BURNS EL, 1993, J BIOL CHEM, V268, P25632; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANTLEY LG, 1994, J BIOL CHEM, V269, P15358; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; GARAY RP, 1973, J PHYSIOL-LONDON, V231, P297, DOI 10.1113/jphysiol.1973.sp010234; Higuchi R, 1989, PCR TECHNOLOGY PRINC, P31; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JOHNSON CL, 1995, ARCH BIOCHEM BIOPHYS, V317, P133, DOI 10.1006/abbi.1995.1145; KRETZ KA, 1989, NUCLEIC ACIDS RES, V17, P5864, DOI 10.1093/nar/17.14.5864; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; KUSUKAWA N, 1990, BIOTECHNIQUES, V9, P66; Leung DW, 1989, TECHNIQUE, V1, P11; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SHULL GE, 1985, NATURE, V316, P691, DOI 10.1038/316691a0; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201	25	26	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15879	15883		10.1074/jbc.271.27.15879	http://dx.doi.org/10.1074/jbc.271.27.15879			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663108	hybrid, Green Published			2022-12-27	WOS:A1996UW35200009
J	Farwell, AP; Safran, M; Dubord, S; Leonard, JL				Farwell, AP; Safran, M; Dubord, S; Leonard, JL			Degradation and recycling of the substrate-binding subunit of type II iodothyronine 5'-deiodinase in astrocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLIAL-CELLS; ACTIN POLYMERIZATION; ENZYME INACTIVATION; ORGANELLE STRUCTURE; THYROID-HORMONE; BREFELDIN-A; ENDOSOMES; INTERNALIZATION; RECEPTOR; PROTEINS	Thyroxine dynamically regulates levels of type II iodothyronine 5'-deiodinase (5'D-II) by modulating enzyme inactivation and targeting the enzyme to different pathways of internalization. 5'D-II is an similar to 200-kDa multimeric protein containing a 29-kDa substrate-binding subunit (p29) and an unknown number of other subunits, In the absence of thyroxine (T-4), p29 is slowly endocytosed and transported to the lysosomes, T-4 treatment rapidly activates an actin-mediated endocytotic pathway and targets the enzyme to the endosomes, In this study, we have characterized the influence of T-4 on the intracellular trafficking of 5'D-II. We show that T-4 accelerates the rate of 5'D-II inactivation by translocating the enzyme to the interior of the cell and by sequestering p29 in the endosomal pool without accelerating the rate of degradation of p29. This dichotomy between the rapid inactivation of catalytic activity and the much slower degradation of p29 is consistent with the reuse of p29 in the production of 5'D-II activity, Immunocytochemical analysis with a specific anti-p29 IgG shows that pulse affinity-labeled p29 reappears on the plasma membrane similar to 2 h after enzyme internalization in the presence of T-4, indicating that p29 is recycled, Despite the ability of p29 to be recycled in the T-4-treated cell, 5'D-II catalytic activity requires ongoing protein synthesis, presumably of another enzyme component(s) or an accessory enzyme-related protein, In the absence of T-4, enzyme inactivation and p29 degradation are temporally linked, and pulse affinity-labeled p29 is internalized and sequestered in discrete intracellular pools, These data suggest that T-4 regulates fundamental processes involved with the turnover of integral membrane proteins and participates in regulating the inter-relationships between the degradation, recycling, and synthetic pathways.	UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,DEPT MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,DEPT NUCL MED,WORCESTER,MA 01655; UNIV MASSACHUSETTS,SCH MED,MOLEC ENDOCRINOL LAB,DEPT MOLEC & CELLULAR PHYSIOL,WORCESTER,MA 01655	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Farwell, Alan/0000-0001-7716-2719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K08DK002005, R01DK038772] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK-38772, DK 02005] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		CIECHANOVER A, 1983, J BIOL CHEM, V258, P9681; DAMKE H, 1991, J BIOL CHEM, V266, P24829; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; FARWELL AP, 1992, ENDOCRINOLOGY, V131, P721, DOI 10.1210/en.131.2.721; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; FEANY MB, 1993, NATURE, V364, P537, DOI 10.1038/364537a0; HELENIUS A, 1983, TRENDS BIOCHEM SCI, V8, P245, DOI 10.1016/0968-0004(83)90350-X; KELLY RB, 1993, NATURE, V364, P487, DOI 10.1038/364487a0; KLAUSNER RD, 1992, J CELL BIOL, V116, P1071, DOI 10.1083/jcb.116.5.1071; LEONARD JL, 1984, ENDOCRINOLOGY, V114, P998, DOI 10.1210/endo-114-3-998; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1994, ENDOCRINOLOGY, V135, P548, DOI 10.1210/en.135.2.548; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Leonard JL, 1986, THYROID HORMONE META, P189; LIPPINCOTTSCHWARTZ J, 1991, CELL, V67, P601, DOI 10.1016/0092-8674(91)90534-6; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; MCCARTHY KD, 1978, J CYCLIC NUCL PROT, V4, P15; MUELLER SC, 1986, J CELL BIOL, V102, P932, DOI 10.1083/jcb.102.3.932; PRYER NK, 1992, ANNU REV BIOCHEM, V61, P471; ROTHMAN JE, 1992, NATURE, V355, P409, DOI 10.1038/355409a0; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; SAFRAN M, 1993, J BIOL CHEM, V268, P14224; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1996, J BIOL CHEM, V261, P16363; SUDHOF TC, 1991, NEURON, V6, P665, DOI 10.1016/0896-6273(91)90165-V; SUDHOF TC, 1993, CELL, V75, P1; VALLEE RB, 1990, ANNU REV BIOCHEM, V59, P909, DOI 10.1146/annurev.biochem.59.1.909; VISSER TJ, 1983, J CLIN INVEST, V71, P992, DOI 10.1172/JCI110854; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; WOLENSKI JS, 1993, J EXP ZOOL, V267, P33, DOI 10.1002/jez.1402670106	31	24	25	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16369	16374		10.1074/jbc.271.27.16369	http://dx.doi.org/10.1074/jbc.271.27.16369			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663170	hybrid			2022-12-27	WOS:A1996UW35200076
J	Keating, DH; Cronan, JE				Keating, DH; Cronan, JE			An isoleucine to valine substitution in Escherichia coli acyl carrier protein results in a functional protein of decreased molecular radius at elevated pH	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FATTY-ACID BIOSYNTHESIS; SPINACH; MUTANTS; FORMS	Escherichia coli acyl carrier protein (ACP) has been reported to exist in at least two distinct conformers in solution, A novel form of ACP having an increased electrophoretic mobility on polyacrylamide gel electrophoresis was noted previously during work on beta-ketoacyl-acyl carrier protein synthase II (fabF) mutants off. coli (Jackowski, S,, and Rock, C, O. (1987) J. Bacteriol. 169, 1469-1473), These workers reported that the increased electrophoretic mobility of the ACP from fabF strains occurred irrespective of prosthetic group attachment or the state of acylation of the prosthetic group, Since these workers were unable to detect a difference between the amino acid sequence of the ACP from the fabF mutants and that of wild type ACP, they suggested that the increased electrophoretic mobility was due to an unknown post-translational modification of the polypeptide chain, We have reinvestigated these mutants and report that the increased electrophoretic mobility is due to a mutation within the gene (acpP) that encodes ACP. This mutation results in substitution of isoleucine for valine 43 of ACP, Site-directed mutagenesis of a synthetic ACP gene demonstrated that the amino acid substitution at residue 43 is the cause of the increased electrophoretic mobility, Gel filtration experiments indicated that the increased electrophoretic mobility results from the more compact structure of V43I ACP at high pH. The altered residue lies within the ACP region of greatest conformational lability, and thus the V43I substitution may shift the equilibrium toward the more compact conformation(s), The disulfide-linked dimer of V43I ACP was readily formed and had an electrophoretic migration greater than the dimer of wild type ACP, suggesting that formation of ACP ACP dimers does not require structural deformation of the protein.	UNIV ILLINOIS,DEPT MICROBIOL,URBANA,IL 61801; UNIV ILLINOIS,DEPT BIOCHEM,URBANA,IL 61801	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign			Cronan, John/V-6626-2019		NCRR NIH HHS [RR07141] Funding Source: Medline; NIAID NIH HHS [AI15650] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R37AI015650, R01AI015650] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ANDREC M, 1995, PROTEIN SCI, V4, P983; CHANG YY, 1995, J BIOL CHEM, V270, P7896, DOI 10.1074/jbc.270.14.7896; CRONAN JE, 1988, GENE, V70, P161, DOI 10.1016/0378-1119(88)90114-X; CRONAN JE, 1982, J BIOL CHEM, V257, P5013; Davis R., 1980, ADV BACTERIAL GENETI; DAVIS TN, 1982, VIROLOGY, V120, P287, DOI 10.1016/0042-6822(82)90031-9; GELMANN EP, 1972, J BACTERIOL, V112, P381, DOI 10.1128/JB.112.1.381-387.1972; HOLAK TA, 1988, BIOCHEMISTRY-US, V27, P6135, DOI 10.1021/bi00416a046; HOLAK TA, 1988, EUR J BIOCHEM, V175, P9, DOI 10.1111/j.1432-1033.1988.tb14159.x; JACKOWSKI S, 1983, J BIOL CHEM, V258, P5186; JACKOWSKI S, 1987, J BACTERIOL, V169, P1469, DOI 10.1128/jb.169.4.1469-1473.1987; JONES PJ, 1987, BIOCHEMISTRY-US, V26, P3493, DOI 10.1021/bi00386a037; KEATING DH, 1995, J BIOL CHEM, V270, P22229, DOI 10.1074/jbc.270.38.22229; KIM Y, 1989, BIOCHEMISTRY-US, V28, P8792, DOI 10.1021/bi00448a017; KIM YM, 1990, BIOCHEM PHARMACOL, V40, P7; KIM YM, 1990, PROTEINS, V8, P377, DOI 10.1002/prot.340080411; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; MAGNUSON K, 1995, J BACTERIOL, V177, P3593, DOI 10.1128/jb.177.12.3593-3595.1995; MAGNUSON K, 1993, MICROBIOL REV, V57, P522, DOI 10.1128/MMBR.57.3.522-542.1993; POSTBEITTENMILLER D, 1991, J BIOL CHEM, V266, P1858; RAWLINGS M, 1992, J BIOL CHEM, V267, P5751; Rock C O, 1981, Methods Enzymol, V71 Pt C, P341; ROCK CO, 1979, J BIOL CHEM, V254, P9778; ROCK CO, 1981, J BIOL CHEM, V256, P2669; SCHULZ H, 1975, J BIOL CHEM, V250, P2299; SCHULZ H, 1977, FEBS LETT, V78, P303, DOI 10.1016/0014-5793(77)80329-3; TABOR S, 1989, P NATL ACAD SCI USA, V86, P4076, DOI 10.1073/pnas.86.11.4076; ULRICH AK, 1983, J BACTERIOL, V154, P221, DOI 10.1128/JB.154.1.221-230.1983; VALLARI DS, 1988, J BACTERIOL, V170, P3961, DOI 10.1128/jb.170.9.3961-3966.1988; VANDENBOOM T, 1989, ANNU REV MICROBIOL, V43, P317, DOI 10.1146/annurev.micro.43.1.317	30	18	18	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15905	15910		10.1074/jbc.271.27.15905	http://dx.doi.org/10.1074/jbc.271.27.15905			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663183	hybrid			2022-12-27	WOS:A1996UW35200013
J	Nanda, A; Brumell, JH; Nordstrom, T; Kjeldsen, L; Sengelov, H; Borregaard, N; Rotstein, OD; Grinstein, S				Nanda, A; Brumell, JH; Nordstrom, T; Kjeldsen, L; Sengelov, H; Borregaard, N; Rotstein, OD; Grinstein, S			Activation of proton pumping in human neutrophils occurs by exocytosis of vesicles bearing vacuolar-type H+-ATPases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; PLASMA-MEMBRANE; NADPH OXIDASE; PH REGULATION; SUBCELLULAR-LOCALIZATION; MAMMALIAN KIDNEY; INTRACELLULAR PH; CYTOPLASMIC PH; MACROPHAGES; CELLS	Proton pump activity is not measurable in the plasma membrane of unstimulated neutrophils but becomes readily detectable upon activation by soluble agonists. The mechanism of pump activation was investigated in this report. V-type H+ pump activity, estimated as a bafilomycin A(1)-sensitive elevation of the cytosolic pH, was stimulated in suspended neutrophils by chemotactic peptides and by phorbol esters. Stimulation of pump activity induced by the agonists was greatly enhanced by cytochalasin B, an agent known to potentiate granular secretion in neutrophils. We therefore compared the rate and extent of pump activation with the pattern of exocytosis of the four types of secretory organelles present in neutrophils, using flow cytometry and enzyme-linked immunosorbent assay, The kinetics of exocytosis of secretory vesicles and secondary and tertiary granules but not primary granules paralleled the appearance of pump activity, The subcellular localization of the pump was defined by cellular fractionation and immunoblotting using an antibody to the C subunit of the V-type ATPase. The pump was abundant in tertiary granules, with significant amounts present also in primary granules and secretory vesicles. The pump was scarce in secondary granules and not detectable in the cytosol. Finally, the agonists failed to stimulate pump activity in neutrophil cytoplasts, which are intact cell fragments devoid of acidic granules, Together, our results suggest that the V-type H+-ATPase is not constitutively present in the plasma membrane of neutrophils but is delivered to the surface membrane by exocytosis during cellular activation, Tertiary granules and secretory vesicles are the most likely source of V-ATPases, Following insertion in the plasma membrane, the pump is poised to effectively extrude the excess metabolic acid that is generated during chemotaxis and bacterial killing.	HOSP SICK CHILDREN, DIV CELL BIOL, TORONTO, ON M5G 1X8, CANADA; UNIV TORONTO, DEPT BIOCHEM, TORONTO, ON M5S 1A8, CANADA; TORONTO HOSP, DEPT SURG, TORONTO, ON M5G 2C4, CANADA; RIGSHOSP, DEPT HAEMATOL L, CRANULOCYTE RES LAB, DK-2100 COPENHAGEN, DENMARK	University of Toronto; University Toronto Affiliates; Hospital for Sick Children (SickKids); University of Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Rigshospitalet; University of Copenhagen			Kjeldsen, Lars/AAF-2096-2019; Nordström, Tommy/H-9111-2016	Nordström, Tommy/0000-0002-2153-5819; Sengelov, Henrik/0000-0002-5991-2958				ALAWQATI Q, 1986, ANNU REV CELL BIOL, V2, P179, DOI 10.1146/annurev.cellbio.2.1.179; ANDERSON RGW, 1988, J CELL BIOL, V106, P539, DOI 10.1083/jcb.106.3.539; ARONSON PS, 1985, ANNU REV PHYSIOL, V47, P545, DOI 10.1146/annurev.ph.47.030185.002553; BIDANI A, 1990, AM J PHYSIOL, V259, pC586, DOI 10.1152/ajpcell.1990.259.4.C586; BJERRUM OW, 1989, SCAND J CLIN LAB INV, V49, P613, DOI 10.3109/00365518909091536; BLAIR HC, 1989, SCIENCE, V245, P855, DOI 10.1126/science.2528207; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P318; BORREGAARD N, 1992, J CLIN INVEST, V90, P86, DOI 10.1172/JCI115860; BORREGAARD N, 1993, EUR J HAEMATOL, V51, P187; BOWMAN EJ, 1988, P NATL ACAD SCI USA, V85, P7972, DOI 10.1073/pnas.85.21.7972; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; Cochrane CG, 1990, CELLULAR MOL MECHANI, P83; COLLETTE J, 1956, J AM CHEM SOC, V78, P3819, DOI 10.1021/ja01596a070; CROSS AR, 1986, BIOCHEM J, V237, P111, DOI 10.1042/bj2370111; DROSE S, 1993, BIOCHEMISTRY-US, V32, P3902, DOI 10.1021/bi00066a008; GALLIN JI, 1984, J IMMUNOL, V133, P415; GRINSTEIN S, 1986, AM J PHYSIOL, V251, pC55, DOI 10.1152/ajpcell.1986.251.1.C55; HENDERSON LM, 1987, BIOCHEM J, V246, P325, DOI 10.1042/bj2460325; HENDERSON LM, 1988, BIOCHEM J, V251, P563, DOI 10.1042/bj2510563; Johnson K J, 1992, Immunol Ser, V57, P1; KALLIO DM, 1971, J ULTRA MOL STRUCT R, V37, P169, DOI 10.1016/S0022-5320(71)80048-5; KANE PM, 1995, J BIOL CHEM, V270, P17025; KAPUS A, 1992, BIOCHEM J, V281, P697, DOI 10.1042/bj2810697; KJELDSEN L, 1994, BLOOD, V83, P1640, DOI 10.1182/blood.V83.6.1640.bloodjournal8361640; KOZA EP, 1975, P SOC EXP BIOL MED, V149, P476; MOLLINEDO F, 1984, J BIOL CHEM, V259, P7143; MOLLINEDO F, 1986, J BIOL CHEM, V261, P1077; MOREL F, 1991, EUR J BIOCHEM, V201, P523, DOI 10.1111/j.1432-1033.1991.tb16312.x; NANDA A, 1992, J BIOL CHEM, V267, P22740; NANDA A, 1995, J CELL PHYSIOL, V165, P588, DOI 10.1002/jcp.1041650317; NANDA A, 1991, P NATL ACAD SCI USA, V88, P10816, DOI 10.1073/pnas.88.23.10816; NIESSEN HWM, 1992, CELL SIGNAL, V4, P501, DOI 10.1016/0898-6568(92)90019-5; NORDSTROM T, 1994, FEBS LETT, V350, P82, DOI 10.1016/0014-5793(94)00738-1; ODONNELL VB, 1993, BIOCHEM J, V290, P41, DOI 10.1042/bj2900041; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROOS D, 1983, J CELL BIOL, V97, P368, DOI 10.1083/jcb.97.2.368; SCHWARTZ GJ, 1986, ANNU REV PHYSIOL, V48, P153; SEGAL AW, 1995, PROTOPLASMA, V184, P86, DOI 10.1007/BF01276905; SENGELOV H, 1995, J IMMUNOL, V154, P4157; SENGELOV H, 1993, J IMMUNOL, V150, P1535; SENGELOV H, 1992, J BIOL CHEM, V267, P14912; SENGELOV H, 1993, J CLIN INVEST, V92, P1467, DOI 10.1172/JCI116724; SHAAFI RI, 1988, PROG ALLERGY, V42, P1; SUMNER JP, 1995, J BIOL CHEM, V270, P5649, DOI 10.1074/jbc.270.10.5649; SWALLOW CJ, 1990, J BIOL CHEM, V265, P7645; TAPPER H, 1992, BIOCHEM J, V281, P245, DOI 10.1042/bj2810245; TAPPER H, 1996, IN PRESS J LEUKOCYTE; THOMAS JA, 1979, BIOCHEMISTRY-US, V18, P2210, DOI 10.1021/bi00578a012; UMEKI S, 1994, ANN HEMATOL, V68, P267, DOI 10.1007/BF01695032; VAANANEN HK, 1990, J CELL BIOL, V111, P1305, DOI 10.1083/jcb.111.3.1305; XIE XS, 1993, J BIOL CHEM, V268, P25063; ZHANG K, 1992, J BIOL CHEM, V267, P14539; ZHANG K, 1992, J BIOL CHEM, V267, P9701	53	86	87	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15963	15970		10.1074/jbc.271.27.15963	http://dx.doi.org/10.1074/jbc.271.27.15963			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663143	hybrid			2022-12-27	WOS:A1996UW35200021
J	Himeno, S; Chittum, HS; Burk, RF				Himeno, S; Chittum, HS; Burk, RF			Isoforms of selenoprotein P in rat plasma - Evidence for a full-length form and another form that terminates at the second UGA in the open reading frame	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLUTATHIONE-PEROXIDASE GENE; 3' UNTRANSLATED REGION; SELENOCYSTEINE; PROTEINS; SEQUENCES; DEIODINASE; CODON; CDNA; TGA; RNA	Several forms of selenoprotein P that share the same N-terminal sequence have been identified in rat plasma, but only one selenoprotein P mRNA has been characterized. The open reading frame of the mRNA contains 10 UGAs that presumably code for selenocysteine residues. Using heparin-Sepharose, we isolated two of the protein forms from immunoaffinity-purified selenoprotein P. One of the forms, Se-P-45B, migrates at 45 kDa on SDS-polyacrylamide gel electrophoresis, and the other, Se-P-57B, migrates at 57 kDa. These two forms were cleaved with cyanogen bromide, and both yielded 40-kDa fragments that were consistent with those fragments being an inter-methionine peptide near the N terminus of the predicted polypeptide. A 20-kDa fragment present in the cleavage products of Se-P-57B was absent from the products of Se-P-45B. This result suggested that Se-P-45B lacks the C-terminal region of the predicted polypeptide. Carboxypeptidase P digestion of Se-P-45B indicated that its C-terminal amino acid is Ser(244), the amino acid immediately upstream from the predicted second selenocysteine. C-terminal analysis of Se-P-57B indicated that its final residue is Asn(366), the last amino acid predicted by the cDNA sequence. Amino acid composition analyses of the two forms were consistent with both arising from the same mRNA Immunoaffinity-purified selenoprotein P was digested with proteases, and the resulting peptides were separated and sequenced. Only amino acid sequences predicted by the cDNA were found, and 80% of the predicted amino acid sequence was confirmed. These results are compatible with Se-P-45B arising from termination of translation at the second in-frame UGA codon and all of the 10 in-frame UGA codons being read through to produce Se-P-57B. These findings demonstrate that selenoprotein P isoforms of differing peptide lengths are present in plasma. They raise the possibility that the second UGA codon in selenoprotein P mRNA can have alternative functions: coding for the incorporation of selenocysteine or coding for termination of translation.	VANDERBILT UNIV,MED CTR,SCH MED,DEPT MED,DIV GASTROENTEROL,NASHVILLE,TN 37232; VANDERBILT UNIV,SCH MED,CTR MOLEC TOXICOL,NASHVILLE,TN 37232	Vanderbilt University; Vanderbilt University			Himeno, Seiichiro/AAW-3421-2020	Himeno, Seiichiro/0000-0002-0773-2373	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P30DK026657] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R37ES002497, R01ES002497, P30ES000267] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 26657] Funding Source: Medline; NIEHS NIH HHS [ES 00267, ES 02497] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		BAROUCH W W, 1990, Peptide Research, V3, P73; BERRY MJ, 1991, NATURE, V349, P438, DOI 10.1038/349438a0; BERRY MJ, 1991, NATURE, V353, P273, DOI 10.1038/353273a0; BERRY MJ, 1993, EMBO J, V12, P315; BIDLINGMEYER BA, 1984, J CHROMATOGR, V336, P93, DOI 10.1016/S0378-4347(00)85133-6; BOCK A, 1994, SELENIUM BIOL HUMAN, P9; BRIGELIUS-FLOHE R, 1994, J BIOL CHEM, V269, P7342; BURK RF, 1991, FASEB J, V5, P2274, DOI 10.1096/fasebj.5.9.1830557; BURK RF, 1994, J NUTR, V124, P1891, DOI 10.1093/jn/124.10.1891; BURK RF, 1993, ANNU REV NUTR, V13, P65, DOI 10.1146/annurev.nu.13.070193.000433; BURNETTE WN, 1981, ANAL BIOCHEM, V112, P195, DOI 10.1016/0003-2697(81)90281-5; CHAMBERS I, 1986, EMBO J, V5, P1221, DOI 10.1002/j.1460-2075.1986.tb04350.x; Chittum HS, 1996, ARCH BIOCHEM BIOPHYS, V325, P124, DOI 10.1006/abbi.1996.0015; DWEK RA, 1993, ANNU REV BIOCHEM, V62, P65, DOI 10.1146/annurev.bi.62.070193.000433; HASELBECK A, 1990, GLYCOCONJUGATE J, V7, P63, DOI 10.1007/BF01050403; Hill K. E., 1994, Selenium in biology and human health., P117; HILL KE, 1993, P NATL ACAD SCI USA, V90, P537, DOI 10.1073/pnas.90.2.537; HILL KE, 1991, J BIOL CHEM, V266, P10050; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEINFELDER W, 1989, J BIOL CHEM, V264, P9720; MATSUDAIRA P, 1987, J BIOL CHEM, V262, P10035; READ R, 1990, J BIOL CHEM, V265, P17899; TAKAHASHI K, 1990, J BIOCHEM-TOKYO, V108, P145, DOI 10.1093/oxfordjournals.jbchem.a123172; TAPPEL AL, 1984, METHOD ENZYMOL, V107, P602; WILKINSON JM, 1986, PRACTICAL PROTEIN CH, P122; YOSHIMURA S, 1991, J BIOCHEM-TOKYO, V109, P918, DOI 10.1093/oxfordjournals.jbchem.a123480	26	65	70	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15769	15775		10.1074/jbc.271.26.15769	http://dx.doi.org/10.1074/jbc.271.26.15769			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663023	hybrid			2022-12-27	WOS:A1996UV29900070
J	Mellgren, RL; Lu, Q; Zhang, WL; Lakkis, M; Shaw, E; Mericle, MT				Mellgren, RL; Lu, Q; Zhang, WL; Lakkis, M; Shaw, E; Mericle, MT			Isolation of a Chinese hamster ovary cell clone possessing decreased mu-calpain content and a reduced proliferative growth rate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THIOL PROTEINASES; NUCLEAR PROTEINS; HUMAN PLATELETS; INHIBITORS; DEGRADATION; CYCLIN; ASSAY; DNA	A Chinese hamster ovary cell line (CHOP) was cultured in the presence of benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone (ZLLY-CHN2), to select for resistance to this cell-permeant calpain inhibitor, A clone isolated after several courses of exposure (SHI cells) demonstrated decreased sensitivity to ZLLY-CHN2 toxicity and a decreased growth rate, SHI cells also possessed less mu-calpain isozyme relative to CHOP cells, as determined by activity measurement or by protein immunoblotting. Activities of m-calpain, calpastatin, cathepsin B, cathepsin L, and glycogen phosphorylase were not altered, SHI mu-calpain was partially purified by sequential chromatography on Bio-Gel A-1.5m and DEAE-Sepharose. Its chromatographic behavior in either system was the same as for CHOP mu-calpain, Further studies with the partially purified SHI and CHOP mu-calpain fractions failed to distinguish any difference in Ca2+ requirement or in sensitivity to inhibition by calpastatin or ZLLY-CHN2 for these enzymes, These experiments suggest that SHI cells underproduce a form of mu-calpain which is very similar to, if not identical with, CHOP mu-calpain. SHI cells displayed a population doubling time of 29 h compared with 19 h for CHOP cells, The decreased growth rate of SHI cells was the result of a prolonged G(1) phase, Introduction of purified human mu-calpain into SHI cells by electroporation transiently restored the growth rate and also increased toxicity associated with exposure to ZLLY-CHN2. SHI cells should be a valuable model in further studies to delineate the function of mu-calpain in cell proliferative growth.	MED COLL OHIO, DEPT THERAPEUT & PHARMACOL, TOLEDO, OH 43699 USA; FRIEDRICH MIESCHER INST, CH-4002 BASEL, SWITZERLAND	Friedrich Miescher Institute for Biomedical Research					NHLBI NIH HHS [HL 36573] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL036573] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ANAGLI J, 1993, BIOCHEM J, V289, P93, DOI 10.1042/bj2890093; ANAGLI J, 1991, BIOCHEM J, V274, P497, DOI 10.1042/bj2740497; BARRETT AJ, 1972, ANAL BIOCHEM, V47, P280, DOI 10.1016/0003-2697(72)90302-8; BLAKE MS, 1984, ANAL BIOCHEM, V136, P175, DOI 10.1016/0003-2697(84)90320-8; BROWN KD, 1994, J CELL BIOL, V125, P1303, DOI 10.1083/jcb.125.6.1303; CARILLO S, 1994, ONCOGENE, V9, P1679; CRAWFORD C, 1988, BIOCHEM J, V253, P751, DOI 10.1042/bj2530751; Crawford C., 1990, INTRACELLULAR CALCIU, P75; FRESHNEY RI, 1987, CULTURE ANIMAL CELLS, P236; GLOTZER M, 1991, NATURE, V349, P132, DOI 10.1038/349132a0; Goll D E, 1985, Prog Clin Biol Res, V180, P151; HECK MMS, 1988, P NATL ACAD SCI USA, V85, P1086, DOI 10.1073/pnas.85.4.1086; HERSHKO A, 1991, J BIOL CHEM, V266, P16376; HIRAI S, 1991, FEBS LETT, V287, P57, DOI 10.1016/0014-5793(91)80015-U; ILLINGWORTH B, 1953, BIOCHEM PREPARAT, V3, P1; JARIELENCONTRE I, 1995, J BIOL CHEM, V270, P11623, DOI 10.1074/jbc.270.19.11623; KATUNUMA N, 1983, CURR TOP CELL REGUL, V22, P71; KATZUNG BG, 1992, BASIC CLIN PHARM, P623; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUKAS J, 1994, J IMMUNOL METHODS, V170, P255, DOI 10.1016/0022-1759(94)90400-6; Maki M., 1990, INTRACELLULAR CALCIU, P37; MARCH KL, 1993, CIRC RES, V72, P413, DOI 10.1161/01.RES.72.2.413; MEHDI S, 1991, TRENDS BIOCHEM SCI, V16, P150, DOI 10.1016/0968-0004(91)90058-4; MELLGREN RL, 1994, EXP CELL RES, V215, P164, DOI 10.1006/excr.1994.1328; MELLGREN RL, 1993, J BIOL CHEM, V268, P653; MELLGREN RL, 1982, J BIOL CHEM, V257, P7203; MELLGREN RL, 1991, J BIOL CHEM, V266, P13920; MELLGREN RL, 1988, BIOCHEM BIOPH RES CO, V150, P170, DOI 10.1016/0006-291X(88)90501-3; MINSHULL J, 1989, J CELL SCI, P77; MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4; MURRAY A, 1994, CELL CYCLE, P106; MURRAY AW, 1989, NATURE, V339, P280, DOI 10.1038/339280a0; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; SCHEFFNER M, 1990, CELL, V63, P1129, DOI 10.1016/0092-8674(90)90409-8; SCHOLLMEYER JE, 1988, SCIENCE, V240, P911, DOI 10.1126/science.2834825; SHARMA RC, 1992, J BIOL CHEM, V267, P5731; SHAW E, 1981, METHOD ENZYMOL, V80, P820; SUZUKI K, 1992, ANN NY ACAD SCI, V674, P218, DOI 10.1111/j.1749-6632.1992.tb27490.x; TACK BF, 1980, J BIOL CHEM, V255, P8842; Takahashi K, 1990, INTRACELLULAR CALCIU, P55; URLAUB G, 1980, P NATL ACAD SCI-BIOL, V77, P4216, DOI 10.1073/pnas.77.7.4216; WANG KKW, 1990, TRENDS PHARMACOL SCI, V11, P139, DOI 10.1016/0165-6147(90)90060-L	43	20	21	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15568	15574		10.1074/jbc.271.26.15568	http://dx.doi.org/10.1074/jbc.271.26.15568			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663205	hybrid			2022-12-27	WOS:A1996UV29900041
J	Daniel, S; Zhang, SY; DePaoliRoach, AA; Kim, KH				Daniel, S; Zhang, SY; DePaoliRoach, AA; Kim, KH			Dephosphorylation of Sp1 by protein phosphatase 1 is involved in the glucose-mediated activation of the acetyl-CoA carboxylase gene	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BOX-BINDING-PROTEINS; RNA POLYMERASE-II; DNA-BINDING; MESSENGER-RNA; FATTY-ACIDS; TRANSCRIPTION; PHOSPHORYLATION; PROMOTER; EXPRESSION; DOMAINS	When mouse 30A5 preadipocytes are exposed to high glucose concentrations, acetyl-CoA carboxylase is induced through glucose activation of promoter II of the acetyl-CoA carboxylase gene. Glucose treatment of the cells increases Sp1 binding to two GC rich glucose response elements in promoter II. We have investigated the mechanism by which glucose increases Sp1 binding and transactivation of promoter II in 30A5 cells. DNA mobility shift assays have shown that nuclear extracts from glucose-treated cells exhibit increased Sp1 binding activity. This increase in the binding activity is not due to glucose-mediated changes in the amount of Sp1 in the nucleus but to an increase in the activity that modifies Sp1 so that it binds more effectively to the promoter sequence, This Sp1 modifying activity is inhibited by okadaic acid and phosphatase inhibitor 2, and has a molecular mass of 38-42 kDa. The catalytic subunit of type 1 protein phosphatase, whose molecular mass is 38 kDa, also increased the ability of Sp1 to bind to prometer II. Treatment of nuclear extract with antibodies against the catalytic subunit partially suppressed the nuclear activity for Sp1 activation. From these results, we conclude that the Sp1 transcription factor exhibits enhanced binding to promoter II and transcriptional activation is the result of glucose induced dephosphorylation by type 1 phosphatase.	PURDUE UNIV,DEPT BIOCHEM,W LAFAYETTE,IN 47907; INDIANA UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,INDIANAPOLIS,IN 46202	Purdue University System; Purdue University; Purdue University West Lafayette Campus; Indiana University System; Indiana University-Purdue University Indianapolis					NCI NIH HHS [CA46882] Funding Source: Medline; NIDDK NIH HHS [DK36569] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA046882] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK036569] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BOYLE WJ, 1991, CELL, V64, P573, DOI 10.1016/0092-8674(91)90241-P; BRUN T, 1993, J BIOL CHEM, V268, P18905; CORKEY BE, 1989, J BIOL CHEM, V264, P21608; COUREY AJ, 1988, CELL, V55, P887, DOI 10.1016/0092-8674(88)90144-4; Daniel S, 1996, J BIOL CHEM, V271, P1385, DOI 10.1074/jbc.271.3.1385; DEPAOLIROACH AA, 1994, ADV ENZYME REGUL, V34, P199, DOI 10.1016/0065-2571(94)90017-5; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; DYNAN WS, 1983, CELL, V35, P79, DOI 10.1016/0092-8674(83)90210-6; DYNAN WS, 1985, NATURE, V316, P774, DOI 10.1038/316774a0; GIDONI D, 1984, NATURE, V312, P409, DOI 10.1038/312409a0; HAGEN G, 1992, NUCLEIC ACIDS RES, V20, P5519, DOI 10.1093/nar/20.21.5519; HAYSTEAD TAJ, 1989, NATURE, V337, P78, DOI 10.1038/337078a0; HUNTER T, 1992, CELL, V70, P375, DOI 10.1016/0092-8674(92)90162-6; JACKSON SP, 1990, CELL, V63, P155, DOI 10.1016/0092-8674(90)90296-Q; JAMES G, 1990, BIOCHEMISTRY-US, V29, P2628; KADONAGA JT, 1986, TRENDS BIOCHEM SCI, V11, P20, DOI 10.1016/0968-0004(86)90226-4; KADONAGA JT, 1987, CELL, V51, P1079, DOI 10.1016/0092-8674(87)90594-0; KADONAGA JT, 1988, SCIENCE, V242, P1566, DOI 10.1126/science.3059495; KINGSLEY C, 1992, MOL CELL BIOL, V12, P4251, DOI 10.1128/MCB.12.10.4251; LI R, 1991, CELL, V65, P493, DOI 10.1016/0092-8674(91)90467-D; LOPEZCASILLAS F, 1989, J BIOL CHEM, V264, P7176; LUO XC, 1990, NUCLEIC ACIDS RES, V18, P3249, DOI 10.1093/nar/18.11.3249; LUSCHER B, 1990, NATURE, V344, P517, DOI 10.1038/344517a0; MUMBY MC, 1993, PHYSIOL REV, V73, P673, DOI 10.1152/physrev.1993.73.4.673; Numa S, 1974, Curr Top Cell Regul, V8, P197; ORDWAY RW, 1991, TRENDS NEUROSCI, V14, P96, DOI 10.1016/0166-2236(91)90069-7; PARK IK, 1994, J BIOL CHEM, V269, P944; PASCAL E, 1991, GENE DEV, V5, P1646, DOI 10.1101/gad.5.9.1646; SIVARAM P, 1990, J BIOL CHEM, V265, P5774; TAE HJ, 1995, J BIOL CHEM, V270, P21487, DOI 10.1074/jbc.270.37.21487; UDVADIA AJ, 1995, P NATL ACAD SCI USA, V92, P3953, DOI 10.1073/pnas.92.9.3953; UDVADIA AJ, 1993, P NATL ACAD SCI USA, V90, P3265, DOI 10.1073/pnas.90.8.3265; VAULONT S, 1994, FASEB J, V8, P28, DOI 10.1096/fasebj.8.1.8299888; WERA S, 1995, BIOCHEM J, V311, P17, DOI 10.1042/bj3110017; ZHANG S, 1995, J ENDOCRINOL, V147, P33, DOI 10.1677/joe.0.1470033	35	129	129	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14692	14697		10.1074/jbc.271.25.14692	http://dx.doi.org/10.1074/jbc.271.25.14692			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663083	hybrid			2022-12-27	WOS:A1996UT10600011
J	Schanstra, JP; Kingma, J; Janssen, DB				Schanstra, JP; Kingma, J; Janssen, DB			Specificity and kinetics of haloalkane dehalogenase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALKALINE-PHOSPHATASE; CATALYTIC MECHANISM; ESCHERICHIA-COLI; EXPRESSION; SITE; PH	Haloalkane dehalogenase converts halogenated alkanes to their corresponding alcohols, The active site is buried inside the protein and lined with hydrophobic residues, The reaction proceeds via a covalent substrate-enzyme complex, This paper describes a steady-state and pre-steady-state kinetic analysis of the conversion of a number of substrates of the dehalogenase, The kinetic mechanism for the ''natural'' substrate 1,2-dichloroethane and for the brominated analog and nematocide 1,2-dibromoethane are given, In general, brominated substrates had a lower K-m, but a similar k(cat) than the chlorinated analogs, The rate of C-Br bond cleavage was higher than the rate of C-CL bond cleavage, which is in agreement with the leaving group abilities of these halogens, The lower K-m for brominated compounds therefore originates both from the higher rate of C-Br bond cleavage and from a lower K-m for bromo-compounds, However, the rate-determining step in the conversion (k(cat)) of 1,2-dibromoethane and 1,2-dichloroethane was found to be release of the charged halide ion out of the active site cavity, explaining the different K-m but similar k(cat) values for these compounds, The study provides a basis for the analysis of rate-determining steps in the hydrolysis of various environmentally important substrates.	UNIV GRONINGEN,DEPT BIOCHEM,GRONINGEN BIOMOLEC SCI & BIOTECHNOL INST,9747 AG GRONINGEN,NETHERLANDS	University of Groningen			Schanstra, Joost P/X-7724-2018	Schanstra, Joost P/0000-0002-7471-372X				BLOCH W, 1980, BIOCHEMISTRY-US, V19, P5008, DOI 10.1021/bi00563a012; FERSHT A, 1985, ENZYME STRUCTURE MEC, P121; FRIEDEN C, 1994, METHOD ENZYMOL, V240, P311; Huang C Y, 1979, Methods Enzymol, V63, P54; HULL WE, 1976, BIOCHEMISTRY-US, V15, P1547, DOI 10.1021/bi00652a028; Johnson K. A., 1992, ENZYMES, V20, P1, DOI DOI 10.1016/S1874-6047(08)60019-0; KENNES C, 1995, EUR J BIOCHEM, V228, P403; KEUNING S, 1985, J BACTERIOL, V163, P635, DOI 10.1128/JB.163.2.635-639.1985; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LEATHERBARROW RJ, 1987, NONLINEAR REGRESSION; LIU RQ, 1995, J AM CHEM SOC, V117, P5003, DOI 10.1021/ja00122a035; MENDES P, 1993, COMPUT APPL BIOSCI, V9, P563; PRIES F, 1994, J BIOL CHEM, V269, P17490; PRIES F, 1995, J BIOL CHEM, V270, P10405, DOI 10.1074/jbc.270.18.10405; PRIES F, 1994, BIOCHEMISTRY-US, V33, P1242, DOI 10.1021/bi00171a026; SCHANSTRA JP, 1993, PROTEIN EXPRES PURIF, V4, P479, DOI 10.1006/prep.1993.1063; SCHANSTRA JP, 1996, IN PRESS BIOCHEMISTR; STUCKI G, 1995, ENVIRON SCI TECHNOL, V29, P2339, DOI 10.1021/es00009a028; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VANDENWIJNGAARD AJ, 1992, APPL ENVIRON MICROB, V58, P976, DOI 10.1128/AEM.58.3.976-983.1992; VERSCHUEREN KHG, 1993, BIOCHEMISTRY-US, V32, P9031, DOI 10.1021/bi00086a008; VERSCHUEREN KHG, 1993, J MOL BIOL, V232, P856, DOI 10.1006/jmbi.1993.1436; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	23	83	84	1	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14747	14753		10.1074/jbc.271.25.14747	http://dx.doi.org/10.1074/jbc.271.25.14747			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662955	Green Published, hybrid			2022-12-27	WOS:A1996UT10600020
J	Wood, SM; Gleadle, JM; Pugh, CW; Hankinson, O; Ratcliffe, PJ				Wood, SM; Gleadle, JM; Pugh, CW; Hankinson, O; Ratcliffe, PJ			The role of the aryl hydrocarbon receptor nuclear translocator (ARNT) in hypoxic induction of gene expression - Studies in ARNT-deficient cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOUSE HEPATOMA LINE; INDUCIBLE FACTOR-I; ERYTHROPOIETIN GENE; AH-RECEPTOR; DIOXIN RECEPTOR; PROTEIN; TRANSCRIPTION; HYDROXYLASE; ENHANCER; CLONING	Hypoxia-inducible factor-1 (HIF-1), a DNA-binding complex implicated in the regulation of gene expression by oxygen, has been shown to consist of a heterodimer of two basic helix-loop-helix Per-AHR-ARNT Sim (PAS) proteins, HIF-1 alpha, and HIF-1 beta. One partner, HIF-1 beta, had been recognized previously as the aryl hydrocarbon receptor nuclear translocator (ARNT), an essential component of the xenobiotic response. In the present work, ARNT-deficient mutant cells, originally derived from the mouse hepatoma line Hepa1c1c7, have been used to analyze the role of ARNT/HIF-1 beta in oxygen-regulated gene expression, Two stimuli were examined: hypoxia itself and desferrioxamine, an iron-chelating agent that also activates HIF-1. Induction of the DNA binding and transcriptional activity of HIF-1 was absent in the mutant cells, indicating an essential role for ARNT/HIF-1 beta. Analysis of deleted ARNT/HIF-1 beta genes indicated that the basic, helix-loop-helix, and PAS domains, but not the amino or carboxyl termini, were necessary for function in the response to hypoxia, Comparison of gene expression in wild type and mutant cells demonstrated the critical importance of ARNT/HIF-1 beta in the hypoxic induction of a wide variety of genes, Nevertheless, for some genes a reduced response to hypoxia and desferrioxamine persisted in these mutant cells, clearly distinguishing ARNT/HIF-1 beta-dependent and ARNT/HIF-1 beta-independent mechanisms of gene activation by both these stimuli.	JOHN RADCLIFFE HOSP,INST MOLEC MED,ERYTHROPROT GRP,OXFORD OX3 9DU,ENGLAND; UNIV CALIF LOS ANGELES,SCH MED,DEPT PATHOL & LAB MED,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,JONSSON COMPREHENS CANC CTR,LOS ANGELES,CA 90095	University of Oxford; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; UCLA Jonsson Comprehensive Cancer Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA			Gleadle, Jonathan M/K-4188-2012	Gleadle, Jonathan M/0000-0002-5215-7208; Ratcliffe, Peter/0000-0002-2853-806X; Pugh, Chris/0000-0002-5170-1662	NATIONAL CANCER INSTITUTE [R01CA028868] Funding Source: NIH RePORTER; NCI NIH HHS [CA 28868] Funding Source: Medline; Wellcome Trust Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); Wellcome Trust(Wellcome TrustEuropean Commission)		BECK I, 1993, BLOOD, V82, P704; BURBACH KM, 1992, P NATL ACAD SCI USA, V89, P8185, DOI 10.1073/pnas.89.17.8185; DENISON MS, 1988, J BIOL CHEM, V263, P17221; DIGNAM JD, 1983, NUCLEIC ACIDS RES, V11, P1475, DOI 10.1093/nar/11.5.1475; EBERT BL, 1995, J BIOL CHEM, V270, P29083, DOI 10.1074/jbc.270.49.29083; EMA M, 1992, BIOCHEM BIOPH RES CO, V184, P246, DOI 10.1016/0006-291X(92)91185-S; FIRTH JD, 1995, J BIOL CHEM, V270, P21021, DOI 10.1074/jbc.270.36.21021; FIRTH JD, 1994, P NATL ACAD SCI USA, V91, P6496, DOI 10.1073/pnas.91.14.6496; FUJISAWASEHARA A, 1987, NUCLEIC ACIDS RES, V15, P4179, DOI 10.1093/nar/15.10.4179; GLEADLE JM, 1995, AM J PHYSIOL-CELL PH, V268, pC1362, DOI 10.1152/ajpcell.1995.268.6.C1362; GOLDBERG MA, 1988, SCIENCE, V242, P1412, DOI 10.1126/science.2849206; GRAEBER TG, 1994, MOL CELL BIOL, V14, P6264, DOI 10.1128/MCB.14.9.6264; HANKINSON O, 1995, ANNU REV PHARMACOL, V35, P307, DOI 10.1146/annurev.pharmtox.35.1.307; HANKINSON O, 1994, ADV ENZYME REGUL, V34, P159, DOI 10.1016/0065-2571(94)90015-9; HANKINSON O, 1983, SOMAT CELL GENET, V9, P497, DOI 10.1007/BF01543050; HANKINSON O, 1979, P NATL ACAD SCI USA, V76, P373, DOI 10.1073/pnas.76.1.373; HOFFMAN EC, 1991, SCIENCE, V252, P954, DOI 10.1126/science.1852076; JAIN S, 1994, J BIOL CHEM, V269, P31518; JELKMANN W, 1992, PHYSIOL REV, V72, P449, DOI 10.1152/physrev.1992.72.2.449; KOONG AC, 1994, CANCER RES, V54, P1425; LEVY AP, 1995, J BIOL CHEM, V270, P13333, DOI 10.1074/jbc.270.22.13333; LI H, 1994, J BIOL CHEM, V269, P28098; LIU YX, 1995, CIRC RES, V77, P638, DOI 10.1161/01.RES.77.3.638; MAXWELL PH, 1993, P NATL ACAD SCI USA, V90, P2423, DOI 10.1073/pnas.90.6.2423; MELILLO G, 1995, J EXP MED, V182, P1683, DOI 10.1084/jem.182.6.1683; MINCHENKO A, 1994, CELL MOL BIOL RES, V40, P35; NORRIS ML, 1995, J BIOL CHEM, V270, P23774, DOI 10.1074/jbc.270.40.23774; PROBST MR, 1993, MOL PHARMACOL, V44, P511; PUGH CW, 1994, BBA-GENE STRUCT EXPR, V1217, P297, DOI 10.1016/0167-4781(94)90289-5; REISZPORSZASZ S, 1994, MOL CELL BIOL, V14, P6075, DOI 10.1128/MCB.14.9.6075; SEMENZA GL, 1992, MOL CELL BIOL, V12, P5447, DOI 10.1128/MCB.12.12.5447; SEMENZA GL, 1994, J BIOL CHEM, V269, P23757; VANGURP JR, 1984, MOL CELL BIOL, V4, P1597, DOI 10.1128/MCB.4.8.1597; WANG GL, 1993, P NATL ACAD SCI USA, V90, P4304, DOI 10.1073/pnas.90.9.4304; WANG GL, 1993, BLOOD, V82, P3610; WANG GL, 1995, J BIOL CHEM, V270, P1230, DOI 10.1074/jbc.270.3.1230; WANG GL, 1995, P NATL ACAD SCI USA, V92, P5510, DOI 10.1073/pnas.92.12.5510; WATSON AJ, 1992, MOL CELL BIOL, V12, P2115, DOI 10.1128/MCB.12.5.2115; WEBSTER KA, 1994, CIRC RES, V74, P679, DOI 10.1161/01.RES.74.4.679	39	245	256	1	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15117	15123		10.1074/jbc.271.25.15117	http://dx.doi.org/10.1074/jbc.271.25.15117			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662957	hybrid			2022-12-27	WOS:A1996UT10600070
J	Bu, CH; Pourmotabbed, T				Bu, CH; Pourmotabbed, T			Mechanism of Ca2+-dependent activity of human neutrophil gelatinase B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EGF-LIKE REPEATS; MATRIX METALLOPROTEINASES; BASEMENT-MEMBRANE; 92-KDA GELATINASE; CRYSTAL-STRUCTURE; CELLS; PURIFICATION; COLLAGENASE; ACTIVATION; INVASION	Progelatinase B can be activated in vitro by organomercurial compounds and by proteolytic enzymes such as trypsin, chymotrypsin, and stromelysin, Activation of the proenzyme by either 4-aminophenylmercuric acetate or chymotrypsin yielded proteins that absolutely required Ca2+ for activity, regardless of the pH of the reaction mixture, The trypsin- and stromelysin-activated gelatinases, on the other hand, did not require Ca2+ for activity at pH 7.5, but the activity of the trypsin-activated enzyme became Ca2+ dependent as the pH increased. The pH study revealed that an amino acid residue with an apparent pK(alpha) of 8.8 was involved in this process. The NH2-terminal analyses showed that trypsin- and stromelysin-activated enzymes had the same NH2 termini (Phe(88)), but 4-aminophenylmercuric acetate- and chymotrypsin-activated enzymes had Met(75) and Gln(89) or Glu(92) as the NH2-terminal amino acid, respectively, These data, in conjunction with the x-ray crystal structure of collagenase, suggest that a salt linkage involving Phe(88) is responsible for the Ca2+-independent activity of trypsin- and stromelysin-activated gelatinase. Replacing Asp(432) in progelatinase with either Glu, Asn, Gly, or Lys resulted in the proteins that, upon activation by trypsin, required Ca2+ for activity, These substitutions did not significantly affect K-m for the synthetic substrate but decreased the k(cat) and increased the half-maximal Ca2+ concentration required for enzyme activity (K-Ca) by severalfold, The effects on k(cat) and K-Ca depended on both charge and size of the side chains of the substituted amino acids, The decrease in k(cat) correlated well with the increase in K-Ca of the mutants, The orders of decrease in k(cat) and increase in cat K-Ca were wild type greater than or equal to D432E > D432N > D432G > D432K and wild type less than or equal to D432E < D432N < D432G < D432K, respectively, These data suggest that in trypsin- or stromelysin-activated enzyme, the NH2-terminal Phe(88) forms a salt linkage with Asp(432), rendering the enzyme Ca2+ independent, Ca2+ affects catalytic activity of the 4-aminophenylmercuric acetate- and chymotrypsin-activated enzymes by substituting for the salt linkage and interacting with Asp(432), This interaction generates a similar, if not identical, conformational change to that generated by the salt linkage in the protein, leading to catalysis.	UNIV TENNESSEE,DEPT BIOCHEM,MEMPHIS,TN 38163	University of Tennessee System; University of Tennessee Health Science Center					NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R29AR041843, R01AR041843] Funding Source: NIH RePORTER; NIAMS NIH HHS [AR-41843] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ALBINI A, 1991, J NATL CANCER I, V83, P775, DOI 10.1093/jnci/83.11.775; Alexander CM, 1989, CURR OPIN CELL BIOL, V1, P974, DOI 10.1016/0955-0674(89)90068-9; BERNHARD EJ, 1990, CANCER RES, V50, P3872; BERNHARD EJ, 1994, P NATL ACAD SCI USA, V91, P4293, DOI 10.1073/pnas.91.10.4293; BIRKEDALHANSEN H, 1993, CRIT REV ORAL BIOL M, V4, P197, DOI 10.1177/10454411930040020401; BODE W, 1994, EMBO J, V13, P1263, DOI 10.1002/j.1460-2075.1994.tb06378.x; BU CH, 1995, J BIOL CHEM, V270, P18563, DOI 10.1074/jbc.270.31.18563; DECLERCK YA, 1991, CANCER RES, V51, P2151; DECLERCK YA, 1992, CANCER RES, V52, P701; Fersht A. R., 1985, ENZYME STRUCTURE MEC, P155; FERSHT AR, 1972, J MOL BIOL, V64, P497, DOI 10.1016/0022-2836(72)90513-X; HANDFORD PA, 1991, NATURE, V351, P164, DOI 10.1038/351164a0; HERZBERG O, 1988, J MOL BIOL, V203, P761, DOI 10.1016/0022-2836(88)90208-2; HIBBS MS, 1985, J BIOL CHEM, V260, P2493; HIROSE T, 1993, P NATL ACAD SCI USA, V90, P2569, DOI 10.1073/pnas.90.7.2569; HOUSLEY TJ, 1993, J BIOL CHEM, V268, P4481; KNIGHT CG, 1992, FEBS LETT, V296, P263, DOI 10.1016/0014-5793(92)80300-6; LEBIODA L, 1991, BIOCHEMISTRY-US, V30, P2817, DOI 10.1021/bi00225a012; LIOTTA LA, 1986, ANNU REV BIOCHEM, V55, P1037, DOI 10.1146/annurev.biochem.55.1.1037; LOVEJOY B, 1994, BIOCHEMISTRY-US, V33, P8207, DOI 10.1021/bi00193a006; LOVEJOY B, 1994, SCIENCE, V263, P375, DOI 10.1126/science.8278810; LOWRY CL, 1992, PROTEINS, V12, P42, DOI 10.1002/prot.340120106; Mareel MM, 1991, MECHANISMS INVASION, P73; MATRISIAN LM, 1992, BIOESSAYS, V14, P455, DOI 10.1002/bies.950140705; MATRISIAN LM, 1990, TRENDS GENET, V6, P121, DOI 10.1016/0168-9525(90)90126-Q; MATTHEWS BW, 1993, ANNU REV BIOCHEM, V62, P139, DOI 10.1146/annurev.bi.62.070193.001035; MORDOMI T, 1992, BIOCHEM J, V285, P603; NAGAI Y, 1972, BIOCHIM BIOPHYS ACTA, V263, P564, DOI 10.1016/0005-2795(72)90037-2; NAKAJIMA M, 1987, CANCER RES, V47, P4869; OKADA Y, 1992, J BIOL CHEM, V267, P21712; OKADA Y, 1986, J BIOL CHEM, V261, P14245; PANTOLIANO MW, 1988, BIOCHEMISTRY-US, V27, P8311, DOI 10.1021/bi00422a004; POURMOTABBED T, 1994, BBA-PROTEIN STRUCT M, V1204, P97, DOI 10.1016/0167-4838(94)90038-8; POURMOTABBED T, 1995, J PROTEIN CHEM, V14, P527, DOI 10.1007/BF01886879; REINEMER P, 1994, FEBS LETT, V338, P227, DOI 10.1016/0014-5793(94)80370-6; REZAIE AR, 1994, J BIOL CHEM, V269, P3151; Schultz R M, 1991, Cancer Treat Res, V54, P119; SELTZER JL, 1976, ARCH BIOCHEM BIOPHYS, V173, P355, DOI 10.1016/0003-9861(76)90270-8; SHIMA I, 1993, BRIT J CANCER, V67, P721, DOI 10.1038/bjc.1993.132; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; TRIEBEL S, 1992, FEBS LETT, V298, P280, DOI 10.1016/0014-5793(92)80077-T; VASSIN H, 1987, EMBO J, V6, P3431, DOI 10.1002/j.1460-2075.1987.tb02666.x; WHARTON KA, 1985, CELL, V43, P567, DOI 10.1016/0092-8674(85)90229-6; WILHELM SM, 1993, J BIOL CHEM, V268, P21906; WOESSNER JF, 1991, FASEB J, V5, P2145, DOI 10.1096/fasebj.5.8.1850705	45	14	14	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14308	14315		10.1074/jbc.271.24.14308	http://dx.doi.org/10.1074/jbc.271.24.14308			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662913	hybrid			2022-12-27	WOS:A1996UQ66000058
J	Fleury, Y; Dayem, MA; Montagne, JJ; Chaboisseau, E; LeCaer, JP; Nicolas, P; Delfour, A				Fleury, Y; Dayem, MA; Montagne, JJ; Chaboisseau, E; LeCaer, JP; Nicolas, P; Delfour, A			Covalent structure, synthesis, and structure-function studies of mesentericin Y 105(37), a defensive peptide from gram-positive bacteria Leuconostoc mesenteroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LACTIC-ACID BACTERIA; PROTEIN CONFORMATION; LACTOCOCCIN-A; LACTACIN-F; PURIFICATION; SEQUENCE; CLONING; GENE; LACTOBACILLUS; EXPRESSION	A 37-residue cationic antimicrobial peptide named mesentericin Y 105(37) was purified to homogeneity from cell-free culture supernatant of the Gram-positive bacterium Leuconostoc mesenteroides. The complete amino acid sequence of the peptide, KYYGNGVHCTKSGCSVNWGEAASAGIHRLANGGNGFW, has been established by automated Edman degradation, mass spectrometry, and solid phase synthesis. Mesentericin Y 105(37) contains a single intramolecular disulfide bond that forms a 6-membered ring within the molecule, Mesentericin Y 105(37) was synthesized by the solid phase method. The synthetic replicate was shown to be indistinguishable hom the natural peptide with respect to electrophoretic and chromatographic properties, mass spectrometry analysis, automated amino acid sequence determination, and antimicrobial properties. At nanomolar concentrations, synthetic mesentericin Y 105(37) is active against Gram(+) bacteria in the genera Lactobacillus and Carnobacterium. Most interestingly, the peptide is inhibitory to the growth of the food-borne pathogen Listeria. CD spectra of mesentericin Y 105(37) in low polarity medium, which mimic the lipophilicity of the membrane of target organisms, indicated 30-40% alpha-helical conformation, and predictions of secondary structure suggested that the peptide can be configured as an amphipathic helix spanning over residues 1731. To reveal the molecular basis of the specificity of mesentericin Y 105(37) targetting and mode of action, NH2- or COOH-terminally truncated analogs together with point-substituted analogs were synthesized and evaluated for their ability to inhibit the growth of Listeria ivanovii. In sharp contrast with broad spectrum alpha-helical antimicrobial peptides from vertebrate animals, which can be shortened to 14-18 residues without deleterious effect on potency, molecular elements responsible for anti-listeria activity of mesentericin Y 105(37) are to be traced at once to the NH2-terminal tripeptide KYY, the disulfide bridge, the putative alpha-helical domain 17-31, and the COOH-terminal tryptophan residue of the molecule. It is proposed that the amphipathic helical domain of the peptide interacts with lipid bilayers, leading subsequently to alteration of the membrane functions, whereas residues 1-14 form part of a recognition structure for a membrane-bound receptor, which may be critical for peptide targetting. Because mesentericin Y 105(37) is easy to synthesize at low cost, it may represent a useful and tractable tool as a starting point for the design of more potent analogs that may be of potential applicability in foods preservation.	UNIV POITIERS, IBMIG, LAB BIOCHIM PROT, F-86022 POITIERS, FRANCE; UNIV PARIS 07, INST JACQUES MONOD, LAB BIOACTIVAT PEPTIDES, F-75251 PARIS 05, FRANCE; ECOLE SUPER PHYS & CHIM IND VILLE PARIS, LAB NEUROBIOL DIVERSITE CELLULAIRE, F-75005 PARIS 05, FRANCE	Universite de Poitiers; UDICE-French Research Universities; Universite Paris Cite; UDICE-French Research Universities; PSL Research University Paris; Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (ESPCI)			Fleury, Yannick/F-9480-2016; Nicolas, Pierre/C-7908-2009; Fleury, Yannick/AFG-2926-2022	Fleury, Yannick/0000-0002-1638-0963; 				BAREFOOT SF, 1984, ANTIMICROB AGENTS CH, V26, P328, DOI 10.1128/AAC.26.3.328; BHUNIA AK, 1987, J IND MICROBIOL, V2, P319, DOI 10.1007/BF01569434; BIERBAUM G, 1993, ZBL BAKT-INT J MED M, V278, P1; BLONDELLE SE, 1992, BIOCHEMISTRY-US, V31, P12688, DOI 10.1021/bi00165a020; BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.immunol.13.1.61; BOMAN HG, 1981, TRENDS BIOCHEM SCI, V6, P306, DOI 10.1146/annurev.mi.41.100187.000535; CHIN GJ, 1994, SCIENCE, V264, P359, DOI 10.1126/science.264.5157.359; CHOU PY, 1978, ANNU REV BIOCHEM, V47, P251, DOI 10.1146/annurev.bi.47.070178.001343; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FREMAUX C, 1995, MICROBIOL-SGM, V141, P1637, DOI 10.1099/13500872-141-7-1637; HASTINGS JW, 1991, J BACTERIOL, V173, P7491, DOI 10.1128/jb.173.23.7491-7500.1991; HASTINGS JW, 1991, J APPL BACTERIOL, V70, P127, DOI 10.1111/j.1365-2672.1991.tb04438.x; HECHARD Y, 1992, J GEN MICROBIOL, V138, P2725, DOI 10.1099/00221287-138-12-2725; HECHARD Y, 1992, APPL ENVIRON MICROB, V58, P3784; HENDERSON JT, 1992, ARCH BIOCHEM BIOPHYS, V295, P5, DOI 10.1016/0003-9861(92)90480-K; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOFFMANN JA, 1992, IMMUNOL TODAY, V13, P411, DOI 10.1016/0167-5699(92)90092-L; HOLCK A, 1992, J GEN MICROBIOL, V138, P2715, DOI 10.1099/00221287-138-12-2715; HOLCK AL, 1994, FEMS MICROBIOL LETT, V115, P143, DOI [10.1111/j.1574-6968.1994.tb06629.x, 10.1016/0378-1097(94)90005-1]; HOLO H, 1991, J BACTERIOL, V173, P3879, DOI 10.1128/JB.173.12.3879-3887.1991; JACK RW, 1995, MICROBIOL REV, V59, P171, DOI 10.1128/MMBR.59.2.171-200.1995; James R, 1992, BACTERIOCINS MICROCI; JUNG G, 1991, ANGEW CHEM INT EDIT, V30, P1051, DOI 10.1002/anie.199110513; KLAENHAMMER TR, 1993, FEMS MICROBIOL REV, V12, P39, DOI 10.1111/j.1574-6976.1993.tb00012.x; KOLTER R, 1992, ANNU REV MICROBIOL, V46, P141, DOI 10.1146/annurev.mi.46.100192.001041; MARUGG JD, 1992, APPL ENVIRON MICROB, V58, P2360, DOI 10.1128/AEM.58.8.2360-2367.1992; MOR A, 1994, J BIOL CHEM, V269, P1934; MOR A, 1994, EUR J BIOCHEM, V219, P145, DOI 10.1111/j.1432-1033.1994.tb19924.x; MOTLAGH AM, 1992, LETT APPL MICROBIOL, V15, P45, DOI 10.1111/j.1472-765X.1992.tb00721.x; MURIANA PM, 1991, APPL ENVIRON MICROB, V57, P114, DOI 10.1128/AEM.57.1.114-121.1991; MURIANA PM, 1991, J BACTERIOL, V173, P1779, DOI 10.1128/jb.173.5.1779-1788.1991; NETTLES CG, 1993, J FOOD PROTECT, V56, P338, DOI 10.4315/0362-028X-56.4.338; NICOLAS P, 1986, BIOCHEM BIOPH RES CO, V140, P565, DOI 10.1016/0006-291X(86)90769-2; NICOLAS P, 1995, ANNU REV MICROBIOL, V49, P277, DOI 10.1146/annurev.mi.49.100195.001425; QUADRI LEN, 1994, J BIOL CHEM, V269, P12204; SEGREST JP, 1994, ADV PROTEIN CHEM, V45, P303; STODDARD GW, 1992, APPL ENVIRON MICROB, V58, P1952, DOI 10.1128/AEM.58.6.1952-1961.1992; TAGG JR, 1976, BACTERIOL REV, V40, P722, DOI 10.1128/MMBR.40.3.722-756.1976; TICHACZEK PS, 1993, ARCH MICROBIOL, V160, P279, DOI 10.1007/BF00292077; VANBELKUM MJ, 1992, APPL ENVIRON MICROB, V58, P572, DOI 10.1128/AEM.58.2.572-577.1992; VANBELKUM MJ, 1991, APPL ENVIRON MICROB, V57, P492, DOI 10.1128/AEM.57.2.492-498.1991; VENEMA K, 1995, TRENDS MICROBIOL, V3, P299, DOI 10.1016/S0966-842X(00)88958-1; WILBUR WJ, 1983, P NATL ACAD SCI-BIOL, V80, P726, DOI 10.1073/pnas.80.3.726; YANG JT, 1986, METHOD ENZYMOL, V130, P208	44	107	108	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14421	14429		10.1074/jbc.271.24.14421	http://dx.doi.org/10.1074/jbc.271.24.14421			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662868	hybrid			2022-12-27	WOS:A1996UQ66000072
J	Howard, GC; Yamaguchi, Y; Misra, UK; Gawdi, G; Nelsen, A; DeCamp, DL; Pizzo, SV				Howard, GC; Yamaguchi, Y; Misra, UK; Gawdi, G; Nelsen, A; DeCamp, DL; Pizzo, SV			Selective mutations in cloned and expressed alpha-macroglobulin receptor binding fragment alter binding to either the alpha(2)-macroglobulin signaling receptor or the low density lipoprotein receptor-related protein/alpha(2)-macroglobulin receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-2-MACROGLOBULIN RECEPTOR; HIGH-AFFINITY; DOMAIN; PROTEIN; MACROPHAGES; RECOGNITION; PLATELETS; THROMBIN; SITE	alpha(2)-Macroglobulin (alpha(2)M) activated with methylamine binds to two distinct cell-surface receptors: low density-lipoprotein receptor-related protein/alpha(2)M receptors and alpha(2)M signaling receptors, Binding to lipoprotein receptor-related protein/alpha(2)M receptor but not alpha(2)M signal receptor is inhibitable by another ligand, receptor-associated protein, Direct binding studies with a recombinant receptor binding fragment (RBF) from rat alpha(1)M and murine macrophages demonstrate two classes of binding sites of apparent K-d = 90 pM (1500 sites/cell) and 40 nM (60,400 sites/cell), Receptor-associated protein competes with RBF for binding to the lower but not the higher affinity site, Site-directed mutation of Lys-1374 (human numbering) in RBF to Arg or De residues almost completely abolishes signal transduction as compared to wild-type RBF. Direct binding studies with K1374R demonstrated no significant alteration in binding to the lower affinity site; however, binding to the high affinity site is reduced by 83%. Mutation of Lys-1370 to Ala resulted in a 4-5-fold increase in the K-d for binding to the lower affinity site with no significant alteration in binding to the high affinity site or signal transduction properties, Studies demonstrate comparable internalization and degradation of wild-type RBF and R1374R; however, internalization and degradation of K1370A is negligible. These studies suggest that regions around Lys-1370 and Lys-1374 are involved in lipoprotein receptor-related protein/alpha(2)M receptor and alpha(2)M signaling receptor binding, respectively.	UNIV TEXAS,SW MED CTR,DEPT PHARMACOL,DALLAS,TX 75235	University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas	Howard, GC (corresponding author), DUKE UNIV,MED CTR,DEPT PATHOL,DURHAM,NC 27710, USA.				NATIONAL CANCER INSTITUTE [P01CA029589] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL024066, R37HL024066] Funding Source: NIH RePORTER; NCI NIH HHS [CA-29589] Funding Source: Medline; NHLBI NIH HHS [HL-24066] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BERRIDGE MJ, 1983, BIOCHEM J, V212, P709; CHU CT, 1993, J IMMUNOL, V150, P48; CHU CT, 1994, LAB INVEST, V71, P792; CHU CT, 1994, J IMMUNOL, V152, P1538; ENGHILD JJ, 1989, BIOCHEMISTRY-US, V28, P1406, DOI 10.1021/bi00429a069; HARMON JT, 1986, J BIOL CHEM, V261, P5928; HARMON JT, 1985, BIOCHEMISTRY-US, V24, P58, DOI 10.1021/bi00322a010; HERZ J, 1991, J BIOL CHEM, V266, P21232; Howard GC, 1996, J CLIN INVEST, V97, P1193, DOI 10.1172/JCI118533; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; MISRA UK, 1995, BIOCHEM J, V309, P151, DOI 10.1042/bj3090151; MISRA UK, 1994, ANN NY ACAD SCI, V737, P486, DOI 10.1111/j.1749-6632.1994.tb44347.x; MISRA UK, 1993, BIOCHEM J, V290, P885, DOI 10.1042/bj2900885; MISRA UK, 1994, J BIOL CHEM, V269, P12541; MISRA UK, 1994, J BIOL CHEM, V269, P18303; MOESTRUP SK, 1991, J BIOL CHEM, V266, P14011; PROVENCHER SW, 1981, BIOCHEMISTRY-US, V20, P33, DOI 10.1021/bi00504a006; ROCHE PA, 1988, J BIOL CHEM, V263, P6715; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUBENSTEIN DS, 1993, BIOCHEM J, V290, P85, DOI 10.1042/bj2900085; SALVESEN G, 1992, FEBS LETT, V313, P198, DOI 10.1016/0014-5793(92)81443-P; Sottrup-Jensen L., 1987, PLASMA PROTEINS, V5, P191; SOTTRUPJENSEN L, 1986, FEBS LETT, V205, P20, DOI 10.1016/0014-5793(86)80857-2; VANLEUVEN F, 1986, J BIOL CHEM, V261, P1369; Webb DJ, 1995, EUR J BIOCHEM, V234, P714, DOI 10.1111/j.1432-1033.1995.714_a.x; WELINDER KG, 1984, J BIOL CHEM, V259, P8328	26	55	55	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14105	14111		10.1074/jbc.271.24.14105	http://dx.doi.org/10.1074/jbc.271.24.14105			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662881	hybrid			2022-12-27	WOS:A1996UQ66000028
J	Lai, CF; Ripperger, J; Morella, KK; Jurlander, J; Hawley, TS; Carson, WE; Kordula, T; Caliguri, MA; Hawley, RG; Fey, GH; Baumann, H				Lai, CF; Ripperger, J; Morella, KK; Jurlander, J; Hawley, TS; Carson, WE; Kordula, T; Caliguri, MA; Hawley, RG; Fey, GH; Baumann, H			Receptors for interleukin (IL)-10 and IL-6-type cytokines use similar signaling mechanisms for inducing transcription through IL-6 response elements	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RAT ALPHA-2-MACROGLOBULIN GENE; EXPRESSION CLONING; GM-CSF; DNA; PROTEINS; SUBUNIT; CELLS	The cytoplasmic domain of the receptor for interleukin 10 (IL-10R) contains two box 3 sequence motifs that have been identified in the signal-transducing receptor subunits for IL-6-type cytokines and noted to be required for activating STAT3 and inducing transcription through IL-B-responsive elements, To determine whether the IL-10R has signaling functions similar to IL-6R in cells normally expressing these receptors, leukocytes of the B-, T-, and NK cell lineages were treated with either cytokine, Both cytokines activated factors that bound to the sis-inducible element and included STAT1 and STAT3, The cell response to IL-10 characteristically differed from that to IL-2/IL-15, IL-4, and interferon gamma. The signaling capabilities of the IL-10R for activating specific STAT proteins and inducing gene transcription were defined by reconstitution of receptor functions in transfected tissue culture cells, COS-1 cells, co-expressing the human IL-10R and individual STAT proteins, confirmed a preference of the IL-10R for STAT3 and STAT1, Unlike many hematopoietin receptors, the IL-10R did not detectably activate STAT5, The IL-10R, together with reporter gene constructs containing different IL-6-responsive gene elements, reconstituted in hepatoma cells an induction of transcription by IL-10 that was comparable to that by IL-6. This regulation could not be appreciably modified by enhanced expression of STAT proteins, The similar actions of IL-10R and IL GR on the induction of endogenous IL-6-responsive genes were demonstrated in hepatoma cells stably expressing the IL-10R. These receptor functions required the presence of the box 3 motifs, as shown by the analysis of the mouse IL-10R constructs containing progressively truncated cytoplasmic domains, The data demonstrate that the IL-10R, unlike other members of the interferon receptor family, is highly effective in recruiting the signaling pathways of IL-6-type cytokine receptors.	ROSWELL PK CANC INST,DEPT MOLEC & CELLULAR BIOL,BUFFALO,NY 14263; ROSWELL PK CANC INST,DEPT MED & SURG,BUFFALO,NY 14263; UNIV ERLANGEN NURNBERG,D-91068 ERLANGEN,GERMANY; TORONTO HOSP,ONCOL RES LABS,TORONTO,ON M5G 2M1,CANADA; UNIV GEORGIA,DEPT BIOCHEM,ATHENS,GA 30602	Roswell Park Cancer Institute; Roswell Park Cancer Institute; University of Erlangen Nuremberg; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University System of Georgia; University of Georgia			Carson, William E/E-2846-2011	Hawley, Robert/0000-0003-3512-5818; Carson, III, William E./0000-0001-7024-7533	NCI NIH HHS [CA26122] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA026122] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BAUMANN H, 1989, J IMMUNOL, V143, P1163; BELARDELLI F, 1995, APMIS, V103, P161, DOI 10.1111/j.1699-0463.1995.tb01092.x; BERG DJ, 1995, J EXP MED, V182, P99, DOI 10.1084/jem.182.1.99; BIRON CA, 1994, CURR OPIN IMMUNOL, V6, P530, DOI 10.1016/0952-7915(94)90137-6; BRECHNER T, 1991, MOL BIOL MED, V8, P267; BURDIN N, 1995, J IMMUNOL, V154, P2533; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CORRALIZA IM, 1995, BIOCHEM BIOPH RES CO, V206, P667, DOI 10.1006/bbrc.1995.1094; FINBLOOM DS, 1995, J IMMUNOL, V155, P1079; GANTER U, 1989, EMBO J, V8, P3773, DOI 10.1002/j.1460-2075.1989.tb08554.x; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HART PH, 1995, J LEUKOCYTE BIOL, V57, P909, DOI 10.1002/jlb.57.6.909; HAWLEY RG, 1994, GENE THER, V1, P136; HAWLEY RG, 1995, ONCOGENE, V11, P1113; HAYASHIDA K, 1990, P NATL ACAD SCI USA, V87, P9655, DOI 10.1073/pnas.87.24.9655; HIRAOKA O, 1995, J BIOL CHEM, V270, P25928, DOI 10.1074/jbc.270.43.25928; HO ASY, 1993, P NATL ACAD SCI USA, V90, P11267, DOI 10.1073/pnas.90.23.11267; HO ASY, 1995, MOL CELL BIOL, V15, P5043; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; IHLE JN, 1995, NATURE, V377, P591, DOI 10.1038/377591a0; Jurlander J, 1995, BLOOD, V86, P1371; KEEGAN AD, 1994, IMMUNOL TODAY, V15, P423, DOI 10.1016/0167-5699(94)90272-0; KISHIMOTO T, 1995, BLOOD, V86, P1243, DOI 10.1182/blood.V86.4.1243.bloodjournal8641243; KITAMURA T, 1991, CELL, V66, P1165, DOI 10.1016/0092-8674(91)90039-2; Kordula T, 1996, BIOCHEM J, V313, P1019, DOI 10.1042/bj3131019; Kordula T, 1996, J BIOL CHEM, V271, P6752, DOI 10.1074/jbc.271.12.6752; LAI CF, 1995, J BIOL CHEM, V270, P23254, DOI 10.1074/jbc.270.40.23254; LAI CF, 1995, J BIOL CHEM, V270, P14847, DOI 10.1074/jbc.270.25.14847; LAMB P, 1995, NUCLEIC ACIDS RES, V23, P3283, DOI 10.1093/nar/23.16.3283; LARNER AC, 1993, SCIENCE, V261, P1730, DOI 10.1126/science.8378773; LARSEN A, 1990, J EXP MED, V172, P1559, DOI 10.1084/jem.172.6.1559; LEHMANN J, 1994, J IMMUNOL, V153, P165; LICHTENSTEIN A, 1995, CELL IMMUNOL, V162, P248, DOI 10.1006/cimm.1995.1076; LIEW FY, 1994, IMMUNOL LETT, V43, P95, DOI 10.1016/0165-2478(94)00157-X; LIU Y, 1994, J IMMUNOL, V152, P1821; LOPATA MA, 1984, NUCLEIC ACIDS RES, V12, P5707, DOI 10.1093/nar/12.14.5707; MARKOWITZ D, 1988, J VIROL, V62, P1120, DOI 10.1128/JVI.62.4.1120-1124.1988; MATOS ME, 1993, J EXP MED, V178, P1079, DOI 10.1084/jem.178.3.1079; MILLER AD, 1986, MOL CELL BIOL, V6, P2895, DOI 10.1128/MCB.6.8.2895; MORELLA KK, 1995, J BIOL CHEM, V270, P8298, DOI 10.1074/jbc.270.14.8298; NIIRO H, 1995, BLOOD, V85, P3736, DOI 10.1182/blood.V85.12.3736.bloodjournal85123736; NONOYAMA S, 1994, CLIN IMMUNOL IMMUNOP, V72, P373, DOI 10.1006/clin.1994.1155; NORTHEMANN W, 1988, BIOCHEMISTRY-US, V27, P9194, DOI 10.1021/bi00426a018; RICHARDS CD, 1992, J IMMUNOL, V148, P1731; RIPPERGER JA, 1995, J BIOL CHEM, V270, P29998, DOI 10.1074/jbc.270.50.29998; SADOWSKI HB, 1993, SCIENCE, V261, P1739, DOI 10.1126/science.8397445; SHUAI K, 1994, CELL, V76, P821, DOI 10.1016/0092-8674(94)90357-3; STAHL N, 1995, SCIENCE, V267, P1349, DOI 10.1126/science.7871433; TAN JC, 1995, J BIOL CHEM, V270, P12906, DOI 10.1074/jbc.270.21.12906; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WANG P, 1995, J BIOL CHEM, V270, P9558, DOI 10.1074/jbc.270.16.9558; WANG YP, 1995, BLOOD, V86, P1671, DOI 10.1182/blood.V86.5.1671.bloodjournal8651671; WEBERNORDT RM, 1994, J IMMUNOL, V153, P3734	53	83	84	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13968	13975		10.1074/jbc.271.24.13968	http://dx.doi.org/10.1074/jbc.271.24.13968			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662928	hybrid			2022-12-27	WOS:A1996UQ66000009
J	Reinscheid, RK; Ardati, A; Monsma, FJ; Civelli, O				Reinscheid, RK; Ardati, A; Monsma, FJ; Civelli, O			Structure-activity relationship studies on the novel neuropeptide orphanin FQ	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BIOLOGICAL-ACTIVITY; BINDING; ANALOGS; DYNORPHIN-(1-13); PEPTIDES; RECEPTOR; LIGAND	The heptadecapeptide orphanin FQ (OFQ) is an endogenous ligand to an opioid-like G protein-coupled receptor. Although the primary structure of OFQ exhibits some similarity to the opioid peptides, OFQ is not recognized by opioid receptors nor does the OFQ receptor bind opioid ligands. In order to investigate the structural determinants of this ligand/receptor selectivity, we conducted a systematic structure-activity study on OFQ to characterize which sites of the molecule are important for receptor activation. Alanine- and D-amino acid-scanning mutagenesis revealed several residues in the amino-terminal half of OFQ which participate in both receptor binding and activation. Most strikingly, the Phe(1) position could be changed to a tyrosine without loss of biological activity, In addition, the OFQ receptor seemed to require recognition of the complete peptide molecule for activation. These results indicate that the mode of interaction of OFQ with its receptor may be different from that of the opioid peptides with their respective receptors and might therefore account for the observed selectivity.	HOFFMANN LA ROCHE AG,DIV PHARMA,CNS RES,CH-4070 BASEL,SWITZERLAND	Roche Holding			Civelli, Olivier/A-8392-2012					BEDDELL CR, 1977, PROC R SOC SER B-BIO, V198, P249, DOI 10.1098/rspb.1977.0096; BUNZOW JR, 1994, FEBS LETT, V347, P284, DOI 10.1016/0014-5793(94)00561-3; CHAVKIN C, 1981, P NATL ACAD SCI-BIOL, V78, P6543, DOI 10.1073/pnas.78.10.6543; DARLAK K, 1984, PEPTIDES, V5, P687, DOI 10.1016/0196-9781(84)90007-X; GOLDSTEIN A, 1989, MOL PHARMACOL, V36, P265; GOLDSTEIN A, 1982, MOL GENETIC NEUROSCI, P249; HRUBY VJ, 1989, MED RES REV, V9, P343, DOI 10.1002/med.2610090306; HUNTER WM, 1962, NATURE, V194, P495, DOI 10.1038/194495a0; LEMAIRE S, 1986, INT J PEPT PROT RES, V27, P300; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; MOLLEREAU C, 1994, FEBS LETT, V341, P33, DOI 10.1016/0014-5793(94)80235-1; MORLEY JS, 1980, ANNU REV PHARMACOL, V20, P81, DOI 10.1146/annurev.pa.20.040180.000501; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; NICOLAS P, 1984, P NATL ACAD SCI-BIOL, V81, P3074, DOI 10.1073/pnas.81.10.3074; PATERSON SJ, 1984, NEUROPEPTIDES, V5, P177, DOI 10.1016/0143-4179(84)90056-8; RAYNOR K, 1994, MOL PHARMACOL, V45, P330; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; RUDINGER J, 1971, DRUG DESIGN, V2, P319; Sambrook J., 2002, MOL CLONING LAB MANU; Schwyzer R, 1977, Ann N Y Acad Sci, V297, P3, DOI 10.1111/j.1749-6632.1977.tb41843.x; TURCOTTE A, 1984, INT J PEPT PROT RES, V23, P361	21	180	187	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14163	14168		10.1074/jbc.271.24.14163	http://dx.doi.org/10.1074/jbc.271.24.14163			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662940	hybrid			2022-12-27	WOS:A1996UQ66000036
J	Saura, M; PerezSala, D; Canada, FJ; Lamas, S				Saura, M; PerezSala, D; Canada, FJ; Lamas, S			Role of tetrahydrobiopterin availability in the regulation of nitric-oxide synthase expression in human mesangial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VASCULAR SMOOTH-MUSCLE; L-ARGININE; SEPIAPTERIN REDUCTASE; BIOSYNTHESIS; PURIFICATION; REQUIREMENT; CYTOKINES; BIOPTERIN; COFACTOR; ENZYME	Human mesangial cells express an inducible form of nitric-oxide synthase (iNOS) after treatment with cytokines, Tetrahydrobiopterin (BH4), an essential cofactor for NOS, is required for cytokine-induced NO generation, We report here that BH4 is necessary not only for the activity but also for the expression of iNOS in human mesangial cells. Inhibition of de novo BH4 synthesis with 2,4-diamino-6-hydroxypyrimidine (DAHP) significantly attenuated iNOS activity as well as mRNA and protein expression in response to interleukin 1 beta plus tumor necrosis factor alpha (IL-1 beta/TNF-alpha). In contrast, sepiapterin, which provides BH4 through the pterin salvage pathway, strongly potentiated IL-1 beta/TNF-alpha-induced iNOS expression and abrogated the inhibitory effect of DAHP, Inhibition of the pterin salvage pathway with methotrexate abolished sepiapterin potentiation of iNOS induction but did not alter the effect of IL-1 beta/TNF-alpha. Determination of intracellular pteridines confirmed that sepiapterin markedly raised BH4 content, an effect that was blocked by methotrexate. These results suggest that BH4 availability plays an important role in the regulation of iNOS expression, The effect of BH4 appears to be mediated, at least in part, by an increase in mRNA stability, as indicated by the observation that DAHP shortened, whereas sepiapterin prolonged the half-life of IL-1 beta/TNF-alpha-induced iNOS mRNA. Taken together, our results suggest that the biosynthesis of BH4 contributes to cytokine induction of iNOS expression in human mesangial cells through the stabilization of iNOS mRNA.	CSIC,CTR INVEST BIOL,E-28006 MADRID,SPAIN; CSIC,INST QUIM ORGAN GEN,E-28006 MADRID,SPAIN	Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Investigaciones Biologicas (CIB); Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Instituto de Quimica Organica General (IQOG)			Cañada, Francisco J./D-5837-2014; Perez-Sala, Dolores/L-5969-2014; Lamas, Santiago/G-7308-2015	Cañada, Francisco J./0000-0003-4462-1469; Perez-Sala, Dolores/0000-0003-0600-665X; Lamas, Santiago/0000-0001-5166-4155				ALONSO S, 1986, J MOL EVOL, V23, P11, DOI 10.1007/BF02100994; ANTONOZZI I, 1988, J CHROMATOGR, V459, P319, DOI 10.1016/S0021-9673(01)82042-2; BAEK KJ, 1993, J BIOL CHEM, V268, P21120; BOGDAN C, 1995, FEBS LETT, V363, P69, DOI 10.1016/0014-5793(95)00284-G; BOGDAN C, 1982, J LEUKOCYTE, V182, P1155; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOKE JP, 1992, J CLIN INVEST, V90, P1168, DOI 10.1172/JCI115937; CUNHA FQ, 1992, BIOCHEM BIOPH RES CO, V182, P1155, DOI 10.1016/0006-291X(92)91852-H; FUKUSHIMA T, 1980, ANAL BIOCHEM, V102, P176, DOI 10.1016/0003-2697(80)90336-X; GAL EM, 1978, NEUROCHEM RES, V3, P69, DOI 10.1007/BF00964361; GELLER DA, 1993, P NATL ACAD SCI USA, V90, P3491, DOI 10.1073/pnas.90.8.3491; GIOVANELLI J, 1991, P NATL ACAD SCI USA, V88, P7091, DOI 10.1073/pnas.88.16.7091; GRISCAVAGE JM, 1994, J BIOL CHEM, V269, P21644; GROSS SS, 1992, J BIOL CHEM, V267, P25722; HATTORI Y, 1993, BIOCHEM BIOPH RES CO, V195, P435, DOI 10.1006/bbrc.1993.2062; HEVEL JM, 1992, BIOCHEMISTRY-US, V31, P7160, DOI 10.1021/bi00146a019; HYUN J, 1995, BIOCHEM BIOPH RES CO, V206, P380, DOI 10.1006/bbrc.1995.1052; JANSEN A, 1994, KIDNEY INT, V45, P1215, DOI 10.1038/ki.1994.161; KATOH S, 1982, BIOCHEM BIOPH RES CO, V105, P75, DOI 10.1016/S0006-291X(82)80012-0; KLATT P, 1993, J BIOL CHEM, V268, P14781; LASKIN JD, 1994, TRENDS ENDOCRIN MET, V5, P377, DOI 10.1016/1043-2760(94)90105-8; MARSDEN PA, 1990, J EXP MED, V172, P1843, DOI 10.1084/jem.172.6.1843; MAYER B, 1995, J BIOL CHEM, V270, P655, DOI 10.1074/jbc.270.2.655; MENE P, 1989, PHYSIOL REV, V69, P1347, DOI 10.1152/physrev.1989.69.4.1347; MONCADA S, 1993, NEW ENGL J MED, V329, P2002; MUHL H, 1995, J CLIN INVEST, V95, P1941, DOI 10.1172/JCI117876; MUHL H, 1994, KIDNEY INT, V46, P1302, DOI 10.1038/ki.1994.398; NAKAYAMA DK, 1994, AM J PHYSIOL, V266, pL455, DOI 10.1152/ajplung.1994.266.4.L455; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NATHAN C, 1992, FASEB J, V6, P3051, DOI 10.1096/fasebj.6.12.1381691; NATHAN C, 1994, J BIOL CHEM, V269, P13725; NICHOL CA, 1985, ANNU REV BIOCHEM, V54, P729, DOI 10.1146/annurev.biochem.54.1.729; NICOLSON AG, 1993, BIOCHEM BIOPH RES CO, V193, P1269, DOI 10.1006/bbrc.1993.1762; PARK SK, 1994, BIOCHEM BIOPH RES CO, V201, P762, DOI 10.1006/bbrc.1994.1766; PFEILSCHIFTER J, 1990, FEBS LETT, V273, P185, DOI 10.1016/0014-5793(90)81080-8; ROSENKRANZWEISS P, 1994, J CLIN INVEST, V93, P2236, DOI 10.1172/JCI117221; SAKAI N, 1993, MOL PHARMACOL, V43, P6; SAURA M, 1995, KIDNEY INT, V47, P500, DOI 10.1038/ki.1995.63; SCHAFFNER A, 1994, BIOCHEM BIOPH RES CO, V205, P516, DOI 10.1006/bbrc.1994.2695; SCHOEDON G, 1993, EUR J BIOCHEM, V213, P833, DOI 10.1111/j.1432-1033.1993.tb17826.x; SCHOEDON G, 1994, BIOCHEM BIOPH RES CO, V199, P504, DOI 10.1006/bbrc.1994.1257; SCHOEDON G, 1993, BIOCHEM BIOPH RES CO, V196, P1343, DOI 10.1006/bbrc.1993.2400; SCHULTZ PJ, 1991, AM J PHYSIOL, V261, pF600; SHEN R, 1988, BIOCHIM BIOPHYS ACTA, V965, P9, DOI 10.1016/0304-4165(88)90144-4; SUEOKA T, 1985, BIOCHIM BIOPHYS ACTA, V843, P193, DOI 10.1016/0304-4165(85)90139-4; WERNER ER, 1993, P SOC EXP BIOL MED, V203, P1; WERNERFELMAYER G, 1990, J EXP MED, V172, P1599, DOI 10.1084/jem.172.6.1599; WERNERFELMAYER G, 1993, J BIOL CHEM, V268, P1842	48	38	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14290	14295		10.1074/jbc.271.24.14290	http://dx.doi.org/10.1074/jbc.271.24.14290			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662883	Green Published, hybrid			2022-12-27	WOS:A1996UQ66000055
J	Chernousov, MA; Stahl, RC; Carey, DJ				Chernousov, MA; Stahl, RC; Carey, DJ			Schwann cells secrete a novel collagen-like adhesive protein that binds N-syndecan	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARAN-SULFATE PROTEOGLYCAN; LAMININ RECEPTOR; EXTRACELLULAR-MATRIX; INTEGRIN EXPRESSION; MYELIN FORMATION; BASAL LAMINA; INVITRO; DIFFERENTIATION; IDENTIFICATION; ALPHA-6-BETA-4	A heparin-binding glycoprotein was purified from conditioned medium of cultured rat Schwann cells, The protein, p200, which has an apparent molecular mass of approximately 200 kDa, was identified by its ability to bind the cell surface heparan sulfate proteoglycan N-syndecan (syndecan-3) in a membrane overlay assay, Soluble heparan but not chondroitin sulfate inhibited the binding, suggesting the involvement of heparan sulfate chains of proteoglycan in the interaction. Purified p200 promoted the attachment and spreading of Schwann cells, Adhesion to p200 was blocked by heparin, suggesting that heparan sulfate proteoglycans are cell surface receptors for p200, The tissue distribution of p200 was determined by immunoblot analysis with anti-p200 antibodies, Among neonatal rat tissues examined p200 was detected only in sciatic nerve and, at newer levels, in skeletal muscle, p200 expression in sciatic nerve was detectable only during the first 23 weeks of postnatal development and was not detected in adult rats. Immunofluorescent staining of rat sciatic nerve showed that p200 was localized in the extracellular matrix surrounding individual Schwann cells-axon units, Two tryptic peptides from p280 were purified and sequenced, These contained multiple GXY collagen-like repeats, Bacterial collagenase digestion of p200 produced a product with an apparent molecular mass of approximately 90 kDa, These data suggest that Schwann cells secrete an apparently novel collagen-like adhesive protein that interacts with cells through cell surface heparan sulfate proteoglycans.			Chernousov, MA (corresponding author), GEISINGER MED CLIN,WEIS CTR RES,100 N ACAD AVE,DANVILLE,PA 17822, USA.				NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BOXBERG YV, 1994, ANAL BIOCHEM, V219, P32; BUNGE MB, 1993, PERIPHERAL NEUROPATH, P299; CAREY DJ, 1987, J CELL BIOL, V105, P1013, DOI 10.1083/jcb.105.2.1013; CAREY DJ, 1990, J BIOL CHEM, V265, P20627; CAREY DJ, 1993, EXP CELL RES, V208, P10, DOI 10.1006/excr.1993.1217; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CAREY DJ, 1992, J CELL BIOL, V117, P191, DOI 10.1083/jcb.117.1.191; CAREY DJ, 1983, J CELL BIOL, V97, P473, DOI 10.1083/jcb.97.2.473; CAREY DJ, 1986, J CELL BIOL, V102, P2224; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CORNBROOKS CJ, 1983, P NATL ACAD SCI-BIOL, V80, P3850, DOI 10.1073/pnas.80.12.3850; EINHEBER S, 1993, J CELL BIOL, V123, P1223, DOI 10.1083/jcb.123.5.1223; ELDRIDGE CF, 1987, J CELL BIOL, V105, P1023, DOI 10.1083/jcb.105.2.1023; ELDRIDGE CF, 1989, J NEUROSCI, V9, P625; ELICES MJ, 1989, P NATL ACAD SCI USA, V86, P9906, DOI 10.1073/pnas.86.24.9906; FELTRI ML, 1994, DEVELOPMENT, V120, P1287; HALL DE, 1990, J CELL BIOL, V110, P2175, DOI 10.1083/jcb.110.6.2175; HARLOW E, 1988, ANTIBODIES LABORATOR, P162; HSIAO LL, 1991, J CLIN INVEST, V87, P811, DOI 10.1172/JCI115084; KARLSSON JO, 1994, ANAL BIOCHEM, V219, P144, DOI 10.1006/abio.1994.1243; KATO M, 1994, J BIOL CHEM, V269, P18881; KRAMER RH, 1989, J BIOL CHEM, V264, P4684; LAGENAUR C, 1987, P NATL ACAD SCI USA, V84, P7753, DOI 10.1073/pnas.84.21.7753; LEE EC, 1992, J CELL BIOL, V117, P671, DOI 10.1083/jcb.117.3.671; LORIMIER P, 1992, J HISTOCHEM CYTOCHEM, V40, P859, DOI 10.1177/40.6.1588030; MCGARVEY ML, 1984, DEV BIOL, V105, P18, DOI 10.1016/0012-1606(84)90257-4; MITSIADIS TA, 1995, DEVELOPMENT, V121, P37; RAULO E, 1994, J BIOL CHEM, V269, P12999; RAUVALA H, 1994, DEV BRAIN RES, V79, P157, DOI 10.1016/0165-3806(94)90121-X; ROSENFELD J, 1992, ANAL BIOCHEM, V203, P173, DOI 10.1016/0003-2697(92)90061-B; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SANES JR, 1990, J CELL BIOL, V111, P1685, DOI 10.1083/jcb.111.4.1685; SONNENBERG A, 1988, NATURE, V336, P487, DOI 10.1038/336487a0	33	29	29	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13844	13853		10.1074/jbc.271.23.13844	http://dx.doi.org/10.1074/jbc.271.23.13844			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662884	hybrid			2022-12-27	WOS:A1996UP38500081
J	Fowler, GJS; Hunter, CN				Fowler, GJS; Hunter, CN			The synthesis and assembly of functional high and low light LH2 antenna complexes from Rhodopseudomonas palustris in Rhodobacter sphaeroides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HARVESTING COMPLEX; MUTAGENESIS; ACIDOPHILA; BACTERIA; GENOME; GENES	PHotosynthetic bacteria respond to lowered light intensity by increasing the level of the peripheral light-harvesting (LH2) complex. Several species possess an additional mechanism, responding to variations in light conditions by making different types of LH2 complex. However, the study of these complexes in isolation and in the native membrane environment has not been possible. Therefore two LH2 gene pairs from Rhodopseudomonas palustris, associated, respectively, with high light (pucBa(a)) and low light (pucBA(d)) growth conditions, were expressed in Rhodobacter sphaeroides. The high light LH2 complex PucBA(n) was synthesized at appreciable levels in R. sphaeroides, and near-infrared absorption bands at similar to 800-855 nm, and was able to transfer energy efficiently to the native LH1 complex. In contrast, the low light complex PucBA(d) was found at comparatively low levels, had absorption bands at similar to 797-830 nm, and did not transfer energy to the native LH1 complex efficiently. these observations are discussed in the light of site-directed studies on the R. sphaeroids LH2 complex, and the recently elucidated Rhodopseudomonas acidophila 10050 LH2 structure. Potentially important residues for energy transfer between LH2 and LH1 complexes are identified, as well between LH2 and LH1 complexes are identified, as well as some of the factors that influence stability and assembly of LH2 complexes, such as the N-terminal sequences of their protein sub-units and their carotenoid binding sites.	UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, KREBS INST, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND	University of Sheffield	Fowler, GJS (corresponding author), UNIV SHEFFIELD, DEPT MOLEC BIOL & BIOTECHNOL, ROBERT HILL INST PHOTOSYNTH, SHEFFIELD S10 2TN, S YORKSHIRE, ENGLAND.			Fowler, Gregory/0000-0002-0420-7661				AAGAARD J, 1972, PHOTOCHEM PHOTOBIOL, V15, P209, DOI 10.1111/j.1751-1097.1972.tb06240.x; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRUNISHOLZ RA, 1992, J PHOTOCH PHOTOBIO B, V15, P113, DOI 10.1016/1011-1344(92)87010-7; Cogdell R., 1993, PHOTOSYNTHETIC REACT, V1, P23; COGDELL RJ, 1983, BIOCHIM BIOPHYS ACTA, V722, P427, DOI 10.1016/0005-2728(83)90058-0; ELDER DJE, 1993, FEMS MICROBIOL LETT, V111, P23; EVANS MB, 1989, THESIS U GLASGOW; FOWLER GJS, 1992, NATURE, V355, P848, DOI 10.1038/355848a0; FOWLER GJS, 1994, BIOCHEM J, V299, P695, DOI 10.1042/bj2990695; FOWLER GJS, 1995, J BIOL CHEM, V270, P23875, DOI 10.1074/jbc.270.40.23875; GARDINER AT, 1993, PHOTOSYNTH RES, V38, P159, DOI 10.1007/BF00146415; GIBSON LCD, 1992, MOL MICROBIOL, V6, P3171, DOI 10.1111/j.1365-2958.1992.tb01773.x; Hawthornthwaite-Lawless A. M., 1991, CHLOROPHYLLS, P493; Hess S, 1995, P NATL ACAD SCI USA, V92, P12333, DOI 10.1073/pnas.92.26.12333; HESS S, 1994, BIOCHEMISTRY-US, V33, P8300, DOI 10.1021/bi00193a017; Hunter C. N., 1995, ANOXYGENIC PHOTOSYNT, V2, P473, DOI DOI 10.1007/0-306-47954-0_22; HUNTER CN, 1988, J GEN MICROBIOL, V134, P1471; HUNTER CN, 1994, J BACTERIOL, V176, P3693; JONES MR, 1992, MOL MICROBIOL, V6, P1173, DOI 10.1111/j.1365-2958.1992.tb01556.x; LANG HP, 1994, BIOCHEM J, V298, P197, DOI 10.1042/bj2980197; MCDERMOTT G, 1995, NATURE, V374, P517, DOI 10.1038/374517a0; OLSEN JD, 1994, P NATL ACAD SCI USA, V91, P7124, DOI 10.1073/pnas.91.15.7124; PAPIZ MZ, 1989, J MOL BIOL, V209, P833, DOI 10.1016/0022-2836(89)90612-8; SIMON R, 1983, BIO-TECHNOL, V1, P784, DOI 10.1038/nbt1183-784; TADROS MH, 1990, FEMS SYMP, V53, P181; TADROS MH, 1993, EUR J BIOCHEM, V217, P867, DOI 10.1111/j.1432-1033.1993.tb18315.x; TADROS MH, 1989, EMBO J, V8, P1303, DOI 10.1002/j.1460-2075.1989.tb03509.x; VANGRONDELLE R, 1994, BBA-BIOENERGETICS, V1187, P1, DOI 10.1016/0005-2728(94)90166-X; VANMOURIK F, 1992, BIOCHIM BIOPHYS ACTA, V1140, P85, DOI 10.1016/0005-2728(92)90023-U	29	13	15	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13356	13361		10.1074/jbc.271.23.13356	http://dx.doi.org/10.1074/jbc.271.23.13356			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662765	hybrid			2022-12-27	WOS:A1996UP38500011
J	Hsu, DKW; Guo, Y; Alberts, GF; Copeland, NG; Gilbert, DJ; Jenkins, NA; Peifley, KA; Winkles, JA				Hsu, DKW; Guo, Y; Alberts, GF; Copeland, NG; Gilbert, DJ; Jenkins, NA; Peifley, KA; Winkles, JA			Identification of a murine TEF-1-related gene expressed after mitogenic stimulation of quiescent fibroblasts and during myogenic differentiation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-CYCLE PROGRESSION; GROWTH FACTOR-I; ENHANCER FACTOR-I; INTIMAL HYPERPLASIA; HEPARIN-BINDING; POINT MUTATION; SINGLE GENE; RECEPTOR; TRANSCRIPTION; CLONING	Fibroblast growth factor (FGF)-1 binding to cell surface receptors stimulates an intracellular signaling pathway that ultimately promotes the transcriptional activation of specific genes. We have used a mRNA differential display method to identify FGF-1-inducible genes in mouse NIH 3T3 fibroblasts. Here, we report that one of these genes, FGF-regulated (FR)-19, is predicted to encode a member of the transcriptional enhancer factor (TEF)-1 family of structurally related DNA-binding proteins. Specifically, the deduced FR-19 amino acid sequence has similar to 89, 77, and 68% overall identity to chicken TEF-1A, mouse TEF-1, and mouse embryonic TEA domain-containing factor, respectively. Gel mobility shift experiments indicate that FR-19, like TEF-1, and bind the GT-IIC motif found in the SV40 enhancer. The FR-19 gene maps in the distal region of mouse chromosome 6, and analysis of several FR-19 cDNA clones indicates that at least two FR-19 isoforms may be expressed from this locus. FGF-1 induction of FR-19 mRNA expression in mouse fibroblasts is first detectable at 4 h after FGF-1 addition and is dependent on de novo RNA and protein synthesis. FGF-2, calf serum, platelet-derived growth factor-BB, and phorbol 12-myristate 13-acetate can also induce FR-19 mRNA levels. We have also found that FR-19 mRNA expression increases during mouse C2C12 myoblast differentiation in vitro. The FR-19 gene is expressed in vivo in a tissue-specific manner, with a relatively high level detected in lung. These results indicate that increased expression of a TEF-1-related protein may be important for both mitogen-simulated fibroblast proliferation and skeletal muscle cell differentiation.	AMER RED CROSS, DEPT BIOL MOLEC, HOLLAND LAB, ROCKVILLE, MD 20855 USA; NCI, FREDERICK CANC RES & DEV CTR, MAMMALIAN GENET LAB, FREDERICK, MD 21702 USA; NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, FREDERICK, MD 21702 USA; GEORGE WASHINGTON UNIV, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WASHINGTON, DC 20037 USA	American Red Cross; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Science Applications International Corporation (SAIC); SAIC-Frederick; George Washington University					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039727, R29HL039727, T32HL007698] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL-39727, HL-07698] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDRIANOPOULOS A, 1994, MOL CELL BIOL, V14, P2503, DOI 10.1128/MCB.14.4.2503; ASAHARA T, 1995, CIRCULATION, V92, P365, DOI 10.1161/01.CIR.92.9.365; Ausubel FM, 1988, MOL REPROD DEV; BALDIN V, 1993, GENE DEV, V7, P812, DOI 10.1101/gad.7.5.812; BELLOT F, 1991, EMBO J, V10, P2849, DOI 10.1002/j.1460-2075.1991.tb07834.x; BJORNSSON TD, 1991, P NATL ACAD SCI USA, V88, P8651, DOI 10.1073/pnas.88.19.8651; BLATT C, 1993, NUCLEIC ACIDS RES, V21, P747, DOI 10.1093/nar/21.3.747; Burgess W. H., 1996, P154; BURGESS WH, 1990, J CELL BIOL, V111, P2129, DOI 10.1083/jcb.111.5.2129; BURGESS WH, 1990, MOL CELL BIOL, V10, P4770, DOI 10.1128/MCB.10.9.4770; BURGLIN TR, 1991, CELL, V66, P11, DOI 10.1016/0092-8674(91)90132-I; CAMPBELL S, 1992, GENE DEV, V6, P367, DOI 10.1101/gad.6.3.367; CHELLAIAH AT, 1994, J BIOL CHEM, V269, P11620; CHEN Z, 1994, GENE DEV, V8, P2293, DOI 10.1101/gad.8.19.2293; COPELAND NG, 1991, TRENDS GENET, V7, P113, DOI 10.1016/0168-9525(91)90455-Y; CRESCENZI M, 1994, J CELL BIOL, V125, P1137, DOI 10.1083/jcb.125.5.1137; CUEVAS P, 1991, CIRC RES, V69, P360, DOI 10.1161/01.RES.69.2.360; DIONNE CA, 1990, EMBO J, V9, P2685, DOI 10.1002/j.1460-2075.1990.tb07454.x; DONOHUE PJ, 1994, J BIOL CHEM, V269, P8604; DONOHUE PJ, 1995, J BIOL CHEM, V270, P10351, DOI 10.1074/jbc.270.17.10351; EDELMAN ER, 1992, J CLIN INVEST, V89, P465, DOI 10.1172/JCI115607; FORONI L, 1992, J MOL BIOL, V226, P747, DOI 10.1016/0022-2836(92)90630-3; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; FURUKAWA Y, 1990, SCIENCE, V250, P805, DOI 10.1126/science.2237430; Goh KC, 1996, J BIOL CHEM, V271, P5832, DOI 10.1074/jbc.271.10.5832; Green EL, 1981, GENETICS PROBABILITY, P77; GRUDA MC, 1993, MOL CELL BIOL, V13, P961, DOI 10.1128/MCB.13.2.961; GRUNERT S, 1994, EMBO J, V13, P3618, DOI 10.1002/j.1460-2075.1994.tb06669.x; HOU JZ, 1993, PROTEIN SCI, V2, P86; Hsu DKW, 1996, J CELL PHYSIOL, V167, P261, DOI 10.1002/(SICI)1097-4652(199605)167:2<261::AID-JCP9>3.0.CO;2-N; HSU DKW, 1993, BIOCHEM BIOPH RES CO, V197, P1483, DOI 10.1006/bbrc.1993.2644; HUANG JT, 1995, J BIOL CHEM, V270, P5065, DOI 10.1074/jbc.270.10.5065; HWANG JJ, 1993, EMBO J, V12, P2337, DOI 10.1002/j.1460-2075.1993.tb05888.x; ISHIJI T, 1992, EMBO J, V11, P2271, DOI 10.1002/j.1460-2075.1992.tb05286.x; JAHN L, 1994, EXP CELL RES, V212, P297, DOI 10.1006/excr.1994.1147; JENKINS NA, 1982, J VIROL, V43, P26, DOI 10.1128/JVI.43.1.26-36.1982; JOHNSON DE, 1993, ADV CANCER RES, V60, P1; KLINT P, 1995, J BIOL CHEM, V270, P23337, DOI 10.1074/jbc.270.40.23337; KOVARY K, 1991, MOL CELL BIOL, V11, P4466, DOI 10.1128/MCB.11.9.4466; KOZAK M, 1989, J CELL BIOL, V108, P229, DOI 10.1083/jcb.108.2.229; LALOUX I, 1990, MOL CELL BIOL, V10, P3541, DOI 10.1128/MCB.10.7.3541; LINDNER V, 1991, CIRC RES, V68, P106, DOI 10.1161/01.RES.68.1.106; LINDNER V, 1990, J CLIN INVEST, V85, P2004, DOI 10.1172/JCI114665; MCCLELLAND M, 1995, TRENDS GENET, V11, P242, DOI 10.1016/S0168-9525(00)89058-7; MIKI T, 1992, P NATL ACAD SCI USA, V89, P246, DOI 10.1073/pnas.89.1.246; MIYAMOTO M, 1993, MOL CELL BIOL, V13, P4251, DOI 10.1128/MCB.13.7.4251; MOHAMMADI M, 1991, MOL CELL BIOL, V11, P5068, DOI 10.1128/MCB.11.10.5068; MOHAMMADI M, 1992, NATURE, V358, P681, DOI 10.1038/358681a0; MULLER R, 1993, BIOCHIM BIOPHYS ACTA, V1155, P151, DOI 10.1016/0304-419X(93)90003-U; NABEL EG, 1993, NATURE, V362, P844, DOI 10.1038/362844a0; ORNITZ DM, 1992, J BIOL CHEM, V267, P16305; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PU LQ, 1993, CIRCULATION, V88, P208, DOI 10.1161/01.CIR.88.1.208; RON D, 1993, J BIOL CHEM, V268, P5388; SHAOUL E, 1995, ONCOGENE, V10, P1553; SHIMIZU N, 1993, NUCLEIC ACIDS RES, V21, P4103, DOI 10.1093/nar/21.17.4103; SHORT JM, 1988, NUCLEIC ACIDS RES, V16, P7583, DOI 10.1093/nar/16.15.7583; STEWART AFR, 1994, J BIOL CHEM, V269, P3147; TAUTZ D, 1983, ANAL BIOCHEM, V132, P14, DOI 10.1016/0003-2697(83)90419-0; THINAKARAN G, 1993, FEBS LETT, V319, P271, DOI 10.1016/0014-5793(93)80561-8; VAINIKKA S, 1994, J BIOL CHEM, V269, P18320; WANG JK, 1994, MOL CELL BIOL, V14, P181, DOI 10.1128/MCB.14.1.181; WILLIAMS GT, 1992, MOL CELLULAR APPROAC, P115; WINKLES JA, 1995, CARDIOVASCULAR DIS, V2, P109; XIAO JH, 1991, CELL, V65, P551, DOI 10.1016/0092-8674(91)90088-G; YAFFE D, 1977, NATURE, V270, P725, DOI 10.1038/270725a0; YASUNAMI M, 1995, J BIOL CHEM, V270, P18649, DOI 10.1074/jbc.270.31.18649; Yockey CE, 1996, J BIOL CHEM, V271, P3727, DOI 10.1074/jbc.271.7.3727	70	33	36	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13786	13795		10.1074/jbc.271.23.13786	http://dx.doi.org/10.1074/jbc.271.23.13786			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662936	hybrid			2022-12-27	WOS:A1996UP38500073
J	Lesuisse, E; CasterasSimon, M; Labbe, P				Lesuisse, E; CasterasSimon, M; Labbe, P			Evidence for the Saccharomyces cerevisiae ferrireductase system being a multicomponent electron transport chain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON UPTAKE; FERRIC REDUCTASE; ASSIMILATION; CLONING; COMPLEX; GENE	We have studied the relationships between in vivo (whole cells) and in vitro (plasma membranes) ferrireductase activity in Saccharomyces cerevisiae. Isolated plasma membranes were enriched in the product of the FRE1 gene and had NADPH dehydrogenase activity that was, increased when the cells were grown in iron/copper-deprived medium, The diaphorase activity was, however, independent of Fre1p, and Fre1p itself had pro ferrireductase activity in vitro, There were striking similarities between the yeast ferrireductase system and the neutrophil NADPH oxidase: oxygen could act as an electron acceptor in the ferrireductase system, and Fre1p, like gp91, Is a glycosylated hemoprotein with a b-type cytochrome spectrum. The ferrireductase system was sensitive to the NADPH oxidase inhibitor diphenylene iodonium (DPI). DPI inhibition proceeded with two apparent K-i values (high and low affinity binding) in whole wild-type and Delta fre2 cells and with one apparent ent K-i in Delta fre1 cells (high affinity binding) and in plasma membranes (low affinity binding), These results suggest that the Fre1-dependent ferrireductase system involves at least two components (Fre1p and an NADPH dehydrogenase component) differing in their sensitivities to DBH, as in the neutrophil NAPBPH oxidase, A third component, the product of the UTR1 gene, was shown to act synergistically with Fre1p to increase the cell ferrireductase activity.			Lesuisse, E (corresponding author), UNIV PARIS 07, INST JACQUES MONOD, LAB BIOCHIM PORPHYRINES, TOUR 43, 2 PL JUSSIEU, F-75251 PARIS 05, FRANCE.							ANDERSON GJ, 1994, ADV EXP MED BIOL, V356, P81; ANDERSON GJ, 1992, J INORG BIOCHEM, V47, P249, DOI 10.1016/0162-0134(92)84070-4; BORJIGIN J, 1994, J BIOL CHEM, V269, P14715; CAMADRO JM, 1993, TARGET ASSAYS MODERN, P29; CHANOCK SJ, 1994, J BIOL CHEM, V269, P24519; COTTINGHAM IR, 1988, BIOCHEM J, V254, P303, DOI 10.1042/bj2540303; CROSS AR, 1994, J BIOL CHEM, V269, P21448; DANCIS A, 1992, P NATL ACAD SCI USA, V89, P3869, DOI 10.1073/pnas.89.9.3869; DANCIS A, 1990, MOL CELL BIOL, V10, P2294, DOI 10.1128/MCB.10.5.2294; DESILVA DM, 1995, J BIOL CHEM, V270, P1098, DOI 10.1074/jbc.270.3.1098; DOUSSIERE J, 1992, EUR J BIOCHEM, V208, P61, DOI 10.1111/j.1432-1033.1992.tb17159.x; DUFOUR JP, 1988, METHOD ENZYMOL, V157, P513; EIDE D, 1992, J BIOL CHEM, V267, P20774; ESNAULT Y, 1993, EMBO J, V12, P4083, DOI 10.1002/j.1460-2075.1993.tb06092.x; GEORGATSOU E, 1994, MOL CELL BIOL, V14, P3065, DOI 10.1128/MCB.14.5.3065; HASSETT R, 1995, J BIOL CHEM, V270, P128, DOI 10.1074/jbc.270.1.128; HENDERSON LM, 1995, J BIOL CHEM, V270, P5909, DOI 10.1074/jbc.270.11.5909; KLAUSNER RD, 1994, FEBS LETT, V355, P109, DOI 10.1016/0014-5793(94)01111-7; KREMS B, 1995, CURR GENET, V27, P427, DOI 10.1007/BF00311211; Labbe P, 1969, Bull Soc Chim Biol (Paris), V51, P1642; LESUISSE E, 1995, ANAL BIOCHEM, V226, P375, DOI 10.1006/abio.1995.1239; LESUISSE E, 1992, PLANT PHYSIOL, V100, P769, DOI 10.1104/pp.100.2.769; LESUISSE E, 1989, J GEN MICROBIOL, V135, P257; LESUISSE E, 1991, BIOCHEM J, V280, P545, DOI 10.1042/bj2800545; LESUISSE E, 1995, MICROBIOL-UK, V141, P2937, DOI 10.1099/13500872-141-11-2937; LESUISSE E, 1990, BIOCHIM BIOPHYS ACTA, V1038, P253, DOI 10.1016/0167-4838(90)90213-Y; LESUISSE E, 1987, J GEN MICROBIOL, V133, P3228; Lesuisse Emmanuel, 1994, V11, P149; LETO TL, 1990, SCIENCE, V248, P727, DOI 10.1126/science.1692159; MELNICK L, 1993, J MOL BIOL, V233, P372, DOI 10.1006/jmbi.1993.1518; MYERS AM, 1986, GENE, V45, P299, DOI 10.1016/0378-1119(86)90028-4	31	91	95	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13578	13583		10.1074/jbc.271.23.13578	http://dx.doi.org/10.1074/jbc.271.23.13578			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662826	hybrid			2022-12-27	WOS:A1996UP38500043
J	Moriguchi, T; Kuroyanagi, N; Yamaguchi, K; Gotoh, Y; Irie, K; Kano, T; Shirakabe, K; Muro, Y; Shibuya, H; Matsumoto, K; Nishida, E; Hagiwara, M				Moriguchi, T; Kuroyanagi, N; Yamaguchi, K; Gotoh, Y; Irie, K; Kano, T; Shirakabe, K; Muro, Y; Shibuya, H; Matsumoto, K; Nishida, E; Hagiwara, M			A novel kinase cascade mediated by mitogen-activated protein kinase kinase 6 and MKK3	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAP KINASE; FAMILY; CDNA	A cDNA encoding a novel member of the mitogen-activated protein kinase kinase (MAPKK) family, MAPKK6, was isolated and found to encode a protein of 334 amino acids, with a calculated molecular mass of 37 kDa that is 79% identical to MKK3. MAPKK6 was shown to phosphorylate and specifically activate the p38/MPK2 subgroup of the mitogen-activated protein kinase superfamily and could be demonstrated to be phosphorylated and activated in vitro by TAK1, a recently identified MAPKK kinase. MKK3 was also shown to be a good substrate for TAK1 in vitro. Furthermore, when co-expressed with TAK1 in cells in culture, both MAPKK6 and MKK3 were strongly activated. In addition, co-expression of TAK1 and p38/MPK2 in cells resulted in activation of p38/MPK2. These results indicate the existence of a novel kinase cascade consisting of TAK1, MAPKK6/MKK3, and p38/MPK2.	HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN; KYOTO UNIV,INST VIRUS RES,DEPT GENET & MOL BIOL,SAKYO KU,KYOTO 60601,JAPAN; NAGOYA UNIV,SCH MED,DEPT ANAT,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,SCH MED,DEPT DERMATOL,SHOWA KU,NAGOYA,AICHI 466,JAPAN; NAGOYA UNIV,FAC SCI,DEPT MOLEC BIOL,CHIKUSA KU,NAGOYA,AICHI 46401,JAPAN; HOKKAIDO UNIV,FAC PHARMACEUT SCI,SAPPORO,HOKKAIDO 060,JAPAN	Hokkaido University; Kyoto University; Nagoya University; Nagoya University; Nagoya University; Hokkaido University			Moriguchi, Tetsuo/D-7061-2012; MURO, Yoshinao/M-8883-2014	Moriguchi, Tetsuo/0000-0002-9598-4991; Muro, Yoshinao/0000-0003-2329-8375				AHMAD MF, 1994, NATURE, V369, P156; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DERIJARD B, 1994, CELL, V76, P1025, DOI 10.1016/0092-8674(94)90380-8; DERIJARD B, 1995, SCIENCE, V267, P682, DOI 10.1126/science.7839144; ENGLISH JM, 1995, J BIOL CHEM, V270, P28897, DOI 10.1074/jbc.270.48.28897; GOTOH Y, 1991, EMBO J, V10, P2661, DOI 10.1002/j.1460-2075.1991.tb07809.x; HAN J, 1994, SCIENCE, V265, P808, DOI 10.1126/science.7914033; Han JH, 1996, J BIOL CHEM, V271, P2886, DOI 10.1074/jbc.271.6.2886; HAN JH, 1995, BBA-MOL CELL RES, V1265, P224, DOI 10.1016/0167-4889(95)00002-A; HANKS SK, 1988, SCIENCE, V241, P42, DOI 10.1126/science.3291115; LEE JC, 1994, NATURE, V372, P739, DOI 10.1038/372739a0; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; MATSUDA S, 1995, J BIOL CHEM, V270, P12781, DOI 10.1074/jbc.270.21.12781; MERCURIO F, 1995, SCIENCE, V268, P286; MORIGUCHI T, 1995, J BIOL CHEM, V270, P12969, DOI 10.1074/jbc.270.22.12969; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; PAYNE DM, 1991, EMBO J, V10, P885, DOI 10.1002/j.1460-2075.1991.tb08021.x; Raingeaud J, 1996, MOL CELL BIOL, V16, P1247; ROUSE J, 1994, CELL, V78, P1027, DOI 10.1016/0092-8674(94)90277-1; SANCHEZ I, 1994, NATURE, V372, P794, DOI 10.1038/372794a0; SEGER R, 1992, J BIOL CHEM, V267, P25628; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; YAMAGUCHI K, 1995, SCIENCE, V270, P2008, DOI 10.1126/science.270.5244.2008; YAN MH, 1994, NATURE, V372, P798; YASHAR BM, 1993, MOL CELL BIOL, V13, P5738, DOI 10.1128/MCB.13.9.5738; ZHENG CF, 1993, J BIOL CHEM, V268, P11435; ZHOU GC, 1995, J BIOL CHEM, V270, P12665, DOI 10.1074/jbc.270.21.12665	28	406	415	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13675	13679		10.1074/jbc.271.23.13675	http://dx.doi.org/10.1074/jbc.271.23.13675			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663074	hybrid			2022-12-27	WOS:A1996UP38500057
J	Novak, S; Hiesberger, T; Schneider, WJ; Nimpf, J				Novak, S; Hiesberger, T; Schneider, WJ; Nimpf, J			A new low density lipoprotein receptor homologue with 8 ligand binding repeats in brain of chicken and mouse	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							APOLIPOPROTEIN-E; LDL-RECEPTOR; DIFFERENT PROTEINS; OOCYTE RECEPTOR; MESSENGER-RNAS; SPECIFICITY; GENE; EXPRESSION; SEQUENCES; DISEASE	The blood-brain barrier necessitates disparate macromolecular transport systems in the brain and central nervous system. We now report the discovery of a new member of the low density lipoprotein receptor (LDLR) family whose expression is highly restricted to the brain. The full-length cDNA specifying the chicken receptor (open reading frame, 2754 base pairs) as well as a cDNA for the major portion of its murine homologue have been obtained, The novel receptor shows the greatest similarity to the group of LDLR relatives with 8 ligand binding repeats, in chicken termed LR8 and in mammals, very low density lipoprotein receptors. Thus, in addition to 8 tandemly arranged ligand binding repeats, the five-domain receptor contains an O-linked sugar region and the internalization signal, Phe-Asp-Asn-Pro-Val-Tyr, typical for all LDLR gene family members, In chicken, the 6.5-kb receptor transcript is present at high levels in brain and at much lower levels in extraoocytic cells of the ovary; in mouse, the same transcript of 6.5 kb was detected in brain, but not in heart (the major site of very low density lipoprotein receptor expression), lung, liver, kidney, and ovary. An antibody directed against the predicted carboxyl terminus of the avian receptor detected a 130-kDa protein in brain extracts. The apparent size of the immunoreactive protein is compatible with extensive glycosylation of the 894-residue mature form of the receptor. The presence of this novel receptor in brain of a bird and a rodent suggests an important and evolutionary conserved function.	BIOCTR,DEPT MOLEC GENET,A-1030 VIENNA,AUSTRIA; UNIV VIENNA,A-1030 VIENNA,AUSTRIA	University of Vienna				Nimpf, Johannes/0000-0002-9273-3492				BARAKAT HA, 1985, J LIPID RES, V26, P1252; BEISIEGEL U, 1981, J BIOL CHEM, V256, P1923; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; BUJO H, 1995, J BIOL CHEM, V270, P23546, DOI 10.1074/jbc.270.40.23546; BUJO H, 1994, EMBO J, V13, P5165, DOI 10.1002/j.1460-2075.1994.tb06847.x; CHEN WJ, 1990, J BIOL CHEM, V265, P3116; DAWSON PA, 1986, J BIOL CHEM, V261, P5681; ELHAMMER AP, 1993, J BIOL CHEM, V268, P10029; FARQUHAR MG, 1995, J AM SOC NEPHROL, V6, P35; FERRARI S, 1987, GENE, V60, P39, DOI 10.1016/0378-1119(87)90211-3; GAFVELS ME, 1994, ENDOCRINOLOGY, V135, P387, DOI 10.1210/en.135.1.387; HAYASHI K, 1989, J BIOL CHEM, V264, P3131; HEIJNE GV, 1983, EUR J BIOCHEM, V133, P17; HERMIER D, 1985, BIOCHIM BIOPHYS ACTA, V836, P105, DOI 10.1016/0005-2760(85)90226-7; HERZ J, 1993, CELL, V73, P428, DOI 10.1016/0092-8674(93)90130-I; HERZ J, 1992, CELL, V71, P411, DOI 10.1016/0092-8674(92)90511-A; HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x; HERZ J, 1991, J BIOL CHEM, V266, P21232; HIESBERGER T, 1995, J BIOL CHEM, V270, P18219, DOI 10.1074/jbc.270.31.18219; HODITS RA, 1995, J BIOL CHEM, V270, P24078, DOI 10.1074/jbc.270.41.24078; JACOBSEN L, 1995, J BIOL CHEM, V270, P6468, DOI 10.1074/jbc.270.12.6468; Jingami Hisato, 1995, Current Opinion in Lipidology, V6, P104, DOI 10.1097/00041433-199504000-00008; JOKINEN EV, 1994, J BIOL CHEM, V269, P26411; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRIEGER M, 1994, ANNU REV BIOCHEM, V63, P601, DOI 10.1146/annurev.bi.63.070194.003125; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEBLANC AC, 1989, J CELL BIOL, V109, P1245, DOI 10.1083/jcb.109.3.1245; NIMPF J, 1988, J LIPID RES, V29, P657; NIMPF J, 1994, J BIOL CHEM, V269, P212; PITAS RE, 1987, BIOCHIM BIOPHYS ACTA, V917, P148, DOI 10.1016/0005-2760(87)90295-5; REBECK GW, 1993, NEURON, V11, P575; RUSSELL DW, 1989, J BIOL CHEM, V264, P21682; SAITO A, 1994, P NATL ACAD SCI USA, V91, P9725, DOI 10.1073/pnas.91.21.9725; SCHMECHEL DE, 1993, P NATL ACAD SCI USA, V90, P9649, DOI 10.1073/pnas.90.20.9649; SCHNEIDER WJ, 1989, BIOCHIM BIOPHYS ACTA, V988, P303, DOI 10.1016/0304-4157(89)90023-3; Schneider Wolfgang J., 1993, Current Opinion in Lipidology, V4, P205, DOI 10.1097/00041433-199306000-00005; STEVENS PW, 1987, MOL CELL BIOL, V7, P1751, DOI 10.1128/MCB.7.5.1751; STEYRER E, 1990, J BIOL CHEM, V265, P19575; STIFANI S, 1991, J BIOL CHEM, V266, P19079; STRICKLAND DK, 1995, FASEB J, V9, P890, DOI 10.1096/fasebj.9.10.7615159; SUDHOF TC, 1985, SCIENCE, V228, P815, DOI 10.1126/science.2988123; TAKAHASHI S, 1992, P NATL ACAD SCI USA, V89, P9252, DOI 10.1073/pnas.89.19.9252; Weisgraber Karl H., 1994, Current Opinion in Lipidology, V5, P110, DOI 10.1097/00041433-199404000-00007; WILLNOW TE, 1996, IN PRESS EMBO J; YAMAMOTO T, 1984, CELL, V39, P27, DOI 10.1016/0092-8674(84)90188-0	45	92	95	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11732	11736		10.1074/jbc.271.20.11732	http://dx.doi.org/10.1074/jbc.271.20.11732			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662771	hybrid			2022-12-27	WOS:A1996UL25000025
J	Martens, JA; Genereaux, J; Saleh, A; Brandl, CJ				Martens, JA; Genereaux, J; Saleh, A; Brandl, CJ			Transcriptional activation by yeast PDR1p is inhibited by its association with NGG1p/ADA3p	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PLEIOTROPIC DRUG-RESISTANCE; SACCHAROMYCES-CEREVISIAE; GENE; PROTEIN; SUBUNIT; ADA2	NGG1p/ADA3p forms a coactivator/repressor complex (ADA complex) in association with at least two other yeast proteins, ADA2p and GCN5p, that is involved in regulating transcriptional activator proteins including GAL4p and GCN4p. Using a two-hybrid analysis, we found that the carboxyl-terminal transcriptional activation domain of PDR1p, the primary regulatory protein involved in yeast pleiotropic drug resistance, interacts with the amino-terminal 373 amino acids of NGG1p (NGG1p(1-373)), This interaction was confirmed by coimmunoprecipitation of epitope-tagged derivatives of NGG1p and PDR1p from crude extracts. An overlapping region of the related transcriptional activator PDR3p was also found to interact with NGG1p. Amino acids 274-307 of NGG1p were required for interaction with PDR1B, This same region is required for inhibition of transcriptional activation by GAL-lp. The association between NGG1p(1-373) and PDR1p may be indirect, possibly mediated by the ADA complex since the two-hybrid interaction required the presence of full-length NGG1. A partial requirement for ADA2 was also found. This suggests that an additional component of the ADA complex, regulated by ADA2p, may mediate the interaction. Transcriptional activation by a GAL4p DNA binding domain fusion of PDR1p was enhanced in ngg1 and ada2 disruption strains, Similar to its action on GAL4p, the ADA complex acts to inhibit the activation domain of PDR1p.	UNIV WESTERN ONTARIO, DEPT BIOCHEM, LONDON, ON N6A 5C1, CANADA	Western University (University of Western Ontario)				Saleh, Ayman M/0000-0003-1126-6018				AUBLE DT, 1994, GENE DEV, V8, P1920, DOI 10.1101/gad.8.16.1920; AUSUBEL FA, 1990, PROTOCOLS MOL BIOL; BAKER RT, 1992, J BIOL CHEM, V267, P23364; BALZI E, 1987, J BIOL CHEM, V262, P16871; BALZI E, 1995, J BIOENERG BIOMEMBR, V27, P71, DOI 10.1007/BF02110333; BALZI E, 1994, J BIOL CHEM, V269, P2206; BALZI E, 1991, BIOCHIM BIOPHYS ACTA, V1073, P241, DOI 10.1016/0304-4165(91)90128-4; BARLEV NA, 1995, J BIOL CHEM, V270, P19337, DOI 10.1074/jbc.270.33.19337; BERGER SL, 1992, CELL, V70, P251, DOI 10.1016/0092-8674(92)90100-Q; BOEKE JD, 1984, MOL GEN GENET, V197, P345, DOI 10.1007/BF00330984; Brandl CJ, 1996, J BIOL CHEM, V271, P9298, DOI 10.1074/jbc.271.16.9298; BRANDL CJ, 1993, EMBO J, V12, P5255, DOI 10.1002/j.1460-2075.1993.tb06221.x; DECOTTIGNIES A, 1995, J BIOL CHEM, V270, P18150, DOI 10.1074/jbc.270.30.18150; DELAHODDE A, 1995, MOL CELL BIOL, V15, P4043; DELAVEAU T, 1992, YEAST, V8, P761, DOI 10.1002/yea.320080909; DELAVEAU T, 1994, MOL GEN GENET, V244, P501, DOI 10.1007/BF00583901; DEXTER D, 1994, GENETICS, V136, P505; DURFEE T, 1993, GENE DEV, V7, P555, DOI 10.1101/gad.7.4.555; EISENMANN DM, 1992, GENE DEV, V6, P1319, DOI 10.1101/gad.6.7.1319; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FIELD J, 1988, MOL CELL BIOL, V8, P2159, DOI 10.1128/MCB.8.5.2159; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; GEORGAKOPOULOS T, 1995, MOL GEN GENET, V246, P723, DOI 10.1007/BF00290718; GEORGAKOPOULOS T, 1992, EMBO J, V11, P4145, DOI 10.1002/j.1460-2075.1992.tb05507.x; GIETZ RD, 1988, GENE, V74, P527, DOI 10.1016/0378-1119(88)90185-0; GOODRICH LA, 1994, CURR OPIN CELL BIOL, V6, P403, DOI 10.1016/0955-0674(94)90033-7; GUARENTE L, 1983, METHOD ENZYMOL, V101, P181; GUARENTE L, 1995, TRENDS BIOCHEM SCI, V20, P517, DOI 10.1016/S0968-0004(00)89120-3; HIMMELFARB HJ, 1990, CELL, V63, P1299, DOI 10.1016/0092-8674(90)90425-E; HORIUCHI J, 1995, MOL CELL BIOL, V15, P1203; HUISMAN O, 1987, GENETICS, V116, P191; ITO H, 1983, J BACTERIOL, V153, P163, DOI 10.1128/JB.153.1.163-168.1983; KATZMANN DJ, 1994, MOL CELL BIOL, V14, P4653, DOI 10.1128/MCB.14.7.4653; KOLESKE AJ, 1995, TRENDS BIOCHEM SCI, V20, P113, DOI 10.1016/S0968-0004(00)88977-X; KOLODZIEJ P, 1989, MOL CELL BIOL, V9, P5387, DOI 10.1128/MCB.9.12.5387; LEVINE M, 1989, CELL, V59, P405, DOI 10.1016/0092-8674(89)90024-X; MARCUS GA, 1994, EMBO J, V13, P4807, DOI 10.1002/j.1460-2075.1994.tb06806.x; MELCHER K, 1995, MOL CELL BIOL, V15, P2839; MEYERS S, 1992, CURR GENET, V21, P431, DOI 10.1007/BF00351651; PINA B, 1993, MOL CELL BIOL, V13, P5981, DOI 10.1128/MCB.13.10.5981; POON D, 1994, J BIOL CHEM, V269, P23135; POON D, 1995, P NATL ACAD SCI USA, V92, P8224, DOI 10.1073/pnas.92.18.8224; PRESTON RA, 1991, YEAST, V7, P857, DOI 10.1002/yea.320070811; REESE JC, 1994, NATURE, V371, P523, DOI 10.1038/371523a0; ROBERTS SGE, 1995, NATURE, V375, P105, DOI 10.1038/375105a0; SCHULTZ MC, 1991, P NATL ACAD SCI USA, V88, P1004, DOI 10.1073/pnas.88.3.1004; SILVERMAN N, 1994, P NATL ACAD SCI USA, V91, P11665, DOI 10.1073/pnas.91.24.11665; Stolz A, 1990, GENE, V95, P91; SUBIK J, 1986, CURR GENET, V10, P665, DOI 10.1007/BF00410914; SWAFFIELD JC, 1995, NATURE, V374, P88, DOI 10.1038/374088a0; SWAFFIELD JC, 1992, NATURE, V357, P698, DOI 10.1038/357698a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4	52	57	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15884	15890		10.1074/jbc.271.27.15884	http://dx.doi.org/10.1074/jbc.271.27.15884			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663102	hybrid			2022-12-27	WOS:A1996UW35200010
J	Rogers, JC; Qu, YS; Tanada, TN; Scheuer, T; Catterall, WA				Rogers, JC; Qu, YS; Tanada, TN; Scheuer, T; Catterall, WA			Molecular determinants of high affinity binding of alpha-scorpion toxin and sea anemone toxin in the S3-S4 extracellular loop in domain IV of the Na+ channel alpha subunit	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR MAGNETIC-RESONANCE; SODIUM-CHANNEL; RAT-BRAIN; 3-DIMENSIONAL STRUCTURE; DEPENDENT BINDING; TRANSFECTED CELLS; GATING PROPERTIES; MYELINATED NERVE; RECEPTOR-SITE; CHLORAMINE-T	alpha-Scorpion toxins and sea anemone toxins bind to a common extracellular site on the Na+ channel and inhibit fast inactivation, Basic amino acids of the toxins and domains I and IV of the Na+ channel alpha subunit have been previously implicated in toxin binding, To identify acidic residues required for toxin binding, extracellular acidic amino acids in domains I and IV of the type IIa Na+ channel alpha subunit mere converted to neutral or basic amino acids using site-directed mutagenesis, and altered channels were transiently expressed in tsA-201 cells and tested for I-125-alpha scorpion toxin binding, Conversion of Glu(1613) at the extracellular end of transmembrane segment IVS3 to Arg or His blocked measurable alpha-scorpion toxin binding, but did not affect the level of expression or saxitoxin binding affinity, Conversion of individual residues in the IVS3-S4 extracellular loop to differently charged residues or to Ala identified seven additional residues whose mutation caused significant effects on binding of alpha-scorpion toxin or sea anemone toxin, Moreover, chimeric Na+ channels in which amino acid residues at the extracellular end of segment IVS3 of the alpha subunit of cardiac Na+ channels were substituted into the type IIa channel sequence had reduced affinity for alpha-scorpion toxin characteristic of cardiac Na+ channels, Electrophysiological analysis showed that E1613R has 62- and 82-fold lower affinities for alpha-scorpion and sea anemone toxins, respectively, Dissociation of alpha-scorpion toxin is substantially accelerated at all potentials compared to wild-type channels, alpha-Scorpion toxin binding to wild type and E1613R had similar voltage dependence, which was slightly more positive and steeper than the voltage dependence of steady-state inactivation, These results indicate that nonidentical amino acids of the IVS3-S4 loop participate in alpha-scorpion toxin and sea anemone toxin binding to overlapping sites and that neighboring amino acid residues in the IVS3 segment contribute to the difference in alpha-scorpion toxin binding affinity between cardiac and neuronal Na+ channels, The results also support the hypothesis that this region of the Na channel is important for coupling channel activation to fast inactivation.			Rogers, JC (corresponding author), UNIV WASHINGTON,DEPT PHARMACOL,SEATTLE,WA 98195, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL044948] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007270] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS015751] Funding Source: NIH RePORTER; NHLBI NIH HHS [P01 HL44948] Funding Source: Medline; NIGMS NIH HHS [T32-GM07270] Funding Source: Medline; NINDS NIH HHS [R01 NS15751] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ARMSTRONG CM, 1977, J GEN PHYSIOL, V70, P567, DOI 10.1085/jgp.70.5.567; AULD VJ, 1990, P NATL ACAD SCI USA, V87, P323, DOI 10.1073/pnas.87.1.323; AULD VJ, 1988, NEURON, V1, P449, DOI 10.1016/0896-6273(88)90176-6; BARHANIN J, 1981, J BIOL CHEM, V256, P5764; BENESKI DA, 1980, P NATL ACAD SCI-BIOL, V77, P639, DOI 10.1073/pnas.77.1.639; CATTERALL WA, 1980, ANNU REV PHARMACOL, V20, P15, DOI 10.1146/annurev.pa.20.040180.000311; CATTERALL WA, 1981, MOL PHARMACOL, V20, P533; CATTERALL WA, 1978, J BIOL CHEM, V253, P7393; CATTERALL WA, 1995, ANNU REV BIOCHEM, V64, P493, DOI 10.1146/annurev.biochem.64.1.493; CATTERALL WA, 1979, J GEN PHYSIOL, V74, P375, DOI 10.1085/jgp.74.3.375; CATTERALL WA, 1977, J BIOL CHEM, V252, P8660; DARBON H, 1983, BIOCHEM BIOPH RES CO, V115, P415, DOI 10.1016/S0006-291X(83)80160-0; ELAYEB M, 1986, EUR J BIOCHEM, V155, P289; FOGH RH, 1990, BIOCHEMISTRY-US, V28, P1826; FONTECILLACAMPS JC, 1988, P NATL ACAD SCI USA, V85, P7443, DOI 10.1073/pnas.85.20.7443; FONTECILLACAMPS JC, 1982, TOXICON, V20, P1, DOI 10.1016/0041-0101(82)90137-4; GALLAGHER MJ, 1994, J BIOL CHEM, V269, P254; GONOI T, 1984, J NEUROSCI, V4, P2836; GREENBLATT RE, 1985, FEBS LETT, V193, P125, DOI 10.1016/0014-5793(85)80136-8; GUY HR, 1986, P NATL ACAD SCI USA, V83, P508, DOI 10.1073/pnas.83.2.508; Hille B., 1992, IONIC CHANNELS EXCIT; ISOM LL, 1995, J BIOL CHEM, V270, P3306, DOI 10.1074/jbc.270.7.3306; JOVER E, 1978, BIOCHEM BIOPH RES CO, V85, P377, DOI 10.1016/S0006-291X(78)80053-9; JURMAN ME, 1994, BIOTECHNIQUES, V17, P876; KHARRAT R, 1990, TOXICON, V28, P509, DOI 10.1016/0041-0101(90)90295-I; KHARRAT R, 1989, EUR J BIOCHEM, V181, P381, DOI 10.1111/j.1432-1033.1989.tb14735.x; KHERA PK, 1995, BIOCHEMISTRY-US, V34, P8533, DOI 10.1021/bi00027a003; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LEVITT DG, 1988, BIOPHYS J, V53, P33, DOI 10.1016/S0006-3495(88)83063-7; LORET EP, 1994, J BIOL CHEM, V269, P16785; MARGOLSKEE RF, 1993, BIOTECHNIQUES, V15, P906; MEVES H, 1984, PFLUG ARCH EUR J PHY, V402, P24, DOI 10.1007/BF00584827; MONOD J, 1965, J MOL BIOL, V12, P88, DOI 10.1016/S0022-2836(65)80285-6; MOZHAYEVA GN, 1990, GEN PHYSIOL BIOPHYS, V9, P3; MOZHAYEVA GN, 1980, BIOCHIM BIOPHYS ACTA, V597, P587, DOI 10.1016/0005-2736(80)90230-8; MOZHAYEVA GN, 1981, NEUROPHYSIOLOGY, V12, P409; NAGY K, 1988, J MEMBRANE BIOL, V106, P29, DOI 10.1007/BF01871764; NEUMCKE B, 1985, BIOCHIM BIOPHYS ACTA, V814, P111, DOI 10.1016/0005-2736(85)90425-0; NODA M, 1986, NATURE, V320, P188, DOI 10.1038/320188a0; Nonner W, 1979, Adv Cytopharmacol, V3, P345; PETERSON GL, 1983, METHOD ENZYMOL, V91, P95; PTACEK LJ, 1993, ANN NEUROL, V33, P300, DOI 10.1002/ana.410330312; QU YS, 1994, P NATL ACAD SCI USA, V91, P3289, DOI 10.1073/pnas.91.8.3289; ROGART RB, 1989, P NATL ACAD SCI USA, V86, P3170; SHARKEY RG, 1984, BIOCHEMISTRY-US, V23, P6078, DOI 10.1021/bi00320a027; STRICHARTZ GR, 1986, J GEN PHYSIOL, V88, P413, DOI 10.1085/jgp.88.3.413; Stuhmer W, 1992, Curr Opin Neurobiol, V2, P243, DOI 10.1016/0959-4388(92)90110-7; TEJEDOR FJ, 1988, P NATL ACAD SCI USA, V85, P8742, DOI 10.1073/pnas.85.22.8742; THOMSEN WJ, 1989, P NATL ACAD SCI USA, V86, P10161, DOI 10.1073/pnas.86.24.10161; TORDA AE, 1988, FEBS LETT, V239, P266, DOI 10.1016/0014-5793(88)80931-1; WANG GK, 1985, J GEN PHYSIOL, V86, P739, DOI 10.1085/jgp.86.5.739; WEST JW, 1992, NEURON, V8, P59, DOI 10.1016/0896-6273(92)90108-P; WIDMER H, 1989, PROTEINS, V6, P357, DOI 10.1002/prot.340060403; YANG NB, 1995, NEURON, V15, P213, DOI 10.1016/0896-6273(95)90078-0	54	369	378	0	10	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15950	15962		10.1074/jbc.271.27.15950	http://dx.doi.org/10.1074/jbc.271.27.15950			13	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663157	hybrid			2022-12-27	WOS:A1996UW35200020
J	Knol, J; Veenhoff, L; Liang, WJ; Henderson, PJF; Leblanc, G; Poolman, B				Knol, J; Veenhoff, L; Liang, WJ; Henderson, PJF; Leblanc, G; Poolman, B			Unidirectional reconstitution into detergent-destabilized liposomes of the purified lactose transport system of Streptococcus thermophilus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN INSERTION; ESCHERICHIA-COLI; FUNCTIONAL RECONSTITUTION; SARCOPLASMIC-RETICULUM; CARRIER; SOLUBILIZATION; REQUIREMENT; MECHANISMS; BACTERIA	The lactose transport protein (LacS) of Streptococcus thermophilus was amplified to levels as high as 8 and 30% of total membrane protein in Escherichia coli and S, thermophilus, respectively, In both organisms the protein was functional and the expression levels were highest with the streptococcal lacS promoter, Also a LacS deletion mutant, lacking the carboxyl-terminal regulatory domain, could be amplified to levels >20% of membrane protein, Membranes from S, thermophilus proved to be superior in terms of efficient solubilization and ease and extent of purification of LacS; >95% of LacS was solubilized with relatively low concentrations of Triton X-100, n-octyl-beta-D-glucoside, n-dodecyl-beta-D-maltoside, or C(12)E(8). The LacS protein carrying a poly-histidine tag was purified in large quantities (similar to 5 mg/liter of culture) and with a purity >98% in a two-step process involving nickel chelate affinity and anion exchange chromatography, The membrane reconstitution of LacS was studied systematically by stepwise solubilization of preformed liposomes, prepared from E, coli phospholipid and phosphatidylcholine, and protein incorporation at the different stages of liposome solubilization. The detergents were removed by adsorption onto polystyrene beads and H+-lactose symport and lactose counterflow were measured, Highest transport activities were obtained when Triton X-100 was used throughout the solubilization/purification procedure, whereas activity was lost irreversibly with n-octyl-beta-D-glucoside. For reconstitutions mediated by n-dodecyl-beta-D-maltoside, C(12)E(8), and to a lesser extent Triton X-100, the highest transport activities were obtained when the liposomes were titrated with low amounts of detergent (onset of liposome solubilization), Importantly, under these conditions proteoliposomes were obtained in which LacS was reconstituted in an inside-out orientation, as suggested by the outside labeling of a single cysteine mutant with a membrane impermeable biotin maleimide, The results are consistent with a mechanism of reconstitution in which the hydrophilic regions of LacS prevent a random insertion of the protein into the membrane, Consistent with the in vivo lactose/galactose exchange catalyzed by the LacS protein, the maximal rate of lactose counterflow was almost 2 orders of magnitude higher than that of H+-lactose symport.	UNIV GRONINGEN, GRONINGEN BIOMOL SCI & BIOTECHNOL INST, DEPT MICROBIOL, 9751 NN HAREN, NETHERLANDS; UNIV LEEDS, DEPT BIOCHEM & MOLEC BIOL, LEEDS LS2 9JT, W YORKSHIRE, ENGLAND; CEA, DEPT BIOL CELLULAIRE & MOL, LAB J MAETZ, F-06230 VILLEFRANCHE SUR MER, FRANCE	University of Groningen; University of Leeds; CEA			Henderson, Peter JF/Q-1907-2018; Knol, Jan/A-2178-2010; Knol, Jan/AAL-6487-2020	Knol, Jan/0000-0002-2103-5961; Knol, Jan/0000-0002-2103-5961; Veenhoff, Liesbeth/0000-0002-0158-4728; Henderson, Peter/0000-0002-9187-0938				BARON C, 1975, BIOCHIM BIOPHYS ACTA, V382, P276, DOI 10.1016/0005-2736(75)90270-9; BAYER EA, 1985, ANAL BIOCHEM, V149, P529, DOI 10.1016/0003-2697(85)90609-8; CHEN CC, 1984, J BIOL CHEM, V259, P150; DRIESSEN AJM, 1988, BIOCHEMISTRY-US, V27, P865, DOI 10.1021/bi00403a005; DRIESSEN AJM, 1993, METHOD ENZYMOL, V221, P394, DOI 10.1016/0076-6879(93)21032-4; ELLIKER PR, 1956, J DAIRY SCI, V39, P1611, DOI 10.3168/jds.S0022-0302(56)94896-2; EYTAN GD, 1982, BIOCHIM BIOPHYS ACTA, V694, P185, DOI 10.1016/0304-4157(82)90024-7; FOUCAUD C, 1992, J BIOL CHEM, V267, P22087; HJELMELAND LM, 1980, P NATL ACAD SCI-BIOL, V77, P6368, DOI 10.1073/pnas.77.11.6368; HOLLOWAY PW, 1973, ANAL BIOCHEM, V53, P307; KOK J, 1984, APPL ENVIRON MICROB, V48, P726, DOI 10.1128/AEM.48.4.726-731.1984; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEVY D, 1992, BIOCHIM BIOPHYS ACTA, V1107, P283, DOI 10.1016/0005-2736(92)90415-I; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LUND S, 1989, J BIOL CHEM, V264, P4907; MALONEY PC, 1989, ARCH BIOCHEM BIOPHYS, V269, P1, DOI 10.1016/0003-9861(89)90080-5; MAYER LD, 1986, BIOCHIM BIOPHYS ACTA, V858, P161, DOI 10.1016/0005-2736(86)90302-0; MOLLET B, 1993, J BACTERIOL, V175, P4315, DOI 10.1128/JB.175.14.4315-4324.1993; NEWMAN MJ, 1981, J BIOL CHEM, V256, P1804; NEWMAN MJ, 1980, J BIOL CHEM, V255, P583; OTTO R, 1982, J BACTERIOL, V149, P733, DOI 10.1128/JB.149.2.733-738.1982; PATERNOSTRE MT, 1988, BIOCHEMISTRY-US, V27, P2668, DOI 10.1021/bi00408a006; POOLMAN B, 1992, J BIOL CHEM, V267, P9150; POOLMAN B, 1989, J BACTERIOL, V171, P244, DOI 10.1128/jb.171.1.244-253.1989; POOLMAN B, 1995, P NATL ACAD SCI USA, V92, P778, DOI 10.1073/pnas.92.3.778; POOLMAN B, 1983, EUR J BIOCHEM, V135, P41, DOI 10.1111/j.1432-1033.1983.tb07615.x; Poolman B, 1996, MOL MICROBIOL, V19, P911, DOI 10.1046/j.1365-2958.1996.397949.x; POOLMAN B, 1995, J BIOL CHEM, V270, P12995, DOI 10.1074/jbc.270.22.12995; POOLMAN B, 1990, MOL MICROBIOL, V4, P1629, DOI 10.1111/j.1365-2958.1990.tb00539.x; POOLMAN B, 1993, BIOCHIM BIOPHYS ACTA, V1183, P5, DOI 10.1016/0005-2728(93)90003-X; POURCHER T, 1995, BIOCHEMISTRY-US, V34, P4412, DOI 10.1021/bi00013a033; RICHARD P, 1990, EUR J BIOCHEM, V193, P921, DOI 10.1111/j.1432-1033.1990.tb19418.x; RIGAUD JL, 1988, BIOCHEMISTRY-US, V27, P2677, DOI 10.1021/bi00408a007; RIGAUD JL, 1995, LIPOSOMES TOOLS BASI; SAMBROOPK J, 1989, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; WITHOLT B, 1978, BIOCHIM BIOPHYS ACTA, V508, P296, DOI 10.1016/0005-2736(78)90332-2	37	105	105	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15358	15366		10.1074/jbc.271.26.15358	http://dx.doi.org/10.1074/jbc.271.26.15358			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662938	Green Published, hybrid			2022-12-27	WOS:A1996UV29900012
J	Blackburn, MR; Datta, SK; Wakamiya, M; Vartabedian, BS; Kellems, RE				Blackburn, MR; Datta, SK; Wakamiya, M; Vartabedian, BS; Kellems, RE			Metabolic and immunologic consequences of limited adenosine deaminase expression in mice	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-ADENOSYLHOMOCYSTEINE HYDROLASE; SEVERE COMBINED IMMUNODEFICIENCY; DEOXYADENOSINE METABOLISM; DEFICIENT PATIENTS; MOUSE; INACTIVATION; 2'-DEOXYADENOSINE; DISEASE; CELLS; MODEL	Adenosine deaminase (ADA; EC 3.5.4.4) deficiency in humans is an autosomal recessive genetic disorder that results in severe combined immunodeficiency disease, ADA-deficient mice generated by targeted gene disruption die perinatally, preventing postnatal analysis of ADA deficiency. We have recently rescued ADA-deficient fetuses from perinatal lethality by expression of an ADA minigene in the placentas of ADA-deficient fetuses, thus generating postnatal mice admissible to analysis of ADA deficiency, The minigene used also directed ADA expression to the forestomach postnatally, producing adult animals that lacked ADA enzymatic activity in all tissues outside the gastrointestinal tract, Mice with limited ADA expression exhibited profound disturbances in purine metabolism, including thymus-specific accumulations of deoxyadenosine and dATP, and inhibition of S-adenosylhomocysteine hydrolase in the thymus, spleen, and, to a lesser extent, the liver, Lymphopenia and mild immunodeficiency were associated with these tissue-specific metabolic disturbances, These mice represent the first genetic animal model for ADA deficiency and provide insight into the tissue-specific requirements of ADA.	BAYLOR COLL MED,VERNA & MARRS MCLEAN DEPT BIOCHEM,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT MOLEC & HUMAN GENET,HOUSTON,TX 77030; BAYLOR COLL MED,DEPT PEDIAT,HOUSTON,TX 77030	Baylor College of Medicine; Baylor College of Medicine; Baylor College of Medicine				Blackburn, Michael/0000-0002-1394-9966	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD030302] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046207] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM042436] Funding Source: NIH RePORTER; NICHD NIH HHS [HD30302] Funding Source: Medline; NIDDK NIH HHS [DK46207] Funding Source: Medline; NIGMS NIH HHS [GM42436] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ARONOW B, 1989, GENE DEV, V3, P1384, DOI 10.1101/gad.3.9.1384; BENVENISTE P, 1995, P NATL ACAD SCI USA, V92, P8373, DOI 10.1073/pnas.92.18.8373; BLACKBURN MR, 1995, J BIOL CHEM, V270, P23891, DOI 10.1074/jbc.270.41.23891; BLAESE RM, 1995, METABOLIC MOL BASIS, V2, P3895; CARSON DA, 1980, J IMMUNOL, V124, P8; CARSON DA, 1977, P NATL ACAD SCI USA, V74, P5677, DOI 10.1073/pnas.74.12.5677; CHECHIK BE, 1983, J IMMUNOL, V126, P1003; COHEN A, 1978, P NATL ACAD SCI USA, V75, P472, DOI 10.1073/pnas.75.1.472; COLEMAN MS, 1978, J BIOL CHEM, V253, P1619; DOHERTY PJ, 1991, SCAND J IMMUNOL, V33, P405, DOI 10.1111/j.1365-3083.1991.tb01788.x; GAO X, 1994, TERATOLOGY, V49, P1, DOI 10.1002/tera.1420490103; GIBLETT ER, 1972, LANCET, V2, P1067; HERSHFIELD MS, 1979, J CLIN INVEST, V63, P807, DOI 10.1172/JCI109367; HERSHFIELD MS, 1979, J BIOL CHEM, V254, P22; HERSHFIELD MS, 1981, J CLIN INVEST, V67, P696, DOI 10.1172/JCI110085; HERSHFIELD MS, 1995, METABOLIC MOL BASIS, V1, P1725; HIRSCHHORN R, 1993, PEDIATR RES, V33, pS35; HOHMAN RJ, 1985, P NATL ACAD SCI USA, V82, P4578, DOI 10.1073/pnas.82.14.4578; JOHNSTON JM, 1979, J IMMUNOL, V123, P97; KAMINSKA JE, 1980, J LAB CLIN MED, V96, P141; KIZAKI H, 1990, J BIOL CHEM, V265, P5280; KNUDSEN TB, 1991, BIOL REPROD, V44, P171, DOI 10.1095/biolreprod44.1.171; KNUDSEN TB, 1992, TERATOLOGY, V45, P91, DOI 10.1002/tera.1420450109; MIGCHIELSEN AAJ, 1995, NAT GENET, V10, P279, DOI 10.1038/ng0795-279; MORGAN G, 1987, CLIN EXP IMMUNOL, V70, P491; RATECH H, 1981, CLIN IMMUNOL IMMUNOP, V21, P119, DOI 10.1016/0090-1229(81)90200-2; RATECH H, 1985, AM J PATHOL, V119, P65; SANTISTEBAN I, 1993, J CLIN INVEST, V92, P2291, DOI 10.1172/JCI116833; STILES GL, 1992, J BIOL CHEM, V267, P6451; SURH CD, 1994, NATURE, V372, P100, DOI 10.1038/372100a0; TEDDE A, 1980, P NATL ACAD SCI-BIOL, V77, P4899, DOI 10.1073/pnas.77.8.4899; ULLMAN B, 1981, J BIOL CHEM, V256, P848; ULLMAN B, 1978, CELL, V14, P365, DOI 10.1016/0092-8674(78)90122-8; WAKAMIYA M, 1995, P NATL ACAD SCI USA, V92, P3673, DOI 10.1073/pnas.92.9.3673; WINSTON JH, 1992, J BIOL CHEM, V267, P13472; WITTE DP, 1991, J CELL BIOL, V115, P179, DOI 10.1083/jcb.115.1.179	36	47	49	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15203	15210		10.1074/jbc.271.25.15203	http://dx.doi.org/10.1074/jbc.271.25.15203			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663040	hybrid			2022-12-27	WOS:A1996UT10600082
J	Cusack, B; Groshan, K; McCormick, DJ; Pang, YP; Perry, R; Phung, CT; Souder, T; Richelson, E				Cusack, B; Groshan, K; McCormick, DJ; Pang, YP; Perry, R; Phung, CT; Souder, T; Richelson, E			Chimeric rat/human neurotensin receptors localize a region of the receptor sensitive to binding of a novel, species-specific, picomolar affinity peptide	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SINGLE AMINO-ACID; CLONE N1E-115; RAT-BRAIN; EXPRESSION; IDENTIFICATION; ANTAGONIST; SUBTYPES; DISEASE; LIGAND; DNA	Recently, we reported the development of a species-specific neurotensin analog that displays selective binding affinity at the rat and human neurotensin (NT) receptor, L-[3,2'-Nal(11)]NT(8-13) (where Nal is naphthylalanine) (NT19), We have developed another neurotensin analog, L-[3,1'-Nal(11)]NT(8-13), (NT34), that exhibits a 126-fold difference in binding affinities between the rat and human receptors, This compound differs from our previous reported species-specific ligand in the steric positioning of the naphthyl ring on the L-alanine side chain, For NT34, the observed K-d values at the rat and human neurotensin receptors were 0.046 and 5.8 nM, respectively, In stimulating phosphatidylinositol turn over, the observed EC(50) values were 2.8 nM and 130 nM in rat and human, respectively, We constructed a series of chimeric rat/human neurotensin receptor genes and ex; pressed them by transient transfection into human embryonic kidney (HEK-293) cells, Radioligand binding assays were then performed using neurotensin and NT34, Our results led us to propose a region of the neurotensin receptor that may be involved in determining species specificity, i.e. the transmembrane VI, the third extracellular loop, and transmembrane VII regions of the neurotensin receptor.	MAYO CLIN,MAYO PROT CARE FACIL,ROCHESTER,MN 55595	Mayo Clinic	Cusack, B (corresponding author), MAYO FDN MED EDUC & RES,4500 SAN PABLO RD,JACKSONVILLE,FL 32224, USA.		Richelson, Elliott/A-9407-2012; Cusack, Bernadette/D-4606-2013		NATIONAL INSTITUTE OF MENTAL HEALTH [R01MH027692] Funding Source: NIH RePORTER; NIMH NIH HHS [MH27692] Funding Source: Medline	NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		BENZING WC, 1990, BRAIN RES, V537, P298, DOI 10.1016/0006-8993(90)90372-I; BISSETTE G, 1985, ANN NEUROL, V17, P324, DOI 10.1002/ana.410170403; BISSETTE G, 1976, NATURE, V262, P607, DOI 10.1038/262607a0; CAIN ST, 1992, REGUL PEPTIDES, V39, P55, DOI 10.1016/0167-0115(92)90008-I; CARRAWAY R, 1973, J BIOL CHEM, V248, P6854; CLINESCHMIDT BV, 1977, EUR J PHARMACOL, V45, P395; CUSACK B, 1991, EUR J PHARM-MOLEC PH, V206, P339, DOI 10.1016/0922-4106(91)90119-3; CUSACK B, 1993, MOL PHARMACOL, V44, P1036; CUSACK B, 1993, J RECEPTOR RES, V13, P123, DOI 10.3109/10799899309073650; CUSACK B, 1995, J BIOL CHEM, V270, P18359, DOI 10.1074/jbc.270.31.18359; DELEAN A, 1982, MOL PHARMACOL, V21, P5; FLEMING WW, 1972, J PHARMACOL-PARIS, V181, P339; GILBERT JA, 1984, EUR J PHARMACOL, V99, P245, DOI 10.1016/0014-2999(84)90248-6; GOEDERT M, 1984, BRAIN RES, V323, P193, DOI 10.1016/0006-8993(84)90288-9; GRAHAM FL, 1973, VIROLOGY, V52, P456, DOI 10.1016/0042-6822(73)90341-3; HENDERSON R, 1975, NATURE, V257, P28, DOI 10.1038/257028a0; JOLICOEUR FB, 1981, PEPTIDES, V2, P171, DOI 10.1016/S0196-9781(81)80031-9; KAO HT, 1992, FEBS LETT, V307, P324, DOI 10.1016/0014-5793(92)80705-L; KITABGI P, 1977, P NATL ACAD SCI USA, V74, P1846, DOI 10.1073/pnas.74.5.1846; KOBILKA BK, 1988, SCIENCE, V240, P1310, DOI 10.1126/science.2836950; LINK R, 1992, MOL PHARMACOL, V42, P16; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MORBECK DE, 1993, METHODS COMPANION ME, V6, P191; MUNSON PJ, 1980, ANAL BIOCHEM, V107, P220, DOI 10.1016/0003-2697(80)90515-1; OKSENBERG D, 1992, NATURE, V360, P161, DOI 10.1038/360161a0; OSBAHR AJ, 1979, EUR J PHARMACOL, V54, P299, DOI 10.1016/0014-2999(79)90090-6; Pang YP, 1996, J BIOL CHEM, V271, P15060, DOI 10.1074/jbc.271.25.15060; PFENNING MA, 1990, METHODS NEUROTRANSMI, P147; SHI WX, 1992, J NEUROSCI, V12, P2433; STRADER CD, 1989, FASEB J, V3, P1825, DOI 10.1096/fasebj.3.7.2541037; TANAKA K, 1990, NEURON, V4, P847, DOI 10.1016/0896-6273(90)90137-5; TUCKER AL, 1994, J BIOL CHEM, V269, P27900; VITA N, 1993, FEBS LETT, V317, P139, DOI 10.1016/0014-5793(93)81509-X; WATSON M, 1993, MAYO CLIN PROC, V68, P1043, DOI 10.1016/S0025-6196(12)60896-9; WATSON MA, 1992, J NEUROCHEM, V59, P1967, DOI 10.1111/j.1471-4159.1992.tb11035.x; WIDERLOV E, 1982, AM J PSYCHIAT, V139, P1122	36	20	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15054	15059		10.1074/jbc.271.25.15054	http://dx.doi.org/10.1074/jbc.271.25.15054			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662846	hybrid			2022-12-27	WOS:A1996UT10600062
J	Klamo, EM; Drew, ME; Landfear, SM; Kavanaugh, MP				Klamo, EM; Drew, ME; Landfear, SM; Kavanaugh, MP			Kinetics and stoichiometry of a proton/myo-inositol cotransporter	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AMINO-ACID TRANSPORTER; ELECTROGENIC PROPERTIES; GLUCOSE; CHANNELS; CARRIER; MODELS	Voltage clamp recording was used to measure steady-state and presteady state currents mediated by a myoinositol transporter cloned from Leishmania donovani and expressed in Xenopus oocytes, Application of myoinositol resulted in inward currents, which did not require external sodium and which were increased by increasing the extracellular proton concentration and by membrane hyperpolarization, Alkalinization of the extracellular space occurred concomitantly with myo-inositol influx. Correlation of membrane currents with radiolabeled myo-inositol flux revealed that one positive charge is translocated with each molecule of myo-inositol, consistent with cotransport of one proton, The transport concentration dependence on both species suggested ordered binding of a proton followed by a molecule of myo-inositol, In the absence of myo-inositol, a voltage-dependent capacitance was observed that correlated with the transporter expression level, This charge movement obeyed a Boltzmann function, which was used to estimate a turnover of 0.70 +/- 0.06 s(-1) at -60 mV. The pH and voltage dependence of the charge movements were simulated with a model involving alternating access of internal and external protons to sites within an occluded pore.	OREGON HLTH SCI UNIV,VOLLUM INST,PORTLAND,OR 97201; OREGON HLTH SCI UNIV,DEPT MOLEC MICROBIOL & IMMUNOL,PORTLAND,OR 97201	Oregon Health & Science University; Oregon Health & Science University					NIAID NIH HHS [AI25920, AI01162] Funding Source: Medline; NIGMS NIH HHS [GM400879] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025920] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BOORER KJ, 1994, J BIOL CHEM, V269, P20417; CHRISTENSEN HN, 1969, P NATL ACAD SCI USA, V63, P948, DOI 10.1073/pnas.63.3.948; CRANE RK, 1977, REV PHYSIOL BIOCH P, V78, P99, DOI 10.1007/BFb0027722; DREW ME, 1995, MOL CELL BIOL, V15, P5508; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; HIRAYAMA BA, 1994, J BIOL CHEM, V269, P21407; HOSHI T, 1986, BIOCHIM BIOPHYS ACTA, V861, P483, DOI 10.1016/0005-2736(86)90458-X; JAUCH P, 1986, J MEMBRANE BIOL, V94, P117, DOI 10.1007/BF01871192; KAVANAUGH MP, 1993, BIOCHEMISTRY-US, V32, P5781, DOI 10.1021/bi00073a009; LAUGER P, 1980, J MEMBRANE BIOL, V57, P163, DOI 10.1007/BF01869585; Lauger P., 1991, ELECTROGENIC ION PUM, P61; MAGER S, 1993, NEURON, V10, P177, DOI 10.1016/0896-6273(93)90309-F; MARGER MD, 1993, TRENDS BIOCHEM SCI, V18, P13, DOI 10.1016/0968-0004(93)90081-W; NIIYA S, 1982, J BIOL CHEM, V257, P8902; PARENT L, 1992, J MEMBRANE BIOL, V125, P63; SAUER N, 1990, EMBO J, V9, P3045, DOI 10.1002/j.1460-2075.1990.tb07500.x; STEIN WD, 1990, CHANNELS CARRIERS PU, P173; WADICHE JI, 1995, NEURON, V14, P1019, DOI 10.1016/0896-6273(95)90340-2; WANG H, 1991, NATURE, V352, P729, DOI 10.1038/352729a0; WOODHULL AM, 1973, J GEN PHYSIOL, V61, P687, DOI 10.1085/jgp.61.6.687	20	36	37	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14937	14943		10.1074/jbc.271.25.14937	http://dx.doi.org/10.1074/jbc.271.25.14937			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663013	hybrid			2022-12-27	WOS:A1996UT10600047
J	Kole, HK; Garant, MJ; Kole, S; Bernier, M				Kole, HK; Garant, MJ; Kole, S; Bernier, M			A peptide-based protein-tyrosine phosphatase inhibitor specifically enhances insulin receptor function in intact cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							EPIDERMAL-GROWTH-FACTOR; PHOSPHOTYROSINE PHOSPHATASE; FATTY-ACIDS; PHOSPHATIDYLINOSITOL 3-KINASE; MULTISITE PHOSPHORYLATION; CATALYTIC FRAGMENT; SKELETAL-MUSCLE; RAT ADIPOCYTES; KINASE; ACTIVATION	3S-peptide-I is a synthetic tris-sulfotyrosyl dodecapeptide corresponding to the major site of insulin receptor autophosphorylation that potently inhibits dephosphorylation of the insulin receptor in a cell-free system and in digitonin-permeabilized Chinese hamster ovary (CHO) cells overexpressing the human insulin receptors (CHO/HIRc cells) (Liotta, A. S., Kole, H. K., Fales, H. M., Roth, J., and Bernier, M. (1994) J. Biol. Chem. 269, 22996-23001), In the present study, we found that 3S-peptide-I was not capable of inhibiting dephosphorylation of the epidermal growth factor (EGF) receptors in digitonin-permeabilized CHO cells that overexpress human EGF receptors (CHO/EGF-R cells), Moreover, the addition of a N-stearyl derivative of 3S-peptide-I to intact CHO/HIRc cells caused a concentration-dependent increase in insulin-stimulated phosphorylation of the insulin receptor, with a maximum effect (similar to 2.7-fold) at 50 mu M. In contrast, ligand-stimulated EGF receptor phosphorylation in CHO/EGF-R cells was not affected by the presence of stearyl 3S-peptide-I, Furthermore, treatment of CHO/HIRc cells with this N-stearyl peptide led to a significant enhancement of the insulin induced association of phosphatidylinositol (PI) 3-kinase activity with insulin receptor substrate 1 and the activation of mitogen-activated protein kinase, However, stearyl 3S-peptide-I had no effect on the EGF stimulated activation of PI-3-kinase and mitogen-activated protein kinase in CHO/EGF-R cells, These data indicate that this tris-sulfotyrosyl dodecapeptide selectively enhances insulin signal transduction by specifically inhibiting dephosphorylation of the insulin receptor in intact cells.			Kole, HK (corresponding author), NIA,DIABET SECT,LAB CLIN PHYSIOL,GERONTOL RES CTR,NIH,4940 EASTERN AVE,BALTIMORE,MD 21224, USA.		Bernier, Michel/Y-7139-2019; Bernier, Michel/AAO-3983-2021	Bernier, Michel/0000-0002-5948-368X				AHMAD F, 1995, AM J PHYSIOL-ENDOC M, V268, pE932, DOI 10.1152/ajpendo.1995.268.5.E932; AHMAD F, 1995, J CLIN INVEST, V95, P2806, DOI 10.1172/JCI117985; AHN NG, 1991, J BIOL CHEM, V266, P4220; BENNETT PA, 1993, J CELL SCI, V106, P891; BERNIER M, 1994, BIOCHEMISTRY-US, V33, P4343, DOI 10.1021/bi00180a031; BRAUTIGAN DL, 1991, P NATL ACAD SCI USA, V88, P6696, DOI 10.1073/pnas.88.15.6696; BURKE TR, 1994, BIOCHEM BIOPH RES CO, V204, P129, DOI 10.1006/bbrc.1994.2435; CASABIELL X, 1991, BIOCHEM J, V278, P679, DOI 10.1042/bj2780679; CAYLA X, 1990, BIOCHEMISTRY-US, V29, P658, DOI 10.1021/bi00455a010; CHATERJEEE J, 1992, PEPTIDES CHEM BIOL, P553; CHEATHAM B, 1995, ENDOCR REV, V16, P117, DOI 10.1210/er.16.2.117; CHO HJ, 1993, PROTEIN SCI, V2, P977, DOI 10.1002/pro.5560020611; CHO HJ, 1991, BIOCHEMISTRY-US, V30, P6210, DOI 10.1021/bi00239a019; CUTHBERT JA, 1986, J BIOL CHEM, V261, P3620; DAFNIS E, 1994, NEPHRON, V67, P133, DOI 10.1159/000187913; FLINT AJ, 1993, EMBO J, V12, P1937, DOI 10.1002/j.1460-2075.1993.tb05843.x; FRANGIONI JV, 1992, CELL, V68, P545, DOI 10.1016/0092-8674(92)90190-N; GUTKNECHT J, 1988, J MEMBRANE BIOL, V106, P83, DOI 10.1007/BF01871769; HADARI YR, 1993, MOL CELL ENDOCRINOL, V97, P9, DOI 10.1016/0303-7207(93)90206-Y; HASHIMOTO N, 1992, J BIOL CHEM, V267, P13811; INGEBRITSEN TS, 1989, J BIOL CHEM, V264, P7751; KASUGA M, 1982, SCIENCE, V215, P185, DOI 10.1126/science.7031900; KIDO Y, 1995, BIOCHEM BIOPH RES CO, V209, P131, DOI 10.1006/bbrc.1995.1480; KING MJ, 1990, BIOCHEM J, V266, P251, DOI 10.1042/bj2660251; KING MJ, 1991, BIOCHEM J, V275, P413, DOI 10.1042/bj2750413; KLAUSNER RD, 1980, J BIOL CHEM, V255, P1286; KOLE HK, 1995, BIOCHEM BIOPH RES CO, V209, P817, DOI 10.1006/bbrc.1995.1573; KOLE HK, 1995, BIOCHEM J, V311, P1025, DOI 10.1042/bj3111025; KORETZKY GA, 1991, P NATL ACAD SCI USA, V88, P2037, DOI 10.1073/pnas.88.6.2037; KULAS DT, 1995, J BIOL CHEM, V270, P2435, DOI 10.1074/jbc.270.6.2435; KUSARI J, 1994, J CLIN INVEST, V93, P1156, DOI 10.1172/JCI117068; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE JP, 1992, PROTEIN SCI, V1, P1353, DOI 10.1002/pro.5560011015; LIOTTA AS, 1994, J BIOL CHEM, V269, P22996; MCCALLUM CD, 1995, BIOCHEMISTRY-US, V34, P1815, DOI 10.1021/bi00006a001; MCGUIRE MC, 1991, DIABETES, V40, P939, DOI 10.2337/diabetes.40.7.939; MEYEROVITCH J, 1989, J CLIN INVEST, V84, P976, DOI 10.1172/JCI114261; MEYEROVITCH J, 1987, J BIOL CHEM, V262, P6658; MILARSKI KL, 1994, J BIOL CHEM, V269, P21239; MOONEY RA, 1989, ENDOCRINOLOGY, V124, P422, DOI 10.1210/endo-124-1-422; PERKINS LA, 1992, CELL, V70, P225, DOI 10.1016/0092-8674(92)90098-W; PILCH PF, 1980, P NATL ACAD SCI-BIOL, V77, P915, DOI 10.1073/pnas.77.2.915; RAFFIONI S, 1992, P NATL ACAD SCI USA, V89, P9121, DOI 10.1073/pnas.89.19.9121; RAMACHANDRAN C, 1992, BIOCHEMISTRY-US, V31, P4232, DOI 10.1021/bi00132a012; RAY LB, 1987, P NATL ACAD SCI USA, V84, P1502, DOI 10.1073/pnas.84.6.1502; RUDERMAN NB, 1990, P NATL ACAD SCI USA, V87, P1411, DOI 10.1073/pnas.87.4.1411; SHISHEVA A, 1994, ENDOCRINOLOGY, V134, P507, DOI 10.1210/en.134.1.507; SHISHEVA A, 1993, J BIOL CHEM, V268, P6463; SPARKS JW, 1985, J BIOL CHEM, V260, P2042; STROUT HV, 1989, ENDOCRINOLOGY, V124, P1918, DOI 10.1210/endo-124-4-1918; SUN XJ, 1995, NATURE, V377, P173, DOI 10.1038/377173a0; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SWARUP G, 1982, BIOCHEM BIOPH RES CO, V107, P1104, DOI 10.1016/0006-291X(82)90635-0; TAPPIA PS, 1993, BIOCHEM J, V292, P1; TOWNLEY R, 1993, BIOCHEMISTRY-US, V32, P13414, DOI 10.1021/bi00212a006; ULLRICH A, 1984, NATURE, V309, P418, DOI 10.1038/309418a0; ULLRICH A, 1985, NATURE, V313, P756, DOI 10.1038/313756a0; VOGEL W, 1993, SCIENCE, V259, P1611, DOI 10.1126/science.7681217; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; ZHANG ZY, 1993, P NATL ACAD SCI USA, V90, P4446, DOI 10.1073/pnas.90.10.4446; ZHANG ZY, 1994, BIOCHEMISTRY-US, V33, P2285, DOI 10.1021/bi00174a040	63	34	39	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14302	14307		10.1074/jbc.271.24.14302	http://dx.doi.org/10.1074/jbc.271.24.14302			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662948				2022-12-27	WOS:A1996UQ66000057
J	Schultz, DE; Hardin, CC; Lemon, SM				Schultz, DE; Hardin, CC; Lemon, SM			Specific interaction of glyceraldehyde 3-phosphate dehydrogenase with the 5'-nontranslated RNA of hepatitis A virus	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COMPLETE NUCLEOTIDE-SEQUENCE; 5' NONTRANSLATED REGION; INTERNAL TRANSLATION INITIATION; WILD-TYPE VIRUS; A VIRUS; POLIOVIRUS RNA; CELL-CULTURE; PROTEIN; INVITRO; MUTATIONS	Initiation of translation of hepatitis A virus (HAV) RNA occurs by internal entry and is likely to involve the interaction of trans-acting cellular protein factors with cis-acting structural elements of an internal ribosomal entry segment (IRES) within the 5'-nontranslated RNA. To characterize interactions between African green monkey kidney (BS-C-1) cell proteins and the predicted stem-loop IIIa (nucleotides 155-235) located at the 5' border of the HAV IRES, we utilized an electrophoresis mobility shift assay (EMSA) to identify a 39-kDa RNA-binding protein (p39). Amino-terminal amino acid sequencing of highly purified p39 revealed absolute identity with human glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The identity of p39 as simian GAPDH was further confirmed by antigenic and biochemical similarities between p39 and human GAPDH. Analysis of the RNA binding properties of simian GAPDH revealed that this cellular protein interacts with two additional sites in the HAV 5'-nontranslated RNA, one located between nucleotides 1-148 and the other between nucleotides 597-746. Competitive EMSAs also demonstrated that GAPDH and human polypyrimidine tract-binding protein, a putative picornavirus translation initiation factor, compete with each other for binding to stem-loop IIIa, suggesting that the relative cytoplasmic abundance of GAPDH and polypyrimidine tract-binding protein in individual cell-types may be an important determinant of viral translation activity. Human GAPDH was found to destabilize the folded structure of the stem-loop IIIa RNA based upon observed decreases in the circular dichroism spectra of this RNA following binding of the protein. This RNA helix-destabilizing activity of GAPDH could directly influence IRES-dependent translation and/or replication of picornavirus RNA.	UNIV N CAROLINA,DEPT MED,CHAPEL HILL,NC 27599; UNIV N CAROLINA,DEPT MICROBIOL & IMMUNOL,CHAPEL HILL,NC 27599; N CAROLINA STATE UNIV,DEPT BIOCHEM,RALEIGH,NC 27695	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; North Carolina State University					NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007151, R01AI032599] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM047431] Funding Source: NIH RePORTER; NIAID NIH HHS [R01-AI32599, T32-AI07151] Funding Source: Medline; NIGMS NIH HHS [GM47431] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ANDINO R, 1993, EMBO J, V12, P3587, DOI 10.1002/j.1460-2075.1993.tb06032.x; BORMAN A, 1993, J GEN VIROL, V74, P1775, DOI 10.1099/0022-1317-74-9-1775; BOROVJAGIN A, 1994, FEBS LETT, V351, P299, DOI 10.1016/0014-5793(94)00848-5; BROWN BA, 1979, VIROLOGY, V97, P396, DOI 10.1016/0042-6822(79)90350-7; BROWN EA, 1991, J VIROL, V65, P5828, DOI 10.1128/JVI.65.11.5828-5838.1991; BROWN EA, 1994, J VIROL, V68, P1066, DOI 10.1128/JVI.68.2.1066-1074.1994; CHANG KH, 1993, J VIROL, V67, P6716, DOI 10.1128/JVI.67.11.6716-6725.1993; CHANG KH, 1994, VIRAL HEPATITIS LIVE, P132; COHEN JI, 1987, P NATL ACAD SCI USA, V84, P2497, DOI 10.1073/pnas.84.8.2497; COHEN JI, 1987, J VIROL, V61, P50, DOI 10.1128/JVI.61.1.50-59.1987; CONSTANTINIDES SM, 1969, J BIOL CHEM, V244, P5695; DAY SP, 1992, J VIROL, V66, P6533, DOI 10.1128/JVI.66.11.6533-6540.1992; DELANGEL RM, 1989, P NATL ACAD SCI USA, V86, P8299; EMERSON SU, 1993, VIROLOGY, V194, P475, DOI 10.1006/viro.1993.1286; EMERSON SU, 1992, J VIROL, V66, P650, DOI 10.1128/JVI.66.2.650-654.1992; GARCIABLANCO MA, 1989, GENE DEV, V3, P1874, DOI 10.1101/gad.3.12a.1874; GLASS MJ, 1993, VIROLOGY, V193, P1047, DOI 10.1006/viro.1993.1225; HARDIN CC, 1993, BIOCHEMISTRY-US, V32, P5870, DOI 10.1021/bi00073a021; HARRINGT.WF, 1965, J MOL BIOL, V13, P885, DOI 10.1016/S0022-2836(65)80152-8; HARRIS JI, 1965, J MOL BIOL, V13, P876, DOI 10.1016/S0022-2836(65)80151-6; HARRIS KS, 1994, J BIOL CHEM, V269, P27004; HELLEN CUT, 1994, J VIROL, V68, P941, DOI 10.1128/JVI.68.2.941-950.1994; HELLEN CUT, 1993, P NATL ACAD SCI USA, V90, P7642, DOI 10.1073/pnas.90.16.7642; HOAGLAND VD, 1969, BIOCHEMISTRY-US, V8, P594, DOI 10.1021/bi00830a020; HOUSERSCOTT F, 1994, J VIROL, V68, P2194, DOI 10.1128/JVI.68.4.2194-2205.1994; HUITOREL P, 1985, EUR J BIOCHEM, V150, P265, DOI 10.1111/j.1432-1033.1985.tb09016.x; JACKSON RJ, 1994, MOL BIOL REP, V19, P147, DOI 10.1007/BF00986957; JANSEN RW, 1988, VIROLOGY, V163, P299, DOI 10.1016/0042-6822(88)90270-X; JENSEN DE, 1976, J BIOL CHEM, V251, P7215; KARPEL RL, 1981, BIOCHIM BIOPHYS ACTA, V654, P256, DOI 10.1016/0005-2787(81)90180-5; KAWAMOTO RM, 1986, BIOCHEMISTRY-US, V25, P656, DOI 10.1021/bi00351a022; LEMON SM, 1993, SEMIN VIROL, V4, P285, DOI 10.1006/smvy.1993.1025; LIN T, 1986, J BIOL CHEM, V261, P4594; LUO Y, 1993, J BIOL CHEM, V268, P21253; LUZ N, 1991, J VIROL, V65, P6486, DOI 10.1128/JVI.65.12.6486-6494.1991; MEEROVITCH K, 1993, J VIROL, V67, P3798, DOI 10.1128/JVI.67.7.3798-3807.1993; MEEROVITCH K, 1989, GENE DEV, V3, P1026, DOI 10.1101/gad.3.7.1026; MEYERSIEGLER K, 1991, P NATL ACAD SCI USA, V88, P8460, DOI 10.1073/pnas.88.19.8460; MINTON AP, 1981, BIOCHEMISTRY-US, V20, P4821, DOI 10.1021/bi00520a003; NAGY E, 1995, J BIOL CHEM, V270, P2755, DOI 10.1074/jbc.270.6.2755; NAJARIAN R, 1985, P NATL ACAD SCI USA, V82, P2627, DOI 10.1073/pnas.82.9.2627; PATTON JG, 1991, GENE DEV, V5, P1237, DOI 10.1101/gad.5.7.1237; PERUCHO M, 1980, BIOCHIM BIOPHYS ACTA, V606, P181, DOI 10.1016/0005-2787(80)90028-3; PING LH, 1992, J VIROL, V66, P2208, DOI 10.1128/JVI.66.4.2208-2216.1992; Schultz DE, 1996, J VIROL, V70, P1041, DOI 10.1128/JVI.70.2.1041-1049.1996; SHAFFER DR, 1995, J VIROL, V69, P6498, DOI 10.1128/JVI.69.10.6498-6506.1995; SHAFFER DR, 1994, J VIROL, V68, P5568, DOI 10.1128/JVI.68.9.5568-5578.1994; SINGH R, 1995, SCIENCE, V270, P2755; TSUKIYAMAKOHARA K, 1992, J VIROL, V66, P1476, DOI 10.1128/JVI.66.3.1476-1483.1992; WHETTER LE, 1994, J VIROL, V68, P5253, DOI 10.1128/JVI.68.8.5253-5263.1994	51	115	118	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14134	14142		10.1074/jbc.271.24.14134	http://dx.doi.org/10.1074/jbc.271.24.14134			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662893	Green Published			2022-12-27	WOS:A1996UQ66000032
J	OwensGrillo, JK; Czar, MJ; Hutchison, KA; Hoffman, K; Perdew, GH; Pratt, WB				OwensGrillo, JK; Czar, MJ; Hutchison, KA; Hoffman, K; Perdew, GH; Pratt, WB			A model of protein targeting mediated by immunophilins and other proteins that bind to hsp90 via tetratricopeptide repeat domains	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEIN; ROUS-SARCOMA VIRUS; STEROID-RECEPTOR COMPLEXES; MITOCHONDRIAL OUTER-MEMBRANE; CELL-FREE SYSTEM; GLUCOCORTICOID RECEPTOR; PROGESTERONE-RECEPTOR; NUCLEAR-LOCALIZATION; TRANSFORMING PROTEIN; YEAST MITOCHONDRIA	We have shown recently that the CyP-40 and FKBP52/hsp56 bind to a hsp90 and that they exist in separate heterocomplexes with the glucocorticoid receptor (GR). FKBP52/hsp56 binds to hsp90 via its tetratricopeptide repeat (TPR) domains, it is not required for GR . hsp90 heterocomplex assembly, and it is thought to play a role in targeted movement of the GR In this work we examine the hsp90 binding of four proteins (FKBP52/hsp56, CyP-40, p50, Mas70p) thought to be involved in targeted protein trafficking. FKBP52/hsp56 and CyP-40 (each with three TPR), localize to the nucleus and nucleoli, respectively, and form relatively weak complexes with hsp90 that are competed by a CyP-40 fragment containing its three TPRs. The p50 component of the Src . hsp90 and Raf . hsp90 heterocomplexes localizes to cytoskeletal fibers extending from the perinuclear region to the plasma membrane and forming a rim under the plasma membrane of endothelial cells, p50, Mas70p (seven TPRs), which is a receptor for mitochondrial import, and the p60 (six to eight TPRs) component off the steroid receptor . hsp90 heterocomplex assembly system bind very tightly to hsp90 in a manner that is not competed by the CyP-40 fragment, However, bacterially expressed p60 blocks the binding of p50, Mas70p, FKBP52/hsp56, and CyP-40 to purified hsp90. The data are consistent with binding of all of these proteins to a site on hsp90 that is a general TPR domain acceptor. Our localization and binding data are used to develop a model in which proteins that tare chaperoned by hsp90 move as dynamic complexes to their cellular sites of action, with the TPR-containing protein participating in targeting the movement of the complexes.	UNIV MICHIGAN,SCH MED,DEPT PHARMACOL,ANN ARBOR,MI 48109; YALE UNIV,SCH MED,DEPT PHARMACOL,NEW HAVEN,CT 06510; PENN STATE UNIV,DEPT VET SCI,UNIVERSITY PK,PA 16802	University of Michigan System; University of Michigan; Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); Pennsylvania State University; Pennsylvania State University - University Park					NATIONAL CANCER INSTITUTE [R01CA028010] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES004869, R29ES004869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007767] Funding Source: NIH RePORTER; NCI NIH HHS [CA28010] Funding Source: Medline; NIEHS NIH HHS [ES04869] Funding Source: Medline; NIGMS NIH HHS [GM07767] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BOGUSKI MS, 1990, NATURE, V346, P114, DOI 10.1038/346114a0; BRUGGE J, 1983, MOL CELL BIOL, V3, P9, DOI 10.1128/MCB.3.1.9; BRUGGE JS, 1981, CELL, V25, P363, DOI 10.1016/0092-8674(81)90055-6; BRUGGE JS, 1986, CURR TOP MICROBIOL, V123, P1; CALLEBAUT I, 1992, P NATL ACAD SCI USA, V89, P6270, DOI 10.1073/pnas.89.14.6270; COURTNEIDGE SA, 1982, P NATL ACAD SCI-BIOL, V79, P7117, DOI 10.1073/pnas.79.23.7117; CZAR MJ, 1994, J BIOL CHEM, V269, P11155; CZAR MJ, 1995, MOL ENDOCRINOL, V9, P1549, DOI 10.1210/me.9.11.1549; CZAR MJ, 1994, MOL ENDOCRINOL, V8, P1731, DOI 10.1210/me.8.12.1731; DALMAN FC, 1989, J BIOL CHEM, V264, P19815; DeFranco DB, 1995, VITAM HORM, V51, P315, DOI 10.1016/S0083-6729(08)61043-2; HASE T, 1983, EMBO J, V2, P2169, DOI 10.1002/j.1460-2075.1983.tb01718.x; HASE T, 1984, EMBO J, V3, P3157, DOI 10.1002/j.1460-2075.1984.tb02274.x; HINES V, 1993, J BIOL CHEM, V268, P449; HINES V, 1990, EMBO J, V9, P3191, DOI 10.1002/j.1460-2075.1990.tb07517.x; HOFFMANN K, 1995, BIOCHEM J, V307, P5, DOI 10.1042/bj3070005; HONORE B, 1992, J BIOL CHEM, V267, P8485; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13952; HUTCHISON KA, 1995, J BIOL CHEM, V270, P18841, DOI 10.1074/jbc.270.32.18841; HUTCHISON KA, 1994, J BIOL CHEM, V269, P27894; HUTCHISON KA, 1992, J BIOL CHEM, V267, P2902; HUTCHISON KA, 1994, J BIOL CHEM, V269, P5043; JAKOB U, 1994, TRENDS BIOCHEM SCI, V19, P205, DOI 10.1016/0968-0004(94)90023-X; JOHNSON JL, 1995, MOL ENDOCRINOL, V9, P670, DOI 10.1210/me.9.6.670; JOHNSON JL, 1994, MOL CELL BIOL, V14, P1956, DOI 10.1128/MCB.14.3.1956; JOHNSON JL, 1994, J BIOL CHEM, V269, P24989; KANG KI, 1994, P NATL ACAD SCI USA, V91, P340, DOI 10.1073/pnas.91.1.340; KING WJ, 1984, NATURE, V307, P745, DOI 10.1038/307745a0; LEBEAU MC, 1992, J BIOL CHEM, V267, P4281; MILAD M, 1995, MOL ENDOCRINOL, V9, P838, DOI 10.1210/me.9.7.838; OPPERMANN H, 1981, P NATL ACAD SCI-BIOL, V78, P1067, DOI 10.1073/pnas.78.2.1067; OWENSGRILLO JK, 1995, J BIOL CHEM, V270, P20479, DOI 10.1074/jbc.270.35.20479; PEATTIE DA, 1992, P NATL ACAD SCI USA, V89, P10974, DOI 10.1073/pnas.89.22.10974; PERDEW GH, 1991, J BIOL CHEM, V266, P6708; PERROTAPPLANAT M, 1985, ENDOCRINOLOGY, V116, P1473, DOI 10.1210/endo-116-4-1473; PERROTAPPLANAT M, 1995, J CELL SCI, V108, P2037; PICARD D, 1990, CELL REGUL, V1, P291, DOI 10.1091/mbc.1.3.291; PICARD D, 1987, EMBO J, V6, P3333, DOI 10.1002/j.1460-2075.1987.tb02654.x; PRATT WB, 1992, BIOESSAYS, V14, P841, DOI 10.1002/bies.950141209; PRATT WB, 1993, J STEROID BIOCHEM, V46, P269, DOI 10.1016/0960-0760(93)90216-J; PRATT WB, 1993, J BIOL CHEM, V268, P21455; PRATT WB, 1996, IN PRESS STRESS INDU; RADANYI C, 1994, P NATL ACAD SCI USA, V91, P11197, DOI 10.1073/pnas.91.23.11197; Ratajczak T, 1996, J BIOL CHEM, V271, P2961, DOI 10.1074/jbc.271.6.2961; RATAJCZAK T, 1993, J BIOL CHEM, V268, P13187; REDMOND T, 1989, EUR J CELL BIOL, V50, P66; REHBERGER P, 1992, P NATL ACAD SCI USA, V89, P8001, DOI 10.1073/pnas.89.17.8001; RENOIR JM, 1990, J BIOL CHEM, V265, P10740; RENOIR JM, 1995, P NATL ACAD SCI USA, V92, P4977, DOI 10.1073/pnas.92.11.4977; REXIN M, 1991, J BIOL CHEM, V266, P24601; REXIN M, 1992, J BIOL CHEM, V267, P9619; RIEZMAN H, 1983, EMBO J, V2, P1113, DOI 10.1002/j.1460-2075.1983.tb01554.x; RIEZMAN H, 1983, EMBO J, V2, P1105, DOI 10.1002/j.1460-2075.1983.tb01553.x; RUFF VA, 1992, J BIOL CHEM, V267, P21285; SANCHEZ ER, 1990, BIOCHEMISTRY-US, V29, P5145, DOI 10.1021/bi00473a021; SCHMITT J, 1993, GENE, V132, P267, DOI 10.1016/0378-1119(93)90206-I; SEGNITZ B, 1995, P NATL ACAD SCI USA, V92, P2179, DOI 10.1073/pnas.92.6.2179; SHAKNOVICH R, 1992, MOL CELL BIOL, V12, P5059, DOI 10.1128/MCB.12.11.5059; SIKORSKI RS, 1990, CELL, V60, P307, DOI 10.1016/0092-8674(90)90745-Z; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1993, MOL ENDOCRINOL, V7, P1418, DOI 10.1210/me.7.11.1418; SMITH DF, 1993, MOL ENDOCRINOL, V7, P4, DOI 10.1210/me.7.1.4; SMITH DF, 1993, MOL CELL BIOL, V13, P869, DOI 10.1128/MCB.13.2.869; STANCATO LF, 1993, J BIOL CHEM, V268, P21711; SULLIVAN WP, 1993, J BIOL CHEM, V268, P20373; TAI PKK, 1986, BIOCHEMISTRY-US, V25, P5269, DOI 10.1021/bi00366a043; TAI PKK, 1992, SCIENCE, V256, P1315, DOI 10.1126/science.1376003; VANDERLEIJ I, 1993, P NATL ACAD SCI USA, V90, P11782, DOI 10.1073/pnas.90.24.11782; WELSH MJ, 1983, METHOD ENZYMOL, V102, P110; WHITELAW ML, 1991, J BIOL CHEM, V266, P16436; YEM AW, 1992, J BIOL CHEM, V267, P2868	71	160	164	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13468	13475		10.1074/jbc.271.23.13468	http://dx.doi.org/10.1074/jbc.271.23.13468			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662874				2022-12-27	WOS:A1996UP38500027
J	Skiba, PJ; Zha, XH; Maxfield, FR; Schissel, SL; Tabas, I				Skiba, PJ; Zha, XH; Maxfield, FR; Schissel, SL; Tabas, I			The distal pathway of lipoprotein-induced cholesterol esterification, but not sphingomyelinase-induced cholesterol esterification, is energy-dependent	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; MOUSE PERITONEAL-MACROPHAGES; ACYL COENZYME-A; COATED PIT FORMATION; HAMSTER OVARY CELLS; PLASMA-MEMBRANE SPHINGOMYELIN; RECEPTOR-MEDIATED ENDOCYTOSIS; INTRACELLULAR-TRANSPORT; CULTURED FIBROBLASTS; POTASSIUM-DEPLETION	The stimulation of the intracellular cholesterol esterification pathway by atherogenic lipoproteins in macrophages is a key step in the development of atheroma foam cells. The esterification pathway can also be stimulated by hydrolysis of cell-surface sphingomyelin by the enzyme sphingomyelinase (SMase). In both cases, intracellular cholesterol transport to the cholesterol esterifying enzyme, acyl-CoA:cholesterol O-acyltransferase (ACAT), is thought to be critical, although the mechanism of cholesterol transport is not known. In this report, we explore two fundamental properties of the cholesterol esterification pathway, namely its dependence on energy and the effect of other treatments that block membrane vesicle trafficking. After the atherogenic lipoprotein, beta-very low density lipoprotein (beta-VLDL), was internalized by macrophages and hydrolyzed in lysosomes, the cells were depleted of energy by treatment with sodium azide and 2-deoxyglucose or by permeabilization. Under these conditions, which allowed equal beta-VLDL-cholesteryl ester hydrolysis, cholesterol esterification was markedly decreased in the energy-depleted cells. This effect was not due to blockage of lysosomal cholesterol export. IN the permeabilized cell system, energy repletion restored beta-VLDL-induced, but not SMase-induced, cholesterol esterification in Chinese hamster ovary cells. Similar experiments were carried out using N-ethylmaleimide, low potassium medium, or inhibitors of phosphatidylinositol 3-kinase, each of which blocks intracellular membrane vesicle trafficking. These treatments also inhibited beta-VLDL-induced, but not SMase-induced, cholesterol esterification. Finally, we show here that SMase treatment of cells leads to an increase in plasma membrane vesiculation that is relatively resistant to energy depletion. In summary, the stimulation of cholesterol esterification by lipoproteins, but not by SMase, is energy-dependent, N-ethylmaleimide-sensitive, and blocked by both low potassium and phosphatidylinositol 3-kinase inhibitors. The affected step or steps are distal to cholesterol export form lysosomes and not due to direct inhibition of the ACAT enzyme. Thus, the mechanisms, involved in lipoprotein-induced versus SMase-induced cholesterol esterification are different, perhaps due to the involvement of energy-dependent vesicular cholesterol transport in the lipoprotein pathway and a novel, energy-independent vesicular transport mechanism in the SMase pathway.	COLUMBIA UNIV COLL PHYS & SURG, DEPT MED, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT ANAT & CELL BIOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PATHOL, NEW YORK, NY 10032 USA; COLUMBIA UNIV COLL PHYS & SURG, DEPT PHYSIOL, NEW YORK, NY 10032 USA	Columbia University; Columbia University; Columbia University; Columbia University			Maxfield, Fred/M-6747-2019; Maxfield, Fred/A-1718-2011	Maxfield, Fred/0000-0003-4396-8866; 	NHLBI NIH HHS [HL-21006, HL-39703] Funding Source: Medline; NIDDK NIH HHS [DK-27083] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL039703, P50HL021006] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK027083, R37DK027083] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AHNERTHILGER G, 1989, METHOD CELL BIOL, V31, P63; ARCARO A, 1993, BIOCHEM J, V296, P297, DOI 10.1042/bj2960297; BLANCHETTEMACKIE EJ, 1988, P NATL ACAD SCI USA, V85, P8022, DOI 10.1073/pnas.85.21.8022; BRASAEMLE DL, 1990, J LIPID RES, V31, P103; BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255; CARPENTIER JL, 1989, J CELL PHYSIOL, V138, P519, DOI 10.1002/jcp.1041380311; CHANG CCY, 1995, J BIOL CHEM, V270, P29532; CHANG CCY, 1986, BIOCHEMISTRY-US, V25, P1693, DOI 10.1021/bi00355a038; CHATTERJEE S, 1994, J BIOL CHEM, V269, P879; DUNN WA, 1980, J BIOL CHEM, V255, P5971; FUGLER L, 1985, J BIOL CHEM, V260, P4098; FURUCHI T, 1993, J BIOL CHEM, V268, P27345; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GERRITY RG, 1981, AM J PATHOL, V103, P181; GODAY Y, 1995, J CELL BIOL, V112, P823; GOLDSTEIN JL, 1983, METHOD ENZYMOL, V98, P241; GUPTA AK, 1991, J LIPID RES, V32, P125; HANNUN YA, 1989, SCIENCE, V243, P500, DOI 10.1126/science.2643164; HANSEN SH, 1993, J CELL BIOL, V121, P61, DOI 10.1083/jcb.121.1.61; HARMALA AS, 1993, BIOCHIM BIOPHYS ACTA, V1210, P97, DOI 10.1016/0005-2760(93)90054-D; HARMALA AS, 1994, BBA-LIPID LIPID MET, V1211, P317, DOI 10.1016/0005-2760(94)90156-2; KAPLAN MR, 1985, J CELL BIOL, V101, P446, DOI 10.1083/jcb.101.2.446; KAWAGUCHI A, 1981, J BIOCHEM-TOKYO, V89, P337, DOI 10.1093/oxfordjournals.jbchem.a133207; KOLESNICK RN, 1991, PROG LIPID RES, V30, P1, DOI 10.1016/0163-7827(91)90005-P; LABARCA C, 1980, ANAL BIOCHEM, V102, P344, DOI 10.1016/0003-2697(80)90165-7; LANGE Y, 1995, J LIPID RES, V36, P1092; LANGE Y, 1993, J BIOL CHEM, V268, P13838; LANGE Y, 1994, J BIOL CHEM, V269, P3411; LANGE Y, 1979, BIOCHIM BIOPHYS ACTA, V556, P388, DOI 10.1016/0005-2736(79)90127-5; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LENHARD JM, 1992, J BIOL CHEM, V267, P1896; LI GP, 1995, P NATL ACAD SCI USA, V92, P10207, DOI 10.1073/pnas.92.22.10207; Libby Peter, 1993, Current Opinion in Lipidology, V4, P355, DOI 10.1097/00041433-199310000-00003; LIN HC, 1991, J CELL BIOL, V114, P881, DOI 10.1083/jcb.114.5.881; LISCUM L, 1992, J LIPID RES, V33, P1239; LISCUM L, 1990, BIOCHIM BIOPHYS ACTA, V1045, P40, DOI 10.1016/0005-2760(90)90201-8; LISCUM L, 1989, J BIOL CHEM, V264, P11796; MYERS JN, 1993, J CELL BIOL, V123, P1389, DOI 10.1083/jcb.123.6.1389; NAGAWA Y, 1979, BIOCHIM BIOPHYS ACTA, V553, P307; ODA H, 1995, J BIOL CHEM, V270, P15242, DOI 10.1074/jbc.270.25.15242; PODBILEWICZ B, 1990, EMBO J, V9, P3477, DOI 10.1002/j.1460-2075.1990.tb07556.x; PORN MI, 1995, BIOCHEM J, V308, P269; RODMAN J, 1994, ANN NY ACAD SCI, V733, P203, DOI 10.1111/j.1749-6632.1994.tb17270.x; ROSS AC, 1984, J BIOL CHEM, V259, P815; SARRIA AJ, 1992, J BIOL CHEM, V267, P19455; SCHAFFNER T, 1980, AM J PATHOL, V100, P57; SCHISSEL SL, 1995, BIOCHEMISTRY-US, V34, P10463, DOI 10.1021/bi00033a019; SCHMID SL, 1991, J CELL BIOL, V114, P869, DOI 10.1083/jcb.114.5.869; Skoufias DA, 1993, CURR OPIN CELL BIOL, V5, P95, DOI 10.1016/S0955-0674(05)80014-6; SLOTTE JP, 1988, BIOCHEM J, V250, P653, DOI 10.1042/bj2500653; SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264; STEVENS VL, 1986, BIOCHEMISTRY-US, V25, P4287, DOI 10.1021/bi00363a017; TABAS I, 1991, J CELL BIOL, V115, P1547, DOI 10.1083/jcb.115.6.1547; TABAS I, 1987, J BIOL CHEM, V262, P12175; TABAS I, 1988, J BIOL CHEM, V263, P1266; TABAS I, 1990, J CELL BIOL, V111, P929, DOI 10.1083/jcb.111.3.929; TABAS I, 1994, J BIOL CHEM, V269, P22547; TABAS I, 1995, CURR OPIN LIPIDOL, V6, P260, DOI 10.1097/00041433-199510000-00004; van Meer G, 1993, CURR OPIN CELL BIOL, V5, P661, DOI 10.1016/0955-0674(93)90137-F; VLAHOS CJ, 1994, J BIOL CHEM, V269, P5241; WANG HX, 1994, CIRCULATION, V90, P351; WATTENBERG BW, 1983, J BIOL CHEM, V258, P2284; WHITEHEART SW, 1994, J CELL BIOL, V126, P945, DOI 10.1083/jcb.126.4.945; WIEGMANN K, 1994, CELL, V78, P1005, DOI 10.1016/0092-8674(94)90275-5	65	51	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13392	13400		10.1074/jbc.271.23.13392	http://dx.doi.org/10.1074/jbc.271.23.13392			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662777				2022-12-27	WOS:A1996UP38500016
J	Wilson, JE; Aulabaugh, A; Caligan, B; McPherson, S; Wakefield, JK; Jablonski, S; Morrow, CD; Reardon, JE; Furman, PA				Wilson, JE; Aulabaugh, A; Caligan, B; McPherson, S; Wakefield, JK; Jablonski, S; Morrow, CD; Reardon, JE; Furman, PA			Human immunodeficiency virus type-1 reverse transcriptase - Contribution of Met-184 to binding of nucleoside 5'-triphosphate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DNA-POLYMERASE; THYMIDINE 5'-TRIPHOSPHATE; ENANTIOMERS; MUTANTS; INVITRO; RESISTANCE; SUBSTRATE; CARBOVIR; REGION; MOTIF	Mutations were made in recombinant human immunodeficiency virus type-1 reverse transcriptase (RT) by substituting methionine 184 with alanine (M184A) or valine (M184V), and steady-state and pre-steady-state kinetic constants were determined. The K-m values of M184A RT for dNTPs were larger than those of wt RT of RNA-directed synthesis; the k(cat) values of M184A RT for processive or distributive synthesis were similar. In contrast to M184A RT, the K-m and k(cat) values of M184V RT for dNTP substrates were similar to those of wt RT. The K-i values of M184V RT for 1-beta-L-nucleoside analogs were increased 30-500-fold relative to wt RT for both RNA- and DNA-directed synthesis. The K-d and k(p) values of wt RT and M184V RT for dCTP and cis-5-fluoro-1-[2-(hydroxy-methyl)-1,3-oxathiolan-5-yl]cytosine 5'-triphosphate (1-beta-L-FTCTP) were estimated from pre-steady-state kinetics for single nucleotide incorporation. The K-d value of M184V RT for 1-beta-L-FTCTP was 19-fold greater than that of wt RT; the k(p) values of the two enzymes were similar. These results support the hypothesis that methionine 184 in the highly conserved YMDD region of wt RT participates in the binding of the nucleoside (analog) 5'-triphosphate.	BURROUGHS WELLCOME CO, DIV BIOCHEM, RES TRIANGLE PK, NC 27709 USA; BURROUGHS WELLCOME CO, DIV VIROL, RES TRIANGLE PK, NC 27709 USA; UNIV ALABAMA, DEPT MICROBIOL, BIRMINGHAM, AL 35294 USA	Burroughs Wellcome Fund; Burroughs Wellcome Fund; University of Alabama System; University of Alabama Birmingham				Jablonski, Sandra/0000-0001-7220-8159	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI034749, R37AI034749, P01AI027290] Funding Source: NIH RePORTER; NIAID NIH HHS [AI-34749, AI-27290] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARGOS P, 1988, NUCLEIC ACIDS RES, V16, P9909, DOI 10.1093/nar/16.21.9909; BARBER AM, 1990, AIDS RES HUM RETROV, V6, P1061, DOI 10.1089/aid.1990.6.1061; BOUCHER CAB, 1993, ANTIMICROB AGENTS CH, V37, P2231, DOI 10.1128/AAC.37.10.2231; COATES JAV, 1992, ANTIMICROB AGENTS CH, V36, P202, DOI 10.1128/AAC.36.1.202; DICKSON C, 1982, RNA TUMOR VIRUSES, P513; FARAJ A, 1994, ANTIMICROB AGENTS CH, V38, P2300, DOI 10.1128/AAC.38.10.2300; GU ZX, 1992, J VIROL, V66, P7128, DOI 10.1128/JVI.66.12.7128-7135.1992; HAFFEY ML, 1990, J VIROL, V64, P5008, DOI 10.1128/JVI.64.10.5008-5018.1990; JACOBOMOLINA A, 1993, P NATL ACAD SCI USA, V90, P6320, DOI 10.1073/pnas.90.13.6320; JACOBOMOLINA A, 1991, BIOCHEMISTRY-US, V30, P6351, DOI 10.1021/bi00240a001; JOHNSON KA, 1986, METHOD ENZYMOL, V134, P677; KAMER G, 1984, NUCLEIC ACIDS RES, V12, P7269, DOI 10.1093/nar/12.18.7269; KOHLSTAEDT LA, 1992, SCIENCE, V256, P1783, DOI 10.1126/science.1377403; LARDER BA, 1989, P NATL ACAD SCI USA, V86, P4803, DOI 10.1073/pnas.86.13.4803; LARDER BA, 1987, NATURE, V327, P716, DOI 10.1038/327716a0; LEGRICE SFJ, 1991, EMBO J, V10, P3905, DOI 10.1002/j.1460-2075.1991.tb04960.x; LOWE DM, 1991, FEBS LETT, V282, P231, DOI 10.1016/0014-5793(91)80484-K; MARCY AI, 1990, J VIROL, V64, P5883, DOI 10.1128/JVI.64.12.5883-5890.1990; MARTIN JL, 1993, P NATL ACAD SCI USA, V90, P6135, DOI 10.1073/pnas.90.13.6135; MILLER WH, 1992, J BIOL CHEM, V267, P21220; MILLIGAN JF, 1987, NUCLEIC ACIDS RES, V15, P8783, DOI 10.1093/nar/15.21.8783; REARDON JE, 1990, J BIOL CHEM, V265, P20302; REARDON JE, 1993, J BIOL CHEM, V268, P8743; SCHINAZI RF, 1993, ANTIMICROB AGENTS CH, V37, P875, DOI 10.1128/AAC.37.4.875; TISDALE M, 1993, P NATL ACAD SCI USA, V90, P5653, DOI 10.1073/pnas.90.12.5653; TUNIS MJB, 1968, BIOPOLYMERS, V6, P1218, DOI 10.1002/bip.1968.360060816; TUNISSCHNEIDER MJ, 1970, J MOL BIOL, V52, P521, DOI 10.1016/0022-2836(70)90417-1; VANDRAANEN NA, 1992, J BIOL CHEM, V267, P25019; WAKEFIELD JK, 1992, J VIROL, V66, P6806, DOI 10.1128/JVI.66.11.6806-6812.1992; WHITE EL, 1989, BIOCHEM BIOPH RES CO, V161, P393, DOI 10.1016/0006-291X(89)92611-9; WILSON JE, 1993, ANTIMICROB AGENTS CH, V37, P1720, DOI 10.1128/AAC.37.8.1720	31	54	56	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13656	13662		10.1074/jbc.271.23.13656	http://dx.doi.org/10.1074/jbc.271.23.13656			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662909				2022-12-27	WOS:A1996UP38500054
J	Borner, C				Borner, C			Diminished cell proliferation associated with the death-protective activity of Bcl-2	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-FACTOR-BETA; C-MYC; APOPTOSIS; ACTIVATION; CYCLE; PROTEIN; DNA	The oncogene product Bcl-2 effectively spares cells from programmed cell death (apoptosis). The molecular mechanism underlying this death-protective activity has, however, remained enigmatic. Here we show that induction of Bcl-2 expression is consistently associated with a retardation of mammalian cell proliferation due to a prolongation of the G(1) phase of the cell cycle. Whereas cells lacking Bcl-2 expression die from any point of the cell cycle in response to apoptotic agents, Bcl-2-overexpressing cells accumulate in the G(0)/G(1) phase and are protected from cell death. Co-expression of Bax, a negative regulator of Bcl-2, reverts both the cell death protective and proliferation retarding activities of Bcl-2. Moreover, a Bcl-2 mutant defective in death protection does not affect cell division. These findings indicate that Bcl-2 contributes to cell survival by diminishing the rate of cell proliferation.			Borner, C (corresponding author), UNIV FRIBOURG,INST BIOCHEM,RUE MUSEE 5,CH-1700 FRIBOURG,SWITZERLAND.							BELIZARIO JE, 1991, CANCER RES, V51, P2379; BELLAMY COC, 1995, SEMIN CANCER BIOL, V6, P3, DOI 10.1006/scbi.1995.0002; BISSONNETTE RP, 1992, NATURE, V359, P552, DOI 10.1038/359552a0; BORNER C, 1994, J CELL BIOL, V126, P1059, DOI 10.1083/jcb.126.4.1059; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; COLOMBEL M, 1992, CANCER RES, V52, P4313; CRITCHFIELD JM, 1995, CLIN IMMUNOL IMMUNOP, V75, P13, DOI 10.1006/clin.1995.1046; DARZYNKIEWICZ Z, 1995, CELL GROWTH APOPTOSI, P143; EVAN GI, 1992, CELL, V69, P119, DOI 10.1016/0092-8674(92)90123-T; EVANS CA, 1993, CANCER RES, V53, P1735; FERRARI G, 1994, EMBO J, V13, P5922, DOI 10.1002/j.1460-2075.1994.tb06937.x; HAASKOGAN DA, 1995, EMBO J, V14, P461, DOI 10.1002/j.1460-2075.1995.tb07022.x; HARRINGTON EA, 1994, EMBO J, V13, P3286, DOI 10.1002/j.1460-2075.1994.tb06630.x; HOCKENBERY DM, 1993, CELL, V75, P241, DOI 10.1016/0092-8674(93)80066-N; HOSHINA S, 1990, J CELL PHYSIOL, V145, P262, DOI 10.1002/jcp.1041450210; ISHIGAMI T, 1992, J IMMUNOL, V148, P360; JACOBSON MD, 1995, NATURE, V374, P813; KING RW, 1994, CELL, V79, P563, DOI 10.1016/0092-8674(94)90542-8; KRAJEWSKI S, 1993, CANCER RES, V53, P4701; KRAJEWSKI S, 1994, AM J PATHOL, V145, P1323; KRAJEWSKI S, 1995, CANCER RES, V55, P4471; LAM M, 1994, P NATL ACAD SCI USA, V91, P6569, DOI 10.1073/pnas.91.14.6569; LAZEBNIK YA, 1993, CANCER RES, V50, P7307; LINDENBOIM L, 1995, CANCER RES, V55, P1242; MARVEL J, 1994, ONCOGENE, V9, P1117; MEIKRANTZ W, 1994, P NATL ACAD SCI USA, V91, P3754, DOI 10.1073/pnas.91.9.3754; MURRAY A, 1994, CURR OPIN CELL BIOL, V6, P872, DOI 10.1016/0955-0674(94)90059-0; OBERHAMMER F, 1993, EMBO J, V12, P3679, DOI 10.1002/j.1460-2075.1993.tb06042.x; OLTVAI ZN, 1993, CELL, V74, P609, DOI 10.1016/0092-8674(93)90509-O; PACKHAM G, 1994, MOL CELL BIOL, V14, P5741, DOI 10.1128/MCB.14.9.5741; PIETENPOL JA, 1994, CANCER RES, V54, P3714; POPPEMA S, 1992, IMMUNOL REV, V126, P163, DOI 10.1111/j.1600-065X.1992.tb00636.x; RAO L, 1992, P NATL ACAD SCI USA, V89, P7742, DOI 10.1073/pnas.89.16.7742; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; REED JC, 1994, J CELL BIOL, V124, P1, DOI 10.1083/jcb.124.1.1; SAWYERS CL, 1994, CELL, V77, P121, DOI 10.1016/0092-8674(94)90240-2; SCOTT DW, 1986, J EXP MED, V164, P156, DOI 10.1084/jem.164.1.156; SEN S, 1992, FEBS LETT, V307, P122, DOI 10.1016/0014-5793(92)80914-3; SHAN B, 1994, MOL CELL BIOL, V14, P8166, DOI 10.1128/MCB.14.12.8166; SHI L, 1994, SCIENCE, V263, P1143, DOI 10.1126/science.8108732; SHIMIZU S, 1995, NATURE, V374, P811, DOI 10.1038/374811a0; UCKER DS, 1992, MOL CELL BIOL, V12, P3060, DOI 10.1128/MCB.12.7.3060; WARNER GL, 1992, CELL GROWTH DIFFER, V3, P175; Wyllie A H, 1980, Int Rev Cytol, V68, P251; WYLLIE AH, 1980, NATURE, V284, P555, DOI 10.1038/284555a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YIN XM, 1994, NATURE, V369, P321, DOI 10.1038/369321a0	47	176	184	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12695	12698		10.1074/jbc.271.22.12695	http://dx.doi.org/10.1074/jbc.271.22.12695			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663032	hybrid			2022-12-27	WOS:A1996UN47400003
J	Freedman, SJ; Blostein, MD; Baleja, JD; Jacobs, M; Furie, BC; Furie, B				Freedman, SJ; Blostein, MD; Baleja, JD; Jacobs, M; Furie, BC; Furie, B			Identification of the phospholipid binding site in the vitamin K-dependent blood coagulation protein factor IX	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GAMMA-CARBOXYGLUTAMIC ACID; NUCLEAR-MAGNETIC-RESONANCE; FACTOR-X; BOVINE PROTHROMBIN; MEMBRANE-BINDING; DOMAIN; ACTIVATION; FRAGMENT-1; RESIDUES; NMR	The blood coagulation and regulatory proteins that contain gamma-carboxyglutamic acid are a part of a unique class of membrane binding proteins that require calcium for their interaction with cell membranes. Following protein biosynthesis, glutamic acids on these proteins are converted to gamma-carboxyglutamic acid (Gla) in a reaction that requires vitamin K as a cofactor, The vitamin K-dependent proteins undergo a conformational transition upon metal ion binding, but only calcium ions mediate protein-phospholipid interaction. To identify the site on Factor IX that is required for phospholipid binding, we have determined the three-dimensional structure of the Factor IX Gla domain bound to magnesium ions by NMR spectroscopy, By comparison of this structure to that of the Gla domain bound to calcium ions, we localize the membrane binding site to a highly ordered structure including residues 1-11 of the Gla domain, In the presence of Ca2+, Factor IX Gla domain peptides that contain the photoactivatable amino acid p-benzoyl-L-phenylalanine at positions 6 or 9 cross-link to phospholipid following irradiation, while peptides lacking this amino acid analog or with this analog at position 46 did not cross-link. These results indicate that the NH2 terminus of the Gla domain, specifically including leucine 6 and phenylalanine 9 in the hydrophobic patch, is the contact surface on Factor IX that interacts with the phospholipid bilayer.	TUFTS UNIV, SCH MED, DEPT MED, BOSTON, MA 02111 USA; TUFTS UNIV, SCH MED, DEPT BIOCHEM, BOSTON, MA 02111 USA; SACKLER SCH GRAD BIOMED SCI, BOSTON, MA 02111 USA	Tufts University; Tufts University	Freedman, SJ (corresponding author), TUFTS UNIV NEW ENGLAND MED CTR, CTR HEMOSTASIS & THROMBOSIS RES, DIV HEMATOL ONCOL, BOSTON, MA 02111 USA.				NHLBI NIH HHS [HL42443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL042443] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ATKINS JS, 1992, MOL CELL BIOCHEM, V112, P61; BAX A, 1985, J MAGN RESON, V65, P355, DOI 10.1016/0022-2364(85)90018-6; BOROWSKI M, 1986, J BIOL CHEM, V261, P4969; CHEN PS, 1956, ANAL CHEM, V28, P1756, DOI 10.1021/ac60119a033; CHRISTIANSEN WT, 1995, BIOCHEMISTRY-US, V34, P10376, DOI 10.1021/bi00033a008; COLPITTS TL, 1994, BIOCHEMISTRY-US, V33, P3501, DOI 10.1021/bi00178a006; DEITCHER SR, 1994, BLOOD, V84, pA532; DETLEFSEN DJ, 1991, BIOCHEMISTRY-US, V30, P9040, DOI 10.1021/bi00101a019; DORMAN G, 1994, BIOCHEMISTRY-US, V33, P5661, DOI 10.1021/bi00185a001; FREEDMAN SJ, 1995, BIOCHEMISTRY-US, V34, P12126, DOI 10.1021/bi00038a005; FREEDMAN SJ, 1995, J BIOL CHEM, V270, P7980, DOI 10.1074/jbc.270.14.7980; FURIE B, 1988, CELL, V53, P505, DOI 10.1016/0092-8674(88)90567-3; FURIE BC, 1979, J BIOL CHEM, V254, P2521; GITEL SN, 1973, P NATL ACAD SCI USA, V70, P1344, DOI 10.1073/pnas.70.5.1344; GOVERSRIEMSLAG JWP, 1994, EUR J BIOCHEM, V220, P131, DOI 10.1111/j.1432-1033.1994.tb18607.x; HAVEL TF, 1991, PROG BIOPHYS MOL BIO, V56, P43, DOI 10.1016/0079-6107(91)90007-F; HYBERTS SG, 1992, PROTEIN SCI, V1, P736, DOI 10.1002/pro.5560010606; JACOBS M, 1994, J BIOL CHEM, V269, P25494; JORGENSEN MJ, 1987, CELL, V48, P185, DOI 10.1016/0092-8674(87)90422-3; KOTKOW KJ, 1993, J BIOL CHEM, V268, P15633; LIEBMAN HA, 1987, J BIOL CHEM, V262, P7605; LIEBMAN HA, 1985, P NATL ACAD SCI USA, V82, P3879, DOI 10.1073/pnas.82.11.3879; LIM TK, 1977, BIOCHEMISTRY-US, V16, P4177, DOI 10.1021/bi00638a007; MANN KG, 1982, BIOPHYS J, V37, P106, DOI 10.1016/S0006-3495(82)84624-9; NELSESTUEN GL, 1976, J BIOL CHEM, V251, P6886; PIANTINI U, 1982, J AM CHEM SOC, V104, P6800, DOI 10.1021/ja00388a062; PLATEAU P, 1982, J AM CHEM SOC, V104, P7310, DOI 10.1021/ja00389a067; POLLOCK JS, 1988, J BIOL CHEM, V263, P14216; RATCLIFFE JV, 1993, J BIOL CHEM, V268, P24339; RHEE MJ, 1982, BIOCHEMISTRY-US, V21, P4524, DOI 10.1021/bi00262a001; SCHWALBE RA, 1989, J BIOL CHEM, V264, P20288; SHOELSON SE, 1993, J BIOL CHEM, V268, P4085; SORIANOGARCIA M, 1992, BIOCHEMISTRY-US, V31, P2554, DOI 10.1021/bi00124a016; SUNNERHAGEN M, 1995, NAT STRUCT BIOL, V2, P504, DOI 10.1038/nsb0695-504; SUTTIE JW, 1985, ANNU REV BIOCHEM, V54, P459, DOI 10.1146/annurev.bi.54.070185.002331; VANDIEIJEN G, 1981, J BIOL CHEM, V256, P3433; WELSCH DJ, 1988, BIOCHEMISTRY-US, V27, P4939, DOI 10.1021/bi00413a052; WILLIAMS KP, 1993, J BIOL CHEM, V268, P5361; WISHART DS, 1991, J MOL BIOL, V222, P311, DOI 10.1016/0022-2836(91)90214-Q; Wuthrich K, 1986, NMR PROTEINS NUCL AC; YAMADA M, 1995, BIOCHEMISTRY-US, V34, P481, DOI 10.1021/bi00002a012; ZHANG L, 1994, J BIOL CHEM, V269, P3590	42	119	139	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16227	16236		10.1074/jbc.271.27.16227	http://dx.doi.org/10.1074/jbc.271.27.16227			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663165	hybrid			2022-12-27	WOS:A1996UW35200055
J	Lullau, E; Heyse, S; Vogel, H; Marison, I; vonStockar, U; Kraehenbuhl, JP; Corthesy, B				Lullau, E; Heyse, S; Vogel, H; Marison, I; vonStockar, U; Kraehenbuhl, JP; Corthesy, B			Antigen binding properties of purified immunoglobulin A and reconstituted secretory immunoglobulin A antibodies	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCLONAL-ANTIBODY; VIBRIO-CHOLERAE; IGA; COMPONENT; FILMS; LIPOPOLYSACCHARIDES; SPECTROSCOPY; COMPLEXES; MECHANISM; EPITOPES	The hybridoma cell line ZAC3 expresses Vibrio cholerae lipopolysaccharide (LPS)-specific mouse IgA molecules as a heterogeneous population of monomeric (IgA(m)), dimeric (IgA(d)), and polymeric (IgA(p)) forms. We describe a gentle method combining ultrafiltration, ion-exchange chromatography, and size exclusion chromatography for the simultaneous and qualitative separation of the three molecular forms. Milligram quantities of purified IgA molecules were recovered allowing for direct comparison of the biological properties of the three forms, LPS binding specificity was tested after purification; IgA(d) and IgA(p) mere found to bind strongly to LPS whereas IgA(m) did not. Secretory IgA (sIgA) could be reconstituted in vitro by combining recombinant secretory component (rSC) and purified IgA(d) or IgA(p), but not IgA(m). Surface plasmon resonance-based binding experiments using LPS monolayers indicated that purified reconstituted sIgA and IgA molecules recognize LPS with identical affinity (K-A 1.0 x 10(8) M(-1)). Thus, this very sensitive assay provides the first evidence that the function of SC in sIgA complex is not to modify the affinity for the antigen. K-A falls to 6.6 x 10(5) M(-1) when measured by calorimetry using detergent-solubilized LPS and IgA, suggesting that the LPS environment is critical for recognition by the antibody.	SWISS INST EXPTL CANC RES, CH-1066 EPALINGES, SWITZERLAND; ECOLE POLYTECH FED LAUSANNE, INST GENIE CHIM, CH-1015 LAUSANNE, SWITZERLAND; ECOLE POLYTECH FED LAUSANNE, INST CHIM PHYS, CH-1015 LAUSANNE, SWITZERLAND; UNIV LAUSANNE, INST BIOCHIM, CH-1066 EPALINGES, SWITZERLAND; UNIV LAUSANNE, INST BIOL ANIM, CH-1015 LAUSANNE, SWITZERLAND	Swiss Institute Experimental Cancer Research; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; Swiss Federal Institutes of Technology Domain; Ecole Polytechnique Federale de Lausanne; University of Lausanne; University of Lausanne			Vogel, Horst/AAJ-5490-2021					APTER FM, 1993, INFECT IMMUN, V61, P5279, DOI 10.1128/IAI.61.12.5279-5285.1993; BAIN CD, 1989, J AM CHEM SOC, V111, P321, DOI 10.1021/ja00183a049; BLANCHARD TG, 1995, INFECT IMMUN, V63, P1394, DOI 10.1128/IAI.63.4.1394-1399.1995; BOUIGE P, 1990, HYBRIDOMA, V9, P519, DOI 10.1089/hyb.1990.9.519; BRANDENBURG K, 1993, BIOPHYS J, V64, P1215, DOI 10.1016/S0006-3495(93)81488-7; BRANDTZAEG P, 1970, IMMUNOCHEMISTRY, V7, P127, DOI 10.1016/0019-2791(70)90037-6; CARAYANNOPOULOS L, 1994, P NATL ACAD SCI USA, V91, P8348, DOI 10.1073/pnas.91.18.8348; COOPER LJN, 1994, MOL IMMUNOL, V31, P577, DOI 10.1016/0161-5890(94)90165-1; Duschl C, 1996, BIOPHYS J, V70, P1985, DOI 10.1016/S0006-3495(96)79763-1; FUKUOKA S, 1994, MICROBIOS, V78, P169; GOTO Y, 1984, BIOCHEMISTRY-US, V23, P6736, DOI 10.1021/bi00321a070; HENDRICKSON BA, 1995, J EXP MED, V182, P1905, DOI 10.1084/jem.182.6.1905; HEREMANS JF, 1974, ANTIGENS, V2, P365; ISHIZAKA K, 1965, J IMMUNOL, V95, P197; KALB E, 1992, BIOCHIM BIOPHYS ACTA, V1103, P307, DOI 10.1016/0005-2736(92)90101-Q; KERR MA, 1990, BIOCHEM J, V271, P285, DOI 10.1042/bj2710285; KNOLL W, 1991, MRS BULL, V16, P29, DOI 10.1557/S0883769400056517; KOSHLAND ME, 1985, ANNU REV IMMUNOL, V3, P425; Kretschmann E., 1972, Optics Communications, V6, P185, DOI 10.1016/0030-4018(72)90224-6; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE CK, 1994, INFECT IMMUN, V62, P887, DOI 10.1128/IAI.62.3.887-891.1994; LEMAITRECOELHO I, 1977, EUR J IMMUNOL, V7, P588, DOI 10.1002/eji.1830070818; LINDH E, 1976, EUR J BIOCHEM, V62, P263, DOI 10.1111/j.1432-1033.1976.tb10156.x; MACH JP, 1970, NATURE, V228, P1278, DOI 10.1038/2281278a0; MESTECKY J, 1991, GASTROENTEROL CLIN N, V20, P441; MESTECKY J, 1985, METHOD ENZYMOL, V116, P37; MICHETTI P, 1992, INFECT IMMUN, V60, P1786, DOI 10.1128/IAI.60.5.1786-1792.1992; PARR EL, 1995, J IMMUNOL METHODS, V180, P147, DOI 10.1016/0022-1759(94)00310-S; RINDISBACHER L, 1995, J BIOL CHEM, V270, P14220, DOI 10.1074/jbc.270.23.14220; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHWARZ FP, 1995, EUR J BIOCHEM, V228, P388; SIGURSKJOLD BW, 1991, EUR J BIOCHEM, V197, P239, DOI 10.1111/j.1432-1033.1991.tb15904.x; STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50; TAYLOR HP, 1985, J EXP MED, V161, P198, DOI 10.1084/jem.161.1.198; TERRETTAZ S, 1993, LANGMUIR, V9, P1361, DOI 10.1021/la00029a033; TERSKIKH A, 1994, MOL IMMUNOL, V31, P1313, DOI 10.1016/0161-5890(94)90049-3; TSAI CM, 1982, ANAL BIOCHEM, V119, P115, DOI 10.1016/0003-2697(82)90673-X; Ulman A., 1991, INTRO ULTRATHIN ORGA; UNDERDOWN BJ, 1986, ANNU REV IMMUNOL, V4, P389, DOI 10.1146/annurev.iy.04.040186.002133; UZGIRIS EE, 1983, NATURE, V301, P125, DOI 10.1038/301125a0; VAERMAN JP, 1995, IMMUNOL INVEST, V24, P631, DOI 10.3109/08820139509066863; VAERMAN JP, 1972, RES IMMUNOCHEM IMMUN, V3, P1; VANDENHEUVEL DJ, 1993, ANAL BIOCHEM, V215, P223, DOI 10.1006/abio.1993.1579; Vyas NK, 1991, CURR OPIN STRUC BIOL, V1, P732, DOI 10.1016/0959-440X(91)90172-P; WEICKER J, 1975, J IMMUNOL, V114, P1337; WELTZIN R, 1994, ANTIMICROB AGENTS CH, V38, P2785, DOI 10.1128/AAC.38.12.2785; WINNER L, 1991, INFECT IMMUN, V59, P977, DOI 10.1128/IAI.59.3.977-982.1991; WISEMAN T, 1989, ANAL BIOCHEM, V179, P131, DOI 10.1016/0003-2697(89)90213-3; WOODARD CS, 1984, J IMMUNOL, V133, P2116; WRIGHT LL, 1988, BIOPHYS J, V54, P463, DOI 10.1016/S0006-3495(88)82979-5	50	58	79	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16300	16309		10.1074/jbc.271.27.16300	http://dx.doi.org/10.1074/jbc.271.27.16300			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663142	hybrid			2022-12-27	WOS:A1996UW35200066
J	Palmer, TM; Benovic, JL; Stiles, GL				Palmer, TM; Benovic, JL; Stiles, GL			Molecular basis for subtype-specific desensitization of inhibitory molecular adenosine receptors - Analysis of a chimeric A(1)-A(3) adenosine receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							AGONIST-PROMOTED DESENSITIZATION; HETEROLOGOUS DESENSITIZATION; STRUCTURAL BASIS; KINASE FAMILY; CLONING; EXPRESSION; INTERNALIZATION; MECHANISMS; ADIPOCYTES; SYSTEM	The differing effects of short-term agonist exposure on the two inhibitory adenosine receptor (AR) subtypes have been examined using Chinese hamster ovary cells stably expressing the hemagglutinin epitope-tagged human A(1)AR and rat A(3)AR, Under conditions in which exposure of transfected cells to 5 mu M (-)-(R)-N-6-(phenylisopropyl)adenosine resulted in the functional desensitization and phosphorylation of the A(3)AR, neither property was exhibited by the A(1)AR, However, a stably expressed chimeric A(1)-A(3)AR, termed A(1)CT3AR, in which the C-terminal domain of the A(1)AR distal to its predicted palmitoylation site was replaced by the corresponding region of the A(3)AR, was able to undergo functional desensitization and agonist-stimulated phosphorylation in a manner similar to that exhibited by the A(3)AR, More over, purified G-protein-coupled receptor kinases 2, 3, and 5 were each capable of enhancing the agonist-dependent phosphorylation of the A(3)AR and A(1)CT3AR in vitro, Taken together, these data demonstrate that the C terminal domain of the A(3)AR distal to its predicted palmitoylation site is responsible for this receptor's ability to undergo a rapid agonist-dependent desensitization and are consistent with a model in which phosphorylation of the A(3)AR within this domain by one or more G-protein-coupled receptor kinases initiates the desensitization process.	DUKE UNIV, MED CTR, DEPT PHARMACOL, DURHAM, NC 27710 USA; THOMAS JEFFERSON UNIV, JEFFERSON CANC INST, DEPT PHARMACOL, PHILADELPHIA, PA 19107 USA	Duke University; Jefferson University	Palmer, TM (corresponding author), DUKE UNIV, MED CTR, DEPT MED, DURHAM, NC 27710 USA.		Palmer, Timothy/E-7290-2013; Palmer, Timothy/C-4975-2009	Palmer, Timothy/0000-0002-9803-7164; 	NHLBI NIH HHS [P50HL54314, R01 HL35134] Funding Source: Medline; NIGMS NIH HHS [R01 GM44944] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL054314, R01HL035134] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM044944] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		APGAR JR, 1994, MOL BIOL CELL, V5, P313, DOI 10.1091/mbc.5.3.313; BENOVIC JL, 1991, J BIOL CHEM, V266, P14939; CHEN CY, 1993, J BIOL CHEM, V268, P7825; DELEAN A, 1982, MOL PHARMACOL, V22, P290; DUCLOS B, 1991, METHOD ENZYMOL, V201, P10; EASON MG, 1992, J BIOL CHEM, V267, P25473; FERGUSON SSG, 1995, J BIOL CHEM, V270, P24782, DOI 10.1074/jbc.270.42.24782; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GALLORODRIGUEZ C, 1994, J MED CHEM, V37, P636, DOI 10.1021/jm00031a014; GREEN A, 1992, J BIOL CHEM, V267, P3223; GUREVICH VV, 1995, J BIOL CHEM, V270, P720, DOI 10.1074/jbc.270.2.720; HAUSDORFF WP, 1990, FASEB J, V4, P2881, DOI 10.1096/fasebj.4.11.2165947; KIM CM, 1993, RECEPTOR, V3, P39; KUNAPULI P, 1993, P NATL ACAD SCI USA, V90, P5588, DOI 10.1073/pnas.90.12.5588; KUNAPULI P, 1994, J BIOL CHEM, V269, P1099; KUROSE H, 1994, J BIOL CHEM, V269, P10093; LIGGETT SB, 1993, P NATL ACAD SCI USA, V90, P3665, DOI 10.1073/pnas.90.8.3665; LISANTI MP, 1989, J CELL BIOL, V109, P2117, DOI 10.1083/jcb.109.5.2117; LOHSE MJ, 1992, J BIOL CHEM, V267, P8558; MILLIGAN G, 1993, TRENDS PHARMACOL SCI, V14, P413, DOI 10.1016/0165-6147(93)90064-Q; MORO O, 1993, J BIOL CHEM, V268, P6862; NAKATA H, 1992, EUR J BIOCHEM, V206, P171, DOI 10.1111/j.1432-1033.1992.tb16914.x; NANTEL F, 1993, MOL PHARMACOL, V43, P548; NIMAN HL, 1983, P NATL ACAD SCI-BIOL, V80, P4949, DOI 10.1073/pnas.80.16.4949; OLAH ME, 1994, J BIOL CHEM, V269, P24692; OLAH ME, 1992, J BIOL CHEM, V267, P10764; OLAH ME, 1994, MOL PHARMACOL, V45, P978; OLAH ME, 1995, ANNU REV PHARMACOL, V35, P581, DOI 10.1146/annurev.pa.35.040195.003053; ONORATO JJ, 1991, BIOCHEMISTRY-US, V30, P5118, DOI 10.1021/bi00235a002; PALMER TM, 1995, J BIOL CHEM, V270, P29607, DOI 10.1074/jbc.270.49.29607; PARSONS WJ, 1987, J BIOL CHEM, V262, P841; PEI G, 1995, MOL PHARMACOL, V48, P173; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1995, FASEB J, V9, P175, DOI 10.1096/fasebj.9.2.7781920; RAMKUMAR V, 1993, J BIOL CHEM, V268, P16887; RAMKUMAR V, 1991, MOL PHARMACOL, V40, P639; REN HZ, 1994, J BIOL CHEM, V269, P3104; TOWNSENDNICHOLSON A, 1992, MOL BRAIN RES, V16, P365, DOI 10.1016/0169-328X(92)90248-A; VONZASTROW M, 1992, J BIOL CHEM, V267, P3530; ZHOU QY, 1992, P NATL ACAD SCI USA, V89, P7432, DOI 10.1073/pnas.89.16.7432	40	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15272	15278		10.1074/jbc.271.25.15272	http://dx.doi.org/10.1074/jbc.271.25.15272			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663009	hybrid			2022-12-27	WOS:A1996UT10600091
J	Roberts, S; Miller, SJ; Lane, WS; Lee, S; Hahn, S				Roberts, S; Miller, SJ; Lane, WS; Lee, S; Hahn, S			Cloning and functional characterization of the gene encoding the TFIIIB90 subunit of RNA polymerase III transcription factor TFIIIB	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TATA-BINDING PROTEIN; U6 SNRNA GENE; SACCHAROMYCES-CEREVISIAE; ELEMENT; DNA; INITIATION; EXPRESSION; COMPLEXES; PROMOTER; HOMOLOGY	The yeast RNA polymerase III (pol III) general transcription factor TFIIIB is composed of three subunits; the TATA-binding protein (TBP)(1), the TFIIB-related factor (BRF1), and a third factor termed TFIIIB90 or B ''. Here we report the purification of yeast TFIIIB90, cloning of the gene encoding TFIIIB90, and reconstitution of TFIIIB from recombinant polypeptides. The TFIIIB90 open reading frame encodes a 68-kDa polypeptide and has no obvious similarity to any other known protein sequences. The gene encoding TFIIIB90 is essential for viability of yeast. Using recombinant TFIIIB subunits, we found that TFIIIB90 interacts weakly with TBP in the absence of BRF1, and that this interaction is enhanced at least 25-fold by BRF1. In addition, TFIIIB90 showed pol III specificity as it could not interact with the pol II-specific TFIIB-TBP-DNA complex. To localize the regions of the TBP-DNA complex that interact with BRF1 and TFIIIB90, we tested whether the pol II factors TFIIA and TFIIB interfered with the binding of BRF1 and TFIIIB90 to TBP-DNA. Our results suggest that the binding sites for BRF1 and TFIIIB90 on TBP-DNA both overlap the binding sites for TFIIA and TFIIB.	FRED HUTCHINSON CANC RES CTR, SEATTLE, WA 98109 USA; HARVARD UNIV, HARVARD MICROCHEM FACIL, CAMBRIDGE, MA 02138 USA	Fred Hutchinson Cancer Center; Harvard University				Hahn, Steven/0000-0001-7240-2533	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053451] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM53451] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; AUBLE DT, 1993, GENE DEV, V7, P844, DOI 10.1101/gad.7.5.844; BAKER RE, 1987, P NATL ACAD SCI USA, V84, P8768, DOI 10.1073/pnas.84.24.8768; BARTHOLOMEW B, 1993, MOL CELL BIOL, V13, P942, DOI 10.1128/MCB.13.2.942; BROW DA, 1990, GENE DEV, V4, P1345, DOI 10.1101/gad.4.8.1345; BURATOWSKI S, 1992, CELL, V71, P221, DOI 10.1016/0092-8674(92)90351-C; BURATOWSKI S, 1992, SCIENCE, V255, P1130, DOI 10.1126/science.1546314; BURATOWSKI S, 1989, CELL, V56, P549, DOI 10.1016/0092-8674(89)90578-3; BURNOL AF, 1993, J MOL BIOL, V233, P644, DOI 10.1006/jmbi.1993.1542; CARLSON M, 1982, CELL, V28, P145, DOI 10.1016/0092-8674(82)90384-1; COLBERT T, 1992, GENE DEV, V6, P1940, DOI 10.1101/gad.6.10.1940; CUPP JR, 1992, J BIOL CHEM, V267, P16417; DIECI G, 1995, J BIOL CHEM, V270, P13476, DOI 10.1074/jbc.270.22.13476; DIECI G, 1993, J BIOL CHEM, V268, P11199; FEAVER WJ, 1994, J BIOL CHEM, V269, P27549; FERNANDEZ J, 1992, ANAL BIOCHEM, V201, P255, DOI 10.1016/0003-2697(92)90336-6; GEIDUSCHEK EP, 1988, ANNU REV BIOCHEM, V57, P873, DOI 10.1146/annurev.bi.57.070188.004301; GEIDUSCHEK EP, 1992, RNA POLYMERASE, V3, P247; HUNT DF, 1992, SCIENCE, V255, P1261, DOI 10.1126/science.1546328; JOAZEIRO CAP, 1994, MOL CELL BIOL, V14, P2798, DOI 10.1128/MCB.14.4.2798; JONES EW, 1991, METHOD ENZYMOL, V194, P428; KASSAVETIS GA, 1991, P NATL ACAD SCI USA, V88, P7308, DOI 10.1073/pnas.88.16.7308; KASSAVETIS GA, 1990, CELL, V60, P235, DOI 10.1016/0092-8674(90)90739-2; KASSAVETIS GA, 1992, CELL, V71, P1055, DOI 10.1016/0092-8674(92)90399-W; KASSAVETIS GA, 1995, P NATL ACAD SCI USA, V92, P9786, DOI 10.1073/pnas.92.21.9786; KHOO B, 1994, GENE DEV, V8, P2879, DOI 10.1101/gad.8.23.2879; KIM JL, 1993, NATURE, V365, P520, DOI 10.1038/365520a0; KIM YC, 1993, NATURE, V365, P512, DOI 10.1038/365512a0; LANE WS, 1991, J PROTEIN CHEM, V10, P152; LEE DK, 1992, MOL CELL BIOL, V12, P5189, DOI 10.1128/MCB.12.11.5189; LEE S, 1995, NATURE, V376, P609, DOI 10.1038/376609a0; LOPEZDELEON A, 1992, CELL, V71, P211, DOI 10.1016/0092-8674(92)90350-L; MARGOTTIN F, 1991, SCIENCE, V251, P424, DOI 10.1126/science.1989075; NIKOLOV DB, 1995, NATURE, V377, P119, DOI 10.1038/377119a0; ROBERTS S, 1995, GENE DEV, V9, P832, DOI 10.1101/gad.9.7.832; SCHULTZ MC, 1992, CELL, V69, P697, DOI 10.1016/0092-8674(92)90233-3; SHEN SH, 1991, J BIOL CHEM, V266, P1058; SIKORSKI RS, 1989, GENETICS, V122, P19; STARGELL LA, 1995, SCIENCE, V269, P75, DOI 10.1126/science.7604282; STUDIER FW, 1986, J MOL BIOL, V189, P113, DOI 10.1016/0022-2836(86)90385-2; Tang H, 1996, P NATL ACAD SCI USA, V93, P1119, DOI 10.1073/pnas.93.3.1119; WERNER M, 1993, J BIOL CHEM, V268, P20721	42	45	46	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14903	14909		10.1074/jbc.271.25.14903	http://dx.doi.org/10.1074/jbc.271.25.14903			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662956	hybrid			2022-12-27	WOS:A1996UT10600042
J	Chan, SW; Thanabalu, T; Wee, BY; Porter, AG				Chan, SW; Thanabalu, T; Wee, BY; Porter, AG			Unusual amino acid determinants of host range in the Mtx2 family of mosquitocidal toxins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACILLUS-SPHAERICUS SSII-1; SPECIFICITY REGION; CRYSTAL PROTEIN; DELTA-ENDOTOXIN; THURINGIENSIS; TOXICITY; GENE	Five different mosquitocidal toxin (mtx2) gene homologs have been cloned from eight Bacillus sphaericus strains. Pairwise comparisons of the predicted amino acid sequences show between four and eight substitutions compared with the prototype Mtx2 from B. sphaericus strain SSII-1. Mtx2 from strain SSII-1 was similar to 7-fold more toxic to Culex mosquito larvae than the Mtx2 homolog from B. sphaericus strain 31-2. Conversely, Mtx2 from strain 31-2 was similar to 100-fold more toxic to Aedes mosquito larvae than Mtx2 from strain SSLI-1. Lys(224) in Mtx2 was found to be the most important amino acid for toxicity to Culez larvae, and substitution of Lys(224) With threonine abolished the toxicity of Mtx2 from strain SSII-1 to these larvae. In complete contrast, Thr(224) was found to be crucial for the toxicity of Mtx2 from strain 31-2 to Aedes larvae, and substitution of Th-224 with lysine caused a similar to 100-fold drop in toxicity to these larvae. Thus, amino acid 224 in the Mtx2 family of mosquitocidal toxins is an unusual and important determinant of mosquito larvicidal activity and host range.	NATL UNIV SINGAPORE,INST MOLEC & CELL BIOL,SINGAPORE 119260,SINGAPORE	Agency for Science Technology & Research (A*STAR); A*STAR - Institute of Molecular & Cell Biology (IMCB); National University of Singapore			Thanabalu, Thirumaran/A-2216-2011	Thanabalu, Thirumaran/0000-0001-5871-3829				BAUMANN P, 1991, MICROBIOL REV, V55, P425, DOI 10.1128/MMBR.55.3.425-436.1991; BERRY C, 1993, J BACTERIOL, V175, P510, DOI 10.1128/JB.175.2.510-518.1993; Cutting S., 1990, MOL BIOL METHODS BAC; HAIDER MZ, 1989, J MOL BIOL, V208, P183, DOI 10.1016/0022-2836(89)90094-6; HAIDER MZ, 1989, FEMS MICROBIOL LETT, V58, P157, DOI 10.1111/j.1574-6968.1989.tb03037.x; Maniatis T, 1989, DECONTAMINATION DILU; MYERS P, 1979, CAN J MICROBIOL, V25, P1227, DOI 10.1139/m79-193; MYERS P, 1978, INFECT IMMUN, V19, P1047, DOI 10.1128/IAI.19.3.1047-1053.1978; PORTER AG, 1993, MICROBIOL REV, V57, P838, DOI 10.1128/MMBR.57.4.838-861.1993; SCHNEPF HE, 1990, J BIOL CHEM, V265, P20923; SMITH DB, 1988, GENE, V67, P31, DOI 10.1016/0378-1119(88)90005-4; THANABALU T, 1993, J BACTERIOL, V175, P2314, DOI 10.1128/JB.175.8.2314-2320.1993; THANABALU T, 1991, J BACTERIOL, V173, P2776, DOI 10.1128/JB.173.9.2776-2785.1991; Thanabalu T, 1996, GENE, V170, P85, DOI 10.1016/0378-1119(95)00836-5; WIDNER WR, 1990, J BACTERIOL, V172, P2826, DOI 10.1128/jb.172.6.2826-2832.1990; WU D, 1992, J BIOL CHEM, V267, P2311	16	22	30	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14183	14187		10.1074/jbc.271.24.14183	http://dx.doi.org/10.1074/jbc.271.24.14183			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662969	hybrid			2022-12-27	WOS:A1996UQ66000039
J	Fukazawa, T; Miyake, S; Band, V; Band, H				Fukazawa, T; Miyake, S; Band, V; Band, H			Tyrosine phosphorylation of Cbl upon epidermal growth factor (EGF) stimulation and its association with EGF receptor and downstream signaling proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MAMMARY EPITHELIAL-CELLS; P53 PROTEIN; V-CBL; TRUNCATION; ONCOGENE; BINDING; DOMAIN	We and others have shown that Cbl, the protein product of the c-cbl proto-oncogene, is an early target of tyrosine phosphorylation upon stimulation through the immune cell surface receptors, which signal through noncovalently associated cytoplasmic tyrosine kinases. Using human mammary epithelial cells that express a natural epidermal growth factor (EGF) receptor and require EGF as an essential growth factor, we demonstrate here that Cbl is a prominent target of tyrosine phosphorylation upon stimulation through the EGF receptor tyrosine kinase, Phosphorylation of Cbl was EGF dose-dependent, rapid (detectable as early as 5 s and maximal by 2 min), and relatively sustained (detectable even after 1 h), Co-immunoprecipitation studies demonstrated that Cbl became associated with the EGF receptor in an EGF-dependent manner. Cbl was basally associated with the adaptor protein growth factor receptor-binding protein 2 (Grb2), and this interaction was further enhanced by EGF stimulation; however, the interaction was entirely mediated via the Grb2 Src homology 3 (SH3) domains, suggesting that binding of Grb2 SH2 domain to EGF receptor provides one mechanism of Cbl's association with the EGF receptor, EGF stimulation also induced the association of Cbl with Src homology and collagen (She) protein, p85 subunit of the phosphatidylinositol 3-kinase and Crk proteins, in particular with the CrkL isoform, Interactions of Cbl with the EGF receptor and multiple downstream signaling proteins suggest a role for this proto-oncogene product in mitogenic signaling through growth factor receptor kinases.	HARVARD UNIV,BRIGHAM & WOMENS HOSP,SCH MED,DEPT MED,DEPT IMMUNOL & RHEUMATOL,BOSTON,MA 02115; TUFTS UNIV,NEW ENGLAND MED CTR,SCH MED,DEPT RADIAT ONCOL,BOSTON,MA 02111; TUFTS UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02111	Harvard University; Brigham & Women's Hospital; Harvard Medical School; Tufts Medical Center; Tufts University; Tufts University			Fukazawa, Takuya/GLR-7099-2022		NATIONAL CANCER INSTITUTE [R29CA056803] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P60AR036308] Funding Source: NIH RePORTER; NCI NIH HHS [R29CA56803] Funding Source: Medline; NIAMS NIH HHS [AR36308] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		ANDONIOU CE, 1994, EMBO J, V13, P4515, DOI 10.1002/j.1460-2075.1994.tb06773.x; BAND V, 1993, EMBO J, V12, P1847, DOI 10.1002/j.1460-2075.1993.tb05833.x; BAND V, 1990, P NATL ACAD SCI USA, V87, P463, DOI 10.1073/pnas.87.1.463; BAND V, 1990, CANCER RES, V50, P7351; BAND V, 1989, P NATL ACAD SCI USA, V86, P1249, DOI 10.1073/pnas.86.4.1249; BAND V, 1991, J VIROL, V65, P6671, DOI 10.1128/JVI.65.12.6671-6676.1991; BIRGE RB, 1992, J BIOL CHEM, V267, P10588; BLAKE TJ, 1991, ONCOGENE, V6, P653; BLAKE TJ, 1993, EMBO J, V12, P2017, DOI 10.1002/j.1460-2075.1993.tb05851.x; BOWTELL DDL, 1995, ONCOGENE, V11, P1561; CARRAWAY KL, 1994, CELL, V78, P5, DOI 10.1016/0092-8674(94)90564-9; DONOVAN JA, 1994, J BIOL CHEM, V269, P22921; DOWNWARD J, 1994, FEBS LETT, V338, P113, DOI 10.1016/0014-5793(94)80346-3; DRUKER BJ, 1989, NEW ENGL J MED, V321, P1383; FANTL WJ, 1993, ANNU REV BIOCHEM, V62, P453, DOI 10.1146/annurev.bi.62.070193.002321; FUKAZAWA T, 1995, J BIOL CHEM, V270, P20177, DOI 10.1074/jbc.270.34.20177; FUKAZAWA T, 1995, J BIOL CHEM, V270, P19141, DOI 10.1074/jbc.270.32.19141; GALISTEO ML, 1995, J BIOL CHEM, V270, P20242, DOI 10.1074/jbc.270.35.20242; GOTH T, 1995, MOL CELL BIOL, V15, P6746; LANGDON WY, 1989, J VIROL, V63, P5420, DOI 10.1128/JVI.63.12.5420-5424.1989; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; MARCILLA A, 1995, J BIOL CHEM, V270, P9115, DOI 10.1074/jbc.270.16.9115; MEISNER H, 1995, J BIOL CHEM, V270, P25332, DOI 10.1074/jbc.270.43.25332; MEISNER H, 1995, MOL CELL BIOL, V15, P3571; MORAN MF, 1990, P NATL ACAD SCI USA, V87, P8622, DOI 10.1073/pnas.87.21.8622; ODAI H, 1995, J BIOL CHEM, V270, P10800, DOI 10.1074/jbc.270.18.10800; PANCHAMOORTHY G, 1994, MOL CELL BIOL, V14, P6372, DOI 10.1128/MCB.14.9.6372; Panchamoorthy G, 1996, J BIOL CHEM, V271, P3187, DOI 10.1074/jbc.271.6.3187; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; Reedquist KA, 1996, J BIOL CHEM, V271, P8435, DOI 10.1074/jbc.271.14.8435; REEDQUIST KA, 1994, P NATL ACAD SCI USA, V91, P4135, DOI 10.1073/pnas.91.10.4135; RIVEROLEZCANO OM, 1994, J BIOL CHEM, V269, P17363; SCHLESSINGER J, 1992, NEURON, V9, P383, DOI 10.1016/0896-6273(92)90177-F; SCHLESSINGER J, 1994, CURR OPIN GENET DEV, V4, P25, DOI 10.1016/0959-437X(94)90087-6; Soltoff SP, 1996, J BIOL CHEM, V271, P563, DOI 10.1074/jbc.271.1.563; SUEN KL, 1993, MOL CELL BIOL, V13, P5500, DOI 10.1128/MCB.13.9.5500; TANAKA S, 1995, J BIOL CHEM, V270, P14347, DOI 10.1074/jbc.270.24.14347; VANDERGEER P, 1994, ANNU REV CELL BIOL, V10, P251, DOI 10.1146/annurev.cellbio.10.1.251; YOON CH, 1995, SCIENCE, V269, P1102, DOI 10.1126/science.7652556	39	146	150	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14554	14559		10.1074/jbc.271.24.14554	http://dx.doi.org/10.1074/jbc.271.24.14554			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662998	hybrid			2022-12-27	WOS:A1996UQ66000091
J	Liu, XS; Kim, CN; Pohl, J; Wang, XD				Liu, XS; Kim, CN; Pohl, J; Wang, XD			Purification and characterization of an interleukin-1 beta-converting enzyme family protease that activates cysteine protease P32 (CPP32)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LEUCINE ZIPPER PROTEIN; TRANSCRIPTION; INHIBITION	CPP32, a member of the interleukin-1 beta-converting enzyme (ICE) family of cysteine proteases, cleaves poly(ADP ribose) polymerase and sterol regulatory element binding proteins during apoptosis, CPP32 normally exists in the cytosol as a 32-kDa inactive precursor and only becomes activated when cells are undergoing apoptosis, The activation is a proteolytic event that generates a p20/p11 heterodimer. We report here the identification, purification, and characterization of a hamster CPP32-activating protease (CAP) that cleaves and activates CPP32. The biochemical properties of CAP suggest that it is another member of the ICE family of proteases, Purified CAP consists of two prominent polypeptides of 19 and 13 kDa. Protein sequencing revealed that CAP is derived from the hamster homolog of Mch2 alpha, a member of the ICE family recently identified based on the sequence conservation among the ICE family members, CAP activity is inhibited by CrmA, a cowpox virus protein that prevents host cell apoptosis, CAP itself is also activated through proteolytic cleavage. These data are consistent with the idea that the activation of the ICE family of proteases during apoptosis proceeds through a cascade of proteolytic events.	EMORY UNIV,SCH MED,WINSHIP CANC CTR,MICROCHEM FACIL,ATLANTA,GA 30322; EMORY UNIV,SCH MED,WINSHIP CANC CTR,DEPT BIOCHEM,ATLANTA,GA 30322	Emory University; Emory University				Wang, Xiaodong/0000-0001-9885-356X				BENNETT MK, 1995, J BIOL CHEM, V270, P25578, DOI 10.1074/jbc.270.43.25578; BOUDREAU N, 1995, SCIENCE, V267, P891, DOI 10.1126/science.7531366; BUMP NJ, 1995, SCIENCE, V269, P1885, DOI 10.1126/science.7569933; Duan HJ, 1996, J BIOL CHEM, V271, P1621, DOI 10.1074/jbc.271.3.1621; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P6045; FERNANDESALNEMRI T, 1995, CANCER RES, V55, P2737; FERNANDESALNEMRI T, 1994, J BIOL CHEM, V269, P30761; GAGLIARDINI V, 1994, SCIENCE, V263, P826, DOI 10.1126/science.8303301; HUA XX, 1993, P NATL ACAD SCI USA, V90, P11603, DOI 10.1073/pnas.90.24.11603; KAMON R, 1994, CELL, V78, P343; KIM JB, 1995, MOL CELL BIOL, V15, P2582; KUIDA K, 1995, SCIENCE, V267, P2000, DOI 10.1126/science.7535475; LI P, 1995, CELL, V80, P401, DOI 10.1016/0092-8674(95)90490-5; Lippke JA, 1996, J BIOL CHEM, V271, P1825, DOI 10.1074/jbc.271.4.1825; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; RAY CA, 1992, CELL, V69, P597, DOI 10.1016/0092-8674(92)90223-Y; SHI L, 1992, J EXP MED, V176, P521; TANAKA Y, 1984, J BIOL CHEM, V259, P6579; TEWARI M, 1995, CELL, V81, P801, DOI 10.1016/0092-8674(95)90541-3; TEWARI M, 1995, J BIOL CHEM, V270, P22705, DOI 10.1074/jbc.270.39.22705; TEWARI M, 1995, J BIOL CHEM, V270, P3255, DOI 10.1074/jbc.270.7.3255; THORNBERRY NA, 1992, NATURE, V356, P768, DOI 10.1038/356768a0; THORNBERRY NA, 1995, PROTEIN SCI, V4, P3; Wang XD, 1996, EMBO J, V15, P1012, DOI 10.1002/j.1460-2075.1996.tb00438.x; WANG XD, 1995, J BIOL CHEM, V270, P18044, DOI 10.1074/jbc.270.30.18044; WANG XD, 1994, CELL, V77, P53, DOI 10.1016/0092-8674(94)90234-8; WILSON KP, 1994, NATURE, V370, P270, DOI 10.1038/370270a0; XUE D, 1995, NATURE, V377, P248, DOI 10.1038/377248a0; YOKOYAMA C, 1993, CELL, V75, P187, DOI 10.1016/S0092-8674(05)80095-9	29	87	93	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13371	13376		10.1074/jbc.271.23.13371	http://dx.doi.org/10.1074/jbc.271.23.13371			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662833	hybrid			2022-12-27	WOS:A1996UP38500013
J	Virbasius, JV; Guilherme, A; Czech, MP				Virbasius, JV; Guilherme, A; Czech, MP			Mouse p170 is a novel phosphatidylinositol 3-kinase containing a C2 domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN KINASE-C; BINDING; IDENTIFICATION; VACUOLE; VPS34	Phosphatidylinositol (PI) 3-kinases catalyze the formation of 3'-phosphoinositides, which appear to promote cellular responses to growth factors and such membrane trafficking events as insulin-stimulated translocation of intracellular glucose transporters. We report here the cloning of a novel PI 3-kinase, p170, from cDNA of insulin-sensitive mouse 3T3-L1 adipocytes. Mouse p170 utilizes PI and to a limited extent PI 4-P as substrates, in contrast to the PI-specific yeast VPS34 homology PtdIns 3-kinase as the p110 PI 3-kinases, which phosphorylate PI, PI 4-P, and PI 4,5-P-2. Mouse p170 is also distinct from PtdIns 3-kinase of the p110 PI 3-kinases in exhibiting a 10-fold lower sensitivity to wortmannin. Unique structural elements of p170 include C-terminal sequences strikingly similar to the phosphoinositide-binding C2 domain of protein kinase C isoforms, synaptotagmins, and other proteins. These features of mouse p170 are shared with a recently cloned Drosophila PI 3-kinase, DmPI3K-68D. Together, these proteins define a new class of PI 3-kinase likely influenced by cellular regulators distinct from those acting upon p110- or VPS34-like PI 3-kinases.	UNIV MASSACHUSETTS, MED CTR, DEPT BIOCHEM & MOLEC BIOL, WORCESTER, MA 01605 USA	University of Massachusetts System; University of Massachusetts Worcester	Virbasius, JV (corresponding author), UNIV MASSACHUSETTS, MED CTR, PROGRAM MOLEC MED, WORCESTER, MA 01605 USA.			Virbasius, Joseph/0000-0003-1784-6793	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK030648] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK30648] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BURGERING BMT, 1995, NATURE, V376, P599, DOI 10.1038/376599a0; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; CHUNG JK, 1994, NATURE, V370, P71, DOI 10.1038/370071a0; CLARK JD, 1991, CELL, V65, P1043, DOI 10.1016/0092-8674(91)90556-E; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; CZECH MP, 1995, ANNU REV NUTR, V15, P441, DOI 10.1146/annurev.nu.15.070195.002301; DHAND R, 1994, EMBO J, V13, P511, DOI 10.1002/j.1460-2075.1994.tb06289.x; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; FROHMAN MA, 1993, METHOD ENZYMOL, V218, P340; HellerHarrison RA, 1996, J BIOL CHEM, V271, P10200, DOI 10.1074/jbc.271.17.10200; HERMAN PK, 1990, MOL CELL BIOL, V10, P6742, DOI 10.1128/MCB.10.12.6742; HILES ID, 1992, CELL, V70, P419, DOI 10.1016/0092-8674(92)90166-A; HU P, 1993, MOL CELL BIOL, V13, P7677, DOI 10.1128/MCB.13.12.7677; HU P, 1994, MOL CELL BIOL, V14, P2577, DOI 10.1128/MCB.14.4.2577; JOLY M, 1995, J BIOL CHEM, V270, P13225, DOI 10.1074/jbc.270.22.13225; JOLY M, 1994, SCIENCE, V263, P684, DOI 10.1126/science.8303278; KAIBUCHI K, 1989, J BIOL CHEM, V264, P13489; KAPELLER R, 1994, BIOESSAYS, V16, P565, DOI 10.1002/bies.950160810; KLIPPEL A, 1994, MOL CELL BIOL, V14, P2675, DOI 10.1128/MCB.14.4.2675; Macdougall LK, 1995, CURR BIOL, V5, P1404, DOI 10.1016/S0960-9822(95)00278-8; NAKANISHI S, 1995, P NATL ACAD SCI USA, V92, P5317, DOI 10.1073/pnas.92.12.5317; OKADA T, 1994, J BIOL CHEM, V269, P3568; PALMER RH, 1995, J BIOL CHEM, V270, P22412, DOI 10.1074/jbc.270.38.22412; PERIN MS, 1990, NATURE, V345, P260, DOI 10.1038/345260a0; SERUNIAN LA, 1991, METHOD ENZYMOL, V198, P78; SHIRATAKI H, 1993, MOL CELL BIOL, V13, P2061, DOI 10.1128/MCB.13.4.2061; STACK JH, 1994, J BIOL CHEM, V269, P31552; STACK JH, 1993, EMBO J, V12, P2195, DOI 10.1002/j.1460-2075.1993.tb05867.x; STEPHENS L, 1994, CURR BIOL, V4, P203, DOI 10.1016/S0960-9822(00)00049-X; STEPHENS LR, 1993, BIOCHIM BIOPHYS ACTA, V1179, P27, DOI 10.1016/0167-4889(93)90072-W; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; SUTTON RB, 1995, CELL, V80, P929, DOI 10.1016/0092-8674(95)90296-1; TOKER A, 1994, J BIOL CHEM, V269, P32358; UI M, 1995, TRENDS BIOCHEM SCI, V20, P303, DOI 10.1016/S0968-0004(00)89056-8; VOLINIA S, 1995, EMBO J, V14, P3339, DOI 10.1002/j.1460-2075.1995.tb07340.x; WALSH J, 1991, P NATL ACAD SCI USA, V87, P9184; WENG QP, 1995, P NATL ACAD SCI USA, V92, P5744, DOI 10.1073/pnas.92.12.5744	37	128	136	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13304	13307		10.1074/jbc.271.23.13304	http://dx.doi.org/10.1074/jbc.271.23.13304			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8663140				2022-12-27	WOS:A1996UP38500004
J	Lee, JY; Hannun, YA; Obeid, LM				Lee, JY; Hannun, YA; Obeid, LM			Ceramide inactivates cellular protein kinase C alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NECROSIS-FACTOR-ALPHA; RETINOBLASTOMA PROTEIN; SPHINGOMYELIN TURNOVER; INHIBITION; ACTIVATION; INVITRO; CELLS; DIFFERENTIATION; PHOSPHORYLATION; IDENTIFICATION	Ceramide mediates the effects of extracellular agents on cellular growth, differentiation and apoptosis, In this study, we explored the mechanisms by which ceramide induces its cellular effects, In Molt-4 cells, phorbol 12-myristate 13-acetate (PMA) induced retinoblastoma gene product (Rb) phosphorylation, and ceramide inhibited this effect, suggesting an inhibitory effect of ceramide on the protein kinase C (PKC) pathway, the primary target of PMA. Molt-4 cells contained primarily PKC alpha and beta(II) isoforms of PKC, To determine the effects of ceramide on PKC, we developed an immunoprecipitation assay for PKC alpha activity. Exposure of Molt-4 cells to C-6-ceramide resulted in a concentration and time-dependent inhibition of immunoprecipitated protein kinase C alpha (PKC alpha). Initial inhibition was observed as early as 4.5 h after treatment of cells with C-6-ceramide, and the activity was completely lost by 13 h, Inhibition of PKC alpha activity was seen at concentrations of ceramide as low as 5 mu M with maximal effects occurring at a concentration of 15 mu M. Both C-2 and C-6-ceramide were inhibitory, but C-2 and C-6 dihydroceramides were not, Ceramide did not directly inhibit PKC alpha in vitro or modulate the levels of PKC alpha protein, suggesting that ceramide acted indirectly, Moreover, ceramide did not inhibit PMA-induced translocation of PKC alpha. Taken together, these results suggested that ceramide caused inactivation of PKC alpha. Since PKC requires phosphorylation for activity, we determined the effects of ceramide on phosphorylation of PKC alpha. C-6-ceramide inhibited basal and PMA-induced phosphorylation of PKC alpha. In addition, okadaic acid, a potent phosphatase inhibitor, slightly stimulated PKC activity and blocked the effects of ceramide on PKC alpha inhibition. These results demonstrate that ceramide causes inhibition/inactivation of PKC alpha and suggest these effects of ceramide may be mediated by a protein phosphatase.	DUKE UNIV,MED CTR,DEPT MED,DIV GERIATR,DURHAM,NC 27710; DUKE UNIV,MED CTR,DEPT CELL BIOL,DURHAM,NC 27710; VET ADM MED CTR,CTR GERIATR RES EDUC & CLIN,DURHAM,NC 27710	Duke University; Duke University; Geriatric Research Education & Clinical Center; US Department of Veterans Affairs; Veterans Health Administration (VHA)				obeid, lina/0000-0002-0734-0847	NIA NIH HHS [K08AG00520, 5T32 AG00029] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [T32AG000029, K08AG000520] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BELL RM, 1991, J BIOL CHEM, V266, P4661; BORNER C, 1989, J BIOL CHEM, V264, P13902; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CARROLL MP, 1994, J BIOL CHEM, V269, P1249; CAZAUBON S, 1994, BIOCHEM J, V301, P443, DOI 10.1042/bj3010443; CAZAUBON SM, 1993, J BIOL CHEM, V268, P17559; CHAO R, 1992, J BIOL CHEM, V267, P23459; DBAIBO GS, 1995, P NATL ACAD SCI USA, V92, P1347, DOI 10.1073/pnas.92.5.1347; DOBROWSKY RT, 1993, J BIOL CHEM, V268, P15523; DOBROWSKY RT, 1992, J BIOL CHEM, V267, P5048; DRESSLER KA, 1992, SCIENCE, V255, P1715, DOI 10.1126/science.1313189; DUTIL EM, 1994, J BIOL CHEM, V269, P29359; HAIMOVITZFRIEDMAN A, 1994, J EXP MED, V180, P525, DOI 10.1084/jem.180.2.525; HANNUN YA, 1986, J BIOL CHEM, V261, P2604; JARVIS WD, 1994, P NATL ACAD SCI USA, V91, P73, DOI 10.1073/pnas.91.1.73; JAYADEV S, 1995, J BIOL CHEM, V270, P2047, DOI 10.1074/jbc.270.5.2047; JONES MJ, 1995, J BIOL CHEM, V270, P5007, DOI 10.1074/jbc.270.10.5007; KIM MY, 1991, J BIOL CHEM, V266, P484; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAIHO M, 1990, CELL, V62, P175, DOI 10.1016/0092-8674(90)90251-9; LAW B, 1995, J BIOL CHEM, V270, P12808, DOI 10.1074/jbc.270.21.12808; MAY WS, 1994, J BIOL CHEM, V269, P26865; MCCONKEY DJ, 1989, J BIOL CHEM, V264, P13399; MERRILL AH, 1989, BIOCHEMISTRY-US, V28, P3138, DOI 10.1021/bi00434a004; NEWTON AC, 1993, ANNU REV BIOPH BIOM, V22, P1, DOI 10.1146/annurev.bb.22.060193.000245; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; OBEID LM, 1993, SCIENCE, V259, P1769, DOI 10.1126/science.8456305; OKAZAKI T, 1989, J BIOL CHEM, V264, P19076; ORR JW, 1994, J BIOL CHEM, V269, P27715; RAJOTTE D, 1992, J BIOL CHEM, V267, P9980; RESNITZKY D, 1992, P NATL ACAD SCI USA, V89, P402, DOI 10.1073/pnas.89.1.402; TOMEI LD, 1988, BIOCHEM BIOPH RES CO, V155, P324, DOI 10.1016/S0006-291X(88)81088-X; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; Venable ME, 1995, J BIOL CHEM, V270, P30701, DOI 10.1074/jbc.270.51.30701; WETSEL WC, 1992, J CELL BIOL, V117, P121, DOI 10.1083/jcb.117.1.121; WOLFF RA, 1994, J BIOL CHEM, V269, P19605	36	236	241	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13169	13174		10.1074/jbc.271.22.13169	http://dx.doi.org/10.1074/jbc.271.22.13169			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662781	hybrid			2022-12-27	WOS:A1996UN47400074
J	Palmiter, KA; Kitada, Y; Muthuchamy, M; Wieczorek, DF; Solaro, RJ				Palmiter, KA; Kitada, Y; Muthuchamy, M; Wieczorek, DF; Solaro, RJ			Exchange of beta- for alpha-tropomyosin in hearts of transgenic mice induces changes in thin filament response to Ca2+ strong cross-bridge binding, and protein phosphorylation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TROPONIN-C; MYOSIN SUBFRAGMENT-1; STRIATED-MUSCLE; ACTIN; CA-2+	Despite its potential as a key determinant of the functional state of striated muscle, the impact of tropomyosin (Tm) isoform switching on mammalian myofilament activation and regulation in the intact lattice remains unclear. Using a transgenic approach to specifically exchange beta-Tm for the native alpha-Tm in mouse hearts, we have been able to uncover novel functions of Tm isoform switching in the heart. The myofilaments containing beta-Tm demonstrated an increase in the activation of the thin filament by strongly bound cross-bridges, an increase in Ca2+ sensitivity of steady state force, and a decrease in the rightward shift of the Ca2+-force relation induced by cAMP-dependent phosphorylation. Our results are the first to demonstrate the specific effects of Tm isoform switching on mammalian thin filament activation in the intact lattice and suggest an important role for Tm in modulation of myofilament activity by phosphorylation of troponin.	UNIV ILLINOIS, COLL MED, DEPT PHYSIOL & BIOPHYS M C 901, CHICAGO, IL 60612 USA; UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Ohio; University of Cincinnati					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007692, P01HL046826, R01HL022231, R37HL022231] Funding Source: NIH RePORTER; NHLBI NIH HHS [T32 HL-07692, HL 46826, HL 22231] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALHILLAWI E, 1995, EUR J BIOCHEM, V228, P962; AMPHLETT GW, 1976, FEBS LETT, V63, P22, DOI 10.1016/0014-5793(76)80186-X; CHALOVICH JM, 1982, J BIOL CHEM, V257, P2432; CHIU YL, 1982, AM J PHYSIOL, V243, pC299, DOI 10.1152/ajpcell.1982.243.5.C299; CHO YJ, 1990, J BIOL CHEM, V265, P538; CUDA G, 1993, J CLIN INVEST, V91, P2861, DOI 10.1172/JCI116530; CUMMINS P, 1973, BIOCHEM J, V133, P765, DOI 10.1042/bj1330765; DURAND JB, 1995, ANN MED, V27, P311, DOI 10.3109/07853899509002583; GODT RE, 1982, J GEN PHYSIOL, V80, P279, DOI 10.1085/jgp.80.2.279; GREENFIELD NJ, 1994, PROTEIN SCI, V3, P402; GUO XD, 1994, J BIOL CHEM, V269, P15210; HERZIG JW, 1981, PFLUG ARCH EUR J PHY, V391, P208, DOI 10.1007/BF00596172; HILL TL, 1980, P NATL ACAD SCI-BIOL, V77, P3186, DOI 10.1073/pnas.77.6.3186; Huxley H. E., 1972, COLD SPRING HARB SYM, V37, P361; IIO T, 1985, J BIOCHEM-TOKYO, V98, P261, DOI 10.1093/oxfordjournals.jbchem.a135266; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEHMAN W, 1994, NATURE, V368, P65, DOI 10.1038/368065a0; LEHRER SS, 1994, J MUSCLE RES CELL M, V15, P232; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MCKILLOP DFA, 1993, BIOPHYS J, V65, P693, DOI 10.1016/S0006-3495(93)81110-X; MOSS RL, 1992, CIRC RES, V70, P865, DOI 10.1161/01.RES.70.5.865; Muthuchamy M, 1995, J BIOL CHEM, V270, P30593, DOI 10.1074/jbc.270.51.30593; NAKAJIMATANIGUCHI C, 1995, J MOL CELL CARDIOL, V27, P2053, DOI 10.1016/0022-2828(95)90026-8; OBRIEN EJ, 1975, J MOL BIOL, V99, P461, DOI 10.1016/S0022-2836(75)80138-0; Pagani ED, 1984, METHOD PHARMACOL, V5, P44; PALMITER KA, 1995, BIOPHYS J, V68, P57; PAN BS, 1989, J BIOL CHEM, V264, P8495; PEARLSTONE JR, 1982, J BIOL CHEM, V257, P587; PHILLIPS GN, 1986, J MOL BIOL, V192, P111, DOI 10.1016/0022-2836(86)90468-7; POPP D, 1993, J MOL BIOL, V229, P279, DOI 10.1006/jmbi.1993.1032; SOLARO RJ, 1976, NATURE, V262, P615, DOI 10.1038/262615a0; Solaro RJ, 1996, J MOL CELL CARDIOL, V28, P217; STRASBURG GM, 1985, J BIOL CHEM, V260, P366; SUBRAMANIAM A, 1991, J BIOL CHEM, V266, P24613; SWEENEY HL, 1994, J BIOL CHEM, V269, P1603; TAO T, 1990, SCIENCE, V247, P1339, DOI 10.1126/science.2138356; THEIRFELDER L, 1994, CELL, V77, P701; THOMAS L, 1994, BIOPHYS J, V66, pA310; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WATKINS H, 1995, NEW ENGL J MED, V332, P1058, DOI 10.1056/NEJM199504203321603; ZHANG R, 1995, CIRC RES, V76, P1028, DOI 10.1161/01.RES.76.6.1028; [No title captured]	42	78	78	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11611	11614		10.1074/jbc.271.20.11611	http://dx.doi.org/10.1074/jbc.271.20.11611			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662805	hybrid			2022-12-27	WOS:A1996UL25000005
J	Smith, KJ; Scotland, G; Beattie, J; Trayer, IP; Houslay, MD				Smith, KJ; Scotland, G; Beattie, J; Trayer, IP; Houslay, MD			Determination of the structure of the N-terminal splice region of the cyclic AMP-specific phosphodiesterase RD1 (RNPDE4A1) by H-1 NMR and identification of the membrane association domain using chimeric constructs	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ALPHA-HELIX DIPOLE; PEPTIDE-FRAGMENTS; PLASMA-MEMBRANE; S-PEPTIDE; PROTEIN; SEQUENCE; CHAIN; STABILIZATION; HOMOLOGS; CLONING	A 25-residue peptide representing the membrane targeting N-terminal splice region of the cyclic AMP phosphodiesterase RD1 (RNPDE4A1) was synthesized, and its structure was determined by H-1 NMR, Two independently folding helical regions were identified, separated by a highly mobile ''hinge'' region, The first helical region was formed by an N-terminal amphipathic cu-helix, and the second consisted of multiple overlapping turns and contained a distinct compact, hydrophobic, tryptophan-rich domain (residues 14-20), Chimeric molecules, formed between the N-terminal region of RD1 and the soluble bacterial protein chloramphenicol acetyltransferase, were used in an in vitro system to determine the features within the splice region that were required for membrane association, The ability of RD1-chloramphenicol acetyltransferase chimera to become membrane-associated was not affected by deletion of any of the following regions: the apolar section (residues 2-7) of the first helical region, the polar part of this region together with the hinge region (residues 8-13), or the polar end of the C-terminal helical region (residues 21-25), In marked contrast, deletion of the compact, hydrophobic tryptophan-rich domain (residues 14-20) found in the second helical region obliterated membrane association, Replacement of this domain with a hydrophobic cassette of seven alanine residues also abolished membrane association, indicating that membrane association occurred by virtue of specific hydrophobic interactions with residues within the compact, tryptophan-rich domain, The structure of this domain is well defined in the peptide, and although the region is helical, both the backbone and the distribution of side chains are somewhat distorted as compared with an ideal cu-helix, Hydrophobic interactions, such as the ''stacked'' rings of residues Pro(14) and Trp(15), stabilize this domain with the side chain of residue Leu(16) adopting a central position, interacting with the side chains of all three tryptophan residues 15, 19, and 20, These bulky side chains thus form a hydrophobic cluster, In contrast, the side chain of residue Val(17) is relatively exposed, pointing out from the opposite ''face'' of the peptide, Although it appears that this compact, tryptophan-rich domain is responsible for membrane association, at present the target site and hence the specific interactions involved in membrane targeting by the RD1 splice region remain unidentified.	UNIV GLASGOW, INST LIFE & BIOMED SCI, DIV BIOCHEM & MOLEC BIOL, MOLEC PHARMACOL GRP, GLASGOW G12 8QQ, LANARK, SCOTLAND; UNIV BIRMINGHAM, SCH BIOCHEM, BIRMINGHAM B15 2TT, W MIDLANDS, ENGLAND; HANNAH RES INST, AYR KA6 5HL, SCOTLAND	University of Glasgow; University of Birmingham			Houslay, Miles D/A-6825-2011; Houslay, Miles/AAM-5281-2020	Houslay, Miles/0000-0002-3826-8091	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BEAVO JA, 1994, MOL PHARMACOL, V46, P399; BOLGER GB, 1994, CELL SIGNAL, V6, P851, DOI 10.1016/0898-6568(94)90018-3; Bolger GB, 1996, J BIOL CHEM, V271, P1065, DOI 10.1074/jbc.271.2.1065; BrUnger A. T., 1992, X PLOR VERSION 3 1 S; CONTI M, 1995, ENDOCR REV, V16, P370, DOI 10.1210/er.16.3.370; CONTI M, 1992, ADV SEC MESS PHOSPH, V25, P87; DAVIS RL, 1989, P NATL ACAD SCI USA, V86, P3604, DOI 10.1073/pnas.86.10.3604; DYSON HJ, 1988, J MOL BIOL, V201, P161, DOI 10.1016/0022-2836(88)90446-9; DYSON HJ, 1992, J MOL BIOL, V226, P795, DOI 10.1016/0022-2836(92)90633-U; FIORI WR, 1995, BIOPOLYMERS, V37, P243, DOI 10.1002/bip.360370403; FIORI WR, 1994, NAT STRUCT BIOL, V1, P374, DOI 10.1038/nsb0694-374; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HOL WGJ, 1978, NATURE, V273, P443, DOI 10.1038/273443a0; HORTON YM, 1995, BIOCHEM J, V308, P683, DOI 10.1042/bj3080683; HOUSLAY MD, 1981, BIOCHEM J, V198, P703, DOI 10.1042/bj1980703; HOUSLAY MD, 1995, BIOCHEM SOC T, V23, P393, DOI 10.1042/bst0230393; HOUSLAY MD, 1990, MOL PHARM CELL REGUL, V2, P185; KABSCH W, 1990, NATURE, V347, P37, DOI 10.1038/347037a0; KLAUCK TM, 1995, CELL SIGNAL, V7, P747, DOI 10.1016/0898-6568(95)02003-9; KOZAK M, 1986, CELL, V44, P283, DOI 10.1016/0092-8674(86)90762-2; KREBS EG, 1979, ANNU REV BIOCHEM, V48, P923, DOI 10.1146/annurev.bi.48.070179.004423; LAU SYM, 1984, J BIOL CHEM, V259, P3253; MACARTHUR MW, 1991, J MOL BIOL, V218, P397, DOI 10.1016/0022-2836(91)90721-H; MANGANIELLO VC, 1995, ARCH BIOCHEM BIOPHYS, V322, P1, DOI 10.1006/abbi.1995.1429; MCPHEE I, 1995, BIOCHEM J, V310, P965, DOI 10.1042/bj3100965; MILATOVICH A, 1994, SOMAT CELL MOLEC GEN, V20, P75, DOI 10.1007/BF02290677; NELSON JW, 1989, BIOCHEMISTRY-US, V28, P5256, DOI 10.1021/bi00438a050; RICHARDSON JS, 1988, PROTEINS, V4, P229, DOI 10.1002/prot.340040402; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SALI D, 1988, NATURE, V335, P740, DOI 10.1038/335740a0; SCHOLTZ JM, 1993, BIOCHEMISTRY-US, V32, P9668, DOI 10.1021/bi00088a019; SCOTLAND G, 1995, BIOCHEM J, V308, P673, DOI 10.1042/bj3080673; SCOTT JD, 1991, PHARMACOL THERAPEUT, V50, P123, DOI 10.1016/0163-7258(91)90075-W; SHAKUR Y, 1993, BIOCHEM J, V292, P677, DOI 10.1042/bj2920677; SHAKUR Y, 1995, BIOCHEM J, V306, P801, DOI 10.1042/bj3060801; SHEFFIELD VC, 1989, P NATL ACAD SCI USA, V86, P232, DOI 10.1073/pnas.86.1.232; SHOEMAKER KR, 1987, NATURE, V326, P563, DOI 10.1038/326563a0; SWINNEN JV, 1989, P NATL ACAD SCI USA, V86, P5325, DOI 10.1073/pnas.86.14.5325; SZPIRER C, 1995, CYTOGENET CELL GENET, V69, P11, DOI 10.1159/000133927; TIRADORIVES J, 1991, BIOCHEMISTRY-US, V30, P3864, DOI 10.1021/bi00230a009	40	48	50	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16703	16711		10.1074/jbc.271.28.16703	http://dx.doi.org/10.1074/jbc.271.28.16703			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663181	hybrid			2022-12-27	WOS:A1996UX12600046
J	Umar, S; Malavasi, F; Mehta, K				Umar, S; Malavasi, F; Mehta, K			Post-translational modification of CD38 protein into a high molecular weight form alters its catalytic properties	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYCLIC ADP-RIBOSE; LYMPHOCYTE ANTIGEN CD38; LEUKEMIA HL-60 CELLS; EGG-SPECIFIC NADASE; RETINOIC ACID; RECEPTOR DIMERIZATION; 2ND-MESSENGER ENZYME; HUMAN ERYTHROCYTES; OUTER SURFACE; EXPRESSION	Human CD38 is a 45-kDa transmembrane protein that acts as a bifunctional ectoenzyme, catalyzing the synthesis of cyclic ADP-ribose (cADPR) from NAD(+) and the hydrolysis of cADPR to ADP-ribose, All-trans-retinoic acid (RA) is a potent and specific inducer of CD38 in myeloid cells, In this report, we demonstrate that RA-induced CD38 protein hom human myeloid (HL-60) leukemia cells coimmunoprecipitates with another protein of molecular mass approximate to 190 kDa (p190), The p190 protein is localized exclusively in the membranes and is a consequence of post-translational cross-linking of CD38 protein, This conclusion was based on the observations that purified CD38 effectively competes with p190, its accumulation is preceded by the accumulation of CD38, it immunoreacted with three different monospecific anti-CD38 antibodies on immunoblots, and its peptide map revealed several peptides in common with CD38. Furthermore, CD38 could serve as a suitable substrate for transglutaminase (TGase)-catalyzed cross-linking reactions in vitro, and the accumulation of p190 in RA-treated HL-60 cells is effectively blocked by the presence of TGase-specific inhibitor, The purified p190 showed at least three times more cyclase activity than CD38, Conversely, p190 was at least 2.5-fold less active than CD38 in hydrolyzing cADPR to ADPR. These results suggest that post-translational modification of CD38 may represent an important mechanism for regulating the two catalytic activities of this bifunctional enzyme.	UNIV TEXAS,MD ANDERSON CANCER CTR,DEPT BIOIMMUNOTHERAPY,HOUSTON,TX 77030; UNIV ANCONA,SCH MED,INST BIOL & GENET,I-60100 ANCONA,ITALY	University of Texas System; UTMD Anderson Cancer Center; Marche Polytechnic University				MALAVASI, Fabio/0000-0002-1844-174X	Telethon [E.0266] Funding Source: Medline; FDA HHS [FDR-000923] Funding Source: Medline	Telethon(Fondazione Telethon); FDA HHS		AESCHLIMANN D, 1994, THROMB HAEMOSTASIS, V71, P402; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; COCHET C, 1988, J BIOL CHEM, V263, P3290; CORDELLAMIELE E, 1990, J BIOL CHEM, V265, P17180; DAVIES PJA, 1985, J BIOL CHEM, V260, P5166; DRACH J, 1993, BIOCHEM BIOPH RES CO, V195, P545, DOI 10.1006/bbrc.1993.2080; DRACH J, 1994, CANCER RES, V54, P1746; EITAN S, 1994, SCIENCE, V264, P1764, DOI 10.1126/science.7911602; GALIONE A, 1991, SCIENCE, V253, P1143, DOI 10.1126/science.1909457; GLICK DL, 1991, CELL REGUL, V2, P211, DOI 10.1091/mbc.2.3.211; GRAEFF RM, 1994, J BIOL CHEM, V269, P30260; GRAEFF RM, 1994, BIOCHEM BIOPH RES CO, V205, P722, DOI 10.1006/bbrc.1994.2725; GREENBERG CS, 1991, FASEB J, V5, P3071, DOI 10.1096/fasebj.5.15.1683845; GREENLUND AC, 1993, J BIOL CHEM, V268, P18103; HARADA N, 1993, J IMMUNOL, V151, P3111; HELLMICH MR, 1991, CELL REGUL, V2, P193, DOI 10.1091/mbc.2.3.193; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; JACKSON DG, 1990, J IMMUNOL, V144, P2811; KONTANI K, 1993, J BIOL CHEM, V268, P16895; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE HC, 1991, CELL REGUL, V2, P203, DOI 10.1091/mbc.2.3.203; LEE HC, 1993, BIOCHEM BIOPH RES CO, V191, P639, DOI 10.1006/bbrc.1993.1265; LEE HC, 1989, J BIOL CHEM, V264, P1608; LEE HC, 1993, J BIOL CHEM, V268, P293; MALAVASI F, 1994, IMMUNOL TODAY, V15, P95, DOI 10.1016/0167-5699(94)90148-1; MESZAROS LG, 1993, NATURE, V364, P76, DOI 10.1038/364076a0; MULLER HM, 1983, BIOCHEM J, V212, P456; NERVI C, 1989, P NATL ACAD SCI USA, V86, P5854, DOI 10.1073/pnas.86.15.5854; STATES DJ, 1992, TRENDS BIOCHEM SCI, V17, P495, DOI 10.1016/0968-0004(92)90337-9; SUMMERHILL RJ, 1993, FEBS LETT, V335, P231, DOI 10.1016/0014-5793(93)80735-D; TAKASAWA S, 1993, J BIOL CHEM, V268, P26052; TAKASAWA S, 1993, SCIENCE, V259, P370, DOI 10.1126/science.8420005; TOHGO A, 1994, J BIOL CHEM, V269, P28555; ZOCCHI E, 1993, BIOCHEM BIOPH RES CO, V196, P1459, DOI 10.1006/bbrc.1993.2416	35	58	60	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15922	15927		10.1074/jbc.271.27.15922	http://dx.doi.org/10.1074/jbc.271.27.15922			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663150	hybrid			2022-12-27	WOS:A1996UW35200016
J	Arvola, M; Keinanen, K				Arvola, M; Keinanen, K			Characterization of the ligand-binding domains of glutamate receptor (GluR)-B and GluR-D subunits expressed in Escherichia coli as periplasmic proteins	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; PHOSPHORYLATION; IDENTIFICATION; PURIFICATION; MODULATION; CHANNELS; PRODUCT; FAMILY	We recently reported that a functional ligand-binding site of an alpha-amino-5-methyl-3-hydroxy-4-isoxazole propionate (AMPA)-selective glutamate receptor (GluR)-D subunit can be expressed in insect cells as a soluble, N-glycosylated fusion protein consisting of two segments (S1 and S2) that are related by amino acid sequence to bacterial periplasmic binding proteins (Kuusinen, A., Arvola, M., and Keinanen, K., EMBO J. 14, 6327-6332). In an attempt to further characterize the structural determinants for ligand binding, we have now expressed the ligand-binding sites of GluR-B and GluR-D subunits in Escherichia coli as soluble periplasmic proteins. The bacterially expressed S1-S2 fusion proteins bound [H-3]AMPA with a high affinity (K-d of 12 nM for GluR-B, K-d of 60 nM for GluR-D) and with a ligand pharmacology typical of native AMPA receptors, indicating that N-linked glycosylation is not required for the formation or the maintenance of the ligand-binding site. The flip and Bop splice variants of the GluR-D S1-S2 fusion protein bound [H-3]AMPA with equal affinities, whereas deletion of the C-terminal one-third of the S2 segment including the flip/flop sequence resulted in a loss of binding activity, Our results highlight the potential of bacterial expression for the analysis of the binding site and support a close structural similarity between glutamate receptors and bacterial proteins.	VTT,BIOTECHNOL & FOOD RES,FIN-02044 ESPOO,FINLAND	VTT Technical Research Center Finland			Keinanen, Kari/E-9122-2010					BENNETT JA, 1995, NEURON, V14, P373, DOI 10.1016/0896-6273(95)90293-7; BERTIN B, 1992, J BIOL CHEM, V267, P8200; EHRLICH YH, 1986, NATURE, V320, P67, DOI 10.1038/320067a0; EVAN GI, 1985, MOL CELL BIOL, V5, P3610, DOI 10.1128/MCB.5.12.3610; FREISSMUTH M, 1991, P NATL ACAD SCI USA, V88, P8548, DOI 10.1073/pnas.88.19.8548; HOLLMANN M, 1994, ANNU REV NEUROSCI, V17, P31, DOI 10.1146/annurev.ne.17.030194.000335; HOLLMANN M, 1994, NEURON, V13, P1331, DOI 10.1016/0896-6273(94)90419-7; HONORE T, 1988, SCIENCE, V241, P701, DOI 10.1126/science.2899909; HOPP TP, 1988, BIO-TECHNOL, V6, P1204, DOI 10.1038/nbt1088-1204; HULLEBROECK MF, 1992, BRAIN RES, V590, P187, DOI 10.1016/0006-8993(92)91094-U; HUME RI, 1991, SCIENCE, V253, P1028, DOI 10.1126/science.1653450; HUNTER C, 1992, J NEUROCHEM, V58, P1379, DOI 10.1111/j.1471-4159.1992.tb11353.x; KAWAMOTO S, 1995, J NEUROCHEM, V64, P1258; KEINANEN K, 1990, SCIENCE, V249, P556, DOI 10.1126/science.2166337; KEINANEN K, 1994, BIO-TECHNOL, V12, P802, DOI 10.1038/nbt0894-802; KNAPPIK A, 1994, BIOTECHNIQUES, V17, P754; KURYATOV A, 1994, NEURON, V12, P1291, DOI 10.1016/0896-6273(94)90445-6; Kuusinen A, 1995, EMBO J, V14, P6327, DOI 10.1002/j.1460-2075.1995.tb00323.x; LEI SP, 1987, J BACTERIOL, V169, P4379, DOI 10.1128/jb.169.9.4379-4383.1987; LI F, 1995, MOL PHARMACOL, V47, P148; LOMELI H, 1994, SCIENCE, V266, P1709, DOI 10.1126/science.7992055; MAYER ML, 1989, P NATL ACAD SCI USA, V86, P1411, DOI 10.1073/pnas.86.4.1411; NAKANISHI N, 1990, NEURON, V5, P569, DOI 10.1016/0896-6273(90)90212-X; NAKAZAWA K, 1995, NEURON, V15, P697, DOI 10.1016/0896-6273(95)90157-4; OH BH, 1993, J BIOL CHEM, V268, P11348; OH BH, 1994, J BIOL CHEM, V269, P4135; OHARA PJ, 1993, NEURON, V11, P41, DOI 10.1016/0896-6273(93)90269-W; PARTIN KM, 1995, NEURON, V14, P833, DOI 10.1016/0896-6273(95)90227-9; RAYMOND LA, 1993, NATURE, V361, P637, DOI 10.1038/361637a0; ROCHE KW, 1994, J BIOL CHEM, V269, P11679; Sambrook J., 2002, MOL CLONING LAB MANU; SOMMER B, 1990, SCIENCE, V249, P1580, DOI 10.1126/science.1699275; STERNBACH Y, 1994, NEURON, V13, P1345, DOI 10.1016/0896-6273(94)90420-0; TAKKINEN K, 1991, PROTEIN ENG, V4, P837, DOI 10.1093/protein/4.7.837; TAM R, 1993, MICROBIOL REV, V57, P320, DOI 10.1128/MMBR.57.2.320-346.1993; TAVERNA FA, 1994, J BIOL CHEM, V269, P14159; UCHINO S, 1992, FEBS LETT, V308, P253, DOI 10.1016/0014-5793(92)81286-U; VERDOORN TA, 1991, SCIENCE, V252, P1715, DOI 10.1126/science.1710829; WANG LY, 1993, SCIENCE, V259, P1173, DOI 10.1126/science.8382377; WO ZG, 1995, TRENDS NEUROSCI, V18, P161; WO ZG, 1994, P NATL ACAD SCI USA, V91, P7154, DOI 10.1073/pnas.91.15.7154; YAKEL JL, 1995, P NATL ACAD SCI USA, V92, P1376, DOI 10.1073/pnas.92.5.1376; YAO NH, 1994, BIOCHEMISTRY-US, V33, P4769, DOI 10.1021/bi00182a004	43	60	61	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15527	15532		10.1074/jbc.271.26.15527	http://dx.doi.org/10.1074/jbc.271.26.15527			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663017	hybrid			2022-12-27	WOS:A1996UV29900036
J	Beyer, BM; Dunn, BM				Beyer, BM; Dunn, BM			Self-activation of recombinant human lysosomal procathepsin D at a newly engineered cleavage junction, ''short'' pseudocathepsin D	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENZYME CATHEPSIN-D; ASPARTIC PROTEINASE; OLIGOSACCHARIDES; PHOSPHORYLATION; INTERMEDIATE; INHIBITORS; EXPRESSION; PEPSINOGEN; FRAGMENTS; CELLS	To obtain a recombinant model of human cathepsin D with kinetic properties that are identical with native human liver enzyme, we have addressed the significant differences in structure and catalytic function between naturally occurring enzyme and bacterially derived pseudocathepsin D, Human procathepsin D was expressed in a baculovirus system to obtain correctly folded, glycosylated enzyme that upon acidification completely converts to the active intermediate, pseudocathepsin D. The oligosaccharide moieties of this recombinant enzyme contributed to about 5% of the apparent molecular mass of the enzyme, and the carbohydrate composition was quite similar to the native material, However, specificity constants (k(cat)/K-m) of this glycosylated pseudoform for several synthetic chromogenic substrates were considerably less (33%-50%) than those for the native enzyme and were virtually identical with those observed with nonglycosylated pseudocathepsin D. A cleavable junction suitable for self-processing at the normal maturation point of human cathepsin D was en engineered into procathepsin D according to known specificity requirements of this enzyme, and the construct was expressed using baculovirus. Following experiments that demonstrated that the new proenzyme failed to process to the expected point, the new cleavage junction was moved 6 residues toward the amino terminus of procathepsin D and expressed in Escherichia coli, After refolding, the protein containing the newly engineered junction self-processed, generating a shortened mutant form of pseudocathepsin D that is 6 residues longer at the amino terminus than the native material. The kinetic properties of this newly engineered pseudoform proved to be identical with those of the native enzyme, thus establishing an improved recombinant model for this important aspartic proteinase.	UNIV FLORIDA, DEPT BIOCHEM & MOLEC BIOL, GAINESVILLE, FL 32610 USA	State University System of Florida; University of Florida					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK018865] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK18865] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AALTONEN M, 1995, ANTICANCER RES, V15, P1033; AIKAWA J, 1990, J BIOL CHEM, V265, P13955; BALDWIN ET, 1993, P NATL ACAD SCI USA, V90, P6796, DOI 10.1073/pnas.90.14.6796; Barrett A, 1977, PROTEINASES MAMMALIA, P209; CANTOR AB, 1992, J BIOL CHEM, V267, P23349; CANTOR AB, 1992, J BIOL CHEM, V267, P23357; CHEN Z, 1991, J BIOL CHEM, V266, P11718; CONNER GE, 1990, DNA CELL BIOL, V9, P1, DOI 10.1089/dna.1990.9.1; CONNER GE, 1992, J BIOL CHEM, V267, P21738; CONNER GE, 1989, BIOCHEMISTRY-US, V28, P3530, DOI 10.1021/bi00434a057; CONNER GE, 1992, BIOCHEMISTRY-US, V31, P1142, DOI 10.1021/bi00119a024; CONNER GE, 1987, LYSOSOMES THEIR ROLE, P151; DEAN RT, 1976, ESSAYS BIOCHEM, P1; DIMENT S, 1988, J BIOL CHEM, V263, P6901; DUNN BM, 1994, PEPTIDE ANAL PROTOCO, P225; ERICKSON AH, 1983, BIOCHEMISTRY-US, V22, P5201, DOI 10.1021/bi00291a021; FOTENBERRY S, 1995, J BIOL CHEM, V270, P9778; FUKUDA R, 1994, J BIOL CHEM, V269, P9556; GRUENWALD S, 1993, BACULOVIRUS EXPRESSI, P39; HENDERSON P, 1972, J BIOL CHEM, V247, P321; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HUI KY, 1993, FEBS LETT, V327, P355, DOI 10.1016/0014-5793(93)81020-Z; JAMES M, 1995, ADV EXP MED BIOL, V362, P11; JAMES MNG, 1986, NATURE, V319, P33, DOI 10.1038/319033a0; KOELSCH G, 1994, FEBS LETT, V343, P6, DOI 10.1016/0014-5793(94)80596-2; KORNFELD S, 1990, BIOCHEM SOC T, V18, P367, DOI 10.1042/bst0180367; LADROR US, 1994, J BIOL CHEM, V269, P18422; MARCINISZYN J, 1976, J BIOL CHEM, V251, P7095; PILLAI S, 1986, J BIOL CHEM, V261, P4919; Rochefort H, 1990, Semin Cancer Biol, V1, P153; SAMAREL AM, 1989, AM J PHYSIOL, V257, pC1069, DOI 10.1152/ajpcell.1989.257.6.C1069; SANCHEZ LM, 1993, BRIT J CANCER, V67, P1076, DOI 10.1038/bjc.1993.197; SCARBOROUGH PE, 1994, PROTEIN ENG, V7, P495, DOI 10.1093/protein/7.4.495; SCARBOROUGH PE, 1993, PROTEIN SCI, V2, P264; SHEWALE JG, 1984, P NATL ACAD SCI-BIOL, V81, P3703, DOI 10.1073/pnas.81.12.3703; SIMAN R, 1993, J BIOL CHEM, V268, P16602	36	49	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15590	15596		10.1074/jbc.271.26.15590	http://dx.doi.org/10.1074/jbc.271.26.15590			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663051	hybrid			2022-12-27	WOS:A1996UV29900044
J	Duche, D; Izard, J; GonzalezManas, JM; Parker, MW; Crest, M; Chartier, M; Baty, D				Duche, D; Izard, J; GonzalezManas, JM; Parker, MW; Crest, M; Chartier, M; Baty, D			Membrane topology of the colicin a pore-forming domain analyzed by disulfide bond engineering	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLTAGE-DEPENDENT CHANNEL; PLANAR LIPID BILAYERS; TERMINAL FRAGMENT; HELICAL HAIRPIN; TRANSLOCATION; INSERTION; PROTEIN; IDENTIFICATION; PHOSPHOLIPIDS; FLUORESCENCE	Four colicin A double-cysteine mutants possessing a disulfide bond in their pore-forming domain were constructed to study the translocation and the pore formation of colicin A. The disulfide bonds connected alpha-helices 1 and 2, 2 and 10, 3 and 9, or 3 and 10 of the pore-forming domain. The disulfide bonds did not prevent the colicin A translocation through the Escherichia coli envelope. However, the mutated colicins were able to exert their in vivo channel activity only after reduction of their disulfide bonds. In vitro studies with brominated phospholipid vesicles and planar lipid bilayers revealed that the disulfide bond that connects the alpha-helices 2 and 10 prevented the colicin A membrane insertion, whereas the other double-cysteine mutants inserted into Lipid vesicles. The disulfide bonds that connect either the alpha-helices 1 and 2 or 3 and 10 were unable to prevent the formation of a conducting channel in presence of membrane potential. These results indicate that alpha-helices 1, 2, 3, and 10 remain at the membrane surface after application of a membrane potential.	CNRS, INST BIOL STRUCT & MICROBIOL, LAB INGN & DYNAM SYST MEMBRANAIRES, F-13402 MARSEILLE 20, FRANCE; UNIV BASQUE COUNTRY, FAC SCI, DEPT BIOCHEM & MOLEC BIOL, E-48080 BILBAO, SPAIN; ST VINCENTS INST MED RES, FITZROY, VIC 3065, AUSTRALIA; NEUROBIOL LAB, F-13402 MARSEILLE 20, FRANCE	Centre National de la Recherche Scientifique (CNRS); University of Basque Country; St. Vincent's Institute of Medical Research			Izard, Jacques/A-6074-2012; Parker, Michael W/F-9069-2013	Parker, Michael W/0000-0002-3101-1138; Baty, Daniel/0000-0001-8443-4444; Izard, Jacques/0000-0002-5904-5436; GONZALEZ MANAS, JUAN MANUEL/0000-0002-1833-6982; Duche, Denis/0000-0002-4208-6661				ABRAMS CK, 1991, J GEN PHYSIOL, V98, P77, DOI 10.1085/jgp.98.1.77; BATY D, 1988, MOL MICROBIOL, V2, P807, DOI 10.1111/j.1365-2958.1988.tb00092.x; BATY D, 1990, EUR J BIOCHEM, V189, P409, DOI 10.1111/j.1432-1033.1990.tb15503.x; BENEDETTI H, 1992, EMBO J, V11, P441, DOI 10.1002/j.1460-2075.1992.tb05073.x; BOLEN EJ, 1990, BIOCHEMISTRY-US, V29, P9638, DOI 10.1021/bi00493a019; BOURDINEAUD JP, 1990, P NATL ACAD SCI USA, V87, P1037, DOI 10.1073/pnas.87.3.1037; COLLARINI M, 1987, EUR BIOPHYS J BIOPHY, V14, P147, DOI 10.1007/BF00253839; DUCHE D, 1994, J BIOL CHEM, V269, P24820; DUCHE D, 1995, J BACTERIOL, V177, P4935, DOI 10.1128/jb.177.17.4935-4939.1995; DUCHE D, 1994, J BIOL CHEM, V269, P6332; GELI V, 1992, BIOCHEMISTRY-US, V31, P11089, DOI 10.1021/bi00160a019; GHOSH P, 1994, NAT STRUCT BIOL, V1, P597, DOI 10.1038/nsb0994-597; GONZALEZMANAS JM, 1993, EUR J BIOCHEM, V211, P625, DOI 10.1111/j.1432-1033.1993.tb17590.x; GONZALEZMANAS JM, 1992, BIOCHEMISTRY-US, V31, P7294, DOI 10.1021/bi00147a013; HAZES B, 1988, PROTEIN ENG, V2, P119, DOI 10.1093/protein/2.2.119; IZARD J, 1994, PROTEIN ENG, V7, P1495, DOI 10.1093/protein/7.12.1495; JAKES KS, 1990, J BIOL CHEM, V265, P6984; JEANTEUR D, 1994, J MOL BIOL, V235, P898, DOI 10.1006/jmbi.1994.1047; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LAKEY JH, 1993, J MOL BIOL, V230, P1055, DOI 10.1006/jmbi.1993.1218; LAKEY JH, 1992, FEBS LETT, V307, P26, DOI 10.1016/0014-5793(92)80895-N; LAKEY JH, 1991, EUR J BIOCHEM, V196, P599, DOI 10.1111/j.1432-1033.1991.tb15855.x; LAKEY JH, 1994, EUR J BIOCHEM, V220, P155, DOI 10.1111/j.1432-1033.1994.tb18610.x; LLOUBES R, 1986, NUCLEIC ACIDS RES, V14, P2621, DOI 10.1093/nar/14.6.2621; MASSOTTE D, 1989, BIOCHEMISTRY-US, V28, P7713, DOI 10.1021/bi00445a029; MASSOTTE D, 1993, BIOCHEMISTRY-US, V32, P13787, DOI 10.1021/bi00213a006; MEL SF, 1993, BIOCHEMISTRY-US, V32, P9473, DOI 10.1021/bi00087a027; MERRILL AR, 1990, BIOCHEMISTRY-US, V29, P8529, DOI 10.1021/bi00489a004; MUELLER P, 1962, NATURE, V194, P979, DOI 10.1038/194979a0; PALMER LR, 1994, J BIOL CHEM, V269, P4187; PARKER MW, 1990, TRENDS BIOCHEM SCI, V15, P126, DOI 10.1016/0968-0004(90)90205-P; PARKER MW, 1989, NATURE, V337, P93, DOI 10.1038/337093a0; PARKER MW, 1992, J MOL BIOL, V224, P639, DOI 10.1016/0022-2836(92)90550-4; QIU XQ, 1994, J BIOL CHEM, V269, P7483; RAYMOND L, 1986, J MEMBRANE BIOL, V92, P255, DOI 10.1007/BF01869394; SCHEIN SJ, 1978, NATURE, V276, P159, DOI 10.1038/276159a0; SHIN YK, 1993, SCIENCE, V259, P960, DOI 10.1126/science.8382373; SLATIN SL, 1986, J MEMBRANE BIOL, V92, P247, DOI 10.1007/BF01869393; SLATIN SL, 1994, NATURE, V371, P158, DOI 10.1038/371158a0; SONG HY, 1991, J BACTERIOL, V173, P2927, DOI 10.1128/JB.173.9.2927-2934.1991; VANDERGOOT FG, 1993, EUR J BIOCHEM, V213, P217	41	21	21	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15401	15406		10.1074/jbc.271.26.15401	http://dx.doi.org/10.1074/jbc.271.26.15401			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663026	Green Published			2022-12-27	WOS:A1996UV29900018
J	Eckenhoff, RG				Eckenhoff, RG			Amino acid resolution of halothane binding sites in serum albumin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							VOLATILE ANESTHETICS; TRIFLUOROACETIC-ACID; GENERAL-ANESTHETICS; PROTEINS; MEMBRANES; F-19-NMR	Saturable binding of various inhaled anesthetics to serum albumin has been shown with a variety of approaches, In order to determine the location of halothane binding sites in serum albumin, both human and bovine serum albumins (HSA and BSA) were photolabeled with [C-14]halothane, and subjected to proteolysis and microsequencing, BSA was found to have a higher affinity for halothane than HSA, and it contained two specifically labeled sites, One site was characterized by diffuse labeling from Trp(212)-Leu(217), and the other by a more discrete and higher affinity labeling at Trp(134)-Gly(135). HSA contained only a single labeled site, and although lower affinity, was determined to be analogous to BSA Trp(212). The position 130-140 region of HSA, having a leucine instead of tryptophan at position 134, was not labeled, These results demonstrate specific and discrete binding of an inhaled anesthetic to a mammalian-soluble protein, and further suggest the importance of aromatic residues as one feature of inhaled anesthetic binding sites.	UNIV PENN,MED CTR,DEPT ANESTHESIA,PHILADELPHIA,PA 19104; UNIV PENN,MED CTR,DEPT PHYSIOL,PHILADELPHIA,PA 19104	University of Pennsylvania; University of Pennsylvania				Eckenhoff, Roderic/0000-0002-5581-746X	NIGMS NIH HHS [GM50595] Funding Source: Medline	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AKERFELDT KS, 1993, ACCOUNTS CHEM RES, V26, P191, DOI 10.1021/ar00028a009; BALASUBR.D, 1966, P NATL ACAD SCI USA, V55, P762, DOI 10.1073/pnas.55.4.762; BUCH HP, 1990, ACTA ANAESTH SCAND, V34, P35; CALVO R, 1989, ACTA ANAESTH SCAND, V33, P575, DOI 10.1111/j.1399-6576.1989.tb02969.x; CARTER DC, 1994, ADV PROTEIN CHEM, V45, P153; CORNETTE JL, 1987, J MOL BIOL, V195, P659, DOI 10.1016/0022-2836(87)90189-6; DALE O, 1986, BIOCHEM PHARMACOL, V35, P557, DOI 10.1016/0006-2952(86)90347-3; DONG AC, 1994, J BIOL CHEM, V269, P23911; Dougherty DA, 1996, SCIENCE, V271, P163, DOI 10.1126/science.271.5246.163; DUBOIS BW, 1993, P NATL ACAD SCI USA, V90, P6478, DOI 10.1073/pnas.90.14.6478; DUBOIS BW, 1992, BIOCHEMISTRY-US, V31, P7069, DOI 10.1021/bi00146a007; ECKENHOFF RG, 1993, ANESTHESIOLOGY, V79, P96, DOI 10.1097/00000542-199307000-00015; Eckenhoff RG, 1996, P NATL ACAD SCI USA, V93, P2807, DOI 10.1073/pnas.93.7.2807; ELMAGHRABI EA, 1992, P NATL ACAD SCI USA, V89, P4329, DOI 10.1073/pnas.89.10.4329; FERNANDEZBALLESTER G, 1994, BIOCHEMISTRY-US, V33, P4065, DOI 10.1021/bi00179a035; FORMAN SA, 1995, MOL PHARMACOL, V48, P574; FRANKS NP, 1994, NATURE, V367, P607, DOI 10.1038/367607a0; FRANKS NP, 1978, NATURE, V274, P339, DOI 10.1038/274339a0; HANSCH C, 1975, J MED CHEM, V18, P546, DOI 10.1021/jm00240a002; JOHANSSON JS, 1995, ANESTHESIOLOGY, V83, P316, DOI 10.1097/00000542-199508000-00012; JOHANSSON JS, 1996, IN PRESS BIOCH BIOPH; JORGENSEN K, 1993, CHEM PHYS LIPIDS, V65, P205, DOI 10.1016/0009-3084(93)90018-X; MCDONAGH AF, 1992, EXPERIENTIA, V48, P246, DOI 10.1007/BF01930465; NAKAGAWA T, 1994, J MOL BIOL, V238, P297, DOI 10.1006/jmbi.1994.1292; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; RUOHO AE, 1984, MEMBRANES DETERGENTS, P119; SACHSENHEIMER W, 1977, FEBS LETT, V79, P310, DOI 10.1016/0014-5793(77)80809-0; SCHOENBO.BP, 1967, NATURE, V214, P1120, DOI 10.1038/2141120a0; SCHOENBORN BP, 1965, NATURE, V207, P28, DOI 10.1038/207028a0; SCHOENBORN BP, 1976, P NATL ACAD SCI USA, V73, P4195, DOI 10.1073/pnas.73.11.4195; SUAREZ E, 1991, METHOD FIND EXP CLIN, V13, P693; TILTON RF, 1984, BIOCHEMISTRY-US, V23, P2849, DOI 10.1021/bi00308a002; VEIRO JA, 1985, CHEM-BIOL INTERACT, V54, P337, DOI 10.1016/S0009-2797(85)80174-5; VERSCHUEREN KHG, 1993, NATURE, V363, P693, DOI 10.1038/363693a0	34	57	57	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15521	15526		10.1074/jbc.271.26.15521	http://dx.doi.org/10.1074/jbc.271.26.15521			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663164	hybrid			2022-12-27	WOS:A1996UV29900035
J	Gvakharia, BO; Hanson, E; Koonin, EK; Mathews, CK				Gvakharia, BO; Hanson, E; Koonin, EK; Mathews, CK			Identification of a second functional glutaredoxin encoded by the bacteriophage T4 genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RIBONUCLEOTIDE REDUCTASE; MUTANT THIOREDOXINS; THIOLTRANSFERASE; SEQUENCE; ENZYME; ACID	Thioredoxins and glutaredoxins are small ubiquitous redox proteins that were discovered as hydrogen donors for ribonucleotide reductase, the key enzyme for deoxyribonucleotide biosynthesis. Some organisms encode more than one redox protein. In this study, we demonstrate that an open reading frame in the bacteriophage T4 genome, reported earlier and designated as Y55.7 (Tomaschewski, J., and Ruger, W. (1987) Nucleic Acids Res. 15, 3632-3633), encodes a second functional redox protein. Gene y55.7 was cloned and expressed in Escherichia coli. Purified Y55.7 protein had glutathione-dependent thioltransferase and dehydroascorbate reductase activities indicative of a functional glutaredoxin. The protein is expressed at all stages of the T4 infection cycle and can serve as a hydrogen donor for the phage ribonucleotide reductase in in vitro experiments.	OREGON STATE UNIV,DEPT BIOCHEM & BIOPHYS,CORVALLIS,OR 97331; NATL LIB MED,NIH,NATL CTR BIOTECHNOL INFORMAT,BETHESDA,MD 20894	Oregon State University; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM)					NIGMS NIH HHS [GM 87508] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM087508] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AHN BY, 1992, P NATL ACAD SCI USA, V89, P7060, DOI 10.1073/pnas.89.15.7060; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ASLUND F, 1994, P NATL ACAD SCI USA, V91, P9813, DOI 10.1073/pnas.91.21.9813; BJORNSTEDT M, 1994, J BIOL CHEM, V269, P29382; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROT N, 1982, TRENDS BIOCHEM SCI, V7, P137, DOI 10.1016/0968-0004(82)90204-3; DARLING AJ, 1988, J GEN VIROL, V69, P515, DOI 10.1099/0022-1317-69-3-515; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; GAN ZR, 1990, BIOCHEM BIOPH RES CO, V168, P944, DOI 10.1016/0006-291X(90)91120-H; GAN ZR, 1987, J BIOL CHEM, V262, P6699; HOLMGREN A, 1978, J BIOL CHEM, V253, P7424; HOLMGREN A, 1989, J BIOL CHEM, V264, P13963; HOOG JO, 1989, GENE, V43, P13; HOPPER S, 1983, J BIOL CHEM, V258, P3453; HUBER HE, 1986, J BIOL CHEM, V261, P5006; KOONIN EV, 1995, P NATL ACAD SCI USA, V92, P11921, DOI 10.1073/pnas.92.25.11921; KOONIN EV, 1996, IN PRESS CURR BIOL; MORELL S, 1995, FEBS LETT, V369, P149, DOI 10.1016/0014-5793(95)00690-B; MULLER EGD, 1995, ARCH BIOCHEM BIOPHYS, V318, P356, DOI 10.1006/abbi.1995.1240; MYERS EW, 1988, COMPUT APPL BIOSCI, V4, P11, DOI 10.1093/bioinformatics/4.1.11; NIKKOLA MJ, 1991, THESIS SWEDICH U AGR; PAPAYANNOPOULOS IA, 1989, BIOCHEM BIOPH RES CO, V159, P1448, DOI 10.1016/0006-291X(89)92272-9; RAJAGOPAL I, 1995, J BIOL CHEM, V270, P27415, DOI 10.1074/jbc.270.46.27415; ROST B, 1994, PROTEINS, V19, P55, DOI 10.1002/prot.340190108; ROST B, 1993, J MOL BIOL, V232, P584, DOI 10.1006/jmbi.1993.1413; RUSSEL M, 1986, J BIOL CHEM, V261, P4997; SODERBERG BO, 1978, P NATL ACAD SCI USA, V75, P5827, DOI 10.1073/pnas.75.12.5827; Tatusov RL, 1996, CURR BIOL, V6, P279, DOI 10.1016/S0960-9822(02)00478-5; TOMASCHEWSKI J, 1987, NUCLEIC ACIDS RES, V15, P3632, DOI 10.1093/nar/15.8.3632; TSENG MJ, 1992, J BACTERIOL, V174, P5740, DOI 10.1128/JB.174.17.5740-5744.1992; YOUNG P, 1994, J BIOL CHEM, V269, P20229	32	16	16	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15307	15310		10.1074/jbc.271.26.15307	http://dx.doi.org/10.1074/jbc.271.26.15307			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8662944	hybrid			2022-12-27	WOS:A1996UV29900003
J	Li, XL; Bennett, V				Li, XL; Bennett, V			Identification of the spectrin subunit and domains required for formation of spectrin/adducin/actin complexes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ERYTHROCYTE-MEMBRANE SKELETON; PROTEIN KINASE-C; DROSOPHILA BETA-SPECTRIN; ACTIN-BINDING DOMAIN; ALPHA-ACTININ; TERMINAL DOMAIN; BRAIN SPECTRIN; CROSS-LINKING; F-ACTIN; SEQUENCE	Adducin is an actin-binding protein that has been proposed to function as a regulated assembly factor for the spectrin/actin network. This study has addressed the question of the subunit and domains of spectrin required for formation of spectrin/adducin/actin complexes in in vitro assays. Quantitative evidence is presented that the beta-spectrin N-terminal domain plus the first two alpha-helical domains are required for optimal participation of spectrin in spectrin/adducin/actin complexes. The alpha subunit exhibited no detectable activity either alone or following association with beta-spectrin. The critical domains of beta-spectrin involved in complex formation were determined using recombinant proteins expressed in bacteria. The N-terminal domain (residues 1-313) of beta-spectrin associated with F-actin with a K-d of 26 mu M, and promoted adducin binding to F-actin with half-maximal activation at 110 nM. Addition of the first cu-helical domain (residues 1-422) lowered the K-d for F-actin by 4-fold to 6 mu M, but also reduced the capacity by 3-fold and had no effect on interaction with adducin. Further addition of the second cu-helical domain (residues 1-528) did not alter binding to F-actin but resulted in a g-fold increased activity in promoting adducin binding with half-maximal activation at 50 nM. Addition of up to eight additional alpha-helical domains (residues 1-1388) resulted in no further change in F-actin binding or association with adducin. These results demonstrate an unanticipated role of the first repeat of beta-spectrin in actin binding activity and of the second repeat in association with adducin/actin, and imply the possibility of an extended contact between adducin, spectrin, and actin involving several actin subunits.	DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA	Duke University; Duke University; Howard Hughes Medical Institute	Li, XL (corresponding author), DUKE UNIV, MED CTR, DEPT CELL BIOL, DURHAM, NC 27710 USA.			Li, Xiaolin/0000-0001-9611-2434				BENNETT V, 1986, METHOD ENZYMOL, V134, P55; BENNETT V, 1983, METHOD ENZYMOL, V96, P313; BENNETT V, 1990, PHYSIOL REV, V70, P1029, DOI 10.1152/physrev.1990.70.4.1029; BENNETT V, 1993, ANNU REV CELL BIOL, V9, P27, DOI 10.1146/annurev.cellbio.9.1.27; BENNETT V, 1988, J BIOL CHEM, V263, P5860; BENNETT V, 1982, NATURE, V299, P126, DOI 10.1038/299126a0; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYERS TJ, 1989, J CELL BIOL, V109, P1633, DOI 10.1083/jcb.109.4.1633; BYERS TJ, 1985, P NATL ACAD SCI USA, V82, P6153, DOI 10.1073/pnas.82.18.6153; BYERS TJ, 1992, P NATL ACAD SCI USA, V89, P6187, DOI 10.1073/pnas.89.13.6187; CALVERT R, 1980, EUR J BIOCHEM, V107, P355; CORRADO K, 1994, FEBS LETT, V344, P255, DOI 10.1016/0014-5793(94)00397-1; DAVIS J, 1983, J BIOL CHEM, V258, P7757; DERICK LH, 1992, EUR J CELL BIOL, V57, P317; FABBRIZIO E, 1993, BIOCHEMISTRY-US, V32, P10457, DOI 10.1021/bi00090a023; FAIRBANKS G, 1971, BIOCHEMISTRY-US, V10, P2606, DOI 10.1021/bi00789a030; FERAMISCO JR, 1980, J BIOL CHEM, V255, P1194; GARDNER K, 1987, NATURE, V328, P359, DOI 10.1038/328359a0; GARDNER K, 1986, J BIOL CHEM, V261, P1339; GARDNER K, 1988, P293; GILL SC, 1989, ANAL BIOCHEM, V182, P319, DOI 10.1016/0003-2697(89)90602-7; GORLIN JB, 1990, J CELL BIOL, V111, P1089, DOI 10.1083/jcb.111.3.1089; HEMMINGS L, 1992, J CELL BIOL, V116, P1369, DOI 10.1083/jcb.116.6.1369; HU RJ, 1992, J BIOL CHEM, V267, P18715; HUGHES CA, 1995, J BIOL CHEM, V270, P18990, DOI 10.1074/jbc.270.32.18990; JOSHI R, 1990, J BIOL CHEM, V265, P13130; JOSHI R, 1991, J CELL BIOL, V115, P665, DOI 10.1083/jcb.115.3.665; KAISER HW, 1989, J CELL BIOL, V109, P557, DOI 10.1083/jcb.109.2.557; KARINCH AM, 1990, J BIOL CHEM, V265, P11833; Kuhlman PA, 1996, J BIOL CHEM, V271, P7986, DOI 10.1074/jbc.271.14.7986; LEBART MC, 1990, BIOCHEM BIOPH RES CO, V173, P120, DOI 10.1016/S0006-291X(05)81030-7; LEVINE BA, 1992, FEBS LETT, V298, P44, DOI 10.1016/0014-5793(92)80019-D; LING E, 1986, J BIOL CHEM, V261, P13875; LIU SC, 1987, J CELL BIOL, V104, P527, DOI 10.1083/jcb.104.3.527; MATSUDAIRA P, 1991, TRENDS BIOCHEM SCI, V16, P87, DOI 10.1016/0968-0004(91)90039-X; MCGOUGH A, 1994, J CELL BIOL, V126, P433, DOI 10.1083/jcb.126.2.433; MIMURA N, 1987, J BIOL CHEM, V262, P4717; PARDEE JD, 1982, METHOD CELL BIOL, V24, P271; SHEN BW, 1986, J CELL BIOL, V102, P997, DOI 10.1083/jcb.102.3.997; SPEICHER DW, 1992, J BIOL CHEM, V267, P14775; STUDIER FW, 1990, METHOD ENZYMOL, V185, P60; VIEL A, 1994, P NATL ACAD SCI USA, V91, P10839, DOI 10.1073/pnas.91.23.10839; WASEEM A, 1988, EUR J BIOCHEM, V178, P563, DOI 10.1111/j.1432-1033.1988.tb14483.x; WAY M, 1992, J CELL BIOL, V119, P835, DOI 10.1083/jcb.119.4.835; WAY M, 1992, FEBS LETT, V301, P243, DOI 10.1016/0014-5793(92)80249-G; WINDER SJ, 1995, J CELL SCI, V108, P63; WINKELMANN JC, 1990, J BIOL CHEM, V265, P20449; WINKELMANN JC, 1990, J BIOL CHEM, V265, P11827; WINOGRAD E, 1991, P NATL ACAD SCI USA, V88, P10788, DOI 10.1073/pnas.88.23.10788; YAN Y, 1993, SCIENCE, V262, P2027, DOI 10.1126/science.8266097; YU J, 1973, Journal of Supramolecular Structure, V1, P233, DOI 10.1002/jss.400010308	51	62	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15695	15702		10.1074/jbc.271.26.15695	http://dx.doi.org/10.1074/jbc.271.26.15695			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663089	hybrid			2022-12-27	WOS:A1996UV29900060
J	Lo, YYC; Wong, JMS; Cruz, TF				Lo, YYC; Wong, JMS; Cruz, TF			Reactive oxygen species mediate cytokine activation of c-jun NH2-terminal kinases	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; HYDROGEN-PEROXIDE; GENE-EXPRESSION; FREE-RADICALS; NITRIC-OXIDE; FACTOR-ALPHA; INTERLEUKIN-1; PHOSPHORYLATION; CHONDROCYTES; COLLAGENASE	Interleukin 1 (IL-1) and tumor necrosis factor alpha (TNF alpha) are known to induce production of reactive oxygen species (ROS), which have been suggested to act as second messengers. Here we demonstrate that ROS production by bovine chondrocytes upon cytokine stimulation induces c-jun expression. Since c-jun expression is regulated by its own gene product via phosphorylation by c-Jun NH2-terminal kinases (JNKs), we investigated if cytokines and ROS could modulate JNK activity in chondrocyte monolayer cultures. Treatment of bovine chondrocytes with both IL-1 and TNF alpha leads to rapid induction of JNK activity, stimulating JNK activity 7- and 20-fold, respectively. Importantly, the observation that antioxidant treatment antagonizes IL-1 and TNF alpha activation of JNK provides strong evidence that ROS can act as mediators of JNK activity. Moreover, potent activation of JNK is also observed by direct addition of the ROS hydrogen peroxide (H2O2) to the chondrocyte cultures. Nitric oxide (NO), a multifunctional ROS, also appears to simulate JNK albeit to a lesser extent. These findings identify JNK as another molecular target for the actions of NO and H2O2. In addition, the inhibitory effect of diphenyleneiodonium on JNK activation implicates the involvement of flavonoid-containing enzymes in the ROS-mediated signaling process. Overstimulation of JNK activity by excessive production of ROS may, therefore, underlie pathological conditions such as arthritis and cancer.	MT SINAI HOSP,SAMUEL LUNENFELD RES INST,CONNECT TISSUE RES GRP,TORONTO,ON M5G 1X5,CANADA; UNIV TORONTO,BANTING & BEST DEPT MED RES,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT CELLULAR & MOLEC PATHOL,TORONTO,ON M5G 1L5,CANADA; UNIV TORONTO,DEPT MOLEC & MED GENET,TORONTO,ON M5G 1L5,CANADA	University of Toronto; University Toronto Affiliates; Sinai Health System Toronto; Lunenfeld Tanenbaum Research Institute; University of Toronto; University of Toronto; University of Toronto								AGNEL P, 1991, BIOCHIM BIOPHYS ACTA, V1072, P129; ANGEL P, 1988, CELL, V55, P875, DOI 10.1016/0092-8674(88)90143-2; ARORA PD, 1995, J BIOL CHEM, V270, P6042, DOI 10.1074/jbc.270.11.6042; BEG AA, 1993, MOL CELL BIOL, V13, P3301, DOI 10.1128/MCB.13.6.3301; BREDT DS, 1994, ANNU REV BIOCHEM, V63, P175, DOI 10.1146/annurev.bi.63.070194.001135; BRETT J, 1989, J EXP MED, V169, P1977, DOI 10.1084/jem.169.6.1977; CAMUSSI G, 1991, EUR J BIOCHEM, V202, P3, DOI 10.1111/j.1432-1033.1991.tb16337.x; CANO E, 1995, TRENDS BIOCHEM SCI, V20, P117, DOI 10.1016/S0968-0004(00)88978-1; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; CONQUER JA, 1992, BIOCHIM BIOPHYS ACTA, V1134, P1, DOI 10.1016/0167-4889(92)90021-3; COSO OA, 1995, CELL, V81, P1137, DOI 10.1016/S0092-8674(05)80018-2; CRAWFORD D, 1988, ONCOGENE, V3, P27; CRUZ TF, 1990, BIOCHEM J, V269, P717, DOI 10.1042/bj2690717; DAI TN, 1995, ONCOGENE, V10, P849; DAMOULIS PD, 1994, BIOCHEM BIOPH RES CO, V201, P924, DOI 10.1006/bbrc.1994.1790; DENG TL, 1994, NATURE, V371, P171, DOI 10.1038/371171a0; DERIJARD B, 1994, CELL, V76, P1; DEVARY Y, 1991, MOL CELL BIOL, V11, P2804, DOI 10.1128/MCB.11.5.2804; FIALKOW L, 1994, J BIOL CHEM, V269, P31234; FIRESTEIN GS, 1995, J CLIN INVEST, V96, P1631, DOI 10.1172/JCI118202; FRENKEL K, 1992, PHARMACOL THERAPEUT, V53, P127, DOI 10.1016/0163-7258(92)90047-4; GOWEN M, 1983, NATURE, V306, P378, DOI 10.1038/306378a0; HALLIWELL B, 1990, METHOD ENZYMOL, V186, P1; HIBI M, 1993, GENE DEV, V7, P2135, DOI 10.1101/gad.7.11.2135; KNAUER MF, 1990, J CELL PHYSIOL, V142, P469, DOI 10.1002/jcp.1041420305; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUNO K, 1994, J LEUKOCYTE BIOL, V56, P542, DOI 10.1002/jlb.56.5.542; KYRIAKIS JM, 1994, NATURE, V369, P156, DOI 10.1038/369156a0; LAFYATIS R, 1990, MOL ENDOCRINOL, V4, P973, DOI 10.1210/mend-4-7-973; LANDER HM, 1995, J BIOL CHEM, V270, P7017, DOI 10.1074/jbc.270.13.7017; LANDER HM, 1995, J BIOL CHEM, V270, P21195, DOI 10.1074/jbc.270.36.21195; LO YYC, 1995, J BIOL CHEM, V270, P11727, DOI 10.1074/jbc.270.20.11727; MAUVIEL A, 1993, J CELL BIOCHEM, V53, P288, DOI 10.1002/jcb.240530404; MEIER B, 1989, BIOCHEM J, V263, P539, DOI 10.1042/bj2630539; MUEGGE K, 1993, P NATL ACAD SCI USA, V90, P7054, DOI 10.1073/pnas.90.15.7054; MURRELL GAC, 1990, BIOCHEM J, V265, P659, DOI 10.1042/bj2650659; NOSE K, 1991, EUR J BIOCHEM, V201, P99, DOI 10.1111/j.1432-1033.1991.tb16261.x; ONEILL LAJ, 1992, J IMMUNOL, V148, P484; PULVERER BJ, 1991, NATURE, V353, P670, DOI 10.1038/353670a0; QUINN MT, 1993, J BIOL CHEM, V268, P20983; RICHTER J, 1990, P NATL ACAD SCI USA, V87, P9472, DOI 10.1073/pnas.87.23.9472; ROSE RC, 1993, FASEB J, V7, P1135, DOI 10.1096/fasebj.7.12.8375611; SANTOS L, 1994, IMMUNOL CELL BIOL, V72, P406, DOI 10.1038/icb.1994.60; SCHRECK R, 1991, EMBO J, V10, P2247, DOI 10.1002/j.1460-2075.1991.tb07761.x; SCHUTZE S, 1994, J LEUKOCYTE BIOL, V56, P533, DOI 10.1002/jlb.56.5.533; SLUSS HK, 1994, MOL CELL BIOL, V14, P8376, DOI 10.1128/MCB.14.12.8376; SMEAL T, 1991, NATURE, V354, P494, DOI 10.1038/354494a0; STEFANOVICRACIC M, 1993, ARTHRITIS RHEUM, V36, P1036, DOI 10.1002/art.1780360803; STUEHR DJ, 1991, FASEB J, V5, P98, DOI 10.1096/fasebj.5.1.1703974; SUNDARESAN M, 1995, SCIENCE, V270, P296, DOI 10.1126/science.270.5234.296; TIKU ML, 1990, J IMMUNOL, V145, P690; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; VANDAM H, 1993, EMBO J, V12, P479, DOI 10.1002/j.1460-2075.1993.tb05680.x; VOJTEK AB, 1995, CELL, V82, P527, DOI 10.1016/0092-8674(95)90023-3; XANTHOUDAKIS S, 1992, EMBO J, V11, P3323, DOI 10.1002/j.1460-2075.1992.tb05411.x; ZAFARULLAH M, 1992, FEBS LETT, V306, P169, DOI 10.1016/0014-5793(92)80992-P	57	442	450	0	11	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15703	15707		10.1074/jbc.271.26.15703	http://dx.doi.org/10.1074/jbc.271.26.15703			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663189	hybrid			2022-12-27	WOS:A1996UV29900061
J	NarayFejesToth, A; FejesToth, G				NarayFejesToth, A; FejesToth, G			Subcellular localization of the type 2 11 beta-hydroxysteroid dehydrogenase - A green fluorescent protein study	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TARGET-CELLS; TRANSLOCATION; ALDOSTERONE; RECEPTORS; MEMBRANE; ISOFORM	11 beta-Hydroxysteroid dehydrogenase (11 beta-HSD) is thought to confer aldosterone specificity to mineralocorticoid target cells by protecting the inherently nonselective mineralocorticoid receptor (MR) from occupancy by endogenous glucocorticoids. Recently, we characterized a novel isoform of 11 beta-HSD in aldosterone target cells, which has high affinity for its substrate, is unidirectional, and prefers NAD as cofactor, In this study we utilized a green fluorescent protein (GFP) technique to determine the subcellular localization of this isoform, 11 beta-HSD2, We generated a chimeric gene encoding the full-length rabbit 11 beta-HSD2 and, fused to its C terminus, the coding sequence of GFP. This construct was stably transfected into CHO cells, The enzymatic characteristics of the expressed 11 beta-HSD2/GFP fusion protein were undistinguishable from those of the native enzyme: high affinity for corticosterone (K-M 8-10 nar), NAD dependence, and lack of reductase activity, The intracellular location of the recombinant protein was determined by fluorescence microscopy. 11 beta-HSD2-associated fluorescence was observed as a reticular network over the cytoplasm and nuclear envelope, whereas the plasma membrane and the nucleus were negative, suggesting endoplasmic reticulum (ER) localization, Staining of CHO cells expressing 11 beta-HSD2/GFP with established subcellular organelle markers revealed a colocalization of 11 beta-HSD2/GFP only with ER markers and tubulin, To examine the orientation of 11 beta-HSD2 within the ER, we selectively permeabilized CHO cells and stained them with an anti-GFP antibody, Fluorescence microscopy indicated that the C-terminal region of 11 beta-HSD2 is on the cytoplasmic surface of the ER membrane, since it was accessible to the GFP antibody, This conclusion was confirmed by trypsin treatment of permeabilized cells followed by Western blotting, The C-terminal region of 11 beta-HSD2 was accessible to trypsin, indicating that it is on the cytoplasmic side of the ER membrane, These results indicate that 11 beta-HSD2 is localized exclusively to the ER, Since 11 beta-HSD2 does not contain any known ER retrieval signal, experiments are currently under way to determine what structural motifs are responsible for its FR localization.			NarayFejesToth, A (corresponding author), DARTMOUTH COLL SCH MED,DEPT PHYSIOL,LEBANON,NH 03758, USA.				NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK039523, R01DK045647, R01DK041841] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 41841, DK 39523, DK 45647] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		AGARWAL AK, 1994, J BIOL CHEM, V269, P25959; ALBISTON AL, 1994, MOL CELL ENDOCRINOL, V105, pR11, DOI 10.1016/0303-7207(94)90176-7; AUSUBEL FM, 1990, CURRENT PROTOCOLS MO; BROWN RW, 1993, ENDOCRINOLOGY, V132, P2614, DOI 10.1210/en.132.6.2614; CHALFIE M, 1994, SCIENCE, V263, P802, DOI 10.1126/science.8303295; FEJESTOTH G, 1994, J BIOL CHEM, V269, P26717; FUNDER JW, 1988, SCIENCE, V242, P583, DOI 10.1126/science.2845584; FUNDER JW, 1993, SCIENCE, V259, P1132, DOI 10.1126/science.8382375; GomezSanchez EP, 1996, STEROIDS, V61, P110, DOI 10.1016/0039-128X(95)00201-Z; INOUYE S, 1994, FEBS LETT, V341, P277, DOI 10.1016/0014-5793(94)80472-9; LEE SL, 1991, J CELL BIOL, V115, P409; LUZIO JP, 1993, TRENDS BIOCHEM SCI, V18, P395, DOI 10.1016/0968-0004(93)90097-7; MERCER W, 1993, MOL CELL ENDOCRINOL, V92, P247, DOI 10.1016/0303-7207(93)90015-C; MONDER C, 1991, FASEB J, V5, P3047, DOI 10.1096/fasebj.5.15.1743437; MONDER C, 1984, STEROIDS, V44, P383, DOI 10.1016/S0039-128X(84)80001-X; MONDER C, 1991, J STEROID BIOCHEM, V40, P533, DOI 10.1016/0960-0760(91)90273-8; MUNE T, 1995, NAT GENET, V10, P394, DOI 10.1038/ng0895-394; NARAYFEJESTOTH A, 1993, AM J PHYSIOL, V265, pF896, DOI 10.1152/ajprenal.1993.265.6.F896; NARAYFEJESTOTH A, 1995, ENDOCRINOLOGY, V136, P2579, DOI 10.1210/en.136.6.2579; NARAYFEJESTOTH A, 1994, AM J PHYSIOL, V266, pF76, DOI 10.1152/ajprenal.1994.266.1.F76; NARAYFEJESTOTH A, 1994, STEROIDS, V59, P105, DOI 10.1016/0039-128X(94)90085-X; NARAYFEJESTOTH A, 1991, ENDOCRINOLOGY, V129, P17, DOI 10.1210/endo-129-1-17; OGAWA H, 1995, P NATL ACAD SCI USA, V92, P11899, DOI 10.1073/pnas.92.25.11899; OZOLS J, 1995, J BIOL CHEM, V270, P2305, DOI 10.1074/jbc.270.5.2305; PLUMMER T H JR, 1991, Glycobiology, V1, P257, DOI 10.1093/glycob/1.3.257; PRASHER DC, 1992, GENE, V111, P229, DOI 10.1016/0378-1119(92)90691-H; ROBERTSON NM, 1993, MOL ENDOCRINOL, V7, P1226, DOI 10.1210/me.7.9.1226; RUSVAI E, 1993, J BIOL CHEM, V268, P10717; SANDERS SL, 1992, J BIOL CHEM, V267, P13791; SZCZESNASKORUPA E, 1995, J BIOL CHEM, V270, P24327, DOI 10.1074/jbc.270.41.24327; THIGPEN AE, 1993, J BIOL CHEM, V268, P17404; WANG SX, 1994, NATURE, V369, P400, DOI 10.1038/369400a0; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P2263, DOI 10.1210/jc.80.7.2263; WILSON RC, 1995, J CLIN ENDOCR METAB, V80, P3145, DOI 10.1210/jc.80.11.3145; ZHOU MY, 1995, ENDOCRINOLOGY, V136, P3729, DOI 10.1210/en.136.9.3729	35	65	68	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15436	15442		10.1074/jbc.271.26.15436	http://dx.doi.org/10.1074/jbc.271.26.15436			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663122	hybrid			2022-12-27	WOS:A1996UV29900023
J	Fertala, A; Holmes, DF; Kadler, KE; Sieron, AL; Prockop, DJ				Fertala, A; Holmes, DF; Kadler, KE; Sieron, AL; Prockop, DJ			Assembly in vitro of thin and thick fibrils of collagen II from recombinant procollagen II - The monomers in the tips of thick fibrils have the opposite orientation from monomers in the growing tips of collagen I fibrils	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MOLECULAR PACKING; POINTED TIPS; PC-COLLAGEN; INVITRO; CLEAVAGE; PROTEINASE; MECHANISM; DIAMETER; EXAMPLE; GROWTH	Human type II procollagen was prepared in a recombinant system and cleaved to pC-collagen II by procollagen N-proteinase. The pC-collagen II was then used as a substrate to generate collagen II fibrils by cleavage with procollagen C-proteinase at 37 degrees C. Electron microscopy of the fibrils demonstrated that, at the early stages of fibril assembly, very thin fibrils were formed, As the system approached equilibrium over 7-12 h, however, the thin fibrils were largely but not completely replaced by thick fibrils that had diameters of about 240 nm and a distinct D-period banding pattern, One typical fibril was photographed and analyzed in its entirety, The fibril was 776 D-periods (52 mu m) long, It had a central shaft with a uniform diameter that was about 516 D-periods long and two tips of about 100 D-periods each, Most of the central shaft had a symmetrical banding pattern flanked by two transition regions of about 30 D-periods each, Measurements by scanning transmission electron microscopy demonstrated that the mass per unit length from the tips to the shafts increased linearly over approximately 100 D-periods from the fibril end, The linear increase in mass per unit length was consistent with previous observations for collagen I fibrils and established that the tips of collagen II also had a near paraboloidal shape, However, the orientation of monomers in the tips differed from the tips of collagen I fibrils in that the C termini instead of the N termini were directed toward the tips, The thin fibrils that were present at early stages of assembly and at equilibrium were comparable to the collagen II fibrils seen in embryonic tissues and probably represented intermediates on the pathway of thick fibrils formation, The results indicated that the molecular events in the self-assembly of collagen II fibrils are apparently similar to those in self-assembly of collagen I fibrils, but that there are also important differences in the structural information contained in collagen I and collagen II monomers.	THOMAS JEFFERSON UNIV,JEFFERSON MED COLL,DEPT BIOCHEM & MOLEC BIOL,JEFFERSON INST MOLEC MED,PHILADELPHIA,PA 19107; UNIV MANCHESTER,SCH BIOL SCI,MANCHESTER M13 9PT,LANCS,ENGLAND	Jefferson University; University of Manchester			KADLER, KARL/ABI-2403-2020; Sieron, Aleksander L/G-1700-2013	KADLER, KARL/0000-0003-4977-4683; Sieron, Aleksander L./0000-0002-3894-9508	NIAMS NIH HHS [AR-39740] Funding Source: Medline; Wellcome Trust Funding Source: Medline; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P01AR039740] Funding Source: NIH RePORTER	NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); Wellcome Trust(Wellcome TrustEuropean Commission); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BRODSKY B, 1982, METHOD ENZYMOL, V82, P127; CHAPMAN JA, 1989, BIOPOLYMERS, V28, P1367, DOI 10.1002/bip.360280803; COOPER A, 1970, BIOCHEM J, V118, P355, DOI 10.1042/bj1180355; DOGTEROM M, 1993, PHYS REV LETT, V70, P1347, DOI 10.1103/PhysRevLett.70.1347; FERTALA A, 1994, J BIOL CHEM, V269, P11584; FERTALA A, 1994, BIOCHEM J, V298, P31, DOI 10.1042/bj2980031; FRIEDEN C, 1985, ANNU REV BIOPHYS BIO, V14, P189, DOI 10.1146/annurev.bb.14.060185.001201; GUTLER PJG, 1984, J GEN VIROL, V65, P253; HOJIMA Y, 1985, J BIOL CHEM, V260, P5996; HOLMES DF, 1986, INT J BIOL MACROMOL, V8, P161, DOI 10.1016/0141-8130(86)90020-6; HOLMES DF, 1992, P NATL ACAD SCI USA, V89, P9855, DOI 10.1073/pnas.89.20.9855; HULMES DJS, 1979, NATURE, V282, P878, DOI 10.1038/282878a0; HULMES DJS, 1989, J MOL BIOL, V210, P337, DOI 10.1016/0022-2836(89)90335-5; HULMES DJS, 1995, BIOPHYS J, V68, P1661, DOI 10.1016/S0006-3495(95)80391-7; JONES EY, 1991, J MOL BIOL, V218, P209, DOI 10.1016/0022-2836(91)90885-A; KADLER KE, 1990, ANN NY ACAD SCI, V580, P214, DOI 10.1111/j.1749-6632.1990.tb17930.x; KADLER KE, 1987, J BIOL CHEM, V262, P15696; KADLER KE, 1990, BIOCHEM J, V268, P339, DOI 10.1042/bj2680339; Katz E P, 1989, Connect Tissue Res, V21, P149, DOI 10.3109/03008208909050005; KEENE DR, 1995, J HISTOCHEM CYTOCHEM, V43, P967, DOI 10.1177/43.10.7560887; LANDIS WJ, 1993, J STRUCT BIOL, V110, P39, DOI 10.1006/jsbi.1993.1003; LEE SL, 1983, COLLAGEN REL RES, V3, P89; MALLEINGERIN F, 1995, EXP CELL RES, V219, P257, DOI 10.1006/excr.1995.1226; MATSUSHITA M, 1984, PHYS REV LETT, V53, P286, DOI 10.1103/PhysRevLett.53.286; MIYAHARA M, 1982, J BIOL CHEM, V257, P8442; MULLER SA, 1992, ULTRAMICROSCOPY, V46, P317, DOI 10.1016/0304-3991(92)90022-C; NA GC, 1986, J BIOL CHEM, V261, P2290; NITTMANN J, 1987, J PHYS A, V20, pL1184; PARKINSON J, 1994, PHYS REV E, V50, P2963, DOI 10.1103/PhysRevE.50.2963; Parkinson J, 1994, J MOL BIOL, V247, P823; PIEZ KA, 1981, BIOSCIENCE REP, V1, P801, DOI 10.1007/BF01114803; PIEZ KA, 1984, EXTRACELLULAR MATRIX, P1; PROCKOP DJ, 1995, ANNU REV BIOCHEM, V64, P403, DOI 10.1146/annurev.biochem.64.1.403; PROCKOP DJ, 1994, EXTRACELLULAR MATRIX, P47; SCOTT JE, 1988, BIOCHEM J, V252, P313, DOI 10.1042/bj2520313; SILVER D, 1992, P NATL ACAD SCI USA, V89, P9860, DOI 10.1073/pnas.89.20.9860; SILVER D, 1994, J MOL GRAPHICS, V12, P139, DOI 10.1016/0263-7855(94)80078-2; TOMSKI SJ, 1992, ARCH BIOCHEM BIOPHYS, V294, P630, DOI 10.1016/0003-9861(92)90735-F; TORREBLANCO A, 1992, J BIOL CHEM, V267, P4968; VANDERPLAATS GN, 1993, STRUCT OPTIMIZATION, V6, P1, DOI 10.1007/BF01743168; Veis A, 1988, COLLAGEN, V1, P113; WEINER S, 1991, FEBS LETT, V285, P49, DOI 10.1016/0014-5793(91)80722-F; WODHEADGALLOWAY J, 1984, CONNECTIVE TISSUE MA, P133; YAMAUCHI M, 1986, BIOCHEMISTRY-US, V25, P4907, DOI 10.1021/bi00365a027	44	34	35	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14864	14869		10.1074/jbc.271.25.14864	http://dx.doi.org/10.1074/jbc.271.25.14864			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662997				2022-12-27	WOS:A1996UT10600036
J	Sepehrnia, B; Paz, IB; Dasgupta, G; Momand, J				Sepehrnia, B; Paz, IB; Dasgupta, G; Momand, J			Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							WILD-TYPE P53; GLUCOCORTICOID RECEPTOR; ACTIVATING MUTATIONS; STEROID-RECEPTORS; BREAST-CANCER; TUMOR-ANTIGEN; GENE-PRODUCT; DNA-BINDING; COMMON; IDENTIFICATION	Cellular DNA damage results in the increased expression and accumulation of the p53 tumor suppressor protein within the nucleus which leads to cell cycle arrest or apoptosis, In some cases, however, wild-type p53 and some mutant forms of p53 reside in the cytoplasm of cancer cells, To understand the mechanism responsible for its cytoplasmic retention, studies were undertaken to determine if unique proteins form a complex with mutant p53 within the cytoplasm of transformed cells, One protein, with an apparent molecular mass of 92 kDa (p92), was observed to form a complex with a temperature-sensitive mutant p53 (TSp53(Val-135)) in the cytoplasm of transformed rat embryo fibroblasts at the non permissive temperature, p92 copurified with TSp53(Val-135) on a p53-specific immunoaffinity column and a gel filtration column, The protein was purified to homogeneity and identified as hsp84 by partial amino acid sequence analysis, hsp84 is a member of the hsp90 class of proteins, At the non-permissive temperature, TSp53(Val-135) and hsp84 colocalized in the cytoplasm near the nuclear envelope, At the permissive temperature, TSp53(Val-135) resides in the nucleus and expresses a ''wild-type like'' conformation, Under these conditions hsp84 continued to reside in the cytoplasm and little or no hsp84 formed a complex with p53, The results suggest that hsp84 binds mutant p53 in a spatial and/or conformation dependent manner.	CITY HOPE NATL MED CTR,DEPT CELL & TUMOR BIOL,DUARTE,CA 91010	City of Hope			Momand, Jamil/F-8154-2012					ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BAKALKIN G, 1994, P NATL ACAD SCI USA, V91, P413, DOI 10.1073/pnas.91.1.413; BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BLAGOSKLONNY MV, 1995, ONCOGENE, V11, P933; BLONDAL JA, 1994, SEMIN CANCER BIOL, V5, P177; CATELLI MG, 1985, EMBO J, V4, P3131, DOI 10.1002/j.1460-2075.1985.tb04055.x; CLARKE AR, 1993, NATURE, V362, P849, DOI 10.1038/362849a0; CLARKE CF, 1988, MOL CELL BIOL, V8, P1206, DOI 10.1128/MCB.8.3.1206; CLARKE S, 1975, J BIOL CHEM, V250, P5459; COOK A, 1990, BRIT J CANCER, V61, P548, DOI 10.1038/bjc.1990.123; DALMAN FC, 1990, J BIOL CHEM, V265, P3615; DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0; ELDEIRY WS, 1993, CELL, V75, P817, DOI 10.1016/0092-8674(93)90500-P; EWEN ME, 1991, CELL, V66, P1155, DOI 10.1016/0092-8674(91)90038-Z; FINLAY CA, 1988, MOL CELL BIOL, V8, P531, DOI 10.1128/MCB.8.2.531; FINLAY CA, 1989, CELL, V57, P1083, DOI 10.1016/0092-8674(89)90045-7; GANNON JV, 1991, NATURE, V349, P802; GANNON JV, 1990, EMBO J, V9, P1595, DOI 10.1002/j.1460-2075.1990.tb08279.x; GINSBERG D, 1991, MOL CELL BIOL, V11, P582, DOI 10.1128/MCB.11.1.582; GREENBLATT MS, 1994, CANCER RES, V54, P4855; HARLOW E, 1981, J VIROL, V39, P861, DOI 10.1128/JVI.39.3.861-869.1981; HARPER JW, 1993, CELL, V75, P805; HARVEY M, 1995, NAT GENET, V9, P305, DOI 10.1038/ng0395-305; HINDS PW, 1987, MOL CELL BIOL, V7, P2863, DOI 10.1128/MCB.7.8.2863; HUTCHISON KA, 1992, J BIOL CHEM, V267, P13953; KIYOKAWA T, 1985, P NATL ACAD SCI USA, V82, P8359, DOI 10.1073/pnas.82.24.8359; LEE S, 1995, CELL, V81, P1013, DOI 10.1016/S0092-8674(05)80006-6; LIVINGSTONE LR, 1992, CELL, V70, P923, DOI 10.1016/0092-8674(92)90243-6; LOWE SW, 1993, NATURE, V362, P847, DOI 10.1038/362847a0; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MALKIN D, 1990, SCIENCE, V250, P1233, DOI 10.1126/science.1978757; MALTZMAN W, 1984, MOL CELL BIOL, V4, P1689, DOI 10.1128/MCB.4.9.1689; MARTINEZ J, 1991, GENE DEV, V5, P151, DOI 10.1101/gad.5.2.151; MILNER J, 1991, CELL, V65, P765, DOI 10.1016/0092-8674(91)90384-B; MOLL UM, 1995, P NATL ACAD SCI USA, V92, P4407, DOI 10.1073/pnas.92.10.4407; MOLL UM, 1992, P NATL ACAD SCI USA, V89, P7262, DOI 10.1073/pnas.89.15.7262; MOMAND J, 1992, CELL, V69, P1237, DOI 10.1016/0092-8674(92)90644-R; MOORE SK, 1989, J BIOL CHEM, V264, P5343; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; OLSON DC, 1993, ONCOGENE, V8, P2353; OREN M, 1981, MOL CELL BIOL, V1, P101, DOI 10.1128/MCB.1.2.101; OZBUN MA, 1995, ADV CANCER RES, V66, P71, DOI 10.1016/S0065-230X(08)60252-3; PERDEW GH, 1993, EXP CELL RES, V209, P350, DOI 10.1006/excr.1993.1320; PRATT WB, 1993, J BIOL CHEM, V268, P21455; SANCHEZ ER, 1985, J BIOL CHEM, V260, P2398; SCHUH S, 1985, J BIOL CHEM, V260, P4292; SCHULTE TW, 1995, J BIOL CHEM, V270, P24585, DOI 10.1074/jbc.270.41.24585; Selkirk James K., 1994, Applied and Theoretical Electrophoresis, V4, P11; SHAULIAN E, 1992, MOL CELL BIOL, V12, P5581, DOI 10.1128/MCB.12.12.5581; SMITH DF, 1992, J BIOL CHEM, V267, P1350; SMITH DF, 1995, MOL CELL BIOL, V15, P6804; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; STEPHEN CW, 1992, J MOL BIOL, V225, P577, DOI 10.1016/0022-2836(92)90386-X; STURZBECHER HW, 1988, MOL CELL BIOL, V8, P3740; WHITESELL L, 1994, P NATL ACAD SCI USA, V91, P8324, DOI 10.1073/pnas.91.18.8324; WU L, 1995, MOL CELL BIOL, V15, P497, DOI 10.1128/MCB.15.1.497; ZHANG W, 1992, ONCOGENE, V7, P1545	57	104	108	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15084	15090		10.1074/jbc.271.25.15084	http://dx.doi.org/10.1074/jbc.271.25.15084			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663025	hybrid			2022-12-27	WOS:A1996UT10600066
J	Thompson, LJ; Fields, AP				Thompson, LJ; Fields, AP			beta(II) protein kinase C is required for the G(2)/M phase transition of cell cycle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR DIACYLGLYCEROL; GROWTH-FACTOR; LAMIN-B; CALCIUM; PHOSPHORYLATION; PROLIFERATION; FIBROBLASTS; INHIBITOR; MITOSIS; DIFFERENTIATION	Entry into mitosis requires the coordinated action of multiple mitotic protein kinases, In this report, we investigate the involvement of protein kinase C in the control of mitosis in human cells, Treatment of synchronized HL60 cells with the highly selective protein kinase C (PKC) inhibitor chelerythrine chloride leads to profound cell cycle arrest in G(2) phase. The cellular effects of chelerythrine are not due to either direct or indirect inhibition of the known mitotic regulator p34(cdc2)/cyclin B kinase, Rather, several lines of evidence demonstrate that chelerythrine-mediated G(2) phase arrest results from selective inhibition and degradation of beta(II) protein kinase C. First, chelerythrine causes dose-dependent inhibition of beta(II) PKC in vitro with an IC50 identical to that for G(2) phase blockade in whole cells, Second, chelerythrine specifically inhibits beta(II) PKC-mediated lamin B phosphorylation and mitotic nuclear lamina disassembly, Third, chelerythrine leads to selective loss of beta(II) PKC during G, phase in synchronized cells, Fourth, chelerythrine mediates activation-dependent degradation of PKC, indicating that beta(II) PKC is selectively activated during G, phase of cell cycle, Taken together, these data demonstrate that beta(II) PKC activation at G(2) phase is required for mitotic nuclear lamina disassembly and entry into mitosis and that beta(II) PKC-mediated phosphorylation of nuclear lamin B is important in these events.			Thompson, LJ (corresponding author), UNIV TEXAS, MED BRANCH,SEALY CTR ONCOL & HEMATOL,MED RES BLDG, RM 9104, 301 UNIV BLVD, GALVESTON, TX 77555 USA.				NCI NIH HHS [CA56869] Funding Source: Medline; NIGMS NIH HHS [GM43186] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA056869] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R29GM043186] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABE K, 1991, EXP CELL RES, V192, P122, DOI 10.1016/0014-4827(91)90166-R; BANFIC H, 1993, BIOCHEM J, V290, P633, DOI 10.1042/bj2900633; BEMENT WM, 1990, CELL REGUL, V1, P315, DOI 10.1091/mbc.1.3.315; DEKKER LV, 1994, TRENDS BIOCHEM SCI, V19, P73, DOI 10.1016/0968-0004(94)90038-8; DIVECHA N, 1993, BIOCHEM SOC T, V21, P877, DOI 10.1042/bst0210877; DIVECHA N, 1991, EMBO J, V10, P3207, DOI 10.1002/j.1460-2075.1991.tb04883.x; DIVECHA N, 1993, CELL, V74, P405, DOI 10.1016/0092-8674(93)80041-C; Fields A P, 1995, Prog Cell Cycle Res, V1, P271; FIELDS AP, 1988, J BIOL CHEM, V263, P8253; FIELDS AP, 1989, J BIOL CHEM, V264, P21896; FIELDS AP, 1990, J CELL SCI, V96, P107; GOODNIGHT J, 1992, GENE, V122, P305, DOI 10.1016/0378-1119(92)90219-F; GOSS VL, 1994, J BIOL CHEM, V269, P19074; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOCEVAR BA, 1991, J BIOL CHEM, V266, P28; HOCEVAR BA, 1992, J CELL SCI, V101, P671; HOCEVAR BA, 1993, J BIOL CHEM, V268, P7545; HOFMANN J, 1994, BIOCHEM BIOPH RES CO, V199, P937, DOI 10.1006/bbrc.1994.1319; Hunt T, 1991, Semin Cell Biol, V2, P213; IRIE K, 1993, MOL CELL BIOL, V13, P3076, DOI 10.1128/MCB.13.5.3076; KAO JPY, 1990, J CELL BIOL, V111, P183, DOI 10.1083/jcb.111.1.183; KISHIMOTO A, 1989, J BIOL CHEM, V264, P4088; LAMB NJC, 1990, CELL, V60, P151, DOI 10.1016/0092-8674(90)90725-T; LEE KS, 1993, MOL CELL BIOL, V13, P3067, DOI 10.1128/MCB.13.5.3067; LEVIN DE, 1992, J CELL BIOL, V116, P1221, DOI 10.1083/jcb.116.5.1221; LEVIN DE, 1990, CELL, V62, P213, DOI 10.1016/0092-8674(90)90360-Q; MURRAY NR, 1994, J BIOL CHEM, V269, P21385; MURRAY NR, 1993, J BIOL CHEM, V268, P15847; Nigg EA, 1993, CURR OPIN CELL BIOL, V5, P187, DOI 10.1016/0955-0674(93)90101-U; NORBURY C, 1992, ANNU REV BIOCHEM, V61, P441, DOI 10.1146/annurev.bi.61.070192.002301; OTTAVIANO Y, 1985, J BIOL CHEM, V260, P624; PARKER PJ, 1995, BIOCHEM SOC T, V23, P153, DOI 10.1042/bst0230153; PEARS CJ, 1990, EUR J BIOCHEM, V194, P89, DOI 10.1111/j.1432-1033.1990.tb19431.x; PICARD A, 1989, J CELL BIOL, V109, P3347, DOI 10.1083/jcb.109.6.3347; PICARD A, 1991, J CELL BIOL, V115, P337, DOI 10.1083/jcb.115.2.337; POENIE M, 1986, SCIENCE, V233, P886, DOI 10.1126/science.3755550; POENIE M, 1985, NATURE, V315, P147, DOI 10.1038/315147a0; RATAN RR, 1988, J CELL BIOL, V107, P993, DOI 10.1083/jcb.107.3.993; STEINHARDT RA, 1988, NATURE, V332, P364, DOI 10.1038/332364a0; USUI T, 1991, J CELL BIOL, V115, P1275, DOI 10.1083/jcb.115.5.1275; VESELY J, 1994, EUR J BIOCHEM, V224, P771, DOI 10.1111/j.1432-1033.1994.00771.x; YOSHIDA S, 1994, MOL GEN GENET, V242, P631, DOI 10.1007/BF00283416	42	133	138	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15045	15053		10.1074/jbc.271.25.15045	http://dx.doi.org/10.1074/jbc.271.25.15045			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663071	hybrid			2022-12-27	WOS:A1996UT10600061
J	North, MJ; Nicol, K; Sands, TW; Cotter, DA				North, MJ; Nicol, K; Sands, TW; Cotter, DA			Acid-activatable cysteine proteinases in the cellular slime mold Dictyostelium discoideum	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SPORE GERMINATION; CATHEPSIN-L; IDENTIFICATION; DIFFERENTIATION; SECRETION; PRECURSOR; VACUOLES; LATENT; GENES	Studies of the cysteine proteinases of the cellular slime mold Dictyostelium discoideum have been aided by a simple acid treatment step that was incorporated into the standard one-dimensional gelatin-sodium dodecyl sulfate-polyacrylamide gel electrophoresis assay procedure, The step involved immersing the separating gel in 10% (v/v) glacial acetic acid for 30-60 s immediately after electrophoresis, This modified approach revealed the presence of acid-activatable forms of some enzymes with noticeable increases in their ability to hydrolyze gelatin, a substrate present in the sodium dodecyl sulfate-polyacrylamide gels, and peptidyl amidomethylcoumarins, The activation has been analyzed using extracts of dormant spores from which cysteine proteinase activity had previously appeared low or virtually absent, The major acid-activatable proteinase had an apparent molecular mass of 48 kDa, Its activation was not due to autocatalysis as it was not prevented by mercuric chloride, an inhibitor of the enzyme, and was not accompanied by a significant change in electrophoretic mobility. It was most likely due to a conformational change and/or the removal of a low molecular weight inhibitor. The acid treatment has also revealed the presence of acid-activatable cysteine proteinases in vegetative cells, in which cysteine proteinase activity is present at high levels, as well as among enzymes from the developmental cells which have much lower cysteine proteinase activity, Indeed novel developmental forms were de tected at some stages, These results provide additional insight concerning cysteine proteinase expression at various stages during development in the slime molds, A developmental model is presented which suggests that the crypticity of the cysteine proteinases in dormant spores may be governed by proton pumps and endoge nous lysosomotropic agents.	UNIV WINDSOR,FAC SCI,OFF DEAN SCI,DEPT BIOL SCI,WINDSOR,ON N9B 3P4,CANADA; UNIV STIRLING,DEPT BIOL & MOLEC SCI,STIRLING FK9 4LA,SCOTLAND	University of Windsor; University of Stirling								BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BUSH JM, 1989, J BIOL CHEM, V264, P7630; CARDELLI JA, 1989, J BIOL CHEM, V264, P3454; COTTER DA, 1992, BIOCHEM CELL BIOL, V70, P892, DOI 10.1139/o92-137; FAGOTTO F, 1990, ARCH INSECT BIOCHEM, V14, P237, DOI 10.1002/arch.940140404; GREGG JH, 1954, BIOL BULL, V107, P226, DOI 10.2307/1538609; HARA K, 1988, FEBS LETT, V231, P225; KIRSCHKE H, 1994, METHOD ENZYMOL, V244, P500; KLEIN G, 1990, EUR J BIOCHEM, V193, P135, DOI 10.1111/j.1432-1033.1990.tb19314.x; KORTH MJ, 1988, ANAL BIOCHEM, V169, P181, DOI 10.1016/0003-2697(88)90270-9; LOOMIS WF, 1982, DEV DICTYOSTELIUM DI, P1; MACH L, 1994, J BIOL CHEM, V269, P13030; MACIEWICZ RA, 1988, BIOCHEM SOC T, V16, P1056, DOI 10.1042/bst0161056; MASON RW, 1987, BIOCHEM J, V248, P449, DOI 10.1042/bj2480449; MASON RW, 1989, BIOCHEM J, V257, P125, DOI 10.1042/bj2570125; MCDONALD JK, 1988, BIOCHEM BIOPH RES CO, V151, P827; NISHIMURA Y, 1988, ARCH BIOCHEM BIOPHYS, V261, P64, DOI 10.1016/0003-9861(88)90104-X; NOLTA KV, 1991, J BIOL CHEM, V266, P18318; NORTH MJ, 1984, EXP MYCOL, V8, P47, DOI 10.1016/0147-5975(84)90019-7; NORTH MJ, 1988, BIOCHEM J, V254, P269, DOI 10.1042/bj2540269; NORTH MJ, 1990, J GEN MICROBIOL, V136, P827, DOI 10.1099/00221287-136-5-827; NORTH MJ, 1991, DEV GENET, V12, P154, DOI 10.1002/dvg.1020120124; NORTH MJ, 1990, J GEN MICROBIOL, V136, P835, DOI 10.1099/00221287-136-5-835; NORTH MJ, 1988, BIOCHEM J, V254, P261, DOI 10.1042/bj2540261; NORTH MJ, 1994, METHOD ENZYMOL, V244, P523; PADH H, 1991, J BIOL CHEM, V266, P5514; PADH H, 1989, J CELL BIOL, V108, P865, DOI 10.1083/jcb.108.3.865; PEARS CJ, 1985, NUCLEIC ACIDS RES, V13, P8853, DOI 10.1093/nar/13.24.8853; PRESSE F, 1986, MOL GEN GENET, V203, P333, DOI 10.1007/BF00333976; RAWLINGS ND, 1994, METHOD ENZYMOL, V244, P461; ROBERTSON CD, 1992, FEMS MICROBIOL LETT, V94, P127, DOI 10.1111/j.1574-6968.1992.tb05301.x; SOUZA GM, 1995, J BIOL CHEM, V270, P28938, DOI 10.1074/jbc.270.48.28938; VANWART HE, 1990, P NATL ACAD SCI USA, V87, P5578, DOI 10.1073/pnas.87.14.5578; VERNET T, 1991, J BIOL CHEM, V266, P21451; WILLIAMS JG, 1985, EMBO J, V4, P99	35	14	14	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14462	14467		10.1074/jbc.271.24.14462	http://dx.doi.org/10.1074/jbc.271.24.14462			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662904				2022-12-27	WOS:A1996UQ66000077
J	Pfund, WP; Bourdage, JS; Farley, KA				Pfund, WP; Bourdage, JS; Farley, KA			Structural analysis of bovine somatotropin using monoclonal antibodies and the conformation-sensitive immunoassay	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GROWTH-HORMONE; FRAGMENTS; KINETICS; SUBUNIT	Bovine somatotropin was studied with respect to thermal stability, quantitative thermal denaturation kinetics, and refolding potential following thermal denaturation using a panel of 6 monoclonal antibodies and the Conformation-Sensitive Immunoassay (CSI). The antibody panel consisted of 4 conformation-dependent and 2 sequence-specific antibodies. Each of the antibodies revealed unique thermal stability profiles for their respective epitopes suggesting that they each recognize different antigenic determinants. Comparing the thermal stability profiles generated with these antibodies allowed the stability of bovine somatotropin to be ''dissected'' based on individual structural features. The degree to which bovine somatotropin is stabilized by disulfide bonds was examined using CSI-based quantitative thermal denaturation kinetics profiles generated under reducing and nonreducing conditions. All of the conformational epitopes unfolded faster under reducing conditions indicating that the two disulfide bonds within the somatotropin molecule impart some degree of global stabilization. The ability of bovine somatotropin to refold after reducing or nonreducing thermal denaturation was also examined using the antibody panel and the CSI. The results show that, although significant refolding was evident for some epitopes, bovine somatotropin cannot refold to the native state following thermal denaturation under either reducing or nonreducing conditions.	PHARMACIA & UPJOHN INC,ANALYT RES & SPECIFICAT DEV,KALAMAZOO,MI 49001	Pfizer			Farley, Kathleen A/K-3077-2017	Farley, Kathleen A/0000-0001-8935-6852				ALLEN MJ, 1994, BIOCHEMISTRY-US, V33, P3967, DOI 10.1021/bi00179a024; BELL JA, 1985, J BIOL CHEM, V260, P8520; BREMS DN, 1985, BIOCHEMISTRY-US, V24, P7662, DOI 10.1021/bi00347a025; BREMS DN, 1986, BIOCHEMISTRY-US, V25, P6539, DOI 10.1021/bi00369a030; BREMS DN, 1987, J BIOL CHEM, V262, P2590; BREMS DN, 1987, BIOCHEMISTRY-US, V26, P7774, DOI 10.1021/bi00398a036; CHEN CH, 1977, BIOCHEMISTRY-US, V16, P2110, DOI 10.1021/bi00629a010; COLLAWN JF, 1988, J BIOL CHEM, V263, P8625; DAVIO SR, 1993, STABILITY CHARACTERI, P59; FEDOROV AN, 1992, J MOL BIOL, V228, P351, DOI 10.1016/0022-2836(92)90825-5; HAVEL HA, 1986, BIOCHEMISTRY-US, V25, P6533, DOI 10.1021/bi00369a029; HOLZMAN TF, 1990, BIOCHEMISTRY-US, V29, P1255, DOI 10.1021/bi00457a022; HOLZMAN TF, 1986, BIOCHEMISTRY-US, V25, P6907, DOI 10.1021/bi00370a026; KLIBANOV AM, 1978, BIOCHEM BIOPH RES CO, V83, P1012, DOI 10.1016/0006-291X(78)91496-1; MACKENZIE NE, 1989, BIOCHIM BIOPHYS ACTA, V99, P166; MURRYBRELIER A, 1988, BIOCHEMISTRY-US, V27, P7633, DOI 10.1021/bi00420a010; PFUND WP, 1990, MOL IMMUNOL, V27, P495, DOI 10.1016/0161-5890(90)90068-B; SANTOME JA, 1973, EUR J BIOCHEM, V37, P164, DOI 10.1111/j.1432-1033.1973.tb02971.x; SECCHI C, 1991, HYBRIDOMA, V10, P499, DOI 10.1089/hyb.1991.10.499; Volkin DB, 1992, STABILITY PROTEIN A, P215; WALLIS M, 1973, FEBS LETT, V35, P11, DOI 10.1016/0014-5793(73)80566-6; WUTHRICH K, 1986, NMR PROTEINS NUCLEIC, P17; ZALE SE, 1986, BIOCHEMISTRY-US, V25, P5432, DOI 10.1021/bi00367a014	23	9	10	1	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14055	14061		10.1074/jbc.271.24.14055	http://dx.doi.org/10.1074/jbc.271.24.14055			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662950	hybrid			2022-12-27	WOS:A1996UQ66000021
J	Roucard, C; Garban, F; Mooney, NA; Charron, DJ; Ericson, ML				Roucard, C; Garban, F; Mooney, NA; Charron, DJ; Ericson, ML			Conformation of human leukocyte antigen class II molecules - Evidence for superdimers and empty molecules on human antigen presenting cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MHC CLASS-II; MAJOR HISTOCOMPATIBILITY COMPLEX; ALPHA-BETA-HETERODIMERS; HLA-DR MOLECULES; INVARIANT-CHAIN; SURFACE EXPRESSION; INTRACELLULAR-TRANSPORT; LYMPHOID-CELLS; PEPTIDE; BINDING	Subpopulations of human leukocyte antigen (HLA) class II molecules were studied in antigen presenting cells, We present evidence for double dimers or ''super-dimers'' of HLA class II molecules that were stable in an SDS solution at room temperature but dissociated when heated to 50 degrees C into 60-kDa alpha beta heterodimers. Development of an immunofluorescence assay allowed us to quantify the expression of HLA antigens as reflected by the number of bound isotype-specific monoclonal antibodies per cell. The total expression of class II (DR, DQ, and DP) augmented B-fold after a 36-h interferon-gamma (IFN gamma) treatment of freshly isolated monocytes, Next, we used a recombinant and fluorescein-conjugated form of the class II-associated invariant chain as a quantitative probe for empty peptide-binding sites, The fraction of empty class II molecules was 0.73-2.9% in resting monocytes but was reduced to 0.12-0.5% of the total after IFN gamma treatment, The fraction of empty sites in B lymphocytes was 0.09-0.36%, The mean number of empty sites per cell were: 6.3 x 10(3) (monocytes), 7.2 x 10(3) (IFN gamma-activated monocytes), 5.2 x 10(2) (B lymphocytes), and 3.6 x 10(3) (Raji B cells), A minor population (4.3-7.4% of total cells), which expressed a much higher number of empty sites, was consistently present in all cell types studied.	INST BIOMED CORDELIERS,HUMAN IMMUNOGENET LAB,INSERM U396,F-75006 PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Sorbonne Universite; Universite Paris Cite			garban, frederic/M-6130-2014	garban, frederic/0000-0003-3981-0839; Mooney, Nuala/0000-0002-3516-6882				AMIGORENA S, 1994, NATURE, V369, P113, DOI 10.1038/369113a0; ARIMILLI S, 1995, J BIOL CHEM, V270, P971, DOI 10.1074/jbc.270.2.971; BAKKE O, 1990, CELL, V63, P707, DOI 10.1016/0092-8674(90)90137-4; BONNEROT C, 1994, EMBO J, V13, P934, DOI 10.1002/j.1460-2075.1994.tb06338.x; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; BUSCH R, 1990, INT IMMUNOL, V2, P443, DOI 10.1093/intimm/2.5.443; CARREL S, 1981, MOL IMMUNOL, V18, P403, DOI 10.1016/0161-5890(81)90102-4; CASTELLINO F, 1995, IMMUNITY, V2, P73, DOI 10.1016/1074-7613(95)90080-2; CEPPELLINI R, 1989, NATURE, V339, P392, DOI 10.1038/339392a0; CHARRON DJ, 1979, P NATL ACAD SCI USA, V76, P6567, DOI 10.1073/pnas.76.12.6567; CLAESSONWELSH L, 1986, J IMMUNOL, V136, P484; CRESSWELL P, 1994, ANNU REV IMMUNOL, V12, P259, DOI 10.1146/annurev.immunol.12.1.259; DAVIDSON HW, 1991, CELL, V67, P105, DOI 10.1016/0092-8674(91)90575-J; DEMOTZ S, 1990, SCIENCE, V249, P1028, DOI 10.1126/science.2118680; DENZIN LK, 1995, CELL, V82, P155, DOI 10.1016/0092-8674(95)90061-6; ERICSON ML, 1994, J BIOL CHEM, V269, P26531; FARRAR MA, 1993, ANNU REV IMMUNOL, V11, P571, DOI 10.1146/annurev.iy.11.040193.003035; FERMAND JP, 1985, EUR J IMMUNOL, V15, P1183, DOI 10.1002/eji.1830151208; FU XT, 1994, HUM IMMUNOL, V39, P253, DOI 10.1016/0198-8859(94)90268-2; GARBAN F, 1996, IN PRESS BLOOD, V87; GERMAIN RN, 1993, NATURE, V363, P725, DOI 10.1038/363725a0; GERMAIN RN, 1991, NATURE, V353, P134, DOI 10.1038/353134a0; HARDING CV, 1990, NATURE, V346, P574, DOI 10.1038/346574a0; JANEWAY CA, 1992, ANNU REV IMMUNOL, V10, P645, DOI 10.1146/annurev.immunol.10.1.645; KAUFMAN JF, 1984, CELL, V36, P1, DOI 10.1016/0092-8674(84)90068-0; KOCH N, 1991, J IMMUNOL, V147, P2643; KONIG R, 1995, J EXP MED, V182, P779, DOI 10.1084/jem.182.3.779; KORNFELD R, 1985, ANNU REV BIOCHEM, V54, P631, DOI 10.1146/annurev.biochem.54.1.631; LOTTEAU V, 1990, NATURE, V348, P600, DOI 10.1038/348600a0; MOURITSEN S, 1992, J IMMUNOL, V149, P1987; NADLER SG, 1994, EUR J IMMUNOL, V24, P3124, DOI 10.1002/eji.1830241232; NEEFJES JJ, 1990, CELL, V61, P171, DOI 10.1016/0092-8674(90)90224-3; NEEFJES JJ, 1992, IMMUNOL TODAY, V13, P179, DOI 10.1016/0167-5699(92)90123-O; NEEFJES JJ, 1992, EMBO J, V11, P411, DOI 10.1002/j.1460-2075.1992.tb05069.x; NEWCOMB JR, 1993, J IMMUNOL, V150, P499; NYGARD NR, 1994, J IMMUNOL, V152, P1082; PETERS PJ, 1991, NATURE, V349, P669, DOI 10.1038/349669a0; PINET V, 1995, NATURE, V375, P603, DOI 10.1038/375603a0; QIU Y, 1994, J CELL BIOL, V125, P595, DOI 10.1083/jcb.125.3.595; REID PA, 1992, IMMUNOLOGY, V77, P539; REID PA, 1990, NATURE, V346, P655, DOI 10.1038/346655a0; ROBBINS PA, 1988, J IMMUNOL, V141, P1281; ROCHE PA, 1991, P NATL ACAD SCI USA, V88, P3150, DOI 10.1073/pnas.88.8.3150; ROCHE PA, 1993, P NATL ACAD SCI USA, V90, P8581, DOI 10.1073/pnas.90.18.8581; ROMAGNOLI P, 1993, J EXP MED, V177, P583, DOI 10.1084/jem.177.3.583; SADEGHNASSERI S, 1994, NATURE, V370, P647, DOI 10.1038/370647a0; SADEGHNASSERI S, 1991, NATURE, V353, P167, DOI 10.1038/353167a0; SAKIHAMA T, 1995, P NATL ACAD SCI USA, V92, P6444, DOI 10.1073/pnas.92.14.6444; SANDERSON F, 1994, SCIENCE, V266, P1566, DOI 10.1126/science.7985027; SCHAFER PH, 1994, IMMUNITY, V1, P699, DOI 10.1016/1074-7613(94)90040-X; SETTE A, 1992, J IMMUNOL, V148, P844; Sharrow S., 1991, CURRENT PROTOCOLS IM; SHERMAN MA, 1995, IMMUNITY, V3, P197, DOI 10.1016/1074-7613(95)90089-6; SLOAN VS, 1995, NATURE, V375, P802, DOI 10.1038/375802a0; STERN LJ, 1992, CELL, V68, P465, DOI 10.1016/0092-8674(92)90184-E; TULP A, 1994, NATURE, V369, P120, DOI 10.1038/369120a0; VALITUTTI S, 1995, NATURE, V375, P148, DOI 10.1038/375148a0; WATSON AJ, 1983, NATURE, V304, P358, DOI 10.1038/304358a0; WEST MA, 1994, NATURE, V369, P147, DOI 10.1038/369147a0; WRAIGHT CJ, 1990, J BIOL CHEM, V265, P5787	60	36	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13993	14000		10.1074/jbc.271.24.13993	http://dx.doi.org/10.1074/jbc.271.24.13993			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662817	hybrid			2022-12-27	WOS:A1996UQ66000013
J	Tanaka, S; Ito, T; Wands, JR				Tanaka, S; Ito, T; Wands, JR			Neoplastic transformation induced by insulin receptor substrate-1 overexpression requires an interaction with both Grb2 and Syp signaling molecules	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHOSPHATIDYLINOSITOL 3'-KINASE; NCK PROTEIN; SH2 DOMAIN; IRS-1; EXPRESSION; PHOSPHORYLATION; CELLS	The insulin receptor substrate-1 (IRS-1) is the major intracellular substrate of insulin and insulin-like growth factor-I (IGF-I) receptor tyrosine kinase activity, and this protein has been found to be overexpressed in human hepatocellular carcinomas. IRS-1 contains several src homology 2 (SH2) binding motifs that interact following tyrosyl phosphorylation with SH2-containing proteins, and this interaction may be essential for transmitting the growth signal from the cell surface to the nucleus, We have previously reported that overexpression of IRS-1 may induce neoplastic transformation of NIH 3T3 cells. This study examines the role of two SH2-containing molecules, namely the Grb2 adapter and Syp tyrosine phosphatase proteins as important components of the cellular transforming activity of IRS-1. Mutations of tyrosine 897 in the YVNI motif (Y897F) and of tyrosine 1180 in the YIDL motif (Y1180F) reduced the intracellular interaction of IRS-1 with Grb2 and Syp proteins, respectively. Furthermore, a single mutation at either Phe-897 or Phe-1180 substantially but not completely reduced IGF-I-dependent transforming activity of IRS-1, whereas creation of a double mutation of both tyrosine residues (Y897F/Y1180F) strikingly attenuated the transforming activity of IRS-1. Stable expression of the IRS-1 mutant constructs in MH 3T3 cells was associated with a lower level of activation of the mitogen-activated protein kinase kinase (MAPKK)/MAPK cascade following IGF-I stimulation compared with cells stably transfected with the ''wild-type'' IRS-1 gene, These results suggest that IRS-1-induced cellular transformation requires an interaction with both Grb2 and Syp signal transduction molecules since neither interaction alone appears to be required, and this event subsequently leads to activation of the MAPKK/MAPK cascade.	MASSACHUSETTS GEN HOSP,CTR CANC,MOLEC HEPATOL LAB,CHARLESTOWN,MA 02129; HARVARD UNIV,SCH MED,CHARLESTOWN,MA 02129	Harvard University; Massachusetts General Hospital; Harvard University					NATIONAL CANCER INSTITUTE [R01CA035711, R37CA035711] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM [R37AA002666, R01AA002666, R01AA008169] Funding Source: NIH RePORTER; NCI NIH HHS [CA-35711] Funding Source: Medline; NIAAA NIH HHS [AA-02666, AA-08169] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISM(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAAA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA))		BACKER JM, 1992, EMBO J, V11, P3469, DOI 10.1002/j.1460-2075.1992.tb05426.x; BALTENSPERGER K, 1993, SCIENCE, V260, P1950, DOI 10.1126/science.8391166; BASERGA R, 1995, CANCER RES, V55, P249; BESERGA R, 1994, CELL, V79, P927; CHOU MM, 1992, MOL CELL BIOL, V12, P5834, DOI 10.1128/MCB.12.12.5834; COBB MH, 1995, J BIOL CHEM, V270, P14843, DOI 10.1074/jbc.270.25.14843; COWLEY S, 1994, CELL, V77, P841, DOI 10.1016/0092-8674(94)90133-3; DIFIORE PP, 1987, CELL, V51, P1063, DOI 10.1016/0092-8674(87)90592-7; FURUSAKA A, 1994, CANCER LETT, V84, P85, DOI 10.1016/0304-3835(94)90361-1; HU QJ, 1995, MOL CELL BIOL, V15, P1169; IRIE K, 1994, SCIENCE, V265, P1716, DOI 10.1126/science.8085159; Ito T, 1996, MOL CELL BIOL, V16, P943; KALEKO M, 1990, MOL CELL BIOL, V10, P464, DOI 10.1128/MCB.10.2.464; KUHNE MR, 1993, J BIOL CHEM, V268, P11479; KYRIAKIS JM, 1992, NATURE, V358, P417, DOI 10.1038/358417a0; LEE CH, 1993, P NATL ACAD SCI USA, V90, P11713, DOI 10.1073/pnas.90.24.11713; LEROITH D, 1995, ANN INTERN MED, V122, P54, DOI 10.7326/0003-4819-122-1-199501010-00009; LI W, 1992, MOL CELL BIOL, V12, P5824, DOI 10.1128/MCB.12.12.5824; LI W, 1994, MOL CELL BIOL, V14, P509, DOI 10.1128/MCB.14.1.509; MACAULAY VM, 1992, BRIT J CANCER, V65, P311, DOI 10.1038/bjc.1992.65; MANSOUR SJ, 1994, SCIENCE, V265, P966, DOI 10.1126/science.8052857; MILARSKI K, 1994, J BIOL CHEM, V2269, P21239; MYERS MG, 1994, TRENDS BIOCHEM SCI, V19, P289, DOI 10.1016/0968-0004(94)90007-8; MYERS MG, 1992, P NATL ACAD SCI USA, V89, P10350, DOI 10.1073/pnas.89.21.10350; MYERS MG, 1994, MOL CELL BIOL, V14, P3577, DOI 10.1128/MCB.14.6.3577; NISHIYAMA M, 1992, BIOCHEM BIOPH RES CO, V183, P280, DOI 10.1016/0006-291X(92)91640-C; NOGUCHI T, 1994, MOL CELL BIOL, V14, P6674, DOI 10.1128/MCB.14.10.6674; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PRAGER D, 1994, P NATL ACAD SCI USA, V91, P2181, DOI 10.1073/pnas.91.6.2181; SALCINI AE, 1994, ONCOGENE, V9, P2827; SASAKI Y, 1993, J BIOL CHEM, V268, P3805; SASAKI Y, 1994, BIOCHEM BIOPH RES CO, V199, P403, DOI 10.1006/bbrc.1994.1243; SASAOKA T, 1994, J BIOL CHEM, V269, P13689; SELL C, 1994, MOL CELL BIOL, V14, P3604, DOI 10.1128/MCB.14.6.3604; SELL C, 1993, P NATL ACAD SCI USA, V90, P11217, DOI 10.1073/pnas.90.23.11217; SKOLNIK EY, 1993, SCIENCE, V260, P1953, DOI 10.1126/science.8316835; SUN XJ, 1993, MOL CELL BIOL, V13, P7418, DOI 10.1128/MCB.13.12.7418; SUN XJ, 1992, J BIOL CHEM, V267, P22662; WATERS SB, 1993, J BIOL CHEM, V268, P22231; WHITE MF, 1994, J BIOL CHEM, V269, P1; XIAO S, 1994, J BIOL CHEM, V269, P21244; YAMAUCHI K, 1995, P NATL ACAD SCI USA, V92, P664, DOI 10.1073/pnas.92.3.664; YOKOTE K, 1994, J BIOL CHEM, V269, P15337; YONEZAWA K, 1994, J BIOL CHEM, V269, P4634; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	46	81	83	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14610	14616		10.1074/jbc.271.24.14610	http://dx.doi.org/10.1074/jbc.271.24.14610			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662827	hybrid			2022-12-27	WOS:A1996UQ66000099
J	Gadaleta, G; DElia, D; Capaccio, L; Saccone, C; Pepe, G				Gadaleta, G; DElia, D; Capaccio, L; Saccone, C; Pepe, G			Isolation of a 25-kDa protein binding to a curved DNA upstream the origin of the L strand replication in the rat mitochondrial genome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							YEAST TRANSCRIPTION FACTOR; AFFINITY PURIFICATION; SEQUENCE; CURVATURE; REGION	The presence of a curved DNA sequence in the gene for the NADH-dehydrogenase subunit 2 of rat mitochondrial genome, upstream from the origin of the light strand replication have been demonstrated through theoretical analysis and experimental approaches, Gel retardation assays showed that this structure makes a complex with a protein component extracted from the mitochondrial matrix, The isolation and purification of this protein is reported, With a Sepharose CL GB and magnetic DNA affinity chromatography a polypeptide was purified to homogeneity having 25-kDa mass as shown by gel electrophoresis, To functionally characterize this protein, its capability to bind to other sequences of the homologous or heterologous DNA and to specific riboprobes was also investigated, A role for this protein as a trans-acting agent required for the expression of the mammalian mitochondrial genome is suggested.	CNR,CTR STUDIO MITOCONDRI & METAB ENERGET,I-70126 BARI,ITALY	Consiglio Nazionale delle Ricerche (CNR)	Gadaleta, G (corresponding author), UNIV BARI,DEPT BIOCHEM & MOLEC BIOL,VIA ORABONA 4A,I-70126 BARI,ITALY.		D'Elia, Domenica/O-2917-2015	D'Elia, Domenica/0000-0003-3787-3836				BROWN GG, 1986, J MOL BIOL, V192, P503, DOI 10.1016/0022-2836(86)90272-X; CAREY J, 1991, METHOD ENZYMOL, V208, P103; CLAYTON DA, 1992, INT REV CYTOL, V141, P217, DOI 10.1016/S0074-7696(08)62067-7; DIEKMANN S, 1985, J MOL BIOL, V186, P1, DOI 10.1016/0022-2836(85)90251-7; DIEKMANN S, 1987, EMBO J, V6, P4213, DOI 10.1002/j.1460-2075.1987.tb02769.x; EISENBERG H, 1986, TRENDS BIOCHEM SCI, V11, P350, DOI 10.1016/0968-0004(86)90196-9; GABRIELSEN OS, 1989, NUCLEIC ACIDS RES, V17, P6253, DOI 10.1093/nar/17.15.6253; GABRIELSEN OS, 1993, METHOD ENZYMOL, V218, P508; GADALETA G, 1989, J MOL EVOL, V28, P497, DOI 10.1007/BF02602930; GADALETA G, 1995, GENE, V160, P229, DOI 10.1016/0378-1119(95)00122-M; GRAY H, 1992, J BIOL CHEM, V267, P5835; Greenawalt J W, 1974, Methods Enzymol, V31, P310; HAGERMAN PJ, 1985, BIOCHEMISTRY-US, V24, P7033, DOI 10.1021/bi00346a001; HEHMAN GL, 1992, P NATL ACAD SCI USA, V89, P8562, DOI 10.1073/pnas.89.18.8562; KOO HS, 1986, NATURE, V320, P501, DOI 10.1038/320501a0; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEE EH, 1989, P NATL ACAD SCI USA, V86, P9104, DOI 10.1073/pnas.86.23.9104; LILLEY D, 1986, NATURE, V320, P487, DOI 10.1038/320487a0; MAYHOOK AG, 1992, P ROY SOC B-BIOL SCI, V248, P85, DOI 10.1098/rspb.1992.0046; MIZUNO T, 1987, NUCLEIC ACIDS RES, V15, P327; PEPE G, 1989, NUCLEIC ACIDS RES, V17, P8803, DOI 10.1093/nar/17.21.8803; PLASKON RR, 1987, NUCLEIC ACIDS RES, V15, P785, DOI 10.1093/nar/15.2.785; QURESHI SA, 1993, NUCLEIC ACIDS RES, V21, P2801, DOI 10.1093/nar/21.12.2801; SACCONE C, 1993, PRINCIPLES MED BIO B, V1, P37; TRIFONOV EN, 1985, CRC CR REV BIOCH MOL, V19, P89, DOI 10.3109/10409238509082540; WADDELL WJ, 1956, J LAB CLIN MED, V48, P311; WELTER C, 1989, NUCLEIC ACIDS RES, V17, P6077; WONG TW, 1985, CELL, V42, P951, DOI 10.1016/0092-8674(85)90291-0	28	12	12	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13537	13541		10.1074/jbc.271.23.13537	http://dx.doi.org/10.1074/jbc.271.23.13537			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662779	hybrid			2022-12-27	WOS:A1996UP38500036
J	Premont, RT; Matsuoka, I; Mattei, MG; Pouille, Y; Defer, N; Hanoune, J				Premont, RT; Matsuoka, I; Mattei, MG; Pouille, Y; Defer, N; Hanoune, J			Identification and characterization of a widely expressed form of adenylyl cyclase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; INSITU HYBRIDIZATION; GS-ALPHA; CLONING; SEQUENCE; BRAIN; DNA; DESENSITIZATION; LOCALIZATION; INHIBITION	A novel mammalian adenylyl cyclase was identified by reverse transcription-polymerase chain reaction amplification using degenerate primers based on a conserved region of previously described adenylyl cyclases (Premont, R. T. (1994) Methods Enzymol, 238, 116-127), The fall-length cDNA sequence obtained from mouse brain predicts a 1353-amino acid protein possessing a 12-membrane spans topology, and containing two regions of high similarity with the catalytic domains of adenylyl cyclases, Comparison of this novel adenylyl cyclase with the eight previously described mammalian enzymes indicates that this type 9 adenylyl cyclase sequence is the most divergent, defining a sixth distinct subclass of mammalian adenylyl cyclases, The AC9 gene has been localized to human chromosome band 16p13.3-13.2. The 8.5-kb mRNA encoding the type 9 adenylyl cyclase is widely distributed, being readily detected in all tissues tested, and is found at very high levels in skeletal muscle and brain, AC9 mRNA is found throughout rat brain but is particularly abundant in hippocampus, cerebellum, and neocortex, An antiserum directed against the carboxyl terminus of the type 9 adenylyl cyclase detects native and expressed recombinant AC9 protein in tissue and cell membranes. Levels of the AC9 protein are highest in mouse brain membranes. Characterization of expressed recombinant AC9 reveals that the protein is a functional adenylyl cyclase that is stimulated by Mg2+, forskolin, and mutationally activated G(s) alpha. AC9 activity is not affected by Ca2+/calmodulim or by G protein beta gamma-subunits. Thus AC9 represents a functional G protein-regulated adenylyl cyclase found in brain and in most somatic tissues.	HOP HENRI MONDOR,UNITE RECH,INSERM U99,F-94010 CRETEIL,FRANCE; HOP ENFANTS LA TIMONE,INSERM U242,UNITE RECH,F-13385 MARSEILLE,FRANCE	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Institut National de la Sante et de la Recherche Medicale (Inserm); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Aix-Marseille Universite; Assistance Publique-Hopitaux de Marseille	Premont, RT (corresponding author), DUKE UNIV,MED CTR,DEPT MED CARDIOL,BOX 3821,DURHAM,NC 27710, USA.			Matsuoka, Isao/0000-0002-7170-3630; Premont, Richard/0000-0002-8053-5026	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL016037, R01HL016037] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 16037] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKALYAR HA, 1990, SCIENCE, V250, P1403, DOI 10.1126/science.2255909; CALI JJ, 1994, J BIOL CHEM, V269, P12190; CASEY PJ, 1989, BIOCHEMISTRY-US, V28, P611, DOI 10.1021/bi00428a029; CHEN JQ, 1993, J BIOL CHEM, V268, P12253; COOPER DMF, 1995, NATURE, V374, P421, DOI 10.1038/374421a0; DEFER N, 1994, FEBS LETT, V351, P109, DOI 10.1016/0014-5793(94)00836-1; DOGGETT NA, 1993, HUMAN GENE MAPPING, P506; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; GAO BN, 1991, P NATL ACAD SCI USA, V88, P10178, DOI 10.1073/pnas.88.22.10178; Genetic Computer Group, 1994, PROGR MAN WISC PACK; GERARD RD, 1985, MOL CELL BIOL, V5, P3231, DOI 10.1128/MCB.5.11.3231; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; GLATT CE, 1993, NATURE, V361, P536, DOI 10.1038/361536a0; GOLUB EI, 1989, NUCLEIC ACIDS RES, V17, P4902, DOI 10.1093/nar/17.12.4902; GRAZIANO MP, 1989, J BIOL CHEM, V264, P15475; HABER N, 1994, HUM GENET, V94, P69, DOI 10.1007/BF02272844; HELLEVUO K, 1993, BIOCHEM BIOPH RES CO, V192, P311, DOI 10.1006/bbrc.1993.1415; HELLEVUO K, 1995, J BIOL CHEM, V270, P11581, DOI 10.1074/jbc.270.19.11581; HELLEVUO K, 1995, HUM GENET, V95, P197; IWAMI G, 1995, J BIOL CHEM, V270, P12481, DOI 10.1074/jbc.270.21.12481; JACOBOWITZ O, 1994, P NATL ACAD SCI USA, V91, P10630, DOI 10.1073/pnas.91.22.10630; KATSUSHIKA S, 1992, P NATL ACAD SCI USA, V89, P8774, DOI 10.1073/pnas.89.18.8774; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KRUPINSKI J, 1992, J BIOL CHEM, V267, P24858; MATSUOKA I, 1992, J NEUROSCI, V12, P3350; MATTEI MG, 1985, HUM GENET, V69, P268, DOI 10.1007/BF00293038; MONS N, 1994, J NEUROENDOCRINOL, V6, P665, DOI 10.1111/j.1365-2826.1994.tb00633.x; MONS N, 1995, P NATL ACAD SCI USA, V92, P8473, DOI 10.1073/pnas.92.18.8473; Nomura N, 1994, DNA Res, V1, P27, DOI 10.1093/dnares/1.1.27; OLATE J, 1988, J BIOL CHEM, V263, P10394; PARMA J, 1991, BIOCHEM BIOPH RES CO, V179, P455, DOI 10.1016/0006-291X(91)91392-P; PATTERSON JM, 1995, BIOCHEM BIOPH RES CO, V214, P1000; PEARSON WR, 1988, P NATL ACAD SCI USA, V85, P2444, DOI 10.1073/pnas.85.8.2444; PIERONI JP, 1995, J BIOL CHEM, V270, P21368, DOI 10.1074/jbc.270.36.21368; PREMONT RT, 1992, ENDOCRINOLOGY, V131, P2774, DOI 10.1210/en.131.6.2774; PREMONT RT, 1992, P NATL ACAD SCI USA, V89, P9809, DOI 10.1073/pnas.89.20.9809; PREMONT RT, 1994, METHOD ENZYMOL, V238, P116; PREMONT RT, 1988, J BIOL CHEM, V263, P16087; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; PREMONT RT, 1990, G PROTEINS, P147; PREMONT RT, 1993, GTPASES BIOL, V2, P189; ROHLFS EM, 1995, J BIOL CHEM, V270, P10723, DOI 10.1074/jbc.270.18.10723; SALOMON Y, 1974, ANAL BIOCHEM, V58, P541, DOI 10.1016/0003-2697(74)90222-X; Sambrook J., 2002, MOL CLONING LAB MANU; SEAMON KB, 1986, ADV CYCLIC NUCL PROT, V20, P1; SEAMON KB, 1981, J CYCLIC NUCL PROT, V7, P201; SIMMOTEIT R, 1991, FEBS LETT, V285, P99, DOI 10.1016/0014-5793(91)80734-K; SUTKOWSKI EM, 1994, BIOCHEMISTRY-US, V33, P12852, DOI 10.1021/bi00209a017; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; TAUSSIG R, 1995, J BIOL CHEM, V270, P1, DOI 10.1074/jbc.270.1.1; TAUSSIG R, 1993, SCIENCE, V261, P218, DOI 10.1126/science.8327893; WATSON PA, 1994, J BIOL CHEM, V269, P28893; YOSHIMURA M, 1992, P NATL ACAD SCI USA, V89, P6716, DOI 10.1073/pnas.89.15.6716	53	141	146	1	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13900	13907		10.1074/jbc.271.23.13900	http://dx.doi.org/10.1074/jbc.271.23.13900			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662814	hybrid			2022-12-27	WOS:A1996UP38500089
J	Adda, S; Fleischmann, BK; Freedman, BD; Yu, MF; Hay, DWP; Kotlikoff, MI				Adda, S; Fleischmann, BK; Freedman, BD; Yu, MF; Hay, DWP; Kotlikoff, MI			Expression and function of voltage-dependent potassium channel genes in human airway smooth muscle	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECTIFIER K+ CHANNEL; GUINEA-PIG; SUBMUCOSAL ARTERIOLES; IONIC CURRENTS; PORTAL-VEIN; CELLS; CANINE; ARTERY; TRANSMISSION; RELAXATION	Patch clamp and RNA-polymerase chain reaction methods were used to determine the expression of voltage-dependent potassium channel currents and mRNAs in human airway smooth muscle cells, and tension measurements were used to examine the functional role of specific potassium channel gene products in human bronchial smooth muscle, RNA from airway smooth muscle tissue revealed the presence of Kv1.2 (11 kilobases (kb)) and Kv1.5 (3.5 and 4.4 kb) transcripts, as well as Kv1.1 mRNA (9.5 kb), which has not previously been reported in smooth muscle; transcripts from other gene families were not detected. RNA-polymerase chain reaction from cultured human myocytes confirmed that the identified transcripts were expressed by smooth muscle cells, The available voltage-dependent potassium current in human airway myocytes was insensitive to charybdotoxin (200 nM) but blocked by 4-aminopyridine. Dendrotoxin (1-300 nM; inhibits Kv1.1 and Kv1.2 channels), charybdotoxin (10 nM to 1 mu M; inhibits K-Ca, and Kv1.2 channels), and glybenclamide (0.1-100 mu M; inhibits K-ATP channels) had no effect on resting tone, Conversely, 4-aminopyridine increased resting tension with an EC(50) (1.8 mM) equivalent to that observed for current inhibition (1.9 mM). Human airway myocytes express mRNA from several members of the Kv1 gene family; the channel that underlies the predominate voltage dependent current and the regulation of basal tone appears to be Kv1.5.	UNIV PENN, SCH VET MED, DEPT ANIM BIOL, PHILADELPHIA, PA 19104 USA; UNIV PENN, SCH MED, DEPT PATHOL, PHILADELPHIA, PA 19104 USA; SMITHKLINE BEECHAM PHARMACEUT, DEPT PULM PHARMACOL, KING OF PRUSSIA, PA 19406 USA	University of Pennsylvania; University of Pennsylvania; GlaxoSmithKline					NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL041084, T32HL007027] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI060921] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL 41084, T32 HL07027] Funding Source: Medline; NIAID NIH HHS [R01 AI060921] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ATTALI B, 1993, J BIOL CHEM, V268, P24283; BECKH S, 1990, EMBO J, V9, P777, DOI 10.1002/j.1460-2075.1990.tb08173.x; BEECH DJ, 1989, J PHYSIOL-LONDON, V418, P293, DOI 10.1113/jphysiol.1989.sp017841; BENHAM CD, 1986, J PHYSIOL-LONDON, V371, P45, DOI 10.1113/jphysiol.1986.sp015961; BOLTON TB, 1985, EXPERIENTIA, V41, P887, DOI 10.1007/BF01970006; BOLTON TB, 1979, PHYSIOL REV, V59, P606, DOI 10.1152/physrev.1979.59.3.606; BOYLE JP, 1992, J PHYSIOL-LONDON, V447, P329, DOI 10.1113/jphysiol.1992.sp019005; BRAYDEN JE, 1992, SCIENCE, V256, P532, DOI 10.1126/science.1373909; BULBRING E, 1987, PHARMACOL REV, V39, P49; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; EDWARDS FR, 1988, J PHYSIOL-LONDON, V404, P437, DOI 10.1113/jphysiol.1988.sp017298; FLEISCHMANN BK, 1993, J PHYSIOL-LONDON, V469, P625, DOI 10.1113/jphysiol.1993.sp019834; GRISSMER S, 1994, MOL PHARMACOL, V45, P1227; HART PJ, 1993, P NATL ACAD SCI USA, V90, P9659, DOI 10.1073/pnas.90.20.9659; HIRST GDS, 1982, J PHYSIOL-LONDON, V333, P53, DOI 10.1113/jphysiol.1982.sp014438; HIRST GDS, 1986, J PHYSIOL-LONDON, V371, P289, DOI 10.1113/jphysiol.1986.sp015975; HIRST GDS, 1989, PHYSIOL REV, V69, P546, DOI 10.1152/physrev.1989.69.2.546; HONDA K, 1987, JPN J PHYSIOL, V37, P333, DOI 10.2170/jjphysiol.37.333; ICHINOSE M, 1994, AM J RESP CRIT CARE, V150, P388, DOI 10.1164/ajrccm.150.2.7519521; ISACOFF EY, 1990, NATURE, V345, P530, DOI 10.1038/345530a0; ITO Y, 1970, J PHYSIOL-LONDON, V211, P445, DOI 10.1113/jphysiol.1970.sp009286; JAN LY, 1992, ANNU REV PHYSIOL, V54, P535, DOI 10.1146/annurev.physiol.54.1.535; JONES TR, 1990, J PHARMACOL EXP THER, V255, P697; KAJIWARA M, 1981, J PHYSIOL-LONDON, V315, P283, DOI 10.1113/jphysiol.1981.sp013748; KOTLIKOFF MI, 1990, AM J PHYSIOL, V259, pL384, DOI 10.1152/ajplung.1990.259.6.L384; KOTLIKOFF MI, 1987, AM J PHYSIOL, V253, pC561, DOI 10.1152/ajpcell.1987.253.4.C561; KUME H, 1989, NATURE, V341, P152, DOI 10.1038/341152a0; MCCANN JD, 1986, J PHYSIOL-LONDON, V372, P113, DOI 10.1113/jphysiol.1986.sp016000; MIURA M, 1992, AM REV RESPIR DIS, V146, P132, DOI 10.1164/ajrccm/146.1.132; OKABE K, 1987, PFLUG ARCH EUR J PHY, V409, P561, DOI 10.1007/BF00584654; OKABE K, 1990, J PHARMACOL EXP THER, V252, P832; OVERTURF KE, 1994, AM J PHYSIOL-CELL PH, V267, pC1231, DOI 10.1152/ajpcell.1994.267.5.C1231; PANETTIERI RA, 1989, AM J PHYSIOL, V256, pC329, DOI 10.1152/ajpcell.1989.256.2.C329; QUAYLE JM, 1993, AM J PHYSIOL, V265, pC1363, DOI 10.1152/ajpcell.1993.265.5.C1363; ROBERDS SL, 1991, P NATL ACAD SCI USA, V88, P1798, DOI 10.1073/pnas.88.5.1798; ROBERTSON BE, 1994, AM J PHYSIOL-CELL PH, V267, pC1589, DOI 10.1152/ajpcell.1994.267.6.C1589; RUPPERSBERG JP, 1990, NATURE, V345, P535, DOI 10.1038/345535a0; SALKOFF L, 1992, TRENDS NEUROSCI, V15, P161, DOI 10.1016/0166-2236(92)90165-5; STANDEN NB, 1989, SCIENCE, V245, P177, DOI 10.1126/science.2501869; TORPHY TJ, 1993, J PHARMACOL EXP THER, V265, P1213; TYTGAT J, 1995, J BIOL CHEM, V270, P24776, DOI 10.1074/jbc.270.42.24776; VILLANOVE X, 1993, AM REV RESPIR DIS, V148, P107, DOI 10.1164/ajrccm/148.1.107; VOLK KA, 1991, J PHYSIOL-LONDON, V439, P751, DOI 10.1113/jphysiol.1991.sp018691; WALSH JV, 1983, CELL CALCIUM, V4, P321, DOI 10.1016/0143-4160(83)90011-8	44	49	55	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13239	13243		10.1074/jbc.271.22.13239	http://dx.doi.org/10.1074/jbc.271.22.13239			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662756	hybrid			2022-12-27	WOS:A1996UN47400085
J	Arroyo, MP; Downey, KM; So, AG; Wang, TSF				Arroyo, MP; Downey, KM; So, AG; Wang, TSF			Schizosaccharomyces pombe proliferating cell nuclear antigen mutations affect DNA polymerase delta processivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE EXCISION-REPAIR; LAGGING STRAND SYNTHESIS; REPLICATION FACTOR-C; FISSION YEAST; SACCHAROMYCES-CEREVISIAE; ESCHERICHIA-COLI; ACCESSORY PROTEINS; III HOLOENZYME; CALF THYMUS; PCNA	We introduced nine site-directed mutations into seven conserved fission yeast proliferative cell nuclear antigen (PCNA) residues, Leu(2), Asp(63), Arg(64), Gly(69), Gln(201), Glu(259), and Glu(260), either as single or as double mutants, Both the recombinant wild type and mutant PCNAs were able to form homotrimers in solution and to sustain growth of a null pcna strain (Delta pcna). Wild type Schizosaccharomyces pombe PCNA and PCNA proteins with mutations in Asp(63), Gln(201), Glu(259), Or Glu(260) to Ala were able to stimulate DNA synthetic activity and to enhance the processivity of calf thymus DNA polymerase delta holoenzyme similar to calf thymus PCNA, Mutations of Leu(2) to Val or Arg(64) to Ala, either singly eras a double mutant, yielded PCNA mutant proteins that had reduced capacity in enhancing the processivity of DNA polymerase delta but showed no deficiency in stimulation of the ATPase activity of replication factor C, S, pombe Delta pcna strains sustained by these two mutant-pcna alleles had moderate defects in growth and displayed elongated phenotypes, These cells, however, were not sensitive to UV irradiation, Together, these in vitro and in vivo studies suggest that the side chains of Leu(2) and Arg(64) in one face of the PCNA trimer ring structure are two of the several sites involved in tethering DNA polymerase delta for processive DNA synthesis during DNA replication.	STANFORD UNIV, SCH MED, DEPT PATHOL, STANFORD, CA 94305 USA; UNIV MIAMI, SCH MED, DEPT MED, MIAMI, FL 33101 USA; UNIV MIAMI, SCH MED, DEPT BIOCHEM, MIAMI, FL 33101 USA	Stanford University; University of Miami; University of Miami					NCI NIH HHS [CA54415] Funding Source: Medline; NIDDK NIH HHS [DK26206] Funding Source: Medline; NIGMS NIH HHS [GM07365] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA054415] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK026206] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [T32GM007365] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ABOUSSEKHRA A, 1995, CELL, V80, P859, DOI 10.1016/0092-8674(95)90289-9; AYYAGARI R, 1995, MOL CELL BIOL, V15, P4420; BASI G, 1993, GENE, V123, P131, DOI 10.1016/0378-1119(93)90552-E; BAUER GA, 1988, P NATL ACAD SCI USA, V85, P7506, DOI 10.1073/pnas.85.20.7506; BAUER GA, 1988, BIOCHIM BIOPHYS ACTA, V951, P274, DOI 10.1016/0167-4781(88)90097-8; BROWN WC, 1993, J BIOL CHEM, V268, P982; CHIANG CS, 1993, P NATL ACAD SCI USA, V90, P9105, DOI 10.1073/pnas.90.19.9105; DONG Q, 1993, J BIOL CHEM, V268, P24163; DOWNEY KM, 1990, BIOESSAYS, V12, P231, DOI 10.1002/bies.950120507; FLORESROZAS H, 1994, P NATL ACAD SCI USA, V91, P8655, DOI 10.1073/pnas.91.18.8655; FORSBURG SL, 1993, NUCLEIC ACIDS RES, V21, P2955, DOI 10.1093/nar/21.12.2955; FUKUDA K, 1995, J BIOL CHEM, V270, P22527, DOI 10.1074/jbc.270.38.22527; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HARRINGTON JJ, 1994, GENE DEV, V8, P1344, DOI 10.1101/gad.8.11.1344; HINDGES R, 1995, GENE, V158, P241, DOI 10.1016/0378-1119(95)00065-E; KONG XP, 1992, CELL, V69, P425, DOI 10.1016/0092-8674(92)90445-I; KRISHNA TSR, 1994, CELL, V79, P1233, DOI 10.1016/0092-8674(94)90014-0; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; KURIYAN J, 1993, J MOL BIOL, V234, P915, DOI 10.1006/jmbi.1993.1644; LEE SH, 1991, J BIOL CHEM, V266, P22707; LI R, 1994, NATURE, V371, P534, DOI 10.1038/371534a0; LI XY, 1995, J BIOL CHEM, V270, P22109, DOI 10.1074/jbc.270.38.22109; MAUNDRELL K, 1993, GENE, V123, P127, DOI 10.1016/0378-1119(93)90551-D; MAUNDRELL K, 1990, J BIOL CHEM, V265, P10857; MCALEAR MA, 1994, MOL CELL BIOL, V14, P4390, DOI 10.1128/MCB.14.7.4390; MORENO S, 1991, METHOD ENZYMOL, V194, P795; NG L, 1993, J BIOL CHEM, V268, P13571; NG L, 1990, J BIOL CHEM, V265, P11948; NICHOLS AF, 1992, NUCLEIC ACIDS RES, V20, P2441, DOI 10.1093/nar/20.10.2441; ODONNELL M, 1992, MOL BIOL CELL, V3, P953, DOI 10.1091/mbc.3.9.953; PAN ZQ, 1995, J BIOL CHEM, V270, P22008, DOI 10.1074/jbc.270.37.22008; PARK H, 1993, MOL BIOL CELL, V4, P145, DOI 10.1091/mbc.4.2.145; PARK H, 1995, NUCLEIC ACIDS RES, V23, P4337, DOI 10.1093/nar/23.21.4337; PODUST VN, 1992, NUCLEIC ACIDS RES, V20, P4159, DOI 10.1093/nar/20.16.4159; POLESKY AH, 1990, J BIOL CHEM, V265, P14579; PRELICH G, 1987, NATURE, V326, P471, DOI 10.1038/326471a0; PRELICH G, 1988, CELL, V53, P117, DOI 10.1016/0092-8674(88)90493-X; SAZER S, 1990, J CELL SCI, V97, P509; SHIVJI MKK, 1992, CELL, V69, P367, DOI 10.1016/0092-8674(92)90416-A; STILLMAN B, 1994, CELL, V78, P725, DOI 10.1016/S0092-8674(94)90362-X; TAN CK, 1986, J BIOL CHEM, V261, P2310; TSURIMOTO T, 1990, P NATL ACAD SCI USA, V87, P1023, DOI 10.1073/pnas.87.3.1023; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1961; TSURIMOTO T, 1991, J BIOL CHEM, V266, P1950; WAGA S, 1994, J BIOL CHEM, V269, P10923; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WAGA S, 1994, NATURE, V369, P207, DOI 10.1038/369207a0; WANG TSF, 1984, J BIOL CHEM, V259, P1854; WASEEM NH, 1992, EMBO J, V11, P5111, DOI 10.1002/j.1460-2075.1992.tb05618.x; WRIGHT A, 1986, PLASMID, V15, P156, DOI 10.1016/0147-619X(86)90051-X; XIONG Y, 1992, CELL, V71, P505, DOI 10.1016/0092-8674(92)90518-H; YAMAGUCHI M, 1990, MOL CELL BIOL, V10, P872, DOI 10.1128/MCB.10.3.872; YODER BL, 1991, J BIOL CHEM, V266, P22689	53	35	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					15971	15980		10.1074/jbc.271.27.15971	http://dx.doi.org/10.1074/jbc.271.27.15971			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663159	hybrid			2022-12-27	WOS:A1996UW35200022
J	Baugh, RJ; Krishnaswamy, S				Baugh, RJ; Krishnaswamy, S			Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							COAGULATION FACTOR-X; HUMAN FACTOR-VIIA; BOVINE FACTOR-X; TISSUE FACTOR; FACTOR-IX; STUART FACTOR; FACTOR-VA; PROTEOLYTIC ACTIVATION; HUMAN-PROTHROMBIN; CHRISTMAS-FACTOR	The activation of factor X by the extrinsic coagulation system results from the action of an enzyme complex composed of factor VIIa bound to tissue factor on phospholipid membranes in the presence of calcium ions (extrinsic Xase complex). Proteolysis at the Arg(52)-Ile(53) peptide bond in the heavy chain of factor X leads to the formation of the serine protease, factor Xa, and the generation of a heavily glycosylated activation peptide comprising residues 1-52 of the heavy chain. The role of the activation peptide region in mediating substrate recognition and cleavage by the extrinsic Xase complex is unclear, The protease Agkistrodon rhodostoma hydrolase gamma (ARH gamma), from the venom of the Malayan pit viper, was used to selectively cleave human factor X in the activation peptide region, Three cleavage sites were found within this region and gave products designated X(des1-34), X(des1-43), and X(des1-49). The products were purified to yield X(des 1-49) and a mixture of X(des 1-34) and X(des 1-43). Reversed phase high pressure liquid chromatography analysis indicated that the cleaved portion of the activation peptide was likely removed during purification. All cleaved species were inactive and could be completely activated to factor Xa by the extrinsic Xase complex or by a purified activator from Russell's viper venom, Steady state kinetic studies using tissue factor reconstituted into membranes yielded essentially equivalent kinetic constants for the activation of intact factor K and the cleaved derivatives under a wide range of conditions, Since X(des 1-49) lacks all but three residues of the activation peptide and is devoid of the carbohydrate present in this region, the data suggest that the specific recognition of human factor X by the extrinsic Xase complex is not achieved through specific interactions with residues 1-49 of the activation peptide or with carbohydrate structures attached to these residues.	EMORY UNIV,DEPT MED,DIV HEMATOL ONCOL,ATLANTA,GA 30322	Emory University					NHLBI NIH HHS [HL-52883, HL-47465] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL052883, R01HL047465] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BACH R, 1986, BIOCHEMISTRY-US, V25, P4007, DOI 10.1021/bi00362a005; BAJAJ SP, 1981, J BIOL CHEM, V256, P253; Bevington P.R., 1969, DATA REDUCTION ERROR; BHARADWAJ D, 1995, J BIOL CHEM, V270, P6537, DOI 10.1074/jbc.270.12.6537; BUTENAS S, 1993, BIOCHEMISTRY-US, V32, P6531, DOI 10.1021/bi00077a006; CHASE T, 1970, METHOD ENZYMOL, V19, P20; CHATTOPADHYAY A, 1989, J BIOL CHEM, V264, P11035; CONTINO PB, 1994, BIOPHYS J, V67, P1113, DOI 10.1016/S0006-3495(94)80577-6; DISCIPIO RG, 1978, J CLIN INVEST, V61, P1528, DOI 10.1172/JCI109073; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P5253, DOI 10.1021/bi00643a015; DISCIPIO RG, 1977, BIOCHEMISTRY-US, V16, P698, DOI 10.1021/bi00623a022; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; ESMON CT, 1974, J BIOL CHEM, V249, P7791; FUJIKAWA K, 1974, BIOCHEMISTRY-US, V13, P5290, DOI 10.1021/bi00723a006; Furie B.C., 1976, Methods Enzymol, V45, P191; FURIE BC, 1974, BIOCHIM BIOPHYS ACTA, V365, P121, DOI 10.1016/0005-2795(74)90256-6; GOWDA DC, 1994, J BIOL CHEM, V269, P10644; HERTZBERG MS, 1992, J BIOL CHEM, V267, P14759; HESS HH, 1975, ANAL BIOCHEM, V63, P607, DOI 10.1016/0003-2697(75)90388-7; HIGGINS DL, 1983, J BIOL CHEM, V258, P6503; HORTIN GL, 1990, ANAL BIOCHEM, V188, P271, DOI 10.1016/0003-2697(90)90605-9; IINO M, 1994, J BIOCHEM-TOKYO, V116, P335; INOUE K, 1993, EUR J BIOCHEM, V218, P153, DOI 10.1111/j.1432-1033.1993.tb18361.x; JACKSON CM, 1984, PROG HEMOST THROMB, V7, P55; KOMIYAMA Y, 1990, BIOCHEMISTRY-US, V29, P9418, DOI 10.1021/bi00492a016; KOSOW DP, 1974, THROMB RES, V4, P219, DOI 10.1016/0049-3848(74)90087-5; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P26110; KRISHNASWAMY S, 1992, J BIOL CHEM, V267, P23696; KRISHNASWAMY S, 1987, J BIOL CHEM, V262, P3291; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAWSON JH, 1993, METHOD ENZYMOL, V222, P177; LEYTUS SP, 1986, BIOCHEMISTRY-US, V25, P5098, DOI 10.1021/bi00366a018; LOLLAR P, 1987, BIOCHEMISTRY-US, V26, P7627, DOI 10.1021/bi00398a015; LUCKOW EA, 1989, BIOCHEMISTRY-US, V28, P2348, DOI 10.1021/bi00431a055; MANN KG, 1988, ANNU REV BIOCHEM, V57, P915, DOI 10.1146/annurev.bi.57.070188.004411; MERTENS K, 1980, BIOCHEM J, V185, P647, DOI 10.1042/bj1850647; MYRMEL KH, 1976, BIOCHEMISTRY-US, V15, P1767, DOI 10.1021/bi00653a027; NEMERSON Y, 1988, BLOOD, V71, P1; NEUENSCHWANDER PF, 1994, J BIOL CHEM, V269, P8007; PADMANABHAN K, 1993, J MOL BIOL, V232, P947, DOI 10.1006/jmbi.1993.1441; PRYZDIAL ELG, 1991, J BIOL CHEM, V266, P8969; PRYZDIAL ELG, 1994, BLOOD, V84, P194; REZAIE AR, 1993, J BIOL CHEM, V268, P8176; RUF W, 1992, J BIOL CHEM, V267, P6375; RUF W, 1992, J BIOL CHEM, V267, P22206; RUF W, 1994, FASEB J, V8, P385, DOI 10.1096/fasebj.8.6.8168689; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SINHA U, 1993, J BIOL CHEM, V268, P3048; STUBBS MT, 1995, TRENDS BIOCHEM SCI, V20, P23, DOI 10.1016/S0968-0004(00)88945-8; VALCARCE C, 1994, J BIOL CHEM, V269, P26011; WAXMAN E, 1992, BIOCHEMISTRY-US, V31, P3998, DOI 10.1021/bi00131a015; ZUR M, 1980, J BIOL CHEM, V255, P5703	52	49	53	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16126	16134		10.1074/jbc.271.27.16126	http://dx.doi.org/10.1074/jbc.271.27.16126			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663201	hybrid			2022-12-27	WOS:A1996UW35200042
J	Johnson, DR; Douglas, I; Jahnke, A; Ghosh, S; Pober, JS				Johnson, DR; Douglas, I; Jahnke, A; Ghosh, S; Pober, JS			A sustained reduction in I kappa B-beta may contribute to persistent NF-kappa B activation in human endothelial cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TUMOR-NECROSIS-FACTOR; PHORBOL-MYRISTATE ACETATE; TRANSCRIPTIONAL ACTIVATION; GENE-TRANSCRIPTION; ONCOPROTEIN BCL-3; DNA-BINDING; EXPRESSION; INDUCTION; P50; INTERLEUKIN-1	The responses of vascular endothelial cells (EC) to tumor necrosis factor-alpha (TNF), interleukin-1 alpha (IL-1), and phorbol myristate acetate (PMA) were compared with respect to the kinetics of (i) NF-kappa B activation, (ii) I kappa B-alpha and I kappa B-beta degradation, and (iii) NF-kappa B-dependent cell surface molecule expression, TNF rapidly (less than or equal to 20 min) and persistently (>20 h) activates NF-kappa B; IL-1 rapidly activates NF-kappa B, but activity declines by 3 h and further by 20 h; PMA slowly and transiently activates NF-kappa B, Untreated EC contain the inhibitory proteins I kappa B-alpha and I kappa B-beta, The onset of NF-kappa B activation correlates with degradation of I kappa B-alpha, but I kappa B-alpha reappears by 4 h without resequestration of NF-kappa B. TNF causes a rapid but partial (50%) reduction in I kappa B-beta, which does not recover by 22 h; IL-1 and PMA cause slower and less sustained reductions in I kappa B-beta. All three agonists induce de novo expression of E-selectin (CD62E) and vascular cell adhesion molecule-1 (CD106) and increase expression of intercellular adhesion molecule-1 (CD54) at 4 h. TNF induces sustained increases in vascular cell adhesion molecule-1 and intercellular adhesion molecule-1 and increases human leukocyte antigen class I molecules at 24 h, We conclude that TNF causes persistent activation of NF-kappa B in human EC and that this may result from sustained reductions in I kappa B-beta levels.	YALE UNIV,SCH MED,BOYER CTR MOLEC MED,MOL CARDIOBIOL PROGRAM,NEW HAVEN,CT 06511; YALE UNIV,SCH MED,IMMUNOBIOL SECT,NEW HAVEN,CT 06511; YALE UNIV,SCH MED,HOWARD HUGHES MED INST,DEPT BIOCHEM & MOLEC BIOPHYS,NEW HAVEN,CT 06511	Yale University; Yale University; Howard Hughes Medical Institute; Yale University	Johnson, DR (corresponding author), YALE UNIV,SCH MED,DEPT PATHOL,295 CONGRESS AVE,454 BCMM,NEW HAVEN,CT 06511, USA.				NHLBI NIH HHS [R37-HL36003] Funding Source: Medline; NIAID NIH HHS [R29-AI35099, R01-AI33443] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL036003] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI033443, R29AI035099] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBELDA SM, 1994, FASEB J, V8, P504, DOI 10.1096/fasebj.8.8.8181668; ARENZANASEISDEDOS F, 1995, MOL CELL BIOL, V15, P2689; BLANCHET O, 1992, P NATL ACAD SCI USA, V89, P3488, DOI 10.1073/pnas.89.8.3488; BOURS V, 1993, CELL, V72, P729, DOI 10.1016/0092-8674(93)90401-B; BROWN K, 1995, SCIENCE, V267, P1485, DOI 10.1126/science.7878466; DEMARTIN R, 1993, EMBO J, V12, P2773, DOI 10.1002/j.1460-2075.1993.tb05938.x; DIGNAM JD, 1983, METHOD ENZYMOL, V101, P582; FRANZOSO G, 1993, EMBO J, V12, P3893, DOI 10.1002/j.1460-2075.1993.tb06067.x; FUJITA T, 1992, GENE DEV, V6, P775, DOI 10.1101/gad.6.5.775; GHOSH S, 1990, NATURE, V344, P678, DOI 10.1038/344678a0; HENKEL T, 1992, CELL, V68, P1121, DOI 10.1016/0092-8674(92)90083-O; ISRAEL A, 1989, EMBO J, V8, P3793, DOI 10.1002/j.1460-2075.1989.tb08556.x; JAHNKE A, 1994, FEBS LETT, V354, P220, DOI 10.1016/0014-5793(94)01130-3; JOHNSON DR, 1994, MOL CELL BIOL, V14, P1322, DOI 10.1128/MCB.14.2.1322; KERR LD, 1993, NATURE, V365, P412, DOI 10.1038/365412a0; KOPP EB, 1995, ADV IMMUNOL, V58, P1, DOI 10.1016/S0065-2776(08)60618-5; KRASNOW SW, 1991, CYTOKINE, V3, P372, DOI 10.1016/1043-4666(91)90040-K; LEDEBUR HC, 1995, J BIOL CHEM, V270, P933, DOI 10.1074/jbc.270.2.933; LEHMING N, 1994, NATURE, V371, P175, DOI 10.1038/371175a0; LENARDO MJ, 1989, CELL, V58, P227, DOI 10.1016/0092-8674(89)90833-7; LEWIS H, 1994, MOL CELL BIOL, V14, P5701, DOI 10.1128/MCB.14.9.5701; LIN RT, 1995, J BIOL CHEM, V270, P3123, DOI 10.1074/jbc.270.7.3123; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LOFQUIST AK, 1995, MOL CELL BIOL, V15, P1737; NEISH AS, 1995, MOL CELL BIOL, V15, P2558; NEISH AS, 1992, J EXP MED, V176, P1583, DOI 10.1084/jem.176.6.1583; PLASKIN D, 1993, J EXP MED, V177, P1651; POBER JS, 1987, J IMMUNOL, V138, P3319; READ MA, 1994, J EXP MED, V179, P503, DOI 10.1084/jem.179.2.503; RICE NR, 1992, CELL, V71, P243, DOI 10.1016/0092-8674(92)90353-E; RITCHIE AJ, 1991, J IMMUNOL, V146, P3056; SCHREIBER E, 1989, NUCLEIC ACIDS RES, V17, P6419, DOI 10.1093/nar/17.15.6419; SPIEGEL MR, 1975, PROBABILITY STATISTI; THANOS D, 1995, CELL, V80, P529, DOI 10.1016/0092-8674(95)90506-5; THANOS D, 1992, CELL, V71, P777, DOI 10.1016/0092-8674(92)90554-P; THOMPSON JE, 1995, CELL, V80, P573, DOI 10.1016/0092-8674(95)90511-1; WHELAN J, 1991, NUCLEIC ACIDS RES, V19, P2645, DOI 10.1093/nar/19.10.2645; WULCZYN FG, 1992, NATURE, V358, P597, DOI 10.1038/358597a0; YANO O, 1987, EMBO J, V6, P3317, DOI 10.1002/j.1460-2075.1987.tb02652.x; ZABEL U, 1991, J BIOL CHEM, V266, P252	40	102	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16317	16322		10.1074/jbc.271.27.16317	http://dx.doi.org/10.1074/jbc.271.27.16317			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663191	hybrid			2022-12-27	WOS:A1996UW35200068
J	Puddicombe, SM; Chamberlin, SG; MacGarvie, J; Richter, A; Drummond, DR; Collins, J; Wood, L; Davies, DE				Puddicombe, SM; Chamberlin, SG; MacGarvie, J; Richter, A; Drummond, DR; Collins, J; Wood, L; Davies, DE			The significance of valine 33 as a ligand-specific epitope of transforming growth factor alpha	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; CHEMICAL CHARACTERIZATION; FACTOR-UROGASTRONE; RECEPTOR; CLONING; BINDING; STRAINS; CELLS; YEAST; EGF	Although binding of epidermal growth factor (EGF) and transforming growth factor alpha (TGF alpha) to the EGF receptor (EGFR) is mutually competitive, their binding is not identical, and their biological activities are not always equivalent, To probe for ligand-specific interactions, me have synthesized analogues of TGF alpha with modifications to the residue lying between the fourth and fifth cysteines (the ''hinge''). Although this residue Lies in a structurally conserved region of the protein, it is not conserved within the EGFR ligand family. Our results show that in TGF alpha there is a preference for a bulky hydrophobic hinge residue; this contrasts with EGF, for which a hydrogen bond donor functionality is preferred. Sequence analysis of the human EGFR Ligands revealed that the nature of the hinge residue correlated with the sequence in the B-loop beta-sheet. As this region is an important determinant in recognition of TGF alpha by the chicken EGFR, we assessed the mitogenicity of the TGF alpha hinge mutants, as well as the other EGFR ligands, using chicken embryo fibroblasts. The preference of the chicken EGFR for TGF alpha hinge mutants with hydrophobic side chains paralleled that of the human EGFR. Betacellulin and heparin-binding EGF-like growth factor also possess an hydrophobic hinge; both were at least as potent as TGF alpha for chicken embryo fibroblasts. EGF and amphiregulin, both with hydrogen bond donor functionalities at their hinge, displayed markedly decreased in potency by comparison with TGF alpha. We propose that EGFR ligands can be subclassified into TGF alpha-like and EGF-like and that this is of functional significance, identifying a potential mechanism whereby EGFR can discriminate between its ligands.	SOUTHAMPTON GEN HOSP, CRC, MED ONCOL UNIT, SOUTHAMPTON SO16 6YD, HANTS, ENGLAND	University of Southampton			Davies, Donna E/H-2993-2012	Collins, Jane/0000-0002-9914-3890; Davies, Donna/0000-0002-5117-2991; Drummond, Douglas/0000-0003-4155-3747				ADAM R, 1995, BBA-MOL CELL RES, V1266, P83, DOI 10.1016/0167-4889(94)00224-3; Campbell I D, 1989, Prog Growth Factor Res, V1, P13, DOI 10.1016/0955-2235(89)90038-0; CAMPBELL ID, 1993, CURR OPIN STRUC BIOL, V3, P385, DOI 10.1016/S0959-440X(05)80111-3; CAMPION SR, 1994, PROG NUCLEIC ACID RE, V49, P353; CAMPION SR, 1993, PROTEIN ENG, V6, P651, DOI 10.1093/protein/6.6.651; CLACKSON T, 1995, SCIENCE, V267, P383, DOI 10.1126/science.7529940; CLARE JJ, 1991, GENE, V105, P205, DOI 10.1016/0378-1119(91)90152-2; COWLEY GP, 1986, BRIT J CANCER, V53, P223, DOI 10.1038/bjc.1986.39; EBNER R, 1991, CELL REGUL, V2, P599, DOI 10.1091/mbc.2.8.599; ENGLER DA, 1991, MOL CELL BIOL, V11, P2452; GAN BS, 1987, J PHARMACOL EXP THER, V242, P331; GREGORY H, 1975, NATURE, V257, P325, DOI 10.1038/257325a0; HIGASHIYAMA S, 1992, J BIOL CHEM, V267, P6205; HOLLENBERG MD, 1989, J PHARMACOL EXP THER, V248, P384; HOLT SJ, 1994, BIOCHEM PHARMACOL, V47, P117, DOI 10.1016/0006-2952(94)90444-8; HOMMEL U, 1992, J MOL BIOL, V227, P271, DOI 10.1016/0022-2836(92)90697-I; HOOPER KP, 1995, BIOCHEM BIOPH RES CO, V206, P710, DOI 10.1006/bbrc.1995.1100; KOIDE H, 1992, FEBS LETT, V302, P39, DOI 10.1016/0014-5793(92)80279-P; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LAX I, 1988, MOL CELL BIOL, V8, P1970, DOI 10.1128/MCB.8.5.1970; MASSAGUE J, 1983, J BIOL CHEM, V258, P3606; MATSUNAMI RK, 1991, J CELL BIOCHEM, V46, P242, DOI 10.1002/jcb.240460307; MITAMURA T, 1995, J BIOL CHEM, V270, P1015, DOI 10.1074/jbc.270.3.1015; RICHTER A, 1995, J BIOL CHEM, V270, P1612, DOI 10.1074/jbc.270.4.1612; RICHTER A, 1995, BIOCHEM PHARMACOL, V49, P367, DOI 10.1016/0006-2952(94)00423-J; SAVAGE CR, 1972, J BIOL CHEM, V247, P7609; SCHREIBER AB, 1986, SCIENCE, V232, P1250, DOI 10.1126/science.2422759; SHERMAN F, 1991, METHOD ENZYMOL, V194, P3; SHING Y, 1993, SCIENCE, V259, P1604, DOI 10.1126/science.8456283; SHOYAB M, 1988, P NATL ACAD SCI USA, V85, P6528, DOI 10.1073/pnas.85.17.6528; STERN PH, 1985, J CLIN INVEST, V76, P2016, DOI 10.1172/JCI112202; VIOLAND BN, 1991, INT J PEPT PROT RES, V37, P463; WINKLER ME, 1989, BIOCHEMISTRY-US, V28, P6373, DOI 10.1021/bi00441a033; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9	35	12	13	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15367	15372		10.1074/jbc.271.26.15367	http://dx.doi.org/10.1074/jbc.271.26.15367			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663070	hybrid			2022-12-27	WOS:A1996UV29900013
J	Saito, H; Minamida, T; Arimoto, I; Handa, T; Miyajima, K				Saito, H; Minamida, T; Arimoto, I; Handa, T; Miyajima, K			Physical states of surface and core lipids in lipid emulsions and apolipoprotein binding to the emulsion surface	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY-LIPOPROTEIN; TRIGLYCERIDE-RICH LIPOPROTEINS; NUCLEAR-MAGNETIC-RESONANCE; CHOLESTERYL ESTER; UNESTERIFIED CHOLESTEROL; LECITHIN EMULSIONS; AMPHIPATHIC HELIX; MODEL MEMBRANES; PARTICLE-SIZE; PROTEIN	Plasma triglyceride-rich lipoproteins vary in lipid composition during their metabolism, We investigated the effects of the lipid composition of emulsion particles, specifically those of cholesterol enrichment and core replacement (replacing core triglyceride with cholesteryl oleate), on the physical states of surface and core lipids, Steady-state and time-resolved fluorescence anisotropies were measured in lipid emulsions using 1,6-diphenylhexatriene to probe the core and 1,6-diphenylhexatriene analogues for the outer and inner hydrophobic portions of surface phospholipids. In the absence of cholesterol, core replacement had little effect on the surface rigidity, despite the large difference in core mobility, However, core replacement caused a marked increase in surface rigidity in the presence of cholesterol. Quenching experiments using the fluorescent cholesterol analogue, dehydroergosterol, indicated that core replacement allowed surface dehydroergosterol to redistribute from the inner to the outer regions in the emulsion surface, These results indicated that core replacement modulates the surface properties of the emulsion particles through the redistribution of cholesterol in the surface layers, Furthermore, core replacement significantly decreased the binding of apolipoprotein E to the emulsion surface, whereas the binding of apolipoprotein CII responded to the cholesterol enrichment. This binding behavior of exchangeable apolipoproteins may closely correlate with the location of surface cholesterol and the mobility of core lipids.	KYOTO UNIV, FAC PHARMACEUT SCI, SAKYO KU, KYOTO 60601, JAPAN	Kyoto University								ATKINSON D, 1986, ANNU REV BIOPHYS BIO, V15, P403; AVIRAM M, 1988, J BIOL CHEM, V263, P16842; AVIRAM M, 1991, J BIOL CHEM, V266, P11567; BANUELOS S, 1995, J BIOL CHEM, V270, P29910, DOI 10.1074/jbc.270.50.29910; BARTLETT GR, 1959, J BIOL CHEM, V234, P466; DELMELLE M, 1980, BIOCHEMISTRY-US, V19, P698, DOI 10.1021/bi00545a014; FINEAN JB, 1990, CHEM PHYS LIPIDS, V54, P147, DOI 10.1016/0009-3084(90)90008-F; GINSBURG GS, 1982, J BIOL CHEM, V257, P8216; GRANOT E, 1994, BIOCHEMISTRY-US, V33, P15190, DOI 10.1021/bi00254a030; HANDA T, 1992, BIOCHEMISTRY-US, V31, P1415, DOI 10.1021/bi00120a018; HANDA T, 1994, PHARMACEUT RES, V11, P1283, DOI 10.1023/A:1018990327466; KALB E, 1989, BIOPHYS J, V56, P1245, DOI 10.1016/S0006-3495(89)82771-7; KINOSITA K, 1984, ADV BIOPHYS, V17, P147, DOI 10.1016/0065-227X(84)90027-3; KROON PA, 1994, BIOCHEMISTRY-US, V33, P4879, DOI 10.1021/bi00182a016; LEHRER SS, 1971, BIOCHEMISTRY-US, V10, P3254, DOI 10.1021/bi00793a015; LI QT, 1994, ARCH BIOCHEM BIOPHYS, V315, P473, DOI 10.1006/abbi.1994.1527; LI QT, 1993, BIOCHIM BIOPHYS ACTA, V1166, P145, DOI 10.1016/0005-2760(93)90090-V; LI QT, 1992, J LIPID RES, V33, P503; LI QT, 1990, BIOCHIM BIOPHYS ACTA, V1042, P42, DOI 10.1016/0005-2760(90)90054-2; LIPARI G, 1980, BIOPHYS J, V30, P489, DOI 10.1016/S0006-3495(80)85109-5; MAHLEY RW, 1988, SCIENCE, V240, P622, DOI 10.1126/science.3283935; MARANHAO RC, 1986, BIOCHIM BIOPHYS ACTA, V875, P247, DOI 10.1016/0005-2760(86)90174-8; MILLER KW, 1983, J BIOL CHEM, V258, P3772; MILLER KW, 1982, J COLLOID INTERF SCI, V89, P466, DOI 10.1016/0021-9797(82)90197-7; MILLER KW, 1983, BIOCHEMISTRY-US, V22, P443, DOI 10.1021/bi00271a030; MIMS MP, 1990, BIOCHEMISTRY-US, V29, P6639, DOI 10.1021/bi00480a013; MIMS MP, 1986, BIOCHEMISTRY-US, V25, P474, DOI 10.1021/bi00350a030; QUARFORDT SH, 1995, BBA-LIPID LIPID MET, V1255, P82, DOI 10.1016/0005-2760(94)00218-N; REDGRAVE TG, 1987, BIOCHIM BIOPHYS ACTA, V921, P154, DOI 10.1016/0005-2760(87)90182-2; REISINGER RE, 1990, J LIPID RES, V31, P849; ROBINSON AJ, 1995, BIOPHYS J, V68, P164, DOI 10.1016/S0006-3495(95)80171-2; SAITO H, 1995, LANGMUIR, V11, P3742, DOI 10.1021/la00010a026; SAITO H, 1991, J BIOCHEM, V109, P559, DOI 10.1093/oxfordjournals.jbchem.a123419; SANKARAM MB, 1991, P NATL ACAD SCI USA, V88, P8686, DOI 10.1073/pnas.88.19.8686; SANKARAM MB, 1990, BIOCHEMISTRY-US, V29, P10676, DOI 10.1021/bi00499a015; SEELIG J, 1980, Q REV BIOPHYS, V13, P19, DOI 10.1017/S0033583500000305; SEGREST JP, 1990, PROTEINS, V8, P103, DOI 10.1002/prot.340080202; SEGREST JP, 1992, J LIPID RES, V33, P141; SEHAYEK E, 1991, J BIOL CHEM, V266, P18259; SMALL DM, 1992, PLASMA LIPOPROTEINS, P57; TAJIMA S, 1983, J BIOL CHEM, V258, P73; WEISGRABER KH, 1990, J BIOL CHEM, V265, P22453; WEISGRABER KH, 1994, ADV PROTEIN CHEM, V45, P249; YEAGLE PL, 1985, BIOCHIM BIOPHYS ACTA, V822, P267, DOI 10.1016/0304-4157(85)90011-5; YOKOYAMA S, 1985, J BIOL CHEM, V260, P6375	45	55	56	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15515	15520		10.1074/jbc.271.26.15515	http://dx.doi.org/10.1074/jbc.271.26.15515			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663047	hybrid			2022-12-27	WOS:A1996UV29900034
J	Cousin, X; Bon, S; Duval, N; Massoulie, J; Bon, C				Cousin, X; Bon, S; Duval, N; Massoulie, J; Bon, C			Cloning and expression of acetylcholinesterase from Bungarus fasciatus venom - New type of COOH-terminal domain-involvement of a positively charged residue in the peripheral site	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TORPEDO-CALIFORNICA; NONAMPHIPHILIC FORMS; ANIONIC SUBSITES; CATALYTIC CENTER; BUTYRYLCHOLINESTERASE; CHOLINESTERASES; INHIBITION; BINDING; RAT	As deduced from cDNA clones, the catalytic domain of Bungarus fasciatus venom acetylcholinesterase (AChE) is highly homologous to those of other AChEs, It is, however, associated with a short hydrophilic carboxyl-terminal region, containing no cysteine, that bears no resemblance to the alternative COOH-terminal peptides of the GPI-anchored molecules (H) or of other homomeric or heteromeric tailed molecules (T). Expression of complete and truncated AChE in COS cells showed that active hydrophilic monomers are produced and secreted in all cases, and that cleavage of a very basic 8-residue carboxyl-terminal fragment occurs upon secretion. The COS cells produced Bungarus AChE about 30 times more efficiently than an equivalent secreted monomeric rat AChE. The recombinant Bungarus AChE, like the natural venom enzyme, showed a distinctive ladder pattern in nondenaturing electrophoresis, probably reflecting a variation in the number of sialic acids. By mutagenesis, we showed that two differences (methionine instead of tyrosine at position 70; lysine instead of aspartate or glutamate at position 285) explain the low sensitivity of Bungarus AChE to peripheral site inhibitors, compared to the Torpedo or mammalian AChEs. These results illustrate the importance of both the aromatic and the charged residues, and the fact that peripheral site ligands (propidium, gallamine, D-tubocurarine, and fasciculin 2) interact with diverse subsets of residues.	INST PASTEUR, UNITE VENINS, F-75015 PARIS, FRANCE; NEUROBIOL LAB, CNRS URA 1857, F-75005 PARIS, FRANCE	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris			Cousin, Xavier/E-2542-2013	Cousin, Xavier/0000-0002-8520-3610				ARPAGAUS M, 1994, J BIOL CHEM, V269, P9957; BARAK D, 1994, J BIOL CHEM, V269, P6296; BARRETT JC, 1979, BRIT J PHARMACOL, V67, P199, DOI 10.1111/j.1476-5381.1979.tb08667.x; BERMAN HA, 1980, BIOCHEMISTRY-US, V19, P2226, DOI 10.1021/bi00551a036; BON S, 1991, CELL MOL NEUROBIOL, V11, P157, DOI 10.1007/BF00712807; BON S, 1988, J NEUROCHEM, V51, P776, DOI 10.1111/j.1471-4159.1988.tb01812.x; BON S, 1988, J NEUROCHEM, V51, P786, DOI 10.1111/j.1471-4159.1988.tb01813.x; BOURNE Y, 1995, CELL, V83, P503, DOI 10.1016/0092-8674(95)90128-0; Cervenansky C., 1991, P303; CERVENANSKY C, 1995, EUR J BIOCHEM, V229, P270, DOI 10.1111/j.1432-1033.1995.0270l.x; CERVENANSKY C, 1994, BBA-GEN SUBJECTS, V1199, P1, DOI 10.1016/0304-4165(94)90088-4; CHANGEUX JP, 1966, MOL PHARMACOL, V2, P369; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COHEN P, 1987, BIOCHIMIE, V69, P87, DOI 10.1016/0300-9084(87)90239-2; DREWS U, 1975, PROG HISTOCHEM CYTOC, V7, P3; DUVAL N, 1992, J CELL BIOL, V118, P641, DOI 10.1083/jcb.118.3.641; EASTMAN J, 1995, J BIOL CHEM, V270, P19694, DOI 10.1074/jbc.270.34.19694; EDWARDS JBDM, 1991, NUCLEIC ACIDS RES, V19, P5227, DOI 10.1093/nar/19.19.5227; EICHLER J, 1994, MOL PHARMACOL, V45, P335; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Harel M, 1995, STRUCTURE, V3, P1355, DOI 10.1016/S0969-2126(01)00273-8; HAREL M, 1993, P NATL ACAD SCI USA, V90, P9031, DOI 10.1073/pnas.90.19.9031; KARNOVSKY MJ, 1964, J HISTOCHEM CYTOCHEM, V12, P219, DOI 10.1177/12.3.219; KREIENKAMP HJ, 1991, P NATL ACAD SCI USA, V88, P6117, DOI 10.1073/pnas.88.14.6117; KUMAR V, 1973, EUR J BIOCHEM, V34, P586, DOI 10.1111/j.1432-1033.1973.tb02799.x; LANDT O, 1990, GENE, V96, P125, DOI 10.1016/0378-1119(90)90351-Q; LAYER P G, 1985, Journal of Neurochemistry, V44, pS129; LAYER PG, 1988, DEVELOPMENT, V102, P387; LEGAY C, 1993, FEBS LETT, V315, P163, DOI 10.1016/0014-5793(93)81155-S; LEGAY C, 1995, EUR J NEUROSCI, V7, P1803, DOI 10.1111/j.1460-9568.1995.tb00699.x; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P285; MASSOULIE J, 1992, MULTIDISCIPLINARY APPROACHES TO CHOLINESTERASE FUNCTIONS, P17; MASSOULIE J, 1993, PROG NEUROBIOL, V41, P31, DOI 10.1016/0301-0082(93)90040-Y; MASSOULIE J, 1976, EUR J BIOCHEM, V68, P531, DOI 10.1111/j.1432-1033.1976.tb10841.x; NEVILLE LF, 1990, J NEUROSCI RES, V27, P452, DOI 10.1002/jnr.490270404; ORDENTLICH A, 1995, J BIOL CHEM, V270, P2082, DOI 10.1074/jbc.270.5.2082; ORDENTLICH A, 1993, J BIOL CHEM, V268, P17083; PEITSCH MC, 1995, BIO-TECHNOL, V13, P658, DOI 10.1038/nbt0795-658; Porschke D, 1996, BIOPHYS J, V70, P1603, DOI 10.1016/S0006-3495(96)79759-X; QUINN DM, 1987, CHEM REV, V87, P955, DOI 10.1021/cr00081a005; RACHINSKY TL, 1990, NEURON, V5, P317, DOI 10.1016/0896-6273(90)90168-F; RADIC Z, 1994, J BIOL CHEM, V269, P11233; RADIC Z, 1991, MOL PHARMACOL, V39, P98; RADIC Z, 1993, BIOCHEMISTRY-US, V32, P12074, DOI 10.1021/bi00096a018; RANDALL WR, 1994, BBA-GENE STRUCT EXPR, V1218, P453, DOI 10.1016/0167-4781(94)90204-6; SCHUMACHER M, 1986, NATURE, V319, P407, DOI 10.1038/319407a0; SHAFFERMAN A, 1992, EMBO J, V11, P3561, DOI 10.1002/j.1460-2075.1992.tb05439.x; SIKORAV JL, 1987, EMBO J, V6, P1865, DOI 10.1002/j.1460-2075.1987.tb02445.x; SUSSMAN JL, 1991, SCIENCE, V253, P872, DOI 10.1126/science.1678899; TAYLOR P, 1994, ANNU REV PHARMACOL, V34, P281, DOI 10.1146/annurev.pa.34.040194.001433; TOUTANT JP, 1988, HDB EXP PHARM, V86, P225; VIGNY M, 1978, EUR J BIOCHEM, V85, P317, DOI 10.1111/j.1432-1033.1978.tb12241.x; WEISE C, 1990, EMBO J, V9, P3885, DOI 10.1002/j.1460-2075.1990.tb07607.x	53	81	82	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	ROCKVILLE	11200 ROCKVILLE PIKE, SUITE 302, ROCKVILLE, MD, UNITED STATES	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15099	15108		10.1074/jbc.271.25.15099	http://dx.doi.org/10.1074/jbc.271.25.15099			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662867	hybrid			2022-12-27	WOS:A1996UT10600068
J	Gagnon, Y; Lacoste, L; Champagne, N; Lapointe, J				Gagnon, Y; Lacoste, L; Champagne, N; Lapointe, J			Widespread use of the Glu-tRNA(Gln) transamidation pathway among bacteria - A member of the alpha purple bacteria lacks glutaminyl-tRNA synthetase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSFER-RNA-SYNTHETASE; ESCHERICHIA-COLI; GLTX-GENE; PHYLOGENETIC TREES; BACILLUS-SUBTILIS; RIBOSOMAL-RNA; AMINO-ACIDS; SEQUENCE; CLONING; PROTEIN	The expression of the Rhizobium meliloti glutamyl-tRNA synthetase gene in Escherichia coli under the control of a trc promoter results in a toxic effect upon isopropyl-beta-D-thiogalactopyranoside induction, which is probably caused by a misacylation activity. To further investigate this unexpected result, we looked at the pathway of Gln-tRNA(Gln) formation in R, meliloti. No glutaminyl-tRNA synthetase activity has been found in R. meliloti crude extract, but we detected a specific aminotransferase activity that changes Glu-tRNA(Gln) to Gln-tRNA(Gln). Our results show that R. meliloti, a member of the alpha-subdivision of the purple bacteria, is the first Gram-negative bacteria reported to use a transamidation pathway for Gln-tRNA(Gln) synthesis, A phylogenetic analysis of the contemporary glutamyl-tRNA synthetase and glutaminyl-tRNA synthetase amino acid sequences reveals that a close evolutionary relationship exists between R. meliloti and yeast mitochondrial glutamyl-tRNA synthetases, which is consistent with an origin of mitochondria in the alpha-subdivision of Gram-negative purple bacteria. A 256-amino acid open reading frame closely related to bacterial glutamyl-tRNA synthetases, which probably originates from a glutamyl-tRNA synthetase gene duplication, was found in the 4-min region of the E. coli chromosome. We suggest that this open reading frame is a relic of an ancient transamidation pathway that occurred in an E. coli ancestor before the horizontal transfer of a eukaryotic glutaminyl-tRNA synthetase (Lamour, V., Quevillon, S., Diriong, S., N'Guyen, V. C., Lipinski, M., and Mirande, M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 8670-8674) and that it favored its stable acquisition, From these observations, a revisited model for the evolution of the contemporary glutamyl-tRNA synthetases and glutaminyl-tRNA synthetases that differs from the generally accepted model for the evolution of aminoacyl-tRNA synthetases is proposed.	UNIV LAVAL,DEPT BIOCHIM,FAC SCI & GENIE,ST FOY,PQ G1K 7P4,CANADA	Laval University								AMANN E, 1988, GENE, V69, P301, DOI 10.1016/0378-1119(88)90440-4; Ausubel FM, 1988, MOL REPROD DEV; BACHMANN BJ, 1990, MICROBIOL REV, V54, P130, DOI 10.1128/MMBR.54.2.130-197.1990; BORDELEAU LM, 1977, CAN J PLANT SCI, V57, P433, DOI 10.4141/cjps77-063; BRETON R, 1990, J BIOL CHEM, V265, P18248; BRETON R, 1986, J BIOL CHEM, V261, P610; BRETON R, 1990, THESIS U LAVAL QUEBE; BROWN JR, 1995, P NATL ACAD SCI USA, V92, P2441, DOI 10.1073/pnas.92.7.2441; BRUNIE S, 1990, J MOL BIOL, V216, P411, DOI 10.1016/S0022-2836(05)80331-6; CERINI C, 1991, EMBO J, V10, P4267, DOI 10.1002/j.1460-2075.1991.tb05005.x; CHUNG CT, 1989, P NATL ACAD SCI USA, V86, P8275; COUSINEAU B, 1992, GENE, V120, P33, DOI 10.1016/0378-1119(92)90006-B; CUSACK S, 1990, NATURE, V347, P249, DOI 10.1038/347249a0; Dayhoff M. O., 1978, ATLAS PROTEIN SEQ S3, V5, P345; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DICKERSON RE, 1980, NATURE, V283, P210, DOI 10.1038/283210a0; DYBVIG K, 1994, MOL MICROBIOL, V12, P547, DOI 10.1111/j.1365-2958.1994.tb01041.x; ERIANI G, 1990, NATURE, V347, P203, DOI 10.1038/347203a0; FALAH M, 1994, J BACTERIOL, V176, P7748, DOI 10.1128/JB.176.24.7748-7753.1994; FELSENSTEIN J, 1988, ANNU REV GENET, V22, P521, DOI 10.1146/annurev.ge.22.120188.002513; FETT R, 1991, J BIOL CHEM, V266, P1448; FUJITA N, 1994, NUCLEIC ACIDS RES, V22, P1637, DOI 10.1093/nar/22.9.1637; GOLDING GB, 1995, MOL BIOL EVOL, V12, P1; GRAY MW, 1992, INT REV CYTOL, V141, P233, DOI 10.1016/S0074-7696(08)62068-9; GUPTA R, 1984, J BIOL CHEM, V259, P9461; HANAHAN D, 1983, J MOL BIOL, V166, P557, DOI 10.1016/S0022-2836(83)80284-8; IWABE N, 1989, P NATL ACAD SCI USA, V86, P9355, DOI 10.1073/pnas.86.23.9355; KANG PJ, 1990, J BACTERIOL, V172, P2055, DOI 10.1128/jb.172.4.2055-2064.1990; KERN D, 1979, J BIOL CHEM, V254, P518; KERN D, 1979, BIOCHEMISTRY-US, V18, P5809, DOI 10.1021/bi00593a010; LABERGE S, 1989, J BACTERIOL, V171, P3926, DOI 10.1128/jb.171.7.3926-3932.1989; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAKE JA, 1988, NATURE, V331, P184, DOI 10.1038/331184a0; LAMOUR V, 1994, P NATL ACAD SCI USA, V91, P8670, DOI 10.1073/pnas.91.18.8670; LAPOINTE J, 1982, CAN J BIOCHEM CELL B, V60, P471, DOI 10.1139/o82-055; LAPOINTE J, 1986, J BACTERIOL, V165, P88, DOI 10.1128/jb.165.1.88-93.1986; LIN SX, 1992, PROTEIN EXPRES PURIF, V3, P71, DOI 10.1016/1046-5928(92)90058-5; LUDMERER SW, 1987, J BIOL CHEM, V262, P10801; NAGEL GM, 1995, J MOL EVOL, V40, P487; NAGEL GM, 1991, P NATL ACAD SCI USA, V88, P8155; NUREKI O, 1992, EUR J BIOCHEM, V204, P465, DOI 10.1111/j.1432-1033.1992.tb16656.x; NUREKI O, 1995, SCIENCE, V267, P1958, DOI 10.1126/science.7701318; OLSEN GJ, 1994, J BACTERIOL, V176, P1, DOI 10.1128/JB.176.1.1-6.1994; PERONA JJ, 1993, BIOCHEMISTRY-US, V32, P8758, DOI 10.1021/bi00085a006; ROGERS KC, 1993, BIOCHEMISTRY-US, V32, P14210, DOI 10.1021/bi00214a021; ROGERS KC, 1995, J MOL EVOL, V40, P476; ROULD MA, 1989, SCIENCE, V246, P1135, DOI 10.1126/science.2479982; RUFF M, 1991, SCIENCE, V252, P1682, DOI 10.1126/science.2047877; RUSSELL RRB, 1971, J BACTERIOL, V108, P790, DOI 10.1128/JB.108.2.790-798.1971; SAITOU N, 1987, MOL BIOL EVOL, V4, P406, DOI 10.1093/oxfordjournals.molbev.a040454; SCHIMMEL P, 1993, P NATL ACAD SCI USA, V90, P8763, DOI 10.1073/pnas.90.19.8763; SCHIMMEL P, 1995, CELL, V81, P983, DOI 10.1016/S0092-8674(05)80002-9; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; SHIELDS JM, 1993, THESIS CLEVELAND STA; SOGIN ML, 1989, SCIENCE, V243, P75, DOI 10.1126/science.2911720; STRAUCH MA, 1988, J BACTERIOL, V170, P916, DOI 10.1128/jb.170.2.916-920.1988; VIALE AM, 1994, FEBS LETT, V341, P146, DOI 10.1016/0014-5793(94)80446-X; VINCENT JM, 1970, IBP HDB, V15, P121; WHITE BN, 1972, CAN J BIOCHEM CELL B, V50, P600, DOI 10.1139/o72-082; WICHLAN DG, 1993, J BACTERIOL, V175, P2936, DOI 10.1128/JB.175.10.2936-2942.1993; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; WONG JTF, 1988, MICROBIOL SCI, V5, P174; WONG JTF, 1975, P NATL ACAD SCI USA, V72, P1909, DOI 10.1073/pnas.72.5.1909; YAMAO F, 1982, J BIOL CHEM, V257, P1639; YANG D, 1985, P NATL ACAD SCI USA, V82, P4443, DOI 10.1073/pnas.82.13.4443; YANISCHPERRON C, 1985, GENE, V33, P103, DOI 10.1016/0378-1119(85)90120-9; ZHAO J, 1993, MOL MICROBIOL, V9, P183, DOI 10.1111/j.1365-2958.1993.tb01680.x; ZUBAY G, 1966, ISOLATION TRANSFER R, V1, P455	68	58	63	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14856	14863		10.1074/jbc.271.25.14856	http://dx.doi.org/10.1074/jbc.271.25.14856			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662929				2022-12-27	WOS:A1996UT10600035
J	Vidakovic, MS; Fraczkiewicz, G; Germanas, JP				Vidakovic, MS; Fraczkiewicz, G; Germanas, JP			Expression and spectroscopic characterization of the hydrogenosomal [2Fe-2S] ferredoxin from the protozoan Trichomonas vaginalis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							IRON-SULFUR PROTEINS; RESONANCE RAMAN; CLOSTRIDIUM-PASTEURIANUM; PARAMAGNETIC PROTEIN; RESOLUTION; ANABAENA-7120; SPECTRA	heterologous expression and spectroscopic characterization of the [2Fe-2S] ferredoxin from the sexually transmitted human parasite Trichomonas vaginalis is described. Using oligonucleotide primers based on the deduced DNA sequence, the gene encoding the ferredoxin was amplified by polymerase chain reaction and cloned into a T7 RNA polymerase expression vector. Expression of the gene in Escherichia coli host HMS174(DE3) resulted in the high level production of the protein with the correctly assembled iron-sulfur cluster. The absorption, circular dichroism, resonance Raman, and EPR spectra of the recombinant protein revealed many differences from those of other [2Fe-2S] ferredoxins. The redox potential of the protein (-347 mV versus normal hydrogen electrode) was also determined, Whereas the amino acid sequence of T. vaginalis ferredoxin showed greatest homology to the [2Fe-2S] ferredoxins found in bacteria and vertebrate mitochondria which function in cytochrome P450 oxidation pathways, the spectroscopic properties showed substantial dissimilarity. Differences in the biophysical properties and function of T. vaginalis ferredoxin are proposed to result from the characteristic amino acid sequence of the parasite protein near the cysteine residues that ligate the valence-localized Fe(III) site of the reduced cluster.	UNIV HOUSTON,DEPT CHEM,HOUSTON,TX 77204	University of Houston System; University of Houston				Germanas, Juris/0000-0002-1207-802X				BERTRAND P, 1980, BIOCHIM BIOPHYS ACTA, V625, P337, DOI 10.1016/0005-2795(80)90298-6; BRUL S, 1994, BBA-BIOENERGETICS, V1183, P544, DOI 10.1016/0005-2728(94)90082-5; CARDENAS J, 1976, BIOCHIM BIOPHYS ACTA, V434, P244, DOI 10.1016/0005-2795(76)90056-8; CHENG H, 1994, BIOCHEMISTRY-US, V33, P3155, DOI 10.1021/bi00177a003; CROUSE BR, 1994, J BIOL CHEM, V269, P21030; Czernusxewicx R S, 1993, Methods Mol Biol, V17, P345, DOI 10.1385/0-89603-215-9:345; DAILEY HA, 1994, BIOCHEMISTRY-US, V33, P403, DOI 10.1021/bi00168a003; EASTABROOK RW, 1973, ION SULFUR PROTEINS, V1, P193; FERREIRA GC, 1994, J BIOL CHEM, V269, P7062; FU WG, 1994, BIOCHEMISTRY-US, V33, P13455, DOI 10.1021/bi00249a034; FU WG, 1992, J BIOL CHEM, V267, P15502; FUKUYAMA K, 1995, J BIOCHEM-TOKYO, V117, P1017, DOI 10.1093/oxfordjournals.jbchem.a124800; GORRELL TE, 1984, CARLSBERG RES COMMUN, V49, P259, DOI 10.1007/BF02913954; GRAVES A, 1993, CLIN OBSTET GYNECOL, V36, P145, DOI 10.1097/00003081-199303000-00020; Gunsalus IC, 1973, IRON SULFUR PROTEINS, V1, P151; HAN S, 1989, J AM CHEM SOC, V111, P3496, DOI 10.1021/ja00192a002; HAN S, 1989, J AM CHEM SOC, V111, P3505, DOI 10.1021/ja00192a003; HEINE P, 1993, CLIN OBSTET GYNECOL, V36, P137, DOI 10.1097/00003081-199303000-00019; IKEMIZU S, 1994, ACTA CRYSTALLOGR D, V50, P167, DOI 10.1107/S0907444993009588; JACOBSON BL, 1993, BIOCHEMISTRY-US, V32, P6788, DOI 10.1021/bi00077a033; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; JOHNSON PJ, 1990, P NATL ACAD SCI USA, V87, P6097, DOI 10.1073/pnas.87.16.6097; LANDRUM HL, 1977, J AM CHEM SOC, V99, P3154, DOI 10.1021/ja00451a048; MARCZAK R, 1983, J BIOL CHEM, V258, P2427; MATSUBARA H, 1992, ADV INORG CHEM, V38, P223, DOI 10.1016/S0898-8838(08)60065-3; MATSUBARA H, 1983, PROTEIN NUCLEIC ACID, P168; MEYER J, 1986, BIOCHEMISTRY-US, V25, P6054, DOI 10.1021/bi00368a033; MINO Y, 1987, BIOCHEMISTRY-US, V26, P8059, DOI 10.1021/bi00399a006; MULLER M, 1986, BIOCHEM PHARMACOL, V35, P37, DOI 10.1016/0006-2952(86)90552-6; MULLER M, 1993, J GEN MICROBIOL, V139, P2879, DOI 10.1099/00221287-139-12-2879; PALMER G, 1967, BIOCHEMISTRY-US, V6, P1658, DOI 10.1021/bi00858a012; Rogers L.J, 1987, CYANOBACTERIA, P35; RYPNIEWSKI WR, 1991, BIOCHEMISTRY-US, V30, P4126, DOI 10.1021/bi00231a003; Spiro T. G., 1982, IRON SULFUR PROTEINS; TA DT, 1992, J BIOL CHEM, V267, P11120; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; WEIGUANG F, 1992, J BIOL CHEM, V267, P15502	37	24	25	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14734	14739		10.1074/jbc.271.25.14734	http://dx.doi.org/10.1074/jbc.271.25.14734			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663034	hybrid			2022-12-27	WOS:A1996UT10600018
J	BrinkmanVanderLinden, ECM; Mollicone, R; Oriol, R; Larson, G; VandenEijnden, DH; VanDijk, W				BrinkmanVanderLinden, ECM; Mollicone, R; Oriol, R; Larson, G; VandenEijnden, DH; VanDijk, W			A missense mutation in the FUT6 gene results in total absence of alpha 3-fucosylation of human alpha(1)-acid glycoprotein	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TYPE-2 CHAIN POLYLACTOSAMINE; ALPHA-1-ACID GLYCOPROTEIN; HUMAN-SERUM; H-1-NMR SPECTROSCOPY; FUCOSYL-TRANSFERASE; CANCER; EXPRESSION; ANTIGEN; ALPHA-3-FUCOSYLTRANSFERASES; GLYCOSYLATION	The major alpha 3-fucosyltransferase activity in human plasma is encoded by the gene for fucosyltransferase VI (FUT6). A missense mutation (Gly 739-->Ala) in this gene is responsible for deficiency of enzyme activity in plasma. To examine whether this fucosyltransferase is the sole enzyme responsible for the alpha 3-fucosylation of serum glycoproteins in the liver, we studied the fucosylation of three glycoproteins in sera of individuals with or without inactivated FUT3 and/or FUTG gene(s) but with a functional FUT5 gene. alpha(1)-Acid glycoprotein was used as the principal reporter protein for liver alpha 3-fucosyltransferase activity, because of its high fucose content. In all individuals with the FUTG missense mutation Gly-739-->Ala in double dose, no fucosylation of alpha(1)-acid glycoprotein was found. This alpha(1)-acid glycoprotein was not intrinsically resistant to fucosylation, since it was susceptible to in vitro fucosylation using an alpha 3/4-fucosyltransferase isolated from human milk. The same result was found for alpha(1)-antichymotrypsin and alpha(1)-protease inhibitor. On the other hand in all individuals with alpha 3-fucosyltransferase activity in plasma, alpha 3-fucosylated glycoforms of the glycoproteins studied were found. The degree of fucosylation of alpha(1)-acid glycoprotein was correlated with alpha 3-fucosyltransferase activity (Rs = 0.82). These data indicate that the product of FUTG, but not of FUT3 or of FUT5, is responsible for the alpha 3-fucosylation of glycoproteins produced in liver and suggest that this organ is a major source of alpha 3-fucosyltransferase activity in plasma.	FREE UNIV AMSTERDAM, FAC MED, DEPT MED CHEM, 1081 BT AMSTERDAM, NETHERLANDS; INSERM U178, F-94807 VILLEJUIF, FRANCE; GOTHENBURG UNIV, SAHLGRENS HOSP, DEPT CLIN CHEM & TRANSFUS MED, S-41345 GOTHENBURG, SWEDEN	Vrije Universiteit Amsterdam; Institut National de la Sante et de la Recherche Medicale (Inserm); Sahlgrenska University Hospital; University of Gothenburg			Larson, Göran/AAF-3404-2019					BIERHUIZEN MFA, 1988, EUR J BIOCHEM, V175, P387, DOI 10.1111/j.1432-1033.1988.tb14208.x; BIOU D, 1987, BIOCHIM BIOPHYS ACTA, V913, P308, DOI 10.1016/0167-4838(87)90140-3; BOGHANSE.TC, 1973, ANAL BIOCHEM, V56, P480, DOI 10.1016/0003-2697(73)90215-7; BrinkmanVanderLinden ECM, 1996, GLYCOCONJUGATE J, V13, P27, DOI 10.1007/BF01049676; CAILLARD T, 1988, EXP CLIN IMMUNOGENET, V5, P15; CAMERON HS, 1995, J BIOL CHEM, V270, P20112, DOI 10.1074/jbc.270.34.20112; CANDELIER JJ, 1993, LAB INVEST, V69, P449; CHANDRASEKARAN EV, 1992, J BIOL CHEM, V267, P23806; DEGRAAF TW, 1993, J EXP MED, V177, P657, DOI 10.1084/jem.177.3.657; DEGRAAF TW, 1994, J RHEUMATOL, V21, P2209; DEVRIES T, 1995, J BIOL CHEM, V270, P8712, DOI 10.1074/jbc.270.15.8712; DEVRIES T, 1993, EUR J BIOCHEM, V216, P769, DOI 10.1111/j.1432-1033.1993.tb18197.x; Elmgren A, 1996, VOX SANG, V70, P97, DOI 10.1111/j.1423-0410.1996.tb01300.x; FOURNET B, 1978, BIOCHEMISTRY-US, V17, P5206, DOI 10.1021/bi00617a021; HADA T, 1995, GLYCOCONJUGATE J, V12, P627, DOI 10.1007/BF00731257; HADA T, 1990, Gastroenterologia Japonica, V25, P715; JOHNSON PH, 1995, GLYCOCONJUGATE J, V12, P879, DOI 10.1007/BF00731250; KANNAGI R, 1986, CANCER RES, V46, P2619; KODA Y, 1993, BLOOD, V82, P2915; KUKOWSKALATALLO JF, 1990, GENE DEV, V4, P1288, DOI 10.1101/gad.4.8.1288; LAINE A, 1991, EUR J BIOCHEM, V197, P209, DOI 10.1111/j.1432-1033.1991.tb15901.x; Lowe J B, 1991, Semin Cell Biol, V2, P289; MOLLICONE R, 1992, CARBOHYD RES, V228, P265, DOI 10.1016/S0008-6215(00)90564-0; MOLLICONE R, 1994, J BIOL CHEM, V269, P20987; MOLLICONE R, 1994, J BIOL CHEM, V269, P12662; MOLLICONE R, 1990, EUR J BIOCHEM, V191, P169, DOI 10.1111/j.1432-1033.1990.tb19107.x; NATSUKA S, 1994, J BIOL CHEM, V269, P16789; NISHIHARA S, 1994, J BIOL CHEM, V269, P29271; SAITOH A, 1993, ARCH BIOCHEM BIOPHYS, V303, P281, DOI 10.1006/abbi.1993.1284; SASAKI K, 1994, J BIOL CHEM, V269, P14730; THOMPSON S, 1987, BRIT J CANCER, V56, P605, DOI 10.1038/bjc.1987.249; TUO XH, 1992, CANCER RES, V52, P5744; VANDENEIJNDEN DH, 1993, CURR OPIN STRUC BIOL, V3, P711, DOI 10.1016/0959-440X(93)90054-O; VANDIJK W, 1986, BIOCHEM CELL BIOL, V64, P79, DOI 10.1139/o86-014; VANDIJK W, 1995, ADV EXP MED BIOL, V376, P223; WIERUSZESKI JM, 1988, FEBS LETT, V238, P390, DOI 10.1016/0014-5793(88)80518-0; WOLOSKI BMRNJ, 1986, BIOCHIM BIOPHYS ACTA, V885, P185, DOI 10.1016/0167-4889(86)90087-X; YAZAWA S, 1989, J CANCER RES CLIN, V115, P451, DOI 10.1007/BF00393336; YAZAWA S, 1988, CANCER, V62, P516, DOI 10.1002/1097-0142(19880801)62:3<516::AID-CNCR2820620313>3.0.CO;2-4; YOSHIMA H, 1981, J BIOL CHEM, V256, P8476	40	57	72	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14492	14495		10.1074/jbc.271.24.14492	http://dx.doi.org/10.1074/jbc.271.24.14492			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662894	hybrid			2022-12-27	WOS:A1996UQ66000081
J	Fawcett, TW; Eastman, HB; Martindale, JL; Holbrook, NJ				Fawcett, TW; Eastman, HB; Martindale, JL; Holbrook, NJ			Physical and functional association between GADD153 and CCAAT/enhancer-binding protein beta during cellular stress	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEAR-PROTEIN; GROWTH ARREST; C/EBP; GENE; TRANSCRIPTION; EXPRESSION; ISOFORMS; CELLS; LAP	GADD153, a ubiquitously expressed member of the CCAAT/enhancer-binding protein (C/EBP) family is induced by a wide variety of growth-arresting and DNA-damaging agents. Functionally, GADD153 has been postulated to act as a dominant-negative regulator of C/EBPs. Therefore we sought to gain evidence for interactions between GADD153 and other C/EBPs during cellular responses to stress. In this report we have demonstrated that treatment of rat pheochromocytoma PC12 cells with sodium arsenite leads to enhanced expression of C/ERP-beta and GADD153 (growth arrest and DNA damage inducible gene 153) but not other C/EBPs. Coimmunoprecipitation experiments provided evidence for the formation of endogenous GADD153-C/EBP-beta complexes in arsenite-treated cells. Additional experiments were performed to determine the role of such complexes in regulating GADD153 expression. Previous studies in our laboratory demonstrated that the GADD153 promoter contains a C/EBP binding site through which other C/EBPs interact to transactivate GADD153 expression in liver hepatoma cells. Here, we demonstrate that extracts prepared from arsenite-treated PC12 cells likewise show increased amounts of factors capable of binding to the GADD153-C/EBP site and that these complexes are comprised at least in part of C/EBP-beta. Forced expression of C/EBP-beta was found to be capable of transactivating the GADD153 promoter in PC12 cells cotransfected with plasmids expressing a GADD153 reporter gene and C/EBP-beta protein. However, overexpression of GADD153 inhibited the transactivation of the GADD153 promoter by C/EBP-beta. These findings provide evidence for an autoregulatory loop in which stress-induced GADD153 feeds back to attenuate GADD153 expression during the cellular response to stress.	NIA,GENE EXPRESS & AGING SECT,GERONTOL RES CTR,NIH,BALTIMORE,MD 21224	National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA)			Martindale, Jennifer Luethy/AAD-1963-2022	Martindale, Jennifer Luethy/0000-0002-3234-6861				BAKER SJ, 1990, SCIENCE, V249, P912, DOI 10.1126/science.2144057; BARTLETT JD, 1992, J BIOL CHEM, V267, P20465; BATCHVAROVA N, 1995, EMBO J, V14, P4654, DOI 10.1002/j.1460-2075.1995.tb00147.x; BAUMANN H, 1992, J BIOL CHEM, V267, P19744; BIRKENMEIER EH, 1989, GENE DEV, V3, P1146, DOI 10.1101/gad.3.8.1146; CAO ZD, 1991, GENE DEV, V5, P1538, DOI 10.1101/gad.5.9.1538; CARLSON SG, 1993, MOL CELL BIOL, V13, P4736, DOI 10.1128/MCB.13.8.4736; DESCOMBES P, 1990, GENE DEV, V4, P1541, DOI 10.1101/gad.4.9.1541; DIEHL AM, 1994, HEPATOLOGY, V19, P447; FORNACE AJ, 1989, MOL CELL BIOL, V9, P4196, DOI 10.1128/MCB.9.10.4196; Gately DP, 1996, BRIT J CANCER, V73, P18, DOI 10.1038/bjc.1996.4; GORMAN CM, 1982, MOL CELL BIOL, V2, P1044, DOI 10.1128/MCB.2.9.1044; Guyton KZ, 1996, BIOCHEM J, V314, P547, DOI 10.1042/bj3140547; JUAN TSC, 1993, P NATL ACAD SCI USA, V90, P2584, DOI 10.1073/pnas.90.7.2584; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; LIN FT, 1994, P NATL ACAD SCI USA, V91, P8757, DOI 10.1073/pnas.91.19.8757; MACDOUGALD OA, 1995, J BIOL CHEM, V270, P647, DOI 10.1074/jbc.270.2.647; METZ R, 1991, GENE DEV, V5, P1754, DOI 10.1101/gad.5.10.1754; PARK JS, 1992, GENE, V116, P259, DOI 10.1016/0378-1119(92)90523-R; RAY A, 1994, MOL CELL BIOL, V14, P4324, DOI 10.1128/MCB.14.6.4324; RON D, 1992, GENE DEV, V6, P439, DOI 10.1101/gad.6.3.439; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; SYLVESTER SL, 1994, J BIOL CHEM, V269, P20119	24	102	105	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14285	14289		10.1074/jbc.271.24.14285	http://dx.doi.org/10.1074/jbc.271.24.14285			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662954	hybrid			2022-12-27	WOS:A1996UQ66000054
J	Middleton, SA; Johnson, DL; Jin, RZ; McMahon, FJ; Collins, A; Tullai, J; Gruninger, RH; Jolliffe, LK; Mulcahy, LS				Middleton, SA; Johnson, DL; Jin, RZ; McMahon, FJ; Collins, A; Tullai, J; Gruninger, RH; Jolliffe, LK; Mulcahy, LS			Identification of a critical ligand binding determinant of the human erythropoietin receptor - Evidence for common ligand binding motifs in the cytokine receptor family	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN GROWTH-HORMONE; SIGNAL TRANSDUCTION; PROLACTIN RECEPTOR; EXTRACELLULAR DOMAIN; MUTATIONAL ANALYSIS; ERYTHROID-CELLS; BETA-CHAIN; ACTIVATION; PROLIFERATION; INTERLEUKIN-2	The erythropoietin receptor (EPOR) is a member of a family of cytokine and growth factor receptors that share conserved features in their extracellular and cytoplasmic domains. We have used site-specific mutagenesis within the extracellular domain of the EPOR to search for amino acid residues involved in erythropoietin (EPO) binding, Mutant proteins were expressed in bacteria as soluble EPO binding proteins (EBP) and characterized for EPO binding activity in a number of different assays. Substitution of phenylalanine at position 93 (Phe(93)) with alanine (F93A mutation) resulted in a drastic reduction in EPO binding in the FBP. More conservative tyrosine or tryptophan substitutions at Phe(93) resulted in much less dramatic effects on EPO binding, Biophysical studies indicated that the F93A mutation does not result in gross structural alterations in the EBP, Furthermore, the F93A mutation in full-length EPOR expressed in COS cells abolished detectable EPO binding, This was not a result of processing or transport defects, since mutant receptor was present on the surface of the cells, Mutations in the region immediately around Phe(93) and in residues homologous to other reported ligand binding determinants of the cytokine receptor family had small to moderate effects on EPO binding. These data indicate that Phe(93) is a critical EPO binding determinant of the EPOR. Furthermore, since Phe(93) aligns with critical ligand binding determinants in other receptors of the cytokine receptor family, these data suggest that receptors of this family may use common structural motifs to bind their cognate ligands.			Middleton, SA (corresponding author), RW JOHNSON PHARMACEUT RES INST, 1000 ROUTE 202, POB 300, RARITAN, NJ 08869 USA.		McMahon, Francis J/A-7290-2009	McMahon, Francis J/0000-0002-9469-305X				BASS SH, 1991, P NATL ACAD SCI USA, V88, P4498, DOI 10.1073/pnas.88.10.4498; BAZAN JF, 1990, IMMUNOL TODAY, V11, P350, DOI 10.1016/0167-5699(90)90139-Z; BAZAN JF, 1990, P NATL ACAD SCI USA, V87, P6934, DOI 10.1073/pnas.87.18.6934; BROUDY VC, 1991, BLOOD, V77, P2583, DOI 10.1182/blood.V77.12.2583.2583; CARROLL MP, 1991, J BIOL CHEM, V266, P14964; CORNELIS S, 1995, EMBO J, V14, P3395, DOI 10.1002/j.1460-2075.1995.tb07345.x; COSMAN D, 1990, TRENDS BIOCHEM SCI, V15, P265, DOI 10.1016/0968-0004(90)90051-C; DANDREA A, 1989, CELL, V58, P1023, DOI 10.1016/0092-8674(89)90499-6; DANDREA AD, 1989, CELL, V57, P277, DOI 10.1016/0092-8674(89)90965-3; DEVOS AM, 1992, SCIENCE, V255, P306, DOI 10.1126/science.1549776; DEXTER TM, 1980, J EXP MED, V152, P1036, DOI 10.1084/jem.152.4.1036; DONG YJ, 1993, EXP HEMATOL, V21, P483; DOSHI PD, 1994, BLOOD, V84, P2539, DOI 10.1182/blood.V84.8.2539.bloodjournal8482539; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; HARRIS KW, 1992, J BIOL CHEM, V267, P15205; HERMINE O, 1994, BLOOD, V84, P811; HILTON DJ, 1995, P NATL ACAD SCI USA, V92, P190, DOI 10.1073/pnas.92.1.190; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Ihle J N, 1993, Semin Immunol, V5, P375, DOI 10.1006/smim.1993.1043; IMLER JL, 1992, EMBO J, V11, P2047, DOI 10.1002/j.1460-2075.1992.tb05262.x; Johnson DL, 1996, PROTEIN EXPRES PURIF, V7, P104, DOI 10.1006/prep.1996.0014; JOLLIFFE LK, 1995, NEPHROL DIAL TRANSPL, V10, P28, DOI 10.1093/ndt/10.supp2.28; JONES SS, 1990, BLOOD, V76, P31; KLINGMULLER U, 1995, CELL, V80, P729, DOI 10.1016/0092-8674(95)90351-8; KRANTZ SB, 1991, BLOOD, V77, P419; LIBOI E, 1993, P NATL ACAD SCI USA, V90, P11351, DOI 10.1073/pnas.90.23.11351; LONGMORE GD, 1993, J CELL BIOL, V123, P1305, DOI 10.1083/jcb.123.6.1305; MASUDA S, 1993, J BIOL CHEM, V268, P11208; MIURA O, 1993, ARCH BIOCHEM BIOPHYS, V306, P200, DOI 10.1006/abbi.1993.1501; MIYAKE T, 1977, J BIOL CHEM, V252, P5558; MIYAZAKI T, 1991, EMBO J, V10, P3191, DOI 10.1002/j.1460-2075.1991.tb04881.x; MULLER YA, 1994, BIOCHEMISTRY-US, V33, P1565; NAGAO M, 1992, BIOCHEM BIOPH RES CO, V188, P888, DOI 10.1016/0006-291X(92)91139-H; NAGAO M, 1993, BLOOD, V81, P2503; PATTHY L, 1990, CELL, V61, P13, DOI 10.1016/0092-8674(90)90208-V; QUELLE DE, 1992, MOL CELL BIOL, V12, P4553, DOI 10.1128/MCB.12.10.4553; RONCO LV, 1994, J BIOL CHEM, V269, P277; ROZAKISADCOCK M, 1991, J BIOL CHEM, V266, P16472; ROZAKISADCOCK M, 1992, J BIOL CHEM, V267, P7428; SAWADA K, 1988, J CELL PHYSIOL, V137, P337, DOI 10.1002/jcp.1041370218; WANG HM, 1992, J BIOL CHEM, V267, P979; WOODCOCK JM, 1994, EMBO J, V13, P5176, DOI 10.1002/j.1460-2075.1994.tb06848.x; YAWATA H, 1993, EMBO J, V12, P1705, DOI 10.1002/j.1460-2075.1993.tb05815.x; YET MG, 1993, BLOOD, V82, P1713, DOI 10.1182/blood.V82.6.1713.bloodjournal8261713; YOSHIMURA A, 1992, J BIOL CHEM, V267, P11619; YOUSSOUFIAN H, 1993, BLOOD, V81, P2223	46	45	46	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14045	14054		10.1074/jbc.271.24.14045	http://dx.doi.org/10.1074/jbc.271.24.14045			10	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662939	hybrid			2022-12-27	WOS:A1996UQ66000020
J	Palasis, M; Kuntzweiler, TA; Arguello, JM; Lingrel, JB				Palasis, M; Kuntzweiler, TA; Arguello, JM; Lingrel, JB			Ouabain interactions with the H5-H6 hairpin of the Na,K-ATPase reveal a possible inhibition mechanism via the cation binding domain	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SITE-DIRECTED MUTAGENESIS; ALPHA-SUBUNIT; AMINO-ACIDS; CARDIAC-GLYCOSIDES; RESISTANT ENZYME; NA+,K+-ATPASE; SENSITIVITY; MUTATION; IDENTIFICATION; EXPRESSION	Cardiac glycosides such as ouabain and digoxin specifically inhibit the Na,K-ATPase. Three new residues in the carboxyl half of the Na,K-ATPase, Phe-786, Leu-793 (PFLIF(786)IIANIPL(793)PLGT(797)), and Phe-863 (FTYF(863)VIM) have been identified as ouabain sensitivity determinants using random mutagenesis. Polymerase chain reaction was utilized to randomly mutate the DNA sequence encoding the amino acids between Lys-691 and Lys-945 in the alpha subunit of the Na,K-ATPase. This region contains four transmembrane segments (H5, H6, H7, and H8) and the connecting extracellular and cytoplasmic loops, Diverse substitutions of these three residues resulted in proteins displaying 2.8-48-fold increases in the I-50 of different cardiac glycosides for inhibition of the Na,K-ATPase activity, By locating these residues, in conjunction with Thr-797 (Feng, J., and Lingrel, J. B (1994) Biochemistry 33, 4218-4224), a new region of the protein containing the H5-H6 hairpin and the H7 transmembrane segment emerges as a major determinant of ouabain inhibition. Thus, a link between the cardiac glycoside binding site and the cation transport sites of the Na,K-ATPase transpires giving a structural base to the cation antagonism of ouabain binding, Furthermore, this link suggests a possible mechanism for cardiac glycoside inhibition of the Na,K-ATPase, such that ouabain binding to the implicated region blocks the movement of the H5 and H6 transmembrane domains which may be required for energy transduction and cation transport.	UNIV CINCINNATI, COLL MED, DEPT MOLEC GENET BIOCHEM & MICROBIOL, CINCINNATI, OH 45267 USA	University of Cincinnati			Arguello, Jose/D-1997-2012	Arguello, Jose/0000-0003-3940-6297	NHLBI NIH HHS [HL08612-01, HL 28573, HL 03373] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL008612, R01HL028573, K14HL003373] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		AKERA T, 1978, PHARMACOL REV, V29, P311; ANTOLOVIC R, 1995, FEBS LETT, V368, P169, DOI 10.1016/0014-5793(95)00637-O; ARGUELLO JM, 1991, J BIOL CHEM, V266, P14627; ARGUELLO JM, 1994, J BIOL CHEM, V269, P6892; ARGUELLO JM, 1995, J BIOL CHEM, V270, P22764, DOI 10.1074/jbc.270.39.22764; ASKEW GR, 1994, J BIOL CHEM, V269, P24120; BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAMBERG E, 1994, SODIUM PUMP STRUCTUR; BESANCON M, 1993, BIOCHEMISTRY-US, V32, P2345, DOI 10.1021/bi00060a028; BLOSTEIN R, 1993, J BIOL CHEM, V268, P10654; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BURNS EL, 1993, J BIOL CHEM, V268, P25632; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CANESSA CM, 1992, EMBO J, V11, P1681, DOI 10.1002/j.1460-2075.1992.tb05218.x; CANFIELD V, 1990, MOL CELL BIOL, V10, P1367, DOI 10.1128/MCB.10.4.1367; EMANUEL JR, 1988, J BIOL CHEM, V263, P7726; Feller W., 1970, INTRO PROBABILITY TH, V3; FENG JN, 1994, BIOCHEMISTRY-US, V33, P4218, DOI 10.1021/bi00180a015; FENG JN, 1995, CELL MOL BIOL RES, V41, P29; FORBUSH B, 1978, BIOCHEMISTRY-US, V17, P3667, DOI 10.1021/bi00610a037; GADSBY DC, 1993, SCIENCE, V260, P100, DOI 10.1126/science.7682009; Glynn I. M., 1985, ENZYMES BIOL MEMBR, P35; GREEN NM, 1994, SODIUM PUMP, P110; HANSEN O, 1984, PHARMACOL REV, V36, P143; HILGEMANN DW, 1994, SCIENCE, V263, P1429, DOI 10.1126/science.8128223; ISHII T, 1993, P NATL ACAD SCI USA, V90, P8881, DOI 10.1073/pnas.90.19.8881; JEWELL EA, 1991, J BIOL CHEM, V266, P16925; JEWELLMOTZ EA, 1993, BIOCHEMISTRY-US, V32, P13523, DOI 10.1021/bi00212a018; JORGENSEN PL, 1982, J BIOL CHEM, V257, P7435; JORGENSEN PL, 1992, ACTA PHYSIOL SCAND, V146, P89; JORGENSEN PL, 1992, MOL ASPECTS TRANSPOR, P1; KUNKEL TA, 1985, P NATL ACAD SCI USA, V82, P488, DOI 10.1073/pnas.82.2.488; LANE LK, 1973, J BIOL CHEM, V248, P7197; LANZETTA PA, 1979, ANAL BIOCHEM, V100, P95, DOI 10.1016/0003-2697(79)90115-5; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LUTSENKO S, 1995, P NATL ACAD SCI USA, V92, P7936, DOI 10.1073/pnas.92.17.7936; LUTSENKO S, 1994, J BIOL CHEM, V269, P4555; MALIK B, 1993, PROTEIN SCI, V2, P2103, DOI 10.1002/pro.5560021211; MYERS RM, 1985, SCIENCE, V229, P242, DOI 10.1126/science.2990046; PRICE EM, 1989, J BIOL CHEM, V264, P21902; PRICE EM, 1988, BIOCHEMISTRY-US, V27, P8400, DOI 10.1021/bi00422a016; PRICE EM, 1990, J BIOL CHEM, V265, P6638; ROSSI B, 1980, J BIOL CHEM, V255, P9936; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SCHONFEL W, 1985, N-S ARCH PHARMACOL, V329, P14; SCHULTHEIS PJ, 1993, J BIOL CHEM, V268, P22686; SCHULTHEIS PJ, 1993, BIOCHEMISTRY-US, V32, P544, DOI 10.1021/bi00053a020; SHIN JM, 1993, BIOCHIM BIOPHYS ACTA, V1148, P223, DOI 10.1016/0005-2736(93)90133-K; Thomas R., 1990, ADV DRUG RES, P311; VILSEN B, 1995, BIOCHEMISTRY-US, V34, P1455, DOI 10.1021/bi00004a041; WALLICK ET, 1988, METHOD ENZYMOL, V156, P201; YODA A, 1975, MOL PHARMACOL, V11, P653	53	85	85	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14176	14182		10.1074/jbc.271.24.14176	http://dx.doi.org/10.1074/jbc.271.24.14176			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662895	hybrid			2022-12-27	WOS:A1996UQ66000038
J	Tanguay, RL; Gallie, DR				Tanguay, RL; Gallie, DR			Isolation and characterization of the 102-kilodalton RNA-binding protein that binds to the 5' and 3' translational enhancers of tobacco mosaic virus RNA	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							TRANSCRIPTS INVITRO; POLY(A) TAIL; EXPRESSION; SEQUENCE; GENE; PSEUDOKNOTS; GENOMES; INVIVO; LONG	Tobacco mosaic virus (TMV) is a positive-sense, single-stranded RNA virus the genome of which acts as a mRNA in the cytoplasm, On infection, TMV mRNA is efficiently and selectively translated by the host translation machinery despite the lack of a poly(A) tail, which is normally required for efficient translation, Both the 68-base 5' leader (Omega) and the 205-base 3' untranslated region of TMV promote efficient translation, A 25-base poly(CAA) region within Omega and the upstream pseudoknot domain, a 72-base region composed of three RNA pseudoknots, are responsible for the translational regulation, We have identified, purified, and characterized a 102-kDa RNA-binding protein (p102) from wheat that binds specifically to the poly(CAA) region within Omega and the upstream pseudoknot domain within the TMV 3' untranslated region, Polyclonal antibodies raised against wheat p102 were used to demonstrate that p102 is widely conserved in plant species. Moreover, specific RNA binding activity was detected in all plant species tested. Addition of anti-p102 antibodies to an in vitro translation lysate derived from wheat germ repressed translation, which was subsequently reversed by supplementing the lysate with p102, These findings suggest that this protein may play an important role in determining translational efficiency in plants.	UNIV CALIF RIVERSIDE, DEPT BIOCHEM, RIVERSIDE, CA 92521 USA	University of California System; University of California Riverside								ATWATER JA, 1990, ANNU REV GENET, V24, P519; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BROWNING KS, 1990, J BIOL CHEM, V265, P17967; GALLIE DR, 1994, J BIOL CHEM, V269, P17166; GALLIE DR, 1989, P NATL ACAD SCI USA, V86, P129, DOI 10.1073/pnas.86.1.129; GALLIE DR, 1990, GENE DEV, V4, P1149, DOI 10.1101/gad.4.7.1149; GALLIE DR, 1991, MOL GEN GENET, V228, P258, DOI 10.1007/BF00282474; GALLIE DR, 1992, NUCLEIC ACIDS RES, V20, P4631, DOI 10.1093/nar/20.17.4631; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P3257, DOI 10.1093/nar/15.8.3257; GALLIE DR, 1991, GENE DEV, V5, P2108, DOI 10.1101/gad.5.11.2108; GALLIE DR, 1987, NUCLEIC ACIDS RES, V15, P8693, DOI 10.1093/nar/15.21.8693; HAENNI AL, 1982, PROG NUCLEIC ACID RE, V27, P85, DOI 10.1016/S0079-6603(08)60598-X; Hall T C, 1979, Int Rev Cytol, V60, P1, DOI 10.1016/S0074-7696(08)61257-7; HENTSCHEL CC, 1981, CELL, V25, P301, DOI 10.1016/0092-8674(81)90048-9; LEATHERS V, 1993, MOL CELL BIOL, V13, P5331, DOI 10.1128/MCB.13.9.5331; MUNROE D, 1990, GENE, V91, P151, DOI 10.1016/0378-1119(90)90082-3; NEUPERT B, 1990, NUCLEIC ACIDS RES, V18, P51, DOI 10.1093/nar/18.1.51; RAO ALN, 1989, P NATL ACAD SCI USA, V86, P5335, DOI 10.1073/pnas.86.14.5335; VANBELKUM A, 1985, NUCLEIC ACIDS RES, V13, P7673, DOI 10.1093/nar/13.21.7673; VONBOXBERG Y, 1994, ANAL BIOCHEM, V219, P32, DOI 10.1006/abio.1994.1227; WENGLER G, 1986, J GEN VIROL, V67, P1183, DOI 10.1099/0022-1317-67-6-1183; YISRAELI JK, 1989, METHOD ENZYMOL, V180, P42	22	50	51	1	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14316	14322		10.1074/jbc.271.24.14316	http://dx.doi.org/10.1074/jbc.271.24.14316			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663059	hybrid			2022-12-27	WOS:A1996UQ66000059
J	Jiang, HP; Kuang, YN; Wu, YP; Smrcka, A; Simon, MI; Wu, DQ				Jiang, HP; Kuang, YN; Wu, YP; Smrcka, A; Simon, MI; Wu, DQ			Pertussis toxin-sensitive activation of phospholipase C by the C5a and fMet-Leu-Phe receptors	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BETA-GAMMA-SUBUNITS; G-PROTEINS; SIGNAL TRANSDUCTION; ALPHA-SUBUNITS; ENZYME-SECRETION; INHIBITION; CELLS; DIMERS; FAMILY	Signal transduction pathways that mediate C5a and fMet-Leu-Phe (fMLP)-induced pertussis toxin (PTx)-sensitive activation of phospholipase C (PLC) have been investigated using a cotransfections assay system in COS-7 cells. The abilities of the receptors for C5a and fMLP to activate PLC beta 2 and PLC beta 3 through the G beta gamma subunits of endogenous G(1) proteins in COS-7 cells were tested because both PLC beta 2 and PLC beta 3 were shown to be activated by the beta gamma subunits of G proteins in in vitro reconstitution assays. Neither or the receptors can activate endogenous PLC beta 3 or recombinant PLC beta 3 in transfected COS-7 cells. However, both receptors can clearly activate PLC beta 2 in a PTx-sensitive manner, suggesting that the receptors may interact with endogenous PTx-sensitive G proteins and activate PLC beta 2 probably through the B beta gamma subunits. These findings were further corroborated by the results that PLC beta 3 could only be slightly activated by G(b)eta(1) gamma(1) or G beta(1) gamma(5) in the co-transfection assay, whereas the G beta gamma subunits strongly activated PLC beta 2 under the same conditions. PLC beta 3 can be activated by G(alpha q), G(alpha11), and G(alpha16) in the cotransfection assay. In addition, the G gamma(2) and G gamma(3) mutants wit substitution of the C-terminal Cys residue by a Ser residue, which can inhibit wild type G beta gamma-mediated activation of PLC beta 2, were able to inhibit C5a or fMLP-mediated activation of PLC beta 2. These G gamma mutants, however, showed little effect on m(1)-muscarinic receptor-mediated PLC activation, which is mediated by the G(q) class of G proteins. These results all confirm that the G beta gamma subunits are involved in PLC beta 2 activation by the two chemoattractant receptors and suggest that in COS-7 cells activation of PLC beta 3 by G beta gamma may not be the primary pathway for the receptors.	UNIV ROCHESTER, DEPT PHARMACOL & PHYSIOL & BIOCHEM, ROCHESTER, NY 14534 USA; CALTECH, DIV BIOL, PASADENA, CA 91125 USA	University of Rochester; California Institute of Technology								AMATRUDA TT, 1991, P NATL ACAD SCI USA, V88, P5587, DOI 10.1073/pnas.88.13.5587; AMATRUDA TT, 1993, J BIOL CHEM, V268, P10139; BECKER EL, 1985, J CELL BIOL, V100, P1641, DOI 10.1083/jcb.100.5.1641; BERSTEIN G, 1992, J BIOL CHEM, V267, P8081; BERSTEIN G, 1992, CELL, V70, P411, DOI 10.1016/0092-8674(92)90165-9; BIRNBAUMER L, 1992, CELL, V71, P1069, DOI 10.1016/S0092-8674(05)80056-X; BIRNBAUMER L, 1990, BIOCHIM BIOPHYS ACTA, V1031, P163, DOI 10.1016/0304-4157(90)90007-Y; BLANK JL, 1992, J BIOL CHEM, V267, P23069; BOKOCH GM, 1984, CELL, V39, P301, DOI 10.1016/0092-8674(84)90008-4; BOYER JL, 1992, J BIOL CHEM, V267, P25451; BOYER JL, 1994, J BIOL CHEM, V269, P2814; BRANDT SJ, 1985, P NATL ACAD SCI USA, V82, P3277, DOI 10.1073/pnas.82.10.3277; CONKLIN BR, 1992, J BIOL CHEM, V267, P31; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; FEDERMAN AD, 1992, NATURE, V356, P159, DOI 10.1038/356159a0; GERARD C, 1994, ANNU REV IMMUNOL, V12, P775, DOI 10.1146/annurev.iy.12.040194.004015; GERARD C, 1994, CURR OPIN IMMUNOL, V6, P140, DOI 10.1016/0952-7915(94)90045-0; GILMAN AG, 1987, ANNU REV BIOCHEM, V56, P615, DOI 10.1146/annurev.bi.56.070187.003151; HAWES BE, 1994, J BIOL CHEM, V269, P29825; INGLESE J, 1992, NATURE, V359, P147, DOI 10.1038/359147a0; JIANG HP, 1994, J BIOL CHEM, V269, P7593; KATZ A, 1992, NATURE, V360, P686, DOI 10.1038/360686a0; KLEUSS C, 1992, NATURE, V358, P424, DOI 10.1038/358424a0; KLEUSS C, 1991, NATURE, V353, P43, DOI 10.1038/353043a0; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; LEE SB, 1993, J BIOL CHEM, V268, P25952; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; PARK DG, 1993, J BIOL CHEM, V268, P4573; PITCHER JA, 1992, SCIENCE, V257, P1264, DOI 10.1126/science.1325672; POLAKIS PG, 1988, J BIOL CHEM, V263, P4969; PRONIN AN, 1992, P NATL ACAD SCI USA, V89, P6220, DOI 10.1073/pnas.89.13.6220; REUVENY E, 1994, NATURE, V370, P143, DOI 10.1038/370143a0; ROLLINS TE, 1991, P NATL ACAD SCI USA, V88, P971, DOI 10.1073/pnas.88.3.971; SCHWINN DA, 1991, MOL PHARMACOL, V40, P619; SICILIANO SJ, 1990, J BIOL CHEM, V265, P19568; SIMON MI, 1991, SCIENCE, V252, P802, DOI 10.1126/science.1902986; SIMONDS WF, 1991, J BIOL CHEM, V266, P5363; SMRCKA AV, 1993, J BIOL CHEM, V268, P9667; SNYDERMAN R, 1990, ADP RIBOSYLATING TOX, P295; STEPHENS L, 1994, CELL, V77, P83, DOI 10.1016/0092-8674(94)90237-2; TANG WJ, 1991, SCIENCE, V254, P1500, DOI 10.1126/science.1962211; UEDA N, 1994, J BIOL CHEM, V269, P4388; VERGHESE MW, 1987, J IMMUNOL, V138, P4374; WICKMAN KD, 1994, NATURE, V368, P255, DOI 10.1038/368255a0; WU DQ, 1993, SCIENCE, V261, P101, DOI 10.1126/science.8316840; WU DQ, 1993, P NATL ACAD SCI USA, V90, P5297, DOI 10.1073/pnas.90.11.5297; WU DQ, 1993, J BIOL CHEM, V268, P3704; WU DQ, 1992, J BIOL CHEM, V267, P25798; WU DQ, 1992, J BIOL CHEM, V267, P1811	50	85	86	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13430	13434		10.1074/jbc.271.23.13430	http://dx.doi.org/10.1074/jbc.271.23.13430			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662841	hybrid			2022-12-27	WOS:A1996UP38500021
J	Winzen, R; Kafert, S; Preiss, B; MyliusSpencker, HA; Resch, K; Holtmann, H				Winzen, R; Kafert, S; Preiss, B; MyliusSpencker, HA; Resch, K; Holtmann, H			Interaction between the mRNA of the 55-kDa tumor necrosis factor receptor and cellular proteins - Possible involvement in post-transcriptional regulation of receptor expression	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA STABILITY; 3' UNTRANSLATED REGION; URIDINE BINDING-FACTOR; FACTOR TNF RECEPTOR; PHORBOL ESTER; MONOCLONAL-ANTIBODIES; SURFACE EXPRESSION; MOLECULAR-CLONING; UP-REGULATION; SOLUBLE FORM	Numerous effects of tumor necrosis factor are signaled by its 55-kDa receptors, Studying their expression we found that the level of receptor mRNA was decreased during the phorbol ester-induced differentiation of myelomonocytic cell lines, While only minor changes in transcription were noted, the half-life of receptor mRNA in the differentiated cells was markedly decreased, indicating the involvement of post transcriptional regulation, In an electrophoretic mobility shift assay, formation of complexes between radiolabeled receptor mRNA and cellular proteins was observed, The decrease in receptor mRNA levels during phorbol ester-induced differentiation was paralleled by a change in the pattern of those complexes, Protein-RNA interaction was selective, as it was not competed by unrelated RNAs, Yet, certain mRNAs that contain AU-rich sequences, known to be involved in the control of their stability, did compete with the receptor mRNA, although the latter is devoid of such sequences, A region of 18 nucleotides within its coding region was found to contain an element essential for the formation of all complexes and sufficient for the formation of those with lower molecular mass, Adjacent bases were required in addition for the formation of the complexes with higher molecular mass, The results suggest that proteins interacting with this region of the 55-kDa tumor necrosis factor receptor mRNA contribute to the regulation of its expression.	HANNOVER MED SCH,INST MOLEKPHARMAKOL,D-30623 HANNOVER,GERMANY	Hannover Medical School								AMARA FM, 1994, J BIOL CHEM, V269, P6709; ANGEL P, 1987, CELL, V49, P729, DOI 10.1016/0092-8674(87)90611-8; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BEUTLER B, 1986, NATURE, V320, P584, DOI 10.1038/320584a0; BOHJANEN PR, 1991, MOL CELL BIOL, V11, P3288, DOI 10.1128/MCB.11.6.3288; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRAKEBUSCH C, 1994, J BIOL CHEM, V269, P32488; BREWER G, 1991, MOL CELL BIOL, V11, P2460, DOI 10.1128/MCB.11.5.2460; BROCKHAUS M, 1990, P NATL ACAD SCI USA, V87, P3127, DOI 10.1073/pnas.87.8.3127; CASEY JL, 1989, EMBO J, V8, P3693, DOI 10.1002/j.1460-2075.1989.tb08544.x; CHEN FY, 1993, EMBO J, V12, P3977, DOI 10.1002/j.1460-2075.1993.tb06075.x; CHODOSH LA, 1986, MOL CELL BIOL, V6, P4723, DOI 10.1128/MCB.6.12.4723; DONISKELLER H, 1979, NUCLEIC ACIDS RES, V7, P179, DOI 10.1093/nar/7.1.179; ENGELMANN H, 1990, J BIOL CHEM, V265, P1531; ENGELMANN H, 1990, J BIOL CHEM, V265, P14497; ESPEVIK T, 1990, J EXP MED, V171, P415, DOI 10.1084/jem.171.2.415; GILLIS P, 1991, J BIOL CHEM, V266, P3172; GROUDINE M, 1981, MOL CELL BIOL, V1, P281, DOI 10.1128/MCB.1.3.281; HABERKERN RC, 1973, BIOCHEMISTRY-US, V12, P2389, DOI 10.1021/bi00737a004; HELLER RA, 1990, P NATL ACAD SCI USA, V87, P6151, DOI 10.1073/pnas.87.16.6151; HOLTMANN H, 1987, J IMMUNOL, V139, P1161; IWAI Y, 1991, J BIOL CHEM, V266, P17959; JONES TR, 1987, MOL CELL BIOL, V7, P4513, DOI 10.1128/MCB.7.12.4513; KEMPER O, 1993, GENE, V134, P209, DOI 10.1016/0378-1119(93)90095-K; KLAUSNER RD, 1993, CELL, V72, P19, DOI 10.1016/0092-8674(93)90046-S; KONIG M, 1991, EUR J IMMUNOL, V21, P1741, DOI 10.1002/eji.1830210723; KRUYS V, 1989, SCIENCE, V245, P852, DOI 10.1126/science.2672333; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LARSSON LG, 1994, ONCOGENE, V9, P1247; LEE W, 1987, NATURE, V325, P368, DOI 10.1038/325368a0; LEEUWENBERG JFM, 1994, J IMMUNOL, V152, P5070; LEVINE TD, 1993, MOL CELL BIOL, V13, P3494, DOI 10.1128/MCB.13.6.3494; LINDSTEN T, 1989, SCIENCE, V244, P339, DOI 10.1126/science.2540528; LOETSCHER H, 1990, CELL, V61, P351, DOI 10.1016/0092-8674(90)90815-V; MALTER JS, 1989, SCIENCE, V246, P664, DOI 10.1126/science.2814487; MALTER JS, 1991, J BIOL CHEM, V266, P3167; MCCARTHY JEG, 1995, TRENDS BIOCHEM SCI, V20, P191, DOI 10.1016/S0968-0004(00)89006-4; MERCER JFB, 1985, NUCLEIC ACIDS RES, V13, P7929, DOI 10.1093/nar/13.22.7929; MULLNER EW, 1989, CELL, V58, P373, DOI 10.1016/0092-8674(89)90851-9; NAKAGAWA J, 1995, P NATL ACAD SCI USA, V92, P2051, DOI 10.1073/pnas.92.6.2051; NISHIZUKA Y, 1986, SCIENCE, V233, P305, DOI 10.1126/science.3014651; NOPHAR Y, 1990, EMBO J, V9, P3269, DOI 10.1002/j.1460-2075.1990.tb07526.x; PANDEY NB, 1987, MOL CELL BIOL, V7, P4557, DOI 10.1128/MCB.7.12.4557; PANDITA R, 1992, FEBS LETT, V312, P87, DOI 10.1016/0014-5793(92)81416-J; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; PROKIPCAK RD, 1994, J BIOL CHEM, V269, P9261; RAJAGOPALAN LE, 1994, J BIOL CHEM, V269, P23882; ROSS J, 1995, MICROBIOL REV, V59, P423, DOI 10.1128/MMBR.59.3.423-450.1995; ROTHE J, 1993, NATURE, V364, P798, DOI 10.1038/364798a0; ROTHE J, 1993, MOL IMMUNOL, V30, P165, DOI 10.1016/0161-5890(93)90088-S; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SACHS AB, 1993, CELL, V74, P413, DOI 10.1016/0092-8674(93)80043-E; Sambrook J., 2002, MOL CLONING LAB MANU; SCHALL TJ, 1990, CELL, V61, P361, DOI 10.1016/0092-8674(90)90816-W; SHAW G, 1986, CELL, V46, P659, DOI 10.1016/0092-8674(86)90341-7; SHYU AB, 1989, GENE DEV, V3, P60, DOI 10.1101/gad.3.1.60; SMITH CA, 1990, SCIENCE, V248, P1019, DOI 10.1126/science.2160731; STEPHENS JM, 1992, J BIOL CHEM, V267, P8336; TODARO JG, 1966, SCIENCE, V153, P1253; TRACEY KJ, 1993, ANNU REV CELL BIOL, V9, P317, DOI 10.1146/annurev.cb.09.110193.001533; TREFZER U, 1993, J CLIN INVEST, V92, P462, DOI 10.1172/JCI116589; VAKALOPOULOU E, 1991, MOL CELL BIOL, V11, P3355, DOI 10.1128/MCB.11.6.3355; WHITTEMORE LA, 1990, MOL CELL BIOL, V64, P1329; WINZEN R, 1993, J IMMUNOL, V150, P4346; WINZEN R, 1992, J IMMUNOL, V148, P3454; WISDOM R, 1991, GENE DEV, V5, P232, DOI 10.1101/gad.5.2.232; WODNARFILIPOWICZ A, 1990, P NATL ACAD SCI USA, V87, P777, DOI 10.1073/pnas.87.2.777; YEN TJ, 1988, NATURE, V334, P580, DOI 10.1038/334580a0; YOUNG S, 1991, NUCLEIC ACIDS RES, V19, P2463, DOI 10.1093/nar/19.9.2463; ZHANG W, 1993, MOL CELL BIOL, V13, P7652, DOI 10.1128/MCB.13.12.7652	71	15	15	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13461	13467		10.1074/jbc.271.23.13461	http://dx.doi.org/10.1074/jbc.271.23.13461			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662818	hybrid			2022-12-27	WOS:A1996UP38500026
J	Fritz, LK; Suquet, C; Smerdon, MJ				Fritz, LK; Suquet, C; Smerdon, MJ			Strand breaks are repaired efficiently in human ribosomal genes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SHORT-PATCH REPAIR; DNA-REPAIR; HUMAN-FIBROBLASTS; RNA GENES; PREFERENTIAL REPAIR; TRANSCRIBED STRAND; EXCISION REPAIR; SODIUM-BUTYRATE; BLEOMYCIN; CELLS	We examined repair of DNA strand breaks induced by the anti-cancer drug bleomycin in both Pol I and Pol IT transcribed genes in permeabilized human fibroblasts, The majority of these breaks (>80%) are single strand breaks (SSBs) thought to be repaired by base excision repair enzymes. Repair was examined in each strand of a 7.2-kilobase fragment, completely within the Pol I transcribed region of ribosomal DNA (rDNA) and an 8.3-kilobase fragment completely within the Pol II transcribed region of the dihydrofolate reductase (DHFR) gene. Bleomycin dose-response studies revealed no bias for SSBs in either strand of the rDNA fragment. Furthermore, repair of SSBs is rapid (similar to 80% resealed in 60 min) in both the transcribed and nontranscribed strands of rDNA Rapid repair of SSBs is also observed in both strands of the DBFR gene (similar to 60% resealed in 60 min). In contrast, little (or no) repair of UV photodimers occurs in either strand of human rDNA, regardless of whether cells are confluent or actively growing. Thus, DNA lesions in human ribosomal genes may be more accessible to base excision repair enzymes than those involved in nucleotide excision repair.	WASHINGTON STATE UNIV, DEPT BIOCHEM & BIOPHYS, PULLMAN, WA 99164 USA	Washington State University					NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES002614, R01ES004106, R37ES002614] Funding Source: NIH RePORTER; NIEHS NIH HHS [ES02614, ES04106] Funding Source: Medline	NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS)); NIEHS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS))		ABBOTTS J, 1988, BIOCHEMISTRY-US, V27, P901, DOI 10.1021/bi00403a010; AFFENTRANGER MI, 1995, J HISTOCHEM CYTOCHEM, V43, P229, DOI 10.1177/43.2.7529787; Ausubel FM., 1988, CURRENT PROTOCOLS MO; BENNETT RAO, 1993, BIOCHEMISTRY-US, V32, P3188, DOI 10.1021/bi00063a034; BIANCHI NO, 1990, CANCER RES, V50, P2379; BOHR VA, 1985, CELL, V40, P359, DOI 10.1016/0092-8674(85)90150-3; BOHR VA, 1988, DNA REPAIR LABORATOR, P347; CHRISTIANS FC, 1992, MUTAT RES, V274, P93, DOI 10.1016/0921-8777(92)90056-9; CHRISTIANS FC, 1994, MUTAT RES, V323, P179, DOI 10.1016/0165-7992(94)90031-0; CHRISTIANS FC, 1993, BIOCHEMISTRY-US, V32, P10512, DOI 10.1021/bi00090a030; CONCONI A, 1989, CELL, V57, P753, DOI 10.1016/0092-8674(89)90790-3; COQUERELLE TM, 1987, INT J RADIAT BIOL, V51, P209, DOI 10.1080/09553008714550711; DIGIUSEPPE JA, 1990, CARCINOGENESIS, V11, P1021, DOI 10.1093/carcin/11.6.1021; DIGIUSEPPE JA, 1989, BIOCHEMISTRY-US, V28, P9515, DOI 10.1021/bi00450a040; DRESLER SL, 1985, BIOCHEMISTRY-US, V24, P6861, DOI 10.1021/bi00345a019; FRIEDBERG EC, 1995, DNA REPAIR; FRITZ LK, 1995, BIOCHEMISTRY-US, V34, P13117, DOI 10.1021/bi00040a024; FRITZ LK, 1994, THESIS WASHINGTON U; GONZALEZ IL, 1990, J MOL BIOL, V212, P27, DOI 10.1016/0022-2836(90)90302-3; HUANG JC, 1992, P NATL ACAD SCI USA, V89, P3664, DOI 10.1073/pnas.89.8.3664; KUWAHARA J, 1988, P NATL ACAD SCI USA, V85, P2459, DOI 10.1073/pnas.85.8.2459; LEADON SA, 1991, MUTAT RES, V255, P67, DOI 10.1016/0921-8777(91)90019-L; LEADON SA, 1993, P NATL ACAD SCI USA, V90, P10499, DOI 10.1073/pnas.90.22.10499; LEYS EJ, 1981, MOL CELL BIOL, V1, P961, DOI 10.1128/MCB.1.11.961; LONG EO, 1980, ANNU REV BIOCHEM, V49, P727, DOI 10.1146/annurev.bi.49.070180.003455; LORENZ JD, 1988, MUTAT RES, V193, P167, DOI 10.1016/0167-8817(88)90047-8; Maniatis T., 1982, MOL CLONING; MOSBAUGH DW, 1984, J BIOL CHEM, V259, P247; MURAD AO, 1995, J BIOL CHEM, V270, P3949, DOI 10.1074/jbc.270.8.3949; OZENBERGER BA, 1991, MOL CELL BIOL, V11, P1222, DOI 10.1128/MCB.11.3.1222; POVIRK LF, 1991, MUTAT RES, V257, P127, DOI 10.1016/0165-1110(91)90022-N; REGAN JD, 1974, CANCER RES, V34, P3318; SIDIK K, 1990, CANCER RES, V50, P1613; SIDIK K, 1990, BIOCHEMISTRY-US, V29, P7501, DOI 10.1021/bi00484a020; SMERDON MJ, 1982, J BIOL CHEM, V257, P13441; SMITH CA, 1987, J CELL SCI, P225; SOLLNERWEBB B, 1986, ANNU REV BIOCHEM, V55, P801, DOI 10.1146/annurev.bi.55.070186.004101; STEVNSNER T, 1993, CARCINOGENESIS, V14, P1591, DOI 10.1093/carcin/14.8.1591; STUBBE J, 1987, CHEM REV, V87, P1107, DOI 10.1021/cr00081a011; THNG JPH, 1986, MUTAT RES, V165, P139, DOI 10.1016/0167-8817(86)90048-9; VENEMA J, 1990, NUCLEIC ACIDS RES, V18, P443, DOI 10.1093/nar/18.3.443; WAUTHIER EL, 1990, J CELL BIOCHEM, V43, P173, DOI 10.1002/jcb.240430208; WILSON S, 1988, BIOCHIM BIOPHYS ACTA, V949, P149, DOI 10.1016/0167-4781(88)90078-4	43	20	20	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					12972	12976		10.1074/jbc.271.22.12972	http://dx.doi.org/10.1074/jbc.271.22.12972			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662972	hybrid			2022-12-27	WOS:A1996UN47400046
J	Xu, XX; Yang, WN; Jackowski, S; Rock, CO				Xu, XX; Yang, WN; Jackowski, S; Rock, CO			Cloning of a novel phosphoprotein regulated by colony-stimulating factor 1 shares a domain with the Drosophila disabled gene product (vol 270, pg 14184, 1995)	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Correction, Addition													Jackowski, Suzanne/N-8168-2018	Jackowski, Suzanne/0000-0002-6855-1429				XU XX, 1995, J BIOL CHEM, V270, P14184, DOI 10.1074/jbc.270.23.14184	1	1	2	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13292	13292						1	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8663093				2022-12-27	WOS:A1996UN47400092
J	FigueiredoPereira, ME; Chen, WE; Li, JR; Johdo, O				FigueiredoPereira, ME; Chen, WE; Li, JR; Johdo, O			The antitumor drug aclacinomycin A, which inhibits the degradation of ubiquitinated proteins, shows selectivity for the chymotrypsin-like activity of the bovine pituitary 20 S proteasome	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SENSITIVE NEUTRAL ENDOPEPTIDASE; PEPTIDE-HYDROLYZING ACTIVITY; CATALYTIC ACTIVITY; YEAST PROTEASOME; COMPLEX; SUBUNIT; IDENTIFICATION; GENE; PURIFICATION; SPECIFICITY	The antitumor drug aclacinomycin A was previously shown to inhibit the degradation of ubiquitinated proteins in rabbit reticulocyte lysates with an IC50 of 52 mu M (Isoe, T., Naito, M., Shirai, A., Hirai, R., and Tsuruo, T. (1992) Biochim. Biophys. Acta 1117, 131-135). We report here that from all the catalytic activities of the 20 S proteasome tested, the chymotrypsin-like activity was the only one affected by the antitumor drug, An important requirement for inhibition of the chymotrypsin-like activity seemed to be the presence of hydrophobic nonpolar residues in positions P-1 to P-3. Degradation of Z-E(OtBu)AL-pNA and Z-GGL-AMC at pH 7.5 was dramatically (87-98%) inhibited by 50 mu M of the drug, while that of Z-GGL-pNA (containing uncharged polar residues in positions P-2 and P-3) and succinyl-LLVY-AMC (containing an uncharged polar residue in the P-1 position) was inhibited only 11 and 24%, respectively, Aclacinomycin A had no effect on cathepsin B, stimulated trypsin, and inhibited chymotrypsin and, to a lesser extent, calpain, The aglycone and sugar moieties of the cytotoxic drug are essential for inhibition. The results presented here support a major role for the chymotrypsin-like activity in the degradation of ubiquitinated proteins, Aclacino mycin A is the first described non-peptidic inhibitor showing discrete selectivity for the chymotrypsin-like activity of the 20 S proteasome.	MERCIAN CORP,PROC DEV LABS,FUJISAWA,KANAGAWA 251,JAPAN		FigueiredoPereira, ME (corresponding author), CUNY MT SINAI SCH MED,DEPT PHARMACOL,1 GUSTAVE L LEVY PL,NEW YORK,NY 10029, USA.				NINDS NIH HHS [NS-29936] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS029936] Funding Source: NIH RePORTER	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAJKOWSKI AS, 1975, ANAL BIOCHEM, V68, P119, DOI 10.1016/0003-2697(75)90685-5; BARRETT AJ, 1981, METHOD ENZYMOL, V80, P535; BASILE G, 1992, MOL CELL BIOL, V12, P3235, DOI 10.1128/MCB.12.7.3235; CARDOZO C, 1992, BIOCHEMISTRY-US, V31, P7373, DOI 10.1021/bi00147a023; COUX O, 1994, MOL GEN GENET, V245, P769, DOI 10.1007/BF00297284; DICK LR, 1992, BIOCHEMISTRY-US, V31, P7347, DOI 10.1021/bi00147a020; ENENKEL C, 1994, FEBS LETT, V341, P193, DOI 10.1016/0014-5793(94)80455-9; FENTEANY G, 1995, SCIENCE, V268, P726, DOI 10.1126/science.7732382; FIGUEIREDOPEREI.B, 1995, J NEUROCHEM, V63, P1578; FIGUEIREDOPEREIRA ME, 1994, J NEUROCHEM, V62, P1989; FIGUEIREDOPEREIRA ME, 1994, J BIOL CHEM, V269, P621; FUGUEIREDOPEREI.ME, 1995, ARCH BIOCHEM BIOPHYS, V317, P69; FURONO K, 1990, J BIOL CHEM, V265, P8550; GIULIVI C, 1994, ARCH BIOCHEM BIOPHYS, V311, P329, DOI 10.1006/abbi.1994.1245; GOLDBERG AL, 1995, CHEM BIOL, V2, P503, DOI 10.1016/1074-5521(95)90182-5; GREGORI L, 1995, J BIOL CHEM, V270, P1702; HEINEMEYER W, 1991, EMBO J, V10, P555, DOI 10.1002/j.1460-2075.1991.tb07982.x; HEINMEYER W, 1983, J BIOL CHEM, V268, P5115; HILT W, 1993, J BIOL CHEM, V268, P3479; ISOE T, 1992, BIOCHIM BIOPHYS ACTA, V1117, P131, DOI 10.1016/0304-4165(92)90070-B; KOPP F, 1993, J MOL BIOL, V229, P14, DOI 10.1006/jmbi.1993.1003; LOWE J, 1995, SCIENCE, V268, P533, DOI 10.1126/science.7725097; LUPAS A, 1993, ENZYME PROTEIN, V47, P252, DOI 10.1159/000468684; NISHIMURA C, 1993, FEBS LETT, V336, P462, DOI 10.1016/0014-5793(93)80856-P; OKI T, 1979, J ANTIBIOT, V32, P801, DOI 10.7164/antibiotics.32.801; OKI T, 1981, RECENT RES CANCER, V76, P21; ORLOWSKI M, 1993, BIOCHEMISTRY-US, V32, P1563, DOI 10.1021/bi00057a022; ORLOWSKI M, 1989, BIOCHEMISTRY-US, V28, P9270, DOI 10.1021/bi00450a006; PEREIRA ME, 1992, J BIOL CHEM, V267, P7949; PEREIRA ME, 1992, ARCH BIOCHEM BIOPHYS, V294, P1, DOI 10.1016/0003-9861(92)90128-J; RECHSTEINER M, 1993, J BIOL CHEM, V268, P6065; SATO S, 1990, BIOCHIM BIOPHYS ACTA, V1041, P269, DOI 10.1016/0167-4838(90)90283-L; SAVORY PJ, 1993, BIOCHEM J, V289, P45, DOI 10.1042/bj2890045; SEEMULLER E, 1995, SCIENCE, V268, P579, DOI 10.1126/science.7725107; SEGEL IH, 1975, ENZYME KINETICS, P125; STRACK PR, 1992, INT J BIOCHEM, V24, P887, DOI 10.1016/0020-711X(92)90093-G; TSUBUKI S, 1994, FEBS LETT, V344, P229, DOI 10.1016/0014-5793(94)00388-2; WAGNER BJ, 1991, CURR EYE RES, V10, P485, DOI 10.3109/02713689109001756; WILK S, 1980, J NEUROCHEM, V35, P1172, DOI 10.1111/j.1471-4159.1980.tb07873.x; WILK S, 1979, LIFE SCI, V24, P457, DOI 10.1016/0024-3205(79)90218-2; WILK S, 1983, J NEUROCHEM, V40, P842, DOI 10.1111/j.1471-4159.1983.tb08056.x; YANG DZ, 1994, BIOCHEMISTRY-US, V33, P6595, DOI 10.1021/bi00187a029; YU B, 1991, J BIOL CHEM, V266, P17396	43	57	73	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16455	16459		10.1074/jbc.271.28.16455	http://dx.doi.org/10.1074/jbc.271.28.16455			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663210				2022-12-27	WOS:A1996UX12600007
J	Caccuri, AM; Ascenzi, P; Antonini, G; Parker, MW; Oakley, AJ; Chiessi, E; Nuccetelli, M; Battistoni, A; Bellizia, A; Ricci, G				Caccuri, AM; Ascenzi, P; Antonini, G; Parker, MW; Oakley, AJ; Chiessi, E; Nuccetelli, M; Battistoni, A; Bellizia, A; Ricci, G			Structural flexibility modulates the activity of human glutathione transferase P1-1 - Influence of a poor co-substrate on dynamics and kinetics of human glutathione transferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							S-TRANSFERASE; COMPLEX	Presteady-state and steady-state kinetics of human glutathione transferase P1-1 (EC 2.5.1.18) have been studied at pH 5.0 by using 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole, a poor co-substrate for this isoenzyme. Steady state kinetics fits well with the simplest rapid equilibrium random sequential bi-bi mechanism and reveals a strong intrasubunit synergistic modulation between the GSH-binding site (G-site) and the hydrophobic binding site for the co-substrate (II-site); the affinity of the G-site for GSH increases about 30 times at saturating co-substrate and vice versa. Presteady state experiments and thermodynamic data indicate that the rate-limiting step is a physical event and, probably, a structural transition of the ternary complex. Similar to that observed with 1-chloro-2,4-dinitrobenzene (Ricci, G., Caccuri, A. M., Lo Bello, M., Rosato, N., Mei, G., Nicotra, M., Chiessi, E., Mazzetti, A. P., and Federici, G. (1996) J. Biol. Chem. 271, 16187-16192), this event may be related to the frequency of enzyme motions. The observed low, viscosity-independent k(cat) value suggests that these motions are slow and diffusion-independent for an in creased internal viscosity, In fact, molecular modeling suggests that the hydroxyl group of Tyr-108, which resides in helix 4, may be in hydrogen bonding distance of the oxygen atom of this new substrate, thus yielding a less flexible II-site. This effect might be transmitted to the G-site via helix 4, In addition, a new homotropic behavior exhibited by 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole is found in Cys-47 mutants revealing a structural intersubunit communication between the two H-sites.	UNIV ROMA TOR VERGATA,DEPT BIOL,I-00133 ROME,ITALY; UNIV ROME 3,DEPT BIOL,I-00154 ROME,ITALY; UNIV LAQUILA,DEPT PURE & APPL BIOL,I-67010 LAQUILA,ITALY; ST VINCENTS INST MED RES,IAN POTTER FDN PROT CRYSTALLOG LAB,FITZROY,VIC 3065,AUSTRALIA; UNIV ROMA TOR VERGATA,DEPT CHEM SCI & TECHNOL,I-00133 ROME,ITALY	University of Rome Tor Vergata; Roma Tre University; University of L'Aquila; St. Vincent's Institute of Medical Research; University of Rome Tor Vergata			Battistoni, Andrea/A-4778-2016; Parker, Michael W/F-9069-2013; Oakley, Aaron/A-9464-2013; CACCURI, ANNA MARIA/AFU-2643-2022	Battistoni, Andrea/0000-0003-4085-7917; Parker, Michael W/0000-0002-3101-1138; Oakley, Aaron/0000-0002-4764-014X; Ricci, Giorgio/0000-0002-7108-2846; Antonini, Giovanni/0000-0002-2115-8961; CACCURI, ANNA MARIA/0000-0002-3756-4163; Chiessi, Ester/0000-0001-7529-2755				CACCURI AM, 1994, BIOCHEM BIOPH RES CO, V200, P1428, DOI 10.1006/bbrc.1994.1610; COLETTA M, 1988, J BIOL CHEM, V263, P18286; GRAMINSKI GF, 1989, BIOCHEMISTRY-US, V28, P6252, DOI 10.1021/bi00441a017; Habig W H, 1981, Methods Enzymol, V77, P398; IVANETICH KM, 1989, BIOCHIM BIOPHYS ACTA, V998, P7, DOI 10.1016/0167-4838(89)90111-8; LOBELLO M, 1993, BIOCHEM BIOPH RES CO, V194, P804, DOI 10.1006/bbrc.1993.1893; LOBELLO M, 1995, J BIOL CHEM, V270, P1249; MENEGATTI E, 1985, BIOCHIM BIOPHYS ACTA, V832, P1, DOI 10.1016/0167-4838(85)90167-0; REINEMER P, 1992, J MOL BIOL, V227, P214, DOI 10.1016/0022-2836(92)90692-D; RICCI G, 1994, ANAL BIOCHEM, V218, P463, DOI 10.1006/abio.1994.1209; RICCI G, 1995, J BIOL CHEM, V270, P1243, DOI 10.1074/jbc.270.3.1243; Ricci G, 1996, J BIOL CHEM, V271, P16187, DOI 10.1074/jbc.271.27.16187; SAMPSON NS, 1992, BIOCHEMISTRY-US, V31, P8488, DOI 10.1021/bi00151a015; Segel I.H., 1975, ENZYME KINETICS; Wolf AV, 1985, HDB CHEM PHYSICS, pD	15	52	52	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16193	16198		10.1074/jbc.271.27.16193	http://dx.doi.org/10.1074/jbc.271.27.16193			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663073	hybrid			2022-12-27	WOS:A1996UW35200051
J	Flint, DH; Tuminello, JF; Miller, TJ				Flint, DH; Tuminello, JF; Miller, TJ			Studies on the synthesis of the Fe-S cluster of dihydroxy-acid dehydratase in Escherichia coli crude extract - Isolation of O-acetylserine sulfhydrylases A and B and beta-cystathionase based on their ability to mobilize sulfur from cysteine and to participate in Fe-S cluster synthesis	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NUCLEOTIDE-SEQUENCE; SALMONELLA-TYPHIMURIUM; ACTIVATED ACONITASE; 4FE-4S CLUSTER; ENZYME; BIOSYNTHESIS; SYNTHASE; BINDING; PURIFICATION; INACTIVATION	The apoprotein of Escherichia coli dihydroxy-acid dehydratase, which contains a catalytically essential [4Fe-4S] cluster in its active form, has been used as a substrate to investigate Fe-S cluster synthesis. The inactive apoprotein could be reactivated in vitro by factors present in the crude extract of E. coli and to a much smaller extent in the presence of Fe3+, S2-, and dithiothreitol. This reactivation occurs as a result of Fe-S cluster synthesis. It is anticipated that the Fe-S cluster synthesis observed in crude extracts in vitro may involve some of the components that participate in Fe-S cluster synthesis in vivo. The origin of the sulfur used to form Fe-S clusters was investigated. Four enzymatic activities in the crude extract of E. coli were found that can provide sulfur for Fe-S cluster synthesis in vitro by mobilizing the sulfur from cysteine, The purification of the proteins responsible for three of these activities is reported in this paper. The three proteins have been identified as O-acetylserine sulfhydrylase A, O-acetylserine sulfhydrylase B, and beta-cystathionase. The rate and extent of sulfide mobilization from cysteine in the reaction catalyzed by O-acetylserine sulfhydrylases A and B depend on the presence of nucleophiles that can add to the aminoacrylate formed on the enzyme following the removal of sulfide from cysteine. A new amino acid is formed when the nucleophiles add to the aminoacrylate. Sulfur mobilization by beta-cystathionase does not require a nucleophile, and the reaction is a minor variation on the cleavage of beta-cystathionine, with pyruvate, ammonia, and sulfide being the products. Once sulfur is mobilized by these enzymes, its efficient use in Fe-S cluster synthesis seems to be affected by the presence of yet unidentified factors present in crude extract. In crude extract and partially purified preparations from E. coli where these factors are present, the rapidity with which Fe-S clusters are formed and the efficiency with which sulfur is used imply an orderly controlled formation of Fe-S clusters that is generally typified by enzymatic reactions.			Flint, DH (corresponding author), DUPONT CO INC, CENT RES & DEV, EXPT STN, POB 80328, WILMINGTON, DE 19880 USA.							ARNON DI, 1957, NATURE, V180, P182, DOI 10.1038/180182a0; BECKER MA, 1969, J BIOL CHEM, V244, P2418; BELFAIZA J, 1986, P NATL ACAD SCI USA, V83, P867, DOI 10.1073/pnas.83.4.867; BERNLOHR DA, 1981, BIOCHEMISTRY-US, V20, P5675, DOI 10.1021/bi00523a006; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BYRNE CR, 1988, J BACTERIOL, V170, P3150, DOI 10.1128/jb.170.7.3150-3157.1988; COOK PF, 1992, BIOCHEMISTRY-US, V31, P2298, DOI 10.1021/bi00123a013; DAVENPORT HE, 1952, PROC R SOC SER B-BIO, V139, P346, DOI 10.1098/rspb.1952.0017; DWIVEDI CM, 1982, BIOCHEMISTRY-US, V21, P3064, DOI 10.1021/bi00256a005; EMPTAGE MH, 1983, P NATL ACAD SCI-BIOL, V80, P4674, DOI 10.1073/pnas.80.15.4674; EMPTAGE MH, 1988, METAL CLUSTERS PROTE, P343; FLEISCHMANN RD, 1995, SCIENCE, V269, P496, DOI 10.1126/science.7542800; FLINT DH, 1993, J BIOL CHEM, V268, P25547; FLINT DH, 1992, BIOCHEMISTRY-US, V31, P10331, DOI 10.1021/bi00157a022; FLINT DH, 1993, J BIOL CHEM, V268, P14732; FLINT DH, 1993, J BIOL CHEM, V268, P22369; FLINT DH, 1988, J BIOL CHEM, V263, P3558; Flint DH, 1996, J BIOL CHEM, V271, P16068; FRASER CM, 1995, SCIENCE, V270, P397, DOI 10.1126/science.270.5235.397; Frey P A, 1993, Adv Enzymol Relat Areas Mol Biol, V66, P1; GOSSELIN RE, 1976, CLIN TOXICOLOGY COMM, P169; GRANDONI JA, 1989, J BIOL CHEM, V264, P6058; HAGEN KS, 1983, J AM CHEM SOC, V105, P3905, DOI 10.1021/ja00350a028; HINE J, 1962, PHYSICAL ORGANIC CHE, P161; HOLM RH, 1977, IRON SULFUR PROTEINS, V3, P208; HONG JS, 1967, BIOCHEM BIOPH RES CO, V29, P246, DOI 10.1016/0006-291X(67)90595-5; IKEGAMI F, 1993, PHYTOCHEMISTRY, V32, P31, DOI 10.1016/0031-9422(92)80101-J; IKEGAMI F, 1990, PHYTOCHEMISTRY, V29, P3461, DOI 10.1016/0031-9422(90)85258-H; IKEGAMI F, 1990, PHYTOCHEMISTRY OXF, V28, P2507; IKEGAMI F, 1988, PHYTOCHEMISTRY OXF, V27, P3378; JACOBSON MR, 1989, MOL GEN GENET, V219, P49, DOI 10.1007/BF00261156; JOHNSON MK, 1994, ENCY INORGANIC CHEM, V4, P1896; KAMPFENKEL K, 1995, PLANT PHYSIOL, V107, P725, DOI 10.1104/pp.107.3.725; KENNEDY MC, 1988, J BIOL CHEM, V263, P8194; KIM J, 1994, BIOCHEMISTRY-US, V33, P389, DOI 10.1021/bi00168a001; KREDICH NM, 1972, J BIOL CHEM, V247, P7157; KUO CF, 1992, SCIENCE, V258, P434, DOI 10.1126/science.1411536; LAWTHER RP, 1987, NUCLEIC ACIDS RES, V15, P2137, DOI 10.1093/nar/15.5.2137; LEONGMORGENTHAL.PM, 1993, J BACTERIOL, V175, P1433; LEVY S, 1988, MOL MICROBIOL, V2, P777, DOI 10.1111/j.1365-2958.1988.tb00089.x; LIOCHEV SI, 1993, ARCH BIOCHEM BIOPHYS, V301, P379, DOI 10.1006/abbi.1993.1159; Lippard S.J, 1994, PRINCIPLES BIOINORGA, P115; LOVENBERG W, 1977, IRON SULFUR PROTEINS, V3; Lovenberg W, 1973, IRON SULFUR PROTEINS, VI; Lovenberg W, 1973, IRON SULFUR PROTEINS, VII; MALKIN R, 1966, BIOCHEM BIOPH RES CO, V23, P822, DOI 10.1016/0006-291X(66)90561-4; MORTENSON LE, 1962, BIOCHEM BIOPH RES CO, V7, P448, DOI 10.1016/0006-291X(62)90333-9; OWAIS WM, 1988, MUTAT RES, V197, P313, DOI 10.1016/0027-5107(88)90101-7; Raymond KN, 1995, NATO ADV SCI INST SE, V459, P25; REICHARD P, 1993, J BIOL CHEM, V268, P8383; ROBBINS AH, 1989, P NATL ACAD SCI USA, V86, P3639, DOI 10.1073/pnas.86.10.3639; ROUAULT TA, 1991, CELL, V64, P881, DOI 10.1016/0092-8674(91)90312-M; SANPIETRO A, 1958, J BIOL CHEM, V231, P211; SIEGEL LM, 1965, ANAL BIOCHEM, V11, P126, DOI 10.1016/0003-2697(65)90051-5; SIRKO A, 1990, J BACTERIOL, V172, P3351, DOI 10.1128/jb.172.6.3351-3357.1990; Spiro T. G., 1982, IRON SULFUR PROTEINS; SUN DX, 1993, J BACTERIOL, V175, P1423, DOI 10.1128/JB.175.5.1423-1432.1993; TAI CH, 1993, BIOCHEMISTRY-US, V32, P6433, DOI 10.1021/bi00076a017; WOOD JL, 1987, METHOD ENZYMOL, V143, P25; YU L, 1993, BIOCHEMISTRY-US, V32, P8251, DOI 10.1021/bi00083a028; ZHENG LM, 1993, P NATL ACAD SCI USA, V90, P2754, DOI 10.1073/pnas.90.7.2754; ZHENG LM, 1994, J BIOL CHEM, V269, P18723	62	70	71	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16053	16067		10.1074/jbc.271.27.16053	http://dx.doi.org/10.1074/jbc.271.27.16053			15	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663055	hybrid			2022-12-27	WOS:A1996UW35200033
J	Mohri, H; Tanabe, J; Katoh, K; Okubo, T				Mohri, H; Tanabe, J; Katoh, K; Okubo, T			Identification of a novel binding site to the integrin alpha(IIb)beta(3) located in the C-terminal heparin-binding domain of human plasma fibronectin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							GLYCOPROTEIN-IIB-IIIA; INHIBITS PLATELET-AGGREGATION; STIMULATED HUMAN-PLATELETS; VONWILLEBRAND-FACTOR; FIBRINOGEN BINDING; ACTIVATED PLATELETS; CELL-ADHESION; GPIIB-IIIA; PEPTIDES; COMPLEX	Fibronectin has been shown to bind to integrin alpha(IIb)beta(3) in Arg-Gly-Asp (RGD)-dependent and -independent manners, A recent study has indicated that a 29-kDa dispase-digestive fragment from the C-terminal heparin-binding domain of human plasma fibronectin (lacking RGD sequence) inhibits binding of fibronectin to thrombin-stimulated platelets and ADP induced aggregation (Tanabe, J., Fujita, H., Iwamatsu, A., Mohri, H., and Ohkubo, T. (1993) J. Biol. Chem. 268, 27145-27147). We provide here the evidence that a peptide corresponding to residues from Ala(1704) to Glu(1718) (designated F1) from this fragment inhibited binding of I-125-labeled 29-kDa fragment of fibronectin to thrombin-stimulated platelets and ADP-induced aggregation, The F1 peptide bound directly to alpha(IIb)beta(3) integrin receptor. These results indicate that a novel binding site in the C-terminal heparin-binding region of fibronectin is localized within the residues from Ala(1704) to Glu(1718). Binding of I-125-labeled 29-kDa fragment of fibronectin to thrombin-stimulated platelets was not inhibited by RGDS peptide and the 12-residue peptide from the cell-binding domain of fibronectin, suggesting that binding site in the C-terminal heparin-binding domain may be different from those of RGDS and the 12-residue peptide, This additional alpha(IIb)beta(3)-binding domain(s) in fibronectin may also play some role for prevention of thrombus formation by direct interaction with alpha(IIb)beta(3).			Mohri, H (corresponding author), YOKOHAMA CITY UNIV,SCH MED,DEPT INTERNAL MED 1,KANAZAWA KU,3-9 FUKUURA,YOKOHAMA,KANAGAWA 236,JAPAN.							BERLINER S, 1988, J BIOL CHEM, V263, P7500; BOWDITCH RD, 1991, J BIOL CHEM, V266, P23323; BOWDITCH RD, 1994, J BIOL CHEM, V269, P10856; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DSOUZA SE, 1988, SCIENCE, V242, P91, DOI 10.1126/science.3262922; EY PL, 1978, IMMUNOCHEMISTRY, V15, P91; FRACKER PJ, 1978, BIOCHEM BIOPH RES CO, V80, P849; FUUJITA H, 1995, EXP CELL RES, V217, P484; GARDNER JM, 1985, CELL, V42, P439, DOI 10.1016/0092-8674(85)90101-1; GARTNER TK, 1985, J BIOL CHEM, V260, P1891; GINSBERG M, 1985, J BIOL CHEM, V260, P3931; GINSBERG MH, 1980, P NATL ACAD SCI-BIOL, V77, P1049, DOI 10.1073/pnas.77.2.1049; GINSBERG MH, 1986, FIBRONECTIN ITS ROLE, P86; HASHIMOTO Y, 1994, AM J CLIN PATHOL, V101, P370, DOI 10.1093/ajcp/101.3.370; HOUDIJK WPM, 1985, J CLIN INVEST, V75, P531, DOI 10.1172/JCI111729; IIDA J, 1992, J CELL BIOL, V118, P431, DOI 10.1083/jcb.118.2.431; IKEDA Y, 1991, J CLIN INVEST, V87, P1234, DOI 10.1172/JCI115124; INGHAM KC, 1994, ARCH BIOCHEM BIOPHYS, V314, P242, DOI 10.1006/abbi.1994.1436; LAM SCT, 1987, J BIOL CHEM, V262, P947; LOMBARDO VT, 1985, J CLIN INVEST, V76, P1950, DOI 10.1172/JCI112193; MCCARTHY JB, 1990, J CELL BIOL, V110, P777, DOI 10.1083/jcb.110.3.777; MOHRI H, 1995, PEPTIDES, V16, P263, DOI 10.1016/0196-9781(94)00180-4; MOHRI H, 1993, PEPTIDES, V14, P861, DOI 10.1016/0196-9781(93)90060-T; MOHRI H, 1993, PEPTIDES, V14, P353, DOI 10.1016/0196-9781(93)90052-I; MOHRI H, 1986, AM J HEMATOL, V22, P391, DOI 10.1002/ajh.2830220408; MOULD AP, 1991, EMBO J, V10, P4089, DOI 10.1002/j.1460-2075.1991.tb04985.x; PARISE LV, 1985, J BIOL CHEM, V260, P698; PARISE LV, 1986, J BIOL CHEM, V261, P14011; PETERSEN TE, 1983, P NATL ACAD SCI-BIOL, V80, P137, DOI 10.1073/pnas.80.1.137; PIERSCHBACHER MD, 1984, NATURE, V309, P30, DOI 10.1038/309030a0; PIOTROWICZ RS, 1988, J CELL BIOL, V106, P1359, DOI 10.1083/jcb.106.4.1359; PLOW EF, 1985, BLOOD, V66, P724; PLOW EF, 1981, J BIOL CHEM, V256, P9477; SANTORO SA, 1987, CELL, V48, P867, DOI 10.1016/0092-8674(87)90083-3; SCHWARZBAUER JE, 1983, CELL, V35, P421, DOI 10.1016/0092-8674(83)90175-7; STEINER B, 1993, J BIOL CHEM, V268, P6870; TANABE J, 1993, J BIOL CHEM, V268, P27143; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WALSH PN, 1977, BRIT J HAEMATOL, V36, P281, DOI 10.1111/j.1365-2141.1977.tb00649.x; WEISS HJ, 1989, J CLIN INVEST, V83, P288, DOI 10.1172/JCI113871	40	17	17	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15724	15728		10.1074/jbc.271.26.15724	http://dx.doi.org/10.1074/jbc.271.26.15724			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663002	hybrid			2022-12-27	WOS:A1996UV29900064
J	Azarani, A; Goltzman, D; Orlowski, J				Azarani, A; Goltzman, D; Orlowski, J			Structurally diverse N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) inhibit the Na+/H+ exchanger NHE3 isoform by binding to the PTH/PTHRP receptor type I and activating distinct signaling pathways	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; EPIDERMAL GROWTH-FACTOR; CYCLIC-AMP; PHEOCHROMOCYTOMA CELLS; EXPRESSION CLONING; OSTEOSARCOMA CELLS; PHORBOL ESTERS; KIDNEY-CELLS; ADENYLYLCYCLASE; IDENTIFICATION	N-terminal peptides of parathyroid hormone (PTH) and PTH-related peptide (PTHRP) elicit a wide variety of biological responses in target cells, including the inhibition of Na+/H+ exchanger NHE3 activity in renal cells, This response is believed to be mediated by ligand binding to a common receptor (i.e. PTH/PTHRP receptor type I) and activation of cAMP dependent and/or Ca2+/phospholipid-dependent protein kinases (PKA and PKC, respectively), However, the mechanism of action of these N-terminal peptides is now unclear because of recent data reporting the existence of additional receptor isoforms, Therefore, to directly examine the ligand binding and signaling characteristics of the PTH/PTHRP receptor type I and its ability to elicit a biological response, cDNAs encoding the rat type I receptor and the rat NHE3 isoform were transfected into Chinese hamster ovary (AP-1) cells that lack endogenous expression of these proteins, Competition binding assays using [I-125-Tyr(36)]PTHRP-(1-36)-NH2 radio-ligand indicated that several biologically active human N-terminal PTH and PTHRP fragments (PTH-(1-34), PTH- (3-34), PTH-(28-42), PTH-(28-48), and PTHRP-(1-34)) were capable of binding to the type I receptor, Both PTH-(1-34) and PTHRP-(1-34) stimulated adenylate cyclase and PKC activities in these cells, whereas PTH-(334), PTH-(28-42), and PTH-(28-48) selectively enhanced only PKC activity, PTHRP-(1-16), a biologically inert fragment, was incapable of binding to this receptor and influencing either the PKA or PKC pathway, Furthermore, all the analogues with the exception of PTHRP-(1-16) inhibited NHE3 activity, Inhibition of PKC by the potent antagonist chelerythrine chloride abolished the depression of NHE3 activity by PTH-(3-34), PTH-(28-42), and PTH-(28-48) but did not alleviate the effects of PTH-(1-34), Likewise, antagonism of PKA by H-89 was unable to prevent the inhibition caused by PTH-(1-34), However, inhibition of both PKA and PKC by the nonselective protein kinase antagonist H-7 abolished the reduction of NHE3 activity by PTH-(1-34), These data indicate that discrete N-terminal analogues of PTH and PTHRP can interact with the classical PTH/PTHRP receptor type I and activate PKA and/or PKC, Activation of either signaling pathway independently leads to inhibition of NHE3.	MCGILL UNIV,DEPT PHYSIOL,MONTREAL,PQ H3G 1Y6,CANADA; MCGILL UNIV,DEPT MED,MONTREAL,PQ H3G 1Y6,CANADA; ROYAL VICTORIA HOSP,CALCIUM RES LAB,MONTREAL,PQ H3A 1Y6,CANADA	McGill University; McGill University; McGill University; Royal Victoria Hospital				Orlowski, John/0000-0001-7371-175X				ABOUSAMRA AB, 1992, P NATL ACAD SCI USA, V89, P2732, DOI 10.1073/pnas.89.7.2732; AMEMIYA M, 1995, AM J PHYSIOL-CELL PH, V269, pC126, DOI 10.1152/ajpcell.1995.269.1.C126; AZARANI A, 1995, J BIOL CHEM, V270, P23166, DOI 10.1074/jbc.270.39.23166; AZARANI A, 1995, J BIOL CHEM, V270, P20004, DOI 10.1074/jbc.270.34.20004; BERNIER SM, 1991, ENDOCRINOLOGY, V128, P2752, DOI 10.1210/endo-128-6-2752; BRINGHURST FR, 1993, ENDOCRINOLOGY, V132, P2090, DOI 10.1210/en.132.5.2090; CHEN C, 1987, MOL CELL BIOL, V7, P2745, DOI 10.1128/MCB.7.8.2745; CHEN RP, 1993, P NATL ACAD SCI USA, V90, P8967, DOI 10.1073/pnas.90.19.8967; CHESNOYMARCHAIS D, 1989, PFLUG ARCH EUR J PHY, V415, P104, DOI 10.1007/BF00373147; CHIJIWA T, 1990, J BIOL CHEM, V265, P5267; FUJIMORI A, 1992, ENDOCRINOLOGY, V130, P29, DOI 10.1210/en.130.1.29; FUKAYAMA S, 1995, P NATL ACAD SCI USA, V92, P10182, DOI 10.1073/pnas.92.22.10182; GAGNON L, 1993, J BONE MINER RES, V8, P497; GOLTZMANN D, 1975, J BIOL CHEM, V250, P3199; HEASLEY LE, 1989, J BIOL CHEM, V264, P8646; HELMLEKOLB C, 1990, PFLUG ARCH EUR J PHY, V415, P461, DOI 10.1007/BF00373624; HENDERSON JE, 1992, ENDOCRINOLOGY, V130, P449, DOI 10.1210/en.130.1.449; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; IIDAKLEIN A, 1995, J BIOL CHEM, V270, P8458, DOI 10.1074/jbc.270.15.8458; INOMATA N, 1995, ENDOCRINOLOGY, V136, P4732, DOI 10.1210/en.136.11.4732; JOUISHOMME H, 1992, ENDOCRINOLOGY, V130, P53, DOI 10.1210/en.130.1.53; JOUISHOMME H, 1994, J BONE MINER RES, V9, P943; JUPPNER H, 1991, SCIENCE, V254, P1024, DOI 10.1126/science.1658941; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KAJI H, 1994, ENDOCRINOLOGY, V134, P1897, DOI 10.1210/en.134.4.1897; KAPUS A, 1994, J BIOL CHEM, V269, P23544; KAUFMANN M, 1994, ENDOCRINOLOGY, V134, P1173, DOI 10.1210/en.134.3.1173; KREMER R, 1982, J BIOL CHEM, V257, P4048; LEE CW, 1995, MOL ENDOCRINOL, V9, P1269, DOI 10.1210/me.9.10.1269; LEE CW, 1994, ENDOCRINOLOGY, V135, P1488, DOI 10.1210/en.135.4.1488; LUSTIG KD, 1993, J BIOL CHEM, V268, P13900; MACGREGOR RR, 1986, J BIOL CHEM, V261, P1929; MALMSTROM K, 1988, BIOCHEM J, V251, P207, DOI 10.1042/bj2510207; MURRAY TM, 1989, ENDOCRINOLOGY, V124, P1097, DOI 10.1210/endo-124-2-1097; ORLOFF JJ, 1995, ENDOCRINOLOGY, V136, P3016, DOI 10.1210/en.136.7.3016; ORLOFF JJ, 1989, ENDOCR REV, V10, P476, DOI 10.1210/edrv-10-4-476; ORLOWSKI J, 1993, J BIOL CHEM, V268, P16369; PAUSOVA Z, 1994, GENOMICS, V20, P20, DOI 10.1006/geno.1994.1122; PINES M, 1994, ENDOCRINOLOGY, V135, P1713, DOI 10.1210/en.135.4.1713; POLLOCK AS, 1986, AM J PHYSIOL, V250, pF217, DOI 10.1152/ajprenal.1986.250.2.F217; RABBANI SA, 1990, BIOCHEMISTRY-US, V29, P10080, DOI 10.1021/bi00495a010; RABBANI SA, 1988, ENDOCRINOLOGY, V123, P2709; ROOS A, 1981, PHYSIOL REV, V61, P296, DOI 10.1152/physrev.1981.61.2.296; ROSENBLATT M, 1986, NEW ENGL J MED, V315, P1004; ROTIN D, 1989, AM J PHYSIOL, V257, pC1158, DOI 10.1152/ajpcell.1989.257.6.C1158; SCHIPANI E, 1993, ENDOCRINOLOGY, V132, P2157, DOI 10.1210/en.132.5.2157; SCHNEIDER H, 1994, FEBS LETT, V351, P281, DOI 10.1016/0014-5793(94)00878-7; SEGRE GV, 1993, TRENDS ENDOCRIN MET, V4, P309, DOI 10.1016/1043-2760(93)90071-L; SPENGLER D, 1993, NATURE, V365, P170, DOI 10.1038/365170a0; URENA P, 1993, ENDOCRINOLOGY, V133, P617, DOI 10.1210/en.133.2.617; USDIN TB, 1995, J BIOL CHEM, V270, P15455, DOI 10.1074/jbc.270.26.15455; USDIN TB, 1993, ENDOCRINOLOGY, V133, P2861, DOI 10.1210/en.133.6.2861; YAMAGUCHI TD, 1987, J BIOL CHEM, V262, P7711; YOSHIMURA M, 1993, J BIOL CHEM, V268, P4604	54	56	64	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14931	14936		10.1074/jbc.271.25.14931	http://dx.doi.org/10.1074/jbc.271.25.14931			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663042	hybrid			2022-12-27	WOS:A1996UT10600046
J	Lin, WJ; Gary, JD; Yang, MC; Clarke, S; Herschman, HR				Lin, WJ; Gary, JD; Yang, MC; Clarke, S; Herschman, HR			The mammalian immediate-early TIS21 protein and the leukemia-associated BTG1 protein interact with a protein-arginine N-methyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBROBLAST GROWTH-FACTOR; MESSENGER-RNA; BOVINE BRAIN; METHYLATION; PURIFICATION; GENE; RESIDUES; ANTIGEN; MYELIN; CELLS	The TIS21 immediate-early gene and leukemia-associated BTG1 gene encode proteins with similar sequences, Two-hybrid analysis identified a protein that interacts with TIS21 and BTG1. Sequence motifs associated with S-adenosyl-L-methionine binding suggested this protein might have methyltransferase activity, A glutathione S-transferase (GST) fusion of the putative methyltransferase modifies arginine residues, in appropriate protein substrates, to form NG-monomethyl and N-G,N-G-dimethylarginine (asymmetric). We term the protein-arginine N-methyltransferase (EC 2.1.1.23) gene ''PRMT1,'' for protein-arginine methyltransferase 1. GST-TIS21 and GST-BTG1 fusion proteins qualitatively and quantitatively modulate endogenous PRMT1 activity, using control and hypomethylated RAT1 cell extracts as methyl-accepting substrates. PRMT1 message appears ubiquitous, and is constitutive in mitogen-stimulated cells, Modulation of PRMT1 activity by transiently expressed regulatory subunits may be an additional mode of signal transduction following ligand stimulation.	UNIV CALIF LOS ANGELES,MOL BIOL INST 341,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT BIOL CHEM,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,DEPT CHEM & BIOCHEM,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM024797, R37GM026020, R01GM026020] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM24797, GM26020] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Bailey JL, 1967, TECHNIQUES PROTEIN C, P340; BALDWIN GS, 1971, SCIENCE, V171, P579, DOI 10.1126/science.171.3971.579; Bartel P. L., 1993, CELLULAR INTERACTION, P153; BRADBURY A, 1991, P NATL ACAD SCI USA, V88, P3353, DOI 10.1073/pnas.88.8.3353; BREEDEN L, 1985, COLD SPRING HARB SYM, V50, P643, DOI 10.1101/SQB.1985.050.01.078; BROSTOFF S, 1971, P NATL ACAD SCI USA, V68, P765, DOI 10.1073/pnas.68.4.765; BURGESS WH, 1991, CELL REGUL, V2, P87, DOI 10.1091/mbc.2.2.87; CACERES JF, 1994, SCIENCE, V265, P1706, DOI 10.1126/science.8085156; CATHALA G, 1983, DNA-J MOLEC CELL BIO, V2, P329, DOI 10.1089/dna.1983.2.329; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; Clarke S, 1993, CURR OPIN CELL BIOL, V5, P977, DOI 10.1016/0955-0674(93)90080-A; DREYFUSS G, 1993, ANNU REV BIOCHEM, V62, P289, DOI 10.1146/annurev.bi.62.070193.001445; FAROOQUI JZ, 1985, J BIOL CHEM, V260, P537; FELDMANN H, 1994, EMBO J, V13, P5795, DOI 10.1002/j.1460-2075.1994.tb06923.x; FIELDS S, 1989, NATURE, V340, P245, DOI 10.1038/340245a0; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; FLETCHER BS, 1991, J BIOL CHEM, V266, P14511; GARY JD, 1995, J BIOL CHEM, V270, P4076, DOI 10.1074/jbc.270.8.4076; Gary JD, 1996, J BIOL CHEM, V271, P12585, DOI 10.1074/jbc.271.21.12585; GHOSH SK, 1988, J BIOL CHEM, V263, P19024; GOTTSCHLING H, 1962, NATURE, V196, P829, DOI 10.1038/196829a0; HAN LM, 1995, MOL CELL BIOL, V15, P1318; HENRIQUEZ R, 1990, J BIOL CHEM, V265, P2209; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HOLLENBERG SM, 1995, MOL CELL BIOL, V15, P3813; HRYCYNA CA, 1994, BIOCHEMISTRY-US, V33, P9806, DOI 10.1021/bi00198a053; KAGAN RM, 1994, ARCH BIOCHEM BIOPHYS, V310, P417, DOI 10.1006/abbi.1994.1187; KUJUBU DA, 1993, J NEUROSCI RES, V36, P58, DOI 10.1002/jnr.490360107; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LAW RE, 1992, MOL CELL BIOL, V12, P103, DOI 10.1128/MCB.12.1.103; LEE HW, 1977, BIOCHEMISTRY-US, V16, P78, DOI 10.1021/bi00620a013; LISCHWE MA, 1985, J BIOL CHEM, V260, P14304; LISCHWE MA, 1985, BIOCHEMISTRY-US, V24, P6025, DOI 10.1021/bi00343a001; LIU Q, 1995, MOL CELL BIOL, V15, P2800; LOUBBARDI A, 1995, J BACTERIOL, V177, P1817, DOI 10.1128/jb.177.7.1817-1823.1995; Lowenson J. D., 1995, DEAMIDATION ISOASPAR, P47; MAYEDA A, 1992, CELL, V68, P365, DOI 10.1016/0092-8674(92)90477-T; MICHAEL WM, 1995, CELL, V83, P416; NAJBAUER J, 1993, J BIOL CHEM, V268, P10501; NAKAJIMA T, 1971, BIOCHIM BIOPHYS ACTA, V230, P212, DOI 10.1016/0304-4165(71)90206-6; OGIMOTO M, 1993, CELL IMMUNOL, V151, P97, DOI 10.1006/cimm.1993.1224; PAIK WK, 1967, BIOCHEM BIOPH RES CO, V29, P14, DOI 10.1016/0006-291X(67)90533-5; PAIK WK, 1968, J BIOL CHEM, V243, P2108; PRATS H, 1989, P NATL ACAD SCI USA, V86, P1836, DOI 10.1073/pnas.86.6.1836; RAJPUROHIT R, 1994, J BIOL CHEM, V269, P1075; RAJPUROHIT R, 1994, BIOCHEM J, V304, P903, DOI 10.1042/bj3040903; RAWAL N, 1994, BIOCHEM J, V300, P483, DOI 10.1042/bj3000483; RIMOKH R, 1991, GENE CHROMOSOME CANC, V3, P24, DOI 10.1002/gcc.2870030106; Rose MD., 1990, METHODS YEAST GENETI; ROUAULT JP, 1993, GENE, V129, P303, DOI 10.1016/0378-1119(93)90284-A; ROUAULT JP, 1992, EMBO J, V11, P1663, DOI 10.1002/j.1460-2075.1992.tb05213.x; SAMBROOK J, 1989, MOL CLONING LABORATO, P1060; SARMAY G, 1995, EUR J IMMUNOL, V25, P262, DOI 10.1002/eji.1830250143; SCHIESTL RH, 1989, CURR GENET, V16, P339, DOI 10.1007/BF00340712; SCHLUCKEBIER G, 1995, J MOL BIOL, V247, P16, DOI 10.1006/jmbi.1994.0117; SHAPIRO VI, 1995, J BIOL CHEM, V92, P1053; SIOMI H, 1995, J CELL BIO, V129, P441; SMITH JB, 1995, J BIOL CHEM, V270, P16756, DOI 10.1074/jbc.270.28.16756; STAUDINGER J, 1995, J CELL BIOL, V128, P263, DOI 10.1083/jcb.128.3.263; THOMAS P, 1981, P NATL ACAD SCI USA, V77, P5201; TUROWSKI P, 1995, J CELL BIOL, V129, P397, DOI 10.1083/jcb.129.2.397; VANET A, 1993, J BACTERIOL, V175, P7178, DOI 10.1128/JB.175.22.7178-7188.1993; VARNUM BC, 1994, J CELL PHYSIOL, V158, P205, DOI 10.1002/jcp.1041580125; WANG H, 1995, J BIOL CHEM, V270, P23322, DOI 10.1074/jbc.270.40.23322; XIE HY, 1994, BIOCHEM BIOPH RES CO, V203, P1710, DOI 10.1006/bbrc.1994.2383; XIE HY, 1993, J BIOL CHEM, V268, P13364; XIE HY, 1994, J BIOL CHEM, V269, P1981	68	384	402	0	13	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15034	15044		10.1074/jbc.271.25.15034	http://dx.doi.org/10.1074/jbc.271.25.15034			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663146	Green Submitted, hybrid			2022-12-27	WOS:A1996UT10600060
J	Rustin, P; Parfait, B; Chretien, D; Bourgeron, T; Djouadi, F; Bastin, J; Rotig, A; Munnich, A				Rustin, P; Parfait, B; Chretien, D; Bourgeron, T; Djouadi, F; Bastin, J; Rotig, A; Munnich, A			Fluxes of nicotinamide adenine dinucleotides through mitochondrial membranes in human cultured cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							REVERSE ELECTRON-TRANSPORT; PLANT-MITOCHONDRIA; ROTENONE; MALATE; NAD+	We report on the loss of mitochondrial nicotinamide adenine dinucleotides in human cultured cells along with cell culture and acidification of the culture medium. This was established both by the direct measure ment of the decrease in the mitochondrial NAD content and by the alteration of the oxidative properties of the mitochondria. In situ, this loss could be reversed in less than 2 h by changing the culture medium or by readjusting the pH of the medium at physiological pH values. By studying the oxidative properties of intact, but NAD-depleted, mitochondria in digitonin-permeabilized cells, we found that a rapid influx of NAD could replenish the mitochondrial NAD pool. This allowed the restoration of an active NAD(+)-dependent substrate oxidation. Depletion of mitochondrial NAD in cells grown under quiescent conditions was further confirmed by fluorimetric measurement of mitochondrial NAD, as was the influx of NAD(+) into the mitochondrial matrix. These data constitute the first evidence of rapid fluxes of NAD through mitochondrial membranes in animal cells. They also point to the possible confusion between a loss of mitochondrial NAD and a defect of respiratory chain complex I in the context of screening procedures for respiratory chain disorder in human.	UNIV PARIS 07,INSERM U319,PARIS,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universite Paris Cite	Rustin, P (corresponding author), HOP NECKER ENFANTS MALAD,INSERM U393,UNITE RECH HANDICAPS GENET ENFANT,149 RUE SEVRES,F-75743 PARIS 15,FRANCE.		PARFAIT, Beatrice/O-7392-2017; DJOUADI, Fatima/C-6187-2019; Bastin, Jean/E-3083-2016; Rötig, Agnès/G-9592-2017	Rötig, Agnès/0000-0003-0589-0703; Djouadi, Fatima/0000-0003-0350-0935; Bastin, Jean/0000-0001-8350-8667				BERGMEYER HU, 1963, METHOD ENZYMAT AN, P1; BOURGERON T, 1992, BIOCHEM BIOPH RES CO, V186, P16, DOI 10.1016/S0006-291X(05)80769-7; BOURGERON T, 1993, J BIOL CHEM, V268, P19369; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; CHRETIEN D, 1990, BIOCHEM BIOPH RES CO, V173, P26, DOI 10.1016/S0006-291X(05)81016-2; Douce R., 1985, MITOCHONDRIA HIGHER, P1; GLOCK GE, 1955, BIOCHEM J, V61, P381, DOI 10.1042/bj0610381; NEUBURGER M, 1983, BIOCHEM J, V216, P443, DOI 10.1042/bj2160443; PALMER JM, 1982, BIOCHEM J, V208, P703, DOI 10.1042/bj2080703; ROBINSON BH, 1985, AM J HUM GENET, V37, P938; ROTIG A, 1990, J CLIN INVEST, V86, P1601, DOI 10.1172/JCI114881; RUSTIN P, 1991, BIOCHEM J, V274, P249, DOI 10.1042/bj2740249; RUSTIN P, 1989, PLANT PHYSIOL BIOCH, V27, P855; RUSTIN P, 1994, CLIN CHIM ACTA, V228, P35, DOI 10.1016/0009-8981(94)90055-8; RUSTIN P, 1979, BIOCHEM BIOPH RES CO, V88, P1123; TYLER DD, 1992, MITOCHONDRION HLTH D, P1; TZAGOLOFF A, 1982, MITOCHONDRIA, P1; Zuurendonk P F, 1979, Methods Enzymol, V56, P207	18	45	47	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14785	14790		10.1074/jbc.271.25.14785	http://dx.doi.org/10.1074/jbc.271.25.14785			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663005	hybrid			2022-12-27	WOS:A1996UT10600025
J	Sarndahl, E; Bokoch, GM; Boulay, F; Stendahl, O; Andersson, T				Sarndahl, E; Bokoch, GM; Boulay, F; Stendahl, O; Andersson, T			Direct or C5a-induced activation of heterotrimeric G(i2) proteins in human neutrophils is associated with interaction between formyl peptide receptors and the cytoskeleton	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C5A CHEMOATTRACTANT RECEPTORS; BETA-ADRENERGIC-RECEPTOR; CHEMOTACTIC PEPTIDE; HUMAN-GRANULOCYTES; ADENYLATE-CYCLASE; DESENSITIZATION; PHOSPHORYLATION; BINDING; FORMYLPEPTIDE; DISSOCIATION	The binding of ligands to N-formyl peptide chemoattractant receptors in human neutrophils results in a rapid association of these receptors with a cytoskeletal fraction and a specific activation and release of G(i2) alpha-subunits from this fraction. In the present study we could show that pretreating neutrophils with GDP beta S prevented the fMet Leu-Phe-induced association of its receptor with a cytoskeletal fraction and also blocked the release of G(i2) alpha-subunits from the same cytoskeletal fraction. In contrast, direct activation of G(i2) proteins by addition of GTP gamma S or AIF(4)(-) not only caused a release of G(i2) alpha-subunits from the cytoskeleton but also an association of formyl peptide receptors with the cytoskeleton. The receptor for complement fragment 5a, which transduces its signaling through the same G(i2) protein, triggers both a release of G(i2) alpha-subunits from the cytoskeleton fraction and, of even greater interest, an association between formyl peptide receptors and the cytoskeleton. The close relationship between the activation and release of G(i2) alpha-subunits from the cytoskeleton and the association of formyl peptide receptors with the cytoskeleton might, however, not be a matter of protein-protein exchange, since the increased binding of formyl peptide receptors to the cytoskeleton occurs more rapidly than the release of G(i2) alpha-subunits from the cytoskeleton. The present findings suggest a possible mechanism for the initiation of formyl peptide receptor desensitization during neutrophil locomotion.	LINKOPING UNIV, FAC HLTH SCI, DEPT MED MICROBIOL, S-58185 LINKOPING, SWEDEN; Scripps Res Inst, DEPT IMMUNOL, LA JOLLA, CA 92037 USA; Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA; CEA GRENOBLE, BIOCHIM LAB, DBMS, F-38054 GRENOBLE, FRANCE	Linkoping University; Scripps Research Institute; Scripps Research Institute; CEA	Sarndahl, E (corresponding author), LINKOPING UNIV, FAC HLTH SCI, DEPT CELL BIOL, S-58185 LINKOPING, SWEDEN.				NIGMS NIH HHS [GM 39434] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM039434] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALI H, 1993, J BIOL CHEM, V268, P24247; BOKOCH GM, 1988, J CELL BIOL, V106, P1927, DOI 10.1083/jcb.106.6.1927; BOULAY F, 1990, BIOCHEM BIOPH RES CO, V168, P1103, DOI 10.1016/0006-291X(90)91143-G; BOYUM A, 1968, SCAND J CLIN LAB INV, VS 21, P77; DIDSBURY JR, 1991, P NATL ACAD SCI USA, V88, P11564, DOI 10.1073/pnas.88.24.11564; FALLMAN M, 1992, J BIOL CHEM, V267, P2656; GERARD NP, 1990, BIOCHEMISTRY-US, V29, P9274, DOI 10.1021/bi00491a024; JANECZEK AH, 1989, J CELL SCI, V94, P155; JESAITIS AJ, 1984, J CELL BIOL, V98, P1378, DOI 10.1083/jcb.98.4.1378; JESAITIS AJ, 1986, J BIOL CHEM, V261, P3662; JESAITIS AJ, 1989, J CELL BIOL, V109, P2783, DOI 10.1083/jcb.109.6.2783; JESAITIS AJ, 1992, COMMENTS MOL CELL BI, V8, P97; KLOTZ KN, 1994, BIOCHEM PHARMACOL, V48, P1297, DOI 10.1016/0006-2952(94)90168-6; KOO C, 1983, J CLIN INVEST, V72, P748, DOI 10.1172/JCI111045; LEFKOWITZ RJ, 1990, TRENDS PHARMACOL SCI, V11, P190, DOI 10.1016/0165-6147(90)90113-M; MCLEISH KR, 1989, MOL PHARMACOL, V36, P384; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; POSNER RG, 1994, MOL PHARMACOL, V45, P65; PROBST WC, 1992, DNA CELL BIOL, V11, P1, DOI 10.1089/dna.1992.11.1; PROSSNITZ ER, 1993, BIOCHEM J, V294, P581, DOI 10.1042/bj2940581; PROSSNITZ ER, 1995, J BIOL CHEM, V270, P1130, DOI 10.1074/jbc.270.3.1130; SARNDAHL E, 1989, J CELL BIOL, V109, P2791, DOI 10.1083/jcb.109.6.2791; SARNDAHL E, 1993, P NATL ACAD SCI USA, V90, P6552, DOI 10.1073/pnas.90.14.6552; SENGELOV H, 1994, BIOCHEM J, V299, P473, DOI 10.1042/bj2990473; SHOWELL HJ, 1979, J RETICULOENDOTH SOC, V25, P139; SIBLEY DR, 1985, J BIOL CHEM, V260, P3883; SIBLEY DR, 1985, NATURE, V317, P124, DOI 10.1038/317124a0; SKLAR LA, 1984, J BIOL CHEM, V259, P5661; TARDIF M, 1993, J IMMUNOL, V150, P3534; WILDEN U, 1986, P NATL ACAD SCI USA, V83, P1174, DOI 10.1073/pnas.83.5.1174; YE RD, 1991, BIOCHEM BIOPH RES CO, V180, P105, DOI 10.1016/S0006-291X(05)81261-6	31	18	18	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15267	15271						5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663057				2022-12-27	WOS:A1996UT10600090
J	Cannon, KS; Hebert, DN; Helenius, A				Cannon, KS; Hebert, DN; Helenius, A			Glycan-dependent and -independent association of vesicular stomatitis virus G protein with calnexin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ENDOPLASMIC-RETICULUM; INFLUENZA HEMAGGLUTININ; AGGREGATION; MECHANISM; TRANSPORT; SITES; CELL	Calnexin (CNX) is a membrane-bound molecular chaperone that associates with newly synthesized proteins in the endoplasmic reticulum. Although several studies have indicated that it interacts exclusively with glycoproteins that carry monoglucosylated N-linked oligosaccharides, others have reported that it can bind to proteins that have no glycans. To address this discrepancy, we translated wild-type vesicular stomatitis virus G protein and nonglycosylated mutant forms in the presence of microsomes and examined their association with CNX. Individual G protein molecules were found to efficiently associate with CNX when both glycans were present and less efficiently if there was only a single glycan. Nonglycosylated G protein also interacted with CNX, but only when misfolded and present in high molecular weight aggregates. The results indicated that CNX can interact with G protein in two ways: through an oligosaccharide-dependent mechanism that involves individual substrate proteins; and in an oligosaccharide-independent association with large aggregates.	YALE UNIV,SCH MED,DEPT CELL BIOL,NEW HAVEN,CT 06520	Yale University					NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052972] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM52972] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; ARUNACHALAM B, 1995, J BIOL CHEM, V270, P2784, DOI 10.1074/jbc.270.6.2784; BALOW JP, 1995, J BIOL CHEM, V270, P29025, DOI 10.1074/jbc.270.48.29025; BONIFACINO J S, 1991, Current Opinion in Cell Biology, V3, P592, DOI 10.1016/0955-0674(91)90028-W; BRAAKMAN I, 1991, J CELL BIOL, V114, P401, DOI 10.1083/jcb.114.3.401; CARRENO BM, 1995, J IMMUNOL, V154, P5173; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; CLEVERS H, 1988, P NATL ACAD SCI USA, V85, P8623, DOI 10.1073/pnas.85.22.8623; DESILVA A, 1993, J CELL BIOL, V120, P647, DOI 10.1083/jcb.120.3.647; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; GIBSON R, 1979, J BIOL CHEM, V254, P3600; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, SCIENCE, V266, P456, DOI 10.1126/science.7939687; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; HEBERT DN, 1995, CELL, V81, P425, DOI 10.1016/0092-8674(95)90395-X; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; HURTLEY SM, 1989, J CELL BIOL, V108, P2117, DOI 10.1083/jcb.108.6.2117; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; KEARSE KP, 1994, EMBO J, V13, P3678, DOI 10.1002/j.1460-2075.1994.tb06677.x; KIM P, 1995, J CELL BIOL, V12, P29; LOMAS DA, 1992, NATURE, V357, P605, DOI 10.1038/357605a0; LOO TW, 1994, J BIOL CHEM, V269, P28683; MACHAMER CE, 1990, J BIOL CHEM, V265, P6879; MACHAMER CE, 1988, J BIOL CHEM, V263, P5955; MACHAMER CE, 1985, MOL CELL BIOL, V5, P3074, DOI 10.1128/MCB.5.11.3074; MARKS MS, 1995, J BIOL CHEM, V270, P10475, DOI 10.1074/jbc.270.18.10475; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; MARQUARDT T, 1993, J BIOL CHEM, V268, P19618; METSIKKO K, 1986, EMBO J, V5, P1913, DOI 10.1002/j.1460-2075.1986.tb04444.x; NAUSEEF WM, 1995, J BIOL CHEM, V270, P4741, DOI 10.1074/jbc.270.9.4741; NICCHITTA CV, 1993, CELL, V73, P989, DOI 10.1016/0092-8674(93)90276-V; ORA A, 1995, J BIOL CHEM, V270, P26060, DOI 10.1074/jbc.270.44.26060; Otteken A, 1996, J BIOL CHEM, V271, P97, DOI 10.1074/jbc.271.1.97; OU WJ, 1993, NATURE, V364, P771, DOI 10.1038/364771a0; PETERSON JR, 1995, MOL BIOL CELL, V6, P1173, DOI 10.1091/mbc.6.9.1173; RAJAGOPALAN S, 1994, SCIENCE, V263, P387, DOI 10.1126/science.8278814; ROSE JK, 1981, J VIROL, V39, P519, DOI 10.1128/JVI.39.2.519-528.1981; SECKLER R, 1992, FASEB J, V6, P2545, DOI 10.1096/fasebj.6.8.1592207; THOMAS PJ, 1995, TRENDS BIOCHEM SCI, V20, P456, DOI 10.1016/S0968-0004(00)89100-8; WADA I, 1995, J BIOL CHEM, V270, P2098; WARE FE, 1995, J BIOL CHEM, V270, P4697, DOI 10.1074/jbc.270.9.4697; ZHANG Q, 1995, J BIOL CHEM, V270, P3944, DOI 10.1074/jbc.270.8.3944	42	77	77	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14280	14284		10.1074/jbc.271.24.14280	http://dx.doi.org/10.1074/jbc.271.24.14280			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662990	hybrid, Green Submitted			2022-12-27	WOS:A1996UQ66000053
J	Chang, DZ; Wu, ZN; Ciardelli, TL				Chang, DZ; Wu, ZN; Ciardelli, TL			A point mutation in interleukin-2 that alters ligand internalization	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RECEPTOR-BETA-CHAIN; HUMAN T-CELLS; IL-2 RECEPTOR; SIGNAL TRANSDUCTION; GAMMA-CHAIN; GROWTH; BINDING; GLYCOSYLPHOSPHATIDYLINOSITOL; DEGRADATION; EXPRESSION	In previous studies, we have identified an interleukin-2 (IL-2) analog containing a point mutation at position 51 (T51P) that expresses nearly wild-type bioactivity, yet has similar to 10-fold lower receptor binding affinity, Since ligand-dependent receptor internalization may be the rate-limiting step controlling the duration of IL-2 receptor signaling, a reduction in the receptor internalization rate could contribute to the observed response enhancement for this analog, To evaluate this possibility, we compared the internalization of IL-2 and T51P in three separate assays, While the internalization rate for IL-2 agreed with values determined by others, the internalization of T51P was markedly reduced, The receptor binding rate constants for this analog were only slightly different; thus, altered binding kinetics could not explain the decreased internalization rate, The effects of reduced internalization were also observable in bioassays, where T51P maintained T-cell proliferation for a longer period compared with IL-2. These results indicate that the T51P point mutation reduces the receptor internalization rate compared with IL-2 in a fashion that is independent of the dissociation rate. This analog may represent a new approach to the preparation of cytokine analogs with potentiated agonist and antagonist properties.	DARTMOUTH COLL,SCH MED,DEPT PHARMACOL & TOXICOL,HANOVER,NH 03755; VET ADM MED CTR,WHITE RIVER JCT,VT 05009	Dartmouth College; US Department of Veterans Affairs; Veterans Health Administration (VHA)					NCI NIH HHS [CA23108] Funding Source: Medline; NIAID NIH HHS [AI23398] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA023108] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI023398] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARIMA N, 1992, J EXP MED, V176, P1265, DOI 10.1084/jem.176.5.1265; ASAO H, 1994, FEBS LETT, V351, P201, DOI 10.1016/0014-5793(94)00831-0; CANTRELL DA, 1984, SCIENCE, V224, P1312, DOI 10.1126/science.6427923; CHANG DZ, 1995, MOL PHARMACOL, V47, P206; COSMAN D, 1993, CYTOKINE, V5, P95, DOI 10.1016/1043-4666(93)90047-9; DUPREZ V, 1988, J BIOL CHEM, V263, P12860; DUPREZ V, 1986, J BIOL CHEM, V261, P5450; DUPREZ V, 1991, J BIOL CHEM, V266, P1497; EARDLEY DD, 1991, SCIENCE, V251, P78, DOI 10.1126/science.1824727; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; FUJII M, 1986, J EXP MED, V163, P550, DOI 10.1084/jem.163.3.550; GILLIS S, 1978, J IMMUNOL, V121, P2077; GULLBERG M, 1986, J EXP MED, V163, P270, DOI 10.1084/jem.163.2.270; HATAKEYAMA M, 1989, CELL, V59, P837, DOI 10.1016/0092-8674(89)90607-7; HATAKEYAMA M, 1989, SCIENCE, V244, P551, DOI 10.1126/science.2785715; HEMAR A, 1995, J CELL BIOL, V129, P55, DOI 10.1083/jcb.129.1.55; HORAK ID, 1991, P NATL ACAD SCI USA, V88, P1996, DOI 10.1073/pnas.88.5.1996; HUNYADY L, 1994, KIDNEY INT, V46, P1496, DOI 10.1038/ki.1994.428; IMLER JL, 1992, J BIOL CHEM, V267, P13185; JOHNSON WC, 1990, PROTEINS, V7, P205, DOI 10.1002/prot.340070302; JOHNSTON JA, 1994, NATURE, V370, P151, DOI 10.1038/370151a0; KUMAR A, 1987, J IMMUNOL, V139, P3680; LANDGRAF B, 1989, J BIOL CHEM, V264, P816; LANDGRAF BE, 1991, PROTEINS, V9, P207, DOI 10.1002/prot.340090306; LANDGRAF BE, 1992, J BIOL CHEM, V267, P18511; LAUFFENBURGER DA, 1996, IN PRESS BIOTECHNOL; LEONARD WJ, 1984, NATURE, V311, P626, DOI 10.1038/311626a0; MATSUOKA M, 1993, EUR J IMMUNOL, V23, P2472, DOI 10.1002/eji.1830231014; MERIDA I, 1990, P NATL ACAD SCI USA, V87, P9421, DOI 10.1073/pnas.87.23.9421; MINAMI Y, 1994, J IMMUNOL, V152, P5680; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUNCK A, 1976, RECEPTORS MECHANIS 1, P1; NAKAMURA Y, 1994, NATURE, V369, P330, DOI 10.1038/369330a0; NAKARAI T, 1994, J EXP MED, V180, P241, DOI 10.1084/jem.180.1.241; NIKAIDO T, 1984, NATURE, V311, P631, DOI 10.1038/311631a0; ROBB RJ, 1981, J EXP MED, V154, P1455, DOI 10.1084/jem.154.5.1455; ROBB RJ, 1987, J EXP MED, V165, P1201, DOI 10.1084/jem.165.4.1201; ROBB RJ, 1984, THYMIC HORMONES LYMP, P247; ROSENTHAL HE, 1967, ANAL BIOCHEM, V20, P525, DOI 10.1016/0003-2697(67)90297-7; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; Smith KA, 1995, ANN NY ACAD SCI, V766, P263, DOI 10.1111/j.1749-6632.1995.tb26674.x; SMITH KA, 1985, P NATL ACAD SCI USA, V82, P864, DOI 10.1073/pnas.82.3.864; SMITH KA, 1989, ANNU REV CELL BIOL, V5, P397; SMITH KA, 1988, SCIENCE, V240, P1169, DOI 10.1126/science.3131876; STEINMAN RM, 1974, J CELL BIOL, V63, P949, DOI 10.1083/jcb.63.3.949; TAKESHITA T, 1992, J IMMUNOL, V148, P2154; TAKESHITA T, 1992, SCIENCE, V257, P379, DOI 10.1126/science.1631559; TSUDO M, 1986, P NATL ACAD SCI USA, V83, P9694, DOI 10.1073/pnas.83.24.9694; WALDMANN TA, 1991, J BIOL CHEM, V266, P2681; WANG HM, 1987, J EXP MED, V166, P1055, DOI 10.1084/jem.166.4.1055; WEISSMAN AM, 1986, P NATL ACAD SCI USA, V83, P1463, DOI 10.1073/pnas.83.5.1463; WELLS A, 1990, SCIENCE, V247, P962, DOI 10.1126/science.2305263; WILLIAMS DP, 1988, NUCLEIC ACIDS RES, V16, P10453, DOI 10.1093/nar/16.22.10453; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0; WU ZN, 1995, J BIOL CHEM, V270, P16045, DOI 10.1074/jbc.270.27.16045; ZMUIDZINAS A, 1991, MOL CELL BIOL, V11, P2794, DOI 10.1128/MCB.11.5.2794	56	23	33	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13349	13355		10.1074/jbc.271.23.13349	http://dx.doi.org/10.1074/jbc.271.23.13349			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662876				2022-12-27	WOS:A1996UP38500010
J	Sorkin, A; Mazzotti, M; Sorkina, T; Scotto, L; Beguinot, L				Sorkin, A; Mazzotti, M; Sorkina, T; Scotto, L; Beguinot, L			Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr(974)-containing internalization motif	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LYSOSOMAL ACID-PHOSPHATASE; LIGAND-INDUCED INTERNALIZATION; HUMAN-FIBROBLASTS; DOWN-REGULATION; COATED PITS; ENDOCYTIC SYSTEM; INVITRO BINDING; KINASE-ACTIVITY; EGF RECEPTOR; DEGRADATION	The carboxyl-terminal regulatory domain of the epidermal growth factor (EGF) receptor is essential for its endocytosis and interaction with the clathrin-associated protein complex AP-2. To identify AP-2 binding motif in the receptor, several single and multiple-point mutations within the region between residues 966 and 977 of the human EGF receptor were made, and the mutant receptors were expressed in NIH3T3 cells. Mutation of tyrosine 974 alone or together with surrounding residues and the deletion of residues 973-975 essentially eliminated AP-2 co-immunoprecipitation with the EGF receptor, Furthermore, a synthetic peptide corresponding to receptor residues 964-978 blocked AP-2 association with the wild-type EGF receptor, These data suggest that AP-2 has only one high-affinity binding site in the EGF receptor composed of Tyr(974)-containing motif. Receptor mutants that did not bind AP-2 displayed a lower rate of internalization, down-regulation, and turnover compared to wild type receptors when expressed at high levels. However, similar receptor mutants expressed at low levels were internalized and down-regulated as efficiently as wild type receptors, Internalization of the mutant receptors lacking the high-affinity binding site for AP-2 was inhibited by K+-depletion of the cells, indicating that their endocytosis required intact coated pits, We suggest that whereas one mechanism of EGF receptor recruitment into coated pits involves high-affinity binding of AP-2 to Tyr(974)-containing motif, another pathway may be mediated by weak receptor/AP-2 interactions or by proteins other than AP-2.	HOSP SAN RAFFAELE, MOLEC ONCOL LAB, DIBIT, I-20132 MILAN, ITALY; HOSP SAN RAFFAELE, CNR, INST NEUROSCI & BIOMMAGINI, I-20132 MILAN, ITALY	Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele; Consiglio Nazionale delle Ricerche (CNR); Vita-Salute San Raffaele University; IRCCS Ospedale San Raffaele	Sorkin, A (corresponding author), UNIV COLORADO, HLTH SCI CTR, DEPT PHARMACOL, 4200 E 9TH AVE, DENVER, CO 80262 USA.			Sorkin, Alexander/0000-0002-4446-1920	NIDDK NIH HHS [DK46817] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R29DK046817] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		BEGUINOT L, 1984, P NATL ACAD SCI-BIOL, V81, P2384, DOI 10.1073/pnas.81.8.2384; BELTZER JP, 1991, EMBO J, V10, P3735, DOI 10.1002/j.1460-2075.1991.tb04942.x; BOLL W, 1995, CURR BIOL, V5, P1168, DOI 10.1016/S0960-9822(95)00233-8; CARPENTER G, 1976, J CELL BIOL, V71, P159, DOI 10.1083/jcb.71.1.159; CHANG CP, 1993, J BIOL CHEM, V268, P19312; CHEN WS, 1989, CELL, V59, P33, DOI 10.1016/0092-8674(89)90867-2; CHIN DJ, 1989, P NATL ACAD SCI USA, V86, P9289, DOI 10.1073/pnas.86.23.9289; CUPERS P, 1994, J CELL BIOL, V127, P725, DOI 10.1083/jcb.127.3.725; FELDER S, 1992, J CELL BIOL, V117, P203, DOI 10.1083/jcb.117.1.203; FRENCH AR, 1994, J BIOL CHEM, V269, P15749; GILBOA L, 1995, J BIOL CHEM, V270, P7061, DOI 10.1074/jbc.270.13.7061; GLENNEY JR, 1988, CELL, V52, P675, DOI 10.1016/0092-8674(88)90405-9; GLICKMAN JN, 1989, EMBO J, V8, P1041, DOI 10.1002/j.1460-2075.1989.tb03471.x; GORDEN P, 1978, P NATL ACAD SCI USA, V75, P5025, DOI 10.1073/pnas.75.10.5025; HAIGLER HT, 1979, J CELL BIOL, V81, P382, DOI 10.1083/jcb.81.2.382; HANOVER JA, 1984, CELL, V39, P283, DOI 10.1016/0092-8674(84)90006-0; HELIN K, 1991, ONCOGENE, V6, P825; HELIN K, 1991, J BIOL CHEM, V266, P8363; HIGUSHI R, 1990, PCR PROTOCOLS GUIDE, P173; HILLE A, 1992, EUR J CELL BIOL, V59, P106; HOPKINS CR, 1983, J CELL BIOL, V97, P508, DOI 10.1083/jcb.97.2.508; LAMAZE C, 1993, MOL BIOL CELL, V4, P715, DOI 10.1091/mbc.4.7.715; LAMAZE C, 1995, J CELL BIOL, V129, P47, DOI 10.1083/jcb.129.1.47; LARKIN JM, 1983, CELL, V33, P273, DOI 10.1016/0092-8674(83)90356-2; LEHMANN LE, 1992, EMBO J, V11, P4391, DOI 10.1002/j.1460-2075.1992.tb05539.x; LUND KA, 1990, J BIOL CHEM, V265, P15713; MILOSO M, 1995, J BIOL CHEM, V270, P19557, DOI 10.1074/jbc.270.33.19557; NESTEROV A, 1995, P NATL ACAD SCI USA, V92, P8719, DOI 10.1073/pnas.92.19.8719; NESTEROV A, 1995, J BIOL CHEM, V270, P6320, DOI 10.1074/jbc.270.11.6320; OHNO H, 1995, SCIENCE, V269, P1872, DOI 10.1126/science.7569928; OPRESKO LK, 1995, J BIOL CHEM, V270, P4325, DOI 10.1074/jbc.270.9.4325; PEARSE BMF, 1990, ANNU REV CELL BIOL, V6, P151, DOI 10.1146/annurev.cb.06.110190.001055; PEARSE BMF, 1988, EMBO J, V7, P3331, DOI 10.1002/j.1460-2075.1988.tb03204.x; ROBINSON MS, 1994, CURR OPIN CELL BIOL, V6, P538, DOI 10.1016/0955-0674(94)90074-4; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SMYTHE E, 1992, J CELL BIOL, V119, P1163, DOI 10.1083/jcb.119.5.1163; SORKIN A, 1992, J BIOL CHEM, V267, P8672; SORKIN A, 1995, J BIOL CHEM, V270, P619, DOI 10.1074/jbc.270.2.619; SORKIN A, 1993, SCIENCE, V261, P612, DOI 10.1126/science.8342026; SORKIN A, 1993, BIOESSAYS, V15, P375, DOI 10.1002/bies.950150603; SOSA MA, 1993, J BIOL CHEM, V268, P12537; STOSCHECK CM, 1984, J CELL BIOL, V98, P1048, DOI 10.1083/jcb.98.3.1048; TAYLOR JW, 1985, NUCLEIC ACIDS RES, V13, P8765; THOMAS DC, 1994, J BIOL CHEM, V269, P15732; TROWBRIDGE IS, 1993, ANNU REV CELL BIOL, V9, P129, DOI 10.1146/annurev.cb.09.110193.001021; VELU TJ, 1989, MOL CELL BIOL, V9, P1772, DOI 10.1128/MCB.9.4.1772; WATERS CM, 1992, J CELL PHYSIOL, V152, P253, DOI 10.1002/jcp.1041520206; WILEY HS, 1988, J CELL BIOL, V107, P801, DOI 10.1083/jcb.107.2.801; WILEY HS, 1991, J BIOL CHEM, V266, P11083	49	136	139	2	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13377	13384		10.1074/jbc.271.23.13377	http://dx.doi.org/10.1074/jbc.271.23.13377			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662849	hybrid			2022-12-27	WOS:A1996UP38500014
J	Hitoshi, S; Kusunoki, S; Kanazawa, I; Tsuji, S				Hitoshi, S; Kusunoki, S; Kanazawa, I; Tsuji, S			Molecular cloning and expression of a third type of rabbit GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferase	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HUMAN-SERUM; TRANSFERASE; PURIFICATION; GENETICS; LEWIS; CDNA	Recent molecular investigation revealed that two closely related structural genes encode distinct GDP-L-fucose:beta-D-galactoside 2-alpha-L-fucosyltransferases (alpha 1,2-fucosyltransferases). Some human cancer cells or tissues may express an aberrant alpha 1,2-fucosyltransferase other than H- and Secretor-type alpha 1,2-fucosyltransferase. However, definite evidence of the existence of a third type of alpha 1,2-fucosyltransferase has not been demonstrated. Here we report the molecular cloning of a third type of rabbit alpha 1,2-fucosyltransferase (RFT-III) from a rabbit genomic DNA library. The DNA sequence included an open reading frame coding for 347 amino acids, and the deduced amino acid sequence of RFT-III showed 59 and 80% identity with those of the previously reported two types of rabbit alpha 1,2-fucosyltransferase, RFT-I and RFT-II, respectively. COS-7 cells transfected with the RFT-III gene exhibited alpha 1,2-fucosyltransferase activity toward phenyl-beta-Gal as a substrate. Neuro2a (a murine neuro blastoma cell line) cells transfected with the RFT-III gene expressed fucosyl G(M1) (type 3 H) but not Ulex europaeus agglutinin-l lectin reactive antigens (type 2 H). Kinetic studies revealed that RFT-III exhibits higher affinity to types 1 (Gal beta 1, 3GlcNAc) and 3 (Gal beta 1, 3GalNAc) than to type 2 (Gal beta 1, 4GlcNAc) oligosaccharides, which suggests that RFT-III as well as RFT-II is a Secretor-type alpha 1,2-fucosyltransferase. RFT-III was expressed in the adult gastrointestinal tract. The RFT-I, -II, and -III genes were assigned within 90 kilobases on pulsed field gel electrophoresis analysis. These results constitute direct evidence that, at least in one mammalian species, three active alpha 1,2-fucosyltransferases exist.	RIKEN,INST PHYS & CHEM RES,FRONTIER RES PROGRAM,WAKO,SAITAMA 35101,JAPAN; UNIV TOKYO,FAC MED,INST BRAIN RES,DEPT NEUROL,TOKYO 113,JAPAN	RIKEN; University of Tokyo								BEYER TA, 1980, J BIOL CHEM, V255, P5373; BLASZCZYKTHURIN M, 1988, BIOCHEM BIOPH RES CO, V151, P100, DOI 10.1016/0006-291X(88)90564-5; HENRY SM, 1994, GLYCOCONJUGATE J, V11, P593, DOI 10.1007/BF00731311; HENRY SM, 1990, VOX SANG, V58, P61, DOI 10.1111/j.1423-0410.1990.tb02057.x; HITOSHI S, 1995, J BIOL CHEM, V270, P8844, DOI 10.1074/jbc.270.15.8844; KELLY RJ, 1995, J BIOL CHEM, V270, P4640, DOI 10.1074/jbc.270.9.4640; KELLY RJ, 1994, P NATL ACAD SCI USA, V91, P5843, DOI 10.1073/pnas.91.13.5843; KUMAZAKI T, 1984, P NATL ACAD SCI-BIOL, V81, P4193, DOI 10.1073/pnas.81.13.4193; KUSUNOKI S, 1992, NEUROSCI RES, V15, P74, DOI 10.1016/0168-0102(92)90019-9; KUSUNOKI S, 1994, BBA-LIPID LIPID MET, V1214, P27, DOI 10.1016/0005-2760(94)90005-1; LARSEN RD, 1990, P NATL ACAD SCI USA, V87, P6674, DOI 10.1073/pnas.87.17.6674; LEPENDU J, 1985, AM J HUM GENET, V37, P749; LEPENDU J, 1982, AM J HUM GENET, V34, P402; MCCUTCHAN JH, 1968, JNCI-J NATL CANCER I, V41, P351; PIAU JP, 1994, BIOCHEM J, V300, P623, DOI 10.1042/bj3000623; RAJAN VP, 1989, J BIOL CHEM, V264, P11158; ROUQUIER S, 1995, J BIOL CHEM, V270, P4632, DOI 10.1074/jbc.270.9.4632; Sambrook J., 2002, MOL CLONING LAB MANU; SARNESTO A, 1990, J BIOL CHEM, V265, P15067; SARNESTO A, 1992, J BIOL CHEM, V267, P2737; Svennerholm L, 1980, Adv Exp Med Biol, V125, P533; TAKEBE Y, 1988, MOL CELL BIOL, V8, P466, DOI 10.1128/MCB.8.1.466; THURIN J, 1995, J BIOL CHEM, V270, P26577, DOI 10.1074/jbc.270.44.26577; Watkins W M, 1980, Adv Hum Genet, V10, P1; YAZAWA S, 1993, JPN J CANCER RES, V84, P989, DOI 10.1111/j.1349-7006.1993.tb00190.x	25	34	38	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 12	1996	271	28					16975	16981		10.1074/jbc.271.28.16975	http://dx.doi.org/10.1074/jbc.271.28.16975			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UX126	8663168	hybrid			2022-12-27	WOS:A1996UX12600083
J	Haimovich, B; Regan, C; DiFazio, L; Ginalis, E; Ji, P; Purohit, U; Rowley, RB; Bolen, J; Greco, R				Haimovich, B; Regan, C; DiFazio, L; Ginalis, E; Ji, P; Purohit, U; Rowley, RB; Bolen, J; Greco, R			The Fc gamma RII receptor triggers pp125(FAK) phosphorylation in platelets	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-TYROSINE KINASE; SIGNAL TRANSDUCTION; PHOSPHOLIPASE-C; CELL ADHERENCE; ACTIVATION; GLYCOPROTEINS; AGGREGATION; ADHESION	Platelets express a single low affinity receptor for immunoglobulin, Fc gamma RII, that triggers multiple cellular responses upon interaction with multivalent immune complexes, In this study we show that immobilized IBG is also a potent stimulant of platelet activation triggering adhesion, aggregation, massive dense granule secretion, and thromboxane production, Platelet adhesion to IgG was blocked by the Fc gamma RII receptor-specific monoclonal antibody, IV.3. Pretreatment of the platelets with cytochalasin D to inhibit actin polymerization similarly prevented cell binding to IgQ having no effect on platelet binding to fibrinogen. Platelet adhesion to IgG also led to the induction of tyrosine phosphorylation of multiple proteins including pp125(FAK) and p72(SYK). These proteins were also tyrosine-phosphorylated in alpha(IIb)beta(3)-deficient IgG-adherent platelets from patients with Glanzmann's thrombasthenia. These data demonstrate that Fc gamma RII mediates pp125(FAK) phosphorylation and platelet adhesion to IgG independent of the integrin alpha(IIb)beta(3). Treatment of the platelets with bisindolylmaleimide to inhibit protein kinase C prevented phosphorylation of pp125(FAK) as well as several other proteins, but not p72(SYK) phosphorylation. This study establishes that the Fc gamma RII receptor mediates pp125(FAK) phosphorylation via protein kinase C.	BRISTOL MYERS SQUIBB,PRINCETON,NJ 08453; DNAX RES INST MOLEC & CELLULAR BIOL INC,PALO ALTO,CA 94304	Bristol-Myers Squibb; Merck & Company; Dnax Research Institute Of Molecular & Cellular Biology Inc.	Haimovich, B (corresponding author), UNIV MED & DENT NEW JERSEY,ROBERT WOOD JOHNSON MED SCH,DEPT SURG,MEB ROOM 434,NEW BRUNSWICK,NJ 08903, USA.							ANDERSON GP, 1990, BLOOD, V76, P1165; BANGA HS, 1986, P NATL ACAD SCI USA, V83, P9197, DOI 10.1073/pnas.83.23.9197; CHACKO GW, 1994, J BIOL CHEM, V269, P32435; CHAN AC, 1992, CELL, V71, P649, DOI 10.1016/0092-8674(92)90598-7; CHEN HC, 1995, J BIOL CHEM, V270, P16995, DOI 10.1074/jbc.270.28.16995; CHEN HC, 1994, P NATL ACAD SCI USA, V91, P10148, DOI 10.1073/pnas.91.21.10148; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; CLARK EA, 1994, J BIOL CHEM, V269, P28859; GHAZIZADEH S, 1995, BIOCHEM J, V305, P669, DOI 10.1042/bj3050669; GOLDSCHMIDTCLERMONT PJ, 1991, SCIENCE, V251, P1231, DOI 10.1126/science.1848725; GREENBERG S, 1994, J BIOL CHEM, V269, P3897; HAIMOVICH B, 1993, J BIOL CHEM, V268, P15868; Haimovich B, 1996, BLOOD, V87, P152, DOI 10.1182/blood.V87.1.152.bloodjournal871152; HAMAWY MM, 1993, J BIOL CHEM, V268, P6851; HAMAWY MM, 1993, J BIOL CHEM, V268, P5227; HEEMSKERK JWM, 1993, J BIOL CHEM, V268, P356; HUANG MM, 1992, J BIOL CHEM, V267, P5467; HUNTER S, 1993, EXP HEMATOL, V21, P1492; HYNES RO, 1992, CELL, V69, P11, DOI 10.1016/0092-8674(92)90115-S; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KANG JH, 1993, BLOOD, V81, P1505; KIEREN PA, 1993, J BIOL CHEM, V268, P24442; KOLANUS W, 1993, CELL, V74, P171, DOI 10.1016/0092-8674(93)90304-9; KUROSAKI T, 1994, J EXP MED, V179, P1725, DOI 10.1084/jem.179.5.1725; LAW CL, 1994, J BIOL CHEM, V269, P12310; LIPFERT L, 1992, J CELL BIOL, V119, P905, DOI 10.1083/jcb.119.4.905; MALAWISTA SE, 1971, YALE J BIOL MED, V44, P286; MCCORMICK F, 1989, CELL, V56, P5, DOI 10.1016/0092-8674(89)90976-8; NISHIBE S, 1990, SCIENCE, V250, P1253, DOI 10.1126/science.1700866; RANKIN S, 1994, J BIOL CHEM, V269, P704; RAVETCH JV, 1994, CELL, V78, P553, DOI 10.1016/0092-8674(94)90521-5; RIVERA VM, 1995, MOL CELL BIOL, V15, P1582; ROSENFELD SI, 1985, J CLIN INVEST, V76, P2317, DOI 10.1172/JCI112242; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHALLER MD, 1994, CURR OPIN CELL BIOL, V6, P705, DOI 10.1016/0955-0674(94)90097-3; SHATTIL SJ, 1994, J BIOL CHEM, V269, P14738; SHEN ZH, 1994, J IMMUNOL, V152, P3017; SIDORENKO SP, 1995, P NATL ACAD SCI USA, V92, P359, DOI 10.1073/pnas.92.2.359; SIESS W, 1989, PHYSIOL REV, V69, P58, DOI 10.1152/physrev.1989.69.1.58; TANIGUCHI T, 1993, J BIOL CHEM, V268, P2277; TING AT, 1995, J BIOL CHEM, V270, P16415, DOI 10.1074/jbc.270.27.16415; TOHYAMA Y, 1994, J BIOL CHEM, V269, P32796; TOULLEC D, 1991, J BIOL CHEM, V266, P15771; TSYGANKOV AY, 1992, J BIOL CHEM, V267, P18259; WEISS A, 1993, CELL, V73, P209, DOI 10.1016/0092-8674(93)90221-B; YAMADA KM, 1995, CURR OPIN CELL BIOL, V7, P681, DOI 10.1016/0955-0674(95)80110-3; YLANNE J, 1990, BLOOD, V76, P570; ZACHARY I, 1993, J BIOL CHEM, V268, P22060	48	34	35	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16332	16337		10.1074/jbc.271.27.16332	http://dx.doi.org/10.1074/jbc.271.27.16332			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663117	hybrid			2022-12-27	WOS:A1996UW35200070
J	Shih, NY; FloydSmith, G				Shih, NY; FloydSmith, G			Protein kinase C-delta mRNA is down-regulated transcriptionally and post-transcriptionally by 12-O-tetradecanoylphorbol-13-acetate	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PHENOL-CHLOROFORM EXTRACTION; SINGLE-STEP METHOD; GENE-EXPRESSION; PHORBOL ESTER; MESSENGER-RNA; HEMATOPOIETIC-CELLS; NEGATIVE REGULATION; EPSILON; GROWTH; PHOSPHORYLATION	Activation of protein kinase C-delta (PKC-delta) by 12-O-tetrade anoylphorbol-13-acetate (TPA) is followed by a gradual decrease in detectable protein 12-24 h later in the mouse B lymphoma cell line A20. Down-regulation is associated with TPA-induced proteolysis and a 50-86% decrease in PKC-delta mRNA 0.5-24 h post-treatment which is due to both a 50% decrease in transcription and accelerated degradation of PKC-delta mRNA as determined using the pulse-chase method. Destabilization of PKC-delta mRNA is also observed when actinomycin D is added to cells pretreated with TPA for 2 h; however, addition of actinomycin D or cycloheximide prior to TPA treatment blocks destabilization. Addition of PKC inhibitors to TPA-treated cells also blocks destabilization of PKC-delta mRNA. Cells treated with TPA for 4 h contain an activity not found in control cells which destabilizes PKC-delta mRNA but not glyceraldehyde-3-phosphate dehydrogenase mRNA in vitro. Addition of TPA to control extracts fails to increase degradation of PKC-delta mRNA in vitro, suggesting that treatment of intact cells is required to induce the synthesis of a factor(s) that destabilizes PKC-delta mRNA. This factor(s) then acts along with transcriptional and post-translational regulatory mechanisms to down-regulate PKC-delta.	ARIZONA STATE UNIV,DEPT ZOOL,PROGRAM MOLEC & CELLULAR BIOL,TEMPE,AZ 85287	Arizona State University; Arizona State University-Tempe			Shih, Neng-Yao/D-2086-2010		NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI024915] Funding Source: NIH RePORTER; NIAID NIH HHS [AI24915] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BASHEERUDDIN K, 1992, J BIOL CHEM, V267, P1219; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; Belasco J.G., 2012, CONTROL MESSENGER RN; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRICKGHANNAM C, 1994, HUM IMMUNOL, V41, P216, DOI 10.1016/0198-8859(94)90039-6; BROOKS G, 1993, J BIOL CHEM, V268, P23868; CHEN CC, 1993, FEBS LETT, V332, P169, DOI 10.1016/0014-5793(93)80506-P; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COLLINS T, 1984, P NATL ACAD SCI-BIOL, V81, P4917, DOI 10.1073/pnas.81.15.4917; DENG GR, 1983, METHOD ENZYMOL, V100, P96; DENNING MF, 1993, J BIOL CHEM, V268, P26079; DENT CL, TRANSCRIPTION FACTOR, P1; DIAMOND MI, 1990, SCIENCE, V249, P1266, DOI 10.1126/science.2119054; FARRELL RE, 1993, RNA METHODOLOGIES, P235; FERRY RC, 1994, J BIOL CHEM, V269, P31850; GERMANO P, 1994, J BIOL CHEM, V269, P23102; GOODE NT, 1994, MOL BIOL CELL, V5, P907, DOI 10.1091/mbc.5.8.907; GOODNIGHT J, 1995, J BIOL CHEM, V270, P9991, DOI 10.1074/jbc.270.17.9991; HENDERSON GS, 1991, BIOTECHNIQUES, V10, P190; HERBERT JM, 1990, BIOCHEM BIOPH RES CO, V172, P993, DOI 10.1016/0006-291X(90)91544-3; HOWCROFT TK, 1993, EMBO J, V12, P3163, DOI 10.1002/j.1460-2075.1993.tb05985.x; HSU W, 1994, MOL CELL BIOL, V14, P268, DOI 10.1128/MCB.14.1.268; IZZO NJ, 1994, J BIOL CHEM, V269, P1705; JUN CD, 1994, BIOCHEM BIOPH RES CO, V204, P105, DOI 10.1006/bbrc.1994.2432; KARIN M, 1990, MOL ASPECTS CELLULAR, V6, P143; KIELBASSA K, 1995, J BIOL CHEM, V270, P6156, DOI 10.1074/jbc.270.11.6156; KOBAYASHI E, 1989, BIOCHEM BIOPH RES CO, V159, P548, DOI 10.1016/0006-291X(89)90028-4; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI WQ, 1994, J BIOL CHEM, V269, P2349; LOMBARDI L, 1995, NUCLEIC ACIDS RES, V23, P2328, DOI 10.1093/nar/23.12.2328; MAIZELS ET, 1992, J BIOL CHEM, V267, P17061; MESSING RO, 1991, J BIOL CHEM, V266, P23428; MISCHAK H, 1993, J BIOL CHEM, V268, P6090; MISCHAK H, 1991, BIOCHEMISTRY-US, V30, P7925, DOI 10.1021/bi00246a008; MISCHAK H, 1993, J BIOL CHEM, V268, P20110; MIZUNO K, 1991, EUR J BIOCHEM, V202, P931, DOI 10.1111/j.1432-1033.1991.tb16453.x; NIINO YS, 1992, J BIOL CHEM, V267, P6158; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; NISHIZUKA Y, 1995, FASEB J, V9, P484, DOI 10.1096/fasebj.9.7.7737456; OCONNER JL, 1992, BIOTECHNIQUES, V12, P238; ODRISCOLL KR, 1995, MOL BIOL CELL, V6, P449, DOI 10.1091/mbc.6.4.449; OGITA K, 1992, P NATL ACAD SCI USA, V89, P1592, DOI 10.1073/pnas.89.5.1592; OHNO S, 1994, J BIOL CHEM, V269, P17495; OLIVIER AR, 1991, EUR J BIOCHEM, V200, P805, DOI 10.1111/j.1432-1033.1991.tb16248.x; PUISSANT C, 1990, BIOTECHNIQUES, V8, P148; RODRIGUEZPENA A, 1984, BIOCHEM BIOPH RES CO, V120, P1053, DOI 10.1016/S0006-291X(84)80213-2; ROSEJOHN S, 1988, GENE, V74, P465, DOI 10.1016/0378-1119(88)90179-5; SABATH DE, 1990, GENE, V91, P185, DOI 10.1016/0378-1119(90)90087-8; SACEDA M, 1991, J BIOL CHEM, V266, P17809; SHIH NY, 1995, MOL IMMUNOL, V32, P643, DOI 10.1016/0161-5890(95)00029-E; SIEBENLIST U, 1994, ANNU REV CELL BIOL, V10, P405, DOI 10.1146/annurev.cb.10.110194.002201; SOLTOFF SP, 1995, J BIOL CHEM, V270, P13490, DOI 10.1074/jbc.270.22.13490; SRIVASTAVA KK, 1993, BIOTECHNIQUES, V15, P226; SZALLASI Z, 1994, J BIOL CHEM, V269, P2118; TERAJIMA J, 1992, CELL IMMUNOL, V142, P197, DOI 10.1016/0008-8749(92)90280-3; TOWBIN H, 1979, P NATL ACAD SCI USA, V76, P4350, DOI 10.1073/pnas.76.9.4350; WAGER RE, 1990, MOL CELL BIOL, V10, P5983, DOI 10.1128/MCB.10.11.5983; WATANABE T, 1992, P NATL ACAD SCI USA, V89, P10159, DOI 10.1073/pnas.89.21.10159; WOODGETT JR, 1987, MOL CELL BIOL, V7, P85, DOI 10.1128/MCB.7.1.85; YOUNG S, 1987, BIOCHEM J, V244, P775, DOI 10.1042/bj2440775; ZHU YY, 1991, J CELL BIOL, V115, P745, DOI 10.1083/jcb.115.3.745	61	16	16	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16040	16046		10.1074/jbc.271.27.16040	http://dx.doi.org/10.1074/jbc.271.27.16040			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663197	hybrid			2022-12-27	WOS:A1996UW35200031
J	VandenKoornhuyse, N; Libessart, N; Delrue, B; Zabawinski, C; Decq, A; Iglesias, A; Carton, A; Preiss, J; Ball, S				VandenKoornhuyse, N; Libessart, N; Delrue, B; Zabawinski, C; Decq, A; Iglesias, A; Carton, A; Preiss, J; Ball, S			Control of starch composition and structure through substrate supply in the monocellular alga Chlamydomonas reinhardtii	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							ADP-GLUCOSE PYROPHOSPHORYLASE; ARABIDOPSIS-THALIANA L; ADPGLUCOSE PYROPHOSPHORYLASE; DEFICIENT MUTANT; GRANULE; AMYLOPECTIN; INHIBITION; SYNTHASE; EXPRESSION; STORAGE	In Chlamydomonas, as in higher plants, synthesis of ADP glucose catalyzed by ADP-glucose pyrophosphorylase is rate-limiting for the building of starch in the chloroplast. We have isolated disruptions of the STA1 ADP-glucose pyrophosphorylase structural gene that rendered the enzyme less responsive to the allosteric activator 3-phosphoglycerate, The structure and composition of the residual starch synthesized by all mutants of the STA1 locus is dramatically altered. The residual polysaccharide is shown to be devoid of amylose despite the presence of granule-bound starch synthase, the amylose biosynthetic enzyme. In addition, the fine structure of the mutant amylopectin revealed the presence of an altered chain-length distribution. This distribution mimicks that which is observed during growth and photosynthesis and differs markedly from that observed during storage, We therefore propose that low nucleotide sugar concentrations are either directly or indirectly responsible for the major differences observed in the composition or structure of starch during storage and photosynthesis.	UNIV SCI & TECH LILLE FLANDRES ARTOIS,UMR CNRS 111,CHIM BIOL LAB,F-59655 VILLENEUVE DASCQ,FRANCE; MICHIGAN STATE UNIV,DEPT BIOCHEM,E LANSING,MI 48824; INST TECHNOL CHASCOMUS,INTECH,RA-7130 CHASCOMUS,ARGENTINA	Centre National de la Recherche Scientifique (CNRS); Universite de Lille - ISITE; Universite de Lille; Michigan State University				Ball, Steven/0000-0003-1629-1650; Iglesias, Alberto/0000-0001-9729-7338	NIAID NIH HHS [AI 022385] Funding Source: Medline	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		BALL S, 1991, PLANTA, V185, P17, DOI 10.1007/BF00194509; BALL SG, 1990, PLANT SCI, V66, P1, DOI 10.1016/0168-9452(90)90162-H; BANKS W, 1971, CARBOHYD RES, V17, P25, DOI 10.1016/S0008-6215(00)81539-6; DELRUE B, 1992, J BACTERIOL, V174, P3612, DOI 10.1128/JB.174.11.3612-3620.1992; FONTAINE T, 1993, J BIOL CHEM, V268, P16223; GHOSH HP, 1966, J BIOL CHEM, V241, P4491; GIDLEY MJ, 1985, CARBOHYD RES, V139, P85; Harris E.H., 1989, CHLAMYDOMONAS SOURCE, P399; Harris EH, 1989, CHLAMYDOMONAS SOURCE, P25, DOI [DOI 10.1016/B978-0-12-326880-8.50007-9, DOI 10.1126/SCIENCE.246.4936.1503-A]; IGLESIAS AA, 1994, PLANT PHYSIOL, V104, P1287, DOI 10.1104/pp.104.4.1287; JENKINS JPJ, 1993, STARCH-STARKE, V45, P417; KINDLE KL, 1990, P NATL ACAD SCI USA, V87, P1228, DOI 10.1073/pnas.87.3.1228; KLOECK G, 1991, Biochimica et Biophysica Acta, V1073, P410; KUIPERS AGJ, 1994, PLANT CELL, V6, P43, DOI 10.1105/tpc.6.1.43; LI L, 1992, CARBOHYD RES, V227, P227, DOI 10.1016/0008-6215(92)85074-A; LIBESSART N, 1995, PLANT CELL, V7, P1117; LIN TP, 1988, PLANT PHYSIOL, V86, P1131, DOI 10.1104/pp.86.4.1131; LIN TP, 1988, PLANT PHYSIOL, V88, P1175, DOI 10.1104/pp.88.4.1175; MACDONALD FD, 1985, PLANT PHYSIOL, V78, P849, DOI 10.1104/pp.78.4.849; MADDELEIN ML, 1994, J BIOL CHEM, V269, P25150; Maniatis T., 1982, MOL CLONING; MANNERS DJ, 1989, CARBOHYD POLYM, V11, P87, DOI 10.1016/0144-8617(89)90018-0; MULLERROBER B, 1992, EMBO J, V11, P1229, DOI 10.1002/j.1460-2075.1992.tb05167.x; MULLERROBER B, 1994, PLANT CELL ENVIRON, V17, P601, DOI 10.1111/j.1365-3040.1994.tb00152.x; NELSON O, 1995, ANNU REV PLANT PHYS, V46, P475, DOI 10.1146/annurev.pp.46.060195.002355; NELSON OE, 1962, BIOCHEM BIOPH RES CO, V9, P297, DOI 10.1016/0006-291X(62)90043-8; PARENTE JP, 1985, CARBOHYD RES, V141, P41, DOI 10.1016/S0008-6215(00)90753-5; Preiss J., 1996, PHOTOASSIMILATE DIST, V3, p63?96; Preiss J, 1993, DENPUN KAGAKU, V40, P117; Preiss J, 1991, OXFORD SURVEYS PLANT, V7, P59; Shannon J., 1984, STARCH CHEM TECHNOLO, P25, DOI 10.1016/B978-0-12-746270-7.50009-4; SMITH AM, 1989, PLANT PHYSIOL, V89, P982, DOI 10.1104/pp.89.3.982; STARK DM, 1992, SCIENCE, V258, P287, DOI 10.1126/science.258.5080.287; TSAI CY, 1974, BIOCHEM GENET, V11, P83, DOI 10.1007/BF00485766; TSAI CY, 1966, SCIENCE, V151, P341, DOI 10.1126/science.151.3708.341; VISSER RGF, 1991, MOL GEN GENET, V225, P289, DOI 10.1007/BF00269861; WANG ZY, 1995, PLANT J, V7, P613, DOI 10.1046/j.1365-313X.1995.7040613.x; WEEKS DP, 1986, ANAL BIOCHEM, V152, P376, DOI 10.1016/0003-2697(86)90423-9	38	77	79	1	16	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16281	16287		10.1074/jbc.271.27.16281	http://dx.doi.org/10.1074/jbc.271.27.16281			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663144	hybrid			2022-12-27	WOS:A1996UW35200063
J	Saiki, K; Nakamura, H; Mogi, T; Anraku, Y				Saiki, K; Nakamura, H; Mogi, T; Anraku, Y			Probing a role of subunit IV of the Escherichia coli bo-type ubiquinol oxidase by deletion and cross-linking analyses	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOCHROME-C-OXIDASE; AEROBIC RESPIRATORY-CHAIN; SITE-DIRECTED MUTAGENESIS; TERMINAL OXIDASE; PARACOCCUS-DENITRIFICANS; BINUCLEAR CENTER; QUINOL OXIDASE; HEME-COPPER; O COMPLEX; CYOE GENE	Subunit TV of the Escherichia cell be-type ubiquinol oxidase is a 12-kDa membrane protein encoded by the cyoD gene and is conserved in the bacterial heme-copper terminal oxidases. To probe the functional role of subunit TV, we carried out deletion analysis and chemical cross-linking experiments with a homobifunctional and cleavable reagent. Spectroscopic properties of the mutant oxidases suggest that the C-terminal two-third (Val(45) to His(109)) containing helices II and III is essential for the functional expression of the oxidase complex and for the Cu-B binding to the heme-copper binuclear center in subunit I. Cross-linking studies indicate that subunit TV is in close vicinity to subunit III. Based on these observations, we propose that subunit IV is present in a cleft formed by subunits I and III and assists the Cu-B binding to subunit I during biosynthesis or assembly of the oxidase complex.	UNIV TOKYO,GRAD SCH SCI,DEPT BIOL SCI,BUNKYO KU,TOKYO 113,JAPAN; RIKEN,INST PHYS & CHEM RES,WAKO,SAITAMA 35101,JAPAN	University of Tokyo; RIKEN			Keitarou, Saiki/AAV-6909-2020					ANRAKU Y, 1987, TRENDS BIOCHEM SCI, V12, P262, DOI 10.1016/0968-0004(87)90131-9; AOYAMA H, 1995, BIOPHYSICS S, V35, P26; BROWN S, 1993, FEBS LETT, V316, P216, DOI 10.1016/0014-5793(93)81296-C; CALHOUN MW, 1993, BIOCHEMISTRY-US, V32, P11524, DOI 10.1021/bi00094a008; CASTOR LN, 1959, J BIOL CHEM, V234, P1587; CASTRESANA J, 1994, EMBO J, V13, P2516, DOI 10.1002/j.1460-2075.1994.tb06541.x; CHEPURI V, 1990, J BIOL CHEM, V265, P11185; CHEPURI V, 1990, J BIOL CHEM, V265, P12978; Denda K, 1995, BIOCHEM BIOPH RES CO, V217, P428, DOI 10.1006/bbrc.1995.2794; FUKAYA M, 1993, J BACTERIOL, V175, P4307, DOI 10.1128/JB.175.14.4307-4314.1993; GARCIAHORSMAN JA, 1994, J BACTERIOL, V176, P5587, DOI 10.1128/JB.176.18.5587-5600.1994; GENNIS RB, 1991, BIOCHIM BIOPHYS ACTA, V1058, P21, DOI 10.1016/S0005-2728(05)80260-9; HALTIA T, 1994, BIOCHEMISTRY-US, V33, P9731, DOI 10.1021/bi00198a044; HENDLER RW, 1991, BIOPHYS J, V60, P415, DOI 10.1016/S0006-3495(91)82067-7; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JARAUSCH J, 1985, EUR J BIOCHEM, V146, P211, DOI 10.1111/j.1432-1033.1985.tb08640.x; KITA K, 1982, J BIOL CHEM, V257, P7933; KITA K, 1984, J BIOL CHEM, V259, P3368; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LEMIEUX LJ, 1992, J BIOL CHEM, V267, P2105; LEMMA E, 1995, ARCH MICROBIOL, V163, P432, DOI 10.1007/BF00272132; LUDWIG B, 1980, P NATL ACAD SCI-BIOL, V77, P196, DOI 10.1073/pnas.77.1.196; MA JX, 1993, BIOCHEMISTRY-US, V32, P7692, DOI 10.1021/bi00081a013; MATSUSHITA K, 1983, P NATL ACAD SCI-BIOL, V80, P4889, DOI 10.1073/pnas.80.16.4889; MINAGAWA J, 1992, J BIOL CHEM, V267, P2096; MINAGAWA J, 1990, J BIOL CHEM, V265, P11198; MINGHETTI KC, 1992, BIOCHEMISTRY-US, V31, P6917, DOI 10.1021/bi00145a008; MOGI T, 1994, J BIOCHEM-TOKYO, V116, P471, DOI 10.1093/oxfordjournals.jbchem.a124548; MOGI T, 1994, MOL MICROBIOL, V14, P391, DOI 10.1111/j.1365-2958.1994.tb02174.x; MOGI T, 1995, FEBS LETT, V370, P259; NAKAMURA H, 1990, J BIOL CHEM, V265, P11193; NAKAMURA H, 1991, THESIS U TOKYO; PAPA S, 1994, CELL BIOL INT, V18, P345, DOI 10.1006/cbir.1994.1084; PROCHASKA LJ, 1996, BIOPHYS J, V70, P252; PUUSTINEN A, 1989, FEBS LETT, V249, P163, DOI 10.1016/0014-5793(89)80616-7; PUUSTINEN A, 1991, BIOCHEMISTRY-US, V30, P3936, DOI 10.1021/bi00230a019; QUIRK PG, 1993, J BIOL CHEM, V268, P678; RICHTER OMH, 1994, J BIOL CHEM, V269, P23079; SAIKI K, 1993, J BIOL CHEM, V268, P26927; SAIKI K, 1992, BIOCHEM BIOPH RES CO, V189, P1491, DOI 10.1016/0006-291X(92)90243-E; SALERNO JC, 1990, J BIOL CHEM, V265, P4364; SANTANA M, 1992, J BIOL CHEM, V267, P10225; SARASTE M, 1991, EUR J BIOCHEM, V195, P517, DOI 10.1111/j.1432-1033.1991.tb15732.x; SARASTE M, 1990, Q REV BIOPHYS, V23, P331, DOI 10.1017/S0033583500005588; SATOWATANABE M, 1995, FEBS LETT, V374, P265, DOI 10.1016/0014-5793(95)01125-X; SATOWATANABE M, 1994, J BIOL CHEM, V269, P28899; SONE N, 1990, FEBS LETT, V262, P249, DOI 10.1016/0014-5793(90)80202-T; TSUBAKI M, 1993, BIOCHEMISTRY-US, V32, P6065, DOI 10.1021/bi00074a018; TSUBAKI M, 1994, J BIOL CHEM, V269, P30861; TSUKIHARA T, 1995, SCIENCE, V269, P1069, DOI 10.1126/science.7652554; UNO T, 1994, J BIOL CHEM, V269, P11912; VANDEROOST J, 1994, FEMS MICROBIOL LETT, V121, P1, DOI 10.1016/0378-1097(94)90137-6; VILLANI G, 1995, BBA-BIOENERGETICS, V1232, P67, DOI 10.1016/0005-2728(95)00112-5; WELTER R, 1994, J BIOL CHEM, V269, P28834; WRAY W, 1981, ANAL BIOCHEM, V118, P197, DOI 10.1016/0003-2697(81)90179-2	55	27	27	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15336	15340		10.1074/jbc.271.26.15336	http://dx.doi.org/10.1074/jbc.271.26.15336			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663126	hybrid			2022-12-27	WOS:A1996UV29900008
J	Hirsch, JR; Loo, DDF; Wright, EM				Hirsch, JR; Loo, DDF; Wright, EM			Regulation of Na+/glucose cotransporter expression by protein kinases in Xenopus laevis oocytes	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							NA+ GLUCOSE COTRANSPORTER; ACTIVATION; PHOSPHORYLATION; INHIBITION; MODULATION; ACID; CAMP	Cotransporters are proteins responsible for the accumulation of nutrients, neurotransmitters, and drugs in cells, As forskolin has been shown to stimulate intestinal Na+/glucose cotransport, we have used electrophysiological techniques to examine the role of protein kinases in regulating Na+/glucose cotransporters, SGLT1, expressed in Xenopus laevis oocytes, We monitored SGLT1 kinetics, the number of SGLT1 cotransporters in the plasma membrane, and plasma membrane area before and after activation of protein kinases, 8-Bromoadenosine 3',5' cyclic monophosphate (8-Br-cAMP) and sn-1,2-dioctanoylglycerol (DOG) were used as membrane permeable activators of protein kinases A (PKA) and C (PKC), respectively, In oocytes expressing rabbit SGLT1 8-Br-cAMP increased by 28 +/- 4% (n = 10), and DOG decreased by 51 +/- 5% (n = 13) the maximum rate of Na+/glucose cotransport, These reversible changes in the maximum transport rate occurred within minutes, and were accompanied by proportional changes in the number of cotransporters in the membrane and area of the plasma membrane, This suggests that protein kinases regulate rabbit SGLT1 activity by controlling the distribution of transporters between intracellular compartments and the plasma membrane, and that this occurs by exo and endocytosis, Similar increases in maximum transport were obtained with activation of PKA in oocytes expressing rabbit, human, and rat SGLT1 isoforms, but with activation of PKC the response was isoform-dependent, PKC activation decreased the maximum rate of transport by rabbit and rat SGLT1, but increased transport by human SGLT1, We conclude that: (i) the regulation of SGLT1 expression in oocytes by protein kinases occurs mainly by regulated endo- and exocytosis; (ii) it is independent of consensus phosphorylation sites in the transporter; and (iii) the effect of a given kinase depends upon the actual sequence of the cotransporter expressed, These considerations may also apply to the regulation of other cotransporters by protein kinases in oocytes, cells, and tissues.			Hirsch, JR (corresponding author), UNIV CALIF LOS ANGELES, SCH MED, DEPT PHYSIOL, LOS ANGELES, CA 90095 USA.				NIDDK NIH HHS [DK 44602, DK 19567] Funding Source: Medline; NINDS NIH HHS [NS25554] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK019567, R01DK044602] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS025554] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BLUMENTHAL EM, 1992, J NEUROSCI, V12, P290; BRADBURY NA, 1994, AM J PHYSIOL, V267, pC1, DOI 10.1152/ajpcell.1994.267.1.C1; BREWER CB, 1995, J CELL SCI, V108, P789; BREWER CB, 1991, J CELL BIOL, V114, P413, DOI 10.1083/jcb.114.3.413; CASADO M, 1993, J BIOL CHEM, V268, P27313; COREY JL, 1994, J BIOL CHEM, V269, P14759; DAVIS RJ, 1985, J BIOL CHEM, V260, P1562; DEBNAM ES, 1994, NEWS PHYSIOL SCI, V9, P84; GRUBB BR, 1995, AM J PHYSIOL-GASTR L, V268, pG505, DOI 10.1152/ajpgi.1995.268.3.G505; HARVEY WR, 1994, J EXP BIOL, V196, P1; HAYES G, 1995, PFLUG ARCH EUR J PHY, V430, P819, DOI 10.1007/BF00386181; HEDIGER MA, 1989, P NATL ACAD SCI USA, V86, P5748, DOI 10.1073/pnas.86.15.5748; HEDIGER MA, 1987, NATURE, V330, P379, DOI 10.1038/330379a0; HEI YJ, 1991, MOL PHARMACOL, V39, P233; HEIDELBERGER R, 1994, NATURE, V371, P513, DOI 10.1038/371513a0; Hirayama BA, 1996, AM J PHYSIOL-GASTR L, V270, pG919, DOI 10.1152/ajpgi.1996.270.6.G919; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; ISOM LL, 1995, CELL, V83, P433, DOI 10.1016/0092-8674(95)90121-3; LEE WS, 1994, J BIOL CHEM, V269, P12032; LOO DDF, 1993, P NATL ACAD SCI USA, V90, P5767, DOI 10.1073/pnas.90.12.5767; PARENT L, 1992, J MEMBRANE BIOL, V125, P49; PIPER RC, 1993, J BIOL CHEM, V268, P16557; RONG LA, 1995, J BIOL CHEM, V270, P6456, DOI 10.1074/jbc.270.12.6456; ROTHMAN JE, 1994, NATURE, V372, P55, DOI 10.1038/372055a0; RUTH P, 1991, EUR J BIOCHEM, V202, P1339, DOI 10.1111/j.1432-1033.1991.tb16509.x; SATO K, 1995, J NEUROCHEM, V65, P1967; SUDHOF TC, 1995, NATURE, V375, P645, DOI 10.1038/375645a0; UMBACH JA, 1990, BIOPHYS J, V57, P1217, DOI 10.1016/S0006-3495(90)82640-0; VASILETS LA, 1990, J MEMBRANE BIOL, V118, P131, DOI 10.1007/BF01868470; WRIGHT E M, 1992, Current Opinion in Cell Biology, V4, P696, DOI 10.1016/0955-0674(92)90091-P; ZAMPIGHI GA, 1995, J MEMBRANE BIOL, V148, P65	31	169	171	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14740	14746		10.1074/jbc.271.25.14740	http://dx.doi.org/10.1074/jbc.271.25.14740			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663046	hybrid			2022-12-27	WOS:A1996UT10600019
J	Kuroda, S; Ohtsuka, T; Yamamori, B; Fukui, K; Shimizu, K; Takai, Y				Kuroda, S; Ohtsuka, T; Yamamori, B; Fukui, K; Shimizu, K; Takai, Y			Different effects of various phospholipids on Ki-Ras-, Ha-Ras-, and Rap1B-induced B-Raf activation	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; SIGNAL-TRANSDUCTION; MAP KINASES; CELLS; GENE; TRANSFORMATION; BINDING; REGION; DOMAIN; RSK	We have recently purified a Ki-Ras- and Ha-Ras-dependent extracellular signal-regulated kinase kinase from bovine brain and identified it as B-Raf protein kinase complexed with 14-3-3 proteins (Yamamori, B., Kuroda, S., Shimizu, K., Fukui, K., Ohtsuka, T., and Takai, Y. (1995) J. Biol. Chem. 270, 11723-11726). Moreover, we found that Rap1B as well as Ki-Ras and Ha-Has stimulate the B-Raf activity. Since B-Raf contains a cysteine-rich domain originally found in protein kinase C as a domain responsible for interaction with phosphatidylserine (PS) and diacylglycerol or 12-O-tetradecanoylphorbol-13-acetate, we have examined here the effect of these compounds on the Ki-Ras-, Ha-Ras-, and Rap1B-induced activation of bovine brain B-Raf. Bovine brain PS enhanced Ki-Ras stimulated B-Raf activity. Phosphatidic acid was slightly active, but other phospholipids, such as phosphatidylcholine, phosphatidylethanolamine, phosphatidylinositol (PI), PI-Li-monophosphate, PI-4,5-bisphosphate, and PI-3,4,5-trisphosphate, were inactive. However, none of the above phospholipids affected the Ha-Has-stimulated B-Raf activity, whereas PI, PS, phosphatidylethanolamine, and phosphatidic acid inhibited the Rap1B-stimulated B-Raf activity. Phosphatidylcholine or PI-4-monophosphate did not show any effect on the Rap1B-stimulated B-Raf activity. Synthetic PS with two unsaturated fatty acids, such as 1,2-dioleoyl-PS or 1,2-dilinoleoyl-PS, showed the same effect toward the Ki-Ras and Rap1B-stimulated B-Raf activities, but synthetic PS with two saturated fatty acids, such as 1,2-distearoyl-PS, was inactive. 12-O-Tetradecanoylphorbol-13-acetate did not affect the stimulatory or inhibitory effect of PS on the Ki Ras and Rap1B-stimulated B-Raf activities, respectively. PS did not affect the Ki-Ras-, Ha-Ras, or Rap1B-independent basal B-Raf activity or the mitogen-activated protein kinase kinase or extracellular signal-regulated kinase activity. These results indicate that various phospholipids differently affect Ki-Ras, Ha-Pas, and Rap1B induced B-Raf activation.	OSAKA UNIV, SCH MED, DEPT MOLEC BIOL & BIOCHEM, SUITA, OSAKA 565, JAPAN; NATL INST PHYSIOL SCI, DEPT CELL PHYSIOL, OKAZAKI, AICHI 444, JAPAN	Osaka University; National Institutes of Natural Sciences (NINS) - Japan; National Institute for Physiological Sciences (NIPS)			KURODA, SHINYA/G-4961-2014					AELST LV, 1993, P NATL ACAD SCI USA, V90, P6213; AMBROSIO L, 1989, NATURE, V342, P288, DOI 10.1038/342288a0; BEITNERJOHNSON D, 1995, J BIOL CHEM, V270, P5187, DOI 10.1074/jbc.270.10.5187; BLENIS J, 1993, P NATL ACAD SCI USA, V90, P5889, DOI 10.1073/pnas.90.13.5889; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; DAUM G, 1994, TRENDS BIOCHEM SCI, V19, P474, DOI 10.1016/0968-0004(94)90133-3; DAVIS RJ, 1993, J BIOL CHEM, V268, P14553; DENT P, 1995, MOL CELL BIOL, V15, P4125; FARNSWORTH CL, 1995, NATURE, V376, P524, DOI 10.1038/376524a0; FELLER SM, 1994, EMBO J, V13, P2341, DOI 10.1002/j.1460-2075.1994.tb06518.x; GHOSH SJ, 1994, J BIOL CHEM, V269, P10000; GLOMSET JA, 1994, ANNU REV CELL BIOL, V10, P181, DOI 10.1146/annurev.cellbio.10.1.181; GOTOH T, 1995, MOL CELL BIOL, V15, P6746; HAN M, 1993, NATURE, V363, P133, DOI 10.1038/363133a0; HERBETTE L, 1984, ARCH BIOCHEM BIOPHYS, V234, P235, DOI 10.1016/0003-9861(84)90345-X; HORWITZ J, 1987, METHOD ENZYMOL, V141, P169; ITOH T, 1993, P NATL ACAD SCI USA, V90, P975, DOI 10.1073/pnas.90.3.975; ITOH T, 1993, J BIOL CHEM, V268, P3025; JACKSON JH, 1990, P NATL ACAD SCI USA, V87, P3042, DOI 10.1073/pnas.87.8.3042; JAISWAL RK, 1994, MOL CELL BIOL, V14, P6944, DOI 10.1128/MCB.14.10.6944; KAWATA M, 1988, J BIOL CHEM, V263, P18965; KAZANIETZ MG, 1994, J BIOL CHEM, V269, P11590; KITAYAMA H, 1989, CELL, V56, P77, DOI 10.1016/0092-8674(89)90985-9; KOIDE H, 1993, P NATL ACAD SCI USA, V90, P8683, DOI 10.1073/pnas.90.18.8683; KURODA S, 1995, J BIOL CHEM, V270, P2460, DOI 10.1074/jbc.270.6.2460; LANGECARTER CA, 1994, SCIENCE, V265, P1458, DOI 10.1126/science.8073291; LEEVERS SJ, 1994, NATURE, V369, P411, DOI 10.1038/369411a0; MCCORMICK F, 1994, CURR OPIN GENET DEV, V4, P71, DOI 10.1016/0959-437X(94)90093-0; MCGEADY P, 1995, J BIOL CHEM, V270, P26347, DOI 10.1074/jbc.270.44.26347; MIZUNO T, 1991, P NATL ACAD SCI USA, V88, P6442, DOI 10.1073/pnas.88.15.6442; MOODIE SA, 1994, MOL CELL BIOL, V14, P7153, DOI 10.1128/MCB.14.11.7153; MOODIE SA, 1993, SCIENCE, V260, P1658, DOI 10.1126/science.8503013; NAKANISHI H, 1993, J BIOL CHEM, V268, P13; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NISHIDA Y, 1988, EMBO J, V7, P775, DOI 10.1002/j.1460-2075.1988.tb02875.x; NISHIZUKA Y, 1992, SCIENCE, V258, P607, DOI 10.1126/science.1411571; Ohtsuka T, 1996, J BIOL CHEM, V271, P1258, DOI 10.1074/jbc.271.3.1258; PIZON V, 1988, ONCOGENE, V3, P201; SHIMIZU K, 1994, J BIOL CHEM, V269, P22917; STOKOE D, 1994, SCIENCE, V264, P1463, DOI 10.1126/science.7811320; TANAKA S, 1994, P NATL ACAD SCI USA, V91, P3443, DOI 10.1073/pnas.91.8.3443; TENHOEVE J, 1994, CANCER RES, V54, P2563; THOMAS SM, 1992, CELL, V68, P1031, DOI 10.1016/0092-8674(92)90075-N; VOJTEK AB, 1993, CELL, V74, P205, DOI 10.1016/0092-8674(93)90307-C; WARNE PH, 1993, NATURE, V364, P352, DOI 10.1038/364352a0; WOOD KW, 1992, CELL, V68, P1041, DOI 10.1016/0092-8674(92)90076-O; YAMAMORI B, 1995, J BIOL CHEM, V270, P11723, DOI 10.1074/jbc.270.20.11723; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	48	22	24	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14680	14683		10.1074/jbc.271.25.14680	http://dx.doi.org/10.1074/jbc.271.25.14680			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663012	hybrid			2022-12-27	WOS:A1996UT10600009
J	Newmyer, SL; deMontellano, PRO				Newmyer, SL; deMontellano, PRO			Rescue of the catalytic activity of an H42A mutant of horseradish peroxidase by exogenous imidazoles	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEME-LINKED IONIZATION; MECHANISM; EXCHANGE	His-42 plays a critical role in the H2O2-dependent catalytic turnover of horseradish peroxidase (HRP), This is clearly illustrated by the finding that an H42A mutation decreases the rate of Compound I formation by a factor of similar to 10(6). As shown here, the addition of 2-substituted imidazoles partially rescues both the rate of formation of Compound I and the peroxidase activity of the H42A mutant, a-Substituted imidazoles are the most effective because they do not coordinate to the iron, In contrast to native HRP, which exhibits a parabolic pH profile, and the H42A mutant, for which the activity increases linearly with increasing pH, the activity of the H42A mutant in the presence of 1,2-dimethylimidazole (pK(a) = 8.0) exhibits a sigmoidal pH dependence with a midpoint at pH 8.0 +/- 0.2. Similar results are obtained with 2-methylimidazole. These results establish that the free base forms of these imidazoles facilitate HRP turnover, The spectroscopic binding constants for 1,2-dimethylimidazole and 2-methylimidazole are K-d = 2.9 +/- 1.3 and 2.5 +/- 0.2 M, respectively. When cyanide is bound to the heme, the K-d for 1,2-dimethylimidazole is 0.17 M. This > 10-fold decrease in K-d may reflect hydrogen bonding of the protonated imidazole to the iron-coordinated cyanide, The log of the rate of Compound I formation exhibits a linear dependence on the molecular volume of the imidazoles used to rescue the activity, If the rates are corrected for differences in the size of the imidazoles, the log of the rates is linearly related to the pK(a) of the imidazoles. This Bronsted analysis predicts that similar to 60% of a positive charge develops on the imidazole in the transition state of Compound I formation, The results confirm the acid-base role of the distal histidine, demonstrate that exogenous histidines can function as surrogates for the missing histidine in the H42A mutant, and provide a transition state model of relevance to the formation of Compound I in the native protein.	UNIV CALIF SAN FRANCISCO,SCH PHARM,DEPT PHARMACEUT CHEM,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco				Newmyer, Sherri/0000-0003-1039-5416	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM032488] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM32488] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ALMUSTAFA J, 1994, BIOCHEMISTRY-US, V33, P2191, DOI 10.1021/bi00174a028; ATOR MA, 1987, J BIOL CHEM, V262, P14954; ATOR MA, 1987, J BIOL CHEM, V262, P1542; BEHERE DV, 1985, BIOCHIM BIOPHYS ACTA, V832, P319, DOI 10.1016/0167-4838(85)90265-1; DEMONTELLANO PRO, 1992, ANNU REV PHARMACOL, V32, P89, DOI 10.1146/annurev.pharmtox.32.1.89; DOLMAN D, 1975, CAN J BIOCHEM CELL B, V53, P495, DOI 10.1139/o75-069; FINZEL BC, 1984, J BIOL CHEM, V259, P3027; FRIDOVICH I, 1963, J BIOL CHEM, V238, P3921; GRIMMETT MR, 1980, ADV HETEROCYCLIC CHE, V27, P242; HASHIMOTO S, 1986, P NATL ACAD SCI USA, V83, P2417, DOI 10.1073/pnas.83.8.2417; Klebanoff S.J., 1991, PEROXIDASES CHEM BIO, P1; KUNISHIMA N, 1994, J MOL BIOL, V235, P331, DOI 10.1016/S0022-2836(05)80037-3; KUO CF, 1988, J BIOL CHEM, V263, P3811; MILLER RD, 1994, CHEM MATER, V6, P1023, DOI 10.1021/cm00043a026; NAGANO S, 1995, BIOCHEM BIOPH RES CO, V207, P417, DOI 10.1006/bbrc.1995.1204; NEWMYER SL, 1995, J BIOL CHEM, V270, P19430, DOI 10.1074/jbc.270.33.19430; PATTERSON WR, 1995, BIOCHEMISTRY-US, V34, P4331, DOI 10.1021/bi00013a023; POULOS TL, 1980, J BIOL CHEM, V255, P8199; POULOS TL, 1993, J BIOL CHEM, V268, P4429; REESE CB, 1993, J CHEM SOC P1, V19, P2291; SITTER AJ, 1985, J BIOL CHEM, V260, P7515; SUNDARAMOORTHY M, 1994, J BIOL CHEM, V269, P32759; TAKEUCHI Y, 1978, J ORG CHEM, V43, P3570, DOI 10.1021/jo00412a034; THANABAL V, 1988, J AM CHEM SOC, V110, P3027, DOI 10.1021/ja00218a005; UNO T, 1994, J AM CHEM SOC, V116, P4107, DOI 10.1021/ja00088a068; YAMADA H, 1974, ARCH BIOCHEM BIOPHYS, V165, P728, DOI 10.1016/0003-9861(74)90301-4	26	76	76	1	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14891	14896		10.1074/jbc.271.25.14891	http://dx.doi.org/10.1074/jbc.271.25.14891			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663036	hybrid			2022-12-27	WOS:A1996UT10600040
J	Sivaram, P; VanniReyes, T; Goldberg, IJ				Sivaram, P; VanniReyes, T; Goldberg, IJ			Endothelial cells synthesize and process apolipoprotein B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							LOW-DENSITY LIPOPROTEINS; MESSENGER-RNA; LIPASE BINDING; B-100; SECRETION; PLASMA; TRANSLOCATION; DEGRADATION; PROTEOLYSIS; EXPRESSION	We reported previously that a 116-kDa lipoprotein lipase (LPL)-binding protein from endothelial cells has sequence homology to the amino terminal region of apolipoprotein (ape) B. We now tested whether endothelial cells synthesize apoB mRNA and protein, Primers were designed to the human apoB cDNA sequence and reverse transcription polymerase chain reaction was performed using total RNA isolated from bovine and human endothelial cells, With primers to the 5' region of the apoB mRNA (amino-terminal region of apoB protein) expected size PCR products were generated from both bovine and human endothelial cells as well as from mouse liver RNA, which was used as a control, Primers designed to the 3' region of apoB mRNA generated PCR products from human endothelial cells and HepG2 cells but not from bovine or mouse cells, These data suggest that endothelial cells contain full-length apoB mRNA and that the 5' or the amino-terminal region of apoB is highly conserved from mouse to human, This was confirmed by direct sequencing of the mouse and bovine PCR products, To test whether apoB protein was pro produced, bovine endothelial cell proteins were metabolically labeled with [S-35]methionine/cysteine or [H-3]leucine and immunoprecipitated with anti human apoB antibodies, Using extracts from cells labeled for 1 h, monoclonal antibody 47, directed to the low density lipoprotein receptor binding region of apoB, precipitated a protein of approximate molecular mass 550,000, the size of full-length apoB. Immunoprecipitation of the 550-kDa protein was abolished in the presence of added unlabeled low density lipoprotein, From cells labeled for 16 h, a 11B-kDa protein was immunoprecipitated by polyclonal anti-apoB antibodies. This protein was partly released from cells by heparin treatment, Pulse-chase analysis showed that the 116-kDa fragment appeared at the same time as the full-length apoB began disappearing, The immunoprecipitated 116-kDa fragment also bound labeled LPL on ligand blot, further suggesting that it is an amino-terminal fragment of apoB. Incubation of endothelial cells with oleic acid (0.25 and 0.5 mM) did not significantly alter the production of either the full-length apoB or the 116-kDa fragment, These data show that endothelial cells synthesize apoB. The full-length apoB appears to be cleaved to form a 118-kDa fragment that can function as a LPL-binding protein.	COLUMBIA UNIV COLL PHYS & SURG,DEPT MED,DIV PREVENT MED & NUTR,NEW YORK,NY 10032	Columbia University					NHLBI NIH HHS [HL 21006 SCOR, HL 45095] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL045095, R37HL045095, P50HL021006] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BLUE ML, 1980, J BIOL CHEM, V255, P48; BOSTROM K, 1988, J BIOL CHEM, V263, P4434; BYRNE RE, 1989, J LIPID RES, V30, P109; CARDIN AD, 1984, J BIOL CHEM, V259, P8522; CHAN L, 1992, J BIOL CHEM, V267, P25621; CHEN GC, 1989, BIOCHEMISTRY-US, V28, P2477, DOI 10.1021/bi00432a019; CHENG CF, 1981, J BIOL CHEM, V256, P2893; CHOI SY, 1995, J BIOL CHEM, V270, P8081, DOI 10.1074/jbc.270.14.8081; CLADARAS C, 1986, EMBO J, V5, P3495, DOI 10.1002/j.1460-2075.1986.tb04675.x; DEMMER LA, 1986, P NATL ACAD SCI USA, V83, P8102, DOI 10.1073/pnas.83.21.8102; DIXON JL, 1991, J BIOL CHEM, V266, P5080; DIXONJL, 1993, J LIPID RES, V34, P34167; DU EZ, 1994, J BIOL CHEM, V269, P24169; EBERT DL, 1989, J LIPID RES, V29, P1501; GREEVE J, 1993, J LIPID RES, V34, P1367; LAW A, 1990, J LIPID RES, V31, P1109; LING P, 1996, IN PRESS J BIOL CHEM, V261; MATSUMOTO A, 1987, BIOCHEM BIOPH RES CO, V142, P92, DOI 10.1016/0006-291X(87)90455-4; MILINE R, 1989, J BIOL CHEM, V264, P19754; PULLINGER CR, 1989, J LIPID RES, V30, P1065; SAKATA N, 1993, J BIOL CHEM, V268, P22967; SALLACH SM, 1995, BBA-MOL CELL RES, V1265, P29, DOI 10.1016/0167-4889(95)00239-O; Sambrook J., 2002, MOL CLONING LAB MANU; SEGREST JP, 1994, ARTERIOSCLER THROMB, V14, P1674, DOI 10.1161/01.ATV.14.10.1674; SHIMADA K, 1981, J CLIN INVEST, V68, P995, DOI 10.1172/JCI110354; SIVARAM P, 1994, J BIOL CHEM, V269, P9409; SIVARAM P, 1992, J BIOL CHEM, V267, P16517; SIVARAM P, 1993, ANAL BIOCHEM, V214, P511, DOI 10.1006/abio.1993.1531; STINS MF, 1993, J LIPID RES, V34, P1853; THRIFT RN, 1992, P NATL ACAD SCI USA, V89, P9161, DOI 10.1073/pnas.89.19.9161; WEISGRABER KH, 1987, J BIOL CHEM, V262, P11097; WETTERAU JR, 1992, SCIENCE, V258, P899; WOLLE J, 1995, BIOCHEM BIOPH RES CO, V216, P906, DOI 10.1006/bbrc.1995.2707; YANG CY, 1989, ARTERIOSCLEROSIS, V9, P96, DOI 10.1161/01.ATV.9.1.96; YAO ZM, 1991, J BIOL CHEM, V266, P3300; YOUNG SG, 1986, ARTERIOSCLEROSIS, V6, P178, DOI 10.1161/01.ATV.6.2.178; YOUNG SG, 1990, CIRCULATION, V82, P1574, DOI 10.1161/01.CIR.82.5.1574	37	17	18	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15261	15266		10.1074/jbc.271.25.15261	http://dx.doi.org/10.1074/jbc.271.25.15261			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663087	hybrid			2022-12-27	WOS:A1996UT10600089
J	Abe, A; Shayman, JA; Radin, NS				Abe, A; Shayman, JA; Radin, NS			A novel enzyme that catalyzes the esterification of N-acetylsphingosine - Metabolism of C-2-ceramides	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN-KINASE-C; GLUCOSYLCERAMIDE; CERAMIDE; GROWTH	A unique transacylase that catalyzes esterification of a short chain ceramide, N-acetylsphingosine, was found in Madin-Darby canine kidney cell and mouse tissue homogenates. It esterified the hydroxyl group at the carbon-1 position of the ceramide. The enzyme has a pH optimum of 4.2 and a K-m of 9.4 mu M for N-acetylsphingosine at pH 4.5, The transacylase activity is independent of free fatty acid or acyl-CoA and instead uses the a-acyl group of phosphatidylethanolamine or phosphatidylcholine. The transacylase activity in the homogenate was present in the 100,000 x g supernatant, and the lipid extracted from the membranous fraction could function as a donor of the acyl group. When liposomes consisting of dioleoylphosphatidylcholine:1-palmitoyl-2-[C-14]arachidonoyl-phosphatidylethanolamine:sulfatide (70:0.2:30) were incubated with the supernatant and N-acetyl-sphingosine, the formation of free arachidonic acid and O-arachidonoyl-n-acetylsphingosine was observed. The ratio of the two products depended on the concentration of ceramide; only the free acid was formed if the truncated ceramide was absent. Both deacylase and transacylase activities were inhibited 50-60% by 20 mu M D-threo-1-phenyl-2-decanoylamino-3-morpholino-1-pro-panol, an inhibitor of several glucosphingolipid synthases. Neither activity was inhibited by nonadecyltetraenyl trifluoromethyl ketone, a potent inhibitor of cytosolic phospholipase A(2). N-Acetyldihydrosphingosine and N-octanoylsphingosine were only 55 and 10%, respectively, as effective as N-acetylsphingosine as acyl accepters, Oleoylsphingosine was only slightly reactive. An esterase that releases the truncated ceramide from its ester linkage appears to be membrane bound, Lecithin was less effective than phosphatidylethanolamine as an acyl donor in the transacylation. Madin-Darby canine kidney cell cultures treated with N-acetyl-[3-H-3]sphingosine formed radioactive polar sphingolipids, long chain ceramide, free sphingosine, and O-acyl-N-acetylsphingosine. This suggests that the deacylation and transacylation reactions observed in vitro occur in growing cells as well.	UNIV MICHIGAN,MED CTR,DEPT INTERNAL MED,DIV NEPHROL,ANN ARBOR,MI 48109	University of Michigan System; University of Michigan					NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK041487, P50DK039255] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK41487, DK39255] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ABE A, 1992, EUR J BIOCHEM, V210, P765, DOI 10.1111/j.1432-1033.1992.tb17479.x; ABE A, 1995, J LIPID RES, V36, P611; Abe A, 1996, BBA-LIPID LIPID MET, V1299, P333, DOI 10.1016/0005-2760(95)00217-0; CHATTERJEE S, IN PRESS GLYCOCONJUG; DBAIBO GS, 1993, J BIOL CHEM, V268, P17762; DENNIS EA, 1994, J BIOL CHEM, V269, P13057; DEVANE WA, 1992, SCIENCE, V258, P1946, DOI 10.1126/science.1470919; GAVER RC, 1966, J AM CHEM SOC, V88, P3643, DOI 10.1021/ja00967a032; HANNUN YA, 1994, J BIOL CHEM, V269, P3125; INOKUCHI J, 1995, J BIOCHEM-TOKYO, V117, P766, DOI 10.1093/oxfordjournals.jbchem.a124774; INOKUCHI JI, 1987, J LIPID RES, V28, P565; KISS Z, 1995, FEBS LETT, V365, P146, DOI 10.1016/0014-5793(95)00445-F; KOLESNICK R, 1994, CELL, V77, P325, DOI 10.1016/0092-8674(94)90147-3; KUDO I, 1993, BIOCHIM BIOPHYS ACTA, V1170, P217, DOI 10.1016/0005-2760(93)90003-R; Lee TC, 1996, J BIOL CHEM, V271, P209, DOI 10.1074/jbc.271.1.209; LOWRY OH, 1951, J BIOL CHEM, V193, P265; MACDONALD JIS, 1991, BIOCHIM BIOPHYS ACTA, V1084, P105, DOI 10.1016/0005-2760(91)90209-Z; OKABE H, 1977, J BIOL CHEM, V252, P7038; RADIN NS, 1991, ENZYME, V45, P67, DOI 10.1159/000468867; RANI CSS, 1995, J BIOL CHEM, V270, P2859, DOI 10.1074/jbc.270.6.2859; REYNOLDS LJ, 1993, BIOCHIM BIOPHYS ACTA, V1167, P272, DOI 10.1016/0005-2760(93)90229-3; RIENDEAU D, 1994, J BIOL CHEM, V269, P15619; SHAYMAN JA, 1991, J BIOL CHEM, V266, P22968; Skipski V P, 1975, Methods Enzymol, V35, P396, DOI 10.1016/0076-6879(75)35178-1; SNYDER F, 1992, PROG LIPID RES, V31, P65, DOI 10.1016/0163-7827(92)90016-C; STREET IP, 1993, BIOCHEMISTRY-US, V32, P5935, DOI 10.1021/bi00074a003; YAVIN E, 1969, BIOCHEMISTRY-US, V8, P1692, DOI 10.1021/bi00832a052	27	83	89	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14383	14389		10.1074/jbc.271.24.14383	http://dx.doi.org/10.1074/jbc.271.24.14383			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662981	hybrid			2022-12-27	WOS:A1996UQ66000067
J	Verbsky, JW; Bach, EA; Fang, YF; Yang, LP; Randolph, DA; Fields, LE				Verbsky, JW; Bach, EA; Fang, YF; Yang, LP; Randolph, DA; Fields, LE			Expression of Janus kinase 3 in human endothelial and other non-lymphoid and non-myeloid cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERLEUKIN-4	Members of the Janus kinase (Jak) family of protein tyrosine kinases have recently been implicated in the proximal signal transduction events of cytokine receptors, Jak3, a newly discovered member of this family, is believed to be normally limited in its expression to cells of the lymphoid and myeloid lineages, Herein we show that Jak3 is expressed in primary human vascular cells, as well as other non-lymphoid and non-myeloid cell types. Reverse transcriptase-polymerase chain reaction and Northern blot analysis revealed that Jak3 mRNA was expressed at low levels in human umbilical vein endothelial cells (HUVEC), human aortic smooth muscle cells (HASMC), A549 (human lung carcinoma), and DLD-1 (human colon adenocarcinoma) cells. Higher basal levels of Jak3 mRNA were detected in HMEC-1 (human microvascular cell line) and HepG2 (human hepatocellular carcinoma) cells. Jak3 mRNA expression was induced in HUVEC, HMEC-1, and HASMC by treatment with interleukin-1 beta, tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharide. Jak3 protein was detectable at low levels in untreated HMEC-1, and these levels increased significantly with cytokine treatment. Furthermore, Jak3 protein was phosphorylated upon treatment of these cells with interleukin-4. This work shows that Jak3 is expressed or inducible in human vascular endothelial, vascular smooth muscle, and other nonlymphoid and non-myeloid cells, suggesting a broader role for Jak3 in the cytokine signal transduction of these cells.	WASHINGTON UNIV, SCH MED, DEPT MED, ST LOUIS, MO 63110 USA; WASHINGTON UNIV, SCH MED, DEPT PATHOL, ST LOUIS, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL)				Bach, Erika/0000-0002-5997-4489				CANCE WG, 1993, INT J CANCER, V54, P571, DOI 10.1002/ijc.2910540409; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; CYBULSKY MI, 1991, SCIENCE, V251, P788, DOI 10.1126/science.1990440; DARNELL JE, 1994, SCIENCE, V264, P1415, DOI 10.1126/science.8197455; FIRMBACHKRAFT I, 1990, ONCOGENE, V5, P1329; HERBERT JM, 1993, FEBS LETT, V328, P268, DOI 10.1016/0014-5793(93)80941-M; HOWELLS G, 1991, EUR J IMMUNOL, V21, P97, DOI 10.1002/eji.1830210115; IADEMARCO MF, 1995, J CLIN INVEST, V95, P264, DOI 10.1172/JCI117650; IHLE JN, 1995, ANNU REV IMMUNOL, V13, P369, DOI 10.1146/annurev.iy.13.040195.002101; KARNITZ LM, 1995, CURR OPIN IMMUNOL, V7, P320, DOI 10.1016/0952-7915(95)80105-7; KAWAMURA M, 1994, P NATL ACAD SCI USA, V91, P6374, DOI 10.1073/pnas.91.14.6374; KISHIMOTO T, 1994, CELL, V76, P253, DOI 10.1016/0092-8674(94)90333-6; LAI KS, 1995, J BIOL CHEM, V270, P25028, DOI 10.1074/jbc.270.42.25028; LOWENTHAL JW, 1988, J IMMUNOL, V140, P456; LUEDERS KK, 1994, BIOTECHNIQUES, V16, P66; MALABARBA MG, 1995, J BIOL CHEM, V270, P9630, DOI 10.1074/jbc.270.16.9630; MARFAINGKOKA A, 1995, J IMMUNOL, V154, P1870; MIYAZAKI T, 1994, SCIENCE, V266, P1045, DOI 10.1126/science.7973659; MUSSO T, 1995, J EXP MED, V181, P1425, DOI 10.1084/jem.181.4.1425; POBER JS, 1990, PHYSIOL REV, V70, P427, DOI 10.1152/physrev.1990.70.2.427; PURI RK, 1993, CANCER INVEST, V11, P473, DOI 10.3109/07357909309018879; ROLLINS BJ, 1991, AM J PATHOL, V138, P1315; RUSSELL SM, 1994, SCIENCE, V266, P1042, DOI 10.1126/science.7973658; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; TAGA T, 1995, CURR OPIN IMMUNOL, V7, P17, DOI 10.1016/0952-7915(95)80024-7; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; TOI M, 1991, BIOCHEM BIOPH RES CO, V174, P1287, DOI 10.1016/0006-291X(91)91561-P; WILKS AF, 1991, MOL CELL BIOL, V11, P2057, DOI 10.1128/MCB.11.4.2057; WITTHUHN BA, 1994, NATURE, V370, P153, DOI 10.1038/370153a0	30	53	61	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13976	13980		10.1074/jbc.271.24.13976	http://dx.doi.org/10.1074/jbc.271.24.13976			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662778	hybrid			2022-12-27	WOS:A1996UQ66000010
J	Geller, D; Taglicht, D; Edgar, R; Tam, A; Pines, O; Michaelis, S; Bibi, E				Geller, D; Taglicht, D; Edgar, R; Tam, A; Pines, O; Michaelis, S; Bibi, E			Comparative topology studies in Saccharomyces cerevisiae and in Escherichia coli - The N-terminal half of the yeast ABC protein Ste6	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MEMBRANE-PROTEIN; P-GLYCOPROTEIN; ENDOPLASMIC-RETICULUM; MULTIDRUG RESISTANCE; ALKALINE-PHOSPHATASE; STRUCTURAL MODEL; CYSTIC-FIBROSIS; EXPORT SIGNALS; SEQUENCE; GENE	Gene fusions have provided a strategy for determining the topology of polytopic membrane proteins in Escherichia coli. To valuate whether this highly effective approach is applicable to heterologously expressed eukaryotic integral membrane proteins, we have carried out a comparative topological study of the eukaryotic membrane protein Ste6 both in bacteria and in yeast, Ste6, is an ATP binding cassette (ABC) protein essential for export of the a-factor mating pheromone in Saccharomyces cerevisiae, The topogenic reporters, invertase in S. cerevisiae and alkaline phosphatase in E. coli, were fused to Ste6 at identical sites and the fusions were expressed in yeast and bacteria, respectively. The results obtained in both systems are similar, although more definitive in E. coli, and support the predicted six-transmembrane spans organization of the N-terminal half of Ste6, Thus, the topological determinants for membrane insertion of polytopic proteins in prokaryotic and in eukaryotic systems appear to be highly similar, In this study we also demonstrate that Ste6 does not contain a cleaved signal sequence.	WEIZMANN INST SCI, DEPT BIOCHEM, IL-76100 REHOVOT, ISRAEL; JOHNS HOPKINS UNIV, SCH MED, DEPT CELL BIOL & ANAT, BALTIMORE, MD 21205 USA; HEBREW UNIV JERUSALEM, HADASSAH MED SCH, DEPT MOLEC BIOL, IL-91010 JERUSALEM, ISRAEL	Weizmann Institute of Science; Johns Hopkins University; Hebrew University of Jerusalem			pines, ophry/C-4086-2011	pines, ophry/0000-0001-7126-2575; Bibi, Eitan/0000-0003-3700-2707	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [P50DK048977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM051508] Funding Source: NIH RePORTER; NIDDK NIH HHS [P50 DK48977] Funding Source: Medline; NIGMS NIH HHS [GM51508] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSSON H, 1994, EMBO J, V13, P2267, DOI 10.1002/j.1460-2075.1994.tb06508.x; BANKAITIS VA, 1986, P NATL ACAD SCI USA, V83, P9075, DOI 10.1073/pnas.83.23.9075; BEJA O, 1995, J BIOL CHEM, V270, P12351; BERKOWER C, 1991, EMBO J, V10, P3777, DOI 10.1002/j.1460-2075.1991.tb04947.x; BERKOWER C, 1994, MOL BIOL CELL, V5, P1185, DOI 10.1091/mbc.5.11.1185; BERKOWER C, 1995, THESIS J HOPKINS U B; BIBI E, 1991, P NATL ACAD SCI USA, V88, P7271, DOI 10.1073/pnas.88.16.7271; BIBI E, 1994, J BIOL CHEM, V269, P19910; BIBI E, 1990, P NATL ACAD SCI USA, V87, P4325, DOI 10.1073/pnas.87.11.4325; BRICKMAN E, 1975, J MOL BIOL, V96, P307, DOI 10.1016/0022-2836(75)90350-2; CALAMIA J, 1992, J MOL BIOL, V224, P539, DOI 10.1016/0022-2836(92)90542-R; CHANG XB, 1994, J BIOL CHEM, V269, P18572; DESHAIES RJ, 1990, MOL CELL BIOL, V10, P6024, DOI 10.1128/MCB.10.11.6024; FELMLEE T, 1985, J BACTERIOL, V163, P94, DOI 10.1128/JB.163.1.94-105.1985; Goldstein A, 1975, Methods Enzymol, V42, P504; GOTTESMAN MM, 1993, ANNU REV BIOCHEM, V62, P385, DOI 10.1146/annurev.bi.62.070193.002125; GREEN N, 1992, MOL CELL BIOL, V12, P276, DOI 10.1128/MCB.12.1.276; Gros P, 1993, Int Rev Cytol, V137C, P169; HENN DK, 1995, P NATL ACAD SCI USA, V92, P7425, DOI 10.1073/pnas.92.16.7425; HIGGINS CF, 1992, ANNU REV CELL BIOL, V8, P67, DOI 10.1146/annurev.cb.08.110192.000435; HIGH S, 1992, MEMBRANE BIOGENESIS, P105; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; JOHNSON LM, 1987, CELL, V48, P875, DOI 10.1016/0092-8674(87)90084-5; KAST C, 1995, BIOCHEMISTRY-US, V34, P4402, DOI 10.1021/bi00013a032; KERPPOLA RE, 1992, J BIOL CHEM, V267, P2329; KOLLING R, 1994, FEBS LETT, V351, P155, DOI 10.1016/0014-5793(94)00825-6; KUCHLER K, 1989, EMBO J, V8, P3973, DOI 10.1002/j.1460-2075.1989.tb08580.x; KYTE J, 1982, J MOL BIOL, V157, P105, DOI 10.1016/0022-2836(82)90515-0; LACATENA RM, 1994, P NATL ACAD SCI USA, V91, P10521, DOI 10.1073/pnas.91.22.10521; LOO TW, 1995, J BIOL CHEM, V270, P843, DOI 10.1074/jbc.270.2.843; MANAVALAN P, 1993, J PROTEIN CHEM, V12, P279, DOI 10.1007/BF01028190; MANOIL C, 1985, P NATL ACAD SCI USA, V82, P8129, DOI 10.1073/pnas.82.23.8129; MANOIL C, 1991, METHOD CELL BIOL, V34, P61; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; MCGRATH JP, 1989, NATURE, V340, P400, DOI 10.1038/340400a0; Michaelis S, 1993, Semin Cell Biol, V4, P17, DOI 10.1006/scel.1993.1003; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P84, DOI 10.1073/pnas.88.1.84; MIMURA CS, 1991, P NATL ACAD SCI USA, V88, P88; NIKAIDO H, 1994, FEBS LETT, V346, P55, DOI 10.1016/0014-5793(94)00315-7; RIORDAN JR, 1989, SCIENCE, V245, P1066; SCHAUER I, 1985, J CELL BIOL, V100, P1664, DOI 10.1083/jcb.100.5.1664; SENGSTAG C, 1990, MOL CELL BIOL, V10, P672, DOI 10.1128/MCB.10.2.672; SHONBERGER O, 1996, IN PRESS P NATL ACAD; SIPOS L, 1993, EUR J BIOCHEM, V213, P1333, DOI 10.1111/j.1432-1033.1993.tb17885.x; SKACH WR, 1993, J BIOL CHEM, V268, P6903; TABOR S, 1985, P NATL ACAD SCI USA, V82, P1074, DOI 10.1073/pnas.82.4.1074; Townsend A, 1993, Semin Cell Biol, V4, P53, DOI 10.1006/scel.1993.1007; VONHEIJNE G, 1992, J MOL BIOL, V225, P487, DOI 10.1016/0022-2836(92)90934-C; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; WANG RC, 1991, J MOL BIOL, V217, P441, DOI 10.1016/0022-2836(91)90748-U; ZHANG JT, 1991, J BIOL CHEM, V266, P18224; ZIEGLER FD, 1988, J BIOL CHEM, V263, P6986	52	21	22	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13746	13753		10.1074/jbc.271.23.13746	http://dx.doi.org/10.1074/jbc.271.23.13746			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662764	hybrid			2022-12-27	WOS:A1996UP38500067
J	Liu, HY; DeWaard, M; Scott, VES; Gurnett, CA; Lennon, VA; Campbell, KP				Liu, HY; DeWaard, M; Scott, VES; Gurnett, CA; Lennon, VA; Campbell, KP			Identification of three subunits of the high affinity omega-conotoxin MVIIC-sensitive Ca2+ channel	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							DEPENDENT CALCIUM CHANNELS; BETA-SUBUNIT; FUNCTIONAL EXPRESSION; MAMMALIAN CNS; BRAIN; CLONING; BINDING; ALPHA-2-SUBUNIT; RECEPTOR; NEURONS	N-, P- and Q-type voltage-dependent Ca2+ channels control neurotransmitter release in the nervous system and are blocked by omega-conotoxin MVIIC. In this study, both a high affinity and a low affinity binding site for omega-conotoxin MVIIC were detected in rabbit brain. The low affinity binding site is shown to be present on the N-type Ca2+ channel. Using optimized conditions for specific labeling of the high affinity omega-conotoxin MVIIC receptor and a panel of subunit specific antibodies, the molecular structure of the high affinity receptor was investigated. We demonstrate for the first time that this receptor is composed of at least alpha(1A), alpha(2) delta, and any one of the four brain beta subunits. Such association of different beta subunits with alpha(1A) and alpha(2) delta components may produce Ca2+ channels with distinct functional properties, such as P- and Q-type.	UNIV IOWA,COLL MED,HOWARD HUGHES MED INST,DEPT PHYSIOL & BIOPHYS,IOWA CITY,IA 52242; UNIV IOWA,COLL MED,PROGRAM NEUROSCI,IOWA CITY,IA 52242; MAYO CLIN & MAYO FDN,DEPT IMMUNOL,NEUROIMMUNOL LAB,ROCHESTER,MN 55905; MAYO CLIN & MAYO FDN,DEPT NEUROL,NEUROIMMUNOL LAB,ROCHESTER,MN 55905	Howard Hughes Medical Institute; University of Iowa; University of Iowa; Mayo Clinic; Mayo Clinic			Tuluc, Petronel/C-2527-2011; De Waard, Michel/G-7406-2014	De Waard, Michel/0000-0002-2782-9615; Gurnett, Christina/0000-0001-9129-315X; Campbell, Kevin/0000-0003-2066-5889	NCI NIH HHS [CA-37343] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA037343] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BRUST PF, 1993, NEUROPHARMACOLOGY, V32, P1089, DOI 10.1016/0028-3908(93)90004-M; CASTELLANO A, 1993, J BIOL CHEM, V268, P12359; CASTELLANO A, 1993, J BIOL CHEM, V268, P3450; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; CATTERALL WA, 1992, TRENDS PHARMACOL SCI, V13, P256, DOI 10.1016/0165-6147(92)90079-L; COLLIN T, 1993, CIRC RES, V72, P1337, DOI 10.1161/01.RES.72.6.1337; DEWAARD M, 1995, J PHYSIOL-LONDON, V485, P619, DOI 10.1113/jphysiol.1995.sp020757; DEWAARD M, 1995, J BIOL CHEM, V270, P12056, DOI 10.1074/jbc.270.20.12056; ELLIS SB, 1988, SCIENCE, V241, P1661, DOI 10.1126/science.2458626; FELDMAN HA, 1972, ANAL BIOCHEM, V48, P317, DOI 10.1016/0003-2697(72)90084-X; GAUR S, 1994, NEUROPHARMACOLOGY, V33, P1211, DOI 10.1016/S0028-3908(05)80012-7; GURNETT CA, 1995, J BIOL CHEM, V270, P9035, DOI 10.1074/jbc.270.16.9035; HILLYARD DR, 1992, NEURON, V9, P69, DOI 10.1016/0896-6273(92)90221-X; HULLIN R, 1992, EMBO J, V11, P885, DOI 10.1002/j.1460-2075.1992.tb05126.x; JAY SD, 1991, J BIOL CHEM, V266, P3287; KRISTIPATI R, 1994, MOL CELL NEUROSCI, V5, P219, DOI 10.1006/mcne.1994.1026; KRIZANOVA O, 1993, CIRCULATION, V87, P44; KRYSTAL G, 1987, ANAL BIOCHEM, V167, P86, DOI 10.1016/0003-2697(87)90136-9; Lennon V. A., 1995, Society for Neuroscience Abstracts, V21, P1283; LENNON VA, 1995, NEW ENGL J MED, V332, P1467, DOI 10.1056/NEJM199506013322203; MAGNELLI Y, 1995, EUR J PHYSL, V429, P762; MARTINMOUTOT N, 1995, FEBS LETT, V366, P21, DOI 10.1016/0014-5793(95)00467-N; MINTZ IM, 1995, NEURON, V15, P675, DOI 10.1016/0896-6273(95)90155-8; MINTZ IM, 1992, NEURON, V9, P85, DOI 10.1016/0896-6273(92)90223-Z; MINTZ IM, 1992, NATURE, V355, P827, DOI 10.1038/355827a0; MORI Y, 1991, NATURE, V350, P398, DOI 10.1038/350398a0; OLIVERA BM, 1994, ANNU REV BIOCHEM, V63, P823, DOI 10.1146/annurev.bi.63.070194.004135; PETERSON GL, 1977, ANAL BIOCHEM, V83, P346, DOI 10.1016/0003-2697(77)90043-4; PRAGNELL M, 1994, NATURE, V368, P67, DOI 10.1038/368067a0; RANDALL A, 1995, J NEUROSCI, V15, P2995; SAKAMOTO J, 1991, J BIOL CHEM, V266, P18914; Scott VES, 1996, J BIOL CHEM, V271, P3207, DOI 10.1074/jbc.271.6.3207; SNUTCH TP, 1990, P NATL ACAD SCI USA, V87, P3391, DOI 10.1073/pnas.87.9.3391; SNUTCH TP, 1991, NEURON, V7, P45, DOI 10.1016/0896-6273(91)90073-9; STEA A, 1994, P NATL ACAD SCI USA, V91, P10576, DOI 10.1073/pnas.91.22.10576; SUGIURA Y, 1995, J NEUROCYTOL, V24, P15, DOI 10.1007/BF01370157; TURNER TJ, 1995, NEUROPHARMACOLOGY, V34, P1469, DOI 10.1016/0028-3908(95)00133-Q; WITCHER DR, 1993, SCIENCE, V261, P486, DOI 10.1126/science.8392754; WITCHER DR, 1993, NEUROPHARMACOLOGY, V32, P1127, DOI 10.1016/0028-3908(93)90007-P; WITCHER DR, 1995, J BIOL CHEM, V270, P18088, DOI 10.1074/jbc.270.30.18088; ZHANG JF, 1993, NEUROPHARMACOLOGY, V32, P1075, DOI 10.1016/0028-3908(93)90003-L	41	129	131	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13804	13810		10.1074/jbc.271.23.13804	http://dx.doi.org/10.1074/jbc.271.23.13804			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662888	hybrid			2022-12-27	WOS:A1996UP38500075
J	Vaziri, C; Faller, DV				Vaziri, C; Faller, DV			Down-regulation of platelet-derived growth factor receptor expression during terminal differentiation of 3T3-L1 pre-adipocyte fibroblasts	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PDGF ALPHA-RECEPTORS; TUMOR PROMOTERS; RESPONSIVENESS INVITRO; CELL-DIFFERENTIATION; SIGNAL TRANSDUCTION; HORMONE RECEPTORS; C-MYC; TRANSFORMATION; PROLIFERATION; CONVERSION	The transcription and expression of platelet-derived growth factor (PDGF) receptors (PDGFRS) is down-regulated as a consequence of entry into the replicative cell cycle (Vaziri, C., and Faller, D. V. (1995) Mol. Cell. Biol, 15, 1244-1253). In this study, we have investigated the expression of PDGFRs during terminal differentiation, a process in which cells exit from the cell cycle, When treated with appropriate hormonal stimuli, 3T3-L1 fibroblasts initiate a differentiation program resulting in conversion to lipid-accumulating, adipocyte-like cells. Pre-adipocytes express amounts of PDGF alpha R and PDGF beta R mRNA and protein that are similar to levels expressed in other murine 3T3 fibroblasts. In contrast, the expression of both alpha and beta receptor transcripts is greatly reduced in differentiated 3T3-L1 cells, The loss of PDGFR mRNA following induction of differentiation precedes morphological conversion as well as the induction of many adipocyte-specific genes, The amounts of cell surface PDGFR protein diminish in parallel with the mRNA levels during differentiation, as shown by Western blotting and PDGF-binding assays. The reduced expression of PDGFRs does not reflect a general down-regulation of growth factor receptors, as expression of the type 1 FGFR is unaffected by terminal differentiation. The PDGF beta R promoter drives strong expression of a luciferase reporter gene in pre-adipocytes, but not in differentiated cells, indicating that the decrease in PDGFR expression following induction of differentiation is a transcriptionally regulated event. Decreased PDGFR expression in differentiated cells is associated with impaired biological responsiveness to PDGF, as shown by reduced activation of mitogen-activated protein-kinase following PDGF stimulation, and decreased chemotactic responsiveness to PDGF. Our data suggest that PDGFR dawn-regulation is an important mechanism for reducing PDGF-responsiveness in terminally differentiated 3T3-L1 cells.	BOSTON UNIV,SCH MED,DEPT MED,CANC RES CTR,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT MICROBIOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PEDIAT,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT PATHOL,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT LAB MED,BOSTON,MA 02118	Boston University; Boston University; Boston University; Boston University; Boston University; Boston University					NATIONAL CANCER INSTITUTE [R01CA050459] Funding Source: NIH RePORTER; NCI NIH HHS [CA50459] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARMELIN HA, 1984, NATURE, V310, P655, DOI 10.1038/310655a0; CLAESSONWELSH L, 1994, J BIOL CHEM, V269, P32023; DIAMOND L, 1977, NATURE, V269, P247, DOI 10.1038/269247a0; DROZDOFF V, 1991, J BIOL CHEM, V266, P17165; ERIKSSON A, 1992, EMBO J, V11, P543, DOI 10.1002/j.1460-2075.1992.tb05085.x; FREYTAG SO, 1992, SCIENCE, V256, P379, DOI 10.1126/science.256.5055.379; FREYTAG SO, 1988, MOL CELL BIOL, V8, P1614, DOI 10.1128/MCB.8.4.1614; GREEN H, 1974, CELL, V1, P113, DOI 10.1016/0092-8674(74)90126-3; GROTENDORST GR, 1984, CELL, V36, P279, DOI 10.1016/0092-8674(84)90221-6; HALEVY O, 1995, SCIENCE, V267, P1018, DOI 10.1126/science.7863327; HAYASHI I, 1981, P NATL ACAD SCI-BIOL, V78, P3969, DOI 10.1073/pnas.78.6.3969; HELDIN CH, 1992, EMBO J, V11, P4251, DOI 10.1002/j.1460-2075.1992.tb05523.x; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HOLYCROSS BJ, 1992, CIRC RES, V71, P1525, DOI 10.1161/01.RES.71.6.1525; JIN P, 1990, J CELL BIOL, V110, P1665, DOI 10.1083/jcb.110.5.1665; KAMB A, 1994, SCIENCE, V264, P436, DOI 10.1126/science.8153634; LAZAROVICI P, 1987, J CELL BIOL, V104, P1611, DOI 10.1083/jcb.104.6.1611; MICHIELI P, 1994, CANCER RES, V54, P3391; PARDEE AB, 1989, SCIENCE, V246, P603, DOI 10.1126/science.2683075; PARKER SB, 1995, SCIENCE, V267, P1024, DOI 10.1126/science.7863329; PAWSON T, 1995, NATURE, V373, P573, DOI 10.1038/373573a0; ROSEN OM, 1978, J BIOL CHEM, V253, P7579; ROSS R, 1986, CELL, V46, P155, DOI 10.1016/0092-8674(86)90733-6; RUBIN CS, 1978, J BIOL CHEM, V253, P7570; RUSSELL TR, 1976, P NATL ACAD SCI USA, V73, P4516, DOI 10.1073/pnas.73.12.4516; SCHER CD, 1982, J CELL PHYSIOL, V113, P211, DOI 10.1002/jcp.1041130205; SEPPA H, 1982, J CELL BIOL, V92, P584, DOI 10.1083/jcb.92.2.584; SHIMIZU Y, 1983, CANCER RES, V43, P4974; STILES CD, 1983, CELL, V33, P653, DOI 10.1016/0092-8674(83)90008-9; TONTONOZ P, 1994, CELL, V79, P1147, DOI 10.1016/0092-8674(94)90006-X; VAZIRI C, 1995, MOL CELL BIOL, V15, P1244; WESTERMARK B, 1991, CANCER RES, V51, P5087; WILLIAMS LT, 1989, SCIENCE, V243, P1564, DOI 10.1126/science.2538922; YABLONKAREUVENI Z, 1990, J CELL BIOL, V111, P1623, DOI 10.1083/jcb.111.4.1623; YEH WC, 1995, GENE DEV, V9, P168, DOI 10.1101/gad.9.2.168	35	40	42	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13642	13648		10.1074/jbc.271.23.13642	http://dx.doi.org/10.1074/jbc.271.23.13642			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662875	hybrid			2022-12-27	WOS:A1996UP38500052
J	Yamamoto, H; Ueno, H; Ooshima, A; Takeshita, A				Yamamoto, H; Ueno, H; Ooshima, A; Takeshita, A			Adenovirus-mediated transfer of a truncated transforming growth factor-beta (TGF-beta) type II receptor completely and specifically abolishes diverse signaling by TGF-beta in vascular wall cells in primary culture	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							KINASE; EXPRESSION; INHIBITION; CLONING; FACTOR-BETA-1; TRANSDUCTION; COMPLEX; REVEALS; MUTANT; FORM	We constructed an adenoviral vector expressing a mutated human type II transforming growth factor-beta (TGF-beta) receptor that was truncated of its kinase domain (AdexCAT beta TR) and examined whether this truncated receptor could abolish signaling by TGF-beta using arterial endothelial cells and smooth muscle cells, as well as a lung epithelial cell line (Mv1Lu). Infection of cells with AdexCAT beta TR induced expression of the truncated receptor, the amount of which would be excessive compared with those of both full length type I and type II receptors, as assessed by levels of their mRNAs. The antiproliferative effect of TGF-beta was completely eliminated in both endothelial cells and Mv1Lu that were infected with AdexCAT beta TR, The transcriptional activation by TGF-beta of plasminogen activator inhibitor-1 and fibronectin was entirely suppressed. Abrogation of the TGF-beta-enhanced production of type I collagen in infected smooth muscle cells was confirmed by immunocytostaining and by [C-14]proline incorporation in a quantitative manner, Mitogenic response to other growth factors remained unaffected in infected cells, Our data demonstrated that the adenovirus-mediated transfer of a truncated type II TGF-beta receptor completely and specifically abolishes the diverse effects of TGF-beta as a dominant-negative mutation, supporting the hypothesis that both the type I and type II receptors are required for all signaling by TGF-beta. This method may facilitate the clarification of the role of TGF-beta both in vitro and in vivo.	KYUSHU UNIV,SCH MED,DEPT CARDIOL,RES INST ANGIOCARDIOL,MOL CARDIOL UNIT,FUKUOKA 81282,JAPAN; WAKAYAMA MED COLL,DEPT PATHOL,WAKAYAMA 640,JAPAN	Kyushu University; Wakayama Medical University								AMAYA E, 1991, CELL, V66, P257, DOI 10.1016/0092-8674(91)90616-7; ARRICK BA, 1992, J CELL BIOL, V118, P715, DOI 10.1083/jcb.118.3.715; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; BASSING CH, 1994, SCIENCE, V263, P87, DOI 10.1126/science.8272871; BORDER WA, 1994, NEW ENGL J MED, V331, P1286; BRAND T, 1993, J BIOL CHEM, V268, P11500; BURTON K, 1956, BIOCHEM J, V62, P315, DOI 10.1042/bj0620315; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CARCAMO J, 1995, MOL CELL BIOL, V15, P1573; CHAMLEYCAMPBELL JH, 1981, J CELL BIOL, V89, P379, DOI 10.1083/jcb.89.2.379; CHEN RH, 1994, J BIOL CHEM, V269, P22868; CHEN RH, 1993, SCIENCE, V260, P1335, DOI 10.1126/science.8388126; COTTAPEREIRA G, 1980, J CELL PHYSL, V102, P83; EBNER R, 1993, SCIENCE, V260, P1344, DOI 10.1126/science.8388127; ELLIS L, 1986, CELL, V45, P721, DOI 10.1016/0092-8674(86)90786-5; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GEISER AG, 1992, J BIOL CHEM, V267, P2588; GRAHAM FL, 1977, J GEN VIROL, V36, P59, DOI 10.1099/0022-1317-36-1-59; HENIS YI, 1994, J CELL BIOL, V126, P139, DOI 10.1083/jcb.126.1.139; KASHLES O, 1991, MOL CELL BIOL, V11, P1454, DOI 10.1128/MCB.11.3.1454; KUMAGAI J, 1994, J ANAT, V185, P279; LAIHO M, 1991, J BIOL CHEM, V266, P9108; LETTERIO JJ, 1994, SCIENCE, V264, P1936, DOI 10.1126/science.8009224; LI JJ, 1995, CARDIOVASC RES, V30, P97, DOI 10.1016/S0008-6363(95)00005-4; LI JJ, 1995, GENE THER, V2, P351; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; MAEGAWA H, 1988, J BIOL CHEM, V263, P12629; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; Massague Joan, 1994, Trends in Cell Biology, V4, P172, DOI 10.1016/0962-8924(94)90202-X; MILLAUER B, 1994, NATURE, V367, P576, DOI 10.1038/367576a0; MIMA T, 1995, P NATL ACAD SCI USA, V92, P467, DOI 10.1073/pnas.92.2.467; Miyake S, 1996, P NATL ACAD SCI USA, V93, P1320, DOI 10.1073/pnas.93.3.1320; NIWA H, 1991, GENE, V108, P193, DOI 10.1016/0378-1119(91)90434-D; OKADOME T, 1994, J BIOL CHEM, V269, P30753; PETERKOFSKY B, 1971, BIOCHEMISTRY-US, V10, P988, DOI 10.1021/bi00782a009; PETERS K, 1994, EMBO J, V13, P3296, DOI 10.1002/j.1460-2075.1994.tb06631.x; ROBERTS AB, 1990, TRANSFORMING GROWTH, P421; SHULL MM, 1992, NATURE, V359, P693, DOI 10.1038/359693a0; SPORN MB, 1992, J CELL BIOL, V119, P1017, DOI 10.1083/jcb.119.5.1017; TENDIJKE P, 1994, SCIENCE, V264, P101, DOI 10.1126/science.8140412; UENO H, 1993, J BIOL CHEM, V268, P22814; UENO H, 1995, ARTERIOSCL THROM VAS, V15, P2246, DOI 10.1161/01.ATV.15.12.2246; UENO H, 1991, SCIENCE, V252, P844, DOI 10.1126/science.1851331; UENO H, 1992, J BIOL CHEM, V267, P1470; VIVIEN D, 1995, J BIOL CHEM, V270, P7134, DOI 10.1074/jbc.270.13.7134; WERNER S, 1993, EMBO J, V12, P2635, DOI 10.1002/j.1460-2075.1993.tb05924.x; WIESER R, 1993, MOL CELL BIOL, V13, P7239, DOI 10.1128/MCB.13.12.7239; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	49	82	91	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16253	16259		10.1074/jbc.271.27.16253	http://dx.doi.org/10.1074/jbc.271.27.16253			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663151	hybrid			2022-12-27	WOS:A1996UW35200058
J	deCrouyChanel, A; Kohiyama, M; Richarme, G				deCrouyChanel, A; Kohiyama, M; Richarme, G			Specificity of DnaK for arginine/lysine and effect of DnaJ on the amino acid specificity of DnaK	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEAT-SHOCK PROTEINS; ESCHERICHIA-COLI; PEPTIDE-BINDING; REPLICATION PROTEIN; CHAPERONE; GRPE; PURIFICATION; AFFINITY; BIP	Molecular chaperones form a class of proteins that bind selectively to nascent, unfolded, misfolded, or aggregated polypeptides and are involved in protein folding, protein targeting to membranes, and protein renaturation after stress, Chaperones70, including the DnaK chaperone of Escherichia coli, interact specifically with peptides enriched in internal hydrophobic residues, with a preference for positively charged peptides, We previously reported that DnaK interacts with the hydrophobic amino acids Ile, Leu, Val, Ala, Phe, Trp, and Tyr. In the present study, we show that DnaK also possesses a specific binding site for the positively charged amino acids arginine and lysine. Furthermore, the binding of arginine and lysine to DnaK is strengthened when its hydrophobic binding sites are occupied, The specificity of DnaK for Arg/Lys is supported by DnaK-peptide binding studies; the homopolypeptides poly-Arg and poly-Lys interact with DnaK, contrasting with other hydrophilic homopolypeptides, and hydrophobic peptides interact more strongly with DnaK if they contain Arg/Lys at their N terminus. Interestingly, the cochaperone DnaJ attenuates the interaction of DnaK with hydrophobic amino acids while strengthening its interaction with arginine or lysine. The interaction of DnaK with both hydrophobic sequences and with arginine and lysine, and its modulation by DnaJ, may have important implications in both protein folding and protein insertion into membranes.	UNIV PARIS 07, INST JACQUES MONOD, F-75005 PARIS, FRANCE	UDICE-French Research Universities; Universite Paris Cite								BIN W, 1992, J BACTERIOL, V174, P5258, DOI 10.1128/JB.174.16.5258-5264.1992; BLONDELGUINDI S, 1993, CELL, V75, P717, DOI 10.1016/0092-8674(93)90492-9; BOYD D, 1990, CELL, V62, P1031, DOI 10.1016/0092-8674(90)90378-R; BUKAU B, 1989, J BACTERIOL, V171, P2337, DOI 10.1128/jb.171.5.2337-2346.1989; CYR DM, 1994, J BIOL CHEM, V269, P9798; DALBEY RE, 1990, TRENDS BIOCHEM SCI, V15, P253, DOI 10.1016/0968-0004(90)90047-F; DECROUYCHANEL A, 1995, J BIOL CHEM, V270, P10571, DOI 10.1074/jbc.270.18.10571; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; ELLIS RJ, 1989, TRENDS BIOCHEM SCI, V14, P339, DOI 10.1016/0968-0004(89)90168-0; FENTON WA, 1994, NATURE, V371, P614, DOI 10.1038/371614a0; FLYNN GC, 1989, SCIENCE, V245, P385, DOI 10.1126/science.2756425; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; GAMER J, 1992, CELL, V69, P833, DOI 10.1016/0092-8674(92)90294-M; GEORGOPOULOS C, 1992, TRENDS BIOCHEM SCI, V17, P295, DOI 10.1016/0968-0004(92)90439-G; GRAGEROV A, 1994, J MOL BIOL, V235, P848, DOI 10.1006/jmbi.1994.1043; HENDRICK JP, 1993, ANNU REV BIOCHEM, V62, P349, DOI 10.1146/annurev.bi.62.070193.002025; Hightower LE, 1994, BIOL HEAT SHOCK PROT, P179; JORDAN R, 1995, J BIOL CHEM, V270, P4563, DOI 10.1074/jbc.270.9.4563; LANGER T, 1992, NATURE, V356, P683, DOI 10.1038/356683a0; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; LIBEREK K, 1991, P NATL ACAD SCI USA, V88, P2874, DOI 10.1073/pnas.88.7.2874; LIBEREK K, 1995, P NATL ACAD SCI USA, V92, P6224, DOI 10.1073/pnas.92.14.6224; LIBEREK K, 1991, J BIOL CHEM, V266, P14491; LIBEREK K, 1992, P NATL ACAD SCI USA, V89, P3516, DOI 10.1073/pnas.89.8.3516; LIN ZL, 1995, J BIOL CHEM, V270, P1011, DOI 10.1074/jbc.270.3.1011; MEURY J, 1991, J BACTERIOL, V173, P4404, DOI 10.1128/JB.173.14.4404-4410.1991; MILLER S, 1987, J MOL BIOL, V196, P641, DOI 10.1016/0022-2836(87)90038-6; MISSIAKAS D, 1993, J BACTERIOL, V175, P2613, DOI 10.1128/JB.175.9.2613-2624.1993; OSIPIUK J, 1993, J BIOL CHEM, V268, P4821; PALLEROS DR, 1991, P NATL ACAD SCI USA, V88, P5719, DOI 10.1073/pnas.88.13.5719; RANDALL LL, 1992, SCIENCE, V257, P241, DOI 10.1126/science.1631545; RICHARME G, 1993, J BIOL CHEM, V268, P24074; RICHARME G, 1994, J BIOL CHEM, V269, P7095; SCHRODER H, 1993, EMBO J, V12, P4137, DOI 10.1002/j.1460-2075.1993.tb06097.x; SHI WY, 1992, J BACTERIOL, V174, P6256, DOI 10.1128/JB.174.19.6256-6263.1992; SHRAKE A, 1973, J MOL BIOL, V79, P351, DOI 10.1016/0022-2836(73)90011-9; VIITANEN PV, 1992, PROTEIN SCI, V1, P363; VONHEIJNE G, 1986, J MOL BIOL, V192, P287, DOI 10.1016/0022-2836(86)90365-7; WAWRZYNOW A, 1995, J BIOL CHEM, V270, P19307, DOI 10.1074/jbc.270.33.19307; WILD J, 1992, GENE DEV, V6, P1165, DOI 10.1101/gad.6.7.1165; ZYLICZ M, 1984, J BIOL CHEM, V259, P8820; ZYLICZ M, 1987, J BIOL CHEM, V262, P17437; ZYLICZ M, 1985, J BIOL CHEM, V260, P7591	43	23	26	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15486	15490		10.1074/jbc.271.26.15486	http://dx.doi.org/10.1074/jbc.271.26.15486			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663088	hybrid			2022-12-27	WOS:A1996UV29900029
J	Graham, C; Hodin, J; Wistow, G				Graham, C; Hodin, J; Wistow, G			A retinaldehyde dehydrogenase as a structural protein in a mammalian eye lens - Gene recruitment of eta-crystallin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CYTOSOLIC ALDEHYDE DEHYDROGENASE; RETINOIC ACID; TRANSGENIC MICE; EXPRESSION; OXIDATION; SEQUENCE; CDNA	eta-Crystallin is a taxon-specific crystallin, a major component of the eye lens in elephant shrews (Macroscelidea). Sequence analysis of eta-crystallin from two genera of elephant shrews and expression of recombinant eta-crystallin show that the protein is a cytoplasmic (class 1) aldehyde dehydrogenase (ALDH1, EC 1.2.1.3) with activity for the oxidation of retinaldehyde to retinoic acid. Unlike many other mammals, elephant shrews have two ALDH1 genes. One encodes ALDH1/eta-crystallin which, in addition to its very high expression in lens, is also the predominant form of ALDH1 expressed in other parts of the eye. The second gene encodes a ''non-lens'' ALDH1 (ALDH1-n1) which is the predominant form expressed in liver. This pattern of tissue preference contrasts with other mammals which make use of the same major ALDH1 transcript in both ocular and non-ocular tissues. Thus the gene recruitment of ALDH1/eta-crystallin as a structural protein in elephant shrew lenses is associated with its collateral recruitment as the major form of ALDH1 expressed in other parts of the eye.	NEI, SECT MOLEC STRUCT & FUNCT, LMDB, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Eye Institute (NEI)								ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BALKAN W, 1992, DEV BIOL, V151, P622, DOI 10.1016/0012-1606(92)90200-Z; Battey, 1986, BASIC METHODS MOL BI; Bhat PV, 1995, GENE, V166, P303, DOI 10.1016/0378-1119(96)81752-5; Chambon Pierre, 1994, Seminars in Cell Biology, V5, P115, DOI 10.1006/scel.1994.1015; DEJONG WW, 1994, PROG RETIN EYE RES, V13, P391, DOI 10.1016/1350-9462(94)90018-3; DEJONG WW, 1993, MAMMAL PHYLOGENY : PLACENTALS, P5; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; DUNN TJ, 1989, J BIOL CHEM, V264, P13057; Frohman M.A., 1990, PCR PROTOCOLS GUIDE, P28; GHENBOT G, 1992, PROTEIN EXPRES PURIF, V3, P470, DOI 10.1016/1046-5928(92)90064-4; GOULD SJ, 1979, PROC R SOC SER B-BIO, V205, P581, DOI 10.1098/rspb.1979.0086; GUDAS LJ, 1994, J BIOL CHEM, V269, P15399; HANSON I, 1995, TRENDS GENET, V11, P268, DOI 10.1016/S0168-9525(00)89073-3; HEMPEL J, 1993, PROTEIN SCI, V2, P1890, DOI 10.1002/pro.5560021111; HENDRIKS W, 1988, P NATL ACAD SCI USA, V85, P7114, DOI 10.1073/pnas.85.19.7114; HSU LC, 1992, J BIOL CHEM, V267, P3030; HSU LC, 1989, GENOMICS, V5, P857, DOI 10.1016/0888-7543(89)90127-4; KIM RY, 1993, FASEB J, V7, P464, DOI 10.1096/fasebj.7.5.8462788; KUMAR S, 1994, COMPUT APPL BIOSCI, V10, P189; LABRECQUE J, 1995, BIOCHEM J, V305, P681, DOI 10.1042/bj3050681; LEE DC, 1994, J MOL BIOL, V236, P669, DOI 10.1006/jmbi.1994.1178; LEE MO, 1991, BIOCHEM PHARMACOL, V42, P1279, DOI 10.1016/0006-2952(91)90266-8; LI HS, 1994, DEV BIOL, V162, P181, DOI 10.1006/dbio.1994.1077; LINDAHL R, 1991, ENZYMOLOGY MOL BIOL, V3, P1; MCCAFFERY P, 1993, DEV BIOL, V158, P390, DOI 10.1006/dbio.1993.1197; MCCAFFERY P, 1992, DEVELOPMENT, V115, P371; Novacek M.J., 1990, Current Mammalogy, V2, P507; NOWAK RM, 1991, WALKERS MAMMALS WORL, P180; Ochman H., 1990, PCR PROTOCOLS GUIDE, P219; PEREZCASTRO AV, 1993, DEVELOPMENT, V119, P363; PIATIGORSKY J, 1992, J BIOL CHEM, V267, P4277; RAO CM, 1992, PHOTOCHEM PHOTOBIOL, V56, P523, DOI 10.1111/j.1751-1097.1992.tb02196.x; RAO PV, 1990, BIOCHEM BIOPH RES CO, V167, P1221, DOI 10.1016/0006-291X(90)90654-6; RICHARDSON J, 1995, P NATL ACAD SCI USA, V92, P4676, DOI 10.1073/pnas.92.10.4676; SAARI JC, 1995, VISUAL NEUROSCI, V12, P263, DOI 10.1017/S095252380000794X; TINI M, 1995, J BIOL CHEM, V270, P20156, DOI 10.1074/jbc.270.34.20156; TINI M, 1993, GENE DEV, V7, P295, DOI 10.1101/gad.7.2.295; TINI M, 1994, MOL ENDOCRINOL, V8, P1494, DOI 10.1210/me.8.11.1494; TURQUE N, 1994, MOL ENDOCRINOL, V8, P929, DOI 10.1210/me.8.7.929; WALTHER C, 1991, DEVELOPMENT, V113, P1435; WEINER H, 1991, ALCOHOL ALCOHOLISM, P91; WEINER H, 1991, ENZYMOLOGY MOL BIOL, V3, P13; WISTOW G, 1990, P NATL ACAD SCI USA, V87, P6277, DOI 10.1073/pnas.87.16.6277; Wistow G, 1994, Biotechnol Genet Eng Rev, V12, P1; WISTOW G, 1993, TRENDS BIOCHEM SCI, V18, P301, DOI 10.1016/0968-0004(93)90041-K; WISTOW G, 1991, J MOL EVOL, V32, P262, DOI 10.1007/BF02342749; Wistow G, 1995, MOL BIOL EVOLUTION C; WISTOW GJ, 1987, NATURE, V326, P622, DOI 10.1038/326622a0; YOSHIDA A, 1992, ENZYME, V46, P239, DOI 10.1159/000468794; [No title captured]	51	48	51	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15623	15628		10.1074/jbc.271.26.15623	http://dx.doi.org/10.1074/jbc.271.26.15623			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663049	hybrid			2022-12-27	WOS:A1996UV29900049
J	Buchler, M; Konig, J; Brom, R; Kartenbeck, J; Spring, H; Horie, T; Keppler, D				Buchler, M; Konig, J; Brom, R; Kartenbeck, J; Spring, H; Horie, T; Keppler, D			cDNA cloning of the hepatocyte canalicular isoform of the multidrug resistance protein, cMrp, reveals a novel conjugate export pump deficient in hyperbilirubinemic mutant rats	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							BACTERIAL TRANSPORT; ANION TRANSPORT; CYSTIC-FIBROSIS; GENE; CELLS; GLUTATHIONE; EXCRETION; SEQUENCES; MEMBRANE; SYSTEM	ATP-dependent transport of glutathione and glucuronate conjugates from hepatocytes into bile is mediated by a distinct member of the ATP-binding cassette superfamily, We have cloned and sequenced the canalicular isoform of the multidrug resistance protein from rat liver, and termed it cMrp, This membrane glycoprotein is composed of 1541 amino acids with an identity of 47.8% with the human multidrug resistance protein (MRP) and of 41.9% with the yeast cadmium factor (YCF1), The carboxyl-terminal 130 amino acids of the human hepatocyte canalicular isoform of MRP (cMRP) were 80.2% identical with rat cMrp. cMrp was not expressed in the liver of two mutant rat strains, the Eisai hyperbilirubinemic rat and the GY/TR(-) mutant, which are deficient in the ATP-dependent transport of conjugates across the canalicular membrane, Immunoblotting using an antibody raised against the carboxyl terminus of cMrp detected the glycoprotein of about 190 kDa only in the canalicular membrane from normal liver, Double immunofluorescence and confocal laser scanning microscopy localized cMrp exclusively to the canalicular membrane domain of hepatocytes and demonstrated its loss in the hyperbilirubinemic mutant rat, The results identify cMrp as a canalicular transport protein with a novel sequence and with a function similar to the one of the MRP.	DEUTSCH KREBSFORSCHUNGSZENTRUM,DIV TUMOR BIOCHEM,D-69120 HEIDELBERG,GERMANY; EISAI RES LABS,IBARAKI,OSAKA 30021,JAPAN	Helmholtz Association; German Cancer Research Center (DKFZ); Eisai Co Ltd			Keppler, Dietrich/A-5528-2013	Keppler, Dietrich/0000-0003-2964-2333; Koenig, Joerg/0000-0001-7016-5482				AGUILARBRYAN L, 1995, SCIENCE, V268, P423, DOI 10.1126/science.7716547; ARIAS IM, 1993, HEPATOLOGY, V17, P318, DOI 10.1002/hep.1840170225; BECKER A, 1986, BIOL CHEM H-S, V367, P681, DOI 10.1515/bchm3.1986.367.2.681; BOHME M, 1993, FEBS LETT, V333, P193, DOI 10.1016/0014-5793(93)80403-H; BOHME M, 1994, GASTROENTEROLOGY, V107, P255; BROWN PC, 1993, NUCLEIC ACIDS RES, V21, P3885, DOI 10.1093/nar/21.16.3885; CHEN CJ, 1986, CELL, V47, P381, DOI 10.1016/0092-8674(86)90595-7; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; CHOWDHURY RC, 1994, LIVER BIOL PATHOLOGY, P471; COLE SPC, 1994, CANCER RES, V54, P5902; COLE SPC, 1992, SCIENCE, V258, P1650, DOI 10.1126/science.1360704; DEVEREUX J, 1984, NUCLEIC ACIDS RES, V12, P387, DOI 10.1093/nar/12.1Part1.387; ELFERINK RPJO, 1995, BBA-REV BIOMEMBRANES, V1241, P215, DOI 10.1016/0304-4157(95)00006-D; FERNANDEZCHECA JC, 1992, J BIOL CHEM, V267, P1667; HIGGINS CF, 1988, BIOESSAYS, V8, P111, DOI 10.1002/bies.950080406; HIGGINS DG, 1989, COMPUT APPL BIOSCI, V5, P151; HOSOKAWA S, 1992, LAB ANIM SCI, V42, P27; HUBER M, 1987, HEPATOLOGY, V7, P224, DOI 10.1002/hep.1840070204; HYDE SC, 1990, NATURE, V346, P362, DOI 10.1038/346362a0; ISHIKAWA T, 1990, J BIOL CHEM, V265, P19279; JANSEN PLM, 1985, HEPATOLOGY, V5, P573, DOI 10.1002/hep.1840050408; Jedlitschky G, 1996, CANCER RES, V56, P988; JEDLITSCHKY G, 1994, CANCER RES, V54, P4833; JOHNSTON M, 1994, SCIENCE, V265, P2077, DOI 10.1126/science.8091229; JONES TR, 1989, CAN J PHYSIOL PHARM, V67, P17, DOI 10.1139/y89-004; Kartenbeck J, 1996, HEPATOLOGY, V23, P1061; KOZAK M, 1984, NUCLEIC ACIDS RES, V12, P857, DOI 10.1093/nar/12.2.857; KRISHNAMACHARY N, 1994, ONCOL RES, V6, P119; KUIPERS F, 1988, J CLIN INVEST, V81, P1593, DOI 10.1172/JCI113493; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Leier I, 1996, BIOCHEM J, V314, P433, DOI 10.1042/bj3140433; LEIER I, 1994, J BIOL CHEM, V269, P27807; MAYER R, 1995, J CELL BIOL, V131, P137, DOI 10.1083/jcb.131.1.137; MULLER M, 1994, P NATL ACAD SCI USA, V91, P13033, DOI 10.1073/pnas.91.26.13033; NISHIDA T, 1992, AM J PHYSIOL, V262, pG629, DOI 10.1152/ajpgi.1992.262.4.G629; PERSSON B, 1994, J MOL BIOL, V237, P182, DOI 10.1006/jmbi.1994.1220; PHILIPSON LH, 1995, SCIENCE, V268, P372, DOI 10.1126/science.7716539; RIORDAN JR, 1989, SCIENCE, V245, P1066; SANGER F, 1980, J MOL BIOL, V143, P161, DOI 10.1016/0022-2836(80)90196-5; SCHNOLZER M, 1992, INT J PEPT PROT RES, V40, P180; SENGER M, 1995, COMPUT METH PROG BIO, V46, P131, DOI 10.1016/0169-2607(94)01610-R; SZCZYPKA MS, 1994, J BIOL CHEM, V269, P22853; TAKIKAWA H, 1991, HEPATOLOGY, V14, P352, DOI 10.1002/hep.1840140223	43	572	586	0	18	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15091	15098						8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662992				2022-12-27	WOS:A1996UT10600067
J	Carey, DJ; Bendt, KM; Stahl, RC				Carey, DJ; Bendt, KM; Stahl, RC			The cytoplasmic domain of syndecan-1 is required for cytoskeleton association but not detergent insolubility - Identification of essential cytoplasmic domain residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-SURFACE PROTEOGLYCAN; MAMMARY EPITHELIAL-CELLS; HEPARAN-SULFATE PROTEOGLYCAN; SMOOTH-MUSCLE CELLS; EXPRESSION; TAIL	Syndecan-1 is a member of a gene family of multifunctional transmembrane heparan sulfate proteoglycans that bind a variety of extracellular ligands and possess highly conserved non catalytic cytoplasmic domains, It has been shown that antibody-mediated clustering of syndecan-1 causes the proteoglycan to become associated with microfilaments and insoluble in non-ionic detergent, A series of truncation and point mutations of the syndecan-1 core protein was constructed to identify specific structural features that were required for these characteristics. The transmembrane domain but not the cytoplasmic domain was required for cell surface expression of syndecan-1, Deletion of the COOH-terminal 11 amino acids of the cytoplasmic domain had no effect, while deletion of an additional 12 amino acids abolished microfilament association, Mutation of a conserved tyrosine residue within the latter region also abolished microfilament association, In contrast, mutation of 2 tyrosine residues outside this region had no effect, Deletion of the entire cytoplasmic domain (except for a short stop-transfer sequence) did not affect insolubility of the proteoglycan in detergent, Analysis of a form of syndecan-1 that lacked glycosaminoglycan acceptor sites revealed that covalently attached glycosaminoglycans were not required for cell surface expression, microfilament association, or detergent insolubility. These results demonstrate that microfilament association is a function of a subregion within the cytoplasmic domain and suggest that insolubility in detergent is a function of the transmembrane domain.			Carey, DJ (corresponding author), WEIS CTR RES,GEISINGER CLIN,26-23,100 ACAD AVE,DANVILLE,PA 17822, USA.				NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL048740] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [R01NS021925] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL48740] Funding Source: Medline; NINDS NIH HHS [NS21925] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		ASUNDI VK, 1995, J BIOL CHEM, V270, P26404, DOI 10.1074/jbc.270.44.26404; BERNFIELD M, 1991, ANN NY ACAD SCI, V638, P182, DOI 10.1111/j.1749-6632.1991.tb49029.x; BERNFIELD M, 1993, DEVELOPMENT, P205; BERNFIELD M, 1992, ANNU REV CELL BIOL, V8, P365, DOI 10.1146/annurev.cb.08.110192.002053; CAREY DJ, 1990, J CELL BIOL, V111, P2053, DOI 10.1083/jcb.111.5.2053; CAREY DJ, 1994, EXP CELL RES, V214, P12, DOI 10.1006/excr.1994.1228; CAREY DJ, 1994, J CELL BIOL, V124, P161, DOI 10.1083/jcb.124.1.161; CHERNOUSOV MA, 1993, J BIOL CHEM, V268, P16810; CIZMECISMITH G, 1993, J BIOL CHEM, V268, P18740; CIZMECISMITH G, 1992, J BIOL CHEM, V267, P15729; CLARK EA, 1995, SCIENCE, V268, P233, DOI 10.1126/science.7716514; ELENIUS K, 1994, J CELL SCI, V107, P2975; ELENIUS K, 1992, J BIOL CHEM, V267, P6435; ELENIUS K, 1991, J CELL BIOL, V114, P585, DOI 10.1083/jcb.114.3.585; HELDIN CH, 1995, CELL, V80, P213, DOI 10.1016/0092-8674(95)90404-2; HINCK L, 1994, J CELL BIOL, V125, P1327, DOI 10.1083/jcb.125.6.1327; IWASHIMA M, 1994, SCIENCE, V263, P1136, DOI 10.1126/science.7509083; KATO M, 1994, J BIOL CHEM, V269, P18881; KIM CW, 1994, MOL BIOL CELL, V5, P797, DOI 10.1091/mbc.5.7.797; LETOURNEUR F, 1992, SCIENCE, V255, P79, DOI 10.1126/science.1532456; MIETTINEN HM, 1994, J CELL SCI, V107, P1571; PERSCHL A, 1995, J CELL SCI, V108, P1033; RAPRAEGER A, 1985, J BIOL CHEM, V260, P1046; RAPRAEGER A, 1986, J CELL BIOL, V103, P2683, DOI 10.1083/jcb.103.6.2683; RAPRAEGER A, 1985, J BIOL CHEM, V260, P4103; RAULO E, 1994, J BIOL CHEM, V269, P12999; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; SANDERSON RD, 1994, J BIOL CHEM, V269, P13100; SPRING J, 1994, P NATL ACAD SCI USA, V91, P3334, DOI 10.1073/pnas.91.8.3334; TANIGUCHI T, 1995, SCIENCE, V268, P251, DOI 10.1126/science.7716517; WOODS A, 1994, MOL BIOL CELL, V5, P183, DOI 10.1091/mbc.5.2.183	31	76	76	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15253	15260		10.1074/jbc.271.25.15253	http://dx.doi.org/10.1074/jbc.271.25.15253			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662979	hybrid			2022-12-27	WOS:A1996UT10600088
J	Grilli, M; Goffi, F; Memo, M; Spano, P				Grilli, M; Goffi, F; Memo, M; Spano, P			Interleukin-1 beta and glutamate activate the NF-kappa B/Rel binding site from the regulatory region of the amyloid precursor protein gene in primary neuronal cultures	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MESSENGER-RNA; ALZHEIMERS-DISEASE; TRANSCRIPTION FACTOR; LYMPHOCYTES-T; EXPRESSION; BRAIN; PROMOTER; CELLS; APP; INDUCTION	We originally reported that members of the family of transcription factors NF-kappa B/Rel can specifically recognize two identical sequences, referred to as APP kappa B sites, which are present in the 5'-regulatory region of the APP gene, Here we show that the APP kappa B sites interact specifically with a complex which contains one of the subunits of the family, defined as p50 protein, and that they act as positive modulators of gene transcription in cells of neural origin, Additionally, the nuclear complex specifically binding to the APP kappa B sites is constitutively expressed in primary neurons from rat cerebellum and it is up-regulated in response to both the inflammatory cytokine interleukin-1 beta (IL-1 beta) and the excitatory amino acid glutamate. Since IL-1, whose levels are known to be induced in brain of individuals affected by Alzheimer's disease, and glutamate, are stimuli which have been regarded as major actors on the stage of neurodegenerative processes, we believe our evidence as potentially relevant for understanding the neuropathology associated with Alzheimer's disease.			Grilli, M (corresponding author), UNIV BRESCIA, SCH MED, DEPT BIOMED SCI & BIOTECHNOL, DIV PHARMACOL, VIA VALSABBINA 19, I-25124 BRESCIA, ITALY.		grilli, mariagrazia/ABF-1542-2020; Memo, Maurizio/C-2555-2011; Memo, Maurizio/AAK-7197-2020; Spano, Pier Franco F/J-9944-2016; Spano, Pier Franco A/E-7621-2010	grilli, mariagrazia/0000-0001-9165-5827; Spano, Pier Franco F/0000-0002-9906-0964; MEMO, Maurizio/0000-0002-7543-0289				ABE K, 1991, NEUROSCI LETT, V125, P169, DOI 10.1016/0304-3940(91)90019-P; ABE K, 1991, NEUROSCI LETT, V125, P172, DOI 10.1016/0304-3940(91)90020-T; ANDREWS NC, 1991, NUCLEIC ACIDS RES, V19, P2499, DOI 10.1093/nar/19.9.2499; CHARTIERHARLIN MC, 1991, NATURE, V353, P844, DOI 10.1038/353844a0; COHEN ML, 1988, P NATL ACAD SCI USA, V85, P1227, DOI 10.1073/pnas.85.4.1227; EDBROOKE MR, 1989, MOL CELL BIOL, V9, P1908, DOI 10.1128/MCB.9.5.1908; FORLONI G, 1992, MOL BRAIN RES, V16, P128, DOI 10.1016/0169-328X(92)90202-M; GALLO V, 1982, P NATL ACAD SCI-BIOL, V79, P7919, DOI 10.1073/pnas.79.24.7919; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; GOLDGABER D, 1989, P NATL ACAD SCI USA, V86, P7606, DOI 10.1073/pnas.86.19.7606; GORMAN CM, 1982, P NATL ACAD SCI-BIOL, V79, P6777, DOI 10.1073/pnas.79.22.6777; GRIFFIN WST, 1989, P NATL ACAD SCI USA, V86, P7611; GRILLI M, 1995, J BIOL CHEM, V270, P26774, DOI 10.1074/jbc.270.45.26774; GRILLI M, 1993, INT REV CYTOL, V143, P1; HIGGINS GA, 1988, P NATL ACAD SCI USA, V85, P1297, DOI 10.1073/pnas.85.4.1297; JOHNSON SA, 1990, SCIENCE, V248, P854, DOI 10.1126/science.2111579; KALTSCHMIDT C, 1993, MECH DEVELOP, V43, P135, DOI 10.1016/0925-4773(93)90031-R; KALTSCHMIDT C, 1994, MOL CELL BIOL, V14, P3981, DOI 10.1128/MCB.14.6.3981; KANG SM, 1992, SCIENCE, V256, P1452, DOI 10.1126/science.1604322; KAWARABAYASHI T, 1991, BRAIN RES, V563, P334, DOI 10.1016/0006-8993(91)91558-I; KOVACS DM, 1995, HUM MOL GENET, V4, P1527, DOI 10.1093/hmg/4.9.1527; LAFAUCI G, 1989, BIOCHEM BIOPH RES CO, V159, P297, DOI 10.1016/0006-291X(89)92437-6; LAHIRI DK, 1991, MOL BRAIN RES, V9, P253, DOI 10.1016/0169-328X(91)90009-M; Liou HC, 1993, CURR OPIN CELL BIOL, V5, P477, DOI 10.1016/0955-0674(93)90014-H; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LUCKOW B, 1987, NUCLEIC ACIDS RES, V15, P5490, DOI 10.1093/nar/15.13.5490; NEVE RL, 1988, NEURON, V1, P669, DOI 10.1016/0896-6273(88)90166-3; POLLWEIN P, 1992, NUCLEIC ACIDS RES, V20, P63, DOI 10.1093/nar/20.1.63; QUERFURTH HW, 1995, MOL BRAIN RES, V28, P319, DOI 10.1016/0169-328X(94)00224-3; QUITSCHKE WW, 1994, J BIOL CHEM, V269, P21229; QUITSCHKE WW, 1992, J BIOL CHEM, V267, P17362; RATTNER A, 1991, MOL CELL BIOL, V11, P1017, DOI 10.1128/MCB.11.2.1017; RATTNER A, 1993, EMBO J, V12, P4261, DOI 10.1002/j.1460-2075.1993.tb06110.x; ROBERTS GW, 1991, LANCET, V338, P1422, DOI 10.1016/0140-6736(91)92724-G; ROTHWELL NJ, 1991, TRENDS PHARMACOL SCI, V12, P430, DOI 10.1016/0165-6147(91)90623-Z; SALBAUM JM, 1988, EMBO J, V7, P2807, DOI 10.1002/j.1460-2075.1988.tb03136.x; SELKOE DJ, 1994, ANNU REV NEUROSCI, V17, P489, DOI 10.1146/annurev.neuro.17.1.489; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; SOLA C, 1993, MOL BRAIN RES, V17, P41, DOI 10.1016/0169-328X(93)90071-V; TREJO J, 1994, J BIOL CHEM, V269, P21682; VALERIO A, 1995, NEUROREPORT, V6, P1317, DOI 10.1097/00001756-199506090-00022; VOSTROV AA, 1995, NUCLEIC ACIDS RES, V23, P2734, DOI 10.1093/nar/23.14.2734; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	44	126	134	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15002	15007		10.1074/jbc.271.25.15002	http://dx.doi.org/10.1074/jbc.271.25.15002			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663145	hybrid			2022-12-27	WOS:A1996UT10600056
J	Jouni, ZE; Wells, MA				Jouni, ZE; Wells, MA			Purification and partial characterization of a lutein-binding protein from the midgut of the silkworm Bombyx mori	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RESONANCE RAMAN; CANTHAXANTHIN-LIPOVITELLIN; BLUE CAROTENOPROTEIN; CIRCULAR-DICHROISM; CRUSTACEA; ANOSTRACA	A lutein-binding protein was purified from fifth instar larval midgut of Bombyx mori by a combination of ammonium sulfate fractionation and three chromatographic procedures, gel filtration, chromatofocusing, and anion exchange chromatography. The protein has a pi of 5.4 and an apparent molecular mass of 35,000 Da, as determined by a linear gradient SDS-polyacrylamide gel electrophoresis. The lutein-protein complex is water-soluble and more stable than the carotenoid or protein alone. The carotenoid moiety was identified by thin layer chromatography, light absorption spectroscopy, and high performance liquid chromatography as all-trans-lutein. Lutein is specifically and stoichiometrically bound to the protein, with a ratio of 3 mol of lutein per mol of protein. Binding of lutein (absorption maxi mum in hexane at 454 nm) to the apoprotein results in a marked red spectral shift of about 38 nm, giving rise to absorption maxima at 432, 462, and 492 nm in 20 mM Tris-HCl, pH 7.0. The lutein-protein complex is characterized by fine spectral structure indicating that lutein is in a relatively rigid environment. This protein is distributed in equal amounts throughout the midgut and in all developmental stages of the larval B. mori.			Jouni, ZE (corresponding author), UNIV ARIZONA,DEPT BIOCHEM,POB 210066,BIOL SCI W,TUCSON,AZ 85721, USA.				NIGMS NIH HHS [GM50008] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050008] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BANASZAK L, 1994, ADV PROTEIN CHEM, V45, P89; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Britton G., 1982, CAROTENOID CHEM BIOC, P237; BRYANT JD, 1992, J AGR FOOD CHEM, V40, P545, DOI 10.1021/jf00016a003; BUCHWALD M, 1968, BIOCHEMISTRY-US, V7, P844, DOI 10.1021/bi00842a043; CHINO H, 1969, BIOCHIM BIOPHYS ACTA, V176, P1; FUJII H, 1988, Journal of Sericultural Science of Japan, V57, P94; GARATE AM, 1986, BIOCHIM BIOPHYS ACTA, V881, P446, DOI 10.1016/0304-4165(86)90038-3; GILBERT LI, 1974, J LIPID RES, V15, P439; GOODWIN TW, 1953, BIOCHEM J, V55, P834, DOI 10.1042/bj0550834; HARASHIMA K, 1972, INSECT BIOCHEM, V2, P29, DOI 10.1016/0020-1790(72)90064-9; KAWAI N, 1976, J INSECT PHYSIOL, V22, P207, DOI 10.1016/0022-1910(76)90027-5; Kayser H., 1985, P367; KAYSER H, 1975, INSECT BIOCHEM, V5, P861, DOI 10.1016/0020-1790(75)90031-1; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; RACUSEN D, 1979, ANAL BIOCHEM, V99, P474, DOI 10.1016/S0003-2697(79)80035-4; RIVAS JDL, 1988, COMP BIOCHEM PHYS B, V89, P65, DOI 10.1016/0305-0491(88)90262-3; SALARES VR, 1979, BIOCHIM BIOPHYS ACTA, V576, P176, DOI 10.1016/0005-2795(79)90496-3; SALARES VR, 1977, J RAMAN SPECTROSC, V6, P282, DOI 10.1002/jrs.1250060605; SHAPIRO JP, 1984, ANNU REV ENTOMOL, V23, P297; SHONE CC, 1978, COMP BIOCH PHYSL, V62, P507; TAZIMA Y, 1978, SILKWORM IMPORTANT L, P53; TERRA WR, 1981, COMP BIOCHEM PHYS B, V68, P89, DOI 10.1016/0305-0491(81)90184-X; WEESIE RJ, 1995, FEBS LETT, V362, P34, DOI 10.1016/0014-5793(95)00191-B; YOSHIDA H, 1992, J LIPID RES, V33, P343; ZAGALSKY PF, 1976, PURE APPL CHEM, V47, P103, DOI 10.1351/pac197647020103; ZAGALSKY PF, 1983, COMP BIOCHEM PHYS B, V74, P647, DOI 10.1016/0305-0491(83)90244-4; ZAGALSKY PF, 1989, COMP BIOCHEM PHYS B, V93, P339, DOI 10.1016/0305-0491(89)90090-4; ZAGALSKY PF, 1983, COMP BIOCHEM PHYS B, V75, P163, DOI 10.1016/0305-0491(83)90055-X	29	43	50	1	9	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14722	14726		10.1074/jbc.271.25.14722	http://dx.doi.org/10.1074/jbc.271.25.14722			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663050				2022-12-27	WOS:A1996UT10600016
J	Kim, DK; Stigger, E; Lee, SH				Kim, DK; Stigger, E; Lee, SH			Role of the 70-kDa subunit of human replication protein A .1. Single-stranded DNA binding activity, but not polymerase stimulatory activity, is required for DNA replication	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SIMIAN VIRUS-40 DNA; ALPHA-PRIMASE; T-ANTIGEN; DELTA; INVITRO; CELLS	Replication protein A (RPA), also known as human single-stranded DNA-binding protein, is a three-subunit protein complex with multiple functions. Here, we investigated the role of the 70-kDa RPA subunit (p70) in DNA replication, by generating a series of deletion mutants. Mutant p70, which lacked 50 amino acids at the C-terminus, failed to interact with the 11-kDa RPA subunit (p11) and, when deleted further at the C terminus, was unable to interact with either the 34-kDa subunit (p54) or with pll, suggesting that p70 directly interacts with both p34 and pll. Studies with purified RPA mutants indicated that deletions at the N-terminal domain of p70 had very little effect on RPA's single-stranded DNA (ssDNA) binding activity, whereas deletion of amino acids 169-246 significantly weakened the DNA binding ability of RPA. By deleting amino acids 296-373 or 374-458, we totally abolished p70's ssDNA binding activity, suggesting that multiple p70 domains are involved in DNA binding. Two p70 domains, the N-terminal domain and the DNA binding domain, were required to stimulate DNA polymerase (pol) alpha, yet the DNA binding domain alone supported pol delta activity. Interestingly, RPA containing p70 with a zinc-finger domain deletion retained its DNA binding activity, but inhibited pol alpha and delta activity. RPA that lacked ssDNA binding activity failed to support simian virus 40 (SV40) DNA replication in vitro, whereas mutant RPA that lacked pol alpha stimulatory activity (including the zinc-finger p70 mutant) functioned normally. We conclude that RPA's DNA binding activity, but not its pol alpha stimulatory activity, is required for DNA replication.	ST JUDE CHILDRENS RES HOSP, DEPT VIROL & MOLEC BIOL, MEMPHIS, TN 38105 USA	St Jude Children's Research Hospital					NCI NIH HHS [5P30 CA 21765] Funding Source: Medline; NIGMS NIH HHS [1RO1 GM52358] Funding Source: Medline; NATIONAL CANCER INSTITUTE [P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM052358] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		BRILL SJ, 1989, NATURE, V342, P92, DOI 10.1038/342092a0; BROWN GW, 1993, MOL BIOCHEM PARASIT, V59, P323, DOI 10.1016/0166-6851(93)90230-U; CARTY MP, 1994, EMBO J, V13, P2114, DOI 10.1002/j.1460-2075.1994.tb06487.x; COLLINS KL, 1991, MOL CELL BIOL, V11, P2108, DOI 10.1128/MCB.11.4.2108; COVERLEY D, 1992, NUCLEIC ACIDS RES, V20, P3873, DOI 10.1093/nar/20.15.3873; DORNREITER I, 1992, EMBO J, V11, P769, DOI 10.1002/j.1460-2075.1992.tb05110.x; DUTTA A, 1992, EMBO J, V11, P2189, DOI 10.1002/j.1460-2075.1992.tb05278.x; ERDILE LF, 1991, J BIOL CHEM, V266, P12090; FAIRMAN MP, 1988, EMBO J, V7, P1211, DOI 10.1002/j.1460-2075.1988.tb02933.x; GOMES XV, 1995, J BIOL CHEM, V270, P4534, DOI 10.1074/jbc.270.9.4534; HE ZG, 1995, NATURE, V374, P566, DOI 10.1038/374566a0; HENRICKSEN LA, 1994, J BIOL CHEM, V269, P11121; KENNY MK, 1990, J BIOL CHEM, V265, P769; KENNY MK, 1989, P NATL ACAD SCI USA, V86, P9757, DOI 10.1073/pnas.86.24.9757; KIM C, 1995, BIOCHEMISTRY-US, V34, P2058, DOI 10.1021/bi00006a028; KIM CS, 1992, MOL CELL BIOL, V12, P3050, DOI 10.1128/MCB.12.7.3050; LEE SH, 1995, J BIOL CHEM, V270, P12801, DOI 10.1074/jbc.270.21.12801; LEE SH, 1995, J BIOL CHEM, V270, P21800, DOI 10.1074/jbc.270.37.21800; LEE SH, 1991, J BIOL CHEM, V266, P594; LEE SH, 1993, NUCLEIC ACIDS RES, V21, P1935, DOI 10.1093/nar/21.8.1935; LI L, 1995, MOL CELL BIOL, V15, P5396; LIU VF, 1993, MOL CELL BIOL, V13, P7222, DOI 10.1128/MCB.13.12.7222; MATSUDA T, 1995, J BIOL CHEM, V270, P4152, DOI 10.1074/jbc.270.8.4152; MELENDY T, 1993, J BIOL CHEM, V268, P3389; MITSIS PG, 1993, BIOCHEMISTRY-US, V32, P5257, DOI 10.1021/bi00070a038; Murti KG, 1996, EXP CELL RES, V223, P279, DOI 10.1006/excr.1996.0083; SALAHUDDIN, 1990, GENE DEV, V4, P968, DOI 10.1101/gad.4.6.968; STIGGER E, 1994, P NATL ACAD SCI USA, V91, P579, DOI 10.1073/pnas.91.2.579; WOBBE CR, 1985, P NATL ACAD SCI USA, V82, P5710, DOI 10.1073/pnas.82.17.5710; WOLD MS, 1988, P NATL ACAD SCI USA, V85, P2523, DOI 10.1073/pnas.85.8.2523	30	61	62	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15124	15129		10.1074/jbc.271.25.15124	http://dx.doi.org/10.1074/jbc.271.25.15124			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663111	hybrid			2022-12-27	WOS:A1996UT10600071
J	Silvente-Poirot, S; Wank, SA				Silvente-Poirot, S; Wank, SA			A segment of five amino acids in the second extracellular loop of the cholecystokinin-B receptor is essential for selectivity of the peptide agonist gastrin	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; NEUROKININ-1 RECEPTOR; BINDING; SPECIFICITY; DOMAINS; ASSAY	The two known receptors mediating the actions of cholecystokinin (CCK) and gastrin, CCK type A (CCKAR) and CCK type B (CCKBR) receptors, are G protein coupled receptors having approximately 50% amino acid homology. Both the CCKAR and CCKBR have high affinity for sulfated CCK peptides, while only the CCKBR has high affinity for gastrin peptides. To determine the structural basis for the selectivity of the CCKBR for gastrin, we first constructed a series of CCKB/AR chimeras in which restriction endonuclease-defined segments of the CCKBR were replaced with the corresponding segments of the CCKAR. Chimeras transiently expressed in COS-1 cells were screened for the selective loss of gastrin affinity according to the displacement of I-125-labeled Bolton-Hunter-CCK-8 binding by gastrin-17-I and CCK-8. The sequence spanning from transmembrane domain III (TM III) to TM. V was the only segment that resulted in the selective loss of gastrin affinity. This segment could account for 100 of the expected 300-fold lower affinity of gastrin-17-I observed for the control CCKAR compared to the control CCKBR. Using site-directed mutagenesis in this segment of the CCKBR, we identified a sequence of 5 amino acids in the second extracellular loop responsible for this 100 fold selective loss in gastrin affinity, I-125-labeled Bolton-Hunter-CCK-8 binding displacement by L365,260 (a CCKBR selective antagonist) was unaffected by the changes in these 5 amino acids. These results present for the first time the identification of the amino acid sequence of the CCKBR conferring the majority of the selectivity for gastrin.	NIDDK, DIGEST DIS BRANCH, NIH, BETHESDA, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)			Poirot, Sandrine/D-5448-2017	Silvente-Poirot, Sandrine/0000-0003-2245-9069				ADACHI M, 1993, J CARDIOVASC PHARM, V22, pS121, DOI 10.1097/00005344-199322008-00033; BEINBORN M, 1993, NATURE, V362, P348, DOI 10.1038/362348a0; CHANG RSL, 1986, BIOCHEM BIOPH RES CO, V134, P895, DOI 10.1016/S0006-291X(86)80504-6; CHINI B, 1995, EMBO J, V14, P2176, DOI 10.1002/j.1460-2075.1995.tb07211.x; CRAWLEY JN, 1994, PEPTIDES, V15, P731, DOI 10.1016/0196-9781(94)90104-X; CULLEN BR, 1987, METHOD ENZYMOL, V152, P684; DELEAN A, 1978, AM J PHYSIOL, V235, pE97, DOI 10.1152/ajpendo.1978.235.2.E97; FATHI Z, 1993, J BIOL CHEM, V268, P14622; FITZPATRICK VD, 1994, J BIOL CHEM, V269, P24621; FONG TM, 1992, J BIOL CHEM, V267, P25664; FONG TM, 1992, BIOCHEMISTRY-US, V31, P11806, DOI 10.1021/bi00162a019; GETHER U, 1993, J BIOL CHEM, V268, P7893; Higuchi R., 1989, PCR TECHNOLOGY, P61; HOLTMANN MH, 1995, J BIOL CHEM, V270, P14394, DOI 10.1074/jbc.270.24.14394; JUPPNER H, 1994, ENDOCRINOLOGY, V134, P879, DOI 10.1210/en.134.2.879; KARNIK SS, 1988, P NATL ACAD SCI USA, V85, P8459, DOI 10.1073/pnas.85.22.8459; KAUPMANN K, 1995, EMBO J, V14, P727, DOI 10.1002/j.1460-2075.1995.tb07051.x; KOPIN AS, 1995, J BIOL CHEM, V270, P5019, DOI 10.1074/jbc.270.10.5019; KRYSTEK SR, 1994, J BIOL CHEM, V269, P12383; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LEE JA, 1994, P NATL ACAD SCI USA, V91, P7164, DOI 10.1073/pnas.91.15.7164; LOTTI VJ, 1989, EUR J PHARMACOL, V162, P273, DOI 10.1016/0014-2999(89)90290-2; SAITO A, 1981, J NEUROCHEM, V37, P483, DOI 10.1111/j.1471-4159.1981.tb00481.x; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; Schwartz Thue W., 1994, Current Opinion in Biotechnology, V5, P434, DOI 10.1016/0958-1669(94)90054-X; SILVENTE-POIROT S, 1993, EUR J BIOCHEM, V215, P513, DOI 10.1111/j.1432-1033.1993.tb18061.x; SOLL AH, 1984, J CLIN INVEST, V73, P1434, DOI 10.1172/JCI111348; STRADER CD, 1994, ANNU REV BIOCHEM, V63, P101, DOI 10.1146/annurev.bi.63.070194.000533; VILARDAGA JP, 1995, BIOCHEM BIOPH RES CO, V211, P885, DOI 10.1006/bbrc.1995.1895; WANG JB, 1994, J BIOL CHEM, V269, P25966; WANK SA, 1992, P NATL ACAD SCI USA, V89, P3125, DOI 10.1073/pnas.89.7.3125; WANK SA, 1995, AM J PHYSIOL-GASTR L, V269, pG628, DOI 10.1152/ajpgi.1995.269.5.G628; WANK SA, 1992, P NATL ACAD SCI USA, V89, P8691, DOI 10.1073/pnas.89.18.8691	34	57	57	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14698	14706		10.1074/jbc.271.25.14698	http://dx.doi.org/10.1074/jbc.271.25.14698			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8663021	hybrid			2022-12-27	WOS:A1996UT10600012
J	Mazur, P; Baginsky, W				Mazur, P; Baginsky, W			In vitro activity of 1,3-beta-D-glucan synthase requires the GTP-binding protein Rho1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CELL-WALL; SACCHAROMYCES-CEREVISIAE; YEAST; BIOSYNTHESIS; SYNTHETASE; GROWTH; DEFECT	In the yeast Saccharomyces cerevisiae, the family of RHO genes are implicated in the control of morphogenetic events although the molecular targets of these GTP-binding proteins remain largely unknown. The activity of 1,3-beta-D-glucan synthase, the product of which is essential for cell wall integrity, is regulated by a GTP-binding protein, which we here present evidence to be Rho1p. Rho1p was found to copurify with Fks1p, a glucan synthase subunit, in preparations of the enzyme purified by product entrapment and was also shown to be depleted by a detergent extraction procedure known to remove the GTP-binding regulatory component, Specific ADP-ribosylation of Rho1p by exoenzyme C3 inactivates glucan synthase activity specified by FKS1 and FKS2 as demonstrated in membrane preparations from fks2 and fks1 deletion strains, respectively, and in the purified enzyme containing Fks1p, Rho1p and Fks1p were co-immunoprecipitated from purified glucan synthase under conditions that maintained enzyme activity in the immunoprecipitate. Putative Rho homologs were also identified and implicated in the regulation of glucan synthase activity from Candida albicans, Aspergillus nidulans, and Cryptococcus neoformans by ribosylation studies. The regulation of 1,3-beta-D-glucan synthase activity by RHO1 is consistent with its observed role in morphogenetic control and osmotic integrity.			Mazur, P (corresponding author), MERCK SHARP & DOHME RES LABS,DEPT BIOCHEM,RAHWAY,NJ 07065, USA.							AWALD PD, 1994, BBA-GEN SUBJECTS, V1201, P312, DOI 10.1016/0304-4165(94)90056-6; CASTRO C, 1995, J BACTERIOL, V177, P5732, DOI 10.1128/jb.177.20.5732-5739.1995; CHARDIN P, 1989, EMBO J, V8, P1087, DOI 10.1002/j.1460-2075.1989.tb03477.x; CID VJ, 1995, MICROBIOL REV, V59, P345, DOI 10.1128/MMBR.59.3.345-386.1995; DIAZ M, 1993, EMBO J, V12, P5245, DOI 10.1002/j.1460-2075.1993.tb06220.x; DOUGLAS CM, 1994, J BACTERIOL, V176, P5686, DOI 10.1128/JB.176.18.5686-5696.1994; Drgonova J, 1996, SCIENCE, V272, P277, DOI 10.1126/science.272.5259.277; ELSHERBEINI M, 1995, ANTIMICROB AGENTS CH, V39, P200, DOI 10.1128/AAC.39.1.200; ELSHERBEINI M, 1995, J BACTERIOL, V177, P3227, DOI 10.1128/jb.177.11.3227-3234.1995; ENDERLIN CS, 1994, P NATL ACAD SCI USA, V91, P9500, DOI 10.1073/pnas.91.20.9500; ENG WK, 1994, GENE, V151, P61, DOI 10.1016/0378-1119(94)90633-5; GARRETTENGELE P, 1995, MOL CELL BIOL, V15, P4103; HONG Z, 1994, MOL CELL BIOL, V14, P1017, DOI 10.1128/MCB.14.2.1017; INOUE SB, 1995, EUR J BIOCHEM, V231, P845, DOI 10.1111/j.1432-1033.1995.tb20770.x; Kamada Y, 1996, J BIOL CHEM, V271, P9193, DOI 10.1074/jbc.271.16.9193; KANG MS, 1986, P NATL ACAD SCI USA, V83, P5808, DOI 10.1073/pnas.83.16.5808; KASAHARA S, 1994, J BACTERIOL, V176, P1488, DOI 10.1128/jb.176.5.1488-1499.1994; KLIS FM, 1994, YEAST, V10, P851, DOI 10.1002/yea.320100702; KURIBARA H, 1995, J BIOL CHEM, V270, P25667, DOI 10.1074/jbc.270.43.25667; MADAULE P, 1987, P NATL ACAD SCI USA, V84, P779, DOI 10.1073/pnas.84.3.779; MATSUI Y, 1992, MOL CELL BIOL, V12, P5690, DOI 10.1128/MCB.12.12.5690; MAZUR P, 1995, MOL CELL BIOL, V15, P5671; MCCAFFREY M, 1991, J CELL BIOL, V115, P309, DOI 10.1083/jcb.115.2.309; MITCHELL A, 1995, YEAST CELL BIOL M, P133; MOL PC, 1994, J BIOL CHEM, V269, P31267; NAKANO K, 1995, GENE, V153, P119; NONAKA H, 1995, EMBO J, V14, P5931, DOI 10.1002/j.1460-2075.1995.tb00281.x; OHYA Y, 1993, MOL BIOL CELL, V4, P1017, DOI 10.1091/mbc.4.10.1017; Qadota H, 1996, SCIENCE, V272, P279, DOI 10.1126/science.272.5259.279; QADOTA H, 1994, P NATL ACAD SCI USA, V91, P9317, DOI 10.1073/pnas.91.20.9317; RAM AFJ, 1995, FEBS LETT, V358, P165, DOI 10.1016/0014-5793(94)01418-Z; SEKINE A, 1989, J BIOL CHEM, V264, P8602; SHEMATEK EM, 1980, J BIOL CHEM, V255, P895; SZANISZLO PJ, 1985, J BACTERIOL, V161, P1188, DOI 10.1128/JB.161.3.1188-1194.1985; YAMOCHI W, 1994, J CELL BIOL, V125, P1077, DOI 10.1083/jcb.125.5.1077; ZHANG J, 1995, J BIOL CHEM, V270, P6589, DOI 10.1074/jbc.270.12.6589; ZHANG J, 1993, J BIOL CHEM, V268, P22251	38	153	161	0	12	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14604	14609		10.1074/jbc.271.24.14604	http://dx.doi.org/10.1074/jbc.271.24.14604			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662910	hybrid			2022-12-27	WOS:A1996UQ66000098
J	Meyer, A; Coyle, AJ; Proudfoot, AEI; Wells, TNC; Power, CA				Meyer, A; Coyle, AJ; Proudfoot, AEI; Wells, TNC; Power, CA			Cloning and characterization of a novel murine macrophage inflammatory protein-1 alpha receptor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FUNCTIONAL EXPRESSION; PROTEIN; IDENTIFICATION; MIP-1-ALPHA; MIP-1-BETA; INHIBITOR; RANTES; CELLS	We have cloned a novel CC chemokine receptor cDNA from mouse thymus. The deduced amino acid sequence shows 74% identity to the human monocyte chemotactic protein (MCP)-1 receptor (CC CKR-2b) and 54% to a recently cloned murine macrophage inflammatory protein (MIP)-1 alpha receptor (Gao, J. L., and Murphy, P. M. (1995) J. Biol. Chem. 270, 17494-17501). Northern blot analysis of mouse tissues showed that the mRNA was also expressed in heart, spleen and liver, and to a lesser extent in lung and brain. The rank order of CC chemokine competition for I-125-labeled human RANTES (regulated on activation, normal T-cell expressed and secreted) binding to human embryonic kidney (HEK) 293 cells stably transfected with the receptor cDNA was murine MIP-1 alpha >> human MIP-1 beta > human RANTES > murine RANTES > murine MIP-1 beta > human MCP-2 > murine MCP-1 (JE) > human MIP-1 alpha > human MCP-3 > human MCP-1. Of the chemokines tested, only murine MIP-1 alpha, human and murine MIP-1 beta and RANTES, human MCP-2, and JE were able to induce mobilization of intracellular Ca2+ from fura-2-loaded HEK 293 cells expressing the receptor. These results suggest that this receptor functions as a high affinity murine MIP-1 alpha receptor; however, it is likely to be an important target for the biological activities of several CC chemokines in mouse.	GLAXO INST MOLEC BIOL SA,CH-1228 PLAN LES OUATES,GENEVA,SWITZERLAND	GlaxoSmithKline				Wells, Timothy/0000-0001-9796-847X				ALOUANI S, 1995, EUR J BIOCHEM, V227, P328, DOI 10.1111/j.1432-1033.1995.tb20393.x; AVALOS BR, 1994, BLOOD, V84, P1790, DOI 10.1182/blood.V84.6.1790.bloodjournal8461790; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CACALANO G, 1994, SCIENCE, V265, P682, DOI 10.1126/science.8036519; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; CHUNG CW, 1995, BIOCHEMISTRY-US, V34, P9307, DOI 10.1021/bi00029a005; COOK DN, 1995, SCIENCE, V269, P1583, DOI 10.1126/science.7667639; COYLE AJ, 1995, J EXP MED, V181, P1229, DOI 10.1084/jem.181.3.1229; DAHINDEN C, 1994, IMMUNOL TODAY, V15, P127; DEANDRES B, 1995, IMMUNOLOGY, V69, P271; DRISCOLL KE, 1994, EXP LUNG RES, V20, P473, DOI 10.3109/01902149409031733; FORSTER R, 1994, CELL MOL BIOL, V40, P381; FRANCI C, 1995, J IMMUNOL, V154, P6511; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; GRAHAM GJ, 1990, NATURE, V344, P442, DOI 10.1038/344442a0; GRAHAM GJ, 1993, CELL GROWTH DIFFER, V4, P137; GRAHAM GJ, 1992, DEV BIOL, V151, P377, DOI 10.1016/0012-1606(92)90177-I; Hoogewerf AJ, 1996, BIOCHEM BIOPH RES CO, V218, P337, DOI 10.1006/bbrc.1996.0059; Kitaura M, 1996, J BIOL CHEM, V271, P7725, DOI 10.1074/jbc.271.13.7725; KOCH AE, 1994, J CLIN INVEST, V93, P921, DOI 10.1172/JCI117097; LAROSA GJ, 1992, J BIOL CHEM, V267, P25402; LODI PJ, 1994, SCIENCE, V263, P1762, DOI 10.1126/science.8134838; LOETSCHER M, 1994, J BIOL CHEM, V269, P232; LORD BI, 1993, INT J HEMATOL, V57, P197; McKie J H, 1994, Drug Des Discov, V11, P47; MISHELL BB, 1980, SELECTED METHODS CEL, P3; MIYAGISHI R, 1995, J NEUROL SCI, V129, P223, DOI 10.1016/0022-510X(95)00004-L; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OH KO, 1991, J IMMUNOL, V147, P2978; POST TW, 1995, J IMMUNOL, V155, P5299; POWER CA, 1995, J BIOL CHEM, V270, P19495, DOI 10.1074/jbc.270.33.19495; POWER CA, 1996, IN PRESS TRENDS PHAR, V17; PROUDFOOT AEI, 1995, FEBS LETT, V376, P19, DOI 10.1016/0014-5793(95)01235-X; SCHALL TJ, 1993, J EXP MED, V177, P1821, DOI 10.1084/jem.177.6.1821; SCHALL TJ, 1994, CYTOKINE HDB, P419; TAUB DD, 1993, SCIENCE, V260, P355, DOI 10.1126/science.7682337; VANRIPER G, 1993, J EXP MED, V177, P851, DOI 10.1084/jem.177.3.851	39	26	36	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14445	14451		10.1074/jbc.271.24.14445	http://dx.doi.org/10.1074/jbc.271.24.14445			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662890	hybrid			2022-12-27	WOS:A1996UQ66000075
J	Trejo, SR; Fahl, WE; Ratner, L				Trejo, SR; Fahl, WE; Ratner, L			c-sis/PDGF-B promoter transactivation by the tax protein of human T-cell leukemia virus type 1	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							I TRANSCRIPTIONAL ACTIVATOR; LONG TERMINAL REPEAT; SIMIAN SARCOMA-VIRUS; HTLV-I; GROWTH-FACTOR; GENE-EXPRESSION; DNA-BINDING; V-SIS; 21-BASE-PAIR REPEATS; HUMAN MEGAKARYOCYTES	The human c-sis proto-oncogene promoter is transactivated by the human T-cell leukemia virus type 1 Tax protein in human Jurkat T-cells, Transactivation was > 7-fold in Jurkat cells stably expressing the Tax protein (Jurkat-Tax) than in Jurkat E6.1 cells and was further enhanced in Jurkat-Tax cells stimulated with 12-O-tetradecanoylphorbol-13-acetate and the calcium ionophore, ionomycin. Deletion analysis showed that a 167-base pair promoter fragment retained full Tax responsiveness. Insertion of this minimal Tax-responsive region into a heterologous, minimal promoter resulted in approximately a 7-fold increase of transcriptional activation in the presence of Tax. Linker scanning insertion analysis of this region identified Tax-responsive elements at nucleotides -64 to -45 (TRE1) and -34 to -15 (TATA box region). TRE1 contains a consensus binding site for the Sp family of transcription factors. The TATA box region corresponds to the TATA box and its 3'-neighboring sequence, Gel-shift and antibody supershift analysis of TRE1-binding proteins in unstimulated Jurkat E6.1 and Jurkat-Tax nuclear extracts identified Spl and Sp3 as the main TRE1 binding factors. Nuclear extracts from stimulated Jurkat E6.1 and Jurkat Tax cells identified an additional TRE1 binding factor, Egr-1. These studies define a novel mechanism whereby Tax transactivates the c-sis promoter.	WASHINGTON UNIV, SCH MED, DIV MOLEC ONCOL, ST LOUIS, MO 63110 USA; UNIV WISCONSIN, SCH MED, MCARDLE LAB CANC RES, MADISON, WI 53706 USA	Washington University (WUSTL); University of Wisconsin System; University of Wisconsin Madison				Ratner, Lee/0000-0003-2744-7294	NATIONAL CANCER INSTITUTE [R01CA063417] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007088] Funding Source: NIH RePORTER; NCI NIH HHS [CA63417] Funding Source: Medline; NHLBI NIH HHS [5 T32 HL07088] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABBOUD HE, 1987, J CLIN INVEST, V80, P675, DOI 10.1172/JCI113121; ALITALO R, 1987, EMBO J, V6, P1213, DOI 10.1002/j.1460-2075.1987.tb02356.x; ARMSTRONG AP, 1993, P NATL ACAD SCI USA, V90, P7303, DOI 10.1073/pnas.90.15.7303; BALLARD DW, 1988, SCIENCE, V241, P1652, DOI 10.1126/science.2843985; BEJCEK BE, 1989, SCIENCE, V245, P1496, DOI 10.1126/science.2551043; BENDAVID Y, 1991, GENE DEV, V5, P908, DOI 10.1101/gad.5.6.908; BHAT NK, 1989, J IMMUNOL, V142, P672; BIRKENMEIER TM, 1991, J BIOL CHEM, V266, P20544; BRASIER AR, 1989, BIOTECHNIQUES, V7, P1116; CAO XM, 1990, MOL CELL BIOL, V10, P1931, DOI 10.1128/MCB.10.5.1931; CLARKE MF, 1984, NATURE, V308, P464, DOI 10.1038/308464a0; DENNIG J, 1995, J BIOL CHEM, V270, P12737, DOI 10.1074/jbc.270.21.12737; DEWET JR, 1987, MOL CELL BIOL, V7, P725, DOI 10.1128/MCB.7.2.725; DITTMER J, 1994, J BIOL CHEM, V269, P21428; DOOLITTLE RF, 1983, SCIENCE, V221, P275, DOI 10.1126/science.6304883; EBERT SN, 1995, J BIOL CHEM, V270, P17299, DOI 10.1074/jbc.270.29.17299; FRANKLIN AA, 1993, J BIOL CHEM, V268, P21225; FUJII M, 1991, ONCOGENE, V6, P1023; FUJII M, 1992, GENE DEV, V6, P2066, DOI 10.1101/gad.6.11.2066; FUJISAWA JI, 1991, J VIROL, V65, P4525, DOI 10.1128/JVI.65.8.4525-4528.1991; GEGONNE A, 1993, EMBO J, V12, P1169, DOI 10.1002/j.1460-2075.1993.tb05758.x; GLADWIN AM, 1990, BRIT J HAEMATOL, V76, P333, DOI 10.1111/j.1365-2141.1990.tb06364.x; Goustin AS, 1990, GROWTH FACTORS, V2, P189, DOI 10.3109/08977199009071505; GOUSTIN AS, 1985, CELL, V41, P301, DOI 10.1016/0092-8674(85)90083-2; HART CE, 1990, J INVEST DERMATOL, V94, pS53, DOI 10.1111/1523-1747.ep12875065; HARTZOG GA, 1993, MOL CELL BIOL, V13, P44, DOI 10.1128/MCB.13.1.44; IADEMARCO MF, 1993, P NATL ACAD SCI USA, V90, P3943, DOI 10.1073/pnas.90.9.3943; JIN HM, 1993, P NATL ACAD SCI USA, V90, P7563, DOI 10.1073/pnas.90.16.7563; JIN HM, 1994, J BIOL CHEM, V269, P28648; JOHNSSON A, 1982, BIOCHEM BIOPH RES CO, V104, P66, DOI 10.1016/0006-291X(82)91941-6; KEATING MT, 1988, SCIENCE, V239, P914, DOI 10.1126/science.2829358; KHACHIGIAN LM, 1994, J BIOL CHEM, V269, P22647; KILBOURNE EJ, 1995, J BIOL CHEM, V270, P7004, DOI 10.1074/jbc.270.12.7004; KIM SJ, 1990, J EXP MED, V172, P121, DOI 10.1084/jem.172.1.121; LAMARCO K, 1991, SCIENCE, V253, P789, DOI 10.1126/science.1876836; LEIDEN JM, 1992, J VIROL, V66, P5890, DOI 10.1128/JVI.66.10.5890-5897.1992; LEUNG K, 1988, NATURE, V333, P776, DOI 10.1038/333776a0; LI M, 1993, MOL CELL BIOL, V13, P6490, DOI 10.1128/MCB.13.10.6490; MACKMAN N, 1995, FASEB J, V9, P883, DOI 10.1096/fasebj.9.10.7615158; MATTHEWS MAH, 1992, MOL CELL BIOL, V12, P1986, DOI 10.1128/MCB.12.5.1986; MIYOSHI I, 1981, NATURE, V294, P770, DOI 10.1038/294770a0; MUTERO A, 1995, J BIOL CHEM, V270, P1866, DOI 10.1074/jbc.270.40.23511; NIMER SD, 1989, ONCOGENE, V4, P671; NIMER SD, 1991, ONCOGENE, V2, P1034; NYBORG JK, 1988, P NATL ACAD SCI USA, V85, P1457, DOI 10.1073/pnas.85.5.1457; PANTAZIS P, 1987, ONCOGENE, V1, P285; RATNER L, 1987, NUCLEIC ACIDS RES, V15, P6017, DOI 10.1093/nar/15.15.6017; RATNER L, 1989, NUCLEIC ACIDS RES, V17, P4101, DOI 10.1093/nar/17.11.4101; RATNER L, 1988, MEDICINE, V67, P401, DOI 10.1097/00005792-198811000-00004; ROSS R, 1978, CELL, V14, P203, DOI 10.1016/0092-8674(78)90107-1; SEELER JS, 1993, VIROLOGY, V196, P442, DOI 10.1006/viro.1993.1500; SEIKI M, 1984, NATURE, V309, P640, DOI 10.1038/309640a0; SEIKI M, 1983, P NATL ACAD SCI-BIOL, V80, P3618, DOI 10.1073/pnas.80.12.3618; SHINGU T, 1994, J BIOL CHEM, V269, P32551; SMITH MR, 1990, GENE DEV, V4, P1875, DOI 10.1101/gad.4.11.1875; SUZUKI T, 1993, P NATL ACAD SCI USA, V90, P610, DOI 10.1073/pnas.90.2.610; THIELAN BJ, 1987, J GEN VIROL, V68, P2265, DOI 10.1099/0022-1317-68-8-2265; THOMPSON CB, 1992, MOL CELL BIOL, V12, P1043, DOI 10.1128/MCB.12.3.1043; WAGNER S, 1993, SCIENCE, V262, P395, DOI 10.1126/science.8211160; WANO Y, 1988, P NATL ACAD SCI USA, V85, P9733, DOI 10.1073/pnas.85.24.9733; WATERFIELD MD, 1983, NATURE, V304, P35, DOI 10.1038/304035a0; YIN MJ, 1995, J VIROL, V69, P6209, DOI 10.1128/JVI.69.10.6209-6218.1995; YU CY, 1991, J BIOL CHEM, V266, P8907; ZHAO LJ, 1992, P NATL ACAD SCI USA, V89, P7070, DOI 10.1073/pnas.89.15.7070; ZHAO LJ, 1991, P NATL ACAD SCI USA, V88, P11445, DOI 10.1073/pnas.88.24.11445	65	24	24	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14584	14590		10.1074/jbc.271.24.14584	http://dx.doi.org/10.1074/jbc.271.24.14584			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662878	hybrid			2022-12-27	WOS:A1996UQ66000095
J	Ventura, F; Liu, F; Doody, J; Massague, J				Ventura, F; Liu, F; Doody, J; Massague, J			Interaction of transforming growth factor-beta receptor I with farnesyl-protein transferase-alpha, in yeast and mammalian cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CLONING; KINASE; FARNESYLTRANSFERASE; EXPRESSION; COMPLEX; SUBUNIT	Transforming growth factor beta (TGF-beta) signals through two transmembrane serine/threonine kinases, known as T beta R-I and T beta R-II. Several lines of evidence suggest that T beta R-II acts as a primary receptor, binding TGF-beta and phosphorylating T beta R-I whose kinase activity then propagates the signal to unknown substrates. We report an interaction between T beta R-I and the farnesyl-protein transferase-alpha subunit (FT-alpha) both in a yeast two-hybrid system and in mammalian cells. These findings raise the possibility that TGF-beta might regulate cellular functions by altering the ability of FT-alpha to catalyze isoprenylation of targets such as G proteins, lamins, or cytoskeletal components, However, we provide evidence that TGF-beta action does not alter the overall protein isoprenyl transferase activity in Mv1Lu mink lung epithelial cells, In fact, the beta subunits of farnesyl transferase and geranylgeranyl transferase, which are necessary for the activity of FT-alpha, prevent the association of FT-alpha with T beta R-I, Furthermore, farnesyl transferase activity is shown to be dispensable for TGF-beta signaling of growth inhibitory and transcriptional responses in these cells, These results suggest that the interaction between T beta R-I and FT-alpha does not affect the known functions of these two proteins.	MEM SLOAN KETTERING CANC CTR,HOWARD HUGHES MED INST,CELL BIOL & GENET PROGRAM,NEW YORK,NY 10021	Howard Hughes Medical Institute; Memorial Sloan Kettering Cancer Center			Ventura, Francesc/ABG-2285-2020; Ventura, Francesc/K-9700-2014	Ventura, Francesc/0000-0001-9673-9405; Ventura, Francesc/0000-0001-9673-9405; Massague, Joan/0000-0001-9324-8408	NCI NIH HHS [CA34610] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA034610, R37CA034610] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ALEXANDROW MG, 1995, CANCER RES, V55, P1452; ANDRES DA, 1993, J BIOL CHEM, V268, P1383; ATTISANO L, 1994, BBA-MOL CELL RES, V1222, P71, DOI 10.1016/0167-4889(94)90026-4; ATTISANO L, 1993, CELL, V75, P671, DOI 10.1016/0092-8674(93)90488-C; Ausubel FM, 1992, CURRENT PROTOCOLS MO; CARCAMO J, 1994, MOL CELL BIOL, V14, P3810, DOI 10.1128/MCB.14.6.3810; CHEN WJ, 1991, P NATL ACAD SCI USA, V88, P11368, DOI 10.1073/pnas.88.24.11368; CLARKE S, 1992, ANNU REV BIOCHEM, V61, P355, DOI 10.1146/annurev.bi.61.070192.002035; EWEN ME, 1993, CELL, V74, P1009, DOI 10.1016/0092-8674(93)90723-4; FRANZEN P, 1993, CELL, V75, P681, DOI 10.1016/0092-8674(93)90489-D; GYURIS J, 1993, CELL, V75, P791, DOI 10.1016/0092-8674(93)90498-F; HANNON GJ, 1994, NATURE, V371, P257, DOI 10.1038/371257a0; JAMES GL, 1993, SCIENCE, V260, P1937, DOI 10.1126/science.8316834; KAWABATA M, 1995, J BIOL CHEM, V270, P5625, DOI 10.1074/jbc.270.10.5625; KAWABATA M, 1995, J BIOL CHEM, V270, P29628; LIN HY, 1992, CELL, V68, P775, DOI 10.1016/0092-8674(92)90152-3; LIU F, 1995, MOL CELL BIOL, V15, P3479; MASSAGUE J, 1990, ANNU REV CELL BIOL, V6, P597, DOI 10.1146/annurev.cb.06.110190.003121; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; REYNISDOTTIR I, 1995, GENE DEV, V9, P1831, DOI 10.1101/gad.9.15.1831; ROBERTS AB, 1990, PEPTIDE GROWTH FACTO, P419; SEPPLORENZINO L, 1995, CANCER RES, V55, P5302; VENTURA F, 1994, EMBO J, V13, P5581, DOI 10.1002/j.1460-2075.1994.tb06895.x; Wang TW, 1996, SCIENCE, V271, P1120, DOI 10.1126/science.271.5252.1120; WANG TW, 1994, SCIENCE, V265, P674, DOI 10.1126/science.7518616; WIESER R, 1995, EMBO J, V14, P2199, DOI 10.1002/j.1460-2075.1995.tb07214.x; WRANA JL, 1992, CELL, V71, P1003, DOI 10.1016/0092-8674(92)90395-S; WRANA JL, 1994, NATURE, V370, P341, DOI 10.1038/370341a0	28	45	47	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13931	13934		10.1074/jbc.271.24.13931	http://dx.doi.org/10.1074/jbc.271.24.13931			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663177	Green Published, hybrid			2022-12-27	WOS:A1996UQ66000002
J	Zhuang, P; Li, H; Williams, JG; Wagner, NV; Seiffert, D; Peterson, CB				Zhuang, P; Li, H; Williams, JG; Wagner, NV; Seiffert, D; Peterson, CB			Characterization of the denaturation and renaturation of human plasma vitronectin .2. Investigation into the mechanism of formation of multimers	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							HEPARIN-BINDING PROPERTIES; SERUM SPREADING FACTOR; HUMAN S-PROTEIN; ANTITHROMBIN-III; PURIFICATION; EXPRESSION; COMPLEMENT; THROMBIN; UREA; ACID	Unfolding and refolding of plasma vitronectin appear irreversible under near physiological conditions, with rearrangements of disulfides and self-association to a multimeric form observed as prominent structural alterations which accompany denaturation. A mechanism for the folding reactions of vitronectin has been proposed (Zhuang, P., Blackburn, M. N., and Peterson, C. B. (1996) J. Biol. Chem. 270, 14323-14332) in which vitronectin acquires a partially folded intermediate structure which is highly prone to oligomerize into a multimeric form. Strongly oxidizing conditions adopted for refolding from urea were effective at preventing disulfide rearrangement which disrupts distal disulfides near the C terminus of the protein. Prohibiting disulfide rearrangement under these conditions, however, was not sufficient to achieve reversibility in folding. In contrast, variations in the ionic strength of the refolding medium affect the partitioning of species so that refolded monomers are obtained at high ionic strength, and self-association is precluded. The effects of ionic strength on the partially folded intermediate in the vitronectin folding pathway appear to favor intramolecular hydrophobic collapse to form a stable hydrophobic core for the monomer versus intermolecular hydrophobic interactions which stabilize multimeric vitronectin. Although both ionic and hydrophobic interactions presumably contribute to subunit interfaces within the multimer, the basic heparin-binding region near the C terminus of the protein does not provide binding interactions which are important for self-association of vitronectin.	UNIV TENNESSEE, DEPT BIOCHEM & CELLULAR & MOLEC BIOL, KNOXVILLE, TN 37996 USA; Scripps Res Inst, DEPT VASC BIOL, LA JOLLA, CA 92037 USA	University of Tennessee System; University of Tennessee Knoxville; Scripps Research Institute					NHLBI NIH HHS [HL50676, HL50704] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R29HL050676, R01HL050676, R29HL050704] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNES DW, 1985, J BIOL CHEM, V260, P9117; BITTORF SV, 1993, J BIOL CHEM, V268, P24838; BUCHNER J, 1992, ANAL BIOCHEM, V205, P263, DOI 10.1016/0003-2697(92)90433-8; BUCHNER J, 1991, BIO-TECHNOL, V9, P157, DOI 10.1038/nbt0291-157; CHERNY RC, 1993, J BIOL CHEM, V268, P9725; DAHLBACK B, 1985, BIOCHEMISTRY-US, V24, P2368, DOI 10.1021/bi00330a036; Harlow E., 1988, ANTIBODIES LAB MANUA; HAYASHI M, 1985, J BIOCHEM-TOKYO, V98, P1135, DOI 10.1093/oxfordjournals.jbchem.a135363; HOGASEN K, 1992, J BIOL CHEM, V267, P23076; HUTH JR, 1993, J BIOL CHEM, V268, P16472; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LILIE H, 1994, J BIOL CHEM, V269, P14290; Pace C.N., 1990, PROTEIN STRUCTURE PR, P311; PREISSNER KT, 1991, THROMB HAEMOSTASIS, V66, P123; PREISSNER KT, 1985, BIOCHEM J, V231, P349, DOI 10.1042/bj2310349; PREISSNER KT, 1987, J BIOL CHEM, V262, P12247; PREISSNER KT, 1989, BLUT, V59, P419, DOI 10.1007/BF00349063; PREISSNER KT, 1991, BIOCHEM J, V7, P275; ROBYT JF, 1987, BICOH TECHNIQUES THE; RUDOLPH R, 1990, MODERN METHOD IN PROTEIN- AND NUCLEIC ACID RESEARCH, P149; SEIFFERT D, 1995, FEBS LETT, V368, P155, DOI 10.1016/0014-5793(95)00630-R; SEIFFERT D, 1994, J BIOL CHEM, V269, P2659; STOCKMANN A, 1993, J BIOL CHEM, V268, P22874; SUZUKI S, 1985, EMBO J, V4, P2519, DOI 10.1002/j.1460-2075.1985.tb03965.x; Tomasini B R, 1991, Prog Hemost Thromb, V10, P269; TOMASINI BR, 1989, BIOCHEMISTRY-US, V28, P7617, DOI 10.1021/bi00445a017; TOMASINI BR, 1988, BLOOD, V72, P903; ZHAO Y, 1993, ARCH BIOCHEM BIOPHYS, V304, P434, DOI 10.1006/abbi.1993.1372; Zhuang P, 1996, J BIOL CHEM, V271, P14323, DOI 10.1074/jbc.271.24.14323	29	35	35	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14333	14343		10.1074/jbc.271.24.14333	http://dx.doi.org/10.1074/jbc.271.24.14333			11	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8663085	hybrid			2022-12-27	WOS:A1996UQ66000061
J	Oppermann, M; Freedman, NJ; Alexander, RW; Lefkowitz, RJ				Oppermann, M; Freedman, NJ; Alexander, RW; Lefkowitz, RJ			Phosphorylation of the type 1A angiotensin II receptor by G protein-coupled receptor kinases and protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							RENAL MESANGIAL CELLS; SITE-DIRECTED MUTAGENESIS; POLYPHOSPHOINOSITIDE HYDROLYSIS; PHOSPHOINOSITIDE HYDROLYSIS; HOMOLOGOUS DESENSITIZATION; DOWN-REGULATION; MOBILIZATION; INHIBITORS; PATHWAYS	The type 1A angiotensin II receptor (AT(1A)-R), which mediates cardiovascular effects of angiotensin II, has been shown to undergo rapid agonist-induced desensitization. We investigated the potential role of second messenger-activated kinases and G protein-coupled receptor kinases (GRKs) in the regulation of this receptor. In 293 cells transfected with the AT(1A)-R, a 3-min challenge with angiotensin II engendered a 46% decrease in subsequent angiotensin II-stimulated phosphoinositide hydrolysis in intact cells. This agonist-induced desensitization correlated temporally and dose-dependently with the phosphorylation of the receptor to a stoichiometry of 1 mol of phosphate/mol of receptor, as assessed by immunoprecipitation of receptors from cells metabolically labeled with P-32(i). Agonist-induced receptor phosphorylation was reduced by 40-50% by either overexpression of a dominant negative K220R mutant GRK2 or treatment of the cells with the protein kinase C (PKC) inhibitor staurosporine, in a virtually additive fashion. Cellular overexpression of GRK2(K220R) not only inhibited agonist-induced AT(1A)-R phosphorylation, but also prevented receptor desensitization, as assessed by angiotensin II-stimulated GTPase activity in membranes prepared from agonist-treated and control cells. In contrast, PKC inhibition by staurosporine did not affect homologous desensitization of the AT(1A)-R. Overexpression of GRKs 2, 3, or 5 significantly augmented the agonist-induced AT(1A)-R phosphorylation 1.5- to 1.7-fold (p < 0.001). These findings suggest a role for receptor phosphorylation by one or several GRKs in the rapid agonist-induced desensitization of the AT(1A)-R.	DUKE UNIV, MED CTR, DEPT MED, HOWARD HUGHES MED INST, DURHAM, NC 27710 USA; DUKE UNIV, MED CTR, DEPT BIOCHEM, DURHAM, NC 27710 USA; EMORY UNIV, SCH MED, DEPT MED, DIV CARDIOL, ATLANTA, GA 30322 USA	Duke University; Howard Hughes Medical Institute; Duke University; Emory University			Lefkowitz, Robert/AAW-2649-2021		NHLBI NIH HHS [HL16037, HL03008] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL016037, R37HL016037] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ABDELLATIF MM, 1991, CIRC RES, V69, P800, DOI 10.1161/01.RES.69.3.800; BARAK LS, 1994, J BIOL CHEM, V269, P2790; BARKER S, 1995, FEBS LETT, V369, P263, DOI 10.1016/0014-5793(95)00725-O; BOULAY G, 1994, ENDOCRINOLOGY, V135, P2130, DOI 10.1210/en.135.5.2130; BRASS LF, 1992, J BIOL CHEM, V267, P6044; CASSEL D, 1976, BIOCHIM BIOPHYS ACTA, V452, P538, DOI 10.1016/0005-2744(76)90206-0; COTECCHIA S, 1992, J BIOL CHEM, V267, P1633; DUNLAY R, 1990, AM J PHYSIOL, V258, pF223, DOI 10.1152/ajprenal.1990.258.2.F223; FREEDMAN NJ, 1995, J BIOL CHEM, V270, P17953, DOI 10.1074/jbc.270.30.17953; GASC JM, 1994, HYPERTENSION, V24, P531, DOI 10.1161/01.HYP.24.5.531; GIERSCHIK P, 1994, METHOD ENZYMOL, V237, P13; Griendling K K, 1994, Adv Pharmacol, V28, P269, DOI 10.1016/S1054-3589(08)60498-6; HALLER H, 1990, BIOCHEM J, V270, P375, DOI 10.1042/bj2700375; HUNYADY L, 1994, J BIOL CHEM, V269, P31378; INGLESE J, 1993, J BIOL CHEM, V268, P23735; ISHII K, 1994, J BIOL CHEM, V269, P1125; ITO M, 1995, P NATL ACAD SCI USA, V92, P3521, DOI 10.1073/pnas.92.8.3521; KAI H, 1994, HYPERTENSION, V24, P523, DOI 10.1161/01.HYP.24.4.523; KONG GH, 1994, J BIOL CHEM, V269, P13084; LEFKOWITZ RJ, 1993, CELL, V74, P409, DOI 10.1016/0092-8674(93)80042-D; LOHSE MJ, 1993, BIOCHIM BIOPHYS ACTA, V1179, P171, DOI 10.1016/0167-4889(93)90139-G; LOHSE MJ, 1990, J BIOL CHEM, V265, P3202; MURPHY TJ, 1991, NATURE, V351, P233, DOI 10.1038/351233a0; OCHSNER M, 1993, EUR J PHARM-MOLEC PH, V245, P15, DOI 10.1016/0922-4106(93)90164-5; OHYAMA K, 1992, BIOCHEM BIOPH RES CO, V189, P677, DOI 10.1016/0006-291X(92)92254-U; PALSRYLAARSDAM R, 1995, J BIOL CHEM, V270, P29004, DOI 10.1074/jbc.270.48.29004; PEACH MJ, 1986, KIDNEY HORMONES, P273; PEI G, 1995, MOL PHARMACOL, V48, P173; PFEILSCHIFTER J, 1988, BIOCHIM BIOPHYS ACTA, V969, P263, DOI 10.1016/0167-4889(88)90061-4; PFEILSCHIFTER J, 1990, FEBS LETT, V261, P307, DOI 10.1016/0014-5793(90)80578-7; PFEILSCHIFTER J, 1989, BIOCHEM J, V262, P285, DOI 10.1042/bj2620285; PIPPIG S, 1993, J BIOL CHEM, V268, P3201; PREMONT RT, 1994, J BIOL CHEM, V269, P6832; ROTH NS, 1991, P NATL ACAD SCI USA, V88, P6201, DOI 10.1073/pnas.88.14.6201; SEFTON BM, 1991, METHOD ENZYMOL, V201, P245; SMIT MJ, 1992, BRIT J PHARMACOL, V107, P448, DOI 10.1111/j.1476-5381.1992.tb12766.x; THOMAS WG, 1995, J BIOL CHEM, V270, P207, DOI 10.1074/jbc.270.1.207; YAMANO Y, 1992, BIOCHEM BIOPH RES CO, V187, P1426, DOI 10.1016/0006-291X(92)90461-S	38	206	209	0	5	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13266	13272		10.1074/jbc.271.22.13266	http://dx.doi.org/10.1074/jbc.271.22.13266			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662816	hybrid			2022-12-27	WOS:A1996UN47400089
J	Torres, M; Ye, RD				Torres, M; Ye, RD			Activation of the mitogen-activated protein kinase pathway by fMet-Leu-Phe in the absence of Lyn and tyrosine phosphorylation of SHC in transfected cells	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FORMYL PEPTIDE RECEPTOR; SIGNAL TRANSDUCTION; HUMAN NEUTROPHILS; RAS; GRB2; STIMULATION; DOMAIN; BINDS	The chemotactic peptide f-Met-Leu-Phe (fMLP) stimulates leukocyte functions through binding and activation of a specific G-protein-coupled formyl peptide receptor (FPR), Recent studies have shown that stimulation of neutrophils with fMLP induces the activation of two members of the mitogen-activated protein kinase (MAP kinase) family, ERK1 and ERK2, through mechanisms that are not completely understood but may involve the phosphorylation of the adapter protein SHC by the Src-related kinase Lyn. In this study, transfected fibroblasts expressing the rabbit FPR were used to investigate further the role of Lyn and SHC phosphorylation in fMLP-stimulated MAP kinase activation. Stimulation of transfected cells with fMLP resulted in the time- and dose-dependent increase in tyrosine phosphorylation and activation of ERK1 and ERK2 and the activation of MEK, the MAP kinase/ERK kinase, The activation of both ERKs and MEK was inhibited by preincubation of the cells with pertussis toxin, indicating that activation was dependent upon a G(i)/G(o)-like protein that couples to the receptor. Our data also show that, unlike neutrophils, FPR-transfected fibroblasts do not. express the Src-related kinase Lyn. In the absence of Lyn, fMLP stimulation did not result in an increased tyrosine phosphorylation of the adapter protein SHC, whereas it was still able to induce MAP kinase activation. These data suggest that Lyn and SHC are not the only upstream signals for activation of the MAP kinase/ERK pathway by fMLP and demonstrate the potential application of the FPR-transfected cells for the delineation of additional signaling mechanisms stimulated by rMLP.	Scripps Res Inst, RES INST, DEPT IMMUNOL, LA JOLLA, CA 92037 USA	Scripps Research Institute	Torres, M (corresponding author), UNIV SO CALIF, CHILDRENS HOSP LOS ANGELES,RES INST,DEPT PEDIAT, 4650 SUNSET BLVD, MS57, LOS ANGELES, CA 90027 USA.		Ye, Richard/O-5223-2016; Ye, Richard/ABF-2413-2020	Ye, Richard/0000-0002-2164-5620; Ye, Richard/0000-0002-2164-5620	NIAID NIH HHS [AI33503] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R56AI033503, R01AI033503] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ALBLAS J, 1993, J BIOL CHEM, V268, P22235; ALESSANDRINI A, 1992, P NATL ACAD SCI USA, V89, P8200, DOI 10.1073/pnas.89.17.8200; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; BUHL AM, 1995, J BIOL CHEM, V270, P19828, DOI 10.1074/jbc.270.34.19828; CAZAUBON SM, 1994, J BIOL CHEM, V269, P24805; CHARDIN P, 1993, SCIENCE, V260, P1338, DOI 10.1126/science.8493579; CHEN YH, 1994, J BIOL CHEM, V269, P27372; CRESPO P, 1994, NATURE, V369, P418, DOI 10.1038/369418a0; DING JB, 1993, J BIOL CHEM, V268, P17326; Downey G P, 1995, Curr Opin Hematol, V2, P76; EDER M, 1993, EMBO J, V12, P1647, DOI 10.1002/j.1460-2075.1993.tb05810.x; ERICKSON AK, 1990, J BIOL CHEM, V265, P19728; FAURE M, 1994, J BIOL CHEM, V269, P7851; FELLER SM, 1994, TRENDS BIOCHEM SCI, V19, P453, DOI 10.1016/0968-0004(94)90129-5; FLORDELLIS CS, 1995, J BIOL CHEM, V270, P3491, DOI 10.1074/jbc.270.8.3491; GARDNER AM, 1993, J BIOL CHEM, V268, P17896; GAUDRY M, 1995, BLOOD, V86, P3567, DOI 10.1182/blood.V86.9.3567.bloodjournal8693567; GRINSTEIN S, 1992, J BIOL CHEM, V267, P18122; HAWES BE, 1995, J BIOL CHEM, V270, P17148, DOI 10.1074/jbc.270.29.17148; HONDA Z, 1994, J BIOL CHEM, V269, P2307; INDIK ZK, 1995, BLOOD, V85, P1175, DOI 10.1182/blood.V85.5.1175.bloodjournal8551175; KEYSE SM, 1995, BBA-MOL CELL RES, V1265, P152, DOI 10.1016/0167-4889(94)00211-V; KNAUS UG, 1995, SCIENCE, V269, P221, DOI 10.1126/science.7618083; KOCH WJ, 1994, J BIOL CHEM, V269, P6193; KOCH WJ, 1994, P NATL ACAD SCI USA, V91, P12706, DOI 10.1073/pnas.91.26.12706; KUSUNOKI T, 1992, BIOCHEM BIOPH RES CO, V183, P789, DOI 10.1016/0006-291X(92)90552-V; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; LI N, 1993, NATURE, V363, P85, DOI 10.1038/363085a0; LOWENSTEIN EJ, 1992, CELL, V70, P431, DOI 10.1016/0092-8674(92)90167-B; LU DJ, 1993, BLOOD CELLS, V19, P343; MANSER E, 1994, NATURE, V367, P40, DOI 10.1038/367040a0; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; OHMICHI M, 1994, J BIOL CHEM, V269, P3783; PACE AM, 1995, MOL BIOL CELL, V6, P1685, DOI 10.1091/mbc.6.12.1685; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; PHILIPS MR, 1993, SCIENCE, V259, P977, DOI 10.1126/science.8438158; PTASZNIK A, 1995, J BIOL CHEM, V270, P19969, DOI 10.1074/jbc.270.34.19969; QUEHENBERGER O, 1992, J BIOL CHEM, V267, P19757; ROLLET E, 1994, J IMMUNOL, V153, P353; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; SCHLESSINGER J, 1993, TRENDS BIOCHEM SCI, V18, P2732; SEGER R, 1995, FASEB J, V9, P726, DOI 10.1096/fasebj.9.9.7601337; THOMASON PA, 1994, J BIOL CHEM, V269, P16525; THOMPSON HL, 1993, BIOCHEM J, V290, P483, DOI 10.1042/bj2900483; THOMPSON HL, 1994, J BIOL CHEM, V269, P9486; TORRES M, 1993, J IMMUNOL, V150, P1563; VANBIESEN T, 1995, NATURE, V376, P781, DOI 10.1038/376781a0; VERGHESE M, 1986, BIOCHEM BIOPH RES CO, V138, P887, DOI 10.1016/S0006-291X(86)80579-4; WIESMULLER L, 1994, CELL SIGNAL, V6, P247, DOI 10.1016/0898-6568(94)90030-2; WORTHEN GS, 1994, J CLIN INVEST, V94, P815, DOI 10.1172/JCI117401; YE RD, 1993, J IMMUNOL, V150, P1383	51	17	19	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 31	1996	271	22					13244	13249		10.1074/jbc.271.22.13244	http://dx.doi.org/10.1074/jbc.271.22.13244			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UN474	8662760				2022-12-27	WOS:A1996UN47400086
J	Safran, M; Farwell, AP; Leonard, JL				Safran, M; Farwell, AP; Leonard, JL			Catalytic activity of type II iodothyronine 5'-deiodinase polypeptide is dependent upon a cyclic AMP activation factor	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							STIMULATED GLIAL-CELLS; REVERSE TRIIODOTHYRONINE; GEL-ELECTROPHORESIS; CEREBRAL-CORTEX; THYROID-HORMONE; PINEAL-GLAND; THYROXINE; RAT; ASTROCYTES; PROTEIN	Type II iodothyronine 5'-deiodinase is an similar to 200-kDa multimeric enzyme in the brain that catalyzes the deiodination of thyroxine (T-4) to its active metabolite, 3,5,3'-triiodothyronine. In astrocytes, cAMP stimulation is required to express catalytically active type II iodothyronine 5'-deiodinase. The affinity ligand N-bromoacetyl-L-T-4 specifically labels the 29-kDa substrate-binding subunit (p29) of this enzyme in cAMP-stimulated astro cytes, To determine the requirements for cAMP-induced activation of this enzyme, we optimized N-bromoacetyl-L-T-4 labeling of p29 in astrocytes lacking type II iodothyronine 5'-deiodinase activity and examined the effects of cAMP on the hydrodynamic properties and subcellular location of the enzyme, We show that the p29 subunit is expressed in unstimulated astrocytes and requires 10-fold higher concentrations of N-bromoacetyl-L-T-4 to achieve incorporation levels equal to those of p29 in cAMP-stimulated cells, Gel filtration showed that p29 was part of a multimeric membrane-associated complex in both cAMP-stimulated and unstimulated astrocytes and that cAMP stimulation led to an increase of similar to 60 kDa in the mass of the holoenzyme, In unstimulated astrocytes, p29 resides in the perinuclear space, Cyclic AMP stimulation leads to the translocation of p29 to the plasma membrane coincident with the appearance of deiodinating activity. These data show that cAMP dependent activation of type II iodothyronine 5'-deiodinase activity results from the synthesis of additional activating factor(s) that associates with inactive enzyme and leads to the translocation of enzyme polypeptide(s) from the perinuclear space to the plasma membrane.	UNIV MASSACHUSETTS, SCH MED, DEPT NUCL MED, MOLEC ENDOCRINOL LAB, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MOLEC & CELLULAR PHYSIOL, MOLEC ENDOCRINOL LAB, WORCESTER, MA 01655 USA; UNIV MASSACHUSETTS, SCH MED, DEPT MED, MOLEC ENDOCRINOL LAB, WORCESTER, MA 01655 USA	University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester; University of Massachusetts System; University of Massachusetts Worcester				Farwell, Alan/0000-0001-7716-2719	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK038772, K08DK002005] Funding Source: NIH RePORTER; NIDDK NIH HHS [DK 02005, DK-38772] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Aronson N N Jr, 1974, Methods Enzymol, V31, P90; BEHNE D, 1988, BIOCHIM BIOPHYS ACTA, V966, P12, DOI 10.1016/0304-4165(88)90123-7; BERRY MJ, 1991, ENDOCRINOLOGY, V129, P550, DOI 10.1210/endo-129-1-550; CHANOINE JP, 1992, ENDOCRINOLOGY, V131, P479, DOI 10.1210/en.131.1.479; CLEVELAND DW, 1977, J BIOL CHEM, V252, P1102; DAVEY JC, 1995, J BIOL CHEM, V270, P26786, DOI 10.1074/jbc.270.45.26786; DUVE CD, 1975, SCIENCE, V189, P186, DOI 10.1126/science.1138375; FARWELL AP, 1989, J BIOL CHEM, V264, P20561; Farwell AP, 1996, J BIOL CHEM, V271, P16369, DOI 10.1074/jbc.271.27.16369; FARWELL AP, 1993, J BIOL CHEM, V268, P5055; FARWELL AP, 1990, J BIOL CHEM, V265, P18546; GUERRERO JM, 1988, ENDOCRINOLOGY, V122, P236, DOI 10.1210/endo-122-1-236; HALPERIN Y, 1994, ENDOCRINOLOGY, V135, P1464, DOI 10.1210/en.135.4.1464; KAISER CA, 1986, ENDOCRINOLOGY, V119, P762, DOI 10.1210/endo-119-2-762; Kaplan MM, 1986, THYROID HORMONE META, P231; KOHRLE J, 1990, J BIOL CHEM, V265, P6155; LEONARD JL, 1990, J BIOL CHEM, V265, P940; LEONARD JL, 1981, SCIENCE, V214, P571, DOI 10.1126/science.7291997; LEONARD JL, 1988, BIOCHEM BIOPH RES CO, V151, P1164, DOI 10.1016/S0006-291X(88)80488-1; Leonard JL, 1986, THYROID HORMONE META, P189; NIKODEM V, 1979, ANAL BIOCHEM, V97, P382, DOI 10.1016/0003-2697(79)90089-7; OSUNA C, 1993, EXPERIENTIA, V49, P329, DOI 10.1007/BF01923413; RISKIND PN, 1987, BRAIN RES, V420, P194, DOI 10.1016/0006-8993(87)90260-5; RUBIO A, 1993, J PINEAL RES, V14, P53, DOI 10.1111/j.1600-079X.1993.tb00485.x; SAFRAN M, 1991, J BIOL CHEM, V266, P13477; SAFRAN M, 1991, J BIOL CHEM, V266, P3233; SAFRAN M, 1991, ENDOCRINOLOGY, V129, P2011, DOI 10.1210/endo-129-4-2011; SCHOENMAKERS CHH, 1995, MOL CELL ENDOCRINOL, V107, P173, DOI 10.1016/0303-7207(94)03440-5; SILVA JE, 1985, ENDOCRINOLOGY, V116, P1627, DOI 10.1210/endo-116-4-1627; VISSER TJ, 1982, P NATL ACAD SCI-BIOL, V79, P5080, DOI 10.1073/pnas.79.16.5080; WYSS M, 1993, BIOCHEM J, V291, P463, DOI 10.1042/bj2910463	31	23	23	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUL 5	1996	271	27					16363	16368		10.1074/jbc.271.27.16363	http://dx.doi.org/10.1074/jbc.271.27.16363			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UW352	8663169	hybrid			2022-12-27	WOS:A1996UW35200075
J	Miao, WY; Eichelberger, L; Baker, L; Marshall, MS				Miao, WY; Eichelberger, L; Baker, L; Marshall, MS			p120 Ras GTPase-activating protein interacts with Ras-GTP through specific conserved residues	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-TERMINAL DOMAIN; SACCHAROMYCES-CEREVISIAE; TRIPHOSPHATE CONFORMATION; CIRCULAR-DICHROISM; ADENYLATE-CYCLASE; NF1 GENE; GAP; P21; NEUROFIBROMIN; MUTAGENESIS	Previous structural studies of RasGAP have failed to clearly localize sites of Pas interaction to individual amino acids, Hypothesizing that sites of interaction with Ras-GTP would be conserved, 11 of the most highly conserved amino acid residues of RasGAP were changed by mutation. Each mutant protein was purified as a glutathione S-transferase catalytic domain fusion and analyzed for protein stability, Pas GTPase stimulating activity, affinity for Ras-GTP, and when possible, secondary structure. The majority of conserved positions were found to be important structurally but with no direct role in Pas interactions, However, Arg(786), Lys(831), and Arg(925) were observed to be essential for binding td Ras-GTP but not for protein structure. RasGAP residues 890-902 (block 3A) were observed to be homologous to residues 1540-1552 of the yeast adenylyl cyclase with amino acid substitutions in both regions resulting in increased affinity for Pas. This is the first example of a conserved Pas interaction motif in distinct Pas effector proteins. Our data are supportive of a model for GAP/Ras-GTP association in which the conserved, positively charged Arg(786), Lys(831), and Arg(925) residues form salt bridges with the conserved, negatively charged residues in the Pas effector loop.	INDIANA UNIV, SCH MED, DEPT MED, DIV HEMATOL ONCOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, DEPT BIOCHEM & MOLEC BIOL, INDIANAPOLIS, IN 46202 USA; INDIANA UNIV, SCH MED, WALTHER ONCOL CTR, INDIANAPOLIS, IN 46202 USA; LILLY RES LABS, CANC DIV, INDIANAPOLIS, IN 46285 USA	Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Indiana University System; Indiana University-Purdue University Indianapolis; Walther Cancer Institute; Eli Lilly								ANDERSEN LB, 1993, MOL CELL BIOL, V13, P487, DOI 10.1128/MCB.13.1.487; AVRUCH J, 1994, TRENDS BIOCHEM SCI, V19, P279, DOI 10.1016/0968-0004(94)90005-1; Barnard D, 1995, ONCOGENE, V10, P1283; BOGUSKI MS, 1993, NATURE, V366, P643, DOI 10.1038/366643a0; BOLLAG G, 1991, ANNU REV CELL BIOL, V7, P601, DOI 10.1146/annurev.cellbio.7.1.601; COLICELLI J, 1990, MOL CELL BIOL, V10, P2539, DOI 10.1128/MCB.10.6.2539; CULLEN PJ, 1995, NATURE, V376, P527, DOI 10.1038/376527a0; DOTTO GP, 1984, J MOL BIOL, V172, P507, DOI 10.1016/S0022-2836(84)80020-0; ECCLESTON JF, 1993, J BIOL CHEM, V268, P27012; FRECH M, 1994, BIOCHEMISTRY-US, V33, P3237, DOI 10.1021/bi00177a014; GARNIER J, 1990, BIOCHIMIE, V72, P513, DOI 10.1016/0300-9084(90)90115-W; GIDEON P, 1992, MOL CELL BIOL, V12, P2050, DOI 10.1128/MCB.12.5.2050; GUTMANN DH, 1993, ONCOGENE, V8, P761; HERRMANN C, 1995, J BIOL CHEM, V270, P2901, DOI 10.1074/jbc.270.7.2901; HETTICH L, 1994, CANCER RES, V54, P5438; HUTCHISON CA, 1978, J BIOL CHEM, V253, P6551; JOHNSON WC, 1985, METHOD BIOCHEM ANAL, V31, P61, DOI 10.1002/9780470110522.ch2; LI Y, 1992, CELL, V69, P275, DOI 10.1016/0092-8674(92)90408-5; MAEKAWA M, 1994, MOL CELL BIOL, V14, P6879, DOI 10.1128/MCB.14.10.6879; MARSHALL MS, 1988, MOL CELL BIOL, V8, P52, DOI 10.1128/MCB.8.1.52; MARSHALL MS, 1993, TRENDS BIOCHEM SCI, V18, P250, DOI 10.1016/0968-0004(93)90175-M; MARSHALL MS, 1993, ONCOGENE, V8, P425; MARSHALL MS, 1989, EMBO J, V8, P1105, DOI 10.1002/j.1460-2075.1989.tb03480.x; MILBURN MV, 1990, SCIENCE, V247, P939, DOI 10.1126/science.2406906; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; PAI EF, 1989, NATURE, V341, P209, DOI 10.1038/341209a0; PAI EF, 1990, EMBO J, V9, P2351, DOI 10.1002/j.1460-2075.1990.tb07409.x; POLAKIS P, 1993, J BIOL CHEM, V268, P9157; POULLET P, 1994, MOL CELL BIOL, V14, P815, DOI 10.1128/MCB.14.1.815; RUBINFELD B, 1991, INT J PEPT PROT RES, V38, P47; SCHABER MD, 1989, PROTEINS, V6, P306, DOI 10.1002/prot.340060313; SCHLICHTING I, 1990, NATURE, V345, P309, DOI 10.1038/345309a0; SCHWEINS T, 1994, NAT STRUCT BIOL, V1, P476, DOI 10.1038/nsb0794-476; SCHWEINS T, 1995, NAT STRUCT BIOL, V2, P36, DOI 10.1038/nsb0195-36; SKINNER RH, 1991, J BIOL CHEM, V266, P14163; UNO I, 1987, MOL GEN GENET, V210, P187, DOI 10.1007/BF00325683; WIESMULLER L, 1992, J BIOL CHEM, V267, P10207; WOOD DR, 1994, J BIOL CHEM, V269, P5322; YAMASAKI K, 1994, BIOCHEMISTRY-US, V33, P65, DOI 10.1021/bi00167a009; YANG JT, 1986, METHOD ENZYMOL, V130, P208; ZHANG XF, 1993, NATURE, V364, P308, DOI 10.1038/364308a0	41	29	29	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 28	1996	271	26					15322	15329		10.1074/jbc.271.26.15322	http://dx.doi.org/10.1074/jbc.271.26.15322			8	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UV299	8663024				2022-12-27	WOS:A1996UV29900006
J	Desai, D; Michalak, M; Singh, NK; Niles, RM				Desai, D; Michalak, M; Singh, NK; Niles, RM			Inhibition of retinoic acid receptor function and retinoic acid-regulated gene expression in mouse melanoma cells by calreticulin - A potential pathway for cyclic AMP regulation of retinoid action	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							CALCIUM-BINDING PROTEIN; THYROID-HORMONE; NUCLEAR RECEPTOR; ENDOPLASMIC-RETICULUM; RESPONSE ELEMENT; NONMUSCLE CELLS; CLONING; GAMMA; BETA; DIFFERENTIATION	Calcium is a second messenger that controls a wide variety of cellular functions. Because of its multiple actions, there is a stringent requirement for calcium ho meostasis, and this is achieved in part by a system of transport and storage proteins such as calreticulin located in the endoplasmic reticulum, Calreticulin is also found in the nucleus, suggesting that it may have a role in transcriptional regulation. It has been reported that calreticulin can inhibit steroid-regulated gene transcription by preventing receptor binding to DNA, Here we report that overexpression of the calreticulin gene in B16 mouse melanoma cells resulted in a decrease in retinoic acid (RA)-stimulated reporter gene expression, Gel shift analysis showed that purified calreticulin inhibited the binding of endogenous RAR 60 a beta-RA response element oligonucleotide, only if added prior to the addition of the oligonucleotide. Co-immunoprecipitation studies suggest a physical interaction between RAR and calreticulin. Transfection of the calreticulin gene into B16 cells inhibited the RA induction of protein kinase C alpha, a marker of RA induced differentiation. We also found that cyclic AMP increased the expression of calreticulin, Cyclic AMP may act to antagonize RA action by both decreasing RAR expression (Y, Xiao, D, Desai, T, Quick, and R, M, Niles, J, Cell Physiol., in press) and stimulating calreticulin levels,	MARSHALL UNIV,SCH MED,DEPT BIOCHEM & MOLEC BIOL,HUNTINGTON,WV 25755; UNIV ALBERTA,DEPT BIOCHEM,MED RES COUNCIL GRP MOLEC BIOL MEMBRANES,EDMONTON,AB T6G 2S2,CANADA; US FDA,CTR BIOL EVALUAT & RES,BETHESDA,MD 20892	Marshall University; University of Alberta; US Food & Drug Administration (FDA)					NATIONAL CANCER INSTITUTE [R01CA059530] Funding Source: NIH RePORTER; NCI NIH HHS [CA 59530] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BEATO M, 1989, CELL, V56, P335, DOI 10.1016/0092-8674(89)90237-7; BERG JM, 1990, J BIOL CHEM, V265, P6513; BURNS K, 1994, NATURE, V367, P476, DOI 10.1038/367476a0; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; DE LUCA LM, 1991, FASEB J, V5, P2924; DEDHAR S, 1994, NATURE, V367, P480, DOI 10.1038/367480a0; EVANS RM, 1988, SCIENCE, V240, P889, DOI 10.1126/science.3283939; GERSTEN DM, 1991, BIOCHIM BIOPHYS ACTA, V1096, P20; HALL RK, 1992, MOL CELL BIOL, V12, P5527, DOI 10.1128/MCB.12.12.5527; KASTNER P, 1990, P NATL ACAD SCI USA, V87, P2700, DOI 10.1073/pnas.87.7.2700; KLIEWER SA, 1992, NATURE, V355, P446, DOI 10.1038/355446a0; KONTANI K, 1993, J BIOL CHEM, V268, P16895; KRUST A, 1989, P NATL ACAD SCI USA, V86, P5310, DOI 10.1073/pnas.86.14.5310; LAUDET V, 1992, EMBO J, V11, P1003, DOI 10.1002/j.1460-2075.1992.tb05139.x; LEID M, 1992, CELL, V68, P377, DOI 10.1016/0092-8674(92)90478-U; LEVIN AA, 1992, NATURE, V355, P359, DOI 10.1038/355359a0; MANGELSDORF DJ, 1990, NATURE, V345, P224, DOI 10.1038/345224a0; MCCAULIFFE DP, 1990, J CLIN INVEST, V85, P1379, DOI 10.1172/JCI114582; MILNER RE, 1992, MOL CELL BIOCHEM, V112, P1; MILNER RE, 1991, J BIOL CHEM, V266, P7155; NILES RM, 1991, J CELL PHYSIOL, V147, P176, DOI 10.1002/jcp.1041470122; OBANION MK, 1993, J VIROL, V67, P3427, DOI 10.1128/JVI.67.6.3427-3434.1993; OPAS M, 1991, J CELL PHYSIOL, V149, P160, DOI 10.1002/jcp.1041490120; PEREZ P, 1993, J BIOL CHEM, V268, P23538; QUICK TC, 1994, RECEPTOR, V4, P65; Sambrook J., 2002, MOL CLONING LAB MANU; SPORN MB, 1983, CANCER RES, V43, P3034; SUCOV HM, 1990, P NATL ACAD SCI USA, V87, P5392, DOI 10.1073/pnas.87.14.5392; THARIN S, 1992, CELL TISSUE RES, V269, P29, DOI 10.1007/BF00384723; Wolbach SB, 1925, J EXP MED, V42, P753, DOI 10.1084/jem.42.6.753; YU VC, 1991, CELL, V67, P1251, DOI 10.1016/0092-8674(91)90301-E; ZELENT A, 1989, NATURE, V339, P714, DOI 10.1038/339714a0; ZHANG XK, 1992, NATURE, V358, P587, DOI 10.1038/358587a0; ZHENG ZS, 1992, CELL GROWTH DIFFER, V3, P225	34	33	34	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					15153	15159		10.1074/jbc.271.25.15153	http://dx.doi.org/10.1074/jbc.271.25.15153			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662962	hybrid			2022-12-27	WOS:A1996UT10600075
J	Estelles, A; Yokoyama, M; Nothias, F; Vincent, JD; Glowinski, J; Vernier, P; Chneiweiss, H				Estelles, A; Yokoyama, M; Nothias, F; Vincent, JD; Glowinski, J; Vernier, P; Chneiweiss, H			The major astrocytic phosphoprotein PEA-15 is encoded by two mRNAs conserved on their full length in mouse and human	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							PROTEIN; SEQUENCES; REGION; RNA; PHOSPHORYLATION; SUPPRESSION; TROPOMYOSIN; GROWTH	Specific phosphoproteins are targets of numerous extracellular signals received by astrocytes. One such target, which we previously described, is PEA-15, a protein kinase C substrate associated with microtubules, Two cDNAs differing in the length of their S'-untranslated region (3'UTR) were cloned from a mouse astrocytic library, Accordingly, Northern blots revealed two transcripts (1.7 and 2.5 kilobase pairs) abundant brain regions but also found in peripheral tissues. PEA-15-deduced protein sequence (130 amino acids) shared no similarity with known proteins but is 96% identical to its human counterpart, In addition, several regions of the 3'UTR share more than 90% identity between mouse and human, Different potential regulatory sequences are found in the 3'UTR, which also completely includes the proto-oncogene MAT1. The high level of conservation of both the coding and the untranslated regions and the differential tissular distribution of the two transcripts of this major brain phosphoprotein suggest that not only the protein but also the 3'UTR of PEA-15 mRNA play a role in astrocytic functions.	COLL FRANCE,INSERM U114,F-75231 PARIS 05,FRANCE; COLL FRANCE,CHAIRE NEUROPHARMACOL,F-75231 PARIS 05,FRANCE; INST ALFRED FESSARD,CNRS UPR2212,F-91998 GIF SUR YVETTE,FRANCE	Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; PSL Research University Paris; College de France; UDICE-French Research Universities; PSL Research University Paris; College de France			herve, chneiweiss/Q-6818-2019	herve, chneiweiss/0000-0001-7675-5061; Nothias-Chahir, Fatiha/0000-0002-2497-2096				AHMED S, 1990, J BIOL CHEM, V265, P13899; ARAUJO H, 1993, J BIOL CHEM, V268, P5911; Ausubel F.M., 1992, SHORT PROTOCOLS MOL; BARRES BA, 1991, J NEUROSCI, V11, P3685; BEELMAN CA, 1995, CELL, V81, P179, DOI 10.1016/0092-8674(95)90326-7; BERA TK, 1994, P NATL ACAD SCI USA, V91, P9789, DOI 10.1073/pnas.91.21.9789; BROWN AJP, 1993, TRENDS CELL BIOL, V3, P1808; CHEN NN, 1995, P NATL ACAD SCI USA, V92, P1087, DOI 10.1073/pnas.92.4.1087; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; COOPER HL, 1985, MOL CELL BIOL, V5, P972, DOI 10.1128/MCB.5.5.972; CURTIS D, 1995, CELL, V81, P171, DOI 10.1016/0092-8674(95)90325-9; DANZIGER N, 1995, J NEUROCHEM, V64, P1016; FERRALLI J, 1994, J CELL SCI, V107, P3115; FRISQUE RJ, 1983, J VIROL, V46, P170, DOI 10.1128/JVI.46.1.170-176.1983; GABBIANI G, 1976, AM J PATHOL, V83, P457; GOODE BL, 1994, J CELL BIOL, V124, P769, DOI 10.1083/jcb.124.5.769; GUBLER U, 1983, GENE, V25, P263, DOI 10.1016/0378-1119(83)90230-5; HARRISON BC, 1992, J NEUROCHEM, V58, P320, DOI 10.1111/j.1471-4159.1992.tb09313.x; HENDERSON CE, 1994, SCIENCE, V266, P1062, DOI 10.1126/science.7973664; HUNTER T, 1995, CELL, V80, P225, DOI 10.1016/0092-8674(95)90405-0; KANAI Y, 1995, NEURON, V14, P421, DOI 10.1016/0896-6273(95)90298-8; KHALILI K, 1988, EMBO J, V7, P1205, DOI 10.1002/j.1460-2075.1988.tb02932.x; KOZAK M, 1987, NUCLEIC ACIDS RES, V15, P8125, DOI 10.1093/nar/15.20.8125; KOZAK M, 1991, J CELL BIOL, V115, P887, DOI 10.1083/jcb.115.4.887; KUBES M, 1994, EUR J NEUROSCI S, V7; LEMESLEVARLOOT L, 1990, BIOCHIMIE, V72, P555, DOI 10.1016/0300-9084(90)90120-6; MALLET J, 1988, EBO PRACTICAL COURSE; MCCARTHY KD, 1985, J NEUROCHEM, V44, P723, DOI 10.1111/j.1471-4159.1985.tb12875.x; MURPHY B, 1993, ASTROCYTES PHARM FUN; NOTHIAS F, 1993, J COMP NEUROL, V334, P370, DOI 10.1002/cne.903340304; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; PRASAD GL, 1993, P NATL ACAD SCI USA, V90, P7039, DOI 10.1073/pnas.90.15.7039; RASTINEJAD F, 1993, CELL, V72, P903, DOI 10.1016/0092-8674(93)90579-F; RASTINEJAD F, 1993, CELL, V75, P1107, DOI 10.1016/0092-8674(93)90320-P; SMITH SJ, 1994, CURR BIOL, V4, P807, DOI 10.1016/S0960-9822(00)00178-0; STJOHNSTON D, 1995, CELL, V81, P161, DOI 10.1016/0092-8674(95)90324-0; Vale Ronald D., 1993, P175	37	57	59	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14800	14806		10.1074/jbc.271.25.14800	http://dx.doi.org/10.1074/jbc.271.25.14800			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662970	hybrid			2022-12-27	WOS:A1996UT10600027
J	Louzao, MC; Ribeiro, CMP; Bird, GS; Putney, JW				Louzao, MC; Ribeiro, CMP; Bird, GS; Putney, JW			Cell type-specific modes of feedback regulation of capacitative calcium entry	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INOSITOL PHOSPHATE; ACTIVATED CALCIUM; ACINAR-CELLS; MAST-CELLS; THAPSIGARGIN; INHIBITION; PATHWAY; RELEASE; POOL	The Ca2+ ATPase inhibitor, thapsigargin, activated Ca2+ entry into pancreatic acinar cells, a process known as capacitative calcium entry, In cells loaded with the calcium chelator BAPTA, the transient Ca2+ release was blunted and the rise of [Ca2+](i) on readdition of Ca2+ was slowed, However, the steady-state [Ca2+](i) due to Ca2+ entry was substantially augmented compared with control cells, This indicates that [Ca2+](i) exerts a negative feedback on Ca2+ entry from a compartment buffered by BAPTA and separated from the bulk of cytoplasmic Ca2+. This interaction probably occurs close to the calcium channel where [Ca2+] is higher than in the bulk of the cytoplasm, In support of this interpretation, the slower Ca2+ chelator, EGTA, also blunted the release of Ca2+ and slowed the rise of the sustained [Ca2+](i) phase but failed to augment steady-state [Ca2+](i). In contrast, Ca2+ entry in NIH 3T3 cells was characterized by a transient rise of [Ca2+](i) that decays to near prestimulus levels, This decay in Ca2+ entry also results from negative feedback by Ca2+ because the decrease in Ca2+ entry was reversed by incubation in a Ca2+ deficient medium, However, unlike its effects in acinar cells, BAPTA neither augmented steady-state [Ca2+](i) nor pre vented the inactivation of entry, Rather, in BAPTA-loaded cells, [Ca2+](i) failed to increase substantially suggesting that negative regulation by Ca2+ may occur at a site distinct from the cytoplasmic compartment and inaccessible to cytoplasmic BAPTA, These two distinct types of feedback behavior may indicate subtypes of store-operated calcium channels expressed in different cells or a single type of channel which is differentially regulated in a cell type-specific manner.	NIEHS,CALCIUM REGULAT SECT,CELLULAR & MOLEC PHARMACOL LAB,NIH,RES TRIANGLE PK,NC 27709	National Institutes of Health (NIH) - USA; NIH National Institute of Environmental Health Sciences (NIEHS)			Louzao, M. Carmen/AAD-3847-2019; Bird, Gary/AAI-8186-2021; Putney, James W/F-7247-2019; Ribeiro, Carla Maria P/A-6955-2009	Bird, Gary/0000-0003-1389-8748; Putney, James W/0000-0002-3379-4789; Louzao, M. Carmen/0000-0002-3072-0637				AGRANOFF BW, 1985, INOSITOL PHOSPHOINOS, pR21; BIRD GS, 1991, NATURE, V352, P162, DOI 10.1038/352162a0; BIRD GS, 1993, J BIOL CHEM, V268, P21486; CLAPHAM DE, 1995, NATURE, V375, P634, DOI 10.1038/375634a0; GILON P, 1995, BIOCHEM J, V311, P649, DOI 10.1042/bj3110649; HOTH M, 1993, J PHYSIOL-LONDON, V465, P359, DOI 10.1113/jphysiol.1993.sp019681; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; KWAN CY, 1990, J BIOL CHEM, V265, P678; LUCKHOFF A, 1994, BIOPHYS J, V67, P177, DOI 10.1016/S0006-3495(94)80467-9; MISSIAEN L, 1994, J BIOL CHEM, V269, P5817; MONTERO M, 1993, J BIOL CHEM, V268, P13055; PAROD RJ, 1980, AM J PHYSIOL, V239, pG99, DOI 10.1152/ajpgi.1980.239.2.G99; PUTNEY JW, 1981, PHILOS T ROY SOC B, V296, P37, DOI 10.1098/rstb.1981.0169; PUTNEY JW, 1986, CELL CALCIUM, V7, P1, DOI 10.1016/0143-4160(86)90026-6; PUTNEY JW, 1993, ENDOCR REV, V14, P610, DOI 10.1210/er.14.5.610; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; SCHILLING WP, 1989, J BIOL CHEM, V264, P12838; TAKEMURA H, 1989, J BIOL CHEM, V264, P12266; THASTRUP O, 1994, AGENTS ACTIONS, V43, P187, DOI 10.1007/BF01986687; VANDERKOOI JM, 1971, ARCH BIOCHEM BIOPHYS, V144, P99, DOI 10.1016/0003-9861(71)90458-9; YAMAGUCHI DT, 1989, J BIOL CHEM, V264, P197; ZWEIFACH A, 1995, J GEN PHYSIOL, V105, P209, DOI 10.1085/jgp.105.2.209; ZWEIFACH A, 1995, J BIOL CHEM, V270, P14445, DOI 10.1074/jbc.270.24.14445	23	50	51	0	3	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14807	14813		10.1074/jbc.271.25.14807	http://dx.doi.org/10.1074/jbc.271.25.14807			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662975	hybrid			2022-12-27	WOS:A1996UT10600028
J	Zahedi, K				Zahedi, K			Characterization of the binding of serum amyloid P to type IV collagen	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							C-REACTIVE PROTEIN; GLOMERULAR BASEMENT-MEMBRANE; BIOLOGICAL-ACTIVITY; HEPARAN-SULFATE; COMPONENT; REGION; LOCALIZATION; FIBRONECTIN; PENTRAXINS; INHIBITION	Serum amyloid P (SAP), a member of the evolutionarily conserved pentraxin family, is a normal component of a number of basement membranes, including glomerular and alveolar, In vitro SAP binds to a variety of proteins including fibronectin, proteoglycans, and the collagen-like region of the complement component C1q. In these studies, binding of SAP to type IV collagen, a major component of basement membrane, was examined, Purified SAP binds to human and mouse type IV collagen but not type I, II, or III collagens, Binding of SAP to type IV collagen is dependent on the presence of Ca2+. This binding is saturable with a K-d approximate to 1.2 x 10(-7) M based on solid phase binding and 4 x 10(-8) M based on the IC50 value from fluid phase binding data, Binding of SAP to type IV collagen was inhibited by both SAP and C-reactive protein (CRP), However, a 5-fold molar excess of CRP as compared with SAP was required to inhibit the SAP binding by 50%. Binding of SAP to type TV collagen was inhibited by both collagen IV and C1q but not by phosphatidylethanolamine or bovine serum albumin, The inhibition data indicate that SAP may bind to the triple helical region of type IV collagen via a site distinct from its galactan binding site, The most likely site of SAP involved in its interaction with type TV collagen may be the region spanning amino acid residues 108-120, which shows a great deal of sequence homology (60% strict identity) with the CRP region implicated in its binding to the collagen-like region of the C1q molecule.	UNIV CINCINNATI, COLL MED, DEPT PEDIAT, CINCINNATI, OH 45229 USA	University System of Ohio; University of Cincinnati	Zahedi, K (corresponding author), CHILDRENS HOSP RES FDN, DIV NEPHROL, 3333 BURNET AVE, CINCINNATI, OH 45229 USA.		Zahedi, Kamyar/AAQ-3428-2021					AGRAWAL A, 1992, J BIOL CHEM, V267, P25352; AGRAWAL A, 1994, J IMMUNOL, V152, P5404; ALMUTLAQ H, 1993, HISTOCHEM J, V25, P219, DOI 10.1007/BF00163818; CHARONIS AS, 1985, J CELL BIOL, V100, P1848, DOI 10.1083/jcb.100.6.1848; COE JE, 1977, P NATL ACAD SCI USA, V74, P730, DOI 10.1073/pnas.74.2.730; DE FRUTOS PG, 1994, J IMMUNOL, V152, P2430; DEBEER FC, 1981, J EXP MED, V154, P1134, DOI 10.1084/jem.154.4.1134; DYCK RF, 1980, LANCET, V2, P607; DYCK RF, 1980, J EXP MED, V152, P1162, DOI 10.1084/jem.152.5.1162; EMSLEY J, 1994, NATURE, V367, P338, DOI 10.1038/367338a0; GEWURZ H, 1982, ADV INTERNAL MED, V27, P345; HAMAZAKI H, 1995, J BIOL CHEM, V270, P10392, DOI 10.1074/jbc.270.18.10392; HAMAZAKI H, 1987, J BIOL CHEM, V262, P1456; JIANG HX, 1991, J IMMUNOL, V146, P2324; KINOSHITA CM, 1992, PROTEIN SCI, V1, P700, DOI 10.1002/pro.5560010602; KLEINMAN HK, 1986, BIOCHEMISTRY-US, V25, P312, DOI 10.1021/bi00350a005; LE PT, 1982, J IMMUNOL, V129, P665; MANTZOURANIS EC, 1985, J BIOL CHEM, V260, P7752; MELVIN T, 1986, AM J PATHOL, V125, P460; OSMAND AP, 1977, P NATL ACAD SCI USA, V74, P739, DOI 10.1073/pnas.74.2.739; PAULSSON M, 1987, COLLAGEN REL RES, V7, P443; POTEMPA LA, 1985, J BIOL CHEM, V260, P2142; SCHITTNY JC, 1988, J CELL BIOL, V107, P1599, DOI 10.1083/jcb.107.4.1599; TENNENT GA, 1995, P NATL ACAD SCI USA, V92, P4299, DOI 10.1073/pnas.92.10.4299; TIMPL R, 1986, INT REV EXP PATHOL, V29, P1; TIMPL R, 1989, EUR J BIOCHEM, V180, P487, DOI 10.1111/j.1432-1033.1989.tb14673.x; TSENG J, 1986, IMMUNOL INVEST, V15, P749, DOI 10.3109/08820138609036360; TSILIBARY EC, 1986, J CELL BIOL, V103, P2467, DOI 10.1083/jcb.103.6.2467; TSILIBARY EC, 1988, J BIOL CHEM, V263, P19112; WOO P, 1985, J BIOL CHEM, V260, P3384; YING SC, 1993, J IMMUNOL, V150, P169; YURCHENCO PD, 1984, BIOCHEMISTRY-US, V23, P1839, DOI 10.1021/bi00303a040	32	28	38	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA	0021-9258	1083-351X		J BIOL CHEM	J. Biol. Chem.	JUN 21	1996	271	25					14897	14902		10.1074/jbc.271.25.14897	http://dx.doi.org/10.1074/jbc.271.25.14897			6	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UT106	8662978	hybrid			2022-12-27	WOS:A1996UT10600041
J	Lerner, DJ; Chen, M; Tram, T; Coughlin, SR				Lerner, DJ; Chen, M; Tram, T; Coughlin, SR			Agonist recognition by proteinase-activated receptor 2 and thrombin receptor - Importance of extracellular loop interactions for receptor function	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MECHANISM; CLEAVAGE	Thrombin receptor and proteinase-activated receptor 2 (PAR2) define a family of G protein-coupled receptors that are activated by a novel proteolytic mechanism. Specific cleavage of their amino-terminal exodomains unmasks a new amino terminus which then serves as a tethered ligand, docking intramolecularly to the body of the receptor to effect signaling. Identification of the docking interactions between tethered ligand domain and receptor is critical for understanding transmembrane signaling by these receptors. Synthetic ''agonist peptides'' that mimic the tethered ligand domains of thrombin receptor and PAR2 act as agonists at their respective receptors, Toward defining the docking interactions which mediate receptor activation, we determined the specificity of the thrombin receptor and PAR2 for their respective agonist peptides and used receptor chimeras to identify the receptor domains responsible for such specificity. PARE responded to both thrombin receptor and PAR2 agonist peptides, In contrast, thrombin receptor was selective for its own agonist peptide. Substitution of the extracellular face of PAR2, its amino-terminal exodomain and three extracellular loops, for the cognate thrombin receptor structures yielded a chimeric receptor with PAR2-like agonist specificity. Substitution of individual extracellular domains revealed that the primary determinant of agonist specificity was extracellular loop 2, Strikingly, substitution of either the amino-terminal exodomain or third extracellular loop alone caused marked loss of receptor function, but the double substitution yielded a functional receptor. Thus, the extracellular domains of these G protein-coupled receptors are more than simply passive links between transmembrane domains. They participate in agonist recognition and must interact, directly or indirectly, for proper receptor function.	UNIV CALIF SAN FRANCISCO,CARDIOVASC RES INST,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DEPT MED,SAN FRANCISCO,CA 94143; UNIV CALIF SAN FRANCISCO,DAIICHI RES CTR,SAN FRANCISCO,CA 94143	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco					NHLBI NIH HHS [T32 HL07731, HL44907] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [T32HL007731, R01HL044907] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BALDWIN JM, 1993, EMBO J, V12, P1693, DOI 10.1002/j.1460-2075.1993.tb05814.x; BAYKAL D, 1995, AM J CARDIOL, V75, pB82, DOI 10.1016/0002-9149(95)80019-O; CHEN J, 1995, J BIOL CHEM, V270, P23398, DOI 10.1074/jbc.270.40.23398; CHEN J, 1994, J BIOL CHEM, V269, P16041; COUGHLIN SR, 1994, TRENDS CARDIOVAS MED, V4, P77, DOI 10.1016/1050-1738(94)90013-2; COUGHLIN SR, 1992, J CLIN INVEST, V89, P351, DOI 10.1172/JCI115592; DONNELLY D, 1994, CURR OPIN STRUC BIOL, V4, P582, DOI 10.1016/S0959-440X(94)90221-6; FENTON JW, 1988, SEMIN THROMB HEMOST, V14, P234, DOI 10.1055/s-2007-1002783; GERSZTEN RE, 1994, NATURE, V368, P648, DOI 10.1038/368648a0; ISHII K, 1993, J BIOL CHEM, V268, P9780; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; Mizobe T, 1996, J BIOL CHEM, V271, P2387, DOI 10.1074/jbc.271.5.2387; NANEVICZ T, 1995, J BIOL CHEM, V270, P21619, DOI 10.1074/jbc.270.37.21619; Nanevicz T, 1996, J BIOL CHEM, V271, P702, DOI 10.1074/jbc.271.2.702; NYSTEDT S, 1995, J BIOL CHEM, V270, P5950, DOI 10.1074/jbc.270.11.5950; NYSTEDT S, 1994, P NATL ACAD SCI USA, V91, P9208, DOI 10.1073/pnas.91.20.9208; Sambrook J., 2002, MOL CLONING LAB MANU; SANGER F, 1977, P NATL ACAD SCI USA, V74, P5463, DOI 10.1073/pnas.74.12.5463; SCARBOROUGH RM, 1992, J BIOL CHEM, V267, P13146; SCHERTLER GFX, 1993, NATURE, V362, P770, DOI 10.1038/362770a0; SURYANARAYANA S, 1992, J BIOL CHEM, V267, P21991; VONHEIJNE G, 1983, EUR J BIOCHEM, V133, P17; VU TKH, 1991, CELL, V64, P1057, DOI 10.1016/0092-8674(91)90261-V; VU TKH, 1991, NATURE, V353, P674, DOI 10.1038/353674a0; WILLIAMS JA, 1988, P NATL ACAD SCI USA, V85, P4939, DOI 10.1073/pnas.85.13.4939	25	94	94	0	4	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					13943	13947		10.1074/jbc.271.24.13943	http://dx.doi.org/10.1074/jbc.271.24.13943			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662993	hybrid			2022-12-27	WOS:A1996UQ66000005
J	Zhang, YY; Xu, AM; Nomen, M; Walsh, M; Keaney, JF; Loscalzo, J				Zhang, YY; Xu, AM; Nomen, M; Walsh, M; Keaney, JF; Loscalzo, J			Nitrosation of tryptophan residue(s) in serum albumin and model dipeptides - Biochemical characterization and bioactivity	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							THERMAL ENERGY ANALYZER; NITRIC-OXIDE; CIRCULAR-DICHROISM; S-NITROSYLATION; RELAXING FACTOR; VOLATILE; CONFORMATION; MECHANISM; CHEMISTRY; KINETICS	Nitrosation of bovine serum albumin with acidified NaNO2 was compared to that of carboxymethyl-bovine serum albumin in which the thiol group is covalently blocked. Differential ultraviolet-visible (UV-Vis) spectroscopy and a modified Saville assay indicated that a non-cysteine residue(s) in carboxymethyl-bovine serum albumin was nitrosated. The nitrosated carboxymethyl-bovine serum albumin exhibited similar vasorelaxation activity as that observed with nitrosated bovine serum albumin. Identification of the nitrosated non-cysteine residue(s) was studied using 16 model dipeptides, each of which contained a glycyl residue and a variable residue. Using photolysis-chemiluminescence analysis, modified Saville assay, differential UV-Vis spectroscopy, and bioassays, L-glycyl-L-tryptophan (Gly-Trp) was found to be the only dipeptide that underwent significant nitrosation under these conditions. Liquid chromatography-W-Vis spectroscopy-mass spectrometry showed that the NO group was attached to the indole nitrogen of tryptophan. Nitrosated Gly-Trp exhibited dose-dependent vasorelaxation and platelet inhibiting activity with apparent EC(50) values of 1.1 +/- 0.3 and 3.5 +/- 0.9 mu M, respectively. Because N-nitroso-Gly-Trp does not release NO radical via spontaneous homolytic N-NO bond fission nor freely diffuse through cellular membranes, the ability of this compound to induce NO.-like biological effects suggests the existence of a (membrane-associated) transnitrosation system that facilitates delivery of -NO to its specific biologic target(s).	BOSTON UNIV,SCH MED,EVANS DEPT MED,WHITAKER CARDIOVASC INST,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOCHEM,BOSTON,MA 02118; BOSTON UNIV,SCH MED,DEPT BIOPHYS,BOSTON,MA 02118; UNIV MED & DENT NEW JERSEY,DEPT CELL BIOL,STRATFORD,NJ 08084	Boston University; Boston University; Boston University; Rutgers State University New Brunswick; Rutgers State University Medical Center			Loscalzo, Joseph/ABD-8980-2021	Keaney, John/0000-0002-0866-1837	NHLBI NIH HHS [HL48743, HL53919, P50 HL 55993] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P50HL055993, P01HL048743, R01HL053919] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BARNETT DJ, 1994, J CHEM SOC PERK T 2, P1131, DOI 10.1039/p29940001131; BARRETT J, 1966, NATURE, V211, P848, DOI 10.1038/211848a0; BONNETT R, 1974, J CHEM SOC PERK T 1, P962, DOI 10.1039/p19740000962; BONNETT R, 1977, HETEROCYCLES, V7, P637, DOI 10.3987/S-1977-01-0637; BRAHMS S, 1980, J MOL BIOL, V138, P149, DOI 10.1016/0022-2836(80)90282-X; BYLER DM, 1983, J AGR FOOD CHEM, V31, P523, DOI 10.1021/jf00117a015; CASTRO A, 1986, J CHEM SOC PERK T 2, P1165, DOI 10.1039/p29860001165; CHALLIS BC, 1989, CANCER SURV, V8, P363; CHANG CT, 1978, ANAL BIOCHEM, V91, P13, DOI 10.1016/0003-2697(78)90812-6; CONBOY JJ, 1989, ANALYST, V114, P155, DOI 10.1039/an9891400155; Creighton T. E., 1990, PROTEIN STRUCTURE PR, P155; DUHE RJ, 1994, J BIOL CHEM, V269, P7290; ELLMAN GL, 1959, ARCH BIOCHEM BIOPHYS, V82, P70, DOI 10.1016/0003-9861(59)90090-6; FINE DH, 1975, ANAL CHEM, V47, P1188, DOI 10.1021/ac60357a073; FINE DH, 1975, J CHROMATOGR, V107, P351, DOI 10.1016/0021-9673(75)80011-2; GOPALAKRISHNA R, 1993, J BIOL CHEM, V268, P27180; GREENFIE.N, 1969, BIOCHEMISTRY-US, V8, P4108, DOI 10.1021/bi00838a031; IGNARRO LJ, 1981, J PHARMACOL EXP THER, V218, P739; JANATOVA J, 1968, J BIOL CHEM, V243, P3612; KEANEY JF, 1993, J CLIN INVEST, V91, P1582, DOI 10.1172/JCI116364; LEI SZ, 1992, NEURON, V8, P1087, DOI 10.1016/0896-6273(92)90130-6; MAO D, 1984, BIOCHEMISTRY-US, V23, P2667, DOI 10.1021/bi00307a020; MATHEWS WR, 1993, J PHARMACOL EXP THER, V267, P1529; MCANINLY J, 1993, J CHEM SOC CHEM COMM, V1758; MEYER TA, 1982, J CHEM SOC PERK T 2, P1383, DOI 10.1039/p29820001383; MIRVISH SS, 1973, JNCI-J NATL CANCER I, V51, P1833, DOI 10.1093/jnci/51.6.1833; MIZRA UA, 1995, J BIOL CHEM, V270, P17185; MYERS PR, 1990, NATURE, V345, P161, DOI 10.1038/345161a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NGUYEN T, 1992, P NATL ACAD SCI USA, V89, P3030, DOI 10.1073/pnas.89.7.3030; PETERS T, 1985, ADV PROTEIN CHEM, V37, P161, DOI 10.1016/S0065-3233(08)60065-0; PRYOR WA, 1982, J ORG CHEM, V47, P156, DOI 10.1021/jo00340a038; REED RG, 1975, BIOCHEMISTRY-US, V14, P4578, DOI 10.1021/bi00692a004; SAVILLE B, 1958, ANALYST, V83, P670, DOI 10.1039/an9588300670; STAMLER JS, 1992, P NATL ACAD SCI USA, V89, P444, DOI 10.1073/pnas.89.1.444; TAMIR S, 1993, CHEM RES TOXICOL, V6, P895, DOI 10.1021/tx00036a021; VEDIA LM, 1992, J BIOL CHEM, V267, P24929; VENITT S, 1980, CARCINOGENESIS, V1, P523, DOI 10.1093/carcin/1.6.523; Williams D.C., 1988, NITROSATION, P1; WINK DA, 1991, SCIENCE, V254, P1001, DOI 10.1126/science.1948068	40	83	88	0	8	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 14	1996	271	24					14271	14279		10.1074/jbc.271.24.14271	http://dx.doi.org/10.1074/jbc.271.24.14271			9	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UQ660	8662958	hybrid			2022-12-27	WOS:A1996UQ66000052
J	Iwamoto, T; Pan, Y; Wakabayashi, S; Imagawa, T; Yamanaka, HI; Shigekawa, M				Iwamoto, T; Pan, Y; Wakabayashi, S; Imagawa, T; Yamanaka, HI; Shigekawa, M			Phosphorylation-dependent regulation of cardiac Na+/Ca2+ exchanger via protein kinase C	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; SMOOTH-MUSCLE CELLS; PHORBOL ESTERS; DYNAMIC PROPERTIES; NA+-CA2+ EXCHANGE; ANGIOTENSIN-II; STEADY-STATE; HEART-CELLS; RAT-HEART; MYOCYTES	The cardiac Na+/Ca2+ exchanger (NCX1) plays a major role in the extrusion of Ca2+ from cardiomyocytes, We studied the role of protein phosphorylation in the regulation of cardiac NCX1 using CCL39 stably overexpressing the canine cardiac NCX1 and rat neonatal cardiomyocytes, In both cell types, the NCX1 protein immunoprecipitated with a chicken anti-NCX1 antibody exhibited a significant basal phosphorylation that was further enhanced by treatment with endothelin-l, acidic fibroblast growth factor, phorbol 12-myristate 13-acetate, or okadaic acid, In contrast, calphostin C, K252a, or EGTA inhibited the phosphorylation, The phosphorylation occurred on two major tryptic phosphopeptides (Pi and P2) exclusively on serine residues, Evidence is presented suggesting that P2 was derived from an N-terminal half (amino acids 240-475) of the central cytoplasmic domain of NCX1 and was phosphorylated directly by protein kinase C (PKC), The agents that increased NCX1 phosphorylation significantly enhanced both the forward and reverse modes of Na+/Ca2+ exchange. This exchange activation exhibited a very good correlation with the NCX1 phosphorylation, In NCX1-transfected cells, PKC down-regulation following prolonged exposure to phorbol 12-myristate 13-acetate abolished the acidic fibroblast growth factor induced activation of exchange activity, On the other hand, cell ATP depletion reduced the exchange activity and abolished the effects of the above agents on exchange activity, These results indicate that the cardiac NCX1 is upregulated by PKC-catalyzed phosphorylation, The cardiac NCX1 thus could play an important role in the previously reported negative inotropic actions of phorbol esters and other PKC-activating agents.	NATL CARDIOVASC CTR,RES INST,DEPT MOLEC PHYSIOL,SUITA,OSAKA 565,JAPAN; KANEBO LTD,NEW DRUG RES LABS,OSAKA 534,JAPAN	National Cerebral & Cardiovascular Center - Japan			Imagawa, Toshiaki/A-4255-2012					BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BERS DM, 1991, ANN NY ACAD SCI, V639, P375, DOI 10.1111/j.1749-6632.1991.tb17326.x; BRIDGE JHB, 1990, SCIENCE, V248, P376, DOI 10.1126/science.2158147; CAPOGROSSI MC, 1991, CIRC RES, V69, P540, DOI 10.1161/01.RES.69.2.540; CAPOGROSSI MC, 1990, CIRC RES, V66, P1143, DOI 10.1161/01.RES.66.4.1143; COLLINS A, 1992, J PHYSIOL-LONDON, V454, P27, DOI 10.1113/jphysiol.1992.sp019253; CONDRESCU M, 1995, J BIOL CHEM, V270, P9137, DOI 10.1074/jbc.270.16.9137; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; DIPOLO R, 1994, AM J PHYSIOL, V266, pC1382, DOI 10.1152/ajpcell.1994.266.5.C1382; DOERING AE, 1994, J PHYSIOL-LONDON, V480, P9, DOI 10.1113/jphysiol.1994.sp020336; EDES I, 1990, CIRC RES, V67, P394, DOI 10.1161/01.RES.67.2.394; FURUKAWA KI, 1988, J BIOL CHEM, V263, P8058; GASSMANN M, 1990, FASEB J, V4, P2528, DOI 10.1096/fasebj.4.8.1970792; HARTMANN M, 1992, EUR J PHARM-MOLEC PH, V226, P225, DOI 10.1016/0922-4106(92)90065-4; HAWORTH RA, 1987, CIRC RES, V60, P586, DOI 10.1161/01.RES.60.4.586; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P905, DOI 10.1085/jgp.100.6.905; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1992, J GEN PHYSIOL, V100, P933, DOI 10.1085/jgp.100.6.933; ITO H, 1993, J CLIN INVEST, V92, P398, DOI 10.1172/JCI116579; IWAMOTO T, 1995, J BIOL CHEM, V270, P8996, DOI 10.1074/jbc.270.15.8996; IWATA Y, 1994, FEBS LETT, V355, P65, DOI 10.1016/0014-5793(94)01174-5; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; LALLEMAIN G, 1984, J BIOL CHEM, V259, P5809; LEATHERMAN GF, 1987, AM J PHYSIOL, V253, pH205, DOI 10.1152/ajpheart.1987.253.1.H205; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22847; LI ZP, 1994, J BIOL CHEM, V269, P17434; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, p3P870; MISHINA M, 1984, NATURE, V307, P604, DOI 10.1038/307604a0; NAKASAKI Y, 1993, J BIOCHEM-TOKYO, V114, P528, DOI 10.1093/oxfordjournals.jbchem.a124211; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PETERS KG, 1992, NATURE, V358, P678, DOI 10.1038/358678a0; PIJUAN V, 1993, AM J PHYSIOL, V264, pC1066, DOI 10.1152/ajpcell.1993.264.4.C1066; SHAM JSK, 1995, P NATL ACAD SCI USA, V92, P121, DOI 10.1073/pnas.92.1.121; SMITH JB, 1990, AM J PHYSIOL, V259, pC302, DOI 10.1152/ajpcell.1990.259.2.C302; WIER WG, 1990, ANNU REV PHYSIOL, V52, P467; WIKMANCOFFELT J, 1991, AM HEART J, V122, P786, DOI 10.1016/0002-8703(91)90526-N; YAMAUCHI T, 1983, EUR J BIOCHEM, V132, P15, DOI 10.1111/j.1432-1033.1983.tb07319.x; YUAN SH, 1987, CIRC RES, V61, P372, DOI 10.1161/01.RES.61.3.372	39	170	172	0	0	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13609	13615		10.1074/jbc.271.23.13609	http://dx.doi.org/10.1074/jbc.271.23.13609			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662755	hybrid			2022-12-27	WOS:A1996UP38500047
J	Nicoll, DA; Hryshko, LV; Matsuoka, S; Frank, JS; Philipson, KD				Nicoll, DA; Hryshko, LV; Matsuoka, S; Frank, JS; Philipson, KD			Mutation of amino acid residues in the putative transmembrane segments of the cardiac sarcolemmal Na+-Ca2+ exchanger	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							SODIUM-CALCIUM EXCHANGE; NA-CA EXCHANGE; ALPHA-SUBUNIT; FUNCTIONAL EXPRESSION; MEMBRANE PATCHES; TRANSPORT; NA,K-ATPASE; SITE; ION; K+	We have examined the role of conserved regions and acidic or basic residues located in the putative transmembrane segments of the cardiac sarcolemmal Na+-Ca2+ exchanger by site-directed mutagenesis, The alpha-1 and alpha-2 repeats are transmembrane regions of internal similarity, which are highly conserved among Na+-Ca2+ exchangers. We find that Na+-Ca2+ exchange activity is highly sensitive to mutagenesis in the alpha-repeats. Mutation at residues Ser 109, Ser-110, Glu-113, Ser-139, Asn-143, Thr-810, Ser-811, Asp-814, Ser-818, or Ser-838 resulted in loss of exchanger activity. Mutation at residues Thr-103, Gly-108, Pro-112, Glu-120, Gly-138, Gly-809, Gly-837, and Asn-842 resulted in reduced exchanger activity, and altered current-voltage relationships were observed with mutations at residues Gly-138 and Gly-837. Only mutation at residue Ser-117 appeared to leave exchanger activity unaffected. Thus, the alpha-repeats appear to be important components for ion binding and translocation. Another region implicated in exchanger function is a region of similarity to the Na+,K+ pump (Nicoll, D.A., Longoni, S., Philipson, K. D. (1990) Science 250, 562-565). Mutations at two residues in the pump-like region, Glu-199 and Thr-203, resulted in nonfunctional exchangers, while mutation at two other residues, Glu-196 and Gly-200, had no effect. The role of acidic and basic residues in the transmembrane segments was also examined. Mutation of several basic residues (Arg-42, His-744, Lys-751, Lys-797, and His-858) did not affect exchange activity. Of the acidic residues located outside of the alpha-repeat and pump-like regions (Asp-740, Asp-785, and Asp-798), only mutation at Asp-785 resulted in reduction of exchanger activity.	UNIV CALIF LOS ANGELES,SCH MED,DEPT PHYSIOL,LOS ANGELES,CA 90095; UNIV CALIF LOS ANGELES,SCH MED,DEPT MED,LOS ANGELES,CA 90095	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Nicoll, DA (corresponding author), UNIV CALIF LOS ANGELES,SCH MED,CARDIOVASC RES LABS,3645 MRL BLDG,LOS ANGELES,CA 90095, USA.			Hryshko, Larry/0000-0003-1079-8549	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL049101] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL49101] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BAKER PF, 1969, J PHYSIOL-LONDON, V200, P431, DOI 10.1113/jphysiol.1969.sp008702; BERS DM, 1994, METHOD CELL BIOL, V40, P3; Blaustein M P, 1974, Rev Physiol Biochem Pharmacol, V70, P33, DOI 10.1007/BFb0034293; CANESSA CM, 1993, J BIOL CHEM, V268, P17722; CLARKE DM, 1993, J BIOL CHEM, V268, P18359; DIPOLO R, 1991, ANN NY ACAD SCI, V639, P100, DOI 10.1111/j.1749-6632.1991.tb17294.x; ELLING CE, 1995, NATURE, V374, P74, DOI 10.1038/374074a0; GMAJ P, 1979, BIOCHEM J, V178, P549, DOI 10.1042/bj1780549; Hilgemann Donald W., 1995, P307; HILGEMANN DW, 1990, NATURE, V344, P242, DOI 10.1038/344242a0; HILGEMANN DW, 1989, PFLUG ARCH EUR J PHY, V415, P247, DOI 10.1007/BF00370601; HILGEMANN DW, 1992, J PHYSIOL-LONDON, V454, P59, DOI 10.1113/jphysiol.1992.sp019254; HRYSHKO LV, 1993, BIOCHIM BIOPHYS ACTA, V1151, P35, DOI 10.1016/0005-2736(93)90068-B; KANO I, 1990, BIOCHEM CELL BIOL, V68, P1262, DOI 10.1139/o90-187; KIMURA J, 1986, NATURE, V319, P596, DOI 10.1038/319596a0; KIMURA M, 1993, J BIOL CHEM, V268, P6874; KOFUJI P, 1994, J BIOL CHEM, V269, P5145; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LEE SL, 1994, J BIOL CHEM, V269, P14849; LEVITSKY DO, 1994, J BIOL CHEM, V269, P22817; LI Z, 1994, J BIOL CHEM, V269, P1734; LI ZP, 1991, J BIOL CHEM, V266, P1014; LINGREL JB, 1994, J BIOL CHEM, V269, P19659; LONGONI S, 1988, AM J PHYSIOL, V255, pC870, DOI 10.1152/ajpcell.1988.255.6.C870; MATSUOKA S, 1995, J GEN PHYSIOL, V105, P403, DOI 10.1085/jgp.105.3.403; MATSUOKA S, 1992, J GEN PHYSIOL, V100, P963, DOI 10.1085/jgp.100.6.963; MATSUOKA S, 1993, P NATL ACAD SCI USA, V90, P3870, DOI 10.1073/pnas.90.9.3870; NICOLL DA, 1990, SCIENCE, V250, P562, DOI 10.1126/science.1700476; PORZIG H, 1993, AM J PHYSIOL, V265, pC748, DOI 10.1152/ajpcell.1993.265.3.C748; REILANDER H, 1992, EMBO J, V11, P1689, DOI 10.1002/j.1460-2075.1992.tb05219.x; STRYNADKA NCJ, 1989, ANNU REV BIOCHEM, V58, P951, DOI 10.1146/annurev.bi.58.070189.004511; TONEY MD, 1993, SCIENCE, V261, P756, DOI 10.1126/science.8342040; Valdivia C., 1995, Biophysical Journal, V68, pA410; VILSEN B, 1993, FEBS LETT, V333, P44, DOI 10.1016/0014-5793(93)80372-2	34	124	128	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13385	13391		10.1074/jbc.271.23.13385	http://dx.doi.org/10.1074/jbc.271.23.13385			7	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662775	hybrid			2022-12-27	WOS:A1996UP38500015
J	Perrella, MA; Patterson, C; Tan, L; Yet, SF; Hsieh, CM; Yoshizumi, M; Lee, ME				Perrella, MA; Patterson, C; Tan, L; Yet, SF; Hsieh, CM; Yoshizumi, M; Lee, ME			Suppression of interleukin-1 beta-induced nitric-oxide synthase promoter/enhancer activity by transforming growth factor-beta 1 in vascular smooth muscle cells - Evidence for mechanisms other than NF-kappa B	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							INTERFERON-GAMMA; GENE-EXPRESSION; LIPOPOLYSACCHARIDE; PROMOTER; SEQUENCE; SHOCK; FOS	Nitric-oxide synthases (NOS) utilize L-arginine to produce NO, a potent vasodilator that contributes to the regulation of vascular tone. We demonstrated previously that transforming growth factor (TGF)-beta 1 down-regulates inducible NOS after its induction by interleukin (IL)-1 beta by decreasing the rate of inducible NOS gene transcription. In the present study we transfected reporter plasmids containing various lengths of the inducible NOS 5'-flanking region into primary cultured rat aortic smooth muscle cells and stimulated the cells with IL-1 beta or vehicle. IL-1 beta increased the activity of the plasmid containing -1485 to +31 of the inducible NOS gene by more than 10-fold, indicating the presence of IL-1 beta-responsive elements. Further deletion analysis revealed that a construct containing -234 to +31 of the inducible NOS gene contained the majority of promoter/enhancer activity after IL-1 beta stimulation. Mutation of the NF-kappa B site within this region partially reduced IL-1 beta-inducible activity; however, a large portion of activity remained independent of the NF-kappa B site. TGF-beta 1 suppressed promoter/enchancer activity after IL-1 beta stimulation, and this suppression was complete in the construct with a mutated NF-kappa B site. In addition, TGF-beta 1 did not decrease the binding of nuclear proteins to the NF-kappa B site. These data suggest that the ability of TGF-beta 1 to suppress inducible NOS promoter/enhancer activity occurs through a site(s) other than the NF-kappa B motif in vascular smooth muscle cells.	HARVARD UNIV,SCH MED,DEPT MED,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV PULM,BOSTON,MA 02115; BRIGHAM & WOMENS HOSP,DIV CARDIOVASC,BOSTON,MA 02115	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital	Perrella, MA (corresponding author), HARVARD UNIV,SCH PUBL HLTH,CARDIOVASC BIOL LAB,BLDG 2,677 HUNTINGTON AVE,BOSTON,MA 02115, USA.		Yet, Shaw-Fang/B-1067-2010; Yet, Shaw-Fang/O-8583-2019	Yet, Shaw-Fang/0000-0001-9097-3962	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL003194] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM053249] Funding Source: NIH RePORTER; NHLBI NIH HHS [KO8HL03194] Funding Source: Medline; NIGMS NIH HHS [R01GM53249] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		EPSTEIN FH, 1993, NEW ENGL J MED, V328, P106; FEN Z, 1993, BIOCHEMISTRY-US, V32, P7932, DOI 10.1021/bi00082a014; GHOSH G, 1995, NATURE, V373, P303, DOI 10.1038/373303a0; GUNTHER S, 1982, J CELL BIOL, V92, P289, DOI 10.1083/jcb.92.2.289; HIGUCHI R, 1988, NUCLEIC ACIDS RES, V16, P7351, DOI 10.1093/nar/16.15.7351; IGNARRO JJ, 1990, ANN REV PHARM TOXICO, V30, P535; KERR LD, 1990, CELL, V61, P267, DOI 10.1016/0092-8674(90)90807-Q; KILBOURN RG, 1990, P NATL ACAD SCI USA, V87, P3629, DOI 10.1073/pnas.87.9.3629; KIMES BW, 1976, EXP CELL RES, V98, P349, DOI 10.1016/0014-4827(76)90446-8; LEE ME, 1990, J BIOL CHEM, V265, P10446; LEE ME, 1991, J BIOL CHEM, V266, P19034; LOWENSTEIN CJ, 1993, P NATL ACAD SCI USA, V90, P9730, DOI 10.1073/pnas.90.20.9730; MACMICKING JD, 1995, CELL, V81, P641, DOI 10.1016/0092-8674(95)90085-3; MARTIN E, 1994, J EXP MED, V180, P977, DOI 10.1084/jem.180.3.977; MAUVIEL A, 1993, CURR BIOL, V3, P822, DOI 10.1016/0960-9822(93)90216-B; MONCADA S, 1991, PHARMACOL REV, V43, P109; MULLER CW, 1995, NATURE, V373, P311, DOI 10.1038/373311a0; NATHAN C, 1994, CELL, V78, P915, DOI 10.1016/0092-8674(94)90266-6; NAVA E, 1992, J CARDIOVASC PHARM, V20, pS132, DOI 10.1097/00005344-199204002-00037; Palmer R M, 1993, Curr Opin Nephrol Hypertens, V2, P122, DOI 10.1097/00041552-199301000-00018; PARRILLO JE, 1993, NEW ENGL J MED, V328, P1471, DOI 10.1056/nejm199305203282008; PERRELLA MA, 1994, J BIOL CHEM, V269, P14595; Sambrook J., 2002, MOL CLONING LAB MANU; SPINK J, 1995, J BIOL CHEM, V270, P29541, DOI 10.1074/jbc.270.49.29541; VODOVOTZ Y, 1993, J EXP MED, V178, P605, DOI 10.1084/jem.178.2.605; WEI XQ, 1995, NATURE, V375, P408, DOI 10.1038/375408a0; XIE QW, 1994, J BIOL CHEM, V269, P4705; XIE QW, 1992, SCIENCE, V256, P225, DOI 10.1126/science.1373522; XIE QW, 1993, J EXP MED, V177, P1779, DOI 10.1084/jem.177.6.1779; YOSHIZUMI M, 1995, MOL CELL BIOL, V15, P3266	30	75	76	0	6	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	JUN 7	1996	271	23					13776	13780		10.1074/jbc.271.23.13776	http://dx.doi.org/10.1074/jbc.271.23.13776			5	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UP385	8662809				2022-12-27	WOS:A1996UP38500071
J	Kurihara, T; Bravo, R				Kurihara, T; Bravo, R			Cloning and functional expression of mCCR2, a murine receptor for the C-C chemokines JE and FIC	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							MONOCYTE CHEMOATTRACTANT PROTEIN-1; MOLECULAR-CLONING; GROWTH-FACTOR; SECRETORY PROTEIN; GENE ENCODES; CYTOKINE; FAMILY; CDNA; MCP-3; SEQUENCE	The C-C chemokines human monocyte chemoattractant protein-1 and -3 (MCP-1 and MCP-3) and mouse JE and FIC are potent activators of monocytes. Several receptors for MCP-1 and MCP-3 have been cloned from human monocytic cell lines, and one of these receptors, CCR2B, binds both MCP-1 and MCP-3. Thus far, no murine receptors for JE or FIC have been reported. We have cloned a novel murine C-C chemokine receptor, designated mouse CCR2 (mCCR2), from the mouse monocyte cell line WEHI265.1. The predicted 373-amino acid sequence of mCCR2 shows highest identity (80%) with CCR2B. When stably expressed in human embryonic kidney 293 cells, mCCR2 specifically bound I-125-JE with high affinity. FIC was less potent than JE in competing I-125-JE binding to mCCR2-expressing cells, while three other mouse chemokines, MIP-1 alpha, C10, and N51/KC, did not compete. mccr2 mRNA expression was detected in elicited peritoneal macrophages as well as in several mouse organs. The cloning of mCCR2 provides an important tool to investigate monocyte/macrophage responses to JE and FIC, to identify other targets for their action, and potentially to study models of CCR2 function in the mouse.	BRISTOL MYERS SQUIBB PHARMACEUT RES INST,DEPT ONCOL,PRINCETON,NJ 08543	Bristol-Myers Squibb								BAGGIOLINI M, 1994, ADV IMMUNOL, V55, P97; BENBARUCH A, 1995, J BIOL CHEM, V270, P22123, DOI 10.1074/jbc.270.38.22123; CARRASCO D, 1994, DEVELOPMENT, V120, P2991; Chang H C, 1989, Int Immunol, V1, P388, DOI 10.1093/intimm/1.4.388; CHARO IF, 1994, P NATL ACAD SCI USA, V91, P2752, DOI 10.1073/pnas.91.7.2752; COCHRAN BH, 1983, CELL, V33, P939, DOI 10.1016/0092-8674(83)90037-5; COMBADIERE C, 1995, J BIOL CHEM, V270, P16491, DOI 10.1074/jbc.270.28.16491; DAVATELIS G, 1988, J EXP MED, V167, P1939, DOI 10.1084/jem.167.6.1939; FRANCI C, 1995, J IMMUNOL, V154, P6511; FUENTES ME, 1995, J IMMUNOL, V155, P5769; FURUTANI Y, 1989, BIOCHEM BIOPH RES CO, V159, P249, DOI 10.1016/0006-291X(89)92430-3; GAO JL, 1995, J BIOL CHEM, V270, P17494, DOI 10.1074/jbc.270.29.17494; GAO JL, 1993, J EXP MED, V177, P1421, DOI 10.1084/jem.177.5.1421; HEINRICH JN, 1994, MOL CELL BIOL, V14, P2849, DOI 10.1128/MCB.14.5.2849; HEINRICH JN, 1993, MOL CELL BIOL, V13, P2020, DOI 10.1128/MCB.13.4.2020; KOCH AE, 1992, J CLIN INVEST, V90, P772, DOI 10.1172/JCI115950; KULMBURG PA, 1992, J EXP MED, V176, P1773, DOI 10.1084/jem.176.6.1773; MILLER MD, 1992, CRIT REV IMMUNOL, V12, P17; MINTY A, 1993, EUR CYTOKINE NETW, V4, P99; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MYERS SJ, 1995, J BIOL CHEM, V270, P5786, DOI 10.1074/jbc.270.11.5786; NALKAN NA, 1991, J CLIN INVEST, V88, P1121; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; OPDENAKKER G, 1993, BIOCHEM BIOPH RES CO, V191, P535, DOI 10.1006/bbrc.1993.1251; OPPENHEIM JJ, 1991, ANNU REV IMMUNOL, V9, P617, DOI 10.1146/annurev.iy.09.040191.003153; OQUENDO P, 1989, J BIOL CHEM, V264, P4133; ORLOFSKY A, 1991, CELL REGUL, V2, P403, DOI 10.1091/mbc.2.5.403; POST TW, 1995, J IMMUNOL, V155, P5299; ROLLINS BJ, 1989, MOL CELL BIOL, V9, P4687, DOI 10.1128/MCB.9.11.4687; ROLLINS BJ, 1988, P NATL ACAD SCI USA, V85, P3738, DOI 10.1073/pnas.85.11.3738; ROLLINS BJ, 1991, MOL CELL BIOL, V11, P3125, DOI 10.1128/MCB.11.6.3125; RUTLEDGE BJ, 1995, J IMMUNOL, V155, P4838; RYSECK RP, 1989, EXP CELL RES, V180, P266, DOI 10.1016/0014-4827(89)90230-9; SCATCHARD G, 1949, ANN NY ACAD SCI, V51, P660, DOI 10.1111/j.1749-6632.1949.tb27297.x; SOZZANI S, 1995, J LEUKOCYTE BIOL, V57, P788, DOI 10.1002/jlb.57.5.788; THIRION S, 1994, BIOCHEM BIOPH RES CO, V201, P493, DOI 10.1006/bbrc.1994.1729; van der Eb A J, 1980, Methods Enzymol, V65, P826; VANDAMME J, 1992, J EXP MED, V176, P59, DOI 10.1084/jem.176.1.59; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; YOSHIMURA T, 1989, FEBS LETT, V244, P487, DOI 10.1016/0014-5793(89)80590-3	40	98	105	0	1	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814	0021-9258			J BIOL CHEM	J. Biol. Chem.	MAY 17	1996	271	20					11603	11606		10.1074/jbc.271.20.11603	http://dx.doi.org/10.1074/jbc.271.20.11603			4	Biochemistry & Molecular Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology	UL250	8662823	hybrid			2022-12-27	WOS:A1996UL25000003
